

APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)



APPROVED DRUG PRODUCTS

WITH


**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

31st EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCE
OFFICE OF GENERIC DRUGS**

2011



APPROVED DRUG PRODUCTS

WITH

**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

31st EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCE
OFFICE OF GENERIC DRUGS

2011

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2010.

31st EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCE
OFFICE OF GENERIC DRUGS

2011

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations**

CONTENTS

PAGE

PREFACE TO THIRTY FIRST EDITION.....	iv
1 INTRODUCTION.....	vi
1.1 Content and Exclusion.....	vi
1.2 Therapeutic Equivalence-Related Terms	vi
1.3 Statistical Criteria for Bioequivalence	viii
1.4 Reference Listed Drug.....	x
1.5 General Policies and Legal Status	xi
1.6 Practitioner/User Responsibilities.....	xi
1.7 Therapeutic Equivalence Evaluations Codes	xiii
1.8 Description of Special Situations.....	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity.....	xxii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product.....	xxiii
1.11 Discontinued Section.....	xxiii
1.12 Changes to the Orange Book.....	xxiv
1.13 Availability of the Edition.....	xxiv
2 HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1 Key Sections for Using the Drug Product Lists	2-1
2.2 Drug Product Illustration	2-3
2.3 Therapeutic Equivalence Evaluations Illustration	2-4
DRUG PRODUCT LISTS	
Prescription Drug Product List	3-1
OTC Drug Product List	4-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	5-1
Discontinued Drug Product List	6-1
Orphan Products Designations and Approvals List	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
APPENDICES	
A. Product Name Index	A-1
B. Product Name Index Listed by Applicant	B-1
C. Uniform Terms	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	AD1
A. Patent and Exclusivity Lists	ADA1
B. Patent and Exclusivity Terms	ADB1

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS**

**with
Therapeutic Equivalence Evaluations**

PREFACE TO THIRTY FIRST EDITION

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register*

on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the List incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Labeling and Program Support, HFD-610, Office of Generic Drugs, Center for Drug and Evaluation and Research, 7500 Standish Place, Rockville, MD 20855. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

1. INTRODUCTION

1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.¹ This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided.

An *Addendum* contains drug patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products are given tentative approvals. The Agency will not include drug products with tentative approval in the List; however, they are available at <http://www.fda.gov/cder/ogd/approvals/default.htm>. When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same

¹ Newly approved products are added to parts 1, 2, or 3, of the List, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

dosage form, route of administration and are identical in strength or concentration (e.g., chlorthalidone hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes

available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(8)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36

adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time. Pharmacokinetic parameters characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ($AUC_{(0-t)}$) and extrapolated to infinity ($AUC_{(0-inf)}$), for extent of absorption; and the maximum or peak drug concentrations (C_{max}), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and C_{max}) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter (C_{max} and AUC). The confidence interval for both pharmacokinetic parameters, AUC and C_{max} , must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject (normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and C_{max}) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted

in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997. The three measures reviewed include $AUC_{(0-t)}$, $AUC_{(0-inf)}$, and C_{max} . The observed average differences between the reference and generic products were $+ 3.47\%$ (SD 2.84) for $AUC_{(0-t)}$, $+ 3.25\%$ (SD 2.97) for $AUC_{(0-inf)}$, and $+ 4.29\%$ (SD 3.72) for C_{max} (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence (reference standard) and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when listed drugs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of a listed drug that is not designated as the reference listed drug may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second listed drug will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes products meeting necessary bioequivalence requirements* explains the (AB, AB1, AB2, AB3... coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two listed products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the-Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, Injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which is purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the List.

Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

Multisource and single-source drug products. FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included on the List, but no therapeutic equivalence code is included with such products. Any drug product

in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

Every product on the List is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product on the List. The main criterion for

inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bio-equivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied for

solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

- (2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents*) generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved, Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. The generic drug products bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of

AB2. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not

published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

The strength of parenteral drugs products is defined as the total drug content of the container. Until recently the strength of liquid parenteral drug products in the Orange Book have not been displayed. The concentration of the liquid parenteral drug product in the Orange Book has been shown as xmg/ml. The amount of dry powder or freeze dried powder in a container has always been identified as the strength.

With the finalization of the Waxman-Hatch amendments that characterized each strength of a drug product as a listed drug, it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end the OGD has started to display the strength of all new approvals of parenteral solutions. Previously we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/ml. If this drug product had a 20 ml and 60 ml container approved the two products would be shown as 1Gm / 20ml (50mg/ml) and 3Gm / 60ml (50mg/ml).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bio-equivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained medicament available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard, such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted, such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence, such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bio-equivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. Following is a description of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Follitropin Alfa and Beta. Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

Gaviscon®. Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium. Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine

sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KING PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHEROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

Patent Certification(s) Reference Listed Drug based upon a suitability petition. An abbreviated new drug application that refers to a Reference Listed Drug (RLD) approved pursuant to a suitability petition must demonstrate that the proposed product is bioequivalent to the RLD, and it must include appropriate patent certification(s) and an exclusivity statement with respect to the listed drug which served as the basis for the approved suitability petition. This concept also applies to an ANDA applicant that cites a RLD that was based upon an NDA that is still covered by patent (s) and/or exclusivity, e.g. a second RLD that was selected when the in vivo

determination of bioequivalence of the original RLD is self evident and the waiver of the in vivo determination of bioequivalence may be granted.

Waived exclusivity. If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7500 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies

of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

1.11 Discontinued Section

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not withdrawn for safety or efficacy reasons have "***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons***" following the product strength. Those drug products are only reflective of citizen petitions determinations made since 1995. The identification of these drug products in the Discontinued Section of the Orange Book should avoid the submission of multiple citizen petitions for the same drug product. FR notices no longer applicable are removed from the Annual Edition (i.e., there is a currently marketed Reference Listed Drug and no applicable patent or exclusivity). [FR Safety or Effectiveness Determinations List](#) lists products that have current and removed notices. The list is updated quarterly. Notices issued during the year are added to the [Electronic Orange Book Query](#) in the month they become effective.

Generally, approved products are added to the Discontinued Section of the Orange Book when the applicant holder notifies the Orange Book staff of the products' not marketed status. Products may also be added if annual reports indicate the product is no longer marketed or other Agency administrative action (e.g., Withdrawal of an Application). Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. Please inform the OBS when products are no longer marketed. Notification of the Orange Book staff to include the newly approved product in the Discontinued Drug Product List rather than parts 1, 2 or 3 of the List (as discussed in Section 1.1) must occur by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update

We can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855

1.13 Availability of the Edition

Commencing with the 25th edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the EOB home page, <http://www.fda.gov/cder/ob/default.htm>, by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Printing Office, 866-512-1800.

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the 12th Cumulative Supplement of the 30th Edition List have been added to the Discontinued Drug Product List appearing in the 31st Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Section of the Orange Book.

Product Name Index (*Prescription and OTC Drug Product Lists*). This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT

ACTIVE INGREDIENT	MEPERIDINE HYDROCHLORIDE			
DOSAGE FORM; ROUTE OF ADMINISTRATION	INJECTABLE; INJECTION			
TRADE OR GENERIC NAMES	<u>HEXANON</u>			
REFERENCE LISTED DRUG	AP + PAGE PHARMA	<u>25MG/ML</u>	N13111 001	
	AP +	<u>50MG/ML</u>	N13111 002	
	AP +	<u>75MG/ML</u>	N13111 003	
	AP +	<u>100MG/ML</u>	AUG 22, 1983	N13111 004
			JAN 04, 1985	
THERAPEUTIC EQUIVALENCE (TE)	MEPERIDINE HCL			
CODE FOR MULTISOURCE PRODUCT	AP GREENBERG PHARM	<u>25MG/ML</u>	N42242 001	
	AP	<u>50MG/ML</u>	N42296 001	
	AP	<u>75MG/ML</u>	N42301 002	
			AUG 27, 1987	
FINAL APPROVAL DATE	AP		N42301 003	
SINGLE SOURCE PRODUCT (NO TE CODE)	AP	10MG/ML	N40000 001	
	HOLOVAC LLC	<u>25MG/ML</u>	N47222 001	
	OBS PHARM	<u>150MG/ML</u>	N47100 001	
APPLICANT	JOHNSON MED			
AVAILABLE STRENGTH(S) OF A PRODUCT				
APPLICATION NUMBER AND PRODUCT NUMBER				
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY				
		100MG/ML		

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY ACTIVE INGREDIENT	HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
PRODUCT INFORMATION	TABLET; ORAL HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL AUG 27, 1982 25MG;15MG;0.1MG N41290 001 JAN 18, 1982

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.

					<u>SULFASALAZINE</u>					
					TABLET; ORAL					
					<u>FAZINE</u>					
PRODUCTS CONSIDERED THERAPEUTICALLY EQUIVALENT TO EACH OTHER	→	<u>AB</u>	PARKLAND	<u>500MG</u>	A42999 001					
		<u>SULAZINE</u>								
PRODUCTS CONSIDERED NOT THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCTS LISTED	→	<u>AB</u>	URSA	<u>500MG</u>	A40222 001					
		<u>SULFASALAZINE</u>								
					BP	BROWN	500MG	A41297 001		
					<u>SULFASALAZINE</u>					
					TABLET; ORAL					
					<u>FAZINE</u>					
PRODUCTS CONSIDERED NOT THERAPEUTICALLY EQUIVALENT TO EACH OTHER	→	<u>AB</u>	PARKLAND	<u>500MG</u>	A42999 001					
		<u>SULFASALAZINE</u>								
					BP	BROWN	500MG	A41297 001		
					SOUTH					
					500MG					
					A40627 001					

NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

PRESCRIPTION DRUG PRODUCT LIST

3 - 1 (of 409)

ABACAVIR SULFATE

SOLUTION; ORAL				
ZIAGEN				
+ VIV HLHCARE	EQ 20MG BASE/ML	N020978	001	Dec 17, 1998
TABLET; ORAL				
ZIAGEN				
+ VIV HLHCARE	EQ 300MG BASE	N020977	001	Dec 17, 1998

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL				
EPZICOM				
+ VIV HLHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL				
TRIZIVIR				
+ VIV HLHCARE	EQ 300MG BASE;150MG;300MG	N021205	001	Nov 14, 2000

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL				
CAMPRAL				
+ FOREST LABS	333MG	N021431	001	Jul 29, 2004

ACARBOSE

TABLET; ORAL				
<u>ACARBOSE</u>				
<u>AB</u> IMPAX LABS	<u>25MG</u>	<u>A078441</u>	<u>001</u>	May 14, 2009
<u>AB</u>	<u>50MG</u>	<u>A078441</u>	<u>002</u>	May 14, 2009
<u>AB</u>	<u>100MG</u>	<u>A078441</u>	<u>003</u>	May 14, 2009
<u>AB</u> MYLAN	<u>25MG</u>	<u>A091053</u>	<u>001</u>	Jan 06, 2011
<u>AB</u>	<u>50MG</u>	<u>A091053</u>	<u>002</u>	Jan 06, 2011
<u>AB</u>	<u>100MG</u>	<u>A091053</u>	<u>003</u>	Jan 06, 2011
<u>AB</u> ROXANE	<u>25MG</u>	<u>A078470</u>	<u>001</u>	May 07, 2008
<u>AB</u>	<u>50MG</u>	<u>A078470</u>	<u>002</u>	May 07, 2008
<u>AB</u>	<u>100MG</u>	<u>A078470</u>	<u>003</u>	May 07, 2008
<u>AB</u> WATSON LABS	<u>25MG</u>	<u>A077532</u>	<u>001</u>	May 07, 2008
<u>AB</u>	<u>50MG</u>	<u>A077532</u>	<u>002</u>	May 07, 2008
<u>AB</u>	<u>100MG</u>	<u>A077532</u>	<u>003</u>	May 07, 2008
<u>AB</u> + <u>PRECOSE</u>				
<u>AB</u> + BAYER HLHCARE	<u>25MG</u>	<u>N020482</u>	<u>004</u>	May 29, 1997
<u>AB</u>	<u>50MG</u>	<u>N020482</u>	<u>001</u>	Sep 06, 1995
<u>AB</u>	<u>100MG</u>	<u>N020482</u>	<u>002</u>	Sep 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL				
<u>ACEBUTOLOL HYDROCHLORIDE</u>				
<u>AB</u> AMNEAL PHARM	<u>EQ 200MG BASE</u>	<u>A075047</u>	<u>001</u>	Dec 30, 1999
<u>AB</u>	<u>EQ 400MG BASE</u>	<u>A075047</u>	<u>002</u>	Dec 30, 1999
<u>AB</u> MYLAN	<u>EQ 200MG BASE</u>	<u>A074288</u>	<u>001</u>	Apr 24, 1995
<u>AB</u>	<u>EQ 400MG BASE</u>	<u>A074288</u>	<u>002</u>	Apr 24, 1995
<u>AB</u> WATSON LABS	<u>EQ 200MG BASE</u>	<u>A074007</u>	<u>001</u>	Oct 18, 1995
<u>AB</u>	<u>EQ 400MG BASE</u>	<u>A074007</u>	<u>002</u>	Oct 18, 1995
<u>AB</u> <u>SECTRAL</u>				
<u>AB</u> PROMIUS PHARMA	<u>EQ 200MG BASE</u>	<u>N018917</u>	<u>001</u>	Dec 28, 1984
<u>AB</u> +	<u>EQ 400MG BASE</u>	<u>N018917</u>	<u>003</u>	Dec 28, 1984

PRESCRIPTION DRUG PRODUCT LIST

3 - 2 (of 409)

ACETAMINOPHEN

SOLUTION; IV (INFUSION)

+ CADENCE PHARMS	1000MG/100ML (10MG/ML)	N022450 001	Nov 02, 2010

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
PHRENILIN FORTE

+ VALEANT	650MG;50MG	A088831 001	Jun 19, 1985

TABLET; ORAL

BUTAPAP

AA MIKART	325MG;50MG	A089987 001	Oct 26, 1992

PHRENILIN

AA + VALEANT	325MG;50MG	A087811 001	Jun 19, 1985

BUTAPAP

+ MIKART	650MG;50MG	A089988 001	Oct 26, 1992

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA WEST WARD	500MG;50MG;40MG	A040261 001	Oct 28, 1998

ESGIC-PLUS

AA + MIKART	500MG;50MG;40MG	A040085 001	Mar 28, 1996

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+ MIKART	325MG;50MG;40MG	A089007 001	Mar 17, 1986

+ NEXGEN PHARMA	300MG;50MG;40MG	A040885 001	Nov 16, 2009

SOLUTION; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+ MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387 001	Jan 31, 2003

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA CONCORD LABS NJ	325MG;50MG;40MG	A040864 001	Dec 01, 2008

AA	500MG;50MG;40MG	A040883 001	Dec 23, 2008

AA MALLINCKRODT	325MG;50MG;40MG	A087804 001	Jan 24, 1985

AA MIKART	325MG;50MG;40MG	A089175 001	Jan 21, 1987

AA VINTAGE PHARMS	325MG;50MG;40MG	A040511 001	Aug 27, 2003

AA	500MG;50MG;40MG	A040513 001	Aug 25, 2003

AA WATSON LABS	500MG;50MG;40MG	A040267 001	Jul 30, 1998

AA WEST WARD	325MG;50MG;40MG	A089718 001	Jun 12, 1995

AA	500MG;50MG;40MG	A040336 001	Aug 18, 1999

ESGIC-PLUS

AA + MIKART	500MG;50MG;40MG	A089451 001	May 23, 1988

FIORICET

AA + WATSON PHARMS	325MG;50MG;40MG	A088616 001	Nov 09, 1984

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+ MIKART	750MG;50MG;40MG	A040496 001	Dec 23, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB NEXGEN PHARMA INC	325MG;50MG;40MG;30MG	A076560 001	Jun 10, 2004

AB VINTAGE PHARMS	325MG;50MG;40MG;30MG	A075929 001	Apr 22, 2002

AB WEST WARD	325MG;50MG;40MG;30MG	A075618 001	Mar 23, 2001

FIORICET W/ CODEINE

AB + WATSON PHARMS	325MG;50MG;40MG;30MG	N020232 001	Jul 30, 1992

PHRENILIN WITH CAFFEINE AND CODEINE

AB VALEANT	325MG;50MG;40MG;30MG	A074911 001	Aug 22, 2001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 3 (of 409)

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

<u>AA</u>	E5 PHARMA INC	<u>356.4MG;30MG;16MG</u>	<u>A040688</u>	<u>001</u>	Apr 03, 2007
<u>AA</u>	+ MIKART	<u>356.4MG;30MG;16MG</u>	<u>A040109</u>	<u>001</u>	Aug 26, 1997

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

<u>AA</u>	BOCA PHARMA	<u>712.8MG;60MG;32MG</u>	<u>A040701</u>	<u>001</u>	Apr 03, 2007
<u>AA</u>	+ MIKART	<u>712.8MG;60MG;32MG</u>	<u>A040316</u>	<u>001</u>	Apr 28, 1999
<u>AA</u>	WEST WARD	<u>712.8MG;60MG;32MG</u>	<u>A040637</u>	<u>001</u>	Sep 22, 2006

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>120MG/5ML;12MG/5ML</u>	<u>A085861</u>	<u>001</u>	
<u>AA</u>	HI TECH PHARMA	<u>120MG/5ML;12MG/5ML</u>	<u>A040119</u>	<u>001</u>	Apr 26, 1996
<u>AA</u>	MIKART	<u>120MG/5ML;12MG/5ML</u>	<u>A089450</u>	<u>001</u>	Oct 27, 1992
<u>AA</u>	PHARM ASSOC	<u>120MG/5ML;12MG/5ML</u>	<u>A087508</u>	<u>001</u>	
<u>AA</u>	WOCKHARDT	<u>120MG/5ML;12MG/5ML</u>	<u>A087006</u>	<u>001</u>	

SUSPENSION; ORAL

CAPITAL AND CODEINE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>120MG/5ML;12MG/5ML</u>	<u>A085883</u>	<u>001</u>	
<u>AA</u>	+ VALEANT	<u>120MG/5ML;12MG/5ML</u>	<u>A086024</u>	<u>001</u>	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	AMNEAL PHARMS NY	<u>300MG;30MG</u>	<u>A040779</u>	<u>001</u>	May 29, 2008
<u>AA</u>	+ DURAMED PHARMS BARR	<u>300MG;15MG</u>	<u>A040223</u>	<u>001</u>	Nov 18, 1997
<u>AA</u>		<u>300MG;30MG</u>	<u>A040223</u>	<u>002</u>	Nov 18, 1997
<u>AA</u>		<u>300MG;60MG</u>	<u>A040223</u>	<u>003</u>	Nov 18, 1997
<u>AA</u>	MALLINCKRODT	<u>300MG;15MG</u>	<u>A040419</u>	<u>001</u>	May 31, 2001
<u>AA</u>		<u>300MG;30MG</u>	<u>A040419</u>	<u>002</u>	May 31, 2001
<u>AA</u>		<u>300MG;60MG</u>	<u>A040419</u>	<u>003</u>	May 31, 2001
<u>AA</u>	MIKART	<u>300MG;30MG</u>	<u>A089238</u>	<u>001</u>	Feb 25, 1986
<u>AA</u>	RANBAXY	<u>300MG;30MG</u>	<u>A085868</u>	<u>001</u>	
<u>AA</u>		<u>300MG;60MG</u>	<u>A087083</u>	<u>001</u>	
<u>AA</u>	TEVA	<u>300MG;15MG</u>	<u>A088627</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;30MG</u>	<u>A088628</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	+ VINTAGE	<u>300MG;60MG</u>	<u>A088629</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;15MG</u>	<u>A089990</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG;30MG</u>	<u>A089805</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG;60MG</u>	<u>A089828</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	WATSON LABS	<u>300MG;15MG</u>	<u>A089997</u>	<u>001</u>	Dec 28, 1994
<u>AA</u>		<u>300MG;30MG</u>	<u>A089998</u>	<u>001</u>	Dec 28, 1994
<u>AA</u>		<u>300MG;60MG</u>	<u>A089999</u>	<u>001</u>	Dec 28, 1994
<u>AA</u>	WATSON LABS FLORIDA	<u>300MG;15MG</u>	<u>A040443</u>	<u>001</u>	Jan 22, 2003
<u>AA</u>		<u>300MG;30MG</u>	<u>A040443</u>	<u>002</u>	Jan 22, 2003
<u>AA</u>		<u>300MG;60MG</u>	<u>A040443</u>	<u>003</u>	Jan 22, 2003
<u>TYLENOL W/ CODEINE NO. 3</u>					
<u>AA</u>	+ ORTHO MCNEIL JANSSEN	<u>300MG;30MG</u>	<u>A085055</u>	<u>003</u>	
<u>TYLENOL W/ CODEINE NO. 4</u>					
<u>AA</u>	ORTHOMCNEIL JANSSEN	<u>300MG;60MG</u>	<u>A085055</u>	<u>004</u>	
<u>ACETAMINOPHEN AND CODEINE PHOSPHATE</u>					
	+ MIKART	650MG;30MG	A089231	001	Mar 03, 1986
	+	650MG;60MG	A089363	001	Sep 09, 1991

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	MIKART	<u>500MG;5MG</u>	<u>A081067</u>	<u>001</u>	Nov 30, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 4 (of 409)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	MIKART	<u>500MG;5MG</u>	<u>A089008</u>	<u>001</u>	Feb 21, 1986

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	KV PHARM	<u>500MG/15ML;7.5MG/15ML</u>	<u>A040366</u>	<u>001</u>	Jan 23, 2002

<u>AA</u>	MALLINCKRODT	<u>500MG/15ML;7.5MG/15ML</u>	<u>A040418</u>	<u>001</u>	Jun 27, 2001

<u>AA</u>	+	MIKART	<u>500MG/15ML;7.5MG/15ML</u>	<u>A081051</u>	<u>001</u>	Aug 28, 1992

<u>AA</u>	PHARM ASSOC	<u>500MG/15ML;7.5MG/15ML</u>	<u>A040182</u>	<u>001</u>	Mar 13, 1998

<u>AA</u>	VINTAGE PHARMS	<u>500MG/15ML;7.5MG/15ML</u>	<u>A040520</u>	<u>001</u>	Oct 30, 2003

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

+	MALLINCKRODT	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003

+	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010

+		325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003

+	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET; ORAL

ANEXSIA

<u>AA</u>	MALLINCKRODT	<u>500MG;5MG</u>	<u>A089160</u>	<u>001</u>	Apr 23, 1987

<u>AA</u>		<u>750MG;10MG</u>	<u>A040468</u>	<u>001</u>	Oct 31, 2002

ANEXSIA 5/325

<u>AA</u>	MALLINCKRODT	<u>325MG;5MG</u>	<u>A040409</u>	<u>001</u>	Oct 20, 2000

ANEXSIA 7.5/325

<u>AA</u>	MALLINCKRODT	<u>325MG;7.5MG</u>	<u>A040405</u>	<u>001</u>	Sep 08, 2000

ANEXSIA 7.5/650

<u>AA</u>	MALLINCKRODT	<u>650MG;7.5MG</u>	<u>A089725</u>	<u>001</u>	Sep 30, 1987

CO-GESIC

<u>AA</u>	UCB INC	<u>500MG;5MG</u>	<u>A087757</u>	<u>001</u>	May 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	AMNEAL PHARMS NY	<u>325MG;5MG</u>	<u>A040736</u>	<u>001</u>	Aug 25, 2006

<u>AA</u>		<u>325MG;10MG</u>	<u>A040746</u>	<u>001</u>	Aug 25, 2006

<u>AA</u>		<u>500MG;5MG</u>	<u>A040729</u>	<u>001</u>	Aug 25, 2006

<u>AA</u>		<u>500MG;7.5MG</u>	<u>A040748</u>	<u>001</u>	Aug 25, 2006

<u>AA</u>		<u>500MG;10MG</u>	<u>A040813</u>	<u>001</u>	Feb 23, 2007

<u>AA</u>		<u>650MG;7.5MG</u>	<u>A040754</u>	<u>001</u>	Aug 25, 2006

<u>AA</u>		<u>650MG;10MG</u>	<u>A040757</u>	<u>001</u>	Aug 25, 2006

<u>AA</u>		<u>750MG;7.5MG</u>	<u>A040769</u>	<u>001</u>	Aug 28, 2006

<u>AA</u>	MALLINCKRODT	<u>325MG;10MG</u>	<u>A040400</u>	<u>001</u>	Jul 26, 2000

<u>AA</u>		<u>500MG;5MG</u>	<u>A040084</u>	<u>002</u>	Jun 01, 1995

<u>AA</u>		<u>500MG;7.5MG</u>	<u>A040201</u>	<u>001</u>	Feb 27, 1998

<u>AA</u>		<u>500MG;10MG</u>	<u>A040201</u>	<u>002</u>	Feb 27, 1998

<u>AA</u>		<u>650MG;10MG</u>	<u>A040084</u>	<u>004</u>	Oct 16, 1996

<u>AA</u>	+	<u>660MG;10MG</u>	<u>A040084</u>	<u>003</u>	Jul 29, 1996

<u>AA</u>		<u>750MG;7.5MG</u>	<u>A040084</u>	<u>001</u>	Jun 01, 1995

<u>AA</u>	MIKART	<u>325MG;7.5MG</u>	<u>A040432</u>	<u>001</u>	Jan 22, 2003

<u>AA</u>	+	<u>500MG;2.5MG</u>	<u>A089698</u>	<u>001</u>	Aug 25, 1989

<u>AA</u>	+	<u>500MG;7.5MG</u>	<u>A089699</u>	<u>001</u>	Aug 25, 1989

<u>AA</u>	+	<u>650MG;7.5MG</u>	<u>A089689</u>	<u>001</u>	Jun 29, 1988

<u>AA</u>	+	<u>650MG;10MG</u>	<u>A081223</u>	<u>001</u>	May 29, 1992

<u>AA</u>	RANBAXY	<u>325MG;10MG</u>	<u>A040826</u>	<u>001</u>	Aug 16, 2007

<u>AA</u>		<u>500MG;5MG</u>	<u>A040825</u>	<u>001</u>	Aug 16, 2007

<u>AA</u>		<u>500MG;10MG</u>	<u>A040824</u>	<u>001</u>	Aug 16, 2007

<u>AA</u>		<u>750MG;7.5MG</u>	<u>A040822</u>	<u>001</u>	Aug 16, 2007

<u>AA</u>	SUN PHARM INDS INC	<u>325MG;5MG</u>	<u>A090118</u>	<u>001</u>	Dec 23, 2008

<u>AA</u>		<u>325MG;7.5MG</u>	<u>A090118</u>	<u>002</u>	Dec 23, 2008

<u>AA</u>		<u>325MG;10MG</u>	<u>A090118</u>	<u>003</u>	Dec 23, 2008

<u>AA</u>		<u>500MG;5MG</u>	<u>A090265</u>	<u>001</u>	Dec 23, 2008

<u>AA</u>		<u>500MG;7.5MG</u>	<u>A090265</u>	<u>002</u>	Dec 23, 2008

<u>AA</u>		<u>500MG;10MG</u>	<u>A090265</u>	<u>003</u>	Dec 23, 2008

<u>AA</u>		<u>650MG;7.5MG</u>	<u>A090380</u>	<u>001</u>	Dec 23, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 5 (of 409)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL				
<u>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</u>				
<u>AA</u>	SUN PHARM INDS INC	<u>650MG;10MG</u>	<u>A090380</u>	<u>002</u> Dec 23, 2008
<u>AA</u>		<u>660MG;10MG</u>	<u>A090380</u>	<u>003</u> Dec 23, 2008
<u>AA</u>		<u>750MG;7.5MG</u>	<u>A090380</u>	<u>004</u> Dec 23, 2008
<u>AA</u>	VINTAGE PHARMS	<u>325MG;5MG</u>	<u>A040655</u>	<u>001</u> Jan 19, 2006
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A040656</u>	<u>001</u> Jan 19, 2006
<u>AA</u>		<u>325MG;10MG</u>	<u>A040355</u>	<u>001</u> May 31, 2000
<u>AA</u>		<u>500MG;2.5MG</u>	<u>A040144</u>	<u>002</u> Apr 25, 1997
<u>AA</u>		<u>500MG;5MG</u>	<u>A089971</u>	<u>001</u> Dec 02, 1988
<u>AA</u>		<u>500MG;7.5MG</u>	<u>A040144</u>	<u>001</u> Feb 22, 1996
<u>AA</u>		<u>500MG;10MG</u>	<u>A040356</u>	<u>001</u> May 31, 2000
<u>AA</u>		<u>650MG;7.5MG</u>	<u>A040155</u>	<u>001</u> Apr 14, 1997
<u>AA</u>		<u>650MG;10MG</u>	<u>A040143</u>	<u>001</u> Feb 22, 1996
<u>AA</u>		<u>660MG;10MG</u>	<u>A040358</u>	<u>001</u> May 31, 2000
<u>AA</u>		<u>750MG;7.5MG</u>	<u>A040157</u>	<u>001</u> Apr 12, 1996
<u>AA</u>	WATSON LABS	<u>325MG;10MG</u>	<u>A040248</u>	<u>002</u> Apr 28, 2000
<u>AA</u>		<u>500MG;2.5MG</u>	<u>A040123</u>	<u>003</u> Mar 04, 1996
<u>AA</u>		<u>500MG;2.5MG</u>	<u>A081079</u>	<u>001</u> Aug 30, 1991
<u>AA</u>		<u>500MG;5MG</u>	<u>A089883</u>	<u>001</u> Dec 01, 1988
<u>AA</u>		<u>500MG;7.5MG</u>	<u>A040123</u>	<u>004</u> Mar 04, 1996
<u>AA</u>		<u>500MG;7.5MG</u>	<u>A081080</u>	<u>001</u> Aug 30, 1991
<u>AA</u>		<u>500MG;10MG</u>	<u>A040148</u>	<u>002</u> Feb 14, 1997
<u>AA</u>		<u>650MG;7.5MG</u>	<u>A040094</u>	<u>001</u> Sep 29, 1995
<u>AA</u>		<u>650MG;7.5MG</u>	<u>A040123</u>	<u>001</u> Mar 04, 1996
<u>AA</u>		<u>650MG;10MG</u>	<u>A040094</u>	<u>002</u> Sep 29, 1995
<u>AA</u>		<u>650MG;10MG</u>	<u>A040123</u>	<u>002</u> Mar 04, 1996
<u>AA</u>		<u>660MG;10MG</u>	<u>A040094</u>	<u>003</u> Aug 08, 2000
<u>AA</u>		<u>750MG;7.5MG</u>	<u>A081083</u>	<u>001</u> Aug 30, 1991
<u>AA</u>	+	<u>750MG;10MG</u>	<u>A040094</u>	<u>004</u> Mar 22, 1999
<u>AA</u>	WATSON LABS FLORIDA	<u>500MG;5MG</u>	<u>A040493</u>	<u>001</u> May 28, 2003
<u>AA</u>		<u>660MG;10MG</u>	<u>A040495</u>	<u>001</u> May 28, 2003
<u>AA</u>		<u>750MG;7.5MG</u>	<u>A040494</u>	<u>001</u> May 28, 2003
<u>LORTAB</u>				
<u>AA</u>	MALLINCKRODT	<u>500MG;5MG</u>	<u>A087722</u>	<u>001</u> Jul 09, 1982
<u>AA</u>	+	<u>500MG;10MG</u>	<u>A040100</u>	<u>001</u> Jan 26, 1996
<u>NORCO</u>				
<u>AA</u>	+	<u>325MG;5MG</u>	<u>A040099</u>	<u>001</u> Jun 25, 1997
<u>AA</u>	+	<u>325MG;7.5MG</u>	<u>A040148</u>	<u>003</u> Sep 12, 2000
<u>AA</u>	+	<u>325MG;10MG</u>	<u>A040148</u>	<u>001</u> Feb 14, 1997
<u>VICODIN</u>				
<u>AA</u>	+	<u>500MG;5MG</u>	<u>A088058</u>	<u>001</u> Jan 07, 1983
<u>VICODIN ES</u>				
<u>AA</u>	+	<u>750MG;7.5MG</u>	<u>A089736</u>	<u>001</u> Dec 09, 1988
<u>VICODIN HP</u>				
<u>AA</u>	ABBOTT	<u>660MG;10MG</u>	<u>A040117</u>	<u>001</u> Sep 23, 1996
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
	MIKART	300MG;5MG	A040658	001 Jan 19, 2006
	+	300MG;7.5MG	A040556	002 Mar 24, 2006
	+	300MG;10MG	A040556	001 Jun 23, 2004
		325MG;2.5MG	A040846	001 Jun 09, 2010
		650MG;5MG	A040849	001 Jun 09, 2010
ZYDONE				
	+	400MG;5MG	A040288	001 Nov 27, 1998
	+	400MG;7.5MG	A040288	002 Nov 27, 1998
	+	400MG;10MG	A040288	003 Nov 27, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 6 (of 409)

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	ACTAVIS TOTOWA	<u>500MG; 5MG</u>	<u>A040199</u>	<u>001</u>	Dec 30, 1998
<u>AA</u>	DURAMED PHARMS BARR	<u>500MG; 5MG</u>	<u>A040289</u>	<u>001</u>	Mar 16, 1999
<u>AA</u>	MALLINCKRODT	<u>500MG; 5MG</u>	<u>A040257</u>	<u>001</u>	Aug 04, 1998
<u>AA</u>	VINTAGE PHARMS	<u>500MG; 5MG</u>	<u>A040106</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	WATSON LABS	<u>500MG; 5MG</u>	<u>A040234</u>	<u>001</u>	Oct 30, 1997

ROXILOX

<u>AA</u>	ROXANE	<u>500MG; 5MG</u>	<u>A040061</u>	<u>001</u>	Jul 03, 1995

TYLOX

<u>AA</u>	+ ORTHO MCNEIL JANSSEN	<u>500MG; 5MG</u>	<u>A088790</u>	<u>001</u>	Dec 12, 1984

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	MALLINCKRODT	<u>325MG/5ML; 5MG/5ML</u>	<u>A040680</u>	<u>001</u>	Sep 29, 2006
<u>AA</u>	+ ROXANE	<u>325MG/5ML; 5MG/5ML</u>	<u>A089351</u>	<u>001</u>	Dec 03, 1986

TABLET; ORAL

OXYCET

<u>AA</u>	MALLINCKRODT	<u>325MG; 5MG</u>	<u>A087463</u>	<u>001</u>	Dec 07, 1983

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	ACTAVIS TOTOWA	<u>325MG; 5MG</u>	<u>A040203</u>	<u>001</u>	Mar 15, 1999
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040777</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040778</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040789</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040789</u>	<u>002</u>	Nov 27, 2007
<u>AA</u>	COASTAL PHARMS	<u>325MG; 2.5MG</u>	<u>A090177</u>	<u>001</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090177</u>	<u>002</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090177</u>	<u>003</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090177</u>	<u>004</u>	Oct 20, 2008
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A090177</u>	<u>005</u>	Oct 20, 2008
<u>AA</u>		<u>650MG; 10MG</u>	<u>A090177</u>	<u>006</u>	Oct 20, 2008
<u>AA</u>	MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040545</u>	<u>001</u>	Jun 30, 2004
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040545</u>	<u>002</u>	Jun 30, 2004
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040550</u>	<u>001</u>	Jun 30, 2004
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040550</u>	<u>002</u>	Jun 30, 2004
<u>AA</u>	VINTAGE PHARMS	<u>325MG; 5MG</u>	<u>A040105</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	WATSON LABS	<u>325MG; 5MG</u>	<u>A040171</u>	<u>001</u>	Oct 30, 1997
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040535</u>	<u>001</u>	Sep 05, 2003
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040535</u>	<u>002</u>	Sep 05, 2003
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040371</u>	<u>001</u>	Dec 29, 2000
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040371</u>	<u>002</u>	Dec 29, 2000

PERCOCET

<u>AA</u>	+ ENDO PHARMS	<u>325MG; 2.5MG</u>	<u>A040330</u>	<u>001</u>	Jun 25, 1999
<u>AA</u>	+	<u>325MG; 5MG</u>	<u>A040330</u>	<u>002</u>	Jun 25, 1999
<u>AA</u>	+	<u>325MG; 7.5MG</u>	<u>A040434</u>	<u>001</u>	Nov 23, 2001
<u>AA</u>	+	<u>325MG; 10MG</u>	<u>A040434</u>	<u>002</u>	Nov 23, 2001
<u>AA</u>	+	<u>500MG; 7.5MG</u>	<u>A040341</u>	<u>001</u>	Jul 26, 1999
<u>AA</u>	+	<u>650MG; 10MG</u>	<u>A040341</u>	<u>002</u>	Jul 26, 1999

ROXICET

<u>AA</u>	ROXANE	<u>325MG; 5MG</u>	<u>A087003</u>	<u>001</u>	
	OXYCODONE AND ACETAMINOPHEN				
	+ MIKART	<u>300MG; 2.5MG</u>	A040608	001	Dec 30, 2005
	+	<u>300MG; 5MG</u>	A040608	002	Dec 30, 2005
	+	<u>300MG; 7.5MG</u>	A040608	003	Dec 30, 2005
	+	<u>300MG; 10MG</u>	A040608	004	Dec 30, 2005
	+	<u>400MG; 2.5MG</u>	A040679	001	May 16, 2006
	+	<u>400MG; 5MG</u>	A040687	001	Apr 27, 2006
	+	<u>400MG; 7.5MG</u>	A040698	001	Apr 27, 2006
	+	<u>400MG; 10MG</u>	A040692	001	Apr 27, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 7 (of 409)

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

MIKART 500MG;10MG

A040676 001 Apr 19, 2006

ROXICET 5/500

+ ROXANE 500MG;5MG

A089775 001 Jan 12, 1989

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDEAB GAVIS PHARMS 650MG;EQ 25MG BASEA076202 001 Aug 02, 2002AB + WATSON LABS 650MG;EQ 25MG BASEA074699 001 Mar 24, 2000ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHENAA + MYLAN 650MG;65MGA083978 001AA VINTAGE PHARMS 650MG;65MGA040507 001 Jul 30, 2003ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100AB + XANODYNE PHARM 650MG;100MGN017122 002DARVOCET-N 50AB XANODYNE PHARM 325MG;50MGN017122 001PROPOXYPHENE NAPSYLATE AND ACETAMINOPHENAB CONCORD LABS NJ 650MG;100MGA077821 001 Feb 11, 2008AB CORNERSTONE 500MG;100MGA076750 001 Jun 28, 2004AB MYLAN 650MG;100MGA070145 001 Jun 12, 1985AB TEVA 650MG;100MGA074119 001 Dec 19, 1994AB VINTAGE PHARMS 325MG;50MGA074843 002 Feb 15, 2001AB 650MG;100MGA074843 001 Feb 12, 1997AB WOCKHARDT 325MG;50MGA077677 001 Mar 16, 2007AB 650MG;100MGA077677 002 Mar 16, 2007

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

CORNERSTONE 325MG;100MG

A076743 001 May 07, 2004

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHENAB AMNEAL PHARMS 325MG;37.5MGA090485 001 Dec 09, 2009AB CARACO 325MG;37.5MGA077184 001 Dec 16, 2005AB MYLAN 325MG;37.5MGA077858 001 Sep 26, 2008AB PAR PHARM 325MG;37.5MGA076475 001 Apr 21, 2005AB WATSON LABS 325MG;37.5MGA076914 001 Jul 26, 2006ULTRACETAB + ORTHO MCNEIL JANSSEN 325MG;37.5MGN021123 001 Aug 15, 2001ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDEAB ZYDUS PHARMS USA INC 500MGA040904 001 Dec 10, 2008DIAMOXAB + DURAMED PHARMS BARR 500MGN012945 001

TABLET; ORAL

ACETAZOLAMIDEAB LANNETT 250MGA084840 001AB MUTUAL PHARM 125MGA089752 001 Jun 22, 1988AB TARO 125MGA040195 001 May 28, 1997

PRESCRIPTION DRUG PRODUCT LIST

3 - 8 (of 409)

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

<u>AB</u>	+ TARO	<u>250MG</u>	<u>A040195</u>	<u>002</u>	May 28, 1997
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A088882</u>	<u>001</u>	Oct 22, 1985

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

<u>AP</u>	BEDFORD	<u>EQ 500MG BASE/VIAL</u>	<u>A040089</u>	<u>001</u>	Feb 28, 1995
<u>AP</u>	X GEN PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040784</u>	<u>001</u>	Dec 10, 2008

DIAMOX

<u>AP</u>	+ DURAMED PHARMS BARR	<u>EQ 500MG BASE/VIAL</u>	<u>N009388</u>	<u>001</u>	Dec 05, 1990

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>250MG/100ML</u>	<u>N018161</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>250MG/100ML</u>	<u>N018523</u>	<u>001</u>	Feb 19, 1982
<u>AT</u>	HOSPIRA	<u>250MG/100ML</u>	<u>N017656</u>	<u>001</u>	

SOLUTION/DROPS; OTIC

ACETASOL

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>2%</u>	<u>A087146</u>	<u>001</u>	

ACETIC ACID

<u>AT</u>	TARO	<u>2%</u>	<u>A088638</u>	<u>001</u>	Sep 06, 1984
<u>AT</u>	VINTAGE	<u>2%</u>	<u>A040607</u>	<u>001</u>	Feb 24, 2005
<u>AT</u>	+ WOCKHARDT	<u>2%</u>	<u>A040166</u>	<u>001</u>	Jul 26, 1996

VOSOL

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>N012179</u>	<u>001</u>	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

	+ BAUSCH AND LOMB	2%; 0.79%	A040063	001	Feb 25, 1994

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>2%; 1%</u>	<u>A087143</u>	<u>001</u>	Jan 13, 1982

HYDROCORTISONE AND ACETIC ACID

<u>AT</u>	TARO	<u>2%; 1%</u>	<u>A088759</u>	<u>001</u>	Mar 04, 1985
<u>AT</u>	VINTAGE	<u>2%; 1%</u>	<u>A040609</u>	<u>001</u>	Feb 06, 2006

VOSOL HC

<u>AT</u>	+ HI TECH PHARMA	<u>2%; 1%</u>	<u>N012770</u>	<u>001</u>	

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

	WATSON LABS	250MG	A071893	001	Nov 25, 1987
	+	500MG	A071894	001	Nov 25, 1987

ACETOHYDROXAMIC ACID

TABLET; ORAL

LITHOSTAT

	+ MISSION PHARMA	250MG	N018749	001	May 31, 1983

PRESCRIPTION DRUG PRODUCT LIST

3 - 9 (of 409)

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC
MIOCHOL-E

+ NOVARTIS	20MG/VIAL	N020213 001	Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS
ACETADOTE

+ CUMBERLAND PHARMS	6GM/30ML (200MG/ML)	N021539 001	Jan 23, 2004

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

<u>AN</u>	BEDFORD	<u>10%</u>	<u>A072323</u>	<u>001</u>	Apr 30, 1992
<u>AN</u>		<u>20%</u>	<u>A072324</u>	<u>001</u>	Apr 30, 1992
<u>AN</u>	HOSPIRA	<u>10%</u>	<u>A073664</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>		<u>20%</u>	<u>A074037</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>	+ LUITPOLD	<u>10%</u>	<u>A072489</u>	<u>001</u>	Jul 28, 1995
<u>AN</u>	+	<u>20%</u>	<u>A072547</u>	<u>001</u>	Jul 28, 1995

ACITRETIN

CAPSULE; ORAL
SORIATANE

STIEFEL LABS INC	10MG	N019821 001	Oct 28, 1996
	17.5MG	N019821 003	Aug 06, 2009
	22.5MG	N019821 004	Aug 06, 2009
+	25MG	N019821 002	Oct 28, 1996

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL
SEMPREX-D

+ UCB INC	8MG;60MG	N019806 001	Mar 25, 1994

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS ELIZABETH	<u>200MG</u>	<u>A074906</u>	<u>001</u>	Aug 26, 1997
<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075677</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>	DAVA PHARMS INC	<u>200MG</u>	<u>A074833</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	GENPHARM	<u>200MG</u>	<u>A074977</u>	<u>001</u>	Apr 13, 1998
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074727</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	RANBAXY	<u>200MG</u>	<u>A074975</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>	STASON	<u>200MG</u>	<u>A075090</u>	<u>001</u>	Jan 26, 1999
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074578</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	WATSON LABS	<u>200MG</u>	<u>A075101</u>	<u>001</u>	Apr 15, 1998

ZOVIRAX

<u>AB</u>	+ GLAXOSMITHKLINE	<u>200MG</u>	<u>N018828</u>	<u>001</u>	Jan 25, 1985

CREAM; TOPICAL

ZOVIRAX

+ GLAXOSMITHKLINE	5%	N021478 001	Dec 30, 2002

OINTMENT; TOPICAL

ZOVIRAX

+ GLAXOSMITHKLINE	5%	N018604 001	Mar 29, 1982

SUSPENSION; ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>200MG/5ML</u>	<u>A074738</u>	<u>001</u>	Apr 28, 1997
<u>AB</u>	HI TECH PHARMA	<u>200MG/5ML</u>	<u>A077026</u>	<u>001</u>	Jun 07, 2005

ZOVIRAX

<u>AB</u>	+ GLAXOSMITHKLINE	<u>200MG/5ML</u>	<u>N019909</u>	<u>001</u>	Dec 22, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 10 (of 409)

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS ELIZABETH	<u>400MG</u>	<u>A074870</u>	<u>001</u>	Jun 05, 1997
<u>AB</u>		<u>800MG</u>	<u>A074870</u>	<u>002</u>	Jun 05, 1997
<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A077309</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A077309</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	CARLSBAD	<u>400MG</u>	<u>A075382</u>	<u>001</u>	Apr 30, 1999
<u>AB</u>		<u>800MG</u>	<u>A075382</u>	<u>002</u>	Apr 30, 1999
<u>AB</u>	DAVA PHARMS INC	<u>400MG</u>	<u>A074946</u>	<u>001</u>	Nov 19, 1997
<u>AB</u>		<u>800MG</u>	<u>A074946</u>	<u>002</u>	Nov 19, 1997
<u>AB</u>	GENPHARM	<u>400MG</u>	<u>A074976</u>	<u>001</u>	Apr 13, 1998
<u>AB</u>		<u>800MG</u>	<u>A074976</u>	<u>002</u>	Apr 13, 1998
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075211</u>	<u>001</u>	Sep 28, 1998
<u>AB</u>		<u>800MG</u>	<u>A075211</u>	<u>002</u>	Sep 28, 1998
<u>AB</u>	RANBAXY	<u>400MG</u>	<u>A074980</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>800MG</u>	<u>A074980</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	TEVA	<u>400MG</u>	<u>A074556</u>	<u>002</u>	Apr 22, 1997
<u>AB</u>		<u>800MG</u>	<u>A074556</u>	<u>003</u>	Apr 22, 1997

ZOVIRAX

<u>AB</u>	GLAXOSMITHKLINE	<u>400MG</u>	<u>N020089</u>	<u>001</u>	Apr 30, 1991
<u>AB</u>	+	<u>800MG</u>	<u>N020089</u>	<u>002</u>	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

<u>AP</u>	+	APP PHARMS	<u>EQ 50MG BASE/ML</u>	<u>A074930</u>	<u>001</u>	May 13, 1998
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A075015</u>	<u>001</u>	Apr 30, 1998
<u>AP</u>		BAXTER HLTHCARE	<u>EQ 500MG BASE/VIAL</u>	<u>A074913</u>	<u>001</u>	Oct 15, 1997
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A074913</u>	<u>002</u>	Oct 15, 1997
<u>AP</u>		BEDFORD	<u>EQ 500MG BASE/VIAL</u>	<u>A074596</u>	<u>002</u>	Apr 22, 1997
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A074596</u>	<u>001</u>	Apr 22, 1997
<u>AP</u>		HOSPIRA	<u>EQ 50MG BASE/ML</u>	<u>A075065</u>	<u>001</u>	Feb 25, 1999
<u>AP</u>		TEVA PARENTERAL	<u>EQ 50MG BASE/ML</u>	<u>A075627</u>	<u>001</u>	Mar 28, 2001
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A074969</u>	<u>001</u>	Aug 26, 1997
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A074969</u>	<u>002</u>	Aug 26, 1997

ZOVIRAX

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 500MG BASE/VIAL</u>	<u>N018603</u>	<u>001</u>	Oct 22, 1982
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>N018603</u>	<u>002</u>	Jun 29, 1989
		ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE				
	+	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997
			EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997
		ACYCLOVIR SODIUM				
	+	HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

ACYCLOVIR AND HYDROCORTISONE

	+	MEDA PHARMS	5%;1%	N022436	001	Jul 31, 2009

ADAPALENE

CREAM; TOPICAL

ADAPALENE

<u>AB</u>		NYCOMED US	<u>0.1%</u>	<u>A090824</u>	<u>001</u>	Jun 30, 2010
<u>AB</u>	+	GALDERMA LABS LP	<u>0.1%</u>	<u>N020748</u>	<u>001</u>	May 26, 2000

GEL; TOPICAL

ADAPALENE

<u>AB</u>		GLENMARK GENERICS	<u>0.1%</u>	<u>A091314</u>	<u>001</u>	Jul 01, 2010
<u>AB</u>		PLIVA HRVATSKA DOO	<u>0.1%</u>	<u>A090962</u>	<u>001</u>	Jun 02, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 11 (of 409)

ADAPALENE

GEL; TOPICAL				
<u>DIFFERIN</u>				
<u>AB</u>	+	GALDERMA LABS LP	<u>0.1%</u>	<u>N020380</u> <u>001</u> May 31, 1996
DIFFERIN				
	+	GALDERMA LABS LP	0.3%	N021753 001 Jun 19, 2007
LOTION; TOPICAL				
DIFFERIN				
	+	GALDERMA R AND D	0.1%	N022502 001 Mar 17, 2010

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL				
EPIDUO				
	+	GALDERMA LABS	0.1%;2.5%	N022320 001 Dec 08, 2008

ADEFOVIR DIPIVOXIL

TABLET; ORAL				
HEPSERA				
	+	GILEAD	10MG	N021449 001 Sep 20, 2002

ADENOSINE

INJECTABLE; INJECTION				
<u>ADENOCARD</u>				
<u>AP</u>	+	ASTELLAS	<u>3MG/ML</u>	<u>N019937</u> <u>002</u> Oct 30, 1989
<u>ADENOSINE</u>				
<u>AP</u>		AKORN	<u>3MG/ML</u>	<u>A078076</u> <u>001</u> Oct 31, 2008
<u>AP</u>		APP PHARMS	<u>3MG/ML</u>	<u>A077133</u> <u>001</u> Apr 27, 2005
<u>AP</u>		BAXTER HLTHCARE	<u>3MG/ML</u>	<u>A076500</u> <u>001</u> Jun 16, 2004
<u>AP</u>			<u>3MG/ML</u>	<u>A076501</u> <u>001</u> Jun 16, 2004
<u>AP</u>		BEDFORD	<u>3MG/ML</u>	<u>A076404</u> <u>001</u> Jun 16, 2004
<u>AP</u>		GLAND PHARMA LTD	<u>3MG/ML</u>	<u>A077283</u> <u>001</u> Jun 14, 2007
<u>AP</u>		LUITPOLD	<u>3MG/ML</u>	<u>A090010</u> <u>001</u> Apr 28, 2009
<u>AP</u>		STRIDES ARCOLAB LTD	<u>3MG/ML</u>	<u>A078686</u> <u>001</u> May 13, 2009
<u>AP</u>		TEVA PARENTERAL	<u>3MG/ML</u>	<u>A076564</u> <u>001</u> Jun 16, 2004
<u>AP</u>			<u>3MG/ML</u>	<u>A078676</u> <u>001</u> Jul 31, 2008
<u>AP</u>		WOCKHARDT	<u>3MG/ML</u>	<u>A090220</u> <u>001</u> Jul 20, 2009
ADENOSCAN				
	+	ASTELLAS	3MG/ML	N020059 001 May 18, 1995

ALBENDAZOLE

TABLET; ORAL				
ALBENZA				
	+	GLAXOSMITHKLINE LLC	200MG	N020666 001 Jun 11, 1996

ALBUMIN HUMAN

INJECTABLE; INJECTION				
OPTISON				
	+	GE HEALTHCARE	10MG/ML	N020899 001 Dec 31, 1997

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION				
JEANATOPE				
		ISO TEX	100UCI/10ML (10UCI/ML)	N017836 003 Jun 08, 2004
			500uCi/0.5ML	N017836 001
	+		1,000uCi/ML	N017836 002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 12 (of 409)

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

+	ISO TEX	0.5mCi/VIAL	N017837	001
+		1mCi/VIAL	N017837	002

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

BX	+	TEVA GLOBAL	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004

PROVENTIL-HFA

BX	+	3M	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996

VENTOLIN HFA

BX	+	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001

SOLUTION; INHALATION

ACCUNEB

AN	+	DEY	EQ 0.021% BASE	N020949	002	Apr 30, 2001

AN	+		EQ 0.042% BASE	N020949	001	Apr 30, 2001

ALBUTEROL SULFATE

AN		ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995

AN		APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010

AN			EQ 0.042% BASE	A078623	002	Apr 05, 2010

AN			EQ 0.083% BASE	A075717	001	Feb 02, 2007

AN	+	BAUSCH AND LOMB	EQ 0.5% BASE	A075050	001	Jun 18, 1998

AN		COBALT LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003

AN	+	DEY	EQ 0.083% BASE	A072652	001	Feb 21, 1992

AN		HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999

AN			EQ 0.5% BASE	A074543	001	Jan 15, 1998

AN		HOLOPACK INTL	EQ 0.083% BASE	A077839	001	Dec 16, 2008

AN		LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006

AN		NEPHRON	EQ 0.021% BASE	A076355	002	Mar 31, 2010

AN			EQ 0.042% BASE	A076355	001	Jun 28, 2004

AN			EQ 0.083% BASE	A074880	001	Sep 17, 1997

AN			EQ 0.5% BASE	A075664	001	Jun 26, 2001

AN		NOVEX	EQ 0.5% BASE	A076391	001	Apr 01, 2003

AN		TEVA PARENTERAL	EQ 0.083% BASE	A075343	001	Nov 09, 1999

AN		WATSON LABS	EQ 0.021% BASE	A077772	001	Sep 25, 2007

AN			EQ 0.042% BASE	A077772	002	Sep 25, 2007

AN		WOCKHARDT	EQ 0.083% BASE	A075394	001	Nov 22, 1999

SYRUP; ORAL

ALBUTEROL SULFATE

AA		ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995

AA		AMNEAL PHARMS	EQ 2MG BASE/5ML	A079241	001	May 12, 2010

AA		HI TECH PHARMA	EQ 2MG BASE/5ML	A074749	001	Jan 30, 1998

AA	+	TEVA	EQ 2MG BASE/5ML	A073419	001	Mar 30, 1992

AA		VINTAGE	EQ 2MG BASE/5ML	A078105	001	Dec 27, 2006

AA		VISTAPHARM	EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATE

AB		MUTUAL PHARM	EQ 2MG BASE	A072637	002	Dec 05, 1989

AB			EQ 4MG BASE	A072637	001	Dec 05, 1989

AB		MYLAN	EQ 2MG BASE	A072894	002	Jan 17, 1991

AB	+		EQ 4MG BASE	A072894	001	Jan 17, 1991

AB		WATSON LABS	EQ 2MG BASE	A072764	001	Aug 28, 1991

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

AB		MYLAN	EQ 4MG BASE	A078092	002	Jan 29, 2007

AB			EQ 8MG BASE	A078092	001	Jan 29, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 13 (of 409)

ALBUTEROL SULFATE

TABLET, EXTENDED RELEASE; ORAL

VOSPIRE ER

<u>AB</u>	DAVA PHARMS INC	<u>EQ 4MG BASE</u>	<u>A076130</u>	<u>002</u>	Sep 26, 2002
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>A076130</u>	<u>003</u>	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

+	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

<u>AN</u>	APOTEX CORP	<u>EQ 0.083% BASE;0.017%</u>	<u>A077117</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	NEPHRON	<u>EQ 0.083% BASE;0.017%</u>	<u>A076749</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	SANDOZ	<u>EQ 0.083% BASE;0.017%</u>	<u>A076867</u>	<u>001</u>	Dec 21, 2006
<u>AN</u>	TEVA PARENTERAL	<u>EQ 0.083% BASE;0.017%</u>	<u>A076724</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	WATSON LABS	<u>EQ 0.083% BASE;0.017%</u>	<u>A077063</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>		<u>EQ 0.083% BASE;0.017%</u>	<u>A077559</u>	<u>001</u>	Dec 31, 2007
	<u>DUONEB</u>				
<u>AN</u>	+ DEY	<u>EQ 0.083% BASE;0.017%</u>	<u>N020950</u>	<u>001</u>	Mar 21, 2001

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

+	VISTAKON PHARMS LLC	0.25%	N022134	001	Jul 28, 2010

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

<u>AB</u>	+	NYCOMED US	<u>0.05%</u>	<u>N018707</u>	<u>001</u>	Dec 14, 1982
		<u>ALCLOMETASONE DIPROPIONATE</u>				
<u>AB</u>		ALTANA	<u>0.05%</u>	<u>A076973</u>	<u>001</u>	Jul 12, 2005
<u>AB</u>		GLENMARK GENERICS	<u>0.05%</u>	<u>A079061</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>		TARO	<u>0.05%</u>	<u>A076587</u>	<u>001</u>	Sep 15, 2005

OINTMENT; TOPICAL

ACLOVATE

<u>AB</u>	+	GLAXOSMITHKLINE	<u>0.05%</u>	<u>N018702</u>	<u>001</u>	Dec 14, 1982
		<u>ALCLOMETASONE DIPROPIONATE</u>				
<u>AB</u>		ALTANA	<u>0.05%</u>	<u>A076884</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>		GLENMARK GENERICS	<u>0.05%</u>	<u>A079227</u>	<u>001</u>	Jul 30, 2009
<u>AB</u>		TARO	<u>0.05%</u>	<u>A076730</u>	<u>001</u>	Jul 29, 2004

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% AND DEXTROSE 5%

<u>AP</u>	+	B BRAUN	<u>5ML/100ML;5GM/100ML</u>	<u>N004589</u>	<u>004</u>	
		<u>ALCOHOL 5% IN D5-W</u>				
<u>AP</u>		HOSPIRA	<u>5ML/100ML;5GM/100ML</u>	<u>A083263</u>	<u>001</u>	
		ALCOHOL 10% AND DEXTROSE 5%				
	+	B BRAUN	10ML/100ML;5GM/100ML	N004589	006	

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

+	MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>	APOTEX	<u>EQ 5MG BASE</u>	<u>A077982</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077982</u>	<u>002</u>	Aug 04, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 14 (of 409)

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>	APOTEX	<u>EQ 35MG BASE</u>	<u>A077982</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A077982</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A090124</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090124</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090124</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 5MG BASE</u>	<u>A090258</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090258</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090258</u>	<u>003</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090258</u>	<u>004</u>	Sep 24, 2009
<u>AB</u>	CADISTA PHARMS	<u>EQ 5MG BASE</u>	<u>A090557</u>	<u>001</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090557</u>	<u>002</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090557</u>	<u>003</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090557</u>	<u>004</u>	Feb 18, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 5MG BASE</u>	<u>A079109</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079109</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A079049</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A079049</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>	GENPHARM ULC	<u>EQ 35MG BASE</u>	<u>A078638</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A078638</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076584</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076584</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076584</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076584</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A075871</u>	<u>001</u>	Apr 22, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075871</u>	<u>002</u>	Apr 22, 2009
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A075871</u>	<u>004</u>	Apr 22, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075871</u>	<u>003</u>	Apr 22, 2009
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075871</u>	<u>005</u>	Apr 22, 2009
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A090022</u>	<u>001</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090022</u>	<u>002</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022</u>	<u>003</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022</u>	<u>004</u>	Sep 10, 2008
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A075710</u>	<u>001</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075710</u>	<u>002</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A075710</u>	<u>003</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075710</u>	<u>004</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075710</u>	<u>005</u>	Feb 06, 2008
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A076768</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076768</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076768</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076984</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076768</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076768</u>	<u>005</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984</u>	<u>003</u>	Aug 04, 2008
<u>FOSAMAX</u>					
<u>AB</u>	MERCK AND CO INC	<u>EQ 5MG BASE</u>	<u>N020560</u>	<u>003</u>	Apr 25, 1997
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N020560</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>N020560</u>	<u>004</u>	Oct 20, 2000
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>N020560</u>	<u>002</u>	Sep 29, 1995
<u>AB</u>	+	<u>EQ 70MG BASE</u>	<u>N020560</u>	<u>005</u>	Oct 20, 2000

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCK

+

EQ 70MG BASE;2,800 IU

EQ 70MG BASE;5,600 IU

N021762 001 Apr 07, 2005

N021762 002 Apr 26, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 15 (of 409)

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

<u>AP</u>	+	AKORN	<u>EQ 0.5MG BASE/ML</u>	<u>N019353</u>	<u>001</u>	Dec 29, 1986

ALFENTANIL

<u>AP</u>		HOSPIRA	<u>EQ 0.5MG BASE/ML</u>	<u>A075221</u>	<u>001</u>	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

+	SANOFI AVENTIS US	10MG		N021287	001	Jun 12, 2003

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

+	GENZYME	80 UNITS/ML		N020057	003	Apr 05, 1991

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

	NOVARTIS	EQ 150MG BASE		N021985	001	Mar 05, 2007

+		EQ 300MG BASE		N021985	002	Mar 05, 2007

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE		N022545	001	Aug 26, 2010

		EQ 150MG BASE;EQ 10MG BASE		N022545	002	Aug 26, 2010

		EQ 300MG BASE;EQ 5MG BASE		N022545	003	Aug 26, 2010

+		EQ 300MG BASE;EQ 10MG BASE		N022545	004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG		N200045	001	Dec 21, 2010

		EQ 300MG BASE;EQ 5MG BASE;12.5MG		N200045	002	Dec 21, 2010

		EQ 300MG BASE;EQ 5MG BASE;25MG		N200045	003	Dec 21, 2010

		EQ 300MG BASE;EQ 10MG BASE;12.5MG		N200045	004	Dec 21, 2010

+		EQ 300MG BASE;EQ 10MG BASE;25MG		N200045	005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

	NOVARTIS	EQ 150MG BASE;12.5MG		N022107	001	Jan 18, 2008

		EQ 150MG BASE;25MG		N022107	002	Jan 18, 2008

+		EQ 300MG BASE;12.5MG		N022107	003	Jan 18, 2008

+		EQ 300MG BASE;25MG		N022107	004	Jan 18, 2008

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

	NOVARTIS	EQ 150MG BASE;160MG		N022217	001	Sep 16, 2009

+		EQ 300MG BASE;320MG		N022217	002	Sep 16, 2009

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+	EISAI INC	EQ 0.1% BASE		N020886	001	Feb 02, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 16 (of 409)

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077353</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>300MG</u>	<u>A077353</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>	CARACO	<u>100MG</u>	<u>A078390</u>	<u>001</u>	Aug 30, 2007
<u>AB</u>		<u>300MG</u>	<u>A078390</u>	<u>002</u>	Aug 30, 2007
<u>AB</u>	MUTUAL PHARM	<u>100MG</u>	<u>A071449</u>	<u>001</u>	Jan 09, 1987
<u>AB</u>		<u>300MG</u>	<u>A071450</u>	<u>001</u>	Jan 09, 1987
<u>AB</u>	MYLAN	<u>100MG</u>	<u>N018659</u>	<u>001</u>	Oct 24, 1986
<u>AB</u>		<u>300MG</u>	<u>N018659</u>	<u>002</u>	Oct 24, 1986
<u>AB</u>	NORTHSTAR HLTHCARE	<u>100MG</u>	<u>A078253</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078253</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>	VINTAGE PHARMS	<u>100MG</u>	<u>A075798</u>	<u>001</u>	Jun 27, 2003
<u>AB</u>		<u>300MG</u>	<u>A075798</u>	<u>002</u>	Jun 27, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>N018832</u>	<u>002</u>	Sep 28, 1984
<u>AB</u>		<u>300MG</u>	<u>N018877</u>	<u>001</u>	Sep 28, 1984
<u>LOPURIN</u>					
<u>AB</u>	DR REDDYS LA	<u>100MG</u>	<u>A071586</u>	<u>001</u>	Apr 02, 1987
<u>AB</u>		<u>300MG</u>	<u>A071587</u>	<u>001</u>	Apr 02, 1987
<u>ZYLOPRIM</u>					
<u>AB</u>	PROMETHEUS LABS	<u>100MG</u>	<u>N016084</u>	<u>001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>N016084</u>	<u>002</u>	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

<u>AP</u>	BEDFORD LABS	<u>EQ 500MG BASE/VIAL</u>	<u>A076870</u>	<u>001</u>	Aug 26, 2004
<u>ALOPRIM</u>					
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N020298</u>	<u>001</u>	May 17, 1996

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

	ORTHO MCNEIL JANSSEN	EQ 6.25MG BASE	N021001	001	May 07, 2001
+		EQ 12.5MG BASE	N021001	002	May 07, 2001

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

	PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003
+		EQ 1MG BASE	N021107	001	Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000

INJECTABLE; IV (INFUSION)

+	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 17 (of 409)

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

+ ROXANE	1MG/ML	A074312	001	Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

<u>AB</u> ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A074342</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	<u>0.5MG</u>	<u>A074342</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>	<u>1MG</u>	<u>A074342</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>	<u>2MG</u>	<u>A074342</u>	<u>004</u>	Oct 31, 1993
<u>AB</u> ALPHAPHARM	<u>0.25MG</u>	<u>A074046</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>	<u>0.5MG</u>	<u>A074046</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>	<u>1MG</u>	<u>A074046</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>	<u>2MG</u>	<u>A074046</u>	<u>004</u>	May 07, 1997
<u>AB</u> APOTEX INC	<u>0.25MG</u>	<u>A077741</u>	<u>001</u>	Jan 19, 2007
<u>AB</u>	<u>0.5MG</u>	<u>A077741</u>	<u>002</u>	Jan 19, 2007
<u>AB</u>	<u>1MG</u>	<u>A077741</u>	<u>003</u>	Jan 19, 2007
<u>AB</u>	<u>2MG</u>	<u>A077741</u>	<u>004</u>	Jan 19, 2007
<u>AB</u> BOCA PHARMA	<u>0.25MG</u>	<u>A090248</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>	<u>0.5MG</u>	<u>A090248</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>	<u>1MG</u>	<u>A090248</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>	<u>2MG</u>	<u>A090248</u>	<u>004</u>	Sep 17, 2010
<u>AB</u> DAVA INTL INC	<u>0.25MG</u>	<u>A074174</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>	<u>0.5MG</u>	<u>A074174</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>	<u>1MG</u>	<u>A074174</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>	<u>2MG</u>	<u>A074174</u>	<u>004</u>	Oct 19, 1993
<u>AB</u> MYLAN	<u>0.25MG</u>	<u>A074215</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>	<u>0.5MG</u>	<u>A074215</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>	<u>1MG</u>	<u>A074215</u>	<u>003</u>	Jan 27, 1994
<u>AB</u>	<u>2MG</u>	<u>A074215</u>	<u>004</u>	Jan 27, 1994
<u>AB</u> SANDOZ	<u>0.25MG</u>	<u>A074112</u>	<u>001</u>	Dec 29, 1995
<u>AB</u>	<u>0.5MG</u>	<u>A074112</u>	<u>002</u>	Dec 29, 1995
<u>AB</u>	<u>1MG</u>	<u>A074112</u>	<u>003</u>	Dec 29, 1995
<u>AB</u>	<u>2MG</u>	<u>A074909</u>	<u>001</u>	Mar 25, 1998
<u>AB</u> SUN PHARMA GLOBAL	<u>0.25MG</u>	<u>A090082</u>	<u>001</u>	Jun 17, 2010
<u>AB</u>	<u>0.5MG</u>	<u>A090082</u>	<u>002</u>	Jun 17, 2010
<u>AB</u>	<u>1MG</u>	<u>A090082</u>	<u>003</u>	Jun 17, 2010
<u>AB</u>	<u>2MG</u>	<u>A090082</u>	<u>004</u>	Jun 17, 2010
<u>AB</u> VINTAGE	<u>0.25MG</u>	<u>A078491</u>	<u>001</u>	Sep 25, 2008
<u>AB</u>	<u>0.5MG</u>	<u>A078491</u>	<u>002</u>	Sep 25, 2008
<u>AB</u>	<u>1MG</u>	<u>A078491</u>	<u>003</u>	Sep 25, 2008
<u>AB</u>	<u>2MG</u>	<u>A078491</u>	<u>004</u>	Dec 12, 2008

XANAX

<u>AB</u> PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276</u>	<u>001</u>	
<u>AB</u>	<u>0.5MG</u>	<u>N018276</u>	<u>002</u>	
<u>AB</u> +	<u>1MG</u>	<u>N018276</u>	<u>003</u>	
<u>AB</u>	<u>2MG</u>	<u>N018276</u>	<u>004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u> ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>	<u>1MG</u>	<u>A078056</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>	<u>2MG</u>	<u>A078056</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>	<u>3MG</u>	<u>A078056</u>	<u>004</u>	Feb 13, 2007
<u>AB</u> AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387</u>	<u>001</u>	May 30, 2008
<u>AB</u>	<u>1MG</u>	<u>A078387</u>	<u>002</u>	May 30, 2008
<u>AB</u>	<u>2MG</u>	<u>A078387</u>	<u>003</u>	May 30, 2008
<u>AB</u>	<u>3MG</u>	<u>A078387</u>	<u>004</u>	May 30, 2008
<u>AB</u> APOTEX INC	<u>0.5MG</u>	<u>A078449</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>	<u>2MG</u>	<u>A078449</u>	<u>002</u>	Nov 12, 2008
<u>AB</u>	<u>3MG</u>	<u>A078449</u>	<u>003</u>	Nov 12, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 18 (of 409)

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	BARR	<u>0.5MG</u>	<u>A077725</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>1MG</u>	<u>A077725</u>	<u>002</u>	Jul 31, 2006
<u>AB</u>		<u>2MG</u>	<u>A077725</u>	<u>004</u>	Jul 31, 2006
<u>AB</u>		<u>3MG</u>	<u>A077725</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	COREPHARMA	<u>0.5MG</u>	<u>A077996</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>1MG</u>	<u>A077996</u>	<u>002</u>	Jan 31, 2007
<u>AB</u>		<u>2MG</u>	<u>A077996</u>	<u>003</u>	Jan 31, 2007
<u>AB</u>		<u>3MG</u>	<u>A077996</u>	<u>004</u>	Jan 31, 2007
<u>AB</u>	IMPAX LABS	<u>0.5MG</u>	<u>A077968</u>	<u>004</u>	May 24, 2007
<u>AB</u>		<u>1MG</u>	<u>A077968</u>	<u>003</u>	May 24, 2007
<u>AB</u>		<u>2MG</u>	<u>A077968</u>	<u>002</u>	May 24, 2007
<u>AB</u>		<u>3MG</u>	<u>A077968</u>	<u>001</u>	May 24, 2007
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A077391</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>1MG</u>	<u>A077391</u>	<u>003</u>	Jan 26, 2006
<u>AB</u>		<u>2MG</u>	<u>A077391</u>	<u>004</u>	Jan 26, 2006
<u>AB</u>		<u>3MG</u>	<u>A077391</u>	<u>001</u>	Jan 26, 2006
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A077777</u>	<u>001</u>	Jun 30, 2006
<u>AB</u>		<u>1MG</u>	<u>A077777</u>	<u>002</u>	Jun 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A077777</u>	<u>003</u>	Jun 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A077777</u>	<u>004</u>	Jun 30, 2006
<u>AB</u>	TEVA PHARMS	<u>0.5MG</u>	<u>A077979</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>1MG</u>	<u>A077979</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		<u>2MG</u>	<u>A077979</u>	<u>003</u>	Feb 28, 2007
<u>AB</u>		<u>3MG</u>	<u>A077979</u>	<u>004</u>	Feb 28, 2007
<u>AB</u>	VINTAGE	<u>0.5MG</u>	<u>A078442</u>	<u>001</u>	Oct 15, 2007
<u>AB</u>		<u>1MG</u>	<u>A078442</u>	<u>002</u>	Oct 15, 2007
<u>AB</u>		<u>2MG</u>	<u>A078442</u>	<u>003</u>	Oct 15, 2007
<u>AB</u>		<u>3MG</u>	<u>A078442</u>	<u>004</u>	Oct 15, 2007
<u>AB</u>	WATSON LABS FLORIDA	<u>0.5MG</u>	<u>A077198</u>	<u>001</u>	May 13, 2010
<u>AB</u>		<u>1MG</u>	<u>A077198</u>	<u>002</u>	May 13, 2010
<u>AB</u>		<u>2MG</u>	<u>A077198</u>	<u>003</u>	May 13, 2010
<u>AB</u>		<u>3MG</u>	<u>A077198</u>	<u>004</u>	May 13, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A078489</u>	<u>001</u>	Oct 17, 2008
<u>AB</u>		<u>1MG</u>	<u>A078489</u>	<u>002</u>	Oct 17, 2008
<u>AB</u>		<u>2MG</u>	<u>A078489</u>	<u>003</u>	Oct 17, 2008
<u>AB</u>		<u>3MG</u>	<u>A078489</u>	<u>004</u>	Oct 17, 2008

XANAX XR

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434</u>	<u>001</u>	Jan 17, 2003
<u>AB</u>		<u>1MG</u>	<u>N021434</u>	<u>002</u>	Jan 17, 2003
<u>AB</u>		<u>2MG</u>	<u>N021434</u>	<u>003</u>	Jan 17, 2003
<u>AB</u>	+	<u>3MG</u>	<u>N021434</u>	<u>004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561</u>	<u>001</u>	Mar 16, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078561</u>	<u>002</u>	Mar 16, 2010
<u>AB</u>		<u>1MG</u>	<u>A078561</u>	<u>003</u>	Mar 16, 2010
<u>AB</u>		<u>2MG</u>	<u>A078561</u>	<u>004</u>	Mar 16, 2010
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A078088</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078088</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>		<u>1MG</u>	<u>A078088</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078088</u>	<u>004</u>	Jan 09, 2009

NIRAVAM

<u>AB</u>	SCHWARZ PHARMA	<u>0.25MG</u>	<u>N021726</u>	<u>001</u>	Jan 19, 2005
<u>AB</u>		<u>0.5MG</u>	<u>N021726</u>	<u>002</u>	Jan 19, 2005
<u>AB</u>	+	<u>1MG</u>	<u>N021726</u>	<u>003</u>	Jan 19, 2005
<u>AB</u>		<u>2MG</u>	<u>N021726</u>	<u>004</u>	Jan 19, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 19 (of 409)

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>	BEDFORD	<u>0.5MG/ML</u>	<u>A074815</u>	<u>001</u>	Jan 20, 1998

<u>AP</u>	TEVA PARENTERAL	<u>0.5MG/ML</u>	<u>A075196</u>	<u>001</u>	Apr 30, 1999

CAVERJECT

<u>AP</u>	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379</u>	<u>001</u>	Jul 06, 1995

<u>AP</u>	+	<u>0.02MG/VIAL</u>	<u>N020379</u>	<u>002</u>	Jul 06, 1995

<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020379</u>	<u>004</u>	May 19, 1997

EDEX

<u>AP</u>	SCHWARZ PHARMA	<u>0.01MG/VIAL</u>	<u>N020649</u>	<u>002</u>	Jun 12, 1997

<u>AP</u>		<u>0.02MG/VIAL</u>	<u>N020649</u>	<u>003</u>	Jun 12, 1997

<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020649</u>	<u>004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.5MG/ML</u>	<u>N018484</u>	<u>001</u>

CAVERJECT

	PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996

CAVERJECT IMPULSE

	PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212	001	Jun 11, 2002

		0.02MG/VIAL	N021212	002	Jun 11, 2002

EDEX

+	SCHWARZ PHARMA	0.01MG/VIAL	N020649	005	Jul 30, 1998

+		0.02MG/VIAL	N020649	006	Jul 30, 1998

+		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY; URETHRAL

MUSE

	VIVUS	0.125MG	N020700	001	Nov 19, 1996

		0.25MG	N020700	002	Nov 19, 1996

		0.5MG	N020700	003	Nov 19, 1996

+		1MG	N020700	004	Nov 19, 1996

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

+	EISAI INC	50MG	N019926	001	Dec 26, 1990

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+	ADOLOR	12MG	N021775	001	May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>100MG</u>	<u>A077659</u>	<u>001</u>	Feb 23, 2006

<u>AB</u>	BANNER PHARMACAPS	<u>100MG</u>	<u>A078720</u>	<u>001</u>	May 29, 2008

<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A071293</u>	<u>001</u>	Feb 18, 1987

<u>AB</u>	+	USL PHARMA	<u>100MG</u>	<u>A070589</u>	<u>001</u>	Aug 05, 1986

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

<u>AA</u>	+	CAROLINA MEDCL	<u>50MG/5ML</u>	<u>A075819</u>	<u>001</u>	Sep 11, 2002

<u>AA</u>	+	HI TECH PHARMA	<u>50MG/5ML</u>	<u>A074170</u>	<u>001</u>	Oct 28, 1994

<u>AA</u>	+	MIKART	<u>50MG/5ML</u>	<u>A074028</u>	<u>001</u>	Jun 28, 1993

<u>AA</u>	+	PHARM ASSOC	<u>50MG/5ML</u>	<u>A074509</u>	<u>001</u>	Jul 17, 1995

<u>AA</u>	+	SILARX	<u>50MG/5ML</u>	<u>A076352</u>	<u>001</u>	Sep 10, 2004

<u>AA</u>	+	VINTAGE	<u>50MG/5ML</u>	<u>A077992</u>	<u>001</u>	Dec 12, 2006

<u>AA</u>	+	WOCKHARDT	<u>50MG/5ML</u>	<u>A075060</u>	<u>001</u>	Dec 24, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 20 (of 409)

AMANTADINE HYDROCHLORIDE

TABLET; ORAL				
AMANTADINE HYDROCHLORIDE				
+	USL PHARMA	100MG	A076186 001	Dec 16, 2002

AMBENONIUM CHLORIDE

TABLET; ORAL				
MYTELASE				
+	SANOFI AVENTIS US	10MG	N010155 002	

AMBRISENTAN

TABLET; ORAL				
LETAIRIS				
	GILEAD	5MG	N022081 001	Jun 15, 2007
+		10MG	N022081 002	Jun 15, 2007

AMCINONIDE

CREAM; TOPICAL				
<u>AMCINONIDE</u>				
<u>AB</u>	+	ALTANA	<u>0.1%</u>	<u>A076065</u> <u>001</u> May 15, 2003
<u>AB</u>		TARO PHARM INDS	<u>0.1%</u>	<u>A076229</u> <u>001</u> May 31, 2002

LOTION; TOPICAL				
AMCINONIDE				
+	ALTANA	0.1%	A076329 001	Nov 06, 2002

OINTMENT; TOPICAL				
<u>AMCINONIDE</u>				
<u>AB</u>	+	ALTANA	<u>0.1%</u>	<u>A076096</u> <u>001</u> Nov 19, 2002
<u>AB</u>		TARO PHARM INDS	<u>0.1%</u>	<u>A076367</u> <u>001</u> Mar 19, 2003

AMIFOSTINE

INJECTABLE; INJECTION				
<u>AMIFOSTINE</u>				
<u>AP</u>		SUN PHARMA GLOBAL	<u>500MG/VIAL</u>	<u>A077126</u> <u>001</u> Mar 14, 2008
<u>ETHYOL</u>				
<u>AP</u>	+	MEDIMMUNE	<u>500MG/VIAL</u>	<u>N020221</u> <u>001</u> Dec 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION				
<u>AMIKACIN SULFATE</u>				
<u>AP</u>	+	BEDFORD	<u>EQ 50MG BASE/ML</u>	<u>A063313</u> <u>001</u> Apr 11, 1994
<u>AP</u>	+		<u>EQ 250MG BASE/ML</u>	<u>A063315</u> <u>001</u> Apr 11, 1994
<u>AP</u>		HOSPIRA	<u>EQ 50MG BASE/ML</u>	<u>A063263</u> <u>001</u> Nov 30, 1994
<u>AP</u>			<u>EQ 250MG BASE/ML</u>	<u>A063264</u> <u>001</u> Nov 30, 1994
<u>AP</u>		TEVA PARENTERAL	<u>EQ 250MG BASE/ML</u>	<u>A064045</u> <u>002</u> Sep 28, 1993
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	HOSPIRA	EQ 500MG BASE/100ML	A064146 001	Apr 02, 1997

AMILORIDE HYDROCHLORIDE

TABLET; ORAL				
<u>AMILORIDE HYDROCHLORIDE</u>				
<u>AB</u>	+	PAR PHARM	<u>5MG</u>	<u>A070346</u> <u>001</u> Jan 22, 1986
<u>AB</u>		SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A079133</u> <u>001</u> Jan 30, 2009
<u>MIDAMOR</u>				
<u>AB</u>		PADDOCK LABS	<u>5MG</u>	<u>N018200</u> <u>001</u>

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL				
<u>AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>		BARR	<u>EQ 5MG ANHYDROUS;50MG</u>	<u>A071111</u> <u>001</u> May 10, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 21 (of 409)

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u> + MYLAN	<u>EQ 5MG ANHYDROUS;50MG</u>	<u>A073209</u> <u>001</u>	Oct 31, 1991

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 10%

HOSPIRA

10% (10GM/100ML)

N017673 003

AMINOSYN 10% (PH6)

HOSPIRA

10% (10GM/100ML)

N017673 008

Nov 18, 1985

AMINOSYN 3.5%

HOSPIRA

3.5% (3.5GM/100ML)

N017789 004

AMINOSYN 5%

HOSPIRA

5% (5GM/100ML)

N017673 001

AMINOSYN 7%

HOSPIRA

7% (7GM/100ML)

N017673 002

AMINOSYN 7% (PH6)

HOSPIRA

7% (7GM/100ML)

N017673 006

Nov 18, 1985

AMINOSYN 8.5%

HOSPIRA

8.5% (8.5GM/100ML)

N017673 004

AMINOSYN 8.5% (PH6)

HOSPIRA

8.5% (8.5GM/100ML)

N017673 007

Nov 18, 1985

AMINOSYN II 10%

HOSPIRA

10% (10GM/100ML)

N019438 005

Apr 03, 1986

AMINOSYN II 10% IN PLASTIC CONTAINER

HOSPIRA

10% (10GM/100ML)

N020015 001

Dec 19, 1991

AMINOSYN II 15% IN PLASTIC CONTAINER

HOSPIRA

15% (15GM/100ML)

N020041 001

Dec 19, 1991

AMINOSYN II 7%

HOSPIRA

7% (7GM/100ML)

N019438 003

Apr 03, 1986

AMINOSYN II 8.5%

HOSPIRA

8.5% (8.5GM/100ML)

N019438 004

Apr 03, 1986

AMINOSYN-HBC 7%

HOSPIRA

7% (7GM/100ML)

N019374 001

Jul 12, 1985

AMINOSYN-HF 8%

HOSPIRA

8% (8GM/100ML)

N020345 001

Apr 04, 1996

AMINOSYN-PF 10%

HOSPIRA

10% (10GM/100ML)

N019492 002

Oct 17, 1986

AMINOSYN-PF 7%

HOSPIRA

7% (7GM/100ML)

N019398 001

Sep 06, 1985

AMINOSYN-RF 5.2%

HOSPIRA

5.2% (5.2GM/100ML)

N018429 001

BRANCHAMIN 4% IN PLASTIC CONTAINER

BAXTER HLTHCARE

4% (4GM/100ML)

N018684 001

Sep 28, 1984

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

CLINTEC NUTR

15% (15GM/100ML)

A020512 001

Aug 30, 1996

FREAMINE HBC 6.9%

B BRAUN

6.9% (6.9GM/100ML)

N016822 006

May 17, 1983

FREAMINE III 10%

B BRAUN

10% (10GM/100ML)

N016822 005

FREAMINE III 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 004

HEPATAMINE 8%

B BRAUN

8% (8GM/100ML)

N018676 001

Aug 03, 1982

HEPATASOL 8%

BAXTER HLTHCARE

8% (8GM/100ML)

N020360 001

Apr 04, 1996

NEPHRAMINE 5.4%

B BRAUN

5.4% (5.4GM/100ML)

N017766 001

NOVAMINE 11.4%

+ HOSPIRA

11.4% (11.4GM/100ML)

N017957 003

Aug 09, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 22 (of 409)

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 15%			
+ HOSPIRA	15% (15GM/100ML)	N017957 004	Nov 28, 1986
PREMASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10GM/100ML)	A075880 002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	6% (6GM/100ML)	A075880 001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	20% (20GM/100ML)	N020849 001	Aug 26, 1998
RENAMIN W/O ELECTROLYTES			
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493 007	Oct 15, 1982
TRAVASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10MG/100ML)	N018931 003	Aug 23, 1984
TRAVASOL 10% W/O ELECTROLYTES			
BAXTER HLTHCARE	10% (10GM/100ML)	N017493 006	
TRAVASOL 5.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931 001	Aug 23, 1984
TRAVASOL 5.5% W/O ELECTROLYTES			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493 004	
TRAVASOL 8.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931 002	Aug 23, 1984
TRAVASOL 8.5% W/O ELECTROLYTES			
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493 005	
TROPHAMINE			
+ B BRAUN	6% (6GM/100ML)	N019018 001	Jul 20, 1984
TROPHAMINE 10%			
+ B BRAUN	10% (10GM/100ML)	N019018 003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE

B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582 001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683 001	Nov 07, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683 002	Nov 07, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683 003	Nov 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 002	Mar 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 005	Mar 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;61MG/100ML;217MG/100ML;112MG/100ML	N020678 001	Mar 26, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 23 (of 409)

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678 009	Mar 26, 1997
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678 011	Mar 26, 1997
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678 012	Mar 26, 1997
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;2 61MG/100ML;297MG/100ML;77MG/100ML	N020678 008	Mar 26, 1997
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678 016	Mar 26, 1997
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678 017	Mar 26, 1997
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678 018	Mar 26, 1997
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678 019	Mar 26, 1997
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678 021	Mar 26, 1997

AMINO ACIDS; DEXTROSEINJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER			
HOSPIRA	3.5%;25GM/100ML	N019681 001	Nov 01, 1988
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	3.5%;5GM/100ML	N019681 002	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER			
HOSPIRA	4.25%;10GM/100ML	N019681 004	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER			
HOSPIRA	4.25%;20GM/100ML	N019681 005	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER			
HOSPIRA	4.25%;25GM/100ML	N019681 003	Nov 01, 1988
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER			
HOSPIRA	5%;25GM/100ML	N019681 006	Nov 01, 1988
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;10GM/100ML	N020734 002	Sep 29, 1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;25GM/100ML	N020734 005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;5GM/100ML	N020734 001	Sep 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;10GM/100ML	N020734 008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;20GM/100ML	N020734 010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;25GM/100ML	N020734 011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;5GM/100ML	N020734 007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;10GM/100ML	N020734 014	Sep 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;15GM/100ML	N020734 015	Sep 29, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 24 (of 409)

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5%;20GM/100ML N020734 016 Sep 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5%;25GM/100ML N020734 017 Sep 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5%;35GM/100ML N020734 018 Sep 29, 1997

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 N019682 001 Nov 01, 1988
0MG/100ML;49.3MG/100ML

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

HOSPIRA 4.25%;5GM/100ML;30MG/100ML;97MG/100ML;1 N019682 002 Nov 01, 1988
20MG/100ML;49.3MG/100MLAMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

B BRAUN 8.5%;110MG/100ML;230MG/100ML;10MG/100ML N016822 007 Jul 01, 1988
;440MG/100ML;690MG/100MLAMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA 3.5%;21MG/100ML;40MG/100ML;128MG/100ML; N017789 003
234MG/100MLAMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES

B BRAUN 3%;54MG/100ML;40MG/100ML;150MG/100ML;20 N016822 003
0MG/100ML;120MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

HOSPIRA 10%;102MG/100ML;45MG/100ML;522MG/100ML; N019437 004 Apr 03, 1986
410MG/100ML

AMINOSYN II 8.5% W/ ELECTROLYTES

HOSPIRA 8.5%;102MG/100ML;45MG/100ML;522MG/100ML N019437 005 Apr 03, 1986
;410MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML;218MG/100ML N020177 001 Oct 23, 1995
;35MG/100ML

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML;218MG/100ML N017493 003
;35MG/100ML

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML;431MG/100M N020173 001 Oct 27, 1995
L;224MG/100ML

PRESCRIPTION DRUG PRODUCT LIST

3 - 25 (of 409)

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 5.5% W/ ELECTROLYTES

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001	

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N020173	002	Oct 27, 1995

TRAVASOL 8.5% W/ ELECTROLYTES

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493	002	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002	

AMINOSYN 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005	

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

<u>AP</u>	LUITPOLD	250MG/ML	A071192	001	Dec 01, 1987

AMINOCAPROIC ACID IN PLASTIC CONTAINER

<u>AP</u> +	HOSPIRA	250MG/ML	A070010	001	Mar 09, 1987

SYRUP; ORAL

AMICAR

<u>AA</u> +	XANODYNE PHARM	1.25GM/5ML	N015230	002	

AMINOCAPROIC ACID

<u>AA</u>	MIKART	1.25GM/5ML	A074759	001	Sep 02, 1998

TABLET; ORAL

AMICAR

<u>AB</u>	XANODYNE PHARM	500MG	N015197	001	

AMINOCAPROIC

<u>AB</u>	MIKART	500MG	A075602	001	May 24, 2001

AMICAR

+	XANODYNE PHARM	1GM	N015197	002	Jun 24, 2004

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

+	MERCK	20%	N005619	001	

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL

LEVULAN

+	DUSA	20%	N020965	001	Dec 03, 1999

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

<u>AP</u> +	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983

<u>AP</u>	INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982

<u>AP</u>	LUITPOLD	25MG/ML	A087600	001	

<u>AP</u>	PHARMA SERVE NY	25MG/ML	A087392	001	Dec 15, 1983

<u>AP</u>	TEVA PARENTERAL	25MG/ML	A081142	001	Sep 25, 1991

PRESCRIPTION DRUG PRODUCT LIST

3 - 26 (of 409)

AMINOPHYLLINE

TABLET; ORAL
AMINOPHYLLINE

+ WEST WARD	100MG	A084540	001	
+	200MG	A085003	001	

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL
PASER

+ JACOBUS	4GM/PACKET	A074346	001	Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

<u>AP</u> + AKORN	<u>50MG/ML</u>	<u>A076232</u>	<u>001</u>	Jul 05, 2006
<u>AP</u> + APP PHARMS	<u>50MG/ML</u>	<u>A075761</u>	<u>001</u>	Oct 15, 2002
<u>AP</u> + BEDFORD	<u>50MG/ML</u>	<u>A076018</u>	<u>001</u>	Oct 15, 2002
<u>AP</u> + BEDFORD LABS	<u>50MG/ML</u>	<u>A076299</u>	<u>001</u>	Oct 24, 2002
<u>AP</u> + BIONICHE PHARMA	<u>50MG/ML</u>	<u>A076217</u>	<u>001</u>	Oct 15, 2002
<u>AP</u> + CLARIS LIFESCIENCES	<u>50MG/ML</u>	<u>A076394</u>	<u>001</u>	Apr 25, 2003
<u>AP</u> + GLAND PHARMA LTD	<u>50MG/ML</u>	<u>A077161</u>	<u>001</u>	Apr 20, 2005
<u>AP</u> HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A077234</u>	<u>001</u>	Feb 25, 2008
<u>AP</u> + HOSPIRA	<u>50MG/ML</u>	<u>A075955</u>	<u>001</u>	Oct 18, 2002
<u>AP</u> + TEVA PARENTERAL	<u>50MG/ML</u>	<u>A076163</u>	<u>001</u>	Sep 05, 2003
<u>AP</u> WOCKHARDT	<u>50MG/ML</u>	<u>A077610</u>	<u>001</u>	Oct 30, 2008
<u>AP</u>	<u>50MG/ML</u>	<u>A077834</u>	<u>001</u>	Oct 30, 2008

NEXTERONE

<u>AP</u> PRISM PHARMS	<u>50MG/ML</u>	<u>N022325</u>	<u>001</u>	Dec 24, 2008
NEXTERONE				
+ PRISM PHARMS	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010
+	360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

<u>AB</u> APOTEX CORP	<u>200MG</u>	<u>A078578</u>	<u>001</u>	Nov 06, 2008
<u>AB</u> AUROSAL PHARMS	<u>200MG</u>	<u>A077069</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>	<u>400MG</u>	<u>A077069</u>	<u>002</u>	Apr 08, 2005
<u>AB</u> BARR	<u>200MG</u>	<u>A075389</u>	<u>001</u>	Jan 25, 2001
<u>AB</u> MYLAN	<u>200MG</u>	<u>A075188</u>	<u>001</u>	Feb 24, 1999
<u>AB</u> SANDOZ	<u>200MG</u>	<u>A075315</u>	<u>001</u>	Dec 23, 1998
<u>AB</u>	<u>400MG</u>	<u>A075315</u>	<u>002</u>	Jun 30, 2000
<u>AB</u> TARO	<u>100MG</u>	<u>A075424</u>	<u>002</u>	Dec 18, 2002
<u>AB</u>	<u>200MG</u>	<u>A075424</u>	<u>001</u>	Mar 30, 2001
<u>AB</u>	<u>400MG</u>	<u>A076362</u>	<u>001</u>	Nov 29, 2002
<u>AB</u> TEVA PHARMS	<u>200MG</u>	<u>A074739</u>	<u>001</u>	Nov 30, 1998
<u>AB</u> ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A079029</u>	<u>001</u>	Sep 16, 2008

CORDARONE

<u>AB</u> + WYETH PHARMS INC	<u>200MG</u>	<u>N018972</u>	<u>001</u>	Dec 24, 1985

PACERONE

<u>AB</u> UPSHER SMITH	<u>100MG</u>	<u>A075135</u>	<u>002</u>	Apr 12, 2005
<u>AB</u>	<u>200MG</u>	<u>A075135</u>	<u>001</u>	Apr 30, 1998
AMIODARONE HYDROCHLORIDE				
TARO	300MG	A076362	002	Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u> CARACO	<u>10MG</u>	<u>A040815</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>	<u>25MG</u>	<u>A040816</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>	<u>50MG</u>	<u>A040817</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>	<u>75MG</u>	<u>A040818</u>	<u>001</u>	Jun 27, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 27 (of 409)

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>	CARACO	<u>100MG</u>	<u>A040819</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>150MG</u>	<u>A040820</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A089398</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>25MG</u>	<u>A089399</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>50MG</u>	<u>A089400</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>75MG</u>	<u>A089401</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>100MG</u>	<u>A089402</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>150MG</u>	<u>A089403</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A086009</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A086009</u>	<u>003</u>	
<u>AB</u>		<u>50MG</u>	<u>A086009</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A086009</u>	<u>004</u>	
<u>AB</u>		<u>100MG</u>	<u>A086009</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009</u>	<u>006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085969</u>	<u>001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085966</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085971</u>	<u>001</u>	
<u>AB</u>		<u>100MG</u>	<u>A085967</u>	<u>001</u>	
<u>AB</u>		<u>150MG</u>	<u>A085970</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218</u>	<u>003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218</u>	<u>004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218</u>	<u>005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218</u>	<u>006</u>	Sep 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE;5MG</u>	<u>A071297</u>	<u>002</u>	Dec 10, 1986
<u>AB</u>		<u>EQ 25MG BASE;10MG</u>	<u>A071297</u>	<u>001</u>	Dec 10, 1986
	<u>LIMBITROL</u>				
<u>AB</u>	VALEANT PHARM INTL	<u>EQ 12.5MG BASE;5MG</u>	<u>N016949</u>	<u>001</u>	
	<u>LIMBITROL DS</u>				
<u>AB</u>	+	<u>EQ 25MG BASE;10MG</u>	<u>N016949</u>	<u>002</u>	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
		10MG;4MG	A071443	003	Nov 10, 1988
	+	25MG;2MG	A071443	004	Nov 10, 1988
	+	25MG;4MG	A071443	005	Nov 10, 1988
	+	50MG;4MG	A071443	001	Nov 10, 1988

AMLEXANOX

PASTE; DENTAL

APHTHASOL

+	ULURU	5%	N020511	001	Dec 17, 1996

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 2.5MG BASE</u>	<u>A078131</u>	<u>001</u>	Sep 04, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078131</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078131</u>	<u>003</u>	Sep 04, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 28 (of 409)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925</u>	<u>001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925</u>	<u>002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925</u>	<u>003</u>	May 04, 2009
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 2.5MG BASE</u>	<u>A078477</u>	<u>001</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078477</u>	<u>002</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078477</u>	<u>003</u>	Jan 16, 2008
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719</u>	<u>001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719</u>	<u>002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719</u>	<u>003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021</u>	<u>001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021</u>	<u>002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021</u>	<u>003</u>	Jul 17, 2007
<u>AB</u>	CARACO	<u>EQ 2.5MG BASE</u>	<u>A078231</u>	<u>001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078231</u>	<u>002</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078231</u>	<u>003</u>	Nov 30, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A076692</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	GEDEON RICHTER USA	<u>EQ 2.5MG BASE</u>	<u>A077333</u>	<u>001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077333</u>	<u>002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077333</u>	<u>003</u>	Jul 17, 2007
<u>AB</u>	GLENMARK GENERICS	<u>EQ 2.5MG BASE</u>	<u>A078552</u>	<u>001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552</u>	<u>002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552</u>	<u>003</u>	Apr 08, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955</u>	<u>001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955</u>	<u>002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955</u>	<u>003</u>	Aug 28, 2007
<u>AB</u>	LEK PHARMS DD	<u>EQ 2.5MG BASE</u>	<u>A076859</u>	<u>001</u>	Sep 10, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076859</u>	<u>002</u>	Sep 10, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076859</u>	<u>003</u>	Sep 10, 2007
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043</u>	<u>001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043</u>	<u>002</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043</u>	<u>003</u>	Jul 12, 2007
<u>AB</u>	MATRIX LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A078224</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078224</u>	<u>002</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078224</u>	<u>003</u>	Feb 27, 2008
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076418</u>	<u>001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418</u>	<u>002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418</u>	<u>003</u>	Oct 03, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453</u>	<u>001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453</u>	<u>002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453</u>	<u>003</u>	Jul 02, 2009
<u>AB</u>	RANBAXY	<u>EQ 2.5MG BASE</u>	<u>A077974</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	ROXANE	<u>EQ 2.5MG BASE</u>	<u>A077262</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	TEVA	<u>EQ 2.5MG BASE</u>	<u>A076846</u>	<u>001</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076846</u>	<u>002</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076846</u>	<u>003</u>	Jun 28, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573</u>	<u>001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573</u>	<u>002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573</u>	<u>003</u>	Sep 22, 2008
<u>AB</u>	UPSHER SMITH	<u>EQ 2.5MG BASE</u>	<u>A077759</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759</u>	<u>003</u>	Jul 09, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 29 (of 409)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	VINTAGE	<u>EQ 2.5MG BASE</u>	<u>A078414</u>	<u>001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414</u>	<u>002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414</u>	<u>003</u>	Apr 07, 2010
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077073</u>	<u>001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A077671</u>	<u>001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073</u>	<u>002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671</u>	<u>002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073</u>	<u>003</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671</u>	<u>003</u>	Jul 19, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500</u>	<u>001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500</u>	<u>002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500</u>	<u>003</u>	Sep 06, 2007
<u>AB</u>	WORLD GEN	<u>EQ 2.5MG BASE</u>	<u>A077516</u>	<u>001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516</u>	<u>002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516</u>	<u>003</u>	Jul 11, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226</u>	<u>003</u>	Jul 09, 2007
<u>NORVASC</u>					
<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N019787</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019787</u>	<u>003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET

PFIZER

EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004
EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004
EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004
EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004
EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004
EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004
EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004
EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004
EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004
EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004
EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A077183</u>	<u>001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077183</u>	<u>002</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077183</u>	<u>003</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077183</u>	<u>004</u>	Apr 15, 2010
<u>AB</u>	LUPIN PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A078466</u>	<u>001</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078466</u>	<u>002</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078466</u>	<u>003</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078466</u>	<u>004</u>	Feb 05, 2010
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE;10MG</u>	<u>A077375</u>	<u>001</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077375</u>	<u>002</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077375</u>	<u>003</u>	May 21, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077375</u>	<u>004</u>	May 21, 2010
<u>AB</u>	PAR PHARM	<u>EQ 2.5MG BASE;10MG</u>	<u>A078381</u>	<u>001</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078381</u>	<u>002</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078381</u>	<u>003</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A078381</u>	<u>005</u>	Jul 29, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 30 (of 409)

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>EQ 10MG BASE;20MG</u>	<u>A078381</u>	<u>004</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078381</u>	<u>006</u>	Jul 29, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077179</u>	<u>001</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077179</u>	<u>002</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077179</u>	<u>003</u>	May 18, 2007
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077179</u>	<u>004</u>	May 18, 2007
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077890</u>	<u>001</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077890</u>	<u>002</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077890</u>	<u>003</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077890</u>	<u>004</u>	Oct 14, 2010
<u>LOTREL</u>					
<u>AB</u>	NOVARTIS	<u>EQ 2.5MG BASE;10MG</u>	<u>N020364</u>	<u>002</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>N020364</u>	<u>003</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>N020364</u>	<u>004</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>N020364</u>	<u>007</u>	Apr 11, 2006
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>N020364</u>	<u>005</u>	Jun 20, 2002
<u>AB</u>	+	<u>EQ 10MG BASE;40MG</u>	<u>N020364</u>	<u>006</u>	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

TRIBENZOR

DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010
	EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010
	EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010
	EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010
+	EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

NOVARTIS	5MG;12.5MG;160MG	N022314	001	Apr 30, 2009
	5MG;25MG;160MG	N022314	002	Apr 30, 2009
	10MG;12.5MG;160MG	N022314	003	Apr 30, 2009
	10MG;25MG;160MG	N022314	004	Apr 30, 2009
+	10MG;25MG;320MG	N022314	005	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AZOR

DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007
	EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007
	EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007
+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TWINSTA

BOEHRINGER INGELHEIM	EQ 5MG BASE;40MG	N022401	001	Oct 16, 2009
	EQ 5MG BASE;80MG	N022401	003	Oct 16, 2009
	EQ 10MG BASE;40MG	N022401	002	Oct 16, 2009
+	EQ 10MG BASE;80MG	N022401	004	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

EXFORGE

NOVARTIS	EQ 5MG BASE;160MG	N021990	002	Jun 20, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 31 (of 409)

AMLODIPINE BESYLATE; VALSARTANTABLET; ORAL
EXFORGE

NOVARTIS

EQ 5MG BASE;320MG

N021990 004 Jun 20, 2007

+ EQ 10MG BASE;160MG

N021990 003 Jun 20, 2007

+ EQ 10MG BASE;320MG

N021990 005 Jun 20, 2007

AMMONIA, N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

+ FEINSTEIN

30MCI-300MCI/8ML (3.75-37.5MCI/ML)

N022119 001 Aug 23, 2007

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

5MEQ/ML

A088366 001 Jun 13, 1984

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATEAB PADDOCKEQ 12% BASEA076829 001 Feb 07, 2006AB PERRIGO NEW YORKEQ 12% BASEA075774 001 May 01, 2002AB TAROEQ 12% BASEA075883 001 Apr 10, 2003LAC-HYDRINAB + RANBAXYEQ 12% BASEN020508 001 Aug 29, 1996

LOTION; TOPICAL

AMMONIUM LACTATEAB PADDOCKEQ 12% BASEA075575 001 Jun 11, 2002AB PERRIGO NEW YORKEQ 12% BASEA075570 001 Jun 23, 2004AB TAROEQ 12% BASEA076216 001 May 28, 2004LAC-HYDRINAB + RANBAXYEQ 12% BASEN019155 001 Apr 24, 1985AMOXAPINE

TABLET; ORAL

AMOXAPINE

WATSON LABS

25MG

A072688 001 Aug 28, 1992

50MG

A072689 001 Aug 28, 1992

100MG

A072690 001 Aug 28, 1992

+ 150MG

A072691 001 Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLINAB AUROBINDO250MGA065271 001 Nov 09, 2005AB500MGA065271 002 Nov 09, 2005AB DAVA PHARMS INC250MGA062884 001 Feb 25, 1988AB500MGA062881 001 Feb 25, 1988AB HIKMA PHARMS250MGA065291 001 Feb 05, 2007AB500MGA065291 002 Feb 05, 2007AB RANBAXY250MGA065016 001 Apr 08, 1999AB500MGA065016 002 Apr 08, 1999AB SANDOZ250MGA064076 001 Sep 30, 1994AB500MGA064076 002 Sep 30, 1994AB TEVA250MGA061926 001AB +500MGA061926 003

FOR SUSPENSION; ORAL

AMOXICILLINAB AUROBINDO200MG/5MLA065334 001 Dec 28, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 32 (of 409)

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>	DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>	HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>	RANBAXY	<u>200MG/5ML</u>	<u>A065113</u>	<u>001</u>	Nov 29, 2002
<u>AB</u>		<u>400MG/5ML</u>	<u>A065113</u>	<u>002</u>	Nov 29, 2002
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>	TEVA	<u>125MG/5ML</u>	<u>A061931</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
<u>AB</u>	+	<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
<u>AB</u>	WOCKHARDT	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>	TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982
<u>AB</u>	GLAXOSMITHKLINE	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>875MG</u>	<u>A065344</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	RANBAXY	<u>500MG</u>	<u>A065059</u>	<u>001</u>	Nov 24, 2000
<u>AB</u>		<u>875MG</u>	<u>A065059</u>	<u>002</u>	Nov 24, 2000
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	+	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

TABLET, CHEWABLE; ORAL

AMOXICILLIN

<u>AB</u>	DAVA PHARMS INC	<u>125MG</u>	<u>A064139</u>	<u>001</u>	Jan 29, 1996
<u>AB</u>		<u>250MG</u>	<u>A064139</u>	<u>002</u>	Jan 29, 1996
<u>AB</u>	RANBAXY	<u>125MG</u>	<u>A065021</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>250MG</u>	<u>A065021</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	TEVA	<u>125MG</u>	<u>A064013</u>	<u>002</u>	Sep 11, 1995
<u>AB</u>	+	<u>250MG</u>	<u>A064013</u>	<u>001</u>	Dec 22, 1992
	AMOXICILLIN				
	RANBAXY	200MG	A065060	001	Nov 29, 2000
		400MG	A065060	002	Nov 29, 2000

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

	+	VICTORY PHARMA	775MG	N050813	001	Jan 23, 2008

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO PHARMA	<u>200MG</u>	<u>A065324</u>	<u>001</u>	Jan 17, 2007
<u>AB</u>		<u>400MG</u>	<u>A065324</u>	<u>002</u>	Jan 17, 2007
	<u>DISPERMOX</u>				
<u>AB</u>	RANBAXY	<u>200MG</u>	<u>A065080</u>	<u>002</u>	Aug 11, 2003
<u>AB</u>	+	<u>400MG</u>	<u>A065080</u>	<u>001</u>	Aug 11, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 33 (of 409)

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL
DISPERMOX

+ RANBAXY	600MG	A065159	001	Dec 04, 2003

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL
PREVPAC

+ TAKEDA PHARMS NA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	N050757	001	Dec 02, 1997

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
<u>AB</u>	LEK PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
<u>AB</u>	LEK PHARMS DD	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>	RANBAXY	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065132</u>	<u>001</u>	Mar 19, 2003
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065132</u>	<u>002</u>	Mar 19, 2003
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065207</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	SANDOZ	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	TEVA	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
<u>AB</u>	+	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
<u>AB</u>	+	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
<u>AB</u>	WOCKHARDT	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A065431</u>	<u>001</u>	Nov 25, 2008
	<u>AUGMENTIN '125'</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>N050575</u>	<u>001</u>	Aug 06, 1984
	<u>AUGMENTIN '250'</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>N050575</u>	<u>002</u>	Aug 06, 1984

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	APOTEX	<u>250MG;EQ 125MG BASE</u>	<u>A065333</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A065333</u>	<u>002</u>	Feb 24, 2009
<u>AB</u>	APOTEX INC	<u>875MG;EQ 125MG BASE</u>	<u>A065317</u>	<u>003</u>	Oct 20, 2008
<u>AB</u>	LEK PHARMS	<u>500MG;EQ 125MG BASE</u>	<u>A065117</u>	<u>001</u>	Nov 27, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065093</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	RANBAXY	<u>500MG;EQ 125MG BASE</u>	<u>A065109</u>	<u>001</u>	Nov 04, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065102</u>	<u>001</u>	Sep 17, 2002
<u>AB</u>	SANDOZ	<u>250MG;EQ 125MG BASE</u>	<u>A065189</u>	<u>001</u>	Aug 23, 2005
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A065064</u>	<u>001</u>	Mar 15, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065063</u>	<u>001</u>	Mar 14, 2002
<u>AB</u>	TEVA	<u>500MG;EQ 125MG BASE</u>	<u>A065101</u>	<u>001</u>	Oct 30, 2002
<u>AB</u>	+	<u>875MG;EQ 125MG BASE</u>	<u>A065096</u>	<u>001</u>	Oct 29, 2002
	<u>AUGMENTIN '250'</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>250MG;EQ 125MG BASE</u>	<u>N050564</u>	<u>001</u>	Aug 06, 1984
	<u>AUGMENTIN '500'</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>500MG;EQ 125MG BASE</u>	<u>N050564</u>	<u>002</u>	Aug 06, 1984
	<u>AUGMENTIN '875'</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>875MG;EQ 125MG BASE</u>	<u>N050720</u>	<u>001</u>	Feb 13, 1996

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	RANBAXY	<u>200MG;EQ 28.5MG BASE</u>	<u>A065161</u>	<u>001</u>	Dec 03, 2003
<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065161</u>	<u>002</u>	Dec 03, 2003
<u>AB</u>	SANDOZ	<u>200MG;EQ 28.5MG BASE</u>	<u>A065065</u>	<u>001</u>	Apr 18, 2002
<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065065</u>	<u>002</u>	Apr 18, 2002
<u>AB</u>	TEVA	<u>200MG;EQ 28.5MG BASE</u>	<u>A065205</u>	<u>001</u>	Feb 09, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 34 (of 409)

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	+ TEVA	<u>400MG;EQ 57MG BASE</u>	<u>A065205</u> <u>002</u>	Feb 09, 2005

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	SANDOZ	<u>1GM;EQ 62.5MG BASE</u>	<u>A090227</u> <u>001</u>	Apr 21, 2010

AUGMENTIN XR

<u>AB</u>	+ GLAXOSMITHKLINE	<u>1GM;EQ 62.5MG BASE</u>	<u>N050785</u> <u>001</u>	Sep 25, 2002

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303	001 Oct 11, 2001

ADDERALL XR 15

	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303	006 May 22, 2002

ADDERALL XR 20

	SHIRE	5MG;5MG;5MG;5MG	N021303	002 Oct 11, 2001

ADDERALL XR 25

	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303	004 May 22, 2002

ADDERALL XR 30

	+ SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303	003 Oct 11, 2001

ADDERALL XR 5

	SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303	005 May 22, 2002

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	BARR	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040422</u> <u>001</u>	Feb 11, 2002

<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040422</u> <u>005</u>	Mar 19, 2003

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040422</u> <u>002</u>	Feb 11, 2002

<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040422</u> <u>006</u>	Mar 19, 2003

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040422</u> <u>007</u>	Mar 19, 2003

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040422</u> <u>003</u>	Feb 11, 2002

<u>AB</u>	+	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040422</u> <u>004</u>	Feb 11, 2002

<u>AB</u>	COREPHARMA	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040444</u> <u>001</u>	Jun 19, 2002

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040444</u> <u>002</u>	Jun 19, 2002

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040444</u> <u>003</u>	Jun 19, 2002

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040444</u> <u>004</u>	Jun 19, 2002

<u>AB</u>	MALLINCKRODT	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040440</u> <u>001</u>	Oct 07, 2003

<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040440</u> <u>002</u>	Oct 07, 2003

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040440</u> <u>003</u>	Oct 07, 2003

<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040440</u> <u>004</u>	Oct 07, 2003

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040440</u> <u>005</u>	Oct 07, 2003

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040440</u> <u>006</u>	Oct 07, 2003

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040440</u> <u>007</u>	Oct 07, 2003

<u>AB</u>	SANDOZ	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040439</u> <u>004</u>	Sep 27, 2002

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040439</u> <u>001</u>	Jun 14, 2002

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040439</u> <u>002</u>	Jun 14, 2002

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040439</u> <u>003</u>	Jun 14, 2002

<u>AB</u>	TEVA PHARMS	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040472</u> <u>001</u>	Sep 30, 2003

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040472</u> <u>002</u>	Sep 30, 2003

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040472</u> <u>003</u>	Sep 30, 2003

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040472</u> <u>004</u>	Sep 30, 2003

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

<u>AP</u>	TEVA PARENTERAL	<u>50MG/VIAL</u>	<u>A064062</u> <u>001</u>	Mar 31, 1995

<u>AP</u>	X GEN PHARMS	<u>50MG/VIAL</u>	<u>A063206</u> <u>001</u>	Apr 29, 1992

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 35 (of 409)

AMPHOTERICIN B

INJECTABLE; INJECTION

FUNGIZONE

<u>AP</u>	+ APOTHECON	<u>50MG/VIAL</u>	<u>A060517</u>	<u>001</u>	
	INJECTABLE, LIPID COMPLEX; INJECTION				
	ABELCET				
	+ SIGMA TAU	5MG/ML	N050724	001	Nov 20, 1995
	AMPHOTEC				
	+ THREE RIVERS PHARMS	50MG/VIAL	N050729	001	Nov 22, 1996
	+	100MG/VIAL	N050729	002	Nov 22, 1996
	INJECTABLE, LIPOSOMAL; INJECTION				
	AMBISOME				
	+ ASTELLAS	50MG/VIAL	N050740	001	Aug 11, 1997

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	ACIC FINE CHEMS	<u>EQ 250MG BASE/VIAL</u>	<u>A090354</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090354</u>	<u>002</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090354</u>	<u>003</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090354</u>	<u>004</u>	Dec 28, 2009
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 125MG BASE/VIAL</u>	<u>A065499</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A065499</u>	<u>002</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065499</u>	<u>003</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065499</u>	<u>004</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065499</u>	<u>005</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065493</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>	HANFORD GC	<u>EQ 250MG BASE/VIAL</u>	<u>A063145</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063146</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062772</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A063140</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063142</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>	IBI	<u>EQ 250MG BASE/VIAL</u>	<u>A062719</u>	<u>001</u>	May 12, 1987
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062719</u>	<u>003</u>	May 12, 1987
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062719</u>	<u>002</u>	May 12, 1987
<u>AP</u>	INSTITUTO BIOCHEMICO	<u>EQ 125MG BASE/VIAL</u>	<u>A062797</u>	<u>001</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062797</u>	<u>002</u>	Jul 12, 1993
<u>AP</u>	+ SANDOZ	<u>EQ 125MG BASE/VIAL</u>	<u>A061395</u>	<u>001</u>	
<u>AP</u>	+	<u>EQ 250MG BASE/VIAL</u>	<u>A061395</u>	<u>002</u>	
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A061395</u>	<u>003</u>	
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A061395</u>	<u>004</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062738</u>	<u>001</u>	Feb 19, 1987
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A061395</u>	<u>005</u>	
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062738</u>	<u>002</u>	Feb 19, 1987
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A061395</u>	<u>006</u>	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403</u>	<u>001</u>	Dec 23, 2009
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074</u>	<u>001</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074</u>	<u>002</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076</u>	<u>001</u>	Mar 19, 2002
<u>AP</u>	BIONICHE PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065316</u>	<u>001</u>	Jun 29, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065316</u>	<u>002</u>	Jun 29, 2007
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176</u>	<u>001</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176</u>	<u>002</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188</u>	<u>001</u>	Nov 25, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 36 (of 409)

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	INSTITUTO BIOCHIMICO	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222</u>	<u>001</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222</u>	<u>002</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314</u>	<u>001</u>	Nov 27, 2006
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240</u>	<u>001</u>	Jul 25, 2006
<u>UNASYN</u>					
<u>AP</u>	PFIZER	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901</u>	<u>001</u>	Nov 23, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608</u>	<u>002</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608</u>	<u>001</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608</u>	<u>005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

<u>AB</u>	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062883</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A062882</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064082</u>	<u>001</u>	Aug 29, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A064082</u>	<u>002</u>	Aug 29, 1995

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

<u>AB</u>	DAVA PHARMS INC	<u>EQ 125MG BASE/5ML</u>	<u>A062982</u>	<u>001</u>	Feb 10, 1989
<u>PRINCIPEN</u>					
<u>AB</u>	APOTHECON	<u>EQ 125MG BASE/5ML</u>	<u>A061394</u>	<u>002</u>	
<u>AMPICILLIN TRIHYDRATE</u>					
+	DAVA PHARMS INC	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989

AMPICILLIN; SULBACTAM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340</u>	<u>002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349</u>	<u>002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339</u>	<u>001</u>	Sep 20, 2010

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

<u>AB</u>	SHIRE	<u>EQ 0.5MG BASE</u>	<u>N020333</u>	<u>001</u>	Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

<u>AB</u>	ALPHAPHARM	<u>EQ 0.5MG BASE</u>	<u>A077613</u>	<u>001</u>	Jun 27, 2006
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077613</u>	<u>002</u>	Jun 27, 2006
<u>AB</u>	BARR	<u>EQ 0.5MG BASE</u>	<u>A076530</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076530</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>	IMPAX LABS	<u>EQ 0.5MG BASE</u>	<u>A076910</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076910</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 0.5MG BASE</u>	<u>A076468</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>A076468</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A076811</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076811</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A076683</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076683</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>	WATSON LABS	<u>EQ 0.5MG BASE</u>	<u>A076417</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076417</u>	<u>002</u>	Apr 18, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 37 (of 409)

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

<u>AB</u>	ACCORD HLTHCARE INC	<u>1MG</u>	<u>A090568</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A090732</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	FRESENIUS KABI ONCOL	<u>1MG</u>	<u>A090088</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	KUDCO IRELAND	<u>1MG</u>	<u>A091331</u>	<u>001</u>	Jan 05, 2011
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A091051</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	NATCO PHARMA LTD	<u>1MG</u>	<u>A079220</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	ROXANE	<u>1MG</u>	<u>A078485</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A079007</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	STASON PHARMS	<u>1MG</u>	<u>A078944</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	SYNTHON PHARMS	<u>1MG</u>	<u>A078322</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A078058</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	THREE RIVERS PHARMS	<u>1MG</u>	<u>A091164</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A078984</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1MG</u>	<u>A078921</u>	<u>001</u>	Jun 28, 2010

ARIMIDEX

<u>AB</u>	+ ASTRAZENECA	<u>1MG</u>	<u>N020541</u>	<u>001</u>	Dec 27, 1995

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

+	VICURON	50MG/VIAL	N021632	001	Feb 17, 2006
+		100MG/VIAL	N021632	002	Nov 14, 2006

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

+	IPSEN BIOPHARM LTD	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004

APRACLOPIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLOPIDINE HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>EQ 0.5% BASE</u>	<u>A077764</u>	<u>001</u>	Mar 12, 2009
	<u>IOPIDINE</u>				
<u>AT</u>	+ ALCON	<u>EQ 0.5% BASE</u>	<u>N020258</u>	<u>001</u>	Jul 30, 1993
	IOPIDINE				
+	ALCON	EQ 1% BASE	N019779	001	Dec 31, 1987

APREPITANT

CAPSULE; ORAL

EMEND

	MERCK	40MG	N021549	003	Jun 30, 2006
		80MG	N021549	001	Mar 26, 2003
+		125MG	N021549	002	Mar 26, 2003

APROTIMIN

INJECTABLE; INJECTION

TRASYLOL

+	BAYER HLTHCARE	10,000KIU/ML	N020304	001	Dec 29, 1993

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

BROVANA

+	SUNOVION	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 38 (of 409)

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

+	PFIZER	100MG/ML	N020883 001	Jun 30, 2000

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10

+	PHARMACIA AND UPJOHN	10GM/100ML	N016931 001	

ARIPIPIRAZOLE

INJECTABLE; INTRAMUSCULAR

ABILIFY

+	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866 001	Sep 20, 2006

SOLUTION; ORAL

ABILIFY

+	OTSUKA	1MG/ML	N021713 001	Dec 10, 2004

TABLET; ORAL

ABILIFY

	OTSUKA	2MG	N021436 006	Nov 15, 2002
+		5MG	N021436 005	Nov 15, 2002
+		10MG	N021436 001	Nov 15, 2002
		15MG	N021436 002	Nov 15, 2002
		20MG	N021436 003	Nov 15, 2002
		30MG	N021436 004	Nov 15, 2002

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

+	OTSUKA	10MG	N021729 002	Jun 07, 2006
		15MG	N021729 003	Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

NUVIGIL

	CEPHALON	50MG	N021875 001	Jun 15, 2007
		150MG	N021875 003	Jun 15, 2007
+		250MG	N021875 004	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX

+	CEPHALON	1MG/ML	N021248 001	Sep 25, 2000

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

+	NOVARTIS	20MG;120MG	N022268 001	Apr 07, 2009

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

<u>AP</u>	HOSPIRA	<u>4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)</u>	<u>A079138 001</u>	Jun 18, 2010

SEPTOCAINE

<u>AP</u>	+ DEPROCO	<u>4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)</u>	<u>N020971 001</u>	Apr 03, 2000

ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE

	PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466 001	Feb 26, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 39 (of 409)

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE

+ PIERREL	4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466 002	Feb 26, 2010

SEPTOCAINE

+ DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010 001	Mar 30, 2006

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265 001	Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646 001	Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920 001	Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I. -12 (WITHOUT VITAMIN K)

+ HOSPIRA	20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809 006	Sep 09, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625 001	Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643 001	Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

+ SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	N021881 001	Aug 02, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 40 (of 409)

ASENAPINE MALEATE

TABLET; SUBLINGUAL
SAPHRIS

ORGANON USA INC	EQ 5MG BASE	N022117 001	Aug 13, 2009
+	EQ 10MG BASE	N022117 002	Aug 13, 2009

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA + WATSON PHARMS	325MG;50MG;40MG	N017534 005	Apr 16, 1986

LANORINAL

AA LANNETT	325MG;50MG;40MG	A086996 002	Oct 11, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710 002	Aug 23, 1983

AA + WEST WARD	325MG;50MG;40MG	A086162 002	Feb 16, 1984

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB NEXGEN PHARMA INC	325MG;50MG;40MG;30MG	A075231 001	Nov 30, 2001

AB STEVENS J	325MG;50MG;40MG;30MG	A074951 001	Aug 31, 1998

AB WATSON LABS	325MG;50MG;40MG;30MG	A074359 001	Aug 31, 1995

FIORINAL W/CODEINE

AB + WATSON PHARMS	325MG;50MG;40MG;30MG	N019429 003	Oct 26, 1990

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ CARACO	356.4MG;30MG;16MG	N011483 004	Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

AB SANDOZ	385MG;30MG;25MG	A074817 001	Nov 27, 1996

INVAGESIC FORTE

AB SANDOZ	770MG;60MG;50MG	A074817 002	Nov 27, 1996

NORGESIC

AB GRACEWAY	385MG;30MG;25MG	N013416 003	Oct 27, 1982

NORGESIC FORTE

AB + GRACEWAY	770MG;60MG;50MG	N013416 004	Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB SANDOZ	385MG;30MG;25MG	A074654 001	Dec 31, 1996

AB	770MG;60MG;50MG	A074654 002	Dec 31, 1996

AB STEVENS J	385MG;30MG;25MG	A074988 001	Apr 30, 1999

AB	770MG;60MG;50MG	A074988 002	Apr 30, 1999

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB ACTAVIS TOTOWA	325MG;200MG	A040252 001	Dec 10, 1997

AB CONCORD LABS NJ	325MG;200MG	A040832 001	Jan 07, 2010

AB HERITAGE PHARMS INC	325MG;200MG	A089594 001	Mar 31, 1989

AB SANDOZ	325MG;200MG	A040116 001	Apr 25, 1996

SOMA COMPOUND

AB + MEDA PHARMS	325MG;200MG	N012365 005	Jul 11, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 41 (of 409)

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

<u>AB</u>	ACTAVIS TOTOWA	<u>325MG;200MG;16MG</u>	<u>A040283</u>	<u>001</u>	Dec 29, 1998
<u>AB</u>	CONCORD LABS NJ	<u>325MG;200MG;16MG</u>	<u>A040860</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>	SANDOZ	<u>325MG;200MG;16MG</u>	<u>A040118</u>	<u>001</u>	Apr 16, 1996
<u>SOMA COMPOUND W/ CODEINE</u>					
<u>AB</u>	+ MEDA PHARMS	<u>325MG;200MG;16MG</u>	<u>N012366</u>	<u>002</u>	Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOX

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>25MG;200MG</u>	<u>N020884</u>	<u>001</u>	Nov 22, 1999
<u>ASPIRIN AND DIPYRIDAMOLE</u>					
<u>AB</u>	BARR	<u>25MG;200MG</u>	<u>A078804</u>	<u>001</u>	Aug 14, 2009

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

	+ STEVENS J	325MG;400MG	A081145	001	Jan 31, 1995

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

PERCODAN

	+ ENDO PHARMS	325MG;4.8355MG	N007337	007	Aug 05, 2005

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

	WATSON LABS	325MG;4.5MG;0.38MG	A040255	001	Feb 27, 1998

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N021567	001	Jun 20, 2003
		EQ 150MG BASE	N021567	002	Jun 20, 2003
		EQ 200MG BASE	N021567	003	Jun 20, 2003
	+	EQ 300MG BASE	N021567	004	Oct 16, 2006

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078512</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>50MG</u>	<u>A078512</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>		<u>100MG</u>	<u>A078512</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>	CARACO	<u>25MG</u>	<u>A078210</u>	<u>001</u>	Jul 10, 2007
<u>AB</u>		<u>50MG</u>	<u>A078210</u>	<u>002</u>	Jul 10, 2007
<u>AB</u>		<u>100MG</u>	<u>A078210</u>	<u>003</u>	Jul 10, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A074099</u>	<u>001</u>	Apr 28, 1992
<u>AB</u>		<u>50MG</u>	<u>A073542</u>	<u>001</u>	Dec 19, 1991
<u>AB</u>		<u>100MG</u>	<u>A073543</u>	<u>001</u>	Dec 19, 1991
<u>AB</u>	GENPHARM	<u>25MG</u>	<u>A074126</u>	<u>003</u>	Aug 26, 1998
<u>AB</u>		<u>50MG</u>	<u>A074126</u>	<u>001</u>	Mar 23, 1994
<u>AB</u>		<u>100MG</u>	<u>A074126</u>	<u>002</u>	Mar 23, 1994
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A077877</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077877</u>	<u>002</u>	Dec 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077877</u>	<u>003</u>	Dec 27, 2006
<u>AB</u>	IPR	<u>25MG</u>	<u>A073646</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A072303</u>	<u>001</u>	Jul 15, 1988

PRESCRIPTION DRUG PRODUCT LIST

3 - 42 (of 409)

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	IPR	<u>100MG</u>	<u>A072304</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A074499</u>	<u>001</u>	Jul 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A073475</u>	<u>001</u>	Mar 30, 1993
<u>AB</u>		<u>100MG</u>	<u>A073476</u>	<u>001</u>	Mar 30, 1993
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A073457</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>		<u>50MG</u>	<u>A073456</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>		<u>100MG</u>	<u>A073457</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>	NORTHSTAR HLTHCARE	<u>25MG</u>	<u>A078254</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>50MG</u>	<u>A078254</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>100MG</u>	<u>A078254</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074052</u>	<u>001</u>	May 01, 1992
<u>AB</u>		<u>50MG</u>	<u>A073025</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>		<u>100MG</u>	<u>A073026</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074056</u>	<u>003</u>	Jul 19, 2004
<u>AB</u>		<u>50MG</u>	<u>A074056</u>	<u>001</u>	Jan 18, 1995
<u>AB</u>		<u>100MG</u>	<u>A074056</u>	<u>002</u>	Jan 18, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A077443</u>	<u>001</u>	Sep 13, 2006
<u>AB</u>		<u>50MG</u>	<u>A077443</u>	<u>002</u>	Sep 13, 2006
<u>AB</u>		<u>100MG</u>	<u>A077443</u>	<u>003</u>	Sep 13, 2006
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A073352</u>	<u>001</u>	Dec 27, 1991
<u>AB</u>		<u>100MG</u>	<u>A073353</u>	<u>001</u>	Dec 27, 1991
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900</u>	<u>003</u>	Jan 28, 2005
<u>TENORMIN</u>					
<u>AB</u>	ASTRAZENECA	<u>25MG</u>	<u>N018240</u>	<u>004</u>	Apr 09, 1990
<u>AB</u>		<u>50MG</u>	<u>N018240</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018240</u>	<u>002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	IPR	<u>50MG; 25MG</u>	<u>A072301</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>100MG; 25MG</u>	<u>A072302</u>	<u>001</u>	May 31, 1990
<u>AB</u>	MUTUAL PHARM	<u>50MG; 25MG</u>	<u>A073581</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073582</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>	MYLAN	<u>50MG; 25MG</u>	<u>A074203</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A074203</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>50MG; 25MG</u>	<u>A073665</u>	<u>001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073665</u>	<u>002</u>	Jul 02, 1992
<u>TENORETIC 100</u>					
<u>AB</u>	+	<u>100MG; 25MG</u>	<u>N018760</u>	<u>001</u>	Jun 08, 1984
<u>TENORETIC 50</u>					
<u>AB</u>	ASTRAZENECA	<u>50MG; 25MG</u>	<u>N018760</u>	<u>002</u>	Jun 08, 1984

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A078940</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>18MG</u>	<u>A078940</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>25MG</u>	<u>A078940</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078940</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>60MG</u>	<u>A078940</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078940</u>	<u>006</u>	Aug 30, 2010
<u>AB</u>		<u>100MG</u>	<u>A078940</u>	<u>007</u>	Aug 30, 2010
<u>AB</u>	AUROBINDO PHARM	<u>10MG</u>	<u>A079016</u>	<u>001</u>	Sep 13, 2010
<u>AB</u>		<u>18MG</u>	<u>A079016</u>	<u>002</u>	Sep 13, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 43 (of 409)

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARM	<u>25MG</u>	<u>A079016</u>	<u>003</u>	Sep 13, 2010
<u>AB</u>		<u>40MG</u>	<u>A079016</u>	<u>004</u>	Sep 13, 2010
<u>AB</u>		<u>60MG</u>	<u>A079016</u>	<u>005</u>	Sep 13, 2010
<u>AB</u>		<u>80MG</u>	<u>A079016</u>	<u>006</u>	Sep 13, 2010
<u>AB</u>		<u>100MG</u>	<u>A079016</u>	<u>007</u>	Sep 13, 2010
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A079021</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>18MG</u>	<u>A079021</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>25MG</u>	<u>A079021</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A079021</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>60MG</u>	<u>A079021</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A079021</u>	<u>006</u>	Aug 30, 2010
<u>AB</u>		<u>100MG</u>	<u>A079021</u>	<u>007</u>	Aug 30, 2010
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A079018</u>	<u>001</u>	Sep 13, 2010
<u>AB</u>		<u>18MG</u>	<u>A079018</u>	<u>002</u>	Sep 13, 2010
<u>AB</u>		<u>25MG</u>	<u>A079018</u>	<u>003</u>	Sep 13, 2010
<u>AB</u>		<u>40MG</u>	<u>A079018</u>	<u>004</u>	Sep 13, 2010
<u>AB</u>		<u>60MG</u>	<u>A079018</u>	<u>005</u>	Sep 13, 2010
<u>AB</u>		<u>80MG</u>	<u>A079018</u>	<u>006</u>	Sep 13, 2010
<u>AB</u>		<u>100MG</u>	<u>A079018</u>	<u>007</u>	Sep 13, 2010
<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG</u>	<u>A079020</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>18MG</u>	<u>A079020</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>25MG</u>	<u>A079020</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A079020</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>60MG</u>	<u>A079020</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A079020</u>	<u>006</u>	Aug 30, 2010
<u>AB</u>		<u>100MG</u>	<u>A079020</u>	<u>007</u>	Aug 30, 2010
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A079022</u>	<u>001</u>	Oct 01, 2010
<u>AB</u>		<u>18MG</u>	<u>A079022</u>	<u>002</u>	Oct 01, 2010
<u>AB</u>		<u>25MG</u>	<u>A079022</u>	<u>003</u>	Oct 01, 2010
<u>AB</u>		<u>40MG</u>	<u>A079022</u>	<u>004</u>	Oct 01, 2010
<u>AB</u>		<u>60MG</u>	<u>A079022</u>	<u>005</u>	Oct 01, 2010
<u>AB</u>		<u>80MG</u>	<u>A079022</u>	<u>006</u>	Oct 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A079022</u>	<u>007</u>	Oct 01, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>18MG</u>	<u>A079017</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>25MG</u>	<u>A079017</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>40MG</u>	<u>A079017</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>		<u>60MG</u>	<u>A079017</u>	<u>004</u>	Sep 17, 2010
<u>AB</u>		<u>80MG</u>	<u>A079017</u>	<u>005</u>	Sep 17, 2010
<u>AB</u>		<u>100MG</u>	<u>A079017</u>	<u>006</u>	Sep 17, 2010
<u>AB</u>	<u>STRATTERA</u>				
<u>AB</u>	LILLY	<u>10MG</u>	<u>N021411</u>	<u>002</u>	Nov 26, 2002
<u>AB</u>		<u>18MG</u>	<u>N021411</u>	<u>003</u>	Nov 26, 2002
<u>AB</u>		<u>25MG</u>	<u>N021411</u>	<u>004</u>	Nov 26, 2002
<u>AB</u>		<u>40MG</u>	<u>N021411</u>	<u>005</u>	Nov 26, 2002
<u>AB</u>	+	<u>60MG</u>	<u>N021411</u>	<u>006</u>	Nov 26, 2002
<u>AB</u>		<u>80MG</u>	<u>N021411</u>	<u>007</u>	Feb 14, 2005
<u>AB</u>		<u>100MG</u>	<u>N021411</u>	<u>008</u>	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET; ORAL

LIPITOR

PFIZER

EQ 10MG BASE

N020702 001 Dec 17, 1996

EQ 20MG BASE

N020702 002 Dec 17, 1996

EQ 40MG BASE

N020702 003 Dec 17, 1996

+

EQ 80MG BASE

N020702 004 Apr 07, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 44 (of 409)

ATOVAQUONE

SUSPENSION; ORAL

MEPRON

+ GLAXOSMITHKLINE LLC 750MG/5ML

N020500 001 Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

MALARONE

+ GLAXOSMITHKLINE 250MG;100MG

N021078 001 Jul 14, 2000

MALARONE PEDIATRIC

GLAXOSMITHKLINE 62.5MG;25MG

N021078 002 Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

+ BEDFORD 10MG/ML

A074901 001 Jul 18, 1997

ATRACURIUM BESYLATE PRESERVATIVE FREE

+ BEDFORD 10MG/ML

A074900 001 Jul 18, 1997

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+ MERIDIAN MEDCL TECHN EQ 0.25MG SULFATE/0.3ML

N017106 004 Sep 17, 2004

+ EQ 0.5MG SULFATE/0.7ML

N017106 003 Jun 19, 2003

+ EQ 1MG SULFATE/0.7ML

N017106 002 Jun 19, 2003

+ EQ 2MG SULFATE/0.7ML

N017106 001

ATROPINE SULFATE

INJECTABLE; IM-IV-SC

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

HOSPIRA 0.05MG/ML

N021146 002 Jul 09, 2001

+ 0.1MG/ML

N021146 001 Jul 09, 2001

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+ VALEANT 0.025MG;1MG

N017744 002

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATEAA ROXANE 0.025MG/5ML;2.5MG/5MLA087708 001 May 03, 1982LOMOTILAA + GD SEARLE LLC 0.025MG/5ML;2.5MG/5MLN012699 001

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATEAA LANNETT 0.025MG;2.5MGA085372 001AA MYLAN 0.025MG;2.5MGA085762 001AA PAR PHARM 0.025MG;2.5MGA040357 001 May 02, 2000LOMOTILAA + GD SEARLE LLC 0.025MG;2.5MGN012462 001LONOXAA SANDOZ 0.025MG;2.5MGA085311 002ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+ BIONICHE PHARMA 0.14MG/ML;10MG/ML

N019677 001 Nov 06, 1991

+ 0.14MG/ML;10MG/ML

N019678 001 Nov 06, 1991

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 45 (of 409)

ATROPINE; PRALIDOXIME CHLORIDEINJECTABLE; INTRAMUSCULAR
DUODOTE

+ MERIDIAN MEDCL 2.1MG/0.7ML;600MG/2ML N021983 001 Sep 28, 2006

AURANOFINCAPSULE; ORAL
RIDAURA

+ PROMETHEUS LABS 3MG N018689 001 May 24, 1985

AZACITIDINEINJECTABLE; IV-SC
VIDAZA

+ CELGENE 100MG/VIAL N050794 001 May 19, 2004

AZATHIOPRINE

TABLET; ORAL

AZASAN

<u>AB</u>	AAIPHARMA LLC	<u>25MG</u>	<u>A075252</u>	<u>002</u>	Feb 03, 2003
<u>AB</u>		<u>50MG</u>	<u>A075252</u>	<u>001</u>	Jun 07, 1999
<u>AB</u>		<u>75MG</u>	<u>A075252</u>	<u>003</u>	Feb 03, 2003
<u>AB</u>		<u>100MG</u>	<u>A075252</u>	<u>004</u>	Feb 03, 2003

AZATHIOPRINE

<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075568</u>	<u>001</u>	Dec 13, 1999
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A074069</u>	<u>001</u>	Feb 16, 1996
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077621</u>	<u>002</u>	Sep 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A077621</u>	<u>001</u>	Mar 15, 2007
<u>AB</u>		<u>75MG</u>	<u>A077621</u>	<u>003</u>	Sep 05, 2008
<u>AB</u>		<u>100MG</u>	<u>A077621</u>	<u>004</u>	Sep 05, 2008

IMURAN

<u>AB</u>	+ PROMETHEUS LABS	<u>50MG</u>	<u>N016324</u>	<u>001</u>	

AZATHIOPRINE SODIUMINJECTABLE; INJECTION
AZATHIOPRINE SODIUM

+ BEDFORD EQ 100MG BASE/VIAL A074419 001 Mar 31, 1995

AZELAIC ACIDCREAM; TOPICAL
AZELEX

+ ALLERGAN 20% N020428 001 Sep 13, 1995

GEL; TOPICAL
FINACEA

+ INTENDIS 15% N021470 001 Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

<u>AT</u>	APOTEX INC	<u>0.05%</u>	<u>A078621</u>	<u>001</u>	Aug 03, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.05%</u>	<u>A078738</u>	<u>001</u>	Jun 21, 2010

OPTIVAR

<u>AT</u>	+ MEDA PHARMS	<u>0.05%</u>	<u>N021127</u>	<u>001</u>	May 22, 2000

SPRAY, METERED; NASAL

ASTELIN

<u>AB</u>	+ MEDA PHARMS	<u>EQ 0.125MG BASE/SPRAY</u>	<u>N020114</u>	<u>001</u>	Nov 01, 1996

AZELASTINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A077954</u>	<u>001</u>	Apr 30, 2009
	ASTEPRO				
	+ MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 46 (of 409)

AZELASTINE HYDROCHLORIDESPRAY, METERED; NASAL
ASTEPRO

+ MEDA PHARMS

EQ 0.1876MG BASE/SPRAY

N022371 001

Aug 31, 2009

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCINAB PLIVAEQ 100MG BASE/5MLA065246 002

Jul 05, 2006

ABEQ 200MG BASE/5MLA065246 001

Jul 05, 2006

AB SANDOZEQ 100MG BASE/5MLA065297 001

Sep 18, 2006

ABEQ 200MG BASE/5MLA065297 002

Sep 18, 2006

AB TEVA PHARMSEQ 100MG BASE/5MLA065419 001

Jun 24, 2008

ABEQ 200MG BASE/5MLA065419 002

Jun 24, 2008

ZITHROMAXAB PFIZEREQ 100MG BASE/5MLN050710 001

Oct 19, 1995

AB +EQ 200MG BASE/5MLN050710 002

Oct 19, 1995

ZITHROMAX

+ PFIZER

EQ 1GM BASE/PACKET

N050693 001

Sep 28, 1994

FOR SUSPENSION, EXTENDED RELEASE; ORAL

ZMAX

+ PFIZER GLOBAL

EQ 2GM BASE/BOT

N050797 001

Jun 10, 2005

INJECTABLE; INJECTION

AZITHROMYCINAP APP PHARMSEQ 500MG BASE/VIALA065179 001

Dec 13, 2005

AP GLAND PHARMA LTDEQ 500MG BASE/VIALA065501 001

Nov 09, 2009

AP HOSPIRAEQ 500MG BASE/VIALA065500 001

Jun 26, 2009

APEQ 500MG BASE/VIALA065511 001

Jun 26, 2009

AP PLIVA HRVATSKA DOOEQ 500MG BASE/VIALA065265 001

Jan 18, 2007

AP SAGENT STRIDESEQ 500MG BASE/VIALA065506 001

Mar 24, 2009

AP + TEVA PARENTERALEQ 500MG BASE/VIALN050809 001

Dec 19, 2006

ZITHROMAXAP + PFIZEREQ 500MG BASE/VIALN050733 001

Jan 30, 1997

AZITHROMYCIN

+ TEVA PARENTERAL

EQ 2.5GM BASE/VIAL

N050809 002

Dec 19, 2006

SOLUTION/DROPS; OPHTHALMIC

+ INSPIRE

1%

N050810 001

Apr 27, 2007

TABLET; ORAL

AZITHROMYCINAB MYLANEQ 250MG BASEA065365 001

May 30, 2007

ABEQ 500MG BASEA065366 001

May 30, 2007

ABEQ 600MG BASEA065360 001

Jan 08, 2007

AB PLIVAEQ 250MG BASEA065225 001

Nov 14, 2005

ABEQ 500MG BASEA065223 001

Nov 14, 2005

ABEQ 600MG BASEA065218 001

Nov 14, 2005

AB SANDOZEQ 250MG BASEA065211 001

Nov 14, 2005

ABEQ 500MG BASEA065212 001

Nov 14, 2005

ABEQ 600MG BASEA065209 001

Nov 14, 2005

AB TEVAEQ 250MG BASEA065153 001

Nov 14, 2005

ABEQ 500MG BASEA065193 001

Nov 14, 2005

ABEQ 600MG BASEA065150 001

Nov 14, 2005

AB WOCKHARDTEQ 250MG BASEA065404 001

Feb 11, 2008

ABEQ 500MG BASEA065405 001

Feb 11, 2008

ABEQ 600MG BASEA065302 003

Feb 11, 2008

ZITHROMAXAB PFIZEREQ 250MG BASEN050711 001

Jul 18, 1996

ABEQ 500MG BASEN050784 001

May 24, 2002

AB +EQ 600MG BASEN050730 001

Jun 12, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 47 (of 409)

AZTREONAM

FOR SOLUTION; INHALATION				
CAYSTON				
	+ GILEAD	75MG/VIAL	N050814 001	Feb 22, 2010
INJECTABLE; INJECTION				
<u>AZACTAM</u>				
<u>AP</u>	+ BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580 002</u>	Dec 31, 1986
<u>AP</u>	+	<u>2GM/VIAL</u>	<u>N050580 003</u>	Dec 31, 1986
<u>AZTREONAM</u>				
<u>AP</u>	APP PHARMS	<u>1GM/VIAL</u>	<u>A065439 002</u>	Jun 18, 2010
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065439 003</u>	Jun 18, 2010
AZACTAM IN PLASTIC CONTAINER				
	+ BRISTOL MYERS SQUIBB	20MG/ML	N050632 002	May 24, 1989
	+	40MG/ML	N050632 001	May 24, 1989
AZTREONAM				
	APP PHARMS	500MG/VIAL	A065439 001	Jun 18, 2010

BACITRACIN

INJECTABLE; INJECTION				
<u>BACIIM</u>				
<u>AP</u>	X GEN PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A064153 001</u>	May 09, 1997
<u>BACITRACIN</u>				
<u>AP</u>	APP PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A065116 001</u>	Dec 03, 2002
<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>50,000 UNITS/VIAL</u>	<u>A060733 002</u>	
<u>AP</u>	SAGENT STRIDES	<u>50,000 UNITS/VIAL</u>	<u>A090211 001</u>	May 11, 2010
BACITRACIN				
	PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733 001	
OINTMENT; OPHTHALMIC				
BACITRACIN				
	+ ALTANA	500 UNITS/GM	A061212 001	
POWDER; FOR RX COMPOUNDING				
BACI-RX				
	X GEN PHARMS	5,000,000 UNITS/BOT	A061580 001	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE				
	+ BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068 001	Oct 30, 1995
OINTMENT; TOPICAL				
CORTISPORIN				
	+ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168 002	May 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
<u>NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC</u>				
<u>AT</u>	AKORN	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065088 001</u>	Feb 06, 2004
<u>AT</u>	ALTANA	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A060764 002</u>	
<u>AT</u>	+ BAUSCH AND LOMB	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064064 001</u>	Oct 30, 1995

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
<u>BACITRACIN ZINC AND POLYMYXIN B SULFATE</u>				
<u>AT</u>	AKORN	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064028 001</u>	Jan 30, 1995
<u>AT</u>	ALTANA	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A065022 001</u>	Feb 27, 2002
<u>AT</u>	+ BAUSCH AND LOMB	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064046 001</u>	Jan 26, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 48 (of 409)

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002	

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

CNS THERAP	0.05MG/ML	N022462	001	Nov 19, 2010
	0.5MG/ML	N022462	002	Nov 19, 2010
	2MG/ML	N022462	003	Nov 19, 2010

LIORESAL

+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996
+		0.5MG/ML	N020075	001	Jun 17, 1992
+		2MG/ML	N020075	002	Jun 17, 1992

TABLET; ORAL

BACLOFEN

<u>AB</u>	ACTAVIS TOTOWA	<u>10MG</u>	<u>A077089</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077088</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>	CARACO	<u>10MG</u>	<u>A077984</u>	<u>001</u>	Aug 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077862</u>	<u>002</u>	Aug 14, 2006
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A078146</u>	<u>001</u>	Oct 26, 2007
<u>AB</u>		<u>20MG</u>	<u>A077971</u>	<u>002</u>	Oct 26, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A072234</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>	+	<u>20MG</u>	<u>A072235</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>	LANNETT	<u>10MG</u>	<u>A078220</u>	<u>001</u>	Jul 06, 2007
<u>AB</u>		<u>20MG</u>	<u>A077241</u>	<u>001</u>	Dec 20, 2005
<u>AB</u>	MATRIX LABS LTD	<u>10MG</u>	<u>A090334</u>	<u>001</u>	Feb 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090334</u>	<u>002</u>	Feb 18, 2010
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A077181</u>	<u>001</u>	Jul 29, 2005
<u>AB</u>		<u>20MG</u>	<u>A077121</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078504</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>		<u>20MG</u>	<u>A078401</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>	USL PHARMA	<u>10MG</u>	<u>A074584</u>	<u>001</u>	Aug 19, 1996
<u>AB</u>		<u>20MG</u>	<u>A074584</u>	<u>002</u>	Aug 19, 1996
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A077156</u>	<u>001</u>	Aug 30, 2005
<u>AB</u>		<u>20MG</u>	<u>A077068</u>	<u>001</u>	Aug 30, 2005
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A072824</u>	<u>001</u>	Sep 18, 1991
<u>AB</u>		<u>20MG</u>	<u>A072825</u>	<u>001</u>	Sep 18, 1991

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

<u>AB</u>	APOTEX INC	<u>750MG</u>	<u>A077883</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077807</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	ROXANE	<u>750MG</u>	<u>A077806</u>	<u>001</u>	Dec 28, 2007

COLAZAL

<u>AB</u>	+	SALIX PHARMS	<u>750MG</u>	<u>N020610</u>	<u>001</u>	Jul 18, 2000

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+	TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000

QVAR 80

+	TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 49 (of 409)

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL
BECONASE AQ

+ GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY

N019389 001 Jul 27, 1987

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077128</u>	<u>001</u>	Mar 08, 2006
<u>AB</u>		<u>10MG</u>	<u>A077128</u>	<u>002</u>	Mar 08, 2006
<u>AB</u>		<u>20MG</u>	<u>A077128</u>	<u>003</u>	Mar 08, 2006
<u>AB</u>		<u>40MG</u>	<u>A077128</u>	<u>004</u>	Mar 08, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A078212</u>	<u>001</u>	May 22, 2008
<u>AB</u>		<u>20MG</u>	<u>A078212</u>	<u>002</u>	May 22, 2008
<u>AB</u>		<u>40MG</u>	<u>A078212</u>	<u>003</u>	May 22, 2008
<u>AB</u>	BIOKEY	<u>5MG</u>	<u>A076820</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A076820</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>20MG</u>	<u>A076820</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>		<u>40MG</u>	<u>A076820</u>	<u>004</u>	Feb 03, 2006
<u>AB</u>	HUAHAI US INC	<u>5MG</u>	<u>A076118</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076333</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076333</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076333</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076333</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076430</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076430</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076430</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076430</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076344</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A076402</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG</u>	<u>A076267</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076267</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076267</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076267</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848</u>	<u>003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848</u>	<u>004</u>	May 23, 2008
	<u>LOTENSIN</u>				
<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N019851</u>	<u>001</u>	Jun 25, 1991
<u>AB</u>		<u>10MG</u>	<u>N019851</u>	<u>002</u>	Jun 25, 1991
<u>AB</u>		<u>20MG</u>	<u>N019851</u>	<u>003</u>	Jun 25, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019851</u>	<u>004</u>	Jun 25, 1991

PRESCRIPTION DRUG PRODUCT LIST

3 - 50 (of 409)

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	GENPHARM	<u>5MG; 6.25MG</u>	<u>A076612</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076612</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076612</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076612</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG; 6.25MG</u>	<u>A076348</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076348</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076348</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076348</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG; 6.25MG</u>	<u>A077483</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A077483</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A077483</u>	<u>003</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 25MG</u>	<u>A077483</u>	<u>004</u>	Sep 08, 2005
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG; 6.25MG</u>	<u>A076342</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076342</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076342</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076342</u>	<u>004</u>	Feb 11, 2004
	<u>LOTENSIN HCT</u>				
<u>AB</u>	NOVARTIS	<u>5MG; 6.25MG</u>	<u>N020033</u>	<u>001</u>	May 19, 1992
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>N020033</u>	<u>002</u>	May 19, 1992
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>N020033</u>	<u>004</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 25MG</u>	<u>N020033</u>	<u>003</u>	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009
+		100MG/VIAL	N022249	001	Mar 20, 2008

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

<u>AB</u>	KING PHARMS	<u>5MG; 40MG</u>	<u>N018647</u>	<u>001</u>	May 25, 1983
<u>AB</u>	+	<u>5MG; 80MG</u>	<u>N018647</u>	<u>002</u>	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	MYLAN	<u>5MG; 40MG</u>	<u>A078688</u>	<u>001</u>	Feb 15, 2008
<u>AB</u>		<u>5MG; 80MG</u>	<u>A078688</u>	<u>002</u>	Feb 15, 2008

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	IMPAX LABS	<u>5MG; 40MG</u>	<u>A077833</u>	<u>001</u>	Mar 30, 2007
<u>AB</u>		<u>5MG; 80MG</u>	<u>A077833</u>	<u>002</u>	Mar 30, 2007

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>	BANNER PHARMACAPS	<u>100MG</u>	<u>A081297</u>	<u>001</u>	Jan 29, 1993
<u>AA</u>		<u>200MG</u>	<u>A081297</u>	<u>002</u>	Oct 30, 2007
<u>AA</u>	KV PHARM	<u>100MG</u>	<u>A040795</u>	<u>001</u>	Oct 31, 2007
<u>AA</u>		<u>200MG</u>	<u>A040795</u>	<u>002</u>	Oct 31, 2007
<u>AA</u>	MIKART	<u>100MG</u>	<u>A040851</u>	<u>001</u>	Nov 09, 2009
<u>AA</u>		<u>200MG</u>	<u>A040851</u>	<u>003</u>	Nov 09, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 51 (of 409)

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>	ORIT LABS LLC	<u>100MG</u>	<u>A040682</u>	<u>001</u>	Jul 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040682</u>	<u>002</u>	Jul 30, 2007
<u>AA</u>	SUN PHARM INDS INC	<u>100MG</u>	<u>A040587</u>	<u>001</u>	Mar 19, 2008
<u>AA</u>		<u>200MG</u>	<u>A040587</u>	<u>002</u>	Mar 19, 2008
<u>AA</u>	THE PHARMA NETWORK	<u>100MG</u>	<u>A040627</u>	<u>001</u>	Mar 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040749</u>	<u>001</u>	Jul 25, 2007
<u>AA</u>	ZYDUS PHARMS USA	<u>100MG</u>	<u>A040597</u>	<u>001</u>	Jun 08, 2007
<u>AA</u>		<u>200MG</u>	<u>A040597</u>	<u>002</u>	Jun 08, 2007

TESSALON

<u>AA</u>	+ FOREST LABS	<u>100MG</u>	<u>N011210</u>	<u>001</u>	
<u>AA</u>		<u>200MG</u>	<u>N011210</u>	<u>003</u>	Jun 25, 1999
	BENZONATATE				
	MIKART	150MG	A040851	002	Nov 09, 2009

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

<u>AB</u>	SANOFI AVENTIS US	<u>5%;EQ 1% BASE</u>	<u>N050756</u>	<u>001</u>	Dec 21, 2000
	<u>CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>				
<u>AB</u>	DOW PHARM SCIENCES	<u>5%;EQ 1% BASE</u>	<u>A065443</u>	<u>001</u>	Aug 11, 2009
	BENZACLIN				
BT	+ SANOFI AVENTIS US	5%;EQ 1% BASE	N050756	002	Apr 20, 2007
	DUAC				
BT	+ STIEFEL	5%;EQ 1% BASE	N050741	001	Aug 26, 2002
	ACANYA				
	+ DOW PHARM SCI	2.5%;1.2%	N050819	001	Oct 23, 2008

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

<u>AB</u>	+ SANOFI AVENTIS US	<u>5%;3%</u>	<u>N050557</u>	<u>001</u>	Oct 26, 1984
	<u>ERYTHROMYCIN AND BENZOYL PEROXIDE</u>				
<u>AB</u>	TOLMAR	<u>5%;3%</u>	<u>A065112</u>	<u>001</u>	Mar 29, 2004
	BENZAMYCIN PAK				
	+ SANOFI AVENTIS US	5%;3%	N050769	001	Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

<u>AA</u>	COREPHARMA	<u>50MG</u>	<u>A040714</u>	<u>001</u>	Oct 29, 2007
<u>AA</u>	IMPAX LABS	<u>50MG</u>	<u>A040845</u>	<u>001</u>	Nov 18, 2008
<u>AA</u>	KVK TECH	<u>50MG</u>	<u>A090968</u>	<u>001</u>	Jul 20, 2010
<u>AA</u>	MIKART	<u>25MG</u>	<u>A090473</u>	<u>001</u>	Sep 15, 2010
<u>AA</u>		<u>50MG</u>	<u>A090473</u>	<u>002</u>	Sep 15, 2010
<u>AA</u>	PADDOCK	<u>50MG</u>	<u>A040578</u>	<u>001</u>	Apr 17, 2006
<u>AA</u>	TEDOR PHARM	<u>50MG</u>	<u>A040747</u>	<u>001</u>	Mar 30, 2007
<u>AA</u>	TYCO HLTHCARE	<u>50MG</u>	<u>A040773</u>	<u>001</u>	Apr 25, 2007

DIDREX

<u>AA</u>	+ PHARMACIA AND UPJOHN	<u>50MG</u>	<u>N012427</u>	<u>002</u>	

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A090287</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>	NEXUS PHARMS	<u>1MG/ML</u>	<u>A090233</u>	<u>001</u>	Jul 28, 2009
<u>AP</u>	PHARMAFORCE	<u>1MG/ML</u>	<u>A091152</u>	<u>001</u>	Mar 29, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 52 (of 409)

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

COGENTIN

<u>AP</u>	+	LUNDBECK INC	<u>1MG/ML</u>	<u>N012015</u>	<u>001</u>	

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>		ACTAVIS TOTOWA	<u>0.5MG</u>	<u>A040699</u>	<u>001</u>	Feb 14, 2008
<u>AA</u>			<u>1MG</u>	<u>A040705</u>	<u>001</u>	Feb 14, 2008
<u>AA</u>			<u>2MG</u>	<u>A040706</u>	<u>001</u>	Feb 14, 2008
<u>AA</u>		COREPHARMA	<u>0.5MG</u>	<u>A072264</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>			<u>1MG</u>	<u>A072265</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>			<u>2MG</u>	<u>A072266</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>		INVAGEN PHARMS	<u>0.5MG</u>	<u>A090294</u>	<u>001</u>	Mar 29, 2010
<u>AA</u>			<u>1MG</u>	<u>A090294</u>	<u>002</u>	Mar 29, 2010
<u>AA</u>			<u>2MG</u>	<u>A090294</u>	<u>003</u>	Mar 29, 2010
<u>AA</u>	+	LANNETT	<u>0.5MG</u>	<u>A088877</u>	<u>001</u>	Apr 11, 1985
<u>AA</u>	+		<u>1MG</u>	<u>A088894</u>	<u>001</u>	Apr 11, 1985
<u>AA</u>	+		<u>2MG</u>	<u>A088895</u>	<u>001</u>	Apr 11, 1985
<u>AA</u>		PLIVA	<u>0.5MG</u>	<u>A089058</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>			<u>1MG</u>	<u>A089059</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>			<u>2MG</u>	<u>A089060</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>		USL PHARMA	<u>0.5MG</u>	<u>A040103</u>	<u>001</u>	Dec 12, 1996
<u>AA</u>			<u>1MG</u>	<u>A040103</u>	<u>002</u>	Dec 12, 1996
<u>AA</u>			<u>2MG</u>	<u>A040103</u>	<u>003</u>	Dec 12, 1996
<u>AA</u>		VINTAGE	<u>0.5MG</u>	<u>A040738</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>			<u>1MG</u>	<u>A040742</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>			<u>2MG</u>	<u>A040715</u>	<u>003</u>	Aug 27, 2007

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

	+	SHIONOGI PHARMA	5%	N022129	001	Apr 09, 2009

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

	+	ALLERQUEST	60UMOLAR	N050114	001	

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

	+	ISTA PHARMS	1.5%	N022288	001	Sep 08, 2009

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

	+	ROSS LABS	25MG/ML	N020032	001	Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

	+	BAUSCH AND LOMB	EQ 0.6% BASE	N022308	001	May 28, 2009

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

	+	RARE DIS THERAP	1GM/SC00PFUL	N020576	001	Oct 25, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 53 (of 409)

BETAMETHASONE

SYRUP; ORAL
CELESTONE
+ SCHERING

0.6MG/5ML

N014215 002

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB	LUITPOLD	3MG/ML;EQ 3MG BASE/ML	A090747 001	Jul 31, 2009

CELESTONE SOLUSPAN

AB	+ SCHERING	3MG/ML;EQ 3MG BASE/ML	N014602 001	

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A070885 001	Feb 03, 1987

AB	+ FOUGERA	EQ 0.05% BASE	N019137 001	Jun 26, 1984

AB	TARO	EQ 0.05% BASE	A073552 001	Apr 30, 1992

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ALTANA	EQ 0.05% BASE	A076215 001	Dec 09, 2003

AB	GLENMARK GENERICS	EQ 0.05% BASE	A078930 001	Sep 23, 2008

AB	PERRIGO NEW YORK	EQ 0.05% BASE	A076592 001	Dec 09, 2003

AB	TARO	EQ 0.05% BASE	A076543 001	Dec 09, 2003

AB	TOLMAR	EQ 0.05% BASE	A076603 001	Jan 23, 2004

DIPROLENE AF

AB	+ SCHERING	EQ 0.05% BASE	N019555 001	Apr 27, 1987

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+ ALTANA	EQ 0.05% BASE	A075276 001	May 13, 2003

AB	TARO	EQ 0.05% BASE	A076508 001	Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A070281 001	Jul 31, 1985

AB	+ FOUGERA	EQ 0.05% BASE	A070275 001	Aug 12, 1985

AB	PERRIGO NEW YORK	EQ 0.05% BASE	A072538 001	Jan 31, 1990

AB	TEVA	EQ 0.05% BASE	A071467 001	Aug 10, 1987

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ALTANA	EQ 0.05% BASE	A077111 001	May 21, 2007

AB	TARO	EQ 0.05% BASE	A077477 001	May 21, 2007

DIPROLENE

AB	+ SCHERING	EQ 0.05% BASE	N019716 001	Aug 01, 1988

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A071012 001	Feb 03, 1987

AB	+ FOUGERA	EQ 0.05% BASE	N019141 001	Sep 04, 1984

AB	TARO	EQ 0.05% BASE	A074271 001	Sep 15, 1994

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A074304 001	Aug 31, 1995

AB	ALTANA	EQ 0.05% BASE	A075373 001	Jun 22, 1999

AB	TARO	EQ 0.05% BASE	A076753 001	Oct 12, 2004

DIPROLENE

AB	+ SCHERING	EQ 0.05% BASE	N018741 001	Jul 27, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 54 (of 409)

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

+ LEO PHARM 0.064%;0.005% N021852 001 Jan 09, 2006

SUSPENSION; TOPICAL

TACLONEX SCALP

+ LEO PHARM PRODS 0.064%;0.005% N022185 001 May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATEAB ACTAVIS MID ATLANTIC EQ 0.05% BASE;1% A076002 001 Aug 02, 2002AB ALTANA EQ 0.05% BASE;1% A075502 001 Jun 05, 2001AB TARO EQ 0.05% BASE;1% A075673 001 May 29, 2001LOTTRISONEAB + SCHERING EQ 0.05% BASE;1% N018827 001 Jul 10, 1984

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATEAB ALTANA PHARMA EQ 0.05% BASE;1% A076516 001 Jun 16, 2005AB TARO EQ 0.05% BASE;1% A076493 001 Jul 28, 2004LOTTRISONEAB + SCHERING PLOUGH RES EQ 0.05% BASE;1% N020010 001 Dec 08, 2000BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

+ CONNECTICS EQ 0.12% BASE N020934 001 Feb 28, 1999

CREAM; TOPICAL

BETAMETHASONE VALERATEAB + FOUGERA EQ 0.1% BASE N018861 001 Aug 31, 1983BETA-VALAB TEVA EQ 0.1% BASE N018642 001 Mar 24, 1983DERMABETAB TARO EQ 0.1% BASE A072041 001 Jan 06, 1988VALNACAB ACTAVIS MID ATLANTIC EQ 0.1% BASE A070050 001 Oct 10, 1984

LOTION; TOPICAL

BETAMETHASONE VALERATEAB + FOUGERA EQ 0.1% BASE N018866 001 Aug 31, 1983AB STAT TRADE EQ 0.1% BASE A070052 001 Jul 31, 1985BETA-VALAB TEVA EQ 0.1% BASE A070072 001 Jun 27, 1985

OINTMENT; TOPICAL

BETAMETHASONE VALERATEAB ACTAVIS MID ATLANTIC EQ 0.1% BASE A070051 001 Oct 10, 1984AB + FOUGERA EQ 0.1% BASE N018865 001 Aug 31, 1983BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDEAT AKORN EQ 0.5% BASE A075386 001 Jun 30, 2000AT BAUSCH AND LOMB EQ 0.5% BASE A075630 001 Apr 12, 2001AT NOVEX EQ 0.5% BASE A075446 001 Sep 28, 2000AT WOCKHARDT EQ 0.5% BASE A078694 001 Nov 16, 2009BETOPTICAT + ALCON EQ 0.5% BASE N019270 001 Aug 30, 1985

SUSPENSION/DROPS; OPHTHALMIC

+ ALCON EQ 0.25% BASE N019845 001 Dec 29, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 55 (of 409)

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>10MG</u>	<u>A075541</u>	<u>001</u>	Oct 22, 1999
<u>AB</u>	+	<u>20MG</u>	<u>A075541</u>	<u>002</u>	Oct 22, 1999
<u>AB</u>	KVK TECH	<u>10MG</u>	<u>A078962</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>20MG</u>	<u>A078962</u>	<u>002</u>	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

<u>AA</u>	ACTAVIS TOTOWA	<u>5MG</u>	<u>A040552</u>	<u>001</u>	Oct 28, 2004
<u>AA</u>		<u>10MG</u>	<u>A040553</u>	<u>001</u>	Oct 28, 2004
<u>AA</u>		<u>25MG</u>	<u>A040554</u>	<u>001</u>	Oct 28, 2004
<u>AA</u>	AMNEAL PHARM	<u>5MG</u>	<u>A040855</u>	<u>001</u>	Nov 21, 2007
<u>AA</u>		<u>10MG</u>	<u>A040855</u>	<u>002</u>	Nov 21, 2007
<u>AA</u>		<u>25MG</u>	<u>A040855</u>	<u>003</u>	Nov 21, 2007
<u>AA</u>		<u>50MG</u>	<u>A040855</u>	<u>004</u>	Nov 21, 2007
<u>AA</u>	EMCURE USA	<u>5MG</u>	<u>A091256</u>	<u>001</u>	May 04, 2010
<u>AA</u>		<u>10MG</u>	<u>A091256</u>	<u>002</u>	May 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A091256</u>	<u>003</u>	May 04, 2010
<u>AA</u>		<u>50MG</u>	<u>A091256</u>	<u>004</u>	May 04, 2010
<u>AA</u>	IMPAX LABS	<u>5MG</u>	<u>A040739</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>		<u>10MG</u>	<u>A040741</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>		<u>25MG</u>	<u>A040740</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>		<u>50MG</u>	<u>A040721</u>	<u>004</u>	Nov 01, 2006
<u>AA</u>	LANNETT	<u>5MG</u>	<u>A040703</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>		<u>10MG</u>	<u>A040704</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>		<u>25MG</u>	<u>A040678</u>	<u>003</u>	Mar 27, 2008
<u>AA</u>		<u>50MG</u>	<u>A040677</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>	PHARMAX	<u>5MG</u>	<u>A040725</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>		<u>10MG</u>	<u>A040726</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>		<u>25MG</u>	<u>A040727</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>		<u>50MG</u>	<u>A040728</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A040897</u>	<u>001</u>	Apr 22, 2009
<u>AA</u>		<u>10MG</u>	<u>A040897</u>	<u>002</u>	Apr 22, 2009
<u>AA</u>		<u>25MG</u>	<u>A040897</u>	<u>003</u>	Apr 22, 2009
<u>AA</u>		<u>50MG</u>	<u>A040897</u>	<u>004</u>	Apr 22, 2009
<u>AA</u>	UPSHER SMITH	<u>5MG</u>	<u>A040633</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>		<u>10MG</u>	<u>A040634</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>		<u>25MG</u>	<u>A040635</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>		<u>50MG</u>	<u>A040636</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>	WOCKHARDT	<u>5MG</u>	<u>A040532</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>		<u>10MG</u>	<u>A040533</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>		<u>25MG</u>	<u>A040534</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>		<u>50MG</u>	<u>A040518</u>	<u>001</u>	Sep 29, 2003
<u>DUVOID</u>					
<u>AA</u>	WELLSPRING PHARM	<u>10MG</u>	<u>A086262</u>	<u>001</u>	
<u>AA</u>		<u>25MG</u>	<u>A086263</u>	<u>001</u>	
<u>AA</u>		<u>50MG</u>	<u>A085882</u>	<u>003</u>	
<u>URECHOLINE</u>					
<u>AA</u>	+	<u>5MG</u>	<u>A089095</u>	<u>001</u>	Dec 19, 1985
<u>AA</u>	+	<u>10MG</u>	<u>A088440</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+	<u>25MG</u>	<u>A088441</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A089096</u>	<u>001</u>	Dec 19, 1985

BEXAROTENE

CAPSULE; ORAL

TARGRETIN

+ EISAI INC 75MG

N021055 001 Dec 29, 1999

PRESCRIPTION DRUG PRODUCT LIST

3 - 56 (of 409)

BEXAROTENE

GEL; TOPICAL
TARGRETIN

+ EISAI INC	1%	N021056 001	Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>50MG</u>	<u>A078917</u> <u>001</u>	Jul 06, 2009
<u>AB</u>	ACTAVIS TOTOWA	<u>50MG</u>	<u>A078634</u> <u>001</u>	Aug 28, 2009
<u>AB</u>	FRESENIUS KABI ONCOL	<u>50MG</u>	<u>A079045</u> <u>001</u>	May 13, 2010
<u>AB</u>	KUDCO IRELAND	<u>50MG</u>	<u>A077995</u> <u>001</u>	Jul 06, 2009
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A079185</u> <u>001</u>	Jul 06, 2009
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A078575</u> <u>001</u>	Jul 06, 2009
<u>AB</u>	SUN PHARMA GLOBAL	<u>50MG</u>	<u>A079110</u> <u>001</u>	Jul 06, 2009
<u>AB</u>	SYNTHON PHARMS	<u>50MG</u>	<u>A077973</u> <u>001</u>	Jul 06, 2009
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076932</u> <u>001</u>	Jul 06, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A079089</u> <u>001</u>	Jul 06, 2009

CASODEX

<u>AB</u>	+ ASTRAZENECA	<u>50MG</u>	<u>N020498</u> <u>001</u>	Oct 04, 1995

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC
LUMIGAN

+ ALLERGAN	0.01%	N022184 001	Aug 31, 2010
+	0.03%	N021275 001	Mar 16, 2001

SOLUTION/DROPS; TOPICAL

+ ALLERGAN	0.03%	N022369 001	Dec 24, 2008

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL
AKINETON

+ ABBOTT	2MG	N012003 001

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL
HALFLYTELY

+ BRAINTREE	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM ; N/A, 5.6GM	N021551 003	Jul 16, 2010

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL
PYLERA

+ AXCAN SCANDIPHARM	140MG; 125MG; 125MG	N050786 001	Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL
HELIDAC

+ PROMETHEUS LABS	262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 5 00MG	N050719 001	Aug 15, 1996

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077910</u> <u>001</u>	Dec 27, 2006
<u>AB</u>		<u>10MG</u>	<u>A077910</u> <u>002</u>	Dec 27, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075831</u> <u>001</u>	Dec 14, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 57 (of 409)

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075831</u>	<u>002</u>	Dec 14, 2005
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A075643</u>	<u>001</u>	Nov 16, 2000
<u>AB</u>		<u>10MG</u>	<u>A075643</u>	<u>002</u>	Nov 16, 2000
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A075644</u>	<u>001</u>	Jun 26, 2001
<u>AB</u>		<u>10MG</u>	<u>A075644</u>	<u>002</u>	Jun 26, 2001
<u>AB</u>	UNICHEM PHARMS (USA)	<u>5MG</u>	<u>A078635</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>10MG</u>	<u>A078635</u>	<u>002</u>	Aug 18, 2009
<u>ZEBETA</u>					
<u>AB</u>	DURAMED PHARMS BARR	<u>5MG</u>	<u>N019982</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>10MG</u>	<u>N019982</u>	<u>001</u>	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>2.5MG; 6.25MG</u>	<u>A075672</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075672</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075672</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	MYLAN	<u>2.5MG; 6.25MG</u>	<u>A075768</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075768</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075768</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	SANDOZ	<u>2.5MG; 6.25MG</u>	<u>A075579</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075579</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075579</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	UNICHEM	<u>2.5MG; 6.25MG</u>	<u>A079106</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A079106</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A079106</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>	WATSON LABS	<u>2.5MG; 6.25MG</u>	<u>A075469</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075469</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075469</u>	<u>003</u>	Sep 25, 2000
<u>ZIAC</u>					
<u>AB</u>	DURAMED PHARMS BARR	<u>2.5MG; 6.25MG</u>	<u>N020186</u>	<u>003</u>	Mar 26, 1993
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>N020186</u>	<u>001</u>	Mar 26, 1993
<u>AB</u>	+	<u>10MG; 6.25MG</u>	<u>N020186</u>	<u>002</u>	Mar 26, 1993

BIVALIRUDININJECTABLE; INTRAVENOUS
ANGIOMAX

+	MEDICINES CO	250MG/VIAL	N020873	001	Dec 15, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<u>AP</u>	+	APP PHARMS	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>001</u>	Jan 28, 2008
<u>AP</u>	+		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>002</u>	Jan 28, 2008
<u>AP</u>		BEDFORD	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>002</u>	Oct 17, 2001
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>001</u>	Oct 17, 2001
<u>AP</u>		HOSPIRA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>001</u>	Mar 10, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>002</u>	Mar 10, 2000
<u>AP</u>		PHARMACHEMIE BV	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065201</u>	<u>001</u>	Dec 13, 2007
<u>AP</u>		TEVA PARENTERAL	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>001</u>	Jun 27, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>002</u>	Jun 27, 2000

BORTEZOMIBINJECTABLE; INTRAVENOUS
VELCADE

+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 58 (of 409)

BOSENTAN

TABLET; ORAL

TRACLEER

ACTELION	62.5MG	N021290 001	Nov 20, 2001
+	125MG	N021290 002	Nov 20, 2001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u> + B BRAUN	<u>200MG/100ML</u>	<u>N019121 002</u>	Apr 29, 1986
<u>AP</u> +	<u>400MG/100ML</u>	<u>N019121 003</u>	Apr 29, 1986
<u>AP</u> + HOSPIRA	<u>200MG/100ML</u>	<u>N019008 002</u>	Apr 29, 1986
<u>AP</u> +	<u>400MG/100ML</u>	<u>N019008 003</u>	Apr 29, 1986
BRETYLIUM TOSYLATE			
+ HOSPIRA	50MG/ML	N019030 001	Apr 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
+ B BRAUN	100MG/100ML	N019121 001	Apr 29, 1986

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

<u>AT</u> + ALLERGAN	<u>0.15%</u>	<u>N021262 001</u>	Mar 16, 2001
<u>BRIMONIDINE TARTRATE</u>			
<u>AT</u> AKORN	<u>0.2%</u>	<u>A076439 001</u>	Mar 14, 2006
<u>AT</u> ALCON	<u>0.2%</u>	<u>A076254 001</u>	Sep 16, 2003
<u>AT</u> ALCON RES	<u>0.15%</u>	<u>N021764 001</u>	May 22, 2006
<u>AT</u> + BAUSCH AND LOMB	<u>0.2%</u>	<u>A076260 001</u>	May 28, 2003
<u>AT</u> SANDOZ	<u>0.2%</u>	<u>A078075 001</u>	Jan 30, 2008
<u>AT</u> TEVA PARENTERAL	<u>0.2%</u>	<u>A076372 001</u>	Sep 10, 2004
ALPHAGAN P			
+ ALLERGAN	0.1%	N021770 001	Aug 19, 2005

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COMBIGAN

+ ALLERGAN	0.2%;0.5%	N021398 001	Oct 30, 2007

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

+ ALCON	1%	N020816 001	Apr 01, 1998

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

ISTA PHARMS

0.09%	N021664 002	Oct 16, 2010

XIBROM

+ ISTA PHARMS	0.09%	N021664 001 Mar 24, 2005

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

<u>AB</u> MYLAN	<u>EQ 5MG BASE</u>	<u>A077226 001</u>	Apr 04, 2005
<u>AB</u> ZYDUS PHARMS USA INC	<u>EQ 5MG BASE</u>	<u>A078899 001</u>	Jul 30, 2008
<u>PARLODEL</u>			
<u>AB</u> + NOVARTIS	<u>EQ 5MG BASE</u>	<u>N017962 002</u>	Mar 01, 1982

TABLET; ORAL

BROMOCRIPTINE MESYLATE

<u>AB</u> LEK PHARMS	<u>EQ 2.5MG BASE</u>	<u>A074631 001</u>	Jan 13, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 59 (of 409)

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076962</u>	<u>001</u>	Sep 24, 2004
<u>AB</u>	PADDOCK	<u>EQ 2.5MG BASE</u>	<u>A077646</u>	<u>001</u>	Oct 01, 2008
<u>PARLODEL</u>					
<u>AB</u>	+ NOVARTIS	<u>EQ 2.5MG BASE</u>	<u>N017962</u>	<u>001</u>	
	CYCLOSET				
	+ VEROSCIENCE	EQ 0.8MG BASE	N020866	001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

	+ WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985

BUDESONIDE

CAPSULE; ORAL

ENTOCORT EC

	+ ASTRAZENECA	3MG	N021324	001	Oct 02, 2001

POWDER, METERED; INHALATION

PULMICORT

	+ ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997

PULMICORT FLEXHALER

	ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006

	+	0.16MG/INH	N021949	002	Jul 12, 2006

SPRAY, METERED; NASAL

RHINOCORT

	+ ASTRAZENECA	0.032MG/INH	N020746	001	Oct 01, 1999

SUSPENSION; INHALATION

BUDESONIDE

<u>AN</u>	APOTEX	<u>0.25MG/2ML</u>	<u>A078202</u>	<u>001</u>	Mar 30, 2009
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A078202</u>	<u>002</u>	Mar 30, 2009
<u>AN</u>	TEVA PARENTERAL	<u>0.25MG/2ML</u>	<u>A077519</u>	<u>001</u>	Nov 18, 2008
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A077519</u>	<u>002</u>	Nov 18, 2008
<u>PULMICORT RESPULES</u>					
<u>AN</u>	ASTRAZENECA	<u>0.25MG/2ML</u>	<u>N020929</u>	<u>001</u>	Aug 08, 2000
<u>AN</u>		<u>0.5MG/2ML</u>	<u>N020929</u>	<u>002</u>	Aug 08, 2000
	PULMICORT RESPULES				
	+ ASTRAZENECA	1MG/2ML	N020929	003	Aug 08, 2000

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

SPRAY, METERED; INHALATION

SYMBICORT

	+ ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006

	+	0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<u>AP</u>	BAXTER HLTHCARE	<u>0.25MG/ML</u>	<u>A079196</u>	<u>001</u>	Apr 30, 2008
<u>AP</u>	+ BEDFORD	<u>0.25MG/ML</u>	<u>A074441</u>	<u>001</u>	Jan 27, 1995
<u>AP</u>	HOSPIRA	<u>0.25MG/ML</u>	<u>A074332</u>	<u>001</u>	Oct 31, 1994
<u>AP</u>	TEVA PARENTERAL	<u>0.25MG/ML</u>	<u>A074613</u>	<u>001</u>	Nov 18, 1997

TABLET; ORAL

BUMETANIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A074225</u>	<u>001</u>	Apr 24, 1995
<u>AB</u>		<u>1MG</u>	<u>A074225</u>	<u>002</u>	Apr 24, 1995
<u>AB</u>		<u>2MG</u>	<u>A074225</u>	<u>003</u>	Apr 24, 1995
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074700</u>	<u>001</u>	Nov 21, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 60 (of 409)

BUMETANIDE

TABLET; ORAL

BUMETANIDE

<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A074700</u>	<u>002</u>	Nov 21, 1996
<u>AB</u> +		<u>2MG</u>	<u>A074700</u>	<u>003</u>	Nov 21, 1996

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	HOSPIRA	0.25%	A070583	001	Feb 17, 1987
AP		0.25%	A070586	001	Mar 03, 1987
AP		0.25%	A070590	001	Feb 17, 1987
AP		0.25%	N018053	002	
AP		0.5%	A070584	001	Feb 17, 1986
AP		0.5%	A070597	001	Mar 03, 1987
AP		0.5%	A070609	001	Mar 03, 1987
AP		0.5%	N018053	001	
AP		0.75%	A070585	001	Mar 03, 1987
AP		0.75%	A070587	001	Mar 03, 1987
AP		0.75%	N018053	003	

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	INTL MEDICATED	<u>0.25%</u>	<u>A076012</u>	<u>001</u>	Jan 09, 2002
AP		<u>0.5%</u>	<u>A076012</u>	<u>002</u>	Jan 09, 2002
AP		<u>0.75%</u>	<u>A076012</u>	<u>003</u>	Jan 09, 2002

MARCAINE HYDROCHLORIDE

<u>AP</u>	+	<u>HOSPIRA</u>	<u>0.25%</u>	<u>N016964</u>	<u>001</u>
<u>AP</u>	+		<u>0.5%</u>	<u>N016964</u>	<u>006</u>

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	+	HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>012</u>
AP	+		<u>0.5%</u>	<u>N016964</u>	<u>005</u>
AP	+		<u>0.75%</u>	<u>N016964</u>	<u>009</u>

SENSORCAINE

AP	APP PHARMS	<u>0.25%</u>	<u>A070552</u>	<u>001</u>	May 21, 1986
AP		<u>0.25%</u>	<u>N018304</u>	<u>001</u>	
AP		<u>0.5%</u>	<u>A070553</u>	<u>001</u>	May 21, 1986
AP		<u>0.5%</u>	<u>N018304</u>	<u>002</u>	
AP		<u>0.75%</u>	<u>A070554</u>	<u>001</u>	May 21, 1986
AP		<u>0.75%</u>	<u>N018304</u>	<u>003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

AP	HOSPIRA	0.75%	A071810	001	Dec 11, 1987
	MARCAINE				
AP	+ HOSPIRA	0.75%	N018692	001	May 04, 1984
	SENSORCAINE				
AP	APP PHARMS	0.75%	A071202	001	Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	+	HOSPIRA	<u>0.5%;0.005MG/ML</u>	<u>A071168</u>	<u>001</u>	Jun 16, 1988
<u>AP</u>			<u>0.5%;0.005MG/ML</u>	<u>A071170</u>	<u>001</u>	Jun 16, 1988
		BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE				
	+	HOSPIRA	0.25%;0.005MG/ML	A071165	001	Jun 16, 1988
			0.25%;0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	SEPTODONT	<u>0.5%;0.0091MG/ML</u>	<u>A077250 001</u>	Sep 27, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 61 (of 409)

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

<u>BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE</u>					
<u>AP</u>	+ HOSPIRA	<u>0.5%;0.0091MG/ML</u>	<u>N022046</u>	<u>001</u>	Jul 13, 1983
<u>MARCAINE HYDROCHLORIDE W/ EPINEPHRINE</u>					
<u>AP</u>	+ HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>004</u>	
<u>AP</u>	+	<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>008</u>	
<u>MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE</u>					
<u>AP</u>	+ HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>013</u>	
<u>AP</u>	+	<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>007</u>	
<u>AP</u>	+	<u>0.75%;0.0091MG/ML</u>	<u>N016964</u>	<u>010</u>	
<u>SENSORCAINE</u>					
<u>AP</u>	APP PHARMS	<u>0.25%;0.0091MG/ML</u>	<u>A070966</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>		<u>0.25%;0.0091MG/ML</u>	<u>A070967</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>		<u>0.5%;0.0091MG/ML</u>	<u>A070968</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>		<u>0.5%;0.0091MG/ML</u>	<u>N018304</u>	<u>004</u>	Sep 02, 1983
<u>AP</u>		<u>0.75%;0.0091MG/ML</u>	<u>N018304</u>	<u>005</u>	Sep 02, 1983

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTRANS

PURDUE PHARMA LP	5MCG/HR	N021306	001	Jun 30, 2010
	10MCG/HR	N021306	002	Jun 30, 2010
+	20MCG/HR	N021306	003	Jun 30, 2010

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

<u>BUPRENEX</u>					
<u>AP</u>	+ RECKITT BENCKISER	<u>EQ 0.3MG BASE/ML</u>	<u>N018401</u>	<u>001</u>	
<u>BUPRENORPHINE HYDROCHLORIDE</u>					
<u>AP</u>	BEDFORD	<u>EQ 0.3MG BASE/ML</u>	<u>A076931</u>	<u>001</u>	Mar 02, 2005
<u>AP</u>	HOSPIRA	<u>EQ 0.3MG BASE/ML</u>	<u>A074137</u>	<u>001</u>	Jun 03, 1996
<u>AP</u>	LUITPOLD	<u>EQ 0.3MG BASE/ML</u>	<u>A078331</u>	<u>001</u>	Mar 27, 2007

TABLET; SUBLINGUAL

<u>BUPRENORPHINE HYDROCHLORIDE</u>					
<u>AB</u>	BARR	<u>EQ 2MG BASE</u>	<u>A090360</u>	<u>001</u>	May 07, 2010
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090360</u>	<u>002</u>	May 07, 2010
<u>AB</u>	ETHYPHARM	<u>EQ 2MG BASE</u>	<u>A090622</u>	<u>001</u>	Sep 24, 2010
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090622</u>	<u>002</u>	Sep 24, 2010
<u>AB</u>	ROXANE	<u>EQ 2MG BASE</u>	<u>A078633</u>	<u>001</u>	Oct 08, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078633</u>	<u>002</u>	Oct 08, 2009
<u>SUBUTEX</u>					
<u>AB</u>	RECKITT BENCKISER	<u>EQ 2MG BASE</u>	<u>N020732</u>	<u>002</u>	Oct 08, 2002
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>N020732</u>	<u>003</u>	Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	2MG;0.5MG	N020733	001	Oct 08, 2002
+	8MG;2MG	N020733	002	Oct 08, 2002

BUPRENORPHINE; NALOXONE

FILM; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	2MG;0.5MG	N022410	001	Aug 30, 2010
+	8MG;2MG	N022410	002	Aug 30, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 62 (of 409)

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
APLENZIN

BIOVAIL LABS INTL	174MG	N022108	001	Apr 23, 2008
+	348MG	N022108	002	Apr 23, 2008
	522MG	N022108	003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A076143</u>	<u>001</u>	Jan 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A076143</u>	<u>002</u>	Jan 17, 2006
<u>AB</u>	MYLAN	<u>75MG</u>	<u>A075491</u>	<u>001</u>	Apr 17, 2000
<u>AB</u>		<u>100MG</u>	<u>A075491</u>	<u>002</u>	Apr 17, 2000
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A075584</u>	<u>001</u>	Feb 07, 2000
<u>AB</u>		<u>100MG</u>	<u>A075584</u>	<u>002</u>	Feb 07, 2000
<u>AB</u>	TEVA	<u>75MG</u>	<u>A075310</u>	<u>001</u>	Nov 29, 1999
<u>AB</u>		<u>100MG</u>	<u>A075310</u>	<u>002</u>	Nov 29, 1999
<u>WELLBUTRIN</u>					
<u>AB</u>	GLAXOSMITHKLINE	<u>75MG</u>	<u>N018644</u>	<u>002</u>	Dec 30, 1985
<u>AB</u>	+	<u>100MG</u>	<u>N018644</u>	<u>003</u>	Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>	ACTAVIS	<u>100MG</u>	<u>A077455</u>	<u>001</u>	Jul 19, 2010
<u>AB1</u>		<u>150MG</u>	<u>A077455</u>	<u>002</u>	Mar 12, 2008
<u>AB1</u>		<u>200MG</u>	<u>A077455</u>	<u>003</u>	Jul 19, 2010
<u>AB1</u>	IMPAX LABS	<u>100MG</u>	<u>A075913</u>	<u>001</u>	Jan 28, 2004
<u>AB1</u>		<u>150MG</u>	<u>A075913</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A076711</u>	<u>001</u>	Dec 03, 2004
<u>AB1</u>	MYLAN	<u>100MG</u>	<u>A090325</u>	<u>001</u>	Apr 08, 2010
<u>AB1</u>		<u>150MG</u>	<u>A090325</u>	<u>002</u>	Apr 08, 2010
<u>AB1</u>		<u>200MG</u>	<u>A090325</u>	<u>003</u>	Apr 08, 2010
<u>AB1</u>	SANDOZ	<u>100MG</u>	<u>A075932</u>	<u>001</u>	Nov 25, 2003
<u>AB1</u>		<u>150MG</u>	<u>A075932</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A075932</u>	<u>003</u>	Jun 22, 2005
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A078866</u>	<u>001</u>	Apr 06, 2010
<u>AB1</u>		<u>150MG</u>	<u>A078866</u>	<u>002</u>	Apr 06, 2010
<u>AB1</u>		<u>200MG</u>	<u>A078866</u>	<u>003</u>	Apr 06, 2010
<u>AB1</u>	WATSON LABS	<u>100MG</u>	<u>A079095</u>	<u>001</u>	Mar 24, 2009
<u>AB1</u>		<u>150MG</u>	<u>A079095</u>	<u>002</u>	Mar 24, 2009
<u>AB1</u>		<u>200MG</u>	<u>A079095</u>	<u>003</u>	Mar 24, 2009
<u>WELLBUTRIN SR</u>					
<u>AB1</u>	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358</u>	<u>002</u>	Oct 04, 1996
<u>AB1</u>	+	<u>150MG</u>	<u>N020358</u>	<u>003</u>	Oct 04, 1996
<u>AB1</u>		<u>200MG</u>	<u>N020358</u>	<u>004</u>	Jun 14, 2002
<u>BUPROPION HYDROCHLORIDE</u>					
<u>AB2</u>	ACTAVIS	<u>150MG</u>	<u>A077475</u>	<u>001</u>	Mar 12, 2008
<u>AB2</u>	IMPAX LABS	<u>150MG</u>	<u>A075914</u>	<u>001</u>	May 27, 2004
<u>AB2</u>	MYLAN	<u>150MG</u>	<u>A090941</u>	<u>001</u>	May 03, 2010
<u>AB2</u>	WATSON LABS	<u>150MG</u>	<u>A079094</u>	<u>001</u>	Mar 24, 2009
<u>ZYBAN</u>					
<u>AB2</u>	+	<u>GLAXOSMITHKLINE</u>	<u>N020711</u>	<u>003</u>	May 14, 1997
<u>BUPROPION HYDROCHLORIDE</u>					
<u>AB3</u>	ACTAVIS	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>		<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>	IMPAX LABS	<u>150MG</u>	<u>A077415</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077415</u>	<u>002</u>	Dec 15, 2006
<u>AB3</u>	MYLAN	<u>150MG</u>	<u>A090942</u>	<u>001</u>	Jul 14, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 63 (of 409)

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

<u>AB3</u>	MYLAN	<u>300MG</u>	<u>A090942</u>	<u>002</u>	Jul 14, 2010
<u>AB3</u>	WATSON LABS	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077715</u>	<u>002</u>	Jun 13, 2007
<u>WELLBUTRIN XL</u>					
<u>AB3</u> +	BIOVAIL LABS INTL	<u>150MG</u>	<u>N021515</u>	<u>001</u>	Aug 28, 2003
<u>AB3</u>		<u>300MG</u>	<u>N021515</u>	<u>002</u>	Aug 28, 2003

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>5MG</u>	<u>N018731</u>	<u>001</u>	Sep 29, 1986

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>5MG</u>	<u>A075388</u>	<u>001</u>	May 09, 2002
<u>AB</u>		<u>10MG</u>	<u>A075388</u>	<u>002</u>	May 09, 2002
<u>AB</u>		<u>15MG</u>	<u>A075388</u>	<u>003</u>	May 09, 2002
<u>AB</u>		<u>30MG</u>	<u>A078302</u>	<u>001</u>	Dec 17, 2007
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A075521</u>	<u>001</u>	Apr 05, 2002
<u>AB</u>		<u>10MG</u>	<u>A075521</u>	<u>002</u>	Apr 05, 2002
<u>AB</u>		<u>15MG</u>	<u>A075521</u>	<u>003</u>	Apr 05, 2002
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078246</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A078246</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246</u>	<u>004</u>	Feb 27, 2009
<u>AB</u>	EGIS	<u>5MG</u>	<u>A075119</u>	<u>001</u>	Mar 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A075119</u>	<u>002</u>	Mar 14, 2002
<u>AB</u>		<u>15MG</u>	<u>A075119</u>	<u>003</u>	Jan 23, 2003
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A075385</u>	<u>001</u>	Mar 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075385</u>	<u>002</u>	Mar 01, 2002
<u>AB</u> +		<u>15MG</u>	<u>A075385</u>	<u>003</u>	Mar 01, 2002
<u>AB</u>	KV PHARM	<u>5MG</u>	<u>A075572</u>	<u>001</u>	Feb 27, 2002
<u>AB</u>		<u>10MG</u>	<u>A075572</u>	<u>002</u>	Feb 27, 2002
<u>AB</u>		<u>15MG</u>	<u>A075572</u>	<u>003</u>	Feb 27, 2002
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075272</u>	<u>001</u>	Mar 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075467</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>7.5MG</u>	<u>A075467</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A075272</u>	<u>002</u>	Mar 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075467</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A075272</u>	<u>003</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A075467</u>	<u>004</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A076008</u>	<u>001</u>	Jun 28, 2001
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022</u>	<u>002</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A075022</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022</u>	<u>004</u>	Mar 25, 2004
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074253</u>	<u>001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253</u>	<u>003</u>	Mar 13, 2002

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+	OTSUKA PHARM	6MG/ML	N020954	001	Feb 04, 1999

TABLET; ORAL

MYLERAN

+	GLAXOSMITHKLINE	2MG	N009386	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 64 (of 409)

BUTABARBITAL SODIUMELIXIR; ORAL
BUTISOL SODIUM

+ MEDA PHARMS 30MG/5ML A085380 001

TABLET; ORAL
BUTISOL SODIUM

+ MEDA PHARMS 30MG N000793 004

+ 50MG N000793 003

BUTENAFINE HYDROCHLORIDECREAM; TOPICAL
MENTAX

+ MYLAN 1% N020524 001 Oct 18, 1996

MENTAX-TC

+ MYLAN 1% N021408 001 Oct 17, 2002

BUTOCONAZOLE NITRATECREAM; VAGINAL
GYNAZOLE-1

+ KV PHARM 2% N019881 001 Feb 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP BEDFORD 2MG/ML A075046 001 Aug 12, 1998

AP CLARIS LIFESCIENCES 2MG/ML A075697 001 Oct 23, 2001

AP HIKMA FARMACEUTICA 1MG/ML A078400 001 May 01, 2009

AP 2MG/ML A078247 001 Apr 29, 2009

AP 2MG/ML A078400 002 May 01, 2009

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP BEDFORD 1MG/ML A075045 001 Aug 12, 1998

AP 2MG/ML A075045 002 Aug 12, 1998

AP CLARIS LIFESCIENCES 1MG/ML A075695 001 Oct 23, 2001

AP 2MG/ML A075695 002 Oct 23, 2001

AP HOSPIRA 1MG/ML A074626 001 Jan 23, 1997

AP 2MG/ML A074626 002 Jan 23, 1997

STADOL

AP + APOTHECON 2MG/ML N017857 004

STADOL PRESERVATIVE FREE

AP + APOTHECON 1MG/ML N017857 001

AP + 2MG/ML N017857 002

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

AB + MYLAN 1MG/SPRAY A075759 001 Aug 08, 2001

AB NOVEX 1MG/SPRAY A075499 001 Dec 04, 2002

AB ROXANE 1MG/SPRAY A075824 001 Mar 12, 2002

CABAZITAXEL

SOLUTION; IV (INFUSION)

+ SANOFI AVENTIS US 60MG/1.5ML (40MG/ML) N201023 001 Jun 17, 2010

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB IMPAX LABS INC 0.5MG A077843 001 Jul 03, 2007

AB IVAX SUB TEVA PHARMS 0.5MG A077750 001 Mar 07, 2007

AB + PAR PHARM 0.5MG A076310 001 Dec 29, 2005

AB WATSON LABS 0.5MG A078035 001 Apr 21, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 65 (of 409)

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS				
<u>CAFCIT</u>				
<u>AP</u>	+ MEAD JOHNSON	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u> <u>001</u>	Sep 21, 1999
<u>CAFFEINE CITRATE</u>				
<u>AP</u>	APP PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077997</u> <u>001</u>	Jul 20, 2007
<u>AP</u>	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077906</u> <u>001</u>	May 15, 2007
<u>AP</u>	PADDOCK LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077233</u> <u>001</u>	Sep 21, 2006
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090077</u> <u>001</u>	Sep 30, 2009
SOLUTION; ORAL				
<u>CAFCIT</u>				
<u>AA</u>	+ MEAD JOHNSON	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u> <u>002</u>	Apr 12, 2000
<u>CAFFEINE CITRATE</u>				
<u>AA</u>	APP PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A078002</u> <u>001</u>	Jan 31, 2008
<u>AA</u>	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090064</u> <u>001</u>	Nov 20, 2009
<u>AA</u>	PADDOCK LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077304</u> <u>001</u>	Sep 21, 2006
<u>AA</u>	SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090357</u> <u>001</u>	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL				
MIGERGOT				
	+ G AND W LABS	100MG;2MG	A086557 001	Oct 04, 1983
TABLET; ORAL				
<u>CAFERGOT</u>				
<u>AA</u>	+ SANDOZ	<u>100MG;1MG</u>	<u>A084294</u> <u>001</u>	
<u>ERGOTAMINE TARTRATE AND CAFFEINE</u>				
<u>AA</u>	MIKART	<u>100MG;1MG</u>	<u>A040590</u> <u>001</u>	Sep 16, 2005
<u>AA</u>	WEST WARD	<u>100MG;1MG</u>	<u>A040510</u> <u>001</u>	Sep 17, 2004

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL				
SORILUX				
	+ STIEFEL LABS INC	0.005%	N022563 001	Oct 06, 2010
CREAM; TOPICAL				
DOVONEX				
	+ LEO PHARM	0.005%	N020554 001	Jul 22, 1996
OINTMENT; TOPICAL				
CALCIPOTRIENE				
	+ GLENMARK GENERICS	0.005%	A090633 001	Mar 24, 2010
SOLUTION; TOPICAL				
<u>CALCIPOTRIENE</u>				
<u>AT</u>	HI TECH PHARMA	<u>0.005%</u>	<u>A077579</u> <u>001</u>	Nov 19, 2009
<u>AT</u>	NYCOMED US	<u>0.005%</u>	<u>A078305</u> <u>001</u>	May 06, 2008
<u>AT</u>	TOLMAR	<u>0.005%</u>	<u>A077029</u> <u>001</u>	Nov 20, 2009
<u>DOVONEX</u>				
<u>AT</u>	+ LEO PHARM	<u>0.005%</u>	<u>N020611</u> <u>001</u>	Mar 03, 1997

CALCITONIN SALMON

INJECTABLE; INJECTION				
MIACALCIN				
	+ NOVARTIS	200 IU/ML	N017808 002	Mar 29, 1991
SPRAY, METERED; NASAL				
<u>CALCITONIN-SALMON</u>				
<u>AB</u>	APOTEX INC	<u>200 IU/SPRAY</u>	<u>A076396</u> <u>001</u>	Nov 17, 2008
<u>AB</u>	PAR PHARM	<u>200 IU/SPRAY</u>	<u>A076979</u> <u>001</u>	Jun 08, 2009
<u>MIACALCIN</u>				
<u>AB</u>	+ NOVARTIS	<u>200 IU/SPRAY</u>	<u>N020313</u> <u>002</u>	Aug 17, 1995

PRESCRIPTION DRUG PRODUCT LIST

3 - 66 (of 409)

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL
FORTICAL

+ UPSHER SMITH	200 IU/SPRAY	N021406 001	Aug 12, 2005

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

<u>AB</u> ROXANE	0.25MCG	A076917 001	Mar 27, 2006
<u>AB</u> TEVA	0.25MCG	A075765 001	Oct 12, 2001
<u>AB</u>	0.5MCG	A075765 002	Oct 12, 2001

ROCALTROL

<u>AB</u> VALIDUS PHARMS	0.25MCG	N018044 001	
<u>AB</u> +	0.5MCG	N018044 002	

INJECTABLE; INJECTION

CALCIJEX

<u>AP</u> + ABBOTT	0.001MG/ML	N018874 001	Sep 25, 1986
<u>AP</u> +	0.002MG/ML	N018874 002	Sep 25, 1986

CALCITRIOL

<u>AP</u> AKORN	0.001MG/ML	A078066 001	Jan 29, 2008
<u>AP</u>	0.002MG/ML	A078066 002	Jan 29, 2008
<u>AP</u> APP PHARMS	0.001MG/ML	A075836 001	Dec 31, 2002
<u>AP</u>	0.002MG/ML	A075836 002	Dec 31, 2002
<u>AP</u> FRESENIUS MEDCL	0.001MG/ML	A075766 001	Feb 20, 2003
<u>AP</u>	0.002MG/ML	A075766 002	Feb 20, 2003
<u>AP</u> GENIX THERAP	0.001MG/ML	A077102 001	Feb 08, 2006
<u>AP</u> LUITPOLD	0.001MG/ML	A075746 001	Sep 26, 2003
<u>AP</u>	0.002MG/ML	A075746 002	Sep 26, 2003
<u>AP</u> LYNE	0.001MG/ML	A076206 001	Sep 17, 2003
<u>AP</u> TEVA PARENTERAL	0.001MG/ML	A075823 001	Mar 31, 2003
<u>AP</u>	0.002MG/ML	A075823 002	Mar 31, 2003

OINTMENT; TOPICAL
VECTICAL

+ GALDERMA LABS LP	3MCG/GM	N022087 001	Jan 23, 2009

SOLUTION; ORAL

CALCITRIOL

<u>AA</u> ROXANE	1MCG/ML	A076242 001	Jul 18, 2003

ROCALTROL

<u>AA</u> + VALIDUS PHARMS	1MCG/ML	N021068 001	Nov 20, 1998

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

<u>AB</u> ROXANE	EQ 169MG CALCIUM	A077728 001	Feb 26, 2008

PHOSLO GELCAPS

<u>AB</u> + FRESENIUS MEDCL	EQ 169MG CALCIUM	N021160 003	Apr 02, 2001

TABLET; ORAL

ELIPHOS

+ CYPRESS PHARM	EQ 169MG CALCIUM	A078502 001	Nov 25, 2008

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+ HOSPIRA	100MG/ML	N021117 001	Jan 28, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 67 (of 409)

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

BSS PLUS

<u>AT</u> + ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/M L;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/M L	N018469 001	

ENDOSOL EXTRA

<u>AT</u> + AKORN	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/M L;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/M L	N020079 001	Nov 27, 1991

NAVSTEL

+ ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/M L;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/M L	N022193 001	Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.0 5GM/1000ML;0.157GM/1000ML;2.21GM/1000ML ;7.07GM/1000ML	N021703 010	Oct 10, 2008

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.0 5GM/1000ML;0.314GM/1000ML;2.21GM/1000ML ;7.07GM/1000ML	N021703 011	Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML; 3.05GM/1000ML;0.314GM/1000ML;2.21GM/100 0ML;7.07GM/1000ML	N021703 013	Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML; 3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML; 6.46GM/1000ML	N021703 006	Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.0 3GM/1000ML;0.157GM/1000ML;3.09GM/1000ML ;6.46GM/1000ML	N021703 002	Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML; 2.03GM/1000ML;0.157GM/1000ML;3.09GM/100 0ML;6.46GM/1000ML	N021703 003	Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.4 4GM/1000ML;0.314GM/1000ML;3.09GM/1000ML ;6.46GM/1000ML	N021703 015	Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML; 3.05GM/1000ML;0.314GM/1000ML;3.09GM/100 0ML;6.46GM/1000ML	N021703 004	Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44 GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46 GM/1000ML	N021703 014	Oct 10, 2008

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2 .03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6 .46GM/1000ML	N021703 001	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/1 00ML;330MG/100ML;88MG/100ML	N019864 001	Jun 10, 1993

PRESCRIPTION DRUG PRODUCT LIST

3 - 68 (of 409)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE;
SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019867 001	Dec 20, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE;
SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390 001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

+ B BRAUN	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807 001	Aug 26, 1983

+	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807 003	Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

+ B BRAUN	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807 004	Aug 26, 1983

+	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807 002	Aug 26, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018379 002	

AT		25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018883 001	Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018883 004	Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N020171 001	Aug 19, 1992

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018379 003	

AT		25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018883 002	Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018883 005	Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N020171 002	Aug 19, 1992

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018379 007	Jun 24, 1988

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018379 001	

AT		25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018883 003	Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018883 006	Nov 30, 1984

PRESCRIPTION DRUG PRODUCT LIST

3 - 69 (of 409)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL					
<u>DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>FRESENIUS MEDCL</u>	<u>18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N020171</u>	<u>003</u>	Aug 19, 1992
<u>DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>FRESENIUS MEDCL</u>	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N018379</u>	<u>004</u>	Jul 07, 1982
<u>DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>FRESENIUS MEDCL</u>	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N018379</u>	<u>005</u>	Jul 07, 1982
<u>DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>FRESENIUS MEDCL</u>	<u>25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N018379</u>	<u>008</u>	Jun 24, 1988
<u>DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>FRESENIUS MEDCL</u>	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N018379</u>	<u>006</u>	Jul 07, 1982
<u>DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>001</u>	
<u>DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>003</u>	
<u>DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;</u> <u>567MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>002</u>	
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020183</u>	<u>001</u>	Dec 04, 1992
<u>DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>007</u>	Jul 09, 1984
<u>DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>008</u>	Jul 09, 1984
<u>DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>010</u>	Nov 18, 1985
<u>DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;</u> <u>567MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>009</u>	Jul 09, 1984
<u>DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>004</u>	
<u>AT</u>		<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020163</u>	<u>001</u>	Dec 04, 1992
<u>DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>005</u>	
<u>AT</u>		<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020163</u>	<u>002</u>	Dec 04, 1992
<u>DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>011</u>	Nov 18, 1985
<u>DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>006</u>	
<u>AT</u>		<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N020163</u>	<u>003</u>	Dec 04, 1992
<u>INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>FRESENIUS</u>	<u>18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020374</u>	<u>001</u>	Jun 13, 1994
<u>INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	<u>FRESENIUS</u>	<u>18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020374</u>	<u>002</u>	Jun 13, 1994

PRESCRIPTION DRUG PRODUCT LIST

3 - 70 (of 409)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS	<u>18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N020374</u>	<u>004</u>	Jun 13, 1994
	DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
	B BRAUN	26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	007	Jan 29, 1986
	DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
	B BRAUN	26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	005	Nov 02, 1983
	DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
	B BRAUN	26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	009	Jan 29, 1986
	DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992
	DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992
	DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992
	INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
	FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020374	003	Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL
ELLIOTT'S B SOLUTION

+	QOL MEDCL	0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML	N020577	001	Sep 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

+	B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	N018258	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018254</u>	<u>001</u>	
	<u>DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER</u>				
<u>AP</u>	B BRAUN	<u>33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020000</u>	<u>001</u>	Apr 17, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N016695</u>	<u>001</u>	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017608</u>	<u>001</u>	
	<u>DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER</u>				
<u>AP</u>	B BRAUN	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019634</u>	<u>003</u>	Feb 24, 1988
	<u>LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016679</u>	<u>001</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 71 (of 409)

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019367 006</u>	Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019367 004</u>	Apr 05, 1985

<u>AP</u>		<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019367 005</u>	Apr 05, 1985

<u>AP</u>	HOSPIRA	<u>20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019685 002</u>	Oct 17, 1988

<u>AP</u>		<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019685 008</u>	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019367 007</u>	Apr 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019367 008</u>	Apr 05, 1985

<u>AP</u>	HOSPIRA	<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019685 004</u>	Oct 17, 1988

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML;300MG/100ML;160MG/100ML	N019634 001	Feb 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367 002	Apr 05, 1985

		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019367 003	Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367 001	Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

+	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N018895 001	Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

+	B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019718 001	Sep 29, 1989

SOLUTION; IRRIGATION

BALANCED SALT

<u>AT</u>	AKORN	<u>0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML</u>	<u>A075503 001</u>	Sep 27, 2006

<u>AT</u>	B BRAUN	<u>0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML</u>	<u>A091387 001</u>	Feb 03, 2010

BSS

<u>AT</u>	+ ALCON	<u>0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML</u>	<u>N020742 001</u>	Dec 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438 001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 72 (of 409)

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML</u>	<u>A075323</u>	<u>001</u>	Apr 21, 2000

PLEGISOL IN PLASTIC CONTAINER

<u>AT</u>	+ HOSPIRA	<u>17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML</u>	<u>N018608</u>	<u>001</u>	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N020002</u>	<u>001</u>	Apr 17, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N016693</u>	<u>001</u>	
<u>AP</u>	HOSPIRA	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N018251</u>	<u>001</u>	

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N018156</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N018495</u>	<u>001</u>	Feb 19, 1982
<u>AT</u>	HOSPIRA	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N017635</u>	<u>001</u>	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019632</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N016682</u>	<u>001</u>	
<u>AP</u>	HOSPIRA	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N017641</u>	<u>001</u>	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N018681</u>	<u>001</u>	Dec 27, 1982
<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N018494</u>	<u>001</u>	Feb 19, 1982
<u>AT</u>		<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N018921</u>	<u>001</u>	Apr 03, 1984
<u>AT</u>		<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019933</u>	<u>001</u>	Aug 29, 1989
<u>AT</u>	HOSPIRA	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019416</u>	<u>001</u>	Jan 17, 1986

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+ ONY	35MG/ML	N020521	001	Jul 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

ASTRAZENECA

4MG

N020838 001 Jun 04, 1998

8MG

N020838 002 Jun 04, 1998

16MG

N020838 003 Jun 04, 1998

+

32MG

N020838 004 Jun 04, 1998

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

ASTRAZENECA

16MG;12.5MG

N021093 001 Sep 05, 2000

32MG;12.5MG

N021093 002 Sep 05, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 73 (of 409)

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL ATACAND HCT				
+ ASTRAZENECA	32MG;25MG	N021093	003	May 16, 2008

CAPECITABINE

TABLET; ORAL XELODA				
HOFFMANN LA ROCHE	150MG	N020896	001	Apr 30, 1998
+	500MG	N020896	002	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION CAPASTAT SULFATE				
+ AKORN	EQ 1GM BASE/VIAL	N050095	001	

CAPSAICIN

PATCH; TOPICAL QUTENZA				
+ NEUROGESX	8%	N022395	001	Nov 16, 2009

CAPTOPRIL

TABLET; ORAL				
<u>CAPOTEN</u>				
<u>AB</u> PAR PHARM	<u>12.5MG</u>	<u>N018343</u>	<u>005</u>	Jan 17, 1985
<u>AB</u>	<u>25MG</u>	<u>N018343</u>	<u>002</u>	
<u>AB</u>	<u>50MG</u>	<u>N018343</u>	<u>001</u>	
<u>AB</u> +	<u>100MG</u>	<u>N018343</u>	<u>003</u>	
<u>CAPTOPRIL</u>				
<u>AB</u> APOTEX	<u>12.5MG</u>	<u>A074737</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>	<u>25MG</u>	<u>A074737</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>	<u>50MG</u>	<u>A074737</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>	<u>100MG</u>	<u>A074737</u>	<u>004</u>	Oct 28, 1998
<u>AB</u> HUAHAI US INC	<u>12.5MG</u>	<u>A074477</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>	<u>25MG</u>	<u>A074477</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>	<u>50MG</u>	<u>A074477</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>	<u>100MG</u>	<u>A074477</u>	<u>004</u>	Feb 13, 1996
<u>AB</u> MYLAN	<u>12.5MG</u>	<u>A074434</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>	<u>25MG</u>	<u>A074434</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>	<u>50MG</u>	<u>A074434</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>	<u>100MG</u>	<u>A074434</u>	<u>004</u>	Feb 13, 1996
<u>AB</u> SANDOZ	<u>12.5MG</u>	<u>A074363</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>	<u>25MG</u>	<u>A074363</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>	<u>50MG</u>	<u>A074363</u>	<u>003</u>	Nov 09, 1995
<u>AB</u>	<u>100MG</u>	<u>A074363</u>	<u>004</u>	Nov 09, 1995
<u>AB</u> STASON	<u>12.5MG</u>	<u>A074677</u>	<u>004</u>	May 30, 1997
<u>AB</u>	<u>25MG</u>	<u>A074677</u>	<u>002</u>	May 30, 1997
<u>AB</u>	<u>50MG</u>	<u>A074677</u>	<u>001</u>	May 30, 1997
<u>AB</u>	<u>100MG</u>	<u>A074677</u>	<u>003</u>	May 30, 1997
<u>AB</u> TEVA	<u>12.5MG</u>	<u>A074322</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>	<u>12.5MG</u>	<u>A074483</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>	<u>25MG</u>	<u>A074322</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>	<u>25MG</u>	<u>A074483</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>	<u>50MG</u>	<u>A074322</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>	<u>50MG</u>	<u>A074483</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>	<u>100MG</u>	<u>A074322</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	<u>100MG</u>	<u>A074483</u>	<u>004</u>	Feb 13, 1996
<u>AB</u> WATSON LABS	<u>12.5MG</u>	<u>A074386</u>	<u>001</u>	May 23, 1996
<u>AB</u>	<u>12.5MG</u>	<u>A074451</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>	<u>25MG</u>	<u>A074386</u>	<u>002</u>	May 23, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 74 (of 409)

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A074451</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074386</u>	<u>003</u>	May 23, 1996
<u>AB</u>		<u>50MG</u>	<u>A074451</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074386</u>	<u>004</u>	May 23, 1996
<u>AB</u>		<u>100MG</u>	<u>A074451</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WEST WARD	<u>12.5MG</u>	<u>A074505</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074505</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074505</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WOCKHARDT	<u>12.5MG</u>	<u>A074532</u>	<u>001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532</u>	<u>002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532</u>	<u>003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532</u>	<u>004</u>	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

<u>AB</u>	APOTHECON	<u>25MG;15MG</u>	<u>N018709</u>	<u>001</u>	Oct 12, 1984
	<u>CAPOZIDE 25/25</u>				
<u>AB</u>	+ APOTHECON	<u>25MG;25MG</u>	<u>N018709</u>	<u>002</u>	Oct 12, 1984
	<u>CAPOZIDE 50/15</u>				
<u>AB</u>	+ APOTHECON	<u>50MG;15MG</u>	<u>N018709</u>	<u>004</u>	Oct 12, 1984
	<u>CAPOZIDE 50/25</u>				
<u>AB</u>	APOTHECON	<u>50MG;25MG</u>	<u>N018709</u>	<u>003</u>	Oct 12, 1984
	<u>CAPTOPRIL AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	MYLAN	<u>25MG;15MG</u>	<u>A074896</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074896</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074896</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074896</u>	<u>003</u>	Dec 29, 1997
<u>AB</u>	TEVA	<u>25MG;15MG</u>	<u>A074827</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074827</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074827</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074827</u>	<u>003</u>	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+ ALCON	0.01%		N016968 001

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

	SHIRE	100MG	N020712	003	Sep 30, 1997
		200MG	N020712	001	Sep 30, 1997
	+	300MG	N020712	002	Sep 30, 1997
	EQUETRO				
	VALIDUS PHARMS INC	100MG	N021710	001	Dec 10, 2004
		200MG	N021710	002	Dec 10, 2004
	+	300MG	N021710	003	Dec 10, 2004

SUSPENSION; ORAL

CARBAMAZEPINE

<u>AB</u>	WOCKHARDT	<u>100MG/5ML</u>	<u>A075714</u>	<u>001</u>	Jun 05, 2002
	<u>TEGRETOL</u>				
<u>AB</u>	+ NOVARTIS	<u>100MG/5ML</u>	<u>N018927</u>	<u>001</u>	Dec 18, 1987
	<u>TERIL</u>				
<u>AB</u>	TARO	<u>100MG/5ML</u>	<u>A076729</u>	<u>001</u>	Sep 20, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 75 (of 409)

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075948</u>	<u>001</u>	Feb 27, 2002
<u>AB</u>	TARO	<u>200MG</u>	<u>A074649</u>	<u>001</u>	Oct 03, 1996
<u>AB</u>	TORRENT PHARMS	<u>200MG</u>	<u>A077272</u>	<u>002</u>	Dec 07, 2005
<u>EPITOL</u>					
<u>AB</u>	TEVA	<u>200MG</u>	<u>A070541</u>	<u>001</u>	Sep 17, 1986
<u>TEGRETOL</u>					
<u>AB</u>	+ NOVARTIS	<u>200MG</u>	<u>N016608</u>	<u>001</u>	
	CARBAMAZEPINE				
	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005
		300MG	A077272	003	Dec 07, 2005
		400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO PHARM INDS	<u>100MG</u>	<u>A075687</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>	TORRENT PHARMS	<u>100MG</u>	<u>A075712</u>	<u>001</u>	Jul 05, 2001
<u>EPITOL</u>					
<u>AB</u>	TEVA	<u>100MG</u>	<u>A073524</u>	<u>001</u>	Jul 29, 1992
<u>TEGRETOL</u>					
<u>AB</u>	+ NOVARTIS	<u>100MG</u>	<u>N018281</u>	<u>001</u>	
	CARBAMAZEPINE				
	+ TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO	<u>100MG</u>	<u>A078115</u>	<u>001</u>	Mar 31, 2009
<u>AB</u>		<u>200MG</u>	<u>A078115</u>	<u>002</u>	Mar 31, 2009
<u>AB</u>		<u>400MG</u>	<u>A078115</u>	<u>003</u>	Mar 31, 2009
<u>TEGRETOL-XR</u>					
<u>AB</u>	NOVARTIS	<u>100MG</u>	<u>N020234</u>	<u>001</u>	Mar 25, 1996
<u>AB</u>		<u>200MG</u>	<u>N020234</u>	<u>002</u>	Mar 25, 1996
<u>AB</u>	+	<u>400MG</u>	<u>N020234</u>	<u>003</u>	Mar 25, 1996

CARBIDOPA

TABLET; ORAL

LODOSYN

+	ATON	25MG	N017830	001	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

STALEVO 100

ORION	25MG;200MG;100MG	N021485	002	Jun 11, 2003

STALEVO 125

ORION	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008

STALEVO 150

ORION	37.5MG;200MG;150MG	N021485	003	Jun 11, 2003

STALEVO 200

+ ORION	50MG;200MG;200MG	N021485	004	Aug 02, 2007

STALEVO 50

+ ORION	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003

STALEVO 75

ORION	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG;100MG</u>	<u>A074260</u>	<u>001</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;100MG</u>	<u>A074260</u>	<u>002</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;250MG</u>	<u>A074260</u>	<u>003</u>	Sep 03, 1993

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 76 (of 409)

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	APOTEX INC	<u>10MG;100MG</u>	<u>A077120</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A077120</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A077120</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A090324</u>	<u>001</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A090324</u>	<u>002</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A090324</u>	<u>003</u>	Sep 28, 2009
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078536</u>	<u>001</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078536</u>	<u>002</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078536</u>	<u>003</u>	Oct 28, 2008
<u>AB</u>	TEVA	<u>10MG;100MG</u>	<u>A073618</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;100MG</u>	<u>A073589</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;250MG</u>	<u>A073607</u>	<u>001</u>	Aug 28, 1992
<u>SINEMET</u>					
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>10MG;100MG</u>	<u>N017555</u>	<u>001</u>	
<u>AB</u>		<u>25MG;100MG</u>	<u>N017555</u>	<u>003</u>	
<u>AB</u>	+	<u>25MG;250MG</u>	<u>N017555</u>	<u>002</u>	

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	APOTEX	<u>25MG;100MG</u>	<u>A076212</u>	<u>001</u>	Jun 16, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076212</u>	<u>002</u>	Jun 16, 2004
<u>AB</u>	IMPAX LABS	<u>25MG;100MG</u>	<u>A076521</u>	<u>001</u>	May 14, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076521</u>	<u>002</u>	May 14, 2004
<u>AB</u>	MYLAN	<u>25MG;100MG</u>	<u>A075091</u>	<u>002</u>	Apr 21, 2000
<u>AB</u>		<u>50MG;200MG</u>	<u>A075091</u>	<u>001</u>	Sep 30, 1999
<u>AB</u>	SUN PHARM INDS	<u>25MG;100MG</u>	<u>A077828</u>	<u>001</u>	Aug 23, 2007
<u>AB</u>		<u>50MG;200MG</u>	<u>A077828</u>	<u>002</u>	Aug 23, 2007
<u>SINEMET CR</u>					
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>25MG;100MG</u>	<u>N019856</u>	<u>002</u>	Dec 24, 1992
<u>AB</u>	+	<u>50MG;200MG</u>	<u>N019856</u>	<u>001</u>	May 30, 1991

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	IMPAX LABS	<u>10MG;100MG</u>	<u>A090631</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090631</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>25MG;250MG</u>	<u>A090631</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A078893</u>	<u>001</u>	Sep 18, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078893</u>	<u>002</u>	Sep 18, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078893</u>	<u>003</u>	Sep 18, 2008
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078690</u>	<u>001</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A078690</u>	<u>002</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A078690</u>	<u>003</u>	Jul 31, 2009
<u>PARCOPA</u>					
<u>AB</u>	SCHWARZ PHARMA	<u>10MG;100MG</u>	<u>A076699</u>	<u>001</u>	Aug 27, 2004
<u>AB</u>		<u>25MG;100MG</u>	<u>A076699</u>	<u>002</u>	Aug 27, 2004
<u>AB</u>	+	<u>25MG;250MG</u>	<u>A076699</u>	<u>003</u>	Aug 27, 2004

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	BOCA PHARMA	<u>4MG/5ML</u>	<u>A040814</u>	<u>001</u>	Feb 26, 2008
<u>AA</u>	CYPRESS PHARM	<u>4MG/5ML</u>	<u>A090418</u>	<u>001</u>	May 04, 2010
<u>AA</u>	+	<u>4MG/5ML</u>	<u>A040458</u>	<u>001</u>	Apr 25, 2003

TABLET; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	BOCA PHARMA	<u>4MG</u>	<u>A040639</u>	<u>002</u>	May 30, 2008
<u>AA</u>	CYPRESS PHARM	<u>4MG</u>	<u>A090417</u>	<u>001</u>	Aug 23, 2010
<u>AA</u>	INVAGEN PHARMS	<u>4MG</u>	<u>A090435</u>	<u>001</u>	Apr 15, 2010
<u>AA</u>	+	<u>4MG</u>	<u>A040442</u>	<u>001</u>	Mar 19, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 77 (of 409)

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	APP PHARMS	<u>50MG/VIAL</u>	<u>A076235</u>	<u>001</u>	Oct 14, 2004
AP		<u>150MG/VIAL</u>	<u>A076235</u>	<u>002</u>	Oct 14, 2004
AP		<u>450MG/VIAL</u>	<u>A076235</u>	<u>003</u>	Oct 14, 2004
AP	BEDFORD	<u>50MG/VIAL</u>	<u>A076099</u>	<u>001</u>	Oct 14, 2004
AP		<u>150MG/VIAL</u>	<u>A076099</u>	<u>002</u>	Oct 14, 2004
AP		<u>450MG/VIAL</u>	<u>A076099</u>	<u>003</u>	Oct 14, 2004
AP	PLIVA	<u>50MG/VIAL</u>	<u>A076602</u>	<u>001</u>	Nov 16, 2004
AP		<u>150MG/VIAL</u>	<u>A076602</u>	<u>002</u>	Nov 16, 2004
AP		<u>450MG/VIAL</u>	<u>A076602</u>	<u>003</u>	Nov 16, 2004
AP	SANDOZ	<u>50MG/VIAL</u>	<u>A076959</u>	<u>001</u>	Mar 18, 2005
AP		<u>150MG/VIAL</u>	<u>A076959</u>	<u>002</u>	Mar 18, 2005
AP		<u>450MG/VIAL</u>	<u>A076959</u>	<u>003</u>	Mar 18, 2005
AP	+ WATSON LABS	<u>50MG/VIAL</u>	<u>A076162</u>	<u>001</u>	Oct 14, 2004
AP		<u>50MG/VIAL</u>	<u>A077383</u>	<u>001</u>	Jan 27, 2006
AP	+	<u>150MG/VIAL</u>	<u>A076162</u>	<u>002</u>	Oct 14, 2004
AP		<u>150MG/VIAL</u>	<u>A077383</u>	<u>002</u>	Jan 27, 2006
AP	+	<u>450MG/VIAL</u>	<u>A076162</u>	<u>003</u>	Oct 14, 2004
AP		<u>450MG/VIAL</u>	<u>A077383</u>	<u>003</u>	Jan 27, 2006

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475</u>	<u>001</u>	Jul 29, 2009
AP		<u>150MG/15ML (10MG/ML)</u>	<u>A090475</u>	<u>002</u>	Jul 29, 2009
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A090475</u>	<u>003</u>	Jul 29, 2009
AP		<u>600MG/60ML (10MG/ML)</u>	<u>A091268</u>	<u>002</u>	Jul 28, 2010
AP	APP PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A077266</u>	<u>001</u>	Feb 15, 2006
AP		<u>150MG/15ML (10MG/ML)</u>	<u>A077266</u>	<u>002</u>	Feb 15, 2006
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A077247</u>	<u>003</u>	Oct 21, 2004
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A077266</u>	<u>003</u>	Feb 15, 2006
AP		<u>600MG/60ML (10MG/ML)</u>	<u>A077266</u>	<u>004</u>	Feb 15, 2006
AP	BEDFORD LABS	<u>50MG/5ML (10MG/ML)</u>	<u>A077244</u>	<u>001</u>	Oct 15, 2004
AP		<u>150MG/15ML (10MG/ML)</u>	<u>A077244</u>	<u>002</u>	Oct 15, 2004
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A077244</u>	<u>003</u>	Oct 15, 2004
AP		<u>600MG/60ML (10MG/ML)</u>	<u>A077244</u>	<u>004</u>	Jan 20, 2006
AP	BIONICHE PHARMA USA	<u>50MG/5ML (10MG/ML)</u>	<u>A077998</u>	<u>001</u>	Apr 24, 2007
AP		<u>150MG/15ML (10MG/ML)</u>	<u>A077998</u>	<u>002</u>	Apr 24, 2007
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A077998</u>	<u>003</u>	Apr 24, 2007
AP	EBEWE PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078280</u>	<u>001</u>	May 08, 2008
AP		<u>150MG/15ML (10MG/ML)</u>	<u>A078280</u>	<u>002</u>	May 08, 2008
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A078280</u>	<u>003</u>	May 08, 2008
AP	FRESENIUS KABI ONCOL	<u>50MG/5ML (10MG/ML)</u>	<u>A077432</u>	<u>001</u>	Sep 29, 2006
AP		<u>150MG/15ML (10MG/ML)</u>	<u>A077432</u>	<u>002</u>	Sep 29, 2006
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A077432</u>	<u>003</u>	Sep 29, 2006
AP	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517</u>	<u>001</u>	Oct 14, 2004
AP		<u>150MG/15ML (10MG/ML)</u>	<u>A076517</u>	<u>002</u>	Oct 14, 2004
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A076517</u>	<u>003</u>	Oct 14, 2004
AP		<u>600MG/60ML (10MG/ML)</u>	<u>A077059</u>	<u>001</u>	Nov 23, 2004
AP	+ PHARMACHEMIE	<u>50MG/5ML (10MG/ML)</u>	<u>A077269</u>	<u>001</u>	Oct 14, 2004
AP	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077269</u>	<u>002</u>	Oct 14, 2004
AP	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077269</u>	<u>003</u>	Oct 14, 2004
AP	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077269</u>	<u>004</u>	Dec 28, 2007
AP	PHARMACHEMIE BV	<u>50MG/5ML (10MG/ML)</u>	<u>A077679</u>	<u>001</u>	Feb 25, 2009
AP		<u>150MG/15ML (10MG/ML)</u>	<u>A077679</u>	<u>002</u>	Feb 25, 2009
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A077679</u>	<u>003</u>	Feb 25, 2009
AP	PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631</u>	<u>001</u>	Dec 02, 2008
AP		<u>150MG/15ML (10MG/ML)</u>	<u>A078631</u>	<u>002</u>	Dec 02, 2008
AP		<u>450MG/45ML (10MG/ML)</u>	<u>A078631</u>	<u>003</u>	Dec 02, 2008
AP		<u>600MG/60ML (10MG/ML)</u>	<u>A078631</u>	<u>004</u>	Dec 02, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 78 (of 409)

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	SUN PHARMA GLOBAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077926</u>	<u>001</u>	Sep 19, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077926</u>	<u>002</u>	Sep 19, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077926</u>	<u>003</u>	Sep 19, 2008
<u>AP</u>	+ TEVA PARENTERAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077139</u>	<u>001</u>	Sep 21, 2005
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077139</u>	<u>002</u>	Sep 21, 2005
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077139</u>	<u>003</u>	Sep 21, 2005
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077139</u>	<u>004</u>	Sep 21, 2005
<u>AP</u>	WATSON LABS	<u>50MG/5ML (10MG/ML)</u>	<u>A077861</u>	<u>001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861</u>	<u>002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861</u>	<u>003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861</u>	<u>004</u>	Jan 18, 2007

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+ PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N017989 001

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+ ORPHAN EUROPE 200MG N022562 001 Mar 18, 2010

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	ACTAVIS TOTOWA	<u>350MG</u>	<u>A040188</u>	<u>001</u>	Mar 07, 1997
<u>AA</u>	ADVENT PHARMS	<u>350MG</u>	<u>A040576</u>	<u>001</u>	Jun 07, 2005
<u>AA</u>	AUROBINDO PHARMA	<u>350MG</u>	<u>A040792</u>	<u>001</u>	Aug 06, 2009
<u>AA</u>	CONCORD LABS NJ	<u>350MG</u>	<u>A040823</u>	<u>001</u>	Oct 22, 2008
<u>AA</u>	COREPHARMA	<u>350MG</u>	<u>A040397</u>	<u>001</u>	Sep 21, 2000
<u>AA</u>	MUTUAL PHARM	<u>350MG</u>	<u>A089346</u>	<u>001</u>	Oct 17, 1991
<u>AA</u>	SUN PHARM INDS LTD	<u>350MG</u>	<u>A040755</u>	<u>001</u>	Feb 27, 2007
<u>AA</u>	VINTAGE PHARMS	<u>350MG</u>	<u>A040245</u>	<u>001</u>	Sep 08, 1997
<u>AA</u>	WATSON LABS	<u>350MG</u>	<u>A087499</u>	<u>001</u>	Apr 20, 1982
<u>AA</u>	WEST WARD	<u>350MG</u>	<u>A040124</u>	<u>001</u>	Jan 24, 1996
	<u>SOMA</u>				
<u>AA</u>	MEDA PHARMS	<u>350MG</u>	<u>N011792</u>	<u>001</u>	
	SOMA				
	+ MEDA PHARMS	250MG	N011792	004	Sep 13, 2007

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+ EISAI INC 7.7MG N020637 001 Sep 23, 1996

INJECTABLE; INJECTION

BICNU

+ BRISTOL 100MG/VIAL N017422 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

<u>AT</u>	ALCON	<u>1%</u>	<u>A075476</u>	<u>001</u>	Jan 03, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>1%</u>	<u>A075546</u>	<u>001</u>	Jan 20, 2000
<u>AT</u>	NOVEX	<u>1%</u>	<u>A076097</u>	<u>001</u>	Feb 06, 2002
	<u>OCUPRESS</u>				
<u>AT</u>	+ NOVARTIS	<u>1%</u>	<u>N019972</u>	<u>001</u>	May 23, 1990

PRESCRIPTION DRUG PRODUCT LIST

3 - 79 (of 409)

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	APOTEX INC	<u>3.125MG</u>	<u>A078165</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078165</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078165</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078165</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>3.125MG</u>	<u>A078332</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078332</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078332</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078332</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	BEXIMCO USA	<u>3.125MG</u>	<u>A078384</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078384</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078384</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078384</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	CARACO	<u>3.125MG</u>	<u>A077346</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077346</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077346</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077346</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>3.125MG</u>	<u>A076649</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076649</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076649</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076649</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	GLENMARK GENERICS	<u>3.125MG</u>	<u>A078251</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078251</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078251</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078251</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	HIKMA	<u>3.125MG</u>	<u>A077887</u>	<u>001</u>	Sep 07, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077887</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077887</u>	<u>003</u>	Sep 07, 2007
<u>AB</u>		<u>25MG</u>	<u>A077887</u>	<u>004</u>	Sep 07, 2007
<u>AB</u>	LUPIN	<u>3.125MG</u>	<u>A078217</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078217</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078217</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078217</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	MYLAN	<u>3.125MG</u>	<u>A077316</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077316</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077316</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077316</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>3.125MG</u>	<u>A078240</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078240</u>	<u>002</u>	Oct 30, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078240</u>	<u>003</u>	Oct 30, 2007
<u>AB</u>		<u>25MG</u>	<u>A078240</u>	<u>004</u>	Oct 30, 2007
<u>AB</u>	RANBAXY	<u>3.125MG</u>	<u>A076989</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	SANDOZ	<u>3.125MG</u>	<u>A078227</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078227</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078227</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	WATSON LABS	<u>3.125MG</u>	<u>A077474</u>	<u>001</u>	Sep 05, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 80 (of 409)

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	WATSON LABS	<u>6.25MG</u>	<u>A077474</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077474</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077474</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	WOCKHARDT	<u>3.125MG</u>	<u>A078786</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>6.25MG</u>	<u>A078786</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>12.5MG</u>	<u>A078786</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078786</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614</u>	<u>003</u>	Sep 05, 2007
<u>COREG</u>					
<u>AB</u>	SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297</u>	<u>004</u>	May 29, 1997
<u>AB</u>		<u>6.25MG</u>	<u>N020297</u>	<u>003</u>	Sep 14, 1995
<u>AB</u>	+	<u>12.5MG</u>	<u>N020297</u>	<u>002</u>	Sep 14, 1995
<u>AB</u>		<u>25MG</u>	<u>N020297</u>	<u>001</u>	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

	SB PHARMC0	10MG	N022012	001	Oct 20, 2006
		20MG	N022012	002	Oct 20, 2006
+		40MG	N022012	003	Oct 20, 2006
		80MG	N022012	004	Oct 20, 2006

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

+	MERCK	50MG/VIAL	N021227	001	Jan 26, 2001
+		70MG/VIAL	N021227	002	Jan 26, 2001

CEFACLOR

CAPSULE; ORAL

CEFACLOR

<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065350</u>	<u>001</u>	Apr 03, 2007
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065350</u>	<u>002</u>	Apr 03, 2007
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A064156</u>	<u>001</u>	Aug 28, 1997
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A064156</u>	<u>002</u>	Aug 28, 1997
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146</u>	<u>001</u>	Jan 22, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065146</u>	<u>002</u>	Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACLOR

+	RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997
+		EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997
+		EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997
+		EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997

TABLET, CHEWABLE; ORAL

RANICLOR

	RANBAXY	EQ 125MG BASE	A065092	001	Dec 22, 2003
		EQ 187MG BASE	A065092	002	Dec 22, 2003
		EQ 250MG BASE	A065092	003	Dec 22, 2003
+		EQ 375MG BASE	A065092	004	Dec 22, 2003

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

<u>AB</u>	TEVA	<u>EQ 500MG BASE</u>	<u>A065058</u>	<u>002</u>	Sep 04, 2002
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065057</u>	<u>001</u>	Jan 05, 2001

PRESCRIPTION DRUG PRODUCT LIST

3 - 81 (of 409)

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

TEVA

EQ 375MG BASE

A065058 001 Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB AUROBINDO PHARMA

EQ 500MG BASE

A065352 001 Jan 25, 2007

AB HIKMA

EQ 500MG BASE

A065311 001 Feb 07, 2006

AB LUPIN

EQ 500MG BASE

A065392 001 May 29, 2007

AB ORCHID HLTHCARE

EQ 500MG BASE

A065309 001 Sep 18, 2006

AB RANBAXY

EQ 500MG BASE

A065015 001 Jun 22, 1999

AB SANDOZ

EQ 500MG BASE

A062291 001

AB + TEVA PHARMS

EQ 500MG BASE

A065282 001 Jan 20, 2006

FOR SUSPENSION; ORAL

CEFADROXIL

AB LUPIN

EQ 250MG BASE/5ML

A065396 001 Feb 21, 2008

AB +

EQ 500MG BASE/5ML

A065396 002 Feb 21, 2008

AB ORCHID HLTHCARE

EQ 250MG BASE/5ML

A065307 002 Oct 16, 2006

AB

EQ 500MG BASE/5ML

A065307 003 Oct 16, 2006

AB RANBAXY

EQ 250MG BASE/5ML

A065115 002 Mar 26, 2003

AB

EQ 500MG BASE/5ML

A065115 003 Mar 26, 2003

AB TEVA PHARMS

EQ 250MG BASE/5ML

A065278 001 Jan 20, 2006

AB

EQ 500MG BASE/5ML

A065278 002 Jan 20, 2006

CEFADROXIL

RANBAXY

EQ 125MG BASE/5ML

A065115 001 Mar 26, 2003

TABLET; ORAL

CEFADROXIL

AB HIKMA

EQ 1GM BASE

A065260 001 Mar 30, 2006

AB ORCHID HLTHCARE

EQ 1GM BASE

A065301 001 Sep 18, 2006

AB RANBAXY

EQ 1GM BASE

A065018 001 Apr 23, 1999

CEFADROXIL

+ IVAX SUB TEVA PHARMS

EQ 1GM BASE

A062774 001 Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP ACS DOBFAR

EQ 500MG BASE/VIAL

A065303 001 Oct 22, 2008

AP

EQ 1GM BASE/VIAL

A065303 002 Oct 22, 2008

AP

EQ 10GM BASE/VIAL

A065306 001 Oct 22, 2008

AP + APP PHARMS

EQ 500MG BASE/VIAL

A064169 001 Aug 14, 1998

AP +

EQ 1GM BASE/VIAL

A064169 002 Aug 14, 1998

AP +

EQ 10GM BASE/VIAL

A064170 001 Mar 18, 1998

AP +

EQ 20GM BASE/VIAL

A064170 002 Mar 18, 1998

AP AUROBINDO PHARMA

EQ 500MG BASE/VIAL

A065395 001 Aug 08, 2008

AP

EQ 1GM BASE/VIAL

A065395 002 Aug 08, 2008

AP CEPHAZONE PHARMA

EQ 500MG BASE/VIAL

A065280 001 Mar 18, 2009

AP

EQ 1GM BASE/VIAL

A065280 002 Mar 18, 2009

AP

EQ 10GM BASE/VIAL

A065295 001 Mar 18, 2009

AP

EQ 20GM BASE/VIAL

A065296 001 Mar 18, 2009

AP HIKMA FARMACEUTICA

EQ 500MG BASE/VIAL

A065047 001 Sep 18, 2001

AP

EQ 1GM BASE/VIAL

A065047 002 Sep 18, 2001

AP

EQ 10GM BASE/VIAL

A065143 001 Oct 18, 2004

AP ORCHID HLTHCARE

EQ 500MG BASE/VIAL

A065226 001 Apr 21, 2005

AP

EQ 1GM BASE/VIAL

A065226 002 Apr 21, 2005

AP

EQ 1GM BASE/VIAL

A065244 001 Aug 12, 2005

AP

EQ 10GM BASE/VIAL

A065247 001 Aug 12, 2005

AP SANDOZ

EQ 500MG BASE/VIAL

A062831 001 Dec 09, 1988

AP

EQ 1GM BASE/VIAL

A062831 002 Dec 09, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 82 (of 409)

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A065345</u>	<u>001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831</u>	<u>003</u>	Sep 25, 1992
<u>AP</u>	STERI PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A063207</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A063208</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063209</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 20GM BASE/VIAL</u>	<u>A063209</u>	<u>002</u>	Apr 30, 1999
<u>KEFZOL</u>					
<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A061773</u>	<u>002</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A061773</u>	<u>003</u>	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A061773</u>	<u>004</u>	
ANCEF IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991
+		EQ 20MG BASE/ML	A063002	002	Mar 28, 1991
CEFAZOLIN AND DEXTROSE					
+	B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
		EQ 2GM BASE/VIAL	N050779	003	Nov 23, 2010
CEFAZOLIN SODIUM					
+	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
+		EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

CEFDINIR

CAPSULE; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>300MG</u>	<u>A065434</u>	<u>001</u>	Jan 07, 2008
<u>AB</u>	LUPIN	<u>300MG</u>	<u>A065264</u>	<u>001</u>	May 19, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>300MG</u>	<u>A065418</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>	+ SANDOZ	<u>300MG</u>	<u>A065330</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A065368</u>	<u>001</u>	May 09, 2007

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065473</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065473</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065259</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259</u>	<u>002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065337</u>	<u>002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332</u>	<u>002</u>	May 04, 2007

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

	CORNERSTONE	200MG	N021222	001	Aug 29, 2001
+		400MG	N021222	002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441</u>	<u>001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441</u>	<u>002</u>	Mar 20, 2008
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE/VIAL</u>	<u>A065369</u>	<u>001</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065369</u>	<u>002</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065369</u>	<u>003</u>	Jun 18, 2007
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A090291</u>	<u>001</u>	Dec 21, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090291</u>	<u>002</u>	Dec 21, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 83 (of 409)

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL</u>	<u>A090291</u>	<u>003</u>	Dec 21, 2010
	<u>MAXIPIME</u>				
<u>AP</u>	+ BRISTOL MYERS SQUIBB	<u>EQ 500MG BASE/VIAL</u>	<u>N050679</u>	<u>001</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N050679</u>	<u>002</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050679</u>	<u>003</u>	Jan 18, 1996
	CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER				
	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010
		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010
	CEFEPIME IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817	001	Aug 05, 2008
	+	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817	002	Aug 05, 2008

CEFIXIME

SUSPENSION; ORAL

SUPRAX

	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004
+		200MG/5ML	A065355	001	Apr 10, 2007

TABLET; ORAL

SUPRAX

+	LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004

TABLET, CHEWABLE; ORAL
SUPRAX

	LUPIN LTD	100MG	A065380	001	Oct 25, 2010
		150MG	A065380	002	Oct 25, 2010
+		200MG	A065380	003	Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

<u>AP</u>	APP PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A064200</u>	<u>001</u>	Mar 24, 2000
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A064200</u>	<u>002</u>	Mar 24, 2000
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A064200</u>	<u>003</u>	Mar 24, 2000
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A064201</u>	<u>001</u>	Mar 24, 2000
<u>AP</u>	HIKMA	<u>EQ 500MG BASE/VIAL</u>	<u>A065072</u>	<u>001</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065072</u>	<u>002</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065072</u>	<u>003</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065071</u>	<u>001</u>	Nov 20, 2002
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065197</u>	<u>001</u>	Aug 29, 2006

CEFOTAXIME SODIUM

<u>AP</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A065517</u>	<u>001</u>	Nov 06, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065517</u>	<u>002</u>	Nov 06, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065517</u>	<u>003</u>	Nov 06, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065516</u>	<u>001</u>	Nov 06, 2009
<u>AP</u>	CEPHAZONE PHARMA	<u>EQ 10GM BASE/VIAL</u>	<u>A065348</u>	<u>001</u>	Jan 25, 2010
<u>AP</u>	LUPIN	<u>EQ 500MG BASE/VIAL</u>	<u>A065124</u>	<u>001</u>	Sep 24, 2003
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065124</u>	<u>002</u>	Sep 24, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065124</u>	<u>003</u>	Sep 24, 2003
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE/VIAL</u>	<u>A065290</u>	<u>001</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065290</u>	<u>002</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065293</u>	<u>001</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065290</u>	<u>003</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065293</u>	<u>002</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065292</u>	<u>001</u>	Aug 10, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 500MG BASE/VIAL</u>	<u>A065197</u>	<u>002</u>	Jun 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065197</u>	<u>003</u>	Jun 20, 2008
	<u>CLAFORAN</u>				
<u>AP</u>	+ SANOFI AVENTIS US	<u>EQ 500MG BASE/VIAL</u>	<u>N050547</u>	<u>001</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 84 (of 409)

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

<u>AP</u>	SANOFI AVENTIS US	<u>EQ 1GM BASE/VIAL</u>	<u>A062659</u>	<u>001</u>	Jan 13, 1987
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N050547</u>	<u>002</u>	
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062659</u>	<u>002</u>	Jan 13, 1987
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050547</u>	<u>003</u>	
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>N050547</u>	<u>004</u>	Dec 29, 1983
	CEFOTAXIME				
	+ APP PHARMS	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000
	CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER				
	+ SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596	002	May 20, 1985
	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

	+ APP PHARMS	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007
	+	EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007
	+	EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007
	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER				
	+ B BRAUN	EQ 1GM BASE/VIAL	A065430	001	Aug 09, 2007
	+	EQ 2GM BASE/VIAL	A065430	002	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065414</u>	<u>001</u>	Jun 12, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065414</u>	<u>002</u>	Jun 12, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065415</u>	<u>001</u>	May 19, 2010
<u>AP</u>	+ APP PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A065012</u>	<u>001</u>	Jul 03, 2000
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A065012</u>	<u>002</u>	Jul 03, 2000
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A065011</u>	<u>001</u>	Jul 03, 2000
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 1GM BASE/VIAL</u>	<u>A065051</u>	<u>001</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065051</u>	<u>002</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065050</u>	<u>001</u>	Sep 11, 2000
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A065238</u>	<u>001</u>	Mar 12, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065238</u>	<u>002</u>	Mar 12, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065239</u>	<u>001</u>	Mar 02, 2010
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 1GM BASE/VIAL</u>	<u>A065313</u>	<u>001</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065313</u>	<u>002</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065312</u>	<u>001</u>	Feb 13, 2006
	<u>CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER</u>				
<u>AP</u>	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>A065214</u>	<u>001</u>	Mar 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065214</u>	<u>002</u>	Mar 10, 2006
	MEFOXIN IN PLASTIC CONTAINER				
	+ BIONICHE PHARMA	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
	+	EQ 40MG BASE/ML	A063182	002	Jan 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE/5ML</u>	<u>A065409</u>	<u>001</u>	Jun 08, 2007
<u>AB</u>	+	<u>EQ 100MG BASE/5ML</u>	<u>A065409</u>	<u>002</u>	Jun 08, 2007
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE/5ML</u>	<u>A065082</u>	<u>001</u>	May 31, 2002
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A065082</u>	<u>002</u>	May 31, 2002
<u>AB</u>	SANDOZ	<u>EQ 50MG BASE/5ML</u>	<u>A090031</u>	<u>001</u>	Jan 14, 2009
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A090031</u>	<u>002</u>	Jan 14, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 85 (of 409)

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370</u>	<u>001</u>	Jun 11, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065370</u>	<u>002</u>	Jun 11, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065388</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>	RANBAXY	<u>EQ 100MG BASE</u>	<u>A065083</u>	<u>001</u>	Aug 20, 2003
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065083</u>	<u>002</u>	Aug 20, 2003
<u>AB</u>	SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462</u>	<u>001</u>	May 28, 2008
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065462</u>	<u>002</u>	May 28, 2008
<u>VANTIN</u>					
<u>AB</u>	PHARMACIA AND UPJOHN	<u>EQ 100MG BASE</u>	<u>N050674</u>	<u>001</u>	Aug 07, 1992
<u>AB</u>	+	<u>EQ 200MG BASE</u>	<u>N050674</u>	<u>002</u>	Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381</u>	<u>001</u>	Jan 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065381</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065261</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065261</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284</u>	<u>002</u>	Dec 30, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065284</u>	<u>001</u>	Dec 30, 2005
<u>AB</u>	RANBAXY	<u>125MG/5ML</u>	<u>A065202</u>	<u>001</u>	Jun 30, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065202</u>	<u>002</u>	Jun 30, 2006
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065257</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065257</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065236</u>	<u>002</u>	Dec 08, 2005

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340</u>	<u>001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340</u>	<u>002</u>	May 24, 2007
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>	+	<u>500MG</u>	<u>A065276</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065198</u>	<u>001</u>	Dec 13, 2006
<u>AB</u>		<u>500MG</u>	<u>A065198</u>	<u>002</u>	Dec 13, 2006
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065235</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235</u>	<u>002</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208</u>	<u>001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208</u>	<u>002</u>	Dec 06, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065428</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>		<u>500MG</u>	<u>A065428</u>	<u>002</u>	Jun 14, 2007

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)

	CEREXA	400MG/VIAL	N200327	001	Oct 29, 2010
	+	600MG/VIAL	N200327	002	Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>500MG/VIAL</u>	<u>A062640</u>	<u>001</u>	Nov 20, 1985
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062640</u>	<u>002</u>	Nov 20, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 86 (of 409)

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>2GM/VIAL</u>	<u>A062640</u>	<u>003</u>	Nov 20, 1985
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062640</u>	<u>004</u>	Feb 03, 1992
<u>AP</u>	AUROBINDO PHARMA	<u>500MG/VIAL</u>	<u>A065481</u>	<u>001</u>	May 28, 2010
<u>AP</u>		<u>1GM/VIAL</u>	<u>A065481</u>	<u>002</u>	May 28, 2010
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065481</u>	<u>003</u>	May 28, 2010
<u>AP</u>		<u>6GM/VIAL</u>	<u>A065482</u>	<u>001</u>	May 28, 2010
<u>AP</u>	WOCKHARDT	<u>1GM/VIAL</u>	<u>A065196</u>	<u>001</u>	Oct 15, 2008
<u>FORTAZ</u>					
<u>AP</u>	+ GLAXOSMITHKLINE	<u>500MG/VIAL</u>	<u>N050578</u>	<u>001</u>	Jul 19, 1985
<u>AP</u>	+	<u>1GM/VIAL</u>	<u>N050578</u>	<u>002</u>	Jul 19, 1985
<u>AP</u>	+	<u>2GM/VIAL</u>	<u>N050578</u>	<u>003</u>	Jul 19, 1985
<u>AP</u>	+	<u>6GM/VIAL</u>	<u>N050578</u>	<u>004</u>	Jul 19, 1985
<u>TAZICEF</u>					
<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A062662</u>	<u>001</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062662</u>	<u>002</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A064032</u>	<u>001</u>	Oct 31, 1993
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062662</u>	<u>003</u>	Mar 06, 1986
<u>AP</u>		<u>2GM/VIAL</u>	<u>A064032</u>	<u>002</u>	Oct 31, 1993
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062662</u>	<u>004</u>	Mar 06, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

+	GLAXOSMITHKLINE	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989
+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+	PERNIX THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995

FOR SUSPENSION; ORAL

CEDAX

+	PERNIX THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

<u>AP</u>	APP PHARMS	<u>EQ 250MG BASE/VIAL</u>	<u>A065245</u>	<u>001</u>	Feb 15, 2006
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065245</u>	<u>002</u>	Feb 15, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065245</u>	<u>003</u>	Feb 15, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065245</u>	<u>004</u>	Feb 15, 2006
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE/VIAL</u>	<u>A065505</u>	<u>001</u>	Jul 31, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065505</u>	<u>002</u>	Jul 31, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065505</u>	<u>003</u>	Jul 31, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065505</u>	<u>004</u>	Jul 31, 2008
<u>AP</u>	BEDFORD	<u>EQ 250MG BASE/VIAL</u>	<u>A065465</u>	<u>001</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065465</u>	<u>002</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065465</u>	<u>003</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065465</u>	<u>004</u>	Aug 18, 2008
<u>AP</u>	CEPHAZONE PHARMA	<u>EQ 250MG BASE/VIAL</u>	<u>A065294</u>	<u>001</u>	Mar 26, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065294</u>	<u>002</u>	Mar 26, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065294</u>	<u>003</u>	Mar 26, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065294</u>	<u>004</u>	Mar 26, 2007
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG BASE/VIAL</u>	<u>A065342</u>	<u>001</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065342</u>	<u>002</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065342</u>	<u>003</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065342</u>	<u>004</u>	Jan 10, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 87 (of 409)

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

<u>AP</u>	<u>LUITPOLD</u>	<u>EQ 250MG BASE/VIAL</u>	<u>A065305</u>	<u>001</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065305</u>	<u>002</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065305</u>	<u>003</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065305</u>	<u>004</u>	Jan 11, 2008
<u>AP</u>	<u>LUPIN</u>	<u>EQ 250MG BASE/VIAL</u>	<u>A065125</u>	<u>001</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065125</u>	<u>002</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065125</u>	<u>003</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065125</u>	<u>004</u>	Sep 30, 2003
<u>AP</u>	<u>ORCHID HLTHCARE</u>	<u>EQ 250MG BASE/VIAL</u>	<u>A065230</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065230</u>	<u>002</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065230</u>	<u>003</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065230</u>	<u>004</u>	Aug 02, 2005
<u>AP</u>	<u>+ SANDOZ</u>	<u>EQ 250MG BASE/VIAL</u>	<u>A065169</u>	<u>001</u>	May 09, 2005
<u>AP</u>	<u>+</u>	<u>EQ 500MG BASE/VIAL</u>	<u>A065169</u>	<u>002</u>	May 09, 2005
<u>AP</u>	<u>+</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A065169</u>	<u>003</u>	May 09, 2005
<u>AP</u>	<u>+</u>	<u>EQ 2GM BASE/VIAL</u>	<u>A065169</u>	<u>004</u>	May 09, 2005
<u>AP</u>	<u>STERI PHARMA</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A065268</u>	<u>001</u>	Feb 28, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065268</u>	<u>002</u>	Feb 28, 2007
<u>AP</u>	<u>TEVA</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A065262</u>	<u>001</u>	Jun 29, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065262</u>	<u>002</u>	Jun 29, 2006
<u>AP</u>	<u>TEVA PARENTERAL</u>	<u>EQ 250MG BASE/VIAL</u>	<u>A065227</u>	<u>001</u>	Mar 15, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065227</u>	<u>002</u>	Mar 15, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065227</u>	<u>003</u>	Mar 15, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065227</u>	<u>004</u>	Mar 15, 2007
<u>AP</u>	<u>WOCKHARDT</u>	<u>EQ 250MG BASE/VIAL</u>	<u>A065391</u>	<u>001</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065391</u>	<u>002</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065391</u>	<u>003</u>	Apr 12, 2007

INJECTABLE; INJECTION

CEFTRIAXONE

<u>AP</u>	<u>ACS DOBFAR</u>	<u>EQ 500MG BASE/VIAL</u>	<u>A065329</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065329</u>	<u>002</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065329</u>	<u>003</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065328</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>	<u>APP PHARMS</u>	<u>EQ 10GM BASE/VIAL</u>	<u>A065252</u>	<u>001</u>	Feb 15, 2006
<u>AP</u>	<u>AUROBINDO PHARMA</u>	<u>EQ 10GM BASE/VIAL</u>	<u>A065504</u>	<u>001</u>	Jul 31, 2008
<u>AP</u>	<u>BEDFORD</u>	<u>EQ 10GM BASE/VIAL</u>	<u>A065475</u>	<u>001</u>	Aug 18, 2008
<u>AP</u>	<u>LUPIN</u>	<u>EQ 10GM BASE/VIAL</u>	<u>A065263</u>	<u>001</u>	Sep 12, 2006
<u>AP</u>	<u>ORCHID HLTHCARE</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A065231</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065231</u>	<u>002</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065232</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>	<u>SANDOZ</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A065204</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065204</u>	<u>002</u>	May 03, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065168</u>	<u>001</u>	May 17, 2005
<u>AP</u>	<u>STERI PHARMA</u>	<u>EQ 10GM BASE/VIAL</u>	<u>A065269</u>	<u>001</u>	Feb 28, 2007
<u>AP</u>	<u>TEVA</u>	<u>EQ 10GM BASE/VIAL</u>	<u>A065274</u>	<u>001</u>	May 01, 2006
<u>AP</u>	<u>WOCKHARDT</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A065180</u>	<u>001</u>	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	<u>+ B BRAUN</u>	<u>EQ 1GM BASE/VIAL</u>	<u>N050796</u>	<u>001</u>	Apr 20, 2005
<u>AP</u>	<u>+</u>	<u>EQ 2GM BASE/VIAL</u>	<u>N050796</u>	<u>002</u>	Apr 20, 2005

ROCEPHIN

<u>AP</u>	<u>+ HOFFMANN LA ROCHE</u>	<u>EQ 500MG BASE/VIAL</u>	<u>A063239</u>	<u>002</u>	Aug 13, 1993
<u>AP</u>	<u>+</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A063239</u>	<u>003</u>	Aug 13, 1993

CEFTRIAXONE IN PLASTIC CONTAINER

	<u>BAXTER HLTHCARE</u>	<u>EQ 20MG BASE/ML</u>	<u>A065224</u>	<u>001</u>	Aug 23, 2005
		<u>EQ 40MG BASE/ML</u>	<u>A065224</u>	<u>002</u>	Aug 23, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 88 (of 409)

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE/5ML</u>	<u>N050672</u>	<u>001</u>	Jun 30, 1994
<u>AB</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>N050672</u>	<u>002</u>	Apr 29, 1997

CEFUROXIME AXETIL

<u>AB</u>	RANBAXY	<u>EQ 125MG BASE/5ML</u>	<u>A065323</u>	<u>001</u>	Feb 05, 2008
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065323</u>	<u>002</u>	Feb 05, 2008

TABLET; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE</u>	<u>N050605</u>	<u>001</u>	Dec 28, 1987
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>N050605</u>	<u>002</u>	Dec 28, 1987
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050605</u>	<u>003</u>	Dec 28, 1987

CEFUROXIME AXETIL

<u>AB</u>	ALKEM	<u>EQ 250MG BASE</u>	<u>A065496</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065496</u>	<u>002</u>	Jun 07, 2010
<u>AB</u>	APOTEX INC	<u>EQ 250MG BASE</u>	<u>A065069</u>	<u>001</u>	Oct 02, 2002
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065069</u>	<u>002</u>	Oct 02, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG BASE</u>	<u>A065308</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065308</u>	<u>002</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065308</u>	<u>003</u>	Mar 29, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065135</u>	<u>001</u>	Jul 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065135</u>	<u>002</u>	Jul 25, 2003
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359</u>	<u>001</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065359</u>	<u>002</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065359</u>	<u>003</u>	Feb 15, 2008
<u>AB</u>	RANBAXY	<u>EQ 125MG BASE</u>	<u>A065043</u>	<u>003</u>	Feb 15, 2002
<u>AB</u>		<u>EQ 125MG BASE</u>	<u>A065118</u>	<u>001</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065043</u>	<u>002</u>	Feb 15, 2002
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065118</u>	<u>002</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065043</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065118</u>	<u>003</u>	Apr 25, 2003
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065190</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065190</u>	<u>002</u>	Oct 18, 2004
<u>AB</u>	WOCKHARDT	<u>EQ 125MG BASE</u>	<u>A065166</u>	<u>001</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065166</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065166</u>	<u>003</u>	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

<u>AB</u>	APP PHARMS	<u>EQ 750MG BASE/VIAL</u>	<u>A065001</u>	<u>001</u>	May 30, 2001
<u>AB</u>	STERI PHARMA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125</u>	<u>001</u>	May 30, 1997
<u>AB</u>	TEVA	<u>EQ 750MG BASE/VIAL</u>	<u>A064192</u>	<u>002</u>	Apr 16, 1998

ZINACEF

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 750MG BASE/VIAL</u>	<u>N050558</u>	<u>002</u>	Oct 19, 1983

CEFUROXIME SODIUM

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 750MG BASE/VIAL</u>	<u>A065483</u>	<u>001</u>	Oct 15, 2008

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+	B BRAUN	<u>EQ 750MG BASE/VIAL</u>	<u>N050780</u>	<u>001</u>	Feb 21, 2001
<u>AP</u>	+		<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780</u>	<u>002</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>	APP PHARMS	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065001</u>	<u>002</u>	May 30, 2001
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065002</u>	<u>001</u>	Sep 28, 1998
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048</u>	<u>002</u>	Jan 09, 2004
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065483</u>	<u>002</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 1.5GM BASE/VIAL</u>	<u>A065503</u>	<u>001</u>	Oct 15, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 89 (of 409)

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

<u>AP</u>	ORCHID HLTHCARE	<u>EQ 7.5GM BASE/VIAL</u>	<u>A065484</u>	<u>001</u>	Oct 15, 2008
<u>AP</u>	STERI PHARMA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125</u>	<u>002</u>	May 30, 1997
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124</u>	<u>001</u>	May 30, 1997
<u>AP</u>	TEVA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064192</u>	<u>001</u>	Apr 16, 1998
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064191</u>	<u>001</u>	Apr 16, 1998
<u>ZINACEF</u>					
<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558</u>	<u>003</u>	Oct 19, 1983
<u>AP</u>	+	<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558</u>	<u>004</u>	Oct 23, 1986
CEFUROXIME SODIUM IN PLASTIC CONTAINER					
	+ SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009
	+	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009
ZINACEF IN PLASTIC CONTAINER					
	+ GLAXOSMITHKLINE	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989
	+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989

CELECOXIB

CAPSULE; ORAL

CELEBREX

	GD SEARLE	50MG	N020998	004	Dec 15, 2006
		100MG	N020998	001	Dec 31, 1998
		200MG	N020998	002	Dec 31, 1998
	+	400MG	N020998	003	Aug 29, 2002

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	ACS DOBFAR INFO SA	<u>EQ 250MG BASE</u>	<u>A062118</u>	<u>001</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062118</u>	<u>002</u>	
<u>AB</u>	ALKEM	<u>EQ 250MG BASE</u>	<u>A090836</u>	<u>001</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090836</u>	<u>002</u>	Dec 20, 2010
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253</u>	<u>001</u>	Nov 16, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065253</u>	<u>002</u>	Nov 16, 2005
<u>AB</u>	BELCHER PHARMS	<u>EQ 250MG BASE</u>	<u>A062713</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062713</u>	<u>002</u>	Jul 15, 1988
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065215</u>	<u>001</u>	Jan 24, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065215</u>	<u>002</u>	Jan 24, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065229</u>	<u>001</u>	Nov 25, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065229</u>	<u>002</u>	Nov 25, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065248</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A065007</u>	<u>001</u>	Sep 16, 1999
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065007</u>	<u>002</u>	Sep 16, 1999
<u>AB</u>	STEVENS J	<u>EQ 250MG BASE</u>	<u>A062870</u>	<u>001</u>	Mar 17, 1988
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 250MG BASE</u>	<u>A062791</u>	<u>001</u>	Jun 11, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062791</u>	<u>002</u>	Jun 11, 1987
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062702</u>	<u>001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062702</u>	<u>002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065152</u>	<u>002</u>	Feb 24, 2005
<u>KEFLEX</u>					
<u>AB</u>	VICTORY PHARMA	<u>EQ 250MG BASE</u>	<u>N050405</u>	<u>002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050405</u>	<u>003</u>	
	KEFLEX				
	+ VICTORY PHARMA	EQ 750MG BASE	N050405	005	May 12, 2006
FOR SUSPENSION; ORAL					
<u>CEPHALEXIN</u>					
<u>AB</u>	ACS DOBFAR INFO SA	<u>EQ 125MG BASE/5ML</u>	<u>A062117</u>	<u>002</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 90 (of 409)

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

<u>AB</u>	+	ACS DOBFAR INFO SA	<u>EQ 250MG BASE/5ML</u>	<u>A062117</u>	<u>003</u>	
<u>AB</u>		HIKMA PHARMS	<u>EQ 125MG BASE/5ML</u>	<u>A065444</u>	<u>001</u>	Aug 28, 2009
<u>AB</u>			<u>EQ 250MG BASE/5ML</u>	<u>A065444</u>	<u>002</u>	Aug 28, 2009
<u>AB</u>		LUPIN	<u>EQ 125MG BASE/5ML</u>	<u>A065234</u>	<u>001</u>	Aug 17, 2005
<u>AB</u>			<u>EQ 250MG BASE/5ML</u>	<u>A065234</u>	<u>002</u>	Aug 17, 2005
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 125MG BASE/5ML</u>	<u>A065326</u>	<u>001</u>	Jul 10, 2006
<u>AB</u>			<u>EQ 250MG BASE/5ML</u>	<u>A065326</u>	<u>002</u>	Jul 10, 2006
<u>AB</u>		RANBAXY	<u>EQ 125MG BASE/5ML</u>	<u>A065081</u>	<u>001</u>	Jul 27, 2001
<u>AB</u>			<u>EQ 250MG BASE/5ML</u>	<u>A065081</u>	<u>002</u>	Jul 27, 2001
<u>AB</u>		TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A062703</u>	<u>001</u>	Feb 13, 1987
<u>AB</u>			<u>EQ 250MG BASE/5ML</u>	<u>A062703</u>	<u>002</u>	Feb 13, 1987
<u>AB</u>		YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065336</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>			<u>EQ 250MG BASE/5ML</u>	<u>A065336</u>	<u>002</u>	Jul 25, 2007

TABLET; ORAL

CEPHALEXIN

		TEVA	EQ 250MG BASE	A063023	001	Jan 12, 1989
+			EQ 500MG BASE	A063024	001	Jan 12, 1989

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

		RANBAXY	EQ 125MG BASE	A065100	002	Sep 11, 2003
+			EQ 250MG BASE	A065100	001	Sep 11, 2003

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

<u>AA</u>		ACTAVIS MID ATLANTIC	<u>5MG/5ML</u>	<u>A078617</u>	<u>001</u>	Feb 02, 2010
<u>AA</u>		AMNEAL PHARMS	<u>5MG/5ML</u>	<u>A090766</u>	<u>001</u>	Oct 07, 2009
<u>AA</u>		APOTEX INC	<u>5MG/5ML</u>	<u>A078412</u>	<u>001</u>	Jun 18, 2008
<u>AA</u>		AUROBINDO PHARMA	<u>5MG/5ML</u>	<u>A090751</u>	<u>001</u>	Dec 16, 2009
<u>AA</u>		CYPRESS PHARM	<u>5MG/5ML</u>	<u>A078488</u>	<u>001</u>	Oct 06, 2008
<u>AA</u>		DR REDDYS LABS LTD	<u>5MG/5ML</u>	<u>A078870</u>	<u>001</u>	Apr 27, 2009
<u>AA</u>		PERRIGO ISRAEL	<u>5MG/5ML</u>	<u>A078398</u>	<u>001</u>	Jun 17, 2008
<u>AA</u>		RANBAXY	<u>5MG/5ML</u>	<u>A077472</u>	<u>001</u>	Jun 18, 2008
<u>AA</u>		SUN PHARM INDS INC	<u>5MG/5ML</u>	<u>A090191</u>	<u>001</u>	Nov 12, 2009
<u>AA</u>		TARO	<u>5MG/5ML</u>	<u>A076601</u>	<u>001</u>	Jun 20, 2008
<u>AA</u>		TEVA PHARMS	<u>5MG/5ML</u>	<u>A077279</u>	<u>001</u>	May 27, 2008
<u>AA</u>		VINTAGE	<u>5MG/5ML</u>	<u>A078496</u>	<u>001</u>	Sep 25, 2009
<u>AA</u>		WOCKHARDT	<u>5MG/5ML</u>	<u>A078757</u>	<u>001</u>	Aug 28, 2009

ZYRTEC

<u>AA</u>	+	MCNEIL CONSUMER	<u>5MG/5ML</u>	<u>N020346</u>	<u>001</u>	Sep 27, 1996

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

+		EMD SERONO	EQ 0.25MG BASE/ML	N021197	001	Aug 11, 2000
+			EQ 3MG BASE/ML	N021197	002	Aug 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

EVOXAC

+		DAIICHI SANKYO CO	30MG	N020989	002	Jan 11, 2000

CHENODIOL

TABLET; ORAL

CHENODIOL

+		NEXGEN PHARMA	250MG	A091019	001	Oct 22, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 91 (of 409)

CHLORAMBUCIL

TABLET; ORAL
LEUKERAN

+ SMITHKLINE BEECHAM 2MG

N010669 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLORAMPHENICOL SODIUM SUCCINATE

+ APP PHARMS EQ 1GM BASE/VIAL

A062365 001 Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB BARR 5MG

A084768 001

AB 10MG

A083116 001

AB 25MG

A084769 001

AB USL PHARMA 10MG

A084623 001

AB WATSON LABS 5MG

A086383 001

AB 10MG

A086294 001

AB 25MG

A086382 001

LIBRIUM

AB VALEANT PHARM INTL 5MG

A085461 001

AB 10MG

A085472 001

AB + 25MG

A085475 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT ACTAVIS MID ATLANTIC 0.12%

A074291 001 Dec 28, 1995

AT HI TECH PHARMA 0.12%

A074356 001 May 07, 1996

AT JOHN O BUTLER CO 0.12%

A076434 001 Nov 29, 2005

AT NOVEX 0.12%

A075561 001 Nov 14, 2000

AT TEVA 0.12%

A074522 001 Dec 15, 1995

AT WOCKHARDT 0.12%

A075006 001 Mar 03, 2004

AT XTTRIUM 0.12%

A077789 001 Jun 18, 2009

PERIDEX

AT + 3M 0.12%

N019028 001 Aug 13, 1986

PERIOGARD

AT COLGATE 0.12%

A073695 001 Jan 14, 1994

TABLET; DENTAL

PERIOCHIP

+ DEXCEL PHARMA 2.5MG

N020774 001 May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP BEDFORD 2%

A040273 001 Sep 09, 1998

AP 3%

A040273 002 Sep 09, 1998

AP HOSPIRA 2%

A087447 001 Apr 16, 1982

AP 3%

A087446 001 Apr 16, 1982

NESACAINE

AP APP PHARMS 2%

N009435 002

NESACAINE-MPF

AP + APP PHARMS 2%

N009435 006 May 02, 1996

AP + 3%

N009435 007 May 02, 1996

NESACAINE

+ APP PHARMS 1%

N009435 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 92 (of 409)

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

<u>AA</u>	+	SANOFI AVENTIS US	<u>EQ 300MG BASE</u>	<u>N006002</u>	<u>001</u>	
<u>CHLOROQUINE PHOSPHATE</u>						
<u>AA</u>		IMPAX LABS	<u>EQ 150MG BASE</u>	<u>A080880</u>	<u>001</u>	
<u>AA</u>			<u>EQ 300MG BASE</u>	<u>A040516</u>	<u>001</u>	Aug 29, 2003
<u>AA</u>		IPCA LABS LTD	<u>EQ 150MG BASE</u>	<u>A090610</u>	<u>001</u>	Dec 03, 2009
<u>AA</u>			<u>EQ 300MG BASE</u>	<u>A090249</u>	<u>001</u>	Dec 03, 2009
<u>AA</u>	+	WEST WARD	<u>EQ 150MG BASE</u>	<u>A083082</u>	<u>001</u>	
<u>AA</u>			<u>EQ 300MG BASE</u>	<u>A083082</u>	<u>002</u>	Sep 17, 1999

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

+	SALIX PHARMS	250MG/5ML	N011870	001	

TABLET; ORAL

CHLOROTHIAZIDE

<u>AB</u>	+	MYLAN	<u>250MG</u>	<u>A084388</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A084217</u>	<u>001</u>	
<u>AB</u>		WEST WARD	<u>250MG</u>	<u>A086028</u>	<u>001</u>	Jul 14, 1982
<u>AB</u>			<u>500MG</u>	<u>A087736</u>	<u>001</u>	Jul 14, 1982

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

<u>AP</u>		APP PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A090896</u>	<u>001</u>	Oct 16, 2009
<u>DIURIL</u>						
<u>AP</u>	+	LUNDBECK INC	<u>EQ 500MG BASE/VIAL</u>	<u>N011145</u>	<u>005</u>	

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

	TYCO HLTHCARE	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007
+		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

<u>AB</u>		TRIS PHARMA INC	<u>EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML</u>	<u>A091632</u>	<u>001</u>	Oct 01, 2010
<u>TUSSIONEX PENNKINETIC</u>						
<u>AB</u>	+	UCB INC	<u>EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML</u>	<u>N019111</u>	<u>001</u>	Dec 31, 1987

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+	BAXTER HLTHCARE	25MG/ML	A083329	001	

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

BP		SANDOZ	10MG	A080439	001	
BP			25MG	A080439	002	
BP			50MG	A080439	003	
BP	+		100MG	A080439	004	
BP			200MG	A080439	005	
BP		USL PHARMA	10MG	A083386	001	
BP			25MG	A084112	001	
BP			50MG	A084113	001	
BP			100MG	A084114	001	
BP			200MG	A084115	001	

PRESCRIPTION DRUG PRODUCT LIST

3 - 93 (of 409)

CHLORPROPAMIDE

TABLET; ORAL				
<u>CHLORPROPAMIDE</u>				
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A088549</u>	<u>002</u> Jun 01, 1984
<u>AB</u>		<u>250MG</u>	<u>A088549</u>	<u>001</u> Jun 01, 1984
<u>AB</u>	PLIVA	<u>100MG</u>	<u>A088921</u>	<u>001</u> Apr 12, 1985
<u>AB</u>		<u>250MG</u>	<u>A088922</u>	<u>001</u> Apr 12, 1985
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A088852</u>	<u>001</u> Sep 26, 1984
<u>AB</u>		<u>250MG</u>	<u>A088826</u>	<u>001</u> Sep 26, 1984
<u>DIABINESE</u>				
<u>AB</u>	PFIZER	<u>100MG</u>	<u>N011641</u>	<u>003</u>
<u>AB</u>	+	<u>250MG</u>	<u>N011641</u>	<u>006</u>

CHLORTHALIDONE

TABLET; ORAL				
<u>CHLORTHALIDONE</u>				
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A086831</u>	<u>002</u>
<u>AB</u>	+	<u>50MG</u>	<u>A086831</u>	<u>001</u>
<u>AB</u>	PLIVA	<u>25MG</u>	<u>A088902</u>	<u>001</u> Sep 19, 1985
<u>AB</u>		<u>50MG</u>	<u>A088903</u>	<u>001</u> Sep 19, 1985
	THALITONE			
	+ MONARCH PHARMS	15MG	N019574	001 Dec 20, 1988

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL				
CLORPRES				
	MYLAN	15MG;0.1MG	A071325	003 Feb 09, 1987
		15MG;0.2MG	A071325	002 Feb 09, 1987
	+	15MG;0.3MG	A071325	001 Feb 09, 1987

CHLORZOXAZONE

TABLET; ORAL				
<u>CHLORZOXAZONE</u>				
<u>AA</u>	ACTAVIS TOTOWA	<u>250MG</u>	<u>A088928</u>	<u>001</u> May 08, 1987
<u>AA</u>		<u>500MG</u>	<u>A040113</u>	<u>001</u> Sep 29, 1995
<u>AA</u>	BARR	<u>500MG</u>	<u>A089895</u>	<u>001</u> May 04, 1988
<u>AA</u>	OHM LABS	<u>250MG</u>	<u>A081298</u>	<u>001</u> Dec 29, 1993
<u>AA</u>		<u>500MG</u>	<u>A081299</u>	<u>001</u> Dec 29, 1993
<u>AA</u>	WATSON LABS	<u>500MG</u>	<u>A040137</u>	<u>001</u> Aug 09, 1996
<u>AA</u>		<u>500MG</u>	<u>A081040</u>	<u>001</u> Aug 22, 1989
<u>AA</u>		<u>500MG</u>	<u>A089859</u>	<u>001</u> May 04, 1988
<u>PARAFON FORTE DSC</u>				
<u>AA</u>	+ ORTHO MCNEIL JANSSEN	<u>500MG</u>	<u>N011529</u>	<u>002</u> Jun 15, 1987
	CHLORZOXAZONE			
	MIKART	375MG	A040861	001 Jun 01, 2010
		750MG	A040861	002 Jun 01, 2010

CHOLESTYRAMINE

POWDER; ORAL				
<u>CHOLESTYRAMINE</u>				
<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/PACKET</u>	<u>A077204</u>	<u>001</u> Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077204</u>	<u>002</u> Aug 26, 2005
<u>AB</u>	SANDOZ	<u>EQ 4GM RESIN/PACKET</u>	<u>A074557</u>	<u>001</u> Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074557</u>	<u>002</u> Aug 15, 1996
<u>CHOLESTYRAMINE LIGHT</u>				
<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077203</u>	<u>002</u> Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>A077203</u>	<u>001</u> Aug 26, 2005
<u>AB</u>	SANDOZ	<u>EQ 4GM RESIN/PACKET</u>	<u>A074558</u>	<u>001</u> Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074558</u>	<u>002</u> Aug 15, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 94 (of 409)

CHOLESTYRAMINE

POWDER; ORAL				
<u>LOCHOLEST</u>				
<u>AB</u>	SANDOZ	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074561</u> <u>002</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>A074561</u> <u>001</u>	Aug 15, 1996
<u>LOCHOLEST LIGHT</u>				
<u>AB</u>	SANDOZ	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074562</u> <u>002</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>A074562</u> <u>001</u>	Aug 15, 1996
<u>PREVALITE</u>				
<u>AB</u>	UPSHER SMITH	<u>EQ 4GM RESIN/PACKET</u>	<u>A073263</u> <u>001</u>	Feb 22, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A073263</u> <u>002</u>	Oct 30, 1997
<u>QUESTRAN</u>				
<u>AB</u>	+ BRISTOL MYERS	<u>EQ 4GM RESIN/PACKET</u>	<u>N016640</u> <u>001</u>	
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>N016640</u> <u>003</u>	
<u>QUESTRAN LIGHT</u>				
<u>AB</u>	BRISTOL MYERS	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>N019669</u> <u>003</u>	Dec 05, 1988
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>N019669</u> <u>001</u>	Dec 05, 1988

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL				
TRILIPIX				
	ABBOTT LABS	EQ 45MG FENOFIBRIC ACID	N022224 001	Dec 15, 2008
	+	EQ 135MG FENOFIBRIC ACID	N022224 002	Dec 15, 2008

CHORIOGONADOTROPIN ALFA

INJECTABLE; SUBCUTANEOUS				
OVIDREL				
	+ EMD SERONO	EQ 0.25MG /0.5ML	N021149 002	Oct 06, 2003

CHROMIC CHLORIDE

INJECTABLE; INJECTION				
CHROMIC CHLORIDE IN PLASTIC CONTAINER				
	+ HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961 001	Jun 26, 1986

CICLESONIDE

AEROSOL, METERED; INHALATION				
ALVESCO				
	NYCOMED US	0.08MG/INH	N021658 002	Jan 10, 2008
	+	0.16MG/INH	N021658 003	Jan 10, 2008
SPRAY, METERED; NASAL				
OMNARIS				
	+ NYCOMED US	0.05MG/INH	N022004 001	Oct 20, 2006

CICLOPIROX

CREAM; TOPICAL				
<u>CICLOPIROX</u>				
<u>AB</u>	ALTANA	<u>0.77%</u>	<u>A076435</u> <u>001</u>	Dec 29, 2004
<u>AB</u>	G AND W LABS INC	<u>0.77%</u>	<u>A078463</u> <u>001</u>	Dec 20, 2010
<u>AB</u>	GLENMARK PHARMS	<u>0.77%</u>	<u>A090273</u> <u>001</u>	Nov 10, 2009
<u>AB</u>	PERRIGO	<u>0.77%</u>	<u>A077364</u> <u>001</u>	Mar 03, 2006
<u>AB</u>	TARO	<u>0.77%</u>	<u>A076790</u> <u>001</u>	Apr 12, 2005
<u>LOPROX</u>				
<u>AB</u>	+ MEDICIS	<u>0.77%</u>	<u>N018748</u> <u>001</u>	Dec 30, 1982
GEL; TOPICAL				
<u>CICLOPIROX</u>				
<u>AB</u>	NYCOMED US	<u>0.77%</u>	<u>A077896</u> <u>001</u>	Jun 10, 2008
<u>AB</u>	PADDOCK	<u>0.77%</u>	<u>A078266</u> <u>001</u>	Jan 07, 2009
<u>LOPROX</u>				
<u>AB</u>	+ MEDICIS	<u>0.77%</u>	<u>N020519</u> <u>001</u>	Jul 21, 1997

PRESCRIPTION DRUG PRODUCT LIST

3 - 95 (of 409)

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

<u>AT</u>	NYCOMED US	<u>1%</u>	<u>A090146</u> <u>001</u>	May 25, 2010
<u>AT</u>	PADDOCK LABS	<u>1%</u>	<u>A090490</u> <u>001</u>	Nov 24, 2009
<u>AT</u>	PERRIGO	<u>1%</u>	<u>A078594</u> <u>001</u>	Feb 16, 2010

LOPROX

<u>AT</u>	+ MEDICIS	<u>1%</u>	<u>N021159</u> <u>001</u>	Feb 28, 2003

SOLUTION; TOPICAL

CICLOPIROX

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>8%</u>	<u>A078046</u> <u>001</u>	Sep 18, 2007
<u>AT</u>	APOTEX CORP	<u>8%</u>	<u>A078172</u> <u>001</u>	Sep 18, 2007
<u>AT</u>	G AND W LABS	<u>8%</u>	<u>A078233</u> <u>001</u>	Sep 18, 2007
<u>AT</u>	HI TECH PHARMA	<u>8%</u>	<u>A078270</u> <u>001</u>	Sep 18, 2007
<u>AT</u>	PERRIGO NEW YORK	<u>8%</u>	<u>A077623</u> <u>001</u>	Sep 18, 2007
<u>AT</u>	SYNERX PHARMA	<u>8%</u>	<u>A078567</u> <u>001</u>	Sep 18, 2007
<u>AT</u>	TARO PHARM INDS	<u>8%</u>	<u>A078144</u> <u>001</u>	Sep 18, 2007
<u>AT</u>	TEVA PHARMS	<u>8%</u>	<u>A078079</u> <u>001</u>	Sep 18, 2007
<u>AT</u>	TOLMAR	<u>8%</u>	<u>A077687</u> <u>001</u>	Sep 18, 2007
<u>AT</u>	VERSAPHARM	<u>8%</u>	<u>A078975</u> <u>001</u>	Feb 17, 2010
<u>AT</u>	WATSON LABS	<u>8%</u>	<u>A078124</u> <u>001</u>	Sep 18, 2007

PENLAC

<u>AT</u>	+ SANOFI AVENTIS US	<u>8%</u>	<u>N021022</u> <u>001</u>	Dec 17, 1999

SUSPENSION; TOPICAL

CICLOPIROX

<u>AB</u>	ALTANA	<u>0.77%</u>	<u>A076422</u> <u>001</u>	Aug 06, 2004
<u>AB</u>	PERRIGO NEW YORK	<u>0.77%</u>	<u>A077676</u> <u>001</u>	Dec 15, 2006
<u>AB</u>	TARO	<u>0.77%</u>	<u>A077092</u> <u>001</u>	Aug 10, 2005

LOPROX

<u>AB</u>	+ MEDICIS	<u>0.77%</u>	<u>N019824</u> <u>001</u>	Dec 30, 1988

CIDOFOVIR

INJECTABLE; INJECTION

VISTIDE

+	GILEAD	EQ 75MG BASE/ML	N020638 001	Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

	MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	A062756 001	Jan 08, 1987
+		EQ 250MG BASE/VIAL;250MG/VIAL	N050587 001	Nov 26, 1985
		EQ 500MG BASE/VIAL;500MG/VIAL	A062756 002	Jan 08, 1987
+		EQ 500MG BASE/VIAL;500MG/VIAL	N050587 002	Nov 26, 1985
		EQ 500MG BASE/VIAL;500MG/VIAL	N050630 001	Dec 14, 1990

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>	ACTAVIS TOTOWA	<u>100MG</u>	<u>A077028</u> <u>002</u>	Nov 26, 2004
<u>AB</u>	ALPHAPHARM	<u>50MG</u>	<u>A077019</u> <u>001</u>	Nov 23, 2004
<u>AB</u>		<u>100MG</u>	<u>A077019</u> <u>002</u>	Nov 23, 2004
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A077030</u> <u>001</u>	Dec 10, 2004
<u>AB</u>		<u>100MG</u>	<u>A077030</u> <u>002</u>	Dec 10, 2004
<u>AB</u>	BRECKENRIDGE PHARM	<u>50MG</u>	<u>A077708</u> <u>001</u>	Sep 28, 2009
<u>AB</u>		<u>100MG</u>	<u>A077708</u> <u>002</u>	Sep 28, 2009
<u>AB</u>	COREPHARMA	<u>50MG</u>	<u>A077150</u> <u>001</u>	Mar 11, 2005
<u>AB</u>		<u>100MG</u>	<u>A077022</u> <u>001</u>	Nov 23, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A077323</u> <u>002</u>	Apr 20, 2006
<u>AB</u>		<u>100MG</u>	<u>A077323</u> <u>001</u>	Apr 20, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 96 (of 409)

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>	PLIVA HRVATSKA DOO	<u>50MG</u>	<u>A077898</u>	<u>001</u>	Oct 29, 2007
<u>AB</u>		<u>100MG</u>	<u>A077898</u>	<u>002</u>	Oct 29, 2007
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A077024</u>	<u>001</u>	May 17, 2005
<u>AB</u>		<u>100MG</u>	<u>A077024</u>	<u>002</u>	May 17, 2005
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A077310</u>	<u>001</u>	Nov 08, 2005
<u>AB</u>		<u>100MG</u>	<u>A077021</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A077027</u>	<u>001</u>	Nov 24, 2004
<u>AB</u>		<u>100MG</u>	<u>A077027</u>	<u>002</u>	Nov 24, 2004
<u>PLETAL</u>					
<u>AB</u>	+ OTSUKA	<u>50MG</u>	<u>N020863</u>	<u>001</u>	Jan 15, 1999
<u>AB</u>	+	<u>100MG</u>	<u>N020863</u>	<u>002</u>	Jan 15, 1999

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>	APOTEX	<u>200MG</u>	<u>A074890</u>	<u>001</u>	Dec 18, 1998
<u>AB</u>		<u>300MG</u>	<u>A074890</u>	<u>002</u>	Dec 18, 1998
<u>AB</u>		<u>400MG</u>	<u>A074890</u>	<u>003</u>	Dec 18, 1998
<u>AB</u>		<u>800MG</u>	<u>A074890</u>	<u>004</u>	Dec 18, 1998
<u>AB</u>	DAVA PHARMS INC	<u>300MG</u>	<u>A074340</u>	<u>001</u>	Jun 23, 1995
<u>AB</u>		<u>400MG</u>	<u>A074340</u>	<u>002</u>	Jun 23, 1995
<u>AB</u>		<u>800MG</u>	<u>A074339</u>	<u>001</u>	Jun 23, 1995
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>200MG</u>	<u>A074424</u>	<u>001</u>	Jul 28, 1995
<u>AB</u>		<u>300MG</u>	<u>A074424</u>	<u>002</u>	Jul 28, 1995
<u>AB</u>		<u>400MG</u>	<u>A074424</u>	<u>003</u>	Jul 28, 1995
<u>AB</u>		<u>800MG</u>	<u>A074424</u>	<u>004</u>	Jul 28, 1995
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246</u>	<u>003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074246</u>	<u>004</u>	May 17, 1994
<u>AB</u>	PLIVA	<u>200MG</u>	<u>A074568</u>	<u>001</u>	Feb 27, 1997
<u>AB</u>		<u>300MG</u>	<u>A074568</u>	<u>002</u>	Feb 27, 1997
<u>AB</u>		<u>400MG</u>	<u>A074568</u>	<u>003</u>	Feb 27, 1997
<u>AB</u>		<u>800MG</u>	<u>A074566</u>	<u>001</u>	Feb 27, 1997
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A074506</u>	<u>001</u>	Jan 24, 1996
<u>AB</u>		<u>300MG</u>	<u>A074506</u>	<u>002</u>	Jan 24, 1996
<u>AB</u>		<u>400MG</u>	<u>A074506</u>	<u>003</u>	Jan 24, 1996
<u>AB</u>		<u>800MG</u>	<u>A074506</u>	<u>004</u>	Jan 24, 1996
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151</u>	<u>003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463</u>	<u>001</u>	May 17, 1994
<u>AB</u>	WATSON LABS	<u>200MG</u>	<u>A074349</u>	<u>001</u>	Aug 30, 1996
<u>AB</u>		<u>300MG</u>	<u>A074349</u>	<u>002</u>	Aug 30, 1996
<u>AB</u>		<u>400MG</u>	<u>A074349</u>	<u>003</u>	Aug 30, 1996
<u>AB</u>		<u>800MG</u>	<u>A074316</u>	<u>001</u>	Feb 28, 1996
<u>TAGAMET</u>					
<u>AB</u>	GLAXOSMITHKLINE	<u>200MG</u>	<u>N017920</u>	<u>002</u>	
<u>AB</u>		<u>300MG</u>	<u>N017920</u>	<u>003</u>	
<u>AB</u>		<u>400MG</u>	<u>N017920</u>	<u>004</u>	Dec 14, 1983
<u>AB</u>	+	<u>800MG</u>	<u>N017920</u>	<u>005</u>	Apr 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

<u>AP</u>	DAVA PHARMS INC	<u>EQ 300MG BASE/2ML</u>	<u>A074428</u>	<u>001</u>	Apr 25, 1996
<u>AP</u>	HOSPIRA	<u>EQ 300MG BASE/2ML</u>	<u>A074344</u>	<u>001</u>	Jan 31, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 97 (of 409)

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>EQ 300MG BASE/2ML</u>	<u>A074345</u>	<u>001</u>	Jan 31, 1995
<u>AP</u>	TEVA PARENTERAL	<u>EQ 300MG BASE/2ML</u>	<u>A074252</u>	<u>001</u>	Nov 26, 1997
	CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	+ HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

<u>AA</u>	+ HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	<u>A074664</u>	<u>001</u>	Oct 28, 1997
<u>AA</u>	NOVEX	<u>EQ 300MG BASE/5ML</u>	<u>A075560</u>	<u>001</u>	Mar 15, 2000
<u>AA</u>	PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553</u>	<u>001</u>	Jan 27, 1997
<u>AA</u>	TEVA	<u>EQ 300MG BASE/5ML</u>	<u>A074610</u>	<u>001</u>	Sep 26, 1996
<u>AA</u>	WOCKHARDT	<u>EQ 300MG BASE/5ML</u>	<u>A074757</u>	<u>001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

AMGEN

EQ 30MG BASE

N021688 001

Mar 08, 2004

EQ 60MG BASE

N021688 002

Mar 08, 2004

+

EQ 90MG BASE

N021688 003

Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

BAYER HLTHCARE

250MG/5ML

N020780 001

Sep 26, 1997

+

500MG/5ML

N020780 002

Sep 26, 1997

INJECTABLE; INJECTION

CIPRO

<u>AP</u>	+ BAYER HLTHCARE	<u>400MG/40ML (10MG/ML)</u>	<u>N019847</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+	<u>200MG/20ML (10MG/ML)</u>	<u>N019847</u>	<u>002</u>	Dec 26, 1990
	<u>CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	+ BAYER HLTHCARE	<u>200MG/100ML</u>	<u>N019857</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+	<u>400MG/200ML</u>	<u>N019857</u>	<u>002</u>	Dec 26, 1990

CIPROFLOXACIN

<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/20ML (10MG/ML)</u>	<u>A078062</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A078062</u>	<u>002</u>	Apr 29, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A076717</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>	HOSPIRA	<u>400MG/40ML (10MG/ML)</u>	<u>A077245</u>	<u>002</u>	Aug 28, 2006
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A077245</u>	<u>001</u>	Aug 28, 2006
<u>AP</u>	TEVA PARENTERAL	<u>400MG/40ML (10MG/ML)</u>	<u>A077782</u>	<u>002</u>	Aug 28, 2006
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A077782</u>	<u>001</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>200MG/100ML</u>	<u>A078252</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078252</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>A077888</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077888</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML</u>	<u>A078024</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078024</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431</u>	<u>001</u>	Nov 18, 2009
<u>AP</u>	HOSPIRA	<u>200MG/100ML</u>	<u>A077753</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077753</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	TEVA PARENTERAL	<u>200MG/100ML</u>	<u>A077138</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077138</u>	<u>002</u>	Mar 18, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 98 (of 409)

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC					
CILOXAN					
	+ ALCON	EQ 0.3% BASE	N020369	001	Mar 30, 1998
SOLUTION/DROPS; OPHTHALMIC					
<u>CILOXAN</u>					
<u>AT</u>	+ ALCON	<u>EQ 0.3% BASE</u>	<u>N019992</u>	<u>001</u>	Dec 31, 1990
<u>CIPROFLOXACIN HYDROCHLORIDE</u>					
<u>AT</u>	AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555</u>	<u>001</u>	Dec 11, 2008
<u>AT</u>	APOTEX	<u>EQ 0.3% BASE</u>	<u>A075928</u>	<u>001</u>	Jun 09, 2004
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.3% BASE</u>	<u>A076754</u>	<u>001</u>	Jun 09, 2004
<u>AT</u>	FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568</u>	<u>001</u>	Jun 30, 2008
<u>AT</u>	HITECH PHARMA	<u>EQ 0.3% BASE</u>	<u>A076673</u>	<u>001</u>	Jan 21, 2005
<u>AT</u>	NEXUS PHARMS	<u>EQ 0.3% BASE</u>	<u>A077689</u>	<u>001</u>	Dec 13, 2006
<u>AT</u>	PHARMAFORCE	<u>EQ 0.3% BASE</u>	<u>A078598</u>	<u>001</u>	Jan 16, 2008
SOLUTION/DROPS; OTIC					
	+ WRASER PHARMS	EQ 0.2% BASE	N021918	001	May 01, 2009
TABLET; ORAL					
<u>CIPRO</u>					
<u>AB</u>	BAYER HLTHCARE	<u>EQ 100MG BASE</u>	<u>N019537</u>	<u>001</u>	Apr 08, 1996
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>N019537</u>	<u>002</u>	Oct 22, 1987
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N019537</u>	<u>003</u>	Oct 22, 1987
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>N019537</u>	<u>004</u>	Oct 22, 1987
<u>CIPROFLOXACIN HYDROCHLORIDE</u>					
<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A076896</u>	<u>001</u>	Nov 04, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076896</u>	<u>002</u>	Nov 04, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076896</u>	<u>003</u>	Nov 04, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859</u>	<u>001</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077859</u>	<u>002</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A077859</u>	<u>003</u>	Apr 26, 2007
<u>AB</u>	CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076126</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076126</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075593</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075593</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075593</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A076558</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076558</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076558</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076089</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076089</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	MYLAN	<u>EQ 100MG BASE</u>	<u>A075817</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075685</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075817</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075685</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075817</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075685</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075817</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A075747</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075747</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075747</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>	TARO	<u>EQ 100MG BASE</u>	<u>A076912</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076912</u>	<u>002</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076912</u>	<u>003</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076912</u>	<u>004</u>	Oct 06, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639</u>	<u>001</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076639</u>	<u>002</u>	Sep 10, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 99 (of 409)

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>	UNIQUE PHARM LABS	<u>EQ 750MG BASE</u>	<u>A076639</u>	<u>003</u>	Sep 10, 2004
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794</u>	<u>001</u>	Feb 10, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076794</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076794</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076794</u>	<u>004</u>	Jun 09, 2004
<u>CIPROFLOXACIN HYDROCHLORIDE</u>					
BX	PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005
BX		EQ 250MG BASE	A076426	002	Jun 15, 2005
BX		EQ 500MG BASE	A076426	003	Jun 15, 2005
BX		EQ 750MG BASE	A076426	004	Jun 15, 2005

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

+	DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

CIPRO HC

+	ALCON	EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

<u>AB</u>	+	BAYER HLTHCARE	<u>212.6MG;EQ 287.5MG BASE</u>	<u>N021473</u>	<u>001</u>	Dec 13, 2002
<u>AB</u>	+		<u>425.2MG;EQ 574.9MG BASE</u>	<u>N021473</u>	<u>002</u>	Aug 28, 2003
<u>CIPROFLOXACIN EXTENDED RELEASE</u>						
<u>AB</u>		DR REDDYS LABS LTD	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A077902</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>			<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077701</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		MYLAN	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078183</u>	<u>001</u>	Mar 22, 2007
<u>AB</u>			<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078183</u>	<u>002</u>	Mar 22, 2007
<u>AB</u>		WATSON LABS FLORIDA	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A077417</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>			<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077809</u>	<u>001</u>	Nov 30, 2010

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

+	ALCON	0.3%;0.1%	N021537	001	Jul 18, 2003

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

NIMBEX

+	ABBOTT	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995

NIMBEX PRESERVATIVE FREE

+	ABBOTT	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995

+		EQ 10MG BASE/ML	N020551	002	Dec 15, 1995

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

<u>AP</u>	+	APP PHARMS	<u>1MG/ML</u>	<u>A074735</u>	<u>001</u>	Jul 16, 1999
<u>AP</u>		BEDFORD	<u>1MG/ML</u>	<u>A075036</u>	<u>001</u>	Nov 07, 2000
<u>AP</u>		PHARMACHEMIE	<u>1MG/ML</u>	<u>A074656</u>	<u>001</u>	May 16, 2000
<u>AP</u>		TEVA PARENTERAL	<u>1MG/ML</u>	<u>A074814</u>	<u>001</u>	May 16, 2000
<u>PLATINOL</u>						
+	BRISTOL MYERS	50MG/VIAL	N018057	002		

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 100 (of 409)

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

ALPHAPHARM

EQ 10MG BASE

A077668 001 Feb 28, 2007

EQ 20MG BASE

A077668 002 Feb 28, 2007

+

EQ 40MG BASE

A077668 003 Feb 28, 2007

SOLUTION; ORAL

CELEXAAA + FOREST LABSEQ 10MG BASE/5MLN021046 001 Dec 22, 1999CITALOPRAM HYDROBROMIDEAA AUROBINDO PHARMA LTDEQ 10MG BASE/5MLA077812 001 Aug 28, 2006AA ROXANEEQ 10MG BASE/5MLA077043 001 Dec 13, 2004AA SILARXEQ 10MG BASE/5MLA077629 001 Jun 15, 2006

TABLET; ORAL

CELEXAAB FOREST LABSEQ 10MG BASEN020822 001 Apr 27, 2000ABEQ 20MG BASEN020822 002 Jul 17, 1998AB +EQ 40MG BASEN020822 003 Jul 17, 1998CITALOPRAM HYDROBROMIDEAB ALPHAPHARMEQ 10MG BASEA077037 001 Nov 05, 2004ABEQ 20MG BASEA077037 002 Nov 05, 2004ABEQ 40MG BASEA077037 003 Nov 05, 2004AB AMNEAL PHARMS NYEQ 10MG BASEA077289 001 Nov 30, 2006ABEQ 20MG BASEA077289 002 Nov 30, 2006ABEQ 40MG BASEA077289 003 Nov 30, 2006AB APOTEX INCEQ 10MG BASEA077046 001 Nov 24, 2004ABEQ 20MG BASEA077046 002 Nov 24, 2004ABEQ 40MG BASEA077046 003 Nov 24, 2004AB AUROBINDOEQ 10MG BASEA077031 001 Oct 28, 2004ABEQ 20MG BASEA077031 002 Oct 28, 2004ABEQ 40MG BASEA077031 003 Oct 28, 2004AB CARACOEQ 10MG BASEA077032 001 Nov 12, 2004ABEQ 20MG BASEA077032 002 Nov 12, 2004ABEQ 40MG BASEA077032 003 Nov 12, 2004AB COREPHARMAEQ 10MG BASEA077036 001 Oct 28, 2004ABEQ 20MG BASEA077036 002 Oct 28, 2004ABEQ 40MG BASEA077036 003 Oct 28, 2004AB DR REDDYS LABS LTDEQ 10MG BASEA077038 001 Oct 28, 2004ABEQ 20MG BASEA077038 002 Oct 28, 2004ABEQ 40MG BASEA077038 003 Oct 28, 2004AB EPIC PHARMAEQ 10MG BASEA077045 003 Apr 29, 2005ABEQ 20MG BASEA077045 002 Apr 29, 2005ABEQ 40MG BASEA077045 001 Apr 29, 2005AB GLENMARK GENERICSEQ 10MG BASEA077654 001 Feb 27, 2009ABEQ 20MG BASEA077654 002 Feb 27, 2009ABEQ 40MG BASEA077654 003 Feb 27, 2009AB INVAGEN PHARMSEQ 10MG BASEA077534 001 Oct 03, 2006ABEQ 20MG BASEA077534 002 Oct 03, 2006ABEQ 40MG BASEA077534 003 Oct 03, 2006AB IVAX SUB TEVA PHARMSEQ 10MG BASEA077048 001 Nov 16, 2004ABEQ 20MG BASEA077048 002 Nov 16, 2004ABEQ 40MG BASEA077048 003 Nov 16, 2004AB MATRIX LABS INCEQ 10MG BASEA077042 001 Nov 05, 2004ABEQ 20MG BASEA077042 002 Nov 05, 2004ABEQ 40MG BASEA077042 003 Nov 05, 2004AB MYLANEQ 10MG BASEA077039 001 Feb 03, 2005ABEQ 20MG BASEA077039 002 Feb 03, 2005ABEQ 40MG BASEA077039 003 Feb 03, 2005AB NATCO PHARMA LTDEQ 20MG BASEA077141 002 Apr 10, 2008ABEQ 40MG BASEA077141 001 Apr 10, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 101 (of 409)

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

<u>AB</u>	PLIVA	<u>EQ 10MG BASE</u>	<u>A077232</u>	<u>001</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077232</u>	<u>002</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077232</u>	<u>003</u>	Oct 31, 2005
<u>AB</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A077035</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077035</u>	<u>002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077035</u>	<u>003</u>	Oct 28, 2004
<u>AB</u>	TORRENT PHARMS	<u>EQ 10MG BASE</u>	<u>A078216</u>	<u>001</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078216</u>	<u>002</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078216</u>	<u>003</u>	Mar 27, 2007
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A077034</u>	<u>001</u>	Jun 30, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077044</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077034</u>	<u>002</u>	Jun 30, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077044</u>	<u>002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077034</u>	<u>003</u>	Jun 30, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077044</u>	<u>003</u>	Nov 05, 2004

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

+ UNITED GUARDIAN 6.602GM/100ML;198MG/100ML;3.177GM/100ML N019481 001 Oct 02, 1990

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+ EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

<u>AP</u>	APP PHARMS	<u>1MG/ML</u>	<u>A076571</u>	<u>001</u>	Apr 22, 2004
<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075405</u>	<u>001</u>	Feb 28, 2000
<u>LEUSTATIN</u>					
<u>AP</u>	+ ORTHO BIOTECH	<u>1MG/ML</u>	<u>N020229</u>	<u>001</u>	Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

<u>AB</u>	ABBOTT	<u>125MG/5ML</u>	<u>N050698</u>	<u>001</u>	Dec 23, 1993
<u>AB</u>	+	<u>250MG/5ML</u>	<u>N050698</u>	<u>002</u>	Dec 23, 1993
<u>CLARITHROMYCIN</u>					
<u>AB</u>	RANBAXY	<u>125MG/5ML</u>	<u>A065382</u>	<u>001</u>	Aug 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065382</u>	<u>002</u>	Aug 30, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065283</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065283</u>	<u>003</u>	Sep 04, 2007

TABLET; ORAL

BIAXIN

<u>AB</u>	+ ABBOTT	<u>250MG</u>	<u>N050662</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>	+	<u>500MG</u>	<u>N050662</u>	<u>002</u>	Oct 31, 1991
<u>CLARITHROMYCIN</u>					
<u>AB</u>	APOTEX CORP	<u>250MG</u>	<u>A065384</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>		<u>500MG</u>	<u>A065384</u>	<u>002</u>	Aug 20, 2007
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A065195</u>	<u>001</u>	Mar 11, 2005
<u>AB</u>		<u>500MG</u>	<u>A065195</u>	<u>002</u>	Mar 11, 2005
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065174</u>	<u>001</u>	Sep 24, 2004
<u>AB</u>		<u>500MG</u>	<u>A065174</u>	<u>002</u>	Sep 24, 2004
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A065178</u>	<u>002</u>	May 25, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 102 (of 409)

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

<u>AB</u>	ROXANE	<u>500MG</u>	<u>A065178</u>	<u>001</u>	May 25, 2004
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065144</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>		<u>500MG</u>	<u>A065136</u>	<u>001</u>	Aug 25, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065155</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>500MG</u>	<u>A065155</u>	<u>002</u>	May 31, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065266</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>500MG</u>	<u>A065266</u>	<u>002</u>	May 31, 2006

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

<u>AB</u>	+ ABBOTT	<u>500MG</u>	<u>N050775</u>	<u>001</u>	Mar 03, 2000
	<u>CLARITHROMYCIN</u>				
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065250</u>	<u>001</u>	Aug 25, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065154</u>	<u>001</u>	May 18, 2005
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A065145</u>	<u>001</u>	Jun 24, 2004

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

+	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987
		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986
+		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985
+		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985
	TIMENTIN IN PLASTIC CONTAINER				
+	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.5MG BASE/5ML</u>	<u>A074075</u>	<u>001</u>	Oct 31, 1993
<u>AA</u>	NOVEX	<u>EQ 0.5MG BASE/5ML</u>	<u>A075703</u>	<u>001</u>	Nov 27, 2000
<u>AA</u>	SILARX	<u>EQ 0.5MG BASE/5ML</u>	<u>A074884</u>	<u>001</u>	Dec 17, 1997
<u>AA</u>	+ TEVA	<u>EQ 0.5MG BASE/5ML</u>	<u>A073399</u>	<u>001</u>	Jun 30, 1994
<u>AA</u>	WOCKHARDT	<u>EQ 0.5MG BASE/5ML</u>	<u>A074863</u>	<u>001</u>	Mar 13, 1998

TABLET; ORAL

CLEMASTINE FUMARATE

<u>AB</u>	SANDOZ	<u>2.68MG</u>	<u>A073459</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	+ TEVA	<u>2.68MG</u>	<u>A073283</u>	<u>001</u>	Jan 31, 1992

CLEVIDIPINE BUTYRATE

EMULSION; INTRAVENOUS

CLEVIPREX

+	MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE</u>	<u>N050162</u>	<u>001</u>	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>N050162</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N050162</u>	<u>003</u>	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A065442</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065442</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>	COREPHARMA	<u>EQ 150MG BASE</u>	<u>A065194</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065194</u>	<u>002</u>	Mar 22, 2004
<u>AB</u>	LANNETT	<u>EQ 75MG BASE</u>	<u>A065242</u>	<u>001</u>	Aug 12, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 103 (of 409)

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>EQ 150MG BASE</u>	<u>A065242</u>	<u>002</u>	Aug 12, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065243</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>	RANBAXY	<u>EQ 150MG BASE</u>	<u>A065061</u>	<u>001</u>	Feb 02, 2001
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065061</u>	<u>002</u>	Feb 02, 2001
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A063029</u>	<u>001</u>	Sep 20, 1989
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063029</u>	<u>002</u>	Aug 05, 2005
<u>AB</u>	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A063083</u>	<u>001</u>	Jul 31, 1991
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063083</u>	<u>002</u>	Mar 18, 2003
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217</u>	<u>001</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065217</u>	<u>002</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065217</u>	<u>003</u>	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

<u>AA</u>	+ PHARMACIA AND UPJOHN	<u>EQ 75MG BASE/5ML</u>	<u>A062644</u>	<u>001</u>	Apr 07, 1986
	<u>CLINDAMYCIN PALMITATE HYDROCHLORIDE</u>				
<u>AA</u>	PADDOCK LABS	<u>EQ 75MG BASE/5ML</u>	<u>A090902</u>	<u>001</u>	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

<u>AT</u>	PERRIGO UK FINCO	<u>1%</u>	<u>A090785</u>	<u>001</u>	Mar 31, 2010
	<u>EVOCLIN</u>				
<u>AT</u>	+ STIEFEL LABS INC	<u>1%</u>	<u>N050801</u>	<u>001</u>	Oct 22, 2004

CREAM; VAGINAL

CLEOCIN

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 2% BASE</u>	<u>N050680</u>	<u>002</u>	Mar 02, 1998
	<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AB</u>	NYCOMED US	<u>EQ 2% BASE</u>	<u>A065139</u>	<u>001</u>	Dec 27, 2004
	CLINDESSE				
	+ KV PHARM	EQ 2% BASE	N050793	001	Nov 30, 2004

GEL; TOPICAL

CLEOCIN T

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050615</u>	<u>001</u>	Jan 07, 1987
	<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AB</u>	ALTANA	<u>EQ 1% BASE</u>	<u>A064160</u>	<u>001</u>	Jan 28, 2000
	CLINDAGEL				
BT	GALDERMA LABS LP	EQ 1% BASE	N050782	001	Nov 27, 2000

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

<u>AP</u>	PHARMACIA AND UPJOHN	<u>EQ 150MG BASE/ML</u>	<u>A062803</u>	<u>001</u>	Oct 16, 1987
<u>AP</u>	+	<u>EQ 150MG BASE/ML</u>	<u>N050441</u>	<u>001</u>	
	<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AP</u>	APP PHARMS	<u>EQ 150MG BASE/ML</u>	<u>A065346</u>	<u>001</u>	Mar 29, 2007
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A065347</u>	<u>001</u>	May 09, 2007
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 150MG BASE/ML</u>	<u>A062889</u>	<u>001</u>	Apr 25, 1988
<u>AP</u>	BEDFORD	<u>EQ 150MG BASE/ML</u>	<u>A065206</u>	<u>001</u>	Sep 24, 2004
<u>AP</u>	HOSPIRA	<u>EQ 150MG BASE/ML</u>	<u>A062800</u>	<u>001</u>	Jul 24, 1987
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062801</u>	<u>001</u>	Jul 24, 1987
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062943</u>	<u>001</u>	Sep 29, 1988
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	+ PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989
	+	EQ 12MG BASE/ML	N050639	002	Aug 30, 1989
	+	EQ 18MG BASE/ML	N050639	003	Apr 10, 1991
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
	+ ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635	001	Dec 22, 1989

PRESCRIPTION DRUG PRODUCT LIST

3 - 104 (of 409)

CLINDAMYCIN PHOSPHATE

LOTION; TOPICAL				
<u>CLEOCIN T</u>				
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050600</u> <u>001</u>	May 31, 1989
<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AB</u>	ALTANA	<u>EQ 1% BASE</u>	<u>A065067</u> <u>001</u>	Jan 31, 2002
SOLUTION; TOPICAL				
<u>CLEOCIN T</u>				
<u>AT</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537</u> <u>001</u>	
<u>CLINDA-DERM</u>				
<u>AT</u>	PADDOCK	<u>EQ 1% BASE</u>	<u>A063329</u> <u>001</u>	Sep 30, 1992
<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>EQ 1% BASE</u>	<u>A062811</u> <u>001</u>	Sep 01, 1988
<u>AT</u>	ALTANA	<u>EQ 1% BASE</u>	<u>A065254</u> <u>001</u>	Feb 14, 2006
<u>AT</u>	FOUGERA	<u>EQ 1% BASE</u>	<u>A064159</u> <u>001</u>	Jun 05, 1997
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A064050</u> <u>001</u>	Nov 30, 1995
<u>AT</u>	TARO PHARM INDS	<u>EQ 1% BASE</u>	<u>A065184</u> <u>001</u>	Mar 31, 2004
<u>AT</u>	WOCKHARDT	<u>EQ 1% BASE</u>	<u>A063304</u> <u>001</u>	Jul 15, 1997
SUPPOSITORY; VAGINAL				
CLEOCIN				
	+ PHARMACIA AND UPJOHN	100MG	N050767 001	Aug 13, 1999
SWAB; TOPICAL				
<u>CLEOCIN</u>				
<u>AT</u>	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537</u> <u>002</u>	Feb 22, 1994
<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A065049</u> <u>001</u>	May 25, 2000
<u>AT</u>	VERSAPHARM	<u>EQ 1% BASE</u>	<u>A065513</u> <u>001</u>	Jun 17, 2010
<u>CLINDETS</u>				
<u>AT</u>	PERRIGO	<u>EQ 1% BASE</u>	<u>A064136</u> <u>001</u>	Sep 30, 1996
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN</u>				
GEL; TOPICAL				
VELTIN				
BX	STIEFEL GSK	1.2%;0.025%	N050803 001	Jul 16, 2010
ZIANA				
BX	+ MEDICIS	1.2%;0.025%	N050802 001	Nov 07, 2006
<u>CLOBETASOL PROPIONATE</u>				
AEROSOL, FOAM; TOPICAL				
<u>CLOBETASOL PROPIONATE</u>				
<u>AB</u>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A077763</u> <u>001</u>	Mar 10, 2008
<u>OLUX</u>				
<u>AB</u>	+ CONNETICS	<u>0.05%</u>	<u>N021142</u> <u>001</u>	May 26, 2000
OLUX E				
	+ STIEFEL LABS INC	0.05%	N022013 001	Jan 12, 2007
CREAM; TOPICAL				
<u>CLOBETASOL PROPIONATE</u>				
<u>AB1</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A074139</u> <u>001</u>	Aug 03, 1994
<u>AB1</u>	FOUGERA	<u>0.05%</u>	<u>A074392</u> <u>001</u>	Sep 30, 1996
<u>AB1</u>	TARO	<u>0.05%</u>	<u>A074249</u> <u>001</u>	Jul 08, 1996
<u>AB1</u>	TEVA PHARMS	<u>0.05%</u>	<u>A074087</u> <u>001</u>	Feb 16, 1994
<u>CORMAX</u>				
<u>AB1</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A074220</u> <u>001</u>	May 16, 1997
<u>TEMOVATE</u>				
<u>AB1</u>	+ ALTANA	<u>0.05%</u>	<u>N019322</u> <u>001</u>	Dec 27, 1985
<u>CLOBETASOL PROPIONATE (EMOLLIENT)</u>				
<u>AB2</u>	ALTANA	<u>0.05%</u>	<u>A075430</u> <u>001</u>	May 26, 1999
<u>AB2</u>	TARO	<u>0.05%</u>	<u>A075633</u> <u>001</u>	May 17, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 105 (of 409)

CLOBETASOL PROPIONATE

CREAM; TOPICAL				
<u>EMBELINE E</u>				
<u>AB2</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A075325</u> <u>001</u>	Dec 24, 1998
<u>TEMOVATE E</u>				
<u>AB2</u> +	ALTANA	<u>0.05%</u>	<u>N020340</u> <u>001</u>	Jun 17, 1994
GEL; TOPICAL				
<u>CLOBETASOL PROPIONATE</u>				
<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A075368</u> <u>001</u>	Feb 15, 2000
<u>AB</u>	PERRIGO	<u>0.05%</u>	<u>A075027</u> <u>001</u>	Oct 31, 1997
<u>AB</u>	TARO	<u>0.05%</u>	<u>A075279</u> <u>001</u>	May 28, 1999
<u>EMBELINE</u>				
<u>AB</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A076141</u> <u>001</u>	Apr 12, 2002
<u>TEMOVATE</u>				
<u>AB</u> +	ALTANA	<u>0.05%</u>	<u>N020337</u> <u>001</u>	Apr 29, 1994
LOTION; TOPICAL				
<u>CLOBETASOL PROPIONATE</u>				
<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A078223</u> <u>001</u>	Dec 04, 2008
<u>CLOBEX</u>				
<u>AB</u> +	GALDERMA LABS LP	<u>0.05%</u>	<u>N021535</u> <u>001</u>	Jul 24, 2003
OINTMENT; TOPICAL				
<u>CLOBETASOL PROPIONATE</u>				
<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A074128</u> <u>001</u>	Aug 03, 1994
<u>AB</u>	NYCOMED US	<u>0.05%</u>	<u>A074407</u> <u>001</u>	Feb 23, 1996
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074248</u> <u>001</u>	Jul 12, 1996
<u>AB</u>	TEVA PHARMS	<u>0.05%</u>	<u>A074089</u> <u>001</u>	Feb 16, 1994
<u>EMBELINE</u>				
<u>AB</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A074221</u> <u>001</u>	Mar 31, 1995
<u>TEMOVATE</u>				
<u>AB</u> +	ALTANA	<u>0.05%</u>	<u>N019323</u> <u>001</u>	Dec 27, 1985
SHAMPOO; TOPICAL				
CLOBEX				
+	GALDERMA LABS	0.05%	N021644 001	Feb 05, 2004
SOLUTION; TOPICAL				
<u>CLOBETASOL PROPIONATE</u>				
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A074331</u> <u>001</u>	Dec 15, 1995
<u>AT</u>	ALTANA	<u>0.05%</u>	<u>A075391</u> <u>001</u>	Feb 08, 1999
<u>AT</u>	TARO	<u>0.05%</u>	<u>A075224</u> <u>001</u>	Nov 16, 1998
<u>AT</u>		<u>0.05%</u>	<u>A075363</u> <u>001</u>	Dec 29, 2000
<u>AT</u>	TOLMAR	<u>0.05%</u>	<u>A076977</u> <u>001</u>	Aug 05, 2005
<u>AT</u>	WOCKHARDT	<u>0.05%</u>	<u>A075205</u> <u>001</u>	Nov 13, 1998
<u>EMBELINE</u>				
<u>AT</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A074222</u> <u>001</u>	Dec 06, 1995
<u>TEMOVATE</u>				
<u>AT</u> +	ALTANA	<u>0.05%</u>	<u>N019966</u> <u>001</u>	Feb 22, 1990
SPRAY; TOPICAL				
CLOBEX				
+	GALDERMA LABS LP	0.05%	N021835 001	Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM; TOPICAL				
CLODERM				
+	DOW PHARM SCIENCES	0.1%	N017765 001	

CLOFARABINE

INJECTABLE; IV (INFUSION)				
CLOLAR				
+	GENZYME	20MG/20ML (1MG/ML)	N021673 001	Dec 28, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 106 (of 409)

CLOFAZIMINE

CAPSULE; ORAL
LAMPRENE
+ NOVARTIS

50MG

N019500 002 Dec 15, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMID
AB + SANOFI AVENTIS US **50MG**

N016131 **002**

CLOMIPHENE CITRATE
AB PAR PHARM **50MG**

A075528 **001** Aug 30, 1999

SEROPHENE
AB EMD SERONO **50MG**

N018361 **001** Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL
AB TYCO HLTHCARE **25MG**

N019906 **001** Dec 29, 1989

AB + **50MG**

N019906 **002** Dec 29, 1989

AB **75MG**

N019906 **003** Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE
AB MYLAN **25MG**

A074947 **001** Apr 30, 1998

AB **50MG**

A074947 **002** Apr 30, 1998

AB **75MG**

A074947 **003** Apr 30, 1998

AB SANDOZ **25MG**

A074364 **001** Mar 29, 1996

AB **50MG**

A074364 **002** Mar 29, 1996

AB **75MG**

A074364 **003** Mar 29, 1996

AB TARO **25MG**

A074694 **001** Dec 31, 1996

AB **50MG**

A074694 **002** Dec 31, 1996

AB **75MG**

A074694 **003** Dec 31, 1996

AB TEVA **25MG**

A074958 **001** Aug 26, 1997

AB **50MG**

A074958 **002** Aug 26, 1997

AB **75MG**

A074958 **003** Aug 26, 1997

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM
AB ACCORD HLTHCARE INC **0.5MG**

A077147 **001** May 02, 2005

AB **1MG**

A077147 **002** May 02, 2005

AB **2MG**

A077147 **003** May 02, 2005

AB ACTAVIS ELIZABETH **0.5MG**

A074869 **001** Oct 31, 1996

AB **1MG**

A074869 **002** Oct 31, 1996

AB **2MG**

A074869 **003** Oct 31, 1996

AB ALPHAPHARM **0.5MG**

A074940 **001** Oct 30, 1997

AB **1MG**

A074940 **002** Oct 30, 1997

AB **2MG**

A074940 **003** Oct 30, 1997

AB APOTEX **0.5MG**

A075468 **001** Oct 06, 2000

AB **1MG**

A075468 **002** Oct 06, 2000

AB **2MG**

A075468 **003** Oct 06, 2000

AB CARACO **0.5MG**

A075423 **001** Apr 27, 2001

AB **1MG**

A075423 **002** Apr 27, 2001

AB **2MG**

A075423 **003** Apr 27, 2001

AB MYLAN **0.5MG**

A075150 **001** Oct 05, 1998

AB **1MG**

A075150 **002** Oct 05, 1998

AB **2MG**

A075150 **003** Oct 05, 1998

AB SANDOZ **0.5MG**

A074979 **001** Aug 29, 1997

AB **1MG**

A074979 **002** Aug 29, 1997

AB **2MG**

A074979 **003** Aug 29, 1997

AB TEVA **0.5MG**

A074569 **001** Sep 10, 1996

AB **1MG**

A074569 **002** Sep 10, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 107 (of 409)

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	TEVA	<u>2MG</u>	<u>A074569</u>	<u>003</u>	Sep 10, 1996
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077856</u>	<u>001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856</u>	<u>002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856</u>	<u>003</u>	Jun 28, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964</u>	<u>001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964</u>	<u>002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964</u>	<u>003</u>	Dec 30, 1997

KLONOPIN

<u>AB</u>	ROCHE	<u>0.5MG</u>	<u>N017533</u>	<u>001</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N017533</u>	<u>002</u>	
<u>AB</u>		<u>2MG</u>	<u>N017533</u>	<u>003</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194</u>	<u>001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194</u>	<u>002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194</u>	<u>003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194</u>	<u>004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194</u>	<u>005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171</u>	<u>001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171</u>	<u>002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171</u>	<u>003</u>	Aug 03, 2005
<u>AB</u>	+	<u>1MG</u>	<u>A077171</u>	<u>004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171</u>	<u>005</u>	Aug 03, 2005

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891</u>	<u>001</u>	Oct 10, 1984

CATAPRES-TTS-2

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891</u>	<u>002</u>	Oct 10, 1984

CATAPRES-TTS-3

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.3MG/24HR</u>	<u>N018891</u>	<u>003</u>	Oct 10, 1984

CLONIDINE

<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157</u>	<u>002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157</u>	<u>003</u>	Aug 18, 2009
<u>AB</u>	BARR	<u>0.1MG/24HR</u>	<u>A079090</u>	<u>001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090</u>	<u>002</u>	Aug 20, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090</u>	<u>003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166</u>	<u>001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166</u>	<u>002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166</u>	<u>003</u>	Jul 16, 2010

SUSPENSION, EXTENDED RELEASE; ORAL

CLONIDINE

+	TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE

	TRIS PHARMA INC	EQ 0.17MG BASE	N022500	001	Dec 03, 2009
+		EQ 0.26MG BASE	N022500	002	Dec 03, 2009

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	LUITPOLD	<u>1 MG/10 ML (0.1 MG/ML)</u>	<u>A091104</u>	<u>001</u>	Oct 08, 2009
<u>AP</u>		<u>5 MG/10 ML (0.5 MG/ML)</u>	<u>A091104</u>	<u>002</u>	Oct 08, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 108 (of 409)

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

<u>AP</u>	BIONICHE PHARMA USA	<u>1 MG/10 ML (0.1 MG/ML)</u>	<u>N020615</u>	<u>001</u>	Oct 02, 1996
<u>AP</u>	+	<u>5 MG/10 ML (0.5 MG/ML)</u>	<u>N020615</u>	<u>002</u>	Apr 27, 1999

TABLET; ORAL

CATAPRES

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407</u>	<u>001</u>	
<u>AB</u>		<u>0.2MG</u>	<u>N017407</u>	<u>002</u>	
<u>AB</u>	+	<u>0.3MG</u>	<u>N017407</u>	<u>003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>	DAVA PHARMS INC	<u>0.1MG</u>	<u>A071783</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.2MG</u>	<u>A071784</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.3MG</u>	<u>A071785</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099</u>	<u>001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099</u>	<u>002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099</u>	<u>003</u>	Aug 27, 2009
<u>AB</u>	MUTUAL PHARM	<u>0.1MG</u>	<u>A070925</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070924</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>	MYLAN	<u>0.1MG</u>	<u>A070317</u>	<u>002</u>	Jul 09, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070317</u>	<u>003</u>	Jun 09, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070317</u>	<u>001</u>	Jun 09, 1987
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895</u>	<u>003</u>	Aug 26, 2009
<u>AB</u>	VINTAGE	<u>0.1MG</u>	<u>A077901</u>	<u>001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901</u>	<u>002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901</u>	<u>003</u>	Mar 09, 2007
<u>AB</u>	WATSON LABS	<u>0.3MG</u>	<u>A070963</u>	<u>001</u>	Jul 08, 1986

TABLET, EXTENDED RELEASE; ORAL

JENLOGA

	SHIONOGI PHARMA	0.1MG	N022331	001	Sep 30, 2009
+		0.2MG	N022331	002	May 25, 2010
	KAPVAY				
	SHIONOGI PHARMA	0.1MG	N022331	003	Sep 28, 2010
		0.2MG	N022331	004	Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET; ORAL

PLAVIX

	SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997
+		EQ 300MG BASE	N020839	002	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	MYLAN	<u>3.75MG</u>	<u>A071858</u>	<u>002</u>	Jul 17, 1987
<u>AB</u>		<u>7.5MG</u>	<u>A071858</u>	<u>003</u>	Jul 17, 1987
<u>AB</u>		<u>15MG</u>	<u>A071858</u>	<u>001</u>	Jul 17, 1987
<u>AB</u>	RANBAXY	<u>3.75MG</u>	<u>A076911</u>	<u>001</u>	Sep 29, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A076911</u>	<u>002</u>	Sep 29, 2004
<u>AB</u>		<u>15MG</u>	<u>A076911</u>	<u>003</u>	Sep 29, 2004
<u>AB</u>	TARO	<u>3.75MG</u>	<u>A075731</u>	<u>003</u>	Apr 27, 2000
<u>AB</u>		<u>7.5MG</u>	<u>A075731</u>	<u>002</u>	Apr 27, 2000
<u>AB</u>		<u>15MG</u>	<u>A075731</u>	<u>001</u>	Apr 27, 2000
<u>AB</u>	WATSON LABS	<u>3.75MG</u>	<u>A071852</u>	<u>001</u>	Feb 09, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 109 (of 409)

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	WATSON LABS	<u>7.5MG</u>	<u>A071853</u>	<u>001</u>	Feb 09, 1988
<u>AB</u>		<u>15MG</u>	<u>A071854</u>	<u>001</u>	Feb 09, 1988
	<u>GEN-XENE</u>				
<u>AB</u>	ALRA	<u>3.75MG</u>	<u>A071787</u>	<u>001</u>	Apr 26, 1988
<u>AB</u>		<u>7.5MG</u>	<u>A071788</u>	<u>001</u>	Apr 26, 1988
<u>AB</u>		<u>15MG</u>	<u>A071789</u>	<u>001</u>	Apr 26, 1988
	<u>TRANXENE</u>				
<u>AB</u>	LUNDBECK INC	<u>3.75MG</u>	<u>N017105</u>	<u>006</u>	
<u>AB</u>		<u>7.5MG</u>	<u>N017105</u>	<u>007</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017105</u>	<u>008</u>	

CLOTTRIMAZOLE

CREAM; TOPICAL

CLOTTRIMAZOLE

<u>AB</u>	GLENMARK PHARMS	<u>1%</u>	<u>A090219</u>	<u>001</u>	Aug 03, 2010
<u>AB</u>	NYCOMED US	<u>1%</u>	<u>A078338</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>	+	<u>1%</u>	<u>A072640</u>	<u>001</u>	Aug 31, 1993

SOLUTION; TOPICAL

CLOTTRIMAZOLE

<u>AT</u>	TARO	<u>1%</u>	<u>A074580</u>	<u>001</u>	Jul 29, 1996
<u>AT</u>	TEVA	<u>1%</u>	<u>A073306</u>	<u>001</u>	Feb 28, 1995
	<u>MYCELEX</u>				
<u>AT</u>	+	<u>1%</u>	<u>N018181</u>	<u>001</u>	

TROCHE/LOZENGE; ORAL

CLOTTRIMAZOLE

<u>AB</u>	PADDOCK	<u>10MG</u>	<u>A076763</u>	<u>001</u>	Oct 28, 2005
<u>AB</u>	ROXANE	<u>10MG</u>	<u>A076387</u>	<u>001</u>	Jul 29, 2004
	<u>MYCELEX</u>				
<u>AB</u>	+	<u>10MG</u>	<u>N018713</u>	<u>001</u>	Jun 17, 1983

CLOZAPINE

TABLET; ORAL

CLOZAPINE

<u>AB</u>	CARACO	<u>25MG</u>	<u>A075713</u>	<u>001</u>	Nov 15, 2002
<u>AB</u>		<u>50MG</u>	<u>A075713</u>	<u>003</u>	Aug 19, 2005
<u>AB</u>		<u>100MG</u>	<u>A075713</u>	<u>002</u>	Nov 15, 2002
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A074949</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074949</u>	<u>004</u>	Apr 25, 2005
<u>AB</u>		<u>50MG</u>	<u>A076809</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>		<u>100MG</u>	<u>A074949</u>	<u>002</u>	Nov 26, 1997
<u>AB</u>		<u>100MG</u>	<u>A076809</u>	<u>002</u>	Dec 16, 2005
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075417</u>	<u>001</u>	May 27, 1999
<u>AB</u>		<u>100MG</u>	<u>A075417</u>	<u>002</u>	May 27, 1999
	<u>CLOZARTIL</u>				
<u>AB</u>	NOVARTIS	<u>25MG</u>	<u>N019758</u>	<u>001</u>	Sep 26, 1989
<u>AB</u>	+	<u>100MG</u>	<u>N019758</u>	<u>002</u>	Sep 26, 1989

CLOZAPINE

IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003
	200MG	A076809	001	Dec 16, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

AZUR PHARMA INTL

	12.5MG	N021590	004	May 30, 2007
	25MG	N021590	001	Feb 10, 2004
+	100MG	N021590	002	Feb 10, 2004
	150MG	N021590	005	Jul 09, 2010
	200MG	N021590	006	Jul 09, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 110 (of 409)

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

<u>AA</u>	VINTAGE	<u>10MG/5ML; 5MG/5ML; 6.25MG/5ML</u>	<u>A040660</u>	<u>001</u>	Dec 07, 2006

PROMETH VC W/ CODEINE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10MG/5ML; 5MG/5ML; 6.25MG/5ML</u>	<u>A088764</u>	<u>001</u>	Oct 31, 1984

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A088763</u>	<u>001</u>	Oct 31, 1984

<u>AA</u>	HI TECH PHARMA	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A040151</u>	<u>001</u>	Aug 26, 1997

<u>AA</u>	PHARM ASSOC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A089647</u>	<u>001</u>	Dec 22, 1988

<u>AA</u>	SUN PHARM INDS INC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A090180</u>	<u>001</u>	Mar 17, 2010

<u>AA</u>	WOCKHARDT	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A088875</u>	<u>001</u>	Dec 17, 1984

PROMETHAZINE WITH CODEINE

<u>AA</u>	VINTAGE	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A040650</u>	<u>001</u>	Jan 31, 2006

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

	+ STI PHARMA LLC	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A088704	001	Mar 22, 1985

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATE

ROXANE

	15MG	N022402	001	Jul 16, 2009

	30MG	N022402	002	Jul 16, 2009

+	60MG	N022402	003	Jul 16, 2009

COLCHICINE

TABLET; ORAL

COLCRYS

	+ AR HOLDING CO INC	0.6MG	N022352	001	Jul 29, 2009

COLCHICINE; PROBENECID

TABLET; ORAL

COL - PROBENECID

<u>AB</u>	+ WATSON LABS	<u>0.5MG; 500MG</u>	<u>A084279</u>	<u>001</u>	

PROBENECID AND COLCHICINE

<u>AB</u>	CONCORD LABS NJ	<u>0.5MG; 500MG</u>	<u>A040618</u>	<u>001</u>	May 13, 2008

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

WELCHOL

	DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009

+		3.75GM/PACKET	N022362	002	Oct 02, 2009

TABLET; ORAL

WELCHOL

	+ DAIICHI SANKYO	625MG	N021176	001	May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>5GM/PACKET</u>	<u>N017563</u>	<u>004</u>	Sep 22, 1995

<u>AB</u>		<u>5GM/SC00PFUL</u>	<u>N017563</u>	<u>003</u>	Sep 22, 1995

COLESTIPOL HYDROCHLORIDE

<u>AB</u>	IMPAX LABS	<u>5GM/PACKET</u>	<u>A077277</u>	<u>002</u>	May 02, 2006

<u>AB</u>		<u>5GM/SC00PFUL</u>	<u>A077277</u>	<u>001</u>	May 02, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 111 (of 409)

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

FLAVORED COLESTID

PHARMACIA AND UPJOHN 5GM/PACKET
5GM/SCOOPFUL

N017563 001
N017563 002

TABLET; ORAL

COLESTID

AB + PHARMACIA AND UPJOHN 1GM

N020222 001 Jul 19, 1994

COLESTIPOL HYDROCHLORIDE

AB IMPAX LABS 1GM

A077510 001 Oct 24, 2006

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP APP PHARMS EQ 150MG BASE/VIAL

A065364 001 Apr 17, 2008

AP PADDock EQ 150MG BASE/VIAL

A065177 001 Mar 19, 2004

AP X GEN PHARMS EQ 150MG BASE/VIAL

A064216 001 Feb 26, 1999

COLY-MYCIN M

AP + JHP PHARMS EQ 150MG BASE/VIAL

N050108 002

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+ JHP PHARMS EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG
BASE/ML;0.5MG/ML

N050356 001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

+ ASTELLAS 20MG/100ML (0.2MG/ML)

N021697 002 Oct 08, 2008

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+ DURAMED RES 309MG/COPPER

N018680 001 Nov 15, 1984

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION

ACTHREL

+ FERRING EQ 0.1MG BASE/VIAL

N020162 001 May 23, 1996

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

+ QUESTCOR PHARMS 80 UNITS/ML

N008372 008

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

+ WEST WARD 25MG

A080776 002

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

AP + AMPHASTAR 0.25MG/VIAL

N016750 001

COSYNTROPIN

AP BIONICHE PHARMA 0.25MG/VIAL

A090574 001 Dec 17, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 112 (of 409)

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

SANDOZ

0.25MG/ML (0.25MG/ML)

N022028 001 Feb 21, 2008

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

+ KING PHARMS

0.8MG/INH

N018887 001 Dec 05, 1985

CONCENTRATE; ORAL

GASTROCROM

+ AZUR PHARMA

100MG/5ML

N020479 001 Feb 29, 1996

SOLUTION; INHALATION

CROMOLYN SODIUMAN ACTAVIS MID ATLANTIC10MG/MLA075067 001 Jul 19, 1999AN BAUSCH AND LOMB10MG/MLA075585 001 Dec 21, 2000AN DEY10MG/MLA074209 001 Apr 26, 1994AN NOVEX10MG/MLA075333 001 Apr 30, 2002AN + TEVA PARENTERAL10MG/MLA075271 001 Jan 18, 2000AN WATSON LABS10MG/MLA076469 001 Jun 17, 2005AN WOCKHARDT10MG/MLA075346 001 Oct 25, 1999

SOLUTION/DROPS; OPHTHALMIC

CROLOMAT BAUSCH AND LOMB4%A074443 001 Jan 30, 1995CROMOLYN SODIUMAT AKORN4%A074706 001 Apr 29, 1998AT ALCON4%A075282 001 Jun 16, 1999AT NOVEX4%A075615 001 Jan 26, 2001OPTICROMAT + ALLERGAN4%N018155 001 Oct 03, 1984CROTAMITON

CREAM; TOPICAL

EURAX

+ RANBAXY

10%

N006927 001

LOTION; TOPICAL

CROTANAT SUMMERS10%A087204 001EURAXAT + RANBAXY10%N009112 003CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.4MG COPPER/ML

N018960 001 Jun 26, 1986

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMINAP + LUITPOLD1MG/MLA080737 001VIBISONEAP + APP PHARMS1MG/MLA080557 003

SPRAY, METERED; NASAL

NASCOBAL

+ PAR PHARM

0.5MG/SPRAY

N021642 001 Jan 31, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 113 (of 409)

CYCLOBENZAPRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
AMRIX

ANESTA AG	15MG	N021777	001	Feb 01, 2007
+	30MG	N021777	002	Feb 01, 2007

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>5MG</u>	<u>A077291</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A077209</u>	<u>001</u>	Oct 04, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078643</u>	<u>001</u>	Sep 26, 2008
<u>AB</u>		<u>10MG</u>	<u>A078643</u>	<u>002</u>	Sep 26, 2008
<u>AB</u>	CADISTA PHARMS	<u>5MG</u>	<u>A077563</u>	<u>001</u>	Apr 19, 2006
<u>AB</u>		<u>10MG</u>	<u>A077563</u>	<u>002</u>	Apr 19, 2006
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A090478</u>	<u>001</u>	Jul 23, 2010
<u>AB</u>		<u>10MG</u>	<u>A090478</u>	<u>002</u>	Jul 23, 2010
<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A073541</u>	<u>002</u>	Apr 06, 2006
<u>AB</u>		<u>10MG</u>	<u>A073541</u>	<u>001</u>	May 23, 1995
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A073144</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A073144</u>	<u>001</u>	May 30, 1991
<u>AB</u>	ORIT LABS LLC	<u>10MG</u>	<u>A078218</u>	<u>001</u>	Apr 18, 2008
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A074421</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A078722</u>	<u>001</u>	May 12, 2008
<u>AB</u>		<u>7.5MG</u>	<u>A078722</u>	<u>002</u>	May 12, 2008
<u>AB</u>		<u>10MG</u>	<u>A078722</u>	<u>003</u>	May 12, 2008
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A072854</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A072854</u>	<u>001</u>	Nov 19, 1991
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077797</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>10MG</u>	<u>A077797</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A071611</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A071611</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A071611</u>	<u>001</u>	May 03, 1989
	<u>FLEXERIL</u>				
<u>AB</u>	MCNEIL PED	<u>5MG</u>	<u>N017821</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N017821</u>	<u>002</u>	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

<u>AT</u>	AKORN	<u>1%</u>	<u>A040164</u>	<u>001</u>	Jan 13, 1997
<u>AT</u>		<u>2%</u>	<u>A040165</u>	<u>001</u>	Jan 13, 1997

CYCLOGYL

<u>AT</u>	+	ALCON	<u>1%</u>	<u>A084110</u>	<u>001</u>
<u>AT</u>	+		<u>2%</u>	<u>A084108</u>	<u>001</u>

PENTOLAIR

<u>AT</u>	BAUSCH AND LOMB	<u>1%</u>	<u>A040075</u>	<u>001</u>	Apr 29, 1994
	CYCLOGYL				
	+	ALCON	0.5%	A084109	001

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

+	ALCON	0.2%;1%	A084300	001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

<u>AP</u>	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>A040745</u>	<u>001</u>	May 21, 2008
<u>AP</u>		<u>1GM/VIAL</u>	<u>A040745</u>	<u>002</u>	May 21, 2008
<u>AP</u>		<u>2GM/VIAL</u>	<u>A040745</u>	<u>003</u>	May 21, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 114 (of 409)

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>N012142</u>	<u>003</u>	
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>N012142</u>	<u>004</u>	Aug 30, 1982
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N012142</u>	<u>005</u>	Aug 30, 1982
TABLET; ORAL						
		CYCLOPHOSPHAMIDE				
		ROXANE	25MG	A040032	001	Aug 17, 1999
	+		50MG	A040032	002	Aug 17, 1999

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

+	PURDUE GMP	250MG	A060593	001	

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

<u>AB1</u>		IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A065110</u>	<u>003</u>	Mar 29, 2005
<u>AB1</u>			<u>50MG</u>	<u>A065110</u>	<u>001</u>	Mar 29, 2005
<u>AB1</u>			<u>100MG</u>	<u>A065110</u>	<u>002</u>	Mar 29, 2005
<u>AB1</u>		PLIVA	<u>25MG</u>	<u>A065044</u>	<u>002</u>	Dec 20, 2000
<u>AB1</u>			<u>100MG</u>	<u>A065044</u>	<u>001</u>	Dec 20, 2000
<u>AB1</u>		SANDOZ	<u>25MG</u>	<u>A065017</u>	<u>002</u>	Jan 13, 2000
<u>AB1</u>			<u>100MG</u>	<u>A065017</u>	<u>001</u>	Jan 13, 2000
<u>GENGRAF</u>						
<u>AB1</u>		ABBOTT	<u>25MG</u>	<u>A065003</u>	<u>001</u>	May 12, 2000
<u>AB1</u>			<u>50MG</u>	<u>A065003</u>	<u>002</u>	May 12, 2000
<u>AB1</u>			<u>100MG</u>	<u>A065003</u>	<u>003</u>	May 12, 2000
<u>NEORAL</u>						
<u>AB1</u>		NOVARTIS	<u>25MG</u>	<u>N050715</u>	<u>001</u>	Jul 14, 1995
<u>AB1</u>	+		<u>100MG</u>	<u>N050715</u>	<u>002</u>	Jul 14, 1995
<u>CYCLOSPORINE</u>						
<u>AB2</u>		APOTEX	<u>25MG</u>	<u>A065040</u>	<u>001</u>	May 09, 2002
<u>AB2</u>			<u>100MG</u>	<u>A065040</u>	<u>002</u>	May 09, 2002
<u>SANDIMMUNE</u>						
<u>AB2</u>		NOVARTIS	<u>25MG</u>	<u>N050625</u>	<u>001</u>	Mar 02, 1990
<u>AB2</u>	+		<u>100MG</u>	<u>N050625</u>	<u>002</u>	Mar 02, 1990
BX		SANDIMMUNE				
		NOVARTIS	50MG	N050625	003	Nov 23, 1992
EMULSION; OPHTHALMIC						
		RESTASIS				
	+	ALLERGAN	0.05%	N050790	001	Dec 23, 2002
INJECTABLE; INJECTION						
<u>CYCLOSPORINE</u>						
<u>AP</u>		BEDFORD	<u>50MG/ML</u>	<u>A065004</u>	<u>001</u>	Oct 29, 1999
<u>AP</u>		LUITPOLD	<u>50MG/ML</u>	<u>A065151</u>	<u>001</u>	Oct 07, 2003
<u>SANDIMMUNE</u>						
<u>AP</u>	+	NOVARTIS	<u>50MG/ML</u>	<u>N050573</u>	<u>001</u>	Nov 14, 1983
SOLUTION; ORAL						
<u>CYCLOSPORINE</u>						
<u>AB1</u>		ABBOTT	<u>100MG/ML</u>	<u>A065025</u>	<u>001</u>	Mar 03, 2000
<u>AB1</u>		IVAX SUB TEVA PHARMS	<u>100MG/ML</u>	<u>A065078</u>	<u>001</u>	Mar 25, 2005
<u>AB1</u>		NOVEX	<u>100MG/ML</u>	<u>A065167</u>	<u>001</u>	Jan 05, 2005
<u>AB1</u>		WATSON LABS	<u>100MG/ML</u>	<u>A065054</u>	<u>001</u>	Dec 18, 2001
<u>NEORAL</u>						
<u>AB1</u>	+	NOVARTIS	<u>100MG/ML</u>	<u>N050716</u>	<u>001</u>	Jul 14, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 115 (of 409)

CYCLOSPORINE

SOLUTION; ORAL

CYCLOSPORINE

<u>AB2</u>	WOCKHARDT	<u>100MG/ML</u>	<u>A065133</u>	<u>001</u>	Sep 17, 2004

SANDIMMUNE

<u>AB2</u> +	NOVARTIS	<u>100MG/ML</u>	<u>N050574</u>	<u>001</u>	Nov 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u> +	ACTAVIS MID ATLANTIC	<u>2MG/5ML</u>	<u>A086833</u>	<u>001</u>	

<u>AA</u>	LYNE	<u>2MG/5ML</u>	<u>A040668</u>	<u>001</u>	Jun 28, 2006

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	COREPHARMA	<u>4MG</u>	<u>A040537</u>	<u>001</u>	Sep 30, 2003

<u>AA</u> +	IVAX SUB TEVA PHARMS	<u>4MG</u>	<u>A087056</u>	<u>001</u>	

<u>AA</u>	PAR PHARM	<u>4MG</u>	<u>A087129</u>	<u>001</u>	

<u>AA</u>	STASON PHARMS	<u>4MG</u>	<u>A040644</u>	<u>001</u>	May 30, 2006

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

MYLAN

EQ 50MG BASE

N020392	001	Aug 15, 1994

+	EQ 150MG BASE	

N020392	002	Aug 15, 1994

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

<u>AP</u> +	APP PHARMS	<u>100MG/ML</u>	<u>A076512</u>	<u>001</u>	Jan 15, 2004

<u>AP</u>	BEDFORD	<u>100MG/VIAL</u>	<u>A071471</u>	<u>001</u>	Aug 02, 1989

<u>AP</u>		<u>500MG/VIAL</u>	<u>A071472</u>	<u>001</u>	Aug 02, 1989

<u>AP</u>		<u>1GM/VIAL</u>	<u>A074245</u>	<u>001</u>	Aug 31, 1994

<u>AP</u>		<u>2GM/VIAL</u>	<u>A074245</u>	<u>002</u>	Aug 31, 1994

<u>AP</u> +	HOSPIRA	<u>20MG/ML</u>	<u>A071868</u>	<u>001</u>	Jun 04, 1990

<u>AP</u> +		<u>20MG/ML</u>	<u>A072168</u>	<u>001</u>	Aug 31, 1990

<u>AP</u> +		<u>20MG/ML</u>	<u>A072945</u>	<u>001</u>	Feb 28, 1994

<u>AP</u>		<u>100MG/ML</u>	<u>A075383</u>	<u>001</u>	Nov 22, 1999

CYTOSAR-U

<u>AP</u>	TEVA PARENTERAL	<u>100MG/VIAL</u>	<u>A075206</u>	<u>001</u>	Dec 30, 1998

<u>AP</u> +		<u>500MG/VIAL</u>	<u>A075206</u>	<u>002</u>	Dec 30, 1998

<u>AP</u> +		<u>1GM/VIAL</u>	<u>A075206</u>	<u>004</u>	Dec 30, 1998

<u>AP</u> +		<u>2GM/VIAL</u>	<u>A075206</u>	<u>003</u>	Dec 30, 1998

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+	PACIRA PHARMS INC	10MG/ML

N021041	001	Apr 01, 1999

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

PRADAXA

BOEHRINGER INGELHEIM 75MG

N022512	001	Oct 18, 2010

+	150MG	

N022512	002	Oct 18, 2010

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

<u>AP</u>	APP PHARMS	<u>100MG/VIAL</u>	<u>A075371</u>	<u>001</u>	Aug 27, 1999

<u>AP</u>		<u>200MG/VIAL</u>	<u>A075371</u>	<u>002</u>	Aug 27, 1999

<u>AP</u>	BEDFORD	<u>200MG/VIAL</u>	<u>A075812</u>	<u>001</u>	Jun 15, 2001

<u>AP</u>		<u>500MG/VIAL</u>	<u>A075812</u>	<u>002</u>	Oct 31, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 116 (of 409)

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

<u>AP</u>	HOSPIRA	<u>200MG/VIAL</u>	<u>A075940</u>	<u>001</u>	Oct 18, 2001
<u>AP</u>	TEVA PARENTERAL	<u>200MG/VIAL</u>	<u>A075259</u>	<u>002</u>	Aug 27, 1998
<u>AP</u>	+	<u>500MG/VIAL</u>	<u>A075259</u>	<u>001</u>	Sep 22, 2000
<u>DTIC-DOME</u>					
<u>AP</u>	+ BAYER HLTHCARE	<u>100MG/VIAL</u>	<u>N017575</u>	<u>001</u>	
<u>AP</u>	+	<u>200MG/VIAL</u>	<u>N017575</u>	<u>002</u>	

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

<u>AP</u>	+ LUNDBECK INC	<u>0.5MG/VIAL</u>	<u>N050682</u>	<u>001</u>	
<u>DACTINOMYCIN</u>					
<u>AP</u>	BEDFORD	<u>0.5MG/VIAL</u>	<u>A090304</u>	<u>001</u>	Mar 16, 2010

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

+	ACORDA	10MG	N022250	001	Jan 22, 2010

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+	KING PHARMS	350MG/VIAL;150MG/VIAL	N050748	001	Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

EISAI INC

		2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002
		10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007
		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOL

<u>AB</u>	BARR	<u>50MG</u>	<u>A074582</u>	<u>003</u>	May 29, 1998
<u>AB</u>		<u>100MG</u>	<u>A074582</u>	<u>002</u>	May 29, 1998
<u>AB</u>	+	<u>200MG</u>	<u>A074582</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>	LANNETT	<u>50MG</u>	<u>A078214</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>		<u>100MG</u>	<u>A078214</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>200MG</u>	<u>A077246</u>	<u>001</u>	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

<u>AB</u>	JHP PHARMS	<u>25MG</u>	<u>N017443</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>N017443</u>	<u>003</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N017443</u>	<u>002</u>	
<u>DANTROLENE SODIUM</u>					
<u>AB</u>	ACTAVIS TOTOWA	<u>25MG</u>	<u>A076686</u>	<u>001</u>	Oct 24, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 117 (of 409)

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

<u>AB</u>	ACTAVIS TOTOWA	<u>50MG</u>	<u>A076686</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>		<u>100MG</u>	<u>A076686</u>	<u>003</u>	Oct 24, 2005
<u>AB</u>	IMPAX LABS	<u>25MG</u>	<u>A076856</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>50MG</u>	<u>A076856</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>100MG</u>	<u>A076856</u>	<u>003</u>	Mar 01, 2005

INJECTABLE; INJECTION

DANTRIUM

<u>AP</u>	+ JHP PHARMS	<u>20MG/VIAL</u>	<u>N018264</u>	<u>001</u>	
	<u>DANTROLENE SODIUM</u>				
<u>AP</u>	US WORLDMEDS	<u>20MG/VIAL</u>	<u>A078378</u>	<u>001</u>	Jul 24, 2007

DAPSONE

GEL; TOPICAL

ACZONE

	+ ALLERGAN	5%	N021794	001	Jul 07, 2005

TABLET; ORAL

DAPSONE

	JACOBUS	25MG	A086841	001	
	+	100MG	A086842	001	

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

	+ CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

	NOVARTIS	EQ 7.5MG BASE	N021513	001	Dec 22, 2004
	+	EQ 15MG BASE	N021513	002	Dec 22, 2004

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

	TIBOTEC	EQ 75MG BASE	N021976	004	Dec 18, 2008
		EQ 150MG BASE	N021976	005	Dec 18, 2008
		EQ 300MG BASE	N021976	001	Jun 23, 2006
		EQ 400MG BASE	N021976	003	Oct 21, 2008
	+	EQ 600MG BASE	N021976	002	Feb 25, 2008

DASATINIB

TABLET; ORAL

SPRYCEL

	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006
		50MG	N021986	002	Jun 28, 2006
		70MG	N021986	003	Jun 28, 2006
		80MG	N021986	005	Oct 28, 2010
		100MG	N021986	004	May 30, 2008
	+	140MG	N021986	006	Oct 28, 2010

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

	+ GILEAD	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 118 (of 409)

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

<u>AP</u>	+	BEDFORD	<u>EQ 20MG BASE/VIAL</u>	<u>A064103</u>	<u>001</u>	Feb 03, 1995
<u>AP</u>		<u>DAUNORUBICIN HYDROCHLORIDE</u>				
<u>AP</u>		APP PHARMS	<u>EQ 20MG BASE/VIAL</u>	<u>A065000</u>	<u>001</u>	May 25, 1999
<u>AP</u>	+	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>N050731</u>	<u>001</u>	Jan 30, 1998
<u>AP</u>		TEVA PARENTERAL	<u>EQ 5MG BASE/ML</u>	<u>A065035</u>	<u>001</u>	Jan 24, 2000
		DAUNORUBICIN HYDROCHLORIDE				
		APP PHARMS	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001

DECITABINE

INJECTABLE; INTRAVENOUS

DACOGEN

+	EISAI INC	50MG/VIAL	N021790	001	May 02, 2006

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

EXJADE

	NOVARTIS	125MG	N021882	001	Nov 02, 2005
		250MG	N021882	002	Nov 02, 2005
+		500MG	N021882	003	Nov 02, 2005

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

<u>AP</u>		APP PHARMS	<u>500MG/VIAL</u>	<u>A078718</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>			<u>2GM/VIAL</u>	<u>A078718</u>	<u>002</u>	Sep 15, 2009
<u>AP</u>		BEDFORD	<u>500MG/VIAL</u>	<u>A078086</u>	<u>001</u>	May 30, 2007
<u>AP</u>			<u>2GM/VIAL</u>	<u>A078086</u>	<u>002</u>	May 30, 2007
<u>AP</u>		HOSPIRA	<u>500MG/VIAL</u>	<u>A076019</u>	<u>001</u>	Mar 17, 2004
<u>AP</u>			<u>2GM/VIAL</u>	<u>A076019</u>	<u>002</u>	Mar 17, 2004
<u>AP</u>		WATSON LABS	<u>500MG/VIAL</u>	<u>A076806</u>	<u>001</u>	Mar 31, 2006
<u>AP</u>			<u>2GM/VIAL</u>	<u>A076806</u>	<u>002</u>	Mar 31, 2006
		<u>DEFERFERAL</u>				
<u>AP</u>	+	NOVARTIS	<u>500MG/VIAL</u>	<u>N016267</u>	<u>001</u>	
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N016267</u>	<u>002</u>	May 25, 2000

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

	FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
+		EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008

DELAVIRDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

	VIIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997
+		200MG	N020705	002	Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

<u>AB</u>		STIEFEL	<u>150MG</u>	<u>N050261</u>	<u>002</u>	
<u>AB</u>	+		<u>300MG</u>	<u>N050261</u>	<u>003</u>	
		<u>DEMECLOCYCLINE HYDROCHLORIDE</u>				
<u>AB</u>		AMNEAL PHARM	<u>150MG</u>	<u>A065425</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>			<u>300MG</u>	<u>A065425</u>	<u>002</u>	Feb 27, 2008
<u>AB</u>		BARR	<u>150MG</u>	<u>A065171</u>	<u>001</u>	Dec 13, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 119 (of 409)

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>300MG</u>	<u>A065171</u>	<u>002</u>	Dec 13, 2004
<u>AB</u>	COVENANT PHARMA INC	<u>150MG</u>	<u>A065389</u>	<u>001</u>	Dec 01, 2008
<u>AB</u>		<u>300MG</u>	<u>A065389</u>	<u>002</u>	Dec 01, 2008
<u>AB</u>	IMPAX LABS	<u>150MG</u>	<u>A065094</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>		<u>300MG</u>	<u>A065094</u>	<u>002</u>	Mar 22, 2004

DESFLURANE

LIQUID; INHALATION

SUPRANE

+	BAXTER HLTHCARE CORP	99.9%	N020118	001	Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>10MG</u>	<u>A074430</u>	<u>001</u>	Feb 09, 1996
<u>AB</u>		<u>25MG</u>	<u>A071601</u>	<u>001</u>	Jun 05, 1987
<u>AB</u>		<u>75MG</u>	<u>A071602</u>	<u>001</u>	Oct 05, 1987
<u>AB</u>		<u>100MG</u>	<u>A071766</u>	<u>001</u>	Oct 05, 1987
<u>AB</u>		<u>150MG</u>	<u>A074430</u>	<u>002</u>	Feb 09, 1996
<u>AB</u>	AMIDE PHARM	<u>50MG</u>	<u>A071588</u>	<u>001</u>	Jun 05, 1987
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A072099</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>25MG</u>	<u>A072100</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>50MG</u>	<u>A072101</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>75MG</u>	<u>A072102</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>100MG</u>	<u>A072103</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>150MG</u>	<u>A072104</u>	<u>001</u>	Jun 20, 1988
<u>NORPRAMIN</u>					
<u>AB</u>	SANOFI AVENTIS US	<u>10MG</u>	<u>N014399</u>	<u>007</u>	Feb 11, 1982
<u>AB</u>		<u>25MG</u>	<u>N014399</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>N014399</u>	<u>003</u>	
<u>AB</u>		<u>75MG</u>	<u>N014399</u>	<u>004</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N014399</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>N014399</u>	<u>006</u>	

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+	CANYON	15MG/VIAL	N021271	001	Apr 04, 2003

DESLOMATADINE

SYRUP; ORAL

CLARINEX

+	SCHERING	0.5MG/ML	N021300	001	Sep 01, 2004

TABLET; ORAL

CLARINEX

<u>AB</u>	+	SCHERING PLOUGH	<u>5MG</u>	<u>N021165</u>	<u>001</u>	Dec 21, 2001
		<u>DESLOMATADINE</u>				
<u>AB</u>		LUPIN PHARMS	<u>5MG</u>	<u>A078352</u>	<u>001</u>	Oct 25, 2010
<u>AB</u>		ORCHID HLTHCARE	<u>5MG</u>	<u>A078357</u>	<u>001</u>	Feb 19, 2010
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A078364</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>		SUN PHARM INDS	<u>5MG</u>	<u>A078359</u>	<u>001</u>	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

<u>AB</u>		SCHERING	<u>2.5MG</u>	<u>N021312</u>	<u>002</u>	Jul 14, 2005
<u>AB</u>	+		<u>5MG</u>	<u>N021312</u>	<u>001</u>	Jun 26, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 120 (of 409)

DESLORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL

DESLORATADINE

<u>AB</u>	REDDYS	<u>2.5MG</u>	<u>A078367</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>		<u>5MG</u>	<u>A078367</u>	<u>002</u>	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

+ SCHERING 5MG;240MG N021605 001 Mar 03, 2005

CLARINEX-D 12 HOUR

+ SCHERING 2.5MG;120MG N021313 001 Feb 01, 2006

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

<u>AP</u>	+ SANOFI AVENTIS US	<u>0.004MG/ML</u>	<u>N018938</u>	<u>001</u>	Mar 30, 1984

DESMOPRESSIN ACETATE

<u>AP</u>	HOSPIRA	<u>0.004MG/ML</u>	<u>A075220</u>	<u>001</u>	Aug 28, 2000

<u>AP</u>	TEVA PARENTERAL	<u>0.004MG/ML</u>	<u>A074888</u>	<u>001</u>	Oct 15, 1997

SOLUTION; NASAL

DDAVP

+ SANOFI AVENTIS US 0.01% N017922 001

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)

<u>AB</u>	+ SANOFI AVENTIS US	<u>0.01MG/SPRAY</u>	<u>N017922</u>	<u>003</u>	Aug 07, 1996

DESMOPRESSIN ACETATE

<u>AB</u>	+ BAUSCH AND LOMB	<u>0.01MG/SPRAY</u>	<u>A074830</u>	<u>001</u>	Jan 25, 1999

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

<u>AB</u>	APOTEX INC	<u>0.01MG/SPRAY</u>	<u>A076703</u>	<u>001</u>	Jan 27, 2005

MINIRIN

<u>AB</u>	+ FERRING	<u>0.01MG/SPRAY</u>	<u>N021333</u>	<u>001</u>	Sep 16, 2002

STIMATE

+ CSL BEHRING 0.15MG/SPRAY N020355 001 Mar 07, 1994

STIMATE (NEEDS NO REFRIGERATION)

+ CSL BEHRING 1.5MG/SPRAY N020355 002 Oct 24, 2007

TABLET; ORAL

DDAVP

<u>AB</u>	SANOFI AVENTIS US	<u>0.1MG</u>	<u>N019955</u>	<u>001</u>	Sep 06, 1995

<u>AB</u>	+	<u>0.2MG</u>	<u>N019955</u>	<u>002</u>	Sep 06, 1995

DESMOPRESSIN ACETATE

<u>AB</u>	APOTEX INC	<u>0.1MG</u>	<u>A077414</u>	<u>001</u>	Mar 07, 2006

<u>AB</u>		<u>0.2MG</u>	<u>A077414</u>	<u>002</u>	Mar 07, 2006

<u>AB</u>	TEVA PHARMS	<u>0.1MG</u>	<u>A077122</u>	<u>001</u>	Jan 25, 2006

<u>AB</u>		<u>0.2MG</u>	<u>A077122</u>	<u>002</u>	Jan 25, 2006

<u>AB</u>	WATSON LABS	<u>0.1MG</u>	<u>A076470</u>	<u>001</u>	Jul 01, 2005

<u>AB</u>		<u>0.2MG</u>	<u>A076470</u>	<u>002</u>	Jul 01, 2005

DESMOPRESSIN ACETATE

FERRING 0.1MG N021795 001 May 08, 2008

+ 0.2MG N021795 002 May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

CYCLESSA

<u>AB</u>	+ ORGANON USA INC	<u>0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG</u>	<u>N021090</u>	<u>001</u>	Dec 20, 2000

DESOGEN

<u>AB</u>	ORGANON USA INC	<u>0.15MG; 0.03MG</u>	<u>N020071</u>	<u>002</u>	Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	DURAMED PHARMS BARR	<u>0.15MG; 0.03MG</u>	<u>A075256</u>	<u>002</u>	Aug 12, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 121 (of 409)

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	WATSON LABS	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A076916</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.15MG; 0.03MG</u>	<u>A076915</u>	<u>001</u>	Jul 29, 2005
	<u>KARIVA</u>				
<u>AB</u>	BARR	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A075863</u>	<u>001</u>	Apr 05, 2002
	<u>MIRCETTE</u>				
<u>AB</u>	+ TEVA WOMENS	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>N020713</u>	<u>001</u>	Apr 22, 1998
	<u>ORTHO-CEPT</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.15MG; 0.03MG</u>	<u>N020301</u>	<u>002</u>	Dec 14, 1992
	<u>VELIVET</u>				
<u>AB</u>	DURAMED PHARMS BARR	<u>0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG</u>	<u>A076455</u>	<u>001</u>	Feb 24, 2004

DESONIDEAEROSOL, FOAM; TOPICAL
VERDESO

+ STIEFEL LABS INC 0.05% N021978 001 Sep 19, 2006

CREAM; TOPICAL

DESONIDE

<u>AB</u>	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017010</u>	<u>001</u>	
<u>AB</u>	TARO	<u>0.05%</u>	<u>A073548</u>	<u>001</u>	Jun 30, 1992
	<u>DESOWEN</u>				
<u>AB</u>	GALDERMA LABS LP	<u>0.05%</u>	<u>N019048</u>	<u>001</u>	Dec 14, 1984

GEL; TOPICAL
DESONATE

+ INTENDIS 0.05% N021844 001 Oct 20, 2006

LOTION; TOPICAL

DESONIDE

<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A075860</u>	<u>001</u>	Mar 19, 2002
	<u>DESOWEN</u>				
<u>AB</u>	+ GALDERMA LABS LP	<u>0.05%</u>	<u>A072354</u>	<u>001</u>	Jan 24, 1992

OINTMENT; TOPICAL

DESONIDE

<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A075751</u>	<u>001</u>	Mar 12, 2001
<u>AB</u>	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017426</u>	<u>001</u>	
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074254</u>	<u>001</u>	Aug 03, 1994
	<u>DESOWEN</u>				
<u>AB</u>	GALDERMA LABS LP	<u>0.05%</u>	<u>A071425</u>	<u>001</u>	Jun 15, 1988

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

<u>AB</u>	NYCOMED US	<u>0.25%</u>	<u>A078369</u>	<u>001</u>	Jun 29, 2010
<u>AB</u>	PERRIGO NEW YORK	<u>0.25%</u>	<u>A076510</u>	<u>001</u>	Jul 01, 2003
<u>AB</u>	TARO	<u>0.05%</u>	<u>A073210</u>	<u>001</u>	Nov 30, 1990
<u>AB</u>		<u>0.25%</u>	<u>A073193</u>	<u>001</u>	Nov 30, 1990

TOPICORT

<u>AB</u>	+ TARO PHARMS NORTH	<u>0.25%</u>	<u>N017856</u>	<u>001</u>	

TOPICORT LP

<u>AB</u>	+ TARO PHARMS NORTH	<u>0.05%</u>	<u>N018309</u>	<u>001</u>	

GEL; TOPICAL

DESOXIMETASONE

<u>AB</u>	PERRIGO NEW YORK	<u>0.05%</u>	<u>A077552</u>	<u>001</u>	Jan 09, 2006
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074904</u>	<u>001</u>	Jul 14, 1998
	<u>TOPICORT</u>				
<u>AB</u>	+ TARO PHARMS NORTH	<u>0.05%</u>	<u>N018586</u>	<u>001</u>	Mar 29, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 122 (of 409)

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

<u>AB</u>	TARO	<u>0.25%</u>	<u>A074286</u>	<u>001</u>	Jun 07, 1996

TOPICORT

<u>AB</u>	+ TARO PHARMS NORTH	<u>0.25%</u>	<u>N018763</u>	<u>001</u>	Sep 30, 1983

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

PRISTIQ

+	WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008

+		EQ 100MG BASE	N021992	002	Feb 29, 2008

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

+	ROXANE	1MG/ML	A088252	001	Sep 01, 1983

ELIXIR; ORAL

DEXAMETHASONE

<u>AA</u>	+ STI PHARMA LLC	<u>0.5MG/5ML</u>	<u>A084754</u>	<u>001</u>	

<u>AA</u>	+ WOCKHARDT	<u>0.5MG/5ML</u>	<u>A088254</u>	<u>001</u>	Jul 27, 1983

IMPLANT; INTRAVITREAL

OZURDEX

+	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009

SOLUTION; ORAL

DEXAMETHASONE

+	ROXANE	0.5MG/5ML	A088248	001	Sep 01, 1983

SUSPENSION/DROPS; OPHTHALMIC

+	ALCON	0.1%	N013422	001	

TABLET; ORAL

DEXAMETHASONE

<u>AB</u>	ECR	<u>1.5MG</u>	<u>A040700</u>	<u>001</u>	Aug 15, 2008

<u>AB</u>	ROXANE	<u>1.5MG</u>	<u>A084610</u>	<u>001</u>	

DEXAMETHASONE

ROXANE

0.5MG	A084611	001

0.75MG	A084613	001

1MG	A088306	001	Sep 15, 1983

2MG	A087916	001	Aug 26, 1982

4MG	A084612	001

+	6MG	A088316	001	Sep 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

<u>AP</u>	AKORN STRIDES	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A040803</u>	<u>001</u>	Aug 29, 2008

<u>AP</u>		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040802</u>	<u>001</u>	Aug 29, 2008

<u>AP</u>	APP PHARMS	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084916</u>	<u>001</u>	

<u>AP</u>		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040491</u>	<u>001</u>	Apr 11, 2003

<u>AP</u>		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040572</u>	<u>001</u>	Apr 22, 2005

<u>AP</u>	+ BAXTER HLTHCARE	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A087702</u>	<u>001</u>	Sep 07, 1982

<u>AP</u>	+ LUITPOLD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A087440</u>	<u>001</u>	Jul 21, 1982

<u>AP</u>	+ TEVA PARENTERAL	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A081126</u>	<u>001</u>	Aug 31, 1990

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

<u>AT</u>	+ ALCON UNIVERSAL	<u>EQ 0.1% PHOSPHATE</u>	<u>A088771</u>	<u>001</u>	Jan 16, 1985

<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.1% PHOSPHATE</u>	<u>A040069</u>	<u>001</u>	Jul 26, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 123 (of 409)

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

<u>AT</u>	+ FALCON PHARMS	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050065</u>	<u>002</u>	
	<u>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE</u>				
<u>AT</u>	BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064063</u>	<u>001</u>	Jul 25, 1994
<u>AT</u>	FOUGERA	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A062938</u>	<u>001</u>	Jul 31, 1989

SUSPENSION/DROPS; OPHTHALMIC

DEXASPORIN

<u>AT</u>	BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064135</u>	<u>001</u>	Sep 13, 1995
	<u>MAXITROL</u>				
<u>AT</u>	ALCON	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062341</u>	<u>001</u>	May 22, 1984
<u>AT</u>	+ FALCON PHARMS	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050023</u>	<u>002</u>	
	<u>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE</u>				
<u>AT</u>	ALCON UNIVERSAL	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062721</u>	<u>001</u>	Nov 17, 1986

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBRADEX

	+ ALCON	0.1%;0.3%	N050616	001	Sep 28, 1988

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX

<u>AB</u>	+ ALCON	<u>0.1%;0.3%</u>	<u>N050592</u>	<u>001</u>	Aug 18, 1988
	<u>TOBRAMYCIN AND DEXAMETHASONE</u>				
<u>AB</u>	BAUSCH AND LOMB	<u>0.1%;0.3%</u>	<u>A064134</u>	<u>001</u>	Oct 27, 1999
	<u>TOBRADEX ST</u>				
	+ ALCON	0.05%;0.3%	N050818	001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

	+ WOCKHARDT	2MG/5ML	A088251	001	Mar 23, 1984

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXILANT

	TAKEDA PHARMS	30MG	N022287	001	Jan 30, 2009
		60MG	N022287	002	Jan 30, 2009

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRECEDEX

	+ HOSPIRA	EQ 100MCG BASE/ML (EQ100MCG BASE/ML)	N021038	001	Dec 17, 1999

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

	NOVARTIS	5MG	N021802	001	May 26, 2005
		10MG	N021802	002	May 26, 2005
		15MG	N021802	004	Aug 01, 2006
		20MG	N021802	003	May 26, 2005
		30MG	N021802	005	Oct 23, 2009
		40MG	N021802	006	Aug 11, 2010

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A077107</u>	<u>003</u>	Jan 29, 2007
<u>AB</u>		<u>5MG</u>	<u>A077107</u>	<u>001</u>	Jan 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077107</u>	<u>002</u>	Jan 29, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 124 (of 409)

DESMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

FOCALIN

<u>AB</u>	NOVARTIS	<u>2.5MG</u>	<u>N021278</u>	<u>001</u>	Nov 13, 2001
<u>AB</u>		<u>5MG</u>	<u>N021278</u>	<u>002</u>	Nov 13, 2001
<u>AB</u>	+	<u>10MG</u>	<u>N021278</u>	<u>003</u>	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 250MG BASE/VIAL</u>	<u>A076068</u>	<u>001</u>	Sep 28, 2004
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068</u>	<u>002</u>	Sep 28, 2004
<u>ZINECARD</u>					
<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212</u>	<u>001</u>	May 26, 1995
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N020212</u>	<u>002</u>	May 26, 1995
	TOTECT				
	+ TOPOTARGET	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

<u>AB</u>	SMITHKLINE BEECHAM	<u>5MG</u>	<u>N017078</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>N017078</u>	<u>002</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017078</u>	<u>003</u>	

DEXTROAMPHETAMINE SULFATE

<u>AB</u>	BARR	<u>5MG</u>	<u>A076137</u>	<u>001</u>	Jan 18, 2002
<u>AB</u>		<u>10MG</u>	<u>A076137</u>	<u>002</u>	Jan 18, 2002
<u>AB</u>		<u>15MG</u>	<u>A076137</u>	<u>003</u>	Jan 18, 2002
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A076353</u>	<u>001</u>	May 06, 2003
<u>AB</u>		<u>10MG</u>	<u>A076353</u>	<u>002</u>	May 06, 2003
<u>AB</u>		<u>15MG</u>	<u>A076353</u>	<u>003</u>	May 06, 2003

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

	+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	BARR	<u>5MG</u>	<u>A040361</u>	<u>001</u>	Jan 31, 2001
<u>AA</u>	+	<u>10MG</u>	<u>A040361</u>	<u>002</u>	Jan 31, 2001
<u>AA</u>	KV PHARM	<u>5MG</u>	<u>A040365</u>	<u>001</u>	Oct 31, 2002
<u>AA</u>		<u>10MG</u>	<u>A040367</u>	<u>001</u>	Oct 31, 2002
<u>AA</u>	MALLINCKRODT	<u>5MG</u>	<u>A040436</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>		<u>10MG</u>	<u>A040436</u>	<u>002</u>	Jan 29, 2002

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

<u>AA</u>	+	ACTAVIS MID ATLANTIC	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088762</u>	<u>001</u>	Oct 31, 1984

PROMETHAZINE DM

<u>AA</u>	VINTAGE	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040649</u>	<u>001</u>	Feb 14, 2006

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

<u>AA</u>	HI TECH PHARMA	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040027</u>	<u>001</u>	Jul 31, 1996

PROMETHAZINE W/ DEXTROMETHORPHAN

<u>AA</u>	WOCKHARDT	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088864</u>	<u>001</u>	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

NUEDEXTA

	+	AVANIR PHARMS	20MG; 10MG	N021879	001	Oct 29, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 125 (of 409)

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>10GM/100ML</u>	<u>N019626</u>	<u>004</u>	Feb 02, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N016694</u>	<u>001</u>	
<u>AP</u>	+ HOSPIRA	<u>10GM/100ML</u>	<u>N018080</u>	<u>001</u>	

DEXTROSE 20% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N017521</u>	<u>004</u>	
<u>AP</u>	+ HOSPIRA	<u>20GM/100ML</u>	<u>N018564</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 30% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>30GM/100ML</u>	<u>N017521</u>	<u>003</u>	
<u>AP</u>	+ HOSPIRA	<u>30GM/100ML</u>	<u>N019345</u>	<u>001</u>	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>40GM/100ML</u>	<u>N017521</u>	<u>002</u>	
<u>AP</u>	+ HOSPIRA	<u>40GM/100ML</u>	<u>N018562</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>50MG/ML</u>	<u>N016730</u>	<u>002</u>	
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N016730</u>	<u>001</u>	
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N019626</u>	<u>002</u>	Feb 02, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>50MG/ML</u>	<u>N016673</u>	<u>003</u>	Oct 30, 1985
<u>AP</u>	+	<u>50MG/ML</u>	<u>N020179</u>	<u>002</u>	Dec 07, 1992
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N016673</u>	<u>001</u>	
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N020179</u>	<u>001</u>	Dec 07, 1992
<u>AP</u>	+ HOSPIRA	<u>50MG/ML</u>	<u>N016367</u>	<u>002</u>	
<u>AP</u>	+	<u>50MG/ML</u>	<u>N019222</u>	<u>001</u>	Jul 13, 1984
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N019466</u>	<u>001</u>	Jul 15, 1985
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N019479</u>	<u>001</u>	Sep 17, 1985

DEXTROSE 50% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>50GM/100ML</u>	<u>N017521</u>	<u>001</u>	
<u>AP</u>	+	<u>50GM/100ML</u>	<u>N020047</u>	<u>001</u>	Jul 02, 1991
<u>AP</u>	HOSPIRA	<u>500MG/ML</u>	<u>N019445</u>	<u>001</u>	Jun 03, 1986
<u>AP</u>	+	<u>50GM/100ML</u>	<u>N018563</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+	<u>50GM/100ML</u>	<u>N019894</u>	<u>001</u>	Dec 26, 1989

DEXTROSE 60% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>60GM/100ML</u>	<u>N017521</u>	<u>005</u>	Mar 26, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>70GM/100ML</u>	<u>N017521</u>	<u>006</u>	Mar 26, 1982
<u>AP</u>	+	<u>70GM/100ML</u>	<u>N020047</u>	<u>003</u>	Jul 02, 1991
<u>AP</u>	+ HOSPIRA	<u>70GM/100ML</u>	<u>N018561</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+	<u>70GM/100ML</u>	<u>N019893</u>	<u>001</u>	Dec 26, 1989

DEXTROSE 25%

+	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML;234MG/100ML	N017385	001	

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019873	001	Jun 10, 1993

PRESCRIPTION DRUG PRODUCT LIST

3 - 126 (of 409)

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC;
SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515 001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC;
SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484 001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC;
SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513 001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N019844 001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE;
SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019843 001	Aug 09, 1993

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017609 001	

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451 001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP	BRISTOL MYERS SQUIBB	5GM/100ML;75MG/100ML	N017634 004	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	BRISTOL MYERS SQUIBB	5GM/100ML;150MG/100ML	N017634 001	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP	BRISTOL MYERS SQUIBB	5GM/100ML;224MG/100ML	N017634 003	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	BRISTOL MYERS SQUIBB	5GM/100ML;300MG/100ML	N017634 002	

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML	N018744 001	Nov 09, 1982

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;150MG/100ML	N018744 002	Nov 09, 1982

AP		5GM/100ML;150MG/100ML	N019699 004	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;300MG/100ML	N018744 004	Nov 09, 1982

AP		5GM/100ML;300MG/100ML	N019699 006	Sep 29, 1989

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;224MG/100ML	N018371 003	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 127 (of 409)

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;220MG/100ML

N018744 003 Nov 09, 1982

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;149MG/100ML

N018371 001

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;298MG/100ML

N018371 002

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML

N019514 001 May 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML

N019870 001 Jun 10, 1993

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML

N018840 001 Jun 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQAP BAXTER HLTHCARE 5GM/100ML;75MG/100ML;200MG/100MLN018037 006 Apr 13, 1982AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML;200MG/100MLN018037 007 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML;200MG/100MLN018037 004DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQAP BAXTER HLTHCARE 5GM/100ML;150MG/100ML;200MG/100MLN018037 008 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML;200MG/100MLN018037 001DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQAP BAXTER HLTHCARE 5GM/100ML;224MG/100ML;200MG/100MLN018037 005 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQAP BAXTER HLTHCARE 5GM/100ML;300MG/100ML;200MG/100MLN018037 009 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQAP BAXTER HLTHCARE 5GM/100ML;75MG/100ML;200MG/100MLN018037 002DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML;200MG/100MLN018037 003DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;75MG/100ML;330MG/100MLN018629 005 Mar 23, 1982AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML;330MG/100MLN018629 002 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;224MG/100ML;330MG/100MLN018629 003 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;150MG/100ML;330MG/100MLN018629 004 Mar 23, 1982AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML;330MG/100MLN018629 006 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;224MG/100ML;330MG/100MLN018629 007 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;300MG/100ML;330MG/100MLN018629 008 Mar 23, 1982

PRESCRIPTION DRUG PRODUCT LIST

3 - 128 (of 409)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION					
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;330MG/100ML</u>	<u>N018629 001</u>	Mar 23,	1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N018008 010</u>		
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;200MG/100ML</u>	<u>N019630 008</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;330MG/100ML</u>	<u>N019630 014</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;450MG/100ML</u>	<u>N019630 020</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;900MG/100ML</u>	<u>N019630 026</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;200MG/100ML</u>	<u>N019630 010</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;330MG/100ML</u>	<u>N019630 016</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N019630 022</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019630 028</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;200MG/100ML</u>	<u>N019630 012</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;330MG/100ML</u>	<u>N019630 018</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N019630 024</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019630 030</u>	Feb 17,	1988
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;450MG/100ML</u>	<u>N018008 005</u>	Apr 28,	1982
<u>AP</u>		<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 006</u>	Apr 28,	1982
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 005</u>	Mar 28,	1988
<u>AP</u>		<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 009</u>	Jul 05,	1983
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;900MG/100ML</u>	<u>N019308 004</u>	Apr 05,	1985
<u>AP</u>		<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 002</u>	Apr 05,	1985
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691 002</u>	Mar 24,	1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 004</u>	Mar 24,	1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362 006</u>	Mar 28,	1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691 006</u>	Mar 24,	1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 007</u>	Apr 28,	1982
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362 010</u>	Jul 05,	1983
<u>AP</u>		<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362 007</u>	Mar 28,	1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 005</u>	Apr 05,	1985
<u>AP</u>		<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308 003</u>	Apr 05,	1985
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 005</u>	Mar 24,	1988
<u>AP</u>		<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691 008</u>	Mar 24,	1988
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018008 008</u>	Apr 28,	1982
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362 002</u>		
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019308 006</u>	Apr 05,	1985
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691 007</u>	Mar 24,	1988
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N018008 009</u>	Apr 28,	1982

PRESCRIPTION DRUG PRODUCT LIST

3 - 129 (of 409)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION				
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
<u>AP</u>	HOSPIRA	<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362 003</u>	
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308 007</u>	Apr 05, 1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691 009</u>	Mar 24, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 004</u>	
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 008</u>	Mar 28, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362 004</u>	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 001</u>	Apr 05, 1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691 001</u>	Mar 24, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 003</u>	Mar 24, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630 031	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630 037	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630 043	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630 001	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630 007	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630 013	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;37MG/100ML;450MG/100ML	N019630 019	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;37MG/100ML;900MG/100ML	N019630 025	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;75MG/100ML;200MG/100ML	N019630 032	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;75MG/100ML;450MG/100ML	N019630 038	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;75MG/100ML;900MG/100ML	N019630 044	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;75MG/100ML;300MG/100ML	N019630 049	May 07, 1992
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;75MG/100ML;110MG/100ML	N019630 002	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML;200MG/100ML	N019630 033	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML;450MG/100ML	N019630 039	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML;900MG/100ML	N019630 045	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;110MG/100ML;300MG/100ML	N019630 050	May 07, 1992
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;110MG/100ML	N019630 003	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;200MG/100ML	N019630 009	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;330MG/100ML	N019630 015	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;450MG/100ML	N019630 021	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;900MG/100ML	N019630 027	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;150MG/100ML;200MG/100ML	N019630 034	Feb 17, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 130 (of 409)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;450MG/100ML	N019630 040	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;900MG/100ML	N019630 046	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;150MG/100ML;300MG/100ML	N019630 051	May 07, 1992
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;150MG/100ML;110MG/100ML	N019630 004	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;200MG/100ML	N019630 035	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;450MG/100ML	N019630 041	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML	N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML	N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML	N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML	N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML	N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML	N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML	N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML	N019630 053	May 07, 1992
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML	N019630 006	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365 002	Jul 05, 1983
	5GM/100ML;149MG/100ML;225MG/100ML	N018365 006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 001	Jan 17, 1986
	5GM/100ML;149MG/100ML;300MG/100ML	N018876 006	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365 008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N018876 007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;149MG/100ML;225MG/100ML	N018365 001	
	5GM/100ML;298MG/100ML;225MG/100ML	N018365 009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N018876 008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;149MG/100ML;300MG/100ML	N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;298MG/100ML;225MG/100ML	N018365 004	Jul 05, 1983

PRESCRIPTION DRUG PRODUCT LIST

3 - 131 (of 409)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N018876 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365 005	Mar 28, 1988
	5GM/100ML;149MG/100ML;225MG/100ML	N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 005	Mar 28, 1988
	5GM/100ML;149MG/100ML;300MG/100ML	N018876 009	Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>10GM/100ML;900MG/100ML</u>	<u>N019631 015</u> Feb 24, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML;900MG/100ML</u>	<u>N016696 001</u>
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>2.5GM/100ML;450MG/100ML</u>	<u>N019631 004</u> Feb 24, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>2.5GM/100ML;450MG/100ML</u>	<u>N016697 001</u>
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>5GM/100ML;200MG/100ML</u>	<u>N019631 007</u> Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>5GM/100ML;330MG/100ML</u>	<u>N019631 008</u> Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>5GM/100ML;450MG/100ML</u>	<u>N019631 009</u> Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;450MG/100ML</u>	<u>N017607 001</u>
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>5GM/100ML;900MG/100ML</u>	<u>N019631 010</u> Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;900MG/100ML</u>	<u>N017585 001</u>
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;200MG/100ML</u>	<u>N016689 001</u>
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;330MG/100ML</u>	<u>N016687 001</u>
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;450MG/100ML</u>	<u>N016683 001</u>
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;900MG/100ML</u>	<u>N016678 001</u>
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>			
	B BRAUN	10GM/100ML;110MG/100ML	N019631 011 Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
	B BRAUN	10GM/100ML;200MG/100ML	N019631 012 Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
	B BRAUN	10GM/100ML;330MG/100ML	N019631 013 Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
	B BRAUN	10GM/100ML;450MG/100ML	N019631 014 Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>			
	B BRAUN	2.5GM/100ML;110MG/100ML	N019631 001 Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
	B BRAUN	2.5GM/100ML;200MG/100ML	N019631 002 Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
	B BRAUN	2.5GM/100ML;330MG/100ML	N019631 003 Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
	B BRAUN	2.5GM/100ML;900MG/100ML	N019631 005 Feb 24, 1988
<u>DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER</u>			
	B BRAUN	3.3GM/100ML;300MG/100ML	N019631 016 Jan 19, 1990
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>			
	B BRAUN	5GM/100ML;110MG/100ML	N019631 006 Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER</u>			
	HOSPIRA	5GM/100ML;225MG/100ML	N017606 001
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER</u>			
	HOSPIRA	5GM/100ML;300MG/100ML	N017799 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 132 (of 409)

DIATRIZOATE MEGLUMINESOLUTION; URETHRAL
CYSTOGRAMIN

BRACCO 30%

N010040 018

CYSTOGRAMIN DILUTE

BRACCO 18%

N010040 022 Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76RAP + MALLINCKRODT 66%;10%N019292 001 Sep 29, 1989RENOGRAFIN-76AP + BRACCO 66%;10%N010040 001

SOLUTION; ORAL, RECTAL

GASTROGRAFINAA + BRACCO 66%;10%N011245 003MD-GASTROVIEWAA MALLINCKRODT 66%;10%A087388 001DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAMIN

+ BRACCO 52.7%;26.8%

N011324 002

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM INTENSOL

+ ROXANE 5MG/ML

A071415 001 Apr 03, 1987

GEL; RECTAL

DIASTAT

VALEANT 2.5MG/0.5ML (5MG/ML)

N020648 001 Jul 29, 1997

DIASTAT ACUDIAL

VALEANT 10MG/2ML (5MG/ML)

N020648 007 Sep 15, 2005

+ 20MG/4ML (5MG/ML)

N020648 006 Sep 15, 2005

INJECTABLE; INJECTION

DIAZEPAMAP + HOSPIRA 5MG/MLA071583 001 Oct 13, 1987AP 5MG/MLA071584 001 Oct 13, 1987AP 5MG/MLA072079 001 Dec 20, 1988AP WATSON LABS 5MG/MLA070296 001 Feb 12, 1986

SOLUTION; ORAL

DIAZEPAM

+ ROXANE 5MG/5ML

A070928 001 Apr 03, 1987

TABLET; ORAL

DIAZEPAMAB ACTAVIS ELIZABETH 2MGA070781 001 Mar 19, 1986AB 5MGA070706 001 Mar 19, 1986AB 10MGA070707 001 Mar 19, 1986AB BARR 2MGA070152 001 Nov 01, 1985AB 10MGA070154 001 Nov 01, 1985AB DAVA PHARMS INC 2MGA070226 001 Sep 26, 1985AB IVAX SUB TEVA PHARMS 2MGA071307 001 Dec 10, 1986AB 5MGA071321 001 Dec 10, 1986AB 10MGA071322 001 Dec 10, 1986AB MYLAN 2MGA070325 002 Sep 04, 1985AB 5MGA070325 003 Sep 04, 1985AB 10MGA070325 001 Sep 04, 1985AB VINTAGE PHARMS 2MGA077749 001 Mar 31, 2006AB 5MGA077749 002 Mar 31, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 133 (of 409)

DIAZEPAM

TABLET; ORAL

DIAZEPAM

<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A077749</u>	<u>003</u>	Mar 31, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A071134</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>		<u>5MG</u>	<u>A071135</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>		<u>10MG</u>	<u>A071136</u>	<u>001</u>	Feb 03, 1987

VALIUM

<u>AB</u>	ROCHE	<u>2MG</u>	<u>N013263</u>	<u>002</u>	
<u>AB</u>		<u>5MG</u>	<u>N013263</u>	<u>004</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N013263</u>	<u>006</u>	

DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

+	TEVA GLOBAL	50MG/ML	N017453	001	

DICLOFENAC EPOLAMINE

PATCH; TOPICAL

FLECTOR

+	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

+	XANODYNE PHARM	25MG	N022202	001	Jun 16, 2009

FOR SOLUTION; ORAL

CAMBIA

+	NAUTILUS NEUROSCIENC	50MG	N022165	001	Jun 17, 2009

TABLET; ORAL

CATAFLAM

<u>AB</u>	+	NOVARTIS	<u>50MG</u>	<u>N020142</u>	<u>002</u>	Nov 24, 1993

DICLOFENAC POTASSIUM

<u>AB</u>	APOTEX	<u>50MG</u>	<u>A076561</u>	<u>001</u>	Mar 18, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075463</u>	<u>001</u>	Jul 26, 1999
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A075229</u>	<u>001</u>	Nov 20, 1998
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075219</u>	<u>001</u>	Aug 06, 1998

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+	NYCOMED US	3%	N021005	001	Oct 16, 2000

VOLTAREN

+	NOVARTIS	1%	N022122	001	Oct 17, 2007

SOLUTION; TOPICAL

PENNSAID

+	MALLINCKRODT	1.5%	N020947	001	Nov 04, 2009

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

<u>AT</u>	AKORN	<u>0.1%</u>	<u>A077845</u>	<u>001</u>	Apr 17, 2008
<u>AT</u>	ALCON	<u>0.1%</u>	<u>A078031</u>	<u>001</u>	Feb 06, 2008
<u>AT</u>	APOTEX INC	<u>0.1%</u>	<u>A077600</u>	<u>001</u>	Nov 13, 2008
<u>AT</u>	BAUSCH AND LOMB	<u>0.1%</u>	<u>A078792</u>	<u>001</u>	Dec 28, 2007
<u>AT</u>	NEXUS PHARMS	<u>0.1%</u>	<u>A078553</u>	<u>001</u>	Dec 28, 2007

VOLTAREN

<u>AT</u>	+	NOVARTIS	<u>0.1%</u>	<u>N020037</u>	<u>001</u>	Mar 28, 1991

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

<u>AB</u>	ACTAVIS ELIZABETH	<u>50MG</u>	<u>A074514</u>	<u>001</u>	Mar 26, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 134 (of 409)

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

<u>AB</u>	ACTAVIS ELIZABETH	<u>75MG</u>	<u>A074514</u>	<u>002</u>	Mar 26, 1996
<u>AB</u>	ALPHAPHARM	<u>50MG</u>	<u>A075281</u>	<u>002</u>	Feb 12, 2002
<u>AB</u>		<u>75MG</u>	<u>A075281</u>	<u>003</u>	Feb 12, 2002
<u>AB</u>	CARLSBAD	<u>25MG</u>	<u>A075185</u>	<u>002</u>	Nov 13, 1998
<u>AB</u>		<u>50MG</u>	<u>A075185</u>	<u>003</u>	Nov 13, 1998
<u>AB</u>		<u>75MG</u>	<u>A075185</u>	<u>001</u>	Nov 13, 1998
<u>AB</u>	+ SANDOZ	<u>25MG</u>	<u>A074376</u>	<u>001</u>	Sep 28, 1995
<u>AB</u>	+	<u>50MG</u>	<u>A074376</u>	<u>002</u>	Sep 28, 1995
<u>AB</u>	+	<u>75MG</u>	<u>A074394</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A090066</u>	<u>001</u>	Dec 01, 2010
<u>AB</u>		<u>50MG</u>	<u>A090066</u>	<u>002</u>	Dec 01, 2010
<u>AB</u>		<u>75MG</u>	<u>A077863</u>	<u>003</u>	Jun 08, 2007

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075910</u>	<u>001</u>	Jan 07, 2002
<u>AB</u>	BIOVAIL	<u>100MG</u>	<u>A075492</u>	<u>001</u>	Feb 11, 2000
<u>AB</u>	DEXCEL LTD	<u>100MG</u>	<u>A076201</u>	<u>001</u>	Nov 06, 2002
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A076152</u>	<u>001</u>	Dec 13, 2001
	<u>VOLTAREN-XR</u>				
<u>AB</u>	+ NOVARTIS	<u>100MG</u>	<u>N020254</u>	<u>001</u>	Mar 08, 1996

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

	GD SEARLE LLC	50MG;0.2MG	N020607	001	Dec 24, 1997
	+	75MG;0.2MG	N020607	002	Dec 24, 1997

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A061454</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A061454</u>	<u>003</u>	
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062286</u>	<u>001</u>	Jun 03, 1982
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062286</u>	<u>002</u>	Jun 03, 1982
	DICLOXACILLIN SODIUM				
	SANDOZ	EQ 125MG BASE	A061454	002	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

<u>AB</u>	+ AXCAN	<u>10MG</u>	<u>N007409</u>	<u>003</u>	Oct 15, 1984
	<u>DICYCLOMINE HYDROCHLORIDE</u>				
<u>AB</u>	LANNETT	<u>10MG</u>	<u>A084285</u>	<u>001</u>	
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A040319</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A085082</u>	<u>001</u>	Jun 19, 1986
<u>AB</u>	WEST WARD	<u>10MG</u>	<u>A040204</u>	<u>001</u>	Feb 28, 1997

INJECTABLE; INJECTION

BENTYL

<u>AP</u>	+ AXCAN	<u>10MG/ML</u>	<u>N008370</u>	<u>001</u>	Oct 15, 1984
	<u>BENTYL PRESERVATIVE FREE</u>				
<u>AP</u>	+ AXCAN	<u>10MG/ML</u>	<u>N008370</u>	<u>002</u>	Oct 15, 1984
	<u>DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)</u>				
<u>AP</u>	BEDFORD	<u>10MG/ML</u>	<u>A040465</u>	<u>001</u>	Jun 30, 2003

SYRUP; ORAL

BENTYL

<u>AA</u>	+ AXCAN	<u>10MG/5ML</u>	<u>N007961</u>	<u>002</u>	Oct 15, 1984

PRESCRIPTION DRUG PRODUCT LIST

3 - 135 (of 409)

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

<u>AA</u>	MIKART	<u>10MG/5ML</u>	<u>A040169</u>	<u>001</u>	Mar 24, 2005

TABLET; ORAL

BENTYL

<u>AB</u>	+ AXCAN	<u>20MG</u>	<u>N007409</u>	<u>001</u>	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>20MG</u>	<u>A040230</u>	<u>001</u>	Feb 26, 1999
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A040317</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A085223</u>	<u>001</u>	Jul 30, 1986
<u>AB</u>	WEST WARD	<u>20MG</u>	<u>A040161</u>	<u>001</u>	Oct 01, 1996

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

<u>AB</u>	AUROBINDO PHARMA	<u>125MG</u>	<u>A090094</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>		<u>200MG</u>	<u>A090094</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>		<u>250MG</u>	<u>A090094</u>	<u>003</u>	Sep 24, 2008
<u>AB</u>		<u>400MG</u>	<u>A090094</u>	<u>004</u>	Sep 24, 2008
<u>AB</u>	BARR	<u>200MG</u>	<u>A077167</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>		<u>250MG</u>	<u>A077167</u>	<u>002</u>	Dec 03, 2004
<u>AB</u>		<u>400MG</u>	<u>A077167</u>	<u>003</u>	Dec 03, 2004
<u>AB</u>	MATRIX LABS LTD	<u>125MG</u>	<u>A090788</u>	<u>001</u>	Apr 08, 2010
<u>AB</u>		<u>200MG</u>	<u>A090788</u>	<u>002</u>	Apr 08, 2010
<u>AB</u>		<u>250MG</u>	<u>A090788</u>	<u>003</u>	Apr 08, 2010
<u>AB</u>		<u>400MG</u>	<u>A090788</u>	<u>004</u>	Apr 08, 2010

VIDEX EC

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>125MG</u>	<u>N021183</u>	<u>001</u>	Oct 31, 2000
<u>AB</u>		<u>200MG</u>	<u>N021183</u>	<u>002</u>	Oct 31, 2000
<u>AB</u>		<u>250MG</u>	<u>N021183</u>	<u>003</u>	Oct 31, 2000
<u>AB</u>	+	<u>400MG</u>	<u>N021183</u>	<u>004</u>	Oct 31, 2000

FOR SOLUTION; ORAL

DIDANOSINE

<u>AA</u>	AUROBINDO PHARMA	<u>10MG/ML</u>	<u>A078112</u>	<u>001</u>	Mar 08, 2007

VIDEX

<u>AA</u>	+ BRISTOL MYERS SQUIBB	<u>10MG/ML</u>	<u>N020156</u>	<u>001</u>	Oct 09, 1991

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL-28

NATAZIA

	+ BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A	N022252	001	May 06, 2010

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AA</u>	AVANTHI INC	<u>25MG</u>	<u>A201212</u>	<u>001</u>	Dec 22, 2010
<u>AA</u>	COREPHARMA	<u>25MG</u>	<u>A040828</u>	<u>001</u>	Nov 05, 2008
<u>AA</u>	+ WATSON PHARMS	<u>25MG</u>	<u>N011722</u>	<u>002</u>	

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

	+ WATSON PHARMS	75MG	N012546	001	

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

<u>AB1</u>	+ ALTANA	<u>0.05%</u>	<u>A075187</u>	<u>001</u>	Mar 30, 1998
<u>AB1</u>	TARO	<u>0.05%</u>	<u>A075508</u>	<u>001</u>	Apr 24, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 136 (of 409)

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE
BX + ALTANA 0.05% A076263 001 Dec 20, 2002

OINTMENT; TOPICAL
DIFLORASONE DIACETATE
AB ALTANA 0.05% A075374 001 Apr 27, 1999
AB + TARO 0.05% A075331 001 May 14, 1999

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL
+ TEVA 500MG A073673 001 Jul 31, 1992

DIFLUPREDNATE

EMULSION; OPHTHALMIC
DUREZOL
+ ALCON RES 0.05% N022212 001 Jun 23, 2008

DIGOXIN

ELIXIR; ORAL
DIGOXIN
+ ROXANE 0.05MG/ML N021648 001 Aug 26, 2004

INJECTABLE; INJECTION
DIGOXIN
AP BAXTER HLTHCARE 0.25MG/ML A083391 001
AP HOSPIRA 0.25MG/ML A040093 001 May 16, 1996
AP SANDOZ 0.25MG/ML A040481 001 Aug 21, 2003

LANOXIN
AP + GLAXOSMITHKLINE LLC 0.25MG/ML N009330 002
LANOXIN PEDIATRIC
+ GLAXOSMITHKLINE LLC 0.1MG/ML N009330 004

TABLET; ORAL
DIGOXIN
AB ACTAVIS TOTOWA 0.125MG A040282 001 Dec 23, 1999
AB 0.25MG A040282 002 Dec 23, 1999
AB CARACO 0.125MG A076363 001 Jan 31, 2003
AB 0.25MG A076363 002 Jan 31, 2003
AB IMPAX LABS 0.125MG A078556 001 Jul 20, 2009
AB 0.25MG A078556 002 Jul 20, 2009
AB STEVENS J 0.125MG A076268 001 Jul 26, 2002
AB 0.25MG A076268 002 Jul 26, 2002
AB WEST WARD 0.125MG A077002 002 Oct 30, 2007
AB 0.25MG A077002 001 Oct 30, 2007

LANOXIN
AB SMITHKLINE BEECHAM 0.125MG N020405 002 Sep 30, 1997
AB + 0.25MG N020405 004 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION
D.H.E. 45
AP + VALEANT 1MG/ML N005929 001
DIHYDROERGOTAMINE MESYLATE
AP BEDFORD LABS 1MG/ML A040453 001 Jun 09, 2003
AP PADDOCK 1MG/ML A040475 001 Apr 28, 2003

SPRAY, METERED; NASAL
MIGRANAL
+ VALEANT 0.5MG/INH N020148 001 Dec 08, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 137 (of 409)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILACOR XR

<u>AB2</u>	WATSON LABS	<u>120MG</u>	<u>N020092</u>	<u>001</u>	May 29, 1992
<u>AB2</u>		<u>180MG</u>	<u>N020092</u>	<u>002</u>	May 29, 1992
<u>AB2</u> +		<u>240MG</u>	<u>N020092</u>	<u>003</u>	May 29, 1992

DILTIAZEM HYDROCHLORIDE

<u>AB2</u>	APOTEX	<u>120MG</u>	<u>A074943</u>	<u>003</u>	Dec 19, 2000
<u>AB2</u>		<u>180MG</u>	<u>A074943</u>	<u>002</u>	Dec 19, 2000
<u>AB2</u>		<u>240MG</u>	<u>A074943</u>	<u>001</u>	Aug 06, 1998
<u>AB2</u>	MYLAN	<u>120MG</u>	<u>A075124</u>	<u>002</u>	Mar 18, 1998
<u>AB2</u>		<u>180MG</u>	<u>A075124</u>	<u>003</u>	Mar 18, 1998
<u>AB2</u>		<u>240MG</u>	<u>A075124</u>	<u>001</u>	Mar 18, 1998
<u>AB2</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A074852</u>	<u>001</u>	Oct 10, 1997
<u>AB2</u>		<u>180MG</u>	<u>A074852</u>	<u>002</u>	Oct 10, 1997
<u>AB2</u>		<u>240MG</u>	<u>A074852</u>	<u>003</u>	Oct 10, 1997

CARDIZEM CD

<u>AB3</u>	BIOVAIL	<u>120MG</u>	<u>N020062</u>	<u>001</u>	Aug 10, 1992
<u>AB3</u>		<u>180MG</u>	<u>N020062</u>	<u>002</u>	Dec 27, 1991
<u>AB3</u>		<u>240MG</u>	<u>N020062</u>	<u>003</u>	Dec 27, 1991
<u>AB3</u> +		<u>300MG</u>	<u>N020062</u>	<u>004</u>	Dec 27, 1991

CARTIA XT

<u>AB3</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998
<u>AB3</u>		<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>		<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998
<u>AB3</u>		<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998

DILT-CD

<u>AB3</u>	APOTEX	<u>120MG</u>	<u>A076151</u>	<u>001</u>	May 20, 2004
<u>AB3</u>		<u>180MG</u>	<u>A076151</u>	<u>002</u>	May 20, 2004
<u>AB3</u>		<u>240MG</u>	<u>A076151</u>	<u>003</u>	May 20, 2004
<u>AB3</u>		<u>300MG</u>	<u>A076151</u>	<u>004</u>	May 20, 2004

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	BIOVAIL	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999

DILTIAZEM HYDROCHLORIDE

<u>AB4</u>	KV PHARM	<u>120MG</u>	<u>A076563</u>	<u>002</u>	Sep 12, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076563</u>	<u>003</u>	Sep 12, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076563</u>	<u>004</u>	Sep 12, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076563</u>	<u>005</u>	Sep 12, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076563</u>	<u>006</u>	Sep 12, 2006
<u>AB4</u>		<u>420MG</u>	<u>A076563</u>	<u>001</u>	Sep 12, 2006
<u>AB4</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010

DILTZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395</u>	<u>001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395</u>	<u>002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395</u>	<u>003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395</u>	<u>004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395</u>	<u>005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 138 (of 409)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TAZTIA XT

<u>AB4</u>	WATSON LABS FLORIDA	<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	BIOVAIL	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>		<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>		<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>		<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995
<u>AB4</u>		<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u> +		<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998

BC	+ BIOVAIL	360MG	N020062	005	Aug 24, 1999

BC	+ MYLAN	120MG	A074910	003	May 02, 1997

BC	+ MYLAN	60MG	A074910	001	May 02, 1997
		90MG	A074910	002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>	APOTEX INC	<u>5MG/ML</u>	<u>A075375</u>	<u>001</u>	Sep 30, 1999
<u>AP</u>	BAXTER HLTHCARE	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008
<u>AP</u> +	BEDFORD	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>	HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998
<u>AP</u>	INTL MEDICATION	<u>5MG/ML</u>	<u>A075749</u>	<u>001</u>	Nov 21, 2001
<u>AP</u>	TAYLOR PHARMA	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998
<u>AP</u>	TEVA PARENTERAL	<u>5MG/ML</u>	<u>A074894</u>	<u>001</u>	Aug 26, 1997

+ HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002
+ TEVA PARENTERAL	10MG/ML	A074894	002	Apr 19, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	BIOVAIL LABS INTL	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
<u>AB</u>		<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>		<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u> +		<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	DAVA PHARMS INC	<u>30MG</u>	<u>A074093</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A074093</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A074093</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A074093</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>	MYLAN	<u>30MG</u>	<u>A073185</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A073186</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A072837</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

<u>AB</u>	BIOVAIL LABS INTL	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u> +		<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 139 (of 409)

DILTIAZEM HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>		<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>		<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>		<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>		<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>		<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

<u>AP</u>	APP PHARMS	<u>50MG/ML</u>	<u>A040519</u>	<u>001</u>	Jun 23, 2004
<u>AP</u>	+ WATSON LABS	<u>50MG/ML</u>	<u>A080615</u>	<u>001</u>	

DIMERCAPROL

INJECTABLE; INJECTION

BAL

	+ AKORN	10%	N005939	001	

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

<u>AT</u>	BIONICHE PHARMA	<u>50%</u>	<u>A076185</u>	<u>001</u>	Nov 29, 2002
	<u>RIMSO-50</u>				
<u>AT</u>	+ BIONICHE PHARMA	<u>50%</u>	<u>N017788</u>	<u>001</u>	

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

	+ PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

	+ CONTROLLED THERAP	10MG	N020411	001	Mar 30, 1995

SUPPOSITORY; VAGINAL

PROSTIN E2

	+ PHARMACIA AND UPJOHN	20MG	N017810	001	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

	+ BARR	50MG	A080738	001	

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

	+ PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982

INJECTABLE; INJECTION

BENADRYL

<u>AP</u>	+ MCNEIL CONS	<u>50MG/ML</u>	<u>N006146</u>	<u>002</u>	

BENADRYL PRESERVATIVE FREE

<u>AP</u>	+ MCNEIL CONS	<u>50MG/ML</u>	<u>N009486</u>	<u>001</u>	

DIPHENHYDRAMINE HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>50MG/ML</u>	<u>A040466</u>	<u>001</u>	May 28, 2002
<u>AP</u>	BAXTER HLTHCARE	<u>50MG/ML</u>	<u>A080817</u>	<u>002</u>	
<u>AP</u>	BIONICHE PHARMA	<u>50MG/ML</u>	<u>A040498</u>	<u>001</u>	Jul 12, 2005
<u>AP</u>	HOSPIRA	<u>50MG/ML</u>	<u>A040140</u>	<u>001</u>	Nov 20, 1998
<u>AP</u>	WATSON LABS	<u>50MG/ML</u>	<u>A080873</u>	<u>002</u>	
	<u>DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE</u>				
<u>AP</u>	INTL MEDICATION	<u>50MG/ML</u>	<u>A084094</u>	<u>001</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 140 (of 409)

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	WATSON LABS	<u>50MG/ML</u>	<u>A080873</u>	<u>003</u>	
	DIPHENHYDRAMINE HYDROCHLORIDE				
	+ WATSON LABS	10MG/ML	A080873	001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

<u>AT</u>	AKORN	<u>0.1%</u>	<u>A074382</u>	<u>001</u>	Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

<u>AT</u>	FALCON PHARMS	<u>0.1%</u>	<u>A073636</u>	<u>001</u>	Jun 30, 1994

PROPINE

<u>AT</u>	+ ALLERGAN	<u>0.1%</u>	<u>N018239</u>	<u>001</u>	

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

<u>AP</u>	APP PHARMS	<u>5MG/ML</u>	<u>A074956</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>	BAXTER HLTHCARE	<u>5MG/ML</u>	<u>A074521</u>	<u>001</u>	Oct 18, 1996
<u>AP</u>	+ BEDFORD	<u>5MG/ML</u>	<u>A074939</u>	<u>001</u>	Apr 13, 1998
<u>AP</u>	CLARIS LIFESCIENCES	<u>5MG/ML</u>	<u>A075769</u>	<u>001</u>	Nov 27, 2002
<u>AP</u>	HOSPIRA	<u>5MG/ML</u>	<u>A074601</u>	<u>001</u>	Dec 19, 1997
<u>AP</u>	TEVA PARENTERAL	<u>5MG/ML</u>	<u>A074952</u>	<u>001</u>	Nov 26, 1997

TABLET; ORAL

DIPYRIDAMOLE

<u>AB</u>	ACTAVIS TOTOWA	<u>25MG</u>	<u>A040542</u>	<u>001</u>	Apr 21, 2006
<u>AB</u>		<u>50MG</u>	<u>A040542</u>	<u>002</u>	Apr 21, 2006
<u>AB</u>		<u>75MG</u>	<u>A040542</u>	<u>003</u>	Apr 21, 2006
<u>AB</u>	BARR	<u>25MG</u>	<u>A087184</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>		<u>50MG</u>	<u>A087716</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>		<u>75MG</u>	<u>A087717</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A088999</u>	<u>001</u>	Feb 05, 1991
<u>AB</u>		<u>50MG</u>	<u>A089000</u>	<u>001</u>	Feb 05, 1991
<u>AB</u>		<u>75MG</u>	<u>A089001</u>	<u>001</u>	Feb 05, 1991
<u>AB</u>	IMPAX LABS	<u>25MG</u>	<u>A040782</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>		<u>50MG</u>	<u>A040782</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>		<u>75MG</u>	<u>A040782</u>	<u>003</u>	Jul 18, 2007
<u>AB</u>	LANNETT	<u>25MG</u>	<u>A040898</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>		<u>50MG</u>	<u>A040898</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>		<u>75MG</u>	<u>A040898</u>	<u>003</u>	Apr 23, 2008
<u>AB</u>	MURTY PHARMS	<u>25MG</u>	<u>A040733</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>50MG</u>	<u>A040733</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>75MG</u>	<u>A040733</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>	PUREPAC PHARM	<u>25MG</u>	<u>A089425</u>	<u>001</u>	Jul 12, 1990
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A087160</u>	<u>001</u>	Jun 07, 1996
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A040874</u>	<u>001</u>	Jan 28, 2008
<u>AB</u>		<u>50MG</u>	<u>A040874</u>	<u>002</u>	Jan 28, 2008
<u>AB</u>		<u>75MG</u>	<u>A040874</u>	<u>003</u>	Jan 28, 2008
	<u>PERSANTINE</u>				
<u>AB</u>	BOEHRINGER INGELHEIM	<u>25MG</u>	<u>N012836</u>	<u>003</u>	Dec 22, 1986
<u>AB</u>		<u>50MG</u>	<u>N012836</u>	<u>004</u>	Feb 06, 1987
<u>AB</u>	+	<u>75MG</u>	<u>N012836</u>	<u>005</u>	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>	TEVA	<u>EQ 100MG BASE</u>	<u>A070101</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A070102</u>	<u>001</u>	Feb 22, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 141 (of 409)

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A070173</u>	<u>001</u>	May 31, 1985
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A070174</u>	<u>001</u>	May 31, 1985

NORPACE

<u>AB</u>	GD SEARLE LLC	<u>EQ 100MG BASE</u>	<u>N017447</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N017447</u>	<u>002</u>	

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>	KV PHARM	<u>EQ 150MG BASE</u>	<u>A071200</u>	<u>001</u>	Dec 15, 1987

NORPACE CR

<u>AB</u>	+	GD SEARLE LLC	<u>EQ 150MG BASE</u>	<u>N018655</u>	<u>002</u>	Jul 20, 1982
		NORPACE CR				
		GD SEARLE LLC	EQ 100MG BASE	N018655	001	Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSE

	ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983
+		500MG	A088483	001	Dec 08, 1983

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

<u>AB</u>	+	ABBOTT	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680</u>	<u>001</u>	Sep 12, 1989

DIVALPROEX SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979</u>	<u>001</u>	Jan 23, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919</u>	<u>001</u>	Jan 27, 2009

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

<u>AB</u>	ABBOTT	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723</u>	<u>003</u>	Oct 26, 1984
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>N018723</u>	<u>001</u>	Mar 10, 1983
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N018723</u>	<u>002</u>	Mar 10, 1983

DIVALPROEX SODIUM

<u>AB</u>	ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411</u>	<u>001</u>	Nov 03, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078755</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078755</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078790</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078790</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A077254</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 125MG VALPROIC ACID</u>	<u>A090062</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077254</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090062</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077254</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090062</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>	NU PHARM	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077615</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077615</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078853</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078853</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	SANDOZ	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078290</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078290</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078597</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078597</u>	<u>003</u>	Jul 29, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 142 (of 409)

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

<u>AB</u>	TEVA	<u>EQ 125MG VALPROIC ACID</u>	<u>A076941</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A076941</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A076941</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	UPSHER SMITH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078182</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078182</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	VINTAGE	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210</u>	<u>001</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090210</u>	<u>002</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090210</u>	<u>003</u>	Nov 30, 2009
<u>AB</u>	WOCKHARDT	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296</u>	<u>001</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077296</u>	<u>002</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077296</u>	<u>003</u>	Jul 31, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077100</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077100</u>	<u>003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

<u>AB</u>	ABBOTT	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168</u>	<u>002</u>	May 31, 2002
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168</u>	<u>001</u>	Aug 04, 2000

DIVALPROEX SODIUM

<u>AB</u>	ANCHEN PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078445</u>	<u>001</u>	Feb 26, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078445</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791</u>	<u>001</u>	May 06, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078791</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>	TEVA PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078700</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705</u>	<u>001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239</u>	<u>002</u>	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 12.5MG BASE/ML</u>	<u>A074277</u>	<u>001</u>	Oct 31, 1994
<u>AP</u>	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086</u>	<u>001</u>	Nov 29, 1993
<u>AP</u>		<u>EQ 12.5MG BASE/ML</u>	<u>A074292</u>	<u>001</u>	Feb 16, 1995
<u>AP</u>	TEVA PARENTERAL	<u>EQ 12.5MG BASE/ML</u>	<u>A074206</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	WATSON LABS	<u>EQ 12.5MG BASE/ML</u>	<u>A074114</u>	<u>001</u>	Nov 30, 1993

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

<u>AP</u>	+	<u>EQ 50MG BASE/100ML</u>	<u>N020269</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020269</u>	<u>002</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020269</u>	<u>003</u>	Oct 19, 1993

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	<u>EQ 50MG BASE/100ML</u>	<u>N020255</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020255</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020255</u>	<u>004</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 400MG BASE/100ML</u>	<u>N020255</u>	<u>005</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 50MG BASE/100ML</u>	<u>N020201</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020201</u>	<u>002</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020201</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 400MG BASE/100ML</u>	<u>N020201</u>	<u>006</u>	Jul 07, 1994

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 143 (of 409)

DOCETAXELINJECTABLE; INJECTION
TAXOTERE

+	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010
+		EQ 40MG BASE/ML	N020449	001	May 14, 1996
+		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010

DOFETILIDECAPSULE; ORAL
TIKOSYN

	PFIZER	0.125MG	N020931	001	Oct 01, 1999
		0.25MG	N020931	002	Oct 01, 1999
+		0.5MG	N020931	003	Oct 01, 1999

DOLASETRON MESYLATEINJECTABLE; INJECTION
ANZEMET

+	SANOFI AVENTIS US	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001

TABLET; ORAL
ANZEMET

	SANOFI AVENTIS US	50MG	N020623	001	Sep 11, 1997
+		100MG	N020623	002	Sep 11, 1997

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N020690</u>	<u>002</u>	Nov 25, 1996
<u>AB</u>	+	<u>10MG</u>	<u>N020690</u>	<u>001</u>	Nov 25, 1996

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076786</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A076786</u>	<u>002</u>	Nov 26, 2010

ARICEPT

+	EISAI INC	23MG	N022568	001	Jul 23, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N021720</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>	+	<u>10MG</u>	<u>N021720</u>	<u>002</u>	Oct 18, 2004

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	BARR	<u>5MG</u>	<u>A078388</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A078388</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A077975</u>	<u>002</u>	Dec 11, 2009
<u>AB</u>		<u>10MG</u>	<u>A077975</u>	<u>001</u>	Dec 11, 2009

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	+	<u>HOSPIRA</u>	<u>40MG/ML</u>	<u>N018132</u>	<u>001</u>	
<u>AP</u>	+		<u>80MG/100ML</u>	<u>N018132</u>	<u>002</u>	Feb 04, 1982
<u>AP</u>	+		<u>80MG/ML</u>	<u>N018132</u>	<u>004</u>	Jul 09, 1982
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018132</u>	<u>003</u>	Feb 04, 1982
<u>AP</u>	+	<u>LUITPOLD</u>	<u>40MG/ML</u>	<u>A070799</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+		<u>80MG/ML</u>	<u>A070820</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+		<u>160MG/ML</u>	<u>A070826</u>	<u>001</u>	Feb 11, 1987

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

<u>AP</u>	+	<u>B BRAUN</u>	<u>80MG/100ML</u>	<u>N019099</u>	<u>002</u>	Oct 15, 1986
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019099</u>	<u>004</u>	Oct 15, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 144 (of 409)

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>160MG/100ML</u>	<u>N019099</u>	<u>003</u>	Oct 15, 1986
<u>DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ BAXTER HLTHCARE	<u>80MG/100ML</u>	<u>N019615</u>	<u>001</u>	Mar 27, 1987
<u>AP</u>	+	<u>160MG/100ML</u>	<u>N019615</u>	<u>002</u>	Mar 27, 1987
<u>AP</u>	+	<u>320MG/100ML</u>	<u>N019615</u>	<u>003</u>	Mar 27, 1987
<u>AP</u>	+ HOSPIRA	<u>80MG/100ML</u>	<u>N018826</u>	<u>001</u>	Sep 30, 1983
<u>AP</u>	+	<u>160MG/100ML</u>	<u>N018826</u>	<u>002</u>	Sep 30, 1983
<u>AP</u>	+	<u>320MG/100ML</u>	<u>N018826</u>	<u>003</u>	Sep 30, 1983
<u>DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER</u>					
	+ B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986
<u>DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
	+ BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987

DORIPENEM

INJECTABLE; IV (INFUSION)

	ORTHO MCNEIL JANSSEN	250MG/VIAL	N022106	002	Oct 05, 2010
+		500MG/VIAL	N022106	001	Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

<u>AT</u>	ALCON	<u>EQ 2% BASE</u>	<u>A078981</u>	<u>001</u>	Apr 13, 2009
<u>AT</u>	APOTEX INC	<u>EQ 2% BASE</u>	<u>A078395</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE</u>	<u>A090143</u>	<u>001</u>	Jun 25, 2009
<u>AT</u>	HI TECH PHARMA	<u>EQ 2% BASE</u>	<u>A077846</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>	LUITPOLD	<u>EQ 2% BASE</u>	<u>A079186</u>	<u>001</u>	Nov 18, 2009
<u>AT</u>	SANDOZ	<u>EQ 2% BASE</u>	<u>A078748</u>	<u>001</u>	Nov 06, 2008
<u>AT</u>	TEVA PHARMS	<u>EQ 2% BASE</u>	<u>A078756</u>	<u>001</u>	Dec 04, 2008
<u>TRUSOPT</u>					
<u>AT</u>	+ MERCK	<u>EQ 2% BASE</u>	<u>N020408</u>	<u>001</u>	Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

<u>AT</u>	+ MERCK	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>N020869</u>	<u>001</u>	Apr 07, 1998
<u>DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE</u>					
<u>AT</u>	ALCON RES	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090604</u>	<u>001</u>	Nov 18, 2009
<u>AT</u>	APOTEX INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078201</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090037</u>	<u>001</u>	Jul 14, 2009
<u>AT</u>	HI TECH PHARMA	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A077847</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>	SANDOZ	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078749</u>	<u>001</u>	Nov 06, 2008
<u>AT</u>	TEVA PARNTL	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078704</u>	<u>001</u>	Sep 28, 2009

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

<u>AP</u>	+ BAXTER HLTHCARE	<u>20MG/ML</u>	<u>N014879</u>	<u>001</u>	
<u>DOXAPRAM HYDROCHLORIDE</u>					
<u>AP</u>	BEDFORD	<u>20MG/ML</u>	<u>A076266</u>	<u>001</u>	Jan 10, 2003
<u>AP</u>	WATSON LABS	<u>20MG/ML</u>	<u>A073529</u>	<u>001</u>	Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

<u>AB</u>	+ PFIZER	<u>EQ 1MG BASE</u>	<u>N019668</u>	<u>001</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>N019668</u>	<u>002</u>	Nov 02, 1990

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 145 (of 409)

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

<u>AB</u>	PFIZER	<u>EQ 4MG BASE</u>	<u>N019668</u>	<u>003</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N019668</u>	<u>004</u>	Nov 02, 1990

DOXAZOSIN MESYLATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 1MG BASE</u>	<u>A075574</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075574</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075574</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075574</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075580</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075580</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075580</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075580</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	DAVA PHARMS INC	<u>EQ 1MG BASE</u>	<u>A076161</u>	<u>001</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A076161</u>	<u>002</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076161</u>	<u>003</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076161</u>	<u>004</u>	Jun 10, 2004
<u>AB</u>	KV PHARM	<u>EQ 1MG BASE</u>	<u>A075609</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075609</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075609</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075609</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075509</u>	<u>001</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075509</u>	<u>002</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075509</u>	<u>003</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075509</u>	<u>004</u>	Oct 19, 2000
<u>AB</u>	PLIVA	<u>EQ 1MG BASE</u>	<u>A075750</u>	<u>001</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075750</u>	<u>002</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075750</u>	<u>003</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075750</u>	<u>004</u>	Jun 08, 2001
<u>AB</u>	TEVA	<u>EQ 1MG BASE</u>	<u>A075536</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075536</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075536</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075536</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	WATSON LABS	<u>EQ 1MG BASE</u>	<u>A075426</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075426</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075426</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075426</u>	<u>004</u>	Oct 18, 2000

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

	PFIZER	EQ 4MG BASE	N021269	001	Feb 22, 2005
+		EQ 8MG BASE	N021269	002	Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A070791</u>	<u>002</u>	May 13, 1986
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A070791</u>	<u>003</u>	May 13, 1986
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A070791</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A070791</u>	<u>004</u>	May 13, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A070791</u>	<u>005</u>	May 13, 1986
<u>AB</u>	PAR PHARM	<u>EQ 10MG BASE</u>	<u>A071697</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A071437</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A071595</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A071608</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A071422</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A071485</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A071486</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A071238</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A071326</u>	<u>001</u>	Apr 30, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 146 (of 409)

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A071239</u>	<u>001</u>	Apr 30, 1987
	DOXEPIN HYDROCHLORIDE				
	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>	PHARM ASSOC	<u>EQ 10MG BASE/ML</u>	<u>A075924</u>	<u>001</u>	Jan 15, 2004
<u>AA</u>	SILARX	<u>EQ 10MG BASE/ML</u>	<u>A074721</u>	<u>001</u>	Dec 29, 1998
<u>AA</u>	+ TEVA PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A071609</u>	<u>001</u>	Nov 09, 1987
<u>AA</u>	WOCKHARDT	<u>EQ 10MG BASE/ML</u>	<u>A071918</u>	<u>001</u>	Jul 20, 1988

CREAM; TOPICAL

ZONALON

	+ NYCOMED US	5%	N020126	001	Apr 01, 1994

TABLET; ORAL

SILENOR

	SOMAXON	EQ 3MG BASE	N022036	001	Mar 17, 2010
	+	EQ 6MG BASE	N022036	002	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

	GENZYME	0.5MCG	N020862	002	Apr 23, 2004
		1MCG	N020862	003	Jul 13, 2009
	+	2.5MCG	N020862	001	Jun 09, 1999

INJECTABLE; INJECTION

HECTOROL

	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000
	+	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>2MG/ML</u>	<u>A063277</u>	<u>001</u>	Oct 26, 1995
<u>AP</u>	+ BEDFORD	<u>2MG/ML</u>	<u>A062975</u>	<u>001</u>	Mar 17, 1989
<u>AP</u>	+	<u>10MG/VIAL</u>	<u>A062921</u>	<u>001</u>	Mar 17, 1989
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A062921</u>	<u>002</u>	Mar 17, 1989
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A062921</u>	<u>003</u>	Mar 17, 1989
<u>AP</u>	+	<u>200MG/100ML</u>	<u>A064097</u>	<u>001</u>	Sep 13, 1994
<u>AP</u>	PHARMACHEMIE	<u>2MG/ML</u>	<u>A063336</u>	<u>001</u>	Feb 28, 1995
<u>AP</u>		<u>10MG/VIAL</u>	<u>A063097</u>	<u>001</u>	May 21, 1990
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097</u>	<u>002</u>	May 21, 1990
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097</u>	<u>003</u>	May 21, 1990
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336</u>	<u>004</u>	Feb 28, 1995
<u>AP</u>	TEVA PARENTERAL	<u>2MG/ML</u>	<u>A064140</u>	<u>001</u>	Jul 28, 1995
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140</u>	<u>002</u>	Jul 28, 1995

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

	+ ORTHO BIOTECH	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995
	+	50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055</u>	<u>001</u>	Dec 01, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065055</u>	<u>002</u>	Dec 01, 2000
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065053</u>	<u>001</u>	Nov 22, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065053</u>	<u>003</u>	Sep 10, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 147 (of 409)

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	RANBAXY	<u>EQ 100MG BASE</u>	<u>A065053</u>	<u>002</u>	Nov 22, 2000
<u>AB</u>	SANDOZ	<u>EQ 50MG BASE</u>	<u>A065032</u>	<u>001</u>	Jun 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065032</u>	<u>002</u>	Jun 30, 2000
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A065041</u>	<u>001</u>	Apr 28, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065041</u>	<u>002</u>	Apr 28, 2000

MONODOX

<u>AB</u>	WATSON PHARMS	<u>EQ 50MG BASE</u>	<u>N050641</u>	<u>002</u>	Feb 10, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N050641</u>	<u>003</u>	Oct 18, 2006
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N050641</u>	<u>001</u>	Dec 29, 1989

ORACEA

<u>AB</u>	+ GALDERMA LABS LP	<u>40MG</u>	<u>N050805</u>	<u>001</u>	May 26, 2006
	DOXYCYCLINE				
	+ PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005

CAPSULE, DELAYED RELEASE; ORAL

DOXYCYCLINE

<u>AB</u>	MYLAN	<u>40MG</u>	<u>A090855</u>	<u>001</u>	Jul 01, 2010

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 25MG BASE/5ML</u>	<u>A065454</u>	<u>001</u>	Jul 16, 2008

VIBRAMYCIN

<u>AB</u>	+	<u>EQ 25MG BASE/5ML</u>	<u>N050006</u>	<u>001</u>	

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	LANNETT	<u>EQ 50MG BASE</u>	<u>A065285</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285</u>	<u>003</u>	Jul 30, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285</u>	<u>004</u>	Jul 30, 2008
<u>AB</u>	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A065471</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065471</u>	<u>002</u>	Apr 17, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065471</u>	<u>003</u>	Apr 17, 2009
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A065377</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065377</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065377</u>	<u>003</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065427</u>	<u>001</u>	Jun 07, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065070</u>	<u>001</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065070</u>	<u>003</u>	Dec 30, 2002
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065070</u>	<u>002</u>	Dec 15, 2000
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>A065070</u>	<u>004</u>	Jul 14, 2005
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065356</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065356</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065356</u>	<u>003</u>	May 31, 2006
<u>AB</u>	SANDOZ	<u>EQ 50MG BASE</u>	<u>A065353</u>	<u>001</u>	Nov 27, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065353</u>	<u>002</u>	Nov 27, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065353</u>	<u>003</u>	Nov 27, 2006

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

	+	EQ 50MG BASE/5ML	N050480	001	

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 50MG BASE</u>	<u>A062500</u>	<u>001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500</u>	<u>002</u>	Sep 11, 1984
<u>AB</u>	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A062675</u>	<u>001</u>	Jul 10, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 148 (of 409)

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	MUTUAL PHARM	<u>EQ 100MG BASE</u>	<u>A062676</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A062031</u>	<u>002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031</u>	<u>001</u>	
<u>AB</u>	WEST WARD	<u>EQ 50MG BASE</u>	<u>A062396</u>	<u>002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396</u>	<u>001</u>	May 07, 1984

VIBRAMYCIN

<u>AB</u>	PFIZER	<u>EQ 50MG BASE</u>	<u>N050007</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N050007</u>	<u>002</u>	
	DOXYCYCLINE HYCLATE				
	+ WEST WARD	EQ 20MG BASE	A065103	001	May 13, 2005

CAPSULE, DELAYED RELEASE; ORAL

DOXYCYCLINE HYCLATE

	MEDICIS	EQ 75MG BASE	A065281	001	Dec 21, 2005
	+	EQ 100MG BASE	A065281	002	Dec 21, 2005

INJECTABLE; INJECTION

DOXY 100

<u>AP</u>	+	APP PHARMS	<u>EQ 100MG BASE/VIAL</u>	<u>A062475</u>	<u>001</u>	Dec 09, 1983
		<u>DOXYCYCLINE</u>				
<u>AP</u>	+	BEDFORD	<u>EQ 100MG BASE/VIAL</u>	<u>A062569</u>	<u>001</u>	Mar 09, 1988
		DOXY 200				
	+	APP PHARMS	EQ 200MG BASE/VIAL	A062475	002	Dec 09, 1983

SYSTEM, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

	+	TOLMAR	50MG	N050751	001	Sep 03, 1998

TABLET; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	COREPHARMA	<u>EQ 20MG BASE</u>	<u>A065182</u>	<u>001</u>	May 13, 2005
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A065163</u>	<u>001</u>	May 13, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062505</u>	<u>001</u>	Sep 11, 1984
<u>AB</u>	LANNETT	<u>EQ 20MG BASE</u>	<u>A065277</u>	<u>001</u>	Nov 10, 2005
<u>AB</u>	MUTUAL PHARM	<u>EQ 100MG BASE</u>	<u>A062677</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>	MUTUAL PHARMA	<u>EQ 20MG BASE</u>	<u>A065134</u>	<u>001</u>	May 13, 2005
<u>AB</u>	VINTAGE PHARMS	<u>EQ 100MG BASE</u>	<u>A062538</u>	<u>001</u>	Apr 07, 1986
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A062421</u>	<u>001</u>	Feb 02, 1983
<u>AB</u>	WEST WARD	<u>EQ 100MG BASE</u>	<u>A065095</u>	<u>001</u>	Jul 02, 2003

PERIOSTAT

<u>AB</u>	+	GALDERMA LABS LP	<u>EQ 20MG BASE</u>	<u>N050783</u>	<u>001</u>	Feb 02, 2001

VIBRA-TABS

<u>AB</u>	+	PFIZER	<u>EQ 100MG BASE</u>	<u>N050533</u>	<u>001</u>	

TABLET, DELAYED RELEASE; ORAL

DORYX

<u>AB</u>	MAYNE PHARMA	<u>EQ 75MG BASE</u>	<u>N050795</u>	<u>001</u>	May 06, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050795</u>	<u>002</u>	May 06, 2005

DOXYCYCLINE HYCLATE

<u>AB</u>	IMPAX LABS INC	<u>EQ 75MG BASE</u>	<u>A090505</u>	<u>001</u>	Dec 28, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090505</u>	<u>002</u>	Dec 28, 2010
<u>AB</u>	MYLAN	<u>EQ 75MG BASE</u>	<u>A090431</u>	<u>001</u>	Dec 28, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090431</u>	<u>002</u>	Dec 28, 2010
	DORYX				
	+ MAYNE PHARMA INTL	EQ 150MG BASE	N050795	003	Jun 20, 2008

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>	SVC PHARMA	<u>2.5MG</u>	<u>A078292</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>5MG</u>	<u>A078292</u>	<u>002</u>	Jun 27, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 149 (of 409)

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>	SVC PHARMA	<u>10MG</u>	<u>A078292</u>	<u>003</u>	Jun 27, 2008

MARINOL

<u>AB</u>	ABBOTT PRODS	<u>2.5MG</u>	<u>N018651</u>	<u>001</u>	May 31, 1985

<u>AB</u>	+	<u>5MG</u>	<u>N018651</u>	<u>002</u>	May 31, 1985

<u>AB</u>		<u>10MG</u>	<u>N018651</u>	<u>003</u>	May 31, 1985

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

MULTAQ

+	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

<u>AP</u>	HOSPIRA	<u>2.5MG/ML</u>	<u>A071981</u>	<u>001</u>	Feb 29, 1988

<u>AP</u>	LUITPOLD	<u>2.5MG/ML</u>	<u>A072123</u>	<u>001</u>	Oct 24, 1988

INAPSINE

<u>AP</u>	+	AKORN INC	<u>2.5MG/ML</u>	<u>N016796</u>	<u>001</u>

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

+	BAYER HLTHCARE	0.5MG;1MG	N021355	002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u>	BARR	<u>3MG;0.02MG</u>	<u>A078515</u>	<u>001</u>	Mar 30, 2009

YAZ

<u>AB</u>	+	BAYER HLTHCARE	<u>3MG;0.02MG</u>	<u>N021676</u>	<u>001</u>

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u>	BARR	<u>3MG;0.03MG</u>	<u>A077527</u>	<u>001</u>	May 09, 2008

<u>AB</u>	WATSON LABS	<u>3MG;0.03MG</u>	<u>A090081</u>	<u>001</u>	Sep 07, 2010

YASMIN

<u>AB</u>	+	BAYER HLTHCARE	<u>3MG;0.03MG</u>	<u>N021098</u>	<u>001</u>

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ

+	BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010

SAFYRAL

	BAYER HLTHCARE	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

LILLY

	EQ 20MG BASE	N021427	001	Aug 03, 2004

	EQ 30MG BASE	N021427	002	Aug 03, 2004

+	EQ 60MG BASE	N021427	004	Aug 03, 2004

DUTASTERIDE

CAPSULE; ORAL

AVODART

<u>AB</u>	+	GLAXOSMITHKLINE	<u>0.5MG</u>	<u>N021319</u>	<u>001</u>

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 150 (of 409)

DUTASTERIDE

CAPSULE; ORAL

DUTASTERIDE

<u>AB</u>	BARR	<u>0.5MG</u>	<u>A090095</u>	<u>001</u>	Dec 21, 2010

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

JALYN

+	GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010

DYPHYLLINE

TABLET; ORAL

LUFYLLIN

MEDA PHARMS

200MG

A084566 001

+

400MG

A084566 002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

+	WYETH PHARMS INC	0.125%	N011963	001	

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

<u>AB</u>	+	ALTANA	<u>1%</u>	<u>A076075</u>	<u>001</u>	Nov 26, 2002
<u>AB</u>		PERRIGO NEW YORK	<u>1%</u>	<u>A076479</u>	<u>001</u>	Jun 23, 2004
<u>AB</u>		PRASCO	<u>1%</u>	<u>A076574</u>	<u>001</u>	Dec 17, 2004
<u>AB</u>		TARO	<u>1%</u>	<u>A076005</u>	<u>001</u>	Nov 26, 2002

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+	GRACEWAY	200MG/ML	N008922	001	

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

<u>AP</u>		HOSPIRA	<u>10MG/ML</u>	<u>A040131</u>	<u>001</u>	Feb 24, 1998
		<u>ENLON</u>				
<u>AP</u>		BIONICHE PHARMA	<u>10MG/ML</u>	<u>A088873</u>	<u>001</u>	Aug 06, 1985
		<u>TENSILON</u>				
<u>AP</u>	+	VALEANT PHARM INTL	<u>10MG/ML</u>	<u>N007959</u>	<u>001</u>	
		<u>TENSILON PRESERVATIVE FREE</u>				
<u>AP</u>	+	VALEANT PHARM INTL	<u>10MG/ML</u>	<u>N007959</u>	<u>002</u>	

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB 50MG

N020972 001 Sep 17, 1998

+

200MG

N020972 003 Sep 17, 1998

TABLET; ORAL

SUSTIVA

+	BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

+	GILEAD	600MG;200MG;300MG	N021937	001	Jul 12, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 151 (of 409)

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL VANIQA				
+ SKINMEDICA	13.9%	N021145	001	Jul 27, 2000

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL RELPAK				
PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002
+	EQ 40MG BASE	N021016	002	Dec 26, 2002

ELTROMBOPAG OLAMINE

TABLET; ORAL PROMACTA				
GLAXOSMITHKLINE	EQ 25MG ACID	N022291	001	Nov 20, 2008
+	EQ 50MG ACID	N022291	002	Nov 20, 2008
	EQ 75MG ACID	N022291	003	Sep 08, 2009

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC				
+ ALCON	0.05%	N020706	001	Dec 29, 1997

EMTRICITABINE

CAPSULE; ORAL EMTRIVA				
+ GILEAD	200MG	N021500	001	Jul 02, 2003
SOLUTION; ORAL EMTRIVA				
+ GILEAD	10MG/ML	N021896	001	Sep 28, 2005

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL TRUVADA				
+ GILEAD	200MG;300MG	N021752	001	Aug 02, 2004

ENALAPRIL MALEATE

	TABLET; ORAL <u>ENALAPRIL MALEATE</u>			
<u>AB</u>	APOTEX	<u>2.5MG</u>	<u>A075178</u>	<u>002</u> Mar 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075178</u>	<u>001</u> Mar 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075178</u>	<u>003</u> Mar 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075178</u>	<u>004</u> Mar 23, 2001
<u>AB</u>	LEK PHARMS	<u>2.5MG</u>	<u>A075496</u>	<u>001</u> Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075496</u>	<u>002</u> Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075459</u>	<u>001</u> Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075459</u>	<u>002</u> Aug 22, 2000
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A075472</u>	<u>001</u> Aug 22, 2000
<u>AB</u>		<u>2.5MG</u>	<u>A075480</u>	<u>001</u> Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075472</u>	<u>002</u> Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075480</u>	<u>002</u> Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075472</u>	<u>003</u> Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075480</u>	<u>003</u> Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075472</u>	<u>004</u> Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075480</u>	<u>004</u> Aug 22, 2000
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075621</u>	<u>001</u> Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075621</u>	<u>002</u> Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075621</u>	<u>003</u> Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075621</u>	<u>004</u> Aug 22, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 152 (of 409)

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

<u>AB</u>	TARO	<u>2.5MG</u>	<u>A075657</u>	<u>001</u>	Jan 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075657</u>	<u>002</u>	Jan 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075657</u>	<u>003</u>	Jan 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075657</u>	<u>004</u>	Jan 23, 2001
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A075479</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075479</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075479</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075479</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A075501</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075501</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075501</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075501</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	WOCKHARDT USA	<u>2.5MG</u>	<u>A075483</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075483</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075483</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075483</u>	<u>004</u>	Aug 22, 2000
<u>VASOTEC</u>					
<u>AB</u>	BIOVAIL LABS INTL	<u>2.5MG</u>	<u>N018998</u>	<u>005</u>	Jul 26, 1988
<u>AB</u>		<u>5MG</u>	<u>N018998</u>	<u>001</u>	Dec 24, 1985
<u>AB</u>		<u>10MG</u>	<u>N018998</u>	<u>002</u>	Dec 24, 1985
<u>AB</u>	+	<u>20MG</u>	<u>N018998</u>	<u>003</u>	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG;12.5MG</u>	<u>A076486</u>	<u>001</u>	Oct 27, 2004
<u>AB</u>		<u>10MG;25MG</u>	<u>A076486</u>	<u>002</u>	Oct 27, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909</u>	<u>001</u>	Oct 15, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075909</u>	<u>002</u>	Oct 15, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	SANDOZ	<u>5MG;12.5MG</u>	<u>A076116</u>	<u>001</u>	Sep 19, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A076116</u>	<u>002</u>	Sep 19, 2001
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	TEVA	<u>5MG;12.5MG</u>	<u>A075727</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727</u>	<u>002</u>	Sep 18, 2001
<u>VASERETIC</u>					
<u>AB</u>	BIOVAIL LABS INTL	<u>5MG;12.5MG</u>	<u>N019221</u>	<u>003</u>	Jul 12, 1995
<u>AB</u>	+	<u>10MG;25MG</u>	<u>N019221</u>	<u>001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	+	BEDFORD	<u>1.25MG/ML</u>	<u>A075634</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>	+	HOSPIRA	<u>1.25MG/ML</u>	<u>A075458</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		TEVA PARENTERAL	<u>1.25MG/ML</u>	<u>A075578</u>	<u>001</u>	Aug 22, 2000

ENFLURANE

LIQUID; INHALATION

ENFLURANE

<u>AN</u>	<u>PIRAMAL CRITICAL</u>	<u>99.9%</u>	<u>A074396</u>	<u>001</u>	Jul 29, 1994
	<u>ETHRANE</u>				
<u>AN</u>	<u>+ BAXTER HLTHCARE CORP</u>	<u>99.9%</u>	<u>N017087</u>	<u>001</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 153 (of 409)

ENFUVIRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+ ROCHE

90MG/VIAL

N021481 001

Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)AP SANDOZ30MG/0.3ML (100MG/ML)A077857 002

Jul 23, 2010

AP40MG/0.4ML (100MG/ML)A077857 003

Jul 23, 2010

AP60MG/0.6ML (100MG/ML)A077857 004

Jul 23, 2010

AP80MG/0.8ML (100MG/ML)A077857 005

Jul 23, 2010

AP100MG/ML (100MG/ML)A077857 001

Jul 23, 2010

AP120MG/0.8ML (150MG/ML)A077857 006

Jul 23, 2010

AP150MG/ML (150MG/ML)A077857 007

Jul 23, 2010

LOVENOX (PRESERVATIVE FREE)AP SANOFI AVENTIS US30MG/0.3ML (100MG/ML)N020164 001

Mar 29, 1993

AP40MG/0.4ML (100MG/ML)N020164 002

Jan 30, 1998

AP60MG/0.6ML (100MG/ML)N020164 003

Mar 27, 1998

AP80MG/0.8ML (100MG/ML)N020164 004

Mar 27, 1998

AP +100MG/ML (100MG/ML)N020164 005

Mar 27, 1998

AP120MG/0.8ML (150MG/ML)N020164 007

Jun 02, 2000

AP150MG/ML (150MG/ML)N020164 008

Jun 02, 2000

LOVENOX

SANOFI AVENTIS US

300MG/3ML (100MG/ML)

N020164 009

Jan 23, 2003

ENTACAPONE

TABLET; ORAL

COMTAN

+ ORION

200MG

N020796 001

Oct 19, 1999

ENTECAVIR

SOLUTION; ORAL

BARACLUDE

+ BRISTOL MYERS SQUIBB 0.05MG/ML

N021798 001

Mar 29, 2005

TABLET; ORAL

BARACLUDE

BRISTOL MYERS SQUIBB 0.5MG

N021797 001

Mar 29, 2005

+ 1MG

N021797 002

Mar 29, 2005

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

+ ALLERGAN

0.05%

N021565 001

Oct 16, 2003

EPINEPHRINE

INJECTABLE; IM-SC

ADRENALINE

BX + SHIONOGI PHARMA

EQ 0.15MG /DELIVERY

N020800 003

Nov 25, 2009

BX +

EQ 0.3MG /DELIVERY

N020800 004

Nov 25, 2009

EPIPEN

BX + MERIDIAN MEDCL TECHN

0.3MG/DELIVERY

N019430 001

Dec 22, 1987

EPIPEN JR.

BX + MERIDIAN MEDCL TECHN

0.15MG/DELIVERY

N019430 002

Dec 22, 1987

TWINJECT 0.15

BX + SHIONOGI PHARMA

EQ 0.15MG /DELIVERY

N020800 002

May 28, 2004

TWINJECT 0.3

BX + SHIONOGI PHARMA

EQ 0.3MG /DELIVERY

N020800 001

May 30, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 154 (of 409)

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

+ DEPROCO EQ 0.02MG BASE/ML;2% A088389 001 Jan 22, 1985

LIGNOSPAN STANDARD

+ DEPROCO EQ 0.01MG BASE/ML;2% A088390 001 Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

+ DENTSPLY PHARM 0.005MG/ML;4% N021383 001

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP	EASTMAN KODAK	0.01MG/ML;2%	A040057	002	Feb 26, 1993
AP		0.02MG/ML;2%	A040057	001	Feb 26, 1993
AP	HOSPIRA	0.005MG/ML;0.5%	A089635	001	Jun 21, 1988
AP		0.005MG/ML;1.5%	A088571	001	Sep 13, 1985
AP		0.005MG/ML;1.5%	A089645	001	Jun 21, 1988
AP		0.005MG/ML;2%	A089651	001	Jun 21, 1988
AP		0.01MG/ML;1%	A089644	001	Jun 21, 1988
AP		0.01MG/ML;2%	A078772	001	May 12, 2008
AP		0.01MG/ML;2%	A089646	001	Jun 21, 1988
AP		0.02MG/ML;2%	A078772	002	May 12, 2008

OCTOCAINE

AP	SEPTODONT	0.01MG/ML;2%	A084048	001	
AP	+	0.02MG/ML;2%	A084048	002	

XYLOCAINE DENTAL WITH EPINEPHRINE

AP	+ DENTSPLY PHARM	0.01MG/ML;2%	N021381	001	
AP	+	0.02MG/ML;2%	N021381	002	

XYLOCAINE W/ EPINEPHRINE

AP	+ APP PHARMS	0.005MG/ML;0.5%	N006488	012	
AP	+	0.005MG/ML;1%	N006488	018	Nov 13, 1986
AP	+	0.005MG/ML;1.5%	N006488	017	
AP	+	0.005MG/ML;2%	N006488	019	Nov 13, 1986
AP	+	0.01MG/ML;1%	N006488	004	
AP	+	0.02MG/ML;2%	N006488	005	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

AP	+ PFIZER INC	200MG/100ML (2MG/ML)	N050778	001	Sep 15, 1999
AP		50MG/25ML (2MG/ML)	N050778	002	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP	ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008
AP		50MG/25ML (2MG/ML)	A065445	002	Sep 18, 2008
AP		200MG/100ML (2MG/ML)	A065445	003	Sep 18, 2008
AP	AKORN INC	50MG/25ML (2MG/ML)	A090163	001	Jun 24, 2009
AP	APP PHARMS	10MG/5ML (2MG/ML)	A065408	001	Oct 15, 2007
AP		200MG/100ML (2MG/ML)	A065408	004	Oct 15, 2007
AP		50MG/25ML (2MG/ML)	A065408	002	Oct 15, 2007
AP		150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007
AP	BEDFORD	50MG/25ML (2MG/ML)	A065289	001	Jun 27, 2007
AP		200MG/100ML (2MG/ML)	A065289	002	Jun 27, 2007
AP	BIONICHE PHARMA USA	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007
AP		200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007
AP	EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
AP		200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
AP	FRESENIUS KABI ONCOL	50MG/25ML (2MG/ML)	A065411	002	Aug 20, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 155 (of 409)

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI ONCOL	<u>200MG/100ML (2MG/ML)</u>	<u>A065411</u>	<u>001</u>	Aug 20, 2007
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A065343</u>	<u>004</u>	Apr 19, 2007
<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065343</u>	<u>002</u>	Apr 19, 2007
<u>AP</u>		<u>10MG/5ML (2MG/ML)</u>	<u>A065343</u>	<u>001</u>	Apr 19, 2007
<u>AP</u>		<u>150MG/75ML (2MG/ML)</u>	<u>A065343</u>	<u>003</u>	Apr 19, 2007
<u>AP</u>	TEVA PARENTERAL	<u>200MG/100ML (2MG/ML)</u>	<u>A065331</u>	<u>002</u>	Aug 09, 2007
<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065331</u>	<u>001</u>	Aug 09, 2007
<u>AP</u>	WATSON LABS	<u>200MG/100ML (2MG/ML)</u>	<u>A065361</u>	<u>002</u>	Oct 22, 2007
<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065361</u>	<u>001</u>	Oct 22, 2007
<u>AP</u>	X GEN PHARMS	<u>50MG/25ML (2MG/ML)</u>	<u>A090075</u>	<u>001</u>	Mar 25, 2010
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A090075</u>	<u>002</u>	Mar 25, 2010

INJECTABLE; IV (INFUSION)

+	HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>	APOTEX	<u>25MG</u>	<u>A078482</u>	<u>001</u>	Jul 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A078482</u>	<u>002</u>	Jul 30, 2008
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078510</u>	<u>001</u>	Aug 01, 2008
<u>AB</u>		<u>50MG</u>	<u>A078510</u>	<u>002</u>	Aug 01, 2008
	<u>INSPIRA</u>				
<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N021437</u>	<u>001</u>	Sep 27, 2002
<u>AB</u>	+	<u>50MG</u>	<u>N021437</u>	<u>002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>	TEVA PARENTERAL	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>		<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396</u>	<u>002</u>	Apr 23, 2008
	<u>FLOLAN</u>				
<u>AP</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444</u>	<u>001</u>	Sep 20, 1995
<u>AP</u>	+	<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444</u>	<u>002</u>	Sep 20, 1995
	EPOPROSTENOL SODIUM				
	+ ACTELION	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

ABBOTT	EQ 400MG BASE	N020738	005	Dec 22, 1997
+	EQ 600MG BASE	N020738	006	May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

ABBOTT	600MG; 12.5MG	N021268	001	Nov 01, 2001
+	600MG; 25MG	N021268	002	Nov 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+	SCHERING	2MG/ML	N020718	001	May 18, 1998
+		75MG/100ML	N020718	002	May 18, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 156 (of 409)

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

<u>AA</u>	+	SANOFI AVENTIS US	<u>50,000 IU</u>	<u>N003444</u>	<u>001</u>	

ERGOCALCIFEROL

<u>AA</u>		ORIT LABS LLC	<u>50,000 IU</u>	<u>A040833</u>	<u>001</u>	May 20, 2009
<u>AA</u>		SIGMAPHARM LABS LLC	<u>50,000 IU</u>	<u>A091004</u>	<u>001</u>	Jul 14, 2010
<u>AA</u>		STRIDES ARCOLAB LTD	<u>50,000 IU</u>	<u>A090455</u>	<u>001</u>	Aug 03, 2010
<u>AA</u>		SUN PHARM INDS INC	<u>50,000 IU</u>	<u>A040865</u>	<u>001</u>	Dec 29, 2009

VITAMIN D

<u>AA</u>		BANNER PHARMACAPS	<u>50,000 IU</u>	<u>A080704</u>	<u>001</u>	

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

<u>AB</u>		MUTUAL PHARM	<u>1MG</u>	<u>A081113</u>	<u>001</u>	Oct 31, 1991

HYDERGINE

<u>AB</u>	+	NOVARTIS	<u>1MG</u>	<u>N017993</u>	<u>001</u>	

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

		WATSON LABS	0.5MG	A087233	001	

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

	+	ROSEDALE THERAPEUTIC	2MG	A087693	001	Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

	+	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

TARCEVA

		OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004

			EQ 100MG BASE	N021743	002	Nov 18, 2004

+			EQ 150MG BASE	N021743	003	Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

INVANZ

	+	MERCK	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

<u>AB</u>	+	HOSPIRA	<u>250MG</u>	<u>N050536</u>	<u>001</u>	

<u>AB</u>		WARNER CHILCOTT	<u>250MG</u>	<u>A062338</u>	<u>001</u>	

ERYTHROMYCIN

<u>AB</u>		ABBOTT	<u>250MG</u>	<u>A062746</u>	<u>001</u>	Dec 22, 1986

GEL; TOPICAL

E-GLADES

<u>AT</u>		STIEFEL LABS INC	<u>2%</u>	<u>A065009</u>	<u>001</u>	Mar 18, 2002

ERYGEL

<u>AT</u>	+	MERZ PHARMS	<u>2%</u>	<u>N050617</u>	<u>001</u>	Oct 21, 1987

ERYTHROMYCIN

<u>AT</u>		ALTANA	<u>2%</u>	<u>A064184</u>	<u>001</u>	Sep 30, 1997

<u>AT</u>		PERRIGO	<u>2%</u>	<u>A063211</u>	<u>001</u>	Jan 29, 1993

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 157 (of 409)

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A064030</u>	<u>001</u>	Jul 18, 1996
<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A064067</u>	<u>001</u>	Jul 29, 1994
<u>AT</u>	+ FOUGERA	<u>0.5%</u>	<u>A062447</u>	<u>001</u>	Sep 26, 1983

OINTMENT; TOPICAL

AKNE-MYCIN

	+ DOW PHARM SCIENCES	2%	N050584	001	Jan 10, 1985

SOLUTION; TOPICAL

ERYTHRA-DERM

<u>AT</u>	PADDOCK	<u>2%</u>	<u>A062687</u>	<u>001</u>	Feb 05, 1988

ERYTHROMYCIN

<u>AT</u>	+ ALTANA	<u>2%</u>	<u>A064187</u>	<u>001</u>	Sep 30, 1997

<u>AT</u>	PERRIGO NEW YORK	<u>2%</u>	<u>A063038</u>	<u>001</u>	Jan 11, 1991

<u>AT</u>	WOCKHARDT	<u>2%</u>	<u>A062825</u>	<u>001</u>	Oct 23, 1987

ERYTHRO-STATIN

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>A064101</u>	<u>001</u>	Oct 22, 1996

SWAB; TOPICAL

ERYTHROMYCIN

<u>AT</u>	+ ALTANA	<u>2%</u>	<u>A065320</u>	<u>001</u>	Jul 25, 2006

<u>AT</u>	+ PERRIGO	<u>2%</u>	<u>A064126</u>	<u>001</u>	Jul 03, 1996

<u>AT</u>	VERSAPHARM	<u>2%</u>	<u>A090215</u>	<u>001</u>	May 12, 2010

TABLET; ORAL

ERYTHROMYCIN

	ABBOTT	250MG	A061621	001	
	+	500MG	A061621	002	

TABLET, COATED PARTICLES; ORAL

PCE

	ABBOTT	333MG	N050611	001	Sep 09, 1986
	+	500MG	N050611	002	Aug 22, 1990

TABLET, DELAYED RELEASE; ORAL

ERY-TAB

	+ ABBOTT	250MG	A062298	001	
	+	333MG	A062298	003	Mar 29, 1982
	+	500MG	A062298	002	

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

<u>AB</u>	ABBOTT	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>001</u>	

ERYPED

<u>AB</u>	ABBOTT	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>003</u>	Mar 30, 1987

ERYPED

	+ ABBOTT	EQ 400MG BASE/5ML	N050207	002	

SUSPENSION; ORAL

E.E.S. 200

<u>AB</u>	ABBOTT	<u>EQ 200MG BASE/5ML</u>	<u>A061639</u>	<u>001</u>	

E.E.S. 400

<u>AB</u>	+ ABBOTT	<u>EQ 400MG BASE/5ML</u>	<u>A061639</u>	<u>002</u>	

PEDIAMYCIN

<u>AB</u>	ROSS LABS	<u>EQ 200MG BASE/5ML</u>	<u>A062304</u>	<u>001</u>	

PEDIAMYCIN 400

<u>AB</u>	ROSS LABS	<u>EQ 400MG BASE/5ML</u>	<u>A062304</u>	<u>002</u>	

TABLET; ORAL

E.E.S. 400

BX	+ ABBOTT	EQ 400MG BASE	A061905	002	Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

BX	+ ABBOTT	EQ 400MG BASE	A061904	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 158 (of 409)

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

+	BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062759	001	May 20, 1988

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

<u>AP</u>	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062638</u>	<u>001</u>	Oct 31, 1986

<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N050609</u>	<u>001</u>	Sep 24, 1986

<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062638</u>	<u>002</u>	Oct 31, 1986

ERYTHROMYCIN LACTOBIONATE

<u>AP</u>	TEVA PARENTERAL	<u>EQ 500MG BASE/VIAL</u>	<u>A063253</u>	<u>001</u>	Jul 30, 1993

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A063253</u>	<u>002</u>	Jul 30, 1993

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

	ABBOTT	EQ 250MG BASE	A060359	001	

+		EQ 500MG BASE	A060359	003	

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

	ALPHAPHARM	EQ 5MG BASE	A077660	001	Jul 31, 2007

		EQ 10MG BASE	A077660	002	Jul 31, 2007

+		EQ 20MG BASE	A077660	003	Jul 31, 2007

SOLUTION; ORAL

LEXAPRO

+	FOREST LABS	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002

TABLET; ORAL

LEXAPRO

	FOREST LABS	EQ 5MG BASE	N021323	001	Aug 14, 2002

		EQ 10MG BASE	N021323	002	Aug 14, 2002

+		EQ 20MG BASE	N021323	003	Aug 14, 2002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVILOC

<u>AP</u>	+	BAXTER HLTHCARE CORP	<u>10MG/ML</u>	<u>N019386</u>	<u>006</u>	Feb 25, 2003

ESMOLOL HYDROCHLORIDE

<u>AP</u>		APP PHARMS	<u>10MG/ML</u>	<u>A076573</u>	<u>001</u>	May 02, 2005

<u>AP</u>		BEDFORD LABS	<u>10MG/ML</u>	<u>A076323</u>	<u>001</u>	Aug 10, 2004

<u>AP</u>		BIONICHE PHARMA	<u>10MG/ML</u>	<u>A076474</u>	<u>001</u>	May 02, 2005

BREVILOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	2GM/100ML	N019386	005	Jan 27, 2003

BREVILOC IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	1GM/100ML	N019386	004	Feb 16, 2001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

	ASTRAZENECA	EQ 20MG BASE	N021153	001	Feb 20, 2001

+		EQ 40MG BASE	N021153	002	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

	ASTRAZENECA	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008

		EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006

+		EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 159 (of 409)

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

VIMOVO

ASTRAZENECA LP	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010
+	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

NEXIUM IV

+ ASTRAZENECA	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005
+	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

<u>AB</u>	PAR PHARM	<u>1MG</u>	<u>A074826</u>	<u>001</u>	Jul 03, 1997
<u>AB</u>		<u>2MG</u>	<u>A074826</u>	<u>002</u>	Jul 03, 1997
<u>AB</u>	TEVA	<u>1MG</u>	<u>A074921</u>	<u>001</u>	Jul 10, 1997
<u>AB</u>	+	<u>2MG</u>	<u>A074921</u>	<u>002</u>	Jul 10, 1997
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A074818</u>	<u>001</u>	Aug 19, 1997
<u>AB</u>		<u>2MG</u>	<u>A074818</u>	<u>002</u>	Aug 19, 1997

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+ WARNER CHILCOTT	0.01%	A086069	001	Jan 31, 1984

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

<u>AB</u>	BAYER HLTHCARE	<u>0.0375MG/24HR</u>	<u>N020375</u>	<u>005</u>	May 27, 2003
<u>AB</u>		<u>0.06MG/24HR</u>	<u>N020375</u>	<u>006</u>	May 27, 2003

ESTRADIOL

<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.0375MG/24HR</u>	<u>A075182</u>	<u>004</u>	Jul 20, 2006
<u>AB</u>		<u>0.06MG/24HR</u>	<u>A075182</u>	<u>005</u>	Jul 20, 2006

VIVELLE

<u>AB1</u>	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020323</u>	<u>002</u>	Oct 28, 1994
<u>AB1</u>		<u>0.1MG/24HR</u>	<u>N020323</u>	<u>004</u>	Oct 28, 1994

VIVELLE-DOT

<u>AB1</u>	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020538</u>	<u>006</u>	Jan 08, 1999
<u>AB1</u>	+	<u>0.1MG/24HR</u>	<u>N020538</u>	<u>008</u>	Jan 08, 1999

CLIMARA

<u>AB2</u>	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375</u>	<u>004</u>	Mar 05, 1999
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>N020375</u>	<u>001</u>	Dec 22, 1994
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>N020375</u>	<u>003</u>	Mar 23, 1998
<u>AB2</u>	+	<u>0.1MG/24HR</u>	<u>N020375</u>	<u>002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>	MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182</u>	<u>003</u>	Jan 26, 2005
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>A075182</u>	<u>006</u>	Feb 24, 2000
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>A075182</u>	<u>002</u>	Jan 26, 2005
<u>AB2</u>		<u>0.1MG/24HR</u>	<u>A075182</u>	<u>001</u>	Feb 24, 2000

ALORA

BX	WATSON LABS	0.025MG/24HR	N020655	004	Apr 05, 2002
BX		0.05MG/24HR	N020655	001	Dec 20, 1996
BX		0.075MG/24HR	N020655	002	Dec 20, 1996
BX		0.1MG/24HR	N020655	003	Dec 20, 1996

ESTRADERM

BX	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
BX	+	0.1MG/24HR	N019081	003	Sep 10, 1986

VIVELLE-DOT

BX	NOVARTIS	0.025MG/24HR	N020538	009	May 03, 2002
BX		0.0375MG/24HR	N020538	005	Jan 08, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 160 (of 409)

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL					
VIVELLE-DOT					
BX	NOVARTIS	0.075MG/24HR	N020538	007	Jan 08, 1999
MENOSTAR					
+	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004
GEL; TRANSDERMAL					
DIVIGEL					
	UPSHER SMITH	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007
		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007
+		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007
GEL, METERED; TRANSDERMAL					
ELESTRIN					
+	AZUR PHARMA II	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006
ESTROGEL					
+	ASCEND	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004
INSERT, EXTENDED RELEASE; VAGINAL					
ESTRING					
+	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996
SPRAY; TRANSDERMAL					
EVAMIST					
+	KV PHARM	1.53MG/SPRAY	N022014	001	Jul 27, 2007
TABLET; ORAL					
<u>ESTRACE</u>					
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>0.5MG</u>	<u>A081295</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>		<u>1MG</u>	<u>A084499</u>	<u>001</u>	
<u>AB</u>	+	<u>2MG</u>	<u>A084500</u>	<u>001</u>	
<u>ESTRADIOL</u>					
<u>AB</u>	BARR	<u>0.5MG</u>	<u>A040197</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>		<u>1MG</u>	<u>A040197</u>	<u>002</u>	Oct 22, 1997
<u>AB</u>		<u>2MG</u>	<u>A040197</u>	<u>003</u>	Oct 22, 1997
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A040326</u>	<u>001</u>	Apr 21, 1999
<u>AB</u>		<u>1MG</u>	<u>A040326</u>	<u>002</u>	Apr 21, 1999
<u>AB</u>		<u>2MG</u>	<u>A040326</u>	<u>003</u>	Apr 21, 1999
<u>AB</u>	USL PHARMA	<u>0.5MG</u>	<u>A040297</u>	<u>001</u>	Apr 17, 2002
<u>AB</u>		<u>1MG</u>	<u>A040297</u>	<u>002</u>	Apr 17, 2002
<u>AB</u>		<u>2MG</u>	<u>A040297</u>	<u>003</u>	Apr 17, 2002
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A040114</u>	<u>003</u>	Mar 14, 1996
<u>AB</u>		<u>1MG</u>	<u>A040114</u>	<u>001</u>	Mar 14, 1996
<u>AB</u>		<u>2MG</u>	<u>A040114</u>	<u>002</u>	Mar 14, 1996
TABLET; VAGINAL					
VAGIFEM					
+	NOVO NORDISK INC	10MCG	N020908	002	Nov 25, 2009
<u>ESTRADIOL ACETATE</u>					
INSERT, EXTENDED RELEASE; VAGINAL					
FEMRING					
	GALEN LTD	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003
+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003
TABLET; ORAL					
FEMTRACE					
	WARNER CHILCOTT	0.45MG	N021633	001	Aug 20, 2004
		0.9MG	N021633	002	Aug 20, 2004
+		1.8MG	N021633	003	Aug 20, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 161 (of 409)

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

<u>AO</u>	+	PHARMACIA AND UPJOHN	<u>5MG/ML</u>	<u>A085470</u>	<u>003</u>	

ESTRADIOL CYPIONATE

<u>AO</u>		WATSON LABS	<u>5MG/ML</u>	<u>A085620</u>	<u>001</u>	

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+	GRACEWAY	0.25%	N021371	001	Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGEN

<u>AO</u>	+	JHP PHARMS	<u>10MG/ML</u>	<u>N009402</u>	<u>002</u>	

<u>AO</u>	+		<u>20MG/ML</u>	<u>N009402</u>	<u>004</u>	

<u>AO</u>	+		<u>40MG/ML</u>	<u>N009402</u>	<u>003</u>	

ESTRADIOL VALERATE

<u>AO</u>		LUITPOLD	<u>20MG/ML</u>	<u>A090920</u>	<u>001</u>	Jan 19, 2010

<u>AO</u>			<u>40MG/ML</u>	<u>A090920</u>	<u>002</u>	Jan 19, 2010

<u>AO</u>		SANDOZ	<u>10MG/ML</u>	<u>A040628</u>	<u>001</u>	Oct 04, 2007

<u>AO</u>			<u>20MG/ML</u>	<u>A040628</u>	<u>002</u>	Oct 04, 2007

<u>AO</u>			<u>40MG/ML</u>	<u>A040628</u>	<u>003</u>	Oct 04, 2007

<u>AO</u>		WATSON LABS	<u>20MG/ML</u>	<u>A083547</u>	<u>001</u>	

<u>AO</u>			<u>40MG/ML</u>	<u>A083714</u>	<u>001</u>	

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA PRO

+	BAYER HLTHCARE	0.045MG/24HR;0.015MG/24HR	N021258	001	Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

COMBIPATCH

NOVARTIS 0.05MG/24HR;0.14MG/24HR

+		0.05MG/24HR;0.25MG/24HR	N020870	001	Aug 07, 1998

			N020870	002	Aug 07, 1998

TABLET; ORAL

ACTIVELLA

<u>AB</u>	+	NOVO NORDISK INC	<u>1MG;0.5MG</u>	<u>N020907</u>	<u>001</u>	Nov 18, 1998

ESTRADIOL AND NORETHINDRONE ACETATE

<u>AB</u>		BARR	<u>1MG;0.5MG</u>	<u>A079193</u>	<u>001</u>	May 11, 2010

<u>AB</u>		BRECKENRIDGE PHARM	<u>1MG;0.5MG</u>	<u>A078324</u>	<u>001</u>	Apr 17, 2008

ACTIVELLA

		NOVO NORDISK INC	0.5MG;0.1MG	N020907	002	Dec 28, 2006

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

<u>AB</u>		BARR	<u>1MG, 1MG; N/A, 0.09MG</u>	<u>A076812</u>	<u>001</u>	Apr 29, 2005

PREFEST

<u>AB</u>	+	TEVA WOMENS	<u>1MG, 1MG; N/A, 0.09MG</u>	<u>N021040</u>	<u>001</u>	Oct 22, 1999

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL

EMCYT

+	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001	

PRESCRIPTION DRUG PRODUCT LIST

3 - 162 (of 409)

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL				
PREMARIN				
+	WYETH PHARMS INC	0.625MG/GM	N020216 001	
INJECTABLE; INJECTION				
PREMARIN				
+	WYETH PHARMS INC	25MG/VIAL	N010402 001	
TABLET; ORAL				
PREMARIN				
	WYETH PHARMS INC	0.3MG	N004782 003	
		0.45MG	N004782 006	Jul 16, 2003
+		0.625MG	N004782 004	
+		0.9MG	N004782 005	Jan 26, 1984
+		1.25MG	N004782 001	

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL				
SYNTHETIC CONJUGATED ESTROGENS A				
+	TEVA WOMENS	0.625MG/GM	N021788 001	Nov 28, 2008
TABLET; ORAL				
CENESTIN				
	TEVA WOMENS	0.3MG	N020992 001	Jun 21, 2002
		0.45MG	N020992 005	Feb 05, 2004
		0.625MG	N020992 002	Mar 24, 1999
		0.9MG	N020992 003	Mar 24, 1999
+		1.25MG	N020992 004	Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL				
ENJUVIA				
	TEVA WOMENS	0.3MG	N021443 001	Dec 20, 2004
		0.45MG	N021443 002	Dec 20, 2004
		0.625MG	N021443 003	May 10, 2004
		0.9MG	N021443 005	Apr 27, 2007
+		1.25MG	N021443 004	May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28				
PREMPHASE 14/14				
+	WYETH PHARMS INC	0.625MG, 0.625MG; N/A, 5MG	N020527 002	Nov 17, 1995
PREMPRO				
+	WYETH PHARMS INC	0.3MG; 1.5MG	N020527 005	Jun 04, 2003
+		0.45MG; 1.5MG	N020527 004	Mar 12, 2003
+		0.625MG; 2.5MG	N020527 001	Nov 17, 1995
+		0.625MG; 5MG	N020527 003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL				
MENEST				
	MONARCH PHARMS	0.3MG	A084951 001	
		0.625MG	A084948 001	
		1.25MG	A084950 001	
+		2.5MG	A084949 001	

ESTRONE

INJECTABLE; INJECTION				
ESTRONE				
+	WATSON LABS	5MG/ML	A085239 001	

PRESCRIPTION DRUG PRODUCT LIST

3 - 163 (of 409)

ESTROPIPATE

CREAM; VAGINAL				
OGEN				
	+ PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001
TABLET; ORAL				
<u>ESTROPIPATE</u>				
<u>AB</u>	BARR	<u>0.75MG</u>	<u>A040135</u>	<u>001</u> Nov 27, 1996
<u>AB</u>		<u>1.5MG</u>	<u>A040135</u>	<u>002</u> Nov 27, 1996
<u>AB</u>		<u>3MG</u>	<u>A040135</u>	<u>003</u> Nov 27, 1996
<u>AB</u>	MYLAN	<u>0.75MG</u>	<u>A040359</u>	<u>001</u> Aug 26, 1999
<u>AB</u>		<u>1.5MG</u>	<u>A040359</u>	<u>002</u> Aug 26, 1999
<u>AB</u>	WATSON LABS	<u>0.75MG</u>	<u>A081213</u>	<u>001</u> Sep 23, 1993
<u>AB</u>		<u>1.5MG</u>	<u>A081214</u>	<u>001</u> Sep 23, 1993
<u>AB</u>		<u>3MG</u>	<u>A081215</u>	<u>001</u> Sep 23, 1993
<u>AB</u>		<u>6MG</u>	<u>A081216</u>	<u>001</u> Sep 23, 1993
<u>OGEN .625</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.75MG</u>	<u>A083220</u>	<u>001</u>
<u>OGEN 1.25</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>A083220</u>	<u>002</u>
<u>OGEN 2.5</u>				
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>3MG</u>	<u>A083220</u>	<u>003</u>
<u>OGEN 5</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>6MG</u>	<u>A083220</u>	<u>004</u>
<u>ORTHO-EST</u>				
<u>AB</u>	SUN PHARM INDS (IN)	<u>0.75MG</u>	<u>A089567</u>	<u>001</u> Feb 27, 1991
<u>AB</u>		<u>1.5MG</u>	<u>A089582</u>	<u>001</u> Jul 17, 1991

ESZOPICLONE

TABLET; ORAL				
LUNESTA				
	SEPRACOR	1MG	N021476	001 Dec 15, 2004
		2MG	N021476	002 Dec 15, 2004
	+	3MG	N021476	003 Dec 15, 2004

ETHACRYNATE SODIUM

INJECTABLE; INJECTION				
EDECIN				
	+ ATON	EQ 50MG BASE/VIAL	N016093	001

ETHACRYNIC ACID

TABLET; ORAL				
EDECIN				
	+ ATON	25MG	N016092	001

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL				
<u>ETHAMBUTOL HYDROCHLORIDE</u>				
<u>AB</u>	BARR	<u>400MG</u>	<u>A076057</u>	<u>001</u> Nov 26, 2001
<u>AB</u>	LUPIN	<u>100MG</u>	<u>A078939</u>	<u>001</u> Jun 17, 2009
<u>AB</u>		<u>400MG</u>	<u>A078939</u>	<u>002</u> Jun 17, 2009
<u>AB</u>	WEST WARD	<u>100MG</u>	<u>A075095</u>	<u>001</u> Nov 30, 1999
<u>AB</u>	+	<u>400MG</u>	<u>A075095</u>	<u>002</u> Nov 30, 1999
<u>MYAMBUTOL</u>				
<u>AB</u>	STI PHARMA LLC	<u>100MG</u>	<u>N016320</u>	<u>001</u>
<u>AB</u>		<u>400MG</u>	<u>N016320</u>	<u>003</u>

PRESCRIPTION DRUG PRODUCT LIST

3 - 164 (of 409)

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

+ QOL MEDCL	50MG/ML	N019357 001	Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

KELNOR

AB BARR	<u>0.035MG;1MG</u>	<u>A076785</u> <u>001</u>	May 23, 2005

ZOVIA 1/35E-28

AB WATSON LABS	<u>0.035MG;1MG</u>	<u>A072721</u> <u>001</u>	Dec 30, 1991

ZOVIA 1/50E-28

+ WATSON LABS	0.05MG;1MG	A072723 001	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

+ ORGANON USA INC	0.015MG;0.12MG	N021187 001	Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

INTROVALE

AB SANDOZ	<u>0.03MG;0.15MG</u>	<u>A079064</u> <u>001</u>	Sep 27, 2010

QUASENSE

AB WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A077101</u> <u>001</u>	Sep 06, 2006

SEASONALE

AB + DURAMED RES	<u>0.03MG;0.15MG</u>	<u>N021544</u> <u>001</u>	Sep 05, 2003

LOSEASONIQUE

DURAMED	0.02MG,0.01MG;0.1MG,N/A	N022262 001	Oct 24, 2008

LYBREL

+ WYETH PHARMS INC	0.02MG;0.09MG	N021864 001	May 22, 2007

SEASONIQUE

+ DURAMED RES	0.03MG,0.01MG;0.15MG,N/A	N021840 001	May 25, 2006

TABLET; ORAL-28

ALTAVERA

AB SANDOZ	<u>0.03MG;0.15MG</u>	<u>A079102</u> <u>001</u>	Aug 03, 2010

ENPRESSE-28

AB DURAMED PHARMS BARR	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A075809</u> <u>002</u>	Jul 16, 2001

LEVONEST

AB NOVAST LABS LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A090719</u> <u>001</u>	Dec 29, 2010

LEVORA 0.15/30-28

AB WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A073594</u> <u>001</u>	Dec 13, 1993

NORDETTE-28

AB + DURAMED	<u>0.03MG;0.15MG</u>	<u>N018782</u> <u>001</u>	Jul 21, 1982

PORTIA-28

AB BARR	<u>0.03MG;0.15MG</u>	<u>A075866</u> <u>002</u>	May 23, 2002

TRIVORA-28

AB + WATSON LABS	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A074538</u> <u>002</u>	Dec 18, 1997

AVIANE-28

AB1 DURAMED PHARMS BARR	<u>0.02MG;0.1MG</u>	<u>A075796</u> <u>001</u>	Apr 30, 2001

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1 + WATSON LABS	<u>0.02MG;0.1MG</u>	<u>A076625</u> <u>001</u>	Nov 18, 2004

LESSINA-28

AB2 BARR	<u>0.02MG;0.1MG</u>	<u>A075803</u> <u>002</u>	Mar 20, 2002

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2 + WATSON LABS	<u>0.02MG;0.1MG</u>	<u>A077681</u> <u>001</u>	May 31, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 165 (of 409)

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL
ORTHO EVRA

+ ORTHO MCNEIL JANSSEN 0.02MG/24HR;0.15MG/24HR	N021180 001	Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

<u>AB</u>	<u>NORETHIN 1/35E-21</u>		<u>A071480</u>	<u>001</u>	Apr 12, 1988
	WATSON LABS	0.035MG;1MG			
	<u>NORETHINDRONE AND ETHINYL ESTRADIOL</u>				
<u>AB</u>	WATSON LABS	0.035MG;1MG	<u>A070685</u>	<u>001</u>	Jan 29, 1987
	<u>NORINYL 1+35 21-DAY</u>				
<u>AB</u>	WATSON LABS	0.035MG;1MG	<u>N017565</u>	<u>001</u>	
	<u>NORTREL 1/35-21</u>				
<u>AB</u>	BARR	0.035MG;1MG	<u>A072693</u>	<u>001</u>	Feb 28, 1992
	NORETHINDRONE AND ETHINYL ESTRADIOL				
	WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)				
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)				
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991
	NORTREL 7/7/7				
	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET; ORAL-28

	<u>ARANELLE</u>				
<u>AB</u>	BARR	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	<u>A076783</u>	<u>001</u>	Sep 29, 2004
	<u>BALZIVA-28</u>				
<u>AB</u>	BARR	0.035MG;0.4MG	<u>A076238</u>	<u>001</u>	Apr 22, 2004
	<u>BREVICON 28-DAY</u>				
<u>AB</u>	WATSON LABS	0.035MG;0.5MG	<u>N017743</u>	<u>001</u>	
	<u>CYCLAFEM 1/35</u>				
<u>AB</u>	VINTAGE	0.035MG;1MG	<u>A076337</u>	<u>001</u>	Nov 12, 2010
	<u>CYCLAFEM 7/7/7</u>				
<u>AB</u>	VINTAGE	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	<u>A076338</u>	<u>001</u>	Nov 16, 2010
		G			
	<u>MODICON 28</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	0.035MG;0.5MG	<u>N017735</u>	<u>001</u>	
	<u>NORETHIN 1/35E-28</u>				
<u>AB</u>	WATSON LABS	0.035MG;1MG	<u>A071481</u>	<u>001</u>	Apr 12, 1988
	<u>NORETHINDRONE AND ETHINYL ESTRADIOL</u>				
<u>AB</u>	WATSON LABS	0.035MG;0.4MG	<u>A078323</u>	<u>001</u>	Feb 04, 2010
<u>AB</u>		0.035MG;0.5MG	<u>A070686</u>	<u>001</u>	Jan 29, 1987
<u>AB</u>		0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	<u>A076393</u>	<u>001</u>	Feb 04, 2010
		G			
<u>AB</u>		0.035MG;1MG	<u>A070687</u>	<u>001</u>	Jan 29, 1987
	<u>NORINYL 1+35 28-DAY</u>				
<u>AB</u>	WATSON LABS	0.035MG;1MG	<u>N017565</u>	<u>002</u>	
	<u>NORTREL 0.5/35-28</u>				
<u>AB</u>	BARR	0.035MG;0.5MG	<u>A072695</u>	<u>001</u>	Feb 28, 1992
	<u>NORTREL 1/35-28</u>				
<u>AB</u>	BARR	0.035MG;1MG	<u>A072696</u>	<u>001</u>	Feb 28, 1992
	<u>NORTREL 7/7/7</u>				
<u>AB</u>	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	<u>A075478</u>	<u>002</u>	Aug 30, 2002
		G			
	<u>ORTHO-NOVUM 1/35-28</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	0.035MG;1MG	<u>N017919</u>	<u>002</u>	
	<u>ORTHO-NOVUM 7/7/7-28</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	<u>N018985</u>	<u>002</u>	Apr 04, 1984
		G			
	<u>OVCON-35</u>				
<u>AB</u>	+ WARNER CHILCOTT	0.035MG;0.4MG	<u>N017716</u>	<u>001</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 166 (of 409)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

TRI-NORINYL 28-DAY

<u>AB</u>	+	WATSON LABS	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG</u>	<u>N018977</u>	<u>002</u>	Apr 13, 1984
		NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)				
		WATSON LABS	0.035MG, 0.035MG; 0.5MG, 1MG	A071044	001	Apr 01, 1988
		NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)				
		WATSON LABS	0.035MG, 0.035MG; 0.5MG, 1MG	A071042	001	Sep 24, 1991
		OVCON-50				
	+	WARNER CHILCOTT	0.05MG; 1MG	N017576	001	

TABLET, CHEWABLE; ORAL

FEMCON FE

<u>AB</u>	+	WARNER CHILCOTT	<u>0.035MG; 0.4MG</u>	<u>N021490</u>	<u>001</u>	Nov 14, 2003
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE				
<u>AB</u>		BARR	<u>0.035MG; 0.4MG</u>	<u>A078965</u>	<u>001</u>	Aug 05, 2010
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE				
	+	WARNER CHILCOTT	0.025MG; 0.8MG	N022573	001	Dec 22, 2010

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

<u>AB</u>	+	WARNER CHILCOTT	<u>0.005MG; 1MG</u>	<u>N021065</u>	<u>002</u>	Oct 15, 1999
		LOESTRIN 24 FE				
<u>AB</u>	+	WARNER CHILCOTT	<u>0.02MG; 1MG</u>	<u>N021871</u>	<u>001</u>	Feb 17, 2006
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL				
<u>AB</u>		BARR	<u>0.005MG; 1MG</u>	<u>A076221</u>	<u>001</u>	Nov 06, 2009
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE				
<u>AB</u>		WATSON LABS	<u>0.02MG; 1MG</u>	<u>A078267</u>	<u>001</u>	Sep 01, 2009
		FEMHRT				
		WARNER CHILCOTT	0.0025MG; 0.5MG	N021065	001	Jan 14, 2005
		LO LOESTRIN FE				
		WARNER CHILCOTT CO	0.01MG, 0.01MG; 1MG, N/A	N022501	001	Oct 21, 2010

TABLET; ORAL-21

JUNEL 1.5/30

<u>AB</u>		BARR	<u>0.03MG; 1.5MG</u>	<u>A076381</u>	<u>001</u>	May 30, 2003
		JUNEL 1/20				
<u>AB</u>		BARR	<u>0.02MG; 1MG</u>	<u>A076380</u>	<u>001</u>	May 30, 2003
		LOESTRIN 21 1.5/30				
<u>AB</u>		WARNER CHILCOTT	<u>0.03MG; 1.5MG</u>	<u>N017875</u>	<u>001</u>	
		LOESTRIN 21 1/20				
<u>AB</u>		WARNER CHILCOTT	<u>0.02MG; 1MG</u>	<u>N017876</u>	<u>001</u>	
		MICROGESTIN 1.5/30				
<u>AB</u>		WATSON LABS	<u>0.03MG; 1.5MG</u>	<u>A075548</u>	<u>002</u>	Jul 30, 2003
		MICROGESTIN 1/20				
<u>AB</u>		WATSON LABS	<u>0.02MG; 1MG</u>	<u>A075647</u>	<u>002</u>	Jul 30, 2003
		TRI-LEGEST 21				
		BARR	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A076405	001	Oct 26, 2007

TABLET; ORAL-28

ESTROSTEP FE

<u>AB</u>	+	WARNER CHILCOTT	<u>0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG</u>	<u>N020130</u>	<u>002</u>	Oct 09, 1996
		JUNEL FE 1.5/30				
<u>AB</u>		BARR	<u>0.03MG; 1.5MG</u>	<u>A076064</u>	<u>001</u>	Sep 18, 2003
		JUNEL FE 1/20				
<u>AB</u>		BARR	<u>0.02MG; 1MG</u>	<u>A076081</u>	<u>001</u>	Sep 18, 2003
		LOESTRIN FE 1.5/30				
<u>AB</u>	+	WARNER CHILCOTT	<u>0.03MG; 1.5MG</u>	<u>N017355</u>	<u>001</u>	
		LOESTRIN FE 1/20				
<u>AB</u>		WARNER CHILCOTT	<u>0.02MG; 1MG</u>	<u>N017354</u>	<u>001</u>	
		MICROGESTIN FE 1.5/30				
<u>AB</u>		WATSON LABS	<u>0.03MG; 1.5MG</u>	<u>A075548</u>	<u>001</u>	Feb 05, 2001

PRESCRIPTION DRUG PRODUCT LIST

3 - 167 (of 409)

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

<u>MICROGESTIN FE 1/20</u>			
<u>AB</u>	WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647</u> <u>001</u> Feb 05, 2001
<u>NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL</u>			
<u>AB</u>	WATSON LABS	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076629</u> <u>001</u> Mar 18, 2010
<u>NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>			
<u>AB</u>	VINTAGE	<u>0.02MG;1MG</u>	<u>A077077</u> <u>001</u> May 20, 2005
<u>AB</u>		<u>0.03MG;1.5MG</u>	<u>A077075</u> <u>001</u> Apr 28, 2005
<u>TRI-LEGEST FE</u>			
<u>AB</u>	BARR	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076105</u> <u>001</u> Oct 26, 2007

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

<u>NORGESTIMATE AND ETHINYL ESTRADIOL</u>			
<u>AB</u>	WATSON LABS	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A076626</u> <u>001</u> Aug 17, 2006
<u>AB</u>		<u>0.035MG;0.25MG</u>	<u>A076627</u> <u>001</u> Aug 17, 2006
<u>ORTHO CYCLEN-28</u>			
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.035MG;0.25MG</u>	<u>N019653</u> <u>002</u> Dec 29, 1989
<u>ORTHO TRI-CYCLEN</u>			
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>N019697</u> <u>001</u> Jul 03, 1992
<u>ORTHO TRI-CYCLEN LO</u>			
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	<u>N021241</u> <u>001</u> Aug 22, 2002
<u>PREVIFEM</u>			
<u>AB</u>	VINTAGE	<u>0.035MG;0.25MG</u>	<u>A076334</u> <u>001</u> Jan 09, 2004
<u>SPRINTEC</u>			
<u>AB</u>	BARR	<u>0.035MG;0.25MG</u>	<u>A075804</u> <u>001</u> Sep 25, 2002
<u>TRI LO SPRINTEC</u>			
<u>AB</u>	BARR	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	<u>A076784</u> <u>001</u> Jun 29, 2009
<u>TRI-PREVIFEM</u>			
<u>AB</u>	VINTAGE	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A076335</u> <u>001</u> Mar 26, 2004
<u>TRI-SPRINTEC</u>			
<u>AB</u>	BARR	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A075808</u> <u>001</u> Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

<u>CRYSELLE</u>			
<u>AB</u>	DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840</u> <u>001</u> Nov 30, 2001
<u>LOW-OGESTREL-21</u>			
<u>AB</u>	+ WATSON LABS	<u>0.03MG;0.3MG</u>	<u>A075288</u> <u>001</u> Jul 28, 1999

TABLET; ORAL-28

<u>CRYSELLE</u>			
<u>AB</u>	DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840</u> <u>002</u> Nov 30, 2001
<u>LO/OVRAL-28</u>			
<u>AB</u>	AKRIMAX PHARMS	<u>0.03MG;0.3MG</u>	<u>N017802</u> <u>001</u>
<u>LOW-OGESTREL-28</u>			
<u>AB</u>	WATSON LABS	<u>0.03MG;0.3MG</u>	<u>A075288</u> <u>002</u> Jul 28, 1999
OGESTREL 0.5/50-28			
+ WATSON LABS		0.05MG;0.5MG	A075406 002 Dec 15, 1999

ETHIONAMIDE

TABLET; ORAL

TRECATOR			
+ WYETH PHARMS INC		250MG	N013026 002

PRESCRIPTION DRUG PRODUCT LIST

3 - 168 (of 409)

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

<u>AB</u>	BANNER PHARMACAPS	<u>250MG</u>	<u>A040430</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>	COVENANT PHARMA INC	<u>250MG</u>	<u>A040686</u>	<u>001</u>	May 28, 2008

ZARONTIN

<u>AB</u>	+ PARKE DAVIS	<u>250MG</u>	<u>N012380</u>	<u>001</u>	

SYRUP; ORAL

ETHOSUXIMIDE

<u>AA</u>	MIKART	<u>250MG/5ML</u>	<u>A040506</u>	<u>001</u>	Dec 22, 2003
<u>AA</u>	PHARM ASSOC	<u>250MG/5ML</u>	<u>A040253</u>	<u>001</u>	Nov 22, 2000
<u>AA</u>	TEVA PHARMS	<u>250MG/5ML</u>	<u>A081306</u>	<u>001</u>	Jul 30, 1993

ZARONTIN

<u>AA</u>	+ PARKE DAVIS	<u>250MG/5ML</u>	<u>A080258</u>	<u>001</u>	

ETHOTOIN

TABLET; ORAL

PEGANONE

	+ LUNDBECK INC	250MG	N010841	001	

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

<u>AB</u>	PROCTER AND GAMBLE	<u>200MG</u>	<u>N017831</u>	<u>001</u>	
<u>AB</u>	+	<u>400MG</u>	<u>N017831</u>	<u>002</u>	

ETIDRONATE DISODIUM

<u>AB</u>	MYLAN	<u>200MG</u>	<u>A075800</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>400MG</u>	<u>A075800</u>	<u>002</u>	Jan 24, 2003

ETODOLAC

CAPSULE; ORAL

ETODOLAC

<u>AB</u>	APOTEX	<u>200MG</u>	<u>A075419</u>	<u>001</u>	Jul 28, 2000
<u>AB</u>		<u>300MG</u>	<u>A075419</u>	<u>002</u>	Jul 28, 2000
<u>AB</u>	TARO	<u>200MG</u>	<u>A075078</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>	+	<u>300MG</u>	<u>A075078</u>	<u>002</u>	Apr 30, 1998
<u>AB</u>	TEVA	<u>300MG</u>	<u>A075126</u>	<u>002</u>	Sep 16, 1999

TABLET; ORAL

ETODOLAC

<u>AB</u>	ACTAVIS ELIZABETH	<u>400MG</u>	<u>A074819</u>	<u>001</u>	Feb 28, 1997
<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A076004</u>	<u>001</u>	Dec 03, 2002
<u>AB</u>		<u>500MG</u>	<u>A076004</u>	<u>002</u>	Dec 03, 2002
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075104</u>	<u>001</u>	Feb 06, 1998
<u>AB</u>		<u>500MG</u>	<u>A075104</u>	<u>002</u>	Nov 20, 1998
<u>AB</u>	SANDOZ	<u>400MG</u>	<u>A074903</u>	<u>001</u>	Apr 11, 1997
<u>AB</u>		<u>500MG</u>	<u>A074903</u>	<u>002</u>	Apr 19, 1999
<u>AB</u>	TARO PHARM INDS	<u>400MG</u>	<u>A075074</u>	<u>001</u>	Mar 11, 1998
<u>AB</u>	+	<u>500MG</u>	<u>A075074</u>	<u>002</u>	Apr 25, 2000
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075009</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>500MG</u>	<u>A075009</u>	<u>002</u>	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>	TARO	<u>400MG</u>	<u>A076174</u>	<u>001</u>	Mar 13, 2003
<u>AB</u>		<u>500MG</u>	<u>A076174</u>	<u>002</u>	Mar 13, 2003
<u>AB</u>		<u>600MG</u>	<u>A076174</u>	<u>003</u>	Mar 13, 2003
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075665</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>		<u>500MG</u>	<u>A075665</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>	+	<u>600MG</u>	<u>A075665</u>	<u>001</u>	Jul 31, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 169 (of 409)

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	+	HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982

ETOMIDATE

<u>AP</u>		BEDFORD	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996

<u>AP</u>		LUITPOLD	<u>2MG/ML</u>	<u>A078867</u>	<u>001</u>	Dec 22, 2009

<u>AP</u>		STRIDES ARCOLAB LTD	<u>2MG/ML</u>	<u>A078289</u>	<u>001</u>	Jan 02, 2009

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

+	MYLAN	50MG	A075635	001	Sep 19, 2001

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>		ACCORD HLTHCARE INC	<u>20MG/ML</u>	<u>A074513</u>	<u>001</u>	Mar 14, 1996

<u>AP</u>		APP PHARMS	<u>20MG/ML</u>	<u>A074983</u>	<u>001</u>	Sep 30, 1998

<u>AP</u>	+	BEDFORD	<u>20MG/ML</u>	<u>A074290</u>	<u>001</u>	Jul 17, 1995

<u>AP</u>		PHARMACHEMIE	<u>20MG/ML</u>	<u>A074227</u>	<u>001</u>	Feb 22, 1996

<u>AP</u>		TEVA PARENTERAL	<u>20MG/ML</u>	<u>A074284</u>	<u>001</u>	Feb 10, 1994

<u>AP</u>			<u>20MG/ML</u>	<u>A074529</u>	<u>001</u>	Jul 24, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996

ETRAVIRINE

TABLET; ORAL

INTELENCE

+	TIBOTEC	100MG	N022187	001	Jan 18, 2008

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS	2.5MG	N022334	003	Jul 09, 2010

	5MG	N022334	001	Mar 30, 2009

+	10MG	N022334	002	Mar 30, 2009

ZORTRESS

NOVARTIS	0.25MG	N021560	001	Apr 20, 2010

	0.5MG	N021560	002	Apr 20, 2010

+	0.75MG	N021560	003	Apr 20, 2010

EXEMESTANE

TABLET; ORAL

AROMASIN

+	PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999

EXENATIDE SYNTHETIC

INJECTABLE; SUBCUTANEOUS

BYETTA

+	AMYLIN	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005

+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 170 (of 409)

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSP SINGAPORE	10MG	N021445	001	Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSP SINGAPORE	10MG;10MG	N021687	001	Jul 23, 2004
	10MG;20MG	N021687	002	Jul 23, 2004
	10MG;40MG	N021687	003	Jul 23, 2004
+	10MG;80MG	N021687	004	Jul 23, 2004

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

<u>AB</u> TEVA PHARMS	<u>125MG</u>	<u>A077487</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>	<u>250MG</u>	<u>A077487</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>	<u>500MG</u>	<u>A077487</u>	<u>003</u>	Aug 24, 2007

FAMVIR

<u>AB</u> NOVARTIS	<u>125MG</u>	<u>N020363</u>	<u>003</u>	Dec 11, 1995
<u>AB</u>	<u>250MG</u>	<u>N020363</u>	<u>001</u>	Apr 26, 1996
<u>AB</u> +	<u>500MG</u>	<u>N020363</u>	<u>002</u>	Jun 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u> LUPIN LTD	<u>40MG/5ML</u>	<u>A090440</u>	<u>001</u>	Jun 29, 2010
<u>AB</u> NAVINTA LLC	<u>40MG/5ML</u>	<u>A091020</u>	<u>001</u>	May 27, 2010

PEPCID

<u>AB</u> + SALIX PHARMS	<u>40MG/5ML</u>	<u>N019527</u>	<u>001</u>	Feb 02, 1987

INJECTABLE; INJECTION

FAMOTIDINE

<u>AP</u> AKORN STRIDES	<u>10MG/ML</u>	<u>A078641</u>	<u>001</u>	Jun 25, 2008
<u>AP</u> APP PHARMS	<u>10MG/ML</u>	<u>A075709</u>	<u>001</u>	Apr 16, 2001
<u>AP</u> + BAXTER HLTHCARE	<u>10MG/ML</u>	<u>A075488</u>	<u>001</u>	Apr 16, 2001
<u>AP</u> +	<u>10MG/ML</u>	<u>A075799</u>	<u>001</u>	Apr 30, 2002
<u>AP</u> BEDFORD	<u>10MG/ML</u>	<u>A075651</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	<u>10MG/ML</u>	<u>A075684</u>	<u>001</u>	Apr 16, 2001
<u>AP</u> HOSPIRA	<u>10MG/ML</u>	<u>A075870</u>	<u>001</u>	Nov 23, 2001

FAMOTIDINE PRESERVATIVE FREE

<u>AP</u> AKORN STRIDES	<u>10MG/ML</u>	<u>A078642</u>	<u>001</u>	Jun 25, 2008
<u>AP</u> APP PHARMS	<u>10MG/ML</u>	<u>A075813</u>	<u>001</u>	Apr 16, 2001
<u>AP</u> + BAXTER HLTHCARE	<u>10MG/ML</u>	<u>A075486</u>	<u>001</u>	Apr 16, 2001
<u>AP</u> +	<u>10MG/ML</u>	<u>A075789</u>	<u>001</u>	Apr 30, 2002
<u>AP</u> BEDFORD	<u>10MG/ML</u>	<u>A075622</u>	<u>001</u>	Apr 16, 2001
<u>AP</u> BEN VENUE	<u>10MG/ML</u>	<u>A075825</u>	<u>001</u>	Apr 17, 2001
<u>AP</u> CLARIS LIFESCIENCES	<u>10MG/ML</u>	<u>A076324</u>	<u>001</u>	Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

<u>AP</u> CLARIS LIFESCIENCES	<u>10MG/ML</u>	<u>A076322</u>	<u>001</u>	Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u> + BAXTER HLTHCARE	<u>0.4MG/ML</u>	<u>A075591</u>	<u>001</u>	May 10, 2001

PEPCID

<u>AP</u> + MERCK	<u>10MG/ML</u>	<u>N019510</u>	<u>001</u>	Nov 04, 1986

PEPCID PRESERVATIVE FREE

<u>AP</u> + MERCK	<u>10MG/ML</u>	<u>N019510</u>	<u>004</u>	Nov 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u> + MERCK	<u>0.4MG/ML</u>	<u>N020249</u>	<u>001</u>	Feb 18, 1994

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 171 (of 409)

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>20MG</u>	<u>A075650</u>	<u>001</u>	Sep 14, 2001
<u>AB</u>		<u>40MG</u>	<u>A075650</u>	<u>002</u>	Sep 14, 2001
<u>AB</u>	ALEMBIC LTD	<u>20MG</u>	<u>A078916</u>	<u>001</u>	May 22, 2009
<u>AB</u>		<u>40MG</u>	<u>A078916</u>	<u>002</u>	May 22, 2009
<u>AB</u>	APOTEX	<u>20MG</u>	<u>A075611</u>	<u>001</u>	Jul 23, 2001
<u>AB</u>		<u>40MG</u>	<u>A075611</u>	<u>002</u>	Jul 23, 2001
<u>AB</u>	CARLSBAD	<u>20MG</u>	<u>A075805</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	GENPHARM	<u>20MG</u>	<u>A075457</u>	<u>001</u>	Apr 18, 2001
<u>AB</u>		<u>40MG</u>	<u>A075457</u>	<u>002</u>	Apr 18, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A075704</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075704</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	PERRIGO	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A075607</u>	<u>001</u>	May 10, 2001
<u>AB</u>		<u>40MG</u>	<u>A075607</u>	<u>002</u>	May 10, 2001
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075311</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075311</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A075062</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075062</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>	WOCKHARDT	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001
	<u>PEPCID</u>				
<u>AB</u>	MERCK	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>	+	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS	40MG	N021856	001	Feb 13, 2009
+	80MG	N021856	002	Feb 13, 2009

FELBAMATE

SUSPENSION; ORAL

FELBATOL

+ MEDA PHARMS	600MG/5ML	N020189	003	Jul 29, 1993

TABLET; ORAL

FELBATOL

MEDA PHARMS	400MG	N020189	001	Jul 29, 1993
+	600MG	N020189	002	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A090365</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>5MG</u>	<u>A090365</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>10MG</u>	<u>A090365</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A075896</u>	<u>001</u>	Nov 02, 2004
<u>AB</u>		<u>5MG</u>	<u>A075896</u>	<u>002</u>	Nov 02, 2004
<u>AB</u>		<u>10MG</u>	<u>A075896</u>	<u>003</u>	Nov 02, 2004
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A078855</u>	<u>001</u>	Apr 17, 2008
<u>AB</u>		<u>5MG</u>	<u>A078855</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	+	<u>10MG</u>	<u>A078855</u>	<u>003</u>	Apr 17, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 172 (of 409)

FENOFIBRATE

CAPSULE; ORAL				
<u>FENOFIBRATE (MICRONIZED)</u>				
<u>AB</u>	IMPAX LABS	<u>67MG</u>	<u>A075868</u>	<u>001</u> Oct 27, 2003
<u>AB</u>		<u>134MG</u>	<u>A075868</u>	<u>002</u> Oct 27, 2003
<u>AB</u>		<u>200MG</u>	<u>A075868</u>	<u>003</u> Oct 27, 2003
<u>AB</u>	TEVA	<u>67MG</u>	<u>A075753</u>	<u>001</u> Sep 03, 2002
<u>AB</u>		<u>134MG</u>	<u>A075753</u>	<u>002</u> Apr 09, 2002
<u>AB</u>	+	<u>200MG</u>	<u>A075753</u>	<u>003</u> Apr 09, 2002
	ANTARA (MICRONIZED)			
	LUPIN ATLANTIS	43MG	N021695	001 Nov 30, 2004
	+	130MG	N021695	003 Nov 30, 2004
	LIPOFEN			
	CIPHER PHARMS INC	50MG	N021612	001 Jan 11, 2006
		100MG	N021612	002 Jan 11, 2006
	+	150MG	N021612	003 Jan 11, 2006
TABLET; ORAL				
<u>FENOFIBRATE</u>				
<u>AB</u>	IMPAX LABS	<u>54MG</u>	<u>A076509</u>	<u>001</u> Mar 26, 2008
<u>AB</u>		<u>160MG</u>	<u>A076509</u>	<u>002</u> Mar 26, 2008
<u>AB</u>	MYLAN	<u>54MG</u>	<u>A076520</u>	<u>001</u> Oct 25, 2007
<u>AB</u>		<u>160MG</u>	<u>A076520</u>	<u>003</u> Oct 25, 2007
<u>AB</u>	RANBAXY	<u>54MG</u>	<u>A076635</u>	<u>001</u> Oct 31, 2005
<u>AB</u>		<u>160MG</u>	<u>A076635</u>	<u>003</u> Oct 31, 2005
<u>AB</u>	TEVA	<u>54MG</u>	<u>A076433</u>	<u>001</u> May 13, 2005
<u>AB</u>	+	<u>160MG</u>	<u>A076433</u>	<u>002</u> May 13, 2005
	TRIGLIDE			
BX	+ SKYEPHARMA AG	160MG	N021350	002 May 07, 2005
	FENOFIBRATE			
	RANBAXY	107MG	A076635	002 Oct 31, 2005
	FENOGLIDE			
	SHIONOGI PHARMA	40MG	N022118	001 Aug 10, 2007
	+	120MG	N022118	002 Aug 10, 2007
	TRICOR			
	ABBOTT	48MG	N021656	001 Nov 05, 2004
	+	145MG	N021656	002 Nov 05, 2004
	TRIGLIDE			
	SKYEPHARMA AG	50MG	N021350	001 May 07, 2005

FENOFIBRIC ACID

TABLET; ORAL				
FIBRICOR				
	AR HOLDING CO INC	35MG	N022418	001 Aug 14, 2009
	+	105MG	N022418	002 Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION				
<u>CORLOPAM</u>				
<u>AP</u>	+ HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>N019922</u>	<u>001</u> Sep 23, 1997
<u>FENOLDOPAM MESYLATE</u>				
<u>AP</u>	BEDFORD LABS	<u>EQ 10MG BASE/ML</u>	<u>A076582</u>	<u>001</u> Oct 12, 2004
<u>AP</u>	SANDOZ	<u>EQ 10MG BASE/ML</u>	<u>A077155</u>	<u>001</u> Feb 15, 2005
<u>AP</u>	TEVA PARENTERAL	<u>EQ 10MG BASE/ML</u>	<u>A077826</u>	<u>001</u> Mar 07, 2007

FENOPROFEN CALCIUM

CAPSULE; ORAL				
NALFON				
	+	EQ 200MG BASE	N017604	003
		EQ 400MG BASE	N017604	004 Jul 21, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 173 (of 409)

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 600MG BASE</u>	<u>A072557</u>	<u>001</u>	Aug 29, 1988
<u>AB</u>	+ MYLAN	<u>EQ 600MG BASE</u>	<u>A072267</u>	<u>001</u>	Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>100MCG/HR</u>	<u>N019813</u>	<u>001</u>	Aug 07, 1990

DURAGESIC-12

<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>12.5MCG/HR</u>	<u>N019813</u>	<u>005</u>	Feb 04, 2005

DURAGESIC-25

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>25MCG/HR</u>	<u>N019813</u>	<u>004</u>	Aug 07, 1990

DURAGESIC-50

<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>50MCG/HR</u>	<u>N019813</u>	<u>003</u>	Aug 07, 1990

DURAGESIC-75

<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>75MCG/HR</u>	<u>N019813</u>	<u>002</u>	Aug 07, 1990

FENTANYL-100

<u>AB</u>	ACTAVIS	<u>100MCG/HR</u>	<u>A077062</u>	<u>004</u>	Aug 20, 2007

<u>AB</u>	LAVIPHARM LABS	<u>100MCG/HR</u>	<u>A077051</u>	<u>004</u>	Aug 04, 2006

<u>AB</u>	MYLAN TECHNOLOGIES	<u>100MCG/HR</u>	<u>A076258</u>	<u>004</u>	Jan 28, 2005

<u>AB</u>	NOVEN	<u>100MCG/HR</u>	<u>A077775</u>	<u>004</u>	Oct 16, 2009

<u>AB</u>	TEVA PHARMS	<u>100MCG/HR</u>	<u>A077449</u>	<u>004</u>	Oct 20, 2008

<u>AB</u>	WATSON LABS	<u>100MCG/HR</u>	<u>A076709</u>	<u>004</u>	Aug 20, 2007

FENTANYL-12

<u>AB</u>	MYLAN TECHNOLOGIES	<u>12.5MCG/HR</u>	<u>A076258</u>	<u>005</u>	Jan 23, 2007

FENTANYL-25

<u>AB</u>	ACTAVIS	<u>25MCG/HR</u>	<u>A077062</u>	<u>001</u>	Aug 20, 2007

<u>AB</u>	LAVIPHARM LABS	<u>25MCG/HR</u>	<u>A077051</u>	<u>001</u>	Aug 04, 2006

<u>AB</u>	MYLAN TECHNOLOGIES	<u>25MCG/HR</u>	<u>A076258</u>	<u>001</u>	Jan 28, 2005

<u>AB</u>	NOVEN	<u>25MCG/HR</u>	<u>A077775</u>	<u>001</u>	Oct 16, 2009

<u>AB</u>	TEVA PHARMS	<u>25MCG/HR</u>	<u>A077449</u>	<u>001</u>	Oct 20, 2008

<u>AB</u>	WATSON LABS	<u>25MCG/HR</u>	<u>A076709</u>	<u>001</u>	Aug 20, 2007

FENTANYL-50

<u>AB</u>	ACTAVIS	<u>50MCG/HR</u>	<u>A077062</u>	<u>002</u>	Aug 20, 2007

<u>AB</u>	LAVIPHARM LABS	<u>50MCG/HR</u>	<u>A077051</u>	<u>002</u>	Aug 04, 2006

<u>AB</u>	MYLAN TECHNOLOGIES	<u>50MCG/HR</u>	<u>A076258</u>	<u>002</u>	Jan 28, 2005

<u>AB</u>	NOVEN	<u>50MCG/HR</u>	<u>A077775</u>	<u>002</u>	Oct 16, 2009

<u>AB</u>	TEVA PHARMS	<u>50MCG/HR</u>	<u>A077449</u>	<u>002</u>	Oct 20, 2008

<u>AB</u>	WATSON LABS	<u>50MCG/HR</u>	<u>A076709</u>	<u>002</u>	Aug 20, 2007

FENTANYL-75

<u>AB</u>	ACTAVIS	<u>75MCG/HR</u>	<u>A077062</u>	<u>003</u>	Aug 20, 2007

<u>AB</u>	LAVIPHARM LABS	<u>75MCG/HR</u>	<u>A077051</u>	<u>003</u>	Aug 04, 2006

<u>AB</u>	MYLAN TECHNOLOGIES	<u>75MCG/HR</u>	<u>A076258</u>	<u>003</u>	Jan 28, 2005

<u>AB</u>	NOVEN	<u>75MCG/HR</u>	<u>A077775</u>	<u>003</u>	Oct 16, 2009

<u>AB</u>	TEVA PHARMS	<u>75MCG/HR</u>	<u>A077449</u>	<u>003</u>	Oct 20, 2008

<u>AB</u>	WATSON LABS	<u>75MCG/HR</u>	<u>A076709</u>	<u>003</u>	Aug 20, 2007

FENTANYL CITRATE

FILM; BUCCAL

ONSOLIS

MEDA PHARMS

	EQ 0.2MG BASE	N022266	001	Jul 16, 2009

+	EQ 0.4MG BASE	N022266	002	Jul 16, 2009

	EQ 0.6MG BASE	N022266	003	Jul 16, 2009

	EQ 0.8MG BASE	N022266	004	Jul 16, 2009

	EQ 1.2MG BASE	N022266	005	Jul 16, 2009

INJECTABLE; INJECTION

FENTANYL CITRATE

<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>N019115</u>	<u>001</u>	Jan 12, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 174 (of 409)

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 0.05MG BASE/ML</u>	<u>N019101</u>	<u>001</u>	Jul 11, 1984
<u>AP</u>		HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A072786</u>	<u>001</u>	Sep 24, 1991
<u>SUBLIMAZE PRESERVATIVE FREE</u>						
<u>AP</u>	+	AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N016619</u>	<u>001</u>	

TABLET; BUCCAL

FENTANYL CITRATE

<u>AB</u>		WATSON LABS	<u>EQ 0.1MG BASE</u>	<u>A079075</u>	<u>001</u>	Jan 07, 2011
<u>AB</u>			<u>EQ 0.2MG BASE</u>	<u>A079075</u>	<u>002</u>	Jan 07, 2011
<u>AB</u>			<u>EQ 0.4MG BASE</u>	<u>A079075</u>	<u>003</u>	Jan 07, 2011
<u>AB</u>			<u>EQ 0.6MG BASE</u>	<u>A079075</u>	<u>004</u>	Jan 07, 2011
<u>AB</u>			<u>EQ 0.8MG BASE</u>	<u>A079075</u>	<u>005</u>	Jan 07, 2011
<u>FENTORA</u>						
<u>AB</u>		CEPHALON	<u>EQ 0.1MG BASE</u>	<u>N021947</u>	<u>001</u>	Sep 25, 2006
<u>AB</u>			<u>EQ 0.2MG BASE</u>	<u>N021947</u>	<u>002</u>	Sep 25, 2006
<u>AB</u>	+		<u>EQ 0.4MG BASE</u>	<u>N021947</u>	<u>003</u>	Sep 25, 2006
<u>AB</u>			<u>EQ 0.6MG BASE</u>	<u>N021947</u>	<u>004</u>	Sep 25, 2006
<u>AB</u>			<u>EQ 0.8MG BASE</u>	<u>N021947</u>	<u>005</u>	Sep 25, 2006

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

<u>AB</u>		CEPHALON	<u>EQ 0.2MG BASE</u>	<u>N020747</u>	<u>001</u>	Nov 04, 1998
<u>AB</u>	+		<u>EQ 0.4MG BASE</u>	<u>N020747</u>	<u>002</u>	Nov 04, 1998
<u>AB</u>			<u>EQ 0.6MG BASE</u>	<u>N020747</u>	<u>003</u>	Nov 04, 1998
<u>AB</u>			<u>EQ 0.8MG BASE</u>	<u>N020747</u>	<u>004</u>	Nov 04, 1998
<u>AB</u>			<u>EQ 1.2MG BASE</u>	<u>N020747</u>	<u>005</u>	Nov 04, 1998
<u>AB</u>			<u>EQ 1.6MG BASE</u>	<u>N020747</u>	<u>006</u>	Nov 04, 1998

FENTANYL CITRATE

<u>AB</u>		BARR	<u>EQ 0.2MG BASE</u>	<u>A077312</u>	<u>001</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.4MG BASE</u>	<u>A077312</u>	<u>002</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.6MG BASE</u>	<u>A077312</u>	<u>003</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.8MG BASE</u>	<u>A077312</u>	<u>004</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 1.2MG BASE</u>	<u>A077312</u>	<u>005</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 1.6MG BASE</u>	<u>A077312</u>	<u>006</u>	Oct 30, 2009
<u>AB</u>		MALLINCKRODT	<u>EQ 0.2MG BASE</u>	<u>A078907</u>	<u>001</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.4MG BASE</u>	<u>A078907</u>	<u>002</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.6MG BASE</u>	<u>A078907</u>	<u>003</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.8MG BASE</u>	<u>A078907</u>	<u>004</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 1.2MG BASE</u>	<u>A078907</u>	<u>005</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 1.6MG BASE</u>	<u>A078907</u>	<u>006</u>	Oct 30, 2009

FERRIC HEXACYANOFERRATE(II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

+	AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996

FERUMOXSIIL

SUSPENSION; ORAL

GASTROMARK

+	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 175 (of 409)

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

+	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

TOVIAZ

	PFIZER	4MG	N022030	001	Oct 31, 2008
+		8MG	N022030	002	Oct 31, 2008

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006

TABLET; ORAL

ALLEGRA

<u>AB</u>	SANOFI AVENTIS US	<u>30MG</u>	<u>N020872</u>	<u>001</u>	Feb 25, 2000
<u>AB</u>		<u>60MG</u>	<u>N020872</u>	<u>002</u>	Feb 25, 2000
<u>AB</u>	+	<u>180MG</u>	<u>N020872</u>	<u>004</u>	Feb 25, 2000

FEXOFENADINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>30MG</u>	<u>A076191</u>	<u>001</u>	Aug 31, 2005
<u>AB</u>		<u>60MG</u>	<u>A076191</u>	<u>002</u>	Aug 31, 2005
<u>AB</u>		<u>180MG</u>	<u>A076191</u>	<u>003</u>	Aug 31, 2005
<u>AB</u>	DR REDDYS LABS LTD	<u>30MG</u>	<u>A076502</u>	<u>001</u>	Apr 11, 2006
<u>AB</u>		<u>60MG</u>	<u>A076502</u>	<u>002</u>	Apr 11, 2006
<u>AB</u>		<u>180MG</u>	<u>A076502</u>	<u>003</u>	Apr 11, 2006
<u>AB</u>	MYLAN	<u>30MG</u>	<u>A077081</u>	<u>002</u>	Apr 11, 2008
<u>AB</u>		<u>60MG</u>	<u>A077081</u>	<u>003</u>	Apr 11, 2008
<u>AB</u>		<u>180MG</u>	<u>A077081</u>	<u>001</u>	Apr 16, 2007
<u>AB</u>	TEVA	<u>30MG</u>	<u>A076447</u>	<u>001</u>	Sep 01, 2005
<u>AB</u>		<u>60MG</u>	<u>A076447</u>	<u>002</u>	Sep 01, 2005
<u>AB</u>		<u>180MG</u>	<u>A076447</u>	<u>003</u>	Sep 01, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

ALLEGRA

+	SANOFI AVENTIS US	30MG	N021909	001	Jul 26, 2007

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA D 24 HOUR

<u>AB</u>	+	SANOFI AVENTIS US	<u>180MG;240MG</u>	<u>N021704</u>	<u>001</u>	Oct 19, 2004

ALLEGRA-D 12 HOUR

<u>AB</u>	+	SANOFI AVENTIS US	<u>60MG;120MG</u>	<u>N020786</u>	<u>001</u>	Dec 24, 1997

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>60MG;120MG</u>	<u>A076236</u>	<u>001</u>	Apr 14, 2005
<u>AB</u>	DR REDDYS LABS LTD	<u>180MG;240MG</u>	<u>A079043</u>	<u>001</u>	Mar 17, 2010
<u>AB</u>	IMPAX PHARMS	<u>60MG;120MG</u>	<u>A076298</u>	<u>001</u>	Nov 12, 2010

FINASTERIDE

TABLET; ORAL

FINASTERIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>5MG</u>	<u>A090121</u>	<u>001</u>	Feb 23, 2010
<u>AB</u>	ACTAVIS TOTOWA	<u>5MG</u>	<u>A077914</u>	<u>001</u>	Mar 28, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078341</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>	DR REDDYS LABS INC	<u>1MG</u>	<u>A076436</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076437</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>	GEDEON RICHTER USA	<u>5MG</u>	<u>A077251</u>	<u>001</u>	Dec 22, 2006
<u>AB</u>	HETERO DRUGS LTD	<u>5MG</u>	<u>A090061</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077578</u>	<u>001</u>	Dec 18, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 176 (of 409)

FINASTERIDE

TABLET; ORAL

FINASTERIDE

<u>AB</u>	TEVA	<u>5MG</u>	<u>A076511</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078900</u>	<u>001</u>	Dec 28, 2009
<u>PROPECIA</u>					
<u>AB</u>	+ MERCK	<u>1MG</u>	<u>N020788</u>	<u>001</u>	Dec 19, 1997
<u>PROSCAR</u>					
<u>AB</u>	+ MERCK	<u>5MG</u>	<u>N020180</u>	<u>001</u>	Jun 19, 1992

FINGOLIMOD

CAPSULE; ORAL

GILENYA

	+ NOVARTIS	0.5MG	N022527	001	Sep 21, 2010

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>100MG</u>	<u>A076835</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	IMPAX PHARMS	<u>100MG</u>	<u>A076234</u>	<u>001</u>	Aug 28, 2003
<u>AB</u>	PADDOCK	<u>100MG</u>	<u>A076831</u>	<u>001</u>	Dec 16, 2004

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A075442</u>	<u>001</u>	Jul 31, 2001
<u>AB</u>		<u>100MG</u>	<u>A075442</u>	<u>002</u>	Jul 31, 2001
<u>AB</u>		<u>150MG</u>	<u>A075442</u>	<u>003</u>	Jul 31, 2001
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A079164</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>100MG</u>	<u>A079164</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>		<u>150MG</u>	<u>A079164</u>	<u>003</u>	Jul 09, 2009
<u>AB</u>	BARR	<u>50MG</u>	<u>A075882</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>		<u>100MG</u>	<u>A075882</u>	<u>002</u>	Oct 28, 2002
<u>AB</u>		<u>150MG</u>	<u>A075882</u>	<u>003</u>	Oct 28, 2002
<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076421</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>		<u>100MG</u>	<u>A076421</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>		<u>150MG</u>	<u>A076421</u>	<u>003</u>	Mar 28, 2003
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A076278</u>	<u>001</u>	Jan 14, 2003
<u>AB</u>		<u>100MG</u>	<u>A076278</u>	<u>002</u>	Jan 14, 2003
<u>AB</u>		<u>150MG</u>	<u>A076278</u>	<u>003</u>	Jan 14, 2003
<u>TAMBOCOR</u>					
<u>AB</u>	GRACEWAY	<u>50MG</u>	<u>N018830</u>	<u>004</u>	Aug 23, 1988
<u>AB</u>		<u>100MG</u>	<u>N018830</u>	<u>001</u>	Oct 31, 1985
<u>AB</u>	+	<u>150MG</u>	<u>N018830</u>	<u>003</u>	Jun 03, 1988

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

<u>AP</u>	APP PHARMS	<u>500MG/VIAL</u>	<u>A075837</u>	<u>001</u>	Feb 22, 2001
<u>AP</u>	+ BEDFORD	<u>500MG/VIAL</u>	<u>A075387</u>	<u>001</u>	Apr 16, 2000

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

<u>AB</u>	PFIZER	<u>50MG/5ML</u>	<u>N020090</u>	<u>001</u>	Dec 23, 1993
<u>AB</u>	+	<u>200MG/5ML</u>	<u>N020090</u>	<u>002</u>	Dec 23, 1993
<u>FLUCONAZOLE</u>					
<u>AB</u>	AUROBINDO PHARM	<u>50MG/5ML</u>	<u>A079150</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>		<u>200MG/5ML</u>	<u>A079150</u>	<u>002</u>	Sep 18, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG/5ML</u>	<u>A077523</u>	<u>001</u>	Sep 12, 2007

PRESCRIPTION DRUG PRODUCT LIST

3 - 177 (of 409)

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>200MG/5ML</u>	<u>A077523</u>	<u>002</u>	Sep 12, 2007
<u>AB</u>	RANBAXY	<u>50MG/5ML</u>	<u>A076332</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>200MG/5ML</u>	<u>A076332</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>	ROXANE	<u>50MG/5ML</u>	<u>A076246</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>200MG/5ML</u>	<u>A076246</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>	TARO PHARM INDS	<u>50MG/5ML</u>	<u>A076918</u>	<u>001</u>	Dec 18, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A076918</u>	<u>002</u>	Dec 18, 2006

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>003</u>	Sep 29, 1992
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>005</u>	Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>001</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>006</u>	Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>002</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>004</u>	Jan 29, 1990

FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		ACS DOBFAR INFO SA	<u>200MG/100ML (2MG/ML)</u>	<u>A079104</u>	<u>001</u>	Jul 30, 2009
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A079104</u>	<u>002</u>	Jul 30, 2009

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		APOTEX INC	<u>200MG/100ML (2MG/ML)</u>	<u>A076888</u>	<u>001</u>	Mar 25, 2005
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A076888</u>	<u>002</u>	Mar 25, 2005
<u>AP</u>		HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076304</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A076304</u>	<u>002</u>	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

<u>AP</u>		APP PHARMS	<u>200MG/100ML (2MG/ML)</u>	<u>A076145</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A076145</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>		BEDFORD	<u>200MG/100ML (2MG/ML)</u>	<u>A076087</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A076087</u>	<u>003</u>	Jul 29, 2004
<u>AP</u>		CLARIS LIFESCIENCES	<u>200MG/100ML (2MG/ML)</u>	<u>A077947</u>	<u>001</u>	May 26, 2010
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A077947</u>	<u>002</u>	May 26, 2010
<u>AP</u>		HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A076736</u>	<u>001</u>	Aug 23, 2005
<u>AP</u>		TEVA PARENTERAL	<u>200MG/100ML (2MG/ML)</u>	<u>A076653</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A076653</u>	<u>002</u>	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE	<u>200MG/100ML (2MG/ML)</u>	<u>A076766</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A076766</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>		BEDFORD LABS	<u>200MG/100ML (2MG/ML)</u>	<u>A078107</u>	<u>001</u>	Jul 30, 2008
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A078107</u>	<u>002</u>	Jul 30, 2008
<u>AP</u>		CLARIS LIFESCIENCES	<u>200MG/100ML (2MG/ML)</u>	<u>A077909</u>	<u>001</u>	May 26, 2010
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A077909</u>	<u>002</u>	May 26, 2010
<u>AP</u>		HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076303</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A076303</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>		TEVA PARENTERAL	<u>200MG/100ML (2MG/ML)</u>	<u>A076837</u>	<u>001</u>	Jan 13, 2005
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A076837</u>	<u>002</u>	Jan 13, 2005

FULCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		CLARIS LIFESCIENCES	<u>200MG/100ML (2MG/ML)</u>	<u>A077988</u>	<u>001</u>	May 26, 2010
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A077988</u>	<u>002</u>	May 26, 2010

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		BEDFORD	<u>100MG/50ML (2MG/ML)</u>	<u>A076087</u>	<u>002</u>	Sep 26, 2008

TABLET; ORAL

DIFLUCAN

<u>AB</u>		PFIZER	<u>50MG</u>	<u>N019949</u>	<u>001</u>	Jan 29, 1990
<u>AB</u>			<u>100MG</u>	<u>N019949</u>	<u>002</u>	Jan 29, 1990
<u>AB</u>			<u>150MG</u>	<u>N019949</u>	<u>004</u>	Jun 30, 1994
<u>AB</u>	+		<u>200MG</u>	<u>N019949</u>	<u>003</u>	Jan 29, 1990

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 178 (of 409)

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

<u>AB</u>	APOTEX	<u>50MG</u>	<u>A076665</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076665</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076665</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076665</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>50MG</u>	<u>A077731</u>	<u>001</u>	Oct 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A077731</u>	<u>002</u>	Oct 07, 2008
<u>AB</u>		<u>150MG</u>	<u>A077731</u>	<u>003</u>	Oct 07, 2008
<u>AB</u>		<u>200MG</u>	<u>A077731</u>	<u>004</u>	Oct 07, 2008
<u>AB</u>	GENPHARM	<u>50MG</u>	<u>A076042</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076042</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076042</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076042</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	GLENMARK GENERICS	<u>50MG</u>	<u>A077253</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>		<u>100MG</u>	<u>A077253</u>	<u>002</u>	Jan 25, 2006
<u>AB</u>		<u>150MG</u>	<u>A077253</u>	<u>003</u>	Jan 25, 2006
<u>AB</u>		<u>200MG</u>	<u>A077253</u>	<u>004</u>	Jan 25, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A076077</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076077</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076077</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076077</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A076351</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076351</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076351</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076351</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076386</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076386</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076386</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076386</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TARO	<u>50MG</u>	<u>A076507</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076507</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076507</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076507</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074681</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A074681</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A074681</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A074681</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>50MG</u>	<u>A076957</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076957</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>		<u>200MG</u>	<u>A076957</u>	<u>003</u>	Sep 28, 2005
<u>FLUCONAZOLE</u>					
BX	DR REDDYS LABS INC	50MG	A076658	001	Jul 29, 2004
BX		100MG	A076658	002	Jul 29, 2004
BX		150MG	A076658	003	Jul 29, 2004
BX		200MG	A076658	004	Jul 29, 2004
BX	PLIVA	50MG	A076424	001	Jul 29, 2004
BX		100MG	A076424	002	Jul 29, 2004
BX		150MG	A076424	003	Jul 29, 2004
BX		200MG	A076424	004	Jul 29, 2004

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

VALEANT

+

250MG

500MG

N017001 001

N017001 002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 179 (of 409)

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

<u>AP</u>	+ GENZYME	<u>50MG/VIAL</u>	<u>N020038</u>	<u>001</u>	Apr 18, 1991
<u>FLUDARABINE PHOSPHATE</u>					
<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078610</u>	<u>001</u>	Feb 11, 2009
<u>AP</u>	APP PHARMS	<u>50MG/2ML (25MG/ML)</u>	<u>A078393</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078544</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>	BIONICHE PHARMA USA	<u>50MG/2ML (25MG/ML)</u>	<u>A090724</u>	<u>001</u>	Sep 27, 2010
<u>AP</u>	HOSPIRA	<u>50MG/VIAL</u>	<u>A077790</u>	<u>001</u>	Apr 06, 2007
<u>AP</u>	+ SANDOZ	<u>50MG/2ML (25MG/ML)</u>	<u>N022137</u>	<u>001</u>	Sep 21, 2007
<u>AP</u>	TEVA PARENTERAL	<u>50MG/VIAL</u>	<u>A076349</u>	<u>001</u>	Aug 28, 2003
<u>AP</u>	+	<u>50MG/2ML (25MG/ML)</u>	<u>A076661</u>	<u>001</u>	Apr 28, 2004

TABLET; ORAL

OFORTA

+	SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F 18

+	WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004
FLUDEOXYGLUCOSE F18					
+	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005
+		20-300mCi/ML	N021870	002	Nov 21, 2008

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	+ IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	AKORN STRIDES	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078595</u>	<u>002</u>	May 13, 2008
<u>AP</u>	APP PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	BAXTER HLTHCARE	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	BEDFORD LABS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	CLARIS LIFESCIENCES	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076755</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076755</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	SANDOZ	<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>	TEVA PARENTERAL	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076589</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076589</u>	<u>001</u>	Oct 12, 2004
<u>ROMAZICON</u>					
<u>AP</u>	+ HOFFMANN LA ROCHE	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020073</u>	<u>001</u>	Dec 20, 1991
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>N020073</u>	<u>002</u>	Dec 20, 1991

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

+	ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984

PRESCRIPTION DRUG PRODUCT LIST

3 - 180 (of 409)

FLUNISOLIDE

AEROSOL, METERED; INHALATION					
AEROSPAN HFA					
	+ ACTON PHARMS	EQ 78MCG BASE/INH	N021247	001	Jan 27, 2006
SPRAY, METERED; NASAL					
<u>FLUNISOLIDE</u>					
<u>AB</u>	+ BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	QPHARMA	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006
FLUNISOLIDE					
	+ APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL					
<u>FLUOCINOLONE ACETONIDE</u>					
<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982
<u>SYNALAR</u>					
<u>AT</u>	+ MEDICIS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>005</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>002</u>	
IMPLANT; INTRAVITREAL					
RETISERT					
	+ BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005
OIL; TOPICAL					
DERMA-SMOOTH/FS					
	+ HILL DERMAC	0.01%	N019452	002	Nov 09, 2005
	+	0.01%	N019452	001	Feb 03, 1988
OIL/DROPS; OTIC					
	+ HILL DERMAC	0.01%	N019452	003	Nov 09, 2005
OINTMENT; TOPICAL					
<u>FLUOCINOLONE ACETONIDE</u>					
<u>AT</u>	FOUGERA	<u>0.025%</u>	<u>A088168</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.025%</u>	<u>A040041</u>	<u>001</u>	Sep 15, 1994
<u>SYNALAR</u>					
<u>AT</u>	+ MEDICIS	<u>0.025%</u>	<u>N013960</u>	<u>001</u>	
SHAMPOO; TOPICAL					
CAPEX					
	+ GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990
SOLUTION; TOPICAL					
<u>FLUOCINOLONE ACETONIDE</u>					
<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088167</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.01%</u>	<u>A089124</u>	<u>001</u>	Sep 11, 1985
<u>SYNALAR</u>					
<u>AT</u>	+ MEDICIS	<u>0.01%</u>	<u>N015296</u>	<u>001</u>	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL					
TRI-LUMA					
	+ GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002

FLUOCINONIDE

CREAM; TOPICAL					
<u>FLUOCINONIDE</u>					
<u>AB1</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A073085</u>	<u>001</u>	Feb 14, 1992
<u>AB1</u>	FOUGERA	<u>0.05%</u>	<u>A073030</u>	<u>001</u>	Oct 17, 1994
<u>AB1</u>	TARO	<u>0.05%</u>	<u>N019117</u>	<u>001</u>	Jun 26, 1984

PRESCRIPTION DRUG PRODUCT LIST

3 - 181 (of 409)

FLUOCINONIDE

CREAM; TOPICAL				
<u>FLUOCINONIDE</u>				
<u>AB1</u>	TEVA	<u>0.05%</u>	<u>A072488</u>	<u>001</u> Feb 06, 1989
<u>LIDEX</u>				
<u>AB1</u> +	MEDICIS	<u>0.05%</u>	<u>N016908</u>	<u>002</u>
<u>FLUOCINONIDE EMULSIFIED BASE</u>				
<u>AB2</u>	ALTANA	<u>0.05%</u>	<u>A076586</u>	<u>001</u> Jun 23, 2004
<u>AB2</u>	TARO	<u>0.05%</u>	<u>A072494</u>	<u>001</u> Jan 19, 1989
<u>AB2</u>	TEVA	<u>0.05%</u>	<u>A072490</u>	<u>001</u> Feb 07, 1989
<u>LIDEX-E</u>				
<u>AB2</u> +	MEDICIS	<u>0.05%</u>	<u>N016908</u>	<u>003</u>
	VANOS			
	+ MEDICIS	0.1%	N021758	001 Feb 11, 2005
GEL; TOPICAL				
<u>FLUOCINONIDE</u>				
<u>AB</u>	FOUGERA	<u>0.05%</u>	<u>A072933</u>	<u>001</u> Dec 30, 1994
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074935</u>	<u>001</u> Jul 29, 1997
<u>AB</u>	TEVA	<u>0.05%</u>	<u>A072537</u>	<u>001</u> Feb 07, 1989
<u>LIDEX</u>				
<u>AB</u> +	MEDICIS	<u>0.05%</u>	<u>N017373</u>	<u>001</u>
OINTMENT; TOPICAL				
<u>FLUOCINONIDE</u>				
<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A074905</u>	<u>001</u> Aug 26, 1997
<u>AB</u>	TARO	<u>0.05%</u>	<u>A075008</u>	<u>001</u> Jun 30, 1999
<u>AB</u>	TEVA	<u>0.05%</u>	<u>A073481</u>	<u>001</u> Dec 27, 1991
<u>LIDEX</u>				
<u>AB</u> +	MEDICIS	<u>0.05%</u>	<u>N016909</u>	<u>002</u>
SOLUTION; TOPICAL				
<u>FLUOCINONIDE</u>				
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A071535</u>	<u>001</u> Dec 02, 1988
<u>AT</u>	FOUGERA	<u>0.05%</u>	<u>A072934</u>	<u>001</u> Feb 27, 1995
<u>AT</u>	TARO	<u>0.05%</u>	<u>A074799</u>	<u>001</u> Dec 31, 1996
<u>AT</u>	TEVA	<u>0.05%</u>	<u>A072511</u>	<u>001</u> Feb 07, 1989
<u>LIDEX</u>				
<u>AT</u> +	MEDICIS	<u>0.05%</u>	<u>N018849</u>	<u>001</u> Apr 06, 1984

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS				
<u>AK-FLUOR 10%</u>				
<u>AP</u>	AKORN	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N022186</u>	<u>001</u> Aug 08, 2008
<u>FLUORESCITE</u>				
<u>AP</u> +	ALCON	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N021980</u>	<u>001</u> Mar 28, 2006

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC				
FML				
	+ ALLERGAN	0.1%	N017760	001 Sep 04, 1985
SUSPENSION/DROPS; OPHTHALMIC				
FML				
	+ ALLERGAN	0.1%	N016851	002 Jul 28, 1982
FML FORTE				
	ALLERGAN	0.25%	N019216	001 Apr 23, 1986

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC				
	+ ALCON	0.1%	N019079	001 Feb 11, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 182 (of 409)

FLUOROURACIL

CREAM; TOPICAL

EFUDEXAB + VALEANT PHARM INTL 5%N016831 003FLUOROURACILAB SPEAR PHARMS 5%A077524 001 Apr 11, 2008AB TARO 5%A090368 001 Mar 05, 2010

CARAC

+ SANOFI AVENTIS US 0.5%

N020985 001 Oct 27, 2000

FLUOROPLEX

+ ALLERGAN HERBERT 1%

N016988 001

INJECTABLE; INJECTION

FLUOROURACILAP + APP PHARMS 500MG/10ML (50MG/ML)A040279 002 Sep 30, 1998AP + 1GM/20ML (50MG/ML)A040279 001 Sep 30, 1998AP + 2.5GM/50ML (50MG/ML)A040278 001 Sep 30, 1998AP + 5GM/100ML (50MG/ML)A040278 002 Sep 30, 1998AP + BIONICHE PHARMA 500MG/10ML (50MG/ML)A040743 002 Apr 26, 2007AP + 1GM/20ML (50MG/ML)A040743 001 Apr 26, 2007AP + 2.5GM/50ML (50MG/ML)A040798 002 Apr 26, 2007AP + 5GM/100ML (50MG/ML)A040798 001 Apr 26, 2007AP EBEWE PHARMA 500MG/10ML (50MG/ML)A040772 001 Aug 11, 2008AP + TEVA PARENTERAL 500MG/10ML (50MG/ML)A040333 001 Jan 27, 2000AP + 2.5GM/50ML (50MG/ML)A040334 001 Feb 25, 2000AP + 5GM/100ML (50MG/ML)A040334 002 Feb 25, 2000AP + VALEANT 500MG/10ML (50MG/ML)N012209 001

SOLUTION; TOPICAL

EFUDEXAT + VALEANT PHARM INTL 2%N016831 001AT + 5%N016831 002FLUOROURACILAT TARO 2%A076526 001 Nov 05, 2003AT 5%A076526 002 Nov 05, 2003FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDEAB ALEMBIC LTD EQ 40MG BASEA090223 003 Mar 19, 2009AB AUROBINDO PHARMA EQ 40MG BASEA078619 003 Jan 31, 2008AB DR REDDYS LABS INC EQ 40MG BASEA075465 003 Aug 02, 2001AB IVAX SUB TEVA PHARMS EQ 40MG BASEA075245 003 Sep 28, 2004AB MYLAN EQ 40MG BASEA075207 003 May 25, 2007AB RANBAXY EQ 40MG BASEA076990 001 Dec 13, 2004AB SANDOZ EQ 40MG BASEA075049 003 Jan 29, 2002AB TEVA EQ 40MG BASEA075452 003 Jan 29, 2002AB WOCKHARDT EQ 40MG BASEA078143 003 Jan 16, 2008PROZACAB + LILLY EQ 40MG BASEN018936 003 Jun 15, 1999FLUOXETINE HYDROCHLORIDEAB1 ALEMBIC LTD EQ 10MG BASEA090223 001 Mar 19, 2009AB1 EQ 20MG BASEA090223 002 Mar 19, 2009AB1 ALPHAPHARM EQ 10MG BASEA075577 001 Jan 29, 2002AB1 EQ 20MG BASEA075577 002 Jan 29, 2002AB1 AUROBINDO PHARMA EQ 10MG BASEA078619 001 Jan 31, 2008AB1 EQ 20MG BASEA078619 002 Jan 31, 2008AB1 BARR EQ 10MG BASEA074803 002 Jan 30, 2002AB1 EQ 20MG BASEA074803 001 Aug 02, 2001AB1 BEIJING DOUBLE CRANE EQ 10MG BASEA076165 001 Feb 01, 2002AB1 EQ 20MG BASEA076165 002 Feb 01, 2002AB1 CARLSBAD EQ 10MG BASEA076022 001 Jan 30, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 183 (of 409)

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	CARLSBAD	<u>EQ 20MG BASE</u>	<u>A076022</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A075465</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075465</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245</u>	<u>002</u>	Jan 31, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075245</u>	<u>001</u>	Jan 31, 2002
<u>AB1</u>	LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075464</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	MALLINCKRODT	<u>EQ 10MG BASE</u>	<u>A075658</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075658</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075207</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075207</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	PLIVA	<u>EQ 10MG BASE</u>	<u>A076001</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076001</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A075049</u>	<u>001</u>	Aug 02, 2001
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075049</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075452</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075452</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	WOCKHARDT	<u>EQ 10MG BASE</u>	<u>A078143</u>	<u>001</u>	Jan 16, 2008
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A078143</u>	<u>002</u>	Jan 16, 2008

PROZAC

<u>AB1</u>	LILLY	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>006</u>	Dec 23, 1992
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>001</u>	Dec 29, 1987

FLUOXETINE HYDROCHLORIDE

<u>AB2</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078045</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A078045</u>	<u>002</u>	Nov 17, 2008
<u>AB2</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A077469</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A077469</u>	<u>002</u>	Nov 17, 2008
<u>AB2</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076287</u>	<u>001</u>	May 20, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A076287</u>	<u>002</u>	May 20, 2008

SARAFEM

<u>AB2</u>	LILLY	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>007</u>	Jul 06, 2000
<u>AB2</u> +		<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>008</u>	Jul 06, 2000

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 90MG BASE</u>	<u>A076237</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572</u>	<u>001</u>	Mar 22, 2010
<u>PROZAC WEEKLY</u>					
<u>AB</u> +	LILLY	<u>EQ 90MG BASE</u>	<u>N021235</u>	<u>001</u>	Feb 26, 2001

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARM	<u>EQ 20MG BASE/5ML</u>	<u>A079209</u>	<u>001</u>	Mar 20, 2009
<u>AA</u>	LANNETT	<u>EQ 20MG BASE/5ML</u>	<u>A076458</u>	<u>001</u>	May 14, 2004
<u>AA</u>	MALLINCKRODT	<u>EQ 20MG BASE/5ML</u>	<u>A075920</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>	NOVEX	<u>EQ 20MG BASE/5ML</u>	<u>A075292</u>	<u>001</u>	Feb 07, 2002
<u>AA</u> +	PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015</u>	<u>001</u>	Jan 30, 2002
<u>AA</u>	SILARX	<u>EQ 20MG BASE/5ML</u>	<u>A077849</u>	<u>001</u>	Feb 09, 2007
<u>AA</u>	TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506</u>	<u>001</u>	Aug 02, 2001
<u>AA</u>	WOCKHARDT	<u>EQ 20MG BASE/5ML</u>	<u>A075514</u>	<u>001</u>	Aug 29, 2002

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A076006</u>	<u>001</u>	Jan 30, 2002
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075755</u>	<u>001</u>	Aug 02, 2001
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075872</u>	<u>001</u>	Jan 29, 2002
<u>FLUOXETINE HYDROCHLORIDE</u>					
+	MYLAN	EQ 20MG BASE	A075755	002	Aug 02, 2001
<u>SARAFEM</u>					
	WARNER CHILCOTT	EQ 10MG BASE	N021860	001	May 19, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 184 (of 409)

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL
SARAFEM

WARNER CHILCOTT	EQ 15MG BASE	N021860 002	May 19, 2006
+	EQ 20MG BASE	N021860 003	May 19, 2006

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL
SYMBYAX
LILLY

	EQ 25MG BASE;EQ 3MG BASE	N021520 001	Apr 09, 2007
	EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003
	EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003
+	EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003
	EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003

FLUOXYMESTERONE

TABLET; ORAL
FLUOXYMESTERONE
+ USL PHARMA

	10MG	A088342 001	Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

<u>A0</u>	APP PHARMS	<u>25MG/ML</u>	<u>A071413 001</u>	Jul 14, 1987
<u>A0</u>	+	<u>25MG/ML</u>	<u>A074531 001</u>	Aug 30, 1996
<u>A0</u>	CLARIS LIFESCIENCES	<u>25MG/ML</u>	<u>A075918 001</u>	Aug 17, 2001
<u>A0</u>	TEVA PARENTERAL	<u>25MG/ML</u>	<u>A074795 001</u>	Sep 10, 1996

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
FLUPHENAZINE HYDROCHLORIDE

+	PHARM ASSOC	5MG/ML	A074725 001	Sep 16, 1996

ELIXIR; ORAL
FLUPHENAZINE HYDROCHLORIDE

+	PHARM ASSOC	2.5MG/5ML	A040146 001	Aug 21, 1996

INJECTABLE; INJECTION
FLUPHENAZINE HYDROCHLORIDE

+	APP PHARMS	2.5MG/ML	A089556 001	Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>1MG</u>	<u>A089740 001</u>	Aug 25, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089741 001</u>	Aug 25, 1988
<u>AB</u>		<u>5MG</u>	<u>A089742 001</u>	Aug 25, 1988
<u>AB</u>		<u>10MG</u>	<u>A089743 001</u>	Aug 25, 1988
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A089804 002</u>	Aug 12, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089804 003</u>	Aug 12, 1988
<u>AB</u>		<u>5MG</u>	<u>A089804 004</u>	Aug 12, 1988
<u>AB</u>	+	<u>10MG</u>	<u>A089804 001</u>	Aug 12, 1988
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A089583 001</u>	Oct 16, 1987
<u>AB</u>		<u>2.5MG</u>	<u>A089584 001</u>	Oct 16, 1987
<u>AB</u>		<u>5MG</u>	<u>A089585 001</u>	Oct 16, 1987
<u>AB</u>		<u>10MG</u>	<u>A089586 001</u>	Oct 16, 1987

FLURANDRENOLIDE

CREAM; TOPICAL
CORDRAN SP

+	WATSON PHARMS	0.025%	N012806 003	
+		0.05%	N012806 002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 185 (of 409)

FLURANDRENOLIDELOTION; TOPICAL
CORDRAN

+ WATSON LABS 0.05% N013790 001

OINTMENT; TOPICAL
CORDRAN

+ WATSON PHARMS 0.025% N012806 004

+ 0.05% N012806 001

TAPE; TOPICAL
CORDRAN

+ WATSON PHARMS 0.004MG/SQ CM N016455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANEAB VALEANT PHARM INTL 15MGN016721 001AB + 30MGN016721 002FLURAZEPAM HYDROCHLORIDEAB MYLAN 15MGA070345 002 Nov 27, 1985AB 30MGA070345 001 Nov 27, 1985AB WATSON LABS 15MGA071205 001 Nov 25, 1986AB 30MGA071068 001 Nov 25, 1986AB 30MGA072369 001 Mar 30, 1989AB WEST WARD 15MGA071107 001 Dec 08, 1986AB 30MGA071108 001 Dec 08, 1986FLURBIPROFEN

TABLET; ORAL

ANSAIDAB PHARMACIA AND UPJOHN 50MGN018766 002 Oct 31, 1988AB + 100MGN018766 003 Oct 31, 1988FLURBIPROFENAB CARACO 50MGA075058 001 Apr 27, 2001AB 100MGA075058 002 Apr 27, 2001AB MYLAN 50MGA074358 001 Jun 20, 1994AB 100MGA074358 002 Jun 20, 1994AB TEVA 100MGA074431 001 May 31, 1995FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUMAT BAUSCH AND LOMB 0.03%A074447 001 Jan 04, 1995OCUFENAT + ALLERGAN 0.03%N019404 001 Dec 31, 1986FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDEAB GENPHARM 125MGA076224 001 May 09, 2003AB IVAX SUB TEVA PHARMS 125MGA075780 001 Sep 19, 2001AB PAR PHARM 125MGA075298 001 Sep 18, 2001AB + SANDOZ 125MGA075818 001 Sep 18, 2001AB WATSON LABS 125MGA075820 001 Sep 18, 2001FLUTICASONE FUROATESPRAY, METERED; NASAL
VERAMYST

+ GLAXOSMITHKLINE 0.0275MG/INH N022051 001 Apr 27, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 186 (of 409)

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION					
FLOVENT HFA					
	+ GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
	+	0.11MG/INH	N021433	002	May 14, 2004
	+	0.22MG/INH	N021433	001	May 14, 2004
CREAM; TOPICAL					
<u>CUTIVATE</u>					
<u>AB</u>	+ ALTANA	<u>0.05%</u>	<u>N019958</u>	<u>001</u>	Dec 18, 1990
<u>FLUTICASONE PROPIONATE</u>					
<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A076451</u>	<u>001</u>	May 14, 2004
<u>AB</u>	G AND W LABS	<u>0.05%</u>	<u>A077055</u>	<u>001</u>	Jun 30, 2006
<u>AB</u>	KV PHARM	<u>0.05%</u>	<u>A076865</u>	<u>001</u>	Sep 10, 2004
<u>AB</u>	PERRIGO NEW YORK	<u>0.05%</u>	<u>A076793</u>	<u>001</u>	May 14, 2004
<u>AB</u>	TOLMAR	<u>0.05%</u>	<u>A076633</u>	<u>001</u>	May 14, 2004
LOTION; TOPICAL					
<u>CUTIVATE</u>					
	+ NYCOMED US	0.05%	N021152	001	Mar 31, 2005
OINTMENT; TOPICAL					
<u>CUTIVATE</u>					
<u>AB</u>	+ ALTANA	<u>0.005%</u>	<u>N019957</u>	<u>001</u>	Dec 14, 1990
<u>FLUTICASONE PROPIONATE</u>					
<u>AB</u>	ALTANA	<u>0.005%</u>	<u>A076300</u>	<u>001</u>	May 14, 2004
<u>AB</u>	G AND W LABS	<u>0.005%</u>	<u>A077168</u>	<u>001</u>	Mar 03, 2006
<u>AB</u>	PERRIGO NEW YORK	<u>0.005%</u>	<u>A076668</u>	<u>001</u>	May 14, 2004
POWDER; INHALATION					
FLOVENT DISKUS 100					
	+ GLAXOSMITHKLINE	0.1MG/INH	N020833	002	Sep 29, 2000
FLOVENT DISKUS 250					
	+ GLAXOSMITHKLINE	0.25MG/INH	N020833	003	Sep 29, 2000
FLOVENT DISKUS 50					
	+ GLAXOSMITHKLINE	0.05MG/INH	N020833	001	Sep 29, 2000
SPRAY, METERED; NASAL					
<u>FLONASE</u>					
<u>AB</u>	+ GLAXOSMITHKLINE	<u>0.05MG/SPRAY</u>	<u>N020121</u>	<u>001</u>	Oct 19, 1994
<u>FLUTICASONE PROPIONATE</u>					
<u>AB</u>	APOTEX INC	<u>0.05MG/SPRAY</u>	<u>A077538</u>	<u>001</u>	Sep 12, 2007
<u>AB</u>	HI TECH PHARMA	<u>0.05MG/SPRAY</u>	<u>A077570</u>	<u>001</u>	Jan 16, 2008
<u>AB</u>	ROXANE	<u>0.05MG/SPRAY</u>	<u>A076504</u>	<u>001</u>	Feb 22, 2006

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION					
ADVAIR HFA					
	+ GLAXOSMITHKLINE	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
	+	0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
	+	0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006
POWDER; INHALATION					
ADVAIR DISKUS 100/50					
	+ GLAXOSMITHKLINE	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000
ADVAIR DISKUS 250/50					
	+ GLAXOSMITHKLINE	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000
ADVAIR DISKUS 500/50					
	+ GLAXOSMITHKLINE	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000

FLUVASTATIN SODIUM

CAPSULE; ORAL					
LESCOL					
	NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993
	+	EQ 40MG BASE	N020261	002	Dec 31, 1993

PRESCRIPTION DRUG PRODUCT LIST

3 - 187 (of 409)

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL
LESCOL XL
+ NOVARTIS 80MG

N021192 001 Oct 06, 2000

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
LUVOX CR
JAZZ 100MG
+ 150MG

N022033 001 Feb 28, 2008
N022033 002 Feb 28, 2008

TABLET; ORAL

FLUVOXAMINE MALEATE

AB APOTEX 25MG
AB 50MG
AB 100MG
AB BARR 25MG
AB 50MG
AB 100MG
AB CARACO 25MG
AB 50MG
AB 100MG
AB MYLAN 25MG
AB 50MG
AB 100MG
AB SANDOZ 25MG
AB 50MG
AB + 100MG
AB TEVA 25MG
AB 50MG
AB 100MG
AB LUVOX
ANI PHARMS 25MG
AB 50MG
AB 100MG

A075902 001 May 07, 2001
A075902 002 May 07, 2001
A075902 003 May 07, 2001
A075897 001 Jan 25, 2001
A075897 002 Jan 25, 2001
A075897 003 Jan 25, 2001
A075900 001 Feb 23, 2006
A075900 002 Feb 23, 2006
A075900 003 Feb 23, 2006
A075889 001 Nov 29, 2000
A075889 002 Nov 29, 2000
A075889 003 Nov 29, 2000
A075888 001 Nov 29, 2000
A075888 002 Nov 29, 2000
A075888 003 Nov 29, 2000
A075893 001 Sep 10, 2002
A075893 002 Sep 10, 2002
A075893 003 Sep 10, 2002
N021519 001 Dec 20, 2007
N021519 002 Dec 20, 2007
N021519 003 Dec 20, 2007

FOLIC ACID

INJECTABLE; INJECTION
FOLIC ACID
+ APP PHARMS 5MG/ML

A089202 001 Feb 18, 1986

TABLET; ORAL

FOLIC ACID

AA CADISTA PHARMS 1MG
AA CONTRACT PHARMACAL 1MG
AA EXCELLIUM 1MG
AA INVAGEN PHARMS 1MG
AA MUTUAL PHARM 1MG
AA + PHARMAX 1MG
AA VINTAGE 1MG
AA + WATSON LABS 1MG
AA WEST WARD 1MG

A040514 001 Jun 14, 2005
A085061 001
A040796 001 Jan 12, 2009
A090035 001 Jun 09, 2009
A040582 001 Jul 18, 2005
A040625 001 Jul 21, 2005
A040756 001 Jun 04, 2010
A080680 001
A080600 001

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS
FOLLISTIM AQ
+ ORGANON USA INC 75 IU/0.5ML
+ 150 IU/0.5ML
+ 300 IU/0.36ML
+ 600 IU/0.72ML
+ 900 IU/1.08ML

N021273 001 Aug 26, 2005
N021273 002 Aug 26, 2005
N021211 001 Mar 23, 2004
N021211 002 Mar 23, 2004
N021211 004 Feb 11, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 188 (of 409)

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

GONAL-F

+	EMD SERONO	450 IU/VIAL	N020378	005	Mar 26, 2004
		1,050 IU/VIAL	N020378	004	Feb 28, 2001
GONAL-F RFF					
+	EMD SERONO	75 IU/VIAL	N021765	002	Mar 25, 2004
GONAL-F RFF PEN					
+	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004
+		450 IU/0.75ML	N021684	002	May 25, 2004
+		900 IU/1.5ML	N021684	003	May 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

<u>AP</u>	+	PALADIN LABS	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>N020696</u>	<u>001</u>	Dec 04, 1997

FOMEPIZOLE

<u>AP</u>		BIONICHE PHARMA USA	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A079033</u>	<u>001</u>	Apr 07, 2009
<u>AP</u>		LUITPOLD	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368</u>	<u>001</u>	Dec 14, 2007
<u>AP</u>		NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537</u>	<u>001</u>	Mar 06, 2008
<u>AP</u>		SYNERX PHARMA	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639</u>	<u>001</u>	Mar 03, 2008

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

+	GLAXOSMITHKLINE	2.5MG/0.5ML	N021345	001	Dec 07, 2001
		5MG/0.4ML	N021345	002	May 28, 2004
		7.5MG/0.6ML	N021345	003	May 28, 2004
		10MG/0.8ML	N021345	004	May 28, 2004

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+	NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001
+	NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006

SOLUTION; INHALATION

PERFORMIST

+	DEY PHARMA	0.02MG/2ML	N022007	001	May 11, 2007

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	SCHERING	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010
		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+	VIIV HLHCARE	EQ 50MG BASE/ML	N022116	001	Jun 14, 2007

TABLET; ORAL

LEXIVA

+	VIIV HLHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

+	MERCK AND CO INC	EQ 115MG BASE/VIAL	N022023	001	Jan 25, 2008
+		EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 189 (of 409)

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

<u>AP</u>	HOSPIRA	<u>2.4GM/100ML</u>	<u>A077174</u>	<u>001</u>	May 31, 2005

FOSCAVIR

<u>AP</u>	+ CLINIGEN HLTHCARE	<u>2.4GM/100ML</u>	<u>N020068</u>	<u>001</u>	Sep 27, 1991

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

+ ZAMBON SPA

EQ 3GM BASE/PACKET

N050717	001	Dec 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A076906</u>	<u>001</u>	May 17, 2005
<u>AB</u>		<u>20MG</u>	<u>A076906</u>	<u>002</u>	May 17, 2005
<u>AB</u>		<u>40MG</u>	<u>A076906</u>	<u>003</u>	May 17, 2005
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A077222</u>	<u>001</u>	Apr 20, 2005
<u>AB</u>		<u>20MG</u>	<u>A077222</u>	<u>002</u>	Apr 20, 2005
<u>AB</u>		<u>40MG</u>	<u>A077222</u>	<u>003</u>	Apr 20, 2005
<u>AB</u>	RANBAXY	<u>10MG</u>	<u>A076580</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A076580</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A076580</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076483</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A076483</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A076483</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076139</u>	<u>001</u>	Nov 25, 2003
<u>AB</u>		<u>20MG</u>	<u>A076139</u>	<u>002</u>	Nov 25, 2003
<u>AB</u>	+	<u>40MG</u>	<u>A076139</u>	<u>003</u>	Nov 25, 2003
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076987</u>	<u>001</u>	Dec 23, 2004
<u>AB</u>		<u>10MG</u>	<u>A077531</u>	<u>001</u>	Aug 31, 2006
<u>AB</u>		<u>20MG</u>	<u>A076987</u>	<u>002</u>	Dec 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A077531</u>	<u>002</u>	Aug 31, 2006
<u>AB</u>		<u>40MG</u>	<u>A076987</u>	<u>003</u>	Dec 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A077531</u>	<u>003</u>	Aug 31, 2006
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG</u>	<u>A076620</u>	<u>001</u>	Oct 15, 2004
<u>AB</u>		<u>20MG</u>	<u>A076620</u>	<u>002</u>	Oct 15, 2004
<u>AB</u>		<u>40MG</u>	<u>A076620</u>	<u>003</u>	Oct 15, 2004
	<u>MONOPRIL</u>				
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>10MG</u>	<u>N019915</u>	<u>002</u>	May 16, 1991
<u>AB</u>		<u>20MG</u>	<u>N019915</u>	<u>003</u>	May 16, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019915</u>	<u>004</u>	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO PHARMA	<u>10MG;12.5MG</u>	<u>A079245</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079245</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	INVAGEN PHARMS	<u>10MG;12.5MG</u>	<u>A090228</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A090228</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	MYLAN	<u>10MG;12.5MG</u>	<u>A077705</u>	<u>001</u>	Aug 14, 2006
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A077705</u>	<u>002</u>	Aug 14, 2006
<u>AB</u>	RANBAXY	<u>10MG;12.5MG</u>	<u>A076739</u>	<u>001</u>	Dec 17, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076739</u>	<u>002</u>	Dec 17, 2004
<u>AB</u>	SANDOZ	<u>10MG;12.5MG</u>	<u>A076961</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076961</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG;12.5MG</u>	<u>A076608</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076608</u>	<u>002</u>	Dec 03, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 190 (of 409)

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>10MG;12.5MG</u>	<u>A079025</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079025</u>	<u>002</u>	Sep 17, 2010

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

<u>AP</u>	AKORN STRIDES	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078476</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	APOTEX INC	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078126</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	APP PHARMS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078052</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	BEDFORD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765</u>	<u>001</u>	Dec 02, 2009
<u>AP</u>	HOSPIRA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078158</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	LUITPOLD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078277</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A090099</u>	<u>001</u>	May 13, 2010
<u>AP</u>	STRIDES ARCOLAB	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078736</u>	<u>001</u>	Jun 08, 2010
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	TEVA PARENTERAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A076886</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137</u>	<u>001</u>	Aug 06, 2007

FOSPROPOFOL DISODIUMSOLUTION; INTRAVENOUS
LUSEDRA

+	EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

+	ENDO PHARMS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

+	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>	APP PHARMS	<u>10MG/ML</u>	<u>N018902</u>	<u>001</u>	May 22, 1984
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A070578</u>	<u>001</u>	Jul 08, 1987
<u>AP</u>		<u>10MG/ML</u>	<u>A075241</u>	<u>001</u>	May 28, 1999
<u>AP</u>		<u>10MG/ML</u>	<u>N018667</u>	<u>001</u>	May 28, 1982
<u>AP</u>	INTL MEDICATION	<u>10MG/ML</u>	<u>N018025</u>	<u>001</u>	
<u>AP</u>	+	<u>10MG/ML</u>	<u>N018579</u>	<u>001</u>	Nov 30, 1983
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941</u>	<u>001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	+	<u>10MG/ML</u>	<u>A070434</u>	<u>001</u>	Apr 22, 1987
<u>AA</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A070655</u>	<u>001</u>	Oct 02, 1987
	FUROSEMIDE				
	ROXANE	40MG/5ML	A070433	001	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	DAVA PHARMS INC	<u>20MG</u>	<u>N018415</u>	<u>001</u>	Jul 27, 1982
<u>AB</u>		<u>40MG</u>	<u>N018415</u>	<u>002</u>	Jul 27, 1982
<u>AB</u>		<u>80MG</u>	<u>N018415</u>	<u>003</u>	Nov 26, 1984

PRESCRIPTION DRUG PRODUCT LIST

3 - 191 (of 409)

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	<u>EXCELLIUM</u>	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>	<u>IPCA LABS LTD</u>	<u>20MG</u>	<u>A078010</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>		<u>40MG</u>	<u>A078010</u>	<u>002</u>	Sep 18, 2006
<u>AB</u>		<u>80MG</u>	<u>A078010</u>	<u>003</u>	Sep 18, 2006
<u>AB</u>	<u>IVAX SUB TEVA PHARMS</u>	<u>20MG</u>	<u>N018413</u>	<u>001</u>	Nov 30, 1983
<u>AB</u>		<u>40MG</u>	<u>N018413</u>	<u>002</u>	Nov 30, 1983
<u>AB</u>	<u>MYLAN</u>	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>		<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>		<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>	<u>ROXANE</u>	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>		<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>		<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986
<u>AB</u>	<u>SANDOZ</u>	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>		<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984
<u>AB</u>	<u>VINTAGE PHARMS</u>	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>		<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004
<u>AB</u>		<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004
<u>AB</u>	<u>WATSON LABS</u>	<u>20MG</u>	<u>A070412</u>	<u>001</u>	Feb 26, 1986
<u>AB</u>		<u>20MG</u>	<u>A070449</u>	<u>001</u>	Nov 22, 1985
<u>AB</u>		<u>20MG</u>	<u>A071379</u>	<u>001</u>	Jan 02, 1987
<u>AB</u>		<u>40MG</u>	<u>A070450</u>	<u>001</u>	Nov 22, 1985
<u>AB</u>		<u>80MG</u>	<u>A070528</u>	<u>001</u>	Jan 07, 1986
<u>AB</u>		<u>80MG</u>	<u>A071594</u>	<u>001</u>	Feb 09, 1988
<u>LASIX</u>					
<u>AB</u>	<u>SANOFI AVENTIS US</u>	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	<u>+</u>	<u>80MG</u>	<u>N016273</u>	<u>003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	<u>ACTAVIS ELIZABETH</u>	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>		<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>		<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>	<u>ALKEM</u>	<u>100MG</u>	<u>A090858</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>300MG</u>	<u>A090858</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>400MG</u>	<u>A090858</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	<u>AMNEAL PHARMS NY</u>	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>	<u>APOTEX INC</u>	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>	<u>AUROBINDO PHARM</u>	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	<u>HIKMA</u>	<u>100MG</u>	<u>A078150</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078150</u>	<u>002</u>	Sep 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078150</u>	<u>003</u>	Sep 25, 2007
<u>AB</u>	<u>INVAGEN PHARMS</u>	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>		<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>		<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>	<u>RANBAXY</u>	<u>100MG</u>	<u>A076606</u>	<u>001</u>	Oct 07, 2005
<u>AB</u>		<u>300MG</u>	<u>A076606</u>	<u>002</u>	Oct 07, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 192 (of 409)

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	RANBAXY	<u>400MG</u>	<u>A076606</u>	<u>003</u>	Oct 07, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242</u>	<u>003</u>	Aug 24, 2006
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A075435</u>	<u>001</u>	Oct 08, 2004
<u>AB</u>		<u>300MG</u>	<u>A075435</u>	<u>002</u>	Oct 08, 2004
<u>AB</u>		<u>400MG</u>	<u>A075435</u>	<u>003</u>	Oct 08, 2004
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075485</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A075485</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>400MG</u>	<u>A075485</u>	<u>001</u>	May 11, 2007
<u>NEURONTIN</u>					
<u>AB</u>	PFIZER PHARMS	<u>100MG</u>	<u>N020235</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>		<u>300MG</u>	<u>N020235</u>	<u>002</u>	Dec 30, 1993
<u>AB</u>	+	<u>400MG</u>	<u>N020235</u>	<u>003</u>	Dec 30, 1993

SOLUTION; ORAL

NEURONTIN

+	PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000

TABLET; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>600MG</u>	<u>A075694</u>	<u>001</u>	Oct 21, 2004
<u>AB</u>		<u>800MG</u>	<u>A075694</u>	<u>002</u>	Oct 21, 2004
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077894</u>	<u>001</u>	Oct 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077894</u>	<u>002</u>	Oct 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077894</u>	<u>003</u>	Oct 10, 2006
<u>AB</u>		<u>600MG</u>	<u>A077661</u>	<u>004</u>	Sep 13, 2006
<u>AB</u>		<u>800MG</u>	<u>A077661</u>	<u>005</u>	Sep 13, 2006
<u>AB</u>	GLENMARK GENERICS	<u>600MG</u>	<u>A077662</u>	<u>001</u>	Aug 18, 2006
<u>AB</u>		<u>800MG</u>	<u>A077662</u>	<u>002</u>	Aug 18, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A076017</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>		<u>300MG</u>	<u>A076017</u>	<u>002</u>	Apr 28, 2004
<u>AB</u>		<u>400MG</u>	<u>A076017</u>	<u>003</u>	Apr 28, 2004
<u>AB</u>		<u>600MG</u>	<u>A076017</u>	<u>004</u>	Apr 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A076017</u>	<u>005</u>	Apr 29, 2005
<u>AB</u>	MATRIX LABS LTD	<u>600MG</u>	<u>A090335</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>800MG</u>	<u>A090335</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>600MG</u>	<u>A077525</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>800MG</u>	<u>A077525</u>	<u>002</u>	Aug 24, 2006
<u>NEURONTIN</u>					
<u>AB</u>	PFIZER PHARMS	<u>600MG</u>	<u>N020882</u>	<u>001</u>	Oct 09, 1998
<u>AB</u>	+	<u>800MG</u>	<u>N020882</u>	<u>002</u>	Oct 09, 1998

GADOBENATE DIMEGLUMINEINJECTABLE; INTRAVENOUS
MULTIHANCE

+	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
+		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
+		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
+		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004
MULTIHANCE MULTIPACK					
+	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
+		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADODIAMIDEINJECTABLE; INJECTION
OMNISCAN

+	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993
+		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 193 (of 409)

GADOFOSVESET TRISODIUMSOLUTION; INTRAVENOUS
ABLAVAR

LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711 001	Dec 22, 2008
+	3660MG/15ML (244MG/ML)	N021711 002	Dec 22, 2008

GADOPENTETATE DIMEGLUMINEINJECTABLE; INJECTION
MAGNEVIST

+ BAYER HLTHCARE	469.01MG/ML	N019596 001	Jun 02, 1988
+	469.01MG/ML	N021037 001	Mar 10, 2000

GADOTERIDOLINJECTABLE; INJECTION
PROHANCE

+ BRACCO	279.3MG/ML	N020131 001	Nov 16, 1992
PROHANCE MULTIPACK			
+ BRACCO	279.3MG/ML	N021489 001	Oct 09, 2003

GADOVERSETAMIDEINJECTABLE; INJECTION
OPTIMARK

+ MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N020937 001	Dec 08, 1999
+	3309MG/10ML (330.9MG/ML)	N020937 002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)	N020937 003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)	N020937 004	Dec 08, 1999
+	16.545GM/50ML (330.9MG/ML)	N020975 001	Dec 08, 1999
OPTIMARK IN PLASTIC CONTAINER			
+ MALLINCKRODT	3309MG/10ML (330.9MG/ML)	N020976 002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)	N020976 003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)	N020976 004	Dec 08, 1999
+	9927MG/30ML (330.9MG/ML)	N020976 001	Dec 08, 1999

GADOXETATE DISODIUMSOLUTION; INTRAVENOUS
EOVIST

+ BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090 001	Jul 03, 2008

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	BARR	<u>EQ 8MG BASE</u>	<u>A078189 001</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A078189 002</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078189 003</u>	Sep 15, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 8MG BASE</u>	<u>A078484 001</u>	May 27, 2009
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A078484 002</u>	May 27, 2009
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078484 003</u>	May 27, 2009
<u>AB</u>	WATSON LABS	<u>EQ 8MG BASE</u>	<u>A079028 001</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A079028 002</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A079028 003</u>	Dec 15, 2008
<u>RAZADYNE ER</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>EQ 8MG BASE</u>	<u>N021615 001</u>	Apr 01, 2005
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>N021615 002</u>	Apr 01, 2005
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>N021615 003</u>	Apr 01, 2005

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

<u>AA</u>	ROXANE	<u>4MG/ML</u>	<u>A078185 001</u>	Jan 30, 2009
<u>RAZADYNE</u>				
<u>AA</u>	+ ORTHO MCNEIL JANSSEN	<u>4MG/ML</u>	<u>N021224 001</u>	Jun 22, 2001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 194 (of 409)

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 4MG BASE</u>	<u>A077585</u>	<u>001</u>	Sep 15, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077585</u>	<u>002</u>	Sep 15, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077585</u>	<u>003</u>	Sep 15, 2009
<u>AB</u>	BARR	<u>EQ 4MG BASE</u>	<u>A077605</u>	<u>001</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077605</u>	<u>002</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077605</u>	<u>003</u>	Aug 28, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593</u>	<u>001</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077593</u>	<u>002</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077593</u>	<u>003</u>	Sep 11, 2008
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A077590</u>	<u>001</u>	May 29, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077603</u>	<u>001</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077590</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077603</u>	<u>002</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077590</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077603</u>	<u>003</u>	Aug 28, 2008
<u>AB</u>	ROXANE	<u>EQ 4MG BASE</u>	<u>A077608</u>	<u>001</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077608</u>	<u>002</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077608</u>	<u>003</u>	Feb 11, 2009
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589</u>	<u>001</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077589</u>	<u>002</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077589</u>	<u>003</u>	Jun 22, 2009
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A077587</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077587</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077587</u>	<u>003</u>	Jul 09, 2009
<u>RAZADYNE</u>					
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>EQ 4MG BASE</u>	<u>N021169</u>	<u>001</u>	Feb 28, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N021169</u>	<u>002</u>	Feb 28, 2001
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>N021169</u>	<u>003</u>	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS	LANTHEUS MEDCL	2mCi/ML	N017478	001	
BS	MALLINCKRODT	2mCi/ML	N018058	001	

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

+ GENTA	25MG/ML	N019961	002	Jan 17, 1991

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

RANBAXY	250MG	A076457	001	Jun 27, 2003
+	500MG	A076457	002	Jun 27, 2003

GEL; OPHTHALMIC

ZIRGAN

+ BAUSCH AND LOMB	0.15%	N022211	001	Sep 15, 2009

IMPLANT; IMPLANTATION

VITRASERT

+ BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE

<u>AP</u>	+ ROCHE PALO	<u>EQ 500MG BASE/VIAL</u>	<u>N019661</u>	<u>001</u>	Jun 23, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 195 (of 409)

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR

<u>AP</u>	APP PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A090658</u>	<u>001</u>	Jun 21, 2010

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE INJECTION

+	ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057	001	Jul 29, 1999

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

+	ALLERGAN	0.3%	N021493	001	Mar 28, 2003

ZYMAXID

+	ALLERGAN	0.5%	N022548	001	May 18, 2010

GEFITINIB

TABLET; ORAL

IRESSA

+	ASTRAZENECA	250MG	N021399	001	May 05, 2003

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010

GEMZAR

+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996

+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

<u>AB</u>	APOTEX	<u>600MG</u>	<u>A075034</u>	<u>001</u>	Jul 20, 1998
<u>AB</u>	DAVA PHARMS INC	<u>600MG</u>	<u>A074270</u>	<u>001</u>	Sep 27, 1993
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078599</u>	<u>001</u>	Aug 16, 2010
<u>AB</u>	IMPAX PHARMS	<u>600MG</u>	<u>A078207</u>	<u>001</u>	Jun 01, 2007
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A077836</u>	<u>001</u>	Jul 27, 2006
<u>AB</u>	NORTHSTAR HLTHCARE	<u>600MG</u>	<u>A079072</u>	<u>001</u>	Sep 13, 2010
<u>AB</u>	PERRIGO R AND D	<u>600MG</u>	<u>A078012</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A079239</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>	TEVA	<u>600MG</u>	<u>A074256</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>600MG</u>	<u>A074442</u>	<u>001</u>	Apr 28, 1995

LOPID

<u>AB</u>	+	PFIZER PHARMS	<u>600MG</u>	<u>N018422</u>	<u>003</u>	Nov 20, 1986

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+	CORNERSTONE THERAP	EQ 320MG BASE	N021158	001	Apr 04, 2003

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

<u>AT</u>	+	FOUGERA	<u>EQ 0.1% BASE</u>	<u>A062531</u>	<u>001</u>	Jul 05, 1984
<u>AT</u>		PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062307</u>	<u>001</u>	
<u>AT</u>		TARO	<u>EQ 0.1% BASE</u>	<u>A062427</u>	<u>001</u>	May 26, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 196 (of 409)

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

<u>AP</u>	+ APP PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A062356</u>	<u>001</u>	Mar 04, 1982
<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A062356</u>	<u>002</u>	Mar 04, 1982
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A062366</u>	<u>001</u>	Aug 04, 1983
<u>AP</u>	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A062420</u>	<u>001</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A062612</u>	<u>004</u>	Feb 20, 1986
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A062420</u>	<u>002</u>	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>EQ 0.8MG BASE/ML</u>	<u>A062814</u>	<u>001</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 1.2MG BASE/ML</u>	<u>A062814</u>	<u>002</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 1.4MG BASE/ML</u>	<u>A062814</u>	<u>003</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 1.6MG BASE/ML</u>	<u>A062814</u>	<u>004</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 1.8MG BASE/ML</u>	<u>A062814</u>	<u>005</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 2MG BASE/ML</u>	<u>A062814</u>	<u>006</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 2.4MG BASE/ML</u>	<u>A062814</u>	<u>007</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 40MG BASE/100ML</u>	<u>A062814</u>	<u>008</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 60MG BASE/100ML</u>	<u>A062814</u>	<u>009</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 70MG BASE/100ML</u>	<u>A062814</u>	<u>010</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 80MG BASE/100ML</u>	<u>A062814</u>	<u>011</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 90MG BASE/100ML</u>	<u>A062814</u>	<u>012</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>A062814</u>	<u>013</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 120MG BASE/100ML</u>	<u>A062814</u>	<u>014</u>	Aug 28, 1987
<u>AP</u>	HOSPIRA	<u>EQ 1.2MG BASE/ML</u>	<u>A062414</u>	<u>001</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 1.4MG BASE/ML</u>	<u>A062414</u>	<u>002</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 1.6MG BASE/ML</u>	<u>A062414</u>	<u>003</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 1.8MG BASE/ML</u>	<u>A062414</u>	<u>004</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A062414</u>	<u>005</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 60MG BASE/100ML</u>	<u>A062414</u>	<u>006</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 70MG BASE/100ML</u>	<u>A062414</u>	<u>007</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 80MG BASE/100ML</u>	<u>A062414</u>	<u>008</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 90MG BASE/100ML</u>	<u>A062414</u>	<u>009</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 100MG BASE/100ML</u>	<u>A062414</u>	<u>010</u>	Aug 15, 1983

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>EQ 0.8MG BASE/ML</u>	<u>A062373</u>	<u>001</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 1.2MG BASE/ML</u>	<u>A062373</u>	<u>007</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 1.6MG BASE/ML</u>	<u>A062373</u>	<u>008</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A062373</u>	<u>009</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 2.4MG BASE/ML</u>	<u>A062373</u>	<u>010</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 40MG BASE/100ML</u>	<u>A062373</u>	<u>003</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 60MG BASE/100ML</u>	<u>A062373</u>	<u>004</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 80MG BASE/100ML</u>	<u>A062373</u>	<u>002</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 100MG BASE/100ML</u>	<u>A062373</u>	<u>005</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 120MG BASE/100ML</u>	<u>A062373</u>	<u>006</u>	Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

<u>AT</u>	+ AKORN	<u>EQ 0.3% BASE</u>	<u>A064093</u>	<u>001</u>	Aug 31, 1995
<u>AT</u>	ALTANA	<u>EQ 0.3% BASE</u>	<u>A065024</u>	<u>001</u>	Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATE

<u>AT</u>	FOUGERA	<u>EQ 0.1% BASE</u>	<u>A062533</u>	<u>001</u>	Oct 05, 1984
<u>AT</u>	+ PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062351</u>	<u>001</u>	Feb 18, 1982
<u>AT</u>	TARO	<u>EQ 0.1% BASE</u>	<u>A062477</u>	<u>001</u>	Dec 23, 1983

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

<u>AT</u>	ALLERGAN	<u>EQ 0.3% BASE</u>	<u>A062452</u>	<u>001</u>	Oct 10, 1984
<u>AT</u>	<u>GENTAK</u>				
<u>AT</u>	AKORN	<u>EQ 0.3% BASE</u>	<u>A064163</u>	<u>001</u>	Oct 12, 2001

PRESCRIPTION DRUG PRODUCT LIST

3 - 197 (of 409)

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

<u>AT</u>	AKORN	<u>EQ 0.3% BASE</u>	<u>A062635</u>	<u>001</u>	Jan 08, 1987
<u>AT</u>	ALTANA	<u>EQ 0.3% BASE</u>	<u>A065121</u>	<u>001</u>	Jan 30, 2004
<u>AT</u>	+ BAUSCH AND LOMB	<u>EQ 0.3% BASE</u>	<u>A064048</u>	<u>001</u>	May 11, 1994
<u>AT</u>	FALCON PHARMS	<u>EQ 0.3% BASE</u>	<u>A062196</u>	<u>001</u>	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC
PRED-G

	+ ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989

SUSPENSION/DROPS; OPHTHALMIC

	+ ALLERGAN	EQ 0.3% BASE;1%	N050586	001	Jun 10, 1988

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS
COPAXONE

	+ TEVA	20MG/ML	N020622	002	Feb 12, 2002

GLIMEPIRIDE

TABLET; ORAL

AMARYL

<u>AB</u>	+ SANOFI AVENTIS US	<u>1MG</u>	<u>N020496</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>		<u>2MG</u>	<u>N020496</u>	<u>002</u>	Nov 30, 1995
<u>AB</u>		<u>4MG</u>	<u>N020496</u>	<u>003</u>	Nov 30, 1995

GLIMEPIRIDE

<u>AB</u>	ACCORD HLTHCARE	<u>1MG</u>	<u>A078181</u>	<u>001</u>	Aug 23, 2007
<u>AB</u>		<u>2MG</u>	<u>A078181</u>	<u>002</u>	Aug 23, 2007
<u>AB</u>		<u>4MG</u>	<u>A078181</u>	<u>003</u>	Aug 23, 2007
<u>AB</u>	CARLSBAD	<u>1MG</u>	<u>A077911</u>	<u>001</u>	Sep 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A077911</u>	<u>002</u>	Sep 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A077911</u>	<u>003</u>	Sep 22, 2009
<u>AB</u>	COREPHARMA	<u>1MG</u>	<u>A077274</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A077274</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077274</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A077091</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A077091</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077091</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	GENPHARM	<u>1MG</u>	<u>A077486</u>	<u>001</u>	Feb 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077486</u>	<u>002</u>	Feb 10, 2006
<u>AB</u>		<u>4MG</u>	<u>A077486</u>	<u>003</u>	Feb 10, 2006
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A077295</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A077295</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077295</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A077624</u>	<u>001</u>	Nov 28, 2005
<u>AB</u>		<u>2MG</u>	<u>A077624</u>	<u>002</u>	Nov 28, 2005
<u>AB</u>		<u>4MG</u>	<u>A077624</u>	<u>003</u>	Nov 28, 2005
<u>AB</u>	RANBAXY	<u>1MG</u>	<u>A076875</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A076875</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A076875</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>		<u>8MG</u>	<u>A076875</u>	<u>004</u>	Oct 06, 2005
<u>AB</u>	TEVA	<u>1MG</u>	<u>A076802</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A076802</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A076802</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	VINTAGE	<u>1MG</u>	<u>A077370</u>	<u>001</u>	Dec 23, 2005
<u>AB</u>		<u>2MG</u>	<u>A077370</u>	<u>002</u>	Dec 23, 2005
<u>AB</u>		<u>4MG</u>	<u>A077370</u>	<u>003</u>	Dec 23, 2005
<u>AB</u>		<u>8MG</u>	<u>A077370</u>	<u>004</u>	Dec 23, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 198 (of 409)

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A077280</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>2MG</u>	<u>A077280</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>4MG</u>	<u>A077280</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>	WATSON LABS FLORIDA	<u>1MG</u>	<u>A076995</u>	<u>001</u>	Apr 27, 2010
<u>AB</u>		<u>2MG</u>	<u>A076995</u>	<u>002</u>	Apr 27, 2010
<u>AB</u>		<u>4MG</u>	<u>A076995</u>	<u>003</u>	Apr 27, 2010

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

+	TAKEDA GLOBAL	2MG;30MG	N021925	001	Jul 28, 2006
		4MG;30MG	N021925	002	Jul 28, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDARYL

+	SB PHARMCO	1MG;4MG	N021700	001	Nov 23, 2005
		2MG;4MG	N021700	002	Nov 23, 2005
		2MG;8MG	N021700	004	Mar 30, 2007
		4MG;4MG	N021700	003	Nov 23, 2005
		4MG;8MG	N021700	005	Mar 30, 2007

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>5MG</u>	<u>A074550</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>10MG</u>	<u>A074550</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>	ALPHAPHARM	<u>5MG</u>	<u>A074438</u>	<u>001</u>	Jun 20, 1995
<u>AB</u>		<u>10MG</u>	<u>A074438</u>	<u>002</u>	Jun 20, 1995
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A075795</u>	<u>001</u>	Jun 13, 2001
<u>AB</u>		<u>10MG</u>	<u>A075795</u>	<u>002</u>	Jun 13, 2001
<u>AB</u>	CARACO	<u>5MG</u>	<u>A077820</u>	<u>001</u>	Jul 11, 2006
<u>AB</u>		<u>10MG</u>	<u>A077820</u>	<u>002</u>	Jul 11, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A074497</u>	<u>001</u>	Aug 31, 1995
<u>AB</u>		<u>10MG</u>	<u>A074497</u>	<u>002</u>	Aug 31, 1995
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A074226</u>	<u>001</u>	May 10, 1994
<u>AB</u>		<u>10MG</u>	<u>A074226</u>	<u>002</u>	May 10, 1994
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A074305</u>	<u>001</u>	Apr 07, 1995
<u>AB</u>		<u>10MG</u>	<u>A074305</u>	<u>002</u>	Apr 07, 1995
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074223</u>	<u>001</u>	Feb 27, 1995
<u>AB</u>		<u>5MG</u>	<u>A074370</u>	<u>001</u>	Nov 22, 1994
<u>AB</u>		<u>10MG</u>	<u>A074223</u>	<u>002</u>	Feb 27, 1995
<u>AB</u>		<u>10MG</u>	<u>A074370</u>	<u>002</u>	Nov 22, 1994
	<u>GLUCOTROL</u>				
<u>AB</u>	PFIZER	<u>5MG</u>	<u>N017783</u>	<u>001</u>	May 08, 1984
<u>AB</u>	+	<u>10MG</u>	<u>N017783</u>	<u>002</u>	May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076467</u>	<u>003</u>	Mar 27, 2006
<u>AB</u>		<u>5MG</u>	<u>A076467</u>	<u>001</u>	Sep 08, 2003
<u>AB</u>		<u>10MG</u>	<u>A076467</u>	<u>002</u>	Nov 07, 2003
	<u>GLUCOTROL XL</u>				
<u>AB</u>	PFIZER	<u>2.5MG</u>	<u>N020329</u>	<u>003</u>	Aug 10, 1999
<u>AB</u>		<u>5MG</u>	<u>N020329</u>	<u>001</u>	Apr 26, 1994
<u>AB</u>	+	<u>10MG</u>	<u>N020329</u>	<u>002</u>	Apr 26, 1994

PRESCRIPTION DRUG PRODUCT LIST

3 - 199 (of 409)

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	CARACO	<u>2.5MG;250MG</u>	<u>A077620</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A077620</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>		<u>5MG;500MG</u>	<u>A077620</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>	COREPHARMA	<u>2.5MG;250MG</u>	<u>A077507</u>	<u>001</u>	Oct 27, 2005
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A077507</u>	<u>002</u>	Oct 27, 2005
<u>AB</u>		<u>5MG;500MG</u>	<u>A077507</u>	<u>003</u>	Oct 27, 2005
<u>AB</u>	HERITAGE PHARMS INC	<u>2.5MG;250MG</u>	<u>A078728</u>	<u>001</u>	Jun 23, 2010
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A078728</u>	<u>002</u>	Jun 23, 2010
<u>AB</u>		<u>5MG;500MG</u>	<u>A078728</u>	<u>003</u>	Jun 23, 2010
<u>AB</u>	MYLAN	<u>2.5MG;250MG</u>	<u>A078083</u>	<u>001</u>	Apr 12, 2007
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A078083</u>	<u>002</u>	Apr 12, 2007
<u>AB</u>		<u>5MG;500MG</u>	<u>A078083</u>	<u>003</u>	Apr 12, 2007
<u>AB</u>	TEVA PHARMS	<u>2.5MG;250MG</u>	<u>A077270</u>	<u>001</u>	Oct 28, 2005
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A077270</u>	<u>002</u>	Oct 28, 2005
<u>AB</u>		<u>5MG;500MG</u>	<u>A077270</u>	<u>003</u>	Oct 28, 2005

METAGLIP

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>2.5MG;250MG</u>	<u>N021460</u>	<u>001</u>	Oct 21, 2002
<u>AB</u>		<u>2.5MG;500MG</u>	<u>N021460</u>	<u>002</u>	Oct 21, 2002
<u>AB</u>	+	<u>5MG;500MG</u>	<u>N021460</u>	<u>003</u>	Oct 21, 2002

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGON

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION
GLUCAGON

+	LILLY	1MG/VIAL	N020928	001	Sep 11, 1998

GLUTAMINE

FOR SOLUTION; ORAL
NUTRESTORE

+	NUTRITIONAL RESTART	5GM/PACKET	N021667	001	Jun 10, 2004

GLYBURIDE

TABLET; ORAL

GLYBURIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>1.5MG</u>	<u>A075947</u>	<u>001</u>	Nov 14, 2002
<u>AB</u>		<u>3MG</u>	<u>A075947</u>	<u>002</u>	Nov 14, 2002
<u>AB</u>		<u>6MG</u>	<u>A075947</u>	<u>003</u>	Nov 14, 2002
<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG</u>	<u>A077537</u>	<u>001</u>	Oct 18, 2007
<u>AB</u>		<u>2.5MG</u>	<u>A077537</u>	<u>002</u>	Oct 18, 2007
<u>AB</u>		<u>5MG</u>	<u>A077537</u>	<u>003</u>	Oct 18, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG</u>	<u>A076257</u>	<u>001</u>	Jun 27, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A076257</u>	<u>002</u>	Jun 27, 2002
<u>AB</u>		<u>5MG</u>	<u>A076257</u>	<u>003</u>	Jun 27, 2002
<u>AB</u>	TEVA	<u>1.25MG</u>	<u>A074388</u>	<u>001</u>	Aug 29, 1995
<u>AB</u>		<u>2.5MG</u>	<u>A074388</u>	<u>002</u>	Aug 29, 1995
<u>AB</u>	+	<u>5MG</u>	<u>A074388</u>	<u>003</u>	Aug 29, 1995

GLYBURIDE (MICRONIZED)

<u>AB</u>	DAVA PHARMS INC	<u>1.5MG</u>	<u>A074591</u>	<u>001</u>	Dec 22, 1997
<u>AB</u>		<u>3MG</u>	<u>A074591</u>	<u>002</u>	Dec 22, 1997
<u>AB</u>		<u>4.5MG</u>	<u>A074591</u>	<u>003</u>	Dec 22, 1997
<u>AB</u>		<u>6MG</u>	<u>A074591</u>	<u>004</u>	Dec 22, 1997
<u>AB</u>	HIKMA	<u>1.5MG</u>	<u>A075890</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>3MG</u>	<u>A075890</u>	<u>002</u>	Jul 31, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 200 (of 409)

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

<u>AB</u>	HIKMA	<u>6MG</u>	<u>A075890</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>	MYLAN	<u>1.5MG</u>	<u>A074792</u>	<u>001</u>	Jun 26, 1998
<u>AB</u>		<u>3MG</u>	<u>A074792</u>	<u>002</u>	Jun 26, 1998
<u>AB</u>		<u>6MG</u>	<u>A074792</u>	<u>003</u>	Aug 17, 1999
<u>AB</u>	TEVA	<u>1.5MG</u>	<u>A074686</u>	<u>001</u>	Apr 20, 1999
<u>AB</u>		<u>3MG</u>	<u>A074686</u>	<u>002</u>	Apr 20, 1999
<u>AB</u>		<u>4.5MG</u>	<u>A074686</u>	<u>003</u>	Apr 20, 1999
<u>AB</u>		<u>6MG</u>	<u>A074686</u>	<u>004</u>	Apr 20, 1999
<u>GLYNASE</u>					
<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>N020051</u>	<u>001</u>	Mar 04, 1992
<u>AB</u>		<u>3MG</u>	<u>N020051</u>	<u>002</u>	Mar 04, 1992
<u>AB</u>	+	<u>6MG</u>	<u>N020051</u>	<u>004</u>	Sep 24, 1993
<u>DIABETA</u>					
BX	SANOFI AVENTIS US	1.25MG	N017532	001	May 01, 1984
BX		2.5MG	N017532	002	May 01, 1984
BX	+	5MG	N017532	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>1.25MG; 250MG</u>	<u>N021178</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>	+	<u>2.5MG; 500MG</u>	<u>N021178</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>		<u>5MG; 500MG</u>	<u>N021178</u>	<u>003</u>	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG; 250MG</u>	<u>A076716</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076716</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076716</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG; 250MG</u>	<u>A077870</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A077870</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>		<u>5MG; 500MG</u>	<u>A077870</u>	<u>003</u>	Nov 14, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG; 250MG</u>	<u>A076731</u>	<u>001</u>	Nov 19, 2004
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076731</u>	<u>002</u>	Nov 19, 2004
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076731</u>	<u>003</u>	Nov 19, 2004
<u>AB</u>	DR REDDYS LABS INC	<u>1.25MG; 250MG</u>	<u>A079009</u>	<u>001</u>	Jun 03, 2009
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A079009</u>	<u>002</u>	Jun 03, 2009
<u>AB</u>		<u>5MG; 500MG</u>	<u>A079009</u>	<u>003</u>	Jun 03, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1.25MG; 250MG</u>	<u>A076345</u>	<u>001</u>	Feb 18, 2004
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076345</u>	<u>002</u>	Feb 18, 2004
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076345</u>	<u>003</u>	Feb 18, 2004

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>1.5GM/100ML</u>	<u>N017865</u>	<u>001</u>	
<u>GLYCINE 1.5% IN PLASTIC CONTAINER</u>					
<u>AT</u>	B BRAUN	<u>1.5GM/100ML</u>	<u>N016784</u>	<u>001</u>	
<u>AT</u>	HOSPIRA	<u>1.5GM/100ML</u>	<u>N018315</u>	<u>001</u>	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

<u>AP</u>	LUITPOLD	<u>0.2MG/ML</u>	<u>A089335</u>	<u>001</u>	Jul 23, 1986
<u>ROBINUL</u>					
<u>AP</u>	+	<u>0.2MG/ML</u>	<u>N017558</u>	<u>001</u>	

SOLUTION; ORAL

CUVPOSA

+	SHIONOGI PHARMA	1MG/5ML	N022571	001	Jul 28, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 201 (of 409)

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>	COREPHARMA	<u>1MG</u>	<u>A040568</u>	<u>001</u>	Dec 22, 2004
<u>AA</u>		<u>2MG</u>	<u>A040568</u>	<u>002</u>	Dec 22, 2004
<u>AA</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>		<u>2MG</u>	<u>A040847</u>	<u>002</u>	Mar 21, 2008
<u>AA</u>	PAR PHARM	<u>1MG</u>	<u>A040653</u>	<u>001</u>	Aug 31, 2006
<u>AA</u>		<u>2MG</u>	<u>A040653</u>	<u>002</u>	Aug 31, 2006
<u>AA</u>	RANBAXY	<u>1MG</u>	<u>A040844</u>	<u>001</u>	Aug 18, 2009
<u>AA</u>		<u>2MG</u>	<u>A040844</u>	<u>002</u>	Aug 18, 2009
<u>AA</u>	VINTAGE	<u>1MG</u>	<u>A040821</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>		<u>2MG</u>	<u>A040821</u>	<u>002</u>	Dec 29, 2008
<u>AA</u>	WEST WARD	<u>1MG</u>	<u>A040836</u>	<u>001</u>	Mar 05, 2009
<u>AA</u>		<u>2MG</u>	<u>A040836</u>	<u>002</u>	Mar 05, 2009
<u>ROBINUL</u>					
<u>AA</u>	+ SHIONOGI PHARMA	<u>1MG</u>	<u>N012827</u>	<u>001</u>	
<u>ROBINUL FORTE</u>					
<u>AA</u>	+ SHIONOGI PHARMA	<u>2MG</u>	<u>N012827</u>	<u>002</u>	

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

<u>AP</u>	+ APP PHARMS	<u>10,000 UNITS/VIAL</u>	<u>N017067</u>	<u>002</u>	
<u>AP</u>	+ FERRING	<u>10,000 UNITS/VIAL</u>	<u>N017016</u>	<u>007</u>	
<u>PREGNYL</u>					
<u>AP</u>	+ ORGANON USA INC	<u>10,000 UNITS/VIAL</u>	<u>N017692</u>	<u>001</u>	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

	+ ASTRAZENECA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
	+	EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

<u>AT</u>	+ BAUSCH AND LOMB	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A064047</u>	<u>001</u>	Jan 31, 1996
<u>AT</u>	LUITPOLD	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A065187</u>	<u>001</u>	Oct 28, 2005
<u>NEOSPORIN</u>					
<u>AT</u>	+ MONARCH PHARMS	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A060582</u>	<u>001</u>	

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

	+ STRAKAN	3.1MG/24HR	N022198	001	Sep 12, 2008

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119</u>	<u>001</u>	Sep 10, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>002</u>	Sep 14, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>	APP PHARMS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>	BEDFORD LABS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913</u>	<u>001</u>	Jun 26, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 202 (of 409)

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	BEDFORD LABS	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078197</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078198</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078198</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	DR REDDYS LABS INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	EBEWE PHARMA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078808</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	LUITPOLD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091274</u>	<u>001</u>	Sep 22, 2010
<u>AP</u>	SAGENT STRIDES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136</u>	<u>001</u>	Apr 09, 2010
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136</u>	<u>002</u>	Apr 09, 2010
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137</u>	<u>002</u>	Apr 09, 2010
<u>AP</u>	SANDOZ	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534</u>	<u>001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>002</u>	Apr 30, 2009
<u>AP</u>	+ TEVA PARENTERAL	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>	+	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077963</u>	<u>001</u>	Jan 03, 2008
<u>AP</u>	+	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	WATSON LABS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566</u>	<u>001</u>	Feb 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565</u>	<u>001</u>	Jun 30, 2008
<u>GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE</u>					
<u>AP</u>	APP PHARMS	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	DR REDDYS LABS INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	+ TEVA PARENTERAL	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077165</u>	<u>001</u>	Dec 31, 2007
<u>GRANISTERON HYDROCHLORIDE</u>					
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>001</u>	Dec 23, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>002</u>	Dec 23, 2009

SOLUTION; ORAL

GRANISETRON HYDROCHLORIDE

+	PEDIATRX	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>	CIPLA LTD	<u>EQ 1MG BASE</u>	<u>A078037</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>	COREPHARMA	<u>EQ 1MG BASE</u>	<u>A078260</u>	<u>001</u>	Dec 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A078725</u>	<u>001</u>	Jan 30, 2008
<u>AB</u>	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969</u>	<u>001</u>	Jun 22, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678</u>	<u>001</u>	Feb 13, 2008
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A077842</u>	<u>001</u>	Dec 31, 2007
<u>AB</u>	TARO	<u>EQ 1MG BASE</u>	<u>A090817</u>	<u>001</u>	May 28, 2010
<u>AB</u>	+ TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078080</u>	<u>001</u>	Dec 31, 2007

GRISEOFULVIN

SUSPENSION; ORAL

GRISEOFULVIN

<u>AB</u>	VINTAGE	<u>125MG/5ML</u>	<u>A065438</u>	<u>001</u>	Oct 08, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 203 (of 409)

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

<u>AB</u>	+	ORTHONEUTROGENA	<u>125MG/5ML</u>	<u>A062483</u>	<u>001</u>	Jan 26, 1984

GRISEOFULVIN

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394</u>	<u>001</u>	Jul 06, 2007
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>125MG/5ML</u>	<u>A065354</u>	<u>001</u>	Sep 10, 2007
<u>AB</u>		PERRIGO CO TENNESSEE	<u>125MG/5ML</u>	<u>A065200</u>	<u>001</u>	Mar 02, 2005

TABLET; ORAL

GRIFULVIN V

+	ORTHONEUTROGENA	500MG	A062279	003	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

GRIS-PEG

	PEDINOL	125MG	N050475	001	
+		250MG	N050475	002	

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

	IVAX SUB TEVA PHARMS	EQ 4MG BASE	A074149	001	Apr 07, 1995
+		EQ 8MG BASE	A074149	002	Apr 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>		AMNEAL PHARM	<u>EQ 1MG BASE</u>	<u>A075109</u>	<u>001</u>	Nov 25, 1998
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075109</u>	<u>002</u>	Nov 25, 1998
<u>AB</u>		EPIC PHARMA	<u>EQ 1MG BASE</u>	<u>A074673</u>	<u>001</u>	Feb 28, 1997
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A074673</u>	<u>002</u>	Feb 28, 1997
<u>AB</u>		MYLAN	<u>EQ 1MG BASE</u>	<u>A074796</u>	<u>001</u>	Jan 27, 1997
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A074796</u>	<u>002</u>	Jan 27, 1997
<u>AB</u>		WATSON LABS	<u>EQ 1MG BASE</u>	<u>A074145</u>	<u>001</u>	Oct 17, 1995
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A074145</u>	<u>002</u>	Oct 17, 1995
		<u>TENEX</u>				
<u>AB</u>		PROMIUS PHARMA	<u>EQ 1MG BASE</u>	<u>N019032</u>	<u>001</u>	Oct 27, 1986
<u>AB</u>	+		<u>EQ 2MG BASE</u>	<u>N019032</u>	<u>002</u>	Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

INTUNIV

	SHIRE	EQ 1MG BASE	N022037	001	Sep 02, 2009
		EQ 2MG BASE	N022037	002	Sep 02, 2009
		EQ 3MG BASE	N022037	003	Sep 02, 2009
+		EQ 4MG BASE	N022037	004	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE

	SCHERING	125MG	N001546	001	

HALCINONIDE

CREAM; TOPICAL

HALOG

+	RANBAXY	0.1%	N017556	001	

OINTMENT; TOPICAL

HALOG

+	RANBAXY	0.1%	N017824	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 204 (of 409)

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A077001</u>	<u>001</u>	Dec 16, 2004
<u>AB</u>	G AND W LABS	<u>0.05%</u>	<u>A078162</u>	<u>001</u>	Apr 24, 2007
<u>AB</u>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A077123</u>	<u>001</u>	Dec 16, 2004
<u>AB</u>	TARO	<u>0.05%</u>	<u>A077227</u>	<u>001</u>	Aug 04, 2005

ULTRAVATE

<u>AB</u>	+ RANBAXY	<u>0.05%</u>	<u>N019967</u>	<u>001</u>	Dec 27, 1990

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A077109</u>	<u>001</u>	Jun 14, 2005
<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A076903</u>	<u>001</u>	Dec 16, 2004
<u>AB</u>	G AND W LABS	<u>0.05%</u>	<u>A077721</u>	<u>001</u>	Sep 07, 2006
<u>AB</u>	PERRIGO	<u>0.05%</u>	<u>A076872</u>	<u>001</u>	Dec 16, 2004
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076994</u>	<u>001</u>	Dec 16, 2004

ULTRAVATE

<u>AB</u>	+ RANBAXY	<u>0.05%</u>	<u>N019968</u>	<u>001</u>	Dec 17, 1990

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A070278</u>	<u>006</u>	Jun 10, 1986
<u>AB</u>		<u>1MG</u>	<u>A070278</u>	<u>004</u>	Jun 10, 1986
<u>AB</u>		<u>2MG</u>	<u>A070278</u>	<u>001</u>	Jun 10, 1986
<u>AB</u>		<u>5MG</u>	<u>A070278</u>	<u>005</u>	Jun 10, 1986
<u>AB</u>		<u>10MG</u>	<u>A070278</u>	<u>002</u>	Jul 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A070278</u>	<u>003</u>	Jul 16, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071206</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>1MG</u>	<u>A071207</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>	+	<u>2MG</u>	<u>A071208</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>5MG</u>	<u>A071209</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>10MG</u>	<u>A071210</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>		<u>20MG</u>	<u>A071211</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077580</u>	<u>003</u>	Nov 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077580</u>	<u>004</u>	Nov 29, 2007
<u>AB</u>		<u>20MG</u>	<u>A077580</u>	<u>005</u>	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>A0</u>	+ ORTHO MCNEIL JANSSEN	<u>EQ 50MG BASE/ML</u>	<u>N018701</u>	<u>001</u>	Jan 14, 1986
<u>A0</u>	+	<u>EQ 100MG BASE/ML</u>	<u>N018701</u>	<u>002</u>	Jan 31, 1997

HALOPERIDOL DECANOATE

<u>A0</u>	APP PHARMS	<u>EQ 50MG BASE/ML</u>	<u>A074893</u>	<u>001</u>	Dec 19, 1997
<u>A0</u>		<u>EQ 100MG BASE/ML</u>	<u>A074893</u>	<u>002</u>	Dec 19, 1997
<u>A0</u>	BEDFORD	<u>EQ 50MG BASE/ML</u>	<u>A074811</u>	<u>001</u>	Jan 30, 1998
<u>A0</u>		<u>EQ 100MG BASE/ML</u>	<u>A075305</u>	<u>001</u>	Sep 28, 1998
<u>A0</u>	CLARIS LIFESCIENCES	<u>EQ 50MG BASE/ML</u>	<u>A075440</u>	<u>001</u>	Feb 28, 2000
<u>A0</u>		<u>EQ 100MG BASE/ML</u>	<u>A075440</u>	<u>002</u>	Feb 28, 2000
<u>A0</u>	TEVA PARENTERAL	<u>EQ 50MG BASE/ML</u>	<u>A075393</u>	<u>001</u>	May 11, 1999
<u>A0</u>		<u>EQ 100MG BASE/ML</u>	<u>A075393</u>	<u>002</u>	May 11, 1999

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>	PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037</u>	<u>001</u>	Feb 26, 1993
<u>AA</u>	SILARX	<u>EQ 2MG BASE/ML</u>	<u>A073364</u>	<u>001</u>	Sep 28, 1993
<u>AA</u>	+ TEVA PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A071617</u>	<u>001</u>	Dec 01, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 205 (of 409)

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	+ ORTHO MCNEIL JANSSEN	<u>EQ 5MG BASE/ML</u>	<u>N015923</u>	<u>001</u>	
<u>HALOPERIDOL</u>					
<u>AP</u>	AKORN STRIDES	<u>EQ 5MG BASE/ML</u>	<u>A078347</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>	APP PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A075689</u>	<u>001</u>	Mar 09, 2001
<u>AP</u>	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A075858</u>	<u>001</u>	Jun 18, 2001
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 5MG BASE/ML</u>	<u>A076791</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A076828</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>	TEVA PARENTERAL	<u>EQ 5MG BASE/ML</u>	<u>A076035</u>	<u>001</u>	Aug 29, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	+ APP PHARMS	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>001</u>	
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017651</u>	<u>006</u>	
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>003</u>	
<u>AP</u>	+	<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>004</u>	
<u>AP</u>	+ BAXTER HLTHCARE	<u>1,000 UNITS/ML</u>	<u>N017037</u>	<u>001</u>	
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017037</u>	<u>002</u>	
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017037</u>	<u>003</u>	
<u>AP</u>	HOSPIRA	<u>5,000 UNITS/ML</u>	<u>A088100</u>	<u>001</u>	Apr 28, 1983
<u>AP</u>	HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090571</u>	<u>002</u>	Aug 31, 2009
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090571</u>	<u>003</u>	Aug 31, 2009
<u>AP</u>	SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090808</u>	<u>002</u>	Jun 30, 2010
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090808</u>	<u>003</u>	Jun 30, 2010
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>A090809</u>	<u>001</u>	Jun 30, 2010
<u>HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>001</u>	Apr 28, 1982
<u>HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>010</u>	Jun 23, 1989
<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>003</u>	Mar 27, 1985
<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>002</u>	Apr 28, 1982
<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>011</u>	Jun 23, 1989
<u>HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>4,000 UNITS/100ML</u>	<u>N018814</u>	<u>001</u>	Oct 31, 1983
<u>HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805</u>	<u>001</u>	Jan 25, 1989
<u>HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>5,000 UNITS/100ML</u>	<u>N018814</u>	<u>003</u>	Jul 09, 1985
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N018814</u>	<u>004</u>	Jul 02, 1987
<u>HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952</u>	<u>004</u>	Jul 20, 1992
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N019952</u>	<u>005</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339</u>	<u>004</u>	Mar 27, 1985
<u>AP</u>		<u>5,000 UNITS/100ML</u>	<u>N019805</u>	<u>002</u>	Jan 25, 1989
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>002</u>	Mar 27, 1985
<u>HEPARIN SODIUM IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ APP PHARMS	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>013</u>	Dec 05, 1985
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017029</u>	<u>014</u>	Dec 05, 1985
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>015</u>	Dec 05, 1985
<u>AP</u>	+	<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>016</u>	Dec 05, 1985

PRESCRIPTION DRUG PRODUCT LIST

3 - 206 (of 409)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

<u>AP</u>	+	APP PHARMS	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>010</u>	Apr 28, 1986
<u>AP</u>	+	HOSPIRA	<u>10,000 UNITS/ML</u>	<u>A089522</u>	<u>001</u>	May 04, 1987
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090810</u>	<u>001</u>	Jun 30, 2010
		HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
		HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985
		HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
		HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984
		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
		HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
			10,000 UNITS/100ML	N018916	008	Jan 31, 1984

HEXACHLOROPHENE

EMULSION; TOPICAL

PHISOHEX

+	SANOFI AVENTIS US	3%	N006882	001	

SPONGE; TOPICAL

PRE-OP

<u>AT</u>	+	DAVIS AND GECK	<u>480MG</u>	<u>N017433</u>	<u>001</u>	

PRE-OP II

<u>AT</u>		DAVIS AND GECK	<u>480MG</u>	<u>N017433</u>	<u>002</u>	

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+	ENDO PHARM	50MG	N022058	001	May 03, 2007

VANTAS

+	ENDO PHARM	50MG	N021732	001	Oct 12, 2004

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

<u>AA</u>		ACTAVIS MID ATLANTIC	<u>1.5MG/5ML;5MG/5ML</u>	<u>A088017</u>	<u>001</u>	Jul 05, 1983
<u>AA</u>	+	HI TECH PHARMA	<u>1.5MG/5ML;5MG/5ML</u>	<u>A040613</u>	<u>001</u>	Feb 08, 2008
<u>AA</u>		WOCKHARDT	<u>1.5MG/5ML;5MG/5ML</u>	<u>A088008</u>	<u>001</u>	Mar 03, 1983

TABLET; ORAL

TUSSIGON

+	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985

HYALURONIDASE

INJECTABLE; INJECTION

AMPHADASE

+	AMPHASTAR PHARM	150 UNITS/ML	N021665	001	Oct 26, 2004

HYDASE

+	PRIMAPHARM	150 UNITS/ML	N021716	001	Oct 25, 2005

VITRASE

+	ISTA PHARMS	200 UNITS/VIAL	N021640	002	Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HYLENEX RECOMBINANT

+	HALOZYME THERAP	150 UNITS/ML	N021859	001	Dec 02, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 207 (of 409)

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

<u>AP</u>	AKORN	<u>20MG/ML</u>	<u>A040730</u>	<u>001</u>	Apr 21, 2009
<u>AP</u>	APP PHARMS	<u>20MG/ML</u>	<u>A040388</u>	<u>001</u>	Mar 13, 2001
<u>AP</u>	+ LUITPOLD	<u>20MG/ML</u>	<u>A040136</u>	<u>001</u>	Jun 30, 1997

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A090527</u>	<u>001</u>	May 27, 2009
<u>AA</u>		<u>25MG</u>	<u>A090527</u>	<u>002</u>	May 27, 2009
<u>AA</u>		<u>50MG</u>	<u>A090527</u>	<u>003</u>	May 27, 2009
<u>AA</u>		<u>100MG</u>	<u>A090527</u>	<u>004</u>	May 27, 2009
<u>AA</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A086242</u>	<u>001</u>	Feb 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A086242</u>	<u>003</u>	
<u>AA</u>		<u>50MG</u>	<u>A086242</u>	<u>002</u>	
<u>AA</u>		<u>100MG</u>	<u>A086242</u>	<u>004</u>	Feb 04, 2010
<u>AA</u>	HETERO DRUGS LTD	<u>10MG</u>	<u>A040901</u>	<u>001</u>	Sep 12, 2008
<u>AA</u>		<u>25MG</u>	<u>A040901</u>	<u>002</u>	Sep 12, 2008
<u>AA</u>		<u>50MG</u>	<u>A040901</u>	<u>003</u>	Sep 12, 2008
<u>AA</u>		<u>100MG</u>	<u>A040901</u>	<u>004</u>	Sep 12, 2008
<u>AA</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090255</u>	<u>001</u>	Dec 15, 2008
<u>AA</u>		<u>25MG</u>	<u>A090255</u>	<u>002</u>	Dec 15, 2008
<u>AA</u>		<u>50MG</u>	<u>A090255</u>	<u>003</u>	Dec 15, 2008
<u>AA</u>		<u>100MG</u>	<u>A090255</u>	<u>004</u>	Dec 15, 2008
<u>AA</u>	MYLAN	<u>10MG</u>	<u>A090413</u>	<u>001</u>	Dec 08, 2010
<u>AA</u>		<u>25MG</u>	<u>A090413</u>	<u>002</u>	Dec 08, 2010
<u>AA</u>		<u>50MG</u>	<u>A090413</u>	<u>003</u>	Dec 08, 2010
<u>AA</u>		<u>100MG</u>	<u>A090413</u>	<u>004</u>	Dec 08, 2010
<u>AA</u>	PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>		<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>		<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>		<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	+ PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	+	<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	WATSON LABS	<u>25MG</u>	<u>A084504</u>	<u>001</u>	
<u>AA</u>		<u>50MG</u>	<u>A084503</u>	<u>001</u>	
<u>AA</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A040858</u>	<u>001</u>	Feb 26, 2010
<u>AA</u>		<u>25MG</u>	<u>A040858</u>	<u>002</u>	Feb 26, 2010
<u>AA</u>		<u>50MG</u>	<u>A040858</u>	<u>003</u>	Feb 26, 2010
<u>AA</u>		<u>100MG</u>	<u>A040858</u>	<u>004</u>	Feb 26, 2010

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

	PAR PHARM	25MG;25MG	A088957	001	Oct 21, 1985
+		50MG;50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

+	NITROMED	37.5MG;20MG	N020727	001	Jun 23, 2005

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC LTD	<u>12.5MG</u>	<u>A200645</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A078389</u>	<u>001</u>	May 16, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164</u>	<u>001</u>	Sep 18, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 208 (of 409)

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	CADISTA PHARMS	<u>12.5MG</u>	<u>A078391</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A079237</u>	<u>001</u>	Apr 02, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A077005</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075640</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	UNICHEM	<u>12.5MG</u>	<u>A090510</u>	<u>001</u>	Jan 19, 2010
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A075907</u>	<u>001</u>	Sep 17, 2002
<u>AB</u>	WEST WARD	<u>12.5MG</u>	<u>A077885</u>	<u>001</u>	Nov 26, 2007

MICROZIDE

<u>AB</u>	+ WATSON LABS	<u>12.5MG</u>	<u>N020504</u>	<u>001</u>	Dec 27, 1996

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707</u>	<u>001</u>	Feb 27, 2007
<u>AB</u>		<u>25MG</u>	<u>A085054</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085208</u>	<u>001</u>	
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A040774</u>	<u>001</u>	Oct 03, 2007
<u>AB</u>		<u>50MG</u>	<u>A040774</u>	<u>002</u>	Oct 03, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A040780</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040780</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A040809</u>	<u>001</u>	Sep 04, 2007
<u>AB</u>		<u>50MG</u>	<u>A040809</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>	CARACO	<u>12.5MG</u>	<u>A040857</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040810</u>	<u>001</u>	Mar 27, 2007
<u>AB</u>		<u>50MG</u>	<u>A040810</u>	<u>002</u>	Mar 27, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A087059</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A087068</u>	<u>001</u>	
<u>AB</u>	EXCELLIUM	<u>25MG</u>	<u>A040702</u>	<u>001</u>	Mar 16, 2007
<u>AB</u>		<u>50MG</u>	<u>A040702</u>	<u>002</u>	Mar 16, 2007
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085182</u>	<u>001</u>	
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A040807</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>25MG</u>	<u>A040807</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040807</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A083177</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083177</u>	<u>002</u>	
<u>AB</u>	LANNETT	<u>25MG</u>	<u>A084325</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084324</u>	<u>001</u>	
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A040770</u>	<u>001</u>	Jan 23, 2007
<u>AB</u>		<u>25MG</u>	<u>A040735</u>	<u>002</u>	Jan 23, 2007
<u>AB</u>	+	<u>50MG</u>	<u>A040735</u>	<u>003</u>	Jan 23, 2007
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A040907</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>		<u>50MG</u>	<u>A040907</u>	<u>002</u>	Aug 15, 2008
<u>AB</u>	VINTAGE PHARMS	<u>25MG</u>	<u>A040412</u>	<u>001</u>	Mar 29, 2002
<u>AB</u>		<u>50MG</u>	<u>A040412</u>	<u>002</u>	Mar 29, 2002
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A081189</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>	WEST WARD	<u>25MG</u>	<u>A084878</u>	<u>002</u>	Jul 12, 2006
<u>AB</u>		<u>50MG</u>	<u>A084878</u>	<u>001</u>	
	<u>ORETIC</u>				
<u>AB</u>	ABBOTT	<u>50MG</u>	<u>N011971</u>	<u>002</u>	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

	SANOFI AVENTIS US	12.5MG;150MG	N020758	002	Sep 30, 1997
		12.5MG;300MG	N020758	003	Aug 31, 1998
+		25MG;300MG	N020758	004	Mar 15, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 209 (of 409)

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>12.5MG;10MG</u>	<u>A076674</u>	<u>001</u>	Oct 05, 2004
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076674</u>	<u>002</u>	Oct 05, 2004
<u>AB</u>		<u>25MG;20MG</u>	<u>A076674</u>	<u>003</u>	Oct 05, 2004
<u>AB</u>	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606</u>	<u>001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077606</u>	<u>002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077606</u>	<u>003</u>	Mar 14, 2006
<u>AB</u>	HUAHAI US INC	<u>12.5MG;10MG</u>	<u>A076230</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG;10MG</u>	<u>A075776</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A075776</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A075776</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912</u>	<u>001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912</u>	<u>002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912</u>	<u>003</u>	Sep 27, 2006
<u>AB</u>	MYLAN	<u>12.5MG;10MG</u>	<u>A076113</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076113</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076113</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	RANBAXY	<u>12.5MG;10MG</u>	<u>A076007</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076262</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>	WEST WARD	<u>12.5MG;10MG</u>	<u>A076265</u>	<u>001</u>	Jul 08, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076265</u>	<u>002</u>	Jul 08, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076265</u>	<u>003</u>	Jul 08, 2002
	<u>PRINZIDE</u>				
<u>AB</u>	MERCK	<u>12.5MG;10MG</u>	<u>N019778</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>		<u>12.5MG;20MG</u>	<u>N019778</u>	<u>001</u>	Feb 16, 1989
	<u>ZESTORETIC</u>				
<u>AB</u>	ASTRAZENECA	<u>12.5MG;10MG</u>	<u>N019888</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>	+	<u>12.5MG;20MG</u>	<u>N019888</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	+	<u>25MG;20MG</u>	<u>N019888</u>	<u>002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	MERCK	<u>12.5MG;50MG</u>	<u>N020387</u>	<u>001</u>	Apr 28, 1995
<u>AB</u>		<u>12.5MG;100MG</u>	<u>N020387</u>	<u>003</u>	Oct 20, 2005
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N020387</u>	<u>002</u>	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX	<u>12.5MG;50MG</u>	<u>A090150</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090150</u>	<u>002</u>	Aug 11, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090150</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091629</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091629</u>	<u>003</u>	Jan 06, 2010
<u>AB</u>	LUPIN LTD	<u>12.5MG;50MG</u>	<u>A078245</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A078245</u>	<u>002</u>	May 21, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078245</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	MYLAN	<u>12.5MG;50MG</u>	<u>A091652</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091652</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091652</u>	<u>003</u>	Oct 06, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 210 (of 409)

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ROXANE	<u>12.5MG;50MG</u>	<u>A077732</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077732</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077732</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>12.5MG;50MG</u>	<u>A077948</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077948</u>	<u>003</u>	Aug 19, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077948</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>	TEVA PHARMS	<u>12.5MG;50MG</u>	<u>A077157</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077157</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077157</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>12.5MG;50MG</u>	<u>A090528</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090528</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090528</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>12.5MG;50MG</u>	<u>A078385</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078385</u>	<u>002</u>	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	MYLAN	15MG;250MG	A070264	001	Jan 23, 1986
+		25MG;250MG	A070265	001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

<u>AB</u>	NOVARTIS	<u>25MG;50MG</u>	<u>N018303</u>	<u>001</u>	Dec 31, 1984
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N018303</u>	<u>002</u>	Dec 31, 1984
	<u>METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	MYLAN	<u>25MG;50MG</u>	<u>A076792</u>	<u>001</u>	Aug 20, 2004
<u>AB</u>		<u>25MG;100MG</u>	<u>A076792</u>	<u>002</u>	Aug 20, 2004
	<u>METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE</u>				
	MYLAN	50MG;100MG	A076792	003	Aug 20, 2004

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	GLENMARK PHARMS	<u>12.5MG;7.5MG</u>	<u>A090718</u>	<u>001</u>	Mar 17, 2010
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A090718</u>	<u>002</u>	Mar 17, 2010
<u>AB</u>		<u>25MG;15MG</u>	<u>A090718</u>	<u>003</u>	Mar 17, 2010
<u>AB</u>	PADDOCK	<u>12.5MG;7.5MG</u>	<u>A090096</u>	<u>001</u>	Sep 25, 2008
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A090096</u>	<u>002</u>	Sep 25, 2008
<u>AB</u>		<u>25MG;15MG</u>	<u>A090096</u>	<u>003</u>	Sep 25, 2008
<u>AB</u>	TEVA	<u>12.5MG;7.5MG</u>	<u>A076980</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A076980</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>		<u>25MG;15MG</u>	<u>A076980</u>	<u>002</u>	Mar 07, 2007
	<u>UNIRETIC</u>				
<u>AB</u>	UCB INC	<u>12.5MG;7.5MG</u>	<u>N020729</u>	<u>001</u>	Jun 27, 1997
<u>AB</u>		<u>12.5MG;15MG</u>	<u>N020729</u>	<u>003</u>	Feb 14, 2002
<u>AB</u>	+	<u>25MG;15MG</u>	<u>N020729</u>	<u>002</u>	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

	DAIICHI SANKYO	12.5MG;20MG	N021532	002	Jun 05, 2003
		12.5MG;40MG	N021532	003	Jun 05, 2003
+		25MG;40MG	N021532	005	Jun 05, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 211 (of 409)

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

<u>AB</u>	+	AKRIMAX PHARMS	<u>25MG;40MG</u>	<u>N018031</u>	<u>001</u>	
<u>PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>						
<u>AB</u>		MYLAN	<u>25MG;40MG</u>	<u>A070946</u>	<u>001</u>	Mar 04, 1987
<u>AB</u>	+		<u>25MG;80MG</u>	<u>A070947</u>	<u>001</u>	Apr 01, 1987
<u>AB</u>		PLIVA	<u>25MG;40MG</u>	<u>A072042</u>	<u>001</u>	Mar 14, 1988
<u>AB</u>			<u>25MG;80MG</u>	<u>A072043</u>	<u>001</u>	Mar 14, 1988
<u>AB</u>		WATSON LABS	<u>25MG;40MG</u>	<u>A070301</u>	<u>001</u>	Apr 18, 1986
<u>AB</u>			<u>25MG;80MG</u>	<u>A070305</u>	<u>001</u>	Apr 18, 1986

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

<u>AB</u>		PFIZER PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>N020125</u>	<u>001</u>	Dec 28, 1999
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>N020125</u>	<u>002</u>	Dec 28, 1999
<u>AB</u>	+		<u>25MG;EQ 20MG BASE</u>	<u>N020125</u>	<u>003</u>	Dec 28, 1999
<u>QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>						
<u>AB</u>		AUROBINDO PHARMA	<u>12.5MG;EQ 10MG BASE</u>	<u>A078450</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		MYLAN	<u>12.5MG;EQ 10MG BASE</u>	<u>A077093</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A077093</u>	<u>002</u>	Mar 28, 2005
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A077093</u>	<u>003</u>	Mar 28, 2005
<u>AB</u>		RANBAXY	<u>12.5MG;EQ 10MG BASE</u>	<u>A078211</u>	<u>001</u>	Mar 04, 2009
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A078211</u>	<u>002</u>	Mar 04, 2009
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A078211</u>	<u>003</u>	Mar 04, 2009
<u>QUINARETIC</u>						
<u>AB</u>		GAVIS PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A076374</u>	<u>001</u>	Mar 31, 2004
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>002</u>	Mar 31, 2004
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>003</u>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

<u>AB</u>		GD SEARLE LLC	<u>25MG;25MG</u>	<u>N012616</u>	<u>004</u>	Dec 30, 1982
<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>						
<u>AB</u>		MUTUAL PHARM	<u>25MG;25MG</u>	<u>A089534</u>	<u>001</u>	Jul 02, 1987
<u>AB</u>		MYLAN	<u>25MG;25MG</u>	<u>A086513</u>	<u>001</u>	
<u>AB</u>		WATSON LABS	<u>25MG;25MG</u>	<u>A087398</u>	<u>001</u>	
		ALDACTAZIDE				
	+	GD SEARLE LLC	<u>50MG;50MG</u>	<u>N012616</u>	<u>005</u>	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

		BOEHRINGER INGELHEIM	<u>12.5MG;40MG</u>	<u>N021162</u>	<u>001</u>	Nov 17, 2000
			<u>12.5MG;80MG</u>	<u>N021162</u>	<u>002</u>	Nov 17, 2000
	+		<u>25MG;80MG</u>	<u>N021162</u>	<u>003</u>	Apr 19, 2004

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG;37.5MG</u>	<u>N016042</u>	<u>003</u>	Mar 03, 1994
<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>						
<u>AB</u>		DURAMED PHARMS BARR	<u>25MG;37.5MG</u>	<u>A075052</u>	<u>001</u>	Jun 18, 1999
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>25MG;50MG</u>	<u>A074259</u>	<u>001</u>	Mar 30, 1995
<u>AB</u>		MYLAN	<u>25MG;37.5MG</u>	<u>A074701</u>	<u>001</u>	Jun 07, 1996
<u>AB</u>		SANDOZ	<u>25MG;37.5MG</u>	<u>A074821</u>	<u>001</u>	Jun 05, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 212 (of 409)

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	+	SANDOZ	<u>25MG;50MG</u>	<u>A073191</u>	<u>001</u>	Jul 31, 1991

TABLET; ORAL

MAXZIDE

<u>AB</u>	+	MYLAN BERTEK	<u>50MG;75MG</u>	<u>N019129</u>	<u>001</u>	Oct 22, 1984

MAXZIDE-25

<u>AB</u>		MYLAN BERTEK	<u>25MG;37.5MG</u>	<u>N019129</u>	<u>003</u>	May 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		APOTEX INC	<u>25MG;37.5MG</u>	<u>A071251</u>	<u>002</u>	May 05, 1998

<u>AB</u>			<u>50MG;75MG</u>	<u>A071251</u>	<u>001</u>	Apr 17, 1988

<u>AB</u>		PLIVA	<u>25MG;37.5MG</u>	<u>A074026</u>	<u>001</u>	Apr 26, 1996

<u>AB</u>			<u>50MG;75MG</u>	<u>A073467</u>	<u>001</u>	Jan 31, 1996

<u>AB</u>		SANDOZ	<u>25MG;37.5MG</u>	<u>A073281</u>	<u>001</u>	Apr 30, 1992

<u>AB</u>			<u>50MG;75MG</u>	<u>A072011</u>	<u>001</u>	Jun 17, 1988

<u>AB</u>		WATSON LABS	<u>25MG;37.5MG</u>	<u>A073449</u>	<u>001</u>	Sep 23, 1993

<u>AB</u>			<u>50MG;75MG</u>	<u>A071851</u>	<u>001</u>	Nov 30, 1988

<u>AB</u>			<u>50MG;75MG</u>	<u>A071969</u>	<u>001</u>	Apr 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

NOVARTIS

12.5MG;80MG

N020818 001 Mar 06, 1998

12.5MG;160MG

N020818 002 Mar 06, 1998

12.5MG;320MG

N020818 004 Apr 28, 2006

25MG;160MG

N020818 003 Jan 17, 2002

+

25MG;320MG

N020818 005 Apr 28, 2006

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

<u>AB</u>		AMNEAL PHARMS NY	<u>5MG;200MG</u>	<u>A076642</u>	<u>002</u>	Mar 18, 2004

<u>AB</u>			<u>7.5MG;200MG</u>	<u>A076642</u>	<u>001</u>	Oct 12, 2004

<u>AB</u>		TEVA	<u>7.5MG;200MG</u>	<u>A076023</u>	<u>001</u>	Apr 11, 2003

<u>AB</u>		VINTAGE PHARMS	<u>5MG;200MG</u>	<u>A077727</u>	<u>001</u>	Nov 06, 2006

<u>AB</u>			<u>7.5MG;200MG</u>	<u>A077723</u>	<u>001</u>	Nov 06, 2006

<u>AB</u>			<u>10MG;200MG</u>	<u>A077723</u>	<u>002</u>	Nov 06, 2006

<u>AB</u>		WATSON LABS FLORIDA	<u>5MG;200MG</u>	<u>A077454</u>	<u>001</u>	Jun 23, 2010

<u>AB</u>			<u>7.5MG;200MG</u>	<u>A076604</u>	<u>001</u>	Dec 31, 2003

VICOPROFEN

<u>AB</u>	+	ABBOTT	<u>7.5MG;200MG</u>	<u>N020716</u>	<u>001</u>	Sep 23, 1997

REPREXAIN

AMNEAL PHARMS NY

2.5MG;200MG

A076642 003 Oct 19, 2007

10MG;200MG

A076642 004 Oct 19, 2007

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

<u>AT</u>		DEL RAY LABS	<u>1%</u>	<u>A080706</u>	<u>006</u>	

ANUSOL HC

<u>AT</u>		SALIX PHARMS	<u>2.5%</u>	<u>A088250</u>	<u>001</u>	Jun 06, 1984

HYDROCORTISONE

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087795</u>	<u>001</u>	May 03, 1983

<u>AT</u>			<u>2.5%</u>	<u>A089682</u>	<u>001</u>	Mar 10, 1988

<u>AT</u>	+	FOUGERA	<u>1%</u>	<u>A080693</u>	<u>003</u>	

<u>AT</u>	+		<u>2.5%</u>	<u>A089414</u>	<u>001</u>	Dec 16, 1986

<u>AT</u>		LYNE	<u>2.5%</u>	<u>A040879</u>	<u>001</u>	Aug 20, 2010

<u>AT</u>		PERRIGO NEW YORK	<u>2.5%</u>	<u>A085025</u>	<u>001</u>	

<u>AT</u>		TARO	<u>1%</u>	<u>A086155</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3 - 213 (of 409)

HYDROCORTISONE

CREAM; TOPICAL				
<u>HYDROCORTISONE</u>				
<u>AT</u>	TARO	<u>2.5%</u>	<u>A088799</u> <u>001</u>	Nov 09, 1984
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040503</u> <u>001</u>	Mar 12, 2004
<u>SYNACORT</u>				
<u>AT</u>	MEDICIS	<u>1%</u>	<u>A087458</u> <u>001</u>	
<u>AT</u>		<u>2.5%</u>	<u>A087457</u> <u>001</u>	
ENEMA; RECTAL				
<u>COLOCORT</u>				
<u>AB</u>	PADDOCK	<u>100MG/60ML</u>	<u>A075172</u> <u>001</u>	Dec 03, 1999
<u>CORTENEMA</u>				
<u>AB</u> +	ANI PHARMS	<u>100MG/60ML</u>	<u>N016199</u> <u>001</u>	
<u>HYDROCORTISONE</u>				
<u>AB</u>	TEVA PHARMS	<u>100MG/60ML</u>	<u>A074171</u> <u>001</u>	May 27, 1994
LOTION; TOPICAL				
<u>ALA-CORT</u>				
<u>AT</u>	DEL RAY LABS	<u>1%</u>	<u>A083201</u> <u>001</u>	
<u>HYDROCORTISONE</u>				
<u>AT</u> +	ALTANA	<u>2.5%</u>	<u>A040351</u> <u>001</u>	Jul 25, 2000
<u>AT</u>	TARO	<u>2.5%</u>	<u>A040247</u> <u>001</u>	Jul 23, 1999
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040417</u> <u>001</u>	Jul 30, 2003
<u>NUTRACORT</u>				
<u>AT</u>	CORIA	<u>1%</u>	<u>A080443</u> <u>003</u>	
<u>AT</u>		<u>2.5%</u>	<u>A087644</u> <u>001</u>	Aug 24, 1982
<u>STIE-CORT</u>				
<u>AT</u>	PERRIGO	<u>1%</u>	<u>A089066</u> <u>001</u>	Nov 25, 1985
<u>AT</u>		<u>2.5%</u>	<u>A089074</u> <u>001</u>	Nov 26, 1985
ALA-SCALP				
	DEL RAY LABS	2%	A083231	001
OINTMENT; TOPICAL				
<u>HYDROCORTISONE</u>				
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087796</u> <u>001</u>	Oct 13, 1982
<u>AT</u> +	ALTANA	<u>1%</u>	<u>A080692</u> <u>001</u>	
<u>AT</u> +	FOUGERA	<u>2.5%</u>	<u>A081203</u> <u>001</u>	May 28, 1993
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085027</u> <u>001</u>	
<u>AT</u>	TARO	<u>1%</u>	<u>A086257</u> <u>001</u>	
<u>AT</u>		<u>2.5%</u>	<u>A040310</u> <u>001</u>	Dec 29, 2000
<u>HYDROCORTISONE IN ABSORBASE</u>				
<u>AT</u>	CAROLINA MEDCL	<u>1%</u>	<u>A088138</u> <u>001</u>	Sep 06, 1985
POWDER; FOR RX COMPOUNDING				
HYDRO-RX				
	+ X GEN PHARMS	100%	A085982	001
SOLUTION; TOPICAL				
TEXACORT				
	+ JSJ PHARMS	2.5%	A081271	001
TABLET; ORAL				
<u>CORTEF</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>5MG</u>	<u>N008697</u> <u>003</u>	
<u>AB</u>		<u>10MG</u>	<u>N008697</u> <u>001</u>	
<u>AB</u> +		<u>20MG</u>	<u>N008697</u> <u>002</u>	
<u>HYDROCORTISONE</u>				
<u>AB</u>	STIEFEL GSK	<u>5MG</u>	<u>A040646</u> <u>001</u>	Mar 30, 2007
<u>AB</u>		<u>10MG</u>	<u>A040646</u> <u>002</u>	Mar 30, 2007
<u>AB</u>		<u>20MG</u>	<u>A040646</u> <u>003</u>	Mar 30, 2007
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A040761</u> <u>001</u>	Jul 16, 2007
<u>AB</u>		<u>10MG</u>	<u>A040761</u> <u>002</u>	Jul 16, 2007
<u>AB</u>		<u>20MG</u>	<u>A040761</u> <u>003</u>	Jul 16, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 214 (of 409)

HYDROCORTISONE

TABLET; ORAL			
HYDROCORTISONE			
BP	WEST WARD	20MG	A083365 001

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL			
CORTIFOAM			
+	MEDA PHARMS	10%	N017351 001 Feb 10, 1982
CREAM; TOPICAL			
HYDROCORTISONE ACETATE			
+	FERNDAL LABS	2.5%	A040259 001 Jul 29, 1999
MICORT-HC			
+	FERNDAL LABS	2%	A040398 001 Mar 29, 2002
		2.5%	A040396 001 Feb 27, 2001
PASTE; TOPICAL			
ORABASE HCA			
	COLGATE	0.5%	A083205 001
POWDER; FOR RX COMPOUNDING			
HYDROCORTISONE ACETATE			
	X GEN PHARMS	100%	A085981 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL			
CORTISPORIN			
+	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL			
EPIFOAM			
BX	MEDA PHARMS	1%;1%	A086457 001
PROCTOFOAM HC			
BX	MEDA PHARMS	1%;1%	A086195 001
CREAM; TOPICAL			
PRAMOSONE			
	FERNDAL LABS	0.5%;1%	A083778 001
		1%;1%	A085368 001
LOTION; TOPICAL			
PRAMOSONE			
	FERNDAL LABS	1%;1%	A085980 001
		2.5%;1%	A085979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL			
<u>CARMOL HC</u>			
<u>AT</u>	+	NYCOMED US	<u>1%;10%</u> <u>A080505 001</u>
<u>U-CORT</u>			
<u>AT</u>		TARO	<u>1%;10%</u> <u>A089472 001</u> Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL			
<u>HYDROCORTISONE BUTYRATE</u>			
<u>AB</u>		TARO PHARM INDS	<u>0.1%</u> <u>A076654 001</u> Aug 03, 2005
<u>LOCOID</u>			
<u>AB</u>	+	TRIAx PHARMS LLC	<u>0.1%</u> <u>N018514 001</u> Mar 31, 1982
LOCOID LIPOCREAM			
	+	TRIAx PHARMS LLC	0.1% N020769 001 Sep 08, 1997

PRESCRIPTION DRUG PRODUCT LIST

3 - 215 (of 409)

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL				
LOCOID				
	+ TRIAX PHARMS LLC	0.1%	N022076 001	May 18, 2007
OINTMENT; TOPICAL				
<u>HYDROCORTISONE BUTYRATE</u>				
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076842</u> <u>001</u>	Dec 27, 2004
<u>LOCOID</u>				
<u>AB</u>	+ TRIAX PHARMS LLC	<u>0.1%</u>	<u>N018652</u> <u>001</u>	Oct 29, 1982
SOLUTION; TOPICAL				
<u>HYDROCORTISONE BUTYRATE</u>				
<u>AT</u>	TARO PHARM INDS	<u>0.1%</u>	<u>A076364</u> <u>001</u>	Jan 14, 2004
<u>LOCOID</u>				
<u>AT</u>	+ TRIAX PHARMS LLC	<u>0.1%</u>	<u>N019116</u> <u>001</u>	Feb 25, 1987

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL				
PANDEL				
	+ SAVAGE LABS	0.1%	N020453 001	Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION				
<u>A-HYDROCORT</u>				
<u>AP</u>	HOSPIRA	<u>EQ 100MG BASE/VIAL</u>	<u>A040666</u> <u>001</u>	Apr 06, 2006
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A085930</u> <u>001</u>	
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A085931</u> <u>001</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A085932</u> <u>001</u>	
<u>SOLU-CORTEF</u>				
<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 100MG BASE/VIAL</u>	<u>N009866</u> <u>001</u>	
<u>AP</u>	+	<u>EQ 250MG BASE/VIAL</u>	<u>N009866</u> <u>002</u>	
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N009866</u> <u>003</u>	
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N009866</u> <u>004</u>	

HYDROCORTISONE VALERATE

CREAM; TOPICAL				
<u>HYDROCORTISONE VALERATE</u>				
<u>AB</u>	PERRIGO NEW YORK	<u>0.2%</u>	<u>A075666</u> <u>001</u>	May 24, 2000
<u>AB</u>	TARO	<u>0.2%</u>	<u>A075042</u> <u>001</u>	Aug 25, 1998
<u>WESTCORT</u>				
<u>AB</u>	+ RANBAXY	<u>0.2%</u>	<u>N017950</u> <u>001</u>	
OINTMENT; TOPICAL				
<u>HYDROCORTISONE VALERATE</u>				
<u>AB</u>	ALTANA	<u>0.2%</u>	<u>A075085</u> <u>001</u>	Jul 31, 2001
<u>AB</u>	TARO	<u>0.2%</u>	<u>A075043</u> <u>001</u>	Aug 25, 1998
<u>WESTCORT</u>				
<u>AB</u>	+ RANBAXY	<u>0.2%</u>	<u>N018726</u> <u>001</u>	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC				
<u>CORTISPORIN</u>				
<u>AT</u>	+ MONARCH PHARMS	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050479</u> <u>001</u>	
<u>NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE</u>				
<u>AT</u>	ALCON	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062423</u> <u>001</u>	Aug 25, 1983
<u>AT</u>	BAUSCH AND LOMB	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064053</u> <u>001</u>	Dec 29, 1995
<u>AT</u>	LUITPOLD	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A065216</u> <u>001</u>	Oct 31, 2005
SUSPENSION/DROPS; OPHTHALMIC				
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
	+ ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874 001	May 11, 1988

PRESCRIPTION DRUG PRODUCT LIST

3 - 216 (of 409)

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

CORTISPORIN

<u>AT</u>	+ MONARCH PHARMS	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A060613</u>	<u>001</u>	
	<u>NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE</u>				
<u>AT</u>	ALCON UNIVERSAL	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062488</u>	<u>001</u>	Nov 06, 1985
<u>AT</u>	LUITPOLD	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A065219</u>	<u>001</u>	May 01, 2006
	<u>OTICAIR</u>				
<u>AT</u>	BAUSCH AND LOMB	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064065</u>	<u>001</u>	Aug 28, 1996
	<u>PEDIOTIC</u>				
<u>AT</u>	MONARCH PHARMS	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062822</u>	<u>001</u>	Sep 29, 1987

HYDROFLUMETHIAZIDE

TABLET; ORAL

HYDROFLUMETHIAZIDE

<u>AB</u>	PAR PHARM	<u>50MG</u>	<u>A088850</u>	<u>001</u>	May 31, 1985
	<u>SALURON</u>				
<u>AB</u>	+ SHIRE	<u>50MG</u>	<u>N011949</u>	<u>001</u>	

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID-HP

<u>AP</u>	+ PURDUE PHARM PRODS	<u>10MG/ML</u>	<u>N019034</u>	<u>001</u>	Jan 11, 1984
	<u>HYDROMORPHONE HYDROCHLORIDE</u>				
<u>AP</u>	AKORN	<u>10MG/ML</u>	<u>A078228</u>	<u>001</u>	Apr 14, 2010
<u>AP</u>		<u>10MG/ML</u>	<u>A078261</u>	<u>001</u>	Apr 14, 2010
<u>AP</u>	BARR	<u>10MG/ML</u>	<u>A076444</u>	<u>001</u>	Apr 25, 2003
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A074598</u>	<u>001</u>	Jun 19, 1997
<u>AP</u>	HOSPIRA INC	<u>10MG/ML</u>	<u>A078591</u>	<u>001</u>	Jun 17, 2008
	<u>DILAUDID</u>				
	+ PURDUE PHARM PRODS	1MG/ML	N019034	003	Apr 30, 2009
	+	2MG/ML	N019034	004	Apr 30, 2009
	+	4MG/ML	N019034	005	Apr 30, 2009
	<u>DILAUDID-HP</u>				
	+ PURDUE PHARM PRODS	250MG/VIAL	N019034	002	Aug 04, 1994

SOLUTION; ORAL

DILAUDID

<u>AA</u>	+ PURDUE PHARM PRODS	<u>5MG/5ML</u>	<u>N019891</u>	<u>001</u>	Dec 07, 1992
	<u>HYDROMORPHONE HYDROCHLORIDE</u>				
<u>AA</u>	ROXANE	<u>5MG/5ML</u>	<u>A074653</u>	<u>001</u>	Jul 29, 1998

TABLET; ORAL

DILAUDID

<u>AB</u>	PURDUE PHARM PRODS	<u>2MG</u>	<u>N019892</u>	<u>003</u>	Nov 09, 2007
<u>AB</u>		<u>4MG</u>	<u>N019892</u>	<u>002</u>	Nov 09, 2007
<u>AB</u>	+	<u>8MG</u>	<u>N019892</u>	<u>001</u>	Dec 07, 1992
	<u>HYDROMORPHONE HYDROCHLORIDE</u>				
<u>AB</u>	KV PHARM	<u>2MG</u>	<u>A077311</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>4MG</u>	<u>A077311</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		<u>8MG</u>	<u>A077311</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>	LANNETT	<u>2MG</u>	<u>A078439</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>		<u>4MG</u>	<u>A078439</u>	<u>002</u>	Dec 09, 2009
<u>AB</u>		<u>8MG</u>	<u>A077471</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>	MALLINCKRODT	<u>8MG</u>	<u>A076855</u>	<u>001</u>	Dec 23, 2004
<u>AB</u>	MIKAH PHARMA	<u>8MG</u>	<u>A076723</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>	ROXANE	<u>4MG</u>	<u>A074597</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>8MG</u>	<u>A074597</u>	<u>001</u>	Jul 29, 1998
<u>AB</u>	TYCO HLTHCARE	<u>2MG</u>	<u>A078273</u>	<u>001</u>	Sep 19, 2007
<u>AB</u>		<u>4MG</u>	<u>A078273</u>	<u>002</u>	Sep 19, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 217 (of 409)

HYDROMORPHONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
EXALGO

MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010
	12MG	N021217	002	Mar 01, 2010
+	16MG	N021217	003	Mar 01, 2010

HYDROXOCOBALAMININJECTABLE; INJECTION
CYANOKIT

+ MERCK SANTE SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006
HYDROXOCOBALAMIN				
+ WATSON LABS	1MG/ML	A085998	001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

+ AKORN	1%;0.25%	N019261	001	Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

<u>AB</u>	IPCA LABS LTD	<u>200MG</u>	<u>A040766</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A040274</u>	<u>001</u>	May 29, 1998
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A040104</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>		<u>200MG</u>	<u>A040150</u>	<u>001</u>	Jan 27, 1996
<u>AB</u>	TEVA PHARMS	<u>200MG</u>	<u>A040081</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>	WATSON LABS	<u>200MG</u>	<u>A040133</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	WEST WARD	<u>200MG</u>	<u>A040760</u>	<u>001</u>	Aug 15, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A040657</u>	<u>001</u>	Sep 21, 2007

PLAQUENIL

<u>AB</u>	+ SANOFI AVENTIS US	<u>200MG</u>	<u>N009768</u>	<u>001</u>	

HYDROXYPROPYL CELLULOSEINSERT; OPHTHALMIC
LACRISERT

+ ATON	5MG	N018771	001	

HYDROXYUREA

CAPSULE; ORAL

HYDREA

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N016295</u>	<u>001</u>	
	<u>HYDROXYUREA</u>				
<u>AB</u>	BARR	<u>500MG</u>	<u>A075143</u>	<u>001</u>	Oct 16, 1998
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A075340</u>	<u>001</u>	Feb 24, 1999
	DROXIA				
	BRISTOL MYERS SQUIBB	200MG	N016295	002	Feb 25, 1998
		300MG	N016295	003	Feb 25, 1998
		400MG	N016295	004	Feb 25, 1998

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

<u>AP</u>	+ APP PHARMS	<u>25MG/ML</u>	<u>A087329</u>	<u>001</u>	
<u>AP</u>	+	<u>50MG/ML</u>	<u>A087329</u>	<u>002</u>	
<u>AP</u>	LUITPOLD	<u>25MG/ML</u>	<u>A087408</u>	<u>001</u>	
<u>AP</u>		<u>50MG/ML</u>	<u>A087408</u>	<u>002</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 218 (of 409)

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AA</u>	+	HI TECH PHARMA	<u>10MG/5ML</u>	<u>A040010</u>	<u>001</u>	Oct 28, 1994
<u>AA</u>	+	VINTAGE PHARMS	<u>10MG/5ML</u>	<u>A040391</u>	<u>001</u>	Apr 10, 2002
<u>AA</u>	+	WOCKHARDT	<u>10MG/5ML</u>	<u>A087294</u>	<u>001</u>	Apr 12, 1982

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS TOTOWA	<u>10MG</u>	<u>A040600</u>	<u>001</u>	Dec 28, 2004
<u>AB</u>			<u>25MG</u>	<u>A040602</u>	<u>001</u>	Dec 28, 2004
<u>AB</u>			<u>50MG</u>	<u>A040604</u>	<u>001</u>	Dec 28, 2004
<u>AB</u>		AMNEAL PHARM	<u>10MG</u>	<u>A040808</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>			<u>25MG</u>	<u>A040808</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>			<u>50MG</u>	<u>A040808</u>	<u>003</u>	Sep 24, 2008
<u>AB</u>		HERITAGE PHARMS INC	<u>10MG</u>	<u>A040804</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>			<u>25MG</u>	<u>A040804</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>			<u>50MG</u>	<u>A040804</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		HETERO DRUGS LTD	<u>10MG</u>	<u>A040805</u>	<u>001</u>	May 29, 2008
<u>AB</u>			<u>25MG</u>	<u>A040805</u>	<u>002</u>	May 29, 2008
<u>AB</u>			<u>50MG</u>	<u>A040805</u>	<u>003</u>	May 29, 2008
<u>AB</u>		INVAGEN PHARMS	<u>10MG</u>	<u>A040812</u>	<u>001</u>	Mar 12, 2008
<u>AB</u>			<u>25MG</u>	<u>A040812</u>	<u>002</u>	Mar 12, 2008
<u>AB</u>			<u>50MG</u>	<u>A040812</u>	<u>003</u>	Mar 12, 2008
<u>AB</u>		KVK TECH	<u>10MG</u>	<u>A040786</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>			<u>25MG</u>	<u>A040787</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>			<u>50MG</u>	<u>A040788</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>		MUTUAL PHARM	<u>10MG</u>	<u>A089381</u>	<u>001</u>	May 19, 1986
<u>AB</u>			<u>25MG</u>	<u>A089382</u>	<u>001</u>	May 19, 1986
<u>AB</u>			<u>50MG</u>	<u>A089383</u>	<u>001</u>	May 19, 1986
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A091176</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>			<u>25MG</u>	<u>A091176</u>	<u>002</u>	Jun 07, 2010
<u>AB</u>			<u>50MG</u>	<u>A091176</u>	<u>003</u>	Jun 07, 2010
<u>AB</u>		NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A040841</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>			<u>25MG</u>	<u>A040842</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>			<u>50MG</u>	<u>A040840</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>	+	PLIVA	<u>10MG</u>	<u>A088617</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	+		<u>25MG</u>	<u>A088618</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	+		<u>50MG</u>	<u>A088619</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>		SUN PHARM INDS INC	<u>10MG</u>	<u>A040899</u>	<u>001</u>	Jun 10, 2008
<u>AB</u>			<u>25MG</u>	<u>A040899</u>	<u>002</u>	Jun 10, 2008
<u>AB</u>			<u>50MG</u>	<u>A040899</u>	<u>003</u>	Jun 10, 2008
<u>AB</u>		VINTAGE PHARMS	<u>10MG</u>	<u>A040579</u>	<u>001</u>	May 27, 2005
<u>AB</u>			<u>25MG</u>	<u>A040574</u>	<u>001</u>	May 27, 2005
<u>AB</u>			<u>50MG</u>	<u>A040580</u>	<u>001</u>	May 27, 2005
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A081149</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>			<u>10MG</u>	<u>A088348</u>	<u>001</u>	Sep 15, 1983
<u>AB</u>			<u>25MG</u>	<u>A081150</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>			<u>25MG</u>	<u>A088349</u>	<u>001</u>	Sep 15, 1983
<u>AB</u>			<u>50MG</u>	<u>A081151</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>			<u>50MG</u>	<u>A088350</u>	<u>001</u>	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

<u>AB</u>		BARR	<u>EQ 25MG HCL</u>	<u>A088496</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>			<u>EQ 50MG HCL</u>	<u>A088487</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>		SANDOZ	<u>EQ 25MG HCL</u>	<u>A087479</u>	<u>001</u>	
<u>AB</u>			<u>EQ 50MG HCL</u>	<u>A086183</u>	<u>001</u>	
<u>AB</u>		WATSON LABS	<u>EQ 25MG HCL</u>	<u>A040156</u>	<u>001</u>	Jul 15, 1996
<u>AB</u>			<u>EQ 25MG HCL</u>	<u>A081165</u>	<u>001</u>	Jul 31, 1991

PRESCRIPTION DRUG PRODUCT LIST

3 - 219 (of 409)

HYDROXYZINE PAMOATE

CAPSULE; ORAL				
<u>HYDROXYZINE PAMOATE</u>				
<u>AB</u>	WATSON LABS	<u>EQ 50MG HCL</u>	<u>A040156</u> <u>002</u>	Jul 15, 1996
<u>VISTARIL</u>				
<u>AB</u>	PFIZER	<u>EQ 25MG HCL</u>	<u>N011459</u> <u>002</u>	
<u>AB</u>	+	<u>EQ 50MG HCL</u>	<u>N011459</u> <u>004</u>	
	HYDROXYZINE PAMOATE			
	BARR	EQ 100MG HCL	A088488 001	Jun 15, 1984
SUSPENSION; ORAL				
VISTARIL				
	+ PFIZER	EQ 25MG HCL/5ML	N011795 001	

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS				
BONIVA				
	+ ROCHE	EQ 3MG BASE/3ML	N021858 001	Jan 06, 2006
TABLET; ORAL				
BONIVA				
	+ ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005

IBUPROFEN

SOLUTION; INTRAVENOUS				
CALDOLOR				
	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348 001	Jun 11, 2009
	+	800MG/8ML (100MG/ML)	N022348 002	Jun 11, 2009
SUSPENSION; ORAL				
<u>IBUPROFEN</u>				
<u>AB</u>	+ ACTAVIS MID ATLANTIC	<u>100MG/5ML</u>	<u>A074978</u> <u>001</u>	Mar 25, 1998
<u>AB</u>	PERRIGO R AND D	<u>100MG/5ML</u>	<u>A076925</u> <u>001</u>	Sep 23, 2004
TABLET; ORAL				
<u>IBUPROFEN</u>				
<u>AB</u>	AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334</u> <u>001</u>	Nov 25, 1986
<u>AB</u>		<u>400MG</u>	<u>A078558</u> <u>001</u>	Jun 18, 2007
<u>AB</u>		<u>600MG</u>	<u>A071335</u> <u>001</u>	Nov 25, 1986
<u>AB</u>		<u>600MG</u>	<u>A078558</u> <u>002</u>	Jun 18, 2007
<u>AB</u>		<u>800MG</u>	<u>A071935</u> <u>001</u>	Oct 13, 1987
<u>AB</u>		<u>800MG</u>	<u>A078558</u> <u>003</u>	Jun 18, 2007
<u>AB</u>	CONTRACT PHARMACAL	<u>400MG</u>	<u>A071267</u> <u>001</u>	Oct 15, 1986
<u>AB</u>		<u>600MG</u>	<u>A071268</u> <u>001</u>	Oct 15, 1986
<u>AB</u>		<u>800MG</u>	<u>A072300</u> <u>001</u>	Jul 01, 1988
<u>AB</u>	DR REDDYS LA	<u>400MG</u>	<u>A075682</u> <u>001</u>	Nov 14, 2001
<u>AB</u>		<u>600MG</u>	<u>A075682</u> <u>002</u>	Nov 14, 2001
<u>AB</u>	+	<u>800MG</u>	<u>A075682</u> <u>003</u>	Nov 14, 2001
<u>AB</u>	DR REDDYS LABS INC	<u>400MG</u>	<u>A076112</u> <u>001</u>	Oct 31, 2001
<u>AB</u>		<u>600MG</u>	<u>A076112</u> <u>002</u>	Oct 31, 2001
<u>AB</u>		<u>800MG</u>	<u>A076112</u> <u>003</u>	Oct 31, 2001
<u>AB</u>	MARKSANS PHARMA	<u>400MG</u>	<u>A090796</u> <u>001</u>	Dec 21, 2010
<u>AB</u>		<u>600MG</u>	<u>A090796</u> <u>002</u>	Dec 21, 2010
<u>AB</u>		<u>800MG</u>	<u>A090796</u> <u>003</u>	Dec 21, 2010
<u>AB</u>	NORTHSTAR HLTHCARE	<u>400MG</u>	<u>A078132</u> <u>001</u>	Sep 10, 2007
<u>AB</u>		<u>600MG</u>	<u>A078132</u> <u>002</u>	Sep 10, 2007
<u>AB</u>		<u>800MG</u>	<u>A078132</u> <u>003</u>	Sep 10, 2007
<u>AB</u>	OHM LABS	<u>400MG</u>	<u>A070818</u> <u>001</u>	Dec 26, 1985
<u>AB</u>	PERRIGO R AND D	<u>400MG</u>	<u>A077114</u> <u>001</u>	Jul 18, 2005
<u>AB</u>		<u>600MG</u>	<u>A077114</u> <u>002</u>	Jul 18, 2005
<u>AB</u>		<u>800MG</u>	<u>A077114</u> <u>003</u>	Jul 18, 2005
<u>AB</u>	SHASUN USA	<u>400MG</u>	<u>A078329</u> <u>001</u>	Feb 05, 2009
<u>AB</u>		<u>600MG</u>	<u>A078329</u> <u>002</u>	Feb 05, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 220 (of 409)

IBUPROFEN

TABLET; ORAL

IBUPROFEN

<u>AB</u>	SHASUN USA	<u>800MG</u>	<u>A078329</u>	<u>003</u>	Feb 05, 2009
<u>AB</u>	VINTAGE PHARMS	<u>300MG</u>	<u>A071230</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>		<u>400MG</u>	<u>A071231</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>		<u>400MG</u>	<u>A071644</u>	<u>001</u>	Feb 01, 1988
<u>AB</u>		<u>600MG</u>	<u>A071232</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>		<u>800MG</u>	<u>A072004</u>	<u>001</u>	Nov 18, 1987
<u>AB</u>	WATSON LABS	<u>400MG</u>	<u>A070436</u>	<u>001</u>	Aug 21, 1985
<u>AB</u>		<u>600MG</u>	<u>A070437</u>	<u>001</u>	Aug 21, 1985
<u>IBUPROHM</u>					
<u>AB</u>	OHM LABS	<u>400MG</u>	<u>A070469</u>	<u>001</u>	Aug 29, 1985
<u>IBU-TAB</u>					
<u>AB</u>	ALRA	<u>400MG</u>	<u>A071058</u>	<u>001</u>	Aug 11, 1988
<u>AB</u>		<u>600MG</u>	<u>A071059</u>	<u>001</u>	Aug 11, 1988

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS
NEOPROFEN

+	LUNDBECK INC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

<u>AB</u>	+	FOREST LABS	<u>400MG; 5MG</u>	<u>N021378</u>	<u>001</u>	Nov 26, 2004
<u>OXYCODONE HYDROCHLORIDE AND IBUPROFEN</u>						
<u>AB</u>		ACTAVIS ELIZABETH	<u>400MG; 5MG</u>	<u>A078769</u>	<u>001</u>	Jan 04, 2008
<u>AB</u>		BARR	<u>400MG; 5MG</u>	<u>A078316</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>		WATSON LABS	<u>400MG; 5MG</u>	<u>A078394</u>	<u>001</u>	Nov 26, 2007

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.1MG/ML</u>	<u>N020491</u>	<u>001</u>	Dec 28, 1995
<u>IBUTILIDE FUMARATE</u>						
<u>AP</u>		BIONICHE PHARMA USA	<u>0.1MG/ML</u>	<u>A090643</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>			<u>0.1MG/ML</u>	<u>A090924</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>		LUITPOLD	<u>0.1MG/ML</u>	<u>A090240</u>	<u>001</u>	Jan 11, 2010

ICODEXTRIN

SOLUTION; INTRAPERITONEAL
EXTRANEAL

+	BAXTER HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>1MG/ML</u>	<u>N050734</u>	<u>001</u>	Feb 17, 1997
<u>IDARUBICIN HYDROCHLORIDE</u>						
<u>AP</u>		APP PHARMS	<u>1MG/ML</u>	<u>A065440</u>	<u>001</u>	Aug 04, 2009
<u>AP</u>		BEDFORD LABS	<u>1MG/ML</u>	<u>A065275</u>	<u>001</u>	Dec 14, 2006
<u>AP</u>			<u>1MG/ML</u>	<u>A065288</u>	<u>001</u>	May 15, 2007
<u>IDARUBICIN HYDROCHLORIDE PFS</u>						
<u>AP</u>		TEVA PARENTERAL	<u>1MG/ML</u>	<u>A065036</u>	<u>001</u>	May 01, 2002
<u>IDARUBICIN HYDROCHLORIDE</u>						
+		TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002
+			10MG/VIAL	A065037	002	May 01, 2002
+			20MG/VIAL	A065037	001	May 01, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 221 (of 409)

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

DENDRID

<u>AT</u>	+	ALCON	<u>0.1%</u>	<u>N014169</u>	<u>001</u>	

HERPLEX

<u>AT</u>	+	ALLERGAN	<u>0.1%</u>	<u>N013935</u>	<u>002</u>	

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

<u>AP</u>		BAXTER HLTHCARE	<u>1GM/VIAL</u>	<u>N019763</u>	<u>001</u>	Dec 30, 1988

<u>AP</u>			<u>3GM/VIAL</u>	<u>N019763</u>	<u>002</u>	Dec 30, 1988

IFOSFAMIDE

<u>AP</u>	+	APP PHARMS	<u>1GM/VIAL</u>	<u>A076078</u>	<u>001</u>	May 28, 2002

<u>AP</u>			<u>1GM/20ML (50MG/ML)</u>	<u>A090181</u>	<u>001</u>	Sep 22, 2009

<u>AP</u>	+		<u>3GM/VIAL</u>	<u>A076078</u>	<u>002</u>	May 28, 2002

<u>AP</u>			<u>3GM/60ML (50MG/ML)</u>	<u>A090181</u>	<u>002</u>	Sep 22, 2009

<u>AP</u>	+	TEVA PARENTERAL	<u>1GM/20ML (50MG/ML)</u>	<u>A076657</u>	<u>001</u>	Apr 04, 2007

<u>AP</u>	+		<u>3GM/60ML (50MG/ML)</u>	<u>A076657</u>	<u>002</u>	Apr 04, 2007

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+	TEVA PARENTERAL	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002

+		3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002

ILOPERIDONE

TABLET; ORAL

FANAPT

+	NOVARTIS	1MG	N022192	001	May 06, 2009

		12MG	N022192	007	May 06, 2009

	VANDA PHARMS INC	2MG	N022192	002	May 06, 2009

		4MG	N022192	003	May 06, 2009

		6MG	N022192	004	May 06, 2009

		8MG	N022192	005	May 06, 2009

		10MG	N022192	006	May 06, 2009

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+	ACTELION PHARMS LTD	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005

+		20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004

+		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

NOVARTIS

+		EQ 100MG BASE	N021588	001	Apr 18, 2003

+		EQ 400MG BASE	N021588	002	Apr 18, 2003

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME

GENZYME

+		200 UNITS/VIAL	N020367	001	May 23, 1994

+		400 UNITS/VIAL	N020367	002	Sep 22, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 222 (of 409)

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>10MG</u>	<u>A040753</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>		<u>25MG</u>	<u>A040752</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>		<u>50MG</u>	<u>A040751</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>	LUPIN LTD	<u>10MG</u>	<u>A090443</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>		<u>25MG</u>	<u>A090442</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>		<u>50MG</u>	<u>A090441</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A081048</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>25MG</u>	<u>A081049</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>50MG</u>	<u>A081050</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>	PAR PHARM	<u>10MG</u>	<u>A088292</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>		<u>10MG</u>	<u>A089422</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>25MG</u>	<u>A088262</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A084936</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A083745</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084937</u>	<u>001</u>	
<u>TOFRANIL</u>					
<u>AB</u>	TYCO HLTHCARE	<u>10MG</u>	<u>A087844</u>	<u>001</u>	May 22, 1984
<u>AB</u>		<u>25MG</u>	<u>A087845</u>	<u>001</u>	May 22, 1984
<u>AB</u>	+	<u>50MG</u>	<u>A087846</u>	<u>001</u>	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

<u>AB</u>	LUPIN LTD	<u>EQ 75MG HCL</u>	<u>A090444</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A090444</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>A090444</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A090444</u>	<u>004</u>	Apr 16, 2010
<u>AB</u>	ROXANE	<u>EQ 75MG HCL</u>	<u>A091099</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A091099</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>A091099</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A091099</u>	<u>004</u>	Apr 16, 2010
<u>TOFRANIL-PM</u>					
<u>AB</u>	+	<u>EQ 75MG HCL</u>	<u>N017090</u>	<u>001</u>	
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>N017090</u>	<u>004</u>	
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>N017090</u>	<u>003</u>	
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>N017090</u>	<u>002</u>	

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+	<u>GRACEWAY</u>	<u>5%</u>	<u>N020723</u>	<u>001</u>	Feb 27, 1997
<u>IMIQUIMOD</u>						
<u>AB</u>		<u>NYCOMED US</u>	<u>5%</u>	<u>A078548</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>		<u>PERRIGO ISRAEL</u>	<u>5%</u>	<u>A078837</u>	<u>001</u>	Sep 07, 2010
		<u>ZYCLARA</u>				
	+	<u>GRACEWAY</u>	<u>3.75%</u>	<u>N022483</u>	<u>001</u>	Mar 25, 2010

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

	+	<u>BEDFORD</u>	<u>EQ 5MG BASE/ML</u>	<u>A075513</u>	<u>001</u>	May 09, 2000

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG</u>	<u>A074722</u>	<u>001</u>	Jun 17, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074722</u>	<u>002</u>	Jun 17, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 223 (of 409)

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<u>AB</u>	ALPHAPHARM	<u>1.25MG</u>	<u>A075105</u>	<u>001</u>	Jul 23, 1998
<u>AB</u>		<u>2.5MG</u>	<u>A075105</u>	<u>002</u>	Jul 23, 1998
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1.25MG</u>	<u>A074299</u>	<u>002</u>	Apr 29, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074299</u>	<u>001</u>	Jul 27, 1995
<u>AB</u>	MYLAN	<u>1.25MG</u>	<u>A074461</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>	+	<u>2.5MG</u>	<u>A074461</u>	<u>001</u>	Mar 27, 1996
<u>AB</u>	SANDOZ	<u>1.25MG</u>	<u>A074594</u>	<u>001</u>	May 23, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074594</u>	<u>002</u>	May 23, 1996
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A074585</u>	<u>001</u>	Sep 26, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074585</u>	<u>002</u>	Sep 26, 1996

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

	MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000
		EQ 200MG BASE	N020685	003	Mar 13, 1996
+		EQ 400MG BASE	N020685	001	Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992
	INDIUM IN 111 CHLORIDE				
+	MALLINCKRODT	5mCi/0.5ML	N019841	001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+	GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	MALLINCKRODT	3mCi/ML	N020314	001	Jun 02, 1994

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

<u>AP</u>	+	AKORN	<u>25MG/VIAL</u>	<u>N011525</u>	<u>001</u>	
		<u>INDOCYANINE GREEN</u>				
<u>AP</u>		PULSION MEDCL	<u>25MG/VIAL</u>	<u>A040811</u>	<u>001</u>	Nov 21, 2007

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A091276</u>	<u>001</u>	Dec 22, 2010
<u>AB</u>		<u>50MG</u>	<u>A091276</u>	<u>002</u>	Dec 22, 2010
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>N018851</u>	<u>001</u>	May 18, 1984
<u>AB</u>		<u>50MG</u>	<u>N018851</u>	<u>002</u>	May 18, 1984
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A070719</u>	<u>001</u>	Feb 12, 1986
<u>AB</u>		<u>50MG</u>	<u>A070756</u>	<u>001</u>	Feb 12, 1986

PRESCRIPTION DRUG PRODUCT LIST

3 - 224 (of 409)

INDOMETHACIN

CAPSULE; ORAL				
<u>INDOMETHACIN</u>				
<u>AB</u>	MYLAN	<u>25MG</u>	<u>N018858</u>	<u>001</u> Apr 20, 1984
<u>AB</u>	+	<u>50MG</u>	<u>A070624</u>	<u>001</u> Sep 04, 1985
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A070673</u>	<u>001</u> Apr 29, 1987
<u>AB</u>		<u>50MG</u>	<u>A070674</u>	<u>001</u> Apr 29, 1987
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A090403</u>	<u>001</u> Nov 15, 2010
<u>AB</u>		<u>50MG</u>	<u>A090403</u>	<u>002</u> Nov 15, 2010
CAPSULE, EXTENDED RELEASE; ORAL				
<u>INDOCIN SR</u>				
<u>AB</u>	+	<u>75MG</u>	<u>A074464</u>	<u>001</u> May 28, 1998
<u>INDOMETHACIN</u>				
<u>AB</u>	AMNEAL PHARMS	<u>75MG</u>	<u>A091549</u>	<u>001</u> Dec 01, 2010
<u>AB</u>	AVANTHI INC	<u>75MG</u>	<u>A079175</u>	<u>001</u> Mar 06, 2009
<u>AB</u>	PADDOCK LABS	<u>75MG</u>	<u>A200529</u>	<u>001</u> Nov 30, 2010
INJECTABLE; INJECTION				
INDOMETHACIN				
	+	APP PHARMS	EQ 1MG BASE/VIAL	N022536 001 Mar 17, 2010
SUPPOSITORY; RECTAL				
INDOMETHACIN				
	+	G AND W LABS	50MG	A073314 001 Aug 31, 1992
SUSPENSION; ORAL				
INDOCIN				
	+	IROKO PHARMS	25MG/5ML	N018332 001 Oct 10, 1985

INDOMETHACIN SODIUM

INJECTABLE; INJECTION				
<u>INDOCIN</u>				
<u>AP</u>	+	LUNDBECK INC	<u>EQ 1MG BASE/VIAL</u>	<u>N018878</u> <u>001</u> Jan 30, 1985
<u>INDOMETHACIN SODIUM</u>				
<u>AP</u>		BEDFORD	<u>EQ 1MG BASE/VIAL</u>	<u>A078713</u> <u>001</u> Jul 16, 2008

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS				
NOVOLOG MIX 70/30				
	+	NOVO NORDISK INC	70 UNITS/ML;30 UNITS/ML	N021172 001 Nov 01, 2001

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS				
NOVOLOG				
	+	NOVO NORDISK INC	100 UNITS/ML	N020986 001 Jun 07, 2000

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS				
LEVEMIR				
	+	NOVO NORDISK INC	100 UNITS/ML	N021536 001 Jun 16, 2005

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION				
LANTUS				
	+	SANOFI AVENTIS US	100 UNITS/ML	N021081 001 Apr 20, 2000

INSULIN GLULISINE RECOMBINANT

INJECTABLE; IV (INFUSION)-SC				
	+	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N021629 001 Apr 16, 2004
	+		300 UNITS/3ML (100 UNITS/ML)	N021629 002 Dec 20, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 225 (of 409)

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

SANOFI AVENTIS US	300 UNITS/3ML	N021629 003	Feb 24, 2009

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+ LILLY	50 UNITS/ML;50 UNITS/ML	N021018 001	Dec 22, 1999

HUMALOG MIX 50/50 KWIKPEN

+ LILLY	50 UNITS/ML;50 UNITS/ML	N021018 002	Sep 06, 2007

HUMALOG MIX 50/50 PEN

+ LILLY	50 UNITS/ML;50 UNITS/ML	N021018 003	Dec 22, 1999

HUMALOG MIX 75/25

+ LILLY	75 UNITS/ML;25 UNITS/ML	N021017 001	Dec 22, 1999

HUMALOG MIX 75/25 KWIKPEN

+ LILLY	75 UNITS/ML;25 UNITS/ML	N021017 002	Sep 06, 2007

HUMALOG MIX 75/25 PEN

+ LILLY	75 UNITS/ML;25 UNITS/ML	N021017 003	Dec 22, 1999

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY	100 UNITS/ML	N020563 001	Jun 14, 1996

HUMALOG KWIKPEN

+ LILLY	100 UNITS/ML	N020563 003	Sep 06, 2007

HUMALOG PEN

+ LILLY	100 UNITS/ML	N020563 002	Aug 06, 1998

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY	500 UNITS/ML	N018780 004	Mar 31, 1994

IOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS

ADREVIEW

+ GE HEALTHCARE	10MCI/5ML (2MCI/ML)	N022290 001	Sep 19, 2008

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

+ BRACCO	52%	N009321 003	

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

+ GE HEALTHCARE	55%	N020351 001	Mar 22, 1996

	55%	N020808 001	Aug 29, 1997

VISIPAQUE 320

+ GE HEALTHCARE	65.2%	N020351 002	Mar 22, 1996

	65.2%	N020808 002	Aug 29, 1997

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 140

+ GE HEALTHCARE	30.2%	N018956 005	Nov 30, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 226 (of 409)

IOHEXOL

SOLUTION; INJECTION, ORAL

OMNIPAQUE 350

+	GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985
		75.5%	N020608	003	Oct 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+	GE HEALTHCARE	38.8%	N018956	001	Dec 26, 1985

OMNIPAQUE 240

+	GE HEALTHCARE	51.8%	N018956	002	Dec 26, 1985

		51.8%	N020608	001	Oct 24, 1995

OMNIPAQUE 300

+	GE HEALTHCARE	64.7%	N018956	003	Dec 26, 1985

		64.7%	N020608	002	Oct 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

<u>AP</u>	HOSPIRA	<u>41%</u>	<u>A074898</u>	<u>001</u>	Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>41%</u>	<u>A074636</u>	<u>001</u>	Dec 30, 1997

IOPAMIDOL-250

<u>AP</u>	APP PHARMS	<u>51%</u>	<u>A074679</u>	<u>001</u>	Apr 02, 1997

<u>AP</u>	HOSPIRA	<u>51%</u>	<u>A074898</u>	<u>002</u>	Dec 30, 1997

<u>AP</u>		<u>51%</u>	<u>A075005</u>	<u>001</u>	Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>51%</u>	<u>A074636</u>	<u>002</u>	Dec 30, 1997

IOPAMIDOL-300

<u>AP</u>	APP PHARMS	<u>61%</u>	<u>A074679</u>	<u>002</u>	Apr 02, 1997

<u>AP</u>	HOSPIRA	<u>61%</u>	<u>A074898</u>	<u>003</u>	Dec 30, 1997

<u>AP</u>		<u>61%</u>	<u>A075005</u>	<u>002</u>	Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>61%</u>	<u>A074636</u>	<u>003</u>	Dec 30, 1997

<u>AP</u>		<u>61%</u>	<u>A074637</u>	<u>001</u>	Apr 03, 1997

IOPAMIDOL-370

<u>AP</u>	APP PHARMS	<u>76%</u>	<u>A074679</u>	<u>003</u>	Apr 02, 1997

<u>AP</u>	HOSPIRA	<u>76%</u>	<u>A074898</u>	<u>004</u>	Dec 30, 1997

<u>AP</u>		<u>76%</u>	<u>A075005</u>	<u>003</u>	Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>76%</u>	<u>A074636</u>	<u>004</u>	Dec 30, 1997

ISOVUE-200

<u>AP</u>	+	BRACCO	<u>41%</u>	<u>N018735</u>	<u>006</u>	Jul 07, 1987

ISOVUE-250

<u>AP</u>	+	BRACCO	<u>51%</u>	<u>N018735</u>	<u>007</u>	Jul 06, 1992

<u>AP</u>	+		<u>51%</u>	<u>N020327</u>	<u>002</u>	Oct 12, 1994

ISOVUE-300

<u>AP</u>	+	BRACCO	<u>61%</u>	<u>N018735</u>	<u>002</u>	Dec 31, 1985

<u>AP</u>	+		<u>61%</u>	<u>N020327</u>	<u>003</u>	Oct 12, 1994

ISOVUE-370

<u>AP</u>	+	BRACCO	<u>76%</u>	<u>N018735</u>	<u>003</u>	Dec 31, 1985

<u>AP</u>	+		<u>76%</u>	<u>N020327</u>	<u>004</u>	Oct 12, 1994

SCANLUX-300

<u>AP</u>	SANOCHEMIA CORP USA	<u>61%</u>	<u>A090394</u>	<u>001</u>	Jun 18, 2010

SCANLUX-370

<u>AP</u>	SANOCHEMIA CORP USA	<u>76%</u>	<u>A090394</u>	<u>002</u>	Jun 18, 2010

ISOVUE-M 200

+	BRACCO	41%	N018735	001	Dec 31, 1985

ISOVUE-M 300

+	BRACCO	61%	N018735	004	Dec 31, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 227 (of 409)

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+ BAYER HLTHCARE	49.9%	N021425 003	Mar 12, 2004
+	62.3%	N021425 001	Sep 20, 2002
+	76.9%	N021425 002	Sep 20, 2002
ULTRAVIST 150			
+ BAYER HLTHCARE	31.2%	N020220 004	May 10, 1995
ULTRAVIST 240			
+ BAYER HLTHCARE	49.9%	N020220 003	May 10, 1995
ULTRAVIST 300			
+ BAYER HLTHCARE	62.3%	N020220 002	May 10, 1995
ULTRAVIST 300 IN PLASTIC CONTAINER			
+ BAYER HLTHCARE	62.3%	N020220 005	Nov 18, 2008
ULTRAVIST 370			
+ BAYER HLTHCARE	76.9%	N020220 001	May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

+ MALLINCKRODT	60%	N013295 001	
CONRAY 30			
+ MALLINCKRODT	30%	N016983 001	
CONRAY 43			
+ MALLINCKRODT	43%	N013295 002	

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

MALLINCKRODT	17.2%	N017057 002	

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+ MALLINCKRODT	51%	N019710 002	Dec 30, 1988
OPTIRAY 300			
+ MALLINCKRODT	64%	N019710 004	Jan 22, 1992
+	64%	N020923 004	May 13, 1999
OPTIRAY 320			
+ MALLINCKRODT	68%	N019710 001	Dec 30, 1988
OPTIRAY 350			
+ MALLINCKRODT	74%	N019710 005	Jan 22, 1992
+	74%	N020923 003	May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

+ GUERBET	39.3%;19.6%	N018905 002	Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET	62%	N020316 001	Dec 21, 1995

OXILAN-350

GUERBET	73%	N020316 002	Dec 21, 1995

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+ BOEHRINGER INGELHEIM	0.021MG/INH	N021527 001	Nov 27, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 228 (of 409)

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

<u>AN</u>	ACTAVIS MID ATLANTIC	<u>0.02%</u>	<u>A075111</u>	<u>001</u>	Apr 22, 1999
<u>AN</u>	BAUSCH AND LOMB	<u>0.02%</u>	<u>A075835</u>	<u>001</u>	Oct 15, 2001
<u>AN</u>	+ DEY	<u>0.02%</u>	<u>A074755</u>	<u>001</u>	Jan 10, 1997
<u>AN</u>	HOLOPACK INTL	<u>0.02%</u>	<u>A075693</u>	<u>001</u>	Jan 26, 2001
<u>AN</u>	LANDELA PHARM	<u>0.02%</u>	<u>A077072</u>	<u>001</u>	Jul 19, 2005
<u>AN</u>	NEPHRON	<u>0.02%</u>	<u>A075562</u>	<u>001</u>	Sep 27, 2001
<u>AN</u>	NOVEX	<u>0.02%</u>	<u>A075441</u>	<u>001</u>	Mar 28, 2001
<u>AN</u>	TEVA PARENTERAL	<u>0.02%</u>	<u>A075313</u>	<u>001</u>	Feb 07, 2000
<u>AN</u>	WATSON LABS	<u>0.02%</u>	<u>A076291</u>	<u>001</u>	May 09, 2005

SPRAY, METERED; NASAL

ATROVENT

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>0.021MG/SPRAY</u>	<u>N020393</u>	<u>001</u>	Oct 20, 1995
<u>AB</u>	+	<u>0.042MG/SPRAY</u>	<u>N020394</u>	<u>001</u>	Oct 20, 1995

IPRATROPIUM BROMIDE

<u>AB</u>	BAUSCH AND LOMB	<u>0.021MG/SPRAY</u>	<u>A076025</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A076103</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>	DEY	<u>0.021MG/SPRAY</u>	<u>A075552</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A075553</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>	NOVEX	<u>0.021MG/SPRAY</u>	<u>A076156</u>	<u>001</u>	Apr 18, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A076155</u>	<u>001</u>	Apr 18, 2003
<u>AB</u>	ROXANE	<u>0.021MG/SPRAY</u>	<u>A076664</u>	<u>001</u>	Nov 05, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A076598</u>	<u>001</u>	Nov 05, 2003

IRBESARTAN

TABLET; ORAL

AVAPRO

	SANOFI AVENTIS US	75MG	N020757	001	Sep 30, 1997
		150MG	N020757	002	Sep 30, 1997
	+	300MG	N020757	003	Sep 30, 1997

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

<u>AP</u>	+ PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571</u>	<u>001</u>	Jun 14, 1996
<u>AP</u>	+	<u>100MG/5ML (20MG/ML)</u>	<u>N020571</u>	<u>002</u>	Jun 14, 1996

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068</u>	<u>001</u>	Nov 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A079068</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>	ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078589</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726</u>	<u>001</u>	Sep 16, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090726</u>	<u>002</u>	Sep 16, 2009
<u>AP</u>	APP PHARMS	<u>40MG/2ML (20MG/ML)</u>	<u>A077776</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077776</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	BEDFORD LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A078753</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078753</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>	DR REDDYS LABS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A078953</u>	<u>001</u>	Apr 15, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078953</u>	<u>002</u>	Apr 15, 2010
<u>AP</u>	EBEWE PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A090137</u>	<u>001</u>	Nov 12, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090137</u>	<u>002</u>	Nov 12, 2009
<u>AP</u>	FRESENIUS KABI ONCOL	<u>40MG/2ML (20MG/ML)</u>	<u>A078188</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078188</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032</u>	<u>001</u>	Dec 20, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A091032</u>	<u>002</u>	Dec 20, 2010
<u>AP</u>	HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077915</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	+	<u>500MG/25ML (20MG/ML)</u>	<u>A078796</u>	<u>001</u>	Feb 27, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 229 (of 409)

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	PHARMAFORCE	<u>40MG/2ML (20MG/ML)</u>	<u>A090016</u>	<u>001</u>	Jan 28, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090016</u>	<u>002</u>	Jan 28, 2009
<u>AP</u>	PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078122</u>	<u>002</u>	Oct 31, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>40MG/2ML (20MG/ML)</u>	<u>A078805</u>	<u>001</u>	Apr 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078805</u>	<u>002</u>	Apr 21, 2008
<u>AP</u>	TEVA PARENTERAL	<u>40MG/2ML (20MG/ML)</u>	<u>A077260</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077260</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>		<u>500MG/25ML (20MG/ML)</u>	<u>A090101</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>	WATSON LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A077219</u>	<u>001</u>	Feb 20, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077219</u>	<u>002</u>	Feb 20, 2008
	CAMPTOSAR				
	+ PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010

IRON DEXTRANINJECTABLE; INJECTION
DEXFERRUM

BP	LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
	INFED				
BP	+ WATSON LABS (UTAH)	EQ 50MG IRON/ML	N017441	001	
	PROFERDEX				
BP	NEW RIVER	EQ 50MG IRON/ML	N017807	001	

IRON SUCROSEINJECTABLE; INTRAVENOUS
VENOFER

	+ LUITPOLD	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000
		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007

ISOCARBOXAZIDTABLET; ORAL
MARPLAN

	+ VALIDUS PHARMS INC	10MG	N011961	001	

ISOFLURANE

LIQUID; INHALATION

FORANE

<u>AN</u>	+ BAXTER HLTHCARE CORP	<u>99.9%</u>	<u>N017624</u>	<u>001</u>	

ISOFLURANE

<u>AN</u>	HALOCARBON PRODS	<u>99.9%</u>	<u>A075225</u>	<u>001</u>	Oct 20, 1999
<u>AN</u>	HOSPIRA	<u>99.9%</u>	<u>A074097</u>	<u>001</u>	Jan 25, 1993
<u>AN</u>	PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074416</u>	<u>001</u>	Sep 30, 1994
<u>AN</u>	RHODIA	<u>99.9%</u>	<u>A074502</u>	<u>001</u>	Jun 27, 1995

ISONIAZIDINJECTABLE; INJECTION
ISONIAZID

	+ SANDOZ	100MG/ML	A040648	001	Jul 05, 2005

SYRUP; ORAL
ISONIAZID

	+ CAROLINA MEDCL	50MG/5ML	A088235	001	Nov 10, 1983

TABLET; ORAL

ISONIAZID

<u>AA</u>	BARR	<u>100MG</u>	<u>A080936</u>	<u>001</u>	
<u>AA</u>		<u>300MG</u>	<u>A080937</u>	<u>002</u>	
<u>AA</u>	MIKART	<u>100MG</u>	<u>A040090</u>	<u>001</u>	Jun 26, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 230 (of 409)

ISONIAZID

TABLET; ORAL

ISONIAZID

<u>AA</u>	MIKART	<u>300MG</u>	<u>A040090</u>	<u>002</u>	Jun 26, 1997
<u>AA</u>	+ SANDOZ	<u>100MG</u>	<u>N008678</u>	<u>002</u>	
<u>AA</u>	+	<u>300MG</u>	<u>N008678</u>	<u>003</u>	
<u>AA</u>	WATSON LABS	<u>300MG</u>	<u>A080521</u>	<u>001</u>	
<u>AA</u>	WEST WARD	<u>100MG</u>	<u>A080212</u>	<u>001</u>	
<u>AA</u>		<u>300MG</u>	<u>A087425</u>	<u>001</u>	

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

+	SANOFI AVENTIS US	50MG;300MG;120MG	N050705	001	May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

<u>AB</u>	+ SANOFI AVENTIS US	<u>150MG;300MG</u>	<u>A061884</u>	<u>001</u>	
	<u>RIFAMPIN AND ISONIAZID</u>				
<u>AB</u>	WESTWARD	<u>150MG;300MG</u>	<u>A065221</u>	<u>001</u>	Jul 29, 2005

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

<u>AP</u>	INTL MEDICATION	<u>0.2MG/ML</u>	<u>A083724</u>	<u>001</u>	
	<u>ISUPREL</u>				
<u>AP</u>	+ HOSPIRA	<u>0.2MG/ML</u>	<u>N010515</u>	<u>001</u>	

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+	SCHWARZ PHARMA	40MG	N019790	001	Sep 02, 1988

TABLET; ORAL

ISORDIL

<u>AB</u>	BIOVAIL	<u>5MG</u>	<u>N012093</u>	<u>007</u>	Jul 29, 1988
<u>AB</u>		<u>10MG</u>	<u>N012093</u>	<u>002</u>	Jul 29, 1988
<u>AB</u>		<u>20MG</u>	<u>N012093</u>	<u>006</u>	Jul 29, 1988
<u>AB</u>	+	<u>30MG</u>	<u>N012093</u>	<u>005</u>	Jul 29, 1988

ISOSORBIDE DINITRATE

<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A086923</u>	<u>001</u>	Mar 12, 1987
<u>AB</u>		<u>10MG</u>	<u>A086925</u>	<u>001</u>	Mar 12, 1987
<u>AB</u>		<u>20MG</u>	<u>A087537</u>	<u>001</u>	Oct 02, 1987
<u>AB</u>		<u>30MG</u>	<u>A087946</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A086221</u>	<u>001</u>	Jan 07, 1988
<u>AB</u>		<u>10MG</u>	<u>A086223</u>	<u>001</u>	Jan 07, 1988
<u>AB</u>		<u>20MG</u>	<u>A089367</u>	<u>001</u>	Apr 07, 1988
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A086034</u>	<u>001</u>	Jan 06, 1988
<u>AB</u>		<u>10MG</u>	<u>A086032</u>	<u>001</u>	Jan 07, 1988
<u>AB</u>	WEST WARD	<u>5MG</u>	<u>A086067</u>	<u>001</u>	Oct 29, 1987
<u>AB</u>		<u>10MG</u>	<u>A086066</u>	<u>001</u>	Oct 29, 1987
<u>AB</u>		<u>20MG</u>	<u>A088088</u>	<u>001</u>	Nov 02, 1987
<u>AB</u>		<u>30MG</u>	<u>A040591</u>	<u>001</u>	Jan 10, 2007

ISORDIL

+	BIOVAIL	40MG	N012093	001	Jul 29, 1988

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A086033</u>	<u>001</u>	Feb 26, 1988
<u>AB</u>	+	<u>5MG</u>	<u>A086031</u>	<u>001</u>	Sep 29, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 231 (of 409)

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

<u>AB</u>	WEST WARD	<u>2.5MG</u>	<u>A086054</u>	<u>001</u>	Oct 29, 1987
<u>AB</u>		<u>5MG</u>	<u>A086055</u>	<u>001</u>	Nov 02, 1987

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

<u>AB</u>	+ CARACO	<u>40MG</u>	<u>A040009</u>	<u>001</u>	Dec 30, 1998
<u>AB</u>	COREPHARMA	<u>40MG</u>	<u>A040723</u>	<u>001</u>	Mar 17, 2008

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075037</u>	<u>002</u>	Oct 30, 1998
<u>AB</u>		<u>20MG</u>	<u>A075037</u>	<u>001</u>	Oct 30, 1998
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075147</u>	<u>001</u>	Nov 27, 1998
<u>AB</u>	WEST WARD	<u>20MG</u>	<u>A075361</u>	<u>001</u>	Oct 05, 2000

MONOKET

<u>AB</u>	UCB INC	<u>10MG</u>	<u>N020215</u>	<u>002</u>	Jun 30, 1993
<u>AB</u>	+	<u>20MG</u>	<u>N020215</u>	<u>001</u>	Jun 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>30MG</u>	<u>A075306</u>	<u>001</u>	Dec 31, 1998
<u>AB</u>		<u>60MG</u>	<u>A075306</u>	<u>002</u>	Dec 31, 1998
<u>AB</u>	BRIGHTSTONE	<u>60MG</u>	<u>A075166</u>	<u>001</u>	Oct 07, 1999
<u>AB</u>	DEXCEL LTD	<u>60MG</u>	<u>A075522</u>	<u>001</u>	Apr 17, 2000
<u>AB</u>	ELAN PHARM	<u>60MG</u>	<u>A075041</u>	<u>001</u>	Sep 22, 1998
<u>AB</u>	KREMERS URBAN PHARMS	<u>30MG</u>	<u>A075155</u>	<u>002</u>	Jan 13, 2000
<u>AB</u>		<u>60MG</u>	<u>A075155</u>	<u>001</u>	Oct 30, 1998
<u>AB</u>	+	<u>120MG</u>	<u>A075155</u>	<u>003</u>	Aug 04, 2000
<u>AB</u>	KV PHARM	<u>30MG</u>	<u>A075395</u>	<u>001</u>	Mar 16, 2000
<u>AB</u>		<u>60MG</u>	<u>A075395</u>	<u>002</u>	Mar 16, 2000
<u>AB</u>		<u>120MG</u>	<u>A075395</u>	<u>003</u>	Mar 16, 2000
<u>AB</u>	VINTAGE PHARMS	<u>30MG</u>	<u>A090598</u>	<u>001</u>	Aug 11, 2010
<u>AB</u>		<u>60MG</u>	<u>A090598</u>	<u>002</u>	Aug 11, 2010
<u>AB</u>		<u>120MG</u>	<u>A090598</u>	<u>003</u>	Aug 11, 2010
<u>AB</u>	WEST WARD	<u>30MG</u>	<u>A076813</u>	<u>002</u>	Mar 30, 2006
<u>AB</u>		<u>60MG</u>	<u>A076813</u>	<u>001</u>	Jan 07, 2005

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

<u>AP</u>	SYNERX	<u>1%</u>	<u>A090874</u>	<u>001</u>	Jul 20, 2010
	<u>LYMPHAZURIN</u>				
<u>AP</u>	+ COVIDIEN	<u>1%</u>	<u>N018310</u>	<u>001</u>	

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075945</u>	<u>001</u>	Nov 08, 2002
<u>AB</u>	+	<u>20MG</u>	<u>A075945</u>	<u>002</u>	Nov 08, 2002
<u>AB</u>	+	<u>40MG</u>	<u>A075945</u>	<u>003</u>	Nov 08, 2002

CLARAVIS

<u>AB</u>	BARR	<u>10MG</u>	<u>A076356</u>	<u>001</u>	Apr 11, 2003
<u>AB</u>		<u>20MG</u>	<u>A076135</u>	<u>002</u>	Apr 11, 2003
<u>AB</u>		<u>30MG</u>	<u>A076135</u>	<u>003</u>	May 11, 2006
<u>AB</u>		<u>40MG</u>	<u>A076135</u>	<u>001</u>	Apr 11, 2003

SOTRET

<u>AB</u>	RANBAXY	<u>10MG</u>	<u>A076041</u>	<u>001</u>	Dec 24, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 232 (of 409)

ISOTRETINOIN

CAPSULE; ORAL

SOTRET

<u>AB</u>	RANBAXY	<u>20MG</u>	<u>A076041</u>	<u>002</u>	Dec 24, 2002
<u>AB</u>		<u>30MG</u>	<u>A076503</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>		<u>40MG</u>	<u>A076041</u>	<u>003</u>	Dec 24, 2002

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

<u>AB</u>	ACTAVIS TOTOWA	<u>2.5MG</u>	<u>A077169</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>5MG</u>	<u>A077169</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A077317</u>	<u>001</u>	Jan 05, 2006
<u>AB</u>	+	<u>5MG</u>	<u>A077317</u>	<u>002</u>	Jan 05, 2006

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

	GLAXOSMITHKLINE LLC	5MG	N020336	001	Jun 01, 1994
+		10MG	N020336	002	Jun 01, 1994

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

<u>AB</u>	<u>SANDOZ</u>	<u>100MG</u>	<u>A076104</u>	<u>001</u>	May 28, 2004
	<u>SPORANOX</u>				
<u>AB</u>	<u>+ ORTHO MCNEIL JANSSEN</u>	<u>100MG</u>	<u>N020083</u>	<u>001</u>	Sep 11, 1992

INJECTABLE; INJECTION

SPORANOX

+	ORTHO MCNEIL JANSSEN	10MG/ML	N020966	001	Mar 30, 1999

SOLUTION; ORAL

SPORANOX

+	ORTHO MCNEIL JANSSEN	10MG/ML	N020657	001	Feb 21, 1997

TABLET; ORAL

ITRACONAZOLE

+	STIEFEL LABS INC	200MG	N022484	001	Apr 29, 2010

IVERMECTIN

TABLET; ORAL

STROMEKTOL

+	MERCK	3MG	N050742	002	Oct 08, 1998

IXABEPILONE

INJECTABLE; IV (INFUSION)

+	BRISTOL MYERS SQUIBB	15MG/VIAL	N022065	001	Oct 16, 2007
+		45MG/VIAL	N022065	002	Oct 16, 2007

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

	APP PHARMS	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002
+		EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

<u>AP</u>	+	JHP PHARMS	<u>EQ 10MG BASE/ML</u>	<u>N016812</u>	<u>001</u>
<u>AP</u>	+		<u>EQ 50MG BASE/ML</u>	<u>N016812</u>	<u>002</u>
<u>AP</u>	+		<u>EQ 100MG BASE/ML</u>	<u>N016812</u>	<u>003</u>

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 233 (of 409)

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 50MG BASE/ML</u>	<u>A074524</u>	<u>001</u>	Mar 22, 1996
<u>AP</u>		<u>EQ 100MG BASE/ML</u>	<u>A074524</u>	<u>002</u>	Mar 22, 1996
<u>AP</u>	BIONICHE PHARMA	<u>EQ 10MG BASE/ML</u>	<u>A076092</u>	<u>001</u>	Sep 30, 2008
<u>AP</u>		<u>EQ 50MG BASE/ML</u>	<u>A076092</u>	<u>002</u>	Dec 28, 2001
<u>AP</u>		<u>EQ 100MG BASE/ML</u>	<u>A076092</u>	<u>003</u>	Oct 25, 2002
<u>AP</u>	HOSPIRA	<u>EQ 50MG BASE/ML</u>	<u>A074549</u>	<u>001</u>	Jun 27, 1996
<u>AP</u>		<u>EQ 100MG BASE/ML</u>	<u>A074549</u>	<u>002</u>	Jun 27, 1996

KETOCONAZOLEAEROSOL, FOAM; TOPICAL
EXTINA

+	STIEFEL LABS INC	2%	N021738	001	Jun 12, 2007

CREAM; TOPICAL

KETOCONAZOLE

<u>AB</u>	ALTANA	<u>2%</u>	<u>A076294</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>	+ TEVA	<u>2%</u>	<u>A075581</u>	<u>001</u>	Apr 25, 2000
	<u>KETOZOLE</u>				
<u>AB</u>	TARO	<u>2%</u>	<u>A075638</u>	<u>001</u>	Dec 18, 2002

GEL; TOPICAL

XOLEGEL

+	STIEFEL LABS INC	2%	N021946	001	Jul 28, 2006

SHAMPOO; TOPICAL

KETOCONAZOLE

<u>AB</u>	PERRIGO NEW YORK	<u>2%</u>	<u>A076419</u>	<u>001</u>	Jan 07, 2004
<u>AB</u>	TOLMAR	<u>2%</u>	<u>A076942</u>	<u>001</u>	Apr 11, 2005
	<u>NIZORAL</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>2%</u>	<u>N019927</u>	<u>001</u>	Aug 31, 1990

TABLET; ORAL

KETOCONAZOLE

<u>AB</u>	APOTEX	<u>200MG</u>	<u>A075912</u>	<u>001</u>	Jan 10, 2002
<u>AB</u>	MUTUAL PHARMA	<u>200MG</u>	<u>A075314</u>	<u>001</u>	Jun 15, 1999
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A075597</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>	PLIVA	<u>200MG</u>	<u>A075362</u>	<u>001</u>	Jun 15, 1999
<u>AB</u>	TARO	<u>200MG</u>	<u>A075319</u>	<u>001</u>	Jun 15, 1999
<u>AB</u>	TEVA	<u>200MG</u>	<u>A075273</u>	<u>001</u>	Jun 15, 1999

NIZORAL

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>200MG</u>	<u>N018533</u>	<u>001</u>	

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

<u>AB</u>	HERITAGE PHARMS INC	<u>50MG</u>	<u>A074014</u>	<u>002</u>	Jan 29, 1993
<u>AB</u>		<u>75MG</u>	<u>A074014</u>	<u>003</u>	Jan 29, 1993
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A074035</u>	<u>002</u>	Dec 31, 1996
<u>AB</u>		<u>75MG</u>	<u>A074035</u>	<u>003</u>	Dec 31, 1996
<u>AB</u>	TEVA	<u>50MG</u>	<u>A073516</u>	<u>001</u>	Dec 22, 1992
<u>AB</u>	+	<u>75MG</u>	<u>A073517</u>	<u>001</u>	Dec 22, 1992
	KETOPROFEN				
	HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

<u>AB</u>	ELAN PHARM	<u>200MG</u>	<u>A074879</u>	<u>001</u>	Dec 10, 1997
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A075679</u>	<u>003</u>	Feb 20, 2002
<u>AB</u>		<u>150MG</u>	<u>A075679</u>	<u>002</u>	Feb 20, 2002
<u>AB</u>	+	<u>200MG</u>	<u>A075679</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	WATSON LABS FLORIDA	<u>100MG</u>	<u>A075270</u>	<u>002</u>	Mar 24, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 234 (of 409)

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

<u>AB</u>	WATSON LABS FLORIDA	<u>150MG</u>	<u>A075270</u>	<u>003</u>	Mar 24, 1999
<u>AB</u>		<u>200MG</u>	<u>A075270</u>	<u>001</u>	Mar 24, 1999

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>	AKORN STRIDES	<u>15MG/ML</u>	<u>A078299</u>	<u>001</u>	Jul 16, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A078299</u>	<u>002</u>	Jul 16, 2007
<u>AP</u>	APP PHARMS	<u>15MG/ML</u>	<u>A075784</u>	<u>001</u>	Jan 11, 2002
<u>AP</u>		<u>30MG/ML</u>	<u>A075784</u>	<u>002</u>	Jan 11, 2002
<u>AP</u>	BAXTER HLTHCARE	<u>15MG/ML</u>	<u>A075772</u>	<u>001</u>	Jul 21, 2004
<u>AP</u>		<u>30MG/ML</u>	<u>A075772</u>	<u>002</u>	Jul 21, 2004
<u>AP</u>	BAXTER HLTHCARE CORP	<u>15MG/ML</u>	<u>A075299</u>	<u>001</u>	Nov 03, 1999
<u>AP</u>		<u>30MG/ML</u>	<u>A075299</u>	<u>002</u>	Nov 03, 1999
<u>AP</u>	+ BEDFORD	<u>15MG/ML</u>	<u>A075222</u>	<u>001</u>	Apr 26, 1999
<u>AP</u>	+	<u>30MG/ML</u>	<u>A075222</u>	<u>002</u>	Apr 26, 1999
<u>AP</u>	+	<u>30MG/ML</u>	<u>A075228</u>	<u>001</u>	Apr 26, 1999
<u>AP</u>	CLARIS LIFESCIENCES	<u>15MG/ML</u>	<u>A075631</u>	<u>002</u>	Jun 29, 2001
<u>AP</u>		<u>30MG/ML</u>	<u>A075631</u>	<u>001</u>	Jun 29, 2001
<u>AP</u>	HOSPIRA	<u>15MG/ML</u>	<u>A074802</u>	<u>001</u>	Jun 05, 1997
<u>AP</u>		<u>15MG/ML</u>	<u>A074993</u>	<u>001</u>	Jan 27, 1999
<u>AP</u>		<u>30MG/ML</u>	<u>A074802</u>	<u>002</u>	Jun 05, 1997
<u>AP</u>		<u>30MG/ML</u>	<u>A074993</u>	<u>002</u>	Jan 27, 1999
<u>AP</u>	LUITPOLD	<u>15MG/ML</u>	<u>A078145</u>	<u>001</u>	Jan 14, 2008
<u>AP</u>		<u>30MG/ML</u>	<u>A078145</u>	<u>002</u>	Jan 14, 2008
<u>AP</u>	SANDOZ	<u>15MG/ML</u>	<u>A076271</u>	<u>001</u>	Oct 06, 2004
<u>AP</u>		<u>30MG/ML</u>	<u>A076271</u>	<u>002</u>	Oct 06, 2004
<u>AP</u>	SUN PHARMA GLOBAL	<u>15MG/ML</u>	<u>A078737</u>	<u>001</u>	Oct 06, 2008
<u>AP</u>		<u>30MG/ML</u>	<u>A078737</u>	<u>002</u>	Oct 06, 2008
<u>AP</u>	WOCKHARDT	<u>15MG/ML</u>	<u>A077942</u>	<u>001</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077942</u>	<u>002</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077943</u>	<u>001</u>	Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULAR

<u>AT</u>	+ ALLERGAN	<u>0.5%</u>	<u>N019700</u>	<u>001</u>	Nov 09, 1992

ACULAR LS

<u>AT</u>	+ ALLERGAN	<u>0.4%</u>	<u>N021528</u>	<u>001</u>	May 30, 2003

KETOROLAC TROMETHAMINE

<u>AT</u>	AKORN	<u>0.4%</u>	<u>A078399</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A078434</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	ALCON	<u>0.4%</u>	<u>A078721</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076583</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.5%</u>	<u>A090017</u>	<u>001</u>	Nov 05, 2009

ACULAR PRESERVATIVE FREE

	+ ALLERGAN	0.5%	N020811	001	Nov 03, 1997

ACUVAIL

	+ ALLERGAN	0.45%	N022427	001	Jul 22, 2009

SPRAY, METERED; NASAL

SPRIX

	+ ROXRO PHARMA INC	15.75MG/SPRAY	N022382	001	May 14, 2010

TABLET; ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	+ MYLAN	<u>10MG</u>	<u>A074761</u>	<u>001</u>	May 16, 1997
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A075284</u>	<u>001</u>	Jun 23, 1999
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754</u>	<u>001</u>	May 16, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 235 (of 409)

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>5MG/ML</u>	<u>A075303</u>	<u>001</u>	May 28, 1999
<u>AP</u>	CLARIS LIFESCIENCES	<u>5MG/ML</u>	<u>A076051</u>	<u>001</u>	Jul 05, 2002
<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A075239</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>	+	<u>5MG/ML</u>	<u>A075240</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>	TAYLOR	<u>5MG/ML</u>	<u>A075431</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075524</u>	<u>001</u>	Nov 29, 1999

LABETALOL HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>5MG/ML</u>	<u>A079134</u>	<u>001</u>	Feb 03, 2010

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A074787</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A074787</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A074787</u>	<u>003</u>	Aug 03, 1998
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113</u>	<u>001</u>	Aug 04, 1998
<u>AB</u>		<u>200MG</u>	<u>A075113</u>	<u>002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113</u>	<u>003</u>	Aug 04, 1998
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133</u>	<u>003</u>	Aug 03, 1998

TRANDATE

<u>AB</u>	PROMETHEUS LABS	<u>100MG</u>	<u>N018716</u>	<u>001</u>	May 24, 1985
<u>AB</u>	+	<u>200MG</u>	<u>N018716</u>	<u>002</u>	Aug 01, 1984

LACOSAMIDE

SOLUTION; INTRAVENOUS

VIMPAT

+	UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008

SOLUTION; ORAL

VIMPAT

+	UCB INC	10MG/ML	N022255	001	Apr 20, 2010

TABLET; ORAL

VIMPAT

	UCB INC	50MG	N022253	001	Oct 28, 2008
		100MG	N022253	002	Oct 28, 2008
		150MG	N022253	003	Oct 28, 2008
+		200MG	N022253	004	Oct 28, 2008

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+	INALCO	10GM/PACKET	A074712	001	Dec 10, 1997
+		20GM/PACKET	A074712	002	Dec 10, 1997

SOLUTION; ORAL

CONSTILAC

<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071054</u>	<u>001</u>	Jul 26, 1988

CONSTULOSE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A070288</u>	<u>001</u>	Aug 15, 1988

LACTULOSE

<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A078430</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074076</u>	<u>001</u>	Jul 03, 1995
<u>AA</u>	MORTON GROVE	<u>10GM/15ML</u>	<u>A074602</u>	<u>001</u>	Nov 14, 1996
<u>AA</u>	NOVEX	<u>10GM/15ML</u>	<u>A075911</u>	<u>001</u>	Feb 21, 2002
<u>AA</u>	PHARM ASSOC	<u>10GM/15ML</u>	<u>A074623</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	ROXANE	<u>10GM/15ML</u>	<u>A073591</u>	<u>001</u>	May 29, 1992
<u>AA</u>	VINTAGE PHARMS	<u>10GM/15ML</u>	<u>A075993</u>	<u>001</u>	Jul 26, 2001
<u>AA</u>	VISTAPHARM	<u>10GM/15ML</u>	<u>A074138</u>	<u>001</u>	Sep 30, 1992

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 236 (of 409)

LACTULOSE

SOLUTION; ORAL, RECTAL				
<u>CHOLAC</u>				
<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071331</u>	<u>001</u> Jul 26, 1988
<u>ENULOSE</u>				
<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A071548</u>	<u>001</u> Aug 15, 1988
<u>GENERLAC</u>				
<u>AA</u>	MORTON GROVE PHARMS	<u>10GM/15ML</u>	<u>A074603</u>	<u>001</u> Oct 31, 1996
<u>LACTULOSE</u>				
<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A090426</u>	<u>001</u> Nov 21, 2008
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074077</u>	<u>001</u> Jul 03, 1995
<u>AA</u>	NOVEX	<u>10GM/15ML</u>	<u>A076645</u>	<u>001</u> Jul 28, 2003

LAMIVUDINE

SOLUTION; ORAL				
EPIVIR				
	+ VIIIV HLTHCARE	10MG/ML	N020596	001 Nov 17, 1995
EPIVIR-HBV				
	+ GLAXOSMITHKLINE	5MG/ML	N021004	001 Dec 08, 1998
TABLET; ORAL				
EPIVIR				
	VIIIV HLTHCARE	150MG	N020564	001 Nov 17, 1995
	+	300MG	N020564	003 Jun 24, 2002
EPIVIR-HBV				
	+ GLAXOSMITHKLINE	100MG	N021003	001 Dec 08, 1998

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL				
COMBIVIR				
	+ VIIIV HLTHCARE	150MG;300MG	N020857	001 Sep 26, 1997

LAMOTRIGINE

TABLET; ORAL				
<u>LAMICTAL</u>				
<u>AB</u>	+ GLAXOSMITHKLINE	<u>25MG</u>	<u>N020241</u>	<u>005</u> Dec 27, 1994
<u>AB</u>		<u>100MG</u>	<u>N020241</u>	<u>001</u> Dec 27, 1994
<u>AB</u>		<u>150MG</u>	<u>N020241</u>	<u>002</u> Dec 27, 1994
<u>AB</u>		<u>200MG</u>	<u>N020241</u>	<u>003</u> Dec 27, 1994
<u>LAMOTRIGINE</u>				
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A078625</u>	<u>001</u> Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078625</u>	<u>002</u> Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078625</u>	<u>003</u> Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078625</u>	<u>004</u> Jan 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078956</u>	<u>001</u> Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078956</u>	<u>002</u> Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078956</u>	<u>003</u> Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078956</u>	<u>004</u> Jan 27, 2009
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A079132</u>	<u>001</u> Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079132</u>	<u>002</u> Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A079132</u>	<u>003</u> Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079132</u>	<u>004</u> Jan 27, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A076708</u>	<u>001</u> Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076708</u>	<u>002</u> Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u> Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u> Jan 27, 2009
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078691</u>	<u>001</u> Jun 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078691</u>	<u>002</u> Jun 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A078691</u>	<u>003</u> Jun 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A078691</u>	<u>004</u> Jun 01, 2010
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420</u>	<u>001</u> Jan 27, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 237 (of 409)

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A077420</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078645</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078645</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078645</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078645</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078525</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076388</u>	<u>001</u>	Aug 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A076388</u>	<u>002</u>	Aug 30, 2006
<u>AB</u>		<u>150MG</u>	<u>A076388</u>	<u>003</u>	Aug 30, 2006
<u>AB</u>		<u>200MG</u>	<u>A076388</u>	<u>004</u>	Aug 30, 2006
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078310</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>100MG</u>	<u>A078310</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>150MG</u>	<u>A078310</u>	<u>003</u>	Feb 04, 2009
<u>AB</u>		<u>200MG</u>	<u>A078310</u>	<u>004</u>	Feb 04, 2009
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A077783</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A077783</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A077783</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A077783</u>	<u>004</u>	Nov 01, 2010
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633</u>	<u>005</u>	Jan 27, 2009
	LAMOTRIGINE				
	ZYDUS PHARMS USA	50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

<u>AB</u>	GLAXOSMITHKLINE	<u>2MG</u>	<u>N020764</u>	<u>004</u>	Sep 08, 2000
<u>AB</u>		<u>5MG</u>	<u>N020764</u>	<u>001</u>	Aug 24, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020764</u>	<u>002</u>	Aug 24, 1998
	<u>LAMOTRIGINE</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401</u>	<u>002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401</u>	<u>003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A079099</u>	<u>001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099</u>	<u>002</u>	Feb 19, 2009
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076630</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076630</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076420</u>	<u>001</u>	Jun 21, 2006
<u>AB</u>		<u>25MG</u>	<u>A076420</u>	<u>002</u>	Jun 21, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928</u>	<u>003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009</u>	<u>003</u>	Jan 22, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 238 (of 409)

LAMOTRIGINE

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

SMITHKLINE BEECHAM	25MG	N022115	001	May 29, 2009
+	50MG	N022115	002	May 29, 2009
	100MG	N022115	003	May 29, 2009
	200MG	N022115	004	May 29, 2009
	300MG	N022115	005	Apr 14, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

LAMICTAL ODT

SMITHKLINE BEECHAM	25MG	N022251	001	May 08, 2009
+	50MG	N022251	002	May 08, 2009
	100MG	N022251	003	May 08, 2009
	200MG	N022251	004	May 08, 2009

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

+ BEAUFOR IPSEN	EQ 60MG BASE	N022074	001	Aug 30, 2007
+	EQ 90MG BASE	N022074	002	Aug 30, 2007
+	EQ 120MG BASE	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

<u>AB</u>	DR REDDYS LABS LTD	15MG	<u>A091269</u>	<u>001</u>	Oct 15, 2010
<u>AB</u>		30MG	<u>A091269</u>	<u>002</u>	Oct 15, 2010
<u>AB</u>	MATRIX LABS LTD	15MG	<u>A090763</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		30MG	<u>A090763</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	SANDOZ	15MG	<u>A090331</u>	<u>001</u>	Apr 23, 2010
<u>AB</u>		30MG	<u>A090331</u>	<u>002</u>	Apr 23, 2010
<u>AB</u>	TEVA PHARMS	15MG	<u>A077255</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		30MG	<u>A077255</u>	<u>002</u>	Nov 10, 2009

PREVACID

<u>AB</u>	TAKEDA PHARMS NA	15MG	<u>N020406</u>	<u>001</u>	May 10, 1995
<u>AB</u>	+	30MG	<u>N020406</u>	<u>002</u>	May 10, 1995

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

<u>AB</u>	TEVA PHARMS	15MG	<u>A078730</u>	<u>001</u>	Oct 15, 2010
<u>AB</u>		30MG	<u>A078730</u>	<u>002</u>	Oct 15, 2010

PREVACID

<u>AB</u>	TAKEDA PHARMS NA	15MG	<u>N021428</u>	<u>001</u>	Aug 30, 2002
<u>AB</u>	+	30MG	<u>N021428</u>	<u>002</u>	Aug 30, 2002

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

SHIRE	EQ 500MG BASE	N021468	002	Oct 26, 2004
	EQ 750MG BASE	N021468	003	Nov 23, 2005
+	EQ 1GM BASE	N021468	004	Nov 23, 2005

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+ SMITHKLINE BEECHAM	EQ 250MG BASE	N022059	001	Mar 13, 2007

PRESCRIPTION DRUG PRODUCT LIST

3 - 239 (of 409)

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

+ PHARMACIA AND UPJOHN	0.005%	N020597	001	Jun 05, 1996

LEFLUNOMIDE

TABLET; ORAL

ARAVA

<u>AB</u> SANOFI AVENTIS US	<u>10MG</u>	<u>N020905</u>	<u>001</u>	Sep 10, 1998
<u>AB</u> +	<u>20MG</u>	<u>N020905</u>	<u>002</u>	Sep 10, 1998

LEFLUNOMIDE

<u>AB</u> APOTEX INC	<u>10MG</u>	<u>A077090</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	<u>20MG</u>	<u>A077090</u>	<u>002</u>	Sep 13, 2005
<u>AB</u> BARR	<u>10MG</u>	<u>A077083</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	<u>20MG</u>	<u>A077083</u>	<u>002</u>	Sep 13, 2005
<u>AB</u> HERITAGE PHARMS INC	<u>10MG</u>	<u>A077086</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	<u>20MG</u>	<u>A077086</u>	<u>002</u>	Sep 13, 2005
<u>AB</u> SANDOZ	<u>10MG</u>	<u>A077087</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	<u>20MG</u>	<u>A077087</u>	<u>002</u>	Sep 13, 2005
<u>AB</u> TEVA PHARMS	<u>10MG</u>	<u>A077084</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	<u>20MG</u>	<u>A077084</u>	<u>002</u>	Sep 13, 2005

ARAVA

+ SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

CELGENE	5MG	N021880	001	Dec 27, 2005
	10MG	N021880	002	Dec 27, 2005
+	15MG	N021880	003	Jun 29, 2006
+	25MG	N021880	004	Jun 29, 2006

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION

REFLUDAN

+ BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998

LETROZOLE

TABLET; ORAL

FEMARA

<u>AB</u> + NOVARTIS PHARMS	<u>2.5MG</u>	<u>N020726</u>	<u>001</u>	Jul 25, 1997

LETROZOLE

<u>AB</u> MYLAN	<u>2.5MG</u>	<u>A078190</u>	<u>001</u>	Dec 24, 2008

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<u>AP</u> + BEDFORD	<u>EQ 50MG BASE/VIAL</u>	<u>A089384</u>	<u>001</u>	Sep 14, 1987
<u>AP</u> +	<u>EQ 100MG BASE/VIAL</u>	<u>A089717</u>	<u>001</u>	Mar 28, 1988
<u>AP</u> TEVA PARENTERAL	<u>EQ 50MG BASE/VIAL</u>	<u>A081278</u>	<u>001</u>	Sep 28, 1993
<u>AP</u>	<u>EQ 100MG BASE/VIAL</u>	<u>A081277</u>	<u>001</u>	Sep 28, 1993
<u>AP</u>	<u>EQ 350MG BASE/VIAL</u>	<u>A040174</u>	<u>001</u>	Jun 12, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

<u>AP</u> APP PHARMS	<u>EQ 200MG BASE/VIAL</u>	<u>A040258</u>	<u>001</u>	Feb 26, 1999
<u>AP</u> + BEDFORD	<u>EQ 200MG BASE/VIAL</u>	<u>A040056</u>	<u>001</u>	May 23, 1995
<u>AP</u> +	<u>EQ 350MG BASE/VIAL</u>	<u>A040335</u>	<u>001</u>	Apr 20, 2000
<u>AP</u> LUITPOLD	<u>EQ 50MG BASE/VIAL</u>	<u>A040338</u>	<u>001</u>	Jan 31, 2001

LEUCOVORIN CALCIUM PRESERVATIVE FREE

+ APP PHARMS	EQ 500MG BASE/VIAL	A040286	001	Feb 26, 1999
+	BEDFORD	A040347	001	Apr 25, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 240 (of 409)

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u>	BARR	<u>EQ 5MG BASE</u>	<u>A071198</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A071199</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>	ROXANE	<u>EQ 5MG BASE</u>	<u>A072733</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A072735</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A072736</u>	<u>001</u>	Feb 22, 1993
	LEUCOVORIN CALCIUM				
	ROXANE	EQ 10MG BASE	A072734	001	Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<u>AP</u>	GENZYME	<u>1MG/0.2ML</u>	<u>A075721</u>	<u>001</u>	Nov 29, 2001
<u>AP</u>	+	<u>1MG/0.2ML</u>	<u>A074728</u>	<u>001</u>	Aug 04, 1998
<u>AP</u>	SUN PHARMA GLOBAL	<u>1MG/0.2ML</u>	<u>A078885</u>	<u>001</u>	Mar 09, 2009
<u>AP</u>	TEVA PARENTERAL	<u>1MG/0.2ML</u>	<u>A075471</u>	<u>001</u>	Oct 25, 2000
	LUPRON DEPOT				
+	ABBOTT LABS	3.75MG/VIAL	N020011	001	Oct 22, 1990
+		7.5MG/VIAL	N019732	001	Jan 26, 1989
+		11.25MG/VIAL	N020708	001	Mar 07, 1997
+		22.5MG/VIAL	N020517	001	Dec 22, 1995
+		30MG/VIAL	N020517	002	May 30, 1997
	LUPRON DEPOT-PED				
+	ABBOTT LABS	7.5MG/VIAL	N020263	002	Apr 16, 1993
+		11.25MG/VIAL	N020263	005	Jan 21, 1994
+		15MG/VIAL	N020263	006	Jan 21, 1994
	INJECTABLE; SUBCUTANEOUS				
	ELIGARD				
+	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002
+		22.5MG/VIAL	N021379	001	Jul 24, 2002
+		30MG/VIAL	N021488	001	Feb 13, 2003
+		45MG/VIAL	N021731	001	Dec 14, 2004

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	BREATH LTD	<u>EQ 0.0103% BASE</u>	<u>A077756</u>	<u>003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756</u>	<u>001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756</u>	<u>002</u>	Apr 09, 2008
<u>AN</u>	DEY	<u>EQ 0.25% BASE</u>	<u>A078309</u>	<u>001</u>	Mar 20, 2009
	<u>XOPENEX</u>				
<u>AN</u>	+	<u>EQ 0.0103% BASE</u>	<u>N020837</u>	<u>003</u>	Jan 30, 2002
<u>AN</u>	+	<u>EQ 0.021% BASE</u>	<u>N020837</u>	<u>001</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.042% BASE</u>	<u>N020837</u>	<u>002</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.25% BASE</u>	<u>N020837</u>	<u>004</u>	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+	SUNOVION	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

<u>AP</u>	+	<u>UCB INC</u>	<u>500MG/5ML (100MG/ML)</u>	<u>N021872</u>	<u>001</u>	Jul 31, 2006
		<u>LEVETIRACETAM</u>				
<u>AP</u>		NEXUS PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A090813</u>	<u>001</u>	May 26, 2010
<u>AP</u>		SUN PHARM INDS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A090754</u>	<u>001</u>	Jun 16, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 241 (of 409)

LEVETIRACETAM

SOLUTION; ORAL

KEPPRA

<u>AA</u>	<u>+</u>	<u>UCB INC</u>	<u>100MG/ML</u>	<u>N021505</u>	<u>001</u>	Jul 15, 2003
<u>LEVETIRACETAM</u>						
<u>AA</u>		<u>ACTAVIS MID ATLANTIC</u>	<u>100MG/ML</u>	<u>A078976</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>		<u>AMNEAL PHARMS</u>	<u>100MG/ML</u>	<u>A090992</u>	<u>001</u>	Oct 27, 2009
<u>AA</u>		<u>AUROBINDO PHARM</u>	<u>100MG/ML</u>	<u>A079063</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>		<u>CYPRESS PHARM</u>	<u>100MG/ML</u>	<u>A079120</u>	<u>001</u>	Jan 16, 2009
<u>AA</u>		<u>ROXANE</u>	<u>100MG/ML</u>	<u>A078582</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>		<u>SILARX</u>	<u>100MG/ML</u>	<u>A090263</u>	<u>001</u>	Apr 03, 2009
<u>AA</u>		<u>TARO</u>	<u>100MG/ML</u>	<u>A078774</u>	<u>001</u>	Feb 10, 2009
<u>AA</u>		<u>TOLMAR</u>	<u>100MG/ML</u>	<u>A079107</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>		<u>TRIS PHARMA INC</u>	<u>100MG/ML</u>	<u>A090461</u>	<u>001</u>	Sep 30, 2010
<u>AA</u>		<u>WOCKHARDT</u>	<u>100MG/ML</u>	<u>A090028</u>	<u>001</u>	Mar 03, 2010

TABLET; ORAL

KEPPRA

<u>AB</u>		<u>UCB INC</u>	<u>250MG</u>	<u>N021035</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>			<u>500MG</u>	<u>N021035</u>	<u>002</u>	Nov 30, 1999
<u>AB</u>			<u>750MG</u>	<u>N021035</u>	<u>003</u>	Nov 30, 1999
<u>AB</u>	<u>+</u>		<u>1GM</u>	<u>N021035</u>	<u>004</u>	Jan 06, 2006
<u>LEVETIRACETAM</u>						
<u>AB</u>		<u>APOTEX INC</u>	<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>			<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>			<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>			<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>		<u>AUROBINDO PHARMA</u>	<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>BIOKEY</u>	<u>500MG</u>	<u>A090906</u>	<u>001</u>	Nov 05, 2010
<u>AB</u>		<u>BOCA PHARMA</u>	<u>250MG</u>	<u>A077319</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>			<u>500MG</u>	<u>A077319</u>	<u>002</u>	Mar 20, 2009
<u>AB</u>			<u>750MG</u>	<u>A077319</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>		<u>COBALT LABS INC</u>	<u>250MG</u>	<u>A077384</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A077384</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A077384</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>DR REDDYS LABS LTD</u>	<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>HETERO DRUGS LTD</u>	<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>			<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>			<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>			<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>INVAGEN PHARMS</u>	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>LUPIN</u>	<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>METHAPHARM</u>	<u>250MG</u>	<u>A090767</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>			<u>500MG</u>	<u>A090767</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>			<u>750MG</u>	<u>A090767</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>			<u>1GM</u>	<u>A090767</u>	<u>004</u>	Jul 28, 2010
<u>AB</u>		<u>MYLAN</u>	<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>			<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>			<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>			<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 242 (of 409)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090484</u>	<u>001</u>	Aug 05, 2010
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077324</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A077324</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A077324</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A077324</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	SOLCO HLTHCARE	<u>250MG</u>	<u>A078106</u>	<u>001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106</u>	<u>003</u>	Feb 10, 2009
<u>AB</u>		<u>1GM</u>	<u>A078106</u>	<u>004</u>	Feb 10, 2009
<u>AB</u>	TARO	<u>250MG</u>	<u>A078960</u>	<u>004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960</u>	<u>003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960</u>	<u>002</u>	Feb 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A078960</u>	<u>001</u>	Feb 01, 2010
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A078101</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078101</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078101</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A078858</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078858</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	VINTAGE PHARMS	<u>250MG</u>	<u>A091491</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A091491</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A091491</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>		<u>1GM</u>	<u>A091491</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>	WATSON LABS	<u>1GM</u>	<u>A078797</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A079042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A079042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A078918</u>	<u>001</u>	Apr 29, 2009
<u>AB</u>		<u>1GM</u>	<u>A078918</u>	<u>002</u>	Apr 29, 2009
TABLET, EXTENDED RELEASE; ORAL					
	KEPPRA XR				
	UCB INC	500MG	N022285	001	Sep 12, 2008
	+	750MG	N022285	002	Feb 12, 2009

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996

BETAGAN

<u>AT</u>	+ ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+	<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	BAUSCH AND LOMB	<u>0.25%</u>	<u>A074307</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>		<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>	FALCON PHARMS	<u>0.25%</u>	<u>A074851</u>	<u>001</u>	Oct 28, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074850</u>	<u>001</u>	Oct 28, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 243 (of 409)

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	NOVEX	<u>0.25%</u>	<u>A075473</u>	<u>001</u>	Aug 03, 2000
<u>AT</u>		<u>0.5%</u>	<u>A075475</u>	<u>001</u>	Aug 03, 2000

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

<u>AP</u>	+ SIGMA TAU	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992

LEVOCARNITINE

<u>AP</u>	BEDFORD	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001
<u>AP</u>	LUITPOLD	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>	TEVA PARENTERAL	<u>200MG/ML</u>	<u>A075881</u>	<u>001</u>	Mar 29, 2001

SOLUTION; ORAL

CARNITOR

<u>AA</u>	+ SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986

CARNITOR SF

<u>AA</u>	SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007

LEVOCARNITINE

<u>AA</u>	HI TECH PHARMA	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007
<u>AA</u>	LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004

TABLET; ORAL

CARNITOR

<u>AB</u>	+ SIGMA TAU	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985

LEVOCARNITINE

<u>AB</u>	COREPHARMA	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

XYZAL

	+ UCB INC	2.5MG/5ML	N022157	001	Jan 28, 2008

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AB</u>	SYNTHON PHARMS	<u>5MG</u>	<u>A090229</u>	<u>001</u>	Nov 26, 2010

XYZAL

<u>AB</u>	+ UCB INC	<u>5MG</u>	<u>N022064</u>	<u>001</u>	May 25, 2007

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

	+ ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996

	+	EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996

	+	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996

	+	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996

SOLUTION; ORAL

LEVAQUIN

	+ ORTHO MCNEIL JANSSEN	250MG/10ML	N021721	001	Oct 21, 2004

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A090268</u>	<u>001</u>	Dec 20, 2010

<u>AT</u>	APOTEX	<u>0.5%</u>	<u>A078282</u>	<u>001</u>	Dec 20, 2010

<u>AT</u>	NEXUS PHARMS	<u>0.5%</u>	<u>A077700</u>	<u>001</u>	Dec 20, 2010

QUIXIN

<u>AT</u>	+ SANTEN	<u>0.5%</u>	<u>N021199</u>	<u>001</u>	Aug 18, 2000

IQUIX

	+ SANTEN	1.5%	N021571	001	Mar 01, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 244 (of 409)

LEVOFLOXACIN

TABLET; ORAL

LEVAQUIN

ORTHO MCNEIL JANSSEN 250MG

N020634 001 Dec 20, 1996

500MG

N020634 002 Dec 20, 1996

+

750MG

N020634 003 Sep 08, 2000

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

+ SPECTRUM PHARMS EQ 50MG BASE/VIAL

N020140 001 Mar 07, 2008

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

AP NOVOCOL 0.05MG/ML;2%

A084697 001

SCANDONEST L

AP DEPROCO 0.05MG/ML;2%

A088388 001 Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

MIRENA

+ BAYER HLTHCARE 52MG

N021225 001 Dec 06, 2000

TABLET; ORAL

LEVONORGESTREL

AB PERRIGO R AND D 0.75MG

A090740 001 Dec 30, 2010

AB + WATSON LABS 0.75MG

A078665 001 Aug 28, 2009

AB 0.75MG

A078666 001 Jun 24, 2009

PLAN B

AB + DURAMED 0.75MG

N021045 002 Aug 24, 2006

PLAN B ONE-STEP

+ DURAMED 1.5MG

N021998 001 Jul 10, 2009

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

AB + VALEANT PHARM INTL 2MG

N008720 001 Dec 19, 1991

LEVORPHANOL TARTRATE

AB ROXANE 2MG

A074278 001 Mar 31, 2000

LEVOTHYROXINE SODIUM**

Refer to Preface Section 1.8 Levothyroxine Sodium for amplifying information

CAPSULE; ORAL

TIROSINT

INST BIOCHIMIQUE 0.013MG

N022121 001 Aug 01, 2007

INSTITUT BIOCHIMIQUE 0.025MG

N021924 002 Oct 13, 2006

0.05MG

N021924 003 Oct 13, 2006

0.075MG

N021924 004 Oct 13, 2006

0.088MG

N021924 010 Oct 02, 2009

0.1MG

N021924 005 Oct 13, 2006

0.112MG

N021924 008 Oct 02, 2009

0.125MG

N021924 006 Oct 13, 2006

0.137MG

N021924 009 Oct 02, 2009

+

0.15MG

N021924 007 Oct 13, 2006

TABLET; ORAL

LEVO-T

--> ALARA PHARM --> AB2,AB3 0.025MG

N021342 001 Mar 01, 2002

--> --> AB2,AB3 0.05MG

N021342 002 Mar 01, 2002

--> --> AB2,AB3 0.075MG

N021342 003 Mar 01, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 245 (of 409)

LEVOTHYROXINE SODIUM**

Refer to Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL						
LEVO-T						
--> ALARA PHARM	-->	AB2, AB3	0.088MG	N021342	004	Mar 01, 2002
-->	-->	AB2, AB3	0.1MG	N021342	005	Mar 01, 2002
-->	-->	AB2, AB3	0.112MG	N021342	006	Mar 01, 2002
-->	-->	AB2, AB3	0.125MG	N021342	007	Mar 01, 2002
-->	-->	AB2, AB3	0.137MG	N021342	012	Dec 08, 2003
-->	-->	AB2, AB3	0.15MG	N021342	008	Mar 01, 2002
-->	-->	AB2, AB3	0.175MG	N021342	009	Mar 01, 2002
-->	-->	AB2, AB3	0.2MG	N021342	010	Mar 01, 2002
--> +	-->	AB2, AB3	0.3MG	N021342	011	Mar 01, 2002
LEVOTHYROXINE SODIUM						
--> MERCK KGAA	-->	AB2, AB3	0.025MG	A076752	001	Jun 16, 2005
-->	-->	AB2, AB3	0.05MG	A076752	002	Jun 16, 2005
-->	-->	AB2, AB3	0.075MG	A076752	003	Jun 16, 2005
-->	-->	AB2, AB3	0.088MG	A076752	004	Jun 16, 2005
-->	-->	AB2, AB3	0.1MG	A076752	005	Jun 16, 2005
-->	-->	AB2, AB3	0.112MG	A076752	006	Jun 16, 2005
-->	-->	AB2, AB3	0.125MG	A076752	007	Jun 16, 2005
-->	-->	AB2, AB3	0.15MG	A076752	008	Jun 16, 2005
-->	-->	AB2, AB3	0.175MG	A076752	009	Jun 16, 2005
-->	-->	AB2, AB3	0.2MG	A076752	010	Jun 16, 2005
-->	-->	AB2, AB3	0.3MG	A076752	011	Jun 16, 2005
--> MYLAN	-->	AB1, AB2, AB3, AB4	0.025MG	A076187	001	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.05MG	A076187	002	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.075MG	A076187	003	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.088MG	A076187	004	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.1MG	A076187	005	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.112MG	A076187	006	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.125MG	A076187	007	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.137MG	A076187	012	Dec 13, 2006
-->	-->	AB1, AB2, AB3, AB4	0.15MG	A076187	008	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.175MG	A076187	009	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.2MG	A076187	010	Jun 05, 2002
-->	-->	AB1, AB2, AB3, AB4	0.3MG	A076187	011	Jun 05, 2002
LEVOXYL						
--> KING PHARMS	-->	AB1, AB3	0.025MG	N021301	001	May 25, 2001
-->	-->	AB1, AB3	0.05MG	N021301	002	May 25, 2001
-->	-->	AB1, AB3	0.075MG	N021301	003	May 25, 2001
-->	-->	AB1, AB3	0.088MG	N021301	004	May 25, 2001
-->	-->	AB1, AB3	0.1MG	N021301	005	May 25, 2001
-->	-->	AB1, AB3	0.112MG	N021301	006	May 25, 2001
-->	-->	AB1, AB3	0.125MG	N021301	007	May 25, 2001
-->	-->	AB1, AB3	0.137MG	N021301	008	May 25, 2001
-->	-->	AB1, AB3	0.15MG	N021301	009	May 25, 2001
-->	-->	AB1, AB3	0.175MG	N021301	010	May 25, 2001
--> +	-->	AB1, AB3	0.2MG	N021301	011	May 25, 2001
SYNTHROID						
--> ABBOTT	-->	AB1, AB2	0.025MG	N021402	001	Jul 24, 2002
-->	-->	AB1, AB2	0.05MG	N021402	002	Jul 24, 2002
-->	-->	AB1, AB2	0.075MG	N021402	003	Jul 24, 2002
-->	-->	AB1, AB2	0.088MG	N021402	004	Jul 24, 2002
-->	-->	AB1, AB2	0.1MG	N021402	005	Jul 24, 2002
-->	-->	AB1, AB2	0.112MG	N021402	006	Jul 24, 2002
-->	-->	AB1, AB2	0.125MG	N021402	007	Jul 24, 2002
-->	-->	AB1, AB2	0.137MG	N021402	008	Jul 24, 2002
-->	-->	AB1, AB2	0.15MG	N021402	009	Jul 24, 2002
-->	-->	AB1, AB2	0.175MG	N021402	010	Jul 24, 2002

PRESCRIPTION DRUG PRODUCT LIST

3 - 246 (of 409)

LEVOTHYROXINE SODIUM**

Refer to Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL			
SYNTHROID			
-->	ABBOTT	--> AB1,AB2 0.2MG	N021402 012 Jul 24, 2002
--> +		--> AB1,AB2 0.3MG	N021402 011 Jul 24, 2002
UNITHROID			
-->	STEVENS J	--> AB1,AB2,AB3 0.025MG	N021210 001 Aug 21, 2000
-->		--> AB1,AB2,AB3 0.05MG	N021210 002 Aug 21, 2000
-->		--> AB1,AB2,AB3 0.075MG	N021210 003 Aug 21, 2000
-->		--> AB1,AB2,AB3 0.088MG	N021210 004 Aug 21, 2000
-->		--> AB1,AB2,AB3 0.1MG	N021210 005 Aug 21, 2000
-->		--> AB1,AB2,AB3 0.112MG	N021210 006 Aug 21, 2000
-->		--> AB1,AB2,AB3 0.125MG	N021210 007 Aug 21, 2000
-->		--> AB1,AB2,AB3 0.137MG	N021210 012 Feb 08, 2008
-->		--> AB1,AB2,AB3 0.15MG	N021210 008 Aug 21, 2000
-->		--> AB1,AB2,AB3 0.175MG	N021210 009 Aug 21, 2000
-->		--> AB1,AB2,AB3 0.2MG	N021210 010 Aug 21, 2000
--> +		--> AB1,AB2,AB3 0.3MG	N021210 011 Aug 21, 2000
<u>LEVOTHROID</u>			
<u>AB4</u>	<u>LLOYD</u>	<u>0.025MG</u>	<u>N021116 001</u> Oct 24, 2002
<u>AB4</u>		<u>0.05MG</u>	<u>N021116 002</u> Oct 24, 2002
<u>AB4</u>		<u>0.075MG</u>	<u>N021116 003</u> Oct 24, 2002
<u>AB4</u>		<u>0.088MG</u>	<u>N021116 010</u> Oct 24, 2002
<u>AB4</u>		<u>0.1MG</u>	<u>N021116 004</u> Oct 24, 2002
<u>AB4</u>		<u>0.112MG</u>	<u>N021116 011</u> Oct 24, 2002
<u>AB4</u>		<u>0.125MG</u>	<u>N021116 005</u> Oct 24, 2002
<u>AB4</u>		<u>0.137MG</u>	<u>N021116 012</u> Dec 07, 2004
<u>AB4</u>		<u>0.15MG</u>	<u>N021116 006</u> Oct 24, 2002
<u>AB4</u>		<u>0.175MG</u>	<u>N021116 007</u> Oct 24, 2002
<u>AB4</u>		<u>0.2MG</u>	<u>N021116 008</u> Oct 24, 2002
<u>AB4</u> +		<u>0.3MG</u>	<u>N021116 009</u> Oct 24, 2002

LIDOCAINE

OINTMENT; TOPICAL			
<u>LIDOCAINE</u>			
<u>AT</u> +	FOUGERA	<u>5%</u>	<u>A080198 001</u>
<u>AT</u>	TARO	<u>5%</u>	<u>A086724 001</u>

PATCH; TOPICAL			
LIDODERM			
+	TEIKOKU PHARMA USA	5%	N020612 001 Mar 19, 1999

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC			
AKTEN			
+	AKORN	3.5%	N022221 001 Oct 07, 2008

INJECTABLE; INJECTION			
<u>LIDOCAINE HYDROCHLORIDE</u>			
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088328 001</u> May 17, 1984
<u>AP</u>		<u>1%</u>	<u>A083158 001</u>
<u>AP</u>		<u>1%</u>	<u>A088329 001</u> May 17, 1984
<u>AP</u>		<u>2%</u>	<u>A040078 001</u> Jun 23, 1995
<u>AP</u>		<u>2%</u>	<u>A083158 002</u>
<u>AP</u>		<u>2%</u>	<u>A088294 001</u> May 17, 1984
<u>AP</u>		<u>20%</u>	<u>A083158 003</u>
<u>AP</u>	LUITPOLD	<u>1%</u>	<u>A080850 001</u>
<u>AP</u>		<u>2%</u>	<u>A083198 001</u>
<u>AP</u>	STRIDES ARCOLAB LTD	<u>0.5%</u>	<u>A091056 001</u> Dec 08, 2010
<u>AP</u>		<u>0.5%</u>	<u>A091058 001</u> Sep 30, 2010
<u>AP</u>		<u>1%</u>	<u>A091056 002</u> Dec 08, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 247 (of 409)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION			
<u>LIDOCAINE HYDROCHLORIDE</u>			
<u>AP</u>	STRIDES ARCOLAB LTD	<u>1%</u>	<u>A091058</u> <u>002</u> Sep 30, 2010
<u>LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>200MG/100ML</u>	<u>N019830</u> <u>002</u> Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461</u> <u>002</u>
<u>LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>400MG/100ML</u>	<u>N019830</u> <u>003</u> Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461</u> <u>003</u>
<u>LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	HOSPIRA	<u>400MG/100ML</u>	<u>N018388</u> <u>002</u>
<u>LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>800MG/100ML</u>	<u>N019830</u> <u>004</u> Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461</u> <u>004</u> Feb 22, 1982
<u>LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	HOSPIRA	<u>800MG/100ML</u>	<u>N018388</u> <u>003</u> Nov 05, 1982
<u>LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER</u>			
<u>AP</u>	APP PHARMS	<u>1%</u>	<u>A088586</u> <u>001</u> Jul 24, 1985
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088325</u> <u>001</u> Jul 31, 1984
<u>AP</u>		<u>1%</u>	<u>A088299</u> <u>001</u> Jul 31, 1984
<u>AP</u>		<u>2%</u>	<u>A088327</u> <u>001</u> Jul 31, 1984
<u>LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE</u>			
<u>AP</u>	ABRAXIS PHARM	<u>2%</u>	<u>N017584</u> <u>001</u>
<u>AP</u>		<u>4%</u>	<u>N017584</u> <u>002</u>
<u>AP</u>	APP PHARMS	<u>1%</u>	<u>A080404</u> <u>002</u>
<u>AP</u>		<u>2%</u>	<u>A080404</u> <u>003</u>
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A080408</u> <u>001</u>
<u>AP</u>		<u>1.5%</u>	<u>A080408</u> <u>002</u>
<u>AP</u>		<u>4%</u>	<u>A088295</u> <u>001</u> May 17, 1984
<u>AP</u>	INTL MEDICATION	<u>20%</u>	<u>N017702</u> <u>001</u>
<u>AP</u>	STRIDES ARCOLAB LTD	<u>2%</u>	<u>A090665</u> <u>001</u> Sep 27, 2010
<u>LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER</u>			
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A040302</u> <u>001</u> Sep 28, 1998
<u>AP</u>		<u>2%</u>	<u>A040302</u> <u>002</u> Sep 28, 1998
<u>LIDOPEN</u>			
<u>AP</u>	MERIDIAN MEDCL TECHN	<u>10%</u>	<u>N017549</u> <u>001</u>
<u>XYLOCAINE</u>			
<u>AP</u>	+ APP PHARMS	<u>0.5%</u>	<u>N006488</u> <u>008</u>
<u>AP</u>	+	<u>1%</u>	<u>N006488</u> <u>007</u>
<u>AP</u>	+	<u>1.5%</u>	<u>N006488</u> <u>010</u>
<u>AP</u>	+	<u>2%</u>	<u>N006488</u> <u>002</u>
<u>XYLOCAINE 4% PRESERVATIVE FREE</u>			
<u>AP</u>	+ APP PHARMS	<u>4%</u>	<u>N010417</u> <u>001</u>
<u>XYLOCAINE DENTAL</u>			
<u>AP</u>	+ DENTSPLY PHARM	<u>2%</u>	<u>N021380</u> <u>001</u>
<u>XYLOCAINE PRESERVATIVE FREE</u>			
<u>AP</u>	+ APP PHARMS	<u>1%</u>	<u>N016801</u> <u>005</u> Jan 19, 1988
<u>AP</u>	+	<u>2%</u>	<u>N016801</u> <u>001</u>
<u>AP</u>	+	<u>4%</u>	<u>N016801</u> <u>002</u>
<u>AP</u>	+	<u>10%</u>	<u>N016801</u> <u>003</u>
<u>AP</u>	+	<u>20%</u>	<u>N016801</u> <u>004</u>
INJECTABLE; SPINAL			
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%			
	+ HOSPIRA	5%	A083914 001
JELLY; TOPICAL			
<u>ANESTACON</u>			
<u>AT</u>	POLYMEDICA	<u>2%</u>	<u>A080429</u> <u>001</u>
<u>LIDOCAINE HYDROCHLORIDE</u>			
<u>AT</u>	AKORN	<u>2%</u>	<u>A040433</u> <u>001</u> Feb 12, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 248 (of 409)

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

LIDOCAINE HYDROCHLORIDEAT INTL MEDICATION 2%A086283 001AT TEVA PHARMS 2%A081318 001

Apr 29, 1993

XYLOCAINEAT + APP PHARMS 2%N008816 001

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDEAT HI TECH PHARMA 2%A040014 001

Jul 10, 1995

AT WOCKHARDT 2%A087872 001

Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUSAT ACTAVIS MID ATLANTIC 2%A086578 001AT VINTAGE 2%A040708 001

Feb 27, 2007

LIDOCAINE VISCOUSAT ROXANE 2%A088802 001

Apr 26, 1985

XYLOCAINE VISCOUSAT + APP PHARMS 2%N009470 001

SOLUTION; TOPICAL

LARYNG-O-JET KITAT INTL MEDICATION 4%A086364 001LIDOCAINE HYDROCHLORIDEAT ROXANE 4%A088803 001

Apr 03, 1985

AT VINTAGE 4%A040710 001

Feb 27, 2007

AT WOCKHARDT 4%A087881 001

Nov 18, 1982

LTA II KITAT HOSPIRA 4%A080409 001XYLOCAINE 4% PRESERVATIVE FREEAT + APP PHARMS 4%N010417 002

PEDIATRIC LTA KIT

HOSPIRA 2%

A085995 001

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLAAB + APP PHARMS 2.5%;2.5%N019941 001

Dec 30, 1992

LIDOCAINE AND PRILOCAINEAB HI TECH PHARMA 2.5%;2.5%A076290 001

Sep 25, 2003

AB NYCOMED US 2.5%;2.5%A076453 001

Aug 18, 2003

AB TOLMAR 2.5%;2.5%A076320 001

Aug 27, 2003

GEL; PERIODONTAL

ORAQIX

+ DENTSPLY PHARM 2.5%;2.5%

N021451 001

Dec 19, 2003

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

LIDOCAINE AND TETRACAINE

+ GALDERMA LABS LP 7%;7%

N021717 001

Jun 29, 2006

PATCH; TOPICAL

SYNERA

+ ZARS PHARM 70MG;70MG

N021623 001

Jun 23, 2005

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

+ PHARMACIA AND UPJOHN EQ 300MG BASE/ML

N050317 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 249 (of 409)

LINDANE

LOTION; TOPICAL

LINDANE

+	WOCKHARDT	1%	A088190	001	Aug 16, 1984

SHAMPOO; TOPICAL

LINDANE

<u>AT</u>	+	OLTA PHARMS	<u>1%</u>	<u>A087266</u>	<u>001</u>	
<u>AT</u>		WOCKHARDT	<u>1%</u>	<u>A088191</u>	<u>001</u>	Sep 18, 1984

LINEZOLID

FOR SUSPENSION; ORAL

ZYVOX

+	PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000

INJECTABLE; INJECTION

ZYVOX

+	PHARMACIA AND UPJOHN	200MG/100ML	N021131	001	Apr 18, 2000

TABLET; ORAL

ZYVOX

+	PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUM

<u>AP</u>		X GEN PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>A076923</u>	<u>001</u>	Aug 17, 2005

TRIOSTAT

<u>AP</u>	+	JHP PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>N020105</u>	<u>001</u>	Dec 31, 1991

TABLET; ORAL

CYTOMEL

<u>AB</u>		KING PHARMS	<u>EQ 0.005MG BASE</u>	<u>N010379</u>	<u>001</u>	

<u>AB</u>			<u>EQ 0.025MG BASE</u>	<u>N010379</u>	<u>002</u>	

<u>AB</u>	+		<u>EQ 0.05MG BASE</u>	<u>N010379</u>	<u>003</u>	

LIOTHYRONINE SODIUM

<u>AB</u>		COASTAL PHARMS	<u>EQ 0.005MG BASE</u>	<u>A090097</u>	<u>001</u>	Mar 20, 2009

<u>AB</u>			<u>EQ 0.025MG BASE</u>	<u>A090097</u>	<u>002</u>	Mar 20, 2009

<u>AB</u>			<u>EQ 0.05MG BASE</u>	<u>A090097</u>	<u>003</u>	Mar 20, 2009

<u>AB</u>		MYLAN	<u>EQ 0.005MG BASE</u>	<u>A090326</u>	<u>001</u>	Jul 14, 2009

<u>AB</u>			<u>EQ 0.025MG BASE</u>	<u>A090326</u>	<u>002</u>	Jul 14, 2009

<u>AB</u>			<u>EQ 0.05MG BASE</u>	<u>A090326</u>	<u>003</u>	Jul 14, 2009

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

FOREST LABS	0.0125MG;0.0031MG	N016807	001	

THYROLAR-0.5

FOREST LABS	0.025MG;0.0063MG	N016807	005	

THYROLAR-1

FOREST LABS	0.05MG;0.0125MG	N016807	004	

THYROLAR-2

FOREST LABS	0.1MG;0.025MG	N016807	002	

THYROLAR-3

+	FOREST LABS	0.15MG;0.0375MG	N016807	003

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

VICTOZA

+	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 250 (of 409)

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

SHIRE DEVELOPMENT

20MG

N021977 004

Dec 10, 2007

30MG

N021977 001

Feb 23, 2007

40MG

N021977 005

Dec 10, 2007

50MG

N021977 002

Feb 23, 2007

60MG

N021977 006

Dec 10, 2007

+

70MG

N021977 003

Feb 23, 2007

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB APOTEX INC

2.5MGA076102 001

Sep 30, 2002

AB

5MGA076102 002

Sep 30, 2002

AB

10MGA076102 003

Sep 30, 2002

AB

20MGA076102 004

Sep 30, 2002

AB

30MGA076102 005

Sep 30, 2002

AB

40MGA076102 006

Sep 30, 2002

AB

AUROBINDO

2.5MGA077622 001

Feb 22, 2006

AB

5MGA077622 002

Feb 22, 2006

AB

10MGA077622 003

Feb 22, 2006

AB

20MGA077622 004

Feb 22, 2006

AB

30MGA077622 005

Feb 22, 2006

AB

40MGA077622 006

Feb 22, 2006

AB

HUAHAI US INC

2.5MGA076180 001

Jul 01, 2002

AB

5MGA076180 002

Jul 01, 2002

AB

10MGA076180 003

Jul 01, 2002

AB

20MGA076164 001

Jul 01, 2002

AB

30MGA076164 002

Jul 01, 2002

AB

40MGA076164 003

Jul 01, 2002

AB

IVAX SUB TEVA PHARMS

2.5MGA075752 001

Jul 01, 2002

AB

5MGA075752 002

Jul 01, 2002

AB

10MGA075752 003

Jul 01, 2002

AB

20MGA075752 004

Jul 01, 2002

AB

30MGA075752 005

Jul 01, 2002

AB

40MGA075752 006

Jul 01, 2002

AB

LEK PHARMS

2.5MGA075999 001

Jul 01, 2002

AB

5MGA075999 002

Jul 01, 2002

AB

10MGA075999 003

Jul 01, 2002

AB

20MGA075999 004

Jul 01, 2002

AB

30MGA075999 005

Jul 01, 2002

AB

40MGA075999 006

Jul 01, 2002

AB

LUPIN

2.5MGA077321 001

Sep 09, 2005

AB

5MGA077321 002

Sep 09, 2005

AB

10MGA077321 003

Sep 09, 2005

AB

20MGA077321 004

Sep 09, 2005

AB

30MGA077321 005

Sep 09, 2005

AB

40MGA077321 006

Sep 09, 2005

AB

MYLAN

2.5MGA076071 001

Jul 01, 2002

AB

5MGA076071 002

Jul 01, 2002

AB

10MGA076071 003

Jul 01, 2002

AB

20MGA076071 004

Jul 01, 2002

AB

30MGA076071 005

Jul 01, 2002

AB

40MGA076071 006

Jul 01, 2002

AB

RANBAXY

2.5MGA075944 001

Jul 01, 2002

AB

5MGA075944 002

Jul 01, 2002

AB

10MGA075944 003

Jul 01, 2002

AB

20MGA075944 004

Jul 01, 2002

AB

30MGA075944 006

Feb 11, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 251 (of 409)

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>	RANBAXY	<u>40MG</u>	<u>A075944</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075903</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A075994</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075903</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075903</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075903</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075903</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075903</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	VINTAGE	<u>2.5MG</u>	<u>A075743</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WEST WARD	<u>2.5MG</u>	<u>A076063</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076063</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076063</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076063</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076063</u>	<u>006</u>	Jun 27, 2003
<u>AB</u>		<u>40MG</u>	<u>A076063</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A078402</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402</u>	<u>003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402</u>	<u>004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402</u>	<u>005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402</u>	<u>006</u>	Apr 19, 2007
<u>PRINIVIL</u>					
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558</u>	<u>001</u>	Dec 29, 1987
<u>AB</u>		<u>10MG</u>	<u>N019558</u>	<u>002</u>	Dec 29, 1987
<u>AB</u>		<u>20MG</u>	<u>N019558</u>	<u>003</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558</u>	<u>004</u>	Oct 25, 1988
<u>ZESTRIL</u>					
<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N019777</u>	<u>005</u>	Apr 29, 1993
<u>AB</u>		<u>5MG</u>	<u>N019777</u>	<u>001</u>	May 19, 1988
<u>AB</u>		<u>10MG</u>	<u>N019777</u>	<u>002</u>	May 19, 1988
<u>AB</u>		<u>20MG</u>	<u>N019777</u>	<u>003</u>	May 19, 1988
<u>AB</u>		<u>30MG</u>	<u>N019777</u>	<u>006</u>	Jan 20, 1999
<u>AB</u>	+	<u>40MG</u>	<u>N019777</u>	<u>004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ALEMBIC LTD	<u>150MG</u>	<u>A079159</u>	<u>001</u>	Jan 12, 2009
<u>AB</u>		<u>300MG</u>	<u>A079159</u>	<u>002</u>	Jan 12, 2009
<u>AB</u>		<u>600MG</u>	<u>A079159</u>	<u>003</u>	Jan 12, 2009
<u>AB</u>	APOTEX INC	<u>300MG</u>	<u>A076795</u>	<u>001</u>	Nov 22, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 252 (of 409)

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A079139</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>		<u>300MG</u>	<u>A079139</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>		<u>600MG</u>	<u>A079139</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>	HETERO DRUGS LTD	<u>150MG</u>	<u>A090702</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>300MG</u>	<u>A090702</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>600MG</u>	<u>A090702</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	ROXANE	<u>150MG</u>	<u>N017812</u>	<u>002</u>	Jan 28, 1987
<u>AB</u>		<u>300MG</u>	<u>N017812</u>	<u>001</u>	
<u>AB</u>	+	<u>600MG</u>	<u>N017812</u>	<u>003</u>	Jan 28, 1987
<u>AB</u>	WEST WARD	<u>150MG</u>	<u>A076243</u>	<u>002</u>	Feb 24, 2003
<u>AB</u>		<u>300MG</u>	<u>A076243</u>	<u>001</u>	Jun 27, 2002
<u>AB</u>		<u>600MG</u>	<u>A078763</u>	<u>001</u>	Apr 15, 2008

TABLET; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	ROXANE	<u>300MG</u>	<u>N018558</u>	<u>001</u>	Jan 29, 1982
<u>AB</u>		SUN PHARM INDS INC	<u>300MG</u>	<u>A091027</u>	<u>001</u>	Jun 24, 2010
<u>AB</u>		WEST WARD	<u>300MG</u>	<u>A078715</u>	<u>001</u>	Dec 28, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>		GLENMARK GENERICS	<u>300MG</u>	<u>A091544</u>	<u>001</u>	Dec 27, 2010
<u>AB</u>		ROXANE	<u>300MG</u>	<u>A076832</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>	+		<u>450MG</u>	<u>A076691</u>	<u>001</u>	Jan 05, 2004
<u>AB</u>		WEST WARD	<u>450MG</u>	<u>A076490</u>	<u>001</u>	Jun 17, 2003

LITHOBID

<u>AB</u>	+	NOVEN THERAP	<u>300MG</u>	<u>N018027</u>	<u>001</u>	

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

<u>AA</u>	+	ROXANE	<u>EQ 300MG CARBONATE/5ML</u>	<u>N018421</u>	<u>001</u>	
<u>AA</u>		WOCKHARDT	<u>EQ 300MG CARBONATE/5ML</u>	<u>A070755</u>	<u>001</u>	May 21, 1986

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

ALOMIDE

+	ALCON	EQ 0.1% BASE	N020191	001	Sep 23, 1993

LOMUSTINE

CAPSULE; ORAL

CEENU

	BRISTOL MYERS SQUIBB	10MG	N017588	001	
		40MG	N017588	002	
+		100MG	N017588	003	

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

<u>AB</u>	+	MCNEIL CONS	<u>2MG</u>	<u>N017694</u>	<u>001</u>	

LOPERAMIDE HYDROCHLORIDE

<u>AB</u>		MYLAN	<u>2MG</u>	<u>A072741</u>	<u>001</u>	Sep 18, 1991
<u>AB</u>		TEVA	<u>2MG</u>	<u>A073192</u>	<u>001</u>	Apr 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

KALETRA

+	ABBOTT	133.3MG; 33.3MG	N021226	001	Sep 15, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 253 (of 409)

LOPINAVIR; RITONAVIR

SOLUTION; ORAL

KALETRA

+ ABBOTT

80MG/ML; 20MG/ML

N021251 001

Sep 15, 2000

TABLET; ORAL

KALETRA

ABBOTT

100MG; 25MG

N021906 002

Nov 09, 2007

+

200MG; 50MG

N021906 001

Oct 28, 2005

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAMAA AMNEAL PHARMS2MG/MLA091383 001

Dec 23, 2009

AA PADDOCK LABS2MG/MLA079244 001

Apr 28, 2009

AA PHARM ASSOC2MG/MLA090260 001

Jun 15, 2010

LORAZEPAM INTENSOLAA + ROXANE2MG/MLA072755 001

Jun 28, 1991

INJECTABLE; INJECTION

ATIVANAP + BAXTER HLTHCARE CORP2MG/MLN018140 001AP +4MG/MLN018140 002LORAZEPAMAP BEDFORD2MG/MLA077076 001

Jul 13, 2005

AP4MG/MLA077076 002

Jul 13, 2005

AP HOSPIRA2MG/MLA074243 001

Apr 12, 1994

AP2MG/MLA074282 001

May 27, 1994

AP2MG/MLA074300 001

Apr 12, 1994

AP4MG/MLA074243 002

Apr 12, 1994

AP4MG/MLA074282 002

May 27, 1994

AP INTL MEDICATION SYS2MG/MLA076150 001

Nov 15, 2004

AP2MG/MLA074276 001

Apr 15, 1994

AP4MG/MLA074276 002

Apr 15, 1994

LORAZEPAM PRESERVATIVE FREEAP BEDFORD LABS2MG/MLA077074 001

Jul 13, 2005

AP4MG/MLA077074 002

Jul 13, 2005

TABLET; ORAL

ATIVANAB BIOVAIL0.5MGN017794 001AB1MGN017794 002AB +2MGN017794 003LORAZEPAMAB ACTAVIS ELIZABETH0.5MGA071403 001

Apr 21, 1987

AB1MGA071404 001

Apr 21, 1987

AB2MGA071141 001

Apr 21, 1987

AB AMNEAL PHARMS0.5MGA078826 001

Jun 23, 2010

AB1MGA078826 002

Jun 23, 2010

AB2MGA078826 003

Jun 23, 2010

AB EXCELLIUM0.5MGA078203 001

Jul 30, 2007

AB1MGA078203 002

Jul 30, 2007

AB2MGA078203 003

Jul 30, 2007

AB IVAX SUB TEVA PHARMS0.5MGA077396 001

Dec 13, 2006

AB1MGA077396 002

Dec 13, 2006

AB2MGA077396 003

Dec 13, 2006

AB MUTUAL PHARM0.5MGA072553 001

Mar 29, 1991

AB1MGA072554 001

Mar 29, 1991

AB2MGA072555 001

Mar 29, 1991

AB MYLAN0.5MGA071589 001

Oct 13, 1987

AB0.5MGA077657 001

Mar 16, 2006

AB1MGA071590 001

Oct 13, 1987

AB1MGA077657 002

Mar 16, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 254 (of 409)

LORAZEPAM

TABLET; ORAL

LORAZEPAM

<u>AB</u>	MYLAN	<u>2MG</u>	<u>A071591</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>2MG</u>	<u>A077657</u>	<u>003</u>	Mar 16, 2006
<u>AB</u>	RANBAXY	<u>0.5MG</u>	<u>A076045</u>	<u>001</u>	Aug 29, 2001
<u>AB</u>		<u>1MG</u>	<u>A076045</u>	<u>002</u>	Aug 29, 2001
<u>AB</u>		<u>2MG</u>	<u>A076045</u>	<u>003</u>	Aug 29, 2001
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071193</u>	<u>001</u>	Apr 15, 1988
<u>AB</u>		<u>1MG</u>	<u>A071194</u>	<u>001</u>	Apr 15, 1988
<u>AB</u>		<u>2MG</u>	<u>A071195</u>	<u>001</u>	Apr 15, 1988
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077754</u>	<u>001</u>	May 10, 2006
<u>AB</u>		<u>1MG</u>	<u>A077754</u>	<u>002</u>	May 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077754</u>	<u>003</u>	May 10, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A072926</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>1MG</u>	<u>A071118</u>	<u>001</u>	Jul 24, 1986
<u>AB</u>		<u>1MG</u>	<u>A072927</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>2MG</u>	<u>A072928</u>	<u>001</u>	Oct 31, 1991

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

<u>AB</u>	MERCK	<u>25MG</u>	<u>N020386</u>	<u>001</u>	Apr 14, 1995
<u>AB</u>		<u>50MG</u>	<u>N020386</u>	<u>002</u>	Apr 14, 1995
<u>AB</u>	+	<u>100MG</u>	<u>N020386</u>	<u>003</u>	Oct 13, 1998
	<u>LOSARTAN POTASSIUM</u>				
<u>AB</u>	ACTAVIS INC	<u>25MG</u>	<u>A090382</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090382</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090382</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ALEMBIC LTD	<u>25MG</u>	<u>A090428</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090428</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090428</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	APOTEX CORP	<u>25MG</u>	<u>A090790</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090790</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090790</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A090083</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090083</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090083</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078232</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078232</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078232</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ROXANE	<u>25MG</u>	<u>A077459</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077459</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077459</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077424</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077424</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077424</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076958</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A076958</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A076958</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A090467</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090467</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090467</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A090544</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090544</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090544</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A091129</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091129</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091129</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078243</u>	<u>001</u>	Oct 06, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 255 (of 409)

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A078243</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078243</u>	<u>003</u>	Oct 06, 2010

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

ALREX

+	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N020583	001	Mar 09, 1998

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

+	BAUSCH AND LOMB	0.5%;0.3%	N050804	001	Dec 14, 2004

LOVASTATIN

TABLET; ORAL

LOVASTATIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075828</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075828</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075828</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077748</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>20MG</u>	<u>A077748</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		<u>40MG</u>	<u>A077748</u>	<u>003</u>	Feb 28, 2007
<u>AB</u>	CARLSBAD	<u>10MG</u>	<u>A075991</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>20MG</u>	<u>A075991</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>		<u>40MG</u>	<u>A075991</u>	<u>003</u>	Jun 05, 2002
<u>AB</u>	LUPIN	<u>10MG</u>	<u>A078296</u>	<u>001</u>	Mar 14, 2008
<u>AB</u>		<u>20MG</u>	<u>A078296</u>	<u>002</u>	Nov 01, 2007
<u>AB</u>		<u>40MG</u>	<u>A078296</u>	<u>003</u>	Nov 01, 2007
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A077520</u>	<u>001</u>	Apr 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077520</u>	<u>002</u>	Apr 14, 2006
<u>AB</u>		<u>40MG</u>	<u>A077520</u>	<u>003</u>	Apr 14, 2006
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075451</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075935</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075451</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075935</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075451</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075935</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075300</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075636</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075300</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075636</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075300</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075636</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	TEVA	<u>10MG</u>	<u>A075551</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075551</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075551</u>	<u>001</u>	Dec 17, 2001
<u>MEVACOR</u>					
<u>AB</u>	MERCK	<u>20MG</u>	<u>N019643</u>	<u>003</u>	Aug 31, 1987
<u>AB</u>	+	<u>40MG</u>	<u>N019643</u>	<u>004</u>	Dec 14, 1988
TABLET, EXTENDED RELEASE; ORAL					
ALTOPREV					
	ANDRX LABS LLC	20MG	N021316	002	Jun 26, 2002
		40MG	N021316	003	Jun 26, 2002
	+	60MG	N021316	004	Jun 26, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 256 (of 409)

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	ABBOTT	20MG;500MG	N021249 001	Dec 17, 2001
+		20MG;750MG	N021249 002	Dec 17, 2001
+		20MG;1GM	N021249 003	Dec 17, 2001
+		40MG;1GM	N021249 004	Apr 27, 2006

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076762 001</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076762 002</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A076762 003</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076762 004</u>	Nov 01, 2004
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072204 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A072205 001</u>	Jun 15, 1988
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A072206 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A072062 001</u>	Jun 15, 1988

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

	SUCAMPO PHARMS	8MCG	N021908 002	Apr 29, 2008
+		24MCG	N021908 001	Jan 31, 2006

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

	SUNOVION	40MG	N200603 001	Oct 28, 2010
+		80MG	N200603 002	Oct 28, 2010

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

+	EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+	UDL LABS	EQ 85MG BASE/GM	N016763 001	

FOR SOLUTION; TOPICAL

SULFAMYLON

+	UDL LABS	5%	N019832 003	Jun 05, 1998

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047 001	Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696 001	Sep 29, 1989

PRESCRIPTION DRUG PRODUCT LIST

3 - 257 (of 409)

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML</u>	<u>N017378</u>	<u>001</u>	

PLASMA-LYTE A IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML</u>	<u>N017378</u>	<u>002</u>	Nov 22, 1982

ISOLYTE S IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019711	001	Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017586	001	

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019024	001	Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017637	002	Jul 08, 1982

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N018406	002	Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION

NORMOCARB HF 25

+	DIALYSIS SUPS	0.21GM/100ML; 2.8GM/100ML; 9.07GM/100ML	N021910	001	Jul 26, 2006

NORMOCARB HF 35

+	DIALYSIS SUPS	0.21GM/100ML; 3.97GM/100ML; 8.3GM/100ML	N021910	002	Jul 26, 2006

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

	SANTARUS	343MG; 20MG; 750MG	N022456	001	Dec 04, 2009

+		343MG; 40MG; 750MG	N022456	002	Dec 04, 2009

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

<u>AP</u>	+ ABRAXIS PHARM	<u>500MG/ML</u>	<u>N019316</u>	<u>001</u>	Sep 08, 1986
<u>AP</u>	HOSPIRA	<u>500MG/ML</u>	<u>A075151</u>	<u>001</u>	Apr 25, 2000

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995

+		2GM/100ML	N020488	002	Jul 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007

+		4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994

+		4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SUPREP BOWEL PREP KIT

+	BRAINTREE LABS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N022372	001	Aug 05, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 258 (of 409)

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML</u>	<u>N018508</u>	<u>001</u>	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML</u>	<u>N018336</u>	<u>001</u>	

MALATHION

LOTION; TOPICAL

MALATHION

<u>AT</u>	SYNERX PHARMA	<u>0.5%</u>	<u>A078743</u>	<u>001</u>	Mar 06, 2009

OVIDE

<u>AT</u>	+ TARO PHARMS NORTH	<u>0.5%</u>	<u>N018613</u>	<u>001</u>	Aug 02, 1982

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

HOSPIRA

EQ 0.1MG MANGANESE/ML

N018962	001	Jun 26, 1986

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

<u>AP</u>	B BRAUN	<u>10GM/100ML</u>	<u>N016080</u>	<u>002</u>	

MANNITOL 10% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>10GM/100ML</u>	<u>N020006</u>	<u>002</u>	Jul 26, 1993

<u>AP</u>	HOSPIRA	<u>10GM/100ML</u>	<u>N019603</u>	<u>002</u>	Jan 08, 1987

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

<u>AP</u>	B BRAUN	<u>10GM/100ML</u>	<u>N016080</u>	<u>006</u>	

MANNITOL 15%

<u>AP</u>	B BRAUN	<u>15GM/100ML</u>	<u>N016080</u>	<u>003</u>	

MANNITOL 15% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>15GM/100ML</u>	<u>N020006</u>	<u>003</u>	Jul 26, 1993

<u>AP</u>	HOSPIRA	<u>15GM/100ML</u>	<u>N019603</u>	<u>003</u>	Jan 08, 1990

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

<u>AP</u>	B BRAUN	<u>15GM/100ML</u>	<u>N016080</u>	<u>005</u>	

MANNITOL 20%

<u>AP</u>	B BRAUN	<u>20GM/100ML</u>	<u>N014738</u>	<u>001</u>	

<u>AP</u>		<u>20GM/100ML</u>	<u>N016080</u>	<u>004</u>	

MANNITOL 20% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>20GM/100ML</u>	<u>N020006</u>	<u>004</u>	Jul 26, 1993

<u>AP</u>	HOSPIRA	<u>20GM/100ML</u>	<u>N019603</u>	<u>004</u>	Jan 08, 1990

MANNITOL 25%

<u>AP</u>	APP PHARMS	<u>12.5GM/50ML</u>	<u>A080677</u>	<u>001</u>	

<u>AP</u>	HOSPIRA	<u>12.5GM/50ML</u>	<u>N016269</u>	<u>006</u>	Aug 25, 1994

<u>AP</u>	INTL MEDICATION	<u>12.5GM/50ML</u>	<u>A083051</u>	<u>001</u>	

<u>AP</u>	LUITPOLD	<u>12.5GM/50ML</u>	<u>A087409</u>	<u>001</u>	Jan 21, 1982

MANNITOL 5%

<u>AP</u>	B BRAUN	<u>5GM/100ML</u>	<u>N016080</u>	<u>001</u>	

MANNITOL 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML</u>	<u>N020006</u>	<u>001</u>	Jul 26, 1993

<u>AP</u>	HOSPIRA	<u>5GM/100ML</u>	<u>N019603</u>	<u>001</u>	Jan 08, 1987

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

<u>AP</u>	B BRAUN	<u>5GM/100ML</u>	<u>N016080</u>	<u>007</u>	

OSMITROL 10% IN WATER

<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684</u>	<u>002</u>	

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684</u>	<u>006</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 259 (of 409)

MANNITOL

INJECTABLE; INJECTION

OSMITROL 15% IN WATER

<u>AP</u>	BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684</u>	<u>004</u>

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684</u>	<u>008</u>

OSMITROL 20% IN WATER

<u>AP</u>	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684</u>	<u>003</u>

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684</u>	<u>007</u>

OSMITROL 5% IN WATER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684</u>	<u>001</u>

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684</u>	<u>005</u>

POWDER; INHALATION

ARIDOL KIT

+	PHARMAXIS	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

B BRAUN	5GM/100ML	N016772	002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA	540MG/100ML; 2.7GM/100ML	N018316	001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

MYLAN	25MG	A072285	002	Oct 03, 1988
+	50MG	A072285	001	Oct 03, 1988
	75MG	A072285	003	Oct 03, 1988

MARAVIROC

TABLET; ORAL

SELZENTRY

VIIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007
+	300MG	N022128	002	Aug 06, 2007

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

+	TEVA PHARMS	100MG	A073580	001	Jan 04, 1995

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	TERCICA	40MG/4ML (10MG/ML)	N021839	001	Aug 30, 2005

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

MUSTARGEN

+	LUNDBECK INC	10MG/VIAL	N006695	001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

<u>AA</u>	+	PFIZER	<u>12.5MG</u>	<u>N010721</u>	<u>006</u>

<u>AA</u>	+		<u>25MG</u>	<u>N010721</u>	<u>004</u>

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 260 (of 409)

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

<u>AA</u>	+	PFIZER	<u>50MG</u>	<u>N010721</u>	<u>001</u>	Jan 20, 1982
<u>AA</u>		<u>MECLIZINE HYDROCHLORIDE</u>				
<u>AA</u>		CADISTA PHARMS	<u>12.5MG</u>	<u>A040659</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>			<u>25MG</u>	<u>A040659</u>	<u>002</u>	Jun 04, 2010
<u>AA</u>		PAR PHARM	<u>12.5MG</u>	<u>A087127</u>	<u>001</u>	
<u>AA</u>			<u>25MG</u>	<u>A087128</u>	<u>001</u>	
<u>AA</u>			<u>50MG</u>	<u>A089674</u>	<u>001</u>	Mar 31, 1988
<u>AA</u>		SANDOZ	<u>12.5MG</u>	<u>A084843</u>	<u>002</u>	May 22, 1989
<u>AA</u>			<u>25MG</u>	<u>A084092</u>	<u>003</u>	May 22, 1989
<u>AA</u>		VINTAGE PHARMS	<u>12.5MG</u>	<u>A040179</u>	<u>001</u>	Jan 30, 1997
<u>AA</u>			<u>25MG</u>	<u>A040179</u>	<u>002</u>	Jan 30, 1997
<u>AA</u>		WATSON LABS	<u>25MG</u>	<u>A085740</u>	<u>001</u>	

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

<u>AB</u>		MYLAN	<u>EQ 50MG BASE</u>	<u>A071081</u>	<u>002</u>	Sep 03, 1986
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>A071081</u>	<u>001</u>	Sep 03, 1986
<u>AB</u>		WATSON LABS	<u>EQ 50MG BASE</u>	<u>A071468</u>	<u>001</u>	Apr 15, 1987
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A071469</u>	<u>001</u>	Apr 15, 1987

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>150MG/ML</u>	<u>N020246</u>	<u>001</u>	Oct 29, 1992
<u>AB</u>		<u>MEDROXYPROGESTERONE ACETATE</u>				
<u>AB</u>		SANDOZ	<u>150MG/ML</u>	<u>A078711</u>	<u>001</u>	May 20, 2009
<u>AB</u>		TEVA PARENTERAL	<u>150MG/ML</u>	<u>A076552</u>	<u>001</u>	Oct 27, 2004
<u>AB</u>			<u>150MG/ML</u>	<u>A076553</u>	<u>001</u>	Jul 28, 2004

DEPO-PROVERA

+ PHARMACIA AND UPJOHN 400MG/ML

N012541 003

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+ PHARMACIA AND UPJOHN 104MG/0.65ML

N021583 001 Dec 17, 2004

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

<u>AB</u>		BARR	<u>2.5MG</u>	<u>A040159</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>			<u>5MG</u>	<u>A040159</u>	<u>002</u>	Aug 09, 1996
<u>AB</u>			<u>10MG</u>	<u>A040159</u>	<u>003</u>	Aug 09, 1996
<u>AB</u>		<u>PROVERA</u>				
<u>AB</u>		PHARMACIA AND UPJOHN	<u>2.5MG</u>	<u>N011839</u>	<u>001</u>	
<u>AB</u>			<u>5MG</u>	<u>N011839</u>	<u>003</u>	
<u>AB</u>	+		<u>10MG</u>	<u>N011839</u>	<u>004</u>	
<u>BP</u>		<u>MEDROXYPROGESTERONE ACETATE</u>				
<u>BP</u>		USL PHARMA	<u>10MG</u>	<u>A088484</u>	<u>001</u>	Jul 26, 1984

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

<u>AB</u>		MICRO LABS LTD	<u>250MG</u>	<u>A090562</u>	<u>001</u>	Nov 19, 2010
<u>AB</u>		<u>PONSTEL</u>				
<u>AB</u>	+	SHIONOGI PHARMA	<u>250MG</u>	<u>N015034</u>	<u>003</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 261 (of 409)

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>250MG</u>	<u>A076392</u>	<u>001</u>	Dec 29, 2003
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A076523</u>	<u>001</u>	Oct 01, 2004
<u>AB</u>	+ SANDOZ	<u>250MG</u>	<u>A076175</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	WEST WARD	<u>250MG</u>	<u>A077699</u>	<u>001</u>	Apr 21, 2010

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>40MG/ML</u>	<u>N020264</u>	<u>001</u>	Sep 10, 1993
<u>MEGESTROL ACETATE</u>					
<u>AB</u>	APOTEX INC	<u>40MG/ML</u>	<u>A077404</u>	<u>001</u>	Feb 16, 2006
<u>AB</u>	PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>	ROXANE	<u>40MG/ML</u>	<u>A075997</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>	TEVA PHARMS	<u>40MG/ML</u>	<u>A075681</u>	<u>001</u>	May 05, 2003
<u>AB</u>	WOCKHARDT	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004
MEGACE ES					
	+ PAR PHARM	125MG/ML	N021778	001	Jul 05, 2005

TABLET; ORAL

MEGESTROL ACETATE

<u>AB</u>	BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>		<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	+	<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	ROXANE	<u>20MG</u>	<u>A074458</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>40MG</u>	<u>A074458</u>	<u>002</u>	Sep 29, 1995

MELOXICAM

SUSPENSION; ORAL

MOBIC

	+ BOEHRINGER INGELHEIM	7.5MG/5ML	N021530	001	Jun 01, 2004

TABLET; ORAL

MELOXICAM

<u>AB</u>	ACTAVIS TOTOWA	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>		<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>	BEIJING DOUBLE CRANE	<u>7.5MG</u>	<u>A078039</u>	<u>001</u>	Dec 14, 2006
<u>AB</u>		<u>15MG</u>	<u>A078039</u>	<u>002</u>	Dec 14, 2006
<u>AB</u>	BRECKENRIDGE PHARM	<u>7.5MG</u>	<u>A077920</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077920</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARACO	<u>7.5MG</u>	<u>A077937</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077937</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARLSBAD	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>	COREPHARMA	<u>7.5MG</u>	<u>A077930</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077930</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>		<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>	GENPHARM	<u>7.5MG</u>	<u>A077934</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077934</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A077923</u>	<u>001</u>	Jul 19, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 262 (of 409)

MELOXICAM

TABLET; ORAL

MELOXICAM

<u>AB</u>	MYLAN	<u>15MG</u>	<u>A077923</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	STRIDES ARCOLAB LTD	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>	TEVA PHARMS	<u>7.5MG</u>	<u>A077936</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077936</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>	WATSON LABS	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006

MOBIC

<u>AB</u>	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
<u>AB</u>	+	<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

MELPHALAN

TABLET; ORAL

ALKERAN

+	GLAXOSMITHKLINE	2MG	N014691	002	

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 50MG BASE/VIAL</u>	<u>N020207</u>	<u>001</u>	Nov 18, 1992
<u>MELPHALAN HYDROCHLORIDE</u>						
<u>AP</u>		BEDFORD LABS	<u>EQ 50MG BASE/VIAL</u>	<u>A090303</u>	<u>001</u>	Oct 28, 2010
<u>AP</u>		BIONICHE PHARMA USA	<u>EQ 50MG BASE/VIAL</u>	<u>A090299</u>	<u>001</u>	Oct 27, 2009
<u>AP</u>		SYNERX	<u>EQ 50MG BASE/VIAL</u>	<u>A090270</u>	<u>001</u>	Jun 09, 2009

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

	FOREST LABS	7MG	N022525	001	Jun 21, 2010
		14MG	N022525	002	Jun 21, 2010
		21MG	N022525	003	Jun 21, 2010
+		28MG	N022525	004	Jun 21, 2010

SOLUTION; ORAL

NAMENDA

+	FOREST LABS	2MG/ML	N021627	001	Apr 18, 2005

TABLET; ORAL

NAMENDA

	FOREST LABS	5MG	N021487	001	Oct 16, 2003
+		10MG	N021487	002	Oct 16, 2003

MENOTROPINS (FSH;LH)

INJECTABLE; IM-SC

REPRONEX

+	FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999

INJECTABLE; SUBCUTANEOUS

MENOPUR

+	FERRING	75 IU/VIAL;75 IU/VIAL	N021663	001	Oct 29, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 263 (of 409)

MEPENZOLATE BROMIDETABLET; ORAL
CANTIL

+ SANOFI AVENTIS US 25MG N010679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

AP	+	HOSPIRA	25MG/ML	N021171	001
AP	+		50MG/ML	N021171	002
AP	+		75MG/ML	N021171	003
AP	+		100MG/ML	N021171	004

MEPERIDINE HYDROCHLORIDE

AP		BAXTER HLTHCARE CORP	25MG/ML	A080455	007
AP			50MG/ML	A080455	008
AP			75MG/ML	A080455	009
AP			100MG/ML	A080455	010
AP		ELKINS SINN	25MG/ML	A080445	001
AP			50MG/ML	A080445	002
AP			75MG/ML	A080445	003
AP			100MG/ML	A080445	004
AP		WATSON LABS	50MG/ML	A073444	001
AP			100MG/ML	A073445	001

Mar 17, 1992

Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP		ASTRAZENECA	10MG/ML	A081002	001
AP	+	HOSPIRA	10MG/ML	A088432	001
AP		INTL MEDICATION	10MG/ML	A081309	001
AP		WATSON LABS	10MG/ML	A073443	001

Jul 30, 1993

Aug 16, 1984

Aug 30, 1993

Mar 17, 1992

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

+ ROXANE 50MG/5ML A088744 001 Jan 30, 1985

TABLET; ORAL

DEMEROL

AA	+	SANOFI AVENTIS US	50MG	N005010	001
AA	+		100MG	N005010	004

MEPERIDINE HYDROCHLORIDE

AA		BARR	50MG	A088639	001
AA			100MG	A088640	001
AA		CARACO	50MG	A040446	001
AA			100MG	A040446	002
AA		EPIC PHARMA	50MG	A040331	001
AA			100MG	A040331	002
AA		MALLINCKRODT	50MG	A040352	001
AA			100MG	A040352	002
AA		MIKART	50MG	A040893	001
AA			100MG	A040893	003
AA		ROXANE	50MG	A040110	001
AA			100MG	A040110	002
AA		VINTAGE PHARMS	50MG	A040191	001
AA			100MG	A040191	002
AA		WATSON LABS	50MG	A040186	001
AA			100MG	A040186	002

Jul 02, 1984

Sep 19, 1984

Aug 08, 2002

Aug 08, 2002

May 28, 1999

May 28, 1999

Jun 13, 2000

Jun 13, 2000

Jun 24, 2009

Jun 24, 2009

Mar 12, 1997

Mar 12, 1997

Dec 17, 1998

Dec 17, 1998

Jun 30, 1997

Jun 30, 1997

MEPERIDINE HYDROCHLORIDE

MIKART

75MG A040893 002 Jun 24, 2009

150MG A040893 004 Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

AP + HOSPIRA 1% N012250 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 264 (of 409)

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINEAP + HOSPIRA 1.5%N012250 005AP + 2%N012250 002ISOCAINE HYDROCHLORIDEAP + NOVOCOL 3%A080925 001MEPIVACAINE HYDROCHLORIDEAP HOSPIRA INC 3%A040806 001

Apr 28, 2008

AP WATSON LABS 1%A088769 001

Nov 20, 1984

AP 2%A088770 001

Nov 20, 1984

POLOCAINEAP APP PHARMS 1%A089407 001

Dec 01, 1986

AP 2%A089410 001

Dec 01, 1986

AP DENTSPLY PHARM 3%A088653 001

Aug 21, 1984

POLOCAINE-MPFAP APP PHARMS 1%A089406 001

Dec 01, 1986

AP 1.5%A089408 001

Dec 01, 1986

AP 2%A089409 001

Dec 01, 1986

SCANDONEST PLAINAP + DEPROCO 3%A088387 001

Oct 10, 1984

MEPROBAMATE

TABLET; ORAL

MEPROBAMATEAA ALEMBIC LTD 200MGA090122 001

Feb 18, 2009

AA 400MGA090122 002

Feb 18, 2009

AA INVAGEN PHARMS 200MGA040797 001

Feb 27, 2008

AA 400MGA040797 002

Feb 27, 2008

AA + WATSON LABS 200MGA083304 001AA + 400MGA083308 001MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ STIEFEL LABS INC 2%;0.01%

N020922 001

Dec 10, 1999

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINEAB MYLAN 50MGA040594 001

Jul 01, 2005

AB PROMETHEUS LABS 50MGA040461 001

Feb 11, 2004

AB ROXANE 50MGA040528 001

Feb 13, 2004

PURINETHOLAB + TEVA 50MGN009053 002MEROPENEM

INJECTABLE; INJECTION

MEROPENEMAP HOSPIRA INC 500MG/VIALA090940 001

Jun 22, 2010

AP 1GM/VIALA090940 002

Jun 22, 2010

MERREM I.V.AP + ASTRAZENECA 500MG/VIALN050706 003

Jun 21, 1996

AP + 1GM/VIALN050706 001

Jun 21, 1996

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

+ SALIX PHARMS 375MG

N022301 001

Oct 31, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 265 (of 409)

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL				
PENTASA				
	SHIRE	250MG	N020049 001	May 10, 1993
	+	500MG	N020049 002	Jul 08, 2004
ENEMA; RECTAL				
<u>MESALAMINE</u>				
<u>AB</u>	PERRIGO ISRAEL	<u>4GM/60ML</u>	<u>A076751 001</u>	Sep 17, 2004
<u>AB</u>	TEVA	<u>4GM/60ML</u>	<u>A076841 001</u>	Sep 30, 2004
<u>ROWASA</u>				
<u>AB</u>	+ ALAVEN PHARM	<u>4GM/60ML</u>	<u>N019618 001</u>	Dec 24, 1987
<u>SFROWASA</u>				
<u>AB</u>	ALAVEN PHARM	<u>4GM/60ML</u>	<u>N019618 002</u>	Jun 20, 2008
SUPPOSITORY; RECTAL				
CANASA				
	+ AXCAN	1GM	N021252 002	Nov 05, 2004
TABLET, DELAYED RELEASE; ORAL				
ASACOL				
	+ WARNER CHILCOTT INC	400MG	N019651 001	Jan 31, 1992
ASACOL HD				
	+ WARNER CHILCOTT INC	800MG	N021830 001	May 29, 2008
LIALDA				
	+ SHIRE	1.2GM	N022000 001	Jan 16, 2007

MESNA

INJECTABLE; INTRAVENOUS				
<u>MESNA</u>				
<u>AP</u>	APP PHARMS	<u>100MG/ML</u>	<u>A075811 001</u>	Apr 26, 2001
<u>AP</u>	BEDFORD	<u>100MG/ML</u>	<u>A075739 001</u>	Jan 09, 2004
<u>AP</u>	SAGENT STRIDES	<u>100MG/ML</u>	<u>A090913 001</u>	Apr 13, 2010
<u>AP</u>	TEVA PARENTERAL	<u>100MG/ML</u>	<u>A075764 001</u>	Apr 27, 2001
<u>MESNEX</u>				
<u>AP</u>	+ BAXTER HLTHCARE	<u>100MG/ML</u>	<u>N019884 001</u>	Dec 30, 1988
TABLET; ORAL				
MESNEX				
	+ BAXTER HLTHCARE	400MG	N020855 001	Mar 21, 2002

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28				
NORINYL 1+50 28-DAY				
	+ WATSON LABS	0.05MG;1MG	N016659 001	

METAPROTERENOL SULFATE

SOLUTION; INHALATION				
<u>METAPROTERENOL SULFATE</u>				
<u>AN</u>	+ DEY	<u>0.4%</u>	<u>A071786 001</u>	Aug 05, 1988
<u>AN</u>	+	<u>0.6%</u>	<u>A070804 001</u>	Aug 17, 1987
<u>AN</u>	NEPHRON	<u>0.4%</u>	<u>A071855 001</u>	Jul 14, 1988
<u>AN</u>		<u>0.6%</u>	<u>A071726 001</u>	Jul 14, 1988
<u>AN</u>	NOVEX	<u>0.4%</u>	<u>A075402 001</u>	Feb 28, 2001
<u>AN</u>		<u>0.6%</u>	<u>A075403 001</u>	Feb 28, 2001
<u>AN</u>	WOCKHARDT	<u>0.4%</u>	<u>A075586 001</u>	May 30, 2002
<u>AN</u>		<u>0.6%</u>	<u>A075586 002</u>	May 30, 2002
SYRUP; ORAL				
<u>METAPROTERENOL SULFATE</u>				
<u>AA</u>	NOVEX	<u>10MG/5ML</u>	<u>A075235 001</u>	Jan 27, 2000
<u>AA</u>	+ SILARX	<u>10MG/5ML</u>	<u>A073632 001</u>	Jul 22, 1992

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 266 (of 409)

METAPROTERENOL SULFATE

TABLET; ORAL

METAPROTERENOL SULFATE

<u>AB</u>	PAR PHARM	<u>10MG</u>	<u>A072024</u>	<u>001</u>	Jun 28, 1988
<u>AB</u>	+	<u>20MG</u>	<u>A072025</u>	<u>001</u>	Jun 28, 1988
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A073013</u>	<u>001</u>	Jan 31, 1991
<u>AB</u>		<u>20MG</u>	<u>A072795</u>	<u>001</u>	Jan 31, 1991

METARAMINOL BITARTRATEINJECTABLE; INJECTION
METARAMINOL BITARTRATE

+ APP PHARMS EQ 10MG BASE/ML A080722 001

METAXALONE

TABLET; ORAL

METAXALONE

<u>AB</u>	SANDOZ	<u>800MG</u>	<u>A040445</u>	<u>001</u>	Mar 31, 2010
<u>AB</u>	+	<u>800MG</u>	<u>N013217</u>	<u>003</u>	Aug 30, 2002

METFORMIN HYDROCHLORIDESOLUTION; ORAL
RIOMET

+ RANBAXY 500MG/5ML N021591 001 Sep 11, 2003

TABLET; ORAL

GLUCOPHAGE

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N020357</u>	<u>001</u>	Mar 03, 1995
<u>AB</u>		<u>850MG</u>	<u>N020357</u>	<u>002</u>	Mar 03, 1995
<u>AB</u>	+	<u>1GM</u>	<u>N020357</u>	<u>005</u>	Nov 05, 1998
	<u>METFORMIN HYDROCHLORIDE</u>				
<u>AB</u>	ALKEM	<u>500MG</u>	<u>A091184</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>850MG</u>	<u>A091184</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A091184</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>	ALPHAPHARM	<u>500MG</u>	<u>A075969</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075969</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075969</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	ALVOGEN	<u>500MG</u>	<u>A076033</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A076033</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A076033</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A077880</u>	<u>001</u>	Jun 05, 2006
<u>AB</u>		<u>850MG</u>	<u>A077880</u>	<u>002</u>	Jun 05, 2006
<u>AB</u>		<u>1GM</u>	<u>A077880</u>	<u>003</u>	Jun 05, 2006
<u>AB</u>	APOTEX	<u>500MG</u>	<u>A075984</u>	<u>001</u>	Apr 23, 2002
<u>AB</u>		<u>850MG</u>	<u>A075984</u>	<u>002</u>	Apr 23, 2002
<u>AB</u>		<u>1GM</u>	<u>A075984</u>	<u>003</u>	Apr 23, 2002
<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A077095</u>	<u>001</u>	Jan 14, 2005
<u>AB</u>		<u>850MG</u>	<u>A077095</u>	<u>002</u>	Jan 14, 2005
<u>AB</u>		<u>1GM</u>	<u>A077095</u>	<u>003</u>	Jan 14, 2005
<u>AB</u>	CARACO	<u>500MG</u>	<u>A075967</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075967</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>A077787</u>	<u>001</u>	Aug 23, 2006
<u>AB</u>		<u>850MG</u>	<u>A077787</u>	<u>002</u>	Aug 23, 2006
<u>AB</u>		<u>1GM</u>	<u>A077787</u>	<u>003</u>	Aug 23, 2006
<u>AB</u>	GENPHARM	<u>500MG</u>	<u>A075973</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075973</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075973</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	GLENMARK GENERICS	<u>500MG</u>	<u>A078170</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>850MG</u>	<u>A078170</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>1GM</u>	<u>A078170</u>	<u>003</u>	May 23, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 267 (of 409)

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	GRANULES INDIA	<u>500MG</u>	<u>A090564</u>	<u>001</u>	Apr 22, 2010
<u>AB</u>		<u>850MG</u>	<u>A090564</u>	<u>002</u>	Apr 22, 2010
<u>AB</u>		<u>1GM</u>	<u>A090564</u>	<u>003</u>	Apr 22, 2010
<u>AB</u>	INDICUS PHARMA	<u>500MG</u>	<u>A079148</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>850MG</u>	<u>A079148</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>1GM</u>	<u>A079148</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>500MG</u>	<u>A075972</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075972</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075972</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	MUTUAL PHARMA	<u>500MG</u>	<u>A076038</u>	<u>001</u>	Feb 21, 2002
<u>AB</u>		<u>850MG</u>	<u>A076038</u>	<u>002</u>	Feb 21, 2002
<u>AB</u>		<u>1GM</u>	<u>A076038</u>	<u>003</u>	Feb 21, 2002
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A075976</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075976</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075976</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	PROVIDENT PHARM	<u>500MG</u>	<u>A077853</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>		<u>850MG</u>	<u>A077853</u>	<u>002</u>	Jul 28, 2006
<u>AB</u>		<u>1GM</u>	<u>A077853</u>	<u>003</u>	Jul 28, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075965</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075985</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075985</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075965</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075985</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	TEVA	<u>500MG</u>	<u>A075978</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075978</u>	<u>003</u>	Nov 05, 2002
<u>AB</u>	TORRENT PHARMS	<u>500MG</u>	<u>A077711</u>	<u>001</u>	Jan 24, 2007
<u>AB</u>		<u>850MG</u>	<u>A077711</u>	<u>002</u>	Jan 24, 2007
<u>AB</u>		<u>1GM</u>	<u>A077711</u>	<u>003</u>	Jan 24, 2007
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A075979</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075979</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075979</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A075961</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075961</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075961</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>		<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005
	METFORMIN HYDROCHLORIDE				
	IVAX SUB TEVA PHARMS	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N021202</u>	<u>001</u>	Oct 13, 2000
<u>AB</u>	+	<u>750MG</u>	<u>N021202</u>	<u>004</u>	Apr 11, 2003
	<u>METFORMIN HYDROCHLORIDE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A076450</u>	<u>001</u>	Oct 01, 2004
<u>AB</u>		<u>750MG</u>	<u>A076878</u>	<u>001</u>	Apr 13, 2005
<u>AB</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB</u>		<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A076706</u>	<u>001</u>	Dec 14, 2004
<u>AB</u>		<u>750MG</u>	<u>A076706</u>	<u>002</u>	Dec 29, 2005
<u>AB</u>	BARR	<u>750MG</u>	<u>A076863</u>	<u>001</u>	Oct 14, 2004
<u>AB</u>	IMPAX LABS	<u>500MG</u>	<u>A076249</u>	<u>001</u>	Jul 30, 2004
<u>AB</u>		<u>750MG</u>	<u>A076985</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A076650</u>	<u>001</u>	Sep 13, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 268 (of 409)

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL				
<u>METFORMIN HYDROCHLORIDE</u>				
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077113</u>	<u>001</u> Sep 08, 2005
<u>AB</u>	NEUROSCI INC	<u>500MG</u>	<u>A078321</u>	<u>001</u> Apr 17, 2008
<u>AB</u>		<u>750MG</u>	<u>A078321</u>	<u>002</u> Apr 17, 2008
<u>AB</u>	NOSTRUM	<u>500MG</u>	<u>A076756</u>	<u>001</u> Jul 26, 2006
<u>AB</u>	RANBAXY	<u>500MG</u>	<u>A076413</u>	<u>001</u> Jun 18, 2004
<u>AB</u>		<u>750MG</u>	<u>A077211</u>	<u>001</u> Jun 29, 2005
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u> Dec 14, 2004
<u>AB</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u> Feb 09, 2006
<u>AB</u>		<u>750MG</u>	<u>A077336</u>	<u>002</u> Feb 09, 2006
<u>AB</u>	TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u> Jun 18, 2004
<u>AB</u>		<u>750MG</u>	<u>A076864</u>	<u>001</u> Apr 12, 2005
<u>AB</u>	TORRENT PHARM	<u>500MG</u>	<u>A090014</u>	<u>001</u> Dec 30, 2009
<u>AB</u>	TORRENT PHARMS	<u>750MG</u>	<u>A079226</u>	<u>001</u> Feb 18, 2010
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A076818</u>	<u>001</u> Dec 14, 2004
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A076172</u>	<u>001</u> Jun 16, 2004
<u>AB</u>		<u>750MG</u>	<u>A076869</u>	<u>001</u> Apr 12, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077060</u>	<u>001</u> Apr 20, 2005
<u>AB</u>		<u>750MG</u>	<u>A077078</u>	<u>001</u> Apr 21, 2005
FORTAMET				
BX	ANDRX LABS LLC	500MG	N021574	001 Apr 27, 2004
BX +		1GM	N021574	002 Apr 27, 2004
GLUMETZA				
BX	DEPOMED INC	500MG	N021748	001 Jun 03, 2005
BX +		1GM	N021748	002 Jun 03, 2005

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL				
ACTOPLUS MET				
	TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842	001 Aug 29, 2005
+		850MG;EQ 15MG BASE	N021842	002 Aug 29, 2005
TABLET, EXTENDED RELEASE; ORAL				
ACTOPLUS MET XR				
	TAKEDA GLOBAL	1GM;EQ 15MG BASE	N022024	001 May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002 May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL				
PRANDIMET				
	NOVO NORDISK INC	500MG;1MG	N022386	001 Jun 23, 2008
+		500MG;2MG	N022386	002 Jun 23, 2008

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL				
AVANDAMET				
	SB PHARMCO	500MG;EQ 2MG BASE	N021410	002 Oct 10, 2002
		500MG;EQ 4MG BASE	N021410	003 Oct 10, 2002
		1GM;EQ 2MG BASE	N021410	004 Aug 25, 2003
+		1GM;EQ 4MG BASE	N021410	005 Aug 25, 2003

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN

TABLET, EXTENDED RELEASE; ORAL				
KOMBIGLYZE XR				
	BRISTOL MYERS SQUIBB	500MG;5MG	N200678	001 Nov 05, 2010
		1GM;2.5MG	N200678	003 Nov 05, 2010
+		1GM;5MG	N200678	002 Nov 05, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 269 (of 409)

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

MERCK

500MG;EQ 50MG BASE

N022044 001 Mar 30, 2007

+

1GM;EQ 50MG BASE

N022044 002 Mar 30, 2007

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+ METHAPHARM

100MG/VIAL

N019193 001 Oct 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDEAA ROXANE10MG/MLA040180 001 Apr 30, 1998AA VISTAPHARM10MG/MLA040088 001 Nov 30, 1994METHADONE HYDROCHLORIDE INTENSOLAA ROXANE10MG/MLA089897 001 Sep 06, 1988METHADOSEAA + MALLINCKRODT10MG/MLN017116 002

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

+ BIONICHE PHARMA

10MG/ML

N021624 001

POWDER; FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT

500GM/BOT

N006383 002

100GM/BOT

N006383 003

500GM/BOT

N006383 004

SOLUTION; ORAL

METHADONE HYDROCHLORIDEAA + ROXANE5MG/5MLA087393 001AA +10MG/5MLA087997 001 Aug 30, 1982AA VISTAPHARM5MG/5MLA090707 001 Jun 30, 2010AA10MG/5MLA090707 002 Jun 30, 2010

TABLET; ORAL

DOLOPHINE HYDROCHLORIDEAA + ROXANE5MGN006134 002AA +10MGN006134 010METHADONE HYDROCHLORIDEAA MALLINCKRODT5MGA040517 001 Apr 27, 2004AA10MGA040517 002 Apr 27, 2004AA40MGA077142 001 Jul 12, 2005AA + ROXANE40MGN017058 001AA

SANDOZ

10MGA040241 002 May 29, 1998AA40MGA075082 001 Mar 25, 1998AA THE PHARMANETWORK10MGA090635 001 Nov 25, 2009METHADOSEAA MALLINCKRODT5MGA040050 001 Apr 15, 1993AA10MGA040050 002 Apr 15, 1993AA40MGA074184 001 Apr 29, 1993METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYNAA + LUNDBECK INC5MGN005378 002METHAMPHETAMINE HYDROCHLORIDEAA COASTAL PHARMS5MGA091189 001 Apr 21, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 270 (of 409)

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

<u>AB</u>	MIKART	<u>25MG</u>	<u>A040062</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>	+	<u>50MG</u>	<u>A040062</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A040036</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>		<u>50MG</u>	<u>A040036</u>	<u>002</u>	Jun 30, 1993
<u>AB</u>	TEVA PHARMS	<u>25MG</u>	<u>A040001</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>		<u>50MG</u>	<u>A040001</u>	<u>002</u>	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

AB	+ SANOFI AVENTIS US	1GM	N017681	001	
	METHENAMINE HIPPURATE				
AB	COREPHARMA	1GM	A076411	001	Jun 20, 2003
	UREX				
AB	CNTY LINE PHARMS	1GM	N016151	001	

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	ACTAVIS TOTOWA	5MG	A040734	001	Dec 14, 2007
AB		10MG	A040734	002	Dec 14, 2007
AB	CARACO	5MG	A040870	001	Sep 25, 2007
AB		10MG	A040870	002	Sep 25, 2007
AB	CEDAR PHARMS	5MG	A040547	001	Feb 18, 2005
AB		10MG	A040547	002	Feb 18, 2005
AB	MYLAN	5MG	A040350	001	Mar 29, 2000
AB	+	10MG	A040350	002	Mar 29, 2000
AB	SANDOZ	5MG	A040411	001	Mar 27, 2001
AB		10MG	A040411	002	Mar 27, 2001
	TAPAZOLE				
AB	KING PHARMS	5MG	A040320	001	Mar 31, 2000
AB		10MG	A040320	002	Mar 31, 2000

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

AP	WATSON LABS	100MG/ML	A086459	001
	ROBAXIN			
AP +	BAXTER HLTHCARE CORP	100MG/ML	N011790	001

TABLET; ORAL

METHOCARBAMOL

AA	HETERO DRUGS	500MG	A090200	001	Nov 06, 2009
AA		750MG	A090200	002	Nov 06, 2009
AA	LANNETT	500MG	A084756	002	Mar 31, 2003
AA		750MG	A084756	001	
AA	SANDOZ	500MG	A084616	001	
AA		750MG	A084615	001	
AA	VINTAGE PHARMS	500MG	A040489	001	Jan 29, 2003
AA		750MG	A040489	002	Jan 29, 2003
AA	WATSON LABS	500MG	A084277	001	
AA		500MG	A085180	001	
AA		750MG	A084276	002	
AA		750MG	A085192	001	
AA	WEST WARD	500MG	A085159	001	
AA		750MG	A085123	001	
	ROBAXIN				
AA +	SCHWARZ PHARMA	500MG	N011011	004	

PRESCRIPTION DRUG PRODUCT LIST

3 - 271 (of 409)

METHOCARBAMOL

TABLET; ORAL

ROBAXIN-750

<u>AA</u> + SCHWARZ PHARMA	<u>750MG</u>	<u>N011011</u>	<u>006</u>

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+ JHP PHARMS	500MG/VIAL	N011559	001
+	2.5GM/VIAL	N011559	002

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

<u>AP</u> + APP PHARMS	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>001</u>	Feb 26, 1999
<u>AP</u> +	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>002</u>	Feb 26, 1999
<u>AP</u> + HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>010</u>	Dec 15, 2004

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u> + BEDFORD	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340</u>	<u>001</u>	Sep 16, 1986
<u>AP</u> +	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343</u>	<u>001</u>	Sep 16, 1986
<u>AP</u> + BIONICHE PHARMA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767</u>	<u>001</u>	Apr 30, 2007
<u>AP</u> + BIONICHE PHARMA USA	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768</u>	<u>001</u>	Apr 30, 2007
<u>AP</u> +	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716</u>	<u>001</u>	Apr 30, 2007
<u>AP</u> EBEWE PHARMA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>001</u>	Mar 31, 2009
<u>AP</u>	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>002</u>	Mar 31, 2009
<u>AP</u>	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029</u>	<u>001</u>	Mar 31, 2009
<u>AP</u> + HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>012</u>	Apr 13, 2005
<u>AP</u> PHARMACHEMIE BV	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040850</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>	<u>EQ 250MG/10ML (EQ 25MG BASE/ML)</u>	<u>A040853</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>001</u>	Jan 11, 2010

METHOTREXATE SODIUM

+ BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986
+	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

+ BEDFORD	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u> BARR	<u>EQ 2.5MG BASE</u>	<u>A081099</u>	<u>001</u>	Oct 15, 1990
<u>AB</u> + DAVA PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>N008085</u>	<u>002</u>	
<u>AB</u> MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235</u>	<u>001</u>	May 15, 1992
<u>AB</u> ROXANE	<u>EQ 2.5MG BASE</u>	<u>A040054</u>	<u>001</u>	Aug 01, 1994
TREXALL				
BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
	EQ 7.5MG BASE	A040385	002	Mar 21, 2001
	EQ 10MG BASE	A040385	003	Mar 21, 2001
+	EQ 15MG BASE	A040385	004	Mar 21, 2001

METHOXSALEN

CAPSULE; ORAL

8-MOP

+ VALEANT PHARM INTL	10MG	N009048	001	

OXSORALEN-ULTRA

+ VALEANT PHARM INTL	10MG	N019600	001	Oct 30, 1986

INJECTABLE; INJECTION

UVADEX

+ THERAKOS	0.02MG/ML	N020969	001	Feb 25, 1999

LOTION; TOPICAL

OXSORALEN

+ VALEANT PHARM INTL	1%	N009048	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 272 (of 409)

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

<u>AA</u>	BOCA PHARMA	<u>2.5MG</u>	<u>A040624</u>	<u>001</u>	Dec 28, 2006
<u>AA</u>		<u>5MG</u>	<u>A040624</u>	<u>002</u>	Dec 28, 2006
	<u>PAMINE</u>				
<u>AA</u>	+ NYCOMED US	<u>2.5MG</u>	<u>N008848</u>	<u>001</u>	
	<u>PAMINE FORTE</u>				
<u>AA</u>	+ NYCOMED US	<u>5MG</u>	<u>N008848</u>	<u>002</u>	Mar 25, 2003

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

	PARKE DAVIS	150MG	N010596	007	
+		300MG	N010596	008	

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

<u>AB</u>	+ ABBOTT	<u>5MG</u>	<u>N012524</u>	<u>004</u>	
	<u>METHYCLOTHIAZIDE</u>				
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A087672</u>	<u>001</u>	Aug 17, 1982
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A088724</u>	<u>001</u>	Sep 06, 1984
	ENDURON				
	ABBOTT	2.5MG	N012524	001	

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

+	GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004

METHYLDOPA

TABLET; ORAL

METHYLDOPA

<u>AB</u>	ACCORD HLTH	<u>250MG</u>	<u>A070084</u>	<u>001</u>	Oct 15, 1985
<u>AB</u>		<u>500MG</u>	<u>A070085</u>	<u>001</u>	Oct 15, 1985
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>250MG</u>	<u>A070098</u>	<u>001</u>	Feb 20, 1986
<u>AB</u>		<u>500MG</u>	<u>A070343</u>	<u>001</u>	Feb 20, 1986
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A070075</u>	<u>001</u>	Apr 18, 1985
<u>AB</u>	+	<u>500MG</u>	<u>A070076</u>	<u>001</u>	Apr 18, 1985
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A070625</u>	<u>001</u>	Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

<u>AP</u>	+ LUITPOLD	<u>50MG/ML</u>	<u>A071279</u>	<u>001</u>	Oct 02, 1987
<u>AP</u>	TEVA PARENTERAL	<u>50MG/ML</u>	<u>A072974</u>	<u>001</u>	Nov 22, 1991

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

<u>AP</u>	+ NOVARTIS	<u>0.2MG/ML</u>	<u>N006035</u>	<u>004</u>	
	<u>METHYLERGONOVINE MALEATE</u>				
<u>AP</u>	ERGOJECT	<u>0.2MG/ML</u>	<u>A040889</u>	<u>001</u>	Sep 13, 2010
<u>AP</u>	LUITPOLD	<u>0.2MG/ML</u>	<u>A090193</u>	<u>001</u>	Nov 24, 2008

TABLET; ORAL

METHERGINE

+	NOVARTIS	0.2MG	N006035	003	

PRESCRIPTION DRUG PRODUCT LIST

3 - 273 (of 409)

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS
RELISTOR

+ PROGENICS	12MG/0.6ML (12MG/0.6ML)	N021964 001	Apr 24, 2008

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL
DAYTRANA

NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514 001	Apr 06, 2006
	15MG/9HR (1.6MG/HR)	N021514 002	Apr 06, 2006
	20MG/9HR (2.2MG/HR)	N021514 003	Apr 06, 2006
+	30MG/9HR (3.3MG/HR)	N021514 004	Apr 06, 2006

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

BX	UCB INC	10MG	N021259 003	May 27, 2003
BX		20MG	N021259 001	Apr 03, 2001
BX		30MG	N021259 002	Jun 19, 2003
BX		40MG	N021259 004	Feb 19, 2006

BX	RITALIN LA	10MG	N021284 004	Apr 10, 2004
BX	NOVARTIS	20MG	N021284 001	Jun 05, 2002
BX		30MG	N021284 002	Jun 05, 2002
BX +		40MG	N021284 003	Jun 05, 2002

	METADATE CD	50MG	N021259 005	Feb 19, 2006
	UCB INC	60MG	N021259 006	Feb 19, 2006

SOLUTION; ORAL

METHYLIN

<u>AA</u>	+ MALLINCKRODT	<u>5MG/5ML</u>	<u>N021419 001</u>	Dec 19, 2002
<u>AA</u>	+	<u>10MG/5ML</u>	<u>N021419 002</u>	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A091601 001</u>	Jul 23, 2010
<u>AA</u>		<u>10MG/5ML</u>	<u>A091601 002</u>	Jul 23, 2010

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A040321 001</u>	Feb 05, 2002
<u>AB</u>		<u>10MG</u>	<u>A040321 002</u>	Feb 05, 2002
<u>AB</u>		<u>20MG</u>	<u>A040321 003</u>	Feb 05, 2002
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A040300 001</u>	Nov 27, 1998
<u>AB</u>		<u>10MG</u>	<u>A040300 002</u>	Nov 27, 1998
<u>AB</u>		<u>20MG</u>	<u>A040300 003</u>	Nov 27, 1998
<u>AB</u>	UCB INC	<u>5MG</u>	<u>A086429 001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085799 001</u>	
<u>AB</u>		<u>20MG</u>	<u>A086428 001</u>	
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A040220 001</u>	Aug 29, 1997
<u>AB</u>		<u>10MG</u>	<u>A040220 002</u>	Aug 29, 1997
<u>AB</u>		<u>20MG</u>	<u>A040220 003</u>	Aug 29, 1997

RITALIN

<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N010187 003</u>	
<u>AB</u>		<u>10MG</u>	<u>N010187 006</u>	
<u>AB</u> +		<u>20MG</u>	<u>N010187 010</u>	

TABLET, CHEWABLE; ORAL
METHYLIN

MALLINCKRODT	2.5MG	N021475 001	Apr 15, 2003
	5MG	N021475 002	Apr 15, 2003
+	10MG	N021475 003	Apr 15, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 274 (of 409)

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

<u>METADATE ER</u>				
<u>AB</u>	UCB INC	<u>10MG</u>	<u>A040306</u>	<u>001</u> Oct 20, 1999
<u>AB</u>	+	<u>20MG</u>	<u>A089601</u>	<u>001</u> Jun 01, 1988
<u>METHYLIN ER</u>				
<u>AB</u>	MALLINCKRODT	<u>10MG</u>	<u>A075629</u>	<u>001</u> May 09, 2000
<u>AB</u>		<u>20MG</u>	<u>A075629</u>	<u>002</u> May 09, 2000
<u>METHYLPHENIDATE HYDROCHLORIDE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>20MG</u>	<u>A075450</u>	<u>001</u> Dec 21, 2001
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A040410</u>	<u>001</u> Feb 09, 2001
<u>RITALIN-SR</u>				
<u>AB</u>	NOVARTIS	<u>20MG</u>	<u>N018029</u>	<u>001</u> Mar 30, 1982
CONCERTA				
	ORTHO MCNEIL JANSSEN	18MG	N021121	001 Aug 01, 2000
		27MG	N021121	004 Apr 01, 2002
		36MG	N021121	002 Aug 01, 2000
	+	54MG	N021121	003 Dec 08, 2000

METHYLPREDNISOLONE

TABLET; ORAL

<u>MEDROL</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>4MG</u>	<u>N011153</u>	<u>001</u>
<u>AB</u>		<u>8MG</u>	<u>N011153</u>	<u>004</u>
<u>AB</u>		<u>16MG</u>	<u>N011153</u>	<u>003</u>
<u>AB</u>	+	<u>32MG</u>	<u>N011153</u>	<u>006</u>
<u>METHYLPREDNISOLONE</u>				
<u>AB</u>	CADISTA PHARMS	<u>4MG</u>	<u>A040189</u>	<u>001</u> Oct 31, 1997
<u>AB</u>		<u>8MG</u>	<u>A040189</u>	<u>002</u> Oct 31, 1997
<u>AB</u>		<u>16MG</u>	<u>A040189</u>	<u>003</u> Jul 20, 2007
<u>AB</u>		<u>32MG</u>	<u>A040189</u>	<u>004</u> Jul 20, 2007
<u>AB</u>	DURAMED PHARMS BARR	<u>4MG</u>	<u>A088497</u>	<u>001</u> Feb 21, 1984
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A040194</u>	<u>001</u> Oct 31, 1997
<u>AB</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040183</u>	<u>001</u> Dec 22, 1998
<u>AB</u>	WATSON LABS	<u>4MG</u>	<u>A040232</u>	<u>001</u> Oct 16, 1997

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

<u>DEPO-MEDROL</u>				
<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>40MG/ML</u>	<u>N011757</u> <u>001</u>
<u>AB</u>	+		<u>80MG/ML</u>	<u>N011757</u> <u>004</u>
<u>METHYLPREDNISOLONE ACETATE</u>				
<u>AB</u>	SANDOZ	<u>40MG/ML</u>	<u>A040719</u>	<u>001</u> Jan 29, 2009
<u>AB</u>		<u>40MG/ML</u>	<u>A040794</u>	<u>001</u> Mar 05, 2009
<u>AB</u>		<u>80MG/ML</u>	<u>A040719</u>	<u>002</u> Jan 29, 2009
<u>AB</u>		<u>80MG/ML</u>	<u>A040794</u>	<u>002</u> Mar 05, 2009
<u>AB</u>	TEVA PARENTERAL	<u>40MG/ML</u>	<u>A040557</u>	<u>001</u> Feb 23, 2005
<u>AB</u>		<u>40MG/ML</u>	<u>A040620</u>	<u>001</u> Oct 27, 2006
<u>AB</u>		<u>80MG/ML</u>	<u>A040557</u>	<u>002</u> Feb 23, 2005
<u>AB</u>		<u>80MG/ML</u>	<u>A040620</u>	<u>002</u> Oct 27, 2006
DEPO-MEDROL				
	+	PHARMACIA AND UPJOHN	20MG/ML	N011757 002

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

<u>A-METHAPRED</u>				
<u>AP</u>	HEMOPHARM USA	<u>EQ 40MG BASE/VIAL</u>	<u>A040793</u>	<u>001</u> Nov 25, 2008
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040827</u>	<u>001</u> Nov 25, 2008
<u>AP</u>	HOSPIRA	<u>EQ 40MG BASE/VIAL</u>	<u>A040664</u>	<u>001</u> Dec 20, 2005
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040665</u>	<u>001</u> Dec 20, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 275 (of 409)

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

<u>AP</u>	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A089173</u>	<u>001</u>	Aug 18, 1987
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A089174</u>	<u>001</u>	Aug 18, 1987

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>	APP PHARMS	<u>EQ 40MG BASE/VIAL</u>	<u>A040583</u>	<u>001</u>	Jul 30, 2004
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040583</u>	<u>002</u>	Jul 30, 2004
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040612</u>	<u>001</u>	Aug 12, 2004
<u>AP</u>	BEDFORD LABS	<u>EQ 40MG BASE/VIAL</u>	<u>A040662</u>	<u>001</u>	Feb 21, 2007
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040641</u>	<u>002</u>	Feb 21, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A040641</u>	<u>003</u>	Feb 21, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A040709</u>	<u>001</u>	Feb 21, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040641</u>	<u>004</u>	Feb 21, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040709</u>	<u>002</u>	Feb 21, 2007
<u>AP</u>	TEVA PARENTERAL	<u>EQ 125MG BASE/VIAL</u>	<u>A081266</u>	<u>001</u>	Nov 30, 1992

SOLU-MEDROL

<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 40MG BASE/VIAL</u>	<u>N011856</u>	<u>003</u>	
<u>AP</u>	+	<u>EQ 125MG BASE/VIAL</u>	<u>N011856</u>	<u>004</u>	
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N011856</u>	<u>005</u>	
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N011856</u>	<u>006</u>	
	SOLU-MEDROL				
	+ PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N011856	007	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

+	VALEANT PHARM INTL	10MG	A083976	001	

TABLET; ORAL

ANDROID 10

BP	VALEANT PHARM INTL	10MG	A086450	001	

ANDROID 25

BP	+ VALEANT PHARM INTL	25MG	A087147	001	

METHYLTESTOSTERONE

BP	IMPAX LABS	10MG	A080767	002	

BP		25MG	A084310	001	

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

<u>AT</u>	FALCON PHARMS	<u>0.3%</u>	<u>A075720</u>	<u>001</u>	Aug 06, 2001

OPTIPRANOLOL

<u>AT</u>	+ BAUSCH AND LOMB	<u>0.3%</u>	<u>N019907</u>	<u>001</u>	Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>EQ 5MG BASE/ML</u>	<u>A073117</u>	<u>001</u>	Jan 17, 1991
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A073118</u>	<u>001</u>	Jan 17, 1991
<u>AP</u>	TEVA PARENTERAL	<u>EQ 5MG BASE/ML</u>	<u>A073135</u>	<u>001</u>	Nov 27, 1991

REGLAN

<u>AP</u>	+ BAXTER HLTHCARE CORP	<u>EQ 5MG BASE/ML</u>	<u>N017862</u>	<u>001</u>	

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AA</u>	ANI PHARMS	<u>EQ 5MG BASE/5ML</u>	<u>A071402</u>	<u>001</u>	Jun 25, 1993
<u>AA</u>	PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A072744</u>	<u>001</u>	May 28, 1991
<u>AA</u>	SILARX	<u>EQ 5MG BASE/5ML</u>	<u>A073680</u>	<u>001</u>	Oct 27, 1992
<u>AA</u>	VISTAPHARM	<u>EQ 5MG BASE/5ML</u>	<u>A075051</u>	<u>001</u>	Jan 26, 2001
<u>AA</u>	+ WOCKHARDT	<u>EQ 5MG BASE/5ML</u>	<u>A074703</u>	<u>001</u>	Oct 31, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 276 (of 409)

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 10MG BASE</u>	<u>A070581</u>	<u>001</u>	Oct 17, 1985
<u>AB</u>	IPCA LABS LTD	<u>EQ 5MG BASE</u>	<u>A078807</u>	<u>001</u>	Jun 12, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078807</u>	<u>002</u>	Jun 12, 2008
<u>AB</u>	MUTUAL PHARM	<u>EQ 5MG BASE</u>	<u>A071536</u>	<u>002</u>	Jan 16, 1997
<u>AB</u>	NORTHSTAR HLTHCARE	<u>EQ 5MG BASE</u>	<u>A078374</u>	<u>001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078374</u>	<u>002</u>	Nov 30, 2007
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A072801</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A070184</u>	<u>001</u>	Jul 29, 1985
<u>AB</u>	VINTAGE PHARMS	<u>EQ 5MG BASE</u>	<u>A077878</u>	<u>001</u>	Aug 28, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077878</u>	<u>002</u>	Aug 28, 2006
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072750</u>	<u>001</u>	Dec 28, 1995
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A071250</u>	<u>001</u>	Feb 03, 1988
<u>REGLAN</u>					
<u>AB</u>	ALAVEN PHARM	<u>EQ 5MG BASE</u>	<u>N017854</u>	<u>002</u>	May 05, 1987
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N017854</u>	<u>001</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

	SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009
+		EQ 10MG BASE	N022246	002	Sep 04, 2009

METOLAZONE

TABLET; ORAL

METOLAZONE

<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076698</u>	<u>001</u>	Dec 23, 2003
<u>AB</u>		<u>5MG</u>	<u>A076698</u>	<u>002</u>	Oct 19, 2004
<u>AB</u>		<u>10MG</u>	<u>A076698</u>	<u>003</u>	Oct 19, 2004
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076732</u>	<u>001</u>	Dec 19, 2003
<u>AB</u>		<u>5MG</u>	<u>A076466</u>	<u>001</u>	Dec 19, 2003
<u>AB</u>		<u>10MG</u>	<u>A076466</u>	<u>002</u>	Dec 19, 2003
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A076600</u>	<u>001</u>	Jan 06, 2004
<u>AB</u>		<u>5MG</u>	<u>A076833</u>	<u>001</u>	Mar 01, 2004
<u>AB</u>		<u>10MG</u>	<u>A075543</u>	<u>003</u>	Dec 24, 2003
<u>ZAROXOLYN</u>					
<u>AB</u>	UCB INC	<u>2.5MG</u>	<u>N017386</u>	<u>001</u>	
<u>AB</u>	+	<u>5MG</u>	<u>N017386</u>	<u>002</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N017386</u>	<u>003</u>	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

<u>AB</u>	KV PHARM	<u>EQ 25MG TARTRATE</u>	<u>A077779</u>	<u>001</u>	Mar 20, 2008
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A077176</u>	<u>001</u>	May 14, 2008
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A076640</u>	<u>002</u>	May 18, 2007
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A076640</u>	<u>001</u>	May 18, 2007
<u>AB</u>	SANDOZ	<u>EQ 25MG TARTRATE</u>	<u>A076969</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A076969</u>	<u>002</u>	May 18, 2007
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A076969</u>	<u>003</u>	Mar 20, 2008
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A076969</u>	<u>004</u>	Mar 20, 2008
<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 25MG TARTRATE</u>	<u>A077118</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A076862</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A077298</u>	<u>001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A077298</u>	<u>002</u>	Apr 15, 2010
<u>AB</u>	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615</u>	<u>001</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090615</u>	<u>002</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A090615</u>	<u>003</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A090615</u>	<u>004</u>	Jul 22, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 277 (of 409)

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

TOPROL-XL

<u>AB</u>	ASTRAZENECA	<u>EQ 25MG TARTRATE</u>	<u>N019962</u>	<u>004</u>	Feb 05, 2001
<u>AB</u>	+	<u>EQ 50MG TARTRATE</u>	<u>N019962</u>	<u>001</u>	Jan 10, 1992
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>N019962</u>	<u>002</u>	Jan 10, 1992
<u>AB</u>	+	<u>EQ 200MG TARTRATE</u>	<u>N019962</u>	<u>003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

<u>AP</u>	+	NOVARTIS	<u>1MG/ML</u>	<u>N018704</u>	<u>001</u>	Mar 30, 1984
<u>METOPROLOL TARTRATE</u>						
<u>AP</u>		APP PHARMS	<u>1MG/ML</u>	<u>A091045</u>	<u>001</u>	Oct 25, 2010
<u>AP</u>		BEDFORD LABS	<u>1MG/ML</u>	<u>A076495</u>	<u>001</u>	Jul 07, 2003
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761</u>	<u>001</u>	May 30, 2007
<u>AP</u>		HOSPIRA	<u>1MG/ML</u>	<u>A074133</u>	<u>001</u>	Dec 21, 1993
<u>AP</u>			<u>1MG/ML</u>	<u>A075160</u>	<u>001</u>	Jul 06, 1998
<u>AP</u>			<u>1MG/ML</u>	<u>A078085</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		LUITPOLD	<u>1MG/ML</u>	<u>A090386</u>	<u>001</u>	Sep 30, 2009
<u>AP</u>			<u>1MG/ML</u>	<u>A091307</u>	<u>001</u>	Dec 29, 2010
<u>AP</u>		SAGENT STRIDES	<u>1MG/ML</u>	<u>A090317</u>	<u>001</u>	Apr 19, 2010
<u>AP</u>		SANDOZ	<u>1MG/ML</u>	<u>A077360</u>	<u>001</u>	Oct 02, 2007
<u>AP</u>		WATSON LABS	<u>1MG/ML</u>	<u>A074032</u>	<u>001</u>	Dec 21, 1993

TABLET; ORAL

LOPRESSOR

<u>AB</u>		NOVARTIS	<u>50MG</u>	<u>N017963</u>	<u>001</u>	
<u>AB</u>			<u>100MG</u>	<u>N017963</u>	<u>002</u>	
<u>METOPROLOL TARTRATE</u>						
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A077739</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>			<u>50MG</u>	<u>A077739</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>			<u>100MG</u>	<u>A077739</u>	<u>003</u>	Sep 11, 2007
<u>AB</u>		CARACO	<u>25MG</u>	<u>A076670</u>	<u>001</u>	Jan 15, 2004
<u>AB</u>			<u>50MG</u>	<u>A074644</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>			<u>100MG</u>	<u>A074644</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>		IPCA LABS LTD	<u>25MG</u>	<u>A078459</u>	<u>001</u>	Jun 17, 2008
<u>AB</u>			<u>50MG</u>	<u>A078459</u>	<u>002</u>	Jun 17, 2008
<u>AB</u>			<u>100MG</u>	<u>A078459</u>	<u>003</u>	Jun 17, 2008
<u>AB</u>		MUTUAL PHARM	<u>25MG</u>	<u>A073654</u>	<u>002</u>	Jul 15, 2009
<u>AB</u>			<u>50MG</u>	<u>A073653</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>			<u>100MG</u>	<u>A073654</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A076704</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>			<u>50MG</u>	<u>A076704</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>	+		<u>100MG</u>	<u>A076704</u>	<u>003</u>	Jan 16, 2004
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A073288</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>			<u>100MG</u>	<u>A073289</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>		TEVA	<u>50MG</u>	<u>A074141</u>	<u>001</u>	Jan 31, 1995
<u>AB</u>			<u>100MG</u>	<u>A074141</u>	<u>002</u>	Jan 31, 1995
<u>AB</u>		WATSON LABS	<u>50MG</u>	<u>A074217</u>	<u>001</u>	May 27, 1994
<u>AB</u>			<u>100MG</u>	<u>A074217</u>	<u>002</u>	May 27, 1994

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>375MG</u>	<u>N020334</u>	<u>001</u>	May 03, 1995
<u>METRONIDAZOLE</u>						
<u>AB</u>		ALEMBIC LTD	<u>375MG</u>	<u>A079065</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>		PAR PHARM	<u>375MG</u>	<u>A076522</u>	<u>001</u>	Jan 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 278 (of 409)

METRONIDAZOLE

CREAM; TOPICAL					
<u>METROCREAM</u>					
<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531</u>	<u>001</u> Sep 20, 1995
<u>METRONIDAZOLE</u>					
<u>AB</u>		ALTANA	<u>0.75%</u>	<u>A076408</u>	<u>001</u> May 28, 2004
<u>AB</u>		G AND W LABS	<u>0.75%</u>	<u>A077549</u>	<u>001</u> Dec 19, 2007
NORITATE					
	+	SANOFI AVENTIS US	1%	N020743	001 Sep 26, 1997
GEL; TOPICAL					
<u>METROGEL</u>					
<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N019737</u>	<u>001</u> Nov 22, 1988
<u>METRONIDAZOLE</u>					
<u>AB</u>		ALTANA	<u>0.75%</u>	<u>A077018</u>	<u>001</u> Jun 06, 2006
<u>AB</u>		TARO	<u>0.75%</u>	<u>A077819</u>	<u>001</u> Jul 18, 2006
<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077547</u>	<u>001</u> Jul 13, 2006
METROGEL					
	+	GALDERMA LABS LP	1%	N021789	001 Jun 30, 2005
GEL; VAGINAL					
<u>METROGEL - VAGINAL</u>					
<u>AB</u>	+	GRACEWAY	<u>0.75%</u>	<u>N020208</u>	<u>001</u> Aug 17, 1992
<u>METRONIDAZOLE</u>					
<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077264</u>	<u>001</u> Oct 31, 2006
VANDAZOLE					
BX		TEVA PHARMS	0.75%	N021806	001 May 20, 2005
INJECTABLE; INJECTION					
<u>FLAGYL I.V. RTU IN PLASTIC CONTAINER</u>					
<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657</u>	<u>001</u>
<u>AP</u>	+	GD SEARLE LLC	<u>500MG/100ML</u>	<u>N018353</u>	<u>002</u>
<u>METRO I.V. IN PLASTIC CONTAINER</u>					
<u>AP</u>	+	B BRAUN	<u>500MG/100ML</u>	<u>N018900</u>	<u>001</u> Sep 29, 1983
<u>METRONIDAZOLE IN PLASTIC CONTAINER</u>					
<u>AP</u>		CLARIS LIFESCIENCES	<u>500MG/100ML</u>	<u>A078084</u>	<u>001</u> Mar 31, 2008
<u>AP</u>	+	HOSPIRA	<u>500MG/100ML</u>	<u>N018890</u>	<u>002</u> Nov 18, 1983
LOTION; TOPICAL					
<u>METROLOTION</u>					
<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020901</u>	<u>001</u> Nov 24, 1998
<u>METRONIDAZOLE</u>					
<u>AB</u>		ALTANA	<u>0.75%</u>	<u>A077197</u>	<u>001</u> May 24, 2006
TABLET; ORAL					
<u>FLAGYL</u>					
<u>AB</u>		GD SEARLE LLC	<u>250MG</u>	<u>N012623</u>	<u>001</u>
<u>AB</u>	+		<u>500MG</u>	<u>N012623</u>	<u>003</u>
<u>METRONIDAZOLE</u>					
<u>AB</u>		ALEMBIC LTD	<u>250MG</u>	<u>A079067</u>	<u>001</u> Mar 13, 2009
<u>AB</u>			<u>500MG</u>	<u>A079067</u>	<u>002</u> Mar 13, 2009
<u>AB</u>		MUTUAL PHARM	<u>250MG</u>	<u>A070772</u>	<u>001</u> Jul 16, 1986
<u>AB</u>			<u>500MG</u>	<u>A070773</u>	<u>001</u> Jul 16, 1986
<u>AB</u>		PLIVA	<u>250MG</u>	<u>A070027</u>	<u>001</u> Nov 06, 1984
<u>AB</u>			<u>500MG</u>	<u>A070033</u>	<u>001</u> Dec 06, 1984
<u>AB</u>		TEVA	<u>500MG</u>	<u>A070044</u>	<u>001</u> Feb 08, 1985
<u>AB</u>		WATSON LABS	<u>250MG</u>	<u>A070035</u>	<u>001</u> Dec 20, 1984
<u>AB</u>			<u>250MG</u>	<u>N018764</u>	<u>001</u> Sep 17, 1982
<u>AB</u>			<u>500MG</u>	<u>N018764</u>	<u>002</u> Dec 20, 1982
TABLET, EXTENDED RELEASE; ORAL					
<u>FLAGYL ER</u>					
<u>AB</u>	+	GD SEARLE LLC	<u>750MG</u>	<u>N020868</u>	<u>001</u> Nov 26, 1997
<u>METRONIDAZOLE</u>					
<u>AB</u>		ALEMBIC LTD	<u>750MG</u>	<u>A090222</u>	<u>001</u> May 05, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 279 (of 409)

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

+ GD SEARLE LLC

EQ 500MG BASE/VIAL

N018353 001

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+ NOVARTIS

250MG

N012911 002 Aug 09, 1996

METYROSINE

CAPSULE; ORAL

DEMSEER

+ ATON

250MG

N017871 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDEAB TEVA 150MGA074377 001 May 16, 1995AB 200MGA074377 002 May 16, 1995AB + 250MGA074377 003 May 16, 1995AB WATSON LABS 150MGA074711 001 Feb 26, 1997AB 150MGA074865 001 Apr 13, 1998AB 200MGA074711 002 Feb 26, 1997AB 200MGA074865 002 Apr 13, 1998AB 250MGA074711 003 Feb 26, 1997AB 250MGA074865 003 Apr 13, 1998MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+ ASTELLAS

50MG/VIAL

N021506 002 Mar 16, 2005

100MG/VIAL

N021506 003 Jun 27, 2006

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ BIOALLIANCE PHARMA

50MG

N022404 001 Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATEAB ACTAVIS MID ATLANTIC 200MGA073508 001 Nov 19, 1993MONISTAT 3AB + PERSONAL PRODS 200MGN018888 001 Aug 15, 1984MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+ STIEFEL LABS INC

0.25%;81.35%;15%

N021026 001 Feb 16, 2006

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDEAP APP PHARMS EQ 1MG BASE/MLA075154 002 Jun 20, 2000AP EQ 5MG BASE/MLA075154 001 Jun 20, 2000AP BAXTER HLTHCARE EQ 1MG BASE/MLA075243 001 Jun 20, 2000AP EQ 5MG BASE/MLA075243 002 Jun 20, 2000AP BAXTER HLTHCARE CORP EQ 1MG BASE/MLA075324 001 Jun 20, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 280 (of 409)

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>	BAXTER HLTHCARE CORP	<u>EQ 5MG BASE/ML</u>	<u>A075324</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>	BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A075247</u>	<u>002</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075247</u>	<u>001</u>	Jun 23, 2000
<u>AP</u>	BEN VENUE	<u>EQ 1MG BASE/ML</u>	<u>A075421</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075421</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 1MG BASE/ML</u>	<u>A075637</u>	<u>001</u>	Oct 31, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075637</u>	<u>002</u>	Oct 31, 2000
<u>AP</u> +	HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075293</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075409</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075856</u>	<u>001</u>	Jun 13, 2002
<u>AP</u> +		<u>EQ 5MG BASE/ML</u>	<u>A075293</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075856</u>	<u>002</u>	Jun 13, 2002
<u>AP</u>	INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076144</u>	<u>001</u>	Jan 26, 2005
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A076144</u>	<u>002</u>	Jan 26, 2005
<u>AP</u>	INTL MEDICATION	<u>EQ 1MG BASE/ML</u>	<u>A076020</u>	<u>001</u>	Jul 16, 2004
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A076020</u>	<u>002</u>	Jul 16, 2004
<u>AP</u>	TAYLOR	<u>EQ 1MG BASE/ML</u>	<u>A075494</u>	<u>001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075481</u>	<u>001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075494</u>	<u>002</u>	Jun 30, 2000
<u>AP</u>	WOCKHARDT	<u>EQ 1MG BASE/ML</u>	<u>A078141</u>	<u>001</u>	May 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A078511</u>	<u>001</u>	Nov 10, 2008
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A078141</u>	<u>002</u>	May 30, 2008
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A078511</u>	<u>002</u>	Nov 10, 2008
<u>MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE</u>					
<u>AP</u> +	HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075857</u>	<u>001</u>	Jul 22, 2002
<u>AP</u> +		<u>EQ 5MG BASE/ML</u>	<u>A075857</u>	<u>002</u>	Jul 22, 2002
<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090315</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090315</u>	<u>002</u>	Nov 29, 2010

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>	APOTEX INC	<u>EQ 2MG BASE/ML</u>	<u>A077115</u>	<u>001</u>	Sep 09, 2005
<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/ML</u>	<u>A075958</u>	<u>001</u>	Sep 04, 2003
<u>AA</u>	PADDOCK	<u>EQ 2MG BASE/ML</u>	<u>A076379</u>	<u>001</u>	May 02, 2005
<u>AA</u>	RANBAXY	<u>EQ 2MG BASE/ML</u>	<u>A076058</u>	<u>001</u>	Mar 15, 2002
<u>AA</u> +	ROXANE	<u>EQ 2MG BASE/ML</u>	<u>A075873</u>	<u>001</u>	Apr 30, 2002

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A077746</u>	<u>001</u>	Sep 12, 2006
<u>AB</u>		<u>5MG</u>	<u>A077746</u>	<u>002</u>	Sep 12, 2006
<u>AB</u>		<u>10MG</u>	<u>A077746</u>	<u>003</u>	Sep 12, 2006
<u>AB</u>	IMPAX PHARMS	<u>2.5MG</u>	<u>A076449</u>	<u>001</u>	May 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A076449</u>	<u>002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076577</u>	<u>001</u>	Sep 10, 2003
<u>AB</u>		<u>5MG</u>	<u>A076577</u>	<u>002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076514</u>	<u>001</u>	Sep 11, 2003
<u>AB</u>		<u>5MG</u>	<u>A076514</u>	<u>002</u>	Sep 11, 2003
<u>AB</u>		<u>10MG</u>	<u>A076514</u>	<u>003</u>	Jul 02, 2004
<u>ORVATEN</u>					
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076725</u>	<u>001</u>	Nov 03, 2004
<u>AB</u>		<u>5MG</u>	<u>A076725</u>	<u>002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725</u>	<u>003</u>	Nov 03, 2004
<u>PROAMATINE</u>					
<u>AB</u>	SHIRE	<u>2.5MG</u>	<u>N019815</u>	<u>001</u>	Sep 06, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 281 (of 409)

MIDODRINE HYDROCHLORIDE

TABLET; ORAL				
<u>PROAMATINE</u>				
<u>AB</u>	+	SHIRE	<u>5MG</u>	<u>N019815</u> <u>002</u> Sep 06, 1996
<u>AB</u>			<u>10MG</u>	<u>N019815</u> <u>003</u> Mar 20, 2002

MIFEPRISTONE

TABLET; ORAL				
MIFEPREX				
	+	DANCO LABS LLC	200MG	N020687 001 Sep 28, 2000

MIGLITOL

TABLET; ORAL				
GLYSET				
		PHARMACIA AND UPJOHN	25MG	N020682 001 Dec 18, 1996
			50MG	N020682 002 Dec 18, 1996
	+		100MG	N020682 003 Dec 18, 1996

MIGLUSTAT

CAPSULE; ORAL				
ZAVESCA				
	+	ACTELION PHARMS LTD	100MG	N021348 001 Jul 31, 2003

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL				
SAVELLA				
		CYPRESS BIOSCIENCE	12.5MG	N022256 001 Jan 14, 2009
			25MG	N022256 002 Jan 14, 2009
			50MG	N022256 003 Jan 14, 2009
	+		100MG	N022256 004 Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION				
<u>MILRINONE LACTATE</u>				
<u>AP</u>		APP PHARMS	<u>EQ 1MG BASE/ML</u>	<u>A075936</u> <u>001</u> May 28, 2002
<u>AP</u>		BAXTER HLTHCARE	<u>EQ 1MG BASE/ML</u>	<u>A075530</u> <u>001</u> May 28, 2002
<u>AP</u>	+	BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A075660</u> <u>001</u> May 28, 2002
<u>AP</u>		CLARIS LIFESCIENCES	<u>EQ 1MG BASE/ML</u>	<u>A076427</u> <u>001</u> Sep 21, 2004
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A077190</u> <u>001</u> Oct 31, 2006
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML</u>	<u>A077966</u> <u>001</u> Dec 03, 2010
<u>AP</u>		HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075884</u> <u>001</u> May 28, 2002
<u>AP</u>		INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076013</u> <u>001</u> Aug 02, 2002
<u>MILRINONE LACTATE IN DEXTROSE 5%</u>				
<u>AP</u>		CLARIS LIFESCIENCES	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A077151</u> <u>002</u> Jul 20, 2005
<u>MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>		B BRAUN	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A076414</u> <u>001</u> Aug 18, 2004
<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u> <u>001</u> May 28, 2002
<u>AP</u>	+		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u> <u>002</u> May 28, 2002
<u>AP</u>		BEDFORD LABS	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u> <u>001</u> May 21, 2008
<u>AP</u>			<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u> <u>002</u> May 21, 2008
<u>AP</u>		CLARIS LIFESCIENCES	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A077151</u> <u>001</u> Jul 20, 2005
<u>AP</u>		HOSPIRA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u> <u>001</u> May 28, 2002
<u>AP</u>			<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u> <u>002</u> May 28, 2002
<u>MILRINONE LACTATE IN PLASTIC CONTAINER</u>				
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u> <u>001</u> Jan 21, 2010
<u>AP</u>			<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u> <u>002</u> Jan 21, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 282 (of 409)

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

<u>AB</u>	MEDICIS	<u>EQ 75MG BASE</u>	<u>A063067</u>	<u>002</u>	Sep 15, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063067</u>	<u>001</u>	Jul 31, 1990

MINOCIN

<u>AB</u>	TRIAx PHARMS LLC	<u>EQ 50MG BASE</u>	<u>N050649</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050649</u>	<u>002</u>	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A065470</u>	<u>001</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065470</u>	<u>002</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065470</u>	<u>003</u>	Mar 11, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 50MG BASE</u>	<u>A065005</u>	<u>001</u>	Mar 23, 1999
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065005</u>	<u>003</u>	Apr 18, 2001
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065005</u>	<u>002</u>	Mar 23, 1999
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065062</u>	<u>001</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065062</u>	<u>002</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065062</u>	<u>003</u>	Nov 30, 2000
<u>AB</u>	TEVA	<u>EQ 50MG BASE</u>	<u>A063011</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063009</u>	<u>002</u>	Aug 12, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A063009</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A063181</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063065</u>	<u>002</u>	Jun 10, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063065</u>	<u>001</u>	Dec 30, 1991

INJECTABLE; INJECTION

MINOCIN

+	TRIAx PHARMS LLC	EQ 100MG BASE/VIAL	N050444	001	

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+	ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436</u>	<u>001</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065436</u>	<u>002</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065436</u>	<u>003</u>	Dec 26, 2007
<u>AB</u>	MEDICIS	<u>EQ 50MG BASE</u>	<u>A065131</u>	<u>001</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065131</u>	<u>002</u>	Apr 16, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A065131</u>	<u>003</u>	Apr 16, 2003
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065156</u>	<u>001</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065156</u>	<u>002</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156</u>	<u>003</u>	Jan 06, 2004

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 45MG BASE</u>	<u>A065485</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A065485</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A065485</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>	IMPAX LABS INC	<u>EQ 45MG BASE</u>	<u>A090024</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090024</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090024</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>	MATRIX LABS LTD	<u>EQ 45MG BASE</u>	<u>A090911</u>	<u>001</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090911</u>	<u>002</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090911</u>	<u>003</u>	Jul 20, 2010
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422</u>	<u>001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422</u>	<u>002</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090422</u>	<u>003</u>	Aug 13, 2009
<u>AB</u>	<u>SOLODYN</u>				
<u>AB</u>	MEDICIS	<u>EQ 45MG BASE</u>	<u>N050808</u>	<u>001</u>	May 08, 2006
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>N050808</u>	<u>002</u>	May 08, 2006
<u>AB</u>	+	<u>EQ 135MG BASE</u>	<u>N050808</u>	<u>003</u>	May 08, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 283 (of 409)

MINOCYCLINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
SOLODYN

MEDICIS	EQ 55MG BASE	N050808	008	Aug 27, 2010
	EQ 65MG BASE	N050808	004	Jul 23, 2009
	EQ 80MG BASE	N050808	007	Aug 27, 2010
	EQ 105MG BASE	N050808	006	Aug 27, 2010
	EQ 115MG BASE	N050808	005	Jul 23, 2009

MINOXIDIL

TABLET; ORAL

MINOXIDIL

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A072708</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>		<u>10MG</u>	<u>A072709</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344</u>	<u>001</u>	Mar 03, 1987
<u>AB</u> +		<u>10MG</u>	<u>A071345</u>	<u>001</u>	Mar 03, 1987

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A076308</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>		<u>30MG</u>	<u>A076308</u>	<u>002</u>	Jun 20, 2003
<u>AB</u>		<u>45MG</u>	<u>A076308</u>	<u>003</u>	Jun 20, 2003
<u>AB</u>	ACTAVIS TOTOWA	<u>15MG</u>	<u>A076241</u>	<u>001</u>	Jun 25, 2003
<u>AB</u>		<u>30MG</u>	<u>A076241</u>	<u>002</u>	Jun 25, 2003
<u>AB</u>		<u>45MG</u>	<u>A076241</u>	<u>003</u>	Jun 25, 2003
<u>AB</u>	ALPHAPHARM	<u>15MG</u>	<u>A076176</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076176</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076176</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666</u>	<u>001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666</u>	<u>002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666</u>	<u>003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921</u>	<u>001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921</u>	<u>002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921</u>	<u>003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921</u>	<u>004</u>	Oct 22, 2004
<u>AB</u>	CARACO	<u>7.5MG</u>	<u>A076541</u>	<u>004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541</u>	<u>001</u>	Apr 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076541</u>	<u>002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541</u>	<u>003</u>	Apr 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A076219</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076312</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076312</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076312</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS FLORIDA	<u>15MG</u>	<u>A076336</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>		<u>30MG</u>	<u>A076336</u>	<u>002</u>	Jun 20, 2003
<u>AB</u>		<u>45MG</u>	<u>A076336</u>	<u>003</u>	Jun 20, 2003
	<u>REMERON</u>				
<u>AB</u> +	ORGANON USA INC	<u>15MG</u>	<u>N020415</u>	<u>001</u>	Jun 14, 1996
<u>AB</u>		<u>30MG</u>	<u>N020415</u>	<u>002</u>	Jun 14, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 284 (of 409)

MIRTAZAPINE

TABLET; ORAL

REMERON

<u>AB</u>	ORGANON USA INC	<u>45MG</u>	<u>N020415</u>	<u>003</u>	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS TOTOWA	<u>15MG</u>	<u>A076689</u>	<u>001</u>	Aug 31, 2005
<u>AB</u>		<u>30MG</u>	<u>A076689</u>	<u>002</u>	Aug 31, 2005
<u>AB</u>		<u>45MG</u>	<u>A076689</u>	<u>003</u>	Aug 31, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>15MG</u>	<u>A077376</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376</u>	<u>004</u>	Feb 28, 2006
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076901</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>30MG</u>	<u>A076901</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>45MG</u>	<u>A076901</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076307</u>	<u>001</u>	Dec 17, 2003
<u>AB</u>		<u>30MG</u>	<u>A076307</u>	<u>002</u>	Dec 17, 2003
<u>AB</u>		<u>45MG</u>	<u>A076307</u>	<u>003</u>	Feb 28, 2006

<u>REMERON SOLTAB</u>					
<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N021208</u>	<u>001</u>	Jan 12, 2001
<u>AB</u>		<u>30MG</u>	<u>N021208</u>	<u>002</u>	Jan 12, 2001
<u>AB</u>		<u>45MG</u>	<u>N021208</u>	<u>003</u>	Jan 12, 2001

MISOPROSTOL

TABLET; ORAL

CYTOTEC

<u>AB</u>	GD SEARLE LLC	<u>0.1MG</u>	<u>N019268</u>	<u>003</u>	Sep 21, 1990
<u>AB</u>	+	<u>0.2MG</u>	<u>N019268</u>	<u>001</u>	Dec 27, 1988

<u>MISOPROSTOL</u>					
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.1MG</u>	<u>A076095</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>		<u>0.2MG</u>	<u>A076095</u>	<u>002</u>	Jul 10, 2002

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>	+ ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144</u>	<u>001</u>	Apr 30, 1998
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A064144</u>	<u>002</u>	Apr 30, 1998
<u>AP</u>	+	<u>40MG/VIAL</u>	<u>A064144</u>	<u>003</u>	Aug 11, 2009
<u>AP</u>	BAXTER HLTHCARE	<u>5MG/VIAL</u>	<u>A064180</u>	<u>001</u>	Dec 23, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064180</u>	<u>002</u>	Dec 23, 1999
<u>AP</u>	BEDFORD	<u>5MG/VIAL</u>	<u>A064117</u>	<u>001</u>	Apr 19, 1995
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064117</u>	<u>002</u>	Apr 19, 1995

MITOTANE

TABLET; ORAL

LYSODREN

	+ BRISTOL MYERS SQUIBB	500MG	N016885	001	

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	BEDFORD	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	BIONICHE PHARMA USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A078980</u>	<u>001</u>	Apr 13, 2009
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A078980</u>	<u>002</u>	Apr 13, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 285 (of 409)

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A078606</u>	<u>001</u>	May 14, 2008
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A078606</u>	<u>002</u>	May 14, 2008
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A078606</u>	<u>003</u>	May 14, 2008
<u>AP</u>	HOSPIRA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	TEVA PARENTERAL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>003</u>	Apr 11, 2006
<u>NOVANTRONE</u>					
<u>AP</u>	+ EMD SERONO	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>N019297</u>	<u>001</u>	Dec 23, 1987

MODAFINIL

TABLET; ORAL

PROVIGIL

	CEPHALON	100MG	N020717	001	Dec 24, 1998
+		200MG	N020717	002	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A078454</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>15MG</u>	<u>A078454</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A090416</u>	<u>001</u>	Mar 30, 2010
<u>AB</u>		<u>15MG</u>	<u>A090416</u>	<u>002</u>	Mar 30, 2010
<u>AB</u>	PADDOCK	<u>7.5MG</u>	<u>A077536</u>	<u>001</u>	Nov 30, 2006
<u>AB</u>		<u>15MG</u>	<u>A077536</u>	<u>002</u>	Nov 30, 2006
<u>AB</u>	TEVA	<u>7.5MG</u>	<u>A076204</u>	<u>001</u>	May 08, 2003
<u>AB</u>		<u>15MG</u>	<u>A076204</u>	<u>002</u>	May 08, 2003
<u>UNIVASC</u>					
<u>AB</u>	UCB INC	<u>7.5MG</u>	<u>N020312</u>	<u>001</u>	Apr 19, 1995
<u>AB</u>	+	<u>15MG</u>	<u>N020312</u>	<u>002</u>	Apr 19, 1995

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

<u>AB</u>	+ SCHERING	<u>0.1%</u>	<u>N019625</u>	<u>001</u>	May 06, 1987
<u>MOMETASONE FUROATE</u>					
<u>AB</u>	ALTANA	<u>0.1%</u>	<u>A076171</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077447</u>	<u>001</u>	May 22, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078541</u>	<u>001</u>	May 28, 2008
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076679</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076591</u>	<u>001</u>	Apr 18, 2007

LOTION; TOPICAL

ELOCON

<u>AB</u>	+ SCHERING	<u>0.1%</u>	<u>N019796</u>	<u>001</u>	Mar 30, 1989
<u>MOMETASONE FUROATE</u>					
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077678</u>	<u>001</u>	Nov 21, 2007
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A090506</u>	<u>001</u>	Aug 09, 2010
<u>AB</u>	NYCOMED US	<u>0.1%</u>	<u>A075919</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>	PERRIGO	<u>0.1%</u>	<u>A077180</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076788</u>	<u>001</u>	Mar 15, 2006
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076499</u>	<u>001</u>	Nov 21, 2007

OINTMENT; TOPICAL

ELOCON

<u>AB</u>	+ SCHERING	<u>0.1%</u>	<u>N019543</u>	<u>001</u>	Apr 30, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 286 (of 409)

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

<u>AB</u>	ALTANA	<u>0.1%</u>	<u>A077061</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077401</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078571</u>	<u>001</u>	May 28, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076624</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076481</u>	<u>001</u>	Nov 14, 2003

POWDER; INHALATION

ASMANEX TWISTHALER

	SCHERING	0.11MG/INH	N021067	002	Feb 01, 2008
+		0.22MG/INH	N021067	001	Mar 30, 2005

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

+	SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997

MONTELUKAST SODIUM

GRANULE; ORAL

SINGULAIR

+	MERCK	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002

TABLET; ORAL

SINGULAIR

+	MERCK	EQ 10MG BASE	N020829	002	Feb 20, 1998

TABLET, CHEWABLE; ORAL

SINGULAIR

	MERCK	EQ 4MG BASE	N020830	002	Mar 03, 2000
+		EQ 5MG BASE	N020830	001	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX	KING PHARMS	30MG	N021260	001	Mar 20, 2002
BX		60MG	N021260	002	Mar 20, 2002

KADIAN

BX	ACTAVIS ELIZABETH	30MG	N020616	004	Mar 09, 2001
BX		60MG	N020616	005	Mar 09, 2001

AVINZA

	KING PHARMS	45MG	N021260	005	Dec 18, 2008
		75MG	N021260	006	Dec 18, 2008
		90MG	N021260	003	Mar 20, 2002
+		120MG	N021260	004	Mar 20, 2002

KADIAN

+	ACTAVIS ELIZABETH	10MG	N020616	008	Apr 20, 2007
		20MG	N020616	001	Jul 03, 1996
		50MG	N020616	002	Jul 03, 1996
		80MG	N020616	006	Oct 27, 2006
+		100MG	N020616	003	Jul 03, 1996
+		200MG	N020616	007	Feb 27, 2007

INJECTABLE; INJECTION

ASTRAMORPH PF

<u>AP</u>	APP PHARMS	<u>0.5MG/ML</u>	<u>A071050</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>0.5MG/ML</u>	<u>A071051</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071052</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071053</u>	<u>001</u>	Oct 07, 1986

DURAMORPH PF

<u>AP</u>	+	BAXTER HLTHCARE	<u>0.5MG/ML</u>	<u>N018565</u>	<u>001</u>	Sep 18, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 287 (of 409)

MORPHINE SULFATE

INJECTABLE; INJECTION

DURAMORPH PF

<u>AP</u>	<u>+</u>	<u>BAXTER HLTHCARE</u>	<u>1MG/ML</u>	<u>N018565</u>	<u>002</u>	Sep 18, 1984
		<u>MORPHINE SULFATE</u>				
<u>AP</u>		<u>HOSPIRA</u>	<u>0.5MG/ML</u>	<u>A071849</u>	<u>001</u>	May 11, 1988
<u>AP</u>			<u>0.5MG/ML</u>	<u>A073509</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>			<u>1MG/ML</u>	<u>A071850</u>	<u>001</u>	May 11, 1988
<u>AP</u>			<u>1MG/ML</u>	<u>A073510</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>	<u>+</u>		<u>1MG/ML</u>	<u>N019916</u>	<u>001</u>	Oct 30, 1992
<u>AP</u>		<u>WATSON LABS</u>	<u>0.5MG/ML</u>	<u>A073373</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>			<u>0.5MG/ML</u>	<u>A073375</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>			<u>1MG/ML</u>	<u>A073374</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>			<u>1MG/ML</u>	<u>A073376</u>	<u>001</u>	Sep 30, 1991

INFUMORPH

<u>+</u>	<u>BAXTER HLTHCARE</u>	<u>10MG/ML</u>	<u>N018565</u>	<u>003</u>	Jul 19, 1991
<u>+</u>		<u>25MG/ML</u>	<u>N018565</u>	<u>004</u>	Jul 19, 1991
	<u>MORPHINE SULFATE</u>				
<u>+</u>	<u>HOSPIRA</u>	<u>5MG/ML</u>	<u>N019916</u>	<u>002</u>	Oct 27, 2006
<u>+</u>	<u>MERIDIAN MEDCL TECHN</u>	<u>15MG/ML</u>	<u>N019999</u>	<u>001</u>	Jul 12, 1990

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

	<u>EKR THERAP</u>	<u>10MG/ML (10MG/ML)</u>	<u>N021671</u>	<u>001</u>	May 18, 2004
<u>+</u>		<u>15MG/1.5ML (10MG/ML)</u>	<u>N021671</u>	<u>002</u>	May 18, 2004

SOLUTION; ORAL

MORPHINE SULFATE

	<u>ROXANE</u>	<u>10MG/5ML</u>	<u>N022195</u>	<u>001</u>	Mar 17, 2008
		<u>20MG/5ML</u>	<u>N022195</u>	<u>002</u>	Mar 17, 2008
<u>+</u>		<u>100MG/5ML</u>	<u>N022195</u>	<u>003</u>	Jan 25, 2010

TABLET; ORAL

MORPHINE SULFATE

	<u>ROXANE</u>	<u>15MG</u>	<u>N022207</u>	<u>001</u>	Mar 17, 2008
<u>+</u>		<u>30MG</u>	<u>N022207</u>	<u>002</u>	Mar 17, 2008

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

<u>AB</u>	<u>CLONMEL HLTHCARE</u>	<u>15MG</u>	<u>A075407</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	<u>ENDO PHARMS</u>	<u>15MG</u>	<u>A075295</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295</u>	<u>004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295</u>	<u>005</u>	Sep 15, 2000
<u>AB</u>	<u>KV PHARM</u>	<u>15MG</u>	<u>A076733</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>30MG</u>	<u>A076720</u>	<u>002</u>	Dec 23, 2005
<u>AB</u>		<u>60MG</u>	<u>A076720</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>100MG</u>	<u>A077855</u>	<u>001</u>	Sep 27, 2007
<u>AB</u>		<u>200MG</u>	<u>A077855</u>	<u>002</u>	Sep 27, 2007
<u>AB</u>	<u>MALLINCKRODT</u>	<u>15MG</u>	<u>A076412</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438</u>	<u>001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438</u>	<u>002</u>	Jul 03, 2003
<u>AB</u>	<u>RHODES PHARMS</u>	<u>15MG</u>	<u>A074862</u>	<u>001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862</u>	<u>002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862</u>	<u>003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769</u>	<u>001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769</u>	<u>002</u>	Jul 02, 1998
<u>AB</u>	<u>WATSON LABS</u>	<u>100MG</u>	<u>A075656</u>	<u>001</u>	Jan 30, 2001
	<u>MS CONTIN</u>				
<u>AB</u>	<u>PURDUE PHARMA LP</u>	<u>15MG</u>	<u>N019516</u>	<u>003</u>	Sep 12, 1989
<u>AB</u>		<u>30MG</u>	<u>N019516</u>	<u>001</u>	May 29, 1987

PRESCRIPTION DRUG PRODUCT LIST

3 - 288 (of 409)

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL					
<u>MS CONTIN</u>					
<u>AB</u>	PURDUE PHARMA LP	<u>60MG</u>	<u>N019516</u>	<u>002</u>	Apr 08, 1988
<u>AB</u>	+	<u>100MG</u>	<u>N019516</u>	<u>004</u>	Jan 16, 1990
<u>AB</u>		<u>200MG</u>	<u>N019516</u>	<u>005</u>	Nov 08, 1993
ORAMORPH SR					
BC	XANODYNE PHARM	15MG	N019977	004	Nov 23, 1994
BC		30MG	N019977	001	Aug 15, 1991
BC		60MG	N019977	002	Aug 15, 1991
BC	+	100MG	N019977	003	Aug 15, 1991

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
EMBEDA					
	ALPHARMA KING	20MG;0.8MG	N022321	001	Aug 13, 2009
		30MG;1.2MG	N022321	002	Aug 13, 2009
		50MG;2MG	N022321	003	Aug 13, 2009
		60MG;2.4MG	N022321	004	Aug 13, 2009
		80MG;3.2MG	N022321	005	Aug 13, 2009
	+	100MG;4MG	N022321	006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)					
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
	+ BAYER HLTHCARE	160MG/100ML	N021277	001	Nov 30, 2001
SOLUTION/DROPS; OPHTHALMIC					
	+ ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010
	VIGAMOX				
	+ ALCON	EQ 0.5% BASE	N021598	001	Apr 15, 2003
TABLET; ORAL					
AVELOX					
	+ BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999

MUPIROCIN

OINTMENT; TOPICAL					
<u>BACTROBAN</u>					
<u>AB</u>	+ GLAXOSMITHKLINE	<u>2%</u>	<u>N050591</u>	<u>001</u>	Dec 31, 1987
<u>MUPIROCIN</u>					
<u>AB</u>	ALTANA	<u>2%</u>	<u>A065192</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	PERRIGO NEW YORK	<u>2%</u>	<u>A065123</u>	<u>001</u>	Nov 07, 2003
<u>AB</u>	TARO	<u>2%</u>	<u>A065170</u>	<u>001</u>	Sep 23, 2005
<u>AB</u>	TEVA	<u>2%</u>	<u>A065085</u>	<u>001</u>	Nov 07, 2003
CENTANY					
BX	PERRIGO NEW YORK	2%	N050788	001	Dec 04, 2002

MUPIROCIN CALCIUM

CREAM, AUGMENTED; TOPICAL					
BACTROBAN					
	+ GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997
OINTMENT; NASAL					
BACTROBAN					
	+ GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL					
<u>CELLCEPT</u>					
<u>AB</u>	+ ROCHE PALO	<u>250MG</u>	<u>N050722</u>	<u>001</u>	May 03, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 289 (of 409)

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

<u>AB</u>	ACCORD HLTHCARE INC	<u>250MG</u>	<u>A090253</u>	<u>001</u>	May 04, 2009
<u>AB</u>	APOTEX CORP	<u>250MG</u>	<u>A090419</u>	<u>001</u>	Apr 22, 2009
<u>AB</u>	ENDO PHARMS	<u>250MG</u>	<u>A090111</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A065520</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A065410</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065379</u>	<u>001</u>	Oct 15, 2008
<u>AB</u>	STRIDES ARCOLAB LTD	<u>250MG</u>	<u>A090055</u>	<u>001</u>	Jun 10, 2010
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A065491</u>	<u>001</u>	May 06, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A065433</u>	<u>001</u>	May 04, 2009

SUSPENSION; ORAL

CELLCEPT

+	ROCHE PALO	200MG/ML	N050759	001	Oct 01, 1998

TABLET; ORAL

CELLCEPT

<u>AB</u>	+	ROCHE PALO	<u>500MG</u>	<u>N050723</u>	<u>001</u>	Jun 19, 1997

MYCOPHENOLATE MOFETIL

<u>AB</u>	ACCORD HLTHCARE	<u>500MG</u>	<u>A065416</u>	<u>001</u>	May 04, 2009
<u>AB</u>	APOTEX	<u>500MG</u>	<u>A090499</u>	<u>001</u>	Apr 22, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>500MG</u>	<u>A090464</u>	<u>001</u>	Sep 13, 2010
<u>AB</u>	ENDO PHARMS	<u>500MG</u>	<u>A090606</u>	<u>001</u>	Jul 16, 2010
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A065521</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ROXANE	<u>500MG</u>	<u>A065413</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065451</u>	<u>001</u>	Oct 15, 2008
<u>AB</u>	STRIDES ARCOLAB LTD	<u>500MG</u>	<u>A090456</u>	<u>001</u>	Jun 10, 2010
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A065457</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>500MG</u>	<u>A065477</u>	<u>001</u>	May 04, 2009

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

+	ROCHE PALO	500MG/VIAL	N050758	001	Aug 12, 1998

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYFORTIC

	NOVARTIS	180MG	N050791	001	Feb 27, 2004
+		360MG	N050791	002	Feb 27, 2004

NABILONE

CAPSULE; ORAL

CESAMET

+	MEDA PHARMS	1MG	N018677	001	Dec 26, 1985

NABUMETONE

TABLET; ORAL

NABUMETONE

<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A079093</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>750MG</u>	<u>A079093</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>500MG</u>	<u>A078420</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>		<u>750MG</u>	<u>A078420</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>	INVAGEN PHARMS	<u>500MG</u>	<u>A078671</u>	<u>001</u>	Mar 07, 2008
<u>AB</u>		<u>750MG</u>	<u>A078671</u>	<u>002</u>	Mar 07, 2008
<u>AB</u>	MATRIX LABS LTD	<u>500MG</u>	<u>A090516</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>		<u>750MG</u>	<u>A090516</u>	<u>002</u>	Jul 12, 2010
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A076009</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>750MG</u>	<u>A076009</u>	<u>002</u>	Jan 24, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 290 (of 409)

NABUMETONE

TABLET; ORAL

NABUMETONE

<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075280</u>	<u>001</u>	Feb 25, 2002
<u>AB</u>		<u>750MG</u>	<u>A075280</u>	<u>002</u>	Feb 25, 2002
<u>AB</u>	TEVA	<u>500MG</u>	<u>A075189</u>	<u>001</u>	May 26, 2000
<u>AB</u>	+	<u>750MG</u>	<u>A075189</u>	<u>002</u>	Sep 24, 2001

NADOLOL

TABLET; ORAL

CORGARD

<u>AB</u>	KING PHARMS	<u>20MG</u>	<u>N018063</u>	<u>005</u>	Oct 28, 1986
<u>AB</u>		<u>40MG</u>	<u>N018063</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N018063</u>	<u>002</u>	

NADOLOL

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A074229</u>	<u>001</u>	Aug 30, 1996
<u>AB</u>		<u>40MG</u>	<u>A074229</u>	<u>002</u>	Aug 30, 1996
<u>AB</u>		<u>80MG</u>	<u>A074255</u>	<u>001</u>	Jan 24, 1996
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074172</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>40MG</u>	<u>A074172</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>		<u>80MG</u>	<u>A074172</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A074501</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>		<u>40MG</u>	<u>A074501</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>80MG</u>	<u>A074501</u>	<u>003</u>	Nov 09, 1995

NAFARELIN ACETATESPRAY, METERED; NASAL
SYNAREL

+	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	+	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062527</u>	<u>002</u>	Aug 02, 1984
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>A062732</u>	<u>001</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062527</u>	<u>003</u>	Aug 02, 1984
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062732</u>	<u>002</u>	Dec 23, 1986
		NAFCILLIN SODIUM				
	+	SANDOZ	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984
		NALLPEN IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+		EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	1%	N019599	001	Feb 29, 1988

GEL; TOPICAL

NAFTIN

+	MERZ PHARMS	1%	N019356	001	Jun 18, 1990

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>10MG/ML</u>	<u>A070914</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+		<u>10MG/ML</u>	<u>A070915</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+		<u>20MG/ML</u>	<u>A070916</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+		<u>20MG/ML</u>	<u>A070918</u>	<u>001</u>	Feb 03, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 291 (of 409)

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>0.4MG/ML</u>	<u>A070172</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070254</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070256</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070257</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>		INTL MEDICATION	<u>0.4MG/ML</u>	<u>A070639</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>	+		<u>1MG/ML</u>	<u>A072076</u>	<u>001</u>	Mar 24, 1988

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE AND NALOXONE HYDROCHLORIDE

<u>AB</u>		GAVIS PHARMS	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075735</u>	<u>001</u>	Jul 11, 2001
<u>PENTAZOCINE AND NALOXONE HYDROCHLORIDES</u>						
<u>AB</u>		RANBAXY	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075523</u>	<u>001</u>	Mar 17, 2000
<u>AB</u>	+	WATSON LABS	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A074736</u>	<u>001</u>	Jan 21, 1997

NALTREXONEFOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
VIVITROL

+	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

<u>AB</u>		BARR	<u>50MG</u>	<u>A074918</u>	<u>001</u>	May 08, 1998
<u>AB</u>		MALLINCKRODT	<u>50MG</u>	<u>A076264</u>	<u>002</u>	Mar 22, 2002
<u>AB</u>		MIKAH PHARMA	<u>50MG</u>	<u>A075274</u>	<u>001</u>	May 26, 1999
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A075434</u>	<u>001</u>	Mar 08, 2000
<u>REVIA</u>						
<u>AB</u>	+	DURAMED	<u>50MG</u>	<u>N018932</u>	<u>001</u>	Nov 20, 1984
<u>NALTREXONE HYDROCHLORIDE</u>						
		MALLINCKRODT	25MG	A076264	001	Mar 22, 2002
			100MG	A076264	003	Mar 22, 2002

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

+	PHARMAFORCE	200MG/ML	A091252	001	Aug 30, 2010

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

<u>AT</u>	+	ALLERGAN	<u>0.1%</u>	<u>A080248</u>	<u>001</u>	
<u>NAPHAZOLINE HYDROCHLORIDE</u>						
<u>AT</u>		TAYLOR	<u>0.1%</u>	<u>A083590</u>	<u>001</u>	

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

<u>AB</u>	+	ROCHE PALO	<u>25MG/ML</u>	<u>N018965</u>	<u>001</u>	Mar 23, 1987
<u>NAPROXEN</u>						
<u>AB</u>		ROXANE	<u>25MG/ML</u>	<u>A074190</u>	<u>001</u>	Mar 30, 1994

TABLET; ORAL

NAPROSYN

<u>AB</u>		ROCHE PALO	<u>250MG</u>	<u>N017581</u>	<u>002</u>	
<u>AB</u>			<u>375MG</u>	<u>N017581</u>	<u>003</u>	
<u>AB</u>	+		<u>500MG</u>	<u>N017581</u>	<u>004</u>	Apr 15, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 292 (of 409)

NAPROXEN

TABLET; ORAL

NAPROXEN

<u>AB</u>	AMNEAL PHARMS NY	<u>250MG</u>	<u>A075927</u>	<u>001</u>	Dec 18, 2001
<u>AB</u>		<u>375MG</u>	<u>A075927</u>	<u>002</u>	Dec 18, 2001
<u>AB</u>		<u>500MG</u>	<u>A075927</u>	<u>003</u>	Dec 18, 2001
<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A074410</u>	<u>001</u>	Apr 28, 1995
<u>AB</u>		<u>375MG</u>	<u>A074410</u>	<u>002</u>	Apr 28, 1995
<u>AB</u>		<u>500MG</u>	<u>A074410</u>	<u>003</u>	Apr 28, 1995
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A078250</u>	<u>001</u>	Mar 28, 2007
<u>AB</u>		<u>375MG</u>	<u>A078250</u>	<u>002</u>	Mar 28, 2007
<u>AB</u>		<u>500MG</u>	<u>A078250</u>	<u>003</u>	Mar 28, 2007
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A074121</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074121</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074121</u>	<u>003</u>	Dec 21, 1993
<u>AB</u>	PERRIGO R AND D	<u>250MG</u>	<u>A077339</u>	<u>001</u>	Apr 27, 2005
<u>AB</u>		<u>375MG</u>	<u>A077339</u>	<u>002</u>	Apr 27, 2005
<u>AB</u>		<u>500MG</u>	<u>A077339</u>	<u>003</u>	Apr 27, 2005
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A074140</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074140</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074140</u>	<u>003</u>	Dec 21, 1993
<u>AB</u>	TEVA	<u>250MG</u>	<u>A074201</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074201</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074201</u>	<u>003</u>	Dec 21, 1993
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A074457</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>375MG</u>	<u>A074457</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>500MG</u>	<u>A074457</u>	<u>003</u>	May 31, 1995
<u>AB</u>	WESTWARD	<u>250MG</u>	<u>A076494</u>	<u>001</u>	Jan 14, 2004
<u>AB</u>		<u>375MG</u>	<u>A076494</u>	<u>002</u>	Jan 14, 2004
<u>AB</u>		<u>500MG</u>	<u>A076494</u>	<u>003</u>	Jan 14, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>250MG</u>	<u>A078620</u>	<u>001</u>	Jun 07, 2007
<u>AB</u>		<u>375MG</u>	<u>A078620</u>	<u>002</u>	Jun 07, 2007
<u>AB</u>		<u>500MG</u>	<u>A078620</u>	<u>003</u>	Jun 07, 2007

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

<u>AB</u>	+ ROCHE PALO	<u>375MG</u>	<u>N020067</u>	<u>002</u>	Oct 14, 1994
<u>AB</u>	+	<u>500MG</u>	<u>N020067</u>	<u>003</u>	Oct 14, 1994

NAPROXEN

<u>AB</u>	ACTAVIS ELIZABETH	<u>375MG</u>	<u>A074936</u>	<u>001</u>	Feb 24, 1998
<u>AB</u>		<u>500MG</u>	<u>A074936</u>	<u>002</u>	Feb 24, 1998
<u>AB</u>	ALPHAPHARM	<u>375MG</u>	<u>A075390</u>	<u>001</u>	Apr 19, 2001
<u>AB</u>		<u>500MG</u>	<u>A075390</u>	<u>002</u>	Apr 19, 2001
<u>AB</u>	PLIVA	<u>375MG</u>	<u>A075337</u>	<u>001</u>	May 26, 1999
<u>AB</u>		<u>500MG</u>	<u>A075337</u>	<u>002</u>	May 26, 1999
<u>AB</u>	SANDOZ	<u>375MG</u>	<u>A075061</u>	<u>001</u>	Feb 18, 1998
<u>AB</u>		<u>500MG</u>	<u>A075061</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>	TEVA	<u>375MG</u>	<u>A075227</u>	<u>001</u>	Jun 30, 1998
<u>AB</u>		<u>500MG</u>	<u>A075227</u>	<u>002</u>	Jun 30, 1998

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

<u>AB</u>	ROCHE PALO	<u>EQ 250MG BASE</u>	<u>N018164</u>	<u>001</u>	
<u>AB</u>	<u>ANAPROX DS</u>				
<u>AB</u>	+ ROCHE PALO	<u>EQ 500MG BASE</u>	<u>N018164</u>	<u>003</u>	Sep 30, 1987
	<u>NAPROXEN SODIUM</u>				
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 250MG BASE</u>	<u>A078432</u>	<u>001</u>	Apr 25, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078432</u>	<u>002</u>	Apr 25, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486</u>	<u>001</u>	Jul 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078486</u>	<u>002</u>	Jul 26, 2007

PRESCRIPTION DRUG PRODUCT LIST

3 - 293 (of 409)

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

<u>AB</u>	GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078314</u>	<u>001</u>	Apr 27, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078314</u>	<u>002</u>	Apr 27, 2007
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A074480</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074480</u>	<u>001</u>	May 14, 1996
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A074198</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074198</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>	WATSON LABS	<u>EQ 250MG BASE</u>	<u>A074455</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074455</u>	<u>002</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

	STAT TRADE	EQ 375MG BASE	N020353	001	Jan 05, 1996
		EQ 500MG BASE	N020353	002	Jan 05, 1996
+		EQ 750MG BASE	N020353	003	Jan 05, 1996

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+	GLAXOSMITHKLINE	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 1MG BASE</u>	<u>N020763</u>	<u>002</u>	Feb 10, 1998
<u>AB</u>	+	<u>EQ 2.5MG BASE</u>	<u>N020763</u>	<u>001</u>	Feb 10, 1998
	<u>NARATRIPTAN</u>				
<u>AB</u>	PADDOCK LABS	<u>EQ 1MG BASE</u>	<u>A091326</u>	<u>001</u>	Jul 08, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091326</u>	<u>002</u>	Jul 08, 2010
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A090381</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090381</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A090288</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090288</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078751</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A078751</u>	<u>002</u>	Jul 07, 2010

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+	ALCON	5%	N050514	001	

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461</u>	<u>001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077461</u>	<u>002</u>	Sep 09, 2009
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A077463</u>	<u>001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077463</u>	<u>002</u>	Sep 09, 2009
<u>AB</u>	TEVA PHARMS	<u>60MG</u>	<u>A077467</u>	<u>001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077467</u>	<u>002</u>	Sep 09, 2009
	<u>STARLIX</u>				
<u>AB</u>	NOVARTIS	<u>60MG</u>	<u>N021204</u>	<u>001</u>	Dec 22, 2000
<u>AB</u>	+	<u>120MG</u>	<u>N021204</u>	<u>002</u>	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

	FOREST LABS	EQ 2.5MG BASE	N021742	002	Dec 17, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 294 (of 409)

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

FOREST LABS

EQ 5MG BASE

N021742 003 Dec 17, 2007

EQ 10MG BASE

N021742 004 Dec 17, 2007

+

EQ 20MG BASE

N021742 005 Oct 08, 2008

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL

+ ALLERGAN

2%

N021009 001 Dec 08, 1999

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDEAB RANBAXY50MGA076409 001 Sep 16, 2003AB100MGA076409 002 Sep 16, 2003AB150MGA076409 003 Sep 16, 2003AB200MGA076409 004 Sep 16, 2003AB250MGA076409 005 Sep 16, 2003AB

TEVA

50MGA076037 001 Sep 16, 2003AB100MGA076037 002 Sep 16, 2003AB150MGA076037 003 Sep 16, 2003AB200MGA076037 004 Sep 16, 2003AB

+

250MGA076037 005 Sep 16, 2003

NEFAZODONE HYDROCHLORIDE

BX DR REDDYS LABS INC

50MG

A076309 001 Sep 16, 2003

BX

100MG

A076309 002 Sep 16, 2003

BX

150MG

A076309 003 Sep 16, 2003

BX

200MG

A076309 004 Sep 16, 2003

BX

250MG

A076309 005 Sep 16, 2003

NELARABINE

INJECTABLE; IV (INFUSION)

+ SMITHKLINE BEECHAM

250MG/50ML (5MG/ML)

N021877 001 Oct 28, 2005

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

+ AGOURON

EQ 50MG BASE/SC00PFUL

N020778 001 Mar 14, 1997

TABLET; ORAL

VIRACEPT

+ AGOURON

EQ 250MG BASE

N020779 001 Mar 14, 1997

+

EQ 625MG BASE

N021503 001 Apr 30, 2003

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS

100%

A061579 001

SOLUTION; ORAL

NEO-FRADIN

+ X GEN PHARMS

EQ 87.5MG BASE/5ML

A065010 001 May 23, 2002

TABLET; ORAL

NEOMYCIN SULFATEAA OMAN PHARM PRODUCTS500MGA065468 001 Mar 29, 2010AA

+ TEVA

500MGA060304 001AA

X GEN PHARMS

500MGA065220 001 Jul 28, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 295 (of 409)

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

<u>AT</u>	WATSON LABS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A062664</u>	<u>001</u>	Apr 08, 1986
<u>AT</u>	X GEN PHARMS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A065106</u>	<u>001</u>	Jan 31, 2006
<u>AT</u>		<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A065108</u>	<u>001</u>	Jan 31, 2006
<u>NEOSPORIN G.U. IRRIGANT</u>					
<u>AT</u>	+ MONARCH PHARMS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A060707</u>	<u>001</u>	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

+	ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081	002	

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

+	ALCON	0.1%	N021862	001	Aug 19, 2005

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

+	SCIOS	1.5MG/VIAL	N020920	001	Aug 10, 2001

NEVIRAPINE

SUSPENSION; ORAL

VIRAMUNE

+	BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998

TABLET; ORAL

VIRAMUNE

+	BOEHRINGER INGELHEIM	200MG	N020636	001	Jun 21, 1996

NIACIN

TABLET; ORAL

NIACIN

<u>AA</u>	WOCKHARDT	<u>500MG</u>	<u>A081134</u>	<u>001</u>	Apr 28, 1992

NIACOR

<u>AA</u>	+ UPSHER SMITH	<u>500MG</u>	<u>A040378</u>	<u>001</u>	May 03, 2000

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

	ABBOTT	500MG	N020381	002	Jul 28, 1997

+		750MG	N020381	003	Jul 28, 1997

+		1GM	N020381	004	Jul 28, 1997

NIACIN; SIMVASTATIN

TABLET, EXTENDED RELEASE; ORAL

SIMCOR

+	ABBOTT	500MG;20MG	N022078	001	Feb 15, 2008

+		500MG;40MG	N022078	004	Jul 28, 2010

+		750MG;20MG	N022078	002	Feb 15, 2008

+		1GM;20MG	N022078	003	Feb 15, 2008

+		1GM;40MG	N022078	005	Jul 28, 2010

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

<u>AB</u>	EKR THERAP	<u>20MG</u>	<u>N019488</u>	<u>001</u>	Dec 21, 1988

<u>AB</u>	+	<u>30MG</u>	<u>N019488</u>	<u>002</u>	Dec 21, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 296 (of 409)

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>20MG</u>	<u>A074439</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>		<u>30MG</u>	<u>A074439</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>	EPIC PHARMA	<u>20MG</u>	<u>A074928</u>	<u>001</u>	Mar 19, 1998
<u>AB</u>		<u>30MG</u>	<u>A074928</u>	<u>002</u>	Mar 19, 1998
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074642</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>		<u>30MG</u>	<u>A074642</u>	<u>002</u>	Jul 18, 1996
<u>AB</u>	TEVA	<u>20MG</u>	<u>A074540</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>30MG</u>	<u>A074540</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A074670</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>30MG</u>	<u>A074670</u>	<u>002</u>	Oct 28, 1996

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

+	EKR THERAP	30MG	N020005	001	Feb 21, 1992
+		45MG	N020005	002	Feb 21, 1992
+		60MG	N020005	003	Feb 21, 1992

INJECTABLE; INJECTION

CARDENE

<u>AP</u>	+	EKR THERAP	<u>25MG/10ML (2.5MG/ML)</u>	<u>N019734</u>	<u>001</u>	Jan 30, 1992

NICARDIPINE HYDROCHLORIDE

<u>AP</u>		BEDFORD	<u>25MG/10ML (2.5MG/ML)</u>	<u>A078714</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>		BIONICHE PHARMA USA	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090664</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>		EXELA PHARMA SCIENCE	<u>25MG/10ML (2.5MG/ML)</u>	<u>N022276</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>		NAVINTA LLC	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090125</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>		PHARMAFORCE	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090534</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>		SUN PHARMA GLOBAL	<u>25MG/10ML (2.5MG/ML)</u>	<u>A078405</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>		WOCKHARDT	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090671</u>	<u>001</u>	Nov 17, 2009

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+	EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+	EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008

NICOTINE

INHALANT; ORAL

NICOTROL

+	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001	May 02, 1997

SPRAY, METERED; NASAL

NICOTROL

+	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072579</u>	<u>001</u>	Jan 08, 1991
<u>AB</u>	CATALENT	<u>10MG</u>	<u>A073250</u>	<u>001</u>	Oct 08, 1991
<u>AB</u>	INTERGEL PHARM	<u>10MG</u>	<u>A072781</u>	<u>001</u>	Jul 30, 1993

PROCARDIA

<u>AB</u>	+	PFIZER	<u>10MG</u>	<u>N018482</u>	<u>001</u>	
		NIFEDIPINE				
		ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 297 (of 409)

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

<u>AB1</u>	BAYER HLTHCARE	<u>30MG</u>	<u>N020198</u>	<u>001</u>	Apr 21, 1993
<u>AB1</u> +		<u>60MG</u>	<u>N020198</u>	<u>002</u>	Apr 21, 1993
<u>AB1</u> +		<u>90MG</u>	<u>N020198</u>	<u>003</u>	Apr 21, 1993

AFEDITAB CR

<u>AB1</u>	WATSON LABS	<u>30MG</u>	<u>A075128</u>	<u>001</u>	Mar 10, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075659</u>	<u>001</u>	Oct 26, 2001

NIFEDIPINE

<u>AB1</u>	ACTAVIS	<u>30MG</u>	<u>A077899</u>	<u>001</u>	Dec 13, 2006
<u>AB1</u>		<u>60MG</u>	<u>A077899</u>	<u>002</u>	Dec 13, 2006
<u>AB1</u>	BIOVAIL	<u>30MG</u>	<u>A075269</u>	<u>001</u>	Dec 04, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075269</u>	<u>002</u>	Dec 04, 2000
<u>AB1</u>		<u>90MG</u>	<u>A076070</u>	<u>001</u>	Aug 16, 2002
<u>AB1</u>	MYLAN	<u>30MG</u>	<u>A201071</u>	<u>001</u>	Dec 03, 2010
<u>AB1</u>		<u>60MG</u>	<u>A201071</u>	<u>002</u>	Dec 03, 2010
<u>AB1</u>		<u>90MG</u>	<u>A201071</u>	<u>003</u>	Dec 03, 2010

NIFEDIPINE

<u>AB2</u>	BIOVAIL	<u>30MG</u>	<u>A075289</u>	<u>002</u>	Feb 06, 2001
<u>AB2</u>		<u>60MG</u>	<u>A075289</u>	<u>001</u>	Sep 27, 2000
<u>AB2</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A090602</u>	<u>001</u>	Sep 13, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090602</u>	<u>002</u>	Sep 13, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090602</u>	<u>003</u>	Sep 13, 2010
<u>AB2</u>	MYLAN	<u>30MG</u>	<u>A090649</u>	<u>001</u>	Jun 21, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090649</u>	<u>002</u>	Jun 21, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090649</u>	<u>003</u>	Jun 21, 2010
<u>AB2</u>	OSMOTICA PHARM	<u>30MG</u>	<u>A077127</u>	<u>001</u>	Nov 21, 2005
<u>AB2</u>		<u>60MG</u>	<u>A077127</u>	<u>002</u>	Nov 21, 2005
<u>AB2</u>		<u>90MG</u>	<u>A077410</u>	<u>001</u>	Oct 03, 2007

PROCARDIA XL

<u>AB2</u>	PFIZER	<u>30MG</u>	<u>N019684</u>	<u>001</u>	Sep 06, 1989
<u>AB2</u>		<u>60MG</u>	<u>N019684</u>	<u>002</u>	Sep 06, 1989
<u>AB2</u> +		<u>90MG</u>	<u>N019684</u>	<u>003</u>	Sep 06, 1989

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL

TASIGNA

+	NOVARTIS	EQ 200MG BASE	N022068	001	Oct 29, 2007

NILUTAMIDE

TABLET; ORAL

NILANDRON

+	SANOFI AVENTIS US	150MG	N020169	002	Apr 30, 1999

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

<u>AB</u>	BANNER PHARMACAPS	<u>30MG</u>	<u>A076740</u>	<u>001</u>	Jan 17, 2008
<u>AB</u> +	BARR	<u>30MG</u>	<u>A077811</u>	<u>001</u>	May 02, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>30MG</u>	<u>A077067</u>	<u>001</u>	Apr 17, 2007

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

+	MYLAN	20MG	A079051	001	Jul 25, 2008
+		30MG	A079051	002	Jul 25, 2008
+		40MG	A079051	003	Jul 25, 2008
	SULAR				
+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 298 (of 409)

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
SULAR

+ SHIONOGI PHARMA	17MG	N020356 007	Jan 02, 2008
	25.5MG	N020356 006	Jan 02, 2008
+	34MG	N020356 005	Jan 02, 2008

NITAZOXANIDE

FOR SUSPENSION; ORAL
ALINIA

+ ROMARK	100MG/5ML	N021498 001	Nov 22, 2002

TABLET; ORAL
ALINIA

+ ROMARK	500MG	N021497 001	Jul 21, 2004

NITISINONE

CAPSULE; ORAL
ORFADIN

RARE DIS	2MG	N021232 001	Jan 18, 2002
	5MG	N021232 002	Jan 18, 2002
+	10MG	N021232 003	Jan 18, 2002

NITRIC OXIDE

GAS; INHALATION
INOMAX

INO	100PPM	N020845 002	Dec 23, 1999
+	800PPM	N020845 003	Dec 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL
FURADANTIN

+ SHIONOGI PHARMA	25MG/5ML	N009175 001	

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACRODANTIN

<u>AB</u>	ALVOGEN	<u>25MG</u>	<u>N016620 003</u>	
<u>AB</u>		<u>50MG</u>	<u>N016620 001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N016620 002</u>	

NITROFURANTOIN

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A073671 001</u>	Jan 28, 1993
<u>AB</u>		<u>100MG</u>	<u>A073652 001</u>	Jan 28, 1993
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A074967 001</u>	Jul 09, 1997
<u>AB</u>		<u>100MG</u>	<u>A077025 001</u>	Aug 18, 2004
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A073696 001</u>	Dec 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A073696 002</u>	Dec 31, 1992
<u>AB</u>		<u>100MG</u>	<u>A073696 003</u>	Dec 31, 1992

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACROBID

<u>AB</u>	+ ALVOGEN	<u>75MG;25MG</u>	<u>N020064 001</u>	Dec 24, 1991
	<u>NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)</u>			
<u>AB</u>	MYLAN	<u>75MG;25MG</u>	<u>A076648 001</u>	Mar 22, 2004
<u>AB</u>	RANBAXY	<u>75MG;25MG</u>	<u>A076951 001</u>	Mar 30, 2005
<u>AB</u>	SANDOZ	<u>75MG;25MG</u>	<u>A077066 001</u>	Apr 05, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 299 (of 409)

NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL				
NITROMIST				
+	NOVADEL	0.4MG/SPRAY	N021780 001	Nov 02, 2006
FILM, EXTENDED RELEASE; TRANSDERMAL				
<u>MINITRAN</u>				
<u>AB1</u>	GRACEWAY	<u>0.1MG/HR</u>	<u>A089771 001</u>	Aug 30, 1996
<u>AB1</u>		<u>0.2MG/HR</u>	<u>A089772 001</u>	Aug 30, 1996
<u>AB1</u>		<u>0.4MG/HR</u>	<u>A089773 001</u>	Aug 30, 1996
<u>AB1</u>		<u>0.6MG/HR</u>	<u>A089774 001</u>	Aug 30, 1996
<u>NITRO-DUR</u>				
<u>AB1</u> +	KEY PHARMS	<u>0.1MG/HR</u>	<u>N020145 001</u>	Apr 04, 1995
<u>AB1</u> +		<u>0.2MG/HR</u>	<u>N020145 002</u>	Apr 04, 1995
<u>AB1</u> +		<u>0.4MG/HR</u>	<u>N020145 004</u>	Apr 04, 1995
<u>AB1</u> +		<u>0.6MG/HR</u>	<u>N020145 005</u>	Apr 04, 1995
<u>NITROGLYCERIN</u>				
<u>AB1</u>	KREMERS URBAN PHARMS	<u>0.2MG/HR</u>	<u>A075115 001</u>	Aug 10, 2004
<u>AB1</u>		<u>0.4MG/HR</u>	<u>A075115 002</u>	Aug 10, 2004
<u>NITROGLYCERIN</u>				
<u>AB2</u>	HERCON LABS	<u>0.2MG/HR</u>	<u>A089884 001</u>	Oct 30, 1998
<u>AB2</u>		<u>0.4MG/HR</u>	<u>A089885 001</u>	Oct 30, 1998
<u>AB2</u>		<u>0.6MG/HR</u>	<u>A089886 001</u>	Oct 30, 1998
<u>AB2</u> +	MYLAN TECHNOLOGIES	<u>0.2MG/HR</u>	<u>A074559 003</u>	Aug 30, 1996
<u>AB2</u> +		<u>0.4MG/HR</u>	<u>A074559 002</u>	Aug 30, 1996
<u>AB2</u> +		<u>0.6MG/HR</u>	<u>A074559 001</u>	Aug 30, 1996
NITRO-DUR				
+	KEY PHARMS	0.3MG/HR	N020145 003	Apr 04, 1995
+		0.8MG/HR	N020145 006	Apr 04, 1995
NITROGLYCERIN				
+	MYLAN TECHNOLOGIES	0.1MG/HR	A074559 004	Feb 06, 1998
INJECTABLE; INJECTION				
<u>NITROGLYCERIN</u>				
<u>AP</u> +	HOSPIRA	<u>5MG/ML</u>	<u>N018531 001</u>	
<u>AP</u> +	LUITPOLD	<u>5MG/ML</u>	<u>A072034 001</u>	May 24, 1988
<u>NITROGLYCERIN IN DEXTROSE 5%</u>				
<u>AP</u> +	BAXTER HLTHCARE	<u>10MG/100ML</u>	<u>N019970 001</u>	Dec 29, 1989
<u>AP</u> +		<u>20MG/100ML</u>	<u>N019970 002</u>	Dec 29, 1989
<u>AP</u> +		<u>40MG/100ML</u>	<u>N019970 003</u>	Dec 29, 1989
<u>AP</u>	HOSPIRA	<u>10MG/100ML</u>	<u>A071846 001</u>	Aug 31, 1990
<u>AP</u>		<u>20MG/100ML</u>	<u>A071847 001</u>	Aug 31, 1990
<u>AP</u>		<u>40MG/100ML</u>	<u>A071848 001</u>	Aug 31, 1990
OINTMENT; TRANSDERMAL				
NITROGLYCERIN				
+	FOUGERA	2%	A087355 001	Jul 08, 1988
SPRAY, METERED; SUBLINGUAL				
NITROLINGUAL PUMPSPRAY				
+	POHL BOSKAMP	0.4MG/SPRAY	N018705 002	Jan 10, 1997
TABLET; SUBLINGUAL				
NITROSTAT				
	PFIZER PHARMS	0.3MG	N021134 001	May 01, 2000
		0.4MG	N021134 002	May 01, 2000
+		0.6MG	N021134 003	May 01, 2000

NIZATIDINE

CAPSULE; ORAL				
<u>AXID</u>				
<u>AB</u>	SMITHKLINE BEECHAM	<u>150MG</u>	<u>N019508 001</u>	Apr 12, 1988
<u>AB</u> +		<u>300MG</u>	<u>N019508 002</u>	Apr 12, 1988

PRESCRIPTION DRUG PRODUCT LIST

3 - 300 (of 409)

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

<u>AB</u>	APOTEX	<u>150MG</u>	<u>A076383</u>	<u>001</u>	Jan 23, 2003
<u>AB</u>		<u>300MG</u>	<u>A076383</u>	<u>002</u>	Jan 23, 2003
<u>AB</u>	DR REDDYS LABS LTD	<u>150MG</u>	<u>A077314</u>	<u>001</u>	Sep 15, 2005
<u>AB</u>		<u>300MG</u>	<u>A077314</u>	<u>002</u>	Sep 15, 2005
<u>AB</u>	GENPHARM	<u>150MG</u>	<u>A075934</u>	<u>001</u>	Jul 09, 2002
<u>AB</u>		<u>300MG</u>	<u>A075934</u>	<u>002</u>	Jul 09, 2002
<u>AB</u>	MYLAN	<u>150MG</u>	<u>A075806</u>	<u>001</u>	Jul 05, 2002
<u>AB</u>		<u>300MG</u>	<u>A075806</u>	<u>002</u>	Jul 05, 2002
<u>AB</u>	SANDOZ	<u>150MG</u>	<u>A076178</u>	<u>001</u>	Jul 05, 2002
<u>AB</u>		<u>300MG</u>	<u>A076178</u>	<u>002</u>	Jul 05, 2002
<u>AB</u>	TEVA	<u>150MG</u>	<u>A075668</u>	<u>001</u>	Sep 12, 2002
<u>AB</u>		<u>300MG</u>	<u>A075668</u>	<u>002</u>	Sep 12, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075616</u>	<u>001</u>	Jul 09, 2002
<u>AB</u>		<u>300MG</u>	<u>A075616</u>	<u>002</u>	Jul 09, 2002

SOLUTION; ORAL

AXID

<u>AA</u>	+ BRAINTREE	<u>15MG/ML</u>	<u>N021494</u>	<u>001</u>	May 25, 2004
	<u>NIZATIDINE</u>				
<u>AA</u>	AMNEAL PHARMS	<u>15MG/ML</u>	<u>A090576</u>	<u>001</u>	Nov 18, 2009

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

<u>AP</u>	+ HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>N007513</u>	<u>001</u>	
	<u>NOREPINEPHRINE BITARTRATE</u>				
<u>AP</u>	BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A040462</u>	<u>001</u>	Oct 31, 2003
<u>AP</u>	TEVA PARENTERAL	<u>EQ 1MG BASE/ML</u>	<u>A040455</u>	<u>001</u>	Mar 03, 2003

NORETHINDRONE

TABLET; ORAL-28

CAMILA

<u>AB1</u>	BARR	<u>0.35MG</u>	<u>A076177</u>	<u>001</u>	Oct 21, 2002
	<u>HEATHER</u>				
<u>AB1</u>	GLENMARK GENERICS	<u>0.35MG</u>	<u>A090454</u>	<u>001</u>	Apr 23, 2010
	<u>NOR-QD</u>				
<u>AB1</u>	+ WATSON LABS (UTAH)	<u>0.35MG</u>	<u>N017060</u>	<u>001</u>	
	<u>ERRIN</u>				
<u>AB2</u>	BARR	<u>0.35MG</u>	<u>A076225</u>	<u>001</u>	Oct 21, 2002
	<u>MICRONOR</u>				
<u>AB2</u>	+ ORTHO MCNEIL JANSSEN	<u>0.35MG</u>	<u>N016954</u>	<u>001</u>	
	<u>NORETHIDRONE</u>				
<u>AB2</u>	GLENMARK GENERICS	<u>0.35MG</u>	<u>A091209</u>	<u>001</u>	Jul 21, 2010

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

<u>AB</u>	+ DURAMED RES	<u>5MG</u>	<u>N018405</u>	<u>001</u>	Apr 21, 1982
	<u>NORETHINDRONE ACETATE</u>				
<u>AB</u>	BARR	<u>5MG</u>	<u>A075951</u>	<u>001</u>	May 25, 2001
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A091090</u>	<u>001</u>	Jul 21, 2010

NORFLOXACIN

TABLET; ORAL

NOROXIN

	+ MERCK	400MG	N019384	002	Oct 31, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 301 (of 409)

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A074234</u>	<u>001</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074234</u>	<u>002</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074234</u>	<u>003</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074234</u>	<u>004</u>	Jul 26, 1993
<u>AB</u>	TARO	<u>EQ 10MG BASE</u>	<u>A075520</u>	<u>004</u>	May 08, 2000
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A075520</u>	<u>003</u>	May 08, 2000
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A075520</u>	<u>001</u>	May 08, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A075520</u>	<u>002</u>	May 08, 2000
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A074132</u>	<u>001</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074132</u>	<u>002</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074132</u>	<u>003</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074132</u>	<u>004</u>	Mar 27, 1995
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A073553</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A073554</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A073555</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A073556</u>	<u>001</u>	Mar 30, 1992
<u>PAMELOR</u>					
<u>AB</u>	TYCO HLTHCARE	<u>EQ 10MG BASE</u>	<u>N018013</u>	<u>001</u>	
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N018013</u>	<u>002</u>	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N018013</u>	<u>004</u>	
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N018013</u>	<u>003</u>	

SOLUTION; ORAL

AVENTYL HYDROCHLORIDE

<u>AA</u>	+	RANBAXY	<u>EQ 10MG BASE/5ML</u>	<u>N014685</u>	<u>001</u>

NORTRIPTYLINE HYDROCHLORIDE

<u>AA</u>	<u>PHARM ASSOC</u>	<u>EQ 10MG BASE/5ML</u>	<u>A075606</u>	<u>001</u>	Aug 28, 2000
<u>AA</u>	<u>TARO</u>	<u>EQ 10MG BASE/5ML</u>	<u>A077965</u>	<u>001</u>	Jun 20, 2006
<u>PAMELOR</u>					
<u>AA</u>	<u>TYCO HLTHCARE</u>	<u>EQ 10MG BASE/5ML</u>	<u>N018012</u>	<u>001</u>	

NYSTATIN

CREAM; TOPICAL

MYCOSTATIN

<u>AT</u>	+	BRISTOL MYERS SQUIBB	<u>100,000 UNITS/GM</u>	<u>A060575</u>	<u>001</u>

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062949</u>	<u>001</u>	Jun 13, 1988
<u>AT</u>		ALTANA	<u>100,000 UNITS/GM</u>	<u>A062129</u>	<u>001</u>	
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062225</u>	<u>001</u>	
<u>AT</u>		TARO	<u>100,000 UNITS/GM</u>	<u>A064022</u>	<u>001</u>	Jan 29, 1993
<u>AT</u>		VINTAGE	<u>100,000 UNITS/GM</u>	<u>A065315</u>	<u>001</u>	May 31, 2006

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062840</u>	<u>001</u>	Nov 13, 1987
<u>AT</u>	+	ALTANA	<u>100,000 UNITS/GM</u>	<u>A062124</u>	<u>002</u>	Sep 23, 1982
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472</u>	<u>001</u>	Feb 13, 1984

POWDER; TOPICAL

MYCOSTATIN

<u>AT</u>	+	BRISTOL MYERS SQUIBB	<u>100,000 UNITS/GM</u>	<u>A060578</u>	<u>001</u>

NYSTATIN

<u>AT</u>	COASTAL PHARMS	<u>100,000 UNITS/GM</u>	<u>A065203</u>	<u>001</u>	Jul 15, 2004
<u>AT</u>	KV PHARM	<u>100,000 UNITS/GM</u>	<u>A065321</u>	<u>001</u>	Aug 18, 2006
<u>AT</u>	PAR PHARM	<u>100,000 UNITS/GM</u>	<u>A065138</u>	<u>001</u>	Jul 23, 2004
<u>AT</u>	UPSHER SMITH	<u>100,000 UNITS/GM</u>	<u>A065183</u>	<u>001</u>	May 03, 2005
<u>AT</u>	X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175</u>	<u>001</u>	Dec 17, 2004
<u>NYSTOP</u>					
<u>AT</u>	PADDOCK	<u>100,000 UNITS/GM</u>	<u>A064118</u>	<u>001</u>	Aug 16, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 302 (of 409)

NYSTATIN

SUSPENSION; ORAL

NILSTAT

<u>AA</u>	+ GLENMARK GENERICS	<u>100,000 UNITS/ML</u>	<u>N050299</u>	<u>001</u>	

NYSTATIN

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/ML</u>	<u>A062349</u>	<u>001</u>	Jul 14, 1982
<u>AA</u>	BAUSCH AND LOMB	<u>100,000 UNITS/ML</u>	<u>A064042</u>	<u>001</u>	Feb 28, 1994
<u>AA</u>	FOUGERA	<u>100,000 UNITS/ML</u>	<u>A062517</u>	<u>001</u>	Jun 07, 1984
<u>AA</u>	TARO	<u>100,000 UNITS/ML</u>	<u>A062876</u>	<u>001</u>	Feb 29, 1988
<u>AA</u>	VINTAGE PHARMS	<u>100,000 UNITS/ML</u>	<u>A065148</u>	<u>001</u>	Jun 28, 2005
<u>AA</u>	VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142</u>	<u>001</u>	Jun 25, 1998
<u>AA</u>	+ WOCHKHARDT	<u>100,000 UNITS/ML</u>	<u>A062512</u>	<u>001</u>	Oct 29, 1984

TABLET; ORAL

NYSTATIN

<u>AA</u>	MUTUAL PHARM	<u>500,000 UNITS</u>	<u>A062838</u>	<u>001</u>	Dec 22, 1988
<u>AA</u>	+ TEVA	<u>500,000 UNITS</u>	<u>A062506</u>	<u>001</u>	Jan 16, 1984

TABLET; VAGINAL

NYSTATIN

	+ ODYSSEY PHARMS	<u>100,000 UNITS</u>	<u>A062615</u>	<u>001</u>	Oct 17, 1985

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062367</u>	<u>001</u>	May 28, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062599</u>	<u>001</u>	Oct 08, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A062364</u>	<u>001</u>	Dec 22, 1987

OINTMENT; TOPICAL

MYKACET

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062733</u>	<u>001</u>	Mar 09, 1987

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062602</u>	<u>001</u>	Oct 09, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A063305</u>	<u>001</u>	Mar 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	APP PHARMS	<u>EQ 0.2MG BASE/ML</u>	<u>A077450</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>	+ BEDFORD	<u>EQ 0.2MG BASE/ML</u>	<u>A076330</u>	<u>001</u>	Apr 08, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A076330</u>	<u>002</u>	Apr 08, 2005
<u>AP</u>	SUN PHARM INDS	<u>EQ 0.05MG BASE/ML</u>	<u>A077329</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.05MG BASE/ML</u>	<u>A077372</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077329</u>	<u>002</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077372</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077330</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077373</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077329</u>	<u>003</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077372</u>	<u>003</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077331</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077373</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>	TEVA PARENTERAL	<u>EQ 0.05MG BASE/ML</u>	<u>A075957</u>	<u>001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957</u>	<u>002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959</u>	<u>001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957</u>	<u>003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959</u>	<u>002</u>	Nov 21, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	APP PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A077457</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457</u>	<u>002</u>	Feb 10, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 303 (of 409)

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	APP PHARMS	<u>EQ 0.5MG BASE/ML</u>	<u>A077457</u>	<u>003</u>	Feb 10, 2006
<u>AP</u>	+ BEDFORD	<u>EQ 0.05MG BASE/ML</u>	<u>A076313</u>	<u>001</u>	Mar 28, 2005
<u>AP</u>	+	<u>EQ 0.1MG BASE/ML</u>	<u>A076313</u>	<u>003</u>	Mar 28, 2005
<u>AP</u>	+	<u>EQ 0.5MG BASE/ML</u>	<u>A076313</u>	<u>002</u>	Mar 28, 2005
<u>SANDOSTATIN</u>					
<u>AP</u>	+ NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667</u>	<u>001</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.1MG BASE/ML</u>	<u>N019667</u>	<u>002</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.2MG BASE/ML</u>	<u>N019667</u>	<u>004</u>	Jun 12, 1991
<u>AP</u>	+	<u>EQ 0.5MG BASE/ML</u>	<u>N019667</u>	<u>003</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 1MG BASE/ML</u>	<u>N019667</u>	<u>005</u>	Jun 12, 1991
<u>SANDOSTATIN LAR</u>					
	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998
		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998
	+	EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

<u>AT</u>	+ ALLERGAN	<u>0.3%</u>	<u>N019921</u>	<u>001</u>	Jul 30, 1993
<u>OFLOXACIN</u>					
<u>AT</u>	AKORN	<u>0.3%</u>	<u>A076407</u>	<u>001</u>	Apr 15, 2008
<u>AT</u>	ALCON	<u>0.3%</u>	<u>A076231</u>	<u>001</u>	May 14, 2004
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622</u>	<u>001</u>	May 14, 2004
<u>AT</u>	FDC LTD	<u>0.3%</u>	<u>A078559</u>	<u>001</u>	Feb 25, 2009
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076615</u>	<u>001</u>	May 14, 2004
<u>AT</u>	LUITPOLD	<u>0.3%</u>	<u>A076830</u>	<u>001</u>	Aug 31, 2004
<u>AT</u>	NOVEX	<u>0.3%</u>	<u>A076513</u>	<u>001</u>	May 14, 2004
<u>AT</u>	SANDOZ	<u>0.3%</u>	<u>A076848</u>	<u>001</u>	Nov 25, 2008

SOLUTION/DROPS; OTIC

FLOXIN OTIC

<u>AT</u>	+ DAIICHI	<u>0.3%</u>	<u>N020799</u>	<u>001</u>	Dec 16, 1997
<u>OFLOXACIN</u>					
<u>AT</u>	ALCON	<u>0.3%</u>	<u>A078222</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	APOTEX INC	<u>0.3%</u>	<u>A076527</u>	<u>001</u>	Sep 28, 2007
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076616</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	LUITPOLD	<u>0.3%</u>	<u>A090395</u>	<u>001</u>	Aug 11, 2009

TABLET; ORAL

OFLOXACIN

<u>AB</u>	DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098</u>	<u>001</u>	Feb 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077098</u>	<u>002</u>	Feb 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077098</u>	<u>003</u>	Feb 10, 2006
<u>AB</u>	RANBAXY	<u>200MG</u>	<u>A076220</u>	<u>001</u>	Sep 02, 2003
<u>AB</u>		<u>300MG</u>	<u>A076220</u>	<u>002</u>	Sep 02, 2003
<u>AB</u>		<u>400MG</u>	<u>A076220</u>	<u>003</u>	Sep 02, 2003
<u>AB</u>	TEVA	<u>200MG</u>	<u>A076182</u>	<u>001</u>	Sep 02, 2003
<u>AB</u>		<u>300MG</u>	<u>A076182</u>	<u>002</u>	Sep 02, 2003
<u>AB</u>	+	<u>400MG</u>	<u>A076182</u>	<u>003</u>	Sep 02, 2003

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

ZYPREXA

	+ LILLY	10MG/VIAL	N021253	001	Mar 29, 2004

TABLET; ORAL

ZYPREXA

	LILLY	2.5MG	N020592	001	Sep 30, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 305 (of 409)

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A078693</u>	<u>002</u>	Mar 16, 2009
<u>AB</u>		<u>40MG</u>	<u>A075576</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A075785</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A075785</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A075785</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	KREMERS URBAN PHARMS	<u>10MG</u>	<u>A075410</u>	<u>001</u>	Nov 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075410</u>	<u>002</u>	Nov 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075410</u>	<u>003</u>	Jan 23, 2009
<u>AB</u>	LEK PHARMS	<u>10MG</u>	<u>A075757</u>	<u>001</u>	Jan 28, 2003
<u>AB</u>		<u>20MG</u>	<u>A075757</u>	<u>002</u>	Jan 28, 2003
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075876</u>	<u>001</u>	May 29, 2003
<u>AB</u>		<u>20MG</u>	<u>A075876</u>	<u>002</u>	May 29, 2003
<u>AB</u>		<u>40MG</u>	<u>A075876</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	SANDOZ	<u>40MG</u>	<u>A076515</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG</u>	<u>A075347</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A075347</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A075347</u>	<u>003</u>	May 30, 2008
<u>PRILOSEC</u>					
<u>AB</u>	ASTRAZENECA	<u>10MG</u>	<u>N019810</u>	<u>003</u>	Oct 05, 1995
<u>AB</u>	+	<u>20MG</u>	<u>N019810</u>	<u>001</u>	Sep 14, 1989
<u>AB</u>	+	<u>40MG</u>	<u>N019810</u>	<u>002</u>	Jan 15, 1998

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PRILOSEC

	ASTRAZENECA	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	PAR PHARM	<u>20MG;1.1GM</u>	<u>A078966</u>	<u>001</u>	May 25, 2010
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A078966</u>	<u>002</u>	May 25, 2010
<u>ZEGERID</u>					
<u>AB</u>	SANTARUS	<u>20MG;1.1GM</u>	<u>N021849</u>	<u>001</u>	Feb 27, 2006
<u>AB</u>	+	<u>40MG;1.1GM</u>	<u>N021849</u>	<u>002</u>	Feb 27, 2006

FOR SUSPENSION; ORAL

ZEGERID

	SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004
+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004

ONDANSETRON

FILM; ORAL

ZUPLENZ

	PAR PHARM	4MG	N022524	001	Jul 02, 2010
+		8MG	N022524	002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

<u>AB</u>	AUROBINDO PHARMA	<u>4MG</u>	<u>A090469</u>	<u>001</u>	Apr 12, 2010
<u>AB</u>		<u>8MG</u>	<u>A090469</u>	<u>002</u>	Apr 12, 2010
<u>AB</u>	BARR	<u>4MG</u>	<u>A076693</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076693</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	GLENMARK GENERICS	<u>4MG</u>	<u>A078152</u>	<u>001</u>	Jun 27, 2007
<u>AB</u>		<u>8MG</u>	<u>A078152</u>	<u>002</u>	Jun 27, 2007
<u>AB</u>	KV PHARM	<u>4MG</u>	<u>A077717</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A077717</u>	<u>002</u>	Jun 25, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 306 (of 409)

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

<u>AB</u>	MYLAN	<u>4MG</u>	<u>A078139</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A078139</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	PAR PHARM	<u>4MG</u>	<u>A076506</u>	<u>001</u>	Dec 26, 2006
<u>AB</u>		<u>8MG</u>	<u>A076506</u>	<u>002</u>	Dec 26, 2006
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078050</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>		<u>8MG</u>	<u>A078050</u>	<u>002</u>	Aug 13, 2007
<u>AB</u>	SUN PHARM INDS	<u>4MG</u>	<u>A077557</u>	<u>001</u>	Aug 02, 2007
<u>AB</u>		<u>8MG</u>	<u>A077557</u>	<u>002</u>	Aug 02, 2007
<u>AB</u>	TEVA	<u>4MG</u>	<u>A076810</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076810</u>	<u>002</u>	Jun 25, 2007
	<u>ZOFRAN ODT</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>4MG</u>	<u>N020781</u>	<u>001</u>	Jan 27, 1999
<u>AB</u>	+	<u>8MG</u>	<u>N020781</u>	<u>002</u>	Jan 27, 1999
	ONDANSETRON				
	PAR PHARM	16MG	A077406	001	Dec 26, 2006
		24MG	A077406	002	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>	AKORN STRIDES	<u>EQ 2MG BASE/ML</u>	<u>A078257</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>	APOTEX	<u>EQ 2MG BASE/ML</u>	<u>A077368</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	APP PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A076974</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A077365</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	BEDFORD	<u>EQ 2MG BASE/ML</u>	<u>A076967</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	EMCURE PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A090424</u>	<u>001</u>	Apr 16, 2010
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A079224</u>	<u>001</u>	Sep 25, 2009
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076781</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077473</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077840</u>	<u>001</u>	Jan 19, 2007
<u>AP</u>	LANNETT	<u>EQ 2MG BASE/ML</u>	<u>A090116</u>	<u>001</u>	Apr 14, 2010
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A090883</u>	<u>001</u>	Aug 05, 2010
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A077582</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A079039</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	PLIVA HRVATSKA DOO	<u>EQ 2MG BASE/ML</u>	<u>A077544</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077430</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	SPECTRUM PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A078180</u>	<u>001</u>	Mar 26, 2007
<u>AP</u>	SUN PHARM INDS (IN)	<u>EQ 2MG BASE/ML</u>	<u>A077172</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077577</u>	<u>001</u>	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

<u>AP</u>	BEDFORD LABS	<u>EQ 0.64MG BASE/ML</u>	<u>A078291</u>	<u>001</u>	Apr 13, 2009
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 0.64MG BASE/ML</u>	<u>A078308</u>	<u>001</u>	Mar 17, 2008
<u>AP</u>	HOSPIRA	<u>EQ 0.64MG BASE/ML</u>	<u>A077348</u>	<u>001</u>	Feb 01, 2007
<u>AP</u>	TEVA PARENTERAL	<u>EQ 0.64MG BASE/ML</u>	<u>A077480</u>	<u>001</u>	Nov 22, 2006

ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 0.64MG BASE/ML</u>	<u>N021915</u>	<u>002</u>	Dec 27, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AKORN STRIDES	<u>EQ 2MG BASE/ML</u>	<u>A078244</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>	APOTEX INC	<u>EQ 2MG BASE/ML</u>	<u>A077343</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	APP PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A076972</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A077541</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	BEDFORD LABS	<u>EQ 2MG BASE/ML</u>	<u>A077011</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076780</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A077387</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A079032</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077551</u>	<u>001</u>	Jun 27, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 307 (of 409)

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A077173</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	TARO PHARMS IRELAND	<u>EQ 2MG BASE/ML</u>	<u>A078014</u>	<u>001</u>	Mar 21, 2008
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716</u>	<u>001</u>	Dec 26, 2006

ZOFRAN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>001</u>	Jan 04, 1991

ZOFRAN PRESERVATIVE FREE

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>003</u>	Dec 10, 1993

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	APOTEX	<u>EQ 4MG BASE/5ML</u>	<u>A078127</u>	<u>001</u>	Jun 25, 2007
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	ROXANE	<u>EQ 4MG BASE/5ML</u>	<u>A076960</u>	<u>001</u>	Dec 26, 2006
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009</u>	<u>001</u>	Nov 30, 2007

ZOFRAN

<u>AA</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/5ML</u>	<u>N020605</u>	<u>001</u>	Jan 24, 1997

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539</u>	<u>001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539</u>	<u>002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539</u>	<u>003</u>	Jul 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183</u>	<u>003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183</u>	<u>002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183</u>	<u>001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A076930</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076930</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076930</u>	<u>004</u>	Jun 25, 2007
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	PAR PHARM	<u>EQ 4MG BASE</u>	<u>A077303</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077303</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077303</u>	<u>004</u>	Jun 25, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	<u>A077112</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077112</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077112</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077517</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076252</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	WEST WARD	<u>EQ 4MG BASE</u>	<u>A077545</u>	<u>001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077545</u>	<u>002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077545</u>	<u>003</u>	Sep 06, 2007

ZOFRAN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 4MG BASE</u>	<u>N020103</u>	<u>001</u>	Dec 31, 1992
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N020103</u>	<u>002</u>	Dec 31, 1992
<u>AB</u>	+	<u>EQ 24MG BASE</u>	<u>N020103</u>	<u>003</u>	Aug 27, 1999

ONDANSETRON HYDROCHLORIDE

	DR REDDYS LABS LTD	<u>EQ 16MG BASE</u>	<u>A076559</u>	<u>001</u>	Dec 26, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 308 (of 409)

ORLISTATCAPSULE; ORAL
XENICAL

+ HOFFMANN LA ROCHE 120MG N020766 001 Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

AP + GRACEWAY 30MG/ML N013055 001

ORPHENADRINE CITRATE

AP AKORN 30MG/ML A040484 001 May 24, 2006

AP BEDFORD LABS 30MG/ML A040463 001 Mar 04, 2003

AP WATSON LABS 30MG/ML A084779 001 Mar 15, 1982

AP 30MG/ML A087062 001

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB GAVIS PHARMS 100MG A040284 001 Jun 19, 1998

AB IMPAX PHARMS 100MG A040368 001 Jun 23, 2000

AB KIEL 100MG A040249 001 Jan 29, 1999

AB + SANDOZ 100MG A040327 001 Feb 15, 2000

OSELTAMIVIR PHOSPHATECAPSULE; ORAL
TAMIFLU

ROCHE EQ 30MG BASE N021087 003 Jul 02, 2007

EQ 45MG BASE N021087 002 Jul 02, 2007

+ EQ 75MG BASE N021087 001 Oct 27, 1999

FOR SUSPENSION; ORAL

TAMIFLU

+ ROCHE EQ 12MG BASE/ML N021246 001 Dec 14, 2000

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP + SANDOZ EQ 1GM BASE/VIAL A061490 003

AP EQ 1GM BASE/VIAL A062737 001 Dec 23, 1986

AP + EQ 2GM BASE/VIAL A061490 004

AP EQ 2GM BASE/VIAL A062737 002 Dec 23, 1986

AP + EQ 10GM BASE/VIAL A061490 006 May 09, 1991

BACTOCILL IN PLASTIC CONTAINER

+ BAXTER HLTHCARE EQ 20MG BASE/ML N050640 001 Oct 26, 1989

+ EQ 40MG BASE/ML N050640 002 Oct 26, 1989

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

AP + SANOFI AVENTIS US 50MG/10ML (5MG/ML) N021759 001 Jan 31, 2005

AP + 100MG/20ML (5MG/ML) N021759 002 Jan 31, 2005

OXALIPLATIN

AP APP PHARMS 50MG/VIAL A078819 001 Jun 02, 2010

AP 100MG/VIAL A078819 002 Jun 02, 2010

AP EBEWE PHARMA 50MG/10ML (5MG/ML) A078812 001 Aug 07, 2009

AP 100MG/20ML (5MG/ML) A078812 002 Aug 07, 2009

AP FRESENIUS KABI ONCOL 100MG/20ML (5MG/ML) A078811 002 Jun 10, 2010

AP 50MG/10ML (5MG/ML) A078811 001 Jun 10, 2010

AP 50MG/VIAL A078810 001 Aug 07, 2009

AP 100MG/VIAL A078810 002 Aug 07, 2009

AP + HOSPIRA INC 50MG/VIAL A078815 001 Sep 30, 2009

AP + 100MG/VIAL A078815 002 Sep 30, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 309 (of 409)

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

<u>AP</u>	HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078813</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	SUN PHARMA GLOBAL	<u>50MG/VIAL</u>	<u>A078818</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078818</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	TEVA PARENTERAL	<u>50MG/10ML (5MG/ML)</u>	<u>N022160</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>N022160</u>	<u>002</u>	Aug 07, 2009
	ELOXATIN				
	+ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006

OXANDROLONE

TABLET; ORAL

OXANDRIN

<u>AB</u>	SAVIENT PHARMS	<u>2.5MG</u>	<u>N013718</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N013718</u>	<u>002</u>	Nov 05, 2001

OXANDROLONE

<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A077827</u>	<u>001</u>	Jun 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A077827</u>	<u>002</u>	Jun 22, 2007
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076897</u>	<u>001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A076897</u>	<u>002</u>	Dec 01, 2006
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076761</u>	<u>001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A078033</u>	<u>001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+	GD SEARLE	<u>600MG</u>	<u>N018841</u>	<u>004</u>	Oct 29, 1992

OXAPROZIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>600MG</u>	<u>A075843</u>	<u>001</u>	Oct 03, 2001
<u>AB</u>	APOTEX INC	<u>600MG</u>	<u>A075987</u>	<u>001</u>	Sep 02, 2004
<u>AB</u>	CARACO	<u>600MG</u>	<u>A075844</u>	<u>001</u>	Jan 03, 2002
<u>AB</u>	DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	GENPHARM	<u>600MG</u>	<u>A075847</u>	<u>001</u>	Feb 28, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846</u>	<u>001</u>	May 13, 2002
<u>AB</u>	SANDOZ	<u>600MG</u>	<u>A075845</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	TEVA	<u>600MG</u>	<u>A075849</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>	WATSON LABS	<u>600MG</u>	<u>A075848</u>	<u>001</u>	Feb 09, 2001

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072251</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>		<u>15MG</u>	<u>A072252</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>		<u>30MG</u>	<u>A072253</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A070943</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>		<u>15MG</u>	<u>A070944</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>	+	<u>30MG</u>	<u>A070945</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A071813</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>15MG</u>	<u>A071756</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>30MG</u>	<u>A071814</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A072952</u>	<u>001</u>	Sep 28, 1990
<u>AB</u>		<u>15MG</u>	<u>A072953</u>	<u>001</u>	Sep 28, 1990
<u>AB</u>		<u>30MG</u>	<u>A072954</u>	<u>001</u>	Sep 28, 1990

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>	RANBAXY	<u>300MG/5ML</u>	<u>A078734</u>	<u>001</u>	Jun 26, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 310 (of 409)

OXCARBAZEPINE

SUSPENSION; ORAL

TRILEPTAL

<u>AB</u>	+	NOVARTIS	<u>300MG/5ML</u>	<u>N021285</u>	<u>001</u>	May 25, 2001

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>		APOTEX INC	<u>150MG</u>	<u>A077747</u>	<u>001</u>	Apr 09, 2008
<u>AB</u>			<u>300MG</u>	<u>A077747</u>	<u>002</u>	Apr 09, 2008
<u>AB</u>			<u>600MG</u>	<u>A077747</u>	<u>003</u>	Apr 09, 2008
<u>AB</u>		BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>			<u>300MG</u>	<u>A078069</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>			<u>600MG</u>	<u>A078069</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>		CADISTA PHARMS	<u>150MG</u>	<u>A090239</u>	<u>001</u>	Jan 25, 2010
<u>AB</u>			<u>300MG</u>	<u>A090239</u>	<u>002</u>	Jan 25, 2010
<u>AB</u>			<u>600MG</u>	<u>A090239</u>	<u>003</u>	Jan 25, 2010
<u>AB</u>		GLENMARK GENERICS	<u>150MG</u>	<u>A077802</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>			<u>300MG</u>	<u>A077802</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>			<u>600MG</u>	<u>A077802</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>		ROXANE	<u>150MG</u>	<u>A077795</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>			<u>300MG</u>	<u>A077795</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>			<u>600MG</u>	<u>A077795</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>		SUN PHARM INDS	<u>150MG</u>	<u>A077794</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>			<u>300MG</u>	<u>A077794</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>			<u>600MG</u>	<u>A077794</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>		TARO	<u>150MG</u>	<u>A077801</u>	<u>001</u>	Nov 15, 2007
<u>AB</u>			<u>300MG</u>	<u>A077801</u>	<u>002</u>	Nov 15, 2007
<u>AB</u>			<u>600MG</u>	<u>A077801</u>	<u>003</u>	Nov 15, 2007
<u>AB</u>		TEVA PHARMS	<u>150MG</u>	<u>A078005</u>	<u>001</u>	Dec 11, 2007
<u>AB</u>			<u>300MG</u>	<u>A078005</u>	<u>002</u>	Dec 11, 2007
<u>AB</u>			<u>600MG</u>	<u>A078005</u>	<u>003</u>	Dec 11, 2007
<u>AB</u>		<u>TRILEPTAL</u>				
<u>AB</u>		NOVARTIS	<u>150MG</u>	<u>N021014</u>	<u>001</u>	Jan 14, 2000
<u>AB</u>			<u>300MG</u>	<u>N021014</u>	<u>002</u>	Jan 14, 2000
<u>AB</u>	+		<u>600MG</u>	<u>N021014</u>	<u>003</u>	Jan 14, 2000

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	ALTANA	EQ 1% BASE	N019828	001	Dec 30, 1988

LOTION; TOPICAL

OXISTAT

+	ALTANA	EQ 1% BASE	N020209	001	Sep 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+	WARNER CHILCOTT	400MG	A087863	001	May 24, 1983
+		600MG	A086742	001	

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

+	WATSON LABS (UTAH)	3.9MG/24HR	N021351	002	Feb 26, 2003

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+	WATSON LABS	10%(100MG/PACKET)	N022204	001	Jan 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 311 (of 409)

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

<u>AA</u>	MIKART	<u>5MG/5ML</u>	<u>A075039</u>	<u>001</u>	Jan 29, 1999
<u>AA</u>	NOVEX	<u>5MG/5ML</u>	<u>A074997</u>	<u>001</u>	Oct 15, 1997
<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137</u>	<u>001</u>	Dec 18, 1998
<u>AA</u>	SILARX	<u>5MG/5ML</u>	<u>A074520</u>	<u>001</u>	Mar 29, 1996
<u>AA</u>	VINTAGE PHARMS	<u>5MG/5ML</u>	<u>A076682</u>	<u>001</u>	Dec 28, 2004
<u>AA</u>	+ WOCHKHARDT	<u>5MG/5ML</u>	<u>A074868</u>	<u>001</u>	Feb 12, 1997

TABLET; ORAL

DITROPAN

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>5MG</u>	<u>N017577</u>	<u>001</u>	
<u>OXYBUTYNIN CHLORIDE</u>					
<u>AB</u>	PLIVA	<u>5MG</u>	<u>A071655</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	USL PHARMA	<u>5MG</u>	<u>A074625</u>	<u>001</u>	Jul 31, 1996
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A075079</u>	<u>001</u>	Oct 31, 1997

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

<u>AB</u>	ORTHOMCNEIL JANSSEN	<u>5MG</u>	<u>N020897</u>	<u>001</u>	Dec 16, 1998
<u>AB</u>		<u>10MG</u>	<u>N020897</u>	<u>002</u>	Dec 16, 1998
<u>AB</u>	+	<u>15MG</u>	<u>N020897</u>	<u>003</u>	Jun 22, 1999
<u>OXYBUTYNIN CHLORIDE</u>					
<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076745</u>	<u>002</u>	May 09, 2007
<u>AB</u>		<u>10MG</u>	<u>A076745</u>	<u>003</u>	May 09, 2007
<u>AB</u>		<u>15MG</u>	<u>A076745</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076702</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>		<u>10MG</u>	<u>A076644</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>		<u>15MG</u>	<u>A078293</u>	<u>001</u>	May 10, 2007
<u>AB</u>	OSMOTICA PHARM	<u>5MG</u>	<u>A078503</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503</u>	<u>003</u>	Feb 04, 2009

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

+	LEHIGH VALLEY	5MG	N200534	001	Oct 20, 2010

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

+	LEHIGH VALLEY	100MG/5ML	N200535	001	Oct 20, 2010

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>15MG</u>	<u>A076636</u>	<u>001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636</u>	<u>002</u>	Feb 06, 2004
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009
<u>AB</u>		<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393</u>	<u>003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393</u>	<u>004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393</u>	<u>005</u>	Aug 31, 2009
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A090895</u>	<u>001</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A090895</u>	<u>002</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A090895</u>	<u>003</u>	Aug 24, 2009
<u>AB</u>	KV PHARM	<u>5MG</u>	<u>A077290</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290</u>	<u>004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290</u>	<u>005</u>	Dec 08, 2005
<u>AB</u>	MALLINCKRODT	<u>15MG</u>	<u>A076758</u>	<u>001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758</u>	<u>002</u>	Jun 30, 2004
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659</u>	<u>001</u>	Apr 10, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 312 (of 409)

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	SUN PHARM INDS INC	<u>15MG</u>	<u>A090659</u>	<u>002</u>	Apr 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090659</u>	<u>003</u>	Apr 10, 2009
<u>AB</u>	TYCO HLTHCARE	<u>5MG</u>	<u>A078206</u>	<u>001</u>	Mar 19, 2007
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077712</u>	<u>003</u>	Mar 02, 2009
<u>AB</u>		<u>15MG</u>	<u>A077712</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>30MG</u>	<u>A077712</u>	<u>002</u>	Jan 31, 2007
<u>ROXICODONE</u>					
<u>AB</u>	XANODYNE PHARMS	<u>5MG</u>	<u>N021011</u>	<u>003</u>	May 15, 2009
<u>AB</u>	+	<u>15MG</u>	<u>N021011</u>	<u>001</u>	Aug 31, 2000
<u>AB</u>		<u>30MG</u>	<u>N021011</u>	<u>002</u>	Aug 31, 2000

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
		15MG	N022272	002	Apr 05, 2010
		20MG	N022272	003	Apr 05, 2010
		30MG	N022272	004	Apr 05, 2010
	+	40MG	N022272	005	Apr 05, 2010
		60MG	N022272	006	Apr 05, 2010
		80MG	N022272	007	Apr 05, 2010

OXYMETHOLONETABLET; ORAL
ANADROL-50

+	ALAVEN PHARM	50MG	N016848	001	

OXYMORPHONE HYDROCHLORIDEINJECTABLE; INJECTION
OPANA

+	ENDO PHARMS	1MG/ML	N011707	002	

TABLET; ORAL

OPANA

<u>AB</u>	ENDO PHARMS	<u>5MG</u>	<u>N021611</u>	<u>001</u>	Jun 22, 2006
<u>AB</u>	+	<u>10MG</u>	<u>N021611</u>	<u>002</u>	Jun 22, 2006
<u>OXYMORPHONE HYDROCHLORIDE</u>					
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A090964</u>	<u>001</u>	Sep 27, 2010
<u>AB</u>		<u>10MG</u>	<u>A090964</u>	<u>002</u>	Sep 27, 2010

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

<u>AB</u>	ENDO PHARMS	<u>5MG</u>	<u>N021610</u>	<u>001</u>	Jun 22, 2006
<u>AB</u>		<u>7.5MG</u>	<u>N021610</u>	<u>005</u>	Feb 29, 2008
<u>AB</u>		<u>10MG</u>	<u>N021610</u>	<u>002</u>	Jun 22, 2006
<u>AB</u>		<u>15MG</u>	<u>N021610</u>	<u>006</u>	Feb 29, 2008
<u>AB</u>		<u>20MG</u>	<u>N021610</u>	<u>003</u>	Jun 22, 2006
<u>AB</u>		<u>30MG</u>	<u>N021610</u>	<u>007</u>	Feb 29, 2008
<u>AB</u>	+	<u>40MG</u>	<u>N021610</u>	<u>004</u>	Jun 22, 2006
<u>OXYMORPHONE HYDROCHLORIDE</u>					
<u>AB</u>	ACTAVIS	<u>7.5MG</u>	<u>A079046</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>		<u>15MG</u>	<u>A079046</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>	IMPAX LABS	<u>5MG</u>	<u>A079087</u>	<u>001</u>	Jun 14, 2010
<u>AB</u>		<u>7.5MG</u>	<u>A079087</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>		<u>10MG</u>	<u>A079087</u>	<u>003</u>	Jun 14, 2010
<u>AB</u>		<u>15MG</u>	<u>A079087</u>	<u>004</u>	Dec 21, 2010
<u>AB</u>		<u>20MG</u>	<u>A079087</u>	<u>005</u>	Jun 14, 2010
<u>AB</u>		<u>30MG</u>	<u>A079087</u>	<u>006</u>	Jul 22, 2010
<u>AB</u>		<u>40MG</u>	<u>A079087</u>	<u>007</u>	Jun 14, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 313 (of 409)

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
TERRAMYCIN W/ POLYMYXIN B SULFATE
+ PFIZER EQ 5MG BASE/GM;10,000 UNITS/GM A061015 001

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

<u>AP</u>	+	APP PHARMS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018248</u>	<u>001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018248</u>	<u>002</u>	
<u>AP</u>	+	BAXTER HLTHCARE CORP	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018243</u>	<u>001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018243</u>	<u>002</u>	Jan 10, 2007
<u>AP</u>		TEVA PARENTERAL	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>A077453</u>	<u>001</u>	Jan 24, 2008
<u>AP</u>			<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>A077453</u>	<u>002</u>	Jan 24, 2008

PITOCIN

<u>AP</u>	+	JHP PHARMS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018261</u>	<u>001</u>	
<u>AP</u>			<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018261</u>	<u>002</u>	Jul 27, 2007
		OXYTOCIN				
	+	APP PHARMS	300USP UNITS/30ML (10USP UNITS/ML)	N018248	003	Jul 27, 2007

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

	+	ABRAXIS BIOSCIENCE	100MG/VIAL	N021660	001	Jan 07, 2005

INJECTABLE; INJECTION

PACLITAXEL

<u>AP</u>		ACCORD HLTHCARE INC	<u>6MG/ML</u>	<u>A075436</u>	<u>001</u>	Nov 12, 2004
<u>AP</u>		ACTAVIS TOTOWA	<u>6MG/ML</u>	<u>A090130</u>	<u>001</u>	Dec 09, 2009
<u>AP</u>		BEDFORD	<u>6MG/ML</u>	<u>A075190</u>	<u>001</u>	Jan 28, 2002
<u>AP</u>		EBEWE PHARMA	<u>6MG/ML</u>	<u>A078167</u>	<u>001</u>	Dec 26, 2007
<u>AP</u>		FRESENIUS KABI ONCOL	<u>6MG/ML</u>	<u>A077574</u>	<u>001</u>	Nov 27, 2006
<u>AP</u>	+	HOSPIRA	<u>6MG/ML</u>	<u>A076131</u>	<u>001</u>	May 08, 2002
<u>AP</u>		MYLAN	<u>6MG/ML</u>	<u>A075278</u>	<u>001</u>	Jan 25, 2002
<u>AP</u>		TEVA PARENTERAL	<u>6MG/ML</u>	<u>A075184</u>	<u>001</u>	Jan 25, 2002

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

		ORTHO MCNEIL JANSSEN	1.5MG	N021999	006	Aug 26, 2008
			3MG	N021999	001	Dec 19, 2006
	+		6MG	N021999	002	Dec 19, 2006
			9MG	N021999	003	Dec 19, 2006

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

		ORTHO MCNEIL JANSSEN	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
			78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
			117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
			156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009

PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

	+	HELSINN HLTHCARE	EQ 0.5MG BASE	N022233	001	Aug 22, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 314 (of 409)

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

+	HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008
+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

<u>AP</u>	+	NOVARTIS	<u>30MG/VIAL</u>	<u>N020036</u>	<u>001</u>	Oct 31, 1991
<u>AP</u>	+		<u>90MG/VIAL</u>	<u>N020036</u>	<u>004</u>	May 06, 1993

PAMIDRONATE DISODIUM

<u>AP</u>		AESGEN	<u>30MG/VIAL</u>	<u>A075594</u>	<u>001</u>	May 06, 2002
<u>AP</u>			<u>90MG/VIAL</u>	<u>A075594</u>	<u>002</u>	May 06, 2002
<u>AP</u>		AKORN STRIDES	<u>30MG/10ML (3MG/ML)</u>	<u>A078520</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078520</u>	<u>002</u>	Oct 31, 2008
<u>AP</u>		APP PHARMS	<u>30MG/VIAL</u>	<u>A075773</u>	<u>001</u>	May 06, 2002
<u>AP</u>			<u>30MG/10ML (3MG/ML)</u>	<u>A076207</u>	<u>001</u>	May 17, 2002
<u>AP</u>			<u>90MG/VIAL</u>	<u>A075773</u>	<u>002</u>	May 06, 2002
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A076207</u>	<u>002</u>	May 17, 2002
<u>AP</u>		AREVA PHARMS	<u>30MG/VIAL</u>	<u>A077433</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>			<u>60MG/VIAL</u>	<u>A077433</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>			<u>90MG/VIAL</u>	<u>A077433</u>	<u>003</u>	Nov 26, 2008
<u>AP</u>		BEDFORD	<u>30MG/VIAL</u>	<u>A075290</u>	<u>001</u>	Apr 30, 2001
<u>AP</u>	+		<u>30MG/10ML (3MG/ML)</u>	<u>N021113</u>	<u>001</u>	Mar 04, 2002
<u>AP</u>			<u>90MG/VIAL</u>	<u>A075290</u>	<u>003</u>	Apr 30, 2001
<u>AP</u>	+		<u>90MG/10ML (9MG/ML)</u>	<u>N021113</u>	<u>002</u>	Mar 04, 2002
<u>AP</u>		GENERAMEDIX	<u>30MG/10ML (3MG/ML)</u>	<u>A078373</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078373</u>	<u>002</u>	Dec 23, 2008
<u>AP</u>	+	HOSPIRA	<u>30MG/10ML (3MG/ML)</u>	<u>A075841</u>	<u>001</u>	Jun 27, 2002
<u>AP</u>	+		<u>60MG/10ML (6MG/ML)</u>	<u>A075841</u>	<u>002</u>	Jun 27, 2002
<u>AP</u>	+		<u>90MG/10ML (9MG/ML)</u>	<u>A075841</u>	<u>003</u>	Jun 27, 2002
<u>AP</u>		LUITPOLD	<u>30MG/10ML (3MG/ML)</u>	<u>A078942</u>	<u>001</u>	Jul 25, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078942</u>	<u>002</u>	Jul 25, 2008
<u>AP</u>		MN PHARMS	<u>30MG/VIAL</u>	<u>A078300</u>	<u>001</u>	Mar 10, 2009
<u>AP</u>			<u>90MG/VIAL</u>	<u>A078300</u>	<u>002</u>	Mar 10, 2009
<u>AP</u>		PLIVA LACHEMA	<u>30MG/10ML (3MG/ML)</u>	<u>A078156</u>	<u>001</u>	Aug 19, 2008
<u>AP</u>			<u>60MG/10ML (6MG/ML)</u>	<u>A078156</u>	<u>002</u>	Aug 19, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078156</u>	<u>003</u>	Aug 19, 2008
<u>AP</u>		SUN PHARMA GLOBAL	<u>30MG/VIAL</u>	<u>A077703</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>			<u>90MG/VIAL</u>	<u>A077703</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>		TEVA PARENTERAL	<u>30MG/10ML (3MG/ML)</u>	<u>A076153</u>	<u>001</u>	Mar 27, 2002
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A076153</u>	<u>002</u>	Mar 27, 2002

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)CAPSULE, DELAYED RELEASE; ORAL
CREON

	ABBOTT PRODS	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009
		60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009
+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009

PANCREAZE

	ORTHO MCNEIL JANSSEN	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523	001	Apr 12, 2010
		43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523	002	Apr 12, 2010
		70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523	004	Apr 12, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 315 (of 409)

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

+ ORTHO MCNEIL JANSSEN	61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523 003	Apr 12, 2010

ZENPEP

EURAND

27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210 001	Aug 27, 2009

55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210 002	Aug 27, 2009

82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210 003	Aug 27, 2009

+ 109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210 004	Aug 27, 2009

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

<u>AP</u> HOSPIRA	<u>1MG/ML</u>	<u>A072320</u> <u>001</u>	Jan 19, 1989
<u>AP</u> + TEVA PARENTERAL	<u>1MG/ML</u>	<u>A072759</u> <u>001</u>	Jul 31, 1990
<u>AP</u> +	<u>2MG/ML</u>	<u>A072760</u> <u>001</u>	Jul 31, 1990

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PROTONIX

+ WYETH PHARMS INC	EQ 40MG BASE	N022020 001	Nov 14, 2007

INJECTABLE; IV (INFUSION)

+ WYETH PHARMS INC	EQ 40MG BASE/VIAL	N020988 001	Mar 22, 2001

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

<u>AB</u> SUN PHARMA GLOBAL	<u>EQ 20MG BASE</u>	<u>A077058</u> <u>001</u>	Sep 10, 2007
<u>AB</u>	<u>EQ 40MG BASE</u>	<u>A077058</u> <u>002</u>	Sep 10, 2007
<u>AB</u> TEVA	<u>EQ 20MG BASE</u>	<u>A077056</u> <u>001</u>	Aug 02, 2007
<u>AB</u>	<u>EQ 40MG BASE</u>	<u>A077056</u> <u>002</u>	Aug 02, 2007
<u>PROTONIX</u>			
<u>AB</u> WYETH PHARMS INC	<u>EQ 20MG BASE</u>	<u>N020987</u> <u>002</u>	Jun 12, 2001
<u>AB</u> +	<u>EQ 40MG BASE</u>	<u>N020987</u> <u>001</u>	Feb 02, 2000

PARICALCITOL

CAPSULE; ORAL

ZEMPLAR

ABBOTT

1MCG	N021606 001	May 26, 2005

2MCG	N021606 002	May 26, 2005

+ 4MCG	N021606 003	May 26, 2005

INJECTABLE; INJECTION

ZEMPLAR

+ ABBOTT	0.002MG/ML	N020819 002	Feb 01, 2000

+ 0.005MG/ML	N020819 001	Apr 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u> + CARACO	<u>EQ 250MG BASE</u>	<u>A064171</u> <u>001</u>	Jun 30, 1997
<u>AA</u> HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173</u> <u>001</u>	Dec 14, 2007

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u> APOTEX INC	<u>EQ 10MG BASE/5ML</u>	<u>A077395</u> <u>001</u>	Dec 05, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 316 (of 409)

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 10MG BASE/5ML</u>	<u>N020710</u>	<u>001</u>	Jun 25, 1997

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 10MG BASE</u>	<u>A076968</u>	<u>001</u>	Jun 21, 2010
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A076968</u>	<u>002</u>	Jun 21, 2010
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A076968</u>	<u>003</u>	Jun 21, 2010
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A076968</u>	<u>004</u>	Jun 21, 2010
<u>AB</u>		ALPHAPHARM	<u>EQ 10MG BASE</u>	<u>A075716</u>	<u>001</u>	Mar 08, 2004
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A075716</u>	<u>002</u>	Mar 08, 2004
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A075716</u>	<u>003</u>	Mar 08, 2004
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A075716</u>	<u>004</u>	Mar 08, 2004
<u>AB</u>		APOTEX	<u>EQ 10MG BASE</u>	<u>A075356</u>	<u>001</u>	Jul 30, 2003
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A075356</u>	<u>002</u>	Jul 30, 2003
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A075356</u>	<u>003</u>	Jul 30, 2003
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A075356</u>	<u>004</u>	Jul 30, 2003
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A078406</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078406</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078406</u>	<u>004</u>	Jul 25, 2007
<u>AB</u>		CARACO	<u>EQ 10MG BASE</u>	<u>A078194</u>	<u>001</u>	Jun 29, 2007
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A078194</u>	<u>002</u>	Jun 29, 2007
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078194</u>	<u>003</u>	Jun 29, 2007
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078194</u>	<u>004</u>	Jun 29, 2007
<u>AB</u>		MYLAN	<u>EQ 10MG BASE</u>	<u>A078902</u>	<u>001</u>	Mar 13, 2008
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A078902</u>	<u>002</u>	Mar 13, 2008
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078902</u>	<u>003</u>	Mar 13, 2008
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078902</u>	<u>004</u>	Mar 13, 2008
<u>AB</u>		TEVA	<u>EQ 10MG BASE</u>	<u>A076618</u>	<u>001</u>	Aug 15, 2005
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A076618</u>	<u>002</u>	Aug 15, 2005
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A076618</u>	<u>003</u>	Aug 15, 2005
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A076618</u>	<u>004</u>	Aug 15, 2005
<u>AB</u>		ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A077584</u>	<u>002</u>	Mar 07, 2007
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A077584</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077584</u>	<u>004</u>	Mar 07, 2007

PAXIL

<u>AB</u>		GLAXOSMITHKLINE	<u>EQ 10MG BASE</u>	<u>N020031</u>	<u>001</u>	Dec 29, 1992
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>N020031</u>	<u>002</u>	Dec 29, 1992
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>N020031</u>	<u>003</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 40MG BASE</u>	<u>N020031</u>	<u>005</u>	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>		MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873</u>	<u>001</u>	Jun 29, 2007
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A077873</u>	<u>002</u>	Jun 29, 2007
		<u>PAXIL CR</u>				
<u>AB</u>		GLAXOSMITHKLINE	<u>EQ 12.5MG BASE</u>	<u>N020936</u>	<u>001</u>	Feb 16, 1999
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>N020936</u>	<u>002</u>	Feb 16, 1999
		<u>PAXIL CR</u>				
	+	GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936	003	Dec 06, 2000

PAROXETINE MESYLATE

TABLET; ORAL

PEXEVA

		NOVEN THERAP	EQ 10MG BASE	N021299	001	Jul 03, 2003
			EQ 20MG BASE	N021299	002	Jul 03, 2003
			EQ 30MG BASE	N021299	003	Jul 03, 2003
	+		EQ 40MG BASE	N021299	004	Jul 03, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 317 (of 409)

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

GLAXOSMITHKLINE

EQ 200MG BASE

N022465 001

Oct 19, 2009

+

EQ 400MG BASE

N022465 002

Oct 19, 2009

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+ SIGMA TAU

250 UNITS/ML

N019818 001

Mar 21, 1990

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+ EYETECH INC

EQ 0.3MG ACID/0.09ML

N021756 001

Dec 17, 2004

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+ PHARMACIA AND UPJOHN

10MG/VIAL

N021106 001

Mar 25, 2003

+

15MG/VIAL

N021106 002

Mar 25, 2003

+

20MG/VIAL

N021106 003

Mar 25, 2003

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA

+ LILLY

EQ 100MG BASE/VIAL

N021462 002

Sep 07, 2007

+

EQ 500MG BASE/VIAL

N021462 001

Feb 04, 2004

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC

+ SANTEN

0.1%

N021079 001

Sep 24, 1999

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

+ SCHWARZ PHARMA

20MG

N018976 004

Jan 05, 1989

PENCICLOVIR SODIUM

CREAM; TOPICAL

DENA VIR

+ DENCO ASSET

1%

N020629 001

Sep 24, 1996

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

+ ATON

250MG

N019853 001

TABLET; ORAL

DEPEN

+ MEDA PHARMS

250MG

N019854 001

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC + KING PHARMS

600,000 UNITS/ML

N050141 001

PERMAPEN

BC PFIZER

600,000 UNITS/ML

A060014 001

PRESCRIPTION DRUG PRODUCT LIST

3 - 318 (of 409)

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

+ KING PHARMS	300,000 UNITS/ML	N050141	003

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+ KING PHARMS	150,000 UNITS/ML;150,000 UNITS/ML	N050138	002

+	300,000 UNITS/ML;300,000 UNITS/ML	N050138	001

BICILLIN C-R 900/300

+ KING PHARMS	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

<u>AP</u>	APP PHARMS	<u>5,000,000 UNITS/VIAL</u>	<u>A065448</u>	<u>001</u>	Aug 18, 2009
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065448</u>	<u>002</u>	Aug 18, 2009
<u>AP</u>	HANFORD GC	<u>5,000,000 UNITS/VIAL</u>	<u>A065149</u>	<u>002</u>	Jul 23, 2009
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065149</u>	<u>003</u>	Jul 23, 2009
<u>AP</u>	SANDOZ	<u>5,000,000 UNITS/VIAL</u>	<u>A065079</u>	<u>002</u>	Aug 30, 2002
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065079</u>	<u>003</u>	Aug 30, 2002

PFIZERPEN

<u>AP</u>	+ PFIZER	<u>5,000,000 UNITS/VIAL</u>	<u>A060657</u>	<u>002</u>	
<u>AP</u>	+	<u>20,000,000 UNITS/VIAL</u>	<u>A060657</u>	<u>003</u>	
	PENICILLIN G POTASSIUM				
	HANFORD GC	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009
	PENICILLIN G POTASSIUM IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	20,000 UNITS/ML	N050638	001	Jun 25, 1990
	+	40,000 UNITS/ML	N050638	002	Jun 25, 1990
	+	60,000 UNITS/ML	N050638	003	Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

+ KING PHARMS	300,000 UNITS/ML	A060101	002

+	600,000 UNITS/ML	A060101	001

PENICILLIN G SODIUM

INJECTABLE; IM-IV

PENICILLIN G SODIUM

+ SANDOZ	5,000,000 UNITS/VIAL	A065068	001	Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

<u>AA</u>	DAVA PHARMS INC	<u>EQ 125MG BASE/5ML</u>	<u>A062981</u>	<u>001</u>	Feb 10, 1989
<u>AA</u>		<u>EQ 250MG BASE/5ML</u>	<u>A062981</u>	<u>002</u>	Feb 10, 1989
	<u>PENICILLIN-VK</u>				
<u>AA</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A060456</u>	<u>001</u>	
<u>AA</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>A060456</u>	<u>002</u>	

TABLET; ORAL

PENICILLIN V POTASSIUM

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A065435</u>	<u>001</u>	Apr 29, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065435</u>	<u>002</u>	Apr 29, 2008
<u>AB</u>	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062936</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062935</u>	<u>001</u>	Nov 23, 1988
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064071</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A064071</u>	<u>002</u>	Nov 30, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 319 (of 409)

PENICILLIN V POTASSIUM

TABLET; ORAL

PENICILLIN-VKAB TEVAEQ 250MG BASEA060711 002ABEQ 500MG BASEA060711 003PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

+ APP PHARMS

300MG/VIAL

N019887 001

Jun 15, 1989

INJECTABLE; INJECTION

PENTAMAP + APP PHARMS300MG/VIALN019264 001

Oct 16, 1984

PENTAMIDINE ISETHIONATEAP WATSON LABS300MG/VIALA074303 001

Aug 17, 1995

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+ HOSPIRA

EQ 30MG BASE/ML

N016194 001

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+ LUNDBECK INC

50MG/ML

A083246 001

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ ORTHO MCNEIL JANSSEN 100MG

N020193 001

Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENTAP + HOSPIRA INC10MG/VIALN020122 001

Oct 11, 1991

PENTOSTATINAP BEDFORD LABS10MG/VIALA077841 001

Aug 07, 2007

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINEAB APOTEX400MGA075191 001

Jun 09, 1999

AB BIOVAIL400MGA075028 001

Jul 20, 1998

AB IMPAX LABS400MGA075093 001

Aug 10, 1999

AB MYLAN400MGA074425 001

Jul 08, 1997

AB PLIVA400MGA074874 001

May 25, 1999

AB WATSON LABS400MGA075107 001

Sep 04, 1998

PENTOXILAB UPSHER SMITH400MGA074962 001

Mar 31, 1999

TRENTALAB + SANOFI AVENTIS US400MGN018631 001

Aug 30, 1984

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+ LANTHEUS MEDCL

6.52MG/ML

N021064 001

Jul 31, 2001

PRESCRIPTION DRUG PRODUCT LIST

3 - 320 (of 409)

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

<u>AB</u>	ABBOTT PRODS	<u>2MG</u>	<u>N020184</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>		<u>4MG</u>	<u>N020184</u>	<u>002</u>	Dec 30, 1993
<u>AB</u>	+	<u>8MG</u>	<u>N020184</u>	<u>003</u>	Dec 30, 1993

PERINDOPRIL ERBUMINE

<u>AB</u>	APOTEX	<u>2MG</u>	<u>A090463</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>4MG</u>	<u>A090463</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>8MG</u>	<u>A090463</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>2MG</u>	<u>A079070</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>4MG</u>	<u>A079070</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>		<u>8MG</u>	<u>A079070</u>	<u>003</u>	Nov 10, 2009
<u>AB</u>	IVAX PHARMS	<u>2MG</u>	<u>A078138</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>4MG</u>	<u>A078138</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>		<u>8MG</u>	<u>A078138</u>	<u>003</u>	Nov 10, 2009
<u>AB</u>	LUPIN LTD	<u>2MG</u>	<u>A078263</u>	<u>001</u>	Jan 27, 2010
<u>AB</u>		<u>4MG</u>	<u>A078263</u>	<u>002</u>	Jan 27, 2010
<u>AB</u>		<u>8MG</u>	<u>A078263</u>	<u>003</u>	Jan 27, 2010
<u>AB</u>	ROXANE	<u>2MG</u>	<u>A090072</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>4MG</u>	<u>A090072</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>		<u>8MG</u>	<u>A090072</u>	<u>003</u>	Nov 10, 2009

PERMETHRIN

CREAM; TOPICAL

ELIMITE

<u>AB</u>	+	ALLERGAN	<u>5%</u>	<u>N019855</u>	<u>001</u>	Aug 25, 1989
<u>AB</u>		<u>PERMETHRIN</u>				
<u>AB</u>		ACTAVIS MID ATLANTIC	<u>5%</u>	<u>A074806</u>	<u>001</u>	Jan 23, 1998
<u>AB</u>		PERRIGO NEW YORK	<u>5%</u>	<u>A076369</u>	<u>001</u>	Apr 21, 2003

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

<u>AB</u>	SANDOZ	<u>2MG</u>	<u>A089683</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>		<u>4MG</u>	<u>A089684</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>		<u>8MG</u>	<u>A089685</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>	+	<u>16MG</u>	<u>A089686</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>	VINTAGE PHARMS	<u>2MG</u>	<u>A040226</u>	<u>001</u>	Dec 31, 1998
<u>AB</u>		<u>4MG</u>	<u>A040226</u>	<u>002</u>	Dec 31, 1998
<u>AB</u>		<u>8MG</u>	<u>A040226</u>	<u>003</u>	Dec 31, 1998
<u>AB</u>		<u>16MG</u>	<u>A040226</u>	<u>004</u>	Dec 31, 1998

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
BONTRIL

BC	VALEANT	105MG	A088021	001	Sep 21, 1982
	PHENDIMETRAZINE TARTRATE				
BC	+	SANDOZ	N018074	001	

TABLET; ORAL

BONTRIL PDM

<u>AA</u>	+	VALEANT	<u>35MG</u>	<u>A085272</u>	<u>001</u>	
<u>AA</u>		<u>PHENDIMETRAZINE TARTRATE</u>				
<u>AA</u>		ACTAVIS TOTOWA	<u>35MG</u>	<u>A040762</u>	<u>001</u>	Jan 28, 2008
<u>AA</u>		KVK TECH	<u>35MG</u>	<u>A091042</u>	<u>001</u>	Aug 31, 2010
<u>AA</u>		MIKART	<u>35MG</u>	<u>A089452</u>	<u>001</u>	Oct 30, 1991
<u>AA</u>		SANDOZ	<u>35MG</u>	<u>A085588</u>	<u>001</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 321 (of 409)

PHENELZINE SULFATE

TABLET; ORAL

NARDILAB + PARKE DAVIS EQ 15MG BASEN011909 002PHENELZINE SULFATEAB NOVEL LABS INC EQ 15MG BASEA200181 001

Dec 08, 2010

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

+ WELLSRING PHARM 10MG

N008708 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-PAA + TEVA 37.5MGA088023 001

Aug 02, 1983

PHENTERMINE HYDROCHLORIDEAA ACTAVIS TOTOWA 15MGA040460 001

Jan 14, 2003

AA 30MGA040227 001

Jun 18, 1997

AA 30MGA040448 001

Jan 22, 2003

AA 37.5MGA040228 001

Jun 19, 1997

AA BARR 15MGA090591 001

Mar 18, 2010

AA 30MGA090591 002

Mar 18, 2010

AA KVK TECH 15MGA040886 002

Mar 31, 2008

AA 30MGA040875 001

Mar 21, 2008

AA 30MGA040886 001

Mar 31, 2008

AA 37.5MGA040887 001

Apr 24, 2008

AA LANNETT 30MGA087022 001

Feb 03, 1983

AA 30MGA091359 001

Jul 16, 2010

AA MUTUAL PHARM 30MGA040525 001

Oct 23, 2003

AA + SANDOZ 15MGA087190 002AA + 30MGA086945 001

Jul 20, 1983

AA + 30MGA087190 001

TABLET; ORAL

ADIPEX-PAA + TEVA 37.5MGA085128 001PHENTERMINE HYDROCHLORIDEAA ACTAVIS ELIZABETH 37.5MGA040276 001

Nov 25, 1998

AA ACTAVIS TOTOWA 37.5MGA040190 001

May 30, 1997

AA BARR 37.5MGA090470 001

Aug 31, 2009

AA CARACO 37.5MGA040790 001

Aug 21, 2007

AA KVK TECH 37.5MGA040876 001

Mar 31, 2008

AA LANNETT 37.5MGA040555 001

Apr 15, 2005

AA MUTUAL PHARM 37.5MGA040526 001

Oct 23, 2003

AA VINTAGE PHARMS 37.5MGA040377 001

Jan 04, 2002

PHENTERMINE HYDROCHLORIDE

+ SANDOZ 30MG

A088605 001

Sep 28, 1987

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATEAP BEDFORD 5MG/VIALA040235 001

Mar 11, 1998

REGITINEAP + NOVARTIS 5MG/VIALN008278 003

ORAVerse

+ NOVALAR 0.4MG/1.7ML

N022159 001

May 09, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 322 (of 409)

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	VINTAGE	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040654</u>	<u>001</u>	Dec 07, 2006
<u>AA</u>	<u>PROMETH VC PLAIN</u>				
<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A088761</u>	<u>001</u>	Nov 08, 1984
<u>AA</u>	<u>PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE</u>				
<u>AA</u>	AMNEAL PHARMS	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040902</u>	<u>001</u>	Aug 25, 2009

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

<u>AB</u>	+ PARKE DAVIS	<u>125MG/5ML</u>	<u>N008762</u>	<u>001</u>	
<u>AB</u>	<u>PHENYTOIN</u>				
<u>AB</u>	TARO	<u>125MG/5ML</u>	<u>A040521</u>	<u>001</u>	Mar 08, 2004
<u>AB</u>	VISTAPHARM	<u>125MG/5ML</u>	<u>A040342</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>		<u>125MG/5ML</u>	<u>A040610</u>	<u>001</u>	Aug 18, 2005
<u>AB</u>	WOCKHARDT	<u>125MG/5ML</u>	<u>A040420</u>	<u>001</u>	Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN

	+ PFIZER PHARMS	50MG	A084427	001	

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

<u>AB</u>	+ PARKE DAVIS	<u>30MG EXTENDED</u>	<u>A084349</u>	<u>001</u>	
<u>AB</u>		<u>100MG EXTENDED</u>	<u>A084349</u>	<u>002</u>	
	<u>EXTENDED PHENYTOIN SODIUM</u>				
<u>AB</u>	AMNEAL PHARMS NY	<u>100MG EXTENDED</u>	<u>A040765</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>	MYLAN	<u>100MG EXTENDED</u>	<u>A040298</u>	<u>001</u>	Dec 28, 1998
<u>AB</u>	SUN PHARM INDS	<u>200MG EXTENDED</u>	<u>A040731</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>300MG EXTENDED</u>	<u>A040731</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>	SUN PHARM INDS (IN)	<u>100MG EXTENDED</u>	<u>A040621</u>	<u>001</u>	Dec 11, 2006
<u>AB</u>	TARO	<u>100MG EXTENDED</u>	<u>A040684</u>	<u>001</u>	Sep 05, 2006
<u>AB</u>	WOCKHARDT	<u>30MG EXTENDED</u>	<u>A040759</u>	<u>001</u>	Dec 18, 2007
<u>AB</u>	WOCKHARDT USA	<u>100MG EXTENDED</u>	<u>A040732</u>	<u>001</u>	Jan 30, 2008
	<u>PHENYTEK</u>				
<u>AB</u>	MYLAN	<u>200MG EXTENDED</u>	<u>A040298</u>	<u>002</u>	Dec 06, 2001
<u>AB</u>		<u>300MG EXTENDED</u>	<u>A040298</u>	<u>003</u>	Dec 06, 2001

INJECTABLE; INJECTION

PHENYTOIN SODIUM

<u>AP</u>	+ BAXTER HLTHCARE	<u>50MG/ML</u>	<u>A084307</u>	<u>001</u>	
<u>AP</u>	HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A040573</u>	<u>001</u>	Sep 13, 2006
<u>AP</u>	HOSPIRA	<u>50MG/ML</u>	<u>A089521</u>	<u>001</u>	Mar 17, 1987
<u>AP</u>		<u>50MG/ML</u>	<u>A089744</u>	<u>001</u>	Dec 18, 1987
<u>AP</u>	LUITPOLD	<u>50MG/ML</u>	<u>A040781</u>	<u>001</u>	Dec 04, 2007

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	INTL MEDICATION	1MG/0.5ML	A083722	001	
	VITAMIN K1				
BP	+ HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983
	VITAMIN K1				
	+ HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983

TABLET; ORAL

MEPHYTON

	+ ATON	5MG	N010104	003	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 323 (of 409)

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC					
PILOPINE HS					
+	ALCON	4%	N018796	001	Oct 01, 1984
SOLUTION; OPHTHALMIC					
CARPINE					
	ALCON	1%	N200890	001	Jun 22, 2010
		2%	N200890	002	Jun 22, 2010
+		4%	N200890	003	Jun 22, 2010
TABLET; ORAL					
<u>PILOCARPINE HYDROCHLORIDE</u>					
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A076746</u>	<u>001</u>	Nov 16, 2004
<u>AB</u>	IMPAX LABS	<u>5MG</u>	<u>A077248</u>	<u>001</u>	Mar 31, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A077248</u>	<u>002</u>	Mar 31, 2006
<u>AB</u>	LANNETT	<u>5MG</u>	<u>A077220</u>	<u>001</u>	Oct 14, 2005
<u>AB</u>		<u>7.5MG</u>	<u>A077220</u>	<u>002</u>	May 06, 2009
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A076963</u>	<u>001</u>	Dec 22, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A076963</u>	<u>002</u>	Feb 27, 2007
<u>SALAGEN</u>					
<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N020237</u>	<u>001</u>	Mar 22, 1994
<u>AB</u>	+	<u>7.5MG</u>	<u>N020237</u>	<u>002</u>	Apr 18, 2003

PIMECROLIMUS

CREAM; TOPICAL					
ELIDEL					
+	NOVARTIS	1%	N021302	001	Dec 13, 2001

PIMOZIDE

TABLET; ORAL					
ORAP					
	TEVA	1MG	N017473	003	Aug 27, 1997
+		2MG	N017473	001	Jul 31, 1984

PINDOLOL

TABLET; ORAL					
<u>PINDOLOL</u>					
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A074019</u>	<u>001</u>	Sep 03, 1992
<u>AB</u>	+	<u>10MG</u>	<u>A074019</u>	<u>002</u>	Sep 03, 1992
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074437</u>	<u>001</u>	Feb 27, 1995
<u>AB</u>		<u>10MG</u>	<u>A074437</u>	<u>002</u>	Feb 27, 1995

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL					
ACTOS					
	TAKEDA PHARMS NA	EQ 15MG BASE	N021073	001	Jul 15, 1999
		EQ 30MG BASE	N021073	002	Jul 15, 1999
+		EQ 45MG BASE	N021073	003	Jul 15, 1999

PIPERACILLIN SODIUM

INJECTABLE; INJECTION					
PIPERACILLIN					
+	ISTITUTO BIOCHIMICO	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 324 (of 409)

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>	ORCHID HLTHCARE	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065386</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065386</u>	<u>002</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065386</u>	<u>003</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A065446</u>	<u>001</u>	Sep 15, 2009
<u>ZOSYN</u>					
<u>AP</u>	+ WYETH PHARMS INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>N050684</u>	<u>001</u>	Oct 22, 1993
<u>AP</u>	+	<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>N050684</u>	<u>002</u>	Oct 22, 1993
<u>AP</u>	+	<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050684</u>	<u>003</u>	Oct 22, 1993
<u>AP</u>	+	<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>N050684</u>	<u>004</u>	Oct 22, 1993
<u>ZOSYN IN PLASTIC CONTAINER</u>					
	+ WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
	+	EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
	+	EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998

PIPERACILLIN; TAZOBACTAM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065363</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362</u>	<u>002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065363</u>	<u>002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362</u>	<u>003</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065363</u>	<u>003</u>	Oct 21, 2010

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

+	GRACEWAY	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992

PIROXICAM

CAPSULE; ORAL

FELDENE

<u>AB</u>	PFIZER	<u>10MG</u>	<u>N018147</u>	<u>002</u>	Apr 06, 1982
<u>AB</u>	+	<u>20MG</u>	<u>N018147</u>	<u>003</u>	Apr 06, 1982
<u>PIROXICAM</u>					
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A073535</u>	<u>001</u>	Mar 12, 1993
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A074102</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>20MG</u>	<u>A074102</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	NOSTRUM LABS	<u>10MG</u>	<u>A074116</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>		<u>20MG</u>	<u>A074118</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074131</u>	<u>001</u>	Dec 11, 1992
<u>AB</u>		<u>20MG</u>	<u>A074131</u>	<u>002</u>	Dec 11, 1992
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A074287</u>	<u>001</u>	May 16, 1996
<u>AB</u>		<u>10MG</u>	<u>A074460</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>20MG</u>	<u>A074287</u>	<u>002</u>	May 16, 1996
<u>AB</u>		<u>20MG</u>	<u>A074460</u>	<u>002</u>	Sep 29, 1995

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

KOWA

		EQ 1MG BASE	N022363	001	Aug 03, 2009
		EQ 2MG BASE	N022363	002	Aug 03, 2009
+		EQ 4MG BASE	N022363	003	Aug 03, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 325 (of 409)

PLERIXAFORSOLUTION; SUBCUTANEOUS
MOZOBIL

+ GENZYME 24MG/1.2ML (20MG/ML) N022311 001 Dec 15, 2008

PODOFILOXGEL; TOPICAL
CONDYLOX

+ WATSON PHARMS 0.5% N020529 001 Mar 13, 1997

SOLUTION; TOPICAL

CONDYLOX

AT + WATSON PHARMS 0.5% N019795 001 Dec 13, 1990

PODOFILOX

AT COLLEGIUM PHARM 0.5% A090184 001 Jul 21, 2010

AT PADDOCK 0.5% A075600 001 Jan 29, 2002

POLIDOCANOLSOLUTION; INTRAVENOUS
ASCLERACHEMISCH FBRK KRSSLR 10MG/2ML (5MG/ML) N021201 001 Mar 30, 2010
+ 20MG/2ML (10MG/ML) N021201 002 Mar 30, 2010POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

AA SCHWARZ PHARMA 17GM/SC00PFUL A076652 001 Jul 02, 2004

POLYETHYLENE GLYCOL 3350

AA BRECKENRIDGE PHARM 17GM/SC00PFUL A077736 001 May 26, 2006

AA NEXGEN PHARMA INC 17GM/SC00PFUL A077706 001 Sep 27, 2006

AA PADDOCK 17GM/SC00PFUL A077893 001 May 26, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKS

AA PADDOCK 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT A079232 001 Feb 25, 2010

NULYTELY

AA + BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT N019797 001 Apr 22, 1991

NULYTELY-FLAVORED

AA + BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT N019797 002 Nov 18, 1994

PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE

AA MYLAN 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT A090409 001 Apr 02, 2010

AA NOVEL LABS INC 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT A090019 001 May 27, 2009

TRILYTE

AA MEDA PHARMS 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT A076491 001 Feb 05, 2004

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

AA PADDOCK LABS 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT A090769 001 Jun 07, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 326 (of 409)

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

AA	+ ALAVEN PHARM	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989

AA	+	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	007	Jun 12, 1987

COLYTE WITH FLAVOR PACKS

AA	+ ALAVEN PHARM	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998

COLYTE-FLAVORED

AA	+ ALAVEN PHARM	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	008	Nov 14, 1991

AA	+	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	009	Nov 14, 1991

GOLYTELY

AA	+ BRAINTREE	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	N019011	001	Jul 13, 1984

PEG 3350 AND ELECTROLYTES

AA	MYLAN	236GM; 2.97GM; 6.74GM; 5.86GM; 22.74GM	A090928	001	Jan 28, 2010

AA	NOVEL LABS INC	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A090231	001	Jun 01, 2009

AA	+	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A090186	001	Jun 01, 2009

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

AA	PADDOCK LABS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A090712	001	Feb 25, 2010

GOLYTELY

+	BRAINTREE	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N019011	002	Jun 02, 1992

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYXIN B SULFATE

AP	APP PHARMS	EQ 500,000 U BASE/VIAL	A065372	001	Jan 10, 2008

AP	+ BEDFORD	EQ 500,000 U BASE/VIAL	A060716	001	

AP	X GEN PHARMS	EQ 500,000 U BASE/VIAL	A063000	001	Sep 30, 1994

POWDER; FOR RX COMPOUNDING

POLY-RX

+	X GEN PHARMS	100,000,000 UNITS/BOT	A061578	001	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

AT	+ ALLERGAN	10,000 UNITS/ML; EQ 1MG BASE/ML	N050567	001	Oct 20, 1988

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	BAUSCH AND LOMB	10,000 UNITS/ML; EQ 1MG BASE/ML	A064120	001	Feb 14, 1997

AT	FALCON PHARMS	10,000 UNITS/ML; EQ 1MG BASE/ML	A064211	001	Apr 13, 1998

AT	TAYLOR PHARMA	10,000 UNITS/ML; EQ 1MG BASE/ML	A065006	001	Dec 17, 1998

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF

+	CORNERSTONE THERAP	80MG/ML	N020744	001	Nov 18, 1999

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

+	AXCAN	75MG/VIAL	N020451	001	Dec 27, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 327 (of 409)

POSACONAZOLE

SUSPENSION; ORAL

NOXAFIL

+ SCHERING

40MG/ML

N022003 001

Sep 15, 2006

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA

2MEQ/ML

N018896 001

Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-KAB KV PHARM8MEQN018238 001MICRO-K 10AB KV PHARM10MEQN018238 002

May 14, 1984

POTASSIUM CHLORIDEAB WATSON LABS FLORIDA8MEQA077419 001

Jun 02, 2008

AB +10MEQA077419 002

Jun 02, 2008

INJECTABLE; INJECTION

POTASSIUM CHLORIDEAP APP PHARMS2MEQ/MLA080225 001AP B BRAUN2MEQ/MLA085870 001AP BAXTER HLTHCARE2MEQ/MLA085499 001AP + HOSPIRA2MEQ/MLA080205 001AP INTL MEDICATION2MEQ/MLA083163 001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE14.9MG/MLN019904 001

Dec 26, 1989

AP +746MG/100MLN019904 005

Dec 17, 1990

AP HOSPIRA14.9MG/MLN020161 005

Nov 30, 1992

AP745MG/100MLN020161 001

Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE29.8MG/MLN019904 002

Dec 26, 1989

AP +1.49GM/100MLN019904 006

Dec 17, 1990

AP + HOSPIRA29.8MG/MLN020161 006

Aug 11, 1998

AP1.49GM/100MLN020161 002

Nov 30, 1992

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE2.24GM/100MLN019904 003

Dec 26, 1989

AP +2.24GM/100MLN020161 003

Aug 11, 1998

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE2.98GM/100MLN019904 004

Dec 26, 1989

AP +2.98GM/100MLN020161 004

Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINERAP APP PHARMS2MEQ/MLA088901 001

Jan 25, 1985

AP2MEQ/MLA088908 001

Jan 25, 1985

POTASSIUM CHLORIDE

+ APP PHARMS

3MEQ/ML

A080225 003

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10AB UPSHER SMITH10MEQA074726 002

Aug 09, 2000

KLOR-CON M20AB UPSHER SMITH20MEQA074726 001

Nov 20, 1998

POTASSIUM CHLORIDEAB EURAND20MEQA076368 001

Aug 18, 2004

AB KV PHARM20MEQA076044 001

Apr 05, 2002

AB SCHERING10MEQN019439 002

Jun 13, 1986

AB +20MEQN019439 001

Jun 13, 1986

AB WATSON LABS FLORIDA10MEQA075604 001

Apr 10, 2002

AB20MEQA075604 002

Apr 10, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 328 (of 409)

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL					
K+10					
BC	FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
KAON CL-10					
BC	SAVAGE LABS	10MEQ	N017046	002	
KLOR-CON					
BC +	UPSHER SMITH	8MEQ	N019123	001	Apr 17, 1986
BC		10MEQ	N019123	002	Apr 17, 1986
KLOTRIX					
BC	APOTHECON	10MEQ	N017850	001	
K-TAB					
BC	ABBOTT	10MEQ	N018279	001	
POTASSIUM CHLORIDE					
BC	ABBOTT	8MEQ	N018279	002	Aug 01, 1988
KLOR-CON M15					
	UPSHER SMITH	15MEQ	A074726	003	Jun 06, 2003

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION					
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
<u>AP</u>	HOSPIRA	<u>149MG/100ML;450MG/100ML</u>	<u>A078446</u>	<u>001</u>	Sep 10, 2008
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
<u>AP</u> +	BAXTER HLTHCARE	<u>150MG/100ML;450MG/100ML</u>	<u>N017648</u>	<u>005</u>	Nov 26, 2002
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
<u>AP</u>	B BRAUN	<u>150MG/100ML;900MG/100ML</u>	<u>N019708</u>	<u>004</u>	Sep 29, 1989
<u>AP</u>	BAXTER HLTHCARE	<u>150MG/100ML;900MG/100ML</u>	<u>N017648</u>	<u>001</u>	
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
<u>AP</u>	BAXTER HLTHCARE	<u>300MG/100ML;900MG/100ML</u>	<u>N017648</u>	<u>002</u>	
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
<u>AP</u>	HOSPIRA	<u>149MG/100ML;900MG/100ML</u>	<u>N019686</u>	<u>001</u>	Oct 17, 1988
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
<u>AP</u>	HOSPIRA	<u>298MG/100ML;900MG/100ML</u>	<u>N019686</u>	<u>002</u>	Oct 17, 1988
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%					
	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL					
POTASSIUM CITRATE					
<u>AB</u>	COREPHARMA	<u>5MEQ</u>	<u>A077440</u>	<u>001</u>	Jun 09, 2006
<u>AB</u>		<u>10MEQ</u>	<u>A077440</u>	<u>002</u>	Jun 09, 2006
UROCIT-K					
<u>AB</u>	MISSION PHARMA	<u>5MEQ</u>	<u>N019071</u>	<u>001</u>	Aug 30, 1985
<u>AB</u>		<u>10MEQ</u>	<u>N019071</u>	<u>002</u>	Aug 31, 1992
UROCIT-K					
	+ MISSION PHARMA	15MEQ	N019071	003	Dec 30, 2009

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC					
	+ ALCON	5%	N018634	001	Dec 17, 1986

PRALATREXATE

SOLUTION; INTRAVENOUS					
FOLOTYN					
	ALLOS	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009
	+	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 329 (of 409)

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

+ MERIDIAN MEDCL TECHN 300MG/ML

N018986 001 Apr 26, 1983

PROTOPAM CHLORIDE

+ BAXTER HLTHCARE CORP 1GM/VIAL

N014134 001

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.125MG</u>	<u>N020667</u>	<u>001</u>	Jul 01, 1997
<u>AB</u>	+	<u>0.25MG</u>	<u>N020667</u>	<u>002</u>	Jul 01, 1997
<u>AB</u>		<u>0.5MG</u>	<u>N020667</u>	<u>006</u>	Feb 12, 1998
<u>AB</u>		<u>0.75MG</u>	<u>N020667</u>	<u>007</u>	Jul 30, 2007
<u>AB</u>		<u>1MG</u>	<u>N020667</u>	<u>003</u>	Jul 01, 1997
<u>AB</u>		<u>1.5MG</u>	<u>N020667</u>	<u>005</u>	Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ACTAVIS PHARMA	<u>0.125MG</u>	<u>A091254</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091254</u>	<u>002</u>	Nov 30, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091254</u>	<u>003</u>	Nov 30, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A091254</u>	<u>004</u>	Nov 30, 2010
<u>AB</u>		<u>1MG</u>	<u>A091254</u>	<u>005</u>	Nov 30, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091254</u>	<u>006</u>	Nov 30, 2010
<u>AB</u>	ALEMBIC LTD	<u>0.125MG</u>	<u>A078894</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078894</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078894</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A078894</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078894</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077724</u>	<u>001</u>	Feb 19, 2008
<u>AB</u>		<u>0.25MG</u>	<u>A077724</u>	<u>002</u>	Feb 19, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077724</u>	<u>003</u>	Feb 19, 2008
<u>AB</u>		<u>1MG</u>	<u>A077724</u>	<u>004</u>	Feb 19, 2008
<u>AB</u>		<u>1.5MG</u>	<u>A077724</u>	<u>005</u>	Feb 19, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.125MG</u>	<u>A091450</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091450</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091450</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A091450</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091450</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	GLENMARK GENERICS	<u>0.125MG</u>	<u>A090781</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090781</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090781</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090781</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090781</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	MYLAN	<u>0.125MG</u>	<u>A077854</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A077854</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A077854</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090764</u>	<u>001</u>	Apr 09, 2010
<u>AB</u>		<u>1MG</u>	<u>A077854</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A077854</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	SANDOZ	<u>0.125MG</u>	<u>A090190</u>	<u>001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090190</u>	<u>002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090190</u>	<u>003</u>	Jul 06, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090190</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090190</u>	<u>004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090190</u>	<u>005</u>	Jul 06, 2010
<u>AB</u>	TEVA PHARMS	<u>0.125MG</u>	<u>A090241</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090241</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090241</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090241</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090241</u>	<u>005</u>	Oct 08, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 330 (of 409)

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>1.5MG</u>	<u>A090241</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>	TORRENT PHARMS	<u>0.125MG</u>	<u>A090865</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090865</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090865</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090865</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090865</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090865</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>	WATSON LABS	<u>0.125MG</u>	<u>A078551</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078551</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078551</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A078551</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078551</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.125MG</u>	<u>A078920</u>	<u>001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078920</u>	<u>002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078920</u>	<u>003</u>	Jul 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078920</u>	<u>004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078920</u>	<u>005</u>	Jul 06, 2010

TABLET, EXTENDED RELEASE; ORAL
MIRAPEX ER

+	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010
		0.75MG	N022421	002	Feb 19, 2010
		1.5MG	N022421	003	Feb 19, 2010
		3MG	N022421	004	Feb 19, 2010
		4.5MG	N022421	005	Feb 19, 2010

PRAMLINTIDE ACETATEINJECTABLE; SUBCUTANEOUS
SYM LIN

	AMYLIN	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005

PRASUGREL HYDROCHLORIDETABLET; ORAL
EFFIENT

	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009
+		EQ 10MG BASE	N022307	002	Jul 10, 2009

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>10MG</u>	<u>N019898</u>	<u>002</u>	Oct 31, 1991
<u>AB</u>		<u>20MG</u>	<u>N019898</u>	<u>003</u>	Oct 31, 1991
<u>AB</u>		<u>40MG</u>	<u>N019898</u>	<u>004</u>	Mar 22, 1993
<u>AB</u>	+	<u>80MG</u>	<u>N019898</u>	<u>008</u>	Dec 18, 2001
	<u>PRAVASTATIN SODIUM</u>				
<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076341</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987</u>	<u>003</u>	May 11, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 331 (of 409)

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>	GLENMARK GENERICS	<u>80MG</u>	<u>A077987</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	LEK PHARMS DD	<u>10MG</u>	<u>A076397</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076397</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076397</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>20MG</u>	<u>A077917</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917</u>	<u>004</u>	Jan 08, 2008
<u>AB</u>	MATRIX LABS LTD	<u>10MG</u>	<u>A079187</u>	<u>001</u>	May 27, 2010
<u>AB</u>		<u>20MG</u>	<u>A079187</u>	<u>002</u>	May 27, 2010
<u>AB</u>		<u>40MG</u>	<u>A079187</u>	<u>003</u>	May 27, 2010
<u>AB</u>		<u>80MG</u>	<u>A079187</u>	<u>004</u>	May 27, 2010
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A077013</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077013</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077013</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077013</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>10MG</u>	<u>A077730</u>	<u>001</u>	Nov 21, 2006
<u>AB</u>		<u>20MG</u>	<u>A077730</u>	<u>002</u>	Nov 21, 2006
<u>AB</u>		<u>40MG</u>	<u>A077730</u>	<u>005</u>	Nov 21, 2006
<u>AB</u>	RANBAXY	<u>10MG</u>	<u>A076445</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>20MG</u>	<u>A076445</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>		<u>40MG</u>	<u>A076445</u>	<u>003</u>	Apr 23, 2007
<u>AB</u>		<u>80MG</u>	<u>A076445</u>	<u>004</u>	Apr 23, 2007
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056</u>	<u>003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793</u>	<u>001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939</u>	<u>004</u>	Oct 23, 2006
<u>AB</u>		<u>10MG</u>	<u>A077904</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077904</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A077751</u>	<u>001</u>	Apr 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A077751</u>	<u>002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751</u>	<u>003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751</u>	<u>004</u>	Apr 30, 2008
	PRAVASTATIN SODIUM				
	PLIVA HRVATSKA DOO	30MG	A077730	003	Nov 21, 2006

PRAZQUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER HLTHCARE 600MG N018714 001 Dec 29, 1982

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N017442</u>	<u>003</u>	
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N017442</u>	<u>001</u>	

PRAZOSIN HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071994</u>	<u>001</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A071995</u>	<u>001</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A071745</u>	<u>001</u>	Sep 12, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 332 (of 409)

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A072575</u>	<u>003</u>	May 16, 1989
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A072575</u>	<u>002</u>	May 16, 1989
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A072575</u>	<u>001</u>	May 16, 1989

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

<u>AB</u>	+ SANOFI AVENTIS US	<u>0.1%</u>	<u>N020279</u>	<u>001</u>	Oct 29, 1993

PREDNICARBATE

<u>AB</u>	ALTANA	<u>0.1%</u>	<u>A077287</u>	<u>001</u>	Sep 19, 2006

OINTMENT; TOPICAL

DERMATOP

<u>AB</u>	+ SANOFI AVENTIS US	<u>0.1%</u>	<u>N019568</u>	<u>001</u>	Sep 23, 1991

PREDNICARBATE

<u>AB</u>	ALTANA	<u>0.1%</u>	<u>A077236</u>	<u>001</u>	Mar 09, 2007

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

<u>AA</u>	ALPHARMA	<u>15MG/5ML</u>	<u>A040323</u>	<u>001</u>	May 13, 1999
<u>AA</u>	APOTEX INC	<u>5MG/5ML</u>	<u>A040570</u>	<u>001</u>	Aug 25, 2005
<u>AA</u>		<u>15MG/5ML</u>	<u>A040571</u>	<u>001</u>	Aug 25, 2005
<u>AA</u>	HI TECH PHARMA	<u>15MG/5ML</u>	<u>A040401</u>	<u>001</u>	Feb 27, 2003
<u>AA</u>	+ KV PHARM	<u>5MG/5ML</u>	<u>A040423</u>	<u>001</u>	Oct 22, 2001
<u>AA</u>	+	<u>15MG/5ML</u>	<u>A040364</u>	<u>001</u>	Apr 10, 2002
<u>AA</u>	PHARM ASSOC	<u>15MG/5ML</u>	<u>A040399</u>	<u>001</u>	Mar 05, 2003
<u>AA</u>	VINTAGE	<u>15MG/5ML</u>	<u>A040775</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>	WOCKHARDT	<u>15MG/5ML</u>	<u>A040313</u>	<u>001</u>	Sep 10, 2003

PRELONE

<u>AA</u>	TEVA	<u>15MG/5ML</u>	<u>A089081</u>	<u>001</u>	Feb 04, 1986

TABLET; ORAL

PREDNISOLONE

+	WATSON LABS	5MG	A080354	001	

PREDNISOLONE ACETATE

SUSPENSION; ORAL

FLO-PRED

+	TARO	EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

<u>AB</u>	ALCON	<u>1%</u>	<u>N017469</u>	<u>001</u>	

PRED FORTE

<u>AB</u>	+ ALLERGAN	<u>1%</u>	<u>N017011</u>	<u>001</u>	

PRED MILD

+	ALLERGAN	0.12%	N017100	001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

+	ALLERGAN	0.2%;10%	A087748	001	Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+	ALLERGAN	0.2%;10%	N012813	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 333 (of 409)

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

<u>AA</u>	+ SHIONOGI PHARMA	<u>EQ 15MG BASE/5ML</u>	<u>A075117</u>	<u>001</u>	Dec 14, 2000

PEDIAPRED

<u>AA</u>	+ UCB INC	<u>EQ 5MG BASE/5ML</u>	<u>N019157</u>	<u>001</u>	May 28, 1986

PREDNISOLONE SODIUM PHOSPHATE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/5ML</u>	<u>A078345</u>	<u>001</u>	Mar 10, 2009

<u>AA</u>	HI TECH PHARMA	<u>EQ 5MG BASE/5ML</u>	<u>A075183</u>	<u>001</u>	Mar 26, 2003

<u>AA</u>	KV PHARM	<u>EQ 5MG BASE/5ML</u>	<u>A076982</u>	<u>001</u>	May 24, 2005

<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076988</u>	<u>001</u>	May 24, 2005

<u>AA</u>	PADDOCK	<u>EQ 5MG BASE/5ML</u>	<u>A075988</u>	<u>001</u>	May 25, 2004

<u>AA</u>	PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A076123</u>	<u>001</u>	Dec 23, 2002

<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076913</u>	<u>001</u>	Apr 25, 2005

<u>AA</u>	VINTAGE	<u>EQ 5MG BASE/5ML</u>	<u>A078416</u>	<u>001</u>	Oct 31, 2007

<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A079010</u>	<u>001</u>	May 26, 2009

<u>AA</u>	WE PHARMS	<u>EQ 15MG BASE/5ML</u>	<u>A075250</u>	<u>001</u>	Jul 12, 2002

<u>AA</u>	WOCKHARDT	<u>EQ 5MG BASE/5ML</u>	<u>A075099</u>	<u>001</u>	Jun 28, 2002

<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076895</u>	<u>001</u>	Oct 04, 2004

PREDNISOLONE SODIUM PHOSPHATE

	+ PHARM ASSOC	EQ 10MG BASE/5ML	A078465	001	Mar 07, 2008

	+	EQ 20MG BASE/5ML	A078988	001	Jun 09, 2008

	+	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010

SOLUTION/DROPS; OPHTHALMIC

	+ BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

	SHIONOGI PHARMA	EQ 10MG BASE	N021959	001	Jun 01, 2006

		EQ 15MG BASE	N021959	002	Jun 01, 2006

	+	EQ 30MG BASE	N021959	003	Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

<u>AT</u>	ALCON	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A073630</u>	<u>001</u>	May 27, 1993

<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A074449</u>	<u>001</u>	Dec 29, 1995

VASOCIDIN

<u>AT</u>	+ NOVARTIS	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>N018988</u>	<u>001</u>	Aug 26, 1988

PREDNISONE

SOLUTION; ORAL

PREDNISONE

	+ ROXANE	5MG/5ML	A088703	001	Nov 08, 1984

PREDNISONE INTENSOL

	+ ROXANE	5MG/ML	A088810	001	Feb 20, 1985

TABLET; ORAL

PREDNISONE

<u>AB</u>	CADISTA PHARMS	<u>1MG</u>	<u>A040611</u>	<u>001</u>	Jun 06, 2005

<u>AB</u>		<u>5MG</u>	<u>A040362</u>	<u>002</u>	Aug 29, 2001

<u>AB</u>		<u>10MG</u>	<u>A040362</u>	<u>001</u>	Aug 29, 2001

<u>AB</u>		<u>20MG</u>	<u>A040362</u>	<u>003</u>	Jun 29, 2005

<u>AB</u>	CONTRACT PHARMACAL	<u>5MG</u>	<u>A080209</u>	<u>001</u>	

<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A089245</u>	<u>001</u>	Dec 04, 1985

<u>AB</u>		<u>10MG</u>	<u>A089246</u>	<u>001</u>	Dec 04, 1985

<u>AB</u>		<u>20MG</u>	<u>A089247</u>	<u>001</u>	Dec 04, 1985

<u>AB</u>	+ ROXANE	<u>1MG</u>	<u>A087800</u>	<u>001</u>	Apr 22, 1982

<u>AB</u>	+	<u>2.5MG</u>	<u>A087801</u>	<u>001</u>	Apr 22, 1982

<u>AB</u>	+	<u>5MG</u>	<u>A080352</u>	<u>001</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 334 (of 409)

PREDNISONE

TABLET; ORAL

PREDNISONE

<u>AB</u>	+	ROXANE	<u>10MG</u>	<u>A084122</u>	<u>001</u>	
<u>AB</u>	+		<u>20MG</u>	<u>A087342</u>	<u>001</u>	
<u>AB</u>	+		<u>50MG</u>	<u>A084283</u>	<u>001</u>	
<u>AB</u>		VINTAGE PHARMS	<u>1MG</u>	<u>A040584</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>			<u>2.5MG</u>	<u>A040581</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>			<u>5MG</u>	<u>A040256</u>	<u>001</u>	Jul 12, 2002
<u>AB</u>			<u>10MG</u>	<u>A040256</u>	<u>002</u>	Jul 12, 2002
<u>AB</u>			<u>20MG</u>	<u>A040392</u>	<u>001</u>	Feb 12, 2003
<u>AB</u>		WATSON LABS	<u>5MG</u>	<u>A080356</u>	<u>001</u>	
<u>AB</u>			<u>10MG</u>	<u>A085162</u>	<u>001</u>	
<u>AB</u>			<u>20MG</u>	<u>A085161</u>	<u>001</u>	
<u>AB</u>		WEST WARD	<u>2.5MG</u>	<u>A040538</u>	<u>001</u>	Jan 08, 2004
<u>AB</u>			<u>5MG</u>	<u>A080292</u>	<u>001</u>	
<u>AB</u>			<u>10MG</u>	<u>A088832</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>			<u>20MG</u>	<u>A083677</u>	<u>001</u>	
<u>AB</u>		WEST WARD PHARM CORP	<u>1MG</u>	<u>A040890</u>	<u>001</u>	Nov 01, 2010

PREGABALIN

CAPSULE; ORAL

LYRICA

CP PHARMS

25MG	N021446	001	Dec 30, 2004
50MG	N021446	002	Dec 30, 2004
75MG	N021446	003	Dec 30, 2004
100MG	N021446	004	Dec 30, 2004
150MG	N021446	005	Dec 30, 2004
200MG	N021446	006	Dec 30, 2004
225MG	N021446	007	Dec 30, 2004
300MG	N021446	008	Dec 30, 2004

SOLUTION; ORAL

LYRICA

+ PFIZER

20MG/ML	N022488	001	Jan 04, 2010

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

<u>AP</u>	+	DENTSPLY PHARM	<u>4%</u>	<u>N021382</u>	<u>001</u>	
<u>AP</u>		SEPTODONT INC	<u>4%</u>	<u>A079235</u>	<u>001</u>	Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

+ SANOFI AVENTIS US

EQ 15MG BASE	N008316	001	

PRIMIDONE

TABLET; ORAL

MYSOLINE

<u>AB</u>	+	VALEANT	<u>50MG</u>	<u>N009170</u>	<u>003</u>	
<u>AB</u>			<u>250MG</u>	<u>N009170</u>	<u>002</u>	

PRIMIDONE

<u>AB</u>		AMNEAL PHARM	<u>50MG</u>	<u>A040866</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>			<u>250MG</u>	<u>A040866</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>50MG</u>	<u>A040862</u>	<u>001</u>	Oct 03, 2008
<u>AB</u>			<u>250MG</u>	<u>A040862</u>	<u>002</u>	Oct 03, 2008
<u>AB</u>		IMPAX LABS	<u>50MG</u>	<u>A040717</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>			<u>250MG</u>	<u>A040717</u>	<u>002</u>	Feb 12, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 335 (of 409)

PRIMIDONE

TABLET; ORAL

PRIMIDONE

<u>AB</u>	LANNETT	<u>50MG</u>	<u>A084903</u>	<u>002</u>	May 24, 2001
<u>AB</u>		<u>250MG</u>	<u>A084903</u>	<u>001</u>	
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A040626</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>250MG</u>	<u>A040626</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040586</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>250MG</u>	<u>A040586</u>	<u>002</u>	Feb 24, 2005
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A083551</u>	<u>001</u>	
<u>AB</u>	WEST WARD	<u>50MG</u>	<u>A040667</u>	<u>001</u>	Jul 27, 2006
<u>AB</u>		<u>250MG</u>	<u>A040667</u>	<u>002</u>	Jul 27, 2006

PROBENECID

TABLET; ORAL

PROBALAN

<u>AB</u>	LANNETT	<u>500MG</u>	<u>A080966</u>	<u>001</u>	
	<u>PROBENECID</u>				
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>500MG</u>	<u>A083740</u>	<u>001</u>	May 09, 1984
<u>AB</u>	+ MYLAN	<u>500MG</u>	<u>A084211</u>	<u>002</u>	
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A084442</u>	<u>004</u>	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA	<u>100MG/ML</u>	<u>A089069</u>	<u>001</u>	Feb 12, 1986
<u>AP</u>	+	<u>500MG/ML</u>	<u>A089070</u>	<u>001</u>	Feb 12, 1986
<u>AP</u>	INTL MEDICATION	<u>100MG/ML</u>	<u>A088636</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>500MG/ML</u>	<u>A088637</u>	<u>001</u>	Jul 31, 1984

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+	SIGMA TAU	EQ 50MG BASE	N016785	001	

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO

<u>AB</u>	PADDOCK	<u>25MG</u>	<u>A040246</u>	<u>001</u>	Jun 28, 2000
	<u>PROCHLORPERAZINE</u>				
<u>AB</u>	+ G AND W LABS	<u>25MG</u>	<u>A040058</u>	<u>001</u>	Nov 24, 1993

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

<u>AP</u>	+ BAXTER HLTHCARE	<u>EQ 5MG BASE/ML</u>	<u>A089903</u>	<u>001</u>	Aug 29, 1989
<u>AP</u>	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A040540</u>	<u>001</u>	May 28, 2004

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A040185</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040185</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A040101</u>	<u>001</u>	Jul 19, 1996
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>A040101</u>	<u>002</u>	Jul 19, 1996
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A040120</u>	<u>001</u>	Jul 11, 1996
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040120</u>	<u>002</u>	Jul 11, 1996
	<u>PROCOMP</u>				
<u>AB</u>	CADISTA PHARMS	<u>EQ 5MG BASE</u>	<u>A040268</u>	<u>001</u>	Feb 27, 1998

PRESCRIPTION DRUG PRODUCT LIST

3 - 336 (of 409)

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

<u>AB</u>	CADISTA PHARMS	<u>EQ 10MG BASE</u>	<u>A040268</u>	<u>002</u>	Feb 27, 1998

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

	ABBOTT PRODS	100MG	N019781	001	May 14, 1998
+		200MG	N019781	002	Oct 15, 1999

GEL; VAGINAL

CRINONE

	WATSON LABS	4%	N020701	001	Jul 31, 1997
+		8%	N020701	002	Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONE

<u>AO</u>	APP PHARMS	<u>50MG/ML</u>	<u>A075906</u>	<u>001</u>	Apr 25, 2001
<u>AO</u>	HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A091033</u>	<u>001</u>	Oct 28, 2010
<u>AO</u>	LUITPOLD	<u>50MG/ML</u>	<u>A090845</u>	<u>001</u>	Jun 22, 2009
<u>AO</u>	+ WATSON LABS (UTAH)	<u>50MG/ML</u>	<u>N017362</u>	<u>002</u>	

INSERT; VAGINAL

ENDOMETRIN

	+ FERRING	100MG	N022057	001	Jun 21, 2007

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	BAXTER HLTHCARE	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
<u>AP</u>		<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>	HIKMA FARMACEUTICA	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008
<u>AP</u>	HOSPIRA	<u>25MG/ML</u>	<u>A040372</u>	<u>001</u>	Jun 08, 2000
<u>AP</u>	LUITPOLD	<u>25MG/ML</u>	<u>A040515</u>	<u>001</u>	Mar 19, 2003
<u>AP</u>	+ TEVA PARENTERAL	<u>25MG/ML</u>	<u>A040454</u>	<u>001</u>	Aug 22, 2002
<u>AP</u>		<u>50MG/ML</u>	<u>A040454</u>	<u>002</u>	Aug 22, 2002
<u>AP</u>	WOCKHARDT	<u>25MG/ML</u>	<u>A040785</u>	<u>001</u>	Sep 26, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040785</u>	<u>002</u>	Sep 26, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	G AND W LABS	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	+	<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>	PADDOCK	<u>12.5MG</u>	<u>A040479</u>	<u>001</u>	Jun 24, 2003
<u>AB</u>		<u>25MG</u>	<u>A040479</u>	<u>002</u>	Jun 24, 2003
<u>AB</u>	PERRIGO NEW YORK	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>		<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>	TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>		<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
	PROMETHEGAN				
	+ G AND W LABS	50MG	A087165	001	Aug 14, 1987

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>	HI TECH PHARMA	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>	SUN PHARM INDS INC	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>	TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>	VINTAGE	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006

PROMETHAZINE PLAIN

<u>AA</u>	+ WOCKHARDT	<u>6.25MG/5ML</u>	<u>A087953</u>	<u>001</u>	Nov 15, 1982

PRESCRIPTION DRUG PRODUCT LIST

3 - 337 (of 409)

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>12.5MG</u>	<u>A040673</u>	<u>001</u>	Mar 05, 2008
<u>AB</u>		<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>	AMNEAL PHARMS NY	<u>12.5MG</u>	<u>A091179</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>		<u>25MG</u>	<u>A091179</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>		<u>50MG</u>	<u>A091179</u>	<u>003</u>	Dec 13, 2010
<u>AB</u>	IMPAX LABS	<u>12.5MG</u>	<u>A040724</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>		<u>25MG</u>	<u>A040724</u>	<u>002</u>	Feb 12, 2008
<u>AB</u>		<u>50MG</u>	<u>A040791</u>	<u>001</u>	May 20, 2008
<u>AB</u>	KVK TECH	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>		<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A040713</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A084234</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040863</u>	<u>001</u>	Dec 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040863</u>	<u>002</u>	Dec 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A040863</u>	<u>003</u>	Dec 30, 2008
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>		<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>		<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A083426</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083711</u>	<u>001</u>	
<u>AB</u>	ZYDUS PHARMS USA	<u>12.5MG</u>	<u>A040596</u>	<u>001</u>	Nov 18, 2005
<u>AB</u>		<u>25MG</u>	<u>A040596</u>	<u>002</u>	Nov 18, 2005
<u>AB</u>		<u>50MG</u>	<u>A040596</u>	<u>003</u>	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>225MG</u>	<u>A078540</u>	<u>001</u>	Oct 18, 2010
<u>AB</u>		<u>325MG</u>	<u>A078540</u>	<u>002</u>	Oct 18, 2010
<u>AB</u>		<u>425MG</u>	<u>A078540</u>	<u>003</u>	Oct 18, 2010
	<u>RYTHMOL SR</u>				
<u>AB</u>	GLAXOSMITHKLINE LLC	<u>225MG</u>	<u>N021416</u>	<u>001</u>	Sep 04, 2003
<u>AB</u>		<u>325MG</u>	<u>N021416</u>	<u>002</u>	Sep 04, 2003
<u>AB</u>	+	<u>425MG</u>	<u>N021416</u>	<u>003</u>	Sep 04, 2003

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	KV PHARM	<u>150MG</u>	<u>A076193</u>	<u>001</u>	Feb 07, 2002
<u>AB</u>		<u>225MG</u>	<u>A076193</u>	<u>002</u>	Feb 07, 2002
<u>AB</u>		<u>300MG</u>	<u>A076193</u>	<u>003</u>	Feb 07, 2002
<u>AB</u>	MUTUAL PHARM	<u>150MG</u>	<u>A075998</u>	<u>001</u>	Nov 29, 2001
<u>AB</u>		<u>225MG</u>	<u>A075998</u>	<u>002</u>	Nov 29, 2001
<u>AB</u>		<u>300MG</u>	<u>A075998</u>	<u>003</u>	Nov 29, 2001
<u>AB</u>	PLIVA	<u>150MG</u>	<u>A076550</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>225MG</u>	<u>A076550</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>300MG</u>	<u>A076550</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>	VINTAGE PHARMS	<u>150MG</u>	<u>A075938</u>	<u>001</u>	Oct 17, 2002
<u>AB</u>		<u>225MG</u>	<u>A075938</u>	<u>002</u>	Oct 17, 2002
<u>AB</u>		<u>300MG</u>	<u>A075938</u>	<u>003</u>	Oct 17, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075203</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>		<u>225MG</u>	<u>A075203</u>	<u>002</u>	Oct 24, 2000
	<u>RYTHMOL</u>				
<u>AB</u>	GLAXOSMITHKLINE LLC	<u>150MG</u>	<u>N019151</u>	<u>001</u>	Nov 27, 1989
<u>AB</u>		<u>225MG</u>	<u>N019151</u>	<u>003</u>	Nov 20, 1992
<u>AB</u>	+	<u>300MG</u>	<u>N019151</u>	<u>002</u>	Nov 27, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 338 (of 409)

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

<u>ALCAINE</u>				
<u>AT</u>	ALCON	<u>0.5%</u>	<u>A080027</u>	<u>001</u>
<u>OPHTHAINE</u>				
<u>AT</u>	+ APOTHECON	<u>0.5%</u>	<u>N008883</u>	<u>001</u>
<u>OPHTHETIC</u>				
<u>AT</u>	+ ALLERGAN	<u>0.5%</u>	<u>N012583</u>	<u>001</u>
<u>PROPARACAINE HYDROCHLORIDE</u>				
<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A040074</u>	<u>001</u> Sep 29, 1995
<u>AT</u>	TAYLOR PHARMA	<u>0.5%</u>	<u>A040277</u>	<u>001</u> Mar 16, 2000

PROPOFOL

INJECTABLE; INJECTION

<u>DIPRIVAN</u>				
<u>AB</u>	+ APP PHARMS	<u>10MG/ML</u>	<u>N019627</u>	<u>002</u> Jun 11, 1996
<u>PROPOFOL</u>				
<u>AB</u>	HOSPIRA	<u>10MG/ML</u>	<u>A077908</u>	<u>001</u> Mar 17, 2006
<u>AB</u>	TEVA PARENTERAL	<u>10MG/ML</u>	<u>A075102</u>	<u>001</u> Jan 04, 1999

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

<u>DARVON</u>				
<u>AA</u>	+ XANODYNE PHARM	<u>65MG</u>	<u>N010997</u>	<u>003</u>
<u>DOLENE</u>				
<u>AA</u>	HERITAGE PHARMS INC	<u>65MG</u>	<u>A080530</u>	<u>001</u>
<u>PROPOXYPHENE HYDROCHLORIDE</u>				
<u>AA</u>	MYLAN	<u>65MG</u>	<u>A040569</u>	<u>001</u> Dec 16, 2004
<u>AA</u>	TEVA	<u>65MG</u>	<u>A088615</u>	<u>001</u> Oct 22, 1984
<u>AA</u>	VINTAGE PHARMS	<u>65MG</u>	<u>A040908</u>	<u>001</u> Jul 17, 2009
<u>AA</u>	WEST WARD	<u>65MG</u>	<u>A083501</u>	<u>001</u>

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N				
	+ XANODYNE PHARM	100MG	N016862	002

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

<u>INDERAL LA</u>				
<u>AB</u>	AKRIMAX PHARMS	<u>60MG</u>	<u>N018553</u>	<u>004</u> Mar 18, 1987
<u>AB</u>		<u>80MG</u>	<u>N018553</u>	<u>002</u> Apr 19, 1983
<u>AB</u>		<u>120MG</u>	<u>N018553</u>	<u>003</u> Apr 19, 1983
<u>AB</u>	+	<u>160MG</u>	<u>N018553</u>	<u>001</u> Apr 19, 1983
<u>PROPRANOLOL HYDROCHLORIDE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>60MG</u>	<u>A078494</u>	<u>001</u> Aug 10, 2007
<u>AB</u>		<u>80MG</u>	<u>A078494</u>	<u>002</u> Aug 10, 2007
<u>AB</u>		<u>120MG</u>	<u>A078494</u>	<u>003</u> Aug 10, 2007
<u>AB</u>		<u>160MG</u>	<u>A078494</u>	<u>004</u> Aug 10, 2007
<u>AB</u>	MYLAN	<u>60MG</u>	<u>A078022</u>	<u>001</u> Feb 15, 2007
<u>AB</u>		<u>80MG</u>	<u>A078022</u>	<u>002</u> Feb 15, 2007
<u>AB</u>		<u>120MG</u>	<u>A078022</u>	<u>003</u> Feb 15, 2007
<u>AB</u>		<u>160MG</u>	<u>A078022</u>	<u>004</u> Feb 15, 2007
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A078065</u>	<u>001</u> Jan 26, 2007
<u>AB</u>		<u>80MG</u>	<u>A078065</u>	<u>002</u> Jan 26, 2007
<u>AB</u>		<u>120MG</u>	<u>A078065</u>	<u>003</u> Jan 26, 2007
<u>AB</u>		<u>160MG</u>	<u>A078065</u>	<u>004</u> Jan 26, 2007
<u>AB</u>	UPSHER SMITH	<u>60MG</u>	<u>A078311</u>	<u>001</u> Mar 06, 2009
<u>AB</u>		<u>80MG</u>	<u>A078311</u>	<u>002</u> Mar 06, 2009
<u>AB</u>		<u>120MG</u>	<u>A078311</u>	<u>003</u> Mar 06, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 339 (of 409)

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>	UPSHER SMITH	<u>160MG</u>	<u>A078311</u>	<u>004</u>	Mar 06, 2009
	INNOPRAN XL				
BX	GLAXOSMITHKLINE LLC	80MG	N021438	001	Mar 12, 2003
BX		120MG	N021438	002	Mar 12, 2003

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>1MG/ML</u>	<u>A075826</u>	<u>001</u>	Aug 31, 2001
<u>AP</u>	+ BAXTER HLTHCARE CORP	<u>1MG/ML</u>	<u>N016419</u>	<u>001</u>	
<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075792</u>	<u>001</u>	Aug 29, 2000
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077760</u>	<u>001</u>	Jan 31, 2008
<u>AP</u>	SANDOZ	<u>1MG/ML</u>	<u>A076400</u>	<u>001</u>	Feb 26, 2003

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

	+ ROXANE	20MG/5ML	A070979	001	May 15, 1987
	+	40MG/5ML	A070690	001	May 15, 1987

TABLET; ORAL

INDERAL

<u>AB</u>	AKRIMAX PHARMS	<u>40MG</u>	<u>N016418</u>	<u>002</u>	
<u>AB</u>		<u>60MG</u>	<u>N016418</u>	<u>009</u>	Oct 18, 1982
<u>AB</u>	+	<u>80MG</u>	<u>N016418</u>	<u>004</u>	

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>	IPCA LABS LTD	<u>10MG</u>	<u>A078955</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>20MG</u>	<u>A078955</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>		<u>40MG</u>	<u>A078955</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>		<u>60MG</u>	<u>A078955</u>	<u>004</u>	Jun 02, 2008
<u>AB</u>		<u>80MG</u>	<u>A078955</u>	<u>005</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A070213</u>	<u>002</u>	Nov 19, 1985
<u>AB</u>		<u>20MG</u>	<u>A070213</u>	<u>003</u>	Nov 19, 1985
<u>AB</u>		<u>40MG</u>	<u>A070213</u>	<u>001</u>	Nov 19, 1985
<u>AB</u>		<u>80MG</u>	<u>A070213</u>	<u>004</u>	Nov 19, 1985
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078213</u>	<u>001</u>	Jan 10, 2008
<u>AB</u>		<u>20MG</u>	<u>A078213</u>	<u>002</u>	Jan 10, 2008
<u>AB</u>		<u>40MG</u>	<u>A078213</u>	<u>003</u>	Jan 10, 2008
<u>AB</u>		<u>60MG</u>	<u>A078213</u>	<u>004</u>	Jan 10, 2008
<u>AB</u>		<u>80MG</u>	<u>A078213</u>	<u>005</u>	Jan 10, 2008
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A071972</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>20MG</u>	<u>A071973</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>40MG</u>	<u>A071974</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>60MG</u>	<u>A071975</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>	+	<u>80MG</u>	<u>A071976</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A070217</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>20MG</u>	<u>A070218</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>40MG</u>	<u>A070219</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>60MG</u>	<u>A070220</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>		<u>80MG</u>	<u>A070221</u>	<u>001</u>	Apr 14, 1986
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A070175</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>20MG</u>	<u>A070176</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>40MG</u>	<u>A070177</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>80MG</u>	<u>A070178</u>	<u>001</u>	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+ DAVA PHARMS INC	50MG	N006188	001	
BD	WEST WARD	50MG	A080154	001	

PRESCRIPTION DRUG PRODUCT LIST

3 - 340 (of 409)

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

+ APP PHARMS	10MG/ML	A089454 001	Apr 07, 1987

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

<u>AB</u> ROXANE	<u>5MG</u>	<u>A078913</u> <u>001</u>	Sep 16, 2008
<u>AB</u>	<u>10MG</u>	<u>A078913</u> <u>002</u>	Sep 16, 2008
<u>AB</u> SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A090462</u> <u>001</u>	May 03, 2010
<u>AB</u>	<u>10MG</u>	<u>A090462</u> <u>002</u>	May 03, 2010

VIVACTIL

<u>AB</u> ODYSSEY PHARMS	<u>5MG</u>	<u>A073644</u> <u>001</u>	Aug 24, 1995
<u>AB</u> +	<u>10MG</u>	<u>A073645</u> <u>001</u>	Aug 24, 1995

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

<u>AB</u> + DAVA PHARMS INC	<u>500MG</u>	<u>A080157</u> <u>001</u>	
<u>AB</u> MIKART	<u>500MG</u>	<u>A081319</u> <u>001</u>	Jun 30, 1992

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

<u>AP</u> + VALEANT PHARM INTL	<u>5MG/ML</u>	<u>N009830</u> <u>001</u>	

REGONOL

<u>AP</u> SANDOZ	<u>5MG/ML</u>	<u>N017398</u> <u>001</u>	

SYRUP; ORAL

MESTINON

+ VALEANT PHARM INTL	60MG/5ML	N015193 001	

TABLET; ORAL

MESTINON

<u>AB</u> + VALEANT PHARM INTL	<u>60MG</u>	<u>N009829</u> <u>002</u>	

PYRIDOSTIGMINE BROMIDE

<u>AB</u> COREPHARMA	<u>60MG</u>	<u>A040457</u> <u>001</u>	Dec 26, 2002
<u>AB</u> IMPAX LABS	<u>60MG</u>	<u>A040502</u> <u>001</u>	Apr 24, 2003

TABLET, EXTENDED RELEASE; ORAL

MESTINON

+ VALEANT PHARM INTL	180MG	N011665 001	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

+ APP PHARMS	100MG/ML	A080618 001	

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+ GLAXOSMITHKLINE LLC	25MG	N008578 001	

QUAZEPAM

TABLET; ORAL

DORAL

+ QUESTCOR PHARMS	15MG	N018708 001	Dec 27, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 341 (of 409)

QUETIAPINE FUMARATE

TABLET; ORAL

SEROQUEL

+ ASTRAZENECA	EQ 25MG BASE	N020639	001	Sep 26, 1997
	EQ 50MG BASE	N020639	007	Oct 04, 2005
	EQ 100MG BASE	N020639	002	Sep 26, 1997
	EQ 200MG BASE	N020639	003	Sep 26, 1997
+	EQ 300MG BASE	N020639	005	Jul 26, 2000
	EQ 400MG BASE	N020639	006	Oct 04, 2005

TABLET, EXTENDED RELEASE; ORAL

SEROQUEL XR

+ ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007
	EQ 150MG BASE	N022047	005	Aug 11, 2008
+	EQ 200MG BASE	N022047	002	May 17, 2007
	EQ 300MG BASE	N022047	003	May 17, 2007
	EQ 400MG BASE	N022047	004	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCUPRIL

<u>AB</u>	PFIZER PHARMS	<u>EQ 5MG BASE</u>	<u>N019885</u>	<u>001</u>	Nov 19, 1991
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N019885</u>	<u>002</u>	Nov 19, 1991
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N019885</u>	<u>003</u>	Nov 19, 1991
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>N019885</u>	<u>004</u>	Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 5MG BASE</u>	<u>A076459</u>	<u>001</u>	Dec 22, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076459</u>	<u>002</u>	Dec 22, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076459</u>	<u>003</u>	Dec 22, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076459</u>	<u>004</u>	Dec 22, 2004
<u>AB</u>	APOTEX	<u>EQ 5MG BASE</u>	<u>A076240</u>	<u>001</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076240</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076240</u>	<u>003</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076240</u>	<u>004</u>	Jan 26, 2006
<u>AB</u>	GENPHARM	<u>EQ 5MG BASE</u>	<u>A076036</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076036</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076036</u>	<u>003</u>	Jan 28, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076036</u>	<u>004</u>	Jan 28, 2005
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078457</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078457</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078457</u>	<u>004</u>	Aug 24, 2007
<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077690</u>	<u>002</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077690</u>	<u>003</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077690</u>	<u>004</u>	Jun 20, 2006
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076694</u>	<u>001</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076694</u>	<u>002</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076694</u>	<u>003</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076694</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>	RANBAXY	<u>EQ 5MG BASE</u>	<u>A076607</u>	<u>001</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076607</u>	<u>002</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076607</u>	<u>003</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076607</u>	<u>004</u>	Dec 15, 2004
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A076803</u>	<u>001</u>	Mar 02, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076803</u>	<u>002</u>	Mar 02, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076803</u>	<u>003</u>	Mar 02, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076803</u>	<u>004</u>	Mar 02, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 5MG BASE</u>	<u>A090800</u>	<u>001</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090800</u>	<u>002</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090800</u>	<u>003</u>	Jun 18, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 342 (of 409)

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 40MG BASE</u>	<u>A090800</u>	<u>004</u>	Jun 18, 2009
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A075504</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075504</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075504</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075504</u>	<u>004</u>	Aug 24, 2007
<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 5MG BASE</u>	<u>A076049</u>	<u>001</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076049</u>	<u>002</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076049</u>	<u>003</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076049</u>	<u>004</u>	Jan 14, 2005

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+	LILLY	80MG/ML	N007529	002	Feb 10, 1989

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX	+	MUTUAL PHARM	324MG	A089338	001	Feb 11, 1987
BX		WATSON LABS	324MG	A087810	001	Sep 29, 1982

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

<u>AB</u>	MUTUAL PHARM	<u>200MG</u>	<u>A081030</u>	<u>001</u>	Apr 14, 1989
<u>AB</u>		<u>300MG</u>	<u>A081031</u>	<u>001</u>	Apr 14, 1989
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A088072</u>	<u>002</u>	
<u>AB</u>		<u>300MG</u>	<u>A088072</u>	<u>001</u>	Sep 26, 1983
<u>AB</u>	+	WATSON LABS	<u>200MG</u>	<u>A083288</u>	<u>001</u>
<u>AB</u>	+		<u>300MG</u>	<u>A085583</u>	<u>001</u>

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

+	TEVA PHARMS	300MG	A040045	001	Jun 30, 1994

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

+	AR HOLDING CO INC	324MG	N021799	001	Aug 12, 2005

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

+	EISAI INC	20MG	N020973	002	Aug 19, 1999

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTA

+	LILLY	60MG	N020815	001	Dec 09, 1997

RALTEGRAVIR POTASSIUM

TABLET; ORAL

ISENTRESS

+	MERCK SHARP DOHME	EQ 400MG BASE	N022145	001	Oct 12, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 343 (of 409)

RAMELTEON

TABLET; ORAL

ROZEREM

+ TAKEDA GLOBAL

8MG

N021782 001

Jul 22, 2005

RAMIPRIL

CAPSULE; ORAL

ALTACEAB KING PHARMS1.25MGN019901 001

Jan 28, 1991

AB2.5MGN019901 002

Jan 28, 1991

AB5MGN019901 003

Jan 28, 1991

AB +10MGN019901 004

Jan 28, 1991

RAMIPRILAB ACTAVIS ELIZABETH1.25MGA077513 001

Jun 18, 2008

AB2.5MGA077513 002

Jun 18, 2008

AB5MGA077513 003

Jun 18, 2008

AB10MGA077513 004

Jun 18, 2008

AB APOTEX1.25MGA079116 001

Jun 20, 2008

AB2.5MGA079116 002

Jun 20, 2008

AB5MGA079116 003

Jun 20, 2008

AB10MGA079116 004

Jun 20, 2008

AB CIPLA1.25MGA077004 001

Aug 07, 2008

AB2.5MGA077004 002

Aug 07, 2008

AB5MGA077004 003

Aug 07, 2008

AB10MGA077004 004

Aug 07, 2008

AB DR REDDYS LABS LTD1.25MGA078191 001

Jun 18, 2008

AB2.5MGA078191 002

Jun 18, 2008

AB5MGA078191 003

Jun 18, 2008

AB10MGA078191 004

Jun 18, 2008

AB INVAGEN PHARMS1.25MGA078745 001

Jun 18, 2008

AB2.5MGA078745 002

Jun 18, 2008

AB5MGA078745 003

Jun 18, 2008

AB10MGA078745 004

Jun 18, 2008

AB LUPIN1.25MGA077626 001

Jun 09, 2008

AB2.5MGA077626 002

Jun 09, 2008

AB5MGA077626 003

Jun 09, 2008

AB10MGA077626 004

Jun 09, 2008

AB RANBAXY5MGA078849 001

Mar 06, 2009

AB10MGA078849 002

Mar 06, 2009

AB ROXANE1.25MGA077900 001

Jun 18, 2008

AB2.5MGA077900 002

Jun 18, 2008

AB5MGA077900 003

Jun 18, 2008

AB10MGA077900 004

Jun 18, 2008

AB SANDOZ1.25MGA077514 001

Jun 18, 2008

AB2.5MGA077514 002

Jun 18, 2008

AB5MGA077514 003

Jun 18, 2008

AB10MGA077514 004

Jun 18, 2008

AB TEVA PHARMS1.25MGA077470 001

Jun 18, 2008

AB2.5MGA077470 002

Jun 18, 2008

AB5MGA077470 003

Jun 18, 2008

AB10MGA077470 004

Jun 18, 2008

AB WATSON LABS1.25MGA076549 001

Oct 24, 2005

AB2.5MGA076549 002

Oct 24, 2005

AB5MGA076549 003

Oct 24, 2005

AB10MGA076549 004

Oct 24, 2005

AB ZYDUS PHARMS USA1.25MGA078832 001

Sep 02, 2008

AB2.5MGA078832 002

Sep 02, 2008

AB5MGA078832 003

Sep 02, 2008

AB10MGA078832 004

Sep 02, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 344 (of 409)

RAMIPRIL

TABLET; ORAL

ALTACE

<u>AB</u>	KING PHARMS	<u>1.25MG</u>	<u>N022021</u>	<u>001</u>	Feb 27, 2007
<u>AB</u>		<u>2.5MG</u>	<u>N022021</u>	<u>002</u>	Feb 27, 2007
<u>AB</u>		<u>5MG</u>	<u>N022021</u>	<u>003</u>	Feb 27, 2007
<u>AB</u>	+	<u>10MG</u>	<u>N022021</u>	<u>004</u>	Feb 27, 2007

RAMIPRIL

<u>AB</u>	ZYDUS PHARMS USA INC	<u>1.25MG</u>	<u>A090697</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>2.5MG</u>	<u>A090697</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A090697</u>	<u>003</u>	Sep 24, 2009
<u>AB</u>		<u>10MG</u>	<u>A090697</u>	<u>004</u>	Sep 24, 2009

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>A074655</u>	<u>002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 25MG BASE/ML</u>	<u>A077458</u>	<u>001</u>	Feb 16, 2006
<u>AP</u>	BEN VENUE	<u>EQ 25MG BASE/ML</u>	<u>A074777</u>	<u>001</u>	Mar 02, 2005

ZANTAC

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 25MG BASE/ML</u>	<u>N019090</u>	<u>001</u>	Oct 19, 1984
		ZANTAC IN PLASTIC CONTAINER				
	+	GLAXOSMITHKLINE	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	ALPHARMA US PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A076124</u>	<u>001</u>	Feb 21, 2007
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312</u>	<u>001</u>	Sep 02, 2008
<u>AA</u>	APOTEX	<u>EQ 15MG BASE/ML</u>	<u>A077602</u>	<u>001</u>	Sep 17, 2007
<u>AA</u>	AUROBINDO PHARM	<u>EQ 15MG BASE/ML</u>	<u>A090623</u>	<u>001</u>	Jul 28, 2010
<u>AA</u>	CYPRESS PHARM	<u>EQ 15MG BASE/ML</u>	<u>A078684</u>	<u>001</u>	Aug 27, 2009
<u>AA</u>	DR REDDYS LABS LTD	<u>EQ 15MG BASE/ML</u>	<u>A090102</u>	<u>001</u>	May 26, 2009
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>	RANBAXY	<u>EQ 15MG BASE/ML</u>	<u>A078448</u>	<u>001</u>	Dec 13, 2007
<u>AA</u>	SILARX	<u>EQ 15MG BASE/ML</u>	<u>A091288</u>	<u>001</u>	Dec 09, 2010
<u>AA</u>	TOLMAR	<u>EQ 15MG BASE/ML</u>	<u>A090054</u>	<u>001</u>	Nov 15, 2010
<u>AA</u>	VINTAGE PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078890</u>	<u>001</u>	Jul 01, 2010
<u>AA</u>	WOCKHARDT	<u>EQ 15MG BASE/ML</u>	<u>A079211</u>	<u>001</u>	May 26, 2009
<u>AA</u>		<u>EQ 15MG BASE/ML</u>	<u>A079212</u>	<u>001</u>	Feb 23, 2009

ZANTAC

<u>AA</u>	+	GLAXOSMITHKLINE	<u>EQ 15MG BASE/ML</u>	<u>N019675</u>	<u>001</u>	Dec 30, 1988

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824</u>	<u>001</u>	Oct 13, 2006
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077824</u>	<u>002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680</u>	<u>001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680</u>	<u>002</u>	Sep 12, 1997
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>	GENPHARM	<u>EQ 150MG BASE</u>	<u>A074023</u>	<u>001</u>	Aug 22, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074023</u>	<u>002</u>	Aug 22, 1997
<u>AB</u>	GLENMARK GENERICS	<u>EQ 150MG BASE</u>	<u>A078542</u>	<u>001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542</u>	<u>002</u>	Nov 19, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 150MG BASE</u>	<u>A075165</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180</u>	<u>001</u>	Jan 28, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 345 (of 409)

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>EQ 300MG BASE</u>	<u>A075180</u>	<u>002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A074488</u>	<u>001</u>	Jul 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074488</u>	<u>002</u>	Jul 31, 1997
<u>AB</u>	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A074864</u>	<u>001</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077426</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074864</u>	<u>002</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077426</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 150MG BASE</u>	<u>A075208</u>	<u>001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078701</u>	<u>001</u>	Nov 12, 2009
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208</u>	<u>002</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078701</u>	<u>002</u>	Dec 11, 2009
	<u>ZANTAC 150</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 150MG BASE</u>	<u>N018703</u>	<u>001</u>	Jun 09, 1983
	<u>ZANTAC 300</u>				
<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 300MG BASE</u>	<u>N018703</u>	<u>002</u>	Dec 09, 1985

TABLET, EFFERVESCENT; ORAL

ZANTAC 25

+	GLAXOSMITHKLINE	EQ 25MG BASE	N020251	003	Apr 01, 2004

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

	GILEAD	500MG	N021526	002	Jan 27, 2006
+		1GM	N021526	001	Feb 12, 2007

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

	TEVA	EQ 0.5MG BASE	N021641	001	May 16, 2006
+		EQ 1MG BASE	N021641	002	May 16, 2006

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

+	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

	BIONICHE TEORANTA	EQ 1MG BASE/VIAL	N020630	001	Jul 12, 1996
		EQ 2MG BASE/VIAL	N020630	002	Jul 12, 1996
+		EQ 5MG BASE/VIAL	N020630	003	Jul 12, 1996

REPAGLINIDE

TABLET; ORAL

PRANDIN

	NOVO NORDISK INC	0.5MG	N020741	001	Dec 22, 1997
		1MG	N020741	002	Dec 22, 1997
+		2MG	N020741	003	Dec 22, 1997

RESERPINE

TABLET; ORAL

RESERPINE

BP	SANDOZ	0.1MG	N009838	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 346 (of 409)

RESERPINE

TABLET; ORAL			
RESERPINE			
BP + SANDOZ	0.25MG	N009838	002
SERPALAN			
BP LANNETT	0.1MG	N010124	001
BP	0.25MG	N010124	002

RETAPAMULIN

OINTMENT; TOPICAL			
ALTABAX			
+ GLAXO GRP LTD	1%	N022055	001 Apr 12, 2007

RIBAVIRIN

CAPSULE; ORAL			
<u>REBETOL</u>			
<u>AB</u> + SCHERING PLOUGH RES	<u>200MG</u>	<u>N020903</u>	<u>002</u> Jul 25, 2001
<u>RIBASPHERE</u>			
<u>AB</u> THREE RIVERS PHARMS	<u>200MG</u>	<u>A076203</u>	<u>001</u> Apr 06, 2004
<u>RIBAVARIN</u>			
<u>AB</u> AUROBINDO PHARMA	<u>200MG</u>	<u>A079117</u>	<u>001</u> Sep 17, 2009
<u>RIBAVIRIN</u>			
<u>AB</u> SANDOZ	<u>200MG</u>	<u>A076192</u>	<u>001</u> Apr 06, 2004
<u>AB</u> TEVA	<u>200MG</u>	<u>A076277</u>	<u>001</u> Oct 04, 2004
<u>AB</u> ZYDUS PHARMS USA	<u>200MG</u>	<u>A077224</u>	<u>001</u> Oct 28, 2005
REBETOL			
+ SCHERING PLOUGH RES	200MG	N020903	001 Jun 03, 1998
FOR SOLUTION; INHALATION			
VIRAZOLE			
+ VALEANT PHARM INTL	6GM/VIAL	N018859	001 Dec 31, 1985
SOLUTION; ORAL			
REBETOL			
+ SCHERING	40MG/ML	N021546	001 Jul 29, 2003
TABLET; ORAL			
<u>COPEGUS</u>			
<u>AB</u> ROCHE	<u>200MG</u>	<u>N021511</u>	<u>001</u> Dec 03, 2002
<u>RIBAVIRIN</u>			
<u>AB</u> AUROBINDO PHARMA	<u>200MG</u>	<u>A079111</u>	<u>001</u> Sep 17, 2009
<u>AB</u> SANDOZ	<u>200MG</u>	<u>A077743</u>	<u>001</u> Oct 03, 2006
<u>AB</u> TEVA	<u>200MG</u>	<u>A077053</u>	<u>001</u> Dec 05, 2005
<u>AB</u> THREE RIVERS PHARMS	<u>200MG</u>	<u>A077456</u>	<u>001</u> Dec 05, 2005
<u>AB</u>	<u>400MG</u>	<u>A077456</u>	<u>002</u> Dec 05, 2005
<u>AB</u> +	<u>600MG</u>	<u>A077456</u>	<u>003</u> Dec 05, 2005
<u>AB</u> ZYDUS PHARMS USA	<u>200MG</u>	<u>A077094</u>	<u>001</u> Dec 05, 2005
<u>AB</u>	<u>400MG</u>	<u>A077094</u>	<u>002</u> Mar 16, 2007
<u>AB</u>	<u>600MG</u>	<u>A077094</u>	<u>003</u> Mar 16, 2007
RIBAVIRIN			
ZYDUS PHARMS USA	500MG	A077094	004 Apr 18, 2008

RIFABUTIN

CAPSULE; ORAL			
MYCOBUTIN			
+ PHARMACIA AND UPJOHN	150MG	N050689	001 Dec 23, 1992

RIFAMPIN

CAPSULE; ORAL			
<u>RIFADIN</u>			
<u>AB</u> SANOFI AVENTIS US	<u>150MG</u>	<u>A062303</u>	<u>001</u>
<u>AB</u> +	<u>300MG</u>	<u>N050420</u>	<u>001</u>

PRESCRIPTION DRUG PRODUCT LIST

3 - 347 (of 409)

RIFAMPIN

CAPSULE; ORAL

RIFAMPIN

<u>AB</u>	LANNETT	<u>150MG</u>	<u>A065390</u>	<u>001</u>	Mar 28, 2008
<u>AB</u>		<u>300MG</u>	<u>A065390</u>	<u>002</u>	Mar 28, 2008
<u>AB</u>	SANDOZ	<u>150MG</u>	<u>A064150</u>	<u>002</u>	Jan 02, 1998
<u>AB</u>		<u>300MG</u>	<u>A064150</u>	<u>001</u>	May 28, 1997
<u>AB</u>	VERSAPHARM	<u>150MG</u>	<u>A065028</u>	<u>001</u>	Mar 14, 2001
<u>AB</u>		<u>300MG</u>	<u>A065028</u>	<u>002</u>	Mar 14, 2001

RIMACTANE

<u>AB</u>	ACTAVIS TOTOWA	<u>300MG</u>	<u>N050429</u>	<u>001</u>	

INJECTABLE; INJECTION

RIFADIN

<u>AP</u>	+ SANOFI AVENTIS US	<u>600MG/VIAL</u>	<u>N050627</u>	<u>001</u>	May 25, 1989

RIFAMPIN

<u>AP</u>	AKORN STRIDES	<u>600MG/VIAL</u>	<u>A065421</u>	<u>001</u>	May 22, 2008
<u>AP</u>	BEDFORD	<u>600MG/VIAL</u>	<u>A064217</u>	<u>001</u>	Oct 29, 1999
<u>AP</u>	COVENANT PHARMA INC	<u>600MG/VIAL</u>	<u>A065502</u>	<u>001</u>	Sep 21, 2010

RIFAPENTINE

TABLET; ORAL

PRIFTIN

	+ SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998

RIFAXIMIN

TABLET; ORAL

XIFAXAN

	+ SALIX PHARMS	200MG	N021361	001	May 25, 2004
		550MG	N022554	001	Mar 24, 2010

RILUZOLE

TABLET; ORAL

RILUTEK

<u>AB</u>	+ SANOFI AVENTIS US	<u>50MG</u>	<u>N020599</u>	<u>001</u>	Dec 12, 1995

RILUZOLE

<u>AB</u>	IMPAX LABS	<u>50MG</u>	<u>A076173</u>	<u>001</u>	Jan 29, 2003

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

<u>AB</u>	+ CARACO	<u>100MG</u>	<u>N019649</u>	<u>001</u>	Sep 17, 1993

RIMANTADINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>100MG</u>	<u>A076375</u>	<u>001</u>	Jan 14, 2003
<u>AB</u>	COREPHARMA	<u>100MG</u>	<u>A075916</u>	<u>001</u>	Nov 02, 2001
<u>AB</u>	IMPAX LABS	<u>100MG</u>	<u>A076132</u>	<u>001</u>	Aug 30, 2002

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

	+ ALCON	1%	N020474	001	Dec 30, 1994

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

<u>AB</u>	WARNER CHILCOTT	<u>5MG</u>	<u>N020835</u>	<u>002</u>	Apr 14, 2000
<u>AB</u>		<u>30MG</u>	<u>N020835</u>	<u>001</u>	Mar 27, 1998
<u>AB</u>	+	<u>35MG</u>	<u>N020835</u>	<u>003</u>	May 25, 2002

RISEDRONATE SODIUM

<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077132</u>	<u>001</u>	Oct 05, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 348 (of 409)

RISEDRONATE SODIUM

TABLET; ORAL

RISEDRONATE SODIUM

<u>AB</u>	TEVA PHARMS	<u>30MG</u>	<u>A077132</u>	<u>002</u>	Oct 05, 2007
<u>AB</u>		<u>35MG</u>	<u>A077132</u>	<u>003</u>	Oct 05, 2007
	ACTONEL				
	+ WARNER CHILCOTT	150MG	N020835	005	Apr 22, 2008
	TABLET, DELAYED RELEASE; ORAL				
	ATELVIA				
	+ WARNER CHILCOTT	35MG	N022560	001	Oct 08, 2010

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

	ORTHO MCNEIL JANSSEN	12.5MG/VIAL	N021346	004	Apr 12, 2007
	+	25MG/VIAL	N021346	001	Oct 29, 2003
		37.5MG/VIAL	N021346	002	Oct 29, 2003
		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION; ORAL

RISPERDAL

<u>AA</u>	+ ORTHO MCNEIL JANSSEN	<u>1MG/ML</u>	<u>N020588</u>	<u>001</u>	Jun 10, 1996

RISPERIDONE

<u>AA</u>	APOTEX INC	<u>1MG/ML</u>	<u>A077719</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A078452</u>	<u>001</u>	Sep 04, 2009
<u>AA</u>	DR REDDYS LABS LTD	<u>1MG/ML</u>	<u>A078909</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>	PRECISION DOSE	<u>1MG/ML</u>	<u>A076797</u>	<u>001</u>	Jun 28, 2010
<u>AA</u>	ROXANE	<u>1MG/ML</u>	<u>A076904</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>	TEVA	<u>1MG/ML</u>	<u>A076440</u>	<u>001</u>	Jan 30, 2009
<u>AA</u>	VINTAGE	<u>1MG/ML</u>	<u>A079158</u>	<u>001</u>	Dec 03, 2010
<u>AA</u>	WOCKHARDT	<u>1MG/ML</u>	<u>A078744</u>	<u>001</u>	Oct 08, 2009

TABLET; ORAL

RISPERDAL

<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>0.25MG</u>	<u>N020272</u>	<u>008</u>	May 10, 1999
<u>AB</u>		<u>0.5MG</u>	<u>N020272</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>	+	<u>1MG</u>	<u>N020272</u>	<u>001</u>	Dec 29, 1993
<u>AB</u>		<u>2MG</u>	<u>N020272</u>	<u>002</u>	Dec 29, 1993
<u>AB</u>		<u>3MG</u>	<u>N020272</u>	<u>003</u>	Dec 29, 1993
<u>AB</u>		<u>4MG</u>	<u>N020272</u>	<u>004</u>	Dec 29, 1993

RISPERIDONE

<u>AB</u>	ACTAVIS TOTOWA	<u>0.25MG</u>	<u>A078071</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078071</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>		<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>		<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>		<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>		<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077953</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077953</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A077953</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A077953</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A077953</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A077953</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>0.25MG</u>	<u>A078269</u>	<u>001</u>	Oct 08, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078269</u>	<u>002</u>	Oct 08, 2008
<u>AB</u>		<u>1MG</u>	<u>A078269</u>	<u>003</u>	Oct 08, 2008
<u>AB</u>		<u>2MG</u>	<u>A078269</u>	<u>004</u>	Oct 08, 2008
<u>AB</u>		<u>3MG</u>	<u>A078269</u>	<u>005</u>	Oct 08, 2008
<u>AB</u>		<u>4MG</u>	<u>A078269</u>	<u>006</u>	Oct 08, 2008
<u>AB</u>	CADISTA PHARMS	<u>0.25MG</u>	<u>A078828</u>	<u>001</u>	Mar 23, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078828</u>	<u>002</u>	Mar 23, 2009
<u>AB</u>		<u>1MG</u>	<u>A078828</u>	<u>003</u>	Mar 23, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 349 (of 409)

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>	<u>CADISTA PHARMS</u>	<u>2MG</u>	<u>A078828</u>	<u>004</u>	Mar 23, 2009
<u>AB</u>		<u>3MG</u>	<u>A078828</u>	<u>005</u>	Mar 23, 2009
<u>AB</u>		<u>4MG</u>	<u>A078828</u>	<u>006</u>	Mar 23, 2009
<u>AB</u>	<u>DR REDDYS LABS LTD</u>	<u>0.25MG</u>	<u>A076879</u>	<u>001</u>	Oct 24, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076879</u>	<u>002</u>	Oct 24, 2008
<u>AB</u>		<u>1MG</u>	<u>A076879</u>	<u>003</u>	Oct 24, 2008
<u>AB</u>		<u>2MG</u>	<u>A076879</u>	<u>004</u>	Oct 24, 2008
<u>AB</u>		<u>3MG</u>	<u>A076879</u>	<u>005</u>	Oct 24, 2008
<u>AB</u>		<u>4MG</u>	<u>A076879</u>	<u>006</u>	Oct 24, 2008
<u>AB</u>	<u>MYLAN</u>	<u>0.25MG</u>	<u>A076288</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076288</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A076288</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A076288</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A076288</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A076288</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	<u>PLIVA HRVATSKA DOO</u>	<u>0.25MG</u>	<u>A077769</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077769</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A077769</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A077769</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A077769</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A077769</u>	<u>006</u>	Oct 16, 2008
<u>AB</u>	<u>RATIOPHARM</u>	<u>0.25MG</u>	<u>A077784</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A077784</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A077784</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		<u>2MG</u>	<u>A077784</u>	<u>004</u>	Jun 08, 2010
<u>AB</u>		<u>3MG</u>	<u>A077784</u>	<u>005</u>	Jun 08, 2010
<u>AB</u>		<u>4MG</u>	<u>A077784</u>	<u>006</u>	Jun 08, 2010
<u>AB</u>	<u>SANDOZ</u>	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	<u>TEVA</u>	<u>0.25MG</u>	<u>A076228</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076228</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A076228</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A076228</u>	<u>004</u>	Jun 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A076228</u>	<u>005</u>	Jun 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A076228</u>	<u>006</u>	Jun 30, 2008
<u>AB</u>	<u>TORRENT PHARMS</u>	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	<u>VINTAGE</u>	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	<u>WATSON LABS</u>	<u>0.25MG</u>	<u>A077860</u>	<u>001</u>	Dec 05, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077860</u>	<u>002</u>	Dec 05, 2008
<u>AB</u>		<u>1MG</u>	<u>A077860</u>	<u>003</u>	Dec 05, 2008
<u>AB</u>		<u>2MG</u>	<u>A077860</u>	<u>004</u>	Dec 05, 2008
<u>AB</u>		<u>3MG</u>	<u>A077860</u>	<u>005</u>	Dec 05, 2008
<u>AB</u>		<u>4MG</u>	<u>A077860</u>	<u>006</u>	Dec 05, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 350 (of 409)

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>	WEST WARD PHARMS	<u>0.25MG</u>	<u>A078740</u>	<u>001</u>	May 29, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078740</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>1MG</u>	<u>A078740</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>2MG</u>	<u>A078740</u>	<u>004</u>	May 29, 2009
<u>AB</u>		<u>3MG</u>	<u>A078740</u>	<u>005</u>	May 29, 2009
<u>AB</u>		<u>4MG</u>	<u>A078740</u>	<u>006</u>	May 29, 2009
<u>AB</u>	WOCKHARDT	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
<u>AB</u>	+	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>	PAR PHARM	<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	RANBAXY	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>		<u>3MG</u>	<u>A078474</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078474</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009
	RISPERIDONE				
	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009

RITONAVIR

CAPSULE; ORAL

NORVIR

+ ABBOTT 100MG N020945 001 Jun 29, 1999

SOLUTION; ORAL

NORVIR

+ ABBOTT 80MG/ML N020659 001 Mar 01, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 351 (of 409)

RITONAVIR

TABLET; ORAL

NORVIR

+ ABBOTT LABS	100MG	N022417	001	Feb 10, 2010

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007

+	9.5MG/24HR	N022083	002	Jul 06, 2007

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

<u>AB</u> + NOVARTIS	<u>EQ 1.5MG BASE</u>	<u>N020823</u>	<u>003</u>	Apr 21, 2000

<u>AB</u>	<u>EQ 3MG BASE</u>	<u>N020823</u>	<u>004</u>	Apr 21, 2000

<u>AB</u>	<u>EQ 4.5MG BASE</u>	<u>N020823</u>	<u>005</u>	Apr 21, 2000

<u>AB</u>	<u>EQ 6MG BASE</u>	<u>N020823</u>	<u>006</u>	Apr 21, 2000

RIVASTIGMINE TARTRATE

<u>AB</u> DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130</u>	<u>001</u>	Oct 31, 2007

<u>AB</u>	<u>EQ 3MG BASE</u>	<u>A077130</u>	<u>002</u>	Oct 31, 2007

<u>AB</u>	<u>EQ 4.5MG BASE</u>	<u>A077130</u>	<u>003</u>	Oct 31, 2007

<u>AB</u>	<u>EQ 6MG BASE</u>	<u>A077130</u>	<u>004</u>	Oct 31, 2007

<u>AB</u> SUN PHARM INDS	<u>EQ 1.5MG BASE</u>	<u>A077131</u>	<u>001</u>	Oct 22, 2007

<u>AB</u>	<u>EQ 3MG BASE</u>	<u>A077131</u>	<u>002</u>	Oct 22, 2007

<u>AB</u>	<u>EQ 4.5MG BASE</u>	<u>A077131</u>	<u>003</u>	Oct 22, 2007

<u>AB</u>	<u>EQ 6MG BASE</u>	<u>A077131</u>	<u>004</u>	Oct 22, 2007

<u>AB</u> WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129</u>	<u>001</u>	Jan 08, 2008

<u>AB</u>	<u>EQ 3MG BASE</u>	<u>A077129</u>	<u>002</u>	Jan 08, 2008

<u>AB</u>	<u>EQ 4.5MG BASE</u>	<u>A077129</u>	<u>003</u>	Jan 08, 2008

<u>AB</u>	<u>EQ 6MG BASE</u>	<u>A077129</u>	<u>004</u>	Jan 08, 2008

SOLUTION; ORAL

EXELON

+ NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

MERCK	EQ 5MG BASE	N020864	001	Jun 29, 1998

+	EQ 10MG BASE	N020864	002	Jun 29, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

MERCK	EQ 5MG BASE	N020865	001	Jun 29, 1998

+	EQ 10MG BASE	N020865	002	Jun 29, 1998

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u> APP PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A078651</u>	<u>001</u>	Dec 29, 2008

<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A078651</u>	<u>002</u>	Dec 29, 2008

<u>AP</u> BIONICHE PHARMA USA	<u>50MG/5ML (10MG/ML)</u>	<u>A079199</u>	<u>001</u>	Nov 26, 2008

<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A079199</u>	<u>002</u>	Nov 26, 2008

<u>AP</u> HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519</u>	<u>001</u>	Nov 26, 2008

<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A078519</u>	<u>002</u>	Nov 26, 2008

<u>AP</u> SAGENT PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A091458</u>	<u>001</u>	Jul 28, 2010

<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A091458</u>	<u>002</u>	Jul 28, 2010

<u>AP</u> SANDOZ	<u>50MG/5ML (10MG/ML)</u>	<u>A079195</u>	<u>001</u>	Dec 05, 2008

<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A079195</u>	<u>002</u>	Dec 05, 2008

<u>AP</u> TEVA PARENTERAL	<u>50MG/5ML (10MG/ML)</u>	<u>A078717</u>	<u>001</u>	Nov 26, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 352 (of 409)

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	TEVA PARENTERAL	<u>100MG/10ML (10MG/ML)</u>	<u>A078717</u>	<u>002</u>	Nov 26, 2008
	<u>ZEMURON</u>				
<u>AP</u>	+ SCHERING	<u>50MG/5ML (10MG/ML)</u>	<u>N020214</u>	<u>001</u>	Mar 17, 1994
<u>AP</u>	+	<u>100MG/10ML (10MG/ML)</u>	<u>N020214</u>	<u>003</u>	Mar 17, 1994

ROMIDEPSIN

POWDER; IV (INFUSION)

	+ CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 0.25MG BASE</u>	<u>N020658</u>	<u>001</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>N020658</u>	<u>002</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N020658</u>	<u>003</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>N020658</u>	<u>004</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>N020658</u>	<u>006</u>	Jan 27, 1999
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N020658</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N020658</u>	<u>005</u>	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ALEMBIC LTD	<u>EQ 0.25MG BASE</u>	<u>A090429</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090429</u>	<u>002</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090429</u>	<u>003</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090429</u>	<u>004</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090429</u>	<u>005</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090429</u>	<u>006</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090429</u>	<u>007</u>	Mar 24, 2010
<u>AB</u>	COREPHARMA	<u>EQ 0.25MG BASE</u>	<u>A078230</u>	<u>001</u>	May 20, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078230</u>	<u>002</u>	May 20, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078230</u>	<u>003</u>	May 20, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078230</u>	<u>004</u>	May 20, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078230</u>	<u>005</u>	May 20, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078230</u>	<u>006</u>	May 20, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078230</u>	<u>007</u>	May 20, 2008
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.25MG BASE</u>	<u>A090135</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090135</u>	<u>002</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090135</u>	<u>003</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090135</u>	<u>004</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090135</u>	<u>005</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090135</u>	<u>006</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090135</u>	<u>007</u>	Feb 25, 2010
<u>AB</u>	HUAHAI US INC	<u>EQ 0.25MG BASE</u>	<u>A078110</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110</u>	<u>006</u>	May 05, 2008
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881</u>	<u>007</u>	May 19, 2008
<u>AB</u>	ROXANE	<u>EQ 0.25MG BASE</u>	<u>A077852</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077852</u>	<u>002</u>	May 05, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 353 (of 409)

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A077852</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077852</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077852</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077852</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077852</u>	<u>007</u>	May 19, 2008
<u>AB</u>	TEVA	<u>EQ 0.25MG BASE</u>	<u>A077460</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077460</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077460</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077460</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077460</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077460</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077460</u>	<u>007</u>	May 19, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 0.25MG BASE</u>	<u>A079050</u>	<u>001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050</u>	<u>002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050</u>	<u>003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050</u>	<u>004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050</u>	<u>005</u>	May 29, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050</u>	<u>006</u>	May 29, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050</u>	<u>007</u>	May 29, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 0.25MG BASE</u>	<u>A090411</u>	<u>001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411</u>	<u>002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411</u>	<u>003</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090411</u>	<u>004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411</u>	<u>005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411</u>	<u>006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411</u>	<u>007</u>	Jun 01, 2009

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

+	SMITHKLINE BEECHAM	EQ 2MG BASE	N022008	001	Jun 13, 2008
		EQ 4MG BASE	N022008	003	Jun 13, 2008
		EQ 6MG BASE	N022008	006	Apr 10, 2009
		EQ 8MG BASE	N022008	004	Jun 13, 2008
		EQ 12MG BASE	N022008	005	Oct 31, 2008

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION

NAROPIN

	APP PHARMS	2MG/ML	N020533	001	Sep 24, 1996
		5MG/ML	N020533	003	Sep 24, 1996
		7.5MG/ML	N020533	004	Sep 24, 1996
+		10MG/ML	N020533	005	Sep 24, 1996

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

	SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999
		EQ 4MG BASE	N021071	003	May 25, 1999
+		EQ 8MG BASE	N021071	004	May 25, 1999

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

	IPR	5MG	N021366	002	Aug 12, 2003
		10MG	N021366	003	Aug 12, 2003
		20MG	N021366	004	Aug 12, 2003
+		40MG	N021366	005	Aug 12, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 354 (of 409)

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION CARDIOGEN-82 BRACCO	N/A	N019414 001	Dec 29, 1989

RUFINAMIDE

TABLET; ORAL BANZEL EISAI INC	200MG	N021911 002	Nov 14, 2008
+	400MG	N021911 003	Nov 14, 2008

SACROSIDASE

SOLUTION; ORAL SUCRAID + QOL MEDCL	8,500 IU/ML	N020772 001	Apr 09, 1998

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION LIPOSYN II 10% + HOSPIRA	5%;5% (5GM/100ML)	N018997 001	Aug 27, 1984
LIPOSYN II 20% + HOSPIRA	10%;10% (10GM/100ML)	N018991 001	Aug 27, 1984

SALMETEROL XINAFOATE

POWDER; INHALATION SEREVENT + GLAXO GRP LTD	EQ 0.05MG BASE/INH	N020692 001	Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION QUADRAMET + EUSA PHARMA USA	50mCi/ML	N020570 001	Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE

TABLET; ORAL KUVAN + BIOMARIN PHARM	100MG	N022181 001	Dec 13, 2007

SAQUINAVIR MESYLATE

CAPSULE; ORAL INVIRASE + HOFFMANN LA ROCHE	EQ 200MG BASE	N020628 001	Dec 06, 1995
TABLET; ORAL INVIRASE + ROCHE	EQ 500MG BASE	N021785 001	Dec 17, 2004

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL ONGLYZA BRISTOL MYERS SQUIBB	EQ 2.5MG BASE	N022350 001	Jul 31, 2009
+	EQ 5MG BASE	N022350 002	Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL TRANSDERM SCOP + NOVARTIS	1MG/72HR	N017874 001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 355 (of 409)

SECOBARBITAL SODIUMCAPSULE; ORAL
SECONAL SODIUM

+	RANBAXY	50MG	A086101	001	Oct 03, 1983
+		100MG	A086101	002	Oct 03, 1983

SECRETIN SYNTHETIC HUMANFOR SOLUTION; INTRAVENOUS
CHIRHOSTIM

+	CHIRHOCLIN	16MCG/VIAL	N021256	001	Apr 09, 2004
		40MCG/VIAL	N021256	002	Jun 21, 2007

SELEGILINEFILM, EXTENDED RELEASE; TRANSDERMAL
EMSAM

+	SOMERSET	6MG/24HR	N021336	001	Feb 27, 2006
		9MG/24HR	N021336	002	Feb 27, 2006
		12MG/24HR	N021336	003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL

<u>AB</u>	+	SOMERSET	<u>5MG</u>	<u>N020647</u>	<u>001</u>	May 15, 1996

SELEGILINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>5MG</u>	<u>A075321</u>	<u>001</u>	Dec 04, 1998

<u>AB</u>		DAVA PHARMS INC	<u>5MG</u>	<u>A075352</u>	<u>001</u>	Nov 30, 1998

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

<u>AB</u>	+	APOTEX INC	<u>5MG</u>	<u>A074871</u>	<u>001</u>	Jun 06, 1997

<u>AB</u>		DAVA PHARMS INC	<u>5MG</u>	<u>A074641</u>	<u>001</u>	Aug 02, 1996

<u>AB</u>		MYLAN	<u>5MG</u>	<u>A074866</u>	<u>001</u>	Nov 26, 1997

<u>AB</u>		STASON	<u>5MG</u>	<u>A074912</u>	<u>001</u>	Apr 30, 1998

TABLET, ORALLY DISINTEGRATING; ORAL
ZELAPAR

+	VALEANT PHARM INTL	1.25MG	N021479	001	Jun 14, 2006

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>2.5%</u>	<u>A084394</u>	<u>001</u>	

<u>AT</u>		PERRIGO NEW YORK	<u>2.5%</u>	<u>A089996</u>	<u>001</u>	Jan 10, 1991

<u>AT</u>		WOCKHARDT	<u>2.5%</u>	<u>A088228</u>	<u>001</u>	Sep 01, 1983

SELSUN

<u>AT</u>	+	CHATTEM	<u>2.5%</u>	<u>N007936</u>	<u>001</u>	

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	ORTHO DERMATOLOGICS	2%	N021385	001	Dec 10, 2003

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

<u>AA</u>		AUROBINDO PHARMA	<u>EQ 20MG BASE/ML</u>	<u>A078861</u>	<u>001</u>	Oct 31, 2008

<u>AA</u>		RANBAXY	<u>EQ 20MG BASE/ML</u>	<u>A078053</u>	<u>001</u>	Feb 05, 2007

<u>AA</u>		ROXANE	<u>EQ 20MG BASE/ML</u>	<u>A076934</u>	<u>001</u>	Jun 30, 2006

ZOLOFT

<u>AA</u>	+	PFIZER	<u>EQ 20MG BASE/ML</u>	<u>N020990</u>	<u>001</u>	Dec 07, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 356 (of 409)

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 25MG BASE</u>	<u>A078175</u>	<u>001</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078175</u>	<u>002</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078175</u>	<u>003</u>	Jul 21, 2010
<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A076882</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076882</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076882</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A077206</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077206</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077206</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 25MG BASE</u>	<u>A078677</u>	<u>001</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078677</u>	<u>002</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078677</u>	<u>003</u>	Mar 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A076442</u>	<u>001</u>	Apr 30, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076442</u>	<u>002</u>	Apr 30, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076442</u>	<u>003</u>	Apr 30, 2007
<u>AB</u>	GENPHARM	<u>EQ 25MG BASE</u>	<u>A076540</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076540</u>	<u>002</u>	Mar 20, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076540</u>	<u>003</u>	Mar 20, 2007
<u>AB</u>	HIKMA PHARMS	<u>EQ 25MG BASE</u>	<u>A077864</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077864</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077864</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 25MG BASE</u>	<u>A077397</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077397</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077397</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A075719</u>	<u>003</u>	Jun 30, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A075719</u>	<u>001</u>	Jun 30, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A075719</u>	<u>002</u>	Jun 30, 2006
<u>AB</u>	LUPIN	<u>EQ 25MG BASE</u>	<u>A077670</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077670</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077670</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	MATRIX LABS LTD	<u>EQ 25MG BASE</u>	<u>A078626</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078626</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078626</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A076671</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076671</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076671</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 25MG BASE</u>	<u>A077299</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077299</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077299</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	RANBAXY	<u>EQ 25MG BASE</u>	<u>A077977</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077977</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077977</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	ROXANE	<u>EQ 25MG BASE</u>	<u>A076881</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076881</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076881</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 25MG BASE</u>	<u>A078108</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078108</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078108</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076465</u>	<u>001</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076465</u>	<u>002</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076465</u>	<u>003</u>	Aug 11, 2006
<u>AB</u>	TORRENT PHARMS	<u>EQ 25MG BASE</u>	<u>A077765</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077765</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077765</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A077663</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077663</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077663</u>	<u>003</u>	Feb 06, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 357 (of 409)

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>	WOCKHARDT	<u>EQ 25MG BASE</u>	<u>A078403</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078403</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078403</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077106</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077106</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077106</u>	<u>003</u>	Feb 06, 2007
<u>ZOLOFT</u>					
<u>AB</u>	PFIZER	<u>EQ 25MG BASE</u>	<u>N019839</u>	<u>005</u>	Mar 06, 1996
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N019839</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N019839</u>	<u>002</u>	Dec 30, 1991
<u>SERTRALINE HYDROCHLORIDE</u>					
	RANBAXY	EQ 150MG BASE	A077977	004	Feb 06, 2007
		EQ 200MG BASE	A077977	005	Feb 06, 2007

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

REVELA

GENZYME

800MG/PACKET

N022318 001 Aug 12, 2009

+

2.4GM/PACKET

N022318 002 Feb 18, 2009

TABLET; ORAL

REVELA

+ GENZYME

800MG

N022127 001 Oct 19, 2007

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

RENAGEL

GENZYME

400MG

N021179 001 Jul 12, 2000

+

800MG

N021179 002 Jul 12, 2000

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

<u>AN</u>	BAXTER HLTHCARE	<u>100%</u>	<u>A075895</u>	<u>001</u>	Jul 02, 2002
<u>AN</u>	HALOCARBON PRODS	<u>100%</u>	<u>A078650</u>	<u>001</u>	Nov 19, 2007
<u>SOJOURN</u>					
<u>AN</u>	PIRAMAL CRITICAL	<u>100%</u>	<u>A077867</u>	<u>001</u>	May 02, 2007
<u>ULTANE</u>					
<u>AN</u>	+ ABBOTT	<u>100%</u>	<u>N020478</u>	<u>001</u>	Jun 07, 1995

SILDENAFIL CITRATE

SOLUTION; INTRAVENOUS

REVATIO

+ PFIZER

EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)

N022473 001 Nov 18, 2009

TABLET; ORAL

REVATIO

+ PFIZER

EQ 20MG BASE

N021845 001 Jun 03, 2005

VIAGRA

PFIZER IRELAND

EQ 25MG BASE

N020895 001 Mar 27, 1998

EQ 50MG BASE

N020895 002 Mar 27, 1998

+

EQ 100MG BASE

N020895 003 Mar 27, 1998

SILODOSIN

CAPSULE; ORAL

RAPAFLO

WATSON LABS

4MG

N022206 001 Oct 08, 2008

+

8MG

N022206 002 Oct 08, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 358 (of 409)

SILVER SULFADIAZINE

CREAM; TOPICAL

SILVADENE

<u>AB</u>	+ KING PHARMS	<u>1%</u>	<u>N017381</u>	<u>001</u>	
	<u>SSD</u>				
<u>AB</u>	DR REDDYS LA	<u>1%</u>	<u>N018578</u>	<u>001</u>	Feb 25, 1982
	<u>THERMAZENE</u>				
<u>AB</u>	COVIDIEN	<u>1%</u>	<u>N018810</u>	<u>001</u>	Dec 23, 1985
	<u>SSD AF</u>				
BX	DR REDDYS LA	1%	N018578	003	Jul 11, 1990

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>	ACCORD HLTHCARE	<u>10MG</u>	<u>A078155</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078155</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>40MG</u>	<u>A078155</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>		<u>80MG</u>	<u>A078155</u>	<u>001</u>	Feb 26, 2008
<u>AB</u>	ACTAVIS TOTOWA	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077691</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077691</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077691</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077691</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077691</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A077752</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077752</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077752</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077752</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078425</u>	<u>001</u>	Aug 16, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076052</u>	<u>001</u>	Jun 23, 2006
<u>AB</u>		<u>10MG</u>	<u>A076052</u>	<u>002</u>	Jun 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076052</u>	<u>003</u>	Jun 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076052</u>	<u>004</u>	Jun 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076052</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
<u>AB</u>		<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
<u>AB</u>	MATRIX LABS LTD	<u>5MG</u>	<u>A090868</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>10MG</u>	<u>A090868</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>20MG</u>	<u>A090868</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		<u>40MG</u>	<u>A090868</u>	<u>004</u>	Jun 08, 2010
<u>AB</u>		<u>80MG</u>	<u>A090868</u>	<u>005</u>	Jun 08, 2010
<u>AB</u>	PERRIGO R AND D	<u>5MG</u>	<u>A078034</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A078034</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A078034</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A078034</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A078034</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076285</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076285</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076285</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076285</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076285</u>	<u>005</u>	Jun 23, 2006
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A077766</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077766</u>	<u>002</u>	Dec 20, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 359 (of 409)

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A077766</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077766</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077766</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006
<u>ZOCOR</u>					
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991
<u>AB</u>		<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+ BRACCO 0.005MG/VIAL

N017697 001

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+ MEDIGENE 15%

N021902 001 Oct 31, 2006

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+ WYETH PHARMS INC 1MG/ML

N021083 001 Sep 15, 1999

TABLET; ORAL

RAPAMUNE

WYETH PHARMS INC 0.5MG

N021110 004 Jan 25, 2010

1MG

N021110 001 Aug 25, 2000

+ 2MG

N021110 002 Aug 22, 2002

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

MERCK CO INC EQ 25MG BASE

N021995 001 Oct 16, 2006

EQ 50MG BASE

N021995 002 Oct 16, 2006

+ EQ 100MG BASE

N021995 003 Oct 16, 2006

SODIUM ACETATE ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA 2MEQ/ML

N018893 001 May 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)

+ UCYCLYD 10%;10% (5GM/50ML;5GM/50ML)

N020645 001 Feb 17, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 360 (of 409)

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

+	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005
+		1MEQ/ML	A077394	002	Nov 09, 2005

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	APP PHARMS	<u>9MG/ML</u>	<u>A088911</u>	<u>001</u>	Feb 07, 1985
<u>AP</u>	+ HOSPIRA	<u>9MG/ML</u>	<u>N018800</u>	<u>001</u>	Oct 29, 1982

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>450MG/100ML</u>	<u>N019635</u>	<u>001</u>	Mar 09, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>450MG/100ML</u>	<u>N018016</u>	<u>001</u>	
<u>AP</u>	HOSPIRA	<u>450MG/100ML</u>	<u>N018090</u>	<u>001</u>	
<u>AP</u>		<u>450MG/100ML</u>	<u>N019759</u>	<u>001</u>	Jun 08, 1988

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+ APP PHARMS	<u>9MG/ML</u>	<u>A088912</u>	<u>001</u>	Jan 10, 1985
<u>AP</u>	+ B BRAUN	<u>900MG/100ML</u>	<u>N017464</u>	<u>001</u>	
<u>AP</u>	+	<u>900MG/100ML</u>	<u>N019635</u>	<u>002</u>	Mar 09, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>9MG/ML</u>	<u>N016677</u>	<u>004</u>	Oct 30, 1985
<u>AP</u>		<u>9MG/ML</u>	<u>N020178</u>	<u>002</u>	Dec 07, 1992
<u>AP</u>	+	<u>900MG/100ML</u>	<u>N016677</u>	<u>001</u>	
<u>AP</u>	+	<u>900MG/100ML</u>	<u>N020178</u>	<u>001</u>	Dec 07, 1992
<u>AP</u>	FRESENIUS MEDCL	<u>900MG/100ML</u>	<u>A078177</u>	<u>001</u>	Apr 12, 2007
<u>AP</u>	HAEMONETICS	<u>900MG/100ML</u>	<u>A076316</u>	<u>001</u>	Oct 27, 2004
<u>AP</u>	+ HOSPIRA	<u>9MG/ML</u>	<u>N018803</u>	<u>001</u>	Oct 29, 1982
<u>AP</u>	+	<u>9MG/ML</u>	<u>N019217</u>	<u>001</u>	Jul 13, 1984
<u>AP</u>		<u>9MG/ML</u>	<u>N019465</u>	<u>002</u>	Jul 15, 1985
<u>AP</u>	+	<u>900MG/100ML</u>	<u>N016366</u>	<u>001</u>	
<u>AP</u>	+	<u>900MG/100ML</u>	<u>N019465</u>	<u>001</u>	Jul 15, 1985
<u>AP</u>	+	<u>900MG/100ML</u>	<u>N019480</u>	<u>001</u>	Sep 17, 1985
<u>AP</u>	+ TARO PHARMS IRELAND	<u>9MG/ML</u>	<u>A077407</u>	<u>001</u>	Aug 11, 2006

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	MALLINCKRODT	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006
		112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983

SODIUM CHLORIDE IN PLASTIC CONTAINER

HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>450MG/100ML</u>	<u>N017864</u>	<u>001</u>
<u>AT</u>	HOSPIRA	<u>450MG/100ML</u>	<u>N017670</u>	<u>001</u>
<u>AT</u>		<u>450MG/100ML</u>	<u>N018380</u>	<u>001</u>

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>900MG/100ML</u>	<u>N016733</u>	<u>001</u>
<u>AT</u>	BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N017427</u>	<u>001</u>
<u>AT</u>		<u>900MG/100ML</u>	<u>N017867</u>	<u>001</u>
<u>AT</u>	HOSPIRA	<u>900MG/100ML</u>	<u>N017514</u>	<u>001</u>
<u>AT</u>		<u>900MG/100ML</u>	<u>N018314</u>	<u>001</u>

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 361 (of 409)

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION
CHROMITOPÉ SODIUM
BRACCO

200uCi/ML

N013993 001

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION
FERRLECIT

+ SANOFI AVENTIS US

62.5MG/5ML

N020955 001 Feb 18, 1999

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123AA + GE HEALTHCARE100uCiN017630 001AA MALLINCKRODT100uCiA071909 001 Feb 28, 1989AA200uCiA071910 001 Feb 28, 1989AA + SYNCOR PHARMS100uCiN018671 001 May 27, 1982AA +200uCiN018671 002 May 27, 1982

SOLUTION; ORAL

SODIUM IODIDE I 123

+ GE HEALTHCARE

2mCi/ML

N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ MALLINCKRODT

0.8-100mCi

N016517 001

SODIUM IODIDE I-131

DRAXIMAGE

9-100mCi

N021305 006 May 19, 2005

2-200mCi

N021305 004 Nov 18, 2004

SOLUTION; ORAL

HICON

+ DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003

+

1-500mCi/0.5ML

N021305 003 Jan 24, 2003

+

1-1000mCi/ML

N021305 005 Apr 04, 2006

SODIUM IODIDE I 131

+ MALLINCKRODT

3.5-150mCi/VIAL

N016515 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINERAP BAXTER HLTHCARE1.87GM/100MLN016692 001SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINERAP B BRAUN1.87GM/100MLN020004 001 Apr 21, 1992

SODIUM LACTATE IN PLASTIC CONTAINER

+ HOSPIRA

5MEQ/ML

N018947 001 Sep 05, 1984

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESSAP + HOSPIRA25MG/MLA071961 001 Aug 01, 1988SODIUM NITROPRUSSIDEAP TEVA PARENTERAL25MG/MLA073465 001 Mar 30, 1992SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ JAZZ

500MG/ML

N021196 001 Jul 17, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 362 (of 409)

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

+ MEDICIS 3GM/TEASPOONFUL N020573 001 Apr 30, 1996

TABLET; ORAL

BUPHENYL

+ MEDICIS 500MG N020572 001 May 13, 1996

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+ SALIX PHARMS 0.398GM;1.102GM N021892 001 Mar 16, 2006

VISICOL

+ SALIX PHARMS 0.398GM;1.102GM N021097 001 Sep 21, 2000

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

HOSPIRA

142MG/ML;276MG/ML

N018892 001 May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATEAA KVK TECH 454GM/BOT A040905 001 Mar 30, 2009KAYEXALATEAA + SANOFI AVENTIS US 453.6GM/BOT N011287 001KIONEXAA PADDOCK 454GM/BOT A040029 001 Feb 06, 1998SODIUM POLYSTYRENE SULFONATEAA CAROLINA MEDCL 454GM/BOT A089910 001 Jan 19, 1989AA CITRUSPHRMA 454GM/BOT A040909 001 Dec 03, 2008

SUSPENSION; ORAL, RECTAL

KIONEXAA PADDOCK 15GM/60ML A040028 001 Sep 17, 2007SODIUM POLYSTYRENE SULFONATEAA ROXANE 15GM/60ML A089049 001 Nov 17, 1986SPSAA + CAROLINA MEDCL 15GM/60ML A087859 001 Dec 08, 1982SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

BIONICHE PHARMA

20MG/2ML (10MG/ML)

A040541 001 Nov 12, 2004

+ 60MG/2ML (30MG/ML)

A040541 002 Nov 12, 2004

SOLIFENACIN SUCCINATE

TABLET; ORAL

VESICARE

ASTELLAS

5MG

N021518 001 Nov 19, 2004

+ 10MG

N021518 002 Nov 19, 2004

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN

BX + PHARMACIA AND UPJOHN 5.8MG/VIAL N020280 006 Aug 24, 1995

GENOTROPIN PRESERVATIVE FREE

BX PHARMACIA AND UPJOHN 1.5MG/VIAL N020280 004 Aug 24, 1995

HUMATROPE

BX + LILLY 5MG/VIAL N019640 004 Mar 08, 1987

PRESCRIPTION DRUG PRODUCT LIST

3 - 363 (of 409)

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION				
HUMATROPE				
BX	LILLY	6MG/VIAL	N019640 005	Feb 04, 1999
NORDITROPIN				
BX	NOVO NORDISK INC	5MG/1.5ML	N021148 001	Jun 20, 2000
BX		10MG/1.5ML	N021148 002	Jun 20, 2000
NORDITROPIN FLEXPOR				
BX	NOVO NORDISK INC	5MG/1.5ML	N021148 008	Mar 01, 2010
BX		10MG/1.5ML	N021148 009	Mar 01, 2010
NORDITROPIN NORDIFLEX				
BX	NOVO NORDISK INC	5MG/1.5ML	N021148 004	Oct 01, 2004
BX		10MG/1.5ML	N021148 005	Oct 01, 2004
NUTROPIN				
BX	GENENTECH	5MG/VIAL	N020168 001	Nov 17, 1993
OMNITROPE				
BX	SANDOZ	1.5MG/VIAL	N021426 002	May 30, 2006
BX		5MG/1.5ML	N021426 003	Jan 16, 2008
BX		5.8MG/VIAL	N021426 001	May 30, 2006
BX		10MG/1.5ML	N021426 004	Aug 25, 2008
SAIZEN				
BX	EMD SERONO	5MG/VIAL	N019764 002	Oct 08, 1996
SEROSTIM				
BX	EMD SERONO	4MG/VIAL	N020604 003	Jul 25, 1997
BX		5MG/VIAL	N020604 002	Aug 23, 1996
BX		6MG/VIAL	N020604 001	Aug 23, 1996
TEV-TROPIN				
BX +	FERRING	5MG/VIAL	N019774 002	Jan 04, 2002
VALTROPIN				
BX	LG LIFE	5MG/VIAL	N021905 001	Apr 19, 2007
GENOTROPIN				
+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280 007	Oct 23, 1996
GENOTROPIN PRESERVATIVE FREE				
	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280 001	Jan 27, 1998
		0.4MG/VIAL	N020280 002	Jan 27, 1998
		0.6MG/VIAL	N020280 003	Jan 27, 1998
		0.8MG/VIAL	N020280 005	Jan 27, 1998
		1MG/VIAL	N020280 008	Jan 27, 1998
		1.2MG/VIAL	N020280 009	Jan 27, 1998
		1.4MG/VIAL	N020280 010	Jan 27, 1998
		1.6MG/VIAL	N020280 011	Jan 27, 1998
		1.8MG/VIAL	N020280 012	Jan 27, 1998
+		2MG/VIAL	N020280 013	Jan 27, 1998
HUMATROPE				
+	LILLY	12MG/VIAL	N019640 006	Feb 04, 1999
+		24MG/VIAL	N019640 007	Feb 04, 1999
NORDITROPIN				
+	NOVO NORDISK INC	15MG/1.5ML	N021148 003	Jun 20, 2000
NORDITROPIN FLEXPOR				
	NOVO NORDISK INC	15MG/1.5ML	N021148 010	Mar 01, 2010
NORDITROPIN NORDIFLEX				
	NOVO NORDISK INC	15MG/1.5ML	N021148 006	Oct 01, 2004
		30MG/3ML	N021148 007	Mar 10, 2009
NUTROPIN				
+	GENENTECH	10MG/VIAL	N020168 002	Nov 17, 1993
NUTROPIN AQ				
+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522 003	Jan 03, 2008
+		10MG/2ML (5MG/ML)	N020522 001	Dec 29, 1995
+		20MG/2ML (10MG/ML)	N020522 004	Jan 03, 2008
NUTROPIN AQ PEN				
+	GENENTECH	10MG/2ML (5MG/ML)	N020522 002	Apr 22, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 364 (of 409)

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

SAIZEN

+ EMD SERONO 8.8MG/VIAL N019764 003 Aug 29, 2000

ZORBTIVE

+ EMD SERONO 8.8MG/VIAL N021597 004 Dec 01, 2003

SORAFENIB TOSYLATE

TABLET; ORAL

NEXAVAR

+ BAYER HLTHCARE EQ 200MG BASE N021923 001 Dec 20, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML N017863 001

SORBITOL 3.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML N016741 001

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

SOTALOL HYDROCHLORIDE

+ ACADEMIC PHARMS 150MG/10ML (15MG/ML) N022306 001 Jul 02, 2009

TABLET; ORAL

BETAPACEAB1 BAYER HLTHCARE 80MG N019865 001 Oct 30, 1992AB1 120MG N019865 005 Apr 20, 1994AB1 + 160MG N019865 002 Oct 30, 1992AB1 240MG N019865 003 Oct 30, 1992SORINEAB1 UPSHER SMITH 80MG A075500 001 Apr 27, 2001AB1 120MG A075500 004 Apr 27, 2001AB1 160MG A075500 002 Apr 27, 2001AB1 240MG A075500 003 Apr 27, 2001SOTALOL HYDROCHLORIDEAB1 APOTEX INC 80MG A076140 001 Sep 26, 2002AB1 120MG A076140 002 Sep 26, 2002AB1 160MG A076140 003 Sep 26, 2002AB1 240MG A076140 004 Sep 26, 2002AB1 IMPAX PHARMS 80MG A075663 001 Nov 07, 2000AB1 120MG A075663 002 Nov 07, 2000AB1 160MG A075663 003 Nov 07, 2000AB1 240MG A075663 004 Nov 07, 2000AB1 MYLAN 80MG A075237 001 May 01, 2000AB1 80MG A075725 001 Dec 19, 2000AB1 120MG A075237 002 May 01, 2000AB1 120MG A075725 002 Dec 19, 2000AB1 160MG A075237 003 May 01, 2000AB1 160MG A075725 003 Dec 19, 2000AB1 240MG A075237 004 May 01, 2000AB1 240MG A075725 004 Dec 19, 2000AB1 SANDOZ 80MG A075366 001 May 01, 2000AB1 120MG A075366 002 May 01, 2000AB1 160MG A075366 003 May 01, 2000AB1 240MG A075366 004 May 01, 2000AB1 TEVA 80MG A075429 001 May 01, 2000AB1 120MG A075429 002 May 01, 2000AB1 160MG A075429 003 May 01, 2000AB1 240MG A075429 004 May 01, 2000AB1 VINTAGE PHARMS 80MG A075563 001 Nov 07, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 365 (of 409)

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

<u>AB1</u>	VINTAGE PHARMS	<u>120MG</u>	<u>A075563</u>	<u>002</u>	Nov 07, 2003
<u>AB1</u>		<u>160MG</u>	<u>A075563</u>	<u>003</u>	Nov 07, 2003
<u>AB1</u>		<u>240MG</u>	<u>A075563</u>	<u>004</u>	Nov 07, 2003
<u>BETAPACE AF</u>					
<u>AB2</u>	BAYER HLTHCARE	<u>80MG</u>	<u>N021151</u>	<u>001</u>	Feb 22, 2000
<u>AB2</u>		<u>120MG</u>	<u>N021151</u>	<u>002</u>	Feb 22, 2000
<u>AB2</u> +		<u>160MG</u>	<u>N021151</u>	<u>003</u>	Feb 22, 2000
<u>SOTALOL HYDROCHLORIDE</u>					
<u>AB2</u>	AMNEAL PHARM	<u>80MG</u>	<u>A077070</u>	<u>001</u>	Nov 04, 2005
<u>AB2</u>		<u>120MG</u>	<u>A077070</u>	<u>002</u>	Nov 04, 2005
<u>AB2</u>		<u>160MG</u>	<u>A077070</u>	<u>003</u>	Nov 04, 2005
<u>AB2</u>	APOTEX	<u>80MG</u>	<u>A076214</u>	<u>001</u>	Aug 27, 2003
<u>AB2</u>		<u>120MG</u>	<u>A076214</u>	<u>002</u>	Aug 27, 2003
<u>AB2</u>		<u>160MG</u>	<u>A076214</u>	<u>003</u>	Aug 27, 2003
<u>AB2</u>	MYLAN	<u>80MG</u>	<u>A077616</u>	<u>001</u>	Feb 07, 2007
<u>AB2</u>		<u>120MG</u>	<u>A077616</u>	<u>002</u>	Feb 07, 2007
<u>AB2</u>		<u>160MG</u>	<u>A077616</u>	<u>003</u>	Feb 07, 2007
<u>AB2</u>	TEVA	<u>80MG</u>	<u>A076883</u>	<u>001</u>	Jul 26, 2004
<u>AB2</u>		<u>120MG</u>	<u>A076883</u>	<u>002</u>	Jul 26, 2004
<u>AB2</u>		<u>160MG</u>	<u>A076883</u>	<u>003</u>	Jul 26, 2004

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<u>AP</u> +	FRESENIUS	<u>10%</u>	<u>N017643</u>	<u>001</u>	
<u>INTRALIPID 20%</u>					
<u>AP</u> +	FRESENIUS	<u>20%</u>	<u>N018449</u>	<u>001</u>	
<u>AP</u> +		<u>20%</u>	<u>N020248</u>	<u>001</u>	Aug 07, 1996
<u>INTRALIPID 30%</u>					
<u>AP</u> +	FRESENIUS	<u>30%</u>	<u>N019942</u>	<u>001</u>	Dec 30, 1993
<u>LIPOSYN III 10%</u>					
<u>AP</u> +	HOSPIRA	<u>10%</u>	<u>N018969</u>	<u>001</u>	Sep 24, 1984
<u>LIPOSYN III 20%</u>					
<u>AP</u> +	HOSPIRA	<u>20%</u>	<u>N018970</u>	<u>001</u>	Sep 25, 1984
<u>LIPOSYN III 30%</u>					
<u>AP</u> +	HOSPIRA	<u>30%</u>	<u>N020181</u>	<u>001</u>	Jan 13, 1998
<u>NUTRILIPID 10%</u>					
<u>AP</u> +	B BRAUN	<u>10%</u>	<u>N019531</u>	<u>001</u>	May 28, 1993
<u>NUTRILIPID 20%</u>					
<u>AP</u> +	B BRAUN	<u>20%</u>	<u>N019531</u>	<u>002</u>	May 28, 1993

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

+ PHARMACIA AND UPJOHN EQ 2GM BASE/VIAL

N050347 001

SPIRONOLACTONE

TABLET; ORAL

ALDACTONE

<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N012151</u>	<u>009</u>	Dec 30, 1983
<u>AB</u>		<u>50MG</u>	<u>N012151</u>	<u>008</u>	Dec 30, 1982
<u>AB</u> +		<u>100MG</u>	<u>N012151</u>	<u>010</u>	Dec 30, 1983
<u>SPIRONOLACTONE</u>					
<u>AB</u>	ACTAVIS ELIZABETH	<u>25MG</u>	<u>A040353</u>	<u>003</u>	Mar 15, 2006
<u>AB</u>		<u>50MG</u>	<u>A040353</u>	<u>001</u>	Jul 29, 1999
<u>AB</u>		<u>100MG</u>	<u>A040353</u>	<u>002</u>	Jul 29, 1999
<u>AB</u>	AMNEAL PHARMS	<u>25MG</u>	<u>A091426</u>	<u>001</u>	Jun 08, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 366 (of 409)

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB	AMNEAL PHARMS	50MG	A091426	002	Jun 08, 2010
AB		100MG	A091426	003	Jun 08, 2010
AB	MUTUAL PHARM	25MG	A089424	001	Jul 23, 1986
AB		50MG	A089424	002	Aug 11, 1999
AB		100MG	A089424	003	Aug 11, 1999
AB	MYLAN	25MG	A040424	001	Aug 20, 2001
AB		50MG	A040424	002	Aug 20, 2001
AB		100MG	A040424	003	Aug 20, 2001
AB	SANDOZ	25MG	A086809	001	
AB	VINTAGE	25MG	A040750	001	Aug 29, 2006
AB		50MG	A040750	002	Aug 29, 2006
AB		100MG	A040750	003	Aug 29, 2006

STAVUDINE

CAPSULE: ORAL

STAVUDINE

AB	AUROBINDO PHARMA	15MG	A077672	003	Dec 29, 2008
AB		20MG	A077672	004	Dec 29, 2008
AB		30MG	A077672	001	Dec 29, 2008
AB		40MG	A077672	002	Dec 29, 2008
AB	HETERO DRUGS	15MG	A078957	001	Dec 29, 2008
AB		20MG	A078957	002	Dec 29, 2008
AB		30MG	A078957	003	Dec 29, 2008
AB		40MG	A078957	004	Dec 29, 2008
AB	MATRIX LABS LTD	30MG	A078775	001	Jan 05, 2009
AB		40MG	A078775	002	Jan 05, 2009
AB	MYLAN	15MG	A079069	001	Dec 29, 2008
AB		20MG	A079069	002	Dec 29, 2008
AB		30MG	A079069	003	Dec 29, 2008
AB		40MG	A079069	004	Dec 29, 2008

ZERIT

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>15MG</u>	<u>N020412</u>	<u>002</u>	Jun 24, 1994
<u>AB</u>		<u>20MG</u>	<u>N020412</u>	<u>003</u>	Jun 24, 1994
<u>AB</u>		<u>30MG</u>	<u>N020412</u>	<u>004</u>	Jun 24, 1994
<u>AB</u>	+	<u>40MG</u>	<u>N020412</u>	<u>005</u>	Jun 24, 1994

FOR SOLUTION; ORAL

STAVUDINE

AA	AUROBINDO PHARMA	1MG/ML	A077774 001	Dec 29, 2008
AA	CIPLA LTD	1MG/ML	A078030 001	Mar 20, 2009

ZERIT

AA + BRISTOL MYERS SQUIBB 1MG/ML N020413 001 Sep 06, 1996

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	+	HOSPIRA	100%	N018802 001	Oct 27, 1982

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	APP PHARMS	<u>100%</u>	<u>A088400</u>	<u>001</u>	Jan 16, 1984
<u>AP</u>	+ B BRAUN	<u>100%</u>	<u>N019633</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>100%</u>	<u>N018632</u>	<u>002</u>	Apr 19, 1988
<u>AP</u>	+	<u>100%</u>	<u>N018632</u>	<u>001</u>	Jun 30, 1982
<u>AP</u>	+ HOSPIRA	<u>100%</u>	<u>N018233</u>	<u>001</u>	
<u>AP</u>	+	<u>100%</u>	<u>N018801</u>	<u>001</u>	Oct 27, 1982
<u>AP</u>	+	<u>100%</u>	<u>N019869</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>	TARO PHARMS IRELAND	<u>100%</u>	<u>A077393</u>	<u>001</u>	Aug 11, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 367 (of 409)

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER

<u>AT</u>	BAXTER HLTHCARE	<u>100%</u>	<u>N017428</u>	<u>001</u>	

STERILE WATER IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>100%</u>	<u>N016734</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>100%</u>	<u>N017866</u>	<u>001</u>	
<u>AT</u>	HOSPIRA	<u>100%</u>	<u>N017513</u>	<u>001</u>	
<u>AT</u>		<u>100%</u>	<u>N018313</u>	<u>001</u>	

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

+	PFIZER	EQ 1GM BASE/2.5ML	A060111	001	
+	X GEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+	TEVA PARENTERAL	1GM/VIAL	N050577	001	May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE; INJECTION

METASTRON

<u>AP</u>	+	GE HEALTHCARE	<u>1mCi/ML</u>	<u>N020134</u>	<u>001</u>	Jun 18, 1993

STRONTIUM CHLORIDE SR-89

<u>AP</u>		BIO NUCLEONICS	<u>1mCi/ML</u>	<u>A075941</u>	<u>001</u>	Jan 06, 2003

SUCCIMER

CAPSULE; ORAL

CHEMET

+	LUNDBECK INC	100MG	N019998	002	Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

<u>AP</u>	+	SANDOZ	<u>20MG/ML</u>	<u>N008453</u>	<u>002</u>	

QUELICIN

<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845</u>	<u>006</u>	

QUELICIN PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845</u>	<u>001</u>	

QUELICIN PRESERVATIVE FREE

+	HOSPIRA	100MG/ML	N008845	004	

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+	AXCAN	1GM/10ML	N019183	001	Dec 16, 1993

TABLET; ORAL

CARAFATE

<u>AB</u>	+	AXCAN	<u>1GM</u>	<u>N018333</u>	<u>001</u>	

SUCRALFATE

<u>AB</u>		NOSTRUM LABS	<u>1GM</u>	<u>A074415</u>	<u>001</u>	Jun 08, 1998

<u>AB</u>		TEVA	<u>1GM</u>	<u>A070848</u>	<u>001</u>	Mar 29, 1996

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREE

<u>AP</u>	+	AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N019050</u>	<u>001</u>	May 04, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 368 (of 409)

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

<u>AP</u>	BAXTER HLTHCARE	<u>EQ 0.05MG BASE/ML</u>	<u>A074413</u>	<u>001</u>	Dec 15, 1995
<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A074534</u>	<u>001</u>	Dec 11, 1996

SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+	RANBAXY	1%	N018737	001	Feb 28, 1989

SOLUTION; TOPICAL

EXELDERM

+	RANBAXY	1%	N018738	001	Aug 30, 1985

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON

<u>AB</u>	+	SANOFI AVENTIS US	<u>10%</u>	<u>N019931</u>	<u>001</u>	Dec 23, 1996

SULFACETAMIDE SODIUM

<u>AB</u>		ALTANA	<u>10%</u>	<u>A077015</u>	<u>001</u>	Nov 17, 2006
<u>AB</u>		PERRIGO CO TENNESSEE	<u>10%</u>	<u>A078649</u>	<u>001</u>	Mar 23, 2009
<u>AB</u>		TARO	<u>10%</u>	<u>A078668</u>	<u>001</u>	May 20, 2009

OINTMENT; OPHTHALMIC

CETAMIDE

<u>AT</u>	+	ALCON	<u>10%</u>	<u>A080021</u>	<u>001</u>	

SULFACETAMIDE SODIUM

<u>AT</u>		FERA PHARMS	<u>10%</u>	<u>A080029</u>	<u>001</u>	

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10

<u>AT</u>	+	ALLERGAN	<u>10%</u>	<u>A080028</u>	<u>001</u>	

SULFACETAMIDE SODIUM

<u>AT</u>		ALCON UNIVERSAL	<u>10%</u>	<u>A089560</u>	<u>001</u>	Oct 18, 1988
<u>AT</u>		BAUSCH AND LOMB	<u>10%</u>	<u>A040066</u>	<u>001</u>	Dec 28, 1994

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

+	SANDOZ	500MG	A040091	001	Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+	TEVA PARENTERAL	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

<u>AB</u>		AUROBINDO PHARMA	<u>200MG/5ML;40MG/5ML</u>	<u>A091348</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>	+	HI TECH PHARMA	<u>200MG/5ML;40MG/5ML</u>	<u>A074650</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		VINTAGE	<u>200MG/5ML;40MG/5ML</u>	<u>A077785</u>	<u>001</u>	Jan 24, 2007

SULFATRIM PEDIATRIC

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>200MG/5ML;40MG/5ML</u>	<u>N018615</u>	<u>001</u>	Jan 07, 1983

TABLET; ORAL

BACTRIM

<u>AB</u>		MUTUAL PHARM	<u>400MG;80MG</u>	<u>N017377</u>	<u>001</u>	

BACTRIM DS

<u>AB</u>	+	MUTUAL PHARM	<u>800MG;160MG</u>	<u>N017377</u>	<u>002</u>	

SEPTRA

<u>AB</u>		MONARCH PHARMS	<u>400MG;80MG</u>	<u>N017376</u>	<u>001</u>	

SEPTRA DS

<u>AB</u>		MONARCH PHARMS	<u>800MG;160MG</u>	<u>N017376</u>	<u>002</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 369 (of 409)

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

<u>SULFAMETHOPRIM</u>				
<u>AB</u>	NOVEL LABS INC	<u>400MG;80MG</u>	<u>A070022</u>	<u>001</u> Feb 15, 1985
<u>SULFAMETHOPRIM-DS</u>				
<u>AB</u>	NOVEL LABS INC	<u>800MG;160MG</u>	<u>A070032</u>	<u>001</u> Feb 15, 1985
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM</u>				
<u>AB</u>	AMNEAL PHARMS NY	<u>400MG;80MG</u>	<u>A076899</u>	<u>001</u> Jan 27, 2005
<u>AB</u>		<u>800MG;160MG</u>	<u>A076899</u>	<u>002</u> Jan 27, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>400MG;80MG</u>	<u>A090624</u>	<u>001</u> Feb 16, 2010
<u>AB</u>		<u>800MG;160MG</u>	<u>A090624</u>	<u>002</u> Feb 16, 2010
<u>AB</u>	GLENMARK GENERICS	<u>400MG;80MG</u>	<u>A090828</u>	<u>002</u> Dec 22, 2010
<u>AB</u>		<u>800MG;160MG</u>	<u>A090828</u>	<u>001</u> Dec 22, 2010
<u>AB</u>	MUTUAL PHARM	<u>800MG;160MG</u>	<u>A071017</u>	<u>001</u> Aug 25, 1986
<u>AB</u>	VINTAGE	<u>400MG;80MG</u>	<u>A078060</u>	<u>002</u> Jan 25, 2007
<u>AB</u>		<u>800MG;160MG</u>	<u>A078060</u>	<u>001</u> Jan 25, 2007
<u>AB</u>	VISTA PHARMS	<u>400MG;80MG</u>	<u>A076817</u>	<u>001</u> Oct 07, 2005
<u>AB</u>		<u>800MG;160MG</u>	<u>A076817</u>	<u>002</u> Oct 07, 2005
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH</u>				
<u>AB</u>	SANDOZ	<u>800MG;160MG</u>	<u>N018598</u>	<u>004</u> May 19, 1982
<u>AB</u>	TEVA	<u>800MG;160MG</u>	<u>A070037</u>	<u>001</u> Jun 02, 1987
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH</u>				
<u>AB</u>	PLANTEX	<u>400MG;80MG</u>	<u>A070030</u>	<u>001</u> Jun 02, 1987

SULFANILAMIDECREAM; VAGINAL
AVC

+	AZUR PHARMA	15%	N006530	003	Jan 27, 1987

SULFASALAZINESUSPENSION; ORAL
AZULFIDINE

+	PHARMACIA AND UPJOHN	250MG/5ML	A086983	001	

TABLET; ORAL

<u>AZULFIDINE</u>				
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>500MG</u>	<u>N007073</u>	<u>001</u>
<u>SULFASALAZINE</u>				
<u>AB</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A040349</u>	<u>001</u>
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A085828</u>	<u>001</u>
<u>AB</u>		<u>500MG</u>	<u>A087197</u>	<u>001</u>

TABLET, DELAYED RELEASE; ORAL

<u>AZULFIDINE EN-TABS</u>					
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>500MG</u>	<u>N007073</u>	<u>002</u>	Apr 06, 1983
<u>SULFASALAZINE</u>					
<u>AB</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A075339</u>	<u>001</u>	Jan 11, 2002

SULINDAC

TABLET; ORAL

<u>CLINORIL</u>					
<u>AB</u>	+ MERCK	<u>200MG</u>	<u>N017911</u>	<u>002</u>	
<u>SULINDAC</u>					
<u>AB</u>	EPIC PHARMA	<u>150MG</u>	<u>A072710</u>	<u>001</u>	Mar 25, 1991
<u>AB</u>		<u>200MG</u>	<u>A072711</u>	<u>001</u>	Mar 25, 1991
<u>AB</u>	MUTUAL PHARM	<u>150MG</u>	<u>A072050</u>	<u>001</u>	Apr 17, 1991
<u>AB</u>		<u>200MG</u>	<u>A072051</u>	<u>001</u>	Apr 17, 1991
<u>AB</u>	MYLAN	<u>150MG</u>	<u>A073039</u>	<u>002</u>	Jun 22, 1993
<u>AB</u>		<u>200MG</u>	<u>A073039</u>	<u>001</u>	Jun 22, 1993
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A071891</u>	<u>001</u>	Apr 03, 1990
<u>AB</u>		<u>200MG</u>	<u>A071795</u>	<u>001</u>	Apr 03, 1990

PRESCRIPTION DRUG PRODUCT LIST

3 - 370 (of 409)

SUMATRIPTAN

SPRAY; NASAL

IMITREX

+ GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997
+	20MG/SPRAY	N020626	003	Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

<u>AP</u> + GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080</u>	<u>001</u>	Dec 28, 1992
<u>SUMATRIPTAN SUCCINATE</u>				
<u>AP</u> APP PHARMS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242</u>	<u>001</u>	Mar 02, 2009
<u>AP</u>	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079240</u>	<u>002</u>	Sep 18, 2009
<u>AP</u>	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A079240</u>	<u>001</u>	Sep 18, 2009
<u>AP</u> BEDFORD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123</u>	<u>001</u>	Feb 06, 2009
<u>AP</u> BEDFORD LABS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090310</u>	<u>001</u>	Aug 11, 2010
<u>AP</u> JHP PHARMS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077871</u>	<u>001</u>	Jul 09, 2009
<u>AP</u> PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332</u>	<u>001</u>	Oct 09, 2009
<u>AP</u> SAGENT STRIDES	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090314</u>	<u>001</u>	Jun 10, 2010
<u>AP</u>	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090641</u>	<u>001</u>	Jul 28, 2010
<u>AP</u> SANDOZ	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A078067</u>	<u>002</u>	Feb 06, 2009
<u>AP</u>	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078067</u>	<u>001</u>	Feb 06, 2009
<u>AP</u> TEVA PARENTERAL	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A078318</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078318</u>	<u>002</u>	Feb 06, 2009
<u>AP</u>	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077907</u>	<u>001</u>	Feb 06, 2009
<u>AP</u> WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593</u>	<u>001</u>	Feb 06, 2009
ALSUMA				
+ KING PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010
IMITREX STATDOSE				
+ GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006
+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003	Dec 23, 1996
SUMAVEL DOSEPRO				
+ ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009

TABLET; ORAL

IMITREX

<u>AB</u> GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132</u>	<u>002</u>	Jun 01, 1995
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>N020132</u>	<u>003</u>	Jun 01, 1995
<u>AB</u> +	<u>EQ 100MG BASE</u>	<u>N020132</u>	<u>001</u>	Jun 01, 1995
<u>SUMATRIPTAN SUCCINATE</u>				
<u>AB</u> AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A078327</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A078327</u>	<u>003</u>	Aug 10, 2009
<u>AB</u> DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A076847</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A076847</u>	<u>003</u>	Aug 10, 2009
<u>AB</u> MYLAN	<u>EQ 25MG BASE</u>	<u>A077163</u>	<u>001</u>	Nov 02, 2009
<u>AB</u>	<u>EQ 25MG BASE</u>	<u>A077744</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A077163</u>	<u>002</u>	Nov 02, 2009
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A077744</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A077163</u>	<u>003</u>	Nov 02, 2009
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A077744</u>	<u>003</u>	Aug 10, 2009
<u>AB</u> ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A078284</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A078284</u>	<u>003</u>	Aug 10, 2009
<u>AB</u> RANBAXY	<u>EQ 25MG BASE</u>	<u>A076554</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A076554</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A076572</u>	<u>001</u>	Feb 09, 2009
<u>AB</u> ROXANE	<u>EQ 25MG BASE</u>	<u>A078241</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A078241</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A078241</u>	<u>003</u>	Aug 10, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 371 (of 409)

SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN SUCCINATE

<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A076976</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076976</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076976</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078295</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078295</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076840</u>	<u>001</u>	Feb 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076840</u>	<u>002</u>	Feb 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076840</u>	<u>003</u>	Feb 09, 2009
<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076933</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076933</u>	<u>003</u>	Aug 10, 2009

SUNITINIB MALATECAPSULE; ORAL
SUTENT

	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006
		EQ 25MG BASE	N021938	002	Jan 26, 2006
		EQ 37.5MG BASE	N021938	004	Mar 31, 2009
+		EQ 50MG BASE	N021938	003	Jan 26, 2006

TACRINE HYDROCHLORIDECAPSULE; ORAL
COGNEX

	SHIONOGI PHARMA	EQ 10MG BASE	N020070	001	Sep 09, 1993
		EQ 20MG BASE	N020070	002	Sep 09, 1993
		EQ 30MG BASE	N020070	003	Sep 09, 1993
+		EQ 40MG BASE	N020070	004	Sep 09, 1993

TACROLIMUSCAPSULE; ORAL
PROGRAF

<u>AB</u>	ASTELLAS	<u>EQ 0.5MG BASE</u>	<u>N050708</u>	<u>003</u>	Aug 24, 1998
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N050708</u>	<u>001</u>	Apr 08, 1994
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N050708</u>	<u>002</u>	Apr 08, 1994
	<u>TACROLIMUS</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A090509</u>	<u>001</u>	May 12, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090509</u>	<u>002</u>	May 12, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090509</u>	<u>003</u>	May 12, 2010
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090596</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090596</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A065461</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A065461</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A090402</u>	<u>001</u>	Jul 01, 2010

INJECTABLE; INJECTION
PROGRAF

+	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994

OINTMENT; TOPICAL
PROTOPIC

	ASTELLAS	0.03%	N050777	001	Dec 08, 2000
+		0.1%	N050777	002	Dec 08, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 372 (of 409)

TADALAFIL

TABLET; ORAL

ADCIRCA

+ ELI LILLY CO	20MG	N022332	001	May 22, 2009
CIALIS				
LILLY	2.5MG	N021368	004	Jan 07, 2008
	5MG	N021368	001	Nov 21, 2003
	10MG	N021368	002	Nov 21, 2003
+	20MG	N021368	003	Nov 21, 2003

TALC

AEROSOL, METERED; INTRAPLEURAL

SCLEROSOL

+ BRYAN	400MG/SPRAY	N020587	001	Dec 24, 1997

POWDER; INTRAPLEURAL

TALC

+ BRYAN	5GM/BOT	N021388	001	Dec 15, 2003

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

<u>AB</u> AEGIS PHARMS	<u>EQ 10MG BASE</u>	<u>A076398</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>	<u>EQ 20MG BASE</u>	<u>A076398</u>	<u>002</u>	Mar 31, 2003
<u>AB</u> MYLAN	<u>EQ 10MG BASE</u>	<u>A074732</u>	<u>002</u>	Feb 20, 2003
<u>AB</u>	<u>EQ 20MG BASE</u>	<u>A074732</u>	<u>001</u>	Feb 20, 2003
<u>AB</u> TEVA	<u>EQ 10MG BASE</u>	<u>A075797</u>	<u>001</u>	Feb 20, 2003
<u>AB</u> + TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A074858</u>	<u>001</u>	Feb 20, 2003
<u>AB</u> WATSON LABS	<u>EQ 10MG BASE</u>	<u>A070929</u>	<u>001</u>	Feb 20, 2003
<u>AB</u>	<u>EQ 20MG BASE</u>	<u>A070929</u>	<u>002</u>	Feb 20, 2003
<u>AB</u> WATSON LABS FLORIDA	<u>EQ 10MG BASE</u>	<u>A076179</u>	<u>001</u>	Feb 20, 2003
<u>AB</u>	<u>EQ 20MG BASE</u>	<u>A076179</u>	<u>002</u>	Feb 20, 2003

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX

<u>AB</u> + BOEHRINGER INGELHEIM	<u>0.4MG</u>	<u>N020579</u>	<u>001</u>	Apr 15, 1997
<u>TAMSULOSIN HYDROCHLORIDE</u>				
<u>AB</u> IMPAX LABS	<u>0.4MG</u>	<u>A090377</u>	<u>001</u>	Mar 02, 2010
<u>AB</u> MYLAN	<u>0.4MG</u>	<u>A090408</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> SANDOZ	<u>0.4MG</u>	<u>A078015</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> SUN PHARM INDS LTD	<u>0.4MG</u>	<u>A090931</u>	<u>001</u>	Jul 15, 2010
<u>AB</u> SYNTHON PHARMS	<u>0.4MG</u>	<u>A078801</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> TEVA PHARMS	<u>0.4MG</u>	<u>A077630</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> WOCKHARDT	<u>0.4MG</u>	<u>A078938</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> ZYDUS PHARMS USA INC	<u>0.4MG</u>	<u>A078225</u>	<u>001</u>	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

TABLET; ORAL

NUCYNTA

ORTHO MCNEIL JANSSEN	EQ 50MG BASE	N022304	001	Nov 20, 2008
	EQ 75MG BASE	N022304	002	Nov 20, 2008
+	EQ 100MG BASE	N022304	003	Nov 20, 2008

TAZAROTENE

CREAM; TOPICAL

AVAGE

+ ALLERGAN	0.1%	N021184	003	Sep 30, 2002
TAZORAC				
+	0.05%	N021184	001	Sep 29, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 373 (of 409)

TAZAROTENE

CREAM; TOPICAL					
TAZORAC					
+	ALLERGAN	0.1%	N021184	002	Sep 29, 2000
GEL; TOPICAL					
TAZORAC					
+	ALLERGAN	0.05%	N020600	001	Jun 13, 1997
+		0.1%	N020600	002	Jun 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION					
PULMOLITE					
BS	PHARMALUCENCE	N/A	N017776	001	
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT					
BS	DRAXIMAGE	N/A	N017881	001	Dec 30, 1987

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION					
NEUROLITE					
	LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION					
HEPATOLITE					
	PHARMALUCENCE	N/A	N018467	001	Mar 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION					
CERETEC					
+	GE HEALTHCARE	N/A	N019829	001	Dec 30, 1988

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION					
CHOLETEC					
AP	+	BRACCO	N/A	<u>N018963</u>	<u>001</u> Jan 21, 1987
TECHNETIUM TC-99M MEBROFENIN					
AP		PHARMALUCENCE	N/A	<u>A078242</u>	<u>001</u> Jan 29, 2008

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION					
DRAXIMAGE MDP-25					
+	DRAXIMAGE	N/A	N018035	002	Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION					
CIS-MDP					
AP		PHARMALUCENCE	N/A	<u>N018124</u>	<u>001</u>
MDP-BRACCO					
AP		BRACCO	N/A	<u>N018107</u>	<u>001</u>

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION					
TECHNESCAN MAG3					
+	MALLINCKRODT	N/A	N019882	001	Jun 15, 1990

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 374 (of 409)

TECHNETIUM TC-99M OXIDRONATE KITINJECTABLE; INJECTION
TECHNESCAN

+ MALLINCKRODT N/A

N018321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPAAP PHARMALUCENCE N/AN017714 001DTPAAP DRAXIMAGE N/AN018511 001

Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYROAP PHARMALUCENCE N/AN019039 001

Jun 30, 1987

TECHNESCAN PYP KITAP MALLINCKRODT N/AN017538 001TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

MALLINCKRODT N/A

N019981 001

Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITEAP + LANTHEUS MEDCL N/AN019785 001

Dec 21, 1990

TECHNETIUM TC 99M SESTAMIBIAP CARDINAL HEALTH 414 N/AA078809 001

Apr 28, 2009

AP DRAXIMAGE N/AA078806 001

Apr 29, 2009

AP PHARMALUCENCE 10-30mCiA079157 001

Jul 10, 2009

TECHNETIUM TC-99 SESTAMIBIAP MALLINCKRODT N/AA078098 001

Sep 22, 2008

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

TECHNELITE

+ LANTHEUS MEDCL 0.0083-2.7 CI/GENERATOR

N017771 001

ULTRA-TECHNEKOW FM

+ MALLINCKRODT 0.25-3 CI/GENERATOR

N017243 002

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

GE HEALTHCARE N/A

N017944 001

May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

+ PHARMALUCENCE N/A

N017858 001

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVUE

+ GE HEALTHCARE N/A

N020372 001

Feb 09, 1996

MYOVUE 30ML

+ GE HEALTHCARE N/A

N020372 002

Jul 07, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 375 (of 409)

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

THERAVANCE INC	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009
+	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009

TELBIVUDINESOLUTION; ORAL
TYZEKA

+	NOVARTIS	100MG/5ML	N022154	001	Apr 28, 2009

TABLET; ORAL
TYZEKA

+	NOVARTIS	600MG	N022011	001	Oct 25, 2006

TELITHROMYCINTABLET; ORAL
KETEK

SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005
+	400MG	N021144	001	Apr 01, 2004

TELMISARTANTABLET; ORAL
MICARDIS

BOEHRINGER INGELHEIM	20MG	N020850	003	Apr 04, 2000
	40MG	N020850	001	Nov 10, 1998
+	80MG	N020850	002	Nov 10, 1998

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

<u>AB</u>	TYCO HLTHCARE	<u>7.5MG</u>	<u>N018163</u>	<u>003</u>	Oct 25, 1991
<u>AB</u>		<u>15MG</u>	<u>N018163</u>	<u>001</u>	
<u>AB</u>		<u>22.5MG</u>	<u>N018163</u>	<u>004</u>	Nov 02, 2004
<u>AB</u>	+	<u>30MG</u>	<u>N018163</u>	<u>002</u>	

TEMAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A071638</u>	<u>001</u>	Aug 07, 1987
<u>AB</u>		<u>30MG</u>	<u>A071620</u>	<u>001</u>	Aug 07, 1987
<u>AB</u>	MUTUAL PHARM	<u>7.5MG</u>	<u>A078581</u>	<u>001</u>	Sep 08, 2009
<u>AB</u>		<u>22.5MG</u>	<u>A071175</u>	<u>002</u>	Sep 14, 2009
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A070920</u>	<u>002</u>	May 21, 2010
<u>AB</u>		<u>15MG</u>	<u>A070920</u>	<u>004</u>	Jul 07, 1986
<u>AB</u>		<u>22.5MG</u>	<u>A070920</u>	<u>003</u>	Jun 12, 2009
<u>AB</u>		<u>30MG</u>	<u>A070920</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>	NOVEL LABS INC	<u>15MG</u>	<u>A071456</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>		<u>30MG</u>	<u>A071457</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A071427</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>		<u>30MG</u>	<u>A071428</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A071446</u>	<u>001</u>	May 21, 1993
<u>AB</u>		<u>30MG</u>	<u>A071447</u>	<u>001</u>	May 21, 1993

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

<u>AB</u>	SCHERING	<u>5MG</u>	<u>N021029</u>	<u>001</u>	Aug 11, 1999
<u>AB</u>		<u>20MG</u>	<u>N021029</u>	<u>002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>N021029</u>	<u>003</u>	Aug 11, 1999
<u>AB</u>		<u>140MG</u>	<u>N021029</u>	<u>005</u>	Oct 19, 2006
<u>AB</u>		<u>180MG</u>	<u>N021029</u>	<u>006</u>	Oct 19, 2006
<u>AB</u>	+	<u>250MG</u>	<u>N021029</u>	<u>004</u>	Aug 11, 1999

PRESCRIPTION DRUG PRODUCT LIST

3 - 376 (of 409)

TEMOZOLOMIDE

CAPSULE; ORAL				
<u>TEMOZOLOMIDE</u>				
<u>AB</u>	BARR	<u>5MG</u>	<u>A078879</u>	<u>001</u> Mar 01, 2010
<u>AB</u>		<u>20MG</u>	<u>A078879</u>	<u>002</u> Mar 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078879</u>	<u>003</u> Mar 01, 2010
<u>AB</u>		<u>140MG</u>	<u>A078879</u>	<u>005</u> Mar 01, 2010
<u>AB</u>		<u>180MG</u>	<u>A078879</u>	<u>006</u> Mar 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078879</u>	<u>004</u> Mar 01, 2010
POWDER; INTRAVENOUS				
TEMODAR				
	+ SCHERING	100MG/VIAL	N022277	001 Feb 27, 2009

TEMSIROLIMUS

SOLUTION; INTRAVENOUS				
TORISEL				
	+ WYETH PHARMS INC	25MG/ML (25MG/ML)	N022088	001 May 30, 2007

TENIPOSIDE

INJECTABLE; INJECTION				
VUMON				
	+ BRISTOL MYERS SQUIBB	10MG/ML	N020119	001 Jul 14, 1992

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL				
VIREAD				
	+ GILEAD	300MG	N021356	001 Oct 26, 2001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL				
<u>HYTRIN</u>				
<u>AB</u>	ABBOTT	<u>EQ 1MG BASE</u>	<u>N020347</u>	<u>001</u> Dec 14, 1994
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N020347</u>	<u>002</u> Dec 14, 1994
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N020347</u>	<u>003</u> Dec 14, 1994
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N020347</u>	<u>004</u> Dec 14, 1994
<u>TERAZOSIN HYDROCHLORIDE</u>				
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075498</u>	<u>001</u> Apr 12, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075498</u>	<u>002</u> Apr 12, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075498</u>	<u>003</u> Apr 12, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075498</u>	<u>004</u> Apr 12, 2001
<u>AB</u>	CADISTA PHARMS	<u>EQ 1MG BASE</u>	<u>A075317</u>	<u>001</u> Dec 20, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075317</u>	<u>002</u> Dec 20, 2004
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075317</u>	<u>003</u> Dec 20, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075317</u>	<u>004</u> Dec 20, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A075614</u>	<u>002</u> Jan 30, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075614</u>	<u>001</u> Jan 30, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075614</u>	<u>003</u> Jan 30, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075614</u>	<u>004</u> Jan 30, 2001
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075140</u>	<u>002</u> Feb 11, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075140</u>	<u>003</u> Feb 11, 2000
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075140</u>	<u>001</u> Feb 11, 2000
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075140</u>	<u>004</u> Feb 11, 2000
<u>AB</u>	RANBAXY	<u>EQ 1MG BASE</u>	<u>A076021</u>	<u>001</u> Aug 22, 2002
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A076021</u>	<u>002</u> Aug 22, 2002
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076021</u>	<u>003</u> Aug 22, 2002
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076021</u>	<u>004</u> Aug 22, 2002
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A074823</u>	<u>001</u> Mar 30, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074823</u>	<u>002</u> Mar 30, 1998
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A074823</u>	<u>003</u> Mar 30, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 377 (of 409)

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A074823</u>	<u>004</u>	Mar 30, 1998

TABLET; ORAL

HYTRIN

	ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987
+		EQ 2MG BASE	N019057	002	Aug 07, 1987
		EQ 5MG BASE	N019057	003	Aug 07, 1987
		EQ 10MG BASE	N019057	004	Aug 07, 1987

TERBINAFINE HYDROCHLORIDE

GRANULE; ORAL

LAMISIL

	NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007
+		EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007

TABLET; ORAL

LAMISIL

<u>AB</u>	+	NOVARTIS	<u>EQ 250MG BASE</u>	<u>N020539</u>	<u>001</u>	May 10, 1996

TERBINAFINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 250MG BASE</u>	<u>A078199</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A078297</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		BRECKENRIDGE PHARM	<u>EQ 250MG BASE</u>	<u>A077714</u>	<u>001</u>	Jun 04, 2010
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 250MG BASE</u>	<u>A076390</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		GENPHARM	<u>EQ 250MG BASE</u>	<u>A077136</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078157</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		HARRIS PHARM	<u>EQ 250MG BASE</u>	<u>A077919</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		INVAGEN PHARMS	<u>EQ 250MG BASE</u>	<u>A077533</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		MYLAN	<u>EQ 250MG BASE</u>	<u>A077195</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A078163</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		ROXANE	<u>EQ 250MG BASE</u>	<u>A077223</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		TEVA	<u>EQ 250MG BASE</u>	<u>A076377</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		WATSON LABS	<u>EQ 250MG BASE</u>	<u>A077137</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A078229</u>	<u>001</u>	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

<u>AP</u>		AKORN	<u>1MG/ML</u>	<u>A078151</u>	<u>001</u>	Jan 07, 2008
<u>AP</u>		APP PHARMS	<u>1MG/ML</u>	<u>A076887</u>	<u>001</u>	May 26, 2004
<u>AP</u>	+	BEDFORD	<u>1MG/ML</u>	<u>A076770</u>	<u>001</u>	Apr 23, 2004
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078630</u>	<u>001</u>	May 20, 2009
<u>AP</u>		TEVA PARENTERAL	<u>1MG/ML</u>	<u>A076853</u>	<u>001</u>	Jul 20, 2004

TABLET; ORAL

TERBUTALINE SULFATE

<u>AB</u>		IMPAX LABS	<u>2.5MG</u>	<u>A075877</u>	<u>001</u>	Jun 26, 2001
<u>AB</u>			<u>5MG</u>	<u>A075877</u>	<u>002</u>	Jun 26, 2001
<u>AB</u>		LANNETT	<u>2.5MG</u>	<u>A077152</u>	<u>001</u>	Mar 25, 2005
<u>AB</u>			<u>5MG</u>	<u>A077152</u>	<u>002</u>	Mar 25, 2005

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

<u>AB</u>	+	ORTHO MCNEIL JANSSEN	<u>0.8%</u>	<u>N019964</u>	<u>001</u>	Feb 21, 1991

TERAZOL 7

<u>AB</u>	+	ORTHO MCNEIL JANSSEN	<u>0.4%</u>	<u>N019579</u>	<u>001</u>	Dec 31, 1987

TERCONAZOLE

<u>AB</u>		ALTANA	<u>0.4%</u>	<u>A076712</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>		TARO	<u>0.4%</u>	<u>A076043</u>	<u>001</u>	Jan 19, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 378 (of 409)

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

<u>AB</u>	TARO	<u>0.8%</u>	<u>A075953</u>	<u>001</u>	Apr 06, 2004
	TERCONAZOLE				
BX +	NYCOMED US	0.8%	N021735	001	Oct 01, 2004

SUPPOSITORY; VAGINAL

TERAZOL 3

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>80MG</u>	<u>N019641</u>	<u>001</u>	May 24, 1988

TERCONAZOLE

<u>AB</u>	ALTANA	<u>80MG</u>	<u>A076850</u>	<u>001</u>	Jul 12, 2006
<u>AB</u>	PERRIGO NEW YORK	<u>80MG</u>	<u>A077149</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>	TARO	<u>80MG</u>	<u>A077553</u>	<u>001</u>	Mar 09, 2007

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

+ LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

+ THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+ WATSON LABS	2.5MG/24HR	N020489	001	Sep 29, 1995
+	5MG/24HR	N020489	002	May 02, 1997

GEL; TRANSDERMAL

ANDROGEL

BX +	ABBOTT PRODS	1% (5GM/PACKET)	N021015	002	Feb 28, 2000

TESTIM

BX +	AUXILIUM PHARMS	1% (5GM/PACKET)	N021454	001	Oct 31, 2002

ANDROGEL

ABBOTT PRODS	1% (2.5GM/PACKET)	N021015	001	Feb 28, 2000

GEL, METERED; TRANSDERMAL

ANDROGEL

+ ABBOTT PRODS	1% (1.25GM/ACTIVATION)	N021015	003	Sep 26, 2003

FORTESTA

+ ENDO PHARMS	10MG/5GM ACTIVATION	N021463	001	Dec 29, 2010

PELLET; IMPLANTATION

TESTOPEL

+ SLATE PHARMS	75MG	A080911	001	

SOLUTION, METERED; TRANSDERMAL

AXIRON

+ ELI LILLY AND CO	30MG/1.5ML ACTIVATION	N022504	001	Nov 23, 2010

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+ COLUMBIA LABS	30MG	N021543	001	Jun 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

<u>AO</u>	+ PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>A085635</u>	<u>002</u>	

<u>AO</u>	+	<u>200MG/ML</u>	<u>A085635</u>	<u>003</u>	

TESTOSTERONE CYPIONATE

<u>AO</u>	BEDFORD	<u>100MG/ML</u>	<u>A090387</u>	<u>001</u>	Jul 15, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 379 (of 409)

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

<u>AO</u>	BEDFORD	<u>200MG/ML</u>	<u>A090387</u>	<u>002</u>	Jul 15, 2010
<u>AO</u>	PADDOCK	<u>200MG/ML</u>	<u>A040530</u>	<u>001</u>	Jan 31, 2005
<u>AO</u>	SANDOZ	<u>100MG/ML</u>	<u>A040615</u>	<u>001</u>	Aug 10, 2006
<u>AO</u>		<u>200MG/ML</u>	<u>A040615</u>	<u>002</u>	Aug 10, 2006
<u>AO</u>	SYNERX PHARMA	<u>200MG/ML</u>	<u>A040652</u>	<u>001</u>	Dec 11, 2006
<u>AO</u>	WATSON LABS	<u>200MG/ML</u>	<u>A086030</u>	<u>001</u>	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

<u>AO</u>	+ ENDO PHARM	<u>200MG/ML</u>	<u>N009165</u>	<u>003</u>	

TESTOSTERONE ENANTHATE

<u>AO</u>	PADDOCK	<u>200MG/ML</u>	<u>A040575</u>	<u>001</u>	Jun 14, 2006
<u>AO</u>	SYNERX PHARMA	<u>200MG/ML</u>	<u>A040647</u>	<u>001</u>	Oct 05, 2009
<u>AO</u>	WATSON LABS	<u>200MG/ML</u>	<u>A085598</u>	<u>001</u>	

TETRABENAZINE

TABLET; ORAL

XENAZINE

	BIOVAIL AMERICAS	12.5MG	N021894	001	Aug 15, 2008
+		25MG	N021894	002	Aug 15, 2008

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

<u>AB</u>	IMPAX LABS	<u>250MG</u>	<u>A060469</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A060469</u>	<u>003</u>	
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>250MG</u>	<u>A060704</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>A060704</u>	<u>002</u>	
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A061837</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A061837</u>	<u>002</u>	

TETRACYCLINE HYDROCHLORIDE

	IMPAX LABS	100MG	A060469	002	

SUSPENSION; ORAL

SUMYCIN

+	PAR PHARM	125MG/5ML	A060400	001	

TABLET; ORAL

SUMYCIN

	PAR PHARM	250MG	A061147	001	
+		500MG	A061147	004	

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+	NYCOMED US	0.05%	A086576	002	
		0.1%	A086576	001	

SPRAY; NASAL

TYZINE

+	NYCOMED US	0.1%	A086576	003	

THALIDOMIDE

CAPSULE; ORAL

THALOMID

	CELGENE	50MG	N020785	001	Jul 16, 1998
		100MG	N020785	002	Jan 17, 2003
		150MG	N020785	004	Jan 10, 2007

PRESCRIPTION DRUG PRODUCT LIST

3 - 380 (of 409)

THALIDOMIDE

CAPSULE; ORAL

THALOMID

+ CELGENE	200MG	N020785	003	Jan 17, 2003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

AP + GE HEALTHCARE	<u>1mCi/ML</u>	<u>N018110</u>	<u>002</u>	Feb 27, 1996
AP + LANTHEUS MEDCL	<u>1mCi/ML</u>	<u>N017806</u>	<u>001</u>	
AP + MALLINCKRODT	<u>1mCi/ML</u>	<u>N018150</u>	<u>001</u>	

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

AP + LANTHEUS MEDCL	<u>2mCi/ML</u>	<u>N017806</u>	<u>002</u>	Oct 09, 1998
AP MALLINCKRODT	<u>2mCi/ML</u>	<u>A077698</u>	<u>001</u>	Nov 09, 2006

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

BC UCB INC	100MG	A087942	001	Aug 22, 1983
BC	200MG	A087943	001	Aug 22, 1983
BC	300MG	A087944	001	Aug 22, 1983

THEOPHYLLINE

BC INWOOD LABS	100MG	A040052	001	Feb 14, 1994
BC	200MG	A040052	003	Feb 14, 1994
BC +	300MG	A040052	004	Feb 14, 1994

THEO-24

UCB INC	400MG	A081034	001	Feb 28, 1992

THEOPHYLLINE

INWOOD LABS	125MG	A040052	002	Feb 14, 1994

ELIXIR; ORAL

ELIXOPHYLLIN

+ CARACO	80MG/15ML	A085186	001	

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP + B BRAUN	<u>40MG/100ML</u>	<u>N019826</u>	<u>001</u>	Aug 14, 1992

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP + B BRAUN	<u>80MG/100ML</u>	<u>N019826</u>	<u>002</u>	Aug 14, 1992

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP + B BRAUN	<u>160MG/100ML</u>	<u>N019826</u>	<u>003</u>	Aug 14, 1992

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP + B BRAUN	<u>320MG/100ML</u>	<u>N019826</u>	<u>006</u>	Aug 14, 1992

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP + BAXTER HLTHCARE	<u>4MG/ML</u>	<u>N018649</u>	<u>007</u>	Jul 26, 1982
AP +	<u>40MG/100ML</u>	<u>N018649</u>	<u>001</u>	Jul 26, 1982
AP +	<u>80MG/100ML</u>	<u>N018649</u>	<u>002</u>	Jul 26, 1982
AP +	<u>160MG/100ML</u>	<u>N018649</u>	<u>003</u>	Jul 26, 1982
AP +	<u>200MG/100ML</u>	<u>N018649</u>	<u>004</u>	Jul 26, 1982
AP +	<u>320MG/100ML</u>	<u>N018649</u>	<u>006</u>	Nov 13, 1985
AP +	<u>400MG/100ML</u>	<u>N018649</u>	<u>005</u>	Jul 26, 1982

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA	<u>4MG/ML</u>	<u>N019211</u>	<u>007</u>	Dec 14, 1984
AP +	<u>40MG/100ML</u>	<u>N019211</u>	<u>001</u>	Dec 14, 1984
AP +	<u>80MG/100ML</u>	<u>N019211</u>	<u>002</u>	Dec 14, 1984
AP +	<u>160MG/100ML</u>	<u>N019211</u>	<u>003</u>	Dec 14, 1984
AP +	<u>200MG/100ML</u>	<u>N019211</u>	<u>004</u>	Dec 14, 1984
AP +	<u>320MG/100ML</u>	<u>N019211</u>	<u>006</u>	Jan 20, 1988
AP +	<u>400MG/100ML</u>	<u>N019211</u>	<u>005</u>	Dec 14, 1984

PRESCRIPTION DRUG PRODUCT LIST

3 - 381 (of 409)

THEOPHYLLINE

TABLET; ORAL				
THEOLAIR				
	+ GRACEWAY	125MG	A086399	001
	+	250MG	A086399	002
TABLET, EXTENDED RELEASE; ORAL				
<u>THEOCHRON</u>				
<u>AB</u>	CARACO	<u>100MG</u>	<u>A088320</u>	<u>001</u> Feb 21, 1985
<u>AB</u>		<u>200MG</u>	<u>A088321</u>	<u>001</u> Feb 21, 1985
<u>AB</u>		<u>300MG</u>	<u>A087400</u>	<u>002</u> Jan 11, 1983
<u>THEOPHYLLINE</u>				
<u>AB</u>	ALEMBIC LTD	<u>300MG</u>	<u>A090430</u>	<u>001</u> Oct 27, 2010
<u>AB</u>		<u>450MG</u>	<u>A090430</u>	<u>002</u> Oct 27, 2010
<u>AB</u>	GLENMARK GENERICS	<u>400MG</u>	<u>A090355</u>	<u>001</u> Jul 13, 2010
<u>AB</u>		<u>600MG</u>	<u>A090355</u>	<u>002</u> Jul 13, 2010
<u>AB</u>	INWOOD LABS	<u>450MG</u>	<u>A040034</u>	<u>001</u> Apr 28, 1995
<u>AB</u>	NOSTRUM	<u>400MG</u>	<u>A040595</u>	<u>001</u> Apr 21, 2006
<u>AB</u>	+	<u>600MG</u>	<u>A040560</u>	<u>002</u> Apr 21, 2006
<u>AB</u>	+ PLIVA	<u>100MG</u>	<u>A089807</u>	<u>001</u> Apr 30, 1990
<u>AB</u>	+	<u>200MG</u>	<u>A089808</u>	<u>001</u> Apr 30, 1990
<u>AB</u>		<u>300MG</u>	<u>A089763</u>	<u>001</u> Apr 30, 1990
<u>AB</u>	+	<u>450MG</u>	<u>A081236</u>	<u>001</u> Nov 09, 1992

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION				
<u>THIAMINE HYDROCHLORIDE</u>				
<u>AP</u>	+ APP PHARMS	<u>100MG/ML</u>	<u>A080556</u>	<u>001</u>
<u>AP</u>	HOSPIRA	<u>100MG/ML</u>	<u>A040079</u>	<u>001</u> May 03, 1996
<u>AP</u>	WATSON LABS	<u>100MG/ML</u>	<u>A080571</u>	<u>001</u>
	THIAMINE HYDROCHLORIDE			
	+ WATSON LABS	200MG/ML	A080571	002

THIOGUANINE

TABLET; ORAL				
THIOGUANINE				
	+ GLAXOSMITHKLINE	40MG	N012429	001

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL				
<u>THIORIDAZINE HYDROCHLORIDE</u>				
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A089953</u>	<u>004</u> Aug 01, 1986
<u>AB</u>		<u>25MG</u>	<u>A089953</u>	<u>003</u> Aug 01, 1986
<u>AB</u>		<u>50MG</u>	<u>A089953</u>	<u>002</u> Aug 01, 1986
<u>AB</u>		<u>100MG</u>	<u>A089953</u>	<u>001</u> Oct 07, 1988
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A088004</u>	<u>002</u> Mar 15, 1983
<u>AB</u>		<u>25MG</u>	<u>A088004</u>	<u>003</u> Mar 15, 1983
<u>AB</u>		<u>50MG</u>	<u>A088004</u>	<u>004</u> Mar 15, 1983
<u>AB</u>	+	<u>100MG</u>	<u>A088004</u>	<u>001</u> Nov 18, 1983

THIOTEPA

INJECTABLE; INJECTION				
<u>THIOTEPA</u>				
<u>AP</u>	APP PHARMS	<u>15MG/VIAL</u>	<u>A075698</u>	<u>001</u> Sep 20, 2001
<u>AP</u>	BEDFORD	<u>15MG/VIAL</u>	<u>A075547</u>	<u>001</u> Apr 02, 2001
<u>AP</u>	+ TEVA PARENTERAL	<u>15MG/VIAL</u>	<u>A075730</u>	<u>001</u> Apr 20, 2001
	THIOTEPA			
	+ TEVA PARENTERAL	30MG/VIAL	A075730	002 Apr 20, 2001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 382 (of 409)

THIOTHIXENE

CAPSULE; ORAL

NAVANE

<u>AB</u>	PFIZER	<u>1MG</u>	<u>N016584</u>	<u>001</u>	
<u>AB</u>		<u>2MG</u>	<u>N016584</u>	<u>002</u>	
<u>AB</u>	+	<u>5MG</u>	<u>N016584</u>	<u>003</u>	
<u>AB</u>		<u>10MG</u>	<u>N016584</u>	<u>004</u>	

THIOTHIXENE

<u>AB</u>	MYLAN	<u>1MG</u>	<u>A071093</u>	<u>002</u>	Jun 23, 1987
<u>AB</u>		<u>2MG</u>	<u>A071093</u>	<u>003</u>	Jun 23, 1987
<u>AB</u>		<u>5MG</u>	<u>A071093</u>	<u>004</u>	Jun 23, 1987
<u>AB</u>		<u>10MG</u>	<u>A071093</u>	<u>001</u>	Jun 23, 1987
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A071610</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>		<u>2MG</u>	<u>A071570</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>		<u>5MG</u>	<u>A071529</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>		<u>10MG</u>	<u>A071530</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A070601</u>	<u>001</u>	Jun 05, 1987
<u>AB</u>		<u>5MG</u>	<u>A070602</u>	<u>001</u>	Jun 05, 1987

THYROTROPIN ALFAINJECTABLE; INJECTION
THYROGEN

+	GENZYME	1.1MG/VIAL	N020898	001	Nov 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

	CEPHALON	2MG	N020646	005	Apr 16, 1999
+		4MG	N020646	001	Sep 30, 1997
		6MG	N020646	006	Nov 29, 2005
		8MG	N020646	007	Nov 29, 2005
		10MG	N020646	008	Nov 29, 2005
		12MG	N020646	002	Sep 30, 1997
		16MG	N020646	003	Sep 30, 1997

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>250MG</u>	<u>A075253</u>	<u>001</u>	Aug 20, 1999
<u>AB</u>	APOTEX	<u>250MG</u>	<u>A075089</u>	<u>001</u>	Jul 01, 1999
<u>AB</u>	CARACO	<u>250MG</u>	<u>A075526</u>	<u>001</u>	Sep 26, 2002
<u>AB</u>	GENPHARM	<u>250MG</u>	<u>A075161</u>	<u>001</u>	Sep 13, 1999
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A075326</u>	<u>001</u>	Aug 20, 1999
<u>AB</u>	+	<u>250MG</u>	<u>A075149</u>	<u>001</u>	Aug 20, 1999

TIGECYCLINEINJECTABLE; IV (INFUSION)
TYGACIL

+	WYETH PHARMS INC	50MG/VIAL	N021821	001	Jun 15, 2005

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

+	SANOFI AVENTIS US	EQ 200MG BASE	N020707	001	Mar 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

+	SANTEN OY	EQ 0.25% BASE	N020439	001	Mar 31, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 383 (of 409)

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

+ SANTEN OY	EQ 0.5% BASE	N020439 002	Mar 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

<u>AB</u> <u>TIMOLOL MALEATE</u>	<u>EQ 0.25% BASE</u>	<u>N020963</u> <u>001</u>	Oct 21, 1998
<u>AB</u> FALCON PHARMS	<u>EQ 0.5% BASE</u>	<u>N020963</u> <u>002</u>	Oct 21, 1998
<u>AB</u> + <u>TIMOPTIC-XE</u>	<u>EQ 0.25% BASE</u>	<u>N020330</u> <u>001</u>	Nov 04, 1993
<u>AB</u> +	<u>EQ 0.5% BASE</u>	<u>N020330</u> <u>002</u>	Nov 04, 1993

SOLUTION/DROPS; OPHTHALMIC

<u>AT</u> <u>TIMOLOL MALEATE</u>	<u>EQ 0.25% BASE</u>	<u>A074515</u> <u>001</u>	Mar 25, 1997
<u>AT</u> AKORN	<u>EQ 0.5% BASE</u>	<u>A074466</u> <u>001</u>	Mar 25, 1997
<u>AT</u>	<u>EQ 0.5% BASE</u>	<u>A074516</u> <u>001</u>	Mar 25, 1997
<u>AT</u> BAUSCH AND LOMB	<u>EQ 0.25% BASE</u>	<u>A074778</u> <u>001</u>	Mar 25, 1997
<u>AT</u>	<u>EQ 0.5% BASE</u>	<u>A074776</u> <u>001</u>	Mar 25, 1997
<u>AT</u> FALCON PHARMS	<u>EQ 0.25% BASE</u>	<u>A074261</u> <u>001</u>	Apr 28, 1995
<u>AT</u>	<u>EQ 0.5% BASE</u>	<u>A074262</u> <u>001</u>	Apr 28, 1995
<u>AT</u> FDC LTD	<u>EQ 0.25% BASE</u>	<u>A077259</u> <u>001</u>	Apr 30, 2008
<u>AT</u>	<u>EQ 0.5% BASE</u>	<u>A077259</u> <u>002</u>	Apr 30, 2008
<u>AT</u> HI TECH PHARMA	<u>EQ 0.5% BASE</u>	<u>A075163</u> <u>001</u>	Sep 10, 2002
<u>AT</u> NOVEX	<u>EQ 0.25% BASE</u>	<u>A075411</u> <u>001</u>	Sep 08, 2000
<u>AT</u>	<u>EQ 0.5% BASE</u>	<u>A075412</u> <u>001</u>	Sep 08, 2000
<u>AT</u> PACIFIC PHARMA	<u>EQ 0.25% BASE</u>	<u>A074746</u> <u>001</u>	Mar 25, 1997
<u>AT</u>	<u>EQ 0.5% BASE</u>	<u>A074747</u> <u>001</u>	Mar 25, 1997
<u>AT</u> WOCKHARDT	<u>EQ 0.25% BASE</u>	<u>A078771</u> <u>001</u>	Sep 28, 2009
<u>AT</u>	<u>EQ 0.5% BASE</u>	<u>A078771</u> <u>002</u>	Sep 28, 2009
<u>AT</u> + <u>TIMOPTIC</u>	<u>EQ 0.25% BASE</u>	<u>N018086</u> <u>001</u>	
<u>AT</u> +	<u>EQ 0.5% BASE</u>	<u>N018086</u> <u>002</u>	
BT + ISTALOL	EQ 0.5% BASE	N021516 001	Jun 04, 2004
TIMOPTIC IN OCUDOSE			
+ ATON	EQ 0.25% BASE	N019463 001	Nov 05, 1986
+	EQ 0.5% BASE	N019463 002	Nov 05, 1986

TABLET; ORAL

TIMOLOL MALEATE	5MG	A072668 002	Jun 08, 1990
MYLAN	10MG	A072668 003	Jun 08, 1990
+	20MG	A072668 001	Jun 08, 1990

TINIDAZOLE

TABLET; ORAL

TINDAMAX	250MG	N021618 001	May 17, 2004
MISSION PHARMA	500MG	N021618 002	May 17, 2004
+			

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP	20,000 IU/ML	N020484 001	Jul 14, 2000
+ LEO PHARMA AS			

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 384 (of 409)

TIOPRONIN

TABLET; ORAL

TIOPRONIN

+	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988

TIOTROPIUM BROMIDE MONOHYDRATE

POWDER; INHALATION

SPIRIVA

+	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004

TIPRANAVIR

CAPSULE; ORAL

APTIVUS

+	BOEHRINGER INGELHEIM	250MG	N021814	001	Jun 22, 2005

SOLUTION; ORAL

APTIVUS

+	BOEHRINGER INGELHEIM	100MG/ML	N022292	001	Jun 23, 2008

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

		EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002

+		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	N020913	003	Apr 20, 2000

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANAFLEX

ACORDA

		EQ 2MG BASE	N021447	001	Aug 29, 2002

		EQ 4MG BASE	N021447	002	Aug 29, 2002

+		EQ 6MG BASE	N021447	003	Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A076283</u>	<u>001</u>	Jul 12, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076283</u>	<u>002</u>	Jul 12, 2002
<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 2MG BASE</u>	<u>A076281</u>	<u>001</u>	Oct 20, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076281</u>	<u>002</u>	Oct 20, 2003
<u>AB</u>	ALPHAPHARM	<u>EQ 2MG BASE</u>	<u>A076282</u>	<u>001</u>	Dec 16, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076282</u>	<u>002</u>	Dec 16, 2003
<u>AB</u>	APOTEX	<u>EQ 2MG BASE</u>	<u>A076533</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076533</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>	CARACO	<u>EQ 2MG BASE</u>	<u>A076416</u>	<u>001</u>	Sep 29, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076416</u>	<u>002</u>	Sep 29, 2003
<u>AB</u>	COREPHARMA	<u>EQ 2MG BASE</u>	<u>A076347</u>	<u>001</u>	Oct 11, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076347</u>	<u>002</u>	Oct 11, 2002
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2MG BASE</u>	<u>A076286</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076286</u>	<u>002</u>	Jul 03, 2002
<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A076354</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076354</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>	SANDOZ	<u>EQ 2MG BASE</u>	<u>A076399</u>	<u>001</u>	Nov 26, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076280</u>	<u>002</u>	Jun 27, 2002
<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076284</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076284</u>	<u>002</u>	Jul 03, 2002
	<u>ZANAFLEX</u>				
<u>AB</u>	+	<u>ACORDA</u>	<u>N020397</u>	<u>001</u>	Nov 27, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 385 (of 409)

TOBRAMYCIN

OINTMENT; OPHTHALMIC				
TOBREX				
	+ ALCON	0.3%	N050555	001
SOLUTION; INHALATION				
TOBI				
	+ NOVARTIS PHARMS	300MG/5ML	N050753	001 Dec 22, 1997
SOLUTION/DROPS; OPHTHALMIC				
<u>AKTOB</u>				
<u>AT</u>	AKORN	<u>0.3%</u>	<u>A064096</u>	<u>001</u> Jan 31, 1996
<u>TOBRAMYCIN</u>				
<u>AT</u>	ALTANA	<u>0.3%</u>	<u>A065026</u>	<u>001</u> Sep 11, 2001
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A064052</u>	<u>001</u> Nov 29, 1993
<u>AT</u>	NOVEX	<u>0.3%</u>	<u>A065087</u>	<u>001</u> Feb 25, 2002
<u>TOBREX</u>				
<u>AT</u>	ALCON	<u>0.3%</u>	<u>A062535</u>	<u>001</u> Dec 13, 1984
<u>AT</u>	+ FALCON PHARMS	<u>0.3%</u>	<u>N050541</u>	<u>001</u>

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION				
<u>TOBRAMYCIN SULFATE</u>				
<u>AP</u>	AKORN STRIDES	<u>EQ 40MG BASE/ML</u>	<u>A065407</u>	<u>001</u> Mar 11, 2008
<u>AP</u>	APOTHECON	<u>EQ 10MG BASE/ML</u>	<u>A064021</u>	<u>001</u> May 31, 1994
<u>AP</u>	APP PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A065122</u>	<u>001</u> Nov 29, 2002
<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A065122</u>	<u>002</u> Nov 29, 2002
<u>AP</u>		<u>EQ 1.2GM BASE/VIAL</u>	<u>N050789</u>	<u>001</u> Jul 13, 2004
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 40MG BASE/ML</u>	<u>A063117</u>	<u>001</u> Apr 26, 1991
<u>AP</u>	+ HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A063080</u>	<u>001</u> Apr 30, 1991
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A063112</u>	<u>001</u> Apr 30, 1991
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A063111</u>	<u>001</u> Apr 30, 1991
<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A063116</u>	<u>001</u> May 18, 1992
<u>AP</u>	MARSAM PHARMS LLC	<u>EQ 10MG BASE/ML</u>	<u>A062945</u>	<u>001</u> Aug 09, 1989
<u>AP</u>	TEVA PARENTERAL	<u>EQ 40MG BASE/ML</u>	<u>A063100</u>	<u>001</u> Jan 30, 1992
<u>AP</u>	+ X GEN PHARMS	<u>EQ 1.2GM BASE/VIAL</u>	<u>A065013</u>	<u>001</u> Aug 17, 2001
<u>TOBRAMYCIN SULFATE (PHARMACY BULK)</u>				
<u>AP</u>	APP PHARMS	<u>EQ 40MG BASE/ML</u>	<u>A065120</u>	<u>001</u> Nov 29, 2002
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	+ HOSPIRA	EQ 1.2MG BASE/ML	A063081	003 Jul 31, 1990
	+	EQ 1.6MG BASE/ML	A063081	006 Jun 02, 1993
	+	EQ 80MG BASE/100ML	A063081	001 Jul 31, 1990

TOLAZAMIDE

TABLET; ORAL				
<u>TOLAZAMIDE</u>				
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A070259</u>	<u>001</u> Jan 02, 1986
<u>AB</u>	+	<u>500MG</u>	<u>A070259</u>	<u>003</u> Mar 17, 1986
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A070514</u>	<u>001</u> Jan 09, 1986
<u>AB</u>		<u>500MG</u>	<u>A070515</u>	<u>001</u> Jan 09, 1986

TOLBUTAMIDE

TABLET; ORAL				
<u>TOLBUTAMIDE</u>				
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A086445</u>	<u>001</u>
<u>AB</u>	+	<u>500MG</u>	<u>A086109</u>	<u>001</u>
<u>AB</u>		<u>500MG</u>	<u>A087318</u>	<u>001</u>

PRESCRIPTION DRUG PRODUCT LIST

3 - 386 (of 409)

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT PHARM INTL	100MG	N020697	001	Jan 29, 1998
+	200MG	N020697	002	Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

<u>AB</u> ACTAVIS ELIZABETH	<u>EQ 400MG BASE</u>	<u>A073308</u>	<u>001</u>	Jan 24, 1992
<u>AB</u> MYLAN	<u>EQ 400MG BASE</u>	<u>A073393</u>	<u>001</u>	May 27, 1993
<u>AB</u> + TEVA	<u>EQ 400MG BASE</u>	<u>A073290</u>	<u>001</u>	Nov 27, 1991

TABLET; ORAL

TOLMETIN SODIUM

<u>AB</u> MUTUAL PHARM	<u>EQ 200MG BASE</u>	<u>A073310</u>	<u>001</u>	Nov 27, 1991
<u>AB</u> + MYLAN	<u>EQ 600MG BASE</u>	<u>A074473</u>	<u>001</u>	Aug 30, 1994

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LA

PHARMACIA AND UPJOHN	2MG	N021228	001	Dec 22, 2000
+	4MG	N021228	002	Dec 22, 2000

TABLET; ORAL

DETROL

PHARMACIA AND UPJOHN	1MG	N020771	001	Mar 25, 1998
+	2MG	N020771	002	Mar 25, 1998

TOLVAPTAN

TABLET; ORAL

SAMSCA

OTSUKA AMERICA PHARM	15MG	N022275	001	May 19, 2009
+	30MG	N022275	002	May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

<u>AB</u> ORTHO MCNEIL JANSSEN	<u>15MG</u>	<u>N020844</u>	<u>001</u>	Oct 26, 1998
<u>AB</u> +	<u>25MG</u>	<u>N020844</u>	<u>002</u>	Oct 26, 1998

TOPIRAMATE

<u>AB</u> MYLAN	<u>15MG</u>	<u>A078418</u>	<u>001</u>	Oct 14, 2009
<u>AB</u>	<u>25MG</u>	<u>A078418</u>	<u>002</u>	Oct 14, 2009
<u>AB</u> SANDOZ	<u>15MG</u>	<u>A079206</u>	<u>001</u>	Oct 14, 2009
<u>AB</u>	<u>25MG</u>	<u>A079206</u>	<u>002</u>	Oct 14, 2009
<u>AB</u> TEVA	<u>15MG</u>	<u>A076575</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>	<u>25MG</u>	<u>A076575</u>	<u>002</u>	Apr 17, 2009
<u>AB</u> WATSON LABS	<u>15MG</u>	<u>A077868</u>	<u>001</u>	Apr 15, 2009
<u>AB</u>	<u>25MG</u>	<u>A077868</u>	<u>002</u>	Apr 15, 2009
<u>AB</u> ZYDUS PHARMS USA INC	<u>15MG</u>	<u>A078877</u>	<u>001</u>	Oct 14, 2009
<u>AB</u>	<u>25MG</u>	<u>A078877</u>	<u>002</u>	Oct 14, 2009

TABLET; ORAL

TOPAMAX

<u>AB</u> + ORTHO MCNEIL JANSSEN	<u>25MG</u>	<u>N020505</u>	<u>004</u>	Dec 24, 1996
<u>AB</u>	<u>50MG</u>	<u>N020505</u>	<u>005</u>	Dec 24, 1996
<u>AB</u>	<u>100MG</u>	<u>N020505</u>	<u>001</u>	Dec 24, 1996
<u>AB</u>	<u>200MG</u>	<u>N020505</u>	<u>002</u>	Dec 24, 1996

TOPIRAMATE

<u>AB</u> ACCORD HLTHCARE	<u>25MG</u>	<u>A076311</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>	<u>50MG</u>	<u>A076311</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>	<u>100MG</u>	<u>A076311</u>	<u>003</u>	Mar 27, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 387 (of 409)

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>	ACCORD HLTHCARE	<u>200MG</u>	<u>A076311</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077733</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077733</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077733</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077733</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078462</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078462</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078462</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078462</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A076343</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076343</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076343</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076343</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077627</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077627</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077627</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077627</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A079162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076314</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076314</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076314</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076314</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	RANBAXY	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A090162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078499</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499</u>	<u>002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499</u>	<u>003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499</u>	<u>004</u>	Jan 07, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A077643</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077643</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077643</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077643</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	WOCKHARDT USA	<u>25MG</u>	<u>A090353</u>	<u>001</u>	Sep 01, 2010
<u>AB</u>		<u>50MG</u>	<u>A090353</u>	<u>002</u>	Sep 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A090353</u>	<u>003</u>	Sep 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A090353</u>	<u>004</u>	Sep 01, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235</u>	<u>002</u>	Mar 27, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 388 (of 409)

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>	ZYDUS PHARMS USA INC	<u>100MG</u>	<u>A078235</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235</u>	<u>004</u>	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCANTIN

	SMITHKLINE BEECHAM	EQ 0.25MG BASE	N020981	001	Oct 11, 2007
+		EQ 1MG BASE	N020981	002	Oct 11, 2007

INJECTABLE; INJECTION

HYCANTIN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/VIAL</u>	<u>N020671</u>	<u>001</u>	May 28, 1996
<u>AP</u>	<u>TOPOTECAN HYDROCHLORIDE</u>				
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620</u>	<u>001</u>	Dec 02, 2010
<u>AP</u>	APP PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091089</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 4MG BASE/VIAL</u>	<u>A091376</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	THREE RIVERS PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091199</u>	<u>001</u>	Dec 01, 2010

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+	GTX INC	EQ 60MG BASE	N020497	001	May 29, 1997

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

<u>AP</u>	+ BEDFORD LABS	<u>20MG/2ML (10MG/ML)</u>	<u>A078007</u>	<u>001</u>	Jun 11, 2008
<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A078007</u>	<u>002</u>	Jun 11, 2008
<u>AP</u>	LUITPOLD	<u>50MG/5ML (10MG/ML)</u>	<u>A090656</u>	<u>002</u>	Apr 21, 2010
<u>AP</u>		<u>20MG/2ML (10MG/ML)</u>	<u>A090656</u>	<u>001</u>	Apr 21, 2010

TABLET; ORAL

DEMADEX

<u>AB</u>	MEDA PHARMS	<u>5MG</u>	<u>N020136</u>	<u>001</u>	Aug 23, 1993
<u>AB</u>		<u>10MG</u>	<u>N020136</u>	<u>002</u>	Aug 23, 1993
<u>AB</u>	+	<u>20MG</u>	<u>N020136</u>	<u>003</u>	Aug 23, 1993
<u>AB</u>		<u>100MG</u>	<u>N020136</u>	<u>004</u>	Aug 23, 1993

TORSEMIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A076894</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>10MG</u>	<u>A076894</u>	<u>002</u>	May 31, 2005
<u>AB</u>		<u>20MG</u>	<u>A076894</u>	<u>003</u>	May 31, 2005
<u>AB</u>		<u>100MG</u>	<u>A076894</u>	<u>004</u>	May 31, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078249</u>	<u>001</u>	Oct 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A078249</u>	<u>002</u>	Oct 17, 2007
<u>AB</u>		<u>20MG</u>	<u>A078249</u>	<u>003</u>	Oct 17, 2007
<u>AB</u>		<u>100MG</u>	<u>A078249</u>	<u>004</u>	Oct 17, 2007
<u>AB</u>	HETERO DRUGS	<u>5MG</u>	<u>A079234</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A079234</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>20MG</u>	<u>A079234</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079234</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A076226</u>	<u>001</u>	May 27, 2003
<u>AB</u>		<u>10MG</u>	<u>A076226</u>	<u>002</u>	May 27, 2003
<u>AB</u>		<u>20MG</u>	<u>A076226</u>	<u>003</u>	May 27, 2003
<u>AB</u>		<u>100MG</u>	<u>A076226</u>	<u>004</u>	May 27, 2003
<u>AB</u>	PLIVA PHARM IND	<u>5MG</u>	<u>A076346</u>	<u>001</u>	May 30, 2003
<u>AB</u>		<u>10MG</u>	<u>A076346</u>	<u>002</u>	May 30, 2003
<u>AB</u>		<u>20MG</u>	<u>A076346</u>	<u>003</u>	May 30, 2003
<u>AB</u>		<u>100MG</u>	<u>A076346</u>	<u>004</u>	Oct 19, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 389 (of 409)

TORSEMIDE

TABLET; ORAL

TORSEMIDE

<u>AB</u>	ROXANE	<u>5MG</u>	<u>A076943</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>10MG</u>	<u>A076943</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>20MG</u>	<u>A076943</u>	<u>003</u>	Mar 01, 2005
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A078478</u>	<u>001</u>	Feb 26, 2008
<u>AB</u>		<u>10MG</u>	<u>A078478</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078478</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>100MG</u>	<u>A078478</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110</u>	<u>001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110</u>	<u>002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110</u>	<u>003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110</u>	<u>004</u>	May 14, 2002

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
TRAMADOL HYDROCHLORIDE

+	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
		200MG	N022370	002	May 07, 2010
		300MG	N022370	003	May 07, 2010

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>50MG</u>	<u>A075960</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	ALPHAPHARM	<u>50MG</u>	<u>A075980</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	CARACO	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	MALLINCKRODT	<u>50MG</u>	<u>A075983</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A076100</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	NORTHSTAR HLTHCARE	<u>50MG</u>	<u>A078935</u>	<u>001</u>	May 26, 2010
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A075968</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A075962</u>	<u>001</u>	Jun 24, 2002

ULTRAM

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>50MG</u>	<u>N020281</u>	<u>002</u>	Mar 03, 1995

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>100MG</u>	<u>A078783</u>	<u>001</u>	Nov 13, 2009
<u>AB</u>		<u>200MG</u>	<u>A078783</u>	<u>002</u>	Nov 13, 2009

ULTRAM ER

<u>AB</u>	+ BIOVAIL LABS INTL	<u>100MG</u>	<u>N021692</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>200MG</u>	<u>N021692</u>	<u>002</u>	Sep 08, 2005

RYZOLT

BC	+ PURDUE PHARMA	100MG	N021745	001	Dec 30, 2008
BC		200MG	N021745	002	Dec 30, 2008
BC		300MG	N021745	003	Dec 30, 2008

ULTRAM ER

BC	BIOVAIL LABS INTL	300MG	N021692	003	Sep 08, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

+	VICTORY PHARMA	50MG	N021693	001	May 05, 2005

TRANDOLAPRIL

TABLET; ORAL

MAVIK

<u>AB</u>	ABBOTT	<u>1MG</u>	<u>N020528</u>	<u>001</u>	Apr 26, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 390 (of 409)

TRANDOLAPRIL

TABLET; ORAL

MAVIK

<u>AB</u>	ABBOTT	<u>2MG</u>	<u>N020528</u>	<u>002</u>	Apr 26, 1996
<u>AB</u>	+	<u>4MG</u>	<u>N020528</u>	<u>003</u>	Apr 26, 1996
	<u>TRANDOLAPRIL</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A078438</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078438</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078438</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	CIPLA	<u>1MG</u>	<u>A077307</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077307</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077307</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	COREPHARMA	<u>1MG</u>	<u>A077256</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077256</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077256</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A078493</u>	<u>001</u>	Aug 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078493</u>	<u>002</u>	Aug 25, 2008
<u>AB</u>		<u>4MG</u>	<u>A078493</u>	<u>003</u>	Aug 25, 2008
<u>AB</u>	EPIC PHARMA	<u>1MG</u>	<u>A078508</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>2MG</u>	<u>A078508</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>4MG</u>	<u>A078508</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A078320</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078320</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078320</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	LUPIN	<u>1MG</u>	<u>A077522</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077522</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077522</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A078346</u>	<u>001</u>	Apr 28, 2008
<u>AB</u>		<u>2MG</u>	<u>A078346</u>	<u>002</u>	Apr 28, 2008
<u>AB</u>		<u>4MG</u>	<u>A078346</u>	<u>003</u>	Apr 28, 2008
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A077489</u>	<u>001</u>	Dec 12, 2006
<u>AB</u>		<u>2MG</u>	<u>A077489</u>	<u>002</u>	Dec 12, 2006
<u>AB</u>		<u>4MG</u>	<u>A077489</u>	<u>003</u>	Dec 12, 2006
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A077805</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077805</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077805</u>	<u>003</u>	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

<u>AB</u>	ABBOTT	<u>1MG;240MG</u>	<u>N020591</u>	<u>003</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;180MG</u>	<u>N020591</u>	<u>001</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;240MG</u>	<u>N020591</u>	<u>004</u>	Oct 22, 1996
<u>AB</u>	+	<u>4MG;240MG</u>	<u>N020591</u>	<u>002</u>	Oct 22, 1996
	<u>TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>				
<u>AB</u>	GLENMARK GENERICS	<u>1MG;240MG</u>	<u>A079135</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>2MG;180MG</u>	<u>A079135</u>	<u>001</u>	May 26, 2010
<u>AB</u>		<u>2MG;240MG</u>	<u>A079135</u>	<u>002</u>	May 26, 2010
<u>AB</u>		<u>4MG;240MG</u>	<u>A079135</u>	<u>003</u>	May 05, 2010

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

+	PHARMACIA AND UPJOHN	100MG/ML	N019281	001	Dec 30, 1986

TABLET; ORAL

LYSTEDA

+	FERRING PHARMS AS	650MG	N022430	001	Nov 13, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 391 (of 409)

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 10MG BASE</u>	<u>N012342</u>	<u>003</u>	Aug 16, 1985

TRANLYCYPROMINE SULFATE

<u>AB</u>		PAR PHARM	<u>EQ 10MG BASE</u>	<u>A040640</u>	<u>001</u>	Jun 29, 2006

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

+	ALCON	0.004%	N021257	001	Mar 16, 2001

TRAVATAN Z

+	ALCON	0.004%	N021994	001	Sep 21, 2006

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>		ALVOGEN	<u>50MG</u>	<u>A071636</u>	<u>001</u>	Apr 18, 1988

<u>AB</u>			<u>100MG</u>	<u>A071514</u>	<u>001</u>	Apr 18, 1988

<u>AB</u>		APOTEX	<u>50MG</u>	<u>A071258</u>	<u>001</u>	Mar 25, 1987

<u>AB</u>	+	APOTEX INC	<u>100MG</u>	<u>A071196</u>	<u>001</u>	Mar 25, 1987

<u>AB</u>			<u>150MG</u>	<u>A071196</u>	<u>002</u>	Apr 26, 1999

<u>AB</u>			<u>300MG</u>	<u>A071196</u>	<u>003</u>	Apr 26, 1999

<u>AB</u>		MATRIX LABS LTD	<u>50MG</u>	<u>A090514</u>	<u>001</u>	Jun 02, 2009

<u>AB</u>			<u>100MG</u>	<u>A090514</u>	<u>002</u>	Jun 02, 2009

<u>AB</u>			<u>150MG</u>	<u>A090514</u>	<u>003</u>	Jun 02, 2009

<u>AB</u>			<u>300MG</u>	<u>A090514</u>	<u>004</u>	Jun 02, 2009

<u>AB</u>		MUTUAL PHARM	<u>50MG</u>	<u>A073137</u>	<u>002</u>	Mar 24, 1993

<u>AB</u>			<u>100MG</u>	<u>A073137</u>	<u>001</u>	Mar 24, 1993

<u>AB</u>			<u>150MG</u>	<u>A073137</u>	<u>003</u>	Dec 22, 1995

<u>AB</u>		PLIVA	<u>50MG</u>	<u>A071523</u>	<u>001</u>	Dec 11, 1987

<u>AB</u>			<u>100MG</u>	<u>A071524</u>	<u>001</u>	Dec 11, 1987

<u>AB</u>			<u>150MG</u>	<u>A071525</u>	<u>001</u>	Mar 09, 1988

<u>AB</u>		VINTAGE	<u>50MG</u>	<u>A072192</u>	<u>001</u>	Feb 02, 1989

<u>AB</u>			<u>100MG</u>	<u>A072193</u>	<u>001</u>	Feb 02, 1989

<u>AB</u>		WATSON LABS	<u>50MG</u>	<u>A070857</u>	<u>001</u>	Oct 10, 1986

<u>AB</u>			<u>100MG</u>	<u>A070858</u>	<u>001</u>	Oct 10, 1986

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

+	LABOPHARM	150MG	N022411	001	Feb 02, 2010

		300MG	N022411	002	Feb 02, 2010

TREPROSTINIL SODIUM

INJECTABLE; IV (INFUSION)-SC

UNITED THERAP

1MG/ML	N021272	001	May 21, 2002

2.5MG/ML	N021272	002	May 21, 2002

5MG/ML	N021272	003	May 21, 2002

+	10MG/ML	N021272	004	May 21, 2002

SOLUTION; INHALATION

TYVASO

+	UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009

TRETINOIN

CAPSULE; ORAL

TRETINOIN

+	BARR	10MG	A077684	001	Jun 22, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 392 (of 409)

TRETINOIN

CREAM; TOPICAL

<u>AB</u> <u>AVITA</u>					
<u>AB</u>	MYLAN BERTEK	<u>0.025%</u>	<u>N020404</u>	<u>003</u>	Jan 14, 1997
<u>AB</u> <u>RETIN-A</u>					
<u>AB</u>	+ JOHNSON AND JOHNSON	<u>0.025%</u>	<u>N019049</u>	<u>001</u>	Sep 16, 1988
<u>AB</u>	+	<u>0.1%</u>	<u>N017340</u>	<u>001</u>	
<u>AB</u> <u>TRETINOIN</u>					
<u>AB</u>	TRIAx PHARMS LLC	<u>0.025%</u>	<u>A075264</u>	<u>001</u>	Dec 24, 1998
<u>AB</u>		<u>0.1%</u>	<u>A075213</u>	<u>001</u>	Dec 24, 1998
<u>AB1</u> <u>RETIN-A</u>					
<u>AB1</u>	+ JOHNSON AND JOHNSON	<u>0.05%</u>	<u>N017522</u>	<u>001</u>	
<u>AB1</u> <u>TRETINOIN</u>					
<u>AB1</u>	TRIAx PHARMS LLC	<u>0.05%</u>	<u>A075265</u>	<u>001</u>	Dec 24, 1998
<u>AB2</u> <u>RENOVA</u>					
<u>AB2</u>	+ ORTHO DERMATOLOGICS	<u>0.05%</u>	<u>N019963</u>	<u>001</u>	Dec 29, 1995
<u>AB2</u> <u>TRETINOIN</u>					
<u>AB2</u>	SPEAR PHARMS	<u>0.05%</u>	<u>A076498</u>	<u>001</u>	Sep 15, 2005
	RENOVA				
	+ ORTHO DERMATOLOGICS	0.02%	N021108	001	Aug 31, 2000
	TRETINOIN				
	+ TRIAX PHARMS LLC	0.0375%	A090098	001	Mar 22, 2010

GEL; TOPICAL

<u>AB</u> <u>RETIN-A</u>					
<u>AB</u>	+ JOHNSON AND JOHNSON	<u>0.01%</u>	<u>N017955</u>	<u>001</u>	
<u>AB</u>	+	<u>0.025%</u>	<u>N017579</u>	<u>002</u>	
<u>AB</u> <u>TRETINOIN</u>					
<u>AB</u>	TRIAx PHARMS LLC	<u>0.01%</u>	<u>A075589</u>	<u>001</u>	Jun 11, 2002
<u>AB</u>		<u>0.025%</u>	<u>A075529</u>	<u>001</u>	Feb 22, 2000
BT <u>AVITA</u>					
	MYLAN	0.025%	N020400	001	Jan 29, 1998
	ATRALIN				
	+ DOW PHARM SCIENCES	0.05%	N022070	001	Jul 26, 2007
	RETIN-A MICRO				
	+ ORTHO DERMATOLOGICS	0.04%	N020475	002	May 10, 2002
	+	0.1%	N020475	001	Feb 07, 1997

SOLUTION; TOPICAL

<u>AT</u> <u>RETIN-A</u>					
<u>AT</u>	+ JOHNSON AND JOHNSON	<u>0.05%</u>	<u>N016921</u>	<u>001</u>	
<u>AT</u> <u>TRETINOIN</u>					
<u>AT</u>	WOCKHARDT	<u>0.05%</u>	<u>A075260</u>	<u>001</u>	Jan 25, 1999

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT					
	+ ABBOTT	0.1MG/INH	N018117	001	Apr 23, 1982

CREAM; TOPICAL

<u>AT</u> <u>KENALOG</u>					
<u>AT</u>	+ APOTHECON	<u>0.025%</u>	<u>N011601</u>	<u>003</u>	
<u>AT</u>	+	<u>0.1%</u>	<u>N011601</u>	<u>006</u>	
<u>AT</u> <u>TRIACET</u>					
<u>AT</u>	TEVA	<u>0.025%</u>	<u>A084908</u>	<u>001</u>	
<u>AT</u>		<u>0.5%</u>	<u>A084908</u>	<u>003</u>	
<u>AT</u> <u>TRIAMCINOLONE ACETONIDE</u>					
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>0.1%</u>	<u>A087798</u>	<u>001</u>	Jun 04, 1982
<u>AT</u>	ALTANA	<u>0.025%</u>	<u>A085692</u>	<u>001</u>	
<u>AT</u>		<u>0.1%</u>	<u>A085692</u>	<u>003</u>	
<u>AT</u>	+	<u>0.5%</u>	<u>A085692</u>	<u>002</u>	
<u>AT</u>	G AND W LABS	<u>0.025%</u>	<u>A089797</u>	<u>001</u>	May 31, 1991
<u>AT</u>	PERRIGO NEW YORK	<u>0.025%</u>	<u>A086415</u>	<u>001</u>	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 393 (of 409)

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	PERRIGO NEW YORK	<u>0.1%</u>	<u>A086414</u>	<u>001</u>	
<u>AT</u>		<u>0.5%</u>	<u>A086413</u>	<u>001</u>	
<u>AT</u>	TARO	<u>0.025%</u>	<u>A086277</u>	<u>001</u>	
<u>AT</u>		<u>0.1%</u>	<u>A040039</u>	<u>001</u>	Nov 26, 1997
<u>AT</u>		<u>0.1%</u>	<u>A086276</u>	<u>001</u>	
<u>AT</u>		<u>0.5%</u>	<u>A086275</u>	<u>001</u>	
<u>AT</u>	VINTAGE	<u>0.025%</u>	<u>A040671</u>	<u>001</u>	Jun 09, 2006
<u>AT</u>		<u>0.1%</u>	<u>A040671</u>	<u>002</u>	Jun 09, 2006
<u>TRIDERM</u>					
<u>AT</u>	DEL RAY LABS	<u>0.1%</u>	<u>A088042</u>	<u>001</u>	Mar 19, 1984

INJECTABLE; INJECTION

KENALOG-10

<u>AB</u>	APOTHECON	<u>10MG/ML</u>	<u>N012041</u>	<u>001</u>	

KENALOG-40

<u>AB</u>	+ APOTHECON	<u>40MG/ML</u>	<u>N014901</u>	<u>001</u>	

TRIAMCINOLONE ACETONIDE

<u>AB</u>	SANDOZ	<u>10MG/ML</u>	<u>A090166</u>	<u>001</u>	May 27, 2009
<u>AB</u>		<u>40MG/ML</u>	<u>A090164</u>	<u>001</u>	May 27, 2009

INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL
TRIVARIS

	+ ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220	001	Jun 16, 2008

INJECTABLE; INTRAVITREAL
TRIESENCE

	+ ALCON	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	ALTANA	<u>0.025%</u>	<u>A040467</u>	<u>001</u>	Apr 21, 2003
<u>AT</u>		<u>0.1%</u>	<u>A040467</u>	<u>002</u>	Apr 21, 2003
<u>AT</u>	MORTON GROVE	<u>0.025%</u>	<u>A088450</u>	<u>001</u>	Apr 01, 1985
<u>AT</u>	TARO	<u>0.1%</u>	<u>A089129</u>	<u>001</u>	Aug 14, 1986
<u>AT</u>	VINTAGE	<u>0.1%</u>	<u>A040672</u>	<u>002</u>	Dec 13, 2006
<u>AT</u>	+ WOCKHARDT	<u>0.1%</u>	<u>A088451</u>	<u>001</u>	Apr 03, 1985

OINTMENT; TOPICAL

KENALOG

<u>AT</u>	APOTHECON	<u>0.025%</u>	<u>N011600</u>	<u>003</u>	
<u>AT</u>		<u>0.1%</u>	<u>N011600</u>	<u>001</u>	

TRIAMCINOLONE ACETONIDE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>0.1%</u>	<u>A087799</u>	<u>001</u>	Jun 07, 1982
<u>AT</u>	NYCOMED US	<u>0.025%</u>	<u>A085691</u>	<u>001</u>	
<u>AT</u>		<u>0.1%</u>	<u>A085691</u>	<u>003</u>	
<u>AT</u>		<u>0.5%</u>	<u>A085691</u>	<u>002</u>	
<u>AT</u>	+ PERRIGO NEW YORK	<u>0.025%</u>	<u>A087356</u>	<u>001</u>	
<u>AT</u>		<u>0.1%</u>	<u>A087357</u>	<u>001</u>	
<u>AT</u>		<u>0.5%</u>	<u>A087385</u>	<u>001</u>	
<u>AT</u>	TARO	<u>0.025%</u>	<u>A040040</u>	<u>001</u>	Sep 30, 1994
<u>AT</u>		<u>0.025%</u>	<u>A040374</u>	<u>001</u>	Jun 05, 2001
<u>AT</u>		<u>0.1%</u>	<u>A040037</u>	<u>001</u>	Sep 30, 1994
<u>AT</u>		<u>0.1%</u>	<u>A087902</u>	<u>001</u>	Dec 27, 1982
<u>AT</u>		<u>0.5%</u>	<u>A040386</u>	<u>001</u>	Jun 05, 2001

TRIAMCINOLONE ACETONIDE IN ABSORBASE
+ CAROLINA MEDCL 0.05%

A089595	001	Mar 23, 1995

PASTE; DENTAL

ORACORT

<u>AT</u>	+ TARO	<u>0.1%</u>	<u>A070730</u>	<u>001</u>	Oct 01, 1986

TRIAMCINOLONE ACETONIDE

<u>AT</u>	LYNE	<u>0.1%</u>	<u>A040771</u>	<u>001</u>	Jul 01, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 394 (of 409)

TRIAMCINOLONE ACETONIDE

SPRAY; TOPICAL				
KENALOG				
	+ RANBAXY	0.147MG/GM	N012104	001
SPRAY, METERED; NASAL				
<u>NASACORT AQ</u>				
<u>AB</u>	+ SANOFI AVENTIS US	<u>0.055MG/SPRAY</u>	<u>N020468</u>	<u>001</u> May 20, 1996
<u>TRIAMCINOLONE ACETONIDE</u>				
<u>AB</u>	BARR	<u>0.055MG/SPRAY</u>	<u>A078104</u>	<u>001</u> Jul 30, 2009

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION				
ARISTOSPAN				
	+ SANDOZ	5MG/ML	N016466	001
	+	20MG/ML	N016466	002

TRIAMTERENE

CAPSULE; ORAL				
DYRENIUM				
	WELLSPRING PHARM	50MG	N013174	001
	+	100MG	N013174	002

TRIAZOLAM

TABLET; ORAL				
<u>HALCION</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.125MG</u>	<u>N017892</u>	<u>003</u> Apr 26, 1985
<u>AB</u>	+	<u>0.25MG</u>	<u>N017892</u>	<u>001</u> Nov 15, 1982
<u>TRIAZOLAM</u>				
<u>AB</u>	ALPHAPHARM	<u>0.125MG</u>	<u>A074031</u>	<u>001</u> Mar 25, 1994
<u>AB</u>		<u>0.25MG</u>	<u>A074031</u>	<u>002</u> Mar 25, 1994
<u>AB</u>	ROXANE	<u>0.125MG</u>	<u>A074224</u>	<u>001</u> Jun 01, 1994
<u>AB</u>		<u>0.25MG</u>	<u>A074224</u>	<u>002</u> Jun 01, 1994
<u>AB</u>	WATSON LABS	<u>0.125MG</u>	<u>A074445</u>	<u>001</u> Oct 20, 1995
<u>AB</u>		<u>0.25MG</u>	<u>A074445</u>	<u>002</u> Oct 20, 1995

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL				
SYPRINE				
	+ ATON	250MG	N019194	001 Nov 08, 1985

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL				
<u>TRIFLUOPERAZINE HYDROCHLORIDE</u>				
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A040209</u>	<u>001</u> Jul 07, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A040209</u>	<u>002</u> Jul 07, 1997
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A040209</u>	<u>003</u> Jul 07, 1997
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>A040209</u>	<u>004</u> Jul 07, 1997
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A085785</u>	<u>001</u>
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A085786</u>	<u>001</u>
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A085789</u>	<u>001</u>
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A085788</u>	<u>001</u>

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC				
<u>TRIFLURIDINE</u>				
<u>AT</u>	ALCON	<u>1%</u>	<u>A074311</u>	<u>001</u> Oct 06, 1995
<u>VIROPTIC</u>				
<u>AT</u>	+ MONARCH PHARMS	<u>1%</u>	<u>N018299</u>	<u>001</u>

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 395 (of 409)

TRIHXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHXYPHENIDYL HYDROCHLORIDE

<u>AA</u>	MIKART	<u>2MG/5ML</u>	<u>A040251</u>	<u>001</u>	Sep 27, 1999
<u>AA</u>	+ PHARM ASSOC	<u>2MG/5ML</u>	<u>A040177</u>	<u>001</u>	Apr 17, 1997

TABLET; ORAL

TRIHXYPHENIDYL HYDROCHLORIDE

<u>AA</u>	NATCO PHARMA LTD	<u>2MG</u>	<u>A091630</u>	<u>001</u>	Nov 17, 2010
<u>AA</u>		<u>5MG</u>	<u>A091630</u>	<u>002</u>	Nov 17, 2010
<u>AA</u>	VINTAGE PHARMS	<u>2MG</u>	<u>A040254</u>	<u>001</u>	Dec 24, 1998
<u>AA</u>		<u>5MG</u>	<u>A040254</u>	<u>002</u>	Dec 24, 1998
<u>AA</u>	WATSON LABS	<u>2MG</u>	<u>A040184</u>	<u>001</u>	Feb 06, 1998
<u>AA</u>	+	<u>2MG</u>	<u>A084363</u>	<u>001</u>	
<u>AA</u>		<u>5MG</u>	<u>A040184</u>	<u>002</u>	Feb 06, 1998
<u>AA</u>	+	<u>5MG</u>	<u>A084364</u>	<u>001</u>	
<u>AA</u>	WEST WARD	<u>2MG</u>	<u>A040337</u>	<u>002</u>	Feb 16, 2000
<u>AA</u>		<u>5MG</u>	<u>A040337</u>	<u>001</u>	Feb 16, 2000

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

+	ABBOTT	150MG	N005856	009	

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

<u>AB</u>	+	KING PHARMS	<u>300MG</u>	<u>N017531</u>	<u>006</u>	Dec 13, 2001

TRIMETHOBENZAMIDE HYDROCHLORIDE

<u>AB</u>	GAVIS PHARMS	<u>300MG</u>	<u>A076546</u>	<u>001</u>	Aug 20, 2003
<u>AB</u>	MUTUAL PHARMA	<u>300MG</u>	<u>A076570</u>	<u>001</u>	Aug 28, 2003

INJECTABLE; INJECTION

TIGAN

<u>AP</u>	+	JHP PHARMS	<u>100MG/ML</u>	<u>N017530</u>	<u>001</u>	
<u>AP</u>		HOSPIRA	<u>100MG/ML</u>	<u>A088804</u>	<u>001</u>	Apr 03, 1987

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

<u>AB</u>	TEVA	<u>100MG</u>	<u>N018679</u>	<u>001</u>	Jul 30, 1982
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A070049</u>	<u>001</u>	Jun 06, 1985
	TRIMETHOPRIM				
	+ TEVA	200MG	A071259	001	Jun 18, 1987

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+	FSC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

<u>AB</u>	ODYSSEY PHARMS	<u>EQ 25MG BASE</u>	<u>N016792</u>	<u>001</u>	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N016792</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N016792</u>	<u>003</u>	Sep 15, 1982

TRIMIPRAMINE MALEATE

<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 25MG BASE</u>	<u>A077361</u>	<u>001</u>	Aug 02, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077361</u>	<u>002</u>	Aug 02, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077361</u>	<u>003</u>	Aug 02, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 396 (of 409)

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+ WATSON LABS EQ 22.5MG BASE/VIAL N022437 001 Mar 10, 2010

TRELSTAR DEPOT

+ WATSON LABS EQ 3.75MG BASE/VIAL N020715 001 Jun 15, 2000

TRELSTAR LA

+ WATSON LABS EQ 11.25MG BASE/VIAL N021288 001 Jun 29, 2001

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+ HOSPIRA 3.6GM/100ML N013025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYLAT + ALCON 0.5% A084305 001AT + 1% A084306 001TROPICACYLAT AKORN 0.5% A040314 001 Sep 29, 2000AT 1% A040315 001 Sep 29, 2000TROPICAMIDEAT BAUSCH AND LOMB 0.5% A040067 001 Jul 27, 1994AT 1% A040064 001 Jul 27, 1994TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

+ ALLERGAN 60MG N022103 001 Aug 03, 2007

TABLET; ORAL

SANCTURAAB + ALLERGAN 20MG N021595 001 May 28, 2004TROSPIMUM CHLORIDEAB GLENMARK GENERICS 20MG A091575 001 Aug 13, 2010AB PADDOCK LABS 20MG A091573 001 Nov 17, 2010TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+ DORC 0.15% N022278 001 Feb 20, 2009

VISIONBLUE

+ DORC 0.06% N021670 001 Dec 16, 2004

ULIPRISTAL ACETATE

TABLET; ORAL

ELLA

+ LAB HRA PHARMA 30MG N022474 001 Aug 13, 2010

UREA C-13

FOR SOLUTION; ORAL

BREATHTEK UBT FOR H-PYLORI

+ OTSUKA AMERICA EQ 75MG /POUCH N020586 002 May 10, 2001

UREA, C-14

CAPSULE; ORAL

PYTEST

+ AVENT 1uCi N020617 001 May 09, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 397 (of 409)

UREA, C-14CAPSULE; ORAL
PYTEST KIT

+ AVENT 1uCi N020617 002 May 09, 1997

UROFOLLITROPININJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE

+ FERRING 75 IU/VIAL N021289 001 May 06, 2002

URSODIOL

CAPSULE; ORAL

ACTIGALLAB + WATSON PHARMS 300MG N019594 002 Dec 31, 1987URSODIOLAB COREPHARMA 300MG A077895 001 Jul 27, 2006AB EPIC PHARMA 300MG A075517 001 Mar 14, 2000AB LANNETT 300MG A079082 001 Dec 15, 2008AB MYLAN 300MG A090530 001 Feb 17, 2010AB TEVA PHARMS 300MG A075592 001 May 25, 2000

TABLET; ORAL

URSO 250AB AXCAN 250MG N020675 001 Dec 10, 1997URSO FORTEAB + AXCAN 500MG N020675 002 Jul 21, 2004URSODIOLAB TEVA PHARMS 250MG A079184 001 May 13, 2009AB 500MG A079184 002 May 13, 2009VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDEAB AUROBINDO PHARMA EQ 500MG BASE A090682 001 May 24, 2010AB EQ 1GM BASE A090682 002 May 24, 2010AB DR REDDYS LABS LTD EQ 500MG BASE A079012 001 May 24, 2010AB EQ 1GM BASE A079012 002 May 24, 2010AB MATRIX LABS LTD EQ 500MG BASE A078518 001 May 24, 2010AB EQ 1GM BASE A078518 002 May 24, 2010AB MYLAN EQ 500MG BASE A078070 001 May 24, 2010AB EQ 1GM BASE A078070 002 May 24, 2010AB RANBAXY EQ 500MG BASE A076588 001 Jan 31, 2007AB EQ 1GM BASE A076588 002 Jan 31, 2007AB ROXANE EQ 500MG BASE A078656 001 May 24, 2010AB EQ 1GM BASE A078656 002 May 24, 2010AB SANDOZ EQ 500MG BASE A077478 001 May 24, 2010AB EQ 1GM BASE A077478 002 May 24, 2010AB TEVA PHARMS EQ 500MG BASE A077655 001 May 24, 2010AB EQ 1GM BASE A077655 002 May 24, 2010AB WATSON LABS EQ 500MG BASE A077135 001 May 24, 2010AB EQ 1GM BASE A077135 002 May 24, 2010AB WOCKHARDT EQ 500MG BASE A090216 001 May 24, 2010AB EQ 1GM BASE A090216 002 May 24, 2010VALTREXAB GLAXOSMITHKLINE EQ 500MG BASE N020487 001 Jun 23, 1995AB + EQ 1GM BASE N020487 002 Jun 23, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 398 (of 409)

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+	ROCHE PALO	50MG/ML	N022257	001	Aug 28, 2009

TABLET; ORAL

VALCYTE

+	ROCHE PALO	EQ 450MG BASE	N021304	001	Mar 29, 2001

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPAKON

<u>AP</u>	+	ABBOTT	<u>EQ 100MG BASE/ML</u>	<u>N020593</u>	<u>001</u>	Dec 30, 1996

VALPROATE SODIUM

<u>AP</u>		APP PHARMS	<u>EQ 100MG BASE/ML</u>	<u>A076539</u>	<u>001</u>	Jun 26, 2003

<u>AP</u>		BEDFORD	<u>EQ 100MG BASE/ML</u>	<u>A076295</u>	<u>001</u>	Nov 14, 2002

<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523</u>	<u>001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

<u>AB</u>	+	ABBOTT	<u>250MG</u>	<u>N018081</u>	<u>001</u>	

VALPROIC ACID

<u>AB</u>		BANNER PHARMACAPS	<u>250MG</u>	<u>A073484</u>	<u>001</u>	Jun 29, 1993

<u>AB</u>		CATALENT	<u>250MG</u>	<u>A073229</u>	<u>001</u>	Oct 29, 1991

CAPSULE, DELAYED RELEASE; ORAL

STAVZOR

		BANNER PHARMACAPS	125MG	N022152	001	Jul 29, 2008

			250MG	N022152	002	Jul 29, 2008

+			500MG	N022152	003	Jul 29, 2008

SYRUP; ORAL

DEPAKENE

<u>AA</u>	+	ABBOTT	<u>250MG/5ML</u>	<u>N018082</u>	<u>001</u>	

VALPROIC ACID

<u>AA</u>		ALPHARMA	<u>250MG/5ML</u>	<u>A075782</u>	<u>001</u>	Dec 22, 2000

<u>AA</u>		HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060</u>	<u>001</u>	Jan 13, 1995

<u>AA</u>		PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379</u>	<u>001</u>	Dec 15, 2000

<u>AA</u>		SUN PHARM INDS INC	<u>250MG/5ML</u>	<u>A090517</u>	<u>001</u>	May 28, 2010

<u>AA</u>		TEVA PHARMS	<u>250MG/5ML</u>	<u>A073178</u>	<u>001</u>	Aug 25, 1992

<u>AA</u>		VINTAGE	<u>250MG/5ML</u>	<u>A077960</u>	<u>001</u>	Oct 13, 2006

<u>AA</u>		WOCKHARDT	<u>250MG/5ML</u>	<u>A070868</u>	<u>001</u>	Jul 01, 1986

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

+	ENDO PHARM	40MG/ML	N020892	001	Sep 25, 1998

VALSARTAN

TABLET; ORAL

DIOVAN

		NOVARTIS	40MG	N021283	004	Aug 14, 2002

			80MG	N021283	001	Jul 18, 2001

			160MG	N021283	002	Jul 18, 2001

+			320MG	N021283	003	Jul 18, 2001

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

		VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15, 1986

+			EQ 250MG BASE	N050606	002	Apr 15, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 399 (of 409)

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	AKORN STRIDES	EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008
AP		EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008
AP		EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008
AP	+ APP PHARMS	EQ 500MG BASE/VIAL	A062663	001	Mar 17, 1987
AP	+	EQ 1GM BASE/VIAL	A062663	002	Jul 31, 1987
AP	+	EQ 5GM BASE/VIAL	A062663	003	Jun 03, 1988
AP	+	EQ 10GM BASE/VIAL	A062663	004	Nov 28, 1997
AP	BIONICHE PHARMA USA	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008
AP	+ HOSPIRA	EQ 500MG BASE/VIAL	A062911	001	Aug 04, 1988
AP	+	EQ 500MG BASE/VIAL	A062931	001	Oct 29, 1992
AP		EQ 750MG BASE/VIAL	A062912	002	Jan 07, 2009
AP		EQ 750MG BASE/VIAL	A062933	002	May 27, 2009
AP	+	EQ 1GM BASE/VIAL	A062912	001	Aug 04, 1988
AP	+	EQ 1GM BASE/VIAL	A062933	001	Oct 29, 1992
AP	+	EQ 5GM BASE/VIAL	A063076	001	Dec 21, 1990
AP	HOSPIRA INC	EQ 10GM BASE/VIAL	A065455	001	Apr 29, 2009
AP	SANDOZ	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010
AP		EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010
	VANCOCIN HYDROCHLORIDE	IN PLASTIC CONTAINER			
+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
+		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

	BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003
		5MG	N021400	001	Aug 19, 2003
		10MG	N021400	002	Aug 19, 2003
	+	20MG	N021400	004	Aug 19, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

	PFIZER INC	EQ 0.5MG BASE	N021928	001	May 10, 2006
	+	EQ 1MG BASE	N021928	002	May 10, 2006

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>	AKORN STRIDES	<u>10MG/VIAL</u>	<u>A090243</u>	<u>001</u>	May 11, 2010
<u>AP</u>		<u>20MG/VIAL</u>	<u>A090243</u>	<u>002</u>	May 11, 2010
<u>AP</u>	+ BEDFORD	<u>10MG/VIAL</u>	<u>A075549</u>	<u>001</u>	Jun 13, 2000
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075549</u>	<u>002</u>	Jun 13, 2000
<u>AP</u>	HOSPIRA	<u>10MG/VIAL</u>	<u>A075164</u>	<u>001</u>	Oct 21, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075164</u>	<u>002</u>	Oct 21, 1999
<u>AP</u>	MUSTAFA NEVZAT	<u>10MG/VIAL</u>	<u>A078274</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>		<u>20MG/VIAL</u>	<u>A078274</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>10MG/VIAL</u>	<u>A079001</u>	<u>001</u>	Jun 17, 2009
<u>AP</u>		<u>20MG/VIAL</u>	<u>A079001</u>	<u>002</u>	Jun 17, 2009
<u>AP</u>	TEVA PARENTERAL	<u>10MG/VIAL</u>	<u>A074688</u>	<u>001</u>	Aug 25, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A074688</u>	<u>002</u>	Aug 25, 1999
<u>AP</u>	WATSON LABS	<u>10MG/VIAL</u>	<u>A074334</u>	<u>001</u>	Aug 31, 1995
<u>AP</u>		<u>20MG/VIAL</u>	<u>A074334</u>	<u>002</u>	Aug 31, 1995

PRESCRIPTION DRUG PRODUCT LIST

3 - 400 (of 409)

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

VPRIV

SHIRE HUMAN GENETIC 400 UNITS/VIAL

N022575 001 Feb 26, 2010

POWDER; IV (INFUSION)

+ SHIRE HUMAN GENETIC 200 UNITS/VIAL

N022575 002 Feb 26, 2010

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

AB WYETH PHARMS INC EQ 37.5MG BASE

N020699 001 Oct 20, 1997

AB EQ 75MG BASE

N020699 002 Oct 20, 1997

AB + EQ 150MG BASE

N020699 004 Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

AB TEVA EQ 37.5MG BASE

A076565 001 Jun 28, 2010

AB EQ 75MG BASE

A076565 002 Jun 28, 2010

AB EQ 150MG BASE

A076565 003 Jun 28, 2010

TABLET; ORAL

EFFEXOR

AB WYETH PHARMS INC EQ 25MG BASE

N020151 002 Dec 28, 1993

AB EQ 37.5MG BASE

N020151 006 Dec 28, 1993

AB + EQ 50MG BASE

N020151 003 Dec 28, 1993

AB EQ 75MG BASE

N020151 004 Dec 28, 1993

AB EQ 100MG BASE

N020151 005 Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

AB ACTAVIS TOTOWA EQ 25MG BASE

A078554 001 Jan 09, 2009

AB EQ 37.5MG BASE

A078554 002 Jan 09, 2009

AB EQ 50MG BASE

A078554 003 Jan 09, 2009

AB EQ 75MG BASE

A078554 004 Jan 09, 2009

AB EQ 100MG BASE

A078554 005 Jan 09, 2009

AB ALEMBIC LTD EQ 25MG BASE

A078932 001 Dec 14, 2010

AB EQ 37.5MG BASE

A078932 002 Dec 14, 2010

AB EQ 50MG BASE

A078932 003 Dec 14, 2010

AB EQ 75MG BASE

A078932 004 Dec 14, 2010

AB EQ 100MG BASE

A078932 005 Dec 14, 2010

AB AMNEAL PHARMS EQ 25MG BASE

A079098 001 May 11, 2010

AB EQ 37.5MG BASE

A079098 002 May 11, 2010

AB EQ 50MG BASE

A079098 003 May 11, 2010

AB EQ 75MG BASE

A079098 004 May 11, 2010

AB EQ 100MG BASE

A079098 005 May 11, 2010

AB AUROBINDO PHARMA EQ 25MG BASE

A090555 001 Apr 07, 2010

AB EQ 37.5MG BASE

A090555 002 Apr 07, 2010

AB EQ 50MG BASE

A090555 003 Apr 07, 2010

AB EQ 75MG BASE

A090555 004 Apr 07, 2010

AB EQ 100MG BASE

A090555 005 Apr 07, 2010

AB CARACO EQ 25MG BASE

A078627 001 Jun 13, 2008

AB EQ 37.5MG BASE

A078627 002 Jun 13, 2008

AB EQ 50MG BASE

A078627 003 Jun 13, 2008

AB EQ 75MG BASE

A078627 004 Jun 13, 2008

AB EQ 100MG BASE

A078627 005 Jun 13, 2008

AB DR REDDYS LABS LTD EQ 25MG BASE

A078301 001 Jun 13, 2008

AB EQ 37.5MG BASE

A078301 002 Jun 13, 2008

AB EQ 50MG BASE

A078301 003 Jun 13, 2008

AB EQ 75MG BASE

A078301 004 Jun 13, 2008

AB EQ 100MG BASE

A078301 005 Jun 13, 2008

AB MYLAN EQ 25MG BASE

A077166 001 Jun 13, 2008

AB EQ 37.5MG BASE

A077166 002 Jun 13, 2008

AB EQ 50MG BASE

A077166 003 Jun 13, 2008

AB EQ 75MG BASE

A077166 004 Jun 13, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 401 (of 409)

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 100MG BASE</u>	<u>A077166</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 25MG BASE</u>	<u>A078517</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078517</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078517</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078517</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078517</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690</u>	<u>001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690</u>	<u>002</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076690</u>	<u>003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690</u>	<u>004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690</u>	<u>005</u>	Aug 03, 2006
<u>AB</u>	VINTAGE	<u>EQ 25MG BASE</u>	<u>A090027</u>	<u>001</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090027</u>	<u>002</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090027</u>	<u>003</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090027</u>	<u>004</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090027</u>	<u>005</u>	Aug 04, 2010
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653</u>	<u>005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104</u>	<u>001</u>	May 20, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N022104</u>	<u>002</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N022104</u>	<u>003</u>	May 20, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 37.5MG BASE</u>	<u>A091272</u>	<u>001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272</u>	<u>002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272</u>	<u>003</u>	Aug 18, 2010

VENLAFAXINE HYDROCHLORIDE

	OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A078306</u>	<u>001</u>	Aug 09, 2007
<u>AB</u>		<u>120MG</u>	<u>A075138</u>	<u>001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138</u>	<u>002</u>	Apr 20, 1999
<u>AB</u>		<u>200MG</u>	<u>A078306</u>	<u>002</u>	Aug 09, 2007
<u>AB</u>		<u>240MG</u>	<u>A075138</u>	<u>003</u>	Apr 20, 1999
<u>AB</u>		<u>300MG</u>	<u>A078306</u>	<u>003</u>	Aug 09, 2007
	<u>VERELAN</u>				
<u>AB</u>	ELAN DRUG	<u>120MG</u>	<u>N019614</u>	<u>001</u>	May 29, 1990
<u>AB</u>		<u>180MG</u>	<u>N019614</u>	<u>003</u>	Jan 09, 1992
<u>AB</u>		<u>240MG</u>	<u>N019614</u>	<u>002</u>	May 29, 1990
	<u>VERELAN PM</u>				
<u>AB</u>	ELAN DRUG	<u>100MG</u>	<u>N020943</u>	<u>001</u>	Nov 25, 1998
<u>AB</u>		<u>200MG</u>	<u>N020943</u>	<u>002</u>	Nov 25, 1998
<u>AB</u>	+	<u>300MG</u>	<u>N020943</u>	<u>003</u>	Nov 25, 1998
	VERELAN				
	+ ELAN DRUG	360MG	N019614	004	May 10, 1996

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>2.5MG/ML</u>	<u>A070577</u>	<u>001</u>	Feb 02, 1987
<u>AP</u>		<u>2.5MG/ML</u>	<u>A070737</u>	<u>001</u>	May 06, 1987
<u>AP</u>		<u>2.5MG/ML</u>	<u>A070738</u>	<u>001</u>	May 06, 1987
<u>AP</u>		<u>2.5MG/ML</u>	<u>A075136</u>	<u>001</u>	Oct 20, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 402 (of 409)

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	INTL MEDICATION	<u>2.5MG/ML</u>	<u>A070451</u>	<u>001</u>	Dec 16, 1985

TABLET; ORAL

CALAN

<u>AB</u>	GD SEARLE LLC	<u>40MG</u>	<u>N018817</u>	<u>003</u>	Feb 23, 1988

<u>AB</u>		<u>80MG</u>	<u>N018817</u>	<u>001</u>	Sep 10, 1984

<u>AB</u>	+	<u>120MG</u>	<u>N018817</u>	<u>002</u>	Sep 10, 1984

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>80MG</u>	<u>A071019</u>	<u>001</u>	Sep 24, 1986

<u>AB</u>		<u>120MG</u>	<u>A070468</u>	<u>001</u>	Sep 24, 1986

<u>AB</u>	MYLAN	<u>80MG</u>	<u>A071482</u>	<u>001</u>	Feb 15, 1989

<u>AB</u>		<u>120MG</u>	<u>A071483</u>	<u>001</u>	Feb 15, 1989

<u>AB</u>	WATSON LABS	<u>40MG</u>	<u>A072923</u>	<u>001</u>	Jun 29, 1993

<u>AB</u>		<u>40MG</u>	<u>A072924</u>	<u>001</u>	Jun 29, 1993

<u>AB</u>		<u>80MG</u>	<u>A070855</u>	<u>001</u>	Sep 24, 1986

<u>AB</u>		<u>80MG</u>	<u>A070995</u>	<u>001</u>	Oct 01, 1986

<u>AB</u>		<u>80MG</u>	<u>A071366</u>	<u>001</u>	Oct 01, 1986

<u>AB</u>		<u>120MG</u>	<u>A070856</u>	<u>001</u>	Sep 24, 1986

<u>AB</u>		<u>120MG</u>	<u>A070994</u>	<u>001</u>	Oct 01, 1986

<u>AB</u>		<u>120MG</u>	<u>A071367</u>	<u>001</u>	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR

<u>AB</u>	+	RANBAXY	<u>120MG</u>	<u>N019152</u>	<u>003</u>	Mar 06, 1991

<u>AB</u>	+		<u>180MG</u>	<u>N019152</u>	<u>002</u>	Dec 15, 1989

<u>AB</u>	+		<u>240MG</u>	<u>N019152</u>	<u>001</u>	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>240MG</u>	<u>A078906</u>	<u>001</u>	Sep 17, 2009

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568</u>	<u>002</u>	Oct 10, 1997

<u>AB</u>		<u>180MG</u>	<u>A074330</u>	<u>001</u>	Jan 31, 1994

<u>AB</u>		<u>240MG</u>	<u>A073568</u>	<u>001</u>	Jul 31, 1992

<u>AB</u>	MYLAN	<u>120MG</u>	<u>A074587</u>	<u>002</u>	Feb 21, 1997

<u>AB</u>		<u>180MG</u>	<u>A074587</u>	<u>003</u>	Sep 09, 1997

<u>AB</u>		<u>240MG</u>	<u>A074587</u>	<u>001</u>	Mar 23, 1996

<u>AB</u>	PAR PHARM	<u>120MG</u>	<u>A075072</u>	<u>001</u>	May 25, 1999

<u>AB</u>		<u>240MG</u>	<u>A075072</u>	<u>003</u>	May 25, 1999

COVERA-HS

BC	+	GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996

BC	+		240MG	N020552	002	Feb 26, 1996

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

+	QLT	15MG/VIAL	N021119	001	Apr 12, 2000

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK INC	500MG/PACKET	N022006	001	Aug 21, 2009

TABLET; ORAL

SABRIL

+	LUNDBECK INC	500MG	N020427	001	Aug 21, 2009

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

+	APP PHARMS	1MG/ML	A089515	001	Apr 29, 1987

+	BEDFORD	10MG/VIAL	A089395	001	Apr 09, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 403 (of 409)

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE

<u>AP</u>	APP PHARMS	<u>1MG/ML</u>	<u>A076401</u>	<u>001</u>	Oct 28, 2003

VINCRIStINE SULFATE PFS

<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A071484</u>	<u>001</u>	Apr 19, 1988

<u>AP</u>	TEVA PARENTERAL	<u>1MG/ML</u>	<u>A075493</u>	<u>001</u>	Sep 01, 1999

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

<u>AP</u>	+ PIERRE FABRE	<u>EQ 10MG BASE/ML</u>	<u>N020388</u>	<u>001</u>	Dec 23, 1994

VINORELBINE TARTRATE

<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 10MG BASE/ML</u>	<u>A078011</u>	<u>001</u>	Jul 22, 2009

<u>AP</u>	APP PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A076849</u>	<u>001</u>	Apr 18, 2005

<u>AP</u>	BAXTER HLTHCARE	<u>EQ 10MG BASE/ML</u>	<u>A075992</u>	<u>001</u>	Jun 10, 2003

<u>AP</u>	BEDFORD	<u>EQ 10MG BASE/ML</u>	<u>A076461</u>	<u>001</u>	Dec 11, 2003

<u>AP</u>	EBEWE PHARMA	<u>EQ 10MG BASE/ML</u>	<u>A078408</u>	<u>001</u>	Feb 13, 2008

<u>AP</u>	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A076827</u>	<u>001</u>	Jun 02, 2005

<u>AP</u>	TEVA PARENTERAL	<u>EQ 10MG BASE/ML</u>	<u>A076028</u>	<u>001</u>	Feb 03, 2003

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

	+ HOSPIRA	EQ 50,000 UNITS BASE/ML	N006823	001	

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

	+ PFIZER	200MG/5ML	N021630	001	Dec 19, 2003

INJECTABLE; IV (INFUSION)

	+ PFIZER	200MG/VIAL	N021267	001	May 24, 2002

TABLET; ORAL

VFEND

<u>AB</u>	PFIZER	<u>50MG</u>	<u>N021266</u>	<u>001</u>	May 24, 2002

<u>AB</u>	+	<u>200MG</u>	<u>N021266</u>	<u>002</u>	May 24, 2002

VORICONAZOLE

<u>AB</u>	MATRIX LABS LTD	<u>50MG</u>	<u>A090547</u>	<u>001</u>	Apr 22, 2010

<u>AB</u>		<u>200MG</u>	<u>A090547</u>	<u>002</u>	Apr 22, 2010

VORINOSTAT

CAPSULE; ORAL

ZOLINZA

	+ MERCK	100MG	N021991	001	Oct 06, 2006

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

	+ BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995

TABLET; ORAL

COUMADIN

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>1MG</u>	<u>N009218</u>	<u>022</u>	Mar 01, 1990

<u>AB</u>		<u>2MG</u>	<u>N009218</u>	<u>013</u>	

<u>AB</u>		<u>2.5MG</u>	<u>N009218</u>	<u>018</u>	

<u>AB</u>		<u>3MG</u>	<u>N009218</u>	<u>025</u>	Nov 18, 1996

<u>AB</u>		<u>4MG</u>	<u>N009218</u>	<u>023</u>	Aug 24, 1993

<u>AB</u>		<u>5MG</u>	<u>N009218</u>	<u>007</u>	

<u>AB</u>		<u>6MG</u>	<u>N009218</u>	<u>026</u>	Nov 18, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 404 (of 409)

WARFARIN SODIUM

TABLET; ORAL					
<u>COUMADIN</u>					
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>7.5MG</u>	<u>N009218</u>	<u>016</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N009218</u>	<u>005</u>	
<u>JANTOVEN</u>					
<u>AB</u>	USL PHARMA	<u>1MG</u>	<u>A040416</u>	<u>001</u>	Oct 02, 2003
<u>AB</u>		<u>2MG</u>	<u>A040416</u>	<u>002</u>	Oct 02, 2003
<u>AB</u>		<u>2.5MG</u>	<u>A040416</u>	<u>003</u>	Oct 02, 2003
<u>AB</u>		<u>3MG</u>	<u>A040416</u>	<u>004</u>	Oct 02, 2003
<u>AB</u>		<u>4MG</u>	<u>A040416</u>	<u>005</u>	Oct 02, 2003
<u>AB</u>		<u>5MG</u>	<u>A040416</u>	<u>006</u>	Oct 02, 2003
<u>AB</u>		<u>6MG</u>	<u>A040416</u>	<u>007</u>	Oct 02, 2003
<u>AB</u>		<u>7.5MG</u>	<u>A040416</u>	<u>008</u>	Oct 02, 2003
<u>AB</u>		<u>10MG</u>	<u>A040416</u>	<u>009</u>	Oct 02, 2003
<u>WARFARIN SODIUM</u>					
<u>AB</u>	BARR	<u>1MG</u>	<u>A040145</u>	<u>001</u>	Mar 26, 1997
<u>AB</u>		<u>2MG</u>	<u>A040145</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>		<u>2.5MG</u>	<u>A040145</u>	<u>003</u>	Mar 26, 1997
<u>AB</u>		<u>3MG</u>	<u>A040145</u>	<u>008</u>	Nov 05, 1998
<u>AB</u>		<u>4MG</u>	<u>A040145</u>	<u>004</u>	Mar 26, 1997
<u>AB</u>		<u>5MG</u>	<u>A040145</u>	<u>005</u>	Mar 26, 1997
<u>AB</u>		<u>6MG</u>	<u>A040145</u>	<u>009</u>	Nov 05, 1998
<u>AB</u>		<u>7.5MG</u>	<u>A040145</u>	<u>006</u>	Mar 26, 1997
<u>AB</u>		<u>10MG</u>	<u>A040145</u>	<u>007</u>	Mar 26, 1997
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A040415</u>	<u>001</u>	Sep 27, 2004
<u>AB</u>		<u>2MG</u>	<u>A040415</u>	<u>002</u>	Sep 27, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040415</u>	<u>003</u>	Sep 29, 2004
<u>AB</u>		<u>3MG</u>	<u>A040415</u>	<u>004</u>	Sep 27, 2004
<u>AB</u>		<u>4MG</u>	<u>A040415</u>	<u>005</u>	Sep 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A040415</u>	<u>006</u>	Sep 27, 2004
<u>AB</u>		<u>6MG</u>	<u>A040415</u>	<u>007</u>	Sep 27, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A040415</u>	<u>008</u>	Sep 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A040415</u>	<u>009</u>	Sep 27, 2004
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616</u>	<u>009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616</u>	<u>003</u>	Jul 05, 2006
<u>AB</u>		<u>4MG</u>	<u>A040616</u>	<u>004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616</u>	<u>005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616</u>	<u>006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616</u>	<u>007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616</u>	<u>008</u>	Jul 05, 2006
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301</u>	<u>003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301</u>	<u>004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301</u>	<u>005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301</u>	<u>006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 405 (of 409)

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

XENON XE-133

GAS; INHALATION

XENON XE 133

<u>AA</u>	LANTHEUS MEDCL	<u>20mCi/VIAL</u>	<u>N017284</u>	<u>002</u>	
	XENON XE 133				
	LANTHEUS MEDCL	10mCi/VIAL	N017284	001	

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	ASTRAZENECA	<u>10MG</u>	<u>N020547</u>	<u>003</u>	Sep 17, 1999
<u>AB</u>	+	<u>20MG</u>	<u>N020547</u>	<u>001</u>	Sep 26, 1996

ZAFIRLUKAST

<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372</u>	<u>001</u>	Nov 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090372</u>	<u>002</u>	Nov 18, 2010

ZALEPLON

CAPSULE; ORAL

SONATA

<u>AB</u>	KING PHARMS	<u>5MG</u>	<u>N020859</u>	<u>001</u>	Aug 13, 1999
<u>AB</u>	+	<u>10MG</u>	<u>N020859</u>	<u>002</u>	Aug 13, 1999

ZALEPLON

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078829</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078829</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077505</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A077505</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077238</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077238</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A090374</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		<u>10MG</u>	<u>A090374</u>	<u>002</u>	Sep 17, 2009
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077237</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077237</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077239</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077239</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A078989</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078989</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UPSHER SMITH	<u>5MG</u>	<u>A078706</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078706</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	WEST WARD	<u>5MG</u>	<u>A078147</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>10MG</u>	<u>A078147</u>	<u>002</u>	Nov 25, 2008

ZANAMIVIR

POWDER; INHALATION

RELENZA

	+ GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

	+ AZUR PHARMA II	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004
	+	500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004
	+	500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 406 (of 409)

ZIDOVUDINE

CAPSULE; ORAL				
<u>RETROVIR</u>				
<u>AB</u>	+ VIIIV HLHCARE	<u>100MG</u>	<u>N019655</u>	<u>001</u> Mar 19, 1987
<u>ZIDOVUDINE</u>				
<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A078128</u>	<u>001</u> Mar 27, 2006
<u>AB</u>	CIPLA LTD	<u>100MG</u>	<u>A078349</u>	<u>001</u> May 23, 2007
INJECTABLE; INJECTION				
<u>RETROVIR</u>				
<u>AP</u>	+ VIIIV HLHCARE	<u>10MG/ML</u>	<u>N019951</u>	<u>001</u> Feb 02, 1990
<u>ZIDOVUDINE</u>				
<u>AP</u>	PHARMAFORCE	<u>10MG/ML</u>	<u>A091457</u>	<u>001</u> May 06, 2010
SYRUP; ORAL				
<u>RETROVIR</u>				
<u>AA</u>	+ VIIIV HLHCARE	<u>50MG/5ML</u>	<u>N019910</u>	<u>001</u> Sep 28, 1989
<u>ZIDOVUDINE</u>				
<u>AA</u>	AUROBINDO	<u>50MG/5ML</u>	<u>A077268</u>	<u>001</u> Sep 19, 2005
<u>AA</u>	CIPLA LTD	<u>50MG/5ML</u>	<u>A077981</u>	<u>001</u> Jun 26, 2008
TABLET; ORAL				
<u>RETROVIR</u>				
<u>AB</u>	+ VIIIV HLHCARE	<u>300MG</u>	<u>N020518</u>	<u>002</u> Oct 04, 1996
<u>ZIDOVUDINE</u>				
<u>AB</u>	AUROBINDO	<u>300MG</u>	<u>A077267</u>	<u>001</u> Sep 19, 2005
<u>AB</u>	CIPLA	<u>300MG</u>	<u>A090561</u>	<u>001</u> Oct 27, 2010
<u>AB</u>	HETERO DRUGS LTD	<u>300MG</u>	<u>A090092</u>	<u>001</u> Apr 25, 2008
<u>AB</u>	MATRIX LABS LTD	<u>300MG</u>	<u>A078922</u>	<u>001</u> Feb 14, 2008
<u>AB</u>	RANBAXY	<u>300MG</u>	<u>A077327</u>	<u>001</u> Sep 19, 2005
<u>AB</u>	ROXANE	<u>300MG</u>	<u>A076844</u>	<u>001</u> Sep 19, 2005

ZILEUTON

TABLET; ORAL				
ZYFLO				
	+ CORNERSTONE THERAP	600MG	N020471	003 Dec 09, 1996
TABLET, EXTENDED RELEASE; ORAL				
ZYFLO CR				
	+ CORNERSTONE THERAP	600MG	N022052	001 May 30, 2007

ZINC ACETATE

CAPSULE; ORAL				
GALZIN				
	TEVA	EQ 25MG ZINC	N020458	001 Jan 28, 1997
	+	EQ 50MG ZINC	N020458	002 Jan 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION				
ZINC CHLORIDE IN PLASTIC CONTAINER				
	+ HOSPIRA	EQ 1MG ZINC/ML	N018959	001 Jun 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL				
GEODON				
	+ PFIZER	EQ 20MG BASE	N020825	001 Feb 05, 2001
		EQ 40MG BASE	N020825	002 Feb 05, 2001
		EQ 60MG BASE	N020825	003 Feb 05, 2001
		EQ 80MG BASE	N020825	004 Feb 05, 2001
SUSPENSION; ORAL				
GEODON				
	+ PFIZER INC	EQ 10MG BASE/ML	N021483	001 Mar 29, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 407 (of 409)

ZIPRASIDONE MESYLATEINJECTABLE; INTRAMUSCULAR
GEODON

+	PFIZER	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007

ZOMETA

+	NOVARTIS	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003

ZOLMITRIPTANSPRAY; NASAL
ZOMIG

+	ASTRAZENECA	5MG/SPRAY	N021450	004	Sep 30, 2003

TABLET; ORAL
ZOMIG

IPR 2.5MG

N020768 001 Nov 25, 1997

+		5MG	N020768	002	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
ZOMIG-ZMT

ASTRAZENECA 2.5MG

N021231 001 Feb 13, 2001

+		5MG	N021231	002	Sep 17, 2001

ZOLPIDEM TARTRATESPRAY, METERED; ORAL
ZOLPIMIST

+	NOVADEL	5MG/SPRAY	N022196	001	Dec 19, 2008

TABLET; ORAL

AMBIEN

<u>AB</u>	SANOFI AVENTIS US	<u>5MG</u>	<u>N019908</u>	<u>001</u>	Dec 16, 1992

<u>AB</u>	+	<u>10MG</u>	<u>N019908</u>	<u>002</u>	Dec 16, 1992

ZOLPIDEM TARTRATE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077884</u>	<u>001</u>	Apr 23, 2007

<u>AB</u>		<u>10MG</u>	<u>A077884</u>	<u>002</u>	Apr 23, 2007

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078413</u>	<u>001</u>	May 04, 2007

<u>AB</u>		<u>10MG</u>	<u>A078413</u>	<u>002</u>	May 04, 2007

<u>AB</u>	CARACO	<u>5MG</u>	<u>A077359</u>	<u>001</u>	Apr 23, 2007

<u>AB</u>		<u>10MG</u>	<u>A077359</u>	<u>002</u>	Apr 23, 2007

<u>AB</u>	CARLSBAD	<u>5MG</u>	<u>A077990</u>	<u>001</u>	Apr 23, 2007

<u>AB</u>		<u>10MG</u>	<u>A077990</u>	<u>002</u>	Apr 23, 2007

<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A077985</u>	<u>001</u>	Apr 23, 2007

<u>AB</u>		<u>10MG</u>	<u>A077985</u>	<u>002</u>	Apr 23, 2007

<u>AB</u>	GENPHARM	<u>5MG</u>	<u>A078016</u>	<u>001</u>	Apr 23, 2007

<u>AB</u>		<u>10MG</u>	<u>A078016</u>	<u>002</u>	Apr 23, 2007

<u>AB</u>	HIKMA	<u>5MG</u>	<u>A078129</u>	<u>001</u>	Apr 30, 2008

<u>AB</u>		<u>10MG</u>	<u>A078129</u>	<u>002</u>	Apr 30, 2008

<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A078184</u>	<u>001</u>	Sep 07, 2007

<u>AB</u>		<u>10MG</u>	<u>A078184</u>	<u>002</u>	Sep 07, 2007

<u>AB</u>	LEK PHARMS DD	<u>5MG</u>	<u>A077322</u>	<u>001</u>	Apr 23, 2007

<u>AB</u>		<u>10MG</u>	<u>A077322</u>	<u>002</u>	Apr 23, 2007

<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076578</u>	<u>001</u>	Apr 23, 2007

<u>AB</u>		<u>10MG</u>	<u>A076578</u>	<u>002</u>	Apr 23, 2007

<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A078055</u>	<u>001</u>	Apr 23, 2007

<u>AB</u>		<u>10MG</u>	<u>A078055</u>	<u>002</u>	Apr 23, 2007

<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077214</u>	<u>001</u>	Apr 23, 2007

<u>AB</u>		<u>10MG</u>	<u>A077214</u>	<u>002</u>	Apr 23, 2007

<u>AB</u>	TEVA	<u>5MG</u>	<u>A076410</u>	<u>001</u>	Apr 23, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 408 (of 409)

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

<u>AB</u>	TEVA	<u>10MG</u>	<u>A076410</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A077903</u>	<u>001</u>	Aug 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A077903</u>	<u>002</u>	Aug 17, 2007
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A078616</u>	<u>001</u>	Nov 21, 2008
<u>AB</u>		<u>10MG</u>	<u>A078616</u>	<u>002</u>	Nov 21, 2008
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A077773</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077773</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A078426</u>	<u>001</u>	May 15, 2007
<u>AB</u>		<u>10MG</u>	<u>A078426</u>	<u>002</u>	May 15, 2007

TABLET; SUBLINGUAL
EDLUAR

	MEDA PHARMS	5MG	N021997	001	Mar 13, 2009
+		10MG	N021997	002	Mar 13, 2009

TABLET, EXTENDED RELEASE; ORAL

AMBIEN CR

<u>AB</u>	SANOFI AVENTIS US	<u>6.25MG</u>	<u>N021774</u>	<u>002</u>	Sep 02, 2005
<u>AB</u>	+	<u>12.5MG</u>	<u>N021774</u>	<u>001</u>	Sep 02, 2005
	<u>ZOLPIDEM TARTRATE</u>				
<u>AB</u>	ACTAVIS SOUTH	<u>6.25MG</u>	<u>A078179</u>	<u>002</u>	Oct 13, 2010
<u>AB</u>	ANCHEN PHARMS	<u>12.5MG</u>	<u>A078148</u>	<u>001</u>	Dec 03, 2010

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

<u>AB</u>	EISAI INC	<u>25MG</u>	<u>N020789</u>	<u>003</u>	Aug 22, 2003
<u>AB</u>		<u>50MG</u>	<u>N020789</u>	<u>002</u>	Aug 22, 2003
<u>AB</u>	+	<u>100MG</u>	<u>N020789</u>	<u>001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>	ALPHAPHARM	<u>25MG</u>	<u>A077647</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077647</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077647</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077642</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077642</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077642</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	BANNER PHARMACAPS	<u>25MG</u>	<u>A077813</u>	<u>001</u>	Aug 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077813</u>	<u>002</u>	Aug 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077813</u>	<u>003</u>	Aug 16, 2006
<u>AB</u>	BARR	<u>25MG</u>	<u>A077639</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077639</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077639</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	COREPHARMA	<u>25MG</u>	<u>A077876</u>	<u>001</u>	Feb 21, 2007
<u>AB</u>		<u>50MG</u>	<u>A077876</u>	<u>002</u>	Feb 21, 2007
<u>AB</u>		<u>100MG</u>	<u>A077876</u>	<u>003</u>	Feb 21, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A077645</u>	<u>002</u>	Sep 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A077645</u>	<u>003</u>	Sep 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A077645</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077651</u>	<u>001</u>	Jan 30, 2006
<u>AB</u>		<u>50MG</u>	<u>A077651</u>	<u>002</u>	Jan 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A077651</u>	<u>003</u>	Jan 30, 2006
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A077869</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A077869</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869</u>	<u>003</u>	May 31, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077637</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077637</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077637</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077644</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077644</u>	<u>002</u>	Dec 22, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 409 (of 409)

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A077644</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		<u>50MG</u>	<u>A077634</u>	<u>002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634</u>	<u>003</u>	Mar 17, 2006
<u>AB</u>	WOCKHARDT	<u>25MG</u>	<u>A077636</u>	<u>003</u>	Jul 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077636</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077636</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625</u>	<u>001</u>	Oct 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077625</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077625</u>	<u>003</u>	Oct 16, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 1 (of 18)

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS

120MG

N018060 001

325MG

A072344 001

Mar 27, 1992

325MG

N018060 003

Dec 18, 1986

650MG

A072237 001

Mar 27, 1992

650MG

N018060 002

ACETAMINOPHEN

ACTAVIS MID ATLANTIC

120MG

N018337 003

Sep 12, 1983

325MG

N018337 002

+

650MG

N018337 001

PERRIGO NEW YORK

120MG

A070607 001

Apr 06, 1987

650MG

A070608 001

Dec 01, 1986

INFANTS' FEVERALL

ACTAVIS MID ATLANTIC

80MG

N018337 004

Aug 26, 1992

NEOPAP

POLYMEDICA

120MG

N016401 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS

650MG

A076200 001

Mar 19, 2002

PERRIGO

650MG

A075077 001

Feb 25, 2000

RANBAXY

650MG

A090205 001

Nov 18, 2009

TYLENOL (CAPLET)

+

MCNEIL CONS

650MG

N019872 001

Jun 08, 1994

TYLENOL (GELTAB)

+

MCNEIL CONS

650MG

N019872 002

Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO

250MG;250MG;65MG

A075794 001

Nov 26, 2001

EXCEDRIN (MIGRAINE)

+

NOVARTIS

250MG;250MG;65MG

N020802 001

Jan 14, 1998

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE

+

NOVARTIS

500MG;EQ 0.25MG BASE;30MG

N021082 001

Mar 01, 2001

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS

+

SCHERING PLOUGH

500MG;3MG;60MG

N019453 001

May 22, 1987

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+

3M

61%;1%

N021074 001

Jun 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT

GUARDIAN DRUG

80MG;20MG

A071793 001

Sep 04, 1987

GAVISCON

SANOFI AVENTIS US

80MG;20MG

N018685 001

Dec 09, 1983

+

160MG;40MG

N018685 002

Dec 09, 1983

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+

LOREAL USA

2%;2%;10%

N021502 001

Jul 21, 2006

CAPITAL SOLEIL 15

+

LOREAL USA

2%;3%;10%

N021501 001

Oct 02, 2006

OTC DRUG PRODUCT LIST

4 - 2 (of 18)

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL					
ANTHELIOS 20					
+ LOREAL USA	2%;2%;10%;2%		N021471	001	Oct 05, 2006
ANTHELIOS 40					
+ LOREAL USA	2%;3%;10%;5%		N022009	001	Mar 31, 2008
+	2%;3%;10%;5%		N022009	002	Oct 29, 2009

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL					
SHADE UVAGUARD					
+ SCHERING PLOUGH	3%;7.5%;3%		N020045	001	Dec 07, 1992

BENTOQUATAM

LOTION; TOPICAL					
IVY BLOCK					
+ STAND HOMEOPATH	5%		N020532	001	Aug 26, 1996

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL					
LOTRIMIN ULTRA					
+ SCHERING PLOUGH	1%		N021307	001	Dec 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL					
FEMSTAT 3					
+ BAYER	2%		N020421	001	Dec 21, 1995

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL					
CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE					
PERRIGO R AND D	800MG;10MG;165MG		A077355	001	Feb 06, 2008
PEPCID COMPLETE					
+ MERCK SHARP DOHME	800MG;10MG;165MG		N020958	001	Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
BANNER PHARMACAPS	5MG		N022429	001	Jul 23, 2009
+	10MG		N022429	004	Jul 23, 2009
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
BANNER PHARMACAPS	5MG		N022429	003	Jul 23, 2009
+	10MG		N022429	002	Jul 23, 2009
SYRUP; ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
ACTAVIS MID ATLANTIC	5MG/5ML		A090378	002	May 09, 2008
AMNEAL PHARMS	5MG/5ML		A090765	002	Oct 07, 2009
APOTEX	5MG/5ML		A090188	002	Apr 22, 2008
AUROBINDO PHARMA	5MG/5ML		A090750	002	Feb 02, 2010
CYPRESS PHARM	5MG/5ML		A090300	001	Oct 10, 2008
DR REDDYS LABS LTD	5MG/5ML		A090474	002	Mar 30, 2009
PERRIGO R AND D	5MG/5ML		A090254	002	Apr 09, 2008
RANBAXY	5MG/5ML		A090183	002	Apr 24, 2008
TARO	5MG/5ML		A090182	002	Apr 22, 2008
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
ACTAVIS MID ATLANTIC	5MG/5ML		A090378	001	May 09, 2008
AMNEAL PHARMS	5MG/5ML		A090765	001	Oct 07, 2009
APOTEX	5MG/5ML		A090188	001	Apr 22, 2008
AUROBINDO PHARMA	5MG/5ML		A090750	001	Feb 02, 2010
CYPRESS PHARM	5MG/5ML		A090300	002	Oct 10, 2008
DR REDDYS LABS LTD	5MG/5ML		A090474	001	Mar 30, 2009
PERRIGO R AND D	5MG/5ML		A090254	001	Apr 09, 2008
RANBAXY	5MG/5ML		A090183	001	Apr 24, 2008
TARO	5MG/5ML		A090182	001	Apr 22, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 3 (of 18)

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S ZYRTEC ALLERGY

+ MCNEIL CONSUMER 5MG/5ML N022155 002 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ MCNEIL CONSUMER 5MG/5ML N022155 001 Nov 16, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

CARACO 5MG A077631 004 Jan 11, 2008

10MG A077631 003 Jan 11, 2008

SANDOZ 5MG A078692 001 Feb 14, 2008

10MG A078692 002 Feb 14, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

CARACO 5MG A077631 001 Jan 11, 2008

10MG A077631 002 Jan 11, 2008

CHILDREN'S ZYRTEC ALLERGY

PFIZER 5MG N021621 003 Nov 16, 2007

+ 10MG N021621 004 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

PFIZER 5MG N021621 005 Nov 16, 2007

+ 10MG N021621 006 Nov 16, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

ZYRTEC ALLERGY

+ MCNEIL CONSUMER 10MG N022578 001 Sep 03, 2010

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH 5MG A078615 003 Dec 28, 2007

10MG A078615 004 Dec 28, 2007

AMNEAL PHARMS NY 5MG A078780 001 Jan 21, 2010

10MG A078780 004 Jan 21, 2010

APOTEX INC 5MG A078317 001 Dec 27, 2007

10MG A078317 002 Dec 27, 2007

CADISTA PHARMS 5MG A078933 001 Jun 15, 2010

10MG A078933 002 Jun 15, 2010

CARACO 5MG A077499 001 Dec 27, 2007

10MG A077499 002 Dec 27, 2007

CONTRACT PHARMA 5MG A076047 001 Dec 27, 2007

10MG A076047 002 Dec 27, 2007

DR REDDYS LABS LTD 5MG A078343 004 Jan 15, 2008

10MG A078343 003 Jan 15, 2008

MYLAN 5MG A076677 001 Dec 27, 2007

10MG A076677 002 Dec 27, 2007

ORCHID HLTHCARE 5MG A078862 001 Feb 19, 2009

10MG A078862 002 Feb 19, 2009

PERRIGO R AND D 5MG A078336 001 Dec 27, 2007

10MG A078336 002 Dec 27, 2007

RANBAXY 5MG A077498 001 Dec 27, 2007

10MG A077498 002 Dec 27, 2007

SANDOZ 5MG A077946 001 Dec 27, 2007

10MG A077946 002 Dec 27, 2007

TARO 5MG A078072 001 Jul 22, 2009

5MG A078072 003 Jul 22, 2009

TORRENT PHARMS LLC 5MG A079191 001 Apr 15, 2010

10MG A079191 004 Apr 15, 2010

UNICHEM 5MG A078680 003 Jun 26, 2009

10MG A078680 004 Jun 26, 2009

UNIQUE PHARM LABS 5MG A077829 001 Aug 26, 2009

10MG A077829 004 Aug 26, 2009

WOCKHARDT 5MG A078427 003 Dec 28, 2007

10MG A078427 004 Dec 28, 2007

CETIRIZINE HYDROCHLORIDE HIVES

CADISTA PHARMS 5MG A078933 003 Jun 15, 2010

10MG A078933 004 Jun 15, 2010

CARACO 5MG A077499 003 Dec 27, 2007

10MG A077499 004 Dec 27, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 4 (of 18)

CETIRIZINE HYDROCHLORIDE

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
RANBAXY	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010
ZYRTEC ALLERGY				
MCNEIL CONSUMER	5MG	N019835	003	Nov 16, 2007
+	10MG	N019835	004	Nov 16, 2007
ZYRTEC HIVES RELIEF				
MCNEIL CONSUMER	5MG	N019835	005	Nov 16, 2007
+	10MG	N019835	006	Nov 16, 2007

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
SANDOZ	5MG;120MG	A077991	001	Mar 05, 2008
ZYRTEC-D 12 HOUR				
+ MCNEIL	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED; TOPICAL

EXIDINE

+	XTTRIUM	4%	N019127	001	Dec 24, 1984

CLOTH; TOPICAL

CHLORHEXIDINE GLUCONATE

+	SAGE PRODS	2%	N021669	001	Apr 25, 2005

SOLUTION; TOPICAL

BRIAN CARE

	SOAPCO	4%	A071419	001	Dec 17, 1987

CHG SCRUB

	ECOLAB	4%	N019258	002	Jul 22, 1986

CIDA-STAT

	ECOLAB	2%	N019258	001	Jul 22, 1986

DYNA-HEX

	XTTRIUM	0.75%	N020111	001	Sep 11, 1997

EXIDINE

+	XTTRIUM	2%	N019422	001	Dec 17, 1985

		4%	N019125	001	Dec 24, 1984

HIBICLENS

+	REGENT	4%	N017768	001	

HIBISTAT

+	REGENT	0.5%	N018300	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 5 (of 18)

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

BIOSCRUB

GRIFFEN 4%

N019822 001 Mar 31, 1989

CHLORHEXIDINE GLUCONATE

BECTON DICKINSON 4%

A072525 001 Oct 24, 1989

PHARMASEAL SCRUB CARE

+ PHARMASEAL 4%

N019793 001 Dec 02, 1988

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+ CAREFUSION 2%;70% (3ML)

N020832 001 Jul 14, 2000

+ 2%;70% (10.5ML)

N020832 004 Aug 20, 2003

+ 2%;70% (26ML)

N020832 006 Nov 21, 2006

CHLORAPREP ONE-STEP FREPP

+ CAREFUSION 2%;70% (1.5ML)

N020832 003 Apr 26, 2002

CHLORAPREP WITH TINT

+ CAREFUSION 2%;70% (26ML)

N020832 002 May 03, 2005

+ 2%;70% (10.5ML)

N020832 005 Apr 03, 2006

+ 2%;70% (3ML)

N020832 007 Oct 10, 2006

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CAREFUSION 2%;70% (0.67ML)

N021555 001 Oct 07, 2002

CHLORAPREP SINGLE SWABSTICK

+ CAREFUSION 2%;70% (1.75ML)

N021555 002 May 10, 2005

CHLORASCUB MAXI SWABSTICK

+ SOLUMED 3.15%;70% (5.1ML)

N021524 003 Jun 03, 2005

CHLORASCUB SWAB

+ SOLUMED 3.15%;70% (1ML)

N021524 001 Jun 03, 2005

CHLORASCUB SWABSTICK

+ SOLUMED 3.15%;70% (1.6ML)

N021524 002 Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

AVANTHI INC 12MG

A040829 001 May 13, 2009

CHLOR-TRIMETON

+ SCHERING PLOUGH 12MG

N007638 002

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ WYETH CONS 1MG/5ML;100MG/5ML;15MG/5ML

N021587 001 Feb 24, 2004

TABLET; ORAL

ADVIL ALLERGY SINUS

+ WYETH CONS 2MG;200MG;30MG

N021441 001 Dec 19, 2002

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

+ SCHERING PLOUGH 8MG;120MG

N018397 001

CIMETIDINE

TABLET; ORAL

CIMETIDINE

CONTRACT PHARMACAL 200MG

A074961 001 Jun 19, 1998

200MG

A074963 001 Jun 19, 1998

IVAX SUB TEVA PHARMS 200MG

A075345 001 Jun 16, 1999

PERRIGO 200MG

A075285 001 Oct 29, 1998

WATSON LABS 200MG

A075425 001 Jul 29, 1999

TAGAMET HB

+ GLAXOSMITHKLINE 200MG

N020238 002 Aug 21, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 6 (of 18)

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

PERRIGO	1.34MG	A074512	001	Nov 22, 1995
SANDOZ	1.34MG	A073458	001	Oct 31, 1993
TAVIST-1				
+ NOVARTIS	1.34MG	N020925	001	Aug 21, 1992

CLOTRIMAZOLE

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTTRIMIN 3 COMBINATION PACK

+ SCHERING PLOUGH	1%,200MG	N020526	002	Jul 29, 1996

GYNE-LOTTRIMIN COMBINATION PACK

+ SCHERING PLOUGH	1%,100MG	N020289	002	Apr 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER PHARMS	1%,100MG	N020389	002	Jun 23, 1994

CREAM; VAGINAL

CLOTRIMAZOLE

ACTAVIS MID ATLANTIC	1%	A074165	001	Jul 16, 1993

TARO	1%	A072641	001	Dec 04, 1995

GYNE-LOTTRIMIN

+ SCHERING PLOUGH	1%	N018052	002	Nov 30, 1990

GYNE-LOTTRIMIN 3

+ SCHERING PLOUGH	2%	N020574	001	Nov 24, 1998

MYCELEX-7

BAYER PHARMS	1%	N018230	002	Dec 26, 1991

TRIVAGIZOLE 3

TARO	2%	N021143	001	Apr 12, 2000

TABLET; VAGINAL

GYNE-LOTTRIMIN

+ SCHERING PLOUGH	100MG	N017717	002	Nov 30, 1990

GYNE-LOTTRIMIN 3

+ SCHERING PLOUGH	200MG	N020525	001	Jul 29, 1996

MYCELEX-7

BAYER PHARMS	100MG	N018182	002	Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001

+ BAUSCH AND LOMB	5.2MG/SPRAY	A075702	001	Jul 03, 2001

PERRIGO

QPHARMA	5.2MG/SPRAY	A075427	001	Dec 12, 2001

5.2MG/SPRAY

		A077976	001	Sep 07, 2007

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DISOPHROL

SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982

DRIXORAL

+ SCHERING PLOUGH	6MG;120MG	N013483	003	Sep 13, 1982

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

RECKITT BENCKISER	30MG;600MG	N021620	002	Apr 29, 2004

+	60MG;1.2GM	N021620	001	Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+ RECKITT BENCKISER	EQ 30MG HBR/5ML	N018658	001	Oct 08, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 7 (of 18)

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL

ADVIL PM

+	WYETH CONS	38MG;200MG	N021394	001	Dec 21, 2005
	IBUPROFEN AND DIPHENHYDRAMINE CITRATE				
	DR REDDYS LABS LTD	38MG;200MG	A090619	001	Jul 08, 2009
	PERRIGO R AND D	38MG;200MG	A079113	001	Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

ADVIL PM

+	WYETH CONS	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005
	IBUPROFEN AND DIPHENHYDRAMINE				
	BANNER PHARMACAPS	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010

DOCOSANOL

CREAM; TOPICAL

ABREVA

+	GLAXOSMITHKLINE	10%	N020941	001	Jul 25, 2000

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

	LNK	25MG	A040564	001	Aug 27, 2004
	PERRIGO	25MG	A040167	001	Sep 18, 1996
	UNISOM				
+	CHATTEM	25MG	N018066	001	

EPINEPHRINE

AEROSOL, METERED; INHALATION

EPINEPHRINE

	ARMSTRONG PHARMS	0.2MG/INH	A087907	001	May 23, 1984

FAMOTIDINE

TABLET, CHEWABLE; ORAL

FAMOTIDINE

	PERRIGO	10MG	A075715	001	Aug 22, 2003
	PEPCID AC				
+	MERCK SHARP DOHME	20MG	N020801	002	Dec 17, 2007

TABLET; ORAL

FAMOTIDINE

	DR REDDYS LABS LTD	10MG	A075758	001	Aug 17, 2001
		20MG	A077367	001	Sep 25, 2006
	GENPHARM	10MG	A075674	001	Dec 21, 2001
	IVAX SUB TEVA PHARMS	10MG	A075512	001	Jul 26, 2001
	PERRIGO	10MG	A075400	001	Mar 18, 2005
		20MG	A077351	001	Sep 25, 2006
	RANBAXY	10MG	A090283	001	Nov 17, 2009
		20MG	A090283	002	Nov 17, 2009
	SANDOZ	10MG	A076101	001	Oct 21, 2002
	TEVA	10MG	A075312	001	May 31, 2001
	WATSON LABS	10MG	A075404	001	Nov 28, 2001
	WOCKHARDT	10MG	A077146	001	Mar 07, 2005
		20MG	A090837	001	Aug 04, 2010
	PEPCID AC				
	MERCK SHARP DOHME	10MG	N020325	001	Apr 28, 1995
+		20MG	N020325	002	Sep 23, 2003
	PEPCID AC (GELTAB)				
	MERCK SHARP DOHME	10MG	N020902	001	Aug 05, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 8 (of 18)

GUAIFENESINTABLET, EXTENDED RELEASE; ORAL
MUCINEX

RECKITT BENCKISER	600MG	N021282	001	Jul 12, 2002
+	1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
MUCINEX D

RECKITT BENCKISER	600MG;60MG	N021585	001	Jun 22, 2004
+	1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN

CAPSULE; ORAL

ADVIL LIQUI-GELS

+ WYETH CONS	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+ WYETH CONS	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000

IBUPROFEN

BANNER PHARMACAPS	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009

+ CONTRACT PHARMACAL	200MG	A074782	001	Jul 06, 1998

DR REDDYS LABS LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009

MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009

MIDOL LIQUID GELS

+ BANNER PHARMACAPS	200MG	N021472	001	Oct 18, 2002

SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN

+ MCNEIL CONS	40MG/ML	N020603	001	Jun 10, 1996

IBUPROFEN

PERRIGO	40MG/ML	A075217	001	Dec 16, 1998

TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009

PEDIATRIC ADVIL

+ WYETH CONS	100MG/2.5ML	N020812	001	Jan 30, 1998

SUSPENSION; ORAL

CHILDREN'S ADVIL

WYETH CONS	100MG/5ML	N020589	001	Jun 27, 1996

CHILDREN'S ADVIL-FLAVORED

WYETH CONS	100MG/5ML	N020589	002	Nov 07, 1997

CHILDREN'S ELIXSURE

ALTERNA TCHP LLC	100MG/5ML	N021604	001	Jan 07, 2004

CHILDREN'S IBUPROFEN

PERRIGO	100MG/5ML	A074937	001	Dec 22, 1998

CHILDREN'S MOTRIN

+ MCNEIL	100MG/5ML	N020516	001	Jun 16, 1995

IBUPROFEN

ACTAVIS MID ATLANTIC	100MG/5ML	A074916	001	Apr 30, 1999

TABLET, CHEWABLE; ORAL

CHILDREN'S ADVIL

WYETH CONS	50MG	N020944	001	Dec 18, 1998

CHILDREN'S MOTRIN

MCNEIL CONS	50MG	N020601	001	Nov 15, 1996

IBUPROFEN

PERRIGO	50MG	A076359	001	Jan 16, 2004

	100MG	A076359	002	Jan 16, 2004

JUNIOR STRENGTH ADVIL

WYETH CONS	100MG	N020944	002	Dec 18, 1998

JUNIOR STRENGTH MOTRIN

+ MCNEIL CONS	100MG	N020601	003	Nov 15, 1996

TABLET; ORAL

ADVIL

WYETH CONS	200MG	N018989	001	May 18, 1984

IBUPROFEN

ADVENT PHARMS	200MG	A076460	001	Nov 26, 2003

AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987

	200MG	A072199	001	May 23, 1988

OTC DRUG PRODUCT LIST

4 - 9 (of 18)

IBUPROFEN

TABLET; ORAL

IBUPROFEN

CONTRACT PHARMACAL	200MG	A071732	001	Sep 10, 1987
	200MG	A071735	001	Sep 10, 1987
	200MG	A072299	001	Jul 01, 1988
	200MG	A073691	001	Feb 25, 1994
	200MG	A074931	001	Jul 20, 1998
DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
DR REDDYS LABS INC	100MG	A076117	001	Nov 20, 2001
GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
LNK	100MG	A076741	001	Jun 17, 2004
	200MG	A075010	001	Mar 01, 1999
	200MG	A075139	001	Mar 01, 1999
MCNEIL	200MG	A073019	001	Mar 30, 1994
OHM	200MG	A071163	001	Jul 15, 1986
PAR PHARM	200MG	A070481	001	Sep 24, 1986
	200MG	A070985	001	Oct 02, 1987
PERRIGO	200MG	A072096	001	Dec 08, 1987
	200MG	A075995	001	Mar 14, 2002
PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
	200MG	A071639	001	Feb 02, 1988
WATSON LABS	200MG	A070435	001	Mar 05, 1986
IBUPROHM				
OHM LABS	200MG	A071214	001	Dec 01, 1986
IBU-TAB 200				
ALRA	200MG	A071057	001	Aug 11, 1988
JUNIOR STRENGTH ADVIL				
WYETH CONS	100MG	N020267	002	Dec 13, 1996
JUNIOR STRENGTH IBUPROFEN				
PERRIGO	100MG	A075367	001	Apr 22, 1999
JUNIOR STRENGTH MOTRIN				
MCNEIL CONS	100MG	N020602	001	Jun 10, 1996
MOTRIN IB				
+ MCNEIL	200MG	N019012	003	Dec 17, 1990
MOTRIN MIGRAINE PAIN				
+ MCNEIL	200MG	N019012	004	Feb 25, 2000
PROFEN				
CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986
TAB-PROFEN				
PERRIGO	200MG	A072095	001	Dec 08, 1987

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL CONGESTION RELIEF

+ WYETH CONS	200MG;10MG	N022565	001	May 27, 2010

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+ WYETH CONS	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374	001	May 30, 2002

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD

WYETH CONS	100MG/5ML;15MG/5ML	N021373	001	Apr 18, 2002

CHILDREN'S MOTRIN COLD

+ MCNEIL CONS	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO	100MG/5ML;15MG/5ML	A076478	001	Nov 05, 2003

TABLET; ORAL

ADVIL COLD AND SINUS

+ WYETH CONS	200MG;30MG	N019771	001	Sep 19, 1989

OTC DRUG PRODUCT LIST

4 - 10 (of 18)

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL	200MG;30MG	A075588	001	Apr 08, 2002
DR REDDYS LABS LTD	200MG;30MG	A077628	001	Aug 14, 2006
IBUPROHM COLD AND SINUS				
OHM LABS	200MG;30MG	A074567	001	Apr 17, 2001
SINE-AID IB				
MCNEIL CONS	200MG;30MG	N019899	001	Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY	100 UNITS/ML	N018780	001	Oct 28, 1982
HUMULIN R PEN				
+ LILLY	100 UNITS/ML	N018780	005	Aug 06, 1998
NOVOLIN R				
+ NOVO NORDISK INC	100 UNITS/ML	N019938	001	Jun 25, 1991

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 70/30

+ LILLY	30 UNITS/ML;70 UNITS/ML	N019717	001	Apr 25, 1989
HUMULIN 70/30 PEN				
+ LILLY	30 UNITS/ML;70 UNITS/ML	N019717	002	Aug 06, 1998
NOVOLIN 70/30				
+ NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019991	001	Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N

+ LILLY	100 UNITS/ML	N018781	001	Oct 28, 1982
NOVOLIN N				
NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

+ 3M	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006
+	EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+ MCNEIL CONS	1%	N020310	001	Oct 10, 1997

KETOPROFEN

FILM; ORAL

NEXCEDE

+ NOVARTIS	12.5MG	N022470	001	Nov 25, 2009

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+ BAUSCH AND LOMB	EQ 0.025% BASE	N021996	001	Dec 01, 2006
KETOTIFEN FUMARATE				
AKORN	EQ 0.025% BASE	A077958	001	Jul 26, 2007
ALCON	EQ 0.025% BASE	A077200	001	Sep 02, 2008
APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006
ZADITOR				
+ NOVARTIS	EQ 0.025% BASE	N021066	002	Oct 19, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 11 (of 18)

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PREVACID 24 HR

+	NOVARTIS	15MG	N022327	001	May 18, 2009

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

PERRIGO R AND D 0.75MG

A090740 001 Dec 30, 2010

+	WATSON LABS	0.75MG	A078665	001	Aug 28, 2009

PLAN B

+	DURAMED	0.75MG	N021045	002	Aug 24, 2006

PLAN B ONE-STEP

+	DURAMED	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER PHARMACAPS 1MG

N021855 001 Aug 04, 2005

+		2MG	N021855	002	Aug 04, 2005

SOLUTION; ORAL

IMODIUM A-D

+	MCNEIL CONS	1MG/5ML	N019487	001	Mar 01, 1988

LOPERAMIDE HYDROCHLORIDE

HI TECH PHARMA 1MG/5ML

A074352 001 Nov 17, 1995

PERRIGO 1MG/5ML

A073243 001 Jan 21, 1992

ROXANE 1MG/5ML

A073079 001 Apr 30, 1992

WOCKHARDT 1MG/5ML

A074730 001 Aug 28, 1997

SUSPENSION; ORAL

IMODIUM A-D

+	MCNEIL CONS	1MG/7.5ML	N019487	002	Jul 08, 2004

TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+	MCNEIL	2MG	N020448	001	Jul 24, 1997

TABLET; ORAL

IMODIUM A-D

+	MCNEIL CONS	2MG	N019860	001	Nov 22, 1989

LOPERAMIDE HYDROCHLORIDE

CONTRACT PHARMACAL 2MG

A073254 001 Jul 30, 1993

LNK 2MG

A076497 001 Jun 10, 2003

OHM LABS 2MG

A074091 001 Dec 10, 1992

PERRIGO 2MG

A075232 001 Jan 06, 2000

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+	MCNEIL	2MG;125MG	N020606	001	Jun 26, 1996

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

PERRIGO 2MG;125MG

A076029 001 Aug 30, 2002

TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+	MCNEIL CONS	2MG;125MG	N021140	001	Nov 30, 2000

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

RANBAXY 2MG;125MG

A077500 001 Sep 06, 2006

LORATADINE

CAPSULE; ORAL

CLARITIN

+	SCHERING PLOUGH	10MG	N021952	001	Jun 16, 2008

SUSPENSION; ORAL

LORATADINE

+	TARO	1MG/ML	N021734	001	Oct 04, 2005

SYRUP; ORAL

CLARITIN

+	SCHERING PLOUGH	1MG/ML	N020641	002	Nov 27, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 12 (of 18)

LORATADINE

SYRUP; ORAL

LORATADINE

APOTEX INC	1MG/ML	A075565	001	Oct 05, 2004
PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
RANBAXY	1MG/ML	A076529	001	Aug 20, 2004
SILARX	1MG/ML	A077421	001	Jun 29, 2006
TARO	1MG/ML	A076805	001	Aug 20, 2004
TEVA	1MG/ML	A075505	001	Nov 07, 2003
WOCKHARDT	1MG/ML	A075815	001	Aug 20, 2004

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ SCHERING PLOUGH	5MG	N021891	001	Aug 23, 2006

TABLET, ORALLY DISINTEGRATING; ORAL
ALAVERT

WYETH CONS	10MG	N021375	001	Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+ SCHERING PLOUGH	10MG	N020704	003	Nov 19, 2003

CLARITIN REDITABS

+ SCHERING PLOUGH	5MG	N021993	001	Dec 12, 2006

+	10MG	N020704	002	Nov 27, 2002

LORATADINE

IMPAX LABS	10MG	A076011	001	Sep 29, 2003

WATSON LABS FLORIDA	10MG	A075990	001	Nov 03, 2003

WYETH CONS	10MG	A075822	001	Feb 10, 2003

LORATADINE REDIDOSE

RANBAXY	10MG	A077153	001	Apr 11, 2007

TABLET; ORAL

CLARITIN

+ SCHERING PLOUGH	10MG	N019658	002	Nov 27, 2002

CLARITIN HIVES RELIEF

+ SCHERING PLOUGH	10MG	N019658	003	Nov 19, 2003

LORATADINE

APOTEX INC	10MG	A076471	001	Feb 14, 2006

MYLAN	10MG	A075790	001	Nov 07, 2008

	10MG	A076154	001	Aug 20, 2003

PERRIGO	10MG	A076301	001	Jun 25, 2004

RANBAXY	10MG	A076134	001	Aug 18, 2003

SANDOZ	10MG	A075209	001	Jan 21, 2003

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ SCHERING PLOUGH	5MG;120MG	N019670	002	Nov 27, 2002

CLARITIN-D 24 HOUR

+ SCHERING PLOUGH	10MG;240MG	N020470	002	Nov 27, 2002

LORATADINE AND PSEUDOEPHEDRINE SULFATE

IMPAX LABS	5MG;120MG	A076050	001	Jan 30, 2003

	10MG;240MG	A075989	001	Mar 04, 2004

RANBAXY	10MG;240MG	A076557	001	Sep 22, 2004

WATSON LABS FLORIDA	5MG;120MG	A076208	001	Jan 28, 2004

	10MG;240MG	A075706	001	Feb 21, 2003

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL

SALONPAS

+ HISAMITSU	3%;10%	N022029	001	Feb 20, 2008

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

G AND W LABS	2%,100MG	A076585	001	Mar 26, 2004

MICONAZOLE NITRATE

PERRIGO R AND D	2%,1.2GM	A079114	001	Jun 02, 2010

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 13 (of 18)

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL				
MICONAZOLE NITRATE COMBINATION PACK				
PERRIGO 2%, 200MG	A075329	001	Apr 20, 1999	
MONISTAT 1 COMBINATION PACK				
+ JOHNSON AND JOHNSON 2%, 1.2GM	N021308	001	Jun 29, 2001	
MONISTAT 7 COMBINATION PACK				
+ JOHNSON AND JOHNSON 2%, 100MG	N020288	002	Apr 26, 1993	
MONISTAT-3 COMBINATION PACK				
+ JOHNSON AND JOHNSON 2%, 200MG	N020670	002	Apr 16, 1996	
M-ZOLE 3 COMBINATION PACK				
ACTAVIS MID ATLANTIC 2%, 200MG	A074926	001	Apr 16, 1999	
M-ZOLE 7 DUAL PACK				
ACTAVIS MID ATLANTIC 2%, 100MG	A074586	001	Jul 17, 1997	
CREAM; TOPICAL, VAGINAL				
MICONAZOLE 3 COMBINATION PACK				
PERRIGO 2%, 4%	A076357	001	Mar 30, 2004	
MONISTAT 3 COMBINATION PACK				
JOHNSON AND JOHNSON 2%, 4%	N021261	003	Jun 17, 2003	
MONISTAT 3 COMBINATION PACK (PREFILLED)				
+ JOHNSON AND JOHNSON 2%, 4%	N021261	001	Feb 02, 2001	
CREAM; VAGINAL				
MICONAZOLE 3				
TARO 4%	A076773	001	Mar 02, 2005	
MICONAZOLE 7				
ACTAVIS MID ATLANTIC 2%	A074164	001	Mar 29, 1996	
MICONAZOLE NITRATE				
G AND W LABS 2%	A074366	001	Feb 22, 1996	
PERRIGO 2%	A074760	001	May 15, 1997	
PERRIGO R AND D 4%	A091366	001	Jan 15, 2010	
TARO 2%	A074444	001	Jan 13, 1997	
MONISTAT 3				
+ JOHNSON AND JOHNSON 4%	N020827	001	Mar 30, 1998	
MONISTAT 7				
+ JOHNSON AND JOHNSON 2%	N017450	002	Feb 15, 1991	
SUPPOSITORY; VAGINAL				
MICONAZOLE NITRATE				
ACTAVIS MID ATLANTIC 100MG	A073507	001	Nov 19, 1993	
G AND W LABS 100MG	A074414	001	Apr 30, 1997	
+ PERRIGO 100MG	A074395	001	Mar 20, 1997	
MONISTAT 7				
+ JOHNSON AND JOHNSON 100MG	N018520	002	Feb 15, 1991	

MINOXIDIL

AEROSOL, FOAM; TOPICAL				
MEN'S ROGAINE				
+ JOHNSON AND JOHNSON 5%	N021812	001	Jan 20, 2006	
SOLUTION; TOPICAL				
MINOXIDIL (FOR MEN)				
ACTAVIS MID ATLANTIC 2%	A074588	001	Apr 05, 1996	
HI TECH PHARMA 2%	A074731	001	Dec 24, 1996	
NOVEX 2%	A074924	001	Apr 29, 1998	
PERRIGO 2%	A075357	001	Jul 30, 1999	
WOCKHARDT 2%	A074767	001	Feb 28, 1997	
MINOXIDIL (FOR WOMEN)				
HI TECH PHARMA 2%	A074731	002	May 11, 2005	
NOVEX 2%	A074924	002	Apr 29, 1998	
PERRIGO 2%	A075357	002	Jul 30, 1999	
MINOXIDIL EXTRA STRENGTH (FOR MEN)				
ACTAVIS MID ATLANTIC 5%	A075518	001	Nov 17, 2000	
AVACOR PRODS 5%	A075619	001	Nov 17, 2000	
NOVEX 5%	A075839	001	Oct 01, 2001	
PERRIGO 5%	A075598	001	Jun 13, 2001	
PERRIGO NEW YORK 5%	A075737	001	Mar 15, 2002	
WOCKHARDT 5%	A075438	001	Feb 27, 2003	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 14 (of 18)

MINOXIDIL

SOLUTION; TOPICAL

ROGAINE (FOR MEN)

+ JOHNSON AND JOHNSON 2% N019501 002 Feb 09, 1996

ROGAINE (FOR WOMEN)

+ JOHNSON AND JOHNSON 2% N019501 003 Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+ JOHNSON AND JOHNSON 5% N020834 001 Nov 14, 1997

THEROXIDIL

HARMONY LABS

2% A078176 001 Nov 09, 2007

5% A076239 001 Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

ALTAIRE PHARMS INC 0.02675%;0.315% A078208 001 Sep 27, 2010

NAPHCN-A

+ ALCON 0.025%;0.3% N020226 001 Jun 08, 1994

OPCN-A

+ BAUSCH AND LOMB 0.02675%;0.315% N020065 001 Jun 08, 1994

VISINE-A

+ JOHNSON AND JOHNSON 0.025%;0.3% N020485 001 Jan 31, 1996

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

+ BANNER PHARMACAPS EQ 200MG BASE N021920 001 Feb 17, 2006

TABLET; ORAL

ALEVE

+ BAYER EQ 200MG BASE N020204 002 Jan 11, 1994

NAPROXEN SODIUM

AMNEAL PHARMS NY EQ 200MG BASE A079096 001 Dec 16, 2008

CONTRACT PHARMACAL EQ 200MG BASE A074635 001 Jan 13, 1997

EQ 200MG BASE A074789 001 Feb 27, 1997

DR REDDYS LABS INC EQ 200MG BASE A075168 001 Jul 28, 1998

PERRIGO EQ 200MG BASE A074661 001 Jan 13, 1997

SANDOZ EQ 200MG BASE A074646 001 Jan 13, 1997

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALEVE-D SINUS & COLD

+ BAYER 200MG;120MG N021076 001 Nov 29, 1999

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC EQ 220MG BASE;120MG A077381 001 Sep 27, 2006

PERRIGO EQ 200MG BASE;120MG A076518 001 Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

+ NOVARTIS 7MG/24HR N020076 004 Nov 12, 1999

+ 14MG/24HR N020076 005 Nov 12, 1999

+ 21MG/24HR N020076 006 Nov 12, 1999

NICODERM CQ

+ SANOFI AVENTIS US 7MG/24HR N020165 006 Aug 02, 1996

+ 14MG/24HR N020165 005 Aug 02, 1996

+ 21MG/24HR N020165 004 Aug 02, 1996

NICOTINE

AVEVA 7MG/24HR A074645 001 Oct 20, 1997

14MG/24HR A074611 001 Oct 20, 1997

21MG/24HR A074612 001 Oct 20, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 15 (of 18)

NICOTINE POLACRILEXGUM, CHEWING; BUCCAL
NICORETTE

+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612 002	Feb 09, 1996
		EQ 2MG BASE	N018612 004	Sep 25, 2000
+		EQ 4MG BASE	N020066 002	Feb 09, 1996
		EQ 4MG BASE	N020066 004	Sep 25, 2000

NICORETTE (MINT)

GLAXOSMITHKLINE	EQ 2MG BASE	N018612 003	Dec 23, 1998
	EQ 4MG BASE	N020066 003	Dec 23, 1998

NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880 001	Feb 18, 2009
	EQ 4MG BASE	A077850 001	Feb 18, 2009

PERRIGO

EQ 2MG BASE	A076775 001	Sep 16, 2004
EQ 2MG BASE	A076776 001	Sep 16, 2004
EQ 2MG BASE	A076777 001	Sep 16, 2004
EQ 4MG BASE	A076778 001	Sep 16, 2004
EQ 4MG BASE	A076779 001	Sep 16, 2004
EQ 4MG BASE	A076789 001	Sep 16, 2004

PERRIGO R AND D

EQ 2MG BASE	A078325 001	Oct 30, 2006
EQ 2MG BASE	A078547 001	May 24, 2007
EQ 2MG BASE	A078967 001	Apr 23, 2008
EQ 4MG BASE	A078326 001	Oct 30, 2006
EQ 4MG BASE	A078546 001	May 24, 2007
EQ 4MG BASE	A078968 001	Apr 23, 2008

WATSON LABS

EQ 2MG BASE	A074507 001	Mar 15, 1999
EQ 2MG BASE	A076569 001	Jul 29, 2004
EQ 2MG BASE	A078699 001	Dec 29, 2008
EQ 2MG BASE	A079044 001	Jul 08, 2009
EQ 2MG BASE	A079216 001	Jul 08, 2009
EQ 4MG BASE	A074707 001	Mar 19, 1999
EQ 4MG BASE	A076568 002	Jul 29, 2004
EQ 4MG BASE	A078697 001	Dec 29, 2008
EQ 4MG BASE	A079038 001	Jul 08, 2009
EQ 4MG BASE	A079219 001	Jul 08, 2009

THRIVE

NOVARTIS

EQ 2MG BASE	A077658 001	Jun 19, 2007
EQ 4MG BASE	A077656 001	Jun 19, 2007

TROCHE/LOZENGE; ORAL
COMMIT

GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330 001	Oct 31, 2002
+	EQ 4MG BASE	N021330 002	Oct 31, 2002

NICORETTE

GLAXOSMITHKLINE CONS	EQ 2MG BASE	N022360 001	May 18, 2009
+	EQ 4MG BASE	N022360 002	May 18, 2009

NICOTINE POLACRILEX

PERRIGO R AND D	EQ 2MG BASE	A077007 001	Jan 31, 2006
	EQ 2MG BASE	A090711 001	Jul 10, 2009
	EQ 2MG BASE	A090821 001	Jul 10, 2009
	EQ 4MG BASE	A077007 002	Jan 31, 2006
	EQ 4MG BASE	A090711 002	Jul 10, 2009
	EQ 4MG BASE	A090821 002	Jul 10, 2009

NIZATIDINETABLET; ORAL
AXID AR

+	WYETH CONS	75MG	N020555 001	May 09, 1996

NONOXYNOL -9SPONGE; VAGINAL
TODAY

+	AZTIQ PHARMA	1GM	N018683 001	Apr 01, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 16 (of 18)

OMEPRAZOLE

TABLET, DELAYED RELEASE; ORAL

OMEPRAZOLE

+ DEXCEL PHARMA 20MG N022032 001 Dec 04, 2007

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE MAGNESIUM

+ DR REDDYS LABS LTD EQ 20MG BASE A078878 001 Jun 05, 2009

TABLET, DELAYED RELEASE; ORAL

PRILOSEC OTC

+ ASTRAZENECA EQ 20MG BASE N021229 001 Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID OTC

+ SCHERING PLOUGH 20MG;1.1GM N022281 001 Dec 01, 2009

ORLISTAT

CAPSULE; ORAL

ALLI

+ GLAXOSMITHKLINE CONS 60MG N021887 001 Feb 07, 2007

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OCUCLEAR

SCHERING PLOUGH 0.025% N018471 001 May 30, 1986

VISINE L.R.

+ JOHNSON AND JOHNSON 0.025% N019407 001 Mar 31, 1989

PERMETHRIN

LOTION; TOPICAL

NIX

+ INSIGHT PHARMS 1% N019918 001 May 02, 1990

PERMETHRIN

ACTAVIS MID ATLANTIC 1% A075014 001 Mar 28, 2000

PERRIGO NEW YORK 1% A076090 001 Dec 20, 2001

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

+ PFIZER 4%;EQ 0.33% BASE N021043 001 Mar 07, 2000

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

KREMERS URBAN PHARMS 17GM/PACKET A090600 001 Oct 06, 2009

17GM/SC00PFUL A090600 002 Oct 06, 2009

MIRALAX

+ SCHERING PLOUGH 17GM/SC00PFUL N022015 001 Oct 06, 2006

POLYETHYLENE GLYCOL 3350

MYLAN 17GM/PACKET A078915 001 Oct 06, 2009

17GM/SC00PFUL A078915 002 Oct 06, 2009

NEXGEN PHARMA 17GM/SC00PFUL A090812 001 Oct 07, 2009

NOVEL LABS INC 17GM/SC00PFUL A091077 001 Oct 06, 2009

PADDOCK 17GM/SC00PFUL A090567 001 Oct 15, 2009

PERRIGO R AND D 17GM/PACKET A090685 001 Oct 06, 2009

17GM/SC00PFUL A090685 002 Oct 06, 2009

POTASSIUM IODIDE

SOLUTION; ORAL

THYROSHIELD

+ FLEMING 65MG/ML A077218 001 Jan 12, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 17 (of 18)

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

+ ANBEX 130MG N018664 001 Oct 14, 1982

THYROSAFE

+ RECIP 65MG A076350 001 Sep 10, 2002

POVIDONE- IODINE

SOLUTION; TOPICAL

POVIDONE IODINE

+ ALLEGIANCE HLTHCARE 1% N019522 001 Mar 31, 1989

SPONGE; TOPICAL

E-Z SCRUB 201

+ BECTON DICKINSON 20% N019240 001 Nov 29, 1985

E-Z SCRUB 241

+ BECTON DICKINSON 10% N019476 001 Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO 120MG A075153 001 Feb 26, 1999

RANBAXY 120MG A077442 001 Sep 28, 2005

SUDAFED 12 HOUR

+ MCNEIL CONS 120MG A073585 001 Oct 31, 1991

SUDAFED 24 HOUR

+ MCNEIL CONS 240MG N020021 002 Dec 15, 1992

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

AFRINOL

+ SCHERING PLOUGH 120MG N018191 001

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

CONTRACT PHARMACAL EQ 75MG BASE A075094 001 Jun 21, 1999

DR REDDYS LABS LTD EQ 75MG BASE A075294 001 Mar 28, 2000

EQ 150MG BASE A078192 001 Aug 31, 2007

GENPHARM EQ 75MG BASE A075497 001 Jan 14, 2000

IVAX SUB TEVA PHARMS EQ 75MG BASE A075296 001 Jan 14, 2000

PERRIGO EQ 75MG BASE A076195 001 Aug 30, 2002

TORPHARM EQ 75MG BASE A075167 001 May 04, 2000

WATSON LABS EQ 75MG BASE A075212 001 Jan 14, 2000

WOCKHARDT EQ 75MG BASE A076760 001 Feb 24, 2006

EQ 75MG BASE A078884 001 Jul 31, 2008

EQ 150MG BASE A078653 001 Nov 26, 2007

ZANTAC 150

+ BOEHRINGER INGELHEIM EQ 150MG BASE N021698 001 Aug 31, 2004

EQ 150MG BASE N021698 002 Mar 13, 2007

ZANTAC 75

BOEHRINGER INGELHEIM EQ 75MG BASE N020520 001 Dec 19, 1995

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION

BRONCHO SALINE

+ BLAIREX 0.9% N019912 001 Sep 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE 0.24%;0.3% N020231 001 Jul 11, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 18 (of 18)

TERBINAFINE

GEL; TOPICAL LAMISIL AT + NOVARTIS	1%	N021958 001	Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL LAMISIL + NOVARTIS	1%	N020980 001	Mar 09, 1999
TERBINAFINE HYDROCHLORIDE TARO	1%	A077511 001	Jul 02, 2007
SOLUTION; TOPICAL LAMISIL AT + NOVARTIS	1%	N021124 001	Mar 17, 2000
SPRAY; TOPICAL LAMISIL AT + NOVARTIS	1%	N021124 002	Mar 17, 2000

TIOCONAZOLE

OINTMENT; VAGINAL TIOCONAZOLE PERRIGO	6.5%	A075915 001	Nov 21, 2001
VAGISTAT-1 + NOVARTIS	6.5%	N020676 001	Feb 11, 1997

31ST EDITION - 2011- APPROVED DRUG PRODUCT LIST

5 - 1 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

MEDSEP CORPORATION

N760305

Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CYTOSOL

LABORATORIES INC

N020037

Aug 26, 2003

ACD-A SOLUTION

GAMBRO BCT INC

A010228

ANDA

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

ANDA

Feb 06, 2002

AS3 SOLUTION/ACD-A

GAMBRO BCT INC

N001214

May 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N100855

Jun 03, 1959

N160918

Mar 17, 1978

FRESENIUS MEDICAL

N110912

Sep 02, 1959

CARE NORTH AMERICA

MEDSEP CORPORATION

A710497

ANDA

MILES INC

N100102

Dec 14, 1961

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

FRESENIUS MEDICAL

N780519

Apr 23, 1980

CARE NORTH AMERICA

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

MEDSEP CORPORATION

N800077

Nov 06, 1980

31ST EDITION - 2011- APPROVED DRUG PRODUCT LIST

5 - 2 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION		
ADSOL IN PLASTIC CONTAINER		
FENWAL INC	N900223	Dec 27, 1991
CPD BLOOD BAG UNIT IN PLASTIC CONTAINER		
FENWAL INC	N900224	Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION		
MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB		
MACOPRODUCTIONS SAS	N040083	Nov 21, 2005

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION		
NONE		
FENWAL INC	N170401	Dec 06, 1977
	N811012	Jun 28, 1983
FRESENIUS MEDICAL CARE NORTH AMERICA	N160907	May 16, 1973
MEDSEP CORPORATION	N800222	Aug 23, 1982
MILES INC	N160527	Jun 22, 1970
TERUMO MEDICAL CORP	N781211	Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION		
ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION		
FENWAL INC	N811104	May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION		
OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION		
TERUMO MEDICAL CORP	N880217	Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION		
AS-3 NUTRICEL ADDITIVE SYSTEM		
MEDSEP CORP	0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML	N820915 Oct 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION		
AS-2 NUTRICEL ADDITIVE SYSTEM		
MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915 Sep 22, 1983

ANTICOAGULANT ETHYLENEDIAMINE TETRAACETIC ACID (EDTA)

INJECTABLE; INJECTION		
NONE		
FENWAL INC	N090480	Mar 07, 1955

31ST EDITION - 2011- APPROVED DRUG PRODUCT LIST

5 - 3 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT HEPARIN SOLUTION USP

INJECTABLE; INJECTION

NONE

FRESENIUS MEDICAL
CARE NORTH AMERICA

N770822

May 17, 1978

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS
CORPORATION

N980123

Mar 03, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL
LABORATORIES INC

N010409

Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC
FRESENIUS MEDICAL
CARE NORTH AMERICA
TERUMO MEDICAL CORP

N770923

Jan 20, 1978

N160702

Dec 28, 1970

N781214

Feb 08, 1980

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB

N830715

Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

GENTRAN 40

BAXTER HLTHCARE CORP 10GM/100ML;5GM/100ML

N840619

Feb 22, 1985

LMD IN PLASTIC CONTAINER

HOSPIRA INC 10GM/100ML;5GM/100ML

A720563

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC 10GM/100ML;5GM/100ML

N160767

Apr 06, 1970

HOSPIRA INC 10GM/100ML;5GM/100ML

N160375

Jul 25, 1967

MEDA AB 10GM/100ML;5GM/100ML

N140716

Jan 18, 1967

MILES INC 10GM/100ML;5GM/100ML

N160653

Sep 23, 1969

PHARMACHEM CORP 10GM/100ML;5GM/100ML

N160836

Nov 14, 1972

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

GENTRAN 40

BAXTER HLTHCARE CORP 10GM/100ML;0.9GM/100ML

N840620

Feb 22, 1985

LMD IN PLASTIC CONTAINER

HOSPIRA INC 10GM/100ML;0.9GM/100ML

A720562

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML

N160767

Apr 06, 1970

HOSPIRA INC 10GM/100ML;0.9GM/100ML

N160375

Jul 25, 1967

MEDA AB 10GM/100ML;0.9GM/100ML

N140716

Jan 18, 1967

MILES INC 10GM/100ML;0.9GM/100ML

N160653

Sep 23, 1969

PHARMACHEM CORP 10GM/100ML;0.9GM/100ML

N160836

Nov 14, 1972

31ST EDITION - 2011- APPROVED DRUG PRODUCT LIST

5 - 4 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 0.8% NACL 500 ML PVC BAGS

INJECTABLE; INJECTION

RHEOMACRODEX

MEDA AB

N830527

Mar 27, 1985

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 5% DEXTROSE 500 ML PVC BAGS

INJECTABLE; INJECTION

RHEOMACRODEX

MEDA AB

N830627

Mar 27, 1985

DEXTRAN 70, 6% IN DEXTROSE 5%

INJECTABLE; INJECTION

MACRODEX

MEDA AB

6GM/100ML;5GM/100ML

N060826

Jun 08, 1954

NONE

HOSPIRA INC

6GM/100ML;5GM/100ML

N080819

Mar 31, 1953

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

GENTRAIN 70

BAXTER HLTHCARE CORP

N160607

Jan 26, 1970

MACRODEX

MEDA AB

6GM/100ML;5GM/100ML

N060826

Jun 08, 1954

NONE

B BRAUN MEDICAL INC

6GM/100ML;0.9 GM/100ML

N090024

Aug 18, 1969

MILES INC

6GM/100ML;0.9 GM/100ML

N080716

Mar 13, 1953

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 0.9% NACL IN 500 ML PVC BAGS

INJECTABLE; INJECTION

MACRODEX

MEDA AB

N830613

Mar 27, 1985

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 5% DEXTROSE

INJECTABLE; INJECTION

MACRODEX

MEDA AB

N830629

Mar 27, 1985

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

NONE

PHARMACHEM CORP

6GM/100ML;0.9GM/100ML

N080564

Sep 19, 1952

6GM/100ML;0.9GM/100ML

N160759

Aug 19, 1970

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC

6GM/100ML

N200952

Mar 31, 1999

31ST EDITION - 2011- APPROVED DRUG PRODUCT LIST

5 - 5 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC	6GM/100ML;0.9GM/100ML	A740193	ANDA	Jan 30, 1995

HESPA

B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N160889		Jul 17, 1972

HESPA IN PLASTIC CONTAINER

B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N890105		Apr 04, 1991

NONE

B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	A740283	ANDA	Oct 21, 1998

TEVA PARENTERAL MEDICINES INC	6GM/100ML;0.9GM/100ML	A740592	ANDA	Nov 12, 1998

HETASTARCH 6% IN SODIUM CHLORIDE 0.9% NACL 500 ML GLASS BOTTLES

INJECTABLE; INJECTION

NONE

HOSPIRA INC	6GM/100ML;0.9 GM/100ML	A720746	ANDA	Feb 07, 1996

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

VOLUVEN

FRESENIUS KABI DEUTSCHLAND GMBH	6GM/100ML;0.9GM/100ML	N070012	NDA	Dec 27, 2007

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

PENTASPA

B BRAUN MEDICAL INC	10GM/100ML;0.9GM/100ML	N841207		May 19, 1987

PENTASPA IN PLASTIC CONTAINER

B BRAUN MEDICAL INC	10GM/100ML;0.9GM/100ML	N890104		Apr 04, 1991

PERFLUORODECALIN; PERFLUOROTRI-N-PROPYLAMINE

INJECTABLE; INJECTION

FLUOSOL

ALPHA THERAPEUTIC CORP	17.5GM/100ML;7.5GM/100ML	N860909		Dec 26, 1989

RED BLOOD CELL PROCESSING SOLUTION

INJECTABLE; INJECTION

REJUVESOL

CYTOSOL LABS INC		N950522		Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

INJECTABLE; INJECTION

INTERSOL SOLUTION

FENWAL INC.	2.26G/500ML; 2.21G/500ML; 1.59G/500ML; 1.53G/500ML; 0.465G/500ML	N080041	NDA	Dec 09, 2009

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 1 (of 331)

ABARELIXINJECTABLE; INTRAMUSCULAR
PLENAXIS

SPECIALITY EUROPEAN 100MG/VIAL

N021320 001 Nov 25, 2003

ACETAMINOPHENINJECTABLE; INJECTION
INJECTAPAP

ORTHO MCNEIL PHARM 100MG/ML

N017785 001 Mar 07, 1986

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS 120MG

A072218 001 Mar 27, 1992

ACETAMINOPHEN

ABLE 120MG

A073106 001 Feb 27, 1995

325MG

A073107 001 Feb 27, 1995

650MG

A073108 001 Feb 27, 1995

ROXANE 120MG

A071010 001 May 12, 1987

650MG

A071011 001 May 12, 1987

TYLENOL

MCNEIL CONS 120MG

N017756 002

650MG

N017756 001

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART 150MG;180MG;15MG

A081095 001 Oct 26, 1990

150MG;180MG;30MG

A081096 001 Oct 26, 1990

150MG;180MG;60MG

A081097 001 Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS 150MG;180MG;15MG

A085640 001

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS 150MG;180MG;30MG

A085639 001

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS 150MG;180MG;60MG

A085638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS 325MG;50MG

A088889 001 Jan 16, 1986

BUCET

MALLINCKRODT 650MG;50MG

A088991 001 Jun 28, 1985

TENCON

MALLINCKRODT 650MG;50MG

A089405 001 May 15, 1990

TRIAPRIN

DUNHALL 325MG;50MG

A089268 001 Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY 325MG;50MG

A089568 001 Oct 05, 1988

WATSON LABS 325MG;50MG

A087550 001 Oct 19, 1984

SEDAPAP

MAYRAND 650MG;50MG

A088944 001 Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE 325MG;50MG;40MG

A087628 001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM 325MG;50MG;40MG

A088743 001 Jul 18, 1985

325MG;50MG;40MG

A088765 001 Mar 27, 1985

325MG;50MG;40MG

A089067 001 Apr 19, 1985

MALLINCKRODT 325MG;50MG;40MG

A088758 001 Mar 27, 1985

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS 325MG;50MG;40MG

A088825 001 Dec 05, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 2 (of 331)

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FEMCET

MALLINCKRODT

325MG;50MG;40MG

A089102 001 Jun 19, 1985

MEDIGESIC PLUS

US CHEM

325MG;50MG;40MG

A089115 001 Jan 14, 1986

TRIAD

MALLINCKRODT

325MG;50MG;40MG

A089023 001 Jun 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE

325MG;50MG;40MG

A040390 001 Jul 23, 2001

500MG;50MG;40MG

A040394 001 Jul 23, 2001

GILBERT LABS

325MG;50MG;40MG

A087629 001 Nov 13, 1984

MUTUAL PHARM

325MG;50MG;40MG

A040601 001 Jul 29, 2005

WATSON LABS

325MG;50MG;40MG

A089536 001 Feb 16, 1988

ESGIC

FOREST PHARMS

325MG;50MG;40MG

A089660 001 Dec 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE

325MG;50MG;40MG;30MG

A076528 001 Aug 21, 2003

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

DHC PLUS

PHARM RES ASSOC

356.4MG;30MG;16MG

A088584 001 Mar 04, 1986

SYNALGOS-DC-A

LEITNER PHARMS

356.4MG;30MG;16MG

A089166 001 May 14, 1986

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA

300MG;15MG

A088537 001 Jun 04, 1984

300MG;30MG

A088324 001 Dec 29, 1983

300MG;60MG

A088599 001 Jun 01, 1984

PHENAPHEN W/ CODEINE NO. 2

ROBINS AH

325MG;15MG

A084444 001

PHENAPHEN W/ CODEINE NO. 3

ROBINS AH

325MG;30MG

A084445 001

PHENAPHEN W/ CODEINE NO. 4

ROBINS AH

325MG;60MG

A084446 001

PROVAL #3

SOLVAY

325MG;30MG

A085685 001

TYLENOL W/ CODEINE NO. 3

ORTHO MCNEIL PHARM

300MG;30MG

A087422 001

TYLENOL W/ CODEINE NO. 4

ORTHO MCNEIL PHARM

300MG;60MG

A087421 001

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

CLONMEL

120MG/5ML;12MG/5ML

A040098 001 Sep 20, 1996

ROXANE

120MG/5ML;12MG/5ML

A086366 001

TYLENOL W/ CODEINE

ORTHO MCNEIL PHARM

120MG/5ML;12MG/5ML

A085057 001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE

300MG;30MG

A040452 001 Aug 01, 2002

300MG;60MG

A040459 001 Aug 01, 2002

AM THERAP

300MG;15MG

A089478 001 Mar 03, 1987

300MG;15MG

A089481 001 Mar 03, 1987

300MG;30MG

A089479 001 Mar 03, 1987

300MG;30MG

A089482 001 Mar 03, 1987

300MG;60MG

A089480 001 Mar 03, 1987

300MG;60MG

A089483 001 Mar 03, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 3 (of 331)

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

DURAMED PHARMS BARR	300MG;15MG	A088353	001	Feb 06, 1984
	300MG;30MG	A088354	001	Feb 06, 1984
	300MG;60MG	A088355	001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001	
HALSEY	300MG;15MG	A083871	001	
	300MG;30MG	A083872	001	
	300MG;60MG	A086549	001	
KV PHARM	300MG;30MG	A085288	001	
	300MG;60MG	A085365	001	
	325MG;15MG	A085364	001	
	325MG;45MG	A085363	001	
LEDERLE	300MG;30MG	A087141	001	
MIKART	300MG;60MG	A089244	001	Feb 25, 1986
MUTUAL PHARM	300MG;15MG	A085795	001	
	300MG;15MG	A089671	001	Feb 10, 1988
	300MG;30MG	A085794	001	
	300MG;30MG	A089672	001	Feb 10, 1988
	300MG;60MG	A087653	001	Apr 13, 1982
	300MG;60MG	A089673	001	Feb 10, 1988
PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001	
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
ROXANE	300MG;15MG	A084659	001	
	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	
	500MG;15MG	A089511	001	Apr 25, 1989
	500MG;30MG	A089512	001	Apr 25, 1989
	500MG;60MG	A089513	001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001	
	300MG;30MG	A081250	001	Jul 16, 1992
	300MG;30MG	A085291	002	
	300MG;30MG	A085917	001	
	300MG;60MG	A081249	001	Jul 16, 1992
	300MG;60MG	A085964	001	
	300MG;60MG	A087423	001	
SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
	300MG;30MG	A089184	001	Oct 18, 1985
	300MG;30MG	A089253	001	May 19, 1986
	300MG;60MG	A089185	001	Oct 18, 1985
	300MG;60MG	A089254	001	May 19, 1986
USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
	300MG;60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896	001	
VITARINE	300MG;30MG	A085676	001	
WARNER CHILCOTT	300MG;15MG	A085992	001	
	300MG;30MG	A085218	002	
	300MG;60MG	A087306	001	
WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
	300MG;30MG	A087276	001	May 26, 1982
	300MG;60MG	A087275	001	May 26, 1982
WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
	300MG;60MG	A085607	001	
CAPITAL AND CODEINE				
CARNRICK	325MG;30MG	A083643	001	
CODRIX				
WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
	500MG;30MG	A040441	001	Mar 27, 2003
	500MG;60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
GLAXOSMITHKLINE	300MG;30MG	A083951	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 4 (of 331)

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

EMPRACET W/ CODEINE PHOSPHATE #4			
GLAXOSMITHKLINE	300MG;60MG	A083951	002
PAPA-DEINE #3			
VANGARD	300MG;30MG	A088037	001 Mar 20, 1984
PAPA-DEINE #4			
VANGARD	300MG;60MG	A088715	001 Mar 20, 1984
PHENAPHEN-650 W/ CODEINE			
ROBINS AH	650MG;30MG	A085856	001
TYLENOL W/ CODEINE			
ORTHO MCNEIL PHARM	325MG;7.5MG	A085056	001
	325MG;15MG	A085056	002
	325MG;30MG	A085056	003
	325MG;60MG	A085056	004
TYLENOL W/ CODEINE NO. 1			
ORTHO MCNEIL JANSSEN	300MG;7.5MG	A085055	001
TYLENOL W/ CODEINE NO. 2			
ORTHO MCNEIL JANSSEN	300MG;15MG	A085055	002

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE			
CENT PHARMS	500MG;5MG	A088898	001 Mar 27, 1985
ALLAY			
IVAX PHARMS	500MG;5MG	A089907	001 Jan 13, 1989
BANCAP HC			
FOREST PHARMS	500MG;5MG	A087961	001 Mar 17, 1983
CO-GESIC			
CENT PHARMS	500MG;5MG	A089360	001 Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
MALLINCKRODT	500MG;5MG	A088956	001 Jul 19, 1985
	500MG;5MG	A089006	001 Aug 09, 1985
MIKART	500MG;5MG	A081068	001 Nov 30, 1989
	500MG;5MG	A081069	001 Nov 30, 1989
	500MG;5MG	A081070	001 Nov 30, 1989
LORCET-HD			
MALLINCKRODT	500MG;5MG	A087336	001 Jul 08, 1982
SOLUTION; ORAL			
HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
MIKART	500MG/15ML;5MG/15ML	A081226	001 Oct 27, 1992
	500MG/15ML;5MG/15ML	A089557	001 Apr 29, 1992

TABLET; ORAL

DURADYNE DHC			
FOREST PHARMS	500MG;5MG	A087809	001 Mar 17, 1983
HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
ABLE	325MG;5MG	A040478	001 Nov 08, 2002
	325MG;7.5MG	A040464	001 Oct 23, 2002
	325MG;10MG	A040464	002 Oct 23, 2002
	500MG;5MG	A040477	001 Nov 06, 2002
	500MG;7.5MG	A040490	001 May 21, 2003
	500MG;10MG	A040473	001 Nov 06, 2002
	650MG;7.5MG	A040474	001 Jan 02, 2003
	650MG;10MG	A040476	001 Oct 23, 2002
	750MG;7.5MG	A040469	001 Oct 25, 2002
BARR	500MG;2.5MG	A040307	001 Jul 26, 2000
	500MG;5MG	A040308	001 Jul 26, 2000
	500MG;5MG	A088577	001 Dec 21, 1984
	500MG;7.5MG	A040307	002 Jul 26, 2000
	500MG;10MG	A040309	001 Jul 26, 2000
	650MG;7.5MG	A040307	003 Jul 26, 2000
	650MG;10MG	A040307	004 Jul 26, 2000
	750MG;7.5MG	A040308	002 Jul 26, 2000
ENDO PHARMS	500MG;5MG	A040281	001 Sep 30, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 5 (of 331)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ENDO PHARMS	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
MIKART	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG;5MG	A089831	001	Sep 07, 1988
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	500MG;5MG	A040122	001	Mar 04, 1996
	750MG;7.5MG	A040122	002	Mar 04, 1996
HY-PHEN				
ASCHER	500MG;5MG	A087677	001	May 03, 1982
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

BARR	500MG;5MG	A040304	001	Oct 02, 2000
ENDO PHARMS	500MG;5MG	A040303	001	Dec 30, 1999
HALSEY	500MG;5MG	A089994	001	May 04, 1989
MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
TYLOX-325				
ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984

TABLET; ORAL

OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	

OXYCODONE 5/APAP 500

BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	

OXYCODONE AND ACETAMINOPHEN

BARR	325MG;5MG	A087406	001	
DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998
PERCOCET				
ENDO PHARMS	325MG;5MG	A085106	002	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX

ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375	001	

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALACEN

SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458	001	Sep 23, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 6 (of 331)

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET

AAIPHARMA LLC

325MG;32.5MG

N016844 001

DOLENE AP-65

LEDERLE

650MG;65MG

A085100 001

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN

325MG;32MG

A083689 001

SANDOZ

650MG;65MG

A089959 001

Jul 18, 1989

WATSON LABS

650MG;65MG

A040139 001

Dec 16, 1996

WYGESIC

LEITNER PHARMS

650MG;65MG

A084999 001

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

XANODYNE PHARM

500MG;100MG

A076429 001

Sep 10, 2003

PROPACET 100

TEVA

650MG;100MG

A070107 001

Jun 12, 1985

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE

650MG;100MG

A075838 001

Jul 11, 2001

ACTAVIS ELIZABETH

650MG;100MG

A070910 001

Jan 02, 1987

HALSEY

325MG;50MG

A072105 001

May 13, 1988

650MG;100MG

A072106 001

May 13, 1988

IVAX SUB TEVA PHARMS

650MG;100MG

A070146 001

Aug 02, 1985

MALLINCKRODT

650MG;100MG

A075738 001

Feb 02, 2001

MUTUAL PHARM

325MG;50MG

A070115 001

Jun 12, 1985

650MG;100MG

A070116 001

Jun 12, 1985

650MG;100MG

A070615 001

Mar 21, 1986

650MG;100MG

A070771 001

Mar 21, 1986

650MG;100MG

A070775 001

Mar 21, 1986

MYLAN

650MG;100MG

A072195 001

Feb 16, 1988

SANDOZ

650MG;100MG

A070443 001

Jan 23, 1986

SUPERPHARM

650MG;100MG

A071319 001

Jan 06, 1987

TEVA

650MG;100MG

A070732 001

Jan 03, 1986

WATSON LABS

325MG;50MG

A070398 001

Dec 18, 1986

650MG;100MG

A070399 001

Dec 18, 1986

WATSON LABS FLORIDA

500MG;100MG

A077196 001

Jun 28, 2005

650MG;100MG

A076609 001

Nov 16, 2004

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

ALRA

250MG

A083320 001

ASCOT

250MG

A087686 001

Oct 20, 1982

MUTUAL PHARM

250MG

A089753 001

Jun 22, 1988

VANGARD

250MG

A087654 001

Feb 05, 1982

WATSON LABS

250MG

A084498 002

DIAMOX

DURAMED PHARMS BARR

125MG

N008943 001

250MG

N008943 002

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA

EQ 500MG BASE/VIAL

A040108 001

Oct 30, 1995

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

KV PHARM

2%

A085493 001

ORLEX

WARNER CHILCOTT

2%

A086845 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 7 (of 331)

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

BOROFAIR

PHARMAFAIR

2%;0.79%

A088606 001

Aug 21, 1985

DOMEBORO

BAYER PHARMS

2%;0.79%

A084476 001

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC

TRIDESILON

BAYER PHARMS

2%;0.05%

N017914 001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETIC ACID W/ HYDROCORTISONE

KV PHARM

2%;1%

A085492 001

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB

2%;1%

A040097 001

Oct 31, 1994

WOCKHARDT

2%;1%

A040168 001

Aug 30, 1996

ORLEX HC

WARNER CHILCOTT

2%;1%

A086844 001

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

BAYER PHARMS

2%;1%;EQ 0.35% BASE

N050238 001

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

BARR

250MG

A070869 001

Feb 09, 1987

500MG

A070870 001

Feb 09, 1987

USL PHARMA

250MG

A070753 001

Nov 03, 1986

500MG

A070754 001

Nov 03, 1986

DYMELOR

LILLY

250MG

N013378 002

500MG

N013378 001

ACETOPHENAZINE MALEATE

TABLET; ORAL

TINDAL

SCHERING

20MG

N012254 002

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM

53%

N009008 001

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL

NOVARTIS

20MG/VIAL

N016211 001

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA

10%

A071364 001

May 01, 1989

20%

A071365 001

May 01, 1989

ROXANE

10%

A072621 001

Sep 30, 1992

20%

A072622 001

Sep 30, 1992

MUCOMYST

APOTHECON

10%

N013601 002

20%

N013601 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 8 (of 331)

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

MUCOSIL-10

DEY 10%

A070575 001 Oct 14, 1986

MUCOSIL-20

DEY 20%

A070576 001 Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON 10%;0.05%

N017366 001

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS 0.1MG

N009436 001

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING 2MG/GM

N012470 001

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

BELCHER PHARMS 200MG

A074889 001 Oct 31, 1997

DAVA PHARMS INC 200MG

A074872 001 Apr 22, 1997

IVAX SUB TEVA PHARMS 200MG

A074674 001 Apr 22, 1997

LEK PHARM 200MG

A074750 001 Apr 22, 1997

ROXANE 200MG

A074570 002 Apr 22, 1997

TEVA 200MG

A074828 001 Apr 22, 1997

TEVA PHARMS 200MG

A074914 001 Nov 26, 1997

TABLET; ORAL

ACYCLOVIR

BELCHER PHARMS 400MG

A074891 001 Oct 31, 1997

800MG

A074891 002 Oct 31, 1997

DAVA PHARMS INC 400MG

A074834 001 Apr 24, 1997

800MG

A074834 002 Apr 24, 1997

IVAX SUB TEVA PHARMS 400MG

A074836 001 Apr 22, 1997

800MG

A074836 002 Apr 22, 1997

LEK PHARM 400MG

A074658 001 Apr 22, 1997

800MG

A074658 002 Apr 22, 1997

TEVA 200MG

A074556 001 Apr 22, 1997

TEVA PHARMS 400MG

A075021 001 Mar 18, 1998

800MG

A075021 002 Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBOTT EQ 50MG BASE/ML

A075114 001 Jul 26, 1999

ACYCLOVIR SODIUM

APOTHECON EQ 500MG BASE/VIAL

A074897 001 Feb 27, 1998

EQ 1GM BASE/VIAL

A074897 002 Feb 27, 1998

HOSPIRA EQ 500MG BASE/VIAL

A074663 001 Apr 22, 1997

EQ 500MG BASE/VIAL

A074758 001 Apr 22, 1997

EQ 1GM BASE/VIAL

A074663 002 Apr 22, 1997

EQ 1GM BASE/VIAL

A074758 002 Apr 22, 1997

ZOVIRAX

GLAXOSMITHKLINE EQ 250MG BASE/VIAL

N018603 003 Aug 30, 1983

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

GALDERMA LABS LP 0.1%

N020338 001 May 31, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 9 (of 331)

ALATROFLOXACIN MESYLATEINJECTABLE; INJECTION
TROVAN PRESERVATIVE FREE

PFIZER	EQ 200MG BASE/VIAL	N020760	001	Dec 18, 1997
	EQ 300MG BASE/VIAL	N020760	002	Dec 18, 1997

ALBUMIN CHROMATED CR-51 SERUMINJECTABLE; INJECTION
CHROMALBIN

ISO TEX	100uCi/VIAL	N017835	001	
	250uCi/VIAL	N017835	002	
	500uCi/VIAL	N017835	003	

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS	2.5uCi/AMP	N017846	001	

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

MALLINCKRODT	6.67uCi/ML	N017844	003	
	10uCi/ML	N017844	001	
	100uCi/ML	N017844	002	

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX	2mCi/VIAL	N017837	003	
	5uCi/AMP	N017837	004	
	20uCi/AMP	N017837	005	

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988

SOLUTION; INHALATION

ALBUTEROL SULFATE

BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
PROVENTIL				
SCHERING	EQ 0.083% BASE	N019243	002	Jan 14, 1987
	EQ 0.5% BASE	N019243	001	Jan 14, 1987
VENTOLIN				
GLAXOSMITHKLINE	EQ 0.083% BASE	N019773	001	Apr 23, 1992
	EQ 0.5% BASE	N019269	002	Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
SCHERING	EQ 2MG BASE/5ML	N018062	001	Jan 19, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 10 (of 331)

ALBUTEROL SULFATESYRUP; ORAL
VENTOLIN

GLAXOSMITHKLINE

EQ 2MG BASE/5ML

N019621 001 Jun 10, 1987

TABLET; ORAL

ALBUTEROL SULFATE

AM THERAP

EQ 2MG BASE

A072449 001 Dec 05, 1989

EQ 4MG BASE

A072450 001 Dec 05, 1989

COPLEY PHARM

EQ 2MG BASE

A072966 001 Nov 22, 1991

EQ 4MG BASE

A072967 001 Nov 22, 1991

DAVA PHARMS INC

EQ 2MG BASE

A072859 001 Dec 20, 1989

EQ 4MG BASE

A072860 001 Dec 20, 1989

PLIVA

EQ 2MG BASE

A072316 001 Dec 05, 1989

EQ 4MG BASE

A072317 001 Dec 05, 1989

SANDOZ

EQ 2MG BASE

A072151 001 Dec 05, 1989

EQ 4MG BASE

A072152 001 Dec 05, 1989

TEVA

EQ 2MG BASE

A072619 001 Dec 05, 1989

EQ 2MG BASE

A072779 001 Jun 25, 1993

EQ 2MG BASE

A072938 001 Mar 30, 1990

EQ 4MG BASE

A072620 001 Dec 05, 1989

EQ 4MG BASE

A072780 001 Jun 25, 1993

EQ 4MG BASE

A072939 001 Mar 30, 1990

UCB INC

EQ 2MG BASE

A073120 001 Sep 29, 1992

EQ 4MG BASE

A073121 001 Sep 29, 1992

WARNER CHILCOTT

EQ 2MG BASE

A072817 001 Jan 09, 1990

EQ 4MG BASE

A072818 001 Jan 09, 1990

WATSON LABS

EQ 2MG BASE

A072629 001 Jan 31, 1991

EQ 4MG BASE

A072630 001 Jan 31, 1991

EQ 4MG BASE

A072765 001 Aug 28, 1991

PROVENTIL

SCHERING

EQ 2MG BASE

N017853 001 May 07, 1982

EQ 4MG BASE

N017853 002 May 07, 1982

VENTOLIN

GLAXOSMITHKLINE

EQ 2MG BASE

N019112 001 Jul 10, 1986

EQ 4MG BASE

N019112 002 Jul 10, 1986

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL

SCHERING

EQ 4MG BASE

N019383 001 Jul 13, 1987

VOLMAX

MURO

EQ 4MG BASE

N019604 002 Dec 23, 1992

EQ 8MG BASE

N019604 001 Dec 23, 1992

ALCOHOL

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES

5ML/100ML

A083483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE

5ML/100ML; 5GM/100ML

A083256 001

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

TEVA PHARMS

EQ 35MG BASE

A076184 002 Aug 04, 2008

EQ 70MG BASE

A076184 001 Feb 06, 2008

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME

10 UNITS/ML

N020057 004 May 08, 1992

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 11 (of 331)

ALKAVERVIRTABLET; ORAL
VERILOID
3M2MG
3MGN007336 002
N007336 003ALLOPURINOLTABLET; ORAL
ALLOPURINOL

MUTUAL PHARM

100MG
300MGA070466 001 Dec 24, 1985
A070467 001 Dec 24, 1985

PURACAP PHARM

100MG
300MGA070150 001 Dec 10, 1985
A070147 001 Dec 10, 1985

PUREPAC PHARM

100MG
300MGA070579 001 Apr 14, 1986
A070580 001 Apr 14, 1986

SANDOZ

100MG
300MGA070268 001 Dec 31, 1985
A070269 001 Dec 31, 1985

SUPERPHARM

100MG
300MGA070950 001 Nov 30, 1988
A070951 001 Nov 30, 1988

WATSON LABS

100MG
100MG
300MG
300MGN018241 001 Nov 16, 1984
N018785 001 Sep 28, 1984
N018241 002 Nov 16, 1984
N018785 002 Sep 28, 1984

LOPURIN

ABBOTT

100MG
300MGN018297 001
N018297 002ALPRAZOLAMSOLUTION; ORAL
ALPRAZOLAM

ROXANE

0.5MG/5ML

A074314 001 Oct 31, 1993

TABLET; ORAL
ALPRAZOLAM

IVAX SUB TEVA PHARMS

0.25MG
0.5MG
1MG
2MGA074294 001 Jul 29, 1994
A074294 002 Jul 29, 1994
A074294 003 Jul 29, 1994
A074294 004 Jul 29, 1994

ROXANE

0.25MG
0.5MG
1MGA074199 001 Oct 19, 1993
A074199 002 Oct 19, 1993
A074199 003 Oct 19, 1993

TEVA

0.25MG
0.5MG
1MG
2MGA074085 001 Feb 16, 1994
A074085 002 Feb 16, 1994
A074085 003 Feb 16, 1994
A074085 004 Feb 26, 1996

WATSON LABS

0.25MG
0.25MG
0.5MG
0.5MG
1MG
1MGA074456 001 Aug 31, 1995
A074479 001 Jan 21, 1997
A074456 002 Aug 31, 1995
A074479 002 Jan 21, 1997
A074456 003 Aug 31, 1995
A074479 003 Jan 21, 1997ALPROSTADILINJECTABLE; INJECTION
CAVERJECT

PFIZER

0.005MG/ML
0.01MG/ML
0.02MG/MLN020755 001 Oct 31, 1997
N020755 002 Oct 01, 1997
N020755 003 Oct 01, 1997

EDEX

SCHWARZ PHARMA

0.005MG/VIAL

N020649 001 Jun 12, 1997

ALSEROXYLON

TABLET; ORAL

RAUTENSIN

NOVARTIS

2MG

N009215 001

DISCONTINUED DRUG PRODUCT LIST

6 - 12 (of 331)

ALSEROXYLON

TABLET; ORAL				
RAUWILOID				
3M	2MG	N008867	001	

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL				
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE				
PENNEX	80MG;20MG	A089449	001	Nov 27, 1987
FOAMICON				
NOVARTIS	80MG;20MG	A072687	001	Jun 28, 1989

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL				
AMANTADINE HYDROCHLORIDE				
WATSON LABS	100MG	A071382	001	Jan 21, 1987
SYMADINE				
SOLVAY	100MG	A071000	001	Sep 04, 1986
SYMMETREL				
ENDO PHARMS	100MG	N016020	001	
SYRUP; ORAL				
AMANTADINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	50MG/5ML	A072655	001	Oct 30, 1990
TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
SYMMETREL				
ENDO PHARMS	50MG/5ML	N016023	002	
TABLET; ORAL				
SYMMETREL				
ENDO PHARMS	100MG	N018101	001	

AMCINONIDE

CREAM; TOPICAL				
CYCLOCORT				
ASTELLAS	0.025%	N018116	001	
	0.1%	N018116	002	
LOTION; TOPICAL				
CYCLOCORT				
ASTELLAS	0.1%	N019729	001	Jun 13, 1988
OINTMENT; TOPICAL				
CYCLOCORT				
ASTELLAS	0.1%	N018498	001	

AMDINOCILLIN

INJECTABLE; INJECTION				
COACTIN				
ROCHE	250MG/VIAL	N050565	001	Dec 21, 1984
	500MG/VIAL	N050565	002	Dec 21, 1984
	1GM/VIAL	N050565	003	Dec 21, 1984

AMIFOSTINE

INJECTABLE; INJECTION				
ETHYOL				
MEDIMMUNE	375MG/VIAL	N020221	002	Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE; INJECTION				
AMIKACIN SULFATE				
ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
ASTRAZENECA	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
BAXTER HLTHCARE	EQ 50MG BASE/ML	A063274	001	May 18, 1992
	EQ 250MG BASE/ML	A063275	001	May 18, 1992
HOSPIRA	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 13 (of 331)

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

HOSPIRA

EQ 62.5MG BASE/ML

A063283 001 Oct 31, 1994

EQ 250MG BASE/ML

A063350 002 Jul 30, 1993

EQ 250MG BASE/ML

A064098 001 Jun 26, 1995

EQ 250MG BASE/ML

A064099 001 Jun 20, 1995

TEVA PARENTERAL

EQ 50MG BASE/ML

A064045 001 Sep 28, 1993

AMIKIN

APOTHECON

EQ 50MG BASE/ML

A062311 001

EQ 50MG BASE/ML

A062562 001 Sep 20, 1984

EQ 50MG BASE/ML

N050495 001

EQ 250MG BASE/ML

A062311 002

EQ 250MG BASE/ML

A062562 002 Sep 20, 1984

EQ 250MG BASE/ML

N050495 002

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

APOTHECON

EQ 5MG BASE/ML

N050618 002 Nov 30, 1987

EQ 10MG BASE/ML

N050618 001 Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SANDOZ

EQ 5MG ANHYDROUS;50MG

A073357 001 Nov 27, 1991

TEVA

EQ 5MG ANHYDROUS;50MG

A070795 001 Apr 17, 1988

WATSON LABS

EQ 5MG ANHYDROUS;50MG

A073334 001 Jul 19, 1991

HYDRO-RIDE

PAR PHARM

EQ 5MG ANHYDROUS;50MG

A070347 001 Dec 25, 1990

MODURETIC 5-50

MERCK

EQ 5MG ANHYDROUS;50MG

N018201 001

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA

5.2% (5.2GM/100ML)

N018901 001 Apr 06, 1984

AMINOSYN 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N018804 001 May 15, 1984

3.5% (3.5GM/100ML)

N018875 001 Aug 08, 1984

AMINOSYN II 3.5%

HOSPIRA

3.5% (3.5GM/100ML)

N019438 001 Apr 03, 1986

AMINOSYN II 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N019491 001 Oct 10, 1986

AMINOSYN II 5%

HOSPIRA

5% (5GM/100ML)

N019438 002 Apr 03, 1986

AMINOSYN-HBC 7% IN PLASTIC CONTAINER

ABBOTT

7% (7GM/100ML)

N019400 001 Jul 23, 1986

BRANCHAMIN 4%

BAXTER HLTHCARE

4% (4GM/100ML)

N018678 001 Sep 28, 1984

FREAMINE 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 001

FREAMINE II 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 002

NEOPHAM 6.4%

HOSPIRA

6.4% (6.4GM/100ML)

N018792 001 Jan 17, 1984

NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE

15% (15GM/100ML)

N020107 001 Feb 05, 1993

NOVAMINE 8.5%

HOSPIRA

8.5% (8.5GM/100ML)

N017957 002 Aug 09, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT

3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML N019714 001 Sep 12, 1988
;22.4MG/100ML;261MG/100ML;205MG/100ML

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 14 (of 331)

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;
POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714 002	Sep 12, 1988	
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714 004	Sep 12, 1988	
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019714 003	Sep 12, 1988	
HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019683 004	Nov 07, 1988	

AMINO ACIDS; DEXTROSEINJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019118 001	Oct 11, 1984	
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019120 001	Oct 11, 1984	
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019119 001	Oct 11, 1984	
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019505 002	Nov 07, 1986	
	3.5%;25GM/100ML	N019713 006	Sep 09, 1988	
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019506 001	Nov 07, 1986	
	3.5%;5GM/100ML	N019713 002	Sep 09, 1988	
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML	N019713 001	Sep 09, 1988	
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
ABBOTT	4.25%;20GM/100ML	N019713 004	Sep 09, 1988	
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019504 002	Nov 07, 1986	
	4.25%;25GM/100ML	N019713 005	Sep 09, 1988	
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	5%;25GM/100ML	N019565 001	Dec 17, 1986	
	5%;25GM/100ML	N019713 003	Sep 09, 1988	
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;10GM/100ML	N019520 002	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;15GM/100ML	N019520 003	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;20GM/100ML	N019520 004	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML	N019520 005	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML	N019520 001	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML	N019520 007	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;15GM/100ML	N019520 008	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML	N019520 009	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML	N019520 010	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML	N019520 006	Sep 23, 1988	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 15 (of 331)

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712	002	Sep 08, 1988
HOSPIRA				
	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682	003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATEINJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019712	001	Sep 08, 1988
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	003	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	002	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	003	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	004	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	005	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	001	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	007	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	008	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	009	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	010	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	006	Oct 23, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 16 (of 331)

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT

3.5%;21MG/100ML;40MG/100ML;128MG/100ML; N018804 002 May 15, 1984
234MG/100ML3.5%;21MG/100ML;40MG/100ML;128MG/100ML; N018875 002 Aug 08, 1984
234MG/100MLAMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA

3.5%;21MG/100ML;128MG/100ML;234MG/100ML N017789 005

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT

3.5%;32MG/100ML;128MG/100ML;222MG/100ML N019493 001 Oct 16, 1986
;49MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

HOSPIRA

8%;61MG/100ML;211MG/100ML;56MG/100ML;38 N017957 001
8MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 7% W/ ELECTROLYTES

HOSPIRA

7%;102MG/100ML;45MG/100ML;522MG/100ML;4 N019437 006 Apr 03, 1986
10MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

HOSPIRA

3.5%;30MG/100ML;97MG/100ML;120MG/100ML; N019437 007 Apr 03, 1986
49MG/100MLAMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

XANODYNE PHARM

250MG/ML

N015229 002

AMINOCAPROIC ACID

ABRAXIS PHARM

250MG/ML

A070522 001 Jun 17, 1986

BAXTER HLTHCARE

250MG/ML

N018590 001 Oct 29, 1982

HOSPIRA

250MG/ML

A070888 001 Jun 16, 1988

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS

250MG

N018202 001

AMINOPHYLLINE

ENEMA; RECTAL

SOMOPHYLLIN

FISONS

300MG/5ML

N018232 001 Apr 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC

25MG/ML

A087243 001 May 24, 1982

25MG/ML

A087621 001 May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM

25MG/ML

A084568 001

25MG/ML

A087200 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 17 (of 331)

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

ABRAXIS PHARM

25MG/ML

A087250 001

Jan 06, 1982

25MG/ML

A087431 001

25MG/ML

A087886 001

Aug 30, 1983

25MG/ML

A088407 001

Jan 25, 1984

ELKINS SINN

25MG/ML

A087239 001

HOSPIRA

25MG/ML

A087601 001

Jul 23, 1982

INTL MEDICATION

25MG/ML

A087867 001

Nov 10, 1983

25MG/ML

A087868 001

Nov 10, 1983

KING PHARMS

25MG/ML

A086606 001

LUITPOLD

25MG/ML

A087240 001

PHARMA SERVE NY

25MG/ML

A087387 001

Jun 03, 1983

SMITH AND NEPHEW

25MG/ML

A088429 001

May 30, 1985

25MG/ML

A088749 001

May 30, 1985

AMINOPHYLLINE IN SODIUM

CHLORIDE 0.45%

HOSPIRA

100MG/100ML

A088147 002

May 03, 1983

200MG/100ML

A088147 003

May 03, 1983

AMINOPHYLLINE IN SODIUM

CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA

100MG/100ML

N018924 001

Dec 12, 1984

200MG/100ML

N018924 002

Dec 12, 1984

400MG/100ML

N018924 003

Dec 12, 1984

500MG/100ML

N018924 004

Dec 12, 1984

SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE

105MG/5ML

A088156 001

Dec 05, 1983

ROXANE

105MG/5ML

A088126 001

Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC

105MG/5ML

A087727 001

Apr 16, 1982

SOMOPHYLLIN

FISONS

105MG/5ML

A086466 001

SOMOPHYLLIN-DF

FISONS

105MG/5ML

A087045 001

SUPPOSITORY; RECTAL

TRUPHYLLINE

G AND W LABS

250MG

A085498 001

Mar 23, 1983

500MG

A085498 002

Jan 03, 1983

TABLET; ORAL

AMINOPHYLLIN

GD SEARLE LLC

100MG

N002386 002

200MG

N002386 003

AMINOPHYLLINE

ASCOT

100MG

A087522 001

Feb 12, 1982

200MG

A087523 001

Feb 12, 1982

BARR

100MG

A088297 001

Aug 19, 1983

200MG

A088298 001

Aug 19, 1983

DURAMED PHARMS BARR

100MG

A088182 001

Mar 31, 1983

200MG

A088183 001

Mar 31, 1983

HALSEY

100MG

A084674 001

IMPAX LABS

100MG

A084574 001

200MG

A084576 001

KV PHARM

100MG

A085284 001

200MG

A085289 001

LANNETT

100MG

A084588 001

200MG

A084588 002

PAL PAK

100MG

A084533 001

PANRAY

100MG

A084552 001

200MG

A084552 002

PUREPAC PHARM

100MG

A084699 001

200MG

A085333 001

ROXANE

100MG

A087500 001

Feb 09, 1982

200MG

A087501 001

Feb 09, 1982

SANDOZ

100MG

A085261 003

100MG

A085262 002

DISCONTINUED DRUG PRODUCT LIST

6 - 18 (of 331)

AMINOPHYLLINE

TABLET; ORAL				
AMINOPHYLLINE				
SANDOZ	200MG	A085261	002	
VALEANT PHARM INTL	200MG	A084563	001	
VANGARD	100MG	A088314	001	Oct 03, 1983
	200MG	A088319	001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409	001	
	200MG	A085410	001	
WATSON LABS	100MG	A085567	001	
	200MG	A085564	001	
TABLET, DELAYED RELEASE; ORAL				
AMINOPHYLLINE				
IMPAX LABS	100MG	A084577	001	
	200MG	A084575	001	
TABLICAPS	100MG	A084632	002	
VALE	100MG	A084531	001	
	200MG	A084530	001	
TABLET, EXTENDED RELEASE; ORAL				
PHYLLLOCONTIN				
PHARM RES ASSOC	225MG	A086760	001	

AMINOSALICYLATE SODIUM

POWDER; ORAL				
P.A.S. SODIUM				
CENTURY PHARMS	4GM/PACKET	A080947	001	
SODIUM AMINOSALICYLATE				
HEXCEL	100%	A080097	001	
TABLET; ORAL				
PARASAL SODIUM				
PANRAY	500MG	N006811	006	
	1GM	N006811	011	
SODIUM P.A.S.				
LANNETT	500MG	A080138	002	
TEEBACIN				
CONSOLIDATED MIDLAND	500MG	N007320	002	

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL				
NEOPASALATE				
MEDPOINTE PHARM HLC	846MG;112MG	A080059	002	

AMINOSALICYLIC ACID

TABLET; ORAL				
PARASAL				
PANRAY	500MG	N006811	001	
	1GM	N006811	002	

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL				
REZIPAS				
BRISTOL MYERS SQUIBB	EQ 500MG BASE/GM	N009052	001	

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION				
AMIODARONE HYDROCHLORIDE				
BEN VENUE	50MG/ML	A076088	001	Oct 15, 2002
HOSPIRA	50MG/ML	A076108	001	Oct 15, 2002
INTL MEDICATION SYS	50MG/ML	N021594	001	Feb 04, 2004
CORDARONE				
WYETH PHARMS INC	50MG/ML	N020377	001	Aug 03, 1995
TABLET; ORAL				
AMIODARONE HYDROCHLORIDE				
TEVA	200MG	A074895	001	Apr 16, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 19 (of 331)

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE

40MG/ML

A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A085594 001

ELAVIL

ASTRAZENECA

10MG/ML

N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB

10MG

A086454 001

25MG

A086454 002

50MG

A086454 003

75MG

A086454 004

100MG

A086454 005

AMITRIL

WARNER CHILCOTT

10MG

A083939 001

25MG

A083937 001

50MG

A083938 002

75MG

A084957 001

100MG

A085093 001

150MG

A086295 001

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP

25MG

A088672 001 Nov 20, 1984

50MG

A088673 001 Nov 20, 1984

75MG

A088674 001 Nov 20, 1984

100MG

A088675 001 Nov 20, 1984

COPLEY PHARM

10MG

A088421 001 Apr 30, 1984

25MG

A088422 001 Apr 30, 1984

50MG

A088423 001 Apr 30, 1984

75MG

A088424 001 Apr 30, 1984

100MG

A088425 001 Apr 30, 1984

150MG

A088426 001 Apr 30, 1984

HALSEY

10MG

A085923 001

25MG

A085922 001

50MG

A085925 001

50MG

A087557 001 Mar 05, 1982

75MG

A085926 001 May 20, 1983

100MG

A085927 001 May 20, 1983

LEDERLE

10MG

A086744 001

10MG

A087366 001 Jan 04, 1982

25MG

A086746 001

25MG

A087367 001 May 03, 1982

50MG

A086743 001

50MG

A087181 001 Jan 04, 1982

75MG

A086745 001

75MG

A087369 001 Jan 04, 1982

100MG

A086747 001

100MG

A087368 001 May 03, 1982

150MG

A087370 001 Jan 04, 1982

MUTUAL PHARM

10MG

A085744 001

25MG

A085627 001

50MG

A085745 001

75MG

A085743 001

100MG

A085742 002 May 11, 1982

150MG

A089423 001 Feb 17, 1987

PAR PHARM

10MG

A088697 001 Sep 25, 1984

25MG

A088698 001 Sep 25, 1984

50MG

A088699 001 Sep 25, 1984

75MG

A088700 001 Sep 25, 1984

100MG

A088701 001 Sep 25, 1984

150MG

A088702 001 Sep 25, 1984

PLIVA

10MG

A088883 001 Sep 26, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 20 (of 331)

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

PLIVA	25MG	A088884	001	Sep 26, 1984	
	50MG	A088885	001	Sep 26, 1984	
	75MG	A088886	001	Sep 26, 1984	
	100MG	A088887	001	Sep 26, 1984	
	150MG	A088888	001	Sep 26, 1984	
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983	
	10MG	A088084	001	Jul 18, 1983	
	25MG	A088076	001	May 20, 1983	
	25MG	A088085	001	Jul 18, 1983	
	50MG	A088077	001	Sep 16, 1983	
	50MG	A088105	001	Jul 18, 1983	
	75MG	A088078	001	Sep 16, 1983	
	75MG	A088106	001	Jul 18, 1983	
	100MG	A088079	001	Sep 16, 1983	
	100MG	A088107	001	Jul 18, 1983	
ROXANE	10MG	A086002	001		
	10MG	A086144	001		
	25MG	A085944	001		
	25MG	A086145	001		
	50MG	A085945	001		
	50MG	A086143	001		
	75MG	A086004	001		
	75MG	A086147	001		
	100MG	A086003	001		
	100MG	A086146	001		
	150MG	A086090	001		
	150MG	A086148	001		
	SUPERPHARM	10MG	A088853	001	Nov 13, 1984
25MG		A088854	001	Nov 13, 1984	
50MG		A088855	001	Nov 13, 1984	
75MG		A088856	001	Nov 13, 1984	
100MG		A088857	001	Nov 13, 1984	
TEVA	10MG	A084910	003		
	10MG	A086610	001		
	25MG	A085031	001		
	25MG	A086859	001		
	50MG	A085032	001		
	50MG	A086857	001		
	75MG	A085030	001		
	75MG	A086860	001		
	100MG	A085836	001		
	100MG	A086854	001		
	150MG	A086853	001		
	UCB INC	10MG	A085864	001	
		25MG	A085935	001	
50MG		A085936	001		
75MG		A086337	001		
100MG		A086336	001		
150MG		A086335	001		
USL PHARMA	25MG	A087775	001	Feb 10, 1982	
VANGARD	10MG	A087632	001	Feb 01, 1982	
	50MG	A087616	001	Feb 08, 1982	
	75MG	A087617	001	Feb 05, 1982	
	100MG	A087639	001	Feb 08, 1982	
WATSON LABS	10MG	A085816	001		
	10MG	A088620	001	Mar 02, 1984	
	25MG	A085817	001		
	25MG	A088621	001	Mar 02, 1984	
	50MG	A085815	001		
	50MG	A088622	001	Mar 02, 1984	
	75MG	A085819	001		

DISCONTINUED DRUG PRODUCT LIST

6 - 21 (of 331)

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS	75MG	A088633	001	Mar 02, 1984
	100MG	A085820	001	
	100MG	A088634	001	Mar 02, 1984
	150MG	A085821	001	
	150MG	A088635	001	Mar 02, 1984
WEST WARD	10MG	A087647	001	Mar 05, 1982
	25MG	A087278	001	
<u>ELAVIL</u>				
ASTRAZENECA	10MG	N012703	001	
	25MG	N012703	003	
	50MG	N012703	004	
	75MG	N012703	005	
	100MG	N012703	006	
	150MG	N012703	007	
<u>ENDEP</u>				
ROCHE	10MG	A083639	001	
	25MG	A083639	002	
	50MG	A083639	003	
	75MG	A083639	004	
	100MG	A083639	005	
	150MG	A085303	001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MUTUAL PHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277	001	May 09, 1988
	EQ 25MG BASE;10MG	A072278	001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477	001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478	001	Jan 12, 1988
WATSON LABS	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053	001	Dec 16, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10

SCHERING	10MG;2MG	N014713	007	

ETRAFON 2-25

SCHERING	25MG;2MG	N014713	004	

ETRAFON-A

SCHERING	10MG;4MG	N014713	002	

ETRAFON-FORTE

SCHERING	25MG;4MG	N014713	006	

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	10MG;2MG	A070935	001	Sep 11, 1986
	10MG;4MG	A070937	001	Sep 11, 1986
	25MG;2MG	A070936	001	Sep 11, 1986
	25MG;4MG	A070938	001	Sep 11, 1986
	50MG;4MG	A070939	001	Sep 12, 1986
MUTUAL PHARM	10MG;2MG	A071077	001	Nov 12, 1986
	10MG;4MG	A071078	001	Nov 12, 1986
	25MG;2MG	A070297	001	Nov 12, 1986
	25MG;4MG	A071079	001	Nov 12, 1986
	10MG;2MG	A070565	001	Sep 11, 1986
PAR PHARM	10MG;4MG	A070620	001	Sep 11, 1986
	25MG;2MG	A070621	001	Sep 11, 1986
	25MG;4MG	A070595	001	Sep 11, 1986
	50MG;4MG	A070574	001	Sep 11, 1986
	10MG;2MG	A071062	001	Nov 27, 1987
SANDOZ	10MG;4MG	A071862	001	Dec 21, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 22 (of 331)

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

SANDOZ	25MG;2MG	A071063	001	Nov 27, 1987
	25MG;4MG	A071064	001	Nov 27, 1987
WATSON LABS	50MG;4MG	A071863	001	Dec 21, 1987
	10MG;2MG	A070373	001	Aug 25, 1986
	10MG;2MG	A072539	001	Feb 15, 1989
	10MG;2MG	A073007	001	Oct 17, 1991
	10MG;4MG	A070375	001	Aug 25, 1986
	10MG;4MG	A072540	001	Feb 15, 1989
	10MG;4MG	A073009	001	Oct 17, 1991
	25MG;2MG	A070374	001	Aug 25, 1986
	25MG;2MG	A072541	001	Feb 15, 1989
	25MG;2MG	A073008	001	Oct 17, 1991
	25MG;4MG	A070376	001	Aug 25, 1986
	25MG;4MG	A072134	001	Feb 15, 1989
	25MG;4MG	A073010	001	Oct 17, 1991
	50MG;4MG	A070377	001	Nov 04, 1986
	50MG;4MG	A071558	001	Mar 02, 1987
	50MG;4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10 NEW RIVER	10MG;2MG	N014715	004	
TRIAVIL 2-25 NEW RIVER	25MG;2MG	N014715	002	
TRIAVIL 4-10 NEW RIVER	10MG;4MG	N014715	003	
TRIAVIL 4-25 NEW RIVER	25MG;4MG	N014715	005	
TRIAVIL 4-50 NEW RIVER	50MG;4MG	N014715	006	

AMLEXANOX

PATCH; TOPICAL

AMLEXANOX

ULURU	2MG	N021727	001	Sep 29, 2004

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

GENPHARM	EQ 2.5MG BASE	A077362	001	Jul 09, 2007
	EQ 5MG BASE	A077362	002	Jul 09, 2007
	EQ 10MG BASE	A077362	003	Jul 09, 2007
MUTUAL PHARMA	EQ 2.5MG BASE	A078081	001	Jan 31, 2008
	EQ 5MG BASE	A078081	002	Jan 31, 2008
	EQ 10MG BASE	A078081	003	Jan 31, 2008
SYNTHON PHARMS	EQ 2.5MG BASE	A077080	001	Jun 27, 2007
	EQ 5MG BASE	A077080	002	Jun 27, 2007
	EQ 10MG BASE	A077080	003	Jun 27, 2007
TABLET, ORALLY DISINTEGRATING; ORAL				
AMLODIPINE BESYLATE				
SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007
	EQ 5MG BASE	N022026	002	Sep 27, 2007
	EQ 10MG BASE	N022026	003	Sep 27, 2007

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC	2.5MG	N021435	001	Oct 31, 2003
	5MG	N021435	002	Oct 31, 2003
	10MG	N021435	003	Oct 31, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 23 (of 331)

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT 5MEQ/ML
 GD SEARLE LLC 3MEQ/ML
 AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE
 MCGAW 900MG/100ML
 AMMONIUM CHLORIDE 2.14%
 B BRAUN 40MEQ/100ML

A083130 001
 A086205 001
 N006580 001
 A085734 001

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS EQ 200MG BASE

N006441 001

AMOXAPINE

TABLET; ORAL

AMOXAPINE

SANDOZ 25MG
 50MG
 100MG
 150MG
 WATSON LABS 25MG
 50MG
 100MG
 150MG

A072943 001 Jun 28, 1991
 A072944 001 Jun 28, 1991
 A072878 001 Jun 28, 1991
 A072879 001 Jun 28, 1991
 A072418 001 May 11, 1989
 A072419 001 May 11, 1989
 A072420 001 May 11, 1989
 A072421 001 May 11, 1989

ASENDIN

LEDERLE

25MG
 50MG
 100MG
 150MG

N018021 001
 N018021 002
 N018021 003
 N018021 004

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AM ANTIBIOTICS 250MG
 500MG
 LABS ATRAL 250MG
 500MG
 MYLAN 250MG
 500MG
 TEVA 250MG
 250MG
 500MG
 500MG

A062058 001
 A062058 002
 A062528 001 Aug 07, 1985
 A062528 002 Aug 07, 1985
 A062067 001
 A062067 002
 A062853 001 Dec 22, 1987
 A063030 001 Feb 28, 1989
 A062854 001 Dec 22, 1987
 A063031 001 Feb 28, 1989

AMOXIL

GLAXOSMITHKLINE

250MG
 250MG
 250MG
 500MG
 500MG

A062216 001
 A062216 003
 N050459 001
 A062216 004
 N050459 002

TRIMOX

APOTHECON

250MG
 250MG
 250MG
 250MG
 500MG
 500MG
 500MG
 500MG

A061885 001
 A062098 001
 A062152 001
 A063099 001 Mar 20, 1992
 A061885 002
 A062098 002
 A062152 002
 A063099 002 Mar 20, 1992

UTIMOX

PARKE DAVIS

250MG
 500MG

A062107 001
 A062107 002

DISCONTINUED DRUG PRODUCT LIST

6 - 24 (of 331)

AMOXICILLIN

CAPSULE; ORAL
WYMOX

WYETH AYERST	250MG	A062120	001	
	500MG	A062120	002	

FOR SUSPENSION; ORAL
AMOXICILLIN

AM ANTIBIOTICS	125MG/5ML	A062059	001	
	250MG/5ML	A062059	002	
MYLAN	125MG/5ML	A062090	001	
	250MG/5ML	A062090	002	
TEVA	125MG/5ML	A062946	001	Nov 01, 1988
	250MG/5ML	A063001	001	Jan 06, 1989

AMOXIL

GLAXOSMITHKLINE	50MG/ML	A062226	005	
	50MG/ML	N050460	005	
	125MG/5ML	A062226	001	
	125MG/5ML	N050460	001	
	200MG/5ML	N050760	001	Apr 15, 1999
	250MG/5ML	A062226	002	
	250MG/5ML	N050460	002	
	400MG/5ML	N050760	002	Apr 15, 1999

LAROTID

GLAXOSMITHKLINE	50MG/ML	N050460	006	

POLYMOX

APOTHECON	125MG/5ML	A061851	001	
	125MG/5ML	A062323	001	
	250MG/5ML	A061851	002	
	250MG/5ML	A062323	002	

TRIMOX

APOTHECON	50MG/ML	A061886	001	
	125MG/5ML	A061886	002	
	125MG/5ML	A062099	001	
	125MG/5ML	A062154	001	
	125MG/5ML	A062885	001	Mar 08, 1988
	250MG/5ML	A061886	003	
	250MG/5ML	A062099	002	
	250MG/5ML	A062154	002	
	250MG/5ML	A062885	002	Mar 08, 1988

UTIMOX

PARKE DAVIS	125MG/5ML	A062127	001	
	250MG/5ML	A062127	002	

WYMOX

WYETH AYERST	125MG/5ML	A062131	001	
	250MG/5ML	A062131	002	

TABLET; ORAL

AMOXIL

GLAXOSMITHKLINE	500MG	N050754	002	Jul 10, 1998
	875MG	N050754	001	Jul 10, 1998

TABLET, CHEWABLE; ORAL

AMOXICILLIN

APOTHECON	125MG	A064131	001	May 06, 1996
	250MG	A064131	002	May 06, 1996
TEVA	125MG	A064031	001	Dec 19, 1996
	250MG	A064031	002	Dec 19, 1996

AMOXIL

GLAXOSMITHKLINE	125MG	N050542	002	
	200MG	N050761	001	Apr 15, 1999
	250MG	N050542	001	
	400MG	N050761	002	Apr 15, 1999

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 25 (of 331)

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '200'

GLAXOSMITHKLINE 200MG/5ML;EQ 28.5MG BASE/5ML N050725 001 May 31, 1996

AUGMENTIN '400'

GLAXOSMITHKLINE 400MG/5ML;EQ 57MG BASE/5ML N050725 002 May 31, 1996

AUGMENTIN ES-600

SMITHKLINE BEECHAM 600MG/5ML;EQ 42.9MG BASE/5ML N050755 001 Jun 22, 2001

TABLET, CHEWABLE; ORAL

AUGMENTIN '125'

GLAXOSMITHKLINE 125MG;EQ 31.25MG BASE N050597 001 Jul 22, 1985

AUGMENTIN '200'

GLAXOSMITHKLINE 200MG;EQ 28.5MG BASE N050726 001 May 31, 1996

AUGMENTIN '250'

GLAXOSMITHKLINE 250MG;EQ 62.5MG BASE N050597 002 Jul 22, 1985

AUGMENTIN '400'

GLAXOSMITHKLINE 400MG;EQ 57MG BASE N050726 002 May 31, 1996

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE;
DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCOBESE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG A083564 001

2.5MG;2.5MG;2.5MG;2.5MG A083564 002

3.75MG;3.75MG;3.75MG;3.75MG A083564 003

5MG;5MG;5MG;5MG A083564 004

TABLET; ORAL

DELCOBESE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG A083563 004

2.5MG;2.5MG;2.5MG;2.5MG A083563 003

3.75MG;3.75MG;3.75MG;3.75MG A083563 002

5MG;5MG;5MG;5MG A083563 001

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;
DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 10

TEVA WOMENS 2.5MG;2.5MG;2.5MG;2.5MG N011522 007 Feb 13, 1996

ADDERALL 12.5

TEVA WOMENS 3.125MG;3.125MG;3.125MG;3.125MG N011522 012 Aug 31, 2000

ADDERALL 15

TEVA WOMENS 3.75MG;3.75MG;3.75MG;3.75MG N011522 013 Aug 31, 2000

ADDERALL 20

TEVA WOMENS 5MG;5MG;5MG;5MG N011522 008 Feb 13, 1996

ADDERALL 30

TEVA WOMENS 7.5MG;7.5MG;7.5MG;7.5MG N011522 010 May 12, 1997

ADDERALL 5

TEVA WOMENS 1.25MG;1.25MG;1.25MG;1.25MG N011522 009 May 12, 1997

ADDERALL 7.5

TEVA WOMENS 1.875MG;1.875MG;1.875MG;1.875MG N011522 011 Aug 31, 2000

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

MUTUAL PHARM 1.25MG;1.25MG;1.25MG;1.25MG A040480 001 Sep 09, 2003

1.875MG;1.875MG;1.875MG;1.875MG A040480 002 Sep 09, 2003

2.5MG;2.5MG;2.5MG;2.5MG A040480 003 Sep 09, 2003

3.125MG;3.125MG;3.125MG;3.125MG A040480 004 Sep 09, 2003

3.75MG;3.75MG;3.75MG;3.75MG A040480 005 Sep 09, 2003

5MG;5MG;5MG;5MG A040480 006 Sep 09, 2003

7.5MG;7.5MG;7.5MG;7.5MG A040480 007 Sep 09, 2003

WATSON LABS 1.25MG;1.25MG;1.25MG;1.25MG A040456 001 May 06, 2003

2.5MG;2.5MG;2.5MG;2.5MG A040456 002 May 06, 2003

5MG;5MG;5MG;5MG A040456 003 May 06, 2003

7.5MG;7.5MG;7.5MG;7.5MG A040456 004 May 06, 2003

DISCONTINUED DRUG PRODUCT LIST

6 - 26 (of 331)

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5

UCB INC

EQ 6.25MG BASE;EQ 6.25MG BASE

N010093 007

BIPHETAMINE 20

UCB INC

EQ 10MG BASE;EQ 10MG BASE

N010093 003

BIPHETAMINE 7.5

UCB INC

EQ 3.75MG BASE;EQ 3.75MG BASE

N010093 009

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT

5MG

A083901 001

Aug 31, 1984

10MG

A083901 002

Aug 31, 1984

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

APOTHECON

3%

N050314 001

INJECTABLE; INJECTION

AMPHOTERICIN B

ABBOTT

50MG/VIAL

A064141 001

Dec 23, 1996

ABRAXIS PHARM

50MG/VIAL

A062728 001

Apr 13, 1987

LOTION; TOPICAL

FUNGIZONE

APOTHECON

3%

A060570 001

OINTMENT; TOPICAL

FUNGIZONE

APOTHECON

3%

N050313 001

SUSPENSION; ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB

100MG/ML

N050341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

APOTHECON

EQ 125MG BASE/VIAL

A062860 001

Feb 05, 1988

EQ 250MG BASE/VIAL

A062860 002

Feb 05, 1988

EQ 500MG BASE/VIAL

A062860 003

Feb 05, 1988

EQ 1GM BASE/VIAL

A062860 004

Feb 05, 1988

EQ 2GM BASE/VIAL

A062860 005

Feb 05, 1988

BAXTER HLTHCARE

EQ 125MG BASE/VIAL

A062692 001

Jun 24, 1986

EQ 250MG BASE/VIAL

A062692 002

Jun 24, 1986

EQ 500MG BASE/VIAL

A062692 003

Jun 24, 1986

EQ 1GM BASE/VIAL

A062692 004

Jun 24, 1986

EQ 2GM BASE/VIAL

A062692 005

Jun 24, 1986

EQ 10GM BASE/VIAL

A062692 006

Jun 24, 1986

CONSOLIDATED PHARM

EQ 125MG BASE/VIAL

A061936 005

EQ 250MG BASE/VIAL

A061936 001

EQ 500MG BASE/VIAL

A061936 002

EQ 1GM BASE/VIAL

A061936 003

EQ 2GM BASE/VIAL

A061936 004

HANFORD GC

EQ 125MG BASE/VIAL

A063143 001

Apr 15, 1993

EQ 500MG BASE/VIAL

A063147 001

Apr 15, 1993

EQ 1GM BASE/VIAL

A063139 001

Apr 15, 1993

EQ 2GM BASE/VIAL

A063141 001

Apr 15, 1993

INTL MEDICATION

EQ 1GM BASE/VIAL

A062634 002

Jan 09, 1987

EQ 2GM BASE/VIAL

A062634 003

Jan 09, 1987

LILLY

EQ 500MG BASE/VIAL

A062565 001

Apr 04, 1985

EQ 1GM BASE/VIAL

A062565 002

Apr 04, 1985

EQ 2GM BASE/VIAL

A062565 003

Jun 24, 1986

MARSAM PHARMS LLC

EQ 125MG BASE/VIAL

A062816 001

Oct 24, 1988

EQ 250MG BASE/VIAL

A062816 002

Oct 24, 1988

EQ 500MG BASE/VIAL

A062816 003

Oct 24, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 27 (of 331)

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

MARSAM PHARMS LLC

EQ 1GM BASE/VIAL

A062816 004

Oct 24, 1988

EQ 2GM BASE/VIAL

A062816 005

Oct 24, 1988

EQ 10GM BASE/VIAL

A062994 001

Sep 15, 1988

OMNIPEN-N

WYETH AYERST

EQ 125MG BASE/VIAL

A060626 001

EQ 125MG BASE/VIAL

A062718 001

Dec 16, 1986

EQ 250MG BASE/VIAL

A060626 002

EQ 250MG BASE/VIAL

A062718 002

Dec 16, 1986

EQ 500MG BASE/VIAL

A060626 003

EQ 500MG BASE/VIAL

A062718 003

Dec 16, 1986

EQ 1GM BASE/VIAL

A060626 004

EQ 1GM BASE/VIAL

A062718 004

Dec 16, 1986

EQ 2GM BASE/VIAL

A060626 005

EQ 2GM BASE/VIAL

A062718 005

Dec 16, 1986

PENBRITIN-S

WYETH AYERST

EQ 125MG BASE/VIAL

N050072 001

EQ 250MG BASE/VIAL

N050072 002

EQ 500MG BASE/VIAL

N050072 003

EQ 1GM BASE/VIAL

N050072 004

EQ 2GM BASE/VIAL

N050072 005

EQ 4GM BASE/VIAL

N050072 006

POLYCILLIN-N

BRISTOL

EQ 125MG BASE/VIAL

N050309 001

EQ 250MG BASE/VIAL

N050309 002

EQ 500MG BASE/VIAL

N050309 003

EQ 1GM BASE/VIAL

N050309 004

EQ 2GM BASE/VIAL

N050309 005

TOTACILLIN-N

GLAXOSMITHKLINE

EQ 125MG BASE/VIAL

A060677 001

EQ 250MG BASE/VIAL

A060677 002

EQ 500MG BASE/VIAL

A060677 003

EQ 1GM BASE/VIAL

A060677 004

EQ 1GM BASE/VIAL

A062727 001

Dec 19, 1986

EQ 2GM BASE/VIAL

A060677 005

EQ 2GM BASE/VIAL

A062727 002

Dec 19, 1986

EQ 10GM BASE/VIAL

A060677 006

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

PFIZER

EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL

N050608 003

Dec 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS

EQ 250MG BASE

A062041 001

EQ 500MG BASE

A062041 002

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 250MG BASE

A061602 001

EQ 500MG BASE

A061602 002

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A060765 001

EQ 500MG BASE

A060765 002

LEDERLE

EQ 250MG BASE

A062208 001

EQ 500MG BASE

A062208 002

MYLAN

EQ 250MG BASE

A061755 001

EQ 500MG BASE

A061755 002

PUREPAC PHARM

EQ 250MG BASE

A061853 001

EQ 500MG BASE

A061853 002

TEVA

EQ 250MG BASE

A061502 001

EQ 500MG BASE

A061502 002

VITARINE

EQ 250MG BASE

A061387 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 28 (of 331)

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

VITARINE

EQ 500MG BASE

A061387 003

OMNIPEN (AMPICILLIN)

WYETH AYERST

250MG

A060624 001

500MG

A060624 002

PENBRITIN

WYETH AYERST

EQ 250MG BASE

A060908 001

EQ 500MG BASE

A060908 002

PFIZERPEN-A

PFIZER

EQ 250MG BASE

A062050 001

EQ 500MG BASE

A062050 002

POLYCILLIN

BRISTOL

EQ 250MG BASE

N050310 001

EQ 500MG BASE

N050310 002

PRINCIPEN

APOTHECON

EQ 250MG BASE

A062888 001

EQ 500MG BASE

A062888 002

BRISTOL MYERS SQUIBB

EQ 250MG BASE

A061392 001

EQ 500MG BASE

A061392 002

PRINCIPEN '250'

APOTHECON

EQ 250MG BASE

A062157 002

EQ 250MG BASE

N050056 001

PRINCIPEN '500'

APOTHECON

EQ 500MG BASE

A062157 001

EQ 500MG BASE

N050056 002

TOTACILLIN

GLAXOSMITHKLINE

EQ 250MG BASE

A060060 001

EQ 250MG BASE

A062212 001

EQ 500MG BASE

A060060 002

EQ 500MG BASE

A062212 002

FOR SUSPENSION; ORAL

AMCILL

PARKE DAVIS

EQ 125MG BASE/5ML

A062030 001

EQ 250MG BASE/5ML

A062030 002

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 125MG BASE/5ML

A061601 001

EQ 250MG BASE/5ML

A061601 002

MYLAN

EQ 125MG BASE/5ML

A061829 002

EQ 250MG BASE/5ML

A061829 001

PUREPAC PHARM

EQ 125MG BASE/5ML

A061980 001

EQ 250MG BASE/5ML

A061980 002

TEVA

EQ 125MG BASE/5ML

A061370 001

EQ 250MG BASE/5ML

A061370 002

OMNIPEN (AMPICILLIN)

WYETH AYERST

100MG/ML

A060625 001

125MG/5ML

A060625 002

250MG/5ML

A060625 003

500MG/5ML

A060625 004

PENBRITIN

WYETH AYERST

EQ 100MG BASE/ML

N050019 001

EQ 125MG BASE/5ML

N050019 002

EQ 250MG BASE/5ML

N050019 003

PFIZERPEN-A

PFIZER

EQ 125MG BASE/5ML

A062049 001

EQ 250MG BASE/5ML

A062049 002

POLYCILLIN

APOTHECON

EQ 125MG BASE/5ML

A062297 001

EQ 250MG BASE/5ML

A062297 002

BRISTOL

EQ 100MG BASE/ML

N050308 004

EQ 125MG BASE/5ML

N050308 001

EQ 250MG BASE/5ML

N050308 002

EQ 500MG BASE/5ML

N050308 003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 29 (of 331)

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

PRINCIPEN

APOTHECON

EQ 100MG BASE/ML

A061394 001

EQ 250MG BASE/5ML

A061394 003

PRINCIPEN '125'

APOTHECON

EQ 125MG BASE/5ML

A060127 002

EQ 125MG BASE/5ML

A062151 001

PRINCIPEN '250'

APOTHECON

EQ 250MG BASE/5ML

A060127 001

EQ 250MG BASE/5ML

A062151 002

TOTACILLIN

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

A060666 001

EQ 125MG BASE/5ML

A062223 001

EQ 250MG BASE/5ML

A060666 002

EQ 250MG BASE/5ML

A062223 002

TABLET, CHEWABLE; ORAL

POLYCILLIN

BRISTOL

EQ 125MG BASE

N050093 001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL

PRINCIPEN W/ PROBENECID

APOTHECON

EQ 389MG BASE;111MG

A062150 001

EQ 389MG BASE;111MG

N050488 001

FOR SUSPENSION; ORAL

POLYCILLIN-PRB

APOTHECON

EQ 3.5GM BASE/BOT;1GM/BOT

A061898 001

BRISTOL

EQ 3.5GM BASE/BOT;1GM/BOT

N050457 001

PROBAMPACIN

TEVA

EQ 3.5GM BASE/BOT;1GM/BOT

A061741 001

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

GLAXOSMITHKLINE

50MG

N021007 001

Apr 15, 1999

150MG

N021007 002

Apr 15, 1999

SOLUTION; ORAL

AGENERASE

GLAXOSMITHKLINE

15MG/ML

N021039 001

Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

SHIRE

EQ 1MG BASE

N020333 002

Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

ROXANE

EQ 0.5MG BASE

A076489 001

Apr 18, 2005

EQ 1MG BASE

A076489 002

Apr 18, 2005

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE

MERCK

EQ 25MG BASE

N010585 002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK

25MG/ML

N010520 003

ANISINDIONE

TABLET; ORAL

MIRADON

SCHERING

50MG

N010909 003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 30 (of 331)

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS

50MG

A086046 001

VALPIN 50

ENDO PHARMS

50MG

N013428 001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

NOVARTIS

0.5%;0.05%

N018746 002 Jul 11, 1994

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

IPSEN BIOPHARM LTD

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

GENSIA AUTOMEDICS

0.05MG/ML

N020420 001 Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

PHARMACIA AND UPJOHN

5,000 UNITS/0.5ML

N020227 002 May 23, 1997

10,000 UNITS/0.5ML

N020227 001 May 23, 1997

ARIPIPIRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

OTSUKA

20MG

N021729 004 Jun 07, 2006

30MG

N021729 005 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

NUVIGIL

CEPHALON

100MG

N021875 002 Mar 26, 2009

200MG

N021875 005 Mar 26, 2009

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

BEROCCA PN

ROCHE

50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML; N006071 003 Oct 10, 1985

100

IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;

1.5MG/ML;1,650 IU/ML;5 IU/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N018440 002 Aug 08, 1985

0

IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/

ML;0.3MG/ML;330 UNITS/ML;1 IU/ML

M.V.I. -12

HOSPIRA

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N008809 004 Aug 08, 1985

0

IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/

ML;0.3MG/ML;330 UNITS/ML;1 IU/ML

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6-31 (of 331)

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

MVC PLUS

WATSON LABS

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N018439 002 Aug 08, 1985
0
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/
ML;0.3MG/ML;330 UNITS/ML;1 IU/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

HOSPIRA

20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N008809 005 Apr 22, 2004
0
IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M
L;0.6MG/ML;330 UNITS/ML;1 IU/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

ASTRAZENECA

100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15M N018933 002 Aug 08, 1985
G/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4
MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10
MG/VIAL

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA

N/A, 80MG/VIAL;N/A, 0.02MG/VIAL;N/A, 0.001 N020176 001 Dec 29, 1993
MG/VIAL;400
IU/10ML, N/A;N/A, 0.14MG/VIAL;N/A, 17MG/VI
AL;N/A, 5MG/VIAL;0.2MG/10ML, N/A;N/A, 1MG/
VIAL;N/A, 1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ
2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER

500MG

N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER

650MG

N016030 001

MEASURIN

BAYER

650MG

N016030 002

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS

650MG;50MG

A088305 001 Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

MUTUAL PHARM

325MG;50MG;40MG

A078149 001 Jun 13, 2007

WATSON LABS

325MG;50MG;40MG

A086231 002 Feb 12, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

HALSEY

325MG;50MG;40MG

A089448 001 Dec 01, 1986

IVAX PHARMS

325MG;50MG;40MG

A085441 002 Oct 31, 1984

PHARMERL

325MG;50MG;40MG

A087048 002 Dec 09, 1983

QUANTUM PHARMICS

325MG;50MG;40MG

A088972 001 Jun 18, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 32 (of 331)

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

SANDOZ 325MG;50MG;40MG

A086398 002 Apr 06, 1984

WATSON LABS 325MG;50MG;40MG

A086237 002 Mar 23, 1984

FIORINAL

WATSON PHARMS 325MG;50MG;40MG

N017534 003 Apr 16, 1986

LANORINAL

LANNETT 325MG;50MG;40MG

A086986 002 Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

ENDO PHARMS 325MG;50MG;40MG;30MG

A075351 001 Mar 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

SOLCO HLTHCARE 385MG;30MG;25MG

A075141 001 May 29, 1998

ORPHENGESIC FORTE

SOLCO HLTHCARE 770MG;60MG;50MG

A075141 002 May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA 389MG;32.4MG;65MG

A084553 002 Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM 389MG;32.4MG;32MG

N010996 006 Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM 389MG;32.4MG;65MG

N010996 007 Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS 389MG;32.4MG;65MG

A083077 002 Dec 07, 1984

SANDOZ 389MG;32.4MG;65MG

A080044 002 Sep 16, 1983

TEVA 389MG;32.4MG;65MG

A089025 001 Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ 389MG;32.4MG;65MG

A083101 002 Jun 24, 1985

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS 389MG;32.4MG;65MG

A085732 002 Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL COMPOUND

WATSON LABS 325MG;200MG

A088809 001 Oct 03, 1985

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA 500MG;5MG

A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT 500MG;5MG

A086333 001 Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

CARACO 325MG;200MG

N011702 003 Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ 325MG;200MG

A089127 001 Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM 325MG;200MG

A089126 001 Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC 325MG;200MG

A084978 001

Q-GESIC

QUANTUM PHARMICS 325MG;200MG

A088740 001 Jun 01, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 33 (of 331)

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS	325MG;400MG	A087211	001	Dec 22, 1982
MCNEIL	325MG;400MG	A089193	001	Feb 12, 1986
PAR PHARM	325MG;400MG	A089657	001	Nov 04, 1988
ROBAXISAL				
ROBINS AH	325MG;400MG	N012281	001	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY	325MG;4.5MG;0.38MG	A087464	001	Jul 01, 1982
OXYCODONE AND ASPIRIN				
MUTUAL PHARM	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998
	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982
OXYCODONE AND ASPIRIN (HALF-STRENGTH)				
ROXANE	325MG;2.25MG;0.19MG	A087742	001	Jun 04, 1982
PERCODAN				
ENDO PHARMS	325MG;4.5MG;0.38MG	N007337	006	
PERCODAN-DEMI				
ENDO PHARMS	325MG;2.25MG;0.19MG	N007337	005	
ROXIPRIN				
ROXANE	325MG;4.5MG;0.38MG	A087743	001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

SANOFI AVENTIS US	325MG;EQ 12.5MG BASE	N016891	001	

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	325MG,N/A;N/A,80MG	N021387	006	Jun 24, 2003

TABLET, TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG,N/A;N/A,20MG	N021387	001	Jun 24, 2003
	81MG,N/A;N/A,40MG	N021387	002	Jun 24, 2003
	81MG,N/A;N/A,80MG	N021387	003	Jun 24, 2003
	325MG,N/A;N/A,20MG	N021387	004	Jun 24, 2003
	325MG,N/A;N/A,40MG	N021387	005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM	325MG;65MG	N010996	005	

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016829	001	

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016863	001	

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

ASTRAZENECA	0.5MG/ML	N019058	001	Sep 13, 1989

TABLET; ORAL

ATENOLOL

ABLE	25MG	A076907	001	Jul 30, 2004
	50MG	A076907	002	Jul 30, 2004
	100MG	A076907	003	Jul 30, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 34 (of 331)

ATENOLOL

TABLET; ORAL

ATENOLOL

APOTHECON	50MG	A073317	001	Mar 20, 1992
	100MG	A073318	001	Mar 20, 1992
NOSTRUM LABS	50MG	A074127	001	Feb 21, 1995
	100MG	A074127	002	Feb 21, 1995
PLIVA	25MG	A074101	001	Jul 17, 1997
	50MG	A074101	002	Jul 17, 1997
	100MG	A074101	003	Jul 17, 1997
SANDOZ	25MG	A074265	001	Feb 28, 1994
	50MG	A074265	002	Feb 28, 1994
	100MG	A074265	003	Feb 28, 1994
SCS	50MG	A073676	001	Oct 30, 1992
	100MG	A073676	002	Oct 30, 1992
TEVA	50MG	A073315	001	May 28, 1993
	100MG	A073316	001	May 28, 1993
TEVA PHARMS	50MG	A074120	001	Feb 24, 1995
	100MG	A074120	002	Feb 24, 1995

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS	50MG; 25MG	A074404	001	May 14, 1998
	100MG; 25MG	A074404	002	May 14, 1998
PLIVA	50MG; 25MG	A074107	001	Sep 24, 1997
	100MG; 25MG	A074107	002	Sep 24, 1997

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY	5MG	N021411	001	Nov 26, 2002

ATOVAQUONE

TABLET; ORAL

MEPRON

GLAXOSMITHKLINE LLC	250MG	N020259	001	Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE	10MG/ML	A074824	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074753	001	Jan 23, 1997
HOSPIRA	10MG/ML	A074632	001	Dec 23, 1996
	10MG/ML	A074740	001	Mar 28, 1997
MARSAM PHARMS LLC	10MG/ML	A074945	001	Jul 28, 1998
TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997
ATRACURIUM BESYLATE PRESERVATIVE FREE				
BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
	10MG/ML	A074639	001	Mar 25, 1997
	10MG/ML	A074741	001	Mar 28, 1997
MARSAM PHARMS LLC	10MG/ML	A074944	001	Jul 28, 1998
TRACRIUM				
HOSPIRA	10MG/ML	N018831	002	Jun 20, 1985
TRACRIUM PRESERVATIVE FREE				
HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983

ATROPINE

INJECTABLE; INJECTION

ATROPINE

SOLVAY	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 35 (of 331)

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY

EQ 0.36MG BASE/INH

N020056 001

Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

VALEANT

0.025MG;0.5MG

N017744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP

0.025MG;2.5MG

A086440 001

SOLUTION; ORAL

COLONOID

MEDPOINTE PHARM HLC

0.025MG/5ML;2.5MG/5ML

A085735 001

LOMANATE

ALPHARMA US PHARMS

0.025MG/5ML;2.5MG/5ML

A085746 001

TABLET; ORAL

COLONOID

MEDPOINTE PHARM HLC

0.025MG;2.5MG

A085737 001

DI-ATRO

MD PHARM

0.025MG;2.5MG

A085266 001

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE

0.025MG;2.5MG

A040395 001

Nov 27, 2000

ASCOT

0.025MG;2.5MG

A087934 001

Jul 19, 1983

HEATHER

0.025MG;2.5MG

A086798 001

INWOOD LABS

0.025MG;2.5MG

A085509 001

IVAX PHARMS

0.025MG;2.5MG

A086727 001

KV PHARM

0.025MG;2.5MG

A085659 001

LEDERLE

0.025MG;2.5MG

A086950 001

MUTUAL PHARM

0.025MG;2.5MG

A085506 001

PARKE DAVIS

0.025MG;2.5MG

A087131 001

PVT FORM

0.025MG;2.5MG

A085766 001

R AND S PHARMA

0.025MG;2.5MG

A085035 001

ROXANE

0.025MG;2.5MG

A086057 001

SANDOZ

0.025MG;2.5MG

A086173 001

USL PHARMA

0.025MG;2.5MG

A087842 001

Mar 29, 1982

VALEANT PHARM INTL

0.025MG;2.5MG

A087195 001

Feb 16, 1982

WATSON LABS

0.025MG;2.5MG

A085876 001

WEST WARD

0.025MG;2.5MG

A087765 001

Mar 15, 1982

LOGEN

SUPERPHARM

0.025MG;2.5MG

A088962 001

May 10, 1985

LO-TROL

VANGARD

0.025MG;2.5MG

A088009 001

Mar 25, 1983

LOW-QUEL

HALSEY

0.025MG;2.5MG

A085211 001

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

ABBOTT

0.4MG/ML;50MG/ML

A087853 001

Nov 26, 1982

0.4MG/ML;75MG/ML

A087847 001

Nov 26, 1982

0.4MG/ML;100MG/ML

A087848 001

Nov 26, 1982

MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST

0.4MG/ML;50MG/ML

A085121 001

0.4MG/ML;75MG/ML

A085121 002

0.4MG/ML;100MG/ML

A085121 003

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

ATNAA

US ARMY

2.1MG/0.7ML;600MG/0.7ML

N021175 001

Jan 17, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 36 (of 331)

AZATADINE MALEATE

TABLET; ORAL OPTIMINE SCHERING	1MG	N017601	001	

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL TRINALIN SCHERING	1MG;120MG	N018506	001	Mar 23, 1982

AZATHIOPRINE

TABLET; ORAL IMURAN PROMETHEUS LABS	25MG	N016324	002	

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION IMURAN PROMETHEUS LABS	EQ 100MG BASE/VIAL	N017391	001	

AZITHROMYCIN

CAPSULE; ORAL ZITHROMAX PFIZER	EQ 250MG BASE	N050670	001	Nov 01, 1991

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL TROVAN/ZITHROMAX COMPLIANCE PAK PFIZER	EQ 1GM BASE,N/A;N/A,EQ 100MG BASE	N050762	001	Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION AZLIN BAYER PHARMS	EQ 2GM BASE/VIAL	A062388	001	Sep 08, 1982
	EQ 2GM BASE/VIAL	A062417	001	Oct 12, 1982
	EQ 2GM BASE/VIAL	N050562	001	Sep 03, 1982
	EQ 3GM BASE/VIAL	A062388	002	Sep 08, 1982
	EQ 3GM BASE/VIAL	A062417	002	Oct 12, 1982
	EQ 3GM BASE/VIAL	N050562	002	Sep 03, 1982
	EQ 4GM BASE/VIAL	A062388	003	Sep 08, 1982
	EQ 4GM BASE/VIAL	A062417	003	Oct 12, 1982
	EQ 4GM BASE/VIAL	N050562	003	Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION AZACTAM BRISTOL MYERS SQUIBB	500MG/VIAL	N050580	001	Dec 31, 1986
AZACTAM IN PLASTIC CONTAINER BRISTOL MYERS SQUIBB	10MG/ML	N050632	003	May 24, 1989

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL SPECTROBID PFIZER	125MG/5ML	N050556	001	Mar 23, 1982
TABLET; ORAL SPECTROBID PFIZER	400MG	N050520	001	
	800MG	N050520	002	Sep 12, 1983

BACITRACIN

INJECTABLE; INJECTION BACITRACIN PFIZER	50,000 UNITS/VIAL	A060282	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 37 (of 331)

BACITRACIN

OINTMENT; OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN 500 UNITS/GM

A060734 001

BACITRACIN

LILLY 500 UNITS/GM

A060687 001

PHARMADERM 500 UNITS/GM

A062158 001

PHARMAFAIR 500 UNITS/GM

A062453 001 Mar 28, 1984

OINTMENT; TOPICAL

BACITRACIN

COMBE 500 UNITS/GM

A062799 001 May 14, 1987

NASKA 500 UNITS/GM

A062857 001 Nov 13, 1987

POWDER; FOR RX COMPOUNDING

BACITRACIN

APOTHEKERNES 5,000,000 UNITS/BOT

A061699 001

PADDOCK 5,000,000 UNITS/BOT

A062456 001 Jul 27, 1983

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS 500,000 UNITS/BOT

A061737 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG
BASE/GM;10,000 UNITS/GM

N050416 002

ZINC BACITRACIN, NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR 400 UNITS/GM;1%;EQ 3.5MG
BASE/GM;10,000 UNITS/GM

A062389 001 Jul 02, 1982

OINTMENT; TOPICAL

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

PHARMAFAIR 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000
UNITS/GM

A062381 001 Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

LANABIOTIC

COMBE 400 UNITS/GM;40MG/GM;EQ 5MG
BASE/GM;5,000 UNITS/GM

A062499 001 Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000
UNITS/GM

A062386 001 Sep 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM 400 UNITS/GM;EQ 3.5MG BASE/GM;5,000
UNITS/GM

A062167 001

NEO-POLYCIN

DOW PHARM 500 UNITS/GM;EQ 3.5MG BASE/GM;10,000
UNITS/GM

A060647 001

NEOSPORIN

MONARCH PHARMS 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000
UNITS/GM

N050417 001

OINTMENT; TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA 400 UNITS/GM;EQ 3.5MG BASE/GM;5,000
UNITS/GM

A062833 001 Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL

POLYSPORIN

GLAXOSMITHKLINE 10,000 UNITS/GM;2,000,000 UNITS/GM

N050167 002 Mar 01, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 38 (of 331)

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
OCUMYCIN				
PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430	001	Apr 08, 1983
POLYSPORIN				
MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	A061229	001	
OINTMENT; TOPICAL				
BACITRACIN ZINC-POLYMYXIN B SULFATE				
NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849	001	Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE				
ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731	002	

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
MYCITRACIN				
PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048	001	

BACITRACIN; POLYMYXIN B SULFATE

DISC; TOPICAL				
LANABIOTIC				
COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598	001	Sep 22, 1986

BACLOFEN

TABLET; ORAL				
BACLOFEN				
TEVA	10MG	A073043	001	Feb 27, 1992
	20MG	A073044	001	Feb 27, 1992
USL PHARMA	10MG	A071260	001	May 06, 1988
	20MG	A071261	001	May 06, 1988
WATSON LABS	10MG	A073092	001	Jan 28, 1994
	10MG	A074698	001	Aug 20, 1996
	20MG	A073093	001	Jan 28, 1994
	20MG	A074698	002	Aug 20, 1996
LIORESAL				
NOVARTIS	10MG	N017851	001	
	20MG	N017851	003	Jan 20, 1982
TABLET, ORALLY DISINTEGRATING; ORAL				
KEMSTRO				
SCHWARZ PHARMA	10MG	N021589	001	Oct 30, 2003
	20MG	N021589	002	Oct 30, 2003

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION				
BECLOVENT				
GLAXOSMITHKLINE	0.042MG/INH	N018153	001	
VANCERIL				
SCHERING	0.042MG/INH	N017573	001	
VANCERIL DOUBLE STRENGTH				
SCHERING	0.084MG/INH	N020486	001	Dec 24, 1996
AEROSOL, METERED; NASAL				
BECONASE				
GLAXOSMITHKLINE	0.042MG/INH	N018584	001	
VANCENASE				
SCHERING	0.042MG/INH	N018521	001	

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL				
VANCENASE AQ				
SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589	001	Dec 23, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 39 (of 331)

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL VANCENASE AQ SCHERING	EQ 0.084MG DIPROP/SPRAY	N020469	001	Jun 26, 1996

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL BENAZEPRIL HYDROCHLORIDE GENPHARM	5MG 10MG 20MG 40MG	A076476 A076476 A076476 A076476	001 002 003 004	Feb 11, 2004 Feb 11, 2004 Feb 11, 2004 Feb 11, 2004

BENDROFLUMETHIAZIDE

TABLET; ORAL NATURETIN-10 APOTHECON	10MG	N012164	003	
NATURETIN-2.5 APOTHECON	2.5MG	N012164	001	
NATURETIN-5 APOTHECON	5MG	N012164	002	

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC BENOXINATE HYDROCHLORIDE SOLA BARNES HIND	0.4%	A084149	001	

BENTIROMIDE

SOLUTION; ORAL CHYMEX SAVAGE LABS	500MG/7.5ML	N018366	001	Dec 29, 1983

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL DIDREX PHARMACIA AND UPJOHN	25MG	N012427	003	

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION EMETE-CON PFIZER	EQ 50MG BASE/VIAL	N016820	001	
SUPPOSITORY; RECTAL EMETE-CON ROERIG	EQ 100MG BASE	N016818	006	

BENZTHIAZIDE

TABLET; ORAL AQUATAG SOLVAY	25MG 50MG	N016001 N016001	001 002	
BENZTHIAZIDE PVT FORM EXNA	50MG	A083206	001	
AH ROBINS INC FOVANE PFIZER	50MG 50MG	N012489 N012128	001 002	
URESE PFIZER	25MG	N012128	003	

BENZTROPINE MESYLATE

TABLET; ORAL BENZTROPINE MESYLATE MUTUAL PHARM	1MG	A081264	001	Jan 23, 1992

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 40 (of 331)

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

MUTUAL PHARM

2MG

A081265 001

Jan 23, 1992

QUANTUM PHARMICS

0.5MG

A088514 001

Jan 31, 1984

1MG

A088510 001

Jan 31, 1984

2MG

A088511 001

Jan 31, 1984

USL PHARMA

0.5MG

A089211 001

Jun 14, 1988

1MG

A089212 001

Jun 14, 1988

2MG

A089213 001

Jun 14, 1988

COGENTIN

MERCK

0.5MG

N009193 004

1MG

N009193 003

2MG

N009193 002

BENZYL BENZOATE

EMULSION; TOPICAL

BENZYL BENZOATE

LANNETT

50%

A084535 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC

200MG

N019001 001

Dec 28, 1990

300MG

N019001 002

Dec 28, 1990

400MG

N019001 003

Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON

200MG

N019002 001

Dec 28, 1990

300MG

N019002 002

Dec 28, 1990

400MG

N019002 003

Dec 28, 1990

BETA CAROTENE

CAPSULE; ORAL

SOLATENE

ROCHE

30MG

N017589 001

BETAMETHASONE

CREAM; TOPICAL

CELESTONE

SCHERING

0.2%

N014762 001

TABLET; ORAL

CELESTONE

SCHERING

0.6MG

N012657 003

BETAMETHASONE BENZOATE

CREAM; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N016998 002

GEL; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017244 001

LOTION; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017528 001

OINTMENT; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N018089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019138 001

Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072536 001

Jan 31, 1990

DISCONTINUED DRUG PRODUCT LIST

6 - 41 (of 331)

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK	EQ 0.05% BASE	A074579	001	Nov 26, 1997
PHARMADERM	EQ 0.05% BASE	N019136	001	Jun 26, 1984
TARO	EQ 0.05% BASE	A071143	001	Jun 17, 1987
TEVA	EQ 0.05% BASE	A071476	001	Aug 10, 1987

DIPROSONE

SCHERING	EQ 0.05% BASE	N017536	001	

CREAM, AUGMENTED; TOPICAL

DIPROLENE

SCHERING	EQ 0.05% BASE	N019408	001	Jan 31, 1986

DISC; TOPICAL

DIPROSONE

SCHERING	EQ 0.1% BASE	N017829	001	

GEL, AUGMENTED; TOPICAL

DIPROLENE

SCHERING	EQ 0.05% BASE	N019408	002	Nov 22, 1991

LOTION; TOPICAL

ALPHATREX

SAVAGE LABS	EQ 0.05% BASE	A070273	001	Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ALPHARMA US PHARMS	EQ 0.05% BASE	A071085	001	Feb 03, 1987
PHARMADERM	EQ 0.05% BASE	A070274	001	Aug 12, 1985
TARO	EQ 0.05% BASE	A072276	001	Aug 24, 1988
	EQ 0.05% BASE	A074272	001	Sep 30, 1994
TEVA PHARMS	EQ 0.05% BASE	A071882	001	Jun 06, 1988

DIPROSONE

SCHERING	EQ 0.05% BASE	N017781	001	

OINTMENT; TOPICAL

ALPHATREX

SAVAGE LABS	EQ 0.05% BASE	N019143	001	Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK	EQ 0.05% BASE	A072526	001	Jan 31, 1990
PHARMADERM	EQ 0.05% BASE	N019140	001	Sep 04, 1984
TEVA	EQ 0.05% BASE	A071477	001	Aug 10, 1987

DIPROSONE

SCHERING	EQ 0.05% BASE	N017691	001	

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS	EQ 3MG BASE/ML	A085738	001	

CELESTONE

SCHERING	EQ 3MG BASE/ML	N017561	001	

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETADERM

ROACO	EQ 0.1% BASE	N018839	001	Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK	EQ 0.1% BASE	A070053	001	Jun 10, 1986
PHARMADERM	EQ 0.1% BASE	N018860	002	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070485	001	May 29, 1987
TARO	EQ 0.1% BASE	A070062	001	May 14, 1985

BETATREX

SAVAGE LABS	EQ 0.1% BASE	N018862	001	Aug 31, 1983

VALISONE

SCHERING	EQ 0.01% BASE	N016322	002	
	EQ 0.1% BASE	N016322	001	

LOTION; TOPICAL

BETAMETHASONE VALERATE

PHARMADERM	EQ 0.1% BASE	N018870	001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070484	001	May 29, 1987
TEVA PHARMS	EQ 0.1% BASE	A071883	001	Apr 22, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 42 (of 331)

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETATREX

SAVAGE LABS

EQ 0.1% BASE

N018867 001

Aug 31, 1983

VALISONE

SCHERING

EQ 0.1% BASE

N016932 001

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

PERRIGO NEW YORK

EQ 0.1% BASE

A071478 001

Dec 23, 1987

PHARMADERM

EQ 0.1% BASE

N018864 001

Aug 31, 1983

PHARMAFAIR

EQ 0.1% BASE

A070486 001

May 29, 1987

BETATREX

SAVAGE LABS

EQ 0.1% BASE

N018863 001

Aug 31, 1983

BETA-VAL

TEVA

EQ 0.1% BASE

A070069 001

Dec 19, 1985

VALISONE

SCHERING

EQ 0.1% BASE

N016740 001

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL

KERLONE

SANOFI AVENTIS US

10MG

N019507 001

Oct 27, 1989

20MG

N019507 002

Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US

5MG;12.5MG

N019807 001

Oct 30, 1992

10MG;12.5MG

N019807 002

Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

ALCON

EQ 0.25% BASE;1.75%

N020619 001

Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY

50MG/ML

N009344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

ODYSSEY PHARMS

5MG/ML

N006536 001

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE

5MG

A040492 001

Jul 27, 2004

10MG

A040483 001

Jul 27, 2004

25MG

A040485 001

Jul 27, 2004

50MG

A040509 001

Jul 27, 2004

ACTAVIS TOTOWA

50MG

A040551 001

Oct 28, 2004

ASCOT

10MG

A088288 001

Jun 08, 1983

25MG

A088289 001

Jun 08, 1983

IVAX SUB TEVA PHARMS

25MG

A084689 001

LANNETT

5MG

A084702 001

10MG

A084712 001

25MG

A084074 001

SANDOZ

5MG

A084353 001

10MG

A084378 001

10MG

A084379 001

25MG

A084383 001

25MG

A084384 001

WATSON LABS

5MG

A084402 001

5MG

A085230 002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 43 (of 331)

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

WATSON LABS

5MG	A085841	001
10MG	A084408	001
10MG	A085228	001
10MG	A085842	001
25MG	A084441	001
25MG	A085229	001
25MG	A085839	001
50MG	A087397	001
50MG	A087444	001

MYOTONACHOL

GLENWOOD

5MG	A084188	001
10MG	A084188	003
25MG	A084188	004

URECHOLINE

ODYSSEY PHARMS

5MG	N006536	003
10MG	N006536	002
25MG	N006536	004
50MG	N006536	005

BETHANIDINE SULFATE

TABLET; ORAL

TENATHAN

ROBINS AH

10MG	N017675	001
25MG	N017675	002

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

ABBOTT

5MG/ML	N012418	002

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

BRAINTREE

5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM; N/A, 5.6GM	N021551	002	Sep 24, 2007

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

MUTUAL PHARM

5MG	A075474	001	Oct 25, 2002
10MG	A075474	002	Oct 25, 2002

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

APOTHECON

2.5MG; 6.25MG	A075642	002	Dec 27, 2000
5MG; 6.25MG	A075642	001	Dec 27, 2000
10MG; 6.25MG	A075642	003	Dec 27, 2000

IVAX SUB TEVA PHARMS

2.5MG; 6.25MG	A075632	001	Sep 27, 2000
5MG; 6.25MG	A075632	002	Sep 27, 2000
10MG; 6.25MG	A075632	003	Sep 27, 2000

SANDOZ

2.5MG; 6.25MG	A075527	001	Sep 25, 2000
5MG; 6.25MG	A075527	003	Sep 25, 2000
10MG; 6.25MG	A075527	002	Sep 25, 2000

TEVA

2.5MG; 6.25MG	A075686	001	Jan 19, 2001
5MG; 6.25MG	A075686	002	Jan 19, 2001
10MG; 6.25MG	A075686	003	Jan 19, 2001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 44 (of 331)

BITOLTEROL MESYLATEAEROSOL, METERED; INHALATION
TORNALATE

SANOFI AVENTIS US	0.37MG/INH	N018770	001	Dec 28, 1984

SOLUTION; INHALATION
TORNALATE

SANOFI AVENTIS US	0.2%	N019548	001	Feb 19, 1992

BLEOMYCIN SULFATEINJECTABLE; INJECTION
BLENOXANE

BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL	N050443	001	
	EQ 30 UNITS BASE/VIAL	N050443	002	Sep 07, 1995

BLEOMYCIN SULFATE

TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
	EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996

BRETYLIUM TOSYLATEINJECTABLE; INJECTION
BRETYLIUM TOSYLATE

ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
	100MG/ML	A071298	001	Feb 13, 1987
ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
	50MG/ML	A071152	001	Aug 10, 1987
	50MG/ML	A071153	001	Aug 10, 1987
BAXTER HLTHCARE	50MG/ML	A070545	001	May 14, 1986
	50MG/ML	A070546	001	May 14, 1986
HOSPIRA	50MG/ML	N019033	001	Apr 29, 1986
INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988

BRETYLIUM TOSYLATE IN DEXTROSE 5%

ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
	400MG/100ML	N019005	003	Apr 29, 1986
	800MG/100ML	N019005	001	Apr 29, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA	800MG/100ML	N019008	001	Apr 29, 1986

BRETYLOL

HOSPIRA	50MG/ML	N017954	001	

BRIMONIDINE TARTRATESOLUTION/DROPS; OPHTHALMIC
ALPHAGAN

ALLERGAN	0.2%	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997

BROMOCRIPTINE MESYLATECAPSULE; ORAL
BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998

BROMODIPHENHYDRAMINE HYDROCHLORIDECAPSULE; ORAL
AMBODRYL

PARKE DAVIS	25MG	N007984	001	

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATESYRUP; ORAL
AMBENYL

FOREST LABS	12.5MG/5ML;10MG/5ML	N009319	006	Jan 10, 1984

BROMANYL

ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343	001	Aug 15, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 45 (of 331)

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE
WOCKHARDT 12.5MG/5ML;10MG/5ML

A088626 001 Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS 2MG/5ML

A086936 001

KV PHARM 2MG/5ML

A085466 001

PHARM ASSOC 2MG/5ML

A087517 001

USL PHARMA 2MG/5ML

A087964 001 Jan 25, 1983

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS 10MG/ML

A083821 001

100MG/ML

A083820 001

DIMETANE-TEN

WYETH AYERST 10MG/ML

N011418 002

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR 4MG

A084468 001

IVAX SUB TEVA PHARMS 4MG

A084351 001

NEWTRON PHARMS 4MG

A086987 001

NEXGEN PHARMA INC 4MG

A086187 001

PAR PHARM 4MG

A087009 001

PIONEER PHARMS 4MG

A088604 001 Jul 13, 1984

SANDOZ 4MG

A083215 001

VITARINE 4MG

A085850 001

WATSON LABS 4MG

A083123 001

4MG

A085769 001

DIMETANE

WYETH CONS 4MG

N010799 003

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS 8MG

N010799 010 Jun 10, 1983

12MG

N010799 011 Jun 10, 1983

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DC

ALPHARMA US PHARMS 2MG/5ML;10MG/5ML;12.5MG/5ML

A088723 001 Feb 25, 1985

DIMETANE-DC

ROBINS AH 2MG/5ML;10MG/5ML;12.5MG/5ML

N011694 006 Mar 29, 1984

MYPHETANE DC

WOCKHARDT 2MG/5ML;10MG/5ML;12.5MG/5ML

A088904 001 Feb 21, 1985

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS 2MG/5ML;10MG/5ML;30MG/5ML

A088722 001 Mar 07, 1985

BROMFED-DM

WOCKHARDT 2MG/5ML;10MG/5ML;30MG/5ML

A089681 001 Dec 22, 1988

DIMETANE-DX

ROBINS AH 2MG/5ML;10MG/5ML;30MG/5ML

N019279 001 Aug 24, 1984

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

BIPHETAP

MORTON GROVE 4MG/5ML;25MG/5ML

A088687 001 Sep 26, 1984

BROMANATE

ALPHARMA US PHARMS 4MG/5ML;25MG/5ML

A088688 001 Feb 06, 1985

DIMETAPP

WYETH CONS 2MG/5ML;12.5MG/5ML

N013087 003 Mar 29, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 46 (of 331)

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BROMATAPP

COPLEY PHARM

12MG;75MG

A071099 001 Jul 02, 1987

DIMETAPP

WYETH CONS

12MG;75MG

N012436 003 May 14, 1985

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA

16MG;240MG

N019672 001 Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART PHARMS

50MG

N010911 006

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

ASTRAZENECA

0.032MG/INH

N020233 001 Feb 14, 1994

POWDER, METERED; INHALATION

PULMICORT

ASTRAZENECA

0.32MG/INH

N020441 003 Jun 24, 1997

SPRAY, METERED; NASAL

RHINOCORT

ASTRAZENECA

0.064MG/INH

N020746 002 Oct 01, 1999

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

HOSPIRA

0.25MG/ML

A074160 001 Oct 30, 1997

BUMEX

VALIDUS PHARMS INC

0.25MG/ML

N018226 001 Feb 28, 1983

TABLET; ORAL

BUMEX

VALIDUS PHARMS INC

0.5MG

N018225 002 Feb 28, 1983

1MG

N018225 001 Feb 28, 1983

2MG

N018225 003 Jun 14, 1985

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA

0.075%

N019978 001 Sep 03, 1992

0.114%

N019978 002 Sep 03, 1992

0.23%

N019978 003 Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA

0.25%;0.005MG/ML

A071166 001 Jun 16, 1988

0.5%;0.005MG/ML

A071169 001 Jun 16, 1988

0.75%;0.005MG/ML

A071171 001 Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR

EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)

N021496 001 May 23, 2003

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ

75MG

A075613 002 Oct 10, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 47 (of 331)

BUPROPION HYDROCHLORIDE

TABLET; ORAL					
BUPROPION HYDROCHLORIDE					
SANDOZ	100MG	A075613	001	Oct 10, 2000	
WELLBUTRIN					
GLAXOSMITHKLINE	50MG	N018644	001	Dec 30, 1985	
TABLET, EXTENDED RELEASE; ORAL					
BUPROPION HYDROCHLORIDE					
SANDOZ	100MG	A076845	001	Jul 14, 2005	
	150MG	A076834	001	Jul 14, 2005	
	150MG	A076845	002	Jul 14, 2005	
WELLBUTRIN SR					
GLAXOSMITHKLINE	50MG	N020358	001	Oct 04, 1996	
ZYBAN					
GLAXOSMITHKLINE	100MG	N020711	002	May 14, 1997	

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL					
BUSPAR					
BRISTOL MYERS SQUIBB	5MG	N021190	001	Dec 20, 2000	
	7.5MG	N021190	002	Dec 20, 2000	
	10MG	N021190	003	Dec 20, 2000	
	15MG	N021190	004	Dec 20, 2000	
TABLET; ORAL					
BUSPAR					
BRISTOL MYERS SQUIBB	10MG	N018731	002	Sep 29, 1986	
	15MG	N018731	003	Apr 22, 1996	
	30MG	N018731	004	Apr 22, 1996	
BUSPIRONE HYDROCHLORIDE					
SANDOZ	5MG	A075413	001	Mar 19, 2002	
	10MG	A075413	002	Mar 19, 2002	
	15MG	A075413	003	Mar 19, 2002	

BUTABARBITAL SODIUM

CAPSULE; ORAL					
BUTICAPS					
MEDPOINTE PHARM HLC	15MG	A085381	001		
	30MG	A085381	002		
	50MG	A085381	003		
	100MG	A085381	004		
ELIXIR; ORAL					
BUTABARB					
ALPHARMA US PHARMS	30MG/5ML	A085873	001		
BUTABARBITAL SODIUM					
WOCKHARDT	30MG/5ML	A085383	001		
BUTALAN					
LANNETT	33.3MG/5ML	A085880	001		
SARISOL					
HALSEY	30MG/5ML	A084723	001		
TABLET; ORAL					
BUTABARBITAL					
BUNDY	30MG	A085550	001		
BUTABARBITAL SODIUM					
SANDOZ	15MG	A084292	003	Feb 09, 1982	
	15MG	A085938	001		
	30MG	A084272	002		
	30MG	A085934	001		
SOLVAY					
	16.2MG	A083606	001		
	32.4MG	A083898	001		
	48.6MG	A083897	001		
	97.2MG	A083896	001		
TEVA					
	15MG	A088632	001	May 18, 1985	
	30MG	A088631	001	May 01, 1985	
WATSON LABS					
	15MG	A085764	001		

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 48 (of 331)

BUTABARBITAL SODIUM

TABLET; ORAL

BUTABARBITAL SODIUM

WATSON LABS 30MG A085772 001

WHITEWORTH TOWN PLSN 15MG A083325 002

30MG A083337 001

BUTISOL SODIUM

MEDA PHARMS 15MG N000793 002

100MG N000793 005

SARISOL NO. 1

HALSEY 15MG A084719 001

SARISOL NO. 2

HALSEY 30MG A084719 002

SODIUM BUTABARBITAL

IVAX SUB TEVA PHARMS 15MG A083484 001

30MG A084040 001

LANNETT 15MG A085849 001

30MG A085866 001

100MG A085881 001

MARSHALL PHARMA 16.2MG A083524 001

32.4MG A083858 001

WEST WARD 15MG A085418 001

30MG A085432 001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT

ROCHE PALO 2% N019215 001 Nov 25, 1985

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO 100MG N019359 001 Nov 25, 1985

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

HOSPIRA 1MG/ML A075342 001 Nov 04, 1999

1MG/ML A075559 001 Mar 20, 2000

2MG/ML A075342 002 Nov 04, 1999

2MG/ML A075559 002 Mar 20, 2000

BUTORPHANOL TARTRATE PRESERVATIVE FREE

HOSPIRA 1MG/ML A074620 001 Jan 22, 1997

1MG/ML A075170 001 Sep 28, 1998

2MG/ML A074620 002 Jan 22, 1997

2MG/ML A075170 002 Sep 28, 1998

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB 1MG/SPRAY N019890 001 Dec 12, 1991

CABERGOLINE

TABLET; ORAL

DOSTINEX

PHARMACIA AND UPJOHN 0.5MG N020664 001 Dec 23, 1996

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

NOVARTIS 100MG;2MG N009000 002

TABLET; ORAL

CAFERGOT

NOVARTIS 100MG;1MG N006620 001

WIGRAINE

ORGANON USA INC 100MG;1MG A086562 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 49 (of 331)

CALCIFEDIOLCAPSULE; ORAL
CALDEROL

ORGANON USA INC

0.02MG

N018312 001

0.05MG

N018312 002

CALCIPOTRIENEOINTMENT; TOPICAL
DOVONEX

LEO PHARM

0.005%

N020273 001 Dec 29, 1993

CALCITONIN HUMANINJECTABLE; INJECTION
CIBACALCIN

NOVARTIS

0.5MG/VIAL

N018470 001 Oct 31, 1986

CALCITONIN SALMONINJECTABLE; INJECTION
CALCIMAR

SANOFI AVENTIS US

200 IU/ML

N017769 001

400 IU/VIAL

N017497 001

CALCITONIN-SALMON

ASTRAZENECA

200 IU/ML

A073690 001 Apr 14, 1995

MIACALCIN

NOVARTIS

100 IU/ML

N017808 001 Jul 03, 1986

CALCITRIOLINJECTABLE; INJECTION
CALCITRIOL

HOSPIRA

0.001MG/ML

A075816 001 Jan 16, 2004

0.002MG/ML

A075816 002 Jan 16, 2004

CALCIUM ACETATECAPSULE; ORAL
PHOSLO

FRESENIUS MEDCL

EQ 84.5MG CALCIUM

N021160 001 Apr 02, 2001

EQ 169MG CALCIUM

N021160 002 Apr 02, 2001

TABLET; ORAL
CALCIUM ACETATE

ROXANE

EQ 169MG CALCIUM

A077693 001 Jan 30, 2008

PHOSLO

FRESENIUS MEDCL

EQ 169MG CALCIUM

N019976 001 Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUMTABLET, TABLET; ORAL
ACTONEL WITH CALCIUM (COPACKAGED)

WARNER CHILCOTT

EQ 500MG BASE, N/A; N/A, 35MG

N021823 001 Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML;
3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML;
7.07GM/1000ML

N021703 012 Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;
0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 005 Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML;
0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 008 Oct 25, 2006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 50 (of 331)

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05 GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46 GM/1000ML	N021703	007	Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	009	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N018271	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018269	002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	006	Jan 29, 1986

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	001	

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;1.5GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	002	

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	008	Jan 29, 1986

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	004	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018256	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100ML;62MG/100ML	N019634	002	Feb 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017510	001	

MILES	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018499	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 51 (of 331)

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988	
	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988	
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988	
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	001	Oct 17, 1988	

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N019395	001	Mar 26, 1986	
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N019395	002	Mar 26, 1986	
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N019395	003	Mar 26, 1986	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER					
ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N019399	001	Jun 16, 1986	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER					
B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899	001	Oct 31, 1983	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER					
B BRAUN	20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018725	001	Nov 29, 1982	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER					
B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N018721	001	Nov 09, 1982	
SOLUTION; IRRIGATION					
RINGER'S IN PLASTIC CONTAINER					
ABBOTT	33MG/100ML;30MG/100ML;860MG/100ML	N018462	001		

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER					
ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019485	001	Oct 24, 1985	
B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018023	001		
MILES	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018417	001		

DISCONTINUED DRUG PRODUCT LIST

6 - 52 (of 331)

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE

ABBOTT	EQ 90MG CALCIUM/5ML	A080001	001	
	EQ 90MG CALCIUM/5ML	A083159	001	
ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373	001	Apr 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N006470	001	

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION
ISOPAQUE 440

GE HEALTHCARE	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N016847	001	

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION
ISOPAQUE 280

GE HEALTHCARE	0.35MG/ML;140.1MG/ML;461.8MG/ML	N017506	001	

CANDICIDIN

OINTMENT; VAGINAL
VANOBI

SANOFI AVENTIS US	0.6MG/GM	A061596	001	

TABLET; VAGINAL
VANOBI

SANOFI AVENTIS US	3MG	A061613	001	

CAPTOPRIL

TABLET; ORAL
CAPOTEN

PAR PHARM	37.5MG	N018343	006	Sep 17, 1986
	75MG	N018343	007	Jun 13, 1995
	150MG	N018343	004	Jun 13, 1995

CAPTOPRIL

APOTHECON	12.5MG	A074472	001	Mar 31, 1995
	25MG	A074472	002	Mar 31, 1995
	50MG	A074472	003	Mar 31, 1995
	100MG	A074472	004	Mar 31, 1995

CLONMEL HLTHCARE	12.5MG	A074423	001	Feb 13, 1996
	25MG	A074423	002	Feb 13, 1996
	50MG	A074423	003	Feb 13, 1996
	100MG	A074423	004	Feb 13, 1996

EGIS PHARMS	12.5MG	A074748	004	May 29, 1997
	25MG	A074748	002	May 29, 1997
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997

ENDO LABS	12.5MG	A074418	001	Feb 13, 1996
	25MG	A074418	002	Feb 13, 1996
	50MG	A074418	003	Feb 13, 1996
	100MG	A074418	004	Feb 13, 1996

IVAX SUB TEVA PHARMS	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074590	003	Aug 30, 1996

PAR PHARM	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996

PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997

SANDOZ	12.5MG	A074481	001	Feb 13, 1996
	12.5MG	A074519	001	Feb 13, 1996
	25MG	A074481	002	Feb 13, 1996

DISCONTINUED DRUG PRODUCT LIST

6 - 53 (of 331)

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

SANDOZ	25MG	A074519	002	Feb 13, 1996
	50MG	A074481	003	Feb 13, 1996
	50MG	A074519	003	Feb 13, 1996
	100MG	A074481	004	Feb 13, 1996
	100MG	A074519	004	Feb 13, 1996
TEVA	12.5MG	A074433	001	Feb 13, 1996
	25MG	A074433	002	Feb 13, 1996
	50MG	A074433	003	Feb 13, 1996
	100MG	A074433	004	Feb 13, 1996
TEVA PHARMS	12.5MG	A074462	001	Feb 13, 1996
	25MG	A074462	002	Feb 13, 1996
	50MG	A074462	003	Feb 13, 1996
	100MG	A074462	004	Feb 13, 1996
WATSON LABS	12.5MG	A074576	001	Apr 23, 1996
	25MG	A074576	002	Apr 23, 1996
	50MG	A074576	003	Apr 23, 1996
	100MG	A074576	004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

ENDO LABS	25MG;15MG	A074788	001	Dec 29, 1997
	25MG;25MG	A074788	002	Dec 29, 1997
	50MG;15MG	A074788	004	Dec 29, 1997
	50MG;25MG	A074788	003	Dec 29, 1997
IVAX SUB TEVA PHARMS	25MG;15MG	A075055	001	Jun 18, 1998
	25MG;25MG	A075055	002	Jun 18, 1998
	50MG;15MG	A075055	004	Jun 18, 1998
	50MG;25MG	A075055	003	Jun 18, 1998
WATSON LABS	50MG;25MG	A074832	001	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR	0.01%	A070292	001	May 21, 1986
CARBASTAT				
NOVARTIS	0.01%	A073677	001	Apr 28, 1995

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

TARO	100MG/5ML	A075875	001	Dec 21, 2000

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH	200MG	A071696	001	Nov 09, 1987
INWOOD LABS	200MG	A070231	001	Aug 14, 1986
PLIVA	200MG	A071479	001	Jul 24, 1987
USL PHARMA	200MG	A070300	001	May 15, 1986
WARNER CHILCOTT	200MG	A070429	001	Jan 02, 1987

TERIL

TARO	200MG	A076525	001	Sep 26, 2003

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

CADISTA PHARMS	100MG	A071940	001	Feb 01, 1988

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG	EQ 1GM BASE/VIAL	N050306	001	
	EQ 2GM BASE/VIAL	N050306	004	
	EQ 5GM BASE/VIAL	N050306	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 54 (of 331)

CARBENICILLIN DISODIUMINJECTABLE; INJECTION
GEOPEN

ROERIG	EQ 10GM BASE/VIAL	N050306	006
	EQ 30GM BASE/VIAL	N050306	007

PYOPEN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298	001
	EQ 2GM BASE/VIAL	N050298	002
	EQ 5GM BASE/VIAL	N050298	003
	EQ 10GM BASE/VIAL	N050298	006
	EQ 20GM BASE/VIAL	N050298	007

CARBENICILLIN INDANYL SODIUMTABLET; ORAL
GEOCILLIN

PFIZER	EQ 382MG BASE	N050435	001

CARBIDOPA; LEVODOPATABLET; ORAL
CARBIDOPA AND LEVODOPA

SANDOZ	10MG;100MG	A073586	001	Jun 29, 1995
	25MG;100MG	A073587	001	Jun 29, 1995
	25MG;250MG	A073620	001	Jun 29, 1995
SCS	10MG;100MG	A074080	001	Mar 25, 1994
	25MG;100MG	A074080	002	Mar 25, 1994
	25MG;250MG	A074080	003	Mar 25, 1994
WATSON LABS	10MG;100MG	A073381	001	Sep 28, 1993
	25MG;100MG	A073382	001	Sep 28, 1993
	25MG;250MG	A073383	001	Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

KV PHARM	50MG;200MG	A076663	001	Jun 24, 2004

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY	10MG;100MG	A076643	001	Jun 10, 2005
	25MG;100MG	A076643	002	Jun 10, 2005
	25MG;250MG	A076643	003	Jun 10, 2005

CARBINOXAMINE MALEATEELIXIR; ORAL
CLISTIN

MCNEIL	4MG/5ML	N008955	001

TABLET; ORAL

CLISTIN

ORTHO MCNEIL PHARM	4MG	N008915	001

CARBOPLATININJECTABLE; INJECTION
CARBOPLATIN

HOSPIRA	50MG/VIAL	A076473	001	Oct 27, 2004
	150MG/VIAL	A076473	002	Oct 27, 2004
	450MG/VIAL	A076473	003	Oct 27, 2004

PARAPLATIN

BRISTOL MYERS SQUIBB	50MG/VIAL	N019880	001	Mar 03, 1989
	150MG/VIAL	N019880	002	Mar 03, 1989
	450MG/VIAL	N019880	003	Mar 03, 1989

INJECTABLE; IV (INFUSION)

CARBOPLATIN

APP PHARMS	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004
	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004
SPECTRUM PHARMS	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005
	150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005
	450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 55 (of 331)

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

TEVA PARENTERAL	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007

PARAPLATIN

BRISTOL MYERS SQUIBB	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003
	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003
	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003
	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004

CARISOPRODOL

CAPSULE; ORAL

SOMA

MEDA PHARMS	250MG	N011792	003	

TABLET; ORAL

CARISOPRODOL

ABLE	350MG	A040421	001	Jun 21, 2001
PIONEER PHARMS	350MG	A089390	001	Oct 13, 1988
SANDOZ	350MG	A081025	001	Apr 13, 1989
	350MG	A089566	001	Aug 30, 1988
WATSON LABS	350MG	A040152	001	Dec 03, 1996
	350MG	A085433	001	
	350MG	A086179	001	

RELA

SCHERING	350MG	N012155	001	

CARPENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST	50MG/ML	N014173	001	

TABLET; ORAL

PROKETAZINE

WYETH AYERST	12.5MG	N012768	001	
	25MG	N012768	002	
	50MG	N012768	004	

CARPROFEN

TABLET; ORAL

RIMADYL

ROCHE	100MG	N018550	002	Dec 31, 1987
	150MG	N018550	003	Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL

CARTROL

ABBOTT	2.5MG	N019204	001	Dec 28, 1988
	5MG	N019204	002	Dec 28, 1988
	10MG	N019204	003	Dec 28, 1988

CEFACLOR

CAPSULE; ORAL

CECLOR

LILLY	EQ 250MG BASE	N050521	001	
	EQ 500MG BASE	N050521	002	

CEFACLOR

CEPH INTL	EQ 250MG BASE	A062205	001	
	EQ 500MG BASE	A062205	002	
CLONMEL HLTHCARE	EQ 250MG BASE	A064107	001	Apr 27, 1995
	EQ 500MG BASE	A064107	002	Apr 27, 1995
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A064061	001	Apr 27, 1995
	EQ 500MG BASE	A064061	002	Apr 27, 1995
MARSAM PHARMS LLC	EQ 250MG BASE	A064148	001	May 23, 1996
	EQ 500MG BASE	A064148	002	May 23, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 56 (of 331)

CEFACLORCAPSULE; ORAL
CEFACLOR

TEVA	EQ 250MG BASE	A064081	001	Sep 16, 1996
	EQ 250MG BASE	A064145	001	Jun 24, 1996
	EQ 500MG BASE	A064081	002	Sep 16, 1996
	EQ 500MG BASE	A064145	002	Jun 24, 1996

FOR SUSPENSION; ORAL
CECLOR

LILLY	EQ 125MG BASE/5ML	N050522	001	
	EQ 250MG BASE/5ML	N050522	002	

CEFACLOR

ACS DOBFAR INFO SA	EQ 125MG BASE/5ML	A062206	001	
	EQ 187MG BASE/5ML	A062206	003	Apr 20, 1988
	EQ 250MG BASE/5ML	A062206	002	
	EQ 375MG BASE/5ML	A062206	004	Apr 20, 1988
CLONMEL HLTHCARE	EQ 125MG BASE/5ML	A064114	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064115	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064116	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064110	001	Apr 28, 1995
IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML	A064087	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064086	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064085	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064070	001	Apr 28, 1995
MARSAM PHARMS LLC	EQ 125MG BASE/5ML	A064204	001	Feb 18, 1998
	EQ 187MG BASE/5ML	A064205	001	Feb 18, 1998
	EQ 250MG BASE/5ML	A064206	001	Feb 18, 1998
	EQ 375MG BASE/5ML	A064207	001	Feb 18, 1998

TABLET, EXTENDED RELEASE; ORAL
CECLOR CD

LILLY	EQ 375MG BASE	N050673	001	Jun 28, 1996
	EQ 500MG BASE	N050673	002	Jun 28, 1996

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766	001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017	001	Jan 05, 1989
TEVA	EQ 500MG BASE	A062695	001	Feb 10, 1989

DURICEF

WARNER CHILCOTT	EQ 250MG BASE	N050512	002	
	EQ 500MG BASE	N050512	001	

ULTRACEF

BRISTOL	EQ 500MG BASE	A062378	001	Mar 16, 1982

FOR SUSPENSION; ORAL

CEFADROXIL

APOTHECON	EQ 125MG BASE/5ML	A062334	001	
	EQ 250MG BASE/5ML	A062334	002	
	EQ 500MG BASE/5ML	A062334	003	
TEVA	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989
	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989

DURICEF

WARNER CHILCOTT	EQ 125MG BASE/5ML	N050527	002	
	EQ 250MG BASE/5ML	N050527	003	
	EQ 500MG BASE/5ML	N050527	001	

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376	001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376	002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376	003	Mar 16, 1982

TABLET; ORAL

DURICEF

WARNER CHILCOTT	EQ 1GM BASE	N050528	001	

ULTRACEF

APOTHECON	EQ 1GM BASE	A062390	001	Jun 10, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 57 (of 331)

CEFADROXIL/CEFADROXIL HEMIHYDRATE

TABLET; ORAL

ULTRACEF

BRISTOL

EQ 1GM BASE

A062408 001

Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

LILLY

EQ 500MG BASE/VIAL

N050504 001

EQ 1GM BASE/VIAL

A062560 001

Sep 10, 1985

EQ 1GM BASE/VIAL

N050504 002

EQ 2GM BASE/VIAL

A062560 002

Sep 10, 1985

EQ 2GM BASE/VIAL

N050504 003

EQ 10GM BASE/VIAL

N050504 004

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

GLAXOSMITHKLINE

EQ 250MG BASE/VIAL

N050461 001

EQ 500MG BASE/VIAL

N050461 002

EQ 1GM BASE/VIAL

N050461 003

EQ 5GM BASE/VIAL

N050461 004

EQ 10GM BASE/VIAL

N050461 005

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML

N050566 003

Jun 08, 1983

EQ 20MG BASE/ML

N050566 004

Jun 08, 1983

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML

N050566 001

Jun 08, 1983

EQ 20MG BASE/ML

N050566 002

Jun 08, 1983

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 500MG BASE/VIAL

N050779 001

Jul 27, 2000

CEFAZOLIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A062688 002

Nov 17, 1986

EQ 1GM BASE/VIAL

A062688 003

Nov 17, 1986

EQ 10GM BASE/VIAL

A062688 004

Nov 17, 1986

EQ 20GM BASE/VIAL

A062688 005

Aug 03, 1987

BEDFORD

EQ 250MG BASE/VIAL

A062894 001

Jul 21, 1988

EQ 500MG BASE/VIAL

A062894 002

Jul 21, 1988

EQ 1GM BASE/VIAL

A062894 003

Jul 21, 1988

EQ 5GM BASE/VIAL

A062894 004

Jul 21, 1988

EQ 10GM BASE/VIAL

A062894 005

Jul 21, 1988

ELKINS SINN

EQ 250MG BASE/VIAL

A062807 001

Jan 12, 1988

EQ 500MG BASE/VIAL

A062807 002

Jan 12, 1988

EQ 1GM BASE/VIAL

A062807 003

Jan 12, 1988

EQ 5GM BASE/VIAL

A062807 004

Jan 12, 1988

EQ 10GM BASE/VIAL

A062807 005

Jan 12, 1988

EQ 20GM BASE/VIAL

A062807 006

Jan 12, 1988

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A064033 001

Oct 31, 1993

MARSAM PHARMS LLC

EQ 250MG BASE/VIAL

A062988 001

Dec 29, 1989

EQ 500MG BASE/VIAL

A062988 002

Dec 29, 1989

EQ 1GM BASE/VIAL

A062988 003

Dec 29, 1989

EQ 5GM BASE/VIAL

A062989 001

Dec 29, 1989

EQ 10GM BASE/VIAL

A062989 002

Dec 29, 1989

EQ 20GM BASE/VIAL

A062989 003

Dec 29, 1989

STERI PHARMA

EQ 500MG BASE/VIAL

A063214 001

Dec 27, 1991

EQ 500MG BASE/VIAL

A063216 001

Dec 27, 1991

TEVA

EQ 250MG BASE/VIAL

A063016 001

Mar 14, 1989

EQ 500MG BASE/VIAL

A063016 002

Mar 14, 1989

EQ 1GM BASE/VIAL

A063016 003

Mar 14, 1989

EQ 5GM BASE/VIAL

A063018 001

Mar 05, 1990

EQ 10GM BASE/VIAL

A063018 002

Mar 05, 1990

KEFZOL

ACS DOBFAR

EQ 250MG BASE/VIAL

A061773 001

EQ 20GM BASE/VIAL

A061773 005

Sep 08, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 58 (of 331)

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
KEFZOL

LILLY	EQ 500MG BASE/VIAL	A062557	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557	002	Sep 10, 1985

CEFDINIR

CAPSULE; ORAL
OMNICEF

ABBOTT	300MG	N050739	001	Dec 04, 1997

FOR SUSPENSION; ORAL
OMNICEF

ABBOTT	125MG/5ML	N050749	001	Dec 04, 1997
	250MG/5ML	N050749	002	Jul 29, 2004

CEFIXIME

FOR SUSPENSION; ORAL
SUPRAX

LEDERLE	100MG/5ML	N050622	001	Apr 28, 1989

TABLET; ORAL
SUPRAX

LEDERLE	200MG	N050621	001	Apr 28, 1989
	400MG	N050621	002	Apr 28, 1989

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFMAX

TAP PHARM	EQ 500MG BASE/VIAL	N050571	001	Dec 30, 1987
	EQ 1GM BASE/VIAL	N050571	002	Dec 30, 1987
	EQ 2GM BASE/VIAL	N050571	003	Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION
ZEFAZONE

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N050637	001	Dec 11, 1989
	EQ 2GM BASE/VIAL	N050637	002	Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN	EQ 20MG BASE/ML	N050683	001	Dec 29, 1992
	EQ 40MG BASE/ML	N050683	002	Dec 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION
MONOCID

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579	001	May 23, 1984
	EQ 1GM BASE/VIAL	A063295	001	Jul 26, 1993
	EQ 1GM BASE/VIAL	N050579	002	May 23, 1984
	EQ 2GM BASE/VIAL	N050579	003	May 23, 1984
	EQ 10GM BASE/VIAL	N050579	004	May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID

PFIZER	EQ 1GM BASE/VIAL	A063333	001	Mar 31, 1995
	EQ 1GM BASE/VIAL	N050551	001	Nov 18, 1982
	EQ 2GM BASE/VIAL	A063333	002	Mar 31, 1995
	EQ 2GM BASE/VIAL	N050551	002	Nov 18, 1982
	EQ 10GM BASE/VIAL	N050551	003	Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER	EQ 20MG BASE/ML	N050613	002	Jul 31, 1987
	EQ 40MG BASE/ML	N050613	001	Jul 23, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 59 (of 331)

CEFORANIDE

INJECTABLE; INJECTION
PRECEF

APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984
	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER				
B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596	001	May 20, 1985
	EQ 40MG BASE/ML	N050596	003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

ASTRAZENECA	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985
	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985
	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988
CEFOTAN IN PLASTIC CONTAINER				
ASTRAZENECA	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION
CERADON

TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN

BIONICHE PHARMA	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
MERCK	EQ 1GM BASE/VIAL	N050517	001	
	EQ 2GM BASE/VIAL	N050517	002	
	EQ 10GM BASE/VIAL	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
MERCK	EQ 20MG BASE/ML	N050581	003	Sep 20, 1984
	EQ 40MG BASE/ML	N050581	004	Sep 20, 1984
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
MERCK	EQ 20MG BASE/ML	N050581	002	Sep 20, 1984
	EQ 40MG BASE/ML	N050581	001	Sep 20, 1984

CEFPIRAMIDE SODIUM

INJECTABLE; INJECTION
CEFPIRAMIDE SODIUM

WYETH AYERST	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 60 (of 331)

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO

EQ 50MG BASE/5ML
EQ 100MG BASE/5MLN050688 002 Aug 07, 1992
N050688 001 Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN

EQ 50MG BASE/5ML
EQ 100MG BASE/5MLN050675 001 Aug 07, 1992
N050675 002 Aug 07, 1992

TABLET; ORAL

BANAN

SANKYO

EQ 100MG BASE
EQ 200MG BASEN050687 001 Aug 07, 1992
N050687 002 Aug 07, 1992CEFPROZIL

FOR SUSPENSION; ORAL

CEFZIL

BRISTOL MYERS SQUIBB

125MG/5ML
250MG/5MLN050665 001 Dec 23, 1991
N050665 002 Dec 23, 1991

TABLET; ORAL

CEFZIL

BRISTOL MYERS SQUIBB

250MG
500MGN050664 001 Dec 23, 1991
N050664 002 Dec 23, 1991CEFTAZIDIME

INJECTABLE; INJECTION

CEPTAZ

GLAXOSMITHKLINE

500MG/VIAL
1GM/VIAL
2GM/VIAL
10GM/VIALN050646 001 Sep 27, 1990
N050646 002 Sep 27, 1990
N050646 003 Sep 27, 1990
N050646 004 Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE

1GM/VIAL
1GM/VIAL
2GM/VIAL
2GM/VIAL
6GM/VIAL
10GM/VIALA063322 001 Nov 07, 1995
A064006 001 Mar 31, 1992
A063322 002 Nov 07, 1995
A064006 002 Mar 31, 1992
A064008 001 Mar 31, 1992
A064008 002 Mar 31, 1992

TAZIDIME

LILLY

1GM/VIAL
2GM/VIALA062655 001 Nov 20, 1985
A062655 002 Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY

1GM/VIAL
2GM/VIALA062739 001 Jul 10, 1986
A062739 002 Jul 10, 1986CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML
EQ 20MG BASE/ML
EQ 40MG BASE/MLA063221 001 Apr 29, 1993
A063221 002 Apr 29, 1993
A063221 003 Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N050634 001 Apr 28, 1989

CEFTIBUTEN DIHYDRATE

FOR SUSPENSION; ORAL

CEDAX

PERNIX THERAP

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS

EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 1GM BASE/VIALN050560 001 Sep 15, 1983
A063294 002 Mar 31, 1994
N050560 002 Sep 15, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 61 (of 331)

CEFTIZOXIME SODIUMINJECTABLE; INJECTION
CEFIZOX

ASTELLAS	EQ 2GM BASE/VIAL	A063294	003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560	003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER				
ASTELLAS	EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589	002	Oct 03, 1984
CEFIZOX IN PLASTIC CONTAINER				
ASTELLAS	EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589	004	Apr 13, 1995

CEFTRIAZONE SODIUMINJECTABLE; IM-IV
ROCEPHIN

HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	N050585	001	Dec 21, 1984
	EQ 500MG BASE/VIAL	N050585	002	Dec 21, 1984
	EQ 1GM BASE/VIAL	N050585	003	Dec 21, 1984
	EQ 2GM BASE/VIAL	N050585	004	Dec 21, 1984

INJECTABLE; INJECTION
ROCEPHIN

HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	A063239	001	Aug 13, 1993
	EQ 500MG BASE/VIAL	A062654	001	Apr 30, 1987
	EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987
	EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987
	EQ 10GM BASE/VIAL	N050585	005	Dec 21, 1984
ROCHE	EQ 250MG BASE/VIAL	A062510	001	Mar 12, 1985
	EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985
	EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER				
HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987
	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987
	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987

CEFTRIAZONE SODIUM; LIDOCAINEINJECTABLE; INJECTION
ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL, N/A; N/A, 1%	N050585	007	May 08, 1996
	EQ 1GM BASE/VIAL, N/A; N/A, 1%	N050585	006	May 08, 1996

CEFUROXIME AXETILTABLET; ORAL
CEFUROXIME AXETIL

SANDOZ	EQ 250MG BASE	A065126	001	Oct 28, 2003
	EQ 500MG BASE	A065126	002	Oct 28, 2003

CEFUROXIME SODIUMINJECTABLE; IM-IV
CEFUROXIME SODIUM

MARSAM PHARMS LLC	EQ 750MG BASE/VIAL	A064035	001	Feb 26, 1993
KEFUROX				
ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986

INJECTABLE; INJECTION
CEFUROXIME SODIUM

MARSAM PHARMS LLC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993
KEFUROX				
ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591	002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591	003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592	002	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER				
LILLY	EQ 1.5GM BASE/VIAL	A062590	002	Jan 10, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 62 (of 331)

CEFUROXIME SODIUM

INJECTABLE; INTRAVENOUS

KEFUROX

LILLY

EQ 750MG BASE/VIAL

A062592 001 Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY

EQ 750MG BASE/VIAL

A062590 001 Jan 10, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA

2.5GM/PACKET

N018757 002 Dec 28, 1982

300GM/BOT

N018757 003 Oct 16, 1984

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

APOTHECON

EQ 250MG BASE

A062973 001 Nov 08, 1988

EQ 250MG BASE

A063063 001 Sep 29, 1989

EQ 250MG BASE

A063186 001 Dec 30, 1994

EQ 500MG BASE

A062974 001 Nov 23, 1988

EQ 500MG BASE

A063063 002 Sep 29, 1989

EQ 500MG BASE

A063186 002 Dec 30, 1994

BARR

EQ 250MG BASE

A062773 001 Jun 26, 1987

EQ 500MG BASE

A062775 001 Apr 22, 1987

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A061969 001

EQ 500MG BASE

A061969 002

PUREPAC PHARM

EQ 250MG BASE

A062809 001 Apr 22, 1987

EQ 500MG BASE

A062809 002 Apr 22, 1987

STEVENS J

EQ 500MG BASE

A062869 001 Mar 17, 1988

TEVA

EQ 250MG BASE

A062760 001 Apr 24, 1987

EQ 250MG BASE

A062821 001 Feb 05, 1988

EQ 500MG BASE

A062761 001 Apr 24, 1987

EQ 500MG BASE

A062823 001 Feb 05, 1988

YOSHITOMI

EQ 250MG BASE

A062872 001 Jun 20, 1988

EQ 500MG BASE

A062871 001 Jul 05, 1988

KEFLEX

VICTORY PHARMA

EQ 333MG BASE

N050405 004 May 12, 2006

FOR SUSPENSION; ORAL

CEPHALEXIN

ACS DOBFAR INFO SA

EQ 100MG BASE/ML

A062117 001

APOTHECON

EQ 125MG BASE/5ML

A062986 001 Apr 18, 1991

EQ 250MG BASE/5ML

A062987 001 Jul 25, 1989

BARR

EQ 125MG BASE/5ML

A062778 001 Aug 06, 1987

EQ 250MG BASE/5ML

A062777 001 Aug 06, 1987

TEVA

EQ 125MG BASE/5ML

A062767 001 Jun 16, 1987

EQ 125MG BASE/5ML

A062873 001 May 23, 1988

EQ 250MG BASE/5ML

A062768 001 Jun 16, 1987

EQ 250MG BASE/5ML

A062867 001 Apr 15, 1988

VITARINE

EQ 125MG BASE/5ML

A062779 001 Dec 22, 1987

EQ 250MG BASE/5ML

A062781 001 Dec 22, 1987

KEFLEX

LEX PHARMS

EQ 100MG BASE/ML

N050406 003

EQ 125MG BASE/5ML

N050406 001

EQ 250MG BASE/5ML

N050406 002

TABLET; ORAL

CEPHALEXIN

BARR

EQ 250MG BASE

A062826 001 Aug 17, 1987

EQ 500MG BASE

A062827 001 Aug 17, 1987

VITARINE

EQ 250MG BASE

A062863 001 Aug 11, 1988

EQ 500MG BASE

A062863 002 Aug 11, 1988

EQ 1GM BASE

A062863 003 Aug 11, 1988

KEFLET

LILLY

EQ 250MG BASE

A062745 001 Dec 01, 1986

EQ 250MG BASE

N050440 003 Feb 26, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 63 (of 331)

CEPHALEXIN

TABLET; ORAL

KEFLET

LILLY

EQ 500MG BASE

A062745 002

Dec 01, 1986

EQ 500MG BASE

N050440 001

EQ 1GM BASE

N050440 002

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

LILLY

EQ 250MG BASE

N050614 001

Oct 29, 1987

EQ 333MG BASE

N050614 003

May 16, 1988

EQ 500MG BASE

N050614 002

Oct 29, 1987

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

LILLY

250MG

N050219 001

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

INTL MEDICATION

EQ 500MG BASE/VIAL

A062426 001

May 03, 1985

EQ 1GM BASE/VIAL

A062426 002

May 03, 1985

EQ 2GM BASE/VIAL

A062426 003

May 03, 1985

EQ 4GM BASE/VIAL

A062426 004

May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT

EQ 1GM BASE/VIAL

A062547 001

Sep 11, 1985

EQ 1GM BASE/VIAL

A062548 001

Sep 11, 1985

EQ 2GM BASE/VIAL

A062547 002

Sep 11, 1985

EQ 2GM BASE/VIAL

A062548 002

Sep 11, 1985

ABRAXIS PHARM

EQ 1GM BASE/VIAL

A062666 002

Jun 10, 1987

EQ 2GM BASE/VIAL

A062666 001

Jun 10, 1987

BRISTOL

EQ 1GM BASE/VIAL

A062464 001

May 07, 1984

EQ 2GM BASE/VIAL

A062464 002

May 07, 1984

EQ 4GM BASE/VIAL

A062464 003

May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 003

Jan 31, 1984

EQ 20MG BASE/ML

A062422 005

Jul 16, 1991

EQ 20MG BASE/ML

A062730 001

Mar 05, 1987

EQ 40MG BASE/ML

A062422 004

Jan 31, 1984

EQ 40MG BASE/ML

A062422 006

Jul 16, 1991

EQ 40MG BASE/ML

A062730 002

Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 001

Jan 31, 1984

EQ 40MG BASE/ML

A062422 002

Jan 31, 1984

KEFLIN

LILLY

EQ 1GM BASE/VIAL

N050482 001

EQ 2GM BASE/VIAL

N050482 002

EQ 4GM BASE/VIAL

N050482 003

EQ 20GM BASE/VIAL

N050482 007

KEFLIN IN PLASTIC CONTAINER

LILLY

EQ 1GM BASE/VIAL

A062549 001

Sep 10, 1985

EQ 2GM BASE/VIAL

A062549 002

Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A062435 001

Nov 15, 1983

EQ 2GM BASE/VIAL

A062435 002

Nov 15, 1983

EQ 10GM BASE/VIAL

A062435 003

Nov 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON

EQ 500MG BASE/VIAL

A062961 001

Sep 20, 1988

EQ 500MG BASE/VIAL

N050446 005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 64 (of 331)

CEPHAPIRIN SODIUMINJECTABLE; INJECTION
CEFADYL

APOTHECON

EQ 1GM BASE/VIAL	A061769	001	
EQ 1GM BASE/VIAL	A062724	001	Dec 23, 1986
EQ 1GM BASE/VIAL	A062961	002	Sep 20, 1988
EQ 1GM BASE/VIAL	N050446	001	
EQ 2GM BASE/VIAL	A061769	002	
EQ 2GM BASE/VIAL	A062724	002	Dec 23, 1986
EQ 2GM BASE/VIAL	A062961	003	Sep 20, 1988
EQ 2GM BASE/VIAL	N050446	002	
EQ 4GM BASE/VIAL	A061769	003	
EQ 4GM BASE/VIAL	A062961	004	Sep 20, 1988
EQ 4GM BASE/VIAL	N050446	003	
EQ 20GM BASE/VIAL	N050446	004	

CEPHAPIRIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL	A062723	001	Nov 17, 1986
EQ 1GM BASE/VIAL	A062723	002	Nov 17, 1986
EQ 2GM BASE/VIAL	A062723	003	Nov 17, 1986
EQ 4GM BASE/VIAL	A062723	004	Nov 17, 1986
EQ 20GM BASE/VIAL	A062723	005	Nov 17, 1986

BAXTER HLTHCARE

EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987
EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987
EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE

250MG	A061859	001
500MG	A061859	002

CEPHRADINE

BARR

250MG	A062850	001	Apr 22, 1988
500MG	A062851	001	Apr 22, 1988

IVAX SUB TEVA PHARMS

250MG	A062762	001	Mar 06, 1987
500MG	A062762	002	Mar 06, 1987

TEVA

250MG	A062683	001	Jan 09, 1987
500MG	A062683	002	Jan 09, 1987

VITARINE

250MG	A062813	001	Feb 25, 1988
500MG	A062813	002	Feb 25, 1988

VELOSEF

APOTHECON

250MG	A061764	001
500MG	A061764	002

VELOSEF '250'

ERSANA

250MG	N050548	001

VELOSEF '500'

ERSANA

500MG	N050548	002

FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE

125MG/5ML	A061866	001
250MG/5ML	A061866	002

CEPHRADINE

BARR

125MG/5ML	A062858	001	May 19, 1988
250MG/5ML	A062859	001	May 19, 1988

TEVA

125MG/5ML	A062693	001	Jan 09, 1987
250MG/5ML	A062693	002	Jan 09, 1987

VELOSEF '125'

APOTHECON

125MG/5ML	A061763	001

VELOSEF '250'

APOTHECON

250MG/5ML	A061763	002

INJECTABLE; INJECTION

VELOSEF

APOTHECON

250MG/VIAL	A061976	001
500MG/VIAL	A061976	002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 65 (of 331)

CEPHRADINEINJECTABLE; INJECTION
VELOSEF

APOTHECON

1GM/VIAL

A061976 004

2GM/VIAL

A061976 003

4GM/VIAL

A061976 005

TABLET; ORAL
VELOSEF

BRISTOL MYERS SQUIBB 1GM

N050530 001

CERIVASTATIN SODIUMTABLET; ORAL
BAYCOL

BAYER PHARMS

0.05MG

N020740 001 Jun 26, 1997

0.1MG

N020740 002 Jun 26, 1997

0.2MG

N020740 003 Jun 26, 1997

0.3MG

N020740 004 Jun 26, 1997

0.4MG

N020740 005 May 24, 1999

0.8MG

N020740 006 Jul 24, 2000

CERULETIDE DIETHYLAMINEINJECTABLE; INJECTION
TYMTRAN

PHARMACIA AND UPJOHN 0.02MG/ML

N018296 001

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOLFOR SUSPENSION; INTRATRACHEAL
EXOSURF NEONATAL

GLAXOSMITHKLINE

12MG/VIAL;108MG/VIAL;8MG/VIAL

N020044 001 Aug 02, 1990

CHENODIOLTABLET; ORAL
CHENIX

SIGMA TAU

250MG

N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDESYRUP; ORAL
ULO

3M

25MG/5ML

N012126 001

CHLORAMPHENICOLCAPSULE; ORAL
AMPHICOL

FERRANTE

100MG

A060058 001

250MG

A060058 002

CHLORAMPHENICOL

IVAX SUB TEVA PHARMS 250MG

A062247 001

CHLOROMYCETIN

PARKEDALE

50MG

A060591 001

100MG

A060591 003

250MG

A060591 002

MYCHEL

ARMENPHARM

250MG

A060851 001

CREAM; TOPICAL

CHLOROMYCETIN

PARKE DAVIS

1%

N050183 001

FOR SOLUTION; OPHTHALMIC

CHLOROMYCETIN

PARKEDALE

25MG/VIAL

N050143 001

INJECTABLE; INJECTION

CHLOROMYCETIN

PARKE DAVIS

250MG/ML

N050153 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 66 (of 331)

CHLORAMPHENICOLOINTMENT; OPHTHALMIC
CHLORAMPHENICOL

ALTANA 1% A060133 001

CHLOROFAIR

PHARMAFAIR 1% A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE 1% N050156 001

CHLOROPTIC S.O.P.

ALLERGAN 1% A061187 001

ECONOCHLOR

ALCON 1% A061648 001

SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL

AKORN 0.5% A062042 001

ALCON 0.5% A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR 0.5% A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN 0.5% N050091 001

ECONOCHLOR

ALCON 0.5% A061645 001

OPHTHOCHLOR

PARKEDALE 0.5% A061220 001

OPTOMYCIN

OPTOPICS 0.5% A062171 001 Mar 31, 1982

SOLUTION/DROPS; OTIC
CHLOROMYCETIN

PARKEDALE 0.5% N050205 001

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

PARKE DAVIS EQ 150MG BASE/5ML A062301 001

EQ 150MG BASE/5ML N050152 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN EQ 1GM BASE/VIAL A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT EQ 1GM BASE/VIAL A062278 001

CHLOROMYCETIN

PARKEDALE EQ 1GM BASE/VIAL N050155 001

MYCHEL-S

ANGUS EQ 1GM BASE/VIAL A060132 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

PARKE DAVIS 10MG/GM;666 UNITS/GM;1 UNITS/GM N050294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE 12.5MG/VIAL;25MG/VIAL N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKEDALE 10MG/GM;5MG/GM;10,000 UNITS/GM N050201 002

DISCONTINUED DRUG PRODUCT LIST

6 - 67 (of 331)

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC			
CHLOROMYXIN			
PARKE DAVIS	1%;10,000 UNITS/GM	N050203	002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC			
CHLOROPTIC-P S.O.P.			
ALLERGAN	1%;0.5%	A061188	001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL			
LIBRELEASE			
VALEANT PHARM INTL	30MG	N017813	001 Sep 12, 1983
TABLET; ORAL			
LIBRITABS			
VALEANT PHARM INTL	5MG	A085482	001
	10MG	A085481	001
	25MG	A085488	001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL			
A-POXIDE			
ABBOTT	5MG	A085447	001
	5MG	A085517	001
	10MG	A085447	002
	10MG	A085518	001
	25MG	A085447	003
	25MG	A085513	001
CHLORDIAZACHEL			
RACHELLE	5MG	A085086	001
	10MG	A084639	001
	25MG	A085087	001
CHLORDIAZEPOXIDE HYDROCHLORIDE			
ASCOT	5MG	A087525	001 Jan 07, 1982
	10MG	A087524	001 Jan 07, 1982
	25MG	A087512	001 Jan 07, 1982
FERRANTE	5MG	A085118	001
	10MG	A085119	001
	25MG	A085120	001
HALSEY	5MG	A085340	001
	10MG	A085339	001
	25MG	A084685	001
IMPAX LABS	5MG	A086213	001
	10MG	A085113	001
	25MG	A086212	001
IVAX SUB TEVA PHARMS	5MG	A083741	001
	10MG	A083742	001
	25MG	A083570	001
LEDERLE	5MG	A086892	001
	5MG	A087234	001
	10MG	A086876	001
	10MG	A087037	001
	25MG	A086893	001
	25MG	A087231	001
MAST MM	10MG	A086217	001
MYLAN	5MG	A084886	001
	10MG	A084601	001
	25MG	A084887	001
PARKE DAVIS	5MG	A085163	001
	10MG	A084598	001
	25MG	A085164	001
PIONEER PHARMS	10MG	A089533	001 Jul 15, 1988
	25MG	A089558	001 Jul 15, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 68 (of 331)

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SANDOZ	5MG	A084678	001	
	5MG	A084919	001	
	10MG	A084041	001	
	10MG	A084920	001	
	25MG	A084679	002	
SUPERPHARM	25MG	A084823	001	
	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
TEVA	25MG	A088988	001	Apr 25, 1985
	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
USL PHARMA	5MG	A084644	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WEST WARD	5MG	A085014	001	
	10MG	A085000	001	
	25MG	A085294	001	
LIBRIUM				
VALEANT PHARM INTL	5MG	N012249	002	
	10MG	N012249	001	
	25MG	N012249	003	
LYGEN				
ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	
INJECTABLE; INJECTION				
LIBRIUM				
VALEANT PHARM INTL	100MG/AMP	N012301	001	

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 10-4

ROCHE	10MG;0.4MG	N014740	006	

MENRIUM 5-2

ROCHE	5MG;0.2MG	N014740	002	

MENRIUM 5-4

ROCHE	5MG;0.4MG	N014740	004	

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

EXIDINE

XTTRIUM	2.5%	N019421	001	Dec 17, 1985

MICRODERM

J AND J	4%	A072255	001	Apr 15, 1991

PREVACARE R

J AND J	0.5%	A072292	001	Jan 28, 1992

STERI-STAT

MATRIX MEDCL	4%	A070104	001	Jul 24, 1986

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL	4%	N019490	001	Mar 27, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 69 (of 331)

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL				
E-Z SCRUB				
BECTON DICKINSON	4%	A073416	001	Mar 14, 2000
HIBICLENS				
MOLNLYCKE HLTH	4%	N018423	001	
MICRODERM				
J AND J	4%	A072295	001	Feb 28, 1991

CHLORMERODRIN HG-197

INJECTABLE; INJECTION				
CHLORMERODRIN HG 197				
BRACCO	0.6-1.4mCi/ML	N017269	001	

CHLORMEZANONE

TABLET; ORAL				
TRANCOPAL				
SANOFI AVENTIS US	100MG	N011467	003	
	200MG	N011467	005	

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
NESACAINE-MPF				
APP PHARMS	2%	N009435	003	
	3%	N009435	004	

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION				
ARALEN HYDROCHLORIDE				
SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002	002	

CHLOROQUINE PHOSPHATE

TABLET; ORAL				
CHLOROQUINE PHOSPHATE				
MD PHARM	EQ 150MG BASE	A087228	001	
PUREPAC PHARM	EQ 150MG BASE	A080886	001	
TEVA	EQ 150MG BASE	A087504	001	Jan 13, 1982
WATSON LABS	EQ 150MG BASE	A087979	001	Dec 21, 1982
	EQ 300MG BASE	A088030	001	Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL				
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE				
SANOFI AVENTIS US	EQ 300MG BASE;EQ 45MG BASE	N014860	002	

CHLOROTHIAZIDE

TABLET; ORAL				
CHLOROTHIAZIDE				
ABC HOLDING	250MG	A085569	001	
LEDERLE	250MG	A086940	001	
	500MG	A086938	001	
SANDOZ	250MG	A085485	001	
WATSON LABS	250MG	A085165	001	
	250MG	A085173	001	
	250MG	A086795	001	Aug 15, 1983
	500MG	A084026	001	Sep 01, 1982
	500MG	A086796	001	Aug 15, 1983
DIURIL				
LUNDBECK INC	250MG	N011145	004	
	500MG	N011145	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 70 (of 331)

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK

150MG;250MG

N016016 001

ALDOCLOR-250

MERCK

250MG;250MG

N016016 002

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM

150MG;250MG

A070783 001

Nov 06, 1987

250MG;250MG

A070654 001

Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

WEST WARD

250MG;0.125MG

A088557 001

Dec 22, 1983

500MG;0.125MG

A088365 001

Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS

250MG;0.125MG

A084853 001

500MG;0.125MG

A088151 001

Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN

250MG;0.125MG

A087744 001

May 06, 1982

500MG;0.125MG

A087745 001

May 06, 1982

DIUPRES-250

MERCK

250MG;0.125MG

N011635 003

Aug 26, 1987

DIUPRES-500

MERCK

500MG;0.125MG

N011635 006

Aug 26, 1987

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS

12MG

A084652 001

TACE

SANOFI AVENTIS US

12MG

N008102 004

25MG

N011444 001

72MG

N016235 001

CHLOROXINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB

2%

N017594 001

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PHARMACIA AND UPJOHN

400MG

N014217 002

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

SANDOZ

12MG

A070797 001

Aug 12, 1988

TELDRIN

GLAXOSMITHKLINE

8MG

N017369 001

12MG

N017369 002

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE

BEL MAR

10MG/ML

A080821 001

ELKINS SINN

10MG/ML

A080797 001

WATSON LABS

10MG/ML

A083593 001

10MG/ML

A086096 001

100MG/ML

A086095 001

CHLOR-TRIMETON

SCHERING PLOUGH

10MG/ML

N008826 001

100MG/ML

N008794 001

PYRIDAMAL 100

BEL MAR

100MG/ML

A083733 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 71 (of 331)

CHLORPHENIRAMINE MALEATE

SYRUP; ORAL

CHLORPHENIRAMINE MALEATE

PHARM ASSOC 2MG/5ML

A087520 001 Feb 10, 1982

CHLOR-TRIMETON

SCHERING 2MG/5ML

N006921 006

TABLET; ORAL

ANTAGONATE

BAYER PHARMS 4MG

A083381 001

CHLORPHENIRAMINE MALEATE

ANABOLIC 4MG

A083078 001

BELL PHARMA 4MG

A083062 001

ELKINS SINN 4MG

A080938 001

IMPAX LABS 4MG

A080809 001

IVAX SUB TEVA PHARMS 4MG

A080779 001

KV PHARM 4MG

A087164 001

LEDERLE 4MG

A086941 001

MUTUAL PHARM 4MG

A080700 001

NEWTRON PHARMS 4MG

A086519 001

PANRAY 4MG

A083243 001

PHARMAVITE 4MG

A085104 001

PHARMERAL 4MG

A083753 001

PIONEER PHARMS 4MG

A088556 001 Jul 13, 1984

PUREPAC PHARM 4MG

A086306 001

PVT FORM 4MG

A080786 001

ROXANE 4MG

A080626 001

SANDOZ 4MG

A080961 001

VITARINE 4MG

A085837 001

WATSON LABS 4MG

A080696 001

4MG

A080791 001

4MG

A085139 001

WEST WARD 4MG

A083787 001

CHLOR-TRIMETON

SCHERING 4MG

N006921 002

KLOROMIN

HALSEY 4MG

A083629 001

PHENETRON

LANNETT 4MG

A080846 001

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

SCHERING PLOUGH 8MG

N007638 001

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA 16MG

N019746 002 Nov 18, 1994

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE

WATSON LABS 12MG;75MG

A088681 001 Sep 29, 1987

CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE

SANDOZ 12MG;75MG

A088940 001 Jan 26, 1989

COLD CAPSULE IV

GRAHAM DM 12MG;75MG

N018793 001 Apr 25, 1985

COLD CAPSULE V

GRAHAM DM 8MG;75MG

N018794 001 Apr 23, 1985

CONTAC 12 HOUR

GLAXOSMITHKLINE 8MG;75MG

N018099 001

DRIZE

ASCHER 12MG;75MG

A088359 001 Feb 13, 1986

ORNADE

GLAXOSMITHKLINE 12MG;75MG

N012152 004

PHENYLPROPANOLAMINE HYDROCHLORIDE W/ CHLORPHENIRAMINE MALEATE

CENT PHARMS 8MG;75MG

N018809 001 May 07, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 72 (of 331)

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CONTAC

NOVARTIS	12MG;75MG	N019613	001	Jun 13, 1986

DEMAZIN

SCHERING PLOUGH	4MG;25MG	N018556	001	May 14, 1984

TRIAMINIC-12

NOVARTIS	12MG;75MG	N018115	001	

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA	12MG;120MG	N018935	001	Apr 15, 1985

ISOCLOR

FISONS	8MG;120MG	N018747	001	Mar 06, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS	8MG;120MG	N019428	001	Aug 02, 1988

GRAHAM DM	8MG;120MG	N018844	001	Mar 20, 1985

	12MG;120MG	N018843	001	Mar 18, 1985

KV PHARM	12MG;120MG	A071455	001	Mar 01, 1989

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

UCB INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N021369	001	Jun 21, 2004

PENNTUSS

FISONS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N018928	001	Aug 14, 1985

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CORSYM

UCB INC	EQ 4MG MALEATE/5ML;EQ 37.5MG HCL/5ML	N018050	001	Jan 04, 1984

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE

PARKE DAVIS	EQ 65MG BASE	N014696	001	

CHLORPROMAZINE

SUPPOSITORY; RECTAL

THORAZINE

GLAXOSMITHKLINE	25MG	N009149	024	

	100MG	N009149	033	

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

GLAXOSMITHKLINE	30MG	N011120	016	

	75MG	N011120	017	

	150MG	N011120	018	

	200MG	N011120	019	

	300MG	N011120	020	

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A086863	001	

PHARM ASSOC	30MG/ML	A040231	001	Dec 30, 1999

	100MG/ML	A040224	001	Jan 26, 1999

WOCKHARDT	30MG/ML	A087032	001	Jul 08, 1982

	100MG/ML	A087053	001	

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

ROXANE	30MG/ML	A088157	001	Apr 27, 1983

	100MG/ML	A088158	001	Apr 27, 1983

SONAZINE

SANDOZ	30MG/ML	A080983	004	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 73 (of 331)

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SONAZINE

SANDOZ	100MG/ML	A080983	005

THORAZINE

GLAXOSMITHKLINE	30MG/ML	N009149	032

100MG/ML	N009149	043

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM	25MG/ML	A084911	001

MARSAM PHARMS LLC	25MG/ML	A089563	001

WATSON LABS	25MG/ML	A080365	001

25MG/ML	A085591	001

WYETH AYERST	25MG/ML	A080370	001

THORAZINE

GLAXOSMITHKLINE	25MG/ML	N009149	011

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A086712	001

SONAZINE

SANDOZ	10MG/5ML	A083040	001

THORAZINE

GLAXOSMITHKLINE	10MG/5ML	N009149	022

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001

25MG	A084415	001

50MG	A084411	001

100MG	A084412	001

200MG	A084413	001

IVAX SUB TEVA PHARMS	10MG	A083549	001

25MG	A083549	002

50MG	A083549	003

100MG	A083574	001

200MG	A083575	001

KV PHARM	10MG	A085750	002

25MG	A085751	001

50MG	A085484	001

100MG	A085752	001

200MG	A085748	002

LEDERLE	10MG	A084803	001

25MG	A084801	001

50MG	A084800	001

100MG	A084789	001

200MG	A084802	001

PUREPAC PHARM	10MG	A080403	004

25MG	A080403	001

50MG	A080403	002

100MG	A080403	003

200MG	A080403	005

PVT FORM	25MG	A080340	001

50MG	A080340	002

200MG	A080340	003

ROXANE	10MG	A085331	001

25MG	A085331	002

50MG	A085331	003

100MG	A085331	004

200MG	A085331	005

VANGARD	10MG	A088038	001

25MG	A087645	001

50MG	A087646	001

WATSON LABS	10MG	A085959	001

25MG	A085956	001

50MG	A085960	001

100MG	A085957	001

Apr 15, 1988

Jan 04, 1982

Jan 04, 1982

Aug 16, 1982

DISCONTINUED DRUG PRODUCT LIST

6 - 74 (of 331)

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

WATSON LABS	200MG	A085958	001	
WEST WARD	10MG	A087783	001	Sep 16, 1982
	25MG	A087865	001	Sep 16, 1982
	50MG	A087878	001	Sep 15, 1982
	100MG	A087884	001	Sep 15, 1982
	200MG	A087880	001	Sep 16, 1982
PROMAPAR				
PARKE DAVIS	10MG	A086886	001	
	25MG	A084423	001	
	50MG	A086887	001	
	100MG	A086888	001	
	200MG	A086885	001	
THORAZINE				
GLAXOSMITHKLINE	10MG	N009149	002	
	25MG	N009149	007	
	50MG	N009149	013	
	100MG	N009149	018	
	200MG	N009149	020	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

BARR	100MG	A088812	001	Oct 19, 1984
	100MG	A089446	001	Nov 17, 1986
	250MG	A088813	001	Oct 19, 1984
	250MG	A089447	001	Nov 17, 1986
CLONMEL HLTHCARE	100MG	A089561	001	Sep 04, 1987
	250MG	A089562	001	Sep 04, 1987
DURAMED PHARMS BARR	100MG	A088918	001	Oct 16, 1984
	250MG	A088919	001	Oct 16, 1984
HALSEY	100MG	A089321	001	Jan 16, 1986
	250MG	A088662	001	Jan 09, 1986
IVAX PHARMS	100MG	A088840	001	Oct 25, 1984
	250MG	A087353	001	
PAR PHARM	100MG	A088175	001	Feb 27, 1984
	250MG	A088176	001	Feb 27, 1984
SANDOZ	100MG	A088725	001	Aug 31, 1984
	250MG	A084669	001	
	250MG	A088726	001	Aug 31, 1984
SUPERPHARM	100MG	A088694	001	Sep 17, 1984
	250MG	A088695	001	Sep 17, 1984
TEVA	100MG	A088768	001	Oct 11, 1984
USL PHARMA	100MG	A088708	001	Aug 30, 1984
	250MG	A088709	001	Aug 30, 1984
WATSON LABS	100MG	A086865	001	Sep 24, 1984
	100MG	A088608	001	Apr 12, 1984
	250MG	A086866	001	
	250MG	A088568	001	Apr 12, 1984
GLUCAMIDE				
TEVA	250MG	A088641	001	Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE	100MG/5ML	N016149	002

INJECTABLE; INJECTION

TARACTAN

ROCHE	12.5MG/ML	N012487	001

TABLET; ORAL

TARACTAN

ROCHE	10MG	N012486	005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 75 (of 331)

CHLORPROTHIXENE

TABLET; ORAL

TARACTAN

ROCHE

25MG

N012486 004

50MG

N012486 003

100MG

N012486 001

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE

1%

N050404 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT

25MG

A087364 001

50MG

A087384 001

ASCOT

25MG

A087698 001

Oct 20, 1982

50MG

A087699 001

Oct 20, 1982

CLONMEL HLTHCARE

25MG

A087451 001

50MG

A087450 001

IVAX PHARMS

25MG

A087555 001

25MG

A088164 001

Jan 09, 1984

50MG

A087176 001

50MG

A087947 001

Feb 27, 1984

KV PHARM

25MG

A087311 001

50MG

A087312 001

MUTUAL PHARM

25MG

A087292 001

25MG

A089285 001

Jul 21, 1986

25MG

A089738 001

Sep 19, 1988

50MG

A087293 001

50MG

A089286 001

Jul 21, 1986

50MG

A089739 001

Sep 19, 1988

PIONEER PHARMS

50MG

A089591 001

Jul 21, 1988

PUREPAC PHARM

25MG

A088139 001

Jul 16, 1986

50MG

A088140 001

Aug 11, 1983

SANDOZ

25MG

A087380 001

50MG

A087118 001

50MG

A087381 001

SUPERPHARM

25MG

A087473 001

Feb 09, 1983

50MG

A087247 001

Feb 09, 1983

TEVA

50MG

A088651 001

May 30, 1985

USL PHARMA

25MG

A089051 001

Jun 01, 1987

50MG

A089052 001

Jun 01, 1987

VANGARD

25MG

A088012 001

Jul 14, 1982

50MG

A088073 001

Mar 25, 1983

WARNER CHILCOTT

25MG

A087515 001

Jan 24, 1983

50MG

A087516 001

Feb 09, 1983

WATSON LABS

25MG

A087050 001

25MG

A087100 001

25MG

A087296 001

25MG

A087706 001

50MG

A087029 001

50MG

A087082 001

50MG

A087521 001

50MG

A087689 001

HYGROTON

SANOFI AVENTIS US

25MG

N012283 004

50MG

N012283 003

THALITONE

MONARCH PHARMS

25MG

A088051 001

Nov 12, 1982

25MG

N019574 002

Feb 12, 1992

DISCONTINUED DRUG PRODUCT LIST

6 - 76 (of 331)

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG;0.1MG	A071179	001	Dec 16, 1987
	15MG;0.2MG	A071178	001	Dec 16, 1987
	15MG;0.3MG	A071142	001	Dec 16, 1987

COMBIPRES

BOEHRINGER INGELHEIM	15MG;0.1MG	N017503	001	
	15MG;0.2MG	N017503	002	
	15MG;0.3MG	N017503	003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

NOVARTIS	25MG;100MG	N019451	001	Dec 31, 1987
	25MG;200MG	N019451	002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

SANOFI AVENTIS US	25MG;0.125MG	N015103	002	

REGROTON

SANOFI AVENTIS US	50MG;0.25MG	N015103	001	

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

MUTUAL PHARM	500MG	A089970	001	Sep 27, 1990
PAR PHARM	250MG	A087981	001	Sep 20, 1983
PIONEER PHARMS	250MG	A089592	001	Jan 06, 1989
	500MG	A089948	001	Jan 06, 1989
SANDOZ	250MG	A089852	001	May 04, 1988
	500MG	A089853	001	May 04, 1988
WATSON LABS	250MG	A086901	001	
	250MG	A086948	001	Aug 09, 1982
	500MG	A081019	001	Jul 29, 1991

PARAFLEX

ORTHO MCNEIL PHARM	250MG	N011300	003	

STRIFON FORTE DSC

FERNDAL LABS	500MG	A081008	001	Dec 23, 1988

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

PARKE DAVIS	EQ 4GM RESIN/BAR	A071621	001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739	001	May 26, 1988

POWDER; ORAL

CHOLESTYRAMINE

IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771	001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771	002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996
	EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996

CHOLESTYRAMINE LIGHT

TEVA	EQ 4GM RESIN/PACKET	A074348	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555	001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555	002	Sep 30, 1998

TABLET; ORAL

QUESTRAN

APOTHECON	EQ 800MG RESIN	A073403	002	Dec 27, 1999
	EQ 1GM RESIN	A073403	001	Apr 28, 1994

DISCONTINUED DRUG PRODUCT LIST

6 - 77 (of 331)

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION
OVIDREL

EMD SERONO	0.25MG/VIAL	N021149	001	Sep 20, 2000

CHROMIC CHLORIDE

INJECTABLE; INJECTION
CHROMIC CHLORIDE

ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271	001	May 05, 1987

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION
PHOSPHOCOL P32

MALLINCKRODT	5mCi/ML	N017084	001	

CHYMOPAPAIN

INJECTABLE; INJECTION
CHYMODIACTIN

CHART MEDCL	4,000 UNITS/VIAL	N018663	002	Aug 21, 1984
	10,000 UNITS/VIAL	N018663	001	Nov 10, 1982

DISCASE ABBOTT	12,500 UNITS/VIAL	N018625	001	Jan 18, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ALPHA CHYMAR

SOLA BARNES HIND	750 UNITS/VIAL	N011837	001	

CATARASE

CIBA	300 UNITS/VIAL	N016938	001	
NOVARTIS	150 UNITS/VIAL	N018121	001	

ZOLYSE

ALCON	750 UNITS/VIAL	N011903	001	

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION
PRIMAXIN

MERCK	EQ 750MG BASE/VIAL;750MG/VIAL	N050630	002	Dec 14, 1990

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

IVAX SUB TEVA PHARMS	100MG	A077020	002	Mar 01, 2005
MUTUAL PHARM	50MG	A077208	002	Mar 29, 2006
	100MG	A077208	001	Mar 29, 2006

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999

TABLET; ORAL

CIMETIDINE

APOTEX	100MG	A074948	001	Jun 19, 1998
	200MG	A074948	002	Jul 26, 2002
ENDO PHARMS	200MG	A074281	001	May 17, 1994
	300MG	A074281	002	May 17, 1994
	400MG	A074281	003	May 17, 1994
	800MG	A074329	001	May 17, 1994
IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
	300MG	A074401	002	May 30, 1995
	400MG	A074401	003	May 30, 1995
	800MG	A074402	001	May 30, 1995
LEK PHARMS	100MG	A075122	001	Jun 19, 1998
	200MG	A074250	001	Jun 29, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 78 (of 331)

CIMETIDINETABLET; ORAL
CIMETIDINE

LEK PHARMS	200MG	A075122	002	Jun 19, 1998
	300MG	A074250	002	Jun 29, 1995
	400MG	A074250	003	Jun 29, 1995
	800MG	A074250	004	Jun 29, 1995
PERRIGO	100MG	A074972	001	Jun 19, 1998
ROXANE	300MG	A074361	001	Dec 23, 1994
	400MG	A074361	002	Dec 23, 1994
	800MG	A074371	001	Dec 23, 1994
SANDOZ	200MG	A074100	001	Jan 31, 1995
	300MG	A074100	002	Jan 31, 1995
	400MG	A074100	003	Jan 31, 1995
	800MG	A074100	004	Jan 31, 1995
TEVA	200MG	A074365	001	Feb 28, 1995
	300MG	A074365	002	Feb 28, 1995
	400MG	A074365	003	Feb 28, 1995
	800MG	A074365	004	Feb 28, 1995
TAGAMET HB				
GLAXOSMITHKLINE	100MG	N020238	001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

ENDO PHARMS	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994
HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074412	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422	001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353	001	Dec 20, 1994
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 90MG BASE/100ML	A074468	005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994
TAGAMET				
GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N017939	002	
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
GLAXOSMITHKLINE	EQ 6MG BASE/ML	N019434	001	Oct 31, 1985

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994
DURAMED PHARMS BARR	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998
ENDO PHARMS	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994
ROXANE	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997
TEVA PHARMS	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998
TAGAMET				
GLAXOSMITHKLINE	EO 300MG BASE/5ML	N017924	001	

CINOXACIN

CAPSULE; ORAL

CINOXACIN

LILLY	250MG	N018067	001	
	500MG	N018067	002	
CINOXACIN				
TEVA	250MG	A073005	001	Feb 28, 1992
	500MG	A073006	001	Feb 28, 1992

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPRO

BAYER HLTHCARE	1200MG/120ML (10MG/ML)	N019847	003	Dec 26, 1990

DISCONTINUED DRUG PRODUCT LIST

6 - 79 (of 331)

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS 200MG/100ML

N019858 001 Dec 26, 1990

CIPROFLOXACIN

APP PHARMS 200MG/20ML (10MG/ML)

A076484 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A076484 002 Aug 28, 2006

BEDFORD LABS 200MG/20ML (10MG/ML)

A076992 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A076992 002 Aug 28, 2006

1200MG/120ML (10MG/ML)

A076993 001 Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA 200MG/100ML

A076757 001 Apr 21, 2008

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BEDFORD 200MG/100ML

A078114 001 Mar 18, 2008

400MG/200ML

A078114 002 Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

BARR EQ 250MG BASE

A074124 001 Jun 09, 2004

EQ 500MG BASE

A074124 002 Jun 09, 2004

EQ 750MG BASE

A074124 003 Jun 09, 2004

NOSTRUM LABS EQ 250MG BASE

A076138 001 Jun 09, 2004

EQ 500MG BASE

A076138 002 Jun 09, 2004

EQ 750MG BASE

A076138 003 Jun 09, 2004

SANDOZ EQ 100MG BASE

A075939 001 Mar 03, 2005

EQ 250MG BASE

A075939 002 Jun 09, 2004

EQ 250MG BASE

A076593 002 Jun 09, 2004

EQ 500MG BASE

A075939 003 Jun 09, 2004

EQ 500MG BASE

A076593 003 Jun 09, 2004

EQ 750MG BASE

A075939 004 Jun 09, 2004

EQ 750MG BASE

A076593 004 Jun 09, 2004

TEVA EQ 250MG BASE

A076136 001 Jun 09, 2004

EQ 500MG BASE

A076136 002 Jun 09, 2004

EQ 750MG BASE

A076136 003 Jun 09, 2004

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

ANCHEN PHARMS 212.6MG;EQ 287.5MG BASE

A078166 002 Nov 27, 2007

425.2MG;EQ 574.9MG BASE

A078166 001 Nov 27, 2007

SANDOZ 212.6MG;EQ 287.5MG BASE

A078712 001 Dec 11, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID

ORTHO MCNEIL JANSSEN EQ 1MG BASE/ML

N020398 001 Sep 15, 1995

TABLET; ORAL

PROPULSID

ORTHO MCNEIL JANSSEN EQ 10MG BASE

N020210 001 Jul 29, 1993

EQ 20MG BASE

N020210 002 Dec 23, 1993

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA EQ 20MG BASE

N020767 001 Nov 07, 1997

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

BEDFORD 10MG/VIAL

A074713 001 Nov 14, 2000

50MG/VIAL

A074713 002 Nov 14, 2000

PLATINOL

BRISTOL MYERS 10MG/VIAL

N018057 001

PLATINOL-AQ

BRISTOL MYERS 0.5MG/ML

N018057 003 Jul 18, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 80 (of 331)

CISPLATIN

INJECTABLE; INJECTION
PLATINOL-AQ

BRISTOL MYERS	1MG/ML	N018057	004	Nov 08, 1988

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

APOTEX INC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005

TABLET; ORAL

CELEXA

FOREST LABS	EQ 60MG BASE	N020822	004	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 10MG BASE	A077033	001	Oct 28, 2004

	EQ 20MG BASE	A077033	002	Oct 28, 2004

	EQ 40MG BASE	A077033	003	Oct 28, 2004

MUTUAL PHARM	EQ 10MG BASE	A077052	001	Jul 03, 2006

	EQ 20MG BASE	A077052	002	Jul 03, 2006

	EQ 40MG BASE	A077052	003	Jul 03, 2006

ROXANE	EQ 10MG BASE	A077041	001	Nov 23, 2004

	EQ 20MG BASE	A077041	002	Nov 23, 2004

	EQ 40MG BASE	A077041	003	Nov 23, 2004

SANDOZ	EQ 10MG BASE	A077040	001	Aug 17, 2005

	EQ 20MG BASE	A077040	002	Aug 17, 2005

	EQ 40MG BASE	A077040	003	Aug 17, 2005

TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006

	EQ 20MG BASE	A077278	002	Mar 22, 2006

	EQ 40MG BASE	A077278	003	Mar 22, 2006

TEVA PHARMS	EQ 10MG BASE	A077213	001	Mar 31, 2006

	EQ 20MG BASE	A077213	002	Mar 31, 2006

	EQ 40MG BASE	A077213	003	Mar 31, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL	EQ 10MG BASE	N021763	001	Dec 20, 2005

	EQ 20MG BASE	N021763	002	Dec 20, 2005

	EQ 40MG BASE	N021763	003	Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519	001	Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904	001	May 27, 1983

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

ABBOTT	187MG/5ML	N050698	003	Sep 30, 1998

TABLET; ORAL

CLARITHROMYCIN

IVAX SUB TEVA PHARMS	250MG	A065137	001	May 31, 2005

	500MG	A065137	002	May 31, 2005

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

RANBAXY	1GM	A065210	001	Jan 26, 2005

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

TEVA PHARMS	EQ 0.5MG BASE/5ML	A073095	001	Apr 21, 1992

TAVIST

NOVARTIS	EQ 0.5MG BASE/5ML	N018675	001	Jun 28, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 81 (of 331)

CLEMASTINE FUMARATE

TABLET; ORAL				
CLEMASTINE FUMARATE				
TEVA	1.34MG	A073282	001	Jan 31, 1992
	1.34MG	A073282	002	Dec 03, 1992
TAVIST				
NOVARTIS	2.68MG	N017661	001	
TAVIST-1				
NOVARTIS	1.34MG	N017661	002	
	1.34MG	N017661	003	Aug 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL				
TAVIST-D				
NOVARTIS	EQ 1MG BASE; 75MG	N018298	001	Dec 15, 1982
	1.34MG; 75MG	N018298	002	Aug 21, 1992
	1.34MG; 75MG	N020640	001	Aug 09, 1996

CLIDINIUM BROMIDE

CAPSULE; ORAL				
QUARZAN				
ROCHE	2.5MG	N010355	001	
	5MG	N010355	002	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE	A061809	001	
	EQ 150MG BASE	A061809	002	
CLINDAMYCIN HYDROCHLORIDE				
TEVA	EQ 75MG BASE	A063027	001	Sep 20, 1989
WATSON LABS	EQ 75MG BASE	A063082	001	Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	A061827	001	

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 2% BASE	N050680	001	Aug 11, 1992
INJECTABLE; INJECTION				
CLEOCIN PHOSPHATE				
PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A061839	001	
CLINDAMYCIN PHOSPHATE				
ABRAXIS PHARM	EQ 150MG BASE/ML	A062747	001	Jun 03, 1988
ASTRAZENECA	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989
BAXTER HLTHCARE	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987
	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988
	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989
BEDFORD	EQ 150MG BASE/ML	A063163	001	Jun 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML	A062908	001	Feb 01, 1989
LOCH	EQ 150MG BASE/ML	A062905	001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML	A062913	001	Oct 20, 1988
SOLOPAK	EQ 150MG BASE/ML	A062819	001	Mar 15, 1988
	EQ 150MG BASE/ML	A062852	001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML	A063041	001	Dec 29, 1989
	EQ 150MG BASE/ML	A063282	001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML	A062900	001	Jun 08, 1988
	EQ 150MG BASE/ML	A063079	001	Mar 05, 1990
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
ABRAXIS PHARM	EQ 12MG BASE/ML	N050636	001	Dec 22, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 82 (of 331)

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001
	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001
	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML	N050648	001	Dec 29, 1989
	EQ 12MG BASE/ML	N050648	002	Dec 29, 1989
	EQ 900MG BASE/100ML	N050648	003	Dec 29, 1989

SOLUTION; TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN	EQ 1% BASE	A062363	001	Feb 08, 1982

CLINDAMYCIN PHOSPHATE

BOCA PHARMA	EQ 1% BASE	A062930	001	Jun 28, 1989
COPLEY PHARM	EQ 1% BASE	A062944	001	Jan 11, 1989
STIEFEL GSK	EQ 1% BASE	A064108	001	Sep 27, 1996

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL

NYSTAFORM

BAYER PHARMS	10MG/GM;100,000 UNITS/GM	N050235	001	

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

STIEFEL	0.05%	A075338	001	Feb 09, 2001

CLOBETASOL PROPIONATE (EMOLLIENT)

STIEFEL GSK	0.05%	A075733	001	Aug 22, 2001

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

STIEFEL GSK	0.05%	A075057	001	Aug 12, 1998

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

NOVARTIS	100MG	N019500	001	Dec 15, 1986

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

WYETH AYERST	500MG	N016099	002	

CLOFIBRATE

BANNER PHARMACAPS	500MG	A073396	001	Mar 20, 1992
SANDOZ	500MG	A072191	001	May 02, 1988
TEVA	500MG	A072600	001	Jul 25, 1991
USL PHARMA	500MG	A070531	001	Jun 16, 1986
WATSON LABS	500MG	A071603	001	Sep 18, 1987

CLOMIPHENE CITRATE

TABLET; ORAL

MILOPHENE

MILEX	50MG	A072196	001	Dec 20, 1988

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

SANDOZ	25MG	A074953	001	Jun 25, 1997
	50MG	A074953	002	Jun 25, 1997
	75MG	A074953	003	Jun 25, 1997
TEVA	25MG	A074849	001	Apr 04, 1997
	50MG	A074849	002	Apr 04, 1997
	75MG	A074849	003	Apr 04, 1997
WATSON LABS	25MG	A074600	001	Nov 27, 1996
	25MG	A074751	001	Sep 30, 1998

DISCONTINUED DRUG PRODUCT LIST

6 - 83 (of 331)

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

WATSON LABS

50MG

A074600 002 Nov 27, 1996

50MG

A074751 002 Sep 30, 1998

75MG

A074600 003 Nov 27, 1996

75MG

A074751 003 Sep 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

SANDOZ

0.5MG

A074925 001 Sep 30, 1997

1MG

A074925 002 Sep 30, 1997

2MG

A074925 003 Sep 30, 1997

TEVA

0.5MG

A074920 001 Aug 04, 1998

1MG

A074920 002 Aug 04, 1998

2MG

A074920 003 Aug 04, 1998

KLONOPIN

ROCHE

0.125MG

N017533 005 Apr 09, 1997

0.25MG

N017533 006 Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

ROCHE

0.125MG

N020813 001 Dec 23, 1997

0.25MG

N020813 002 Dec 23, 1997

0.5MG

N020813 003 Dec 23, 1997

1MG

N020813 004 Dec 23, 1997

2MG

N020813 005 Dec 23, 1997

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP

0.1MG

A070881 001 Jul 08, 1986

0.2MG

A070882 001 Jul 08, 1986

0.3MG

A070883 001 Jul 08, 1986

DURAMED PHARMS BARR

0.1MG

A071103 001 Aug 14, 1986

0.2MG

A071102 001 Aug 14, 1986

0.3MG

A071101 001 Aug 14, 1986

INTERPHARM

0.1MG

A071252 001 Oct 01, 1986

0.2MG

A071253 001 Oct 01, 1986

0.3MG

A071254 001 Oct 01, 1986

PAR PHARM

0.1MG

A070461 001 Jul 08, 1986

0.2MG

A070460 001 Jul 08, 1986

0.3MG

A070459 001 Jul 08, 1986

SANDOZ

0.1MG

A070887 001 Aug 31, 1988

0.2MG

A070886 001 Aug 31, 1988

0.3MG

A071294 001 Aug 31, 1988

TEVA

0.1MG

A070747 001 Jul 08, 1986

0.2MG

A070702 001 Jul 08, 1986

0.3MG

A070659 001 Jul 08, 1986

WARNER CHILCOTT

0.1MG

A072138 001 Jun 13, 1988

0.2MG

A072139 001 Jun 13, 1988

0.3MG

A072140 001 Jun 13, 1988

WATSON LABS

0.1MG

A070395 001 Mar 23, 1987

0.1MG

A070965 001 Jul 08, 1986

0.2MG

A070396 001 Mar 23, 1987

0.2MG

A070964 001 Jul 08, 1986

0.3MG

A070397 001 Mar 23, 1987

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

DR REDDYS LABS INC

EQ 75MG BASE

A076273 001 Jan 14, 2008

DISCONTINUED DRUG PRODUCT LIST

6 - 84 (of 331)

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071777	001	Jul 14, 1987
	7.5MG	A071778	001	Jul 14, 1987
	15MG	A071779	001	Jul 14, 1987
AM THERAP	3.75MG	A071429	001	Jun 23, 1987
	7.5MG	A071430	001	Jun 23, 1987
	15MG	A071431	001	Jun 23, 1987
CLONMEL HLTHCARE	3.75MG	A071742	001	Dec 14, 1987
	7.5MG	A071743	001	Dec 14, 1987
	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
SANDOZ	3.75MG	A072219	001	Aug 26, 1988
	7.5MG	A072220	001	Aug 26, 1988
	15MG	A072112	001	Aug 26, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988
	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988
TRANXENE				
LUNDBECK INC	3.75MG	N071705	001	
	7.5MG	N071705	002	
	15MG	N071705	003	

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SANDOZ	3.75MG	A072512	001	May 11, 1990
	7.5MG	A072513	001	May 11, 1990
	15MG	A072514	001	May 11, 1990
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 85 (of 331)

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL				
TRANXENE SD				
LUNDBECK INC	11.25MG		N017105	005
	22.5MG		N017105	004

CLOTRIMAZOLE

CREAM; TOPICAL				
LOTTRIMIN				
SCHERING PLOUGH	1%		N017619	001
MYCELEX				
BAYER PHARMS	1%		N018183	001
LOTION; TOPICAL				
LOTTRIMIN				
SCHERING	1%		N018813	001 Feb 17, 1984
SOLUTION; TOPICAL				
LOTTRIMIN				
SCHERING PLOUGH	1%		N017613	001
TABLET; VAGINAL				
GYNIX				
TEVA PHARMS	100MG		A073249	001 Feb 13, 1998
MYCELEX-G				
BAYER PHARMS	500MG		N019069	001 Apr 19, 1985

CLOXACILLIN SODIUM

CAPSULE; ORAL				
CLOXACILLIN SODIUM				
APOTHECON	EQ 250MG BASE		A061452	001
	EQ 500MG BASE		A061452	002
TEVA	EQ 250MG BASE		A062240	001
	EQ 500MG BASE		A062240	002
CLOXAPEN				
GLAXOSMITHKLINE	EQ 250MG BASE		A061806	001
	EQ 250MG BASE		A062233	001
	EQ 500MG BASE		A061806	002
	EQ 500MG BASE		A062233	002
FOR SOLUTION; ORAL				
CLOXACILLIN SODIUM				
TEVA	EQ 125MG BASE/5ML		A062268	001
	EQ 125MG BASE/5ML		A062978	001 Apr 06, 1989
TEGOPEN				
APOTHECON	EQ 125MG BASE/5ML		A061453	001
	EQ 125MG BASE/5ML		N050192	001

CLOZAPINE

TABLET; ORAL				
CLOZAPINE				
PAR PHARM	25MG		A075162	001 Apr 26, 2005
	100MG		A075162	002 Apr 26, 2005
SANDOZ	25MG		A074546	001 Aug 30, 1996
	100MG		A074546	002 Aug 30, 1996
TABLET, ORALLY DISINTEGRATING; ORAL				
FAZACLO ODT				
AZUR PHARMA INTL	50MG		N021590	003 Jun 03, 2005

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A				
RUBRATOPE-57 KIT				
BRACCO	N/A;N/A;N/A;N/A		N016089	001

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A; N/A				
RUBRATOPE-60 KIT				
BRACCO	N/A;N/A;N/A;N/A		N016090	001

DISCONTINUED DRUG PRODUCT LIST

6 - 86 (of 331)

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL					
PHENERGAN VC W/ CODEINE					
ANI PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML	N008306	005	Apr 02, 1984	
PERAZINE VC W/ CODEINE					
HALSEY	10MG/5ML;5MG/5ML;6.25MG/5ML	A088870	001	Mar 02, 1987	
PROMETHAZINE VC W/ CODEINE					
CENCI	10MG/5ML;5MG/5ML;6.25MG/5ML	A088816	001	Nov 22, 1985	
WOCKHARDT	10MG/5ML;5MG/5ML;6.25MG/5ML	A088896	001	Jan 04, 1985	

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL					
PHENERGAN W/ CODEINE					
ANI PHARMS	10MG/5ML;6.25MG/5ML	N008306	004	Apr 02, 1984	
PERAZINE W/ CODEINE					
HALSEY	10MG/5ML;6.25MG/5ML	A088739	001	Dec 23, 1988	
PROMETHAZINE W/ CODEINE					
CENCI	10MG/5ML;6.25MG/5ML	A088814	001	Nov 22, 1985	

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL					
ACTIFED W/ CODEINE					
GLAXOSMITHKLINE	10MG/5ML;30MG/5ML;1.25MG/5ML	N012575	003	Apr 04, 1984	
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE					
CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	A089018	001	Jul 23, 1986	
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE					
WOCKHARDT	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833	001	Nov 16, 1984	

COLCHICINE; PROBENECID

TABLET; ORAL					
COLBENEMID					
MERCK	0.5MG;500MG	N012383	001		
PROBEN-C					
WATSON LABS	0.5MG;500MG	A085552	001		
PROBENECID AND COLCHICINE					
BEECHAM	0.5MG;500MG	A084321	001		
IMPAX LABS	0.5MG;500MG	A083720	002		
IVAX SUB TEVA PHARMS	0.5MG;500MG	A083734	001		
SANDOZ	0.5MG;500MG	A086130	001		
PROBENECID W/ COLCHICINE					
LEDERLE	0.5MG;500MG	A086954	001		
WATSON LABS	0.5MG;500MG	A083221	001		

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL					
WELCHOL					
DAIICHI SANKYO	375MG	N021141	001	May 26, 2000	

COLISTIN SULFATE

SUSPENSION; ORAL					
COLY-MYCIN S					
PARKE DAVIS	EQ 25MG BASE/5ML	N050355	001		

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)					
VAPRISOL					
ASTELLAS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE					
CU-7					
GD SEARLE LLC	89MG	N017408	001		

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 87 (of 331)

COPPERINTRAUTERINE DEVICE; INTRAUTERINE
TATUM-T

GD SEARLE LLC 120MG N018205 001

CORTICOTROPININJECTABLE; INJECTION
ACTHPARKEDALE 25 UNITS/VIAL N008317 002
40 UNITS/VIAL N008317 004

ACTHAR

SANOFI AVENTIS US 25 UNITS/VIAL N007504 002
40 UNITS/VIAL N007504 003

CORTICOTROPIN

ORGANICS LAGRANGE 40 UNITS/ML N010831 001
80 UNITS/ML N010831 002
WATSON LABS 40 UNITS/VIAL A088772 001 Nov 21, 1984

H.P. ACTHAR GEL

QUESTCOR PHARMS 40 UNITS/ML N008372 006

PURIFIED CORTROPHIN GEL

ORGANON USA INC 40 UNITS/ML N008975 001
80 UNITS/ML N008975 002CORTICOTROPIN-ZINC HYDROXIDEINJECTABLE; INJECTION
CORTROPHIN-ZINC

ORGANON USA INC 40 UNITS/ML N009854 001

CORTISONE ACETATEINJECTABLE; INJECTION
CORTISONE ACETATEPHARMACIA AND UPJOHN 25MG/ML N008126 002
WATSON LABS 25MG/ML A083147 003
25MG/ML A085677 001
50MG/ML A083147 004
50MG/ML A085677 002

CORTONE

MERCK 25MG/ML N007110 002
50MG/ML N007110 003

TABLET; ORAL

CORTISONE ACETATE

BARR 25MG A083471 001
ELKINS SINN 25MG A080836 001
EVERYLIFE 25MG A084246 001
HEATHER 25MG A085736 001
IMPAX LABS 25MG N009458 001
INWOOD LABS 25MG A080731 001
IVAX SUB TEVA PHARMS 25MG A080630 001
25MG A083536 001
LANNETT 25MG A080694 001
PANRAY 5MG N008284 002
25MG N008284 001
PHARMACIA AND UPJOHN 5MG N008126 003
10MG N008126 004
25MG N008126 001
PUREPAC PHARM 25MG A080493 001
VITARINE 25MG A080333 001
WATSON LABS 25MG A085884 001
WHITEWORTH TOWN PLSN 25MG A080341 001

CORTONE

MERCK 25MG N007750 003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 88 (of 331)

CROMOLYN SODIUM

CAPSULE; INHALATION INTAL				
SANOFI AVENTIS US	20MG	N016990	001	
CAPSULE; ORAL GASTROCROM				
UCB INC	100MG	N019188	001	Dec 22, 1989
CONCENTRATE; ORAL CROMOLYN SODIUM				
GENERA PHARMS	100MG/5ML	A090954	001	Dec 18, 2009
SOLUTION; INHALATION CROMOLYN SODIUM				
PHARMASCIENCE INC	10MG/ML	A075437	001	Apr 21, 2000
ROXANE	10MG/ML	A075175	001	Sep 30, 1999
INTAL				
KING PHARMS	10MG/ML	N018596	001	May 28, 1982
SOLUTION/DROPS; OPHTHALMIC CROMOPTIC				
KING PHARMS	4%	A075088	001	Apr 27, 1999
SPRAY, METERED; NASAL NASALCROM				
BLACKSMITH BRANDS	5.2MG/SPRAY	N020463	001	Jan 03, 1997

CRYPTENAMINE ACETATES

INJECTABLE; INJECTION UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT/ML	N008814	001	

CRYPTENAMINE TANNATES

TABLET; ORAL UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT	N009217	001	

CUPRIC SULFATE

INJECTABLE; INJECTION CUPRIC SULFATE				
ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987

CYANOCOBALAMIN

GEL, METERED; NASAL NASCOBAL				
PAR PHARM	0.5MG/INH	N019722	001	Nov 05, 1996
INJECTABLE; INJECTION BERUBIGEN				
PHARMACIA AND UPJOHN	1MG/ML	N006798	001	
BETALIN 12				
LILLY	0.1MG/ML	A080855	001	
	1MG/ML	A080855	002	
COBAVITE				
WATSON LABS	0.1MG/ML	A083013	001	
	1MG/ML	A083064	001	
CYANOCOBALAMIN				
ABRAXIS PHARM	0.03MG/ML	A080510	003	
	0.1MG/ML	A080510	001	
	1MG/ML	A080510	002	
	1MG/ML	A083075	001	
AKORN	1MG/ML	A087969	001	Nov 10, 1983
APP PHARMS	0.1MG/ML	A080557	002	
BAXTER HLTHCARE	1MG/ML	A080515	002	
BIONICHE PHARMA	1MG/ML	A040451	001	Sep 23, 2003
DELL LABS	0.03MG/ML	A080689	001	
	0.1MG/ML	A080689	002	
	1MG/ML	A080689	003	
LUITPOLD	0.03MG/ML	A080668	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 89 (of 331)

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

SANOFI AVENTIS US	1MG/ML	A080564	001	Feb 29, 1984
SOLOPAK	1MG/ML	A087551	001	
WARNER CHILCOTT	1MG/ML	N007085	002	
WATSON LABS	0.1MG/ML	A080573	002	
	0.1MG/ML	A083120	001	
	1MG/ML	A080573	001	
	1MG/ML	A083120	002	
WYETH AYERST	0.1MG/ML	A080554	001	
	1MG/ML	A080554	002	
REDISOL				
MERCK	1MG/ML	N006668	010	
RUBIVITE				
BEL MAR	0.03MG/ML	N010791	004	
	0.05MG/ML	N010791	001	
	0.1MG/ML	N010791	002	
	0.12MG/ML	N010791	005	
	1MG/ML	N010791	003	
RUBRAMIN PC				
BRISTOL MYERS SQUIBB	0.1MG/ML	N006799	002	
	1MG/ML	N006799	004	
	1MG/ML	N006799	010	Apr 28, 1988
RUVITE				
SAVAGE LABS	1MG/ML	A080570	002	
VI-TWEL				
BAYER HLTHCARE	1MG/ML	N007012	002	
SPRAY, METERED; NASAL				
CALOMIST				
PAR PHARM	25MCG/SPRAY	N022102	001	Jul 27, 2007
TABLET; ORAL				
CYANOCOBALAMIN				
WEST WARD	1MG	A084264	001	

CYANOCOBALAMIN CO-57

CAPSULE; ORAL

RUBRATOPE-57

BRACCO	0.5-1uCi	N016089	002

CYANOCOBALAMIN CO-60

CAPSULE; ORAL

RUBRATOPE-60

BRACCO	0.5-1uCi	N016090	002

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A; N/A

DICOPAC KIT

GE HEALTHCARE	N/A;N/A;N/A	N017406	001

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

MALLINCKRODT	0.1MG;0.5uCi;60MG	N016635	001

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR

ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML	N011208	001

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W

WYETH AYERST	125MG/5ML	N050508	001

DISCONTINUED DRUG PRODUCT LIST

6 - 90 (of 331)

CYCLACILLIN

FOR SUSPENSION; ORAL
CYCLAPEN-W

WYETH AYERST	250MG/5ML	N050508	002	
	500MG/5ML	N050508	003	

TABLET; ORAL
CYCLACILLIN

TEVA	250MG	A062895	001	Aug 04, 1988
	500MG	A062895	002	Aug 04, 1988

CYCLAPEN-W

WYETH AYERST	250MG	N050509	001	
	500MG	N050509	002	

CYCLIZINE LACTATE

INJECTABLE; INJECTION
MAREZINE

GLAXOSMITHKLINE	50MG/ML	N009495	001	

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

SANDOZ	10MG	A073683	001	Feb 26, 1993
WATSON LABS	10MG	A073143	001	Nov 27, 1991
	10MG	A074436	001	Nov 30, 1994

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AK-PENTOLATE

AKORN	1%	A085555	001	

CYCLOPENTOLATE HYDROCHLORIDE

ALCON UNIVERSAL	1%	A089162	001	Jan 24, 1991
SOLA BARNES HIND	1%	A084150	001	
	1%	A084863	001	

PENTOLAIR

PHARMAFAIR	0.5%	A088643	001	Feb 09, 1987
	1%	A088150	001	Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

BAXTER HLTHCARE	100MG/VIAL	A088371	001	Jul 03, 1986
	200MG/VIAL	A088372	001	Jul 03, 1986
	500MG/VIAL	A088373	001	Jul 03, 1986
	1GM/VIAL	A088374	001	Sep 24, 1986

CYTOXAN

BAXTER HLTHCARE	100MG/VIAL	N012142	001	
	200MG/VIAL	N012142	002	

LYOPHILIZED CYTOXAN

BAXTER HLTHCARE	100MG/VIAL	N012142	006	Dec 05, 1985
	200MG/VIAL	N012142	007	Dec 10, 1985
	500MG/VIAL	N012142	008	Jan 04, 1984
	1GM/VIAL	N012142	010	Sep 24, 1985
	2GM/VIAL	N012142	009	Dec 10, 1985

NEOSAR

TEVA PARENTERAL	100MG/VIAL	A040015	001	Apr 29, 1993
	100MG/VIAL	A087442	001	Feb 16, 1982
	200MG/VIAL	A040015	002	Apr 29, 1993
	200MG/VIAL	A087442	002	Feb 16, 1982
	500MG/VIAL	A040015	003	Apr 29, 1993
	500MG/VIAL	A087442	003	Feb 16, 1982
	1GM/VIAL	A040015	004	Apr 29, 1993
	1GM/VIAL	A087442	004	Jul 08, 1983
	2GM/VIAL	A040015	005	Apr 29, 1993
	2GM/VIAL	A087442	005	Mar 30, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 91 (of 331)

CYCLOPHOSPHAMIDETABLET; ORAL
CYTOXANBAXTER HLTHCARE 25MG
50MGN012141 002
N012141 001CYCLOSPORINECAPSULE; ORAL
NEORAL

NOVARTIS 50MG

N050715 003 Jul 14, 1995

CYCLOTHIAZIDETABLET; ORAL
ANHYDRON

LILLY 2MG

N013157 002

FLUIDIL

PHARMACIA AND UPJOHN 2MG

N018173 001

CYCRIMINE HYDROCHLORIDETABLET; ORAL
PAGITANELILLY 1.25MG
2.5MGN008951 001
N008951 002CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

HALSEY 2MG/5ML

A089199 001 Jul 03, 1986

MORTON GROVE 2MG/5ML

A087001 001 Nov 04, 1982

NASKA 2MG/5ML

A089021 001 Dec 21, 1987

PERIACTIN

MERCK 2MG/5ML

N013220 002

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP 4MG

A088798 001 Feb 15, 1985

ASCOT 4MG

A087685 001 Oct 25, 1982

DURAMED PHARMS BARR 4MG

A088232 001 Oct 25, 1983

HALSEY 4MG

A089057 001 Jul 03, 1986

KV PHARM 4MG

A086737 001

MD PHARM 4MG

A087566 001 Nov 10, 1982

MYLAN 4MG

A086678 001

PIONEER PHARMS 4MG

A087839 001 Feb 08, 1984

PLIVA 4MG

A088205 001 Jul 26, 1983

SANDOZ 4MG

A086808 001

SUPERPHARM 4MG

A087405 001

TG UNITED LABS 4MG

A088212 001 May 26, 1983

VITARINE 4MG

A087284 001

WATSON LABS 4MG

A085245 001

4MG

A086165 001

4MG

A086580 001

PERIACTIN

MERCK 4MG

N012649 001

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

HOSPIRA 7.25%

N019523 001 Oct 22, 1986

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

TEVA PARENTAL 100MG/VIAL

N016793 001

500MG/VIAL

N016793 002

1GM/VIAL

N016793 003 Dec 21, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 92 (of 331)

CYTARABINE

INJECTABLE; INJECTION				
CYTARABINE				
TEVA PARENTERAL	2GM/VIAL	N016793	004	Dec 21, 1987

DACARBAZINE

INJECTABLE; INJECTION				
DACARBAZINE				
ABRAXIS PHARM	100MG/VIAL	A070962	001	Aug 28, 1986
	200MG/VIAL	A070990	001	Aug 28, 1986

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)				
SYNERCID				
KING PHARMS	420MG/VIAL;180MG/VIAL	N050748	002	Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION				
FRAGMIN				
EISAI INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE; INJECTION				
ORGARAN				
ORGANON USA INC	750 UNITS/0.6ML	N020430	001	Dec 24, 1996

DANAZOL

CAPSULE; ORAL				
DANAZOL				
AM THERAP	200MG	A071569	001	Dec 30, 1987
DANOCRINE				
SANOFI AVENTIS US	50MG	N017557	003	
	100MG	N017557	004	
	200MG	N017557	002	

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC				
REV-EYES				
ANGELINI	0.5%	N019849	001	Dec 31, 1990

DAPTOMYCIN

INJECTABLE; IV (INFUSION)				
CUBICIN				
CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION				
CERUBIDINE				
SANOFI AVENTIS US	EQ 20MG BASE/VIAL	A061876	001	
WYETH AYERST	EQ 20MG BASE/VIAL	N050484	001	
DAUNORUBICIN HYDROCHLORIDE				
TEVA PARENTERAL	EQ 20MG BASE/VIAL	A064212	001	Jun 23, 1998
	EQ 50MG BASE/VIAL	A064212	002	May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE; INJECTION				
SYNCURINE				
GLAXOSMITHKLINE	1MG/ML	N006931	002	

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC				
HUMORSOL				
MERCK	0.125%	N011860	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 93 (of 331)

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

HUMORSOL

MERCK

0.25%

N011860 001

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DECLOMYCIN

LEDERLE

150MG

N050262 001

SYRUP; ORAL

DECLOMYCIN

LEDERLE

75MG/5ML

N050257 001

TABLET; ORAL

DECLOMYCIN

STIEFEL

75MG

N050261 001

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBOTT

0.1MG

N010796 001

0.25MG

N010796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBOTT

0.125MG; 25MG

N012148 001

ORETICYL 50

ABBOTT

0.125MG; 50MG

N012148 003

ORETICYL FORTE

ABBOTT

0.25MG; 25MG

N012148 002

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT

0.25MG; 5MG

N012775 001

ENDURONYL FORTE

ABBOTT

0.5MG; 5MG

N012775 002

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS

0.25MG; 5MG

A088486 001

Aug 10, 1984

0.5MG; 5MG

A088452 001

Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US

25MG

N013621 001

50MG

N013621 002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

PLIVA

25MG

A071800 001

Dec 08, 1987

50MG

A071801 001

Dec 08, 1987

75MG

A071802 001

Dec 08, 1987

100MG

A071803 001

May 29, 1997

150MG

A071804 001

May 29, 1997

USL PHARMA

25MG

A071864 001

Sep 09, 1987

50MG

A071865 001

Sep 09, 1987

75MG

A071866 001

Sep 09, 1987

100MG

A071867 001

Sep 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS

0.2MG/ML

N009282 002

DISCONTINUED DRUG PRODUCT LIST

6 - 94 (of 331)

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DDAVP

SANOFI AVENTIS US	0.015MG/ML	N018938	002	Apr 25, 1995

DESMOPRESSIN ACETATE

BEDFORD	0.004MG/ML	A074575	001	Feb 18, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD	0.004MG/ML	A074574	001	Feb 18, 2000

SOLUTION; NASAL
CONCENTRAID

FERRING	0.01%	N019776	001	Dec 26, 1990

SPRAY, METERED; NASAL
DDAVP

SANOFI AVENTIS US	0.01MG/SPRAY	N017922	002	Feb 06, 1989

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGEN

ORGANON USA INC	0.15MG;0.03MG	N020071	001	Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	001	Aug 12, 1999

ORTHO-CEPT

ORTHO MCNEIL JANSSEN	0.15MG;0.03MG	N020301	001	Dec 14, 1992

DESONIDE

CREAM; TOPICAL
DESONIDE

TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992

DESOXIMETASONE

OINTMENT; TOPICAL
DESOXIMETASONE

ALTANA	0.25%	A073440	001	Apr 01, 1998

TOPICORT

TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION
DOCA

ORGANON USA INC	5MG/ML	N001104	001	

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS	125MG	N005151	001	

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION
PERCORTEN

NOVARTIS	25MG/ML	N008822	001	

DEXAMETHASONE

AEROSOL; TOPICAL
AEROSEB-DEX

ALLERGAN HERBERT	0.01%	A083296	002	

DECASPRAY

MERCK	0.04%	N012731	002	

ELIXIR; ORAL

DECADRON

MERCK	0.5MG/5ML	N012376	002	

DEXAMETHASONE

ALPHARMA US PHARMS	0.5MG/5ML	A088997	001	Oct 10, 1986

HEXADROL

ORGANON USA INC	0.5MG/5ML	N012674	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 95 (of 331)

DEXAMETHASONE

GEL; TOPICAL

DECADERM

MERCK

0.1%

N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS

0.1%

A089170 001 May 09, 1989

TABLET; ORAL

DECADRON

MERCK

0.25MG

N011664 004

0.5MG

N011664 001

0.75MG

N011664 002

1.5MG

N011664 003

4MG

N011664 005

6MG

N011664 006 Jul 30, 1982

DEXAMETHASONE

IMPAX LABS

0.75MG

A085376 001

MUTUAL PHARM

0.25MG

A084013 001

0.25MG

A084764 001

0.5MG

A084084 001

0.5MG

A084766 001

0.75MG

A084081 001

0.75MG

A084765 001

1.5MG

A084086 001

1.5MG

A084763 001

PAR PHARM

0.25MG

A088149 001 Apr 28, 1983

0.5MG

A088148 001 Apr 28, 1983

0.75MG

A088160 001 Apr 28, 1983

1.5MG

A088237 001 Apr 28, 1983

4MG

A088238 001 Apr 28, 1983

6MG

A088481 001 Nov 28, 1983

PHOENIX LABS NY

0.75MG

A083806 001

PVT FORM

0.75MG

A083420 001

ROXANE

0.25MG

A084614 001

SANDOZ

0.75MG

A080399 001

UPSHER SMITH

0.75MG

A087534 001

1.5MG

A087533 001

WATSON LABS

0.25MG

A085455 001

0.5MG

A085458 001

0.75MG

A080968 001

0.75MG

A084457 001

0.75MG

A085818 001

1.5MG

A085456 001

1.5MG

A085840 001

WHITEWORTH TOWN PLSN

0.75MG

A084327 001

DEXONE 0.5

SOLVAY

0.5MG

A084991 001

DEXONE 0.75

SOLVAY

0.75MG

A084993 001

DEXONE 1.5

SOLVAY

1.5MG

A084990 001

DEXONE 4

SOLVAY

4MG

A084992 001

HEXADROL

ORGANON USA INC

0.5MG

N012675 004

0.75MG

N012675 007

1.5MG

N012675 009

4MG

N012675 010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

MERCK

EQ 8MG BASE/ML

N016675 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 96 (of 331)

DEXAMETHASONE ACETATEINJECTABLE; INJECTION
DEXAMETHASONE ACETATE

WATSON LABS

EQ 8MG BASE/ML

A084315 001

EQ 16MG BASE/ML

A087711 001

May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N014242 001

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N013413 001

CREAM; TOPICAL

DECADRON

MERCK

EQ 0.1% PHOSPHATE

N011983 002

INJECTABLE; INJECTION

DECADRON

MERCK

EQ 4MG PHOSPHATE/ML

N012071 002

EQ 24MG PHOSPHATE/ML

N012071 004

DEXACEN-4

CENT PHARMS

EQ 4MG PHOSPHATE/ML

A084342 001

DEXAMETHASONE

ABRAXIS PHARM

EQ 4MG PHOSPHATE/ML

A088448 001

Jan 25, 1984

APP PHARMS

EQ 10MG PHOSPHATE/ML

A088469 001

Jan 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

ABRAXIS PHARM

EQ 4MG PHOSPHATE/ML

A087065 001

AKORN

EQ 4MG PHOSPHATE/ML

A084493 001

BAXTER HLTHCARE

EQ 4MG PHOSPHATE/ML

A084282 001

BEL MAR

EQ 4MG PHOSPHATE/ML

A084752 001

DELL LABS

EQ 4MG PHOSPHATE/ML

A083161 001

INTL MEDICATION

EQ 20MG PHOSPHATE/ML

A088522 001

Feb 17, 1984

TEVA PARENTERAL

EQ 4MG PHOSPHATE/ML

A081125 001

Aug 31, 1990

WATSON LABS

EQ 4MG PHOSPHATE/ML

A083702 001

EQ 4MG PHOSPHATE/ML

A084355 001

EQ 4MG PHOSPHATE/ML

A089169 001

Apr 09, 1986

EQ 10MG PHOSPHATE/ML

A087668 001

Jul 01, 1982

EQ 24MG PHOSPHATE/ML

A085606 001

WYETH AYERST

EQ 4MG PHOSPHATE/ML

A085641 001

HEXADROL

ORGANON USA INC

EQ 4MG PHOSPHATE/ML

N014694 002

EQ 10MG PHOSPHATE/ML

N014694 003

EQ 20MG PHOSPHATE/ML

N014694 004

OINTMENT; OPHTHALMIC

DECADRON

MERCK

EQ 0.05% PHOSPHATE

N011977 001

DEXAIR

PHARMAFAIR

EQ 0.05% PHOSPHATE

A088071 001

Dec 28, 1982

MAXIDEX

ALCON

EQ 0.05% PHOSPHATE

A083342 001

SOLUTION/DROPS; OPHTHALMIC

DEXAIR

PHARMAFAIR

EQ 0.1% PHOSPHATE

A088433 001

Dec 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND

EQ 0.1% PHOSPHATE

A084170 001

EQ 0.1% PHOSPHATE

A084173 001

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECADRON

MERCK

EQ 0.1% PHOSPHATE

N011984 001

SOLUTION/DROPS; OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AKORN

EQ 0.1% PHOSPHATE

A084855 001

DISCONTINUED DRUG PRODUCT LIST

6 - 97 (of 331)

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
DECADRON W/ XYLOCAINE				
MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334	002	

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC				
NEODECADRON				
MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324	001	
SOLUTION/DROPS; OPHTHALMIC				
NEODECADRON				
MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322	001	
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE				
BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055	001	Oct 30, 1995
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE				
ALCON UNIVERSAL	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714	001	Jul 21, 1986
PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539	001	Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
DEXACIDIN				
NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566	001	Feb 22, 1985
DEXASPORIN				
PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411	001	May 16, 1983
SUSPENSION/DROPS; OPHTHALMIC				
DEXACIDIN				
NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544	001	Oct 29, 1984
DEXASPORIN				
PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428	001	May 18, 1983

DEXBROMPHENIRAMINE MALEATE

SYRUP; ORAL				
DISOMER				
SCHERING	2MG/5ML	N011814	002	
TABLET; ORAL				
DISOMER				
SCHERING	2MG	N011814	001	

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET; ORAL				
DISOPHROL				
SCHERING	2MG;60MG	N012394	002	
TABLET, EXTENDED RELEASE; ORAL				
BROMPHERIL				
COPLEY PHARM	6MG;120MG	A089116	001	Jan 22, 1987
DISOBROM				
SANDOZ	6MG;120MG	A070770	001	Sep 30, 1991
RESPORAL				
PIONEER PHARMS	6MG;120MG	A089139	001	Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL				
POLARAMINE				
SCHERING	2MG/5ML	A086837	001	Jul 19, 1982
TABLET; ORAL				
DEXCHLORPHENIRAMINE MALEATE				
PLIVA	2MG	A088682	001	Jan 17, 1986
POLARAMINE				
SCHERING	2MG	A086835	001	

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL				
DEXAMPEX				
TEVA	15MG	A085355	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 98 (of 331)

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

ABLE	5MG	A076814	001	Aug 25, 2004
	10MG	A076814	002	Aug 25, 2004
	15MG	A076814	003	Aug 25, 2004

ELIXIR; ORAL

DEXEDRINE

GLAXOSMITHKLINE	5MG/5ML	A083902	001	

TABLET; ORAL

DEXAMPEX

TEVA	5MG	A083735	001	
	10MG	A083735	002	

DEXEDRINE

GLAXOSMITHKLINE	5MG	A084935	001	

DEXTROAMPHETAMINE SULFATE

ENDO PHARMS	5MG	A040299	001	May 13, 1999

HALSEY	10MG	A083930	001	

LANNETT	5MG	A083903	001	

	10MG	A083903	003	

	15MG	A085652	001	

MAST MM	5MG	A086521	001	

PUREPAC PHARM	5MG	A084125	001	

SANDOZ	5MG	A085370	001	

	10MG	A085371	001	

VITARINE	5MG	A084986	001	

	10MG	A085892	001	

DEXTROSTAT

SHIRE	5MG	A084051	001	

	10MG	A084051	002	

FERNDEX

FERNDAL LABS	5MG	A084001	001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM

HALSEY	15MG/5ML; 6.25MG/5ML	A088913	001	Mar 02, 1987

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML	N018046	001	

MILES	10GM/100ML	N018504	001	

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML	N018358	001	

	2.5GM/100ML	N019626	001	Feb 02, 1988

DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT	38.5GM/100ML	N018923	001	Sep 19, 1984

DEXTROSE 5% IN PLASTIC CONTAINER

DHL	5GM/100ML	N019971	001	Sep 28, 1995

DEXTROSE 60%

B BRAUN	60GM/100ML	N017995	002	Sep 22, 1982

DEXTROSE 60% IN PLASTIC CONTAINER

B BRAUN	60GM/100ML	N017995	001	

BAXTER HLTHCARE	60GM/100ML	N020047	002	Jul 02, 1991

HOSPIRA	60GM/100ML	N019346	001	Jan 25, 1985

DEXTROSE 7.7% IN PLASTIC CONTAINER

B BRAUN	7.7GM/100ML	N019626	003	Feb 02, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 99 (of 331)

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019025 001	Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N018273 001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018274 001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;37MG/100ML	N019699 001	Sep 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;75MG/100ML	N019699 002	Sep 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;110MG/100ML	N019699 003	Sep 29, 1989

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML	N019699 005	Sep 29, 1989

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N018270 001	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268 009	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268 004	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268 005	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268 006	

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268 011	Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N018268 012	Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N018268 013	Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N018268 014	Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N018268 010	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N018268 001	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N018268 002	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N018268 003	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 100 (of 331)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008	003
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008	001
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008	002

DEXTROSE; SODIUM CHLORIDEINJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;200MG/100ML	N018386	001
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;450MG/100ML	N018229	001
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;900MG/100ML	N018047	001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;450MG/100ML	N018030	001
HOSPIRA	2.5GM/100ML;450MG/100ML	N018096	001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;900MG/100ML	N018376	001
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	3.3GM/100ML;300MG/100ML	N018055	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML	N018030	005
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;200MG/100ML	N018030	004
MILES	5GM/100ML;200MG/100ML	N018399	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;225MG/100ML	N019482	001 Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;300MG/100ML	N019486	001 Oct 04, 1985
MILES	5GM/100ML;300MG/100ML	N018501	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;330MG/100ML	N018030	003
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;450MG/100ML	N019484	001 Oct 04, 1985
B BRAUN	5GM/100ML;450MG/100ML	N018030	002
MILES	5GM/100ML;450MG/100ML	N018400	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;900MG/100ML	N019483	001 Oct 04, 1985
B BRAUN	5GM/100ML;900MG/100ML	N018026	001
MILES	5GM/100ML;900MG/100ML	N018500	001

DEXTROTHYROXINE SODIUMTABLET; ORALCHOLOXIN

ABBOTT	1MG	N012302	005
	2MG	N012302	002
	4MG	N012302	004
	6MG	N012302	006

DEZOCINEINJECTABLE; INJECTIONDALGAN

ASTRAZENECA	5MG/ML	N019082	001 Dec 29, 1989
	10MG/ML	N019082	002 Dec 29, 1989
	15MG/ML	N019082	003 Dec 29, 1989

DIATRIZOATE MEGLUMINEINJECTABLE; INJECTIONANGIOVIST 282

BAYER HLTHCARE	60%	A087726	001 Sep 23, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 101 (of 331)

DIATRIZOATE MEGLUMINEINJECTABLE; INJECTION
CARDIOGRAFIN

BRACCO 85% N011620 002

DIATRIZOATE MEGLUMINE

BRACCO 76% N010040 017

HYPAQUE

GE HEALTHCARE 30% N016403 002

60% N016403 001

RENO-60

BRACCO 60% N010040 016

RENO-DIP

BRACCO 30% N010040 012

UROVIST MEGLUMINE DIU/CT

BAYER HLTHCARE 30% A087739 001 Sep 23, 1982

SOLUTION; URETERAL

RENO-30

BRACCO 30% N010040 021

UROVIST CYSTO

BAYER HLTHCARE 30% A087729 001 Sep 23, 1982

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE 30% A087731 001 Sep 23, 1982

SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE 30% N016403 003

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE 52%;8% A087724 001 Sep 23, 1982

ANGIOVIST 370

BAYER HLTHCARE 66%;10% A087723 001 Sep 23, 1982

DIATRIZOATE-60

INTL MEDICATION 52%;8% A088166 001 Jun 17, 1983

HYPAQUE-76

GE HEALTHCARE 66%;10% A086505 001

HYPAQUE-M, 75%

GE HEALTHCARE 50%;25% N010220 003

HYPAQUE-M, 90%

GE HEALTHCARE 60%;30% N010220 002

MD-60

MALLINCKRODT 52%;8% A087074 001

MD-76

MALLINCKRODT 66%;10% A087073 001

RENOCAL-76

BRACCO 66%;10% A089347 001 Jun 01, 1988

RENOGRAFIN-60

BRACCO 52%;8% N010040 006

RENOVIST

BRACCO 34.3%;35% N010040 020

RENOVIST II

BRACCO 28.5%;29.1% N010040 019

SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE 66%;10% A087728 001 Sep 23, 1982

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 100% N011386 001

INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE 25% N009561 003

50% N009561 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 102 (of 331)

DIATRIZOATE SODIUMINJECTABLE; INJECTION
MD-50

MALLINCKRODT 50%

A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE 50%

A087725 001

Sep 23, 1982

SOLUTION; ORAL, RECTAL
HYPAQUE

GE HEALTHCARE 40%

N011386 003

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE 20%

N009561 002

DIAZEPAMCAPSULE, EXTENDED RELEASE; ORAL
VALRELEASE

ROCHE 15MG

N018179 001

GEL; RECTAL

DIASTAT

VALEANT 5MG/ML (5MG/ML)

N020648 002 Jul 29, 1997

10MG/2ML (5MG/ML)

N020648 003 Jul 29, 1997

15MG/3ML (5MG/ML)

N020648 004 Jul 29, 1997

20MG/4ML (5MG/ML)

N020648 005 Jul 29, 1997

INJECTABLE; INJECTION
DIAZEPAM

ABRAXIS PHARM 5MG/ML

A070662 001 Jun 25, 1986

BAXTER HLTHCARE 5MG/ML

A070311 001 Dec 16, 1985

5MG/ML

A070312 001 Dec 16, 1985

5MG/ML

A070313 001 Dec 16, 1985

5MG/ML

A071308 001 Jul 17, 1987

5MG/ML

A071309 001 Jul 17, 1987

5MG/ML

A071310 001 Jul 17, 1987

MARSAM PHARMS LLC 5MG/ML

A072370 001 Jan 29, 1993

5MG/ML

A072371 001 Jan 29, 1993

5MG/ML

A072397 001 Jan 29, 1993

PARENTA PHARMS 5MG/ML

A076815 001 Apr 15, 2004

US ARMY 5MG/ML

N020124 001 Dec 05, 1990

WARNER CHILCOTT 5MG/ML

A071613 001 Oct 22, 1987

5MG/ML

A071614 001 Oct 22, 1987

WATSON LABS 5MG/ML

A070911 001 Aug 28, 1986

5MG/ML

A070912 001 Aug 28, 1986

5MG/ML

A070930 001 Dec 01, 1986

DIZAC

PHARMACIA AND UPJOHN 5MG/ML

N019287 001 Jun 18, 1993

VALIUM

ROCHE 5MG/ML

N016087 001

TABLET; ORAL

DIAZEPAM

DAVA PHARMS INC 5MG

A070227 001 Sep 26, 1985

10MG

A070228 001 Sep 26, 1985

DURAMED PHARMS BARR 2MG

A070894 001 Aug 27, 1986

5MG

A070895 001 Aug 27, 1986

10MG

A070896 001 Aug 27, 1986

FERNDALE LABS 2MG

A070903 001 Apr 01, 1987

5MG

A070904 001 Apr 01, 1987

10MG

A070905 001 Apr 01, 1987

HALSEY 2MG

A070987 001 Aug 15, 1986

5MG

A070996 001 Aug 15, 1986

10MG

A070956 001 Aug 15, 1986

IVAX SUB TEVA PHARMS 2MG

A070360 001 Sep 04, 1985

5MG

A070361 001 Sep 04, 1985

10MG

A070362 001 Sep 04, 1985

MARTEC USA LLC 10MG

A072402 001 Apr 25, 1989

PAR PHARM 2MG

A070462 001 Feb 25, 1986

5MG

A070463 001 Feb 25, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 103 (of 331)

DIAZEPAM

TABLET; ORAL DIAZEPAM

PAR PHARM	10MG	A070464	001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787	001	Aug 02, 1988
	5MG	A070788	001	Aug 02, 1988
	10MG	A070776	001	Aug 02, 1988
ROXANE	2MG	A070356	001	Jun 17, 1986
	5MG	A070357	001	Jun 17, 1986
	10MG	A070358	001	Jun 17, 1986
SANDOZ	2MG	A070302	001	Dec 20, 1985
	5MG	A070303	001	Dec 20, 1985
	10MG	A070304	001	Dec 20, 1985
TEVA PHARMS	5MG	A070153	001	Nov 01, 1985
WARNER CHILCOTT	2MG	A070209	001	Sep 04, 1985
	5MG	A070210	001	Sep 04, 1985
	10MG	A070222	001	Sep 04, 1985
WATSON LABS	2MG	A070456	001	Nov 01, 1985
	5MG	A070457	001	Nov 01, 1985
	10MG	A070458	001	Nov 01, 1985
Q-PAM				
QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985
	2MG	A072431	001	Apr 29, 1988
	5MG	A070424	001	Dec 12, 1985
	5MG	A072432	001	Apr 29, 1988
	10MG	A070425	001	Dec 12, 1985
	10MG	A072433	001	Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL PROGLYCEM

TEVA BRANDED PHARM	50MG	N017425	001	
	100MG	N017425	002	

INJECTABLE; INJECTION DIAZOXIDE

ABRAXIS PHARM	15MG/ML	A071519	001	Aug 26, 1987
HYPERSTAT				
SCHERING	15MG/ML	N016996	001	

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION HEAVY SOLUTION NUPERCAINE

NOVARTIS	2.5MG/ML	N006203	001	

DICHLORPHENAMIDE

TABLET; ORAL DARANIDE

TARO	50MG	N011366	001	

DICLOFENAC POTASSIUM

TABLET; ORAL CATAFLAM

NOVARTIS	25MG	N020142	001	Nov 24, 1993
DICLOFENAC POTASSIUM				
MUTUAL PHARM	50MG	A075470	001	Feb 21, 2002
SANDOZ	50MG	A075582	001	Feb 23, 2001
WATSON LABS	50MG	A075152	001	Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC DICLOFENAC SODIUM

FALCON PHARMS	0.1%	N020809	001	May 04, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 104 (of 331)

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

NOSTRUM LABS	50MG	A074986	001	Feb 26, 1999
	75MG	A074986	002	Feb 26, 1999
PLIVA	50MG	A074432	002	Jul 29, 1999
	75MG	A074432	003	Jul 29, 1999
ROXANE	25MG	A074391	001	Jun 29, 1995
	50MG	A074391	002	Jun 29, 1995
	75MG	A074391	003	Jun 29, 1995
TEVA	50MG	A074723	001	Mar 30, 1999
	75MG	A074390	001	Aug 15, 1996
TEVA PHARMS	25MG	A074459	001	Jun 25, 1997
	50MG	A074459	002	Jun 25, 1997
	75MG	A074459	003	Jun 25, 1997
VOLTAREN				
NOVARTIS	25MG	N019201	001	Jul 28, 1988
	50MG	N019201	002	Jul 28, 1988
	75MG	N019201	003	Jul 28, 1988

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A060254	002	
	EQ 250MG BASE	A062238	001	
	EQ 500MG BASE	A060254	003	
	EQ 500MG BASE	A062238	002	
PATHOCIL				
WYETH AYERST	EQ 250MG BASE	N050011	002	
	EQ 500MG BASE	N050011	003	Mar 28, 1983

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

APOTHECON	EQ 62.5MG BASE/5ML	A061455	001	
DYNAPEN				
APOTHECON	EQ 62.5MG BASE/5ML	N050337	002	
PATHOCIL				
WYETH AYERST	EQ 62.5MG BASE/5ML	N050092	001	

DICUMAROL

CAPSULE; ORAL

DICUMAROL

LILLY	25MG	N005509	003	
	50MG	N005509	001	

TABLET; ORAL

DICUMAROL

ABBOTT	25MG	N005545	003	
	50MG	N005545	004	
	100MG	N005545	005	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

MUTUAL PHARM	10MG	A084505	001	Oct 21, 1986
PIONEER PHARMS	10MG	A089361	001	Jan 10, 1989
WATSON LABS	10MG	A083179	001	Feb 12, 1986

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

WATSON LABS	10MG/ML	A080614	001	Feb 11, 1986

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A084479	001	

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

MUTUAL PHARM	20MG	A084600	001	Jul 29, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 105 (of 331)

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

PIONEER PHARMS 20MG

A088585 001 Aug 20, 1986

WATSON LABS 20MG

A084361 001 Feb 06, 1986

DIDANOSINE

FOR SOLUTION; ORAL

VIDEX

BRISTOL MYERS SQUIBB 100MG/PACKET

N020155 003 Oct 09, 1991

167MG/PACKET

N020155 004 Oct 09, 1991

250MG/PACKET

N020155 005 Oct 09, 1991

375MG/PACKET

N020155 006 Oct 09, 1991

TABLET, CHEWABLE; ORAL

VIDEX

BRISTOL MYERS SQUIBB 25MG

N020154 002 Oct 09, 1991

50MG

N020154 003 Oct 09, 1991

100MG

N020154 004 Oct 09, 1991

150MG

N020154 005 Oct 09, 1991

200MG

N020154 006 Oct 28, 1999

DIENESTROL

CREAM; VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM 0.01%

N006110 005

DV

SANOFI AVENTIS US 0.01%

A083518 001

ESTRAGUARD

SOLVAY 0.01%

A084436 001

SUPPOSITORY; VAGINAL

DV

SANOFI AVENTIS US 0.7MG

A083517 001

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL

HETRAZAN

LEDERLE 50MG

N006459 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

SANDOZ 25MG

A085916 001

TEVA 25MG

A088642 001 Sep 20, 1984

TG UNITED LABS 25MG

A088267 001 Aug 25, 1983

25MG

A088268 001 Aug 25, 1983

UCB INC 25MG

A085544 001

WATSON LABS 25MG

A085741 001

TENUATE

SANOFI AVENTIS US 25MG

N017668 001

TEPANIL

3M 25MG

N011673 001

TABLET, EXTENDED RELEASE; ORAL

TENUATE

SANOFI AVENTIS US 75MG

N017669 001

TEPANIL TEN-TAB

3M 75MG

N017956 001

DIETHYLSTILBESTROL

INJECTABLE; INJECTION

STILBESTROL

BRISTOL MYERS SQUIBB 0.2MG/ML

N004056 003

0.5MG/ML

N004056 004

1MG/ML

N004056 005

5MG/ML

N004056 006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 106 (of 331)

DIETHYLSTILBESTROL

SUPPOSITORY; VAGINAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004040	001
	0.5MG	N004040	002

STILBESTROL

BRISTOL MYERS SQUIBB	0.1MG	N004056	001
	0.5MG	N004056	002

TABLET; ORAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004041	002
	0.5MG	N004041	003
	1MG	N004041	004
	5MG	N004041	005

STILBESTROL

TABLICAPS	0.5MG	A083004	001
	1MG	A083002	001
	5MG	A083006	001

STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056	007
	0.25MG	N004056	017
	0.5MG	N004056	008
	1MG	N004056	009
	5MG	N004056	010

TABLET, DELAYED RELEASE; ORAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004039	002
	0.25MG	N004039	005
	0.5MG	N004039	003
	1MG	N004039	004
	5MG	N004039	006

STILBESTROL

TABLICAPS	0.5MG	A083003	001
	1MG	A083005	001
	5MG	A083007	001

STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056	011
	0.5MG	N004056	012
	1MG	N004056	013
	5MG	N004056	014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION

STILPHOSTROL

BAYER PHARMS	250MG/5ML	N010010	001

TABLET; ORAL

STILPHOSTROL

BAYER PHARMS	50MG	N010010	002

DIFLORASONE DIACETATE

CREAM; TOPICAL

FLORONE

PHARMACIA AND UPJOHN	0.05%	N017741	001

FLORONE E

PHARMACIA AND UPJOHN	0.05%	N019259	001	Aug 28, 1985

PSORCON

SANOFI AVENTIS US	0.05%	N020205	001	Nov 20, 1992

OINTMENT; TOPICAL

PSORCON

PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985

PSORCON E

PHARMACIA AND UPJOHN	0.05%	N017994	001

DISCONTINUED DRUG PRODUCT LIST

6 - 107 (of 331)

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

PUREPAC PHARM	250MG	A074285	001	May 07, 1996
	500MG	A074285	002	May 07, 1996
ROXANE	250MG	A073562	001	Nov 27, 1992
	500MG	A073563	001	Nov 27, 1992
SANDOZ	500MG	A074604	001	Jun 10, 1996
TEVA	250MG	A073679	001	Jul 31, 1992
WATSON LABS	250MG	A074400	001	Jul 17, 1997
	500MG	A074400	002	Jul 17, 1997

DOLOBID

MERCK	250MG	N018445	001	Apr 19, 1982
	500MG	N018445	002	Apr 19, 1982

DIGITOXIN

INJECTABLE; INJECTION
CRYSTODIGIN

LILLY	0.2MG/ML	A084100	005	

DIGOXIN

CAPSULE; ORAL
LANOXICAPS

GLAXOSMITHKLINE LLC	0.05MG	N018118	002	Jul 26, 1982
	0.1MG	N018118	003	Jul 26, 1982
	0.15MG	N018118	004	Sep 24, 1984
	0.2MG	N018118	001	Jul 26, 1982

INJECTABLE; INJECTION
DIGOXIN

ABRAXIS PHARM	0.25MG/ML	A083217	001	
HOSPIRA	0.25MG/ML	A040206	001	Aug 28, 1998
WYETH AYERST	0.25MG/ML	A084386	001	

DIGOXIN PEDIATRIC

HOSPIRA	0.1MG/ML	A040092	001	Apr 25, 1996

TABLET; ORAL
LANOXIN

SMITHKLINE BEECHAM	0.0625MG	N020405	001	Sep 30, 1997
	0.1875MG	N020405	003	Sep 30, 1997
	0.375MG	N020405	005	Sep 30, 1997
	0.5MG	N020405	006	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
EMBOLEX

NOVARTIS	0.5MG/0.5ML; 2,500 UNITS/0.5ML; 5.33MG/0.5ML	N018885	001	Nov 30, 1984
	0.5MG/0.7ML; 5,000 UNITS/0.7ML; 7.46MG/0.7ML	N018885	002	Nov 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM SR

BIOVAIL	60MG	N019471	001	Jan 23, 1989
	90MG	N019471	002	Jan 23, 1989
	120MG	N019471	003	Jan 23, 1989
	180MG	N019471	004	Jan 23, 1989

DILTIAZEM HYDROCHLORIDE

BIOVAIL	60MG	A074845	001	Sep 15, 1999
	90MG	A074845	002	Sep 15, 1999
	120MG	A074845	003	Sep 15, 1999
	120MG	N020939	001	Jan 28, 2000
	180MG	N020939	002	Jan 28, 2000
	240MG	N020939	003	Jan 28, 2000
	300MG	N020939	004	Jan 28, 2000

DISCONTINUED DRUG PRODUCT LIST

6 - 108 (of 331)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

BIOVAIL	360MG	N020939	005	Sep 14, 2001
	420MG	N020939	006	Sep 14, 2001
TEVA	60MG	A074079	001	Nov 30, 1993
	90MG	A074079	002	Nov 30, 1993
	120MG	A074079	003	Nov 30, 1993

INJECTABLE; INJECTION
CARDIZEM

BIOVAIL	100MG/VIAL	N020792	001	Sep 05, 1997
BIOVAIL LABS INTL	5MG/ML	N020027	001	Oct 24, 1991
	25MG/VIAL	N020027	003	Aug 18, 1995

DILTIAZEM HYDROCHLORIDE

HOSPIRA	5MG/ML	A075004	001	Feb 16, 2000
	5MG/ML	A075106	001	Apr 29, 1999

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051	001	Mar 31, 1993
	60MG	A074051	002	Mar 31, 1993
	90MG	A074051	003	Mar 31, 1993
	120MG	A074051	004	Mar 31, 1993
IVAX SUB TEVA PHARMS	30MG	A074168	001	Mar 03, 1995
	60MG	A074168	002	Mar 03, 1995
	90MG	A074168	003	Mar 03, 1995
	120MG	A074168	004	Mar 03, 1995
TEVA	30MG	A074084	001	Feb 25, 1994
	60MG	A074084	002	Feb 25, 1994
TEVA PHARMS	30MG	A074067	001	Nov 05, 1992
	60MG	A074067	002	Nov 05, 1992
	90MG	A074067	003	Nov 05, 1992
	120MG	A074067	004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

MERCK	EQ 120MG HCL	N020506	001	Oct 04, 1996
	EQ 180MG HCL	N020506	002	Oct 04, 1996
	EQ 240MG HCL	N020506	003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

BIOVAIL	EQ 180MG HCL;5MG	N020507	001	Oct 04, 1996

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767	001
WATSON LABS	50MG/ML	A083531	001
WYETH AYERST	50MG/ML	A084316	001

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715	001

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841	001
NEXGEN PHARMA INC	50MG	A085985	001
WATSON LABS	50MG	A085166	001

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

IMCOR PHARMS CO	0.92MG/VIAL;0.092MG/VIAL	N021191	001	May 31, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 109 (of 331)

DINOPROST TROMETHAMINEINJECTABLE; INJECTION
PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN EQ 5MG BASE/ML

N017434 001

DIPHEMANIL METHYLSULFATETABLET; ORAL
PRANTAL

SCHERING 100MG

N008114 004

DIPHENHYDRAMINE HYDROCHLORIDECAPSULE; ORAL
BENADRYLMCNEIL CONS 25MG
50MG

N005845 007

N005845 001

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA 25MG

A080519 004

50MG

A080519 003

ANABOLIC 50MG

A083275 001

ELKINS SINN 25MG

A085701 001

50MG

A085701 002

HALSEY 50MG

A087914 001

Jun 04, 1984

HEATHER 25MG

A084524 001

50MG

A083953 001

IMPAX LABS 25MG

A080807 001

50MG

A080807 002

IVAX SUB TEVA PHARMS 25MG

A080762 001

50MG

A080762 002

LANNETT 25MG

A080868 001

50MG

A080868 002

LEDERLE 25MG

A086874 001

50MG

A086875 001

LNK 25MG

A087977 001

Jan 27, 1983

50MG

A087978 001

Jan 27, 1983

MK LABS 25MG

A083087 001

50MG

A083087 002

MUTUAL PHARM 25MG

A084506 001

25MG

A089488 001

Jan 02, 1987

50MG

A089489 001

Jan 02, 1987

NEWTRON PHARMS 25MG

A086543 001

50MG

A086544 001

NEXGEN PHARMA INC 25MG

A083634 001

PERRIGO 25MG

A083061 001

50MG

A083061 002

PIONEER PHARMS 25MG

A089101 001

Dec 20, 1985

50MG

A088880 001

Dec 20, 1985

PUREPAC PHARM 25MG

A085156 001

50MG

A085150 001

PVT FORM 25MG

A083027 001

50MG

A083027 002

ROXANE 50MG

A080635 001

SANDOZ 25MG

A080832 001

25MG

A080845 002

50MG

A080832 002

50MG

A080845 001

SUPERPHARM 25MG

A089040 001

May 15, 1985

50MG

A089041 001

May 15, 1985

TEVA 25MG

A085874 001

50MG

A085874 002

VALEANT PHARM INTL 25MG

A080596 001

50MG

A080592 001

VANGARD 25MG

A088034 001

Oct 27, 1982

50MG

A087630 001

WATSON LABS 25MG

A080728 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 110 (of 331)

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

WATSON LABS	25MG	A083797	001
	25MG	A085138	001
	50MG	A080727	001
	50MG	A083797	002
	50MG	A085083	001
WEST WARD	50MG	A083567	001
WHITEWORTH TOWN PLSN	25MG	A083441	001
	50MG	A080800	001

ELIXIR; ORAL

BELIX

HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983

BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845	004

DIBENIL

CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983

DIPHEN

USL PHARMA	12.5MG/5ML	A084640	001

DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001	
LANNETT	12.5MG/5ML	A080939	002	
LEDERLE	12.5MG/5ML	A086937	001	
MK LABS	12.5MG/5ML	A083088	002	
NASKA	12.5MG/5ML	A088680	001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001	
PUREPAC PHARM	12.5MG/5ML	A083237	001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287	001	
ROXANE	12.5MG/5ML	A080643	001	

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763	002

INJECTABLE; INJECTION

BENADRYL

MCNEIL CONS	10MG/ML	N006146	001

DIPHENHYDRAMINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A087066	001
BAXTER HLTHCARE	50MG/ML	A083183	001
BEL MAR	10MG/ML	A080822	001
WATSON LABS	10MG/ML	A083533	001
WYETH AYERST	50MG/ML	A080577	001

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM	50MG/ML	A080586	002

SYRUP; ORAL

ANTITUSSIVE

PERRIGO	12.5MG/5ML	A071292	001	Apr 10, 1987

BELDIN

HALSEY	12.5MG/5ML	A089179	001	Jun 05, 1986

BENYLIN

PARKE DAVIS	12.5MG/5ML	N006514	004

DIPHEN

MORTON GROVE	12.5MG/5ML	A070118	001	Oct 01, 1985

DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS	12.5MG/5ML	A070497	001	Apr 25, 1989
CUMBERLAND SWAN	12.5MG/5ML	A073611	001	Aug 20, 1992
HI TECH PHARMA	12.5MG/5ML	A072416	001	Sep 28, 1990

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A070205	001	Jan 28, 1986

SILPHEN

SILARX	12.5MG/5ML	A072646	001	Feb 27, 1992

VICKS FORMULA 44

WARNER CHILCOTT	12.5MG/5ML	A070524	001	Jan 14, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 111 (of 331)

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL BENYLIN				
PARKE DAVIS	12.5MG/5ML;30MG/5ML	N019014	001	Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL VONTROL				
GLAXOSMITHKLINE	EQ 25MG BASE	N016033	001	

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL HISPRIL				
GLAXOSMITHKLINE	5MG	N011945	001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC DIPIVEFRIN HYDROCHLORIDE				
BAUSCH AND LOMB	0.1%	A074188	001	May 19, 1995

DIPYRIDAMOLE

INJECTABLE; INJECTION IV PERSANTINE				
BOEHRINGER INGELHEIM	5MG/ML	N019817	001	Dec 13, 1990
TABLET; ORAL DIPYRIDAMOLE				
PUREPAC PHARM	50MG	A089426	001	Jul 12, 1990
	75MG	A089427	001	Jul 12, 1990
SANDOZ	25MG	A086944	002	Apr 16, 1991
	50MG	A087562	001	Feb 25, 1992
	75MG	A087561	001	Feb 25, 1992

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL DYNABAC				
LILLY RES LABS	250MG	N050678	001	Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL DISOPYRAMIDE PHOSPHATE				
INTERPHARM	EQ 100MG BASE	A071190	001	Jan 15, 1987
	EQ 150MG BASE	A071191	001	Jan 15, 1987
IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186	001	Nov 18, 1985
	EQ 150MG BASE	A070187	001	Nov 18, 1985
MUTUAL PHARM	EQ 100MG BASE	A070351	001	Dec 17, 1985
	EQ 150MG BASE	A070352	001	Dec 17, 1985
MYLAN	EQ 100MG BASE	A070138	001	Jun 14, 1985
	EQ 150MG BASE	A070139	001	Jun 14, 1985
SANDOZ	EQ 100MG BASE	A070470	001	Dec 10, 1985
	EQ 150MG BASE	A070471	001	Dec 10, 1985
SUPERPHARM	EQ 100MG BASE	A070940	001	Feb 09, 1987
	EQ 150MG BASE	A070941	001	Feb 09, 1987
WATSON LABS	EQ 100MG BASE	A070240	001	Feb 02, 1986
	EQ 150MG BASE	A070241	001	Feb 02, 1986

DISULFIRAM

TABLET; ORAL ANTABUSE				
TEVA WOMENS	250MG	N007883	003	
	500MG	N007883	002	
DISULFIRAM				
PAR PHARM	250MG	A088792	001	Aug 14, 1984
	500MG	A088793	001	Aug 14, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 112 (of 331)

DISULFIRAM

TABLET; ORAL
DISULFIRAM

WATSON LABS	250MG	A086889	001	
	250MG	A087973	001	Aug 05, 1983
	500MG	A086890	001	
	500MG	A087974	001	Aug 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE CP

ABBOTT	EQ 250MG BASE	N019794	001	Jul 11, 1990
	EQ 500MG BASE	N019794	002	Jul 11, 1990

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

ASTRAZENECA	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995
BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381	001	Sep 26, 1996
HOSPIRA	EQ 1.25GM BASE/100ML	A074634	001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545	001	Jun 25, 1998
MARSAM PHARMS LLC	EQ 12.5MG BASE/ML	A074279	001	Feb 18, 1998
	EQ 12.5MG BASE/ML	A074995	001	Mar 31, 1998
DOBUTREX				
LILLY	EQ 12.5MG BASE/ML	N017820	002	

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL
ARICEPT

EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
	80MG/ML	A070657	001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
	40MG/ML	A070058	001	Mar 20, 1985
	40MG/ML	N018549	001	Mar 11, 1983
	80MG/ML	A070013	001	Jun 12, 1985
	80MG/ML	A070059	001	Mar 20, 1985
	160MG/ML	A070364	001	Dec 04, 1985
ASTRAZENECA	40MG/ML	A070087	001	Oct 23, 1985
	40MG/ML	N018656	001	Jun 28, 1983
	80MG/ML	A070089	001	Oct 23, 1985
	80MG/ML	A070090	001	Oct 23, 1985
	80MG/ML	A070091	001	Oct 23, 1985
	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
INTL MEDICATION	40MG/ML	N018014	001	
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 113 (of 331)

DOPAMINE HYDROCHLORIDEINJECTABLE; INJECTION
INTROPIN

HOSPIRA

40MG/ML

N017395 001

80MG/ML

N017395 002

160MG/ML

N017395 003

DOXACURIUM CHLORIDEINJECTABLE; INJECTION
NUROMAX

ABBOTT

EQ 1MG BASE/ML

N019946 001 Mar 07, 1991

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

GENPHARM

EQ 1MG BASE

A075466 001 Oct 18, 2000

EQ 2MG BASE

A075466 002 Oct 18, 2000

EQ 4MG BASE

A075466 003 Oct 18, 2000

EQ 8MG BASE

A075466 004 Oct 18, 2000

IVAX SUB TEVA PHARMS

EQ 1MG BASE

A075453 001 Oct 18, 2000

EQ 2MG BASE

A075453 002 Oct 18, 2000

EQ 4MG BASE

A075453 003 Oct 18, 2000

EQ 8MG BASE

A075453 004 Oct 18, 2000

SANDOZ

EQ 1MG BASE

A075432 001 Oct 18, 2000

EQ 1MG BASE

A075646 001 Oct 18, 2000

EQ 2MG BASE

A075432 002 Oct 18, 2000

EQ 2MG BASE

A075646 002 Oct 18, 2000

EQ 4MG BASE

A075432 003 Oct 18, 2000

EQ 4MG BASE

A075646 003 Oct 18, 2000

EQ 8MG BASE

A075432 004 Oct 18, 2000

EQ 8MG BASE

A075646 004 Oct 18, 2000

TEVA

EQ 1MG BASE

A075353 001 Jan 12, 2001

EQ 2MG BASE

A075353 002 Jan 12, 2001

EQ 4MG BASE

A075353 003 Jan 12, 2001

EQ 8MG BASE

A075353 004 Jan 12, 2001

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

CLONMEL HLTHCARE

EQ 10MG BASE

A071685 001 Jan 05, 1988

EQ 25MG BASE

A071686 001 Jan 05, 1988

EQ 50MG BASE

A071673 001 Jan 05, 1988

EQ 75MG BASE

A071674 001 Jan 05, 1988

EQ 100MG BASE

A071675 001 Jan 05, 1988

EQ 150MG BASE

A071676 001 Jan 05, 1988

MUTUAL PHARM

EQ 25MG BASE

A071502 001 Feb 18, 1988

EQ 50MG BASE

A071653 001 Feb 18, 1988

EQ 75MG BASE

A071654 001 Feb 18, 1988

EQ 100MG BASE

A071521 001 Feb 18, 1988

NEW RIVER

EQ 10MG BASE

N016987 001

EQ 25MG BASE

N016987 002

EQ 50MG BASE

N016987 003

EQ 75MG BASE

N016987 006

EQ 100MG BASE

N016987 004

EQ 150MG BASE

N016987 007 Apr 13, 1987

PUREPAC PHARM

EQ 10MG BASE

A073054 001 Dec 28, 1990

EQ 25MG BASE

A072109 001 Dec 28, 1990

EQ 50MG BASE

A073055 001 Dec 28, 1990

EQ 75MG BASE

A072386 001 Sep 08, 1988

EQ 100MG BASE

A072110 001 Sep 08, 1988

EQ 150MG BASE

A072387 001 Sep 08, 1988

QUANTUM PHARMICS

EQ 10MG BASE

A070972 001 Sep 29, 1987

EQ 25MG BASE

A070973 001 Sep 29, 1987

EQ 50MG BASE

A070931 001 Sep 29, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 114 (of 331)

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

QUANTUM PHARMICS

EQ 75MG BASE	A070932	001	Sep 29, 1987
EQ 100MG BASE	A072375	001	Mar 15, 1989
EQ 150MG BASE	A072376	001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487	001 Mar 02, 1987
	EQ 25MG BASE	A070827	001 May 15, 1986
	EQ 50MG BASE	A070828	001 May 15, 1986
	EQ 75MG BASE	A070825	001 May 15, 1986
	EQ 100MG BASE	A071562	001 Mar 02, 1987
WATSON LABS	EQ 10MG BASE	A070952	001 Mar 04, 1987
	EQ 10MG BASE	A072985	001 Mar 29, 1991
	EQ 25MG BASE	A070953	001 May 15, 1986
	EQ 25MG BASE	A072986	001 Mar 29, 1991
	EQ 50MG BASE	A070954	001 May 15, 1986
	EQ 50MG BASE	A072987	001 Mar 29, 1991
	EQ 75MG BASE	A071763	001 Feb 09, 1988
	EQ 100MG BASE	A070955	001 May 15, 1986
	EQ 150MG BASE	A071764	001 Feb 09, 1988

SINEQUAN

PFIZER

EQ 10MG BASE	N016798	003	
EQ 25MG BASE	N016798	001	
EQ 50MG BASE	N016798	002	
EQ 75MG BASE	N016798	006	
EQ 100MG BASE	N016798	005	
EQ 150MG BASE	N016798	007	

CONCENTRATE; ORAL

SINEQUAN

PFIZER

EQ 10MG BASE/ML	N017516	001	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

PHARMACIA AND UPJOHN

2MG/ML	A063165	001	Jan 30, 1991
2MG/ML	N050629	001	Dec 23, 1987
200MG/100ML	A063165	002	Jan 30, 1991
200MG/100ML	N050629	002	May 03, 1988

ADRIAMYCIN RDF

PHARMACIA AND UPJOHN

10MG/VIAL	N050467	001	
20MG/VIAL	N050467	003	May 20, 1985
50MG/VIAL	N050467	002	
150MG/VIAL	N050467	004	Jul 22, 1987

RUBEX

BRISTOL MYERS SQUIBB

10MG/VIAL	A062926	001	Apr 13, 1989
50MG/VIAL	A062926	002	Apr 13, 1989
100MG/VIAL	A062926	003	Apr 13, 1989

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

PAR PHARM

EQ 75MG BASE	A065055	004	Apr 18, 2005

FOR SUSPENSION; ORAL

DOXYCHEL

RACHELLE

EQ 25MG BASE/5ML	A061720	001	

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

HALSEY

EQ 50MG BASE	A062119	002	May 24, 1985
EQ 100MG BASE	A062119	001	May 24, 1985

HEATHER

EQ 50MG BASE	A062463	001	Dec 07, 1983
EQ 100MG BASE	A062463	002	Dec 07, 1983

INTERPHARM

EQ 50MG BASE	A062763	001	Sep 02, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 115 (of 331)

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

INTERPHARM	EQ 100MG BASE	A062763	002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418	001	Jan 28, 1983
	EQ 100MG BASE	A062418	002	Jan 28, 1983
MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982
	EQ 100MG BASE	A062337	002	Mar 29, 1982
PAR PHARM	EQ 50MG BASE	A062434	001	Oct 19, 1984
	EQ 100MG BASE	A062442	001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631	001	Jul 24, 1986
	EQ 100MG BASE	A062631	002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479	001	Dec 23, 1983
	EQ 100MG BASE	A062479	002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469	001	Oct 31, 1984
	EQ 100MG BASE	A062469	002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594	001	Dec 05, 1985
	EQ 100MG BASE	A062594	002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717	001	
	EQ 50MG BASE	A062142	001	
	EQ 100MG BASE	A061717	002	
	EQ 100MG BASE	A062142	002	

DOXY-LEMMON

TEVA	EQ 50MG BASE	A062497	001	Aug 23, 1984
	EQ 100MG BASE	A062497	002	Jun 15, 1984

PERIOSTAT

COLLAGENEX	EQ 20MG BASE	N050744	001	Sep 30, 1998

CAPSULE, COATED PELLETS; ORAL

DOXYCYCLINE HYCLATE

PLIVA	EQ 100MG BASE	A063187	001	Jun 30, 1992

CAPSULE, DELAYED RELEASE; ORAL

DORYX

MAYNE PHARMA INTL	EQ 75MG BASE	N050582	002	Aug 13, 2001
	EQ 100MG BASE	N050582	001	Jul 22, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062653	001	Oct 30, 1985

INJECTABLE; INJECTION

DOXYCHEL HYCLATE

RACHELLE	EQ 100MG BASE/VIAL	A061953	001	

DOXYCYCLINE

BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983
BEDFORD	EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988

DOXYCYCLINE HYCLATE

BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989
	EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989

VIBRAMYCIN

PFIZER	EQ 100MG BASE/VIAL	N050442	002	
	EQ 200MG BASE/VIAL	N050442	001	

TABLET; ORAL

DOXYCYCLINE HYCLATE

HEATHER	EQ 100MG BASE	A062462	001	May 11, 1983
INTERPHARM	EQ 100MG BASE	A062764	001	Sep 02, 1988
LARKEN LABS	EQ 20MG BASE	A065287	001	Feb 28, 2006
MUTUAL PHARM	EQ 100MG BASE	A062391	001	Sep 30, 1982
MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983
SUPERPHARM	EQ 100MG BASE	A062494	001	Feb 20, 1985
TRUXTON INC	EQ 50MG BASE	A062269	003	
	EQ 100MG BASE	A062269	002	Nov 08, 1982
WARNER CHILCOTT	EQ 100MG BASE	A062593	001	Aug 28, 1985
WATSON LABS	EQ 50MG BASE	A062392	001	Mar 31, 1983
	EQ 100MG BASE	A062392	002	Mar 31, 1983

DOXY-LEMMON

TEVA	EQ 100MG BASE	A062581	001	Mar 15, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 116 (of 331)

DOXYLAMINE SUCCINATECAPSULE; ORAL
UNISOM

PFIZER 25MG N019440 001 Feb 05, 1986

TABLET; ORAL
DECAPRYNSANOFI AVENTIS US 12.5MG N006412 015
25MG N006412 014

DOXYLAMINE SUCCINATE

COPLY PHARM 25MG A088900 002 Feb 12, 1988

QUANTUM PHARMICS 25MG A088603 001 Aug 07, 1984

DOXY-SLEEP-AID

PAR PHARM 25MG A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
BENDECTIN

SANOFI AVENTIS US 10MG;10MG N010598 002

DROMOSTANOLONE PROPIONATEINJECTABLE; INJECTION
DROLBAN

LILLY 50MG/ML N012936 001

DROPERIDOLINJECTABLE; INJECTION
DROPERIDOL

ABRAXIS PHARM 2.5MG/ML A070992 001 Nov 17, 1986

2.5MG/ML A070993 001 Nov 17, 1986

ASTRAZENECA 2.5MG/ML A072018 001 Oct 20, 1988

2.5MG/ML A072019 001 Oct 19, 1988

2.5MG/ML A072020 001 Oct 19, 1988

2.5MG/ML A072021 001 Oct 19, 1988

HOSPIRA 2.5MG/ML A071645 001 Apr 07, 1988

2.5MG/ML A072272 001 Aug 31, 1995

LUITPOLD 2.5MG/ML A072335 001 Oct 24, 1988

SMITH AND NEPHEW 2.5MG/ML A071750 001 Sep 06, 1988

SOLOPAK 2.5MG/ML A071754 001 Sep 06, 1988

2.5MG/ML A071755 001 Sep 06, 1988

WATSON LABS 2.5MG/ML A073520 001 Nov 27, 1991

2.5MG/ML A073521 001 Nov 27, 1991

2.5MG/ML A073523 001 Nov 27, 1991

DROPERIDOL; FENTANYL CITRATEINJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA 2.5MG/ML;EQ 0.05MG BASE/ML A072026 001 Apr 13, 1989

2.5MG/ML;EQ 0.05MG BASE/ML A072027 001 Apr 13, 1989

2.5MG/ML;EQ 0.05MG BASE/ML A072028 001 Apr 13, 1989

HOSPIRA 2.5MG/ML;EQ 0.05MG BASE/ML A071982 001 May 04, 1988

INNOVAR

AKORN MFG 2.5MG/ML;EQ 0.05MG BASE/ML N016049 001

DYCLONINE HYDROCHLORIDESOLUTION; TOPICAL
DYCLONE

ASTRAZENECA 0.5% N009925 002

1% N009925 001

DYDROGESTERONETABLET; ORAL
GYNOREST

SOLVAY 5MG N017388 001

10MG N017388 002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 117 (of 331)

DYPHYLLINE

ELIXIR; ORAL NEOTHYLLINE TEVA	160MG/15ML	N007794	003
INJECTABLE; INJECTION NEOTHYLLINE TEVA	250MG/ML	N009088	001
TABLET; ORAL DILOR SAVAGE LABS	200MG	A084514	001
DILOR-400 SAVAGE LABS	400MG	A084751	001
NEOTHYLLINE TEVA	200MG	N007794	001
	400MG	N007794	002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC PHOSPHOLINE IODIDE WYETH PHARMS INC	0.03%	N011963	002
	0.06%	N011963	004
	0.25%	N011963	003

ECONAZOLE NITRATE

CREAM; TOPICAL SPECTAZOLE ORTHONEUTROGENA	1%	N018751	001	Dec 23, 1982

EDETATE CALCIUM DISODIUM

TABLET; ORAL CALCIUM DISODIUM VERSENATE GRACEWAY	500MG	N008922	002

EDETATE DISODIUM

INJECTABLE; INJECTION DISODIUM EDETATE WATSON LABS	150MG/ML	A084356	001
EDETATE DISODIUM WATSON LABS	150MG/ML	A080391	001
SODIUM VERSENATE 3M	200MG/ML	N010573	001

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION EDROPHONIUM CHLORIDE WATSON LABS	10MG/ML	A040044	001	Mar 20, 1996
EDROPHONIUM CHLORIDE PRESERVATIVE FREE WATSON LABS	10MG/ML	A040043	001	Mar 20, 1996
REVERSOL ORGANON USA INC	10MG/ML	A089624	001	May 13, 1988

EFAVIRENZ

CAPSULE; ORAL SUSTIVA BRISTOL MYERS SQUIBB	100MG	N020972	002	Sep 17, 1998
TABLET; ORAL SUSTIVA BRISTOL MYERS SQUIBB	300MG	N021360	001	Feb 01, 2002

EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION ORNIDYL SANOFI AVENTIS US	200MG/ML	N019879	002	Nov 28, 1990

DISCONTINUED DRUG PRODUCT LIST

6 - 118 (of 331)

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

APOTHECON

2.5MG

A075583 001 Aug 22, 2000

5MG

A075583 002 Aug 22, 2000

10MG

A075583 003 Aug 22, 2000

20MG

A075583 004 Aug 22, 2000

IVAX SUB TEVA PHARMS

2.5MG

A075482 001 Aug 22, 2000

5MG

A075482 002 Aug 22, 2000

10MG

A075482 003 Aug 22, 2000

20MG

A075482 004 Aug 22, 2000

KRKA DD NOVO MESTO

2.5MG

A075370 001 Aug 22, 2000

5MG

A075370 002 Aug 22, 2000

10MG

A075369 001 Aug 22, 2000

20MG

A075369 002 Aug 22, 2000

RANBAXY

2.5MG

A075556 001 Aug 22, 2000

5MG

A075556 002 Aug 22, 2000

10MG

A075556 003 Aug 22, 2000

20MG

A075556 004 Aug 22, 2000

SANDOZ

2.5MG

A075048 001 Aug 22, 2000

5MG

A075048 002 Aug 22, 2000

10MG

A075048 003 Aug 22, 2000

20MG

A075048 004 Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

ASTRAZENECA

5MG; 2.5MG

N020668 002 Oct 28, 1998

5MG; 5MG

N020668 001 Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS

5MG; 12.5MG

A075736 001 Mar 25, 2003

10MG; 25MG

A075736 002 Mar 25, 2003

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA

1.25MG/ML

A075456 001 Aug 22, 2000

1.25MG/ML

A075571 001 Aug 22, 2000

VASOTEC

BIOVAIL LABS INTL

1.25MG/ML

N019309 001 Feb 09, 1988

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT

99.9%

A070803 001 Sep 08, 1987

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US

200MG

N019616 004 Dec 31, 1991

400MG

N019616 005 Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

SANOFI AVENTIS US

90MG/0.6ML (150MG/ML)

N020164 006 Jun 02, 2000

DISCONTINUED DRUG PRODUCT LIST

6 - 119 (of 331)

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING	0.25MG/INH	N016803	001

PRIMATENE MIST

WYETH CONS	0.2MG/INH	N016126	001

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999
	5MG/ML	N007942	001	

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430	004	Aug 03, 1995

EPIPEN E Z PEN

MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430	003	Aug 03, 1995

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS	0.3MG/INH	N016126	002

MEDIHALER-EPI

3M	0.3MG/INH	N010374	003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA	0.005MG/ML;1%	N017751	006
	0.005MG/ML;1.5%	N017751	007
DENTSPLY PHARM	0.005MG/ML;1.5%	N021384	001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA	0.005MG/ML;4%	N014763	008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA	0.005MG/ML;0.5%	N017751	004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE	0.01MG/ML;2%	A084720	001
	0.02MG/ML;2%	A084732	001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

ELKINS SINN	0.01MG/ML;1%	A080406	001	
	0.01MG/ML;2%	A080406	002	
GRAHAM CHEM	0.01MG/ML;2%	A080504	004	Oct 19, 1983
	0.02MG/ML;2%	A080504	005	Oct 19, 1983
HOSPIRA	0.005MG/ML;1%	A089649	001	Jun 21, 1988
	0.005MG/ML;1.5%	A089650	001	Jun 21, 1988

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT	0.01MG/ML;1%	A083154	001
BEL MAR	0.01MG/ML;1%	A080820	001
	0.01MG/ML;2%	A080757	001
DELL LABS	0.01MG/ML;1%	A083389	001
	0.01MG/ML;2%	A083390	001
INTL MEDICATION	0.01MG/ML;1%	A086402	001
WATSON LABS	0.01MG/ML;1%	A080377	003
	0.01MG/ML;1%	A085463	001
	0.01MG/ML;2%	A080377	004

LIDOCATON

PHARMATON	0.01MG/ML;2%	A084729	001	Aug 17, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 120 (of 331)

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCATON

PHARMATON 0.02MG/ML;2%

A084728 001 Aug 17, 1983

XYLOCAINE W/ EPINEPHRINE

APP PHARMS 0.01MG/ML;2%

N006488 003

ASTRAZENECA 0.005MG/ML;1%

N010418 006

0.005MG/ML;1.5%

N010418 010

0.005MG/ML;2%

N010418 008

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

VYTERIS 1.05MG/PATCH;100MG/PATCH

N021504 001 May 06, 2004

SOLUTION; IONTOPHORESIS

IONTOCAINE

IOMED 0.01MG/ML;2%

N020530 001 Dec 21, 1995

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EMPI 0.01MG/ML;2%

N021486 001 Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE

BEL MAR 0.02MG/ML;1%

A080758 001

0.02MG/ML;2%

A080759 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

HOSPIRA 200MG/VIAL

N050807 002 Sep 15, 2006

EPLERENONE

TABLET; ORAL

INSPRA

GD SEARLE LLC 100MG

N021437 003 Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

ABBOTT EQ 300MG BASE

N020738 004 Dec 22, 1997

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY 50,000 IU

A080884 001

VITAMIN D

CHASE CHEM 50,000 IU

A080747 001

EVERYLIFE 50,000 IU

A080956 001

IMPAX LABS 50,000 IU

A080951 001

LANNETT 50,000 IU

A080825 001

VITARINE 50,000 IU

A084053 001

WEST WARD 50,000 IU

A083102 001

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS 1MG

N018706 001 Jan 18, 1983

SOLUTION; ORAL

HYDERGINE

NOVARTIS 1MG/ML

N018418 001

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM 1MG

A088891 001 Nov 01, 1985

WATSON LABS 1MG

A086433 001 May 27, 1982

1MG

A087244 001 Aug 16, 1982

DISCONTINUED DRUG PRODUCT LIST

6 - 121 (of 331)

ERGOLOID MESYLATES

TABLET; ORAL				
GERIMAL				
WATSON LABS	1MG	A088207	001	Mar 22, 1984
HYDERGINE				
NOVARTIS	0.5MG	N017993	003	
TABLET; SUBLINGUAL				
ALKERGOT				
SANDOZ	0.5MG	A085153	001	
	1MG	A087417	001	
CIRCANOL				
3M	0.5MG	A084868	001	
	1MG	A085809	001	
DEAPRIL-ST				
BRISTOL MYERS SQUIBB	1MG	A085020	002	
ERGOLOID MESYLATES				
KV PHARM	0.5MG	A085899	001	
	0.5MG	A086265	001	
	1MG	A085900	001	
	1MG	A086264	001	
LEDERLE	0.5MG	A086984	001	
	1MG	A086985	001	
MUTUAL PHARM	0.5MG	A087407	001	
	1MG	A087552	001	
SUPERPHARM	0.5MG	A089233	001	Sep 23, 1986
	1MG	A089234	001	Sep 23, 1986
VANGARD	0.5MG	A088013	001	Sep 20, 1982
	1MG	A088014	001	Sep 20, 1982
WATSON LABS	0.5MG	A084930	001	
	1MG	A085177	001	
	1MG	A087183	001	
GERIMAL				
WATSON LABS	0.5MG	A086189	001	
	1MG	A086188	001	
HYDERGINE				
NOVARTIS	0.5MG	N009087	002	
	1MG	N009087	001	
HYDROGENATED ERGOT ALKALOIDS				
IVAX PHARMS	0.5MG	A087186	001	
	1MG	A087185	001	

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION				
MEDIHALER ERGOTAMINE				
3M	0.36MG/INH	N012102	001	
TABLET; SUBLINGUAL				
ERGOSTAT				
PARKE DAVIS	2MG	A088337	001	Jun 08, 1984
WIGRETTES				
ORGANON USA INC	2MG	A086750	001	Jul 29, 1982

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL				
ERYC				
PARKE DAVIS	250MG	A062546	001	Jul 25, 1985
	250MG	A062618	001	Sep 25, 1985
ERYC 125				
PARKE DAVIS	125MG	A062648	001	Oct 24, 1985
ERYC SPRINKLES				
HOSPIRA	125MG	N050593	001	Jul 22, 1985
ERYTHROMYCIN				
BARR	250MG	A063098	001	May 04, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 122 (of 331)

ERYTHROMYCIN

GEL; TOPICAL				
EMGEL				
ALTANA	2%	A063107	001	Aug 23, 1991
LOTION; TOPICAL				
E-SOLVE 2				
SYOSSET	2%	A062467	001	Jul 03, 1985
OINTMENT; OPHTHALMIC				
ERYTHROMYCIN				
PHARMADERM	5MG/GM	A062446	001	Sep 26, 1983
PHARMAFAIR	5MG/GM	A062481	001	Apr 05, 1984
ILOTYCIN				
DISTA	0.5%	N050368	001	
POWDER; FOR RX COMPOUNDING				
ERYTHROMYCIN				
PADDOCK	100%	N050610	001	Nov 07, 1986
SOLUTION; TOPICAL				
A/T/S				
TARO PHARMS NORTH	2%	A062405	001	Nov 18, 1982
C-SOLVE-2				
BIOGLAN PHARMA	2%	A062468	001	Jul 03, 1985
ERYDERM				
ABBOTT	2%	A062290	001	
ERYMAX				
MERZ PHARMS	2%	A062508	002	Jul 11, 1985
ERYTHROMYCIN				
ALPHARMA US PHARMS	1.5%	A062328	001	Apr 19, 1982
	2%	A062326	001	Apr 19, 1982
	2%	A062327	001	Apr 19, 1982
	2%	A062342	001	Feb 25, 1982
	2%	A062957	001	Jul 21, 1988
BAUSCH AND LOMB	2%	A064039	001	Jan 27, 1994
LILLY	2%	N050532	001	
PHARMAFAIR	1.5%	A062485	001	Jul 11, 1984
	2%	A062616	001	Jul 25, 1985
STIEFEL	2%	A064127	001	Feb 14, 1997
SANSAC				
DOW PHARM SCIENCES	2%	A062522	001	Jan 24, 1985
STATICIN				
WESTWOOD SQUIBB	1.5%	N050526	001	
T-STAT				
WESTWOOD SQUIBB	2%	A062436	001	Mar 09, 1983
SWAB; TOPICAL				
C-SOLVE-2				
IVAX SUB TEVA PHARMS	2%	A062751	001	Jul 30, 1993
ERYCETTE				
ORTHONEUTROGENA	2%	N050594	001	Feb 15, 1985
ERYTHROMYCIN				
STIEFEL	2%	A064128	001	Jul 03, 1996
T-STAT				
WESTWOOD SQUIBB	2%	A062748	001	Jul 23, 1987
TABLET, DELAYED RELEASE; ORAL				
E-BASE				
BARR	333MG	A063028	001	May 15, 1990
	333MG	A063086	001	May 15, 1990
	500MG	A062999	001	Nov 25, 1988
E-MYCIN				
ABBOTT	250MG	A060272	001	
	333MG	A060272	002	
ILOTYCIN				
DISTA	250MG	A061910	001	
ROBIMYCIN				
ROBINS AH	250MG	A061633	001	
R-P MYCIN				
SOLVAY	250MG	A061659	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 123 (of 331)

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE

BARR	EQ 125MG BASE	A062162	001
	EQ 250MG BASE	A062162	002
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237	001
WATSON LABS	EQ 250MG BASE	A062087	001

ILOSONE

LILLY	EQ 125MG BASE	A061897	001
	EQ 250MG BASE	A061897	002

FOR SUSPENSION; ORAL

ILOSONE

DISTA	EQ 125MG BASE/5ML	A061893	001

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353	001	Nov 18, 1982
	EQ 250MG BASE/5ML	A062409	001	Dec 16, 1982
BARR	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990
	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990
LIFE LABS	EQ 250MG BASE/5ML	A062362	001	Dec 17, 1982

ILOSONE

LILLY	EQ 125MG BASE/5ML	A061894	001
	EQ 125MG BASE/5ML	N050010	001
	EQ 250MG BASE/5ML	A061894	002
	EQ 250MG BASE/5ML	N050010	002

SUSPENSION/DROPS; ORAL

ILOSONE

LILLY	EQ 100MG BASE/ML	A061894	003

TABLET; ORAL

ILOSONE

LILLY	EQ 500MG BASE	A061896	001

TABLET, CHEWABLE; ORAL

ILOSONE

DISTA	EQ 125MG BASE	A061895	001
	EQ 250MG BASE	A061895	002

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL

ILOSONE SULFA

LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N050599	001	Sep 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

BARR	EQ 200MG BASE/5ML	A062055	001

PEDIAMYCIN

ROSS LABS	EQ 200MG BASE/5ML	A062305	001

SUSPENSION; ORAL

E-MYCIN E

PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198	001
	EQ 400MG BASE/5ML	A062198	002

ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS	EQ 200MG BASE/5ML	A062200	001

	EQ 400MG BASE/5ML	A062200	002

DISTA	EQ 200MG BASE/5ML	A062177	001

	EQ 400MG BASE/5ML	A062177	002

NASKA	EQ 400MG BASE/5ML	A062674	001	Mar 10, 1987

PARKE DAVIS	EQ 200MG BASE/5ML	A062231	001

	EQ 400MG BASE/5ML	A062231	002

PHARMAFAIR	EQ 200MG BASE/5ML	A062559	001	Mar 15, 1985

	EQ 400MG BASE/5ML	A062558	001	Mar 15, 1985

WYAMYCIN E

WYETH AYERST	EQ 200MG BASE/5ML	A062123	002

	EQ 400MG BASE/5ML	A062123	001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 124 (of 331)

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION/DROPS; ORAL

PEDIAMYCIN

ROSS LABS

EQ 100MG BASE/2.5ML

A062305 002

TABLET; ORAL

E.E.S. 400

ABBOTT

EQ 400MG BASE

A061905 001

ERYTHROMYCIN ETHYLSUCCINATE

BARR

EQ 400MG BASE

A062256 001

MYLAN

EQ 400MG BASE

A062847 001

Sep 14, 1988

TABLET, CHEWABLE; ORAL

E.E.S.

ABBOTT

EQ 200MG BASE

N050297 002

ERYPED

ABBOTT

EQ 200MG BASE

N050297 003

Jul 05, 1988

PEDIAMYCIN

ROSS LABS

EQ 200MG BASE

A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYZOLE

ALRA

EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

A062758 001

Jun 15, 1988

PEDIAZOLE

ROSS LABS

EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

N050529 001

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION

ILOTYCIN GLUCEPTATE

DISTA

EQ 250MG BASE/VIAL

N050370 001

EQ 500MG BASE/VIAL

N050370 002

EQ 1GM BASE/VIAL

N050370 003

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

ABBOTT

EQ 500MG BASE/VIAL

A062586 001

Jan 04, 1988

EQ 1GM BASE/VIAL

A062586 002

Jan 04, 1988

HOSPIRA

EQ 500MG BASE/VIAL

N050182 002

EQ 1GM BASE/VIAL

N050182 003

EQ 1GM BASE/VIAL

N050609 002

Sep 24, 1986

ERYTHROMYCIN

ELKINS SINN

EQ 500MG BASE/VIAL

A062563 001

Mar 28, 1985

EQ 1GM BASE/VIAL

A062563 002

Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A062604 001

Nov 24, 1986

EQ 1GM BASE/VIAL

A062604 002

Nov 24, 1986

BAXTER HLTHCARE

EQ 500MG BASE/VIAL

A062993 001

May 09, 1989

EQ 1GM BASE/VIAL

A062993 002

May 09, 1989

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL

EQ 250MG BASE

A061304 001

EQ 250MG BASE

A061887 001

ERYPAR

PARKE DAVIS

EQ 250MG BASE

A062032 001

EQ 500MG BASE

A062032 002

WARNER CHILCOTT

EQ 250MG BASE

A062322 001

ERYTHROCIN STEARATE

ABBOTT

EQ 125MG BASE

A060359 002

ERYTHROMYCIN STEARATE

BARR

EQ 250MG BASE

A061591 001

EQ 500MG BASE

A063179 001

May 15, 1990

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A061461 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 125 (of 331)

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROMYCIN STEARATE

IVAX SUB TEVA PHARMS	EQ 500MG BASE	A061461	002
LEDERLE	EQ 250MG BASE	A062089	001
	EQ 500MG BASE	A062089	002
MYLAN	EQ 250MG BASE	A061505	001
	EQ 500MG BASE	A061505	002
PUREPAC PHARM	EQ 250MG BASE	A061743	001
WATSON LABS	EQ 250MG BASE	A062121	002
	EQ 500MG BASE	A062121	001
ETHRIL 250			
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605	001
ETHRIL 500			
BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605	002
PFIZER-E			
PFIZER	EQ 250MG BASE	A061791	001
	EQ 500MG BASE	A061791	002
WYAMYCIN S			
WYETH AYERST	EQ 250MG BASE	A061675	001
	EQ 500MG BASE	A061675	002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE CORP	10MG/ML	N019386	003	Aug 15, 1988
	20MG/ML	N019386	007	May 28, 2003

ESTAZOLAM

TABLET; ORAL

PROSOM

ABBOTT	1MG	N019080	001	Dec 26, 1990
	2MG	N019080	002	Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847	001	Aug 04, 1998
	0.0375MG/24HR	N020847	002	Aug 04, 1998
	0.05MG/24HR	N020847	003	Aug 04, 1998
	0.075MG/24HR	N020847	004	Aug 04, 1998
	0.1MG/24HR	N020847	005	Aug 04, 1998

ESTRADIOL

ORTHO MCNEIL PHARM	0.05MG/24HR	N021048	001	Sep 20, 1999
	0.075MG/24HR	N021048	002	Sep 20, 1999
	0.1MG/24HR	N021048	003	Sep 20, 1999

FEMPATCH

PARKE DAVIS	0.025MG/24HR	N020417	001	Dec 03, 1996

VIVELLE

NOVARTIS	0.025MG/24HR	N020323	005	Aug 16, 2000
	0.0375MG/24HR	N020323	001	Oct 28, 1994
	0.075MG/24HR	N020323	003	Oct 28, 1994

GEL; TOPICAL

ESTROGEL

ASCEND	0.06%	N021166	001	Feb 09, 2004

TABLET; ORAL

ESTRADIOL

AAI PHARMA INC	0.5MG	A040138	001	Jan 30, 1998
	1MG	A040138	002	Jan 30, 1998
	2MG	A040138	003	Jan 30, 1998
HERITAGE PHARMS INC	0.5MG	A040275	001	Dec 29, 1998
	1MG	A040275	002	Dec 29, 1998
	2MG	A040275	003	Dec 29, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 126 (of 331)

ESTRADIOLTABLET; ORAL
GYNODIOL

DURAMED PHARMS BARR	0.5MG	A040212	001	Dec 29, 1997
	1MG	A040212	002	Dec 29, 1997
	1.5MG	A040212	003	Dec 29, 1997
	2MG	A040212	004	Dec 29, 1997

INNOFEM

NOVO NORDISK INC	0.5MG	A040312	001	Nov 19, 1999
	1MG	A040312	002	Nov 19, 1999
	2MG	A040312	003	Nov 19, 1999

TABLET; VAGINAL
VAGIFEM

NOVO NORDISK INC	25MCG	N020908	001	Mar 26, 1999

ESTRADIOL CYPIONATEINJECTABLE; INJECTION
DEPO-ESTRADIOL

PHARMACIA AND UPJOHN	1MG/ML	A085470	001	
	3MG/ML	A085470	002	

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATEINJECTABLE; INTRAMUSCULAR
LUNELLE

PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATEINJECTABLE; INJECTION
DEPO-TESTADIOL

PHARMACIA AND UPJOHN	2MG/ML; 50MG/ML	N017968	001	
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE				
WATSON LABS	2MG/ML; 50MG/ML	A085603	001	Mar 13, 1986

ESTRADIOL VALERATEINJECTABLE; INJECTION
ESTRADIOL VALERATE

WATSON LABS	10MG/ML	A083546	001	

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATEINJECTABLE; INJECTION
DITATE-DS

SAVAGE LABS	8MG/ML; 180MG/ML	A086423	001	
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE				
WATSON LABS	4MG/ML; 90MG/ML	A085865	001	
	8MG/ML; 180MG/ML	A085860	001	

ESTROGENS, CONJUGATEDTABLET; ORAL
PREMARIN

WYETH PHARMS INC	2.5MG	N004782	002	

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN; CYCRIN 14/14)

WYETH PHARMS INC	0.625MG, 0.625MG; N/A, 5MG	N020303	002	Dec 30, 1994

PREMPRO (PREMARIN; CYCRIN)

WYETH PHARMS INC	0.625MG, 0.625MG; 2.5MG, 2.5MG	N020303	001	Dec 30, 1994

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-200

MEDPOINTE PHARM HLC	0.45MG; 200MG	N011045	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 127 (of 331)

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-400

MEDPOINTE PHARM HLC 0.45MG;400MG

N011045 001

PMB 200

WYETH AYERST 0.45MG;200MG

N010971 005

PMB 400

WYETH AYERST 0.45MG;400MG

N010971 003

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB 0.3MG

A083266 001

0.625MG

A083266 002

1.25MG

A083266 003

2.5MG

A083266 004

ESTERIFIED ESTROGENS

PVT FORM

0.625MG

A083414 001

1.25MG

A083765 001

2.5MG

A085907 001

SANDOZ

1.25MG

A085302 001

ESTRATAB

SOLVAY

0.3MG

A086715 001

0.625MG

A083209 001

1.25MG

A083856 001

2.5MG

A083857 001

EVEX

ROCHE PALO

0.625MG

A084215 001

1.25MG

A083376 002

FEMOGEN

PVT FORM

0.625MG

A085076 001

1.25MG

A085008 001

2.5MG

A085007 001

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE

WYETH AYERST 2MG/ML

A083488 001

ESTRONE

WATSON LABS 2MG/ML

A083397 001

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

WATSON LABS 2MG/ML

A085237 001

Nov 23, 1982

THEELIN

PARKEDALE 1MG/ML

N003977 001

2MG/ML

N003977 002

5MG/ML

N003977 003

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

DURAMED PHARMS BARR 0.75MG

A040296 001

Nov 01, 1999

1.5MG

A040296 002

Nov 01, 1999

3MG

A040296 003

Nov 01, 1999

MYLAN

3MG

A040359 003

Aug 26, 1999

ETHACRYNIC ACID

TABLET; ORAL

EDECRIN

ATON 50MG

N016092 002

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

STI PHARMA LLC 200MG

N016320 002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 128 (of 331)

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL			
MYAMBUTOL			
STI PHARMA LLC	500MG	N016320	004

ETHCHLORVYNOL

CAPSULE; ORAL			
ETHCHLORVYNOL			
BANNER PHARMACAPS	100MG	A084463	001
	200MG	A084463	002
	500MG	A084463	003
	750MG	A084463	004
PLACIDYL			
ABBOTT	100MG	N010021	004
	200MG	N010021	007
	500MG	N010021	002
	750MG	N010021	010

ETHINAMATE

CAPSULE; ORAL			
VALMID			
DISTA	500MG	N009750	001

ETHINYL ESTRADIOL

TABLET; ORAL			
ESTINYL			
SCHERING	0.02MG	N005292	001
	0.05MG	N005292	002
	0.5MG	N005292	003
FEMINONE			
PHARMACIA AND UPJOHN	0.05MG	N016649	001
LYNORAL			
ORGANON USA INC	0.01MG	N005490	003
	0.05MG	N005490	002

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21			
DEMULEN 1/35-21			
GD SEARLE LLC	0.035MG;1MG	N018168	001
DEMULEN 1/50-21			
GD SEARLE LLC	0.05MG;1MG	N016927	001
ZOVIA 1/35E-21			
WATSON LABS	0.035MG;1MG	A072720	001 Dec 30, 1991
ZOVIA 1/50E-21			
WATSON LABS	0.05MG;1MG	A072722	001 Dec 30, 1991
TABLET; ORAL-28			
DEMULEN 1/35-28			
GD SEARLE LLC	0.035MG;1MG	N018160	001
DEMULEN 1/50-28			
GD SEARLE LLC	0.05MG;1MG	N016936	001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28			
NORQUEST FE			
GD SEARLE LLC	0.035MG;75MG;1MG	N018926	001 Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET; ORAL-28			
NORLESTRIN FE 1/50			
PARKE DAVIS	0.05MG;75MG;1MG	N016766	001
NORLESTRIN FE 2.5/50			
PARKE DAVIS	0.05MG;75MG;2.5MG	N016854	001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 129 (of 331)

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

PREVEN EMERGENCY CONTRACEPTIVE KIT

DURAMED	0.05MG;0.25MG	N020946	001	Sep 01, 1998

TABLET; ORAL-21

ALESSE

WYETH PHARMS INC	0.02MG;0.1MG	N020683	001	Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR	0.02MG;0.1MG	A075796	002	Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A075809	001	Jul 16, 2001

LESSINA-21

BARR	0.02MG;0.1MG	A075803	001	Mar 20, 2002

LEVLITE

BAYER HLTHCARE	0.02MG;0.1MG	N020860	001	Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR	0.02MG;0.1MG	A075862	001	Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS	0.03MG;0.15MG	A073592	001	Dec 13, 1993

NORDETTE-21

DURAMED RES	0.03MG;0.15MG	N018668	001	May 10, 1982

PORTIA-21

BARR	0.03MG;0.15MG	A075866	001	May 23, 2002

TRIPHASIL-21

AKRIMAX PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N019192	001	Nov 01, 1984

TRIVORA-21

WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	001	Dec 18, 1997

TABLET; ORAL-28

ALESSE

WYETH PHARMS INC	0.02MG;0.1MG	N020683	002	Mar 27, 1997

LEVLITE

BAYER HLTHCARE	0.02MG;0.1MG	N020860	002	Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR	0.02MG;0.1MG	A075862	002	Apr 29, 2003

TRIPHASIL-28

WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N019190	001	Nov 01, 1984

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR	0.035MG;0.4MG	A076198	001	Apr 22, 2004

BREVICON 21-DAY

WATSON LABS	0.035MG;0.5MG	N017566	001	

GENCEPT 10/11-21

BARR	0.035MG,0.035MG;0.5MG,1MG	A072694	001	Feb 28, 1992

MODICON 21

ORTHO MCNEIL PHARM	0.035MG;0.5MG	N017488	001	

N.E.E. 1/35 21

LPI	0.035MG;1MG	A071541	001	Dec 14, 1987

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM	0.035MG;1MG	A071545	001	Feb 09, 1989

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS	0.035MG;0.5MG	A070684	001	Jan 29, 1987

NORTREL 0.5/35-21

BARR	0.035MG;0.5MG	A072692	001	Feb 28, 1992

ORTHO-NOVUM 1/35-21

ORTHO MCNEIL PHARM	0.035MG;1MG	N017489	002	

ORTHO-NOVUM 10/11-21

ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N018354	001	Jan 11, 1982

ORTHO-NOVUM 7/14-21

ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N019004	001	Apr 04, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 130 (of 331)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

ORTHO-NOVUM 7/7/7-21

ORTHO MCNEIL JANSSEN	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	N018985	001	Apr 04, 1984

OVCON-35

WARNER CHILCOTT

0.035MG; 0.4MG

N018127 001

OVCON-50

WARNER CHILCOTT

0.05MG; 1MG

N018128 001

TRI-NORINYL 21-DAY

WATSON LABS

0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG

N018977 001 Apr 13, 1984

TABLET; ORAL-28

GENCEPT 10/11-28

BARR

0.035MG, 0.035MG; 0.5MG, 1MG

A072697 001 Feb 28, 1992

N.E.E. 1/35 28

LPI

0.035MG; 1MG

A071542 001 Dec 14, 1987

NORCEPT-E 1/35 28

ORTHO MCNEIL PHARM

0.035MG; 1MG

A071546 001 Feb 09, 1989

ORTHO-NOVUM 10/11-28

ORTHO MCNEIL JANSSEN

0.035MG, 0.035MG; 0.5MG, 1MG

N018354 002 Jan 11, 1982

ORTHO-NOVUM 7/14-28

ORTHO MCNEIL PHARM

0.035MG, 0.035MG; 0.5MG, 1MG

N019004 002 Apr 04, 1984

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

ESTROSTEP 21

WARNER CHILCOTT

0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG

N020130 001 Oct 09, 1996

NORLESTRIN 21 1/50

PARKE DAVIS

0.05MG; 1MG

N016749 001

NORLESTRIN 21 2.5/50

PARKE DAVIS

0.05MG; 2.5MG

N016852 001

TABLET; ORAL-28

NORLESTRIN 28 1/50

PARKE DAVIS

0.05MG; 1MG

N016723 001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21

ORTHO CYCLEN-21

ORTHO MCNEIL JANSSEN

0.035MG; 0.25MG

N019653 001 Dec 29, 1989

ORTHO TRI-CYCLEN

ORTHO MCNEIL JANSSEN

0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG

N019697 002 Jul 03, 1992

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

WYETH PHARMS INC

0.03MG; 0.3MG

N017612 001

OGESTREL 0.5/50-21

WATSON LABS

0.05MG; 0.5MG

A075406 001 Dec 15, 1999

OVRAL

AKRIMAX PHARMS

0.05MG; 0.5MG

N016672 001

TABLET; ORAL-28

OVRAL-28

WYETH PHARMS INC

0.05MG; 0.5MG

N016806 001

ETHIODIZED OIL

OIL; INTRALYMPHATIC

ETHIODOL

GUERBET

99%

N009190 001

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL

PARSIDOL

PARKE DAVIS

10MG

N009078 003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 131 (of 331)

ETHOPROPAZINE HYDROCHLORIDETABLET; ORAL
PARSIDOL

PARKE DAVIS

50MG

N009078 006

100MG

N009078 008

ETHOTOINTABLET; ORAL
PEGANONE

LUNDBECK INC

500MG

N010841 003

ETHOXZOLAMIDETABLET; ORAL
CARDRASE

PHARMACIA AND UPJOHN

62.5MG

N011047 002

125MG

N011047 001

ETHAMIDE

ALLERGAN

125MG

N016144 001

ETHYLESTRENOLELIXIR; ORAL
MAXIBOLIN

ORGANON USA INC

2MG/5ML

N014006 002

TABLET; ORAL
MAXIBOLIN

ORGANON USA INC

2MG

N014005 002

ETHYNODIOL DIACETATE; MESTRANOLTABLET; ORAL-20
OVULEN

GD SEARLE LLC

1MG;0.1MG

N016029 002

TABLET; ORAL-21
OVULEN-21

GD SEARLE LLC

1MG;0.1MG

N016029 003

TABLET; ORAL-28
OVULEN-28

GD SEARLE LLC

1MG;0.1MG

N016705 001

ETIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
DURANEST

ASTRAZENECA

0.5%

N017751 003

1%

N017751 005

ETIDRONATE DISODIUMINJECTABLE; INJECTION
DIDRONEL

MGI PHARMA INC

50MG/ML

N019545 001 Apr 20, 1987

ETODOLACCAPSULE; ORAL
ETODOLAC

AAIPHARMA LLC

300MG

A074929 001 Jan 30, 1998

ENDO PHARMS

200MG

A074842 001 Jul 17, 1997

300MG

A074842 002 Jul 17, 1997

GENPHARM

200MG

A075071 001 Sep 30, 1998

300MG

A075071 002 Sep 30, 1998

IVAX SUB TEVA PHARMS

200MG

A074899 001 Jul 08, 1997

300MG

A074899 002 Jul 08, 1997

MYLAN

200MG

A074932 001 May 16, 1997

300MG

A074932 002 May 16, 1997

SANDOZ

200MG

A074840 001 Aug 29, 1997

200MG

A074942 001 Sep 30, 1997

300MG

A074840 002 Aug 29, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 132 (of 331)

ETODOLAC

CAPSULE; ORAL

ETODOLAC

SANDOZ	300MG	A074942	002	Sep 30, 1997
TEVA	200MG	A075126	001	Sep 16, 1999
WATSON LABS	200MG	A074844	001	Dec 23, 1997
	300MG	A074844	002	Dec 23, 1997

LODINE

WYETH PHARMS INC	200MG	N018922	002	Jan 31, 1991
	300MG	N018922	003	Jan 31, 1991

TABLET; ORAL

ETODOLAC

AAIPHARMA LLC	400MG	A074927	001	Oct 30, 1997
ENDO PHARMS	400MG	A074841	001	Jun 27, 1997
GENPHARM	400MG	A075012	001	Sep 30, 1998
	500MG	A075012	002	Sep 30, 1998
IVAX SUB TEVA PHARMS	400MG	A074883	001	Feb 28, 1997
	500MG	A074883	002	Nov 20, 1998
RANBAXY	400MG	A075226	001	Nov 24, 1998
	500MG	A075226	002	Nov 24, 1998
SANDOZ	400MG	A074839	001	Jul 11, 1997
	400MG	A074846	001	Feb 28, 1997
TEVA	400MG	A074847	001	Apr 23, 1999
	500MG	A074847	002	Apr 23, 1999
WATSON LABS	400MG	A074892	001	Apr 16, 1997
	400MG	A075069	001	Apr 16, 1998
	500MG	A074892	002	Oct 29, 1998

LODINE

WYETH PHARMS INC	400MG	N018922	004	Jul 29, 1993
	500MG	N018922	005	Jun 28, 1996

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

POINT HOLDINGS	400MG	A075696	001	Jul 31, 2000
SANDOZ	400MG	A075943	001	Jul 26, 2002
	500MG	A075943	002	Jul 26, 2002
	600MG	A075943	003	Jul 26, 2002
WATSON LABS FLORIDA	400MG	A075829	001	Nov 30, 2001
	500MG	A075829	002	Nov 30, 2001

LODINE XL

WYETH PHARMS INC	400MG	N020584	001	Oct 25, 1996
	500MG	N020584	003	Jan 20, 1998
	600MG	N020584	002	Oct 25, 1996

ETOPOSIDE

CAPSULE; ORAL

VEPESID

BRISTOL MYERS SQUIBB	50MG	N019557	001	Dec 30, 1986
	100MG	N019557	002	Dec 30, 1986

INJECTABLE; INJECTION

ETOPOSIDE

HOSPIRA	20MG/ML	A074320	001	Aug 30, 1995
	20MG/ML	A074351	001	Aug 30, 1995
MARSAM PHARMS LLC	20MG/ML	A074968	001	Jan 09, 1998
PIERRE FABRE	20MG/ML	A074813	001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML	A074510	001	Jun 29, 1995
WATSON LABS	20MG/ML	A074228	001	Oct 15, 1996

TOPOSAR

TEVA PARENTERAL	20MG/ML	A074166	001	Feb 27, 1995

VEPESID

BRISTOL MYERS SQUIBB	20MG/ML	N018768	001	Nov 10, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 133 (of 331)

ETOPOSID PHOSPHATEINJECTABLE; INJECTION
ETOPOPHOS PRESERVATIVE FREEBRISTOL MYERS SQUIBB EQ 500MG BASE/VIAL
EQ 1GM BASE/VIALN020906 001 Feb 27, 1998
N020906 002 Feb 27, 1998ETRETINATE

CAPSULE; ORAL

TEGISON

ROCHE

10MG
25MGN019369 001 Sep 30, 1986
N019369 002 Sep 30, 1986EVANS BLUE

INJECTABLE; INJECTION

EVANS BLUE

PARKE DAVIS

0.5%

N008041 001

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

APOTEX INC

10MG/ML

A075942 001 Aug 02, 2002

APOTHECON

10MG/ML

A075707 001 Apr 16, 2001

HOSPIRA

10MG/ML

A075705 001 Apr 16, 2001

10MG/ML

A075905 001 Nov 23, 2001

FAMOTIDINE PRESERVATIVE FREE

APOTHECON

10MG/ML

A075708 001 Apr 16, 2001

HOSPIRA

10MG/ML

A075669 001 Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBOTT

0.4MG/ML

A075729 001 Dec 17, 2001

TABLET; ORAL

FAMOTIDINE

APOTEX

10MG

A075610 001 Mar 12, 2002

MUTUAL PHARM

20MG

A075639 002 Dec 12, 2001

40MG

A075639 001 Dec 12, 2001

SANDOZ

20MG

A075302 001 Apr 16, 2001

20MG

A075793 001 Apr 16, 2001

40MG

A075302 002 Apr 16, 2001

40MG

A075793 002 Apr 16, 2001

TABLET, CHEWABLE; ORAL

PEPCID AC

MERCK SHARP DOHME

10MG

N020801 001 Sep 24, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

SCHWARZ PHARMA

20MG

N021712 001 Sep 24, 2004

40MG

N021712 002 Sep 24, 2004

PEPCID RPD

MERCK

20MG

N020752 001 May 28, 1998

40MG

N020752 002 May 28, 1998

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

ASTRAZENECA

2.5MG

N019834 004 Sep 22, 1994

5MG

N019834 001 Jul 25, 1991

10MG

N019834 002 Jul 25, 1991

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS

87MG

N021695 002 Nov 30, 2004

LIPIDIL

ABBOTT

100MG

N019304 001 Dec 31, 1993

TRICOR (MICRONIZED)

ABBOTT

67MG

N019304 002 Feb 09, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 134 (of 331)

FENOFIBRATECAPSULE; ORAL
TRICOR (MICRONIZED)

ABBOTT	134MG	N019304	003	Jun 30, 1999
	200MG	N019304	004	Jun 30, 1999

TABLET; ORAL

FENOFIBRATE

MYLAN	107MG	A076520	002	Dec 29, 2005

TRICOR

ABBOTT	54MG	N021203	001	Sep 04, 2001
	160MG	N021203	003	Sep 04, 2001

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

LUITPOLD	EQ 10MG BASE/ML	A076656	001	Dec 01, 2003

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 200MG BASE	A072307	001	Aug 22, 1988
	EQ 300MG BASE	A072308	001	Aug 22, 1988
HALSEY	EQ 200MG BASE	A072355	001	Aug 17, 1988
	EQ 300MG BASE	A072356	001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437	001	Aug 22, 1988
	EQ 300MG BASE	A072438	001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214	001	Aug 17, 1988
	EQ 300MG BASE	A071738	001	Aug 17, 1988
SANDOZ	EQ 200MG BASE	A072394	001	Oct 17, 1988
	EQ 300MG BASE	A072395	001	Oct 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946	001	Apr 30, 1991
	EQ 300MG BASE	A072472	001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294	001	Aug 17, 1988
	EQ 200MG BASE	A072981	001	Aug 19, 1991
	EQ 300MG BASE	A072293	001	Aug 17, 1988
	EQ 300MG BASE	A072982	001	Aug 19, 1991

NALFON

PEDINOL	EQ 300MG BASE	N017604	002	

TABLET; ORAL

FENOPROFEN CALCIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A072274	001	May 02, 1988
AM THERAP	EQ 600MG BASE	A072309	001	Aug 17, 1988
CLONMEL HLTHCARE	EQ 600MG BASE	A072326	001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357	001	Aug 17, 1988
MUTUAL PHARM	EQ 600MG BASE	A072902	001	Dec 21, 1990
PAR PHARM	EQ 600MG BASE	A072429	001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194	001	Aug 17, 1988
SANDOZ	EQ 600MG BASE	A072396	001	Oct 17, 1988
USL PHARMA	EQ 600MG BASE	A072362	001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165	001	Aug 17, 1988
	EQ 600MG BASE	A072407	001	Aug 17, 1988
	EQ 600MG BASE	A072602	001	Oct 11, 1988

NALFON

DISTA	EQ 600MG BASE	N017710	001	

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

ABBOTT	EQ 0.05MG BASE/ML	A070636	001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637	001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488	001	Jun 30, 1992
FENTANYL CITRATE PRESERVATIVE FREE				
MARSAM PHARMS LLC	EQ 0.05MG BASE/ML	A074917	001	Feb 03, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 135 (of 331)

FENTANYL CITRATE

TABLET; BUCCAL

FENTORA

CEPHALON

EQ 0.3MG BASE

N021947 006

Mar 02, 2007

TROCHE/LOZENGE; ORAL

FENTANYL

CEPHALON

EQ 0.1MG BASE

N020195 007

Oct 30, 1995

EQ 0.2MG BASE

N020195 001

Oct 04, 1993

EQ 0.3MG BASE

N020195 002

Oct 04, 1993

EQ 0.4MG BASE

N020195 003

Oct 04, 1993

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL

IONSYS

INCLINE THERAP

10.8MCG

N021338 001

May 22, 2006

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

OTSUKA

600MG/PACKET

N020292 001

Oct 14, 1997

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT

25uCi/ML

N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL

FOLVRON

LEDERLE

182MG;0.33MG

N006012 003

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

SANOFI AVENTIS US

60MG

N020625 001

Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR

60MG

A076169 001

Jul 13, 2005

FIBRINOGEN, I-125

INJECTABLE; INJECTION

IBRIN

GE HEALTHCARE

154uCi/VIAL

N017879 001

RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR

ABBOTT

140uCi/ML

N017787 001

FINASTERIDE

TABLET; ORAL

FINASTERIDE

IVAX SUB TEVA PHARMS 5MG

A076340 001

Jun 19, 2006

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

URISPAS

ORTHO MCNEIL JANSSEN 100MG

N016769 001

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

SANDOZ

50MG

A076030 001

Oct 28, 2002

100MG

A076030 002

Oct 28, 2002

150MG

A076030 003

Oct 28, 2002

TAMBOCOR

GRACEWAY

200MG

N018830 002

Oct 31, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 136 (of 331)

FLOXURIDINEINJECTABLE; INJECTION
FUDR

HOSPIRA 500MG/VIAL N016929 001

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

APOTEX INC 200MG/100ML (2MG/ML) A076889 001 Mar 25, 2005

400MG/200ML (2MG/ML) A076889 002 Mar 25, 2005

HOSPIRA 200MG/100ML (2MG/ML) A076617 001 Jul 29, 2004

400MG/200ML (2MG/ML) A076617 002 Jul 29, 2004

TABLET; ORAL

FLUCONAZOLE

GEDEON RICHTER USA 50MG A076432 001 Jul 29, 2004

100MG A076432 002 Jul 29, 2004

150MG A076432 003 Jul 29, 2004

200MG A076432 004 Jul 29, 2004

ROXANE 50MG A076213 001 Jul 29, 2004

100MG A076213 002 Jul 29, 2004

150MG A076213 003 Jul 29, 2004

200MG A076213 004 Jul 29, 2004

SANDOZ 50MG A076086 001 Jul 29, 2004

100MG A076086 002 Jul 29, 2004

150MG A076086 003 Jul 29, 2004

200MG A076086 004 Jul 29, 2004

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F 18

DOWNSTATE CLINCL 4-40mCi/ML N020306 001 Aug 19, 1994

4-90mCi/ML N020306 002 Sep 25, 2001

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

KING PHARMS 0.1MG N010060 001

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS 0.03% N016379 001

FLUNISOLIDE

SPRAY, METERED; NASAL

NASALIDE

IVAX RES 0.025MG/SPRAY N018148 001

NASAREL

TEVA BRANDED PHARM 0.029MG/SPRAY N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCET

ALPHARMA US PHARMS 0.025% A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.01% A088361 001 Jan 16, 1984

G AND W LABS 0.01% A089526 001 Jul 26, 1988

0.025% A089525 001 Jul 26, 1988

PERRIGO NEW YORK 0.01% A086810 001 Mar 04, 1982

0.025% A086811 001 Mar 04, 1982

PHARMADERM 0.01% A088047 001 Dec 16, 1982

0.025% A088045 001 Dec 16, 1982

PHARMAFAIR 0.01% A088499 001 Aug 02, 1984

0.025% A088506 001 Aug 02, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 137 (of 331)

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

TARO	0.01%	A040035	001	Oct 31, 1994
	0.01%	A087102	001	Apr 27, 1982
	0.025%	A040042	001	Oct 31, 1994
USL PHARMA	0.01%	A088757	001	Feb 11, 1985
	0.025%	A088756	001	Mar 28, 1985

FLUONID

ALLERGAN HERBERT	0.025%	A087156	002	Sep 06, 1984

FLUOTREX

SAVAGE LABS	0.01%	A088174	001	May 06, 1983
	0.025%	A088173	001	Mar 09, 1983

SYNALAR-HP

MEDICIS	0.2%	N016161	002	

GEL; TOPICAL

FLUONID

ALLERGAN HERBERT	0.025%	A087300	001	May 27, 1982

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

G AND W LABS	0.025%	A089524	001	Jul 26, 1988
PHARMADERM	0.025%	A088046	001	Dec 16, 1982
PHARMAFAIR	0.025%	A088507	001	Feb 27, 1984
USL PHARMA	0.025%	A088742	001	Feb 08, 1985

FLUONID

ALLERGAN HERBERT	0.025%	A087157	001	Sep 06, 1984

FLUOTREX

SAVAGE LABS	0.025%	A088172	001	Mar 09, 1983

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.01%	A087159	001	Jun 16, 1982
BAUSCH AND LOMB	0.01%	A040059	001	Dec 20, 1993
MORTON GROVE	0.01%	A088312	001	Jan 27, 1984
PHARMADERM	0.01%	A088048	001	Dec 16, 1982
PHARMAFAIR	0.01%	A088449	001	Feb 08, 1984

FLUONID

ALLERGAN HERBERT	0.01%	A087158	001	Mar 17, 1983

FLUOTREX

SAVAGE LABS	0.01%	A088171	001	Mar 09, 1983

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

MEDICIS	0.025%;EQ 3.5MG BASE/GM	A060700	001	

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

PERRIGO NEW YORK	0.05%	A071790	001	Jul 13, 1988
TARO	0.05%	A071500	001	Jun 10, 1987

FLUOCINONIDE EMULSIFIED BASE

ACTAVIS MID ATLANTIC	0.05%	A074204	001	Jun 13, 1995

SOLUTION; TOPICAL

FLUOCINONIDE

TARO	0.05%	A072857	001	Aug 02, 1989
TEVA PHARMS	0.05%	A072522	001	Sep 28, 1990

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

NOVARTIS	25%	N017869	001	

INJECTABLE; INTRAVENOUS

AK-FLUOR 25%

AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 138 (of 331)

FLUOROMETHOLONECREAM; TOPICAL
OXYLONE

PHARMACIA AND UPJOHN	0.025%	N011748	001	
SUSPENSION/DROPS; OPHTHALMIC				
FLUOR-OP				
NOVARTIS	0.1%	A070185	001	Feb 27, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCINSUSPENSION/DROPS; OPHTHALMIC
TOBRASONE

ALCON	0.1%;0.3%	N050628	001	Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUMSUSPENSION/DROPS; OPHTHALMIC
FML-S

ALLERGAN	0.1%;10%	N019525	001	Sep 29, 1989

FLUOROURACILINJECTABLE; INJECTION
ADRUCIL

PHARMACIA AND UPJOHN	50MG/ML	A081222	001	Jun 28, 1991
	50MG/ML	N017959	001	
TEVA PARENTERAL	50MG/ML	A040023	001	Oct 18, 1991
	50MG/ML	A081225	001	Aug 28, 1991

FLUOROURACIL

ABIC	50MG/ML	A088929	001	Mar 04, 1986
ABRAXIS PHARM	50MG/ML	A089152	001	Mar 21, 1986
	50MG/ML	A089428	001	Jan 12, 1987
	50MG/ML	A089519	001	Mar 12, 1987
APP PHARMS	50MG/ML	A040291	001	Mar 24, 1999
	50MG/ML	A040379	001	Nov 15, 2000
BEDFORD	50MG/ML	A089508	001	Jan 26, 1988
MARCHAR	50MG/ML	A087791	001	Jan 18, 1983
SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
	50MG/ML	A088767	001	Dec 28, 1984
	50MG/ML	A089434	001	Mar 26, 1987
WATSON LABS	50MG/ML	A087792	001	Oct 13, 1982

SOLUTION; TOPICAL
FLUOROPLEX

ELORAC	1%	N016765	001	

FLUOXETINE HYDROCHLORIDECAPSULE; ORAL
FLUOXETINE

MUTUAL PHARMA	EQ 10MG BASE	A075787	001	Jan 29, 2002
	EQ 20MG BASE	A075787	002	Jan 29, 2002
WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
	EQ 20MG BASE	A075662	002	Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

BARR	EQ 40MG BASE	A076251	001	May 18, 2005
PAR PHARM	EQ 10MG BASE	A076922	001	Dec 16, 2004
	EQ 20MG BASE	A076922	002	Dec 16, 2004
	EQ 40MG BASE	A076922	003	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A075807	001	Jan 29, 2002
	EQ 20MG BASE	A075807	002	Jan 29, 2002

PROZAC

LILLY	EQ 60MG BASE	N018936	004	Jun 15, 1999

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690	001	Jan 31, 2002
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002

PROZAC

LILLY	EQ 20MG BASE/5ML	N020101	001	Apr 24, 1991

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 139 (of 331)

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

BARR	EQ 10MG BASE	A075810	001	Feb 01, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865	001	Feb 28, 2002
	EQ 40MG BASE	A075865	003	Aug 30, 2004
SANDOZ	EQ 10MG BASE	A076024	001	Jan 29, 2002
PROZAC				
LILLY	EQ 10MG BASE	N020974	001	Mar 09, 1999
	EQ 20MG BASE	N020974	002	Mar 09, 1999

FLUOXYMESTERONE

TABLET; ORAL

ANDROID-F

VALEANT PHARM INTL	10MG	A087196	001	
FLUOXYMESTERONE				
VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
WATSON LABS	2MG	A088260	001	Dec 06, 1983
	5MG	A088265	001	Dec 06, 1983
	10MG	A088309	001	Dec 06, 1983
HALOTESTIN				
PHARMACIA AND UPJOHN	2MG	N010611	002	
	5MG	N010611	006	
	10MG	N010611	010	
ORA-TESTRYL				
BRISTOL MYERS SQUIBB	2MG	N011359	001	
	5MG	N011359	002	

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

HOSPIRA	25MG/ML	A074966	001	Apr 16, 1998
PROLIXIN DECANOATE				
BRISTOL MYERS SQUIBB	25MG/ML	N016727	001	

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

APOTHECON	25MG/ML	N016110	001	

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	5MG/ML	A073058	001	Aug 30, 1991
PERMITIL				
SCHERING	5MG/ML	N016008	001	
PROLIXIN				
APOTHECON	5MG/ML	A070533	001	Nov 07, 1985

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	2.5MG/5ML	A081310	001	Apr 29, 1993
PROLIXIN				
APOTHECON	2.5MG/5ML	N012145	003	

INJECTABLE; INJECTION

PROLIXIN

APOTHECON	2.5MG/ML	N011751	005	

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

WATSON LABS	1MG	A088555	001	Dec 18, 1987
	2.5MG	A088544	001	Dec 18, 1987
	5MG	A088527	001	Dec 18, 1987
	10MG	A088550	001	Dec 18, 1987
PERMITIL				
SCHERING	0.25MG	N012034	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 140 (of 331)

FLUPHENAZINE HYDROCHLORIDETABLET; ORAL
PERMITIL

SCHERING	2.5MG	N012034	004
	5MG	N012034	005
	10MG	N012034	006

PROLIXIN

APOTHECON	1MG	N011751	004
	2.5MG	N011751	001
	5MG	N011751	003
	10MG	N011751	002

TABLET, EXTENDED RELEASE; ORAL
PERMITIL

SCHERING	1MG	N012419	004

FLUPREDNISOLONETABLET; ORAL
ALPHADROL

PHARMACIA AND UPJOHN	1.5MG	N012259	002

FLURANDRENOLIDELOTION; TOPICAL
FLURANDRENOLIDE

ALPHARMA US PHARMS	0.05%	A087203	001	Apr 29, 1982

FLURANDRENOLIDE; NEOMYCIN SULFATECREAM; TOPICAL
CORDRAN-N

LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001

OINTMENT; TOPICAL
CORDRAN-N

LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

HALSEY	15MG	A071808	001	Jan 07, 1988
	30MG	A071809	001	Jan 07, 1988
MUTUAL PHARM	15MG	A070454	001	Aug 04, 1986
	30MG	A070455	001	Aug 04, 1986
PAR PHARM	15MG	A070444	001	Mar 20, 1986
	30MG	A070445	001	Mar 20, 1986
PUREPAC PHARM	15MG	A071927	001	Sep 09, 1987
	30MG	A071551	001	Sep 09, 1987
SANDOZ	15MG	A071716	001	Jul 31, 1991
	30MG	A071717	001	Jul 31, 1991
SUPERPHARM	15MG	A071659	001	Aug 04, 1988
	30MG	A071660	001	Aug 04, 1988
USL PHARMA	15MG	A070562	001	Jul 09, 1987
	30MG	A070563	001	Jul 09, 1987
WARNER CHILCOTT	15MG	A071767	001	Dec 04, 1987
	30MG	A071768	001	Dec 04, 1987
WATSON LABS	15MG	A072368	001	Mar 30, 1989

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

IVAX SUB TEVA PHARMS	50MG	A074411	001	May 31, 1995
	100MG	A074411	002	May 31, 1995
PLIVA	50MG	A074647	001	Apr 01, 1997
	100MG	A074647	002	Apr 01, 1997
SANDOZ	50MG	A074448	001	Jul 28, 1995
	100MG	A074448	002	Jul 28, 1995
TEVA	50MG	A074405	002	May 24, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 141 (of 331)

FLURBIPROFENTABLET; ORAL
FLURBIPROFEN

TEVA	100MG	A074405	001	May 24, 1995
THERAGEN	100MG	A074560	002	May 16, 1997

FLUTAMIDECAPSULE; ORAL
EULEXIN

SCHERING	125MG	N018554	001	Jan 27, 1989

FLUTICASONE PROPIONATEAEROSOL, METERED; INHALATION
FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020548	001	Mar 27, 1996
	0.11MG/INH	N020548	002	Mar 27, 1996
	0.22MG/INH	N020548	003	Mar 27, 1996

OINTMENT; TOPICAL
FLUTICASONE PROPIONATE

TARO PHARM INDS	0.005%	A077145	001	Jun 14, 2005

POWDER; INHALATION
FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020549	001	Nov 07, 1997
	0.088MG/INH	N020549	002	Nov 07, 1997
	0.22MG/INH	N020549	003	Nov 07, 1997

FLUVOXAMINE MALEATETABLET; ORAL
FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH	25MG	A075901	001	Dec 28, 2000
	50MG	A075901	002	Dec 28, 2000
	100MG	A075901	003	Dec 28, 2000
GENPHARM	50MG	A075950	001	Oct 15, 2001
	100MG	A075950	002	Oct 15, 2001
IVAX SUB TEVA PHARMS	25MG	A075898	001	Mar 12, 2001
	50MG	A075898	002	Mar 12, 2001
	100MG	A075898	003	Mar 12, 2001
MUTUAL PHARM	25MG	A076125	001	Apr 29, 2002
	50MG	A076125	002	Apr 29, 2002
	100MG	A076125	003	Apr 29, 2002
SANDOZ	25MG	A075887	001	Jan 05, 2001
	50MG	A075887	002	Jan 05, 2001
	100MG	A075887	003	Jan 05, 2001
SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
	50MG	A075899	002	Jan 17, 2001
	100MG	A075899	003	Jan 17, 2001
WATSON LABS	25MG	A075894	001	Apr 18, 2001
	50MG	A075894	002	Apr 18, 2001
	100MG	A075894	003	Apr 18, 2001
LUVOX				
SOLVAY	25MG	N020243	001	Dec 05, 1994
	50MG	N020243	002	Dec 05, 1994
	100MG	N020243	003	Dec 05, 1994
	150MG	N020243	004	Dec 05, 1994

FOLIC ACIDINJECTABLE; INJECTION
FOLIC ACID

BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993

FOLVITE

WYETH PHARMS INC	5MG/ML	N005897	008	

TABLET; ORAL
FOLIC ACID

BARR	1MG	A089177	001	Jan 08, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 142 (of 331)

FOLIC ACID

TABLET; ORAL
FOLIC ACID

EVERYLIFE	1MG	A080755	001	
HALSEY	1MG	A083598	001	
IMPAX LABS	1MG	A080686	001	
IVAX SUB TEVA PHARMS	1MG	A083000	001	
LANNETT	1MG	A080816	001	
LILLY	1MG	N006135	003	
MK LABS	1MG	A083526	001	
NEXGEN PHARMA INC	1MG	A084915	001	
PHARMERAL	1MG	A084158	001	
PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784	001	
SANDOZ	1MG	A084472	001	
TABLICAPS	1MG	A083133	002	
UDL	1MG	A088199	001	Mar 29, 1983
USL PHARMA	1MG	A087828	001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903	001	
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	
FOLICET				
MISSION PHARMA	1MG	A087438	001	
FOLVITE				
WYETH PHARMS INC	1MG	N005897	004	

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC
FOLLISTIM

ORGANON USA INC	75 IU/VIAL	N020582	001	Sep 29, 1997
	150 IU/VIAL	N020582	002	Sep 29, 1997
INJECTABLE; SUBCUTANEOUS				
FOLLISTIM AQ				
ORGANON USA INC	150 IU/0.18ML	N021211	003	Feb 11, 2004
GONAL-F				
EMD SERONO	37.5 IU/VIAL	N020378	003	May 25, 2000
	37.5 IU/VIAL	N021765	001	Mar 25, 2004
	75 IU/VIAL	N020378	001	Sep 29, 1997
	150 IU/VIAL	N020378	002	Sep 29, 1997
	150 IU/VIAL	N021765	003	Mar 25, 2004

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION
VITRAVENE PRESERVATIVE FREE
NOVARTIS

6.6MG/ML	N020961	001	Aug 26, 1998

FOSINOPRIL SODIUM

TABLET; ORAL
FOSINOPRIL SODIUM

SANDOZ	10MG	A076188	001	Oct 08, 2004
	20MG	A076188	002	Oct 08, 2004
	40MG	A076188	003	Oct 08, 2004

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

TEVA	10MG;12.5MG	A076945	001	Jul 05, 2006
	20MG;12.5MG	A076945	002	Jul 05, 2006
WATSON LABS	10MG;12.5MG	A077144	001	Aug 16, 2005
	20MG;12.5MG	A077144	002	Aug 16, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 143 (of 331)

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET; ORAL
MONOPRIL-HCTBRISTOL MYERS SQUIBB 10MG;12.5MG
20MG;12.5MGN020286 002 Nov 30, 1994
N020286 001 Nov 30, 1994FOSPHENYTOIN SODIUMINJECTABLE; INJECTION
CEREBYX

PARKE DAVIS EQ 50MG PHENYTOIN NA/ML

N020450 001 Aug 05, 1996

FURAZOLIDONESUSPENSION; ORAL
FUROXONE

SHIRE 50MG/15ML

N011323 002

TABLET; ORAL

FUROXONE

SHIRE 100MG

N011270 002

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDEABRAXIS PHARM 10MG/ML
10MG/MLN018507 001 Jul 30, 1982
N019036 001 Aug 13, 1984ASTRAZENECA 10MG/ML
10MG/MLA070014 001 Sep 09, 1985
A070095 001 Sep 09, 198510MG/ML
BAXTER HLTHCARE 10MG/ML
10MG/MLA070096 001 Sep 09, 1985
A071439 001 Sep 14, 1990
N018267 001HOSPIRA 10MG/ML
10MG/MLA072080 001 Aug 13, 1991
A074337 001 Oct 31, 1994MARSAM PHARMS LLC 10MG/ML
ORGANON USA INC 10MG/MLA074017 001 Jun 30, 1994
A070017 001 Dec 15, 1986SMITH AND NEPHEW 10MG/ML
10MG/MLA070023 001 Feb 05, 1986
A070078 001 Feb 05, 1986WARNER CHILCOTT 10MG/ML
WATSON LABS 10MG/MLN018420 001 Feb 26, 1982
A070019 001 Sep 22, 198610MG/ML
WYETH AYERST 10MG/MLA070604 001 Jan 02, 1987
N018670 001 Jul 20, 1982

LASIX

SANOFI AVENTIS US 10MG/ML
SOLUTION; ORAL

N016363 001

LASIX

SANOFI AVENTIS US 10MG/ML
TABLET; ORAL

N017688 001

FUROSEMIDE

INTL MEDICATION 20MG
40MGN018753 001 Feb 28, 1984
N018753 002 Feb 28, 1984KALAPHARM 20MG
40MGN018868 001 Jun 28, 1983
N018868 002 Jun 28, 1983MUTUAL PHARM 20MG
40MGA070043 001 Sep 26, 1985
N018790 001 Nov 29, 198380MG
SANDOZ 40MGA070100 001 Jan 26, 1988
N018750 002 Jul 30, 1984SUPERPHARM 20MG
40MGN018370 002 Jun 26, 1984
N018370 001 Feb 10, 1983WARNER CHILCOTT 20MG
40MGN018419 001 Jan 31, 1983
N018419 002 Jan 31, 198380MG
WATSON LABS 20MGN018419 003 Nov 13, 1984
N018369 001 May 14, 198240MG
40MGA070413 001 Feb 26, 1986
N018369 002 May 14, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 144 (of 331)

GABAPENTINCAPSULE; ORAL
GABAPENTIN

IVAX SUB TEVA PHARMS	100MG	A075477	001	Mar 23, 2005
	300MG	A075477	002	Mar 23, 2005
	400MG	A075477	003	Mar 23, 2005
MUTUAL PHARM	100MG	A076537	001	Jun 30, 2005
	300MG	A076537	002	Jun 30, 2005
	400MG	A076537	003	Jun 30, 2005
SANDOZ	100MG	A075428	001	Jan 24, 2006
	100MG	A075539	001	Apr 06, 2005
	300MG	A075428	002	Jan 24, 2006
	300MG	A075539	002	Apr 06, 2005
	400MG	A075428	003	Jan 24, 2006
	400MG	A075539	003	Apr 06, 2005

TABLET; ORAL
GABAPENTIN

RANBAXY	600MG	A076605	001	Sep 14, 2005
	800MG	A076605	002	Sep 14, 2005
SANDOZ	600MG	A076120	001	Jan 27, 2006
	600MG	A076877	001	Jul 06, 2006
	800MG	A076120	002	Jan 27, 2006
	800MG	A076877	002	Jul 06, 2006
TEVA	600MG	A075827	001	Dec 15, 2004
	800MG	A075827	002	Dec 15, 2004

GADODIAMIDEINJECTABLE; INJECTION
OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007

GALANTAMINE HYDROBROMIDETABLET; ORAL
GALANTAMINE HYDROBROMIDE

YABAO BIOPHARMS	EQ 4MG BASE	A077604	001	Feb 06, 2009
	EQ 8MG BASE	A077604	002	Feb 06, 2009
	EQ 12MG BASE	A077604	003	Feb 06, 2009

GALLAMINE TRIETHIODIDEINJECTABLE; INJECTION
FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842	001	
	100MG/ML	N007842	002	

GALLIUM CITRATE GA-67INJECTABLE; INJECTION
GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700	001	
NEOSCAN				
GE HEALTHCARE	2mCi/ML	N017655	001	

GANCICLOVIRCAPSULE; ORAL
CYTOVENE

ROCHE PALO	250MG	N020460	001	Dec 22, 1994
	500MG	N020460	002	Dec 12, 1997

GANCICLOVIR SODIUMINJECTABLE; INJECTION
GANCICLOVIR SODIUM

BEDFORD	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 145 (of 331)

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

MYLAN	300MG	A073466	001	Jan 25, 1993

PUREPAC PHARM	300MG	A072929	001	Jan 29, 1993

LOPID

PFIZER PHARMS	200MG	N018422	001	

	300MG	N018422	002	

TABLET; ORAL

GEMFIBROZIL

MYLAN	600MG	A074452	001	Feb 16, 1995

PUREPAC PHARM	600MG	A074360	001	Aug 31, 1994

SANDOZ	600MG	A074615	001	Sep 29, 1995

WATSON LABS	600MG	A074156	001	Oct 24, 1994

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

WYETH PHARMS INC	5MG/VIAL	N021174	001	May 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

SCHERING	EQ 0.1% BASE	A060462	001	

GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062458	001	Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062471	001	Sep 27, 1983

BAUSCH AND LOMB	EQ 0.1% BASE	A064056	001	Apr 29, 1994

PHARMADERM	EQ 1MG BASE/GM	A062530	001	Jul 05, 1984

INJECTABLE; INJECTION

APOGEN

KING PHARMS	EQ 10MG BASE/ML	A062289	001	

	EQ 40MG BASE/ML	A062289	002	

BRISTAGEN

BRISTOL	EQ 40MG BASE/ML	A062288	001	

GARAMYCIN

SCHERING	EQ 1MG BASE/ML	A061716	002	

	EQ 10MG BASE/ML	A061739	001	

	EQ 40MG BASE/ML	A061716	001	

GENTAFAIR

PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985

GENTAMICIN

INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982

	EQ 40MG BASE/ML	A062325	001	

	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983

	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983

	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983

	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983

	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983

	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983

	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983

	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983

	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983

	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983

BAXTER HLTHCARE	EQ 10MG BASE/ML	A062251	002	

	EQ 40MG BASE/ML	A062251	001	

KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982

PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983

SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985

	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985

TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 146 (of 331)

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

TEVA PARENTERAL	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986

U-GENCIN

PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	

INJECTABLE; INTRATHECAL

GARAMYCIN

SCHERING	EQ 2MG BASE/ML	N050505	001	

OINTMENT; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE	N050425	001	

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984

GENTAFAIR

PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983

OINTMENT; TOPICAL

GARAMYCIN

SCHERING	EQ 0.1% BASE	A060463	001	

GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984

BAUSCH AND LOMB	EQ 0.1% BASE	A064054	001	Apr 29, 1994

PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE	N050039	002	

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984

GENTAFAIR

PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983

GENTAMICIN SULFATE

ALCON UNIVERSAL	EQ 0.3% BASE	A062523	001	Nov 25, 1985

PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

SAVAGE LABS	0.4%	A083513	001	

TAMPON; VAGINAL

GENAPAX

KEY PHARMS	5MG	A085017	001	

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

TEVA	20MG/VIAL	N020622	001	Dec 20, 1996

DISCONTINUED DRUG PRODUCT LIST

6 - 147 (of 331)

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

RANBAXY	3MG	A077366	001	Oct 06, 2005
	6MG	A077366	002	Oct 06, 2005

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

ENDO PHARMS	5MG	A074378	001	Nov 28, 1994
	10MG	A074378	002	Nov 28, 1994
PLIVA	5MG	A074619	001	Apr 04, 1997
	10MG	A074619	002	Apr 04, 1997
SANDOZ	5MG	A074542	001	Jun 20, 1995
	10MG	A074542	002	Jun 20, 1995
TEVA	5MG	A074387	001	Mar 04, 1996
	10MG	A074387	002	Mar 04, 1996
GLUCOTROL				
PFIZER	2.5MG	N017783	003	May 11, 1993

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON

LILLY	EQ 1MG BASE/VIAL	N012122	001	
	EQ 10MG BASE/VIAL	N012122	002	

GLUTETHIMIDE

CAPSULE; ORAL
DORIDEN

SANOFI AVENTIS US	500MG	N009519	008	

TABLET; ORAL
DORIDEN

SANOFI AVENTIS US	250MG	N009519	002	
	500MG	N009519	005	

GLUTETHIMIDE

HALSEY	250MG	A089458	001	Oct 10, 1986
	500MG	A089459	001	Oct 10, 1986
LANNETT	250MG	A083475	001	
	500MG	A085571	001	
SANDOZ	500MG	A083234	002	
UCB INC	500MG	A085171	001	
VITARINE	500MG	A087297	001	
WATSON LABS	500MG	A084362	001	
	500MG	A085763	001	

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

SANDOZ	1.5MG	A075174	001	Jun 22, 1998
	3MG	A075174	002	Jun 22, 1998
SANOFI AVENTIS US	1.5MG	N020055	001	Apr 17, 1992
	3MG	N020055	002	Apr 17, 1992
	6MG	N020055	003	Mar 08, 2000

GLYNASE

PHARMACIA AND UPJOHN	4.5MG	N020051	003	Sep 24, 1993

MICRONASE

PHARMACIA AND UPJOHN	1.25MG	N017498	001	May 01, 1984
	2.5MG	N017498	002	May 01, 1984
	5MG	N017498	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE				
TEVA	1.25MG; 250MG	A076821	001	Jan 27, 2005

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 148 (of 331)

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

TEVA	2.5MG;500MG	A076821	002	Jan 27, 2005
	5MG;500MG	A076821	003	Jan 27, 2005

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522	001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633	001	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475	001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393	001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169	001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947	001	Jun 24, 1983

ROBINUL

ROBINS AH	0.2MG/ML	N014764	001	

TABLET; ORAL

GLYCOPYRROLATE

WATSON LABS	1MG	A085562	001	
	1MG	A086902	001	
	2MG	A085563	001	
	2MG	A086178	001	
	2MG	A086900	001	

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

FERRING	5,000 UNITS/VIAL	N017055	001	
	10,000 UNITS/VIAL	N017055	002	
	20,000 UNITS/VIAL	N017055	003	

CHORIONIC GONADOTROPIN

APP PHARMS	5,000 UNITS/VIAL	N017067	001	
	15,000 UNITS/VIAL	N017067	004	
	20,000 UNITS/VIAL	N017067	003	
BEL MAR	5,000 UNITS/VIAL	N017054	001	
	10,000 UNITS/VIAL	N017054	002	
FERRING	2,000 UNITS/VIAL	N017016	009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016	011	Feb 16, 1990
	5,000 UNITS/VIAL	N017016	006	
	15,000 UNITS/VIAL	N017016	010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016	004	

FOLLUTEIN

BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 149 (of 331)

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATESOLUTION/DROPS; OPHTHALMICNEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818	001	Oct 11, 1988

WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788	001	Jun 11, 1987

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383	001	Aug 31, 1982

NEO-POLYCIN

DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427	001	

GRANISETRON HYDROCHLORIDEINJECTABLE; INJECTIONKYTRIL

ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020239	003	Sep 17, 2004
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N020239	004	Mar 11, 1994
	EQ 3MG BASE/ML	N020239	001	Dec 29, 1993
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N020239	002	Mar 11, 1994

SOLUTION; ORALKYTRIL

ROCHE	EQ 2MG BASE/10ML	N021238	001	Jun 27, 2001

TABLET; ORALGRANISETRON HYDROCHLORIDE

BARR	EQ 1MG BASE	A078221	001	Dec 31, 2007

KYTRIL

ROCHE	EQ 1MG BASE	N020305	001	Mar 16, 1995
	EQ 2MG BASE	N020305	002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDETABLET; ORALRAXAR

OTSUKA	EQ 200MG BASE	N020695	001	Nov 06, 1997
	EQ 400MG BASE	N020695	002	May 14, 1998
	EQ 600MG BASE	N020695	003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINECAPSULE; ORALGRISACTIN

WYETH AYERST	125MG	N050051	002	
	250MG	N050051	001	

SUSPENSION; ORALGRIFULVIN V

JOHNSON AND JOHNSON	125MG/5ML	N050448	001	

TABLET; ORALFULVICIN-U/F

ELORAC	250MG	A060569	002	
	500MG	A060569	001	

GRIFULVIN V

J AND J	125MG	A060618	001	
	250MG	A060618	002	
	500MG	A060618	003	
ORTHONEUTROGENA	125MG	A062279	001	
	250MG	A062279	002	

GRISACTIN

WYETH AYERST	500MG	A060212	001	

GRISEOFULVIN, ULTRAMICROCRYSTALLINETABLET; ORALFULVICIN P/G

SCHERING	125MG	A061996	001	
	250MG	A061996	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 150 (of 331)

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL					
FULVICIN P/G 165					
SCHERING	165MG	A061996	003	Apr 06, 1982	
FULVICIN P/G 330					
SCHERING	330MG	A061996	004	Apr 06, 1982	
GRISACTIN ULTRA					
WYETH AYERST	125MG	A062178	001		
	165MG	A062438	001	Nov 17, 1983	
	250MG	A062178	002		
	330MG	A062438	002	Nov 17, 1983	
ULTRAGRIS-165					
PLIVA	165MG	A062645	001	Jun 30, 1992	
ULTRAGRIS-330					
PLIVA	330MG	A062646	001	Jun 30, 1992	

GUANABENZ ACETATE

TABLET; ORAL					
GUANABENZ ACETATE					
SANDOZ	EQ 4MG BASE	A074517	001	Sep 30, 1998	
	EQ 8MG BASE	A074517	002	Sep 30, 1998	
TEVA PHARMS	EQ 4MG BASE	A074267	001	Jun 01, 1994	
	EQ 8MG BASE	A074267	002	Jun 01, 1994	
WATSON LABS	EQ 4MG BASE	A074025	001	Feb 28, 1994	
	EQ 8MG BASE	A074025	002	Feb 28, 1994	
WYTENSIN					
WYETH AYERST	EQ 4MG BASE	N018587	001	Sep 07, 1982	
	EQ 8MG BASE	N018587	002	Sep 07, 1982	
	EQ 16MG BASE	N018587	003	Sep 07, 1982	

GUANADREL SULFATE

TABLET; ORAL					
HYLOREL					
PHARMACIA AND UPJOHN	10MG	N018104	001	Dec 29, 1982	
	25MG	N018104	002	Dec 29, 1982	

GUANETHIDINE MONOSULFATE

TABLET; ORAL					
GUANETHIDINE MONOSULFATE					
WATSON LABS	EQ 10MG SULFATE	A086113	001	Mar 26, 1985	
	EQ 25MG SULFATE	A086114	001	Mar 26, 1985	
ISMELIN					
NOVARTIS	EQ 10MG SULFATE	N012329	001		
	EQ 25MG SULFATE	N012329	002		

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL					
ESIMIL					
NOVARTIS	10MG;25MG	N013553	001		

GUANFACINE HYDROCHLORIDE

TABLET; ORAL					
GUANFACINE HYDROCHLORIDE					
WATSON LABS	EQ 1MG BASE	A074762	001	Jun 25, 1997	
	EQ 2MG BASE	A074762	002	Jun 25, 1997	
TENEX					
PROMIUS PHARMA	EQ 3MG BASE	N019032	003	Nov 07, 1988	

HALAZEPAM

TABLET; ORAL					
PAXIPAM					
SCHERING	20MG	N017736	003		
	40MG	N017736	004		

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 151 (of 331)

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUIBB

0.025%

N017818 001

HALOG-E

RANBAXY

0.1%

N018234 001

OINTMENT; TOPICAL

HALOG

BRISTOL MYERS SQUIBB

0.025%

N018125 001

SOLUTION; TOPICAL

HALOG

RANBAXY

0.1%

N017823 001

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET; ORAL

HALDOL

ORTHO MCNEIL

0.5MG

N015921 001

1MG

N015921 002

2MG

N015921 003

5MG

N015921 004

10MG

N015921 005

20MG

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

DURAMED PHARMS BARR

0.5MG

A071216 001 Dec 04, 1986

1MG

A071217 001 Dec 04, 1986

2MG

A071218 001 Dec 04, 1986

5MG

A071219 001 Dec 04, 1986

10MG

A071220 001 Jul 07, 1987

20MG

A071221 001 Jul 07, 1987

LEDERLE

0.5MG

A072727 001 Sep 19, 1989

1MG

A072728 001 Sep 19, 1989

2MG

A072729 001 Sep 19, 1989

5MG

A072730 001 Sep 19, 1989

10MG

A072731 001 Sep 19, 1989

20MG

A072732 001 Sep 19, 1989

MUTUAL PHARM

0.5MG

A071156 001 Jan 02, 1987

1MG

A071157 001 Jan 02, 1987

2MG

A071172 001 Jan 02, 1987

5MG

A071212 001 Jan 07, 1988

10MG

A071173 001 Jan 07, 1988

20MG

A071177 001 Jan 07, 1988

PAR PHARM

20MG

A071328 001 Jul 20, 1987

PUREPAC PHARM

0.5MG

A071071 001 Nov 03, 1986

1MG

A071072 001 Nov 03, 1986

2MG

A071073 001 Nov 03, 1986

5MG

A071074 001 Nov 03, 1986

10MG

A071075 001 Aug 04, 1987

20MG

A071076 001 Aug 04, 1987

QUANTUM PHARMICS

0.5MG

A071255 001 Feb 17, 1987

1MG

A071269 001 Feb 17, 1987

2MG

A071256 001 Feb 17, 1987

5MG

A071257 001 Feb 17, 1987

ROXANE

0.5MG

A071128 001 Feb 17, 1987

1MG

A071129 001 Feb 17, 1987

2MG

A071130 001 Feb 17, 1987

5MG

A071131 001 Feb 17, 1987

10MG

A071132 001 May 12, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 152 (of 331)

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

ROXANE	20MG	A071133	001	May 12, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
VINTAGE	0.5MG	A071233	001	Nov 03, 1986
	1MG	A071234	001	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071236	001	Nov 03, 1986
	10MG	A071237	001	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001	
HALOPERIDOL				
ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987

HALOPERIDOL INTENSOL

ROXANE	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988

INJECTABLE; INJECTION
HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187	001	Jan 20, 1987
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516	001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517	001	Feb 25, 1993
SANDOZ	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802	001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864	001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713	001	May 17, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 153 (of 331)

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

WATSON LABS

EQ 5MG BASE/ML

A070714 001

May 17, 1988

EQ 5MG BASE/ML

A070744 001

May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC

EQ 1MG BASE/ML

A074536 001

Nov 02, 1995

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB

1%

N016942 001

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB

1%

N016943 001

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST

99.99%

N011338 001

HALOTHANE

BH

99.99%

A084977 001

HALOCARBON

99.99%

A080810 001

HOSPIRA

99.99%

A083254 001

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US

25,000 UNITS/ML

N018237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA

100 UNITS/ML

N005264 010

INTL MEDICATION

10 UNITS/ML

A086357 001

500 UNITS/ML

A086357 002

LUITPOLD

10 UNITS/ML

A089063 001 Oct 09, 1985

100 UNITS/ML

A089064 001 Oct 09, 1985

PARKE DAVIS

10 UNITS/ML

N017346 006

SMITH AND NEPHEW

10 UNITS/ML

A087904 001 Apr 20, 1983

10 UNITS/ML

A087958 001 Apr 20, 1983

10 UNITS/ML

A088458 001 Jul 26, 1984

10 UNITS/ML

A088580 001 Oct 25, 1984

100 UNITS/ML

A087906 001 Apr 20, 1983

100 UNITS/ML

A087959 001 Apr 20, 1983

100 UNITS/ML

A088460 001 Jul 26, 1984

100 UNITS/ML

A088581 001 Oct 25, 1984

SOLOPAK

10 UNITS/ML

A087903 001 Apr 20, 1983

10 UNITS/ML

A088457 001 Oct 25, 1984

100 UNITS/ML

A087905 001 Apr 20, 1983

100 UNITS/ML

A088459 001 Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM

1,000 UNITS/ML

N017033 001

1,000 UNITS/ML

N017979 001

5,000 UNITS/ML

N017979 003

10,000 UNITS/ML

N017979 002

AKORN

1,000 UNITS/ML

N017486 001

5,000 UNITS/ML

N017486 002

10,000 UNITS/ML

N017486 003

20,000 UNITS/ML

N017486 004

40,000 UNITS/ML

N017486 005

APP PHARMS

1,000 UNITS/ML

N017651 005

5,000 UNITS/ML

N017029 002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 154 (of 331)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

APP PHARMS	10,000 UNITS/ML	N017651	003	
	20,000 UNITS/ML	N017651	008	
BAXTER HLTHCARE	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
BAXTER HLTHCARE CORP	1,000 UNITS/ML	N017007	001	
	2,500 UNITS/ML	N017007	007	
	5,000 UNITS/ML	N017007	002	
	5,000 UNITS/0.5ML	N017007	010	
	7,500 UNITS/ML	N017007	003	
	10,000 UNITS/ML	N017007	004	
	15,000 UNITS/ML	N017007	005	
	20,000 UNITS/ML	N017007	006	
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130	001	
	5,000 UNITS/ML	N017130	002	
	10,000 UNITS/ML	N017130	003	
	20,000 UNITS/ML	N017130	004	
DELL LABS	1,000 UNITS/ML	N017540	001	
	5,000 UNITS/ML	N017540	002	
	10,000 UNITS/ML	N017540	003	
	20,000 UNITS/ML	N017540	004	
	40,000 UNITS/ML	N017540	005	
HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
	10,000 UNITS/ML	A040095	001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521	001	
	10,000 UNITS/ML	N005521	002	
	20,000 UNITS/ML	N005521	004	
LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
MARSAM PHARMS LLC	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	A040008	001	Oct 10, 1995
ORGANON USA INC	1,000 UNITS/ML	N000552	008	
	5,000 UNITS/ML	N000552	009	
	10,000 UNITS/ML	N000552	010	
PARKE DAVIS	1,000 UNITS/ML	N017346	001	
	5,000 UNITS/ML	N017346	002	
	7,500 UNITS/ML	N017346	003	
	10,000 UNITS/ML	N017346	004	
	20,000 UNITS/ML	N017346	005	
PHARM SPEC	1,000 UNITS/ML	N017780	001	
	5,000 UNITS/ML	N017780	002	
	10,000 UNITS/ML	N017780	003	
	20,000 UNITS/ML	N017780	004	
	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	
	10,000 UNITS/0.5ML	A087363	001	
WATSON LABS	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	

DISCONTINUED DRUG PRODUCT LIST

6 - 155 (of 331)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%				
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
MARSAM PHARMS LLC	1,000 UNITS/ML	A089464	001	Jun 03, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 156 (of 331)

HEPARIN SODIUMINJECTABLE; INJECTION
LIPO-HEPIN

3M	10,000 UNITS/ML	N017027	009
	15,000 UNITS/0.5ML	N017027	011
	20,000 UNITS/0.5ML	N017027	004
	20,000 UNITS/ML	N017027	007
	40,000 UNITS/ML	N017027	005

LIQUAEMIN LOCK FLUSH
ORGANON USA INC

100 UNITS/ML N000552 007

LIQUAEMIN SODIUM
ORGANON USA INC

1,000 UNITS/ML	N000552	004
5,000 UNITS/ML	N000552	003
10,000 UNITS/ML	N000552	005
20,000 UNITS/ML	N000552	001
40,000 UNITS/ML	N000552	002

LIQUAEMIN SODIUM PRESERVATIVE FREE

ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986

PANHEPRIN

HOSPIRA	1,000 UNITS/ML	N005264	004
	5,000 UNITS/ML	N005264	006
	10,000 UNITS/ML	N005264	007
	20,000 UNITS/ML	N005264	008
	40,000 UNITS/ML	N005264	009

SODIUM HEPARIN

ABRAXIS PHARM	5,000 UNITS/ML	N017033	002
	10,000 UNITS/ML	N017033	003
	20,000 UNITS/ML	N017033	004

BAXTER HLTHCARE	1,000 UNITS/ML	N017036	001	Mar 04, 1988

HETACILLINFOR SUSPENSION; ORAL
VERSAPEN

BRISTOL	EQ 112.5MG AMPICIL/ML	A061398	001
	EQ 112.5MG AMPICIL/5ML	N050060	001
	EQ 112.5MG AMPICIL/ML	N050060	003
	EQ 225MG AMPICIL/5ML	A061398	002

HETACILLIN POTASSIUMCAPSULE; ORAL
VERSAPEN-K

BRISTOL	EQ 225MG AMPICIL	A061396	001
	EQ 450MG AMPICIL	A061396	002

HEXACHLOROPHENEAEROSOL; TOPICAL
SEPTISOL

VESTAL LABS	0.23%	N017424	001

TURGEX

XTTRIUM	3%	N018375	001

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS	3%	N017411	001

PHISOHEX

SANOFI AVENTIS US	3%	N008402	001

SOY-DOME

BAYER PHARMS	3%	N017405	001

TURGEX

XTTRIUM	3%	N019055	001	Nov 30, 1984

SOAP; TOPICAL

GAMOPHEN

ARBROOK	2%	N006270	003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 157 (of 331)

HEXACHLOROPHENESOLUTION; TOPICAL
DIAL

DIAL 0.25% N017421 002

GERMA-MEDICA

HUNTINGTON LABS 1% N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS 0.25% N017412 002

SEPTI-SOFT

CALGON 0.25% N017460 001

SEPTISOL

VESTAL LABS 0.25% N017423 001

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON 450MG N017452 001

HEXASCRUB

PROF DSPLS 3% N018363 001

PHISO-SCRUB

SANOFI AVENTIS US 3% N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M 330MG N017413 001

HEXAFLUORENIUM BROMIDEINJECTABLE; INJECTION
MYLAXEN

MEDPOINTE PHARM HLC 20MG/ML N009789 003

HEXOCYCLIUM METHYLSULFATETABLET; ORAL
TRAL

ABBOTT 25MG N010599 001

HEXYLCAINE HYDROCHLORIDESOLUTION; TOPICAL
CYCLAINE

MERCK 5% N008472 001

HISTAMINE PHOSPHATEINJECTABLE; INJECTION
HISTAMINE PHOSPHATE
LILLY

EQ 0.1MG BASE/ML N000734 003

EQ 0.2MG BASE/ML N000734 002

EQ 1MG BASE/ML N000734 001

HISTRELIN ACETATEINJECTABLE; INJECTION
SUPPRELIN

SHIRE EQ 0.2MG BASE/ML N019836 001 Dec 24, 1991

EQ 0.5MG BASE/ML N019836 002 Dec 24, 1991

EQ 1MG BASE/ML N019836 003 Dec 24, 1991

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

MISSION PHARMA 10MG A086308 001

HOMAPIN-5

MISSION PHARMA 5MG A086309 001

TABLET, CHEWABLE; ORAL
EQUIPIN

MISSION PHARMA 3MG A086310 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 158 (of 331)

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

ENDO PHARMS	1.5MG/5ML;5MG/5ML	N005213	002	Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS	1.5MG/5ML;5MG/5ML	A040285	001	Jul 19, 1999

HYDROPANE

HALSEY	1.5MG/5ML;5MG/5ML	A088066	001	Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS TOTOWA	1.5MG;5MG	A040295	001	Dec 01, 2000

HYCODAN

ENDO PHARMS	1.5MG;5MG	N005213	001	Jul 26, 1988

HYALURONIDASE

INJECTABLE; INJECTION

VITRASE

ISTA PHARMS	6,200 UNITS/VIAL	N021640	001	May 05, 2004

WYDASE

BAXTER HLTHCARE	150 UNITS/ML	N006343	002	

	150 UNITS/VIAL	N006343	006	

	1,500 UNITS/VIAL	N006343	005	

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

NOVARTIS	20MG/ML	N008303	003	

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM	20MG/ML	A089532	001	Aug 11, 1987

SMITH AND NEPHEW	20MG/ML	A088518	001	Apr 20, 1984

SOLOPAK	20MG/ML	A088517	001	Aug 22, 1985

TEVA PARENTERAL	20MG/ML	A040373	001	Feb 23, 2000

TABLET; ORAL

APRESOLINE

NOVARTIS	10MG	N008303	004	

	25MG	N008303	001	

	50MG	N008303	002	

	100MG	N008303	005	

DRALZINE

TEVA	25MG	A084301	001	

HYDRALAZINE HYDROCHLORIDE

ACTAVIS TOTOWA	25MG	A088560	001	Oct 04, 1984

	50MG	A088649	001	Oct 18, 1984

ASCOT	25MG	A088310	001	Dec 19, 1984

	50MG	A088311	001	Dec 19, 1984

HALSEY	10MG	A089218	001	Jan 22, 1986

	25MG	A089130	001	Jan 15, 1986

	50MG	A089222	001	Jan 22, 1986

	100MG	A089178	001	Jan 15, 1986

IMPAX LABS	25MG	A084922	001	

	50MG	A084923	001	

IVAX SUB TEVA PHARMS	10MG	A084443	001	

	25MG	A084437	001	

	50MG	A084469	002	

	100MG	A084581	001	

MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985

	10MG	A089359	001	Jul 25, 1986

	25MG	A084106	002	

	25MG	A089258	001	May 05, 1986

	50MG	A084107	002	

	50MG	A089259	001	May 05, 1986

	100MG	A088729	001	Apr 11, 1985

PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983

	50MG	A088178	001	Aug 15, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 159 (of 331)

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
SANDOZ	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
	50MG	A085088	001	
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
TG UNITED LABS	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A085532	002	May 24, 1982
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS	25MG; 25MG	A084735	001	
	50MG; 50MG	A084810	001	
	100MG; 50MG	A084811	001	

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG; 25MG	A087608	001	Feb 08, 1982
	50MG; 50MG	A087213	001	Feb 08, 1982
	100MG; 50MG	A087609	001	Feb 08, 1982
SUPERPHARM	25MG; 25MG	A089200	001	Feb 09, 1987
	50MG; 50MG	A089201	001	Feb 09, 1987
WATSON LABS	25MG; 25MG	A085457	001	Mar 04, 1982
	50MG; 50MG	A085446	001	Mar 04, 1982
	100MG; 50MG	A085440	001	Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS	100MG; 50MG	A088358	001	Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS	25MG; 25MG	A088356	001	Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS	50MG; 50MG	A088357	001	Apr 10, 1984

HYDRA-ZIDE

PAR PHARM	100MG; 50MG	A088961	001	Oct 21, 1985

TABLET; ORAL

APRESOLINE-ESIDRIX

NOVARTIS	25MG; 15MG	N012026	002	

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG; 15MG	A085827	001	

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG; 15MG	A085373	001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

TG UNITED LABS	25MG; 15MG; 0.1MG	A084897	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 160 (of 331)

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS 25MG;15MG;0.1MG A084291 001

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN 25MG;15MG;0.1MG A087085 001

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS 25MG;15MG;0.1MG A085771 001

HYDRAP-ES

SANDOZ 25MG;15MG;0.1MG A084876 001

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS 25MG;15MG;0.1MG A083770 001

HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS 25MG;15MG;0.1MG A083877 001

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MUTUAL PHARM 25MG;15MG;0.1MG A088570 001 Apr 10, 1984

SOLVAY 25MG;15MG;0.1MG A088376 001 Oct 28, 1983

WATSON LABS 25MG;15MG;0.1MG A085549 001

25MG;15MG;0.1MG A087556 001

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE 25MG;15MG;0.1MG A087709 001 May 13, 1982

SER-A-GEN

SOLVAY 25MG;15MG;0.1MG A087210 001

SER-AP-ES

NOVARTIS 25MG;15MG;0.1MG N012193 005

UNIPRES

SOLVAY 25MG;15MG;0.1MG A085893 001

25MG;15MG;0.1MG A086298 001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP

SANDOZ 25MG;0.1MG A084617 001

SERPASIL-APRESOLINE

NOVARTIS 25MG;0.1MG N009296 004

50MG;0.2MG N009296 002

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

MORTON GROVE 50MG/5ML A089661 001 Jun 20, 1988

ROXANE 50MG/5ML A088587 001 Jul 02, 1984

HYDROCHLOROTHIAZIDE INTENSOL

ROXANE 100MG/ML A088588 001 Jul 02, 1984

TABLET; ORAL

ESIDRIX

NOVARTIS 25MG N011793 005

50MG N011793 008

100MG N011793 009

HYDROCHLOROTHIAZIDE

ABC HOLDING 50MG A085672 001

ALRA 25MG A086369 001

50MG A083554 001

ASCOT 25MG A087539 001 Feb 03, 1982

50MG A087540 001 Feb 03, 1982

BARR 50MG A084771 001

DAVA PHARMS INC 100MG A087060 001

ELKINS SINN 50MG A085152 002

HEATHER 50MG A084135 001

IMPAX LABS 25MG A084029 001

50MG A083607 002

100MG A085098 001

INWOOD LABS 25MG A084776 001

25MG A085067 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 161 (of 331)

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

INWOOD LABS	50MG	A084776	002	
IVAX SUB TEVA PHARMS	50MG	A084658	001	
	100MG	A085022	001	
MAST MM	25MG	A086192	001	
	50MG	A086192	002	
MUTUAL PHARM	25MG	A083972	001	
	50MG	A083972	002	
	100MG	A083972	003	
MYLAN	25MG	A084880	001	
	50MG	A085112	001	
PVT FORM	50MG	A086597	001	
ROXANE	25MG	A085004	001	
	50MG	A084536	002	
	50MG	A085005	001	
SANDOZ	25MG	A083899	001	
	25MG	A087565	001	Mar 09, 1982
	50MG	A084912	001	
	50MG	A085219	001	
SOLVAY	25MG	A085323	001	
SUPERPHARM	25MG	A088827	001	Dec 28, 1984
	50MG	A088828	001	Dec 28, 1984
	100MG	A088829	001	Dec 28, 1984
TEVA	25MG	A088924	001	Feb 07, 1985
	50MG	A088923	001	Feb 07, 1985
TG UNITED LABS	25MG	A085683	001	
	50MG	A083965	001	
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083232	001	
	50MG	A083456	001	
	50MG	A085233	001	
	50MG	A086087	001	
	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WEST WARD	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
HYDRO-D				
HALSEY	25MG	A086504	001	
	50MG	A083891	002	
HYDRODIURIL				
MERCK	25MG	N011835	003	
	50MG	N011835	006	
	100MG	N011835	007	
ORETIC				
ABBOTT	25MG	N011971	001	
ZIDE				
SOLVAY	50MG	A083925	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 162 (of 331)

HYDROCHLOROTHIAZIDE; IRBESARTANTABLET; ORAL
AVALIDE

SANOFI AVENTIS US	12.5MG;75MG	N020758	001	Sep 30, 1997

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDETABLET; ORAL
NORMOZIDE

SCHERING	25MG;100MG	N019046	001	Apr 06, 1987
	25MG;200MG	N019046	002	Apr 06, 1987
	25MG;300MG	N019046	003	Apr 06, 1987
	25MG;400MG	N019046	004	Apr 06, 1987

TRANDATE HCT

GLAXOSMITHKLINE	25MG;100MG	N019174	001	Apr 10, 1987
	25MG;200MG	N019174	002	Apr 10, 1987
	25MG;300MG	N019174	003	Apr 10, 1987
	25MG;400MG	N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ	12.5MG;10MG	A075926	001	Jul 01, 2002
	12.5MG;20MG	A075926	002	Jul 01, 2002
	25MG;20MG	A075926	003	Jul 01, 2002
TEVA	12.5MG;10MG	A075869	001	Jul 01, 2002
	12.5MG;20MG	A075869	002	Jul 01, 2002
	25MG;20MG	A075869	003	Jul 01, 2002

PRINZIDE

MERCK	25MG;20MG	N019778	002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

MERCK	15MG;250MG	N013402	001	

ALDORIL 25

MERCK	25MG;250MG	N013402	002	

ALDORIL D30

MERCK	30MG;500MG	N013402	003	

ALDORIL D50

MERCK	50MG;500MG	N013402	004	

METHYLDOPA AND HYDROCHLOROTHIAZIDE

CLONMEL HLTHCARE	15MG;250MG	A072507	001	Jun 02, 1989
	25MG;250MG	A072508	001	Jun 02, 1989
	30MG;500MG	A072509	001	Jun 02, 1989
	50MG;500MG	A072510	001	Jun 02, 1989
IVAX SUB TEVA PHARMS	15MG;250MG	A071458	001	Mar 08, 1988
	25MG;250MG	A071459	001	Mar 08, 1988
	30MG;500MG	A071460	001	Mar 08, 1988
	50MG;500MG	A071461	001	Mar 08, 1988
PAR PHARM	15MG;250MG	A070616	001	Feb 02, 1987
	25MG;250MG	A070612	001	Feb 02, 1987
	30MG;500MG	A070613	001	Feb 02, 1987
	50MG;500MG	A070614	001	Feb 02, 1987
PARKE DAVIS	15MG;250MG	A071897	001	Nov 23, 1987
	25MG;250MG	A071898	001	Nov 23, 1987
	30MG;500MG	A071899	001	Nov 23, 1987
	50MG;500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM	15MG;250MG	A070853	001	Oct 08, 1986
	25MG;250MG	A070688	001	Apr 24, 1986
	30MG;500MG	A070854	001	Oct 08, 1986
	50MG;500MG	A070689	001	Apr 24, 1986
SANDOZ	15MG;250MG	A070182	001	Jan 15, 1986
	15MG;250MG	A070829	001	Mar 09, 1987
	25MG;250MG	A070183	001	Jan 15, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 163 (of 331)

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

SANDOZ	25MG;250MG	A070830	001	Mar 09, 1987
	30MG;500MG	A070543	001	Jan 15, 1986
	50MG;500MG	A070544	001	Jan 15, 1986
TEVA	15MG;250MG	A071819	001	Apr 08, 1988
	25MG;250MG	A071820	001	Apr 08, 1988
	30MG;500MG	A071821	001	Apr 08, 1988
	50MG;500MG	A071822	001	Apr 08, 1988
	15MG;250MG	A070365	001	Mar 19, 1986
WATSON LABS	15MG;250MG	A070958	001	Feb 06, 1989
	15MG;250MG	A071920	001	Aug 29, 1988
	25MG;250MG	A070366	001	Apr 16, 1986
	25MG;250MG	A070959	001	Jan 19, 1989
	25MG;250MG	A071921	001	Aug 29, 1988
	30MG;500MG	A070367	001	Mar 19, 1986
	30MG;500MG	A071069	001	Jan 19, 1989
	30MG;500MG	A071922	001	Aug 29, 1988
	50MG;500MG	A070368	001	Apr 16, 1986
	50MG;500MG	A070960	001	Feb 06, 1989
	50MG;500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
	12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
	12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

NOVARTIS	50MG;100MG	N018303	003	Dec 31, 1984

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VSKAZIDE

NOVARTIS	25MG;5MG	N018872	001	Jul 22, 1987
	25MG;10MG	N018872	002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

WYETH AYERST	50MG;120MG	N019059	002	Jul 03, 1985

INDERIDE LA 160/50

WYETH AYERST	50MG;160MG	N019059	003	Jul 03, 1985

INDERIDE LA 80/50

WYETH AYERST	50MG;80MG	N019059	001	Jul 03, 1985

TABLET; ORAL

INDERIDE-80/25

AKRIMAX PHARMS	25MG;80MG	N018031	002	

PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE

DURAMED PHARMS BARR	25MG;40MG	A071126	001	Mar 02, 1987

25MG;80MG	A071127	001	Mar 02, 1987

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH	25MG;40MG	A070851	001	May 15, 1986

25MG;80MG	A070852	001	May 15, 1986

BARR	25MG;40MG	A070704	001	Oct 01, 1986

25MG;80MG	A070705	001	Oct 01, 1986

IVAX SUB TEVA PHARMS	25MG;40MG	A071552	001	Dec 01, 1988

25MG;80MG	A071553	001	Dec 01, 1988

SANDOZ	25MG;40MG	A071060	001	Aug 26, 1987

25MG;80MG	A071061	001	Aug 26, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 164 (of 331)

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

WARNER CHILCOTT	25MG;40MG	A071771	001	Jan 26, 1988
	25MG;80MG	A071772	001	Jan 26, 1988
WATSON LABS	25MG;40MG	A071498	001	Dec 18, 1991
	25MG;80MG	A071501	001	Dec 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R. -50

WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338	001	
HYDROCHLOROTHIAZIDE W/ RESERPINE				
IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572	001	
	25MG;0.125MG	A083571	001	
	50MG;0.1MG	A083568	001	
	50MG;0.125MG	A083573	001	
PHARMERAL	25MG;0.125MG	A085421	001	
	50MG;0.125MG	A085420	001	
ROXANE	50MG;0.125MG	A084603	001	
WATSON LABS	25MG;0.125MG	A084466	001	
	25MG;0.125MG	A085317	001	
	25MG;0.125MG	A086330	002	
	50MG;0.125MG	A083666	001	
	50MG;0.125MG	A084467	001	
	50MG;0.125MG	A086331	001	
HYDROPRES 25				
MERCK	25MG;0.125MG	N011958	002	
HYDROPRES 50				
MERCK	50MG;0.125MG	N011958	003	
HYDRO-RESERP				
ABC HOLDING	50MG;0.125MG	A084714	002	Jun 29, 1982
HYDRO-SERP "25"				
SANDOZ	25MG;0.125MG	A084827	001	
HYDRO-SERP "50"				
SANDOZ	50MG;0.125MG	A085213	001	
RESERPINE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;0.125MG	A084580	001	
	50MG;0.125MG	A084579	001	
SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984
SERPASIL-ESIDRIX #1				
NOVARTIS	25MG;0.1MG	N011878	003	
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG;0.1MG	N011878	005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG;25MG	A088025	001	Nov 23, 1984
MUTUAL PHARM	25MG;25MG	A087267	001	
PUREPAC PHARM	25MG;25MG	A087999	001	Nov 06, 1985
SANDOZ	25MG;25MG	A086881	001	
SUPERPHARM	25MG;25MG	A089137	001	Aug 26, 1985
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE				
IVAX PHARMS	25MG;25MG	A087004	002	May 24, 1982
LEDERLE	25MG;25MG	A087511	001	
PARKE DAVIS	25MG;25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG;25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG;25MG	A087553	001	
USL PHARMA	25MG;25MG	A087651	001	
VANGARD	25MG;25MG	A087655	001	
WATSON LABS	25MG;25MG	A085974	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 165 (of 331)

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL				
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE				
WATSON LABS	25MG;25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL				
TIMOLIDE 10-25				
MERCK	25MG;10MG	N018061	001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL				
DYAZIDE				
GLAXOSMITHKLINE LLC	25MG;50MG	N016042	002	
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;37.5MG	A074970	001	Jan 06, 1998
NOVARTIS	25MG;37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG;50MG	A071737	001	Feb 12, 1988
TABLET; ORAL				
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
AM THERAP	50MG;75MG	A072022	001	Apr 17, 1988
QUANTUM PHARMICS	50MG;75MG	A071980	001	Apr 17, 1988

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL				
CODAMINE				
ALPHARMA US PHARMS	5MG/5ML;25MG/5ML	A075103	001	Sep 29, 2000
HYCOMINE				
ENDO PHARMS	5MG/5ML;25MG/5ML	N019410	001	Aug 17, 1990
HYCOMINE PEDIATRIC				
ENDO PHARMS	2.5MG/5ML;12.5MG/5ML	N019411	001	Aug 17, 1990

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL				
MAGNACORT				
PFIZER	0.5%	N010554	001	

HYDROCORTISONE

AEROSOL; TOPICAL				
AEROSEB-HC				
ALLERGAN HERBERT	0.5%	A085805	001	
CREAM; TOPICAL				
CORT-DOME				
BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	
DERMACORT				
MONARCH PHARMS	1%	A083011	002	
ELDECORT				
VALEANT PHARM INTL	1%	A080459	001	
	2.5%	A084055	001	
FLEXICORT				
WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
	1%	A087136	002	Apr 08, 1982
	2.5%	A087136	001	Apr 08, 1982
HC #1				
BAYER PHARMS	0.5%	A080438	001	
HC #4				
BAYER PHARMS	1%	A080438	002	
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080482	003	
	1%	A080482	004	
H-CORT				
PHARM ASSOC	0.5%	A086823	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 166 (of 331)

HYDROCORTISONE

CREAM; TOPICAL

HI-COR

C AND M PHARMA

2.5%

A080483 001

HYDROCORTISONE

ALPHARMA US PHARMS

2.5%

A089754 001

Feb 01, 1989

ALTANA

0.5%

A080848 002

1%

A080848 003

AMBIX

1%

A086080 001

2.5%

A086271 001

EVERYLIFE

0.5%

A080452 001

1%

A080452 002

G AND W LABS

1%

A084059 001

INGRAM PHARM

0.5%

A080456 002

1%

A080456 003

IVAX PHARMS

1%

A085733 001

NASKA

1%

A089706 001

Mar 10, 1988

PERRIGO NEW YORK

0.5%

A084970 002

1%

A085026 001

PHARMADERM

1%

A088845 001

Feb 27, 1986

2.5%

A089413 001

Dec 16, 1986

PHARMAFAIR

1%

A087838 001

Jul 28, 1982

STIEFEL

1%

A086170 001

SYOSSET

0.5%

A085527 001

TARO

0.5%

A086154 001

TEVA

0.5%

A080400 002

1%

A080400 003

1%

A085191 001

2.5%

A080400 004

TOPIDERM

1%

A089273 001

Feb 17, 1989

USL PHARMA

1%

A088027 001

Sep 27, 1983

2.5%

A088029 001

Sep 27, 1983

WHITEWORTH TOWN PLSN

1%

A080496 002

HYTONE

SANOFI AVENTIS US

1%

A080472 003

2.5%

A080472 004

NOGENIC HC

IVAX PHARMS

1%

A087427 001

Apr 04, 1988

NUTRACORT

CORIA

0.5%

A080442 002

1%

A080442 003

PENECORT

ALLERGAN HERBERT

1%

A088216 001

Jun 06, 1984

PROCTOCORT

MONARCH PHARMS

1%

A083011 001

SYNACORT

MEDICIS

0.5%

A087459 001

GEL; TOPICAL

NUTRACORT

HEALTHPOINT

1%

A084698 001

PENECORT

ALLERGAN HERBERT

1%

A088215 001

Jun 06, 1984

INJECTABLE; INJECTION

CORTEF

PHARMACIA AND UPJOHN

50MG/ML

N009864 001

LOTION; TOPICAL

ACTICORT

BAKER NORTON

1%

A086535 001

BALNEOL-HC

SOLVAY

1%

A088041 001

Dec 03, 1982

BETA-HC

BETA DERMAC

1%

A089495 001

Jan 25, 1988

CETACORT

CORIA

0.5%

A080426 002

1%

A080426 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 167 (of 331)

HYDROCORTISONELOTION; TOPICAL
CORT-DOME

BAYER PHARMS	0.5%	N009895	003	
	1%	N009895	001	

DERMACORT

SOLVAY	0.5%	A084573	002	
	1%	A086462	001	

EPICORT

BLULINE	0.5%	A083219	002	

GLYCORT

HERAN	1%	A087489	001	Oct 03, 1983

H-CORT

PHARM ASSOC	0.5%	A086824	001	

HYDROCORTISONE

ALPHARMA US PHARMS	0.5%	A087317	001	Jun 07, 1982
	1%	A087315	001	Jun 07, 1982

MERICON	0.5%	A085282	001	

	1%	A085282	002	Feb 26, 1987

NASKA	1%	A089705	001	Apr 25, 1988

PERRIGO NEW YORK	0.5%	A085662	001	

	1%	A085663	001	

TARO	1%	A089024	001	Feb 12, 1986

HYTONE

SANOFI AVENTIS US	1%	A080473	003	
	2.5%	A080473	004	Nov 30, 1982

NUTRACORT

CORIA	0.5%	A080443	002	

OINTMENT; TOPICAL

CORTRIL

PFIZER GLOBAL	1%	N009176	001	

	2.5%	N009176	002	

HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080481	001	

	1%	A080481	002	

HYDROCORTISONE

ALTANA	0.5%	A080489	002	

	1%	A080489	003	

AMBIX	1%	A086079	001	

	2.5%	A086272	001	

NASKA	1%	A089704	001	Mar 10, 1988

PERRIGO NEW YORK	0.5%	A084969	003	

	1%	A085028	001	

PHARMADERM	1%	A088842	001	Feb 09, 1987

TARO	0.5%	A086256	001	

USL PHARMA	1%	A088061	001	Sep 27, 1983

	2.5%	A088039	001	Sep 27, 1983

HYTONE

DERMIK LABS	1%	A080474	003	

	2.5%	A080474	004	

PENECORT

ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984

POWDER; FOR RX COMPOUNDING

H-CORT

TORCH	100%	A087834	001	Mar 29, 1982

HYDROCORTISONE

PADDOCK	100%	A088082	001	Apr 08, 1983

SOLUTION; TOPICAL

PENECORT

ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984

TEXACORT

JSJ PHARMS	1%	A080425	001	

TABLET; ORAL

CORTRIL

PFIZER	10MG	N009127	005	

DISCONTINUED DRUG PRODUCT LIST

6 - 168 (of 331)

HYDROCORTISONE

TABLET; ORAL

CORTIL

PFIZER

20MG

N009127 003

HYDROCORTISONE

BARR

20MG

A083999 001

ELKINS SINN

20MG

A080624 001

FERRANTE

10MG

A080568 001

20MG

A080568 002

IMPAX LABS

20MG

A080781 001

INWOOD LABS

20MG

A080732 001

LANNETT

20MG

A085070 001

NEXGEN PHARMA INC

20MG

A083140 001

PANRAY

10MG

N009659 001

20MG

N009659 002

PARKE DAVIS

20MG

A084243 001

PUREPAC PHARM

10MG

A084247 003

Aug 31, 1982

20MG

A080395 001

20MG

A084247 002

ROXANE

10MG

A088539 001

Mar 21, 1984

SANDOZ

20MG

A080642 002

WATSON LABS

20MG

A080355 001

WHITEWORTH TOWN PLSN

10MG

A080344 001

20MG

A080344 002

HYDROCORTONE

MERCK

10MG

N008506 007

20MG

N008506 011

TABLET; VAGINAL

CORTIL

PFIPHARMECS

10MG

N009796 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMSOL-HC

ABLE

1%

A081274 001

Jun 19, 1992

HYDROCORTISONE ACETATE

CENCI

1%

A080419 001

Jan 25, 1982

PARKE DAVIS

1%

A089914 001

Jan 03, 1989

PUREPAC PHARM

0.5%

A086050 001

1%

A086052 001

INJECTABLE; INJECTION

CORTEF ACETATE

PHARMACIA AND UPJOHN

50MG/ML

N009378 002

CORTIL

PFIZER

25MG/ML

N009164 001

HYDROCORTISONE ACETATE

AKORN

25MG/ML

N009637 001

50MG/ML

N009637 002

BEL MAR

25MG/ML

A083739 001

50MG/ML

A083739 002

WATSON LABS

25MG/ML

A083128 001

25MG/ML

A083759 001

50MG/ML

A083759 002

50MG/ML

A085214 001

HYDROCORTONE

MERCK

25MG/ML

N008228 001

50MG/ML

N008228 004

LOTION; TOPICAL

DRICORT

INGRAM PHARM

0.5%

A086207 001

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

ALTANA

0.5%

A080828 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 169 (of 331)

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC, OTIC			
HYDROCORTONE			
MERCK	1.5%	N009018	003
OINTMENT; TOPICAL			
CORTEF ACETATE			
PHARMACIA AND UPJOHN	1%	N008917	002
	2.5%	N008917	001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL			
NEO-CORTEF			
PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049	001
	2.5%;EQ 3.5MG BASE/GM	A061049	002
OINTMENT; OPHTHALMIC			
NEO-CORTEF			
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610	001
	1.5%;EQ 3.5MG BASE/GM	A060610	002
OINTMENT; TOPICAL			
NEO-CORTEF			
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751	001
	1%;EQ 3.5MG BASE/GM	A060751	002
	2.5%;EQ 3.5MG BASE/GM	A060751	003
SUSPENSION/DROPS; OPHTHALMIC			
COR-OTICIN			
AKORN	1.5%;EQ 3.5MG BASE/ML	A060188	001
NEO-CORTEF			
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612	002
	1.5%;EQ 3.5MG BASE/ML	A060612	001

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC			
TERRA-CORTRIL			
PFIZER	1.5%;EQ 5MG BASE/ML	A061016	001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL			
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%			
BOCA PHARMA	1%;1%	A089440	001 May 17, 1988
LOTION; TOPICAL			
PRAMOSONE			
FERNDAL LABS	0.5%;1%	A083213	002

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL			
LOCOID			
YAMANOUCHI	0.1%	N018795	001 Jan 07, 1983
OINTMENT; TOPICAL			
LOCOID			
YAMANOUCHI	0.1%	N019106	001 Jul 03, 1984
SOLUTION; TOPICAL			
LOCOID			
YAMANOUCHI	0.1%	N019819	001 Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL			
CORTEF			
PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900	001

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION			
HYDROCORTONE			
MERCK	EQ 50MG BASE/ML	N012052	001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 170 (of 331)

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT

EQ 100MG BASE/VIAL	A085928	001	
EQ 100MG BASE/VIAL	A089577	001	Apr 11, 1989
EQ 250MG BASE/VIAL	A089578	001	Apr 11, 1989
EQ 500MG BASE/VIAL	A089579	001	Apr 11, 1989
EQ 1GM BASE/VIAL	A089580	001	Apr 11, 1989
EQ 100MG BASE/VIAL	A085929	001	

HOSPIRA

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 100MG BASE/VIAL	A088667	001	Jun 08, 1984
EQ 100MG BASE/VIAL	A088712	001	Jun 08, 1984
EQ 250MG BASE/VIAL	A088668	001	Jun 08, 1984
EQ 500MG BASE/VIAL	A088669	001	Jun 08, 1984
EQ 1GM BASE/VIAL	A088670	001	Jun 08, 1984

BAXTER HLTHCARE

EQ 100MG BASE/VIAL	A086619	001	
EQ 250MG BASE/VIAL	A087567	001	
EQ 500MG BASE/VIAL	A087568	001	
EQ 1GM BASE/VIAL	A087569	001	

INTL MEDICATION

EQ 100MG BASE/VIAL	A087532	001	Mar 19, 1982

WATSON LABS

EQ 100MG BASE/VIAL	A084737	002	
EQ 100MG BASE/VIAL	A084738	001	
EQ 250MG BASE/VIAL	A084737	001	
EQ 500MG BASE/VIAL	A084747	001	
EQ 1GM BASE/VIAL	A084748	001	

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

TEVA PHARMS

0.2%	A074489	001	Aug 12, 1998

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

BAYER PHARMS

0.5%;EQ 3.5MG BASE/GM	N050237	006	Jun 05, 1984
1%;EQ 3.5MG BASE/GM	N050237	005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394	001	Sep 29, 1982

OTOCORT

WATSON LABS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730	002	

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

MONARCH PHARMS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001	

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623	001	Sep 24, 1985

SUSPENSION/DROPS; OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617	001	Sep 18, 1985

OTICAIR

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399	001	Nov 18, 1982

OTOBIONE

SCHERING

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816	001	

OTOCORT

WATSON LABS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521	001	Jul 11, 1985

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOBIOITIC

SCHERING

5MG/ML;EQ 10,000 UNITS BASE/ML	A062302	001	

PYOCIDIN

FOREST LABS

5MG/ML;EQ 10,000 UNITS BASE/ML	A061606	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 171 (of 331)

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC				
ACHROMYCIN				
LEDERLE	1.5%;1%	N050272	001	

HYDROCORTISONE; UREA

CREAM; TOPICAL				
ALPHADERM				
BIOGLAN	1%;10%	A086008	001	
CALMURID HC				
PHARMACIA AND UPJOHN	1%;10%	A083947	001	

HYDROFLUMETHIAZIDE

TABLET; ORAL				
DIUCARDIN				
WYETH AYERST	50MG	A083383	001	
HYDROFLUMETHIAZIDE				
WATSON LABS	50MG	A088031	001	Apr 06, 1983
	50MG	A088528	001	Aug 15, 1984

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL				
HYDROFLUMETHIAZIDE AND RESERPINE				
USL PHARMA	50MG;0.125MG	A088195	001	Oct 26, 1983
WATSON LABS	25MG;0.125MG	A088127	001	Mar 22, 1983
	50MG;0.125MG	A088110	001	Mar 22, 1983
RESERPINE AND HYDROFLUMETHIAZIDE				
IVAX PHARMS	50MG;0.125MG	A088932	001	Jan 11, 1985
PAR PHARM	50MG;0.125MG	A088907	001	Sep 20, 1985
SALUTENSIN				
SHIRE	50MG;0.125MG	N012359	003	
SALUTENSIN-DEMI				
SHIRE	25MG;0.125MG	N012359	004	

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL				
PALLADONE				
PURDUE PHARMA LP	12MG	N021044	001	Sep 24, 2004
	16MG	N021044	002	Sep 24, 2004
	24MG	N021044	003	Sep 24, 2004
	32MG	N021044	004	Sep 24, 2004
INJECTABLE; INJECTION				
HYDROMORPHONE HYDROCHLORIDE				
WATSON LABS	10MG/ML	A074317	001	Aug 23, 1995

HYDROXOCOBALAMIN

INJECTABLE; INJECTION				
ALPHAREDISOL				
MERCK	1MG/ML	A080778	001	
HYDROXOCOBALAMIN				
ABRAXIS PHARM	1MG/ML	A084921	001	
WATSON LABS	1MG/ML	A085528	001	
HYDROXOMIN				
BEL MAR	1MG/ML	A084629	001	

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC				
PAREDRIANE				
AKORN	1%	N000004	004	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 172 (of 331)

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

BRISTOL MYERS SQUIBB	125MG/ML	N010347	004
	125MG/ML	N016911	001
	250MG/ML	N010347	002
	250MG/ML	N016911	002

HYDROXYPROGESTERONE CAPROATE

AKORN	125MG/ML	N018004	001
WATSON LABS	125MG/ML	N017439	001
	250MG/ML	N017439	002

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US	225MG/AMP	N009166	001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR	250MG	A075143	002	Sep 21, 2000
DURAMED PHARMS BARR	250MG	A075020	002	Jun 26, 2000
	500MG	A075020	001	Jul 30, 1998
ROXANE	500MG	A074476	001	Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR	1GM	A075734	001	Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE	50MG/ML	A085551	002

HYDROXYZINE HYDROCHLORIDE

ALTANA	25MG/ML	A087273	001	Apr 20, 1982
	50MG/ML	A087273	002	Apr 20, 1982
APP PHARMS	25MG/ML	A088184	001	Mar 31, 1983
	50MG/ML	A088185	001	Mar 31, 1983
BAXTER HLTHCARE	25MG/ML	A085551	001	
HOSPIRA	25MG/ML	A087416	001	
	50MG/ML	A086821	001	
	50MG/ML	A087546	001	
PHARMAFAIR	25MG/ML	A088862	001	Feb 14, 1986
	25MG/ML	A089106	001	Feb 14, 1986
	50MG/ML	A088881	001	Feb 14, 1986
	50MG/ML	A089107	001	Feb 14, 1986
SMITH AND NEPHEW	25MG/ML	A087592	001	
SOLOPAK	25MG/ML	A086822	001	
	25MG/ML	A087591	001	
	50MG/ML	A087310	001	
	50MG/ML	A087593	001	
	50MG/ML	A087595	001	
	50MG/ML	A087596	001	
WATSON LABS	25MG/ML	A085778	001	
	25MG/ML	A087274	001	
	50MG/ML	A085779	001	
	50MG/ML	A087274	002	
WYETH AYERST	25MG/ML	A086258	001	
	50MG/ML	A086258	002	
ORGATRAK				
ORGANON USA INC	25MG/ML	A087014	001	
	50MG/ML	A087014	002	
VISTARIL				
PFIZER	25MG/ML	N011111	001	
	50MG/ML	N011111	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 173 (of 331)

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

ATARAX

ROERIG 10MG/5ML

N010485 001

HYDROXYZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 10MG/5ML

A086880 001

ALPHARMA US PHARMS 10MG/5ML

A088785 001 Feb 03, 1988

KV PHARM 10MG/5ML

A087730 001 Jul 01, 1982

TABLET; ORAL

ATARAX

PFIZER

10MG

N010392 001

25MG

N010392 004

50MG

N010392 006

100MG

N010392 005

HYDROXYZINE HYDROCHLORIDE

ABLE

10MG

A040559 001 Jul 22, 2004

25MG

A040562 001 Jul 22, 2004

50MG

A040563 001 Jul 22, 2004

ACTAVIS TOTOWA

10MG

A089071 001 Jul 22, 1986

25MG

A089072 001 Jul 22, 1986

50MG

A089073 001 Jul 22, 1986

HALSEY

10MG

A089366 001 May 02, 1988

25MG

A089117 001 May 02, 1988

50MG

A089396 001 May 02, 1988

IVAX PHARMS

10MG

A087216 001

25MG

A087410 001

50MG

A087411 001

KV PHARM

10MG

A087819 001 Jun 23, 1982

25MG

A087820 001 Jun 23, 1982

50MG

A087821 001 Jun 23, 1982

100MG

A087822 001 Jun 23, 1982

MUTUAL PHARM

10MG

A088409 001 Nov 15, 1983

25MG

A087857 001 Apr 18, 1983

50MG

A087860 001 Apr 18, 1983

100MG

A087862 001 Apr 18, 1983

PLIVA

100MG

A081054 001 Sep 25, 1995

PUREPAC PHARM

10MG

A088120 001 Sep 25, 1984

25MG

A088121 001 Sep 25, 1984

50MG

A088122 001 Sep 25, 1984

QUANTUM PHARMICS

10MG

A088540 001 Oct 22, 1985

25MG

A088551 001 Oct 22, 1985

50MG

A088529 001 Oct 22, 1985

SANDOZ

10MG

A087246 002

10MG

A087869 001 Dec 20, 1982

25MG

A085247 001

25MG

A087870 001 Dec 20, 1982

50MG

A087245 001

50MG

A087871 001 Dec 20, 1982

SUPERPHARM

10MG

A088794 001 Dec 05, 1984

25MG

A088795 001 Dec 05, 1984

50MG

A088796 001 Dec 05, 1984

USL PHARMA

10MG

A089121 001 Mar 20, 1986

25MG

A089122 001 Mar 20, 1986

50MG

A089123 001 Mar 20, 1986

VINTAGE

10MG

A087602 001 Jan 22, 1982

25MG

A087603 001 Jan 22, 1982

50MG

A087604 001 Jan 22, 1982

WATSON LABS

10MG

A086827 001

25MG

A086829 001

50MG

A086836 001

DISCONTINUED DRUG PRODUCT LIST

6 - 174 (of 331)

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

DURAMED PHARMS BARR	EQ 25MG HCL	A088593	001	Feb 29, 1984
	EQ 50MG HCL	A088594	001	Feb 29, 1984
	EQ 100MG HCL	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HCL	A087761	001	Mar 05, 1982
	EQ 50MG HCL	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HCL	A087656	001	Jun 11, 1982
	EQ 25MG HCL	A089145	001	Mar 17, 1986
	EQ 50MG HCL	A087657	001	Jun 11, 1982
	EQ 50MG HCL	A089146	001	Mar 17, 1986
	EQ 100MG HCL	A087658	001	Jun 11, 1982
SANDOZ	EQ 25MG HCL	A081127	001	Jun 28, 1991
	EQ 50MG HCL	A081128	001	Jun 28, 1991
	EQ 100MG HCL	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HCL	A089031	001	Jan 02, 1987
	EQ 50MG HCL	A089032	001	Jan 02, 1987
	EQ 100MG HCL	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HCL	A088392	001	Sep 19, 1983
	EQ 50MG HCL	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HCL	A086698	001	
	EQ 25MG HCL	A086840	001	Jul 01, 1982
	EQ 50MG HCL	A086695	001	
	EQ 50MG HCL	A086705	001	Jul 01, 1982
	EQ 50MG HCL	A087767	001	Aug 16, 1982
	EQ 100MG HCL	A086697	001	
	EQ 100MG HCL	A086728	001	Oct 05, 1982
	EQ 100MG HCL	A087790	001	Aug 16, 1982
HY-PAM "25"				
TEVA	EQ 25MG HCL	A088713	001	Mar 04, 1985
VISTARIL				
PFIZER	EQ 100MG HCL	N011459	006	

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

ROCHE	EQ 2.5MG BASE	N021455	001	May 16, 2003

IBUPROFEN

CAPSULE; ORAL

MIDOL

BAYER	200MG	A070626	001	Sep 02, 1987
	200MG	A071002	001	Sep 02, 1987

SUSPENSION; ORAL

CHILDREN'S ADVIL

WYETH CONS	100MG/5ML	N019833	002	Sep 19, 1989

IBU

ABBOTT	100MG/5ML	N019784	001	Dec 18, 1989

MOTRIN

MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989

SUSPENSION/DROPS; ORAL

MOTRIN

MCNEIL	40MG/ML	N020476	001	May 25, 1995

TABLET; ORAL

ACHES-N-PAIN

LEDERLE	200MG	A071065	001	May 28, 1987

CAP-PROFEN

PERRIGO	200MG	A072097	001	Dec 08, 1987

IBU

BASF	400MG	A070083	001	Feb 22, 1985

	400MG	N018197	001	

	600MG	A070088	001	Feb 08, 1985

	600MG	A070099	001	Mar 29, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 175 (of 331)

IBUPROFEN

TABLET; ORAL

IBU

BASF	800MG	A070745	001	Jul 23, 1986
IBUPRIN				
PLIVA	200MG	A071773	001	Jul 16, 1987
IBUPROFEN				
ABBOTT	600MG	A070556	001	Jun 14, 1985
	800MG	A071264	001	Jul 25, 1986
HALSEY	200MG	A071027	001	Sep 29, 1987
	300MG	A071028	001	Mar 23, 1987
	400MG	A071029	001	Mar 23, 1987
	600MG	A071030	001	Mar 23, 1987
	800MG	A072137	001	Feb 05, 1988
IVAX SUB TEVA PHARMS	200MG	A071144	001	Jan 20, 1987
	200MG	A071154	001	Oct 27, 1987
	200MG	A072040	001	Apr 29, 1988
	200MG	A072901	001	Dec 19, 1991
	200MG	A072903	001	Dec 19, 1991
	400MG	A071145	001	Sep 23, 1986
	600MG	A071146	001	Sep 23, 1986
	800MG	A071769	001	May 08, 1987
LEDERLE	400MG	A070629	001	Sep 19, 1986
	600MG	A070630	001	Sep 19, 1986
LEINER	300MG	A071266	001	Oct 15, 1986
MCNEIL	400MG	A070081	001	Jun 16, 1986
	600MG	A070476	001	Jun 16, 1986
MUTUAL PHARM	200MG	A070493	001	Dec 24, 1985
	200MG	A070908	001	Sep 26, 1986
	200MG	A071462	001	Oct 02, 1986
	400MG	A070079	001	Jul 24, 1985
	600MG	A070080	001	Jul 24, 1985
	800MG	A071448	001	Feb 18, 1987
MYLAN	200MG	A071870	001	May 05, 1988
	400MG	A070045	001	Sep 24, 1985
	600MG	A070057	001	Sep 24, 1985
	800MG	A071999	001	Dec 03, 1987
PAR PHARM	200MG	A071575	001	May 08, 1987
	300MG	A070328	001	Aug 06, 1985
	400MG	A070329	001	Aug 06, 1985
	600MG	A070330	001	Aug 06, 1985
	800MG	A070986	001	Jul 25, 1986
PERRIGO	200MG	A072098	001	Dec 08, 1987
PLIVA	400MG	A071666	001	Jun 18, 1987
	600MG	A071667	001	Jun 18, 1987
	800MG	A071668	001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122	001	Oct 03, 1986
	200MG	A071664	001	Feb 03, 1987
	300MG	A071123	001	Sep 19, 1986
	400MG	A071124	001	Sep 19, 1986
	600MG	A071125	001	Sep 19, 1986
	800MG	A071964	001	Feb 01, 1988
SANDOZ	200MG	A070733	001	Sep 19, 1986
	200MG	A071807	001	Feb 25, 1988
	200MG	A074525	001	Dec 15, 1995
	200MG	A074533	001	Dec 15, 1995
	300MG	A070734	001	Jun 12, 1986
	400MG	A070735	001	Jun 12, 1986
	400MG	A072064	001	Jan 14, 1988
	600MG	A070736	001	Jun 12, 1986
	600MG	A072065	001	Jan 14, 1988
	800MG	A071938	001	Jan 14, 1988
	800MG	A072169	001	Dec 11, 1987
SUPERPHARM	600MG	A070709	001	Apr 25, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 176 (of 331)

IBUPROFENTABLET; ORAL
IBUPROFEN

TEVA	200MG	A073141	001	May 29, 1992
	400MG	A073343	001	Jun 30, 1992
	600MG	A073344	001	Jun 30, 1992
	800MG	A073345	001	Jun 30, 1992
VINTAGE PHARMS	200MG	A072249	001	Jan 10, 1989
WATSON LABS	200MG	A071765	001	Sep 04, 1987
	200MG	A071905	001	Mar 08, 1988
	300MG	A071338	001	Dec 01, 1986
	400MG	A070038	001	Sep 06, 1985
	600MG	A070041	001	Sep 06, 1985
	800MG	A071547	001	Jul 02, 1987
	800MG	A071911	001	Oct 13, 1987
IBU-TAB				
ALRA	800MG	A071965	001	Aug 11, 1988
MEDIPREN				
MCNEIL	200MG	A070475	001	Feb 06, 1986
	200MG	A071215	001	Jun 26, 1986
MIDOL				
BAYER	200MG	A070591	001	Sep 02, 1987
	200MG	A071001	001	Sep 02, 1987
MOTRIN				
MCNEIL CONSUMER	300MG	N017463	003	
	400MG	N017463	002	
	600MG	N017463	004	
	800MG	N017463	005	May 22, 1985
MCNEIL PED	100MG	N020418	001	Nov 16, 1994
NUPRIN				
BRISTOL MYERS	200MG	A072035	001	Feb 16, 1988
	200MG	A072036	001	Feb 16, 1988
MCNEIL	200MG	N019012	001	May 18, 1984
	200MG	N019012	002	Jul 29, 1987
RUFEN				
BASF	600MG	N018197	002	Mar 05, 1984
TABLET, CHEWABLE; ORAL				
MOTRIN				
MCNEIL PED	50MG	N020135	001	Nov 16, 1994
	100MG	N020135	002	Nov 16, 1994

IDARUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
IDAMYCIN

PHARMACIA AND UPJOHN	5MG/VIAL	N050661	002	Sep 27, 1990
	10MG/VIAL	N050661	001	Sep 27, 1990
	20MG/VIAL	N050661	003	Apr 25, 1995

IDOXURIDINEOINTMENT; OPHTHALMIC
STOXIL

GLAXOSMITHKLINE	0.5%	N015868	001	

SOLUTION/DROPS; OPHTHALMIC
STOXIL

GLAXOSMITHKLINE	0.1%	N013934	001	

IFOSFAMIDE; MESNAINJECTABLE; INJECTION
IFEX/MESNEX KIT

BAXTER HLTHCARE	1GM/VIAL; 100MG/ML	N019763	003	Oct 10, 1992
	3GM/VIAL; 100MG/ML	N019763	004	Oct 10, 1992

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 177 (of 331)

IMATINIB MESYLATECAPSULE; ORAL
GLEEVEC

NOVARTIS

EQ 50MG BASE
EQ 100MG BASEN021335 001 May 10, 2001
N021335 002 May 10, 2001IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS

25MG/ML

A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS

12.5MG/ML

N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE

10MG

A086269 001

25MG

A086267 001

50MG

A086268 001

PAR PHARM

25MG

A089497 001

Jul 14, 1987

50MG

A088276 001

Oct 21, 1983

ROXANE

10MG

A083799 001

25MG

A083799 002

50MG

A083799 003

SANDOZ

10MG

A085200 001

25MG

A084869 002

50MG

A085133 001

TEVA

10MG

A083729 001

25MG

A083729 004

50MG

A083729 003

USL PHARMA

25MG

A087776 001

Feb 10, 1982

VANGARD

10MG

A088036 001

Nov 03, 1982

25MG

A087619 001

Feb 09, 1982

50MG

A087631 001

Jan 04, 1982

WATSON LABS

10MG

A085220 001

10MG

A085875 001

25MG

A084252 002

25MG

A085878 001

50MG

A085221 001

50MG

A085877 001

WEST WARD

25MG

A088222 001

May 26, 1983

50MG

A088223 001

May 26, 1983

JANIMINE

ABBOTT

10MG

N017895 001

25MG

N017895 002

50MG

N017895 003

PRAMINE

ALRA

10MG

A083827 001

25MG

A083827 002

50MG

A083827 003

PRESAMINE

SANOFI AVENTIS US

10MG

N011836 006

25MG

N011836 003

50MG

N011836 007

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP

EQ 5MG BASE/ML

A075542 001

May 10, 2000

HOSPIRA

EQ 5MG BASE/ML

A074616 001

Aug 03, 1998

INOCOR

SANOFI AVENTIS US

EQ 5MG BASE/ML

N018700 001

Jul 31, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 178 (of 331)

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

CADISTA PHARMS	1.25MG	A075201	001	Dec 04, 1998
	2.5MG	A075201	002	Dec 04, 1998
TEVA	1.25MG	A074498	002	Feb 12, 1998
	1.25MG	A074665	001	Apr 04, 1997
	2.5MG	A074498	001	Oct 31, 1996
	2.5MG	A074665	002	Apr 04, 1997
LOZOL				
SANOFI AVENTIS US	1.25MG	N018538	002	Apr 29, 1993
	2.5MG	N018538	001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DECABID

LILLY	EQ 50MG BASE	N019693	001	Dec 29, 1989
	EQ 75MG BASE	N019693	002	Dec 29, 1989
	EQ 100MG BASE	N019693	003	Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL
CRIXIVAN

MERCK SHARP DOHME	EQ 333MG BASE	N020685	005	Dec 17, 1998

INDOCYANINE GREEN

INJECTABLE; INJECTION
IC-GREEN

AKORN	10MG/VIAL	N011525	003	
	40MG/VIAL	N011525	004	
	50MG/VIAL	N011525	002	

INDOMETHACIN

CAPSULE; ORAL
INDOCIN

IROKO PHARMS	25MG	N016059	001	
	50MG	N016059	002	
INDO-LEMMON				
TEVA	25MG	A070266	001	Nov 07, 1985
	50MG	A070267	001	Nov 07, 1985
INDOMETHACIN				
ABLE	25MG	A076666	001	Dec 17, 2003
	50MG	A076666	002	Dec 17, 2003
DURAMED PHARMS BARR	25MG	A070326	001	Oct 18, 1985
	50MG	A070327	001	Oct 18, 1985
HALSEY	25MG	A070782	001	Jun 03, 1987
	50MG	A070635	001	Jun 03, 1987
IVAX SUB TEVA PHARMS	25MG	N018730	001	May 04, 1984
	50MG	N018730	002	May 04, 1984
MUTUAL PHARM	25MG	A070067	001	Oct 03, 1986
	25MG	A070899	001	Feb 09, 1987
	50MG	A070068	001	Oct 03, 1986
	50MG	A070900	001	Feb 09, 1987
MYLAN	50MG	N018858	002	Apr 20, 1984
PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
	50MG	N018806	002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
	50MG	A070592	001	Aug 11, 1986
PLIVA	25MG	A071148	001	Mar 18, 1987
	50MG	A071149	001	Mar 18, 1987
ROXANE	25MG	A070353	001	Jun 18, 1985
	50MG	A070354	001	Jun 18, 1985
SUPERPHARM	25MG	A070487	001	Oct 10, 1986
	50MG	A070488	001	Oct 10, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 179 (of 331)

INDOMETHACINCAPSULE; ORAL
INDOMETHACIN

TEVA	25MG	A071342	001	Apr 18, 1988
	50MG	A071343	001	Apr 18, 1988
VINTAGE	25MG	N018829	002	Aug 06, 1984
	50MG	A070651	001	Mar 05, 1986
	50MG	N018829	001	Aug 06, 1984
WATSON LABS	25MG	A070529	001	Oct 18, 1985
	25MG	A070784	001	Aug 20, 1986
	25MG	A072996	001	Jul 31, 1991
	25MG	N018690	001	Jul 31, 1984
	50MG	A070530	001	Oct 18, 1985
	50MG	A070785	001	Aug 20, 1986
	50MG	A071635	001	May 18, 1987
	50MG	A072997	001	Jul 31, 1991
	50MG	N018690	002	Jul 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL
INDOCIN SR

IROKO PHARMS	75MG	N018185	001	Feb 23, 1982

INDOMETHACIN

ABLE	75MG	A076114	001	Feb 06, 2002
INWOOD LABS	75MG	A072410	001	Mar 15, 1989

SUPPOSITORY; RECTAL

INDOCIN

IROKO PHARMS	50MG	N017814	001	Aug 13, 1984

SUSPENSION; ORAL

INDOMETHACIN

ROXANE	25MG/5ML	A071412	001	Mar 18, 1987

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANTINJECTABLE; SUBCUTANEOUS
NOVOLOG MIX 50/50

NOVO NORDISK INC	50 UNITS/ML;50 UNITS/ML	N021810	001	Aug 26, 2008

INSULIN PORK

INJECTABLE; INJECTION

Iletin I

LILLY	500 UNITS/ML	N017931	001	

INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017926	001	

REGULAR INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017926	003	

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION

REGULAR Iletin II

LILLY	100 UNITS/ML	N018478	001	

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

Iletin II

LILLY	500 UNITS/ML	N018344	002	

REGULAR Iletin II (PORK)

LILLY	100 UNITS/ML	N018344	001	

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC	100 UNITS/ML	N018381	001	

VELOSULIN

NOVO NORDISK INC	100 UNITS/ML	N018193	001	

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N018195	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 180 (of 331)

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION		
HUMULIN BR		
LILLY	100 UNITS/ML	N019529 001 Apr 28, 1986
VELOSULIN BR		
NOVO NORDISK INC	100 UNITS/ML	N021028 001 Jul 19, 1999
POWDER; INHALATION		
EXUBERA		
PFIZER	1MG/INH	N021868 001 Jan 27, 2006
	3MG/INH	N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION		
HUMULIN 50/50		
LILLY	50 UNITS/ML;50 UNITS/ML	N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION		
NOVOLIN R		
NOVO NORDISK INC	100 UNITS/ML	N018778 001 Aug 30, 1983
VELOSULIN BR HUMAN		
NOVO NORDISK INC	100 UNITS/ML	N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION		
MIXTARD HUMAN 70/30		
BAYER PHARMS	30 UNITS/ML;70 UNITS/ML	N019585 001 Mar 11, 1988
NOVOLIN 70/30		
NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019441 001 Jul 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION		
NPH INSULIN		
NOVO NORDISK INC	40 UNITS/ML	N017929 001
	100 UNITS/ML	N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION		
NPH ILETIN I (BEEF-PORK)		
LILLY	40 UNITS/ML	N017936 001
	100 UNITS/ML	N017936 002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION		
NPH ILETIN II		
LILLY	100 UNITS/ML	N018479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION		
INSULIN INSULATARD NPH NORDISK		
NOVO NORDISK INC	100 UNITS/ML	N018194 001
NPH ILETIN II (PORK)		
LILLY	100 UNITS/ML	N018345 001
NPH PURIFIED PORK ISOPHANE INSULIN		
NOVO NORDISK INC	100 UNITS/ML	N018623 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION		
INSULATARD NPH HUMAN		
NOVO NORDISK INC	100 UNITS/ML	N019449 001 May 30, 1986
NOVOLIN N		
NOVO NORDISK INC	100 UNITS/ML	N019065 001 Jan 23, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 181 (of 331)

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION			
PROTAMINE ZINC & ILETIN I (BEEF-PORK)			
LILLY	40 UNITS/ML	N017932	001
	100 UNITS/ML	N017932	002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION			
PROTAMINE ZINC AND ILETIN II			
LILLY	100 UNITS/ML	N018476	001
PROTAMINE ZINC INSULIN			
BRISTOL MYERS SQUIBB	40 UNITS/ML	N017928	001
	100 UNITS/ML	N017928	003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION			
PROTAMINE ZINC AND ILETIN II (PORK)			
LILLY	100 UNITS/ML	N018346	001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION			
LENTE INSULIN			
NOVO NORDISK INC	40 UNITS/ML	N017998	001
	100 UNITS/ML	N017998	003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION			
ULTRALENTE INSULIN			
NOVO NORDISK INC	100 UNITS/ML	N017997	003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION			
ULTRALENTE			
NOVO NORDISK INC	100 UNITS/ML	N018385	001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION				
HUMULIN U				
LILLY	40 UNITS/ML	N019571	001	Jun 10, 1987
	100 UNITS/ML	N019571	002	Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION			
SEMILENTE INSULIN			
NOVO NORDISK INC	100 UNITS/ML	N017996	003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION			
SEMILENTE			
NOVO NORDISK INC	100 UNITS/ML	N018382	001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION			
LENTE ILETIN II			
LILLY	100 UNITS/ML	N018477	001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION			
LENTARD			
NOVO NORDISK INC	100 UNITS/ML	N018384	001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 182 (of 331)

INSULIN ZINC SUSP PURIFIED PORKINJECTABLE; INJECTION
LENTE

NOVO NORDISK INC 100 UNITS/ML N018383 001

LENTE ILETIN II (PORK)

LILLY 100 UNITS/ML N018347 001

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN L

LILLY 100 UNITS/ML N019377 002 Sep 30, 1985

NOVOLIN L

NOVO NORDISK INC 100 UNITS/ML N019965 001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN L

NOVO NORDISK INC 100 UNITS/ML N018777 001 Aug 30, 1983

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX 100MG/ML N002282 001

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10GM/100ML N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE 2.3mCi/ML N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL

CHOLEBRINE

MALLINCKRODT 750MG N017129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65

BRACCO 65% N017902 001

RENOVUE-DIP

BRACCO 24% N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO 10.3% N009321 007

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM

BRACCO 20% N009321 001

IODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE 1mCi/ML N018289 001 Dec 28, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 183 (of 331)

IODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION		
HIPPURAN I 131		
MALLINCKRODT	0.25mCi/ML	N016666 001
HIPPUTOPE		
BRACCO	1-2mCi/VIAL	N015419 002
IODOHIPPURATE SODIUM I 131		
PHARMALUCENCE	0.2mCi/ML	N017313 001

IODOXAMATE MEGLUMINE

INJECTABLE; INJECTION		
CHOLOVUE		
BRACCO	9.9%	N018077 001
	40.3%	N018076 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION		
SPECTAMINE		
IMP	1mCi/ML	N019432 001 Dec 24, 1987

IOHEXOL

INJECTABLE; INJECTION		
OMNIPAQUE 210		
GE HEALTHCARE	45.3%	N018956 006 Jun 30, 1989
SOLUTION; URETHRAL		
OMNIPAQUE 70		
GE HEALTHCARE	15.1%	N018956 007 Jun 01, 1994

IOPAMIDOL

INJECTABLE; INJECTION		
IOPAMIDOL		
BAXTER HLTHCARE	41%	A074629 001 Nov 06, 1996
	51%	A074629 004 Mar 31, 1998
	61%	A074629 002 Nov 06, 1996
	76%	A074629 003 Nov 06, 1996
HOSPIRA	61%	A074734 001 Dec 10, 1996
	76%	A074734 002 Dec 10, 1996
IOPAMIDOL-200		
COOK IMAGING	41%	A074881 001 Jul 28, 2000
IOPAMIDOL-250		
COOK IMAGING	51%	A074881 002 Jul 28, 2000
IOPAMIDOL-300		
ABBOTT	61%	A074638 001 Apr 30, 1997
COOK IMAGING	61%	A074881 003 Jul 28, 2000
IOPAMIDOL-370		
COOK IMAGING	76%	A074881 004 Jul 28, 2000
ISOVUE-128		
BRACCO	26%	N018735 005 Oct 21, 1986
ISOVUE-200		
BRACCO	41%	N020327 001 Oct 12, 1994

IOPANOIC ACID

TABLET; ORAL		
TELEPAQUE		
GE HEALTHCARE	500MG	N008032 001

IOPHENDYLATE

INJECTABLE; INJECTION		
PANTOPAQUE		
ALCON	100%	N005319 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 184 (of 331)

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUMINJECTABLE; INJECTION
VASCORAY

MALLINCKRODT 52%;26% N016783 001

IOTHALAMATE SODIUMINJECTABLE; INJECTION
ANGIO-CONRAY

MALLINCKRODT 80% N013319 001

CONRAY 325

MALLINCKRODT 54.3% N017685 001

CONRAY 400

MALLINCKRODT 66.8% N014295 001

IOTHALAMATE SODIUM I-125INJECTABLE; INJECTION
GLOFIL-125

ISOTEX 250-300uCi/ML N017279 001

IOTROLANINJECTABLE; INTRATHECAL
OSMOVIST 190

BAYER HLTHCARE 40.6% N019580 001 Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE 51.3% N019580 002 Dec 07, 1989

IOVERSOLINJECTABLE; INJECTION
OPTIRAY 160

MALLINCKRODT 34% N019710 003 Dec 30, 1988

OPTIRAY 240

MALLINCKRODT 51% N020923 001 May 28, 1998

OPTIRAY 320

MALLINCKRODT 68% N020923 002 May 29, 1998

IPODATE CALCIUMGRANULE; ORAL
ORAGRAFIN CALCIUM

BRACCO 3GM/PACKET N012968 001

IPODATE SODIUMCAPSULE; ORAL
BILIVIST

BAYER HLTHCARE 500MG A087768 001 Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO 500MG N012967 001

IPRATROPIUM BROMIDEAEROSOL, METERED; INHALATION
ATROVENT

BOEHRINGER INGELHEIM 0.018MG/INH N019085 001 Dec 29, 1986

SOLUTION; INHALATION
ATROVENT

BOEHRINGER INGELHEIM 0.02% N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

PHARMASCIENCE INC 0.02% A075507 001 Jan 19, 2001

ROXANE 0.02% A075867 001 Jul 22, 2002

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

SANDOZ 40MG/2ML (20MG/ML) A077994 001 Feb 27, 2008

100MG/5ML (20MG/ML) A077994 002 Feb 27, 2008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 185 (of 331)

IRON DEXTRANINJECTABLE; INJECTION
IRON DEXTRAN

SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002	

IRON SUCROSEINJECTABLE; INTRAVENOUS
VENOFER

LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005
	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON	1%	A086711	001	

BRONKOSOL

SANOFI AVENTIS US	0.25%	N012339	009	
	1%	N012339	008	

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS	1%	A087101	001	
ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982
	0.062%	A089614	001	Jun 13, 1991
	0.125%	A087938	001	Nov 15, 1982
	0.125%	A089615	001	Jun 13, 1991
	0.167%	A088470	001	Mar 14, 1984
	0.167%	A089616	001	Jun 13, 1991
	0.2%	A088471	001	Mar 14, 1984
	0.2%	A089617	001	Jun 13, 1991
	0.25%	A088472	001	Mar 14, 1984
	0.25%	A089618	001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
	0.14%	A088145	001	Mar 26, 1984
	0.25%	A088146	001	Aug 01, 1983
DEY	0.08%	A088187	001	Dec 03, 1982
	0.1%	A087389	001	
	0.17%	A087390	001	
	0.25%	A088188	001	Dec 03, 1982
	1%	A086763	001	
INTL MEDICATION	0.077%	A086651	001	
	0.08%	A086651	002	
	0.1%	A086651	003	
	0.143%	A086651	004	
	0.167%	A086651	005	
	0.2%	A086651	006	
	0.25%	A086651	007	
	1%	A086651	008	
PARKE DAVIS	0.5%	A085997	001	
	1%	A085889	001	
ROXANE	0.1%	A087396	001	
	0.125%	A087025	001	
	0.167%	A088226	001	Sep 16, 1983
	0.2%	A087324	001	
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 186 (of 331)

ISOETHARINE MESYLATEAEROSOL, METERED; INHALATION
BRONKOMETER

SANOFI AVENTIS US 0.34MG/INH

N012339 007

ISOETHARINE MESYLATE

ALPHARMA US PHARMS 0.34MG/INH

A087858 001 Aug 21, 1984

ISOFLURANELIQUID; INHALATION
ISOFLURANE

MARSAM PHARMS LLC 99.9%

A074393 001 May 12, 1995

ISOFLUROPHATEOINTMENT; OPHTHALMIC
FLOROPRYL

MERCK 0.025%

N010656 001

ISONIAZIDINJECTABLE; INJECTION
NYDRAZID

SANDOZ 100MG/ML

N008662 001

RIMIFON

ROCHE 25MG/ML

N008420 002

100MG/ML

N008420 003

SYRUP; ORAL

ISONIAZID

MIKART 50MG/5ML

A081118 001 Jul 21, 1997

LANIAZID

LANNETT 50MG/5ML

A089243 001 Feb 03, 1986

RIMIFON

ROCHE 50MG/5ML

N008420 001

TABLET; ORAL

DOW-ISONIAZID

DOW PHARM 300MG

A080330 002

HYZYD

MEDPOINTE PHARM HLC 100MG

A080134 003

300MG

A080134 004

INH

NOVARTIS 300MG

A080935 001

ISONIAZID

DURAMED PHARMS BARR 100MG

A088231 001 Mar 17, 1983

300MG

A088119 001 Mar 17, 1983

HALSEY 50MG

A083632 001

IMPAX LABS 100MG

A080153 001

IVAX SUB TEVA PHARMS 100MG

A080270 001

300MG

A083610 001

LILLY 100MG

N008499 002

300MG

N008499 003

MK LABS 100MG

A080941 001

MUTUAL PHARM 100MG

A080136 001

300MG

A083633 001

NEXGEN PHARMA INC 100MG

A084050 001

PANRAY 50MG

N008428 001

100MG

N008428 002

300MG

N008428 003

PERRIGO 100MG

A083060 001

PHARMAVITE 100MG

A085091 001

PHOENIX LABS NY 50MG

A080368 001

100MG

A080368 002

PUREPAC PHARM 50MG

A080132 003 Jul 14, 1982

100MG

A080132 004 Jul 14, 1982

WATSON LABS 50MG

A080522 001

100MG

A080401 001

100MG

A080523 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 187 (of 331)

ISONIAZID

TABLET; ORAL

ISONIAZID

WATSON LABS

100MG

A085790 001

300MG

A083178 001

300MG

A085784 001

WHITEWORTH TOWN PLSN 100MG

A080120 002

LANIAZID

LANNETT

50MG

A080140 001

100MG

A080140 002

300MG

A089776 001

Jun 13, 1988

NYDRAZID

BRISTOL MYERS SQUIBB 100MG

N008392 003

STANOZIDE

EVERYLIFE

100MG

A080126 001

300MG

A080126 002

ISOPROPAMIDE IODIDE

TABLET; ORAL

DARBID

GLAXOSMITHKLINE

EQ 5MG BASE

N010744 001

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M

0.12MG/INH

N010375 004

ALPHARMA US PHARMS

0.12MG/INH

A085904 001

ISUPREL

SANOFI AVENTIS US

0.103MG/INH

N011178 001

DISC; INHALATION

NORISODRINE AEROTROL

ABBOTT

0.25%

N016814 001

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM

0.2MG/ML

A083431 001

BAXTER HLTHCARE

0.2MG/ML

A083486 001

HOSPIRA

0.02MG/ML

A083283 001

0.2MG/ML

A083346 001

SOLUTION; INHALATION

AEROLONE

LILLY

0.25%

N007245 001

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM

0.031%

A087935 001

Nov 18, 1982

0.062%

A087936 001

Nov 18, 1982

DEY

0.5%

A086764 001

Jan 04, 1982

PARKE DAVIS

0.25%

A085994 001

0.5%

A085540 001

ISUPREL

SANOFI AVENTIS US

0.5%

N006327 002

1%

N006327 003

VAPO-ISO

FISONS

0.5%

N016813 001

TABLET; RECTAL, SUBLINGUAL

ISUPREL

SANOFI AVENTIS US

10MG

N006328 001

15MG

N006328 002

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIHALER

3M

0.16MG/INH;0.24MG/INH

N013296 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 188 (of 331)

ISOPROTERENOL SULFATEAEROSOL, METERED; INHALATION
MEDIHALER-ISO

3M 0.08MG/INH

N010375 003

POWDER; INHALATION
NORISODRINEABBOTT 10%
25%N006905 003
N006905 002ISOSORBIDESOLUTION; ORAL
ISMOTIC

ALCON 100GM/220ML

N017063 001

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL
ISORDIL

WYETH AYERST 40MG

N012882 002 Jul 29, 1988

TABLET; ORAL

ISOSORBIDE DINITRATE

MUTUAL PHARM 5MG

A086166 002 Sep 19, 1986

10MG

A086169 001 Sep 19, 1986

20MG

A086167 001 Sep 19, 1986

30MG

A087564 001 Sep 18, 1986

SUPERPHARM

5MG

A089190 001 Feb 17, 1987

10MG

A089191 001 Feb 17, 1987

20MG

A089192 001 Feb 17, 1987

SORBITRATE

ASTRAZENECA

5MG

N016192 001 Apr 01, 1996

10MG

N016192 002 Apr 01, 1996

20MG

A086405 002 Aug 21, 1990

30MG

A088124 001 Aug 21, 1990

40MG

A088125 001 Aug 21, 1990

TABLET; SUBLINGUAL

ISORDIL

BIOVAIL 2.5MG

N012940 004 Jul 29, 1988

5MG

N012940 003 Jul 29, 1988

10MG

N012940 005 Jul 29, 1988

ISOSORBIDE DINITRATE

MUTUAL PHARM 2.5MG

A084204 001 Sep 18, 1986

5MG

A086168 001 Sep 18, 1986

10MG

A087545 001 Sep 18, 1986

SANDOZ

2.5MG

A086225 001 Feb 19, 1988

5MG

A086222 001 Feb 19, 1988

SORBITRATE

ASTRAZENECA

2.5MG

N016191 002 Apr 01, 1996

5MG

N016191 001 Apr 01, 1996

TABLET, CHEWABLE; ORAL

SORBITRATE

ASTRAZENECA 5MG

N016776 002 Apr 01, 1996

10MG

N016776 003 Apr 01, 1996

TABLET, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST 40MG

N012882 001 Jul 29, 1988

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

PROMIUS PHARMA 20MG

N019091 001 Dec 30, 1991

TABLET, EXTENDED RELEASE; ORAL

IMDUR

SCHERING PLOUGH 30MG

N020225 001 Aug 12, 1993

60MG

N020225 002 Aug 12, 1993

120MG

N020225 003 Mar 30, 1995

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 189 (of 331)

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

IVAX SUB TEVA PHARMS	30MG	A075448	002	Aug 07, 2001
	60MG	A075448	001	Jun 19, 2000
	120MG	A075448	003	Aug 07, 2001

ISOTRETINOINCAPSULE; ORAL
ACUTANE

HOFFMANN LA ROCHE	10MG	N018662	002	May 07, 1982
	20MG	N018662	004	Mar 28, 1983
	40MG	N018662	003	May 07, 1982

ISRADIPINECAPSULE; ORAL
DYNACIRC

SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990
	5MG	N019546	002	Dec 20, 1990

IVERMECTINTABLET; ORAL
STROMEKTOL
MERCK

6MG	N050742	001	Nov 22, 1996

KANAMYCIN SULFATECAPSULE; ORAL
KANTREX

APOTHECON	EQ 500MG BASE	A060516	001	
	EQ 500MG BASE	A061911	001	
	EQ 500MG BASE	A062726	001	Mar 06, 1987

INJECTABLE; INJECTION
KANAMYCIN

BAXTER HLTHCARE	EQ 75MG BASE/2ML	A062324	001	
	EQ 500MG BASE/2ML	A062324	002	
	EQ 1GM BASE/3ML	A062324	003	

KANAMYCIN SULFATE
ABRAXIS PHARM

EQ 75MG BASE/2ML	A062504	001	Apr 05, 1984
EQ 500MG BASE/2ML	A062504	002	Apr 05, 1984
EQ 1GM BASE/3ML	A062504	003	Apr 05, 1984

INTL MEDICATION	EQ 500MG BASE/2ML	A062466	001	Sep 30, 1983
	EQ 1GM BASE/3ML	A062466	002	Sep 30, 1983

LOCH	EQ 75MG BASE/2ML	A063021	001	Jul 31, 1992
	EQ 500MG BASE/2ML	A063022	001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025	001	Jul 31, 1992

PHARMAFAIR	EQ 75MG BASE/2ML	A062668	001	May 07, 1987
	EQ 500MG BASE/2ML	A062672	001	May 07, 1987
	EQ 1GM BASE/3ML	A062669	001	May 07, 1987

SOLOPAK	EQ 75MG BASE/2ML	A062605	003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605	001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605	002	Feb 26, 1986

WARNER CHILCOTT	EQ 1GM BASE/3ML	A063092	001	Oct 11, 1989
WATSON LABS	EQ 1GM BASE/3ML	A062520	003	May 09, 1985

KANTREX

APOTHECON	EQ 75MG BASE/2ML	A061655	003	
	EQ 75MG BASE/2ML	A061901	003	
	EQ 75MG BASE/2ML	A062564	001	Sep 21, 1984
	EQ 500MG BASE/2ML	A061655	001	
	EQ 500MG BASE/2ML	A061901	001	
	EQ 500MG BASE/2ML	A062564	002	Sep 21, 1984
	EQ 1GM BASE/3ML	A061655	002	
	EQ 1GM BASE/3ML	A061901	002	
	EQ 1GM BASE/3ML	A062564	003	Sep 21, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 190 (of 331)

KANAMYCIN SULFATEINJECTABLE; INJECTION
KLEBCIL

KING PHARMS

EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3MLA062170 001
A062170 002
A062170 003KETOCONAZOLECREAM; TOPICAL
NIZORAL

JANSSEN PHARMA

2%

N019084 001 Dec 31, 1985

SUSPENSION; ORAL
NIZORAL

JANSSEN PHARMA

100MG/5ML

A070767 001 Nov 07, 1986

TABLET; ORAL

KETOCONAZOLE

AAIPHARMA LLC

200MG

A075341 001 Jul 27, 1999

TEVA

200MG

A074971 001 Jun 15, 1999

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

SANDOZ

50MG

A074024 001 Dec 29, 1995

75MG

A074024 002 Dec 29, 1995

TEVA

25MG

A073515 001 Dec 22, 1992

ORUDIS

WYETH AYERST

25MG

N018754 001 Jul 31, 1987

50MG

N018754 002 Jan 09, 1986

75MG

N018754 003 Jan 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

WYETH PHARMS INC

100MG

N019816 003 Feb 08, 1995

150MG

N019816 002 Feb 08, 1995

200MG

N019816 001 Sep 24, 1993

TABLET; ORAL

ACTRON

BAYER

12.5MG

N020499 001 Oct 06, 1995

KETOPROFEN

PERRIGO

12.5MG

A075364 001 Feb 07, 2002

ORUDIS KT

WYETH CONS

12.5MG

N020429 001 Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AMPHASTAR PHARM

15MG/ML

A076209 001 Jul 21, 2004

30MG/ML

A076209 002 Jul 21, 2004

APOTEX INC

30MG/ML

A075626 001 Jul 24, 2001

30MG/ML

A077201 001 Oct 14, 2005

APOTHECON

15MG/ML

A075348 001 Nov 28, 2000

30MG/ML

A075348 002 Nov 28, 2000

BEDFORD

15MG/ML

A075230 002 Oct 25, 1999

30MG/ML

A075230 001 Oct 25, 1999

GLAND PHARMA LTD

15MG/ML

A076722 001 Jul 27, 2004

30MG/ML

A076722 002 Jul 27, 2004

HOSPIRA

15MG/ML

A074801 001 Jun 05, 1997

30MG/ML

A074801 002 Jun 05, 1997

TORADOL

ROCHE PALO

15MG/ML

N019698 001 Nov 30, 1989

30MG/ML

N019698 002 Nov 30, 1989

TABLET; ORAL

KETOROLAC TROMETHAMINE

ROXANE

10MG

A074790 001 Jun 26, 1997

WATSON LABS

10MG

A074955 001 Sep 19, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 191 (of 331)

KETOROLAC TROMETHAMINE

TABLET; ORAL

TORADOL

ROCHE PALO

10MG

N019645 001

Dec 20, 1991

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GENERATOR

GE HEALTHCARE

N/A

N018088 001

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

APOTHECON

5MG/ML

A075355 001

Nov 29, 1999

HOSPIRA

5MG/ML

A075242 001

Sep 30, 1999

NORMODYNE

SCHERING

5MG/ML

N018686 001

Aug 01, 1984

TRANDATE

PROMETHEUS LABS

5MG/ML

N019425 001

Dec 31, 1985

TABLET; ORAL

LABETALOL HYDROCHLORIDE

APOTHECON

100MG

A075223 001

Nov 20, 1998

200MG

A075223 002

Nov 20, 1998

300MG

A075223 003

Nov 20, 1998

MUTUAL PHARM

100MG

A075215 001

Jul 29, 1999

200MG

A075215 002

Jul 29, 1999

300MG

A075215 003

Jul 29, 1999

TEVA

100MG

A074989 001

Sep 30, 1998

200MG

A074989 002

Sep 30, 1998

300MG

A074989 003

Sep 30, 1998

NORMODYNE

SCHERING

100MG

N018687 001

Aug 31, 1987

200MG

N018687 002

Aug 01, 1984

300MG

N018687 003

Aug 01, 1984

400MG

N018687 004

Aug 01, 1984

TRANDATE

PROMETHEUS LABS

300MG

N018716 003

Aug 01, 1984

400MG

N018716 004

Aug 01, 1984

LACTULOSE

SOLUTION; ORAL

CHRONULAC

SANOFI AVENTIS US

10GM/15ML

N017884 001

DUPHALAC

SOLVAY

10GM/15ML

A072372 001

Mar 22, 1989

EVALOSE

TEVA PHARMS

10GM/15ML

A073497 001

May 28, 1993

LACTULOSE

MORTON GROVE

10GM/15ML

A071841 001

Sep 22, 1988

PACO

10GM/15ML

A073160 001

Aug 25, 1992

LAXILOSE

NOSTRUM LABS

10GM/15ML

A073686 001

May 28, 1993

SOLUTION; ORAL, RECTAL

ACILAC

NOSTRUM LABS

10GM/15ML

A073685 001

May 28, 1993

CEPHULAC

SANOFI AVENTIS US

10GM/15ML

N017657 001

GENERLAC

MORTON GROVE

10GM/15ML

A071842 001

Sep 27, 1988

HEPTALAC

TEVA PHARMS

10GM/15ML

A073504 001

May 28, 1993

LACTULOSE

PACO

10GM/15ML

A072029 001

Aug 25, 1992

ROXANE

10GM/15ML

A073590 001

May 29, 1992

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 192 (of 331)

LACTULOSE

SOLUTION; ORAL, RECTAL

LACTULOSE

SOLVAY

10GM/15ML

N017906 001

PORTALAC

SOLVAY

10GM/15ML

A072374 001 Mar 22, 1989

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

GLAXOSMITHKLINE

50MG

N020241 006 Dec 27, 1994

250MG

N020241 004 Dec 27, 1994

LAMOTRIGINE

MATRIX LABS LTD

25MG

A078443 001 Feb 11, 2009

100MG

A078443 002 Feb 11, 2009

150MG

A078443 003 Feb 11, 2009

200MG

A078443 004 Feb 11, 2009

MYLAN

25MG

A077428 001 Jan 27, 2009

100MG

A077428 002 Jan 27, 2009

150MG

A077428 003 Jan 27, 2009

200MG

A077428 004 Jan 27, 2009

ROXANE

25MG

A077392 001 Jan 27, 2009

100MG

A077392 002 Jan 27, 2009

150MG

A077392 003 Jan 27, 2009

200MG

A077392 004 Jan 27, 2009

WOCKHARDT

25MG

A078982 001 Jan 27, 2009

100MG

A078982 002 Jan 27, 2009

150MG

A078982 003 Jan 27, 2009

200MG

A078982 004 Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

GLAXOSMITHKLINE

100MG

N020764 003 Aug 24, 1998

LAMOTRIGINE

SANDOZ

5MG

A078409 002 Jan 22, 2009

25MG

A078409 003 Jan 22, 2009

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

TAKEDA PHARMS NA

15MG/PACKET

N021281 001 May 03, 2001

30MG/PACKET

N021281 002 May 03, 2001

INJECTABLE; INTRAVENOUS

PREVACID IV

TAKEDA PHARMS NA

30MG/VIAL

N021566 001 May 27, 2004

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAKEDA PHARMS NA

15MG, N/A; N/A, 250MG

N021507 002 Nov 14, 2003

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA

15MG, N/A; N/A, 375MG

N021507 003 Nov 14, 2003

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA

15MG, N/A; N/A, 500MG

N021507 004 Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

SHIRE

EQ 250MG BASE

N021468 001 Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLUM CHLORIDE IODINE COMPLEX

SOLUTION; TOPICAL

VIRAC REX

CHESEBROUGH PONDS

0.5%; 1.8%

N011914 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 193 (of 331)

LEFLUNOMIDE

TABLET; ORAL
LEFLUNOMIDE
SANDOZ

10MG
20MG

A077085 001 Sep 13, 2005
A077085 002 Sep 13, 2005

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL
LEUCOVORIN CALCIUM

HOSPIRA

EQ 60MG BASE/VIAL

N008107 003 Jan 30, 1987

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

ABIC

EQ 3MG BASE/ML

A089352 001 Jun 01, 1988

EQ 50MG BASE/VIAL

A089353 001 Jun 01, 1988

ABRAXIS PHARM

EQ 50MG BASE/VIAL

A088939 001 Dec 01, 1986

ELKINS SINN

EQ 50MG BASE/VIAL

A070480 001 Jan 02, 1987

EQ 100MG BASE/VIAL

A081224 001 Jun 03, 1994

HOSPIRA

EQ 3MG BASE/ML

N008107 001

EQ 50MG BASE/VIAL

N008107 002

EQ 100MG BASE/VIAL

N008107 004 May 23, 1988

EQ 350MG BASE/VIAL

N008107 005 Apr 05, 1989

PHARMACHEMIE

EQ 350MG BASE/VIAL

A040262 001 Dec 15, 1999

PHARMACHEMIE USA

EQ 50MG BASE/VIAL

A089628 001 Apr 17, 1997

EQ 100MG BASE/VIAL

A089915 001 Apr 17, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

HOSPIRA

EQ 10MG BASE/ML

A040147 001 Jun 25, 1997

TEVA PARENTERAL

EQ 10MG BASE/ML

A040332 001 Jun 28, 1999

WELLCOVORIN

GLAXOSMITHKLINE

EQ 5MG BASE/ML

A087439 001 Oct 19, 1982

EQ 25MG BASE/VIAL

A089833 001 Jan 23, 1989

EQ 50MG BASE/VIAL

A089465 001 Jan 23, 1989

EQ 100MG BASE/VIAL

A089834 001 Jan 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM

COREPHARMA

EQ 5MG BASE

A074544 001 Aug 28, 1997

EQ 25MG BASE

A074544 002 Aug 28, 1997

PAR PHARM

EQ 5MG BASE

A071600 001 Oct 14, 1987

EQ 25MG BASE

A071598 001 Oct 14, 1987

PHARMACHEMIE

EQ 5MG BASE

A073099 001 Mar 28, 1997

EQ 25MG BASE

A073101 001 Mar 28, 1997

SANDOZ

EQ 15MG BASE

A075327 001 Mar 24, 1999

XANODYNE PHARM

EQ 5MG BASE

N018459 001 Jan 30, 1986

EQ 10MG BASE

A071962 001 Nov 19, 1987

EQ 15MG BASE

A071104 001 Mar 04, 1987

WELLCOVORIN

GLAXOSMITHKLINE

EQ 5MG BASE

N018342 001 Jul 08, 1983

EQ 25MG BASE

N018342 002 Jul 08, 1983

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION
VIADUR

ORTHO MCNEIL JANSSEN

EQ 65MG BASE

N021088 001 Mar 03, 2000

INJECTABLE; INJECTION
LUPRON

ABBOTT LABS

1MG/0.2ML

N019010 001 Apr 09, 1985

LUPRON DEPOT-PED

ABBOTT LABS

3.75MG/VIAL, 7.5MG/VIAL

N020263 003 Apr 16, 1993

7.5MG/VIAL, 7.5MG/VIAL

N020263 004 Apr 16, 1993

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION
LORFAN

ROCHE

1MG/ML

N010423 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 194 (of 331)

LEVAMISOLE HYDROCHLORIDETABLET; ORAL
ERGAMISOL

JANSSEN PHARMA

EQ 50MG BASE

N020035 001

Jun 18, 1990

LEVETIRACETAMTABLET; ORAL
LEVETIRACETAM

MYLAN

250MG

A078731 001

Feb 10, 2009

500MG

A078731 002

Feb 10, 2009

750MG

A078731 003

Feb 10, 2009

1GM

A078731 004

Feb 10, 2009

WATSON LABS FLORIDA

250MG

A077408 001

Mar 02, 2009

500MG

A077408 002

Mar 02, 2009

750MG

A077408 003

Mar 02, 2009

LEVOBETAXOLOL HYDROCHLORIDESUSPENSION/DROPS; OPHTHALMIC
BETAXON

ALCON

EQ 0.5% BASE

N021114 001

Feb 23, 2000

LEVOPUIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
CHIROCAINE

PURDUE PHARMA LP

EQ 2.5MG BASE/ML

N020997 001

Aug 05, 1999

EQ 5MG BASE/ML

N020997 002

Aug 05, 1999

EQ 7.5MG BASE/ML

N020997 003

Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDESUSPENSION/DROPS; OPHTHALMIC
LIVOSTIN

NOVARTIS

EQ 0.05% BASE

N020219 001

Nov 10, 1993

LEVOCARNITINESOLUTION; ORAL
CARNITOR

SIGMA TAU

1GM/10ML

N018948 002

Apr 27, 1988

LEVODOPACAPSULE; ORAL
BENDOPA

VALEANT PHARM INTL

100MG

N016948 003

250MG

N016948 001

500MG

N016948 002

DOPAR

SHIRE

100MG

N016913 003

250MG

N016913 001

500MG

N016913 002

LARODOPA

ROCHE

100MG

N016912 002

250MG

N016912 001

500MG

N016912 006

TABLET; ORAL
DOPAR

SHIRE

250MG

N016913 004

500MG

N016913 005

LARODOPA

ROCHE

100MG

N016912 005

250MG

N016912 003

500MG

N016912 004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 195 (of 331)

LEVOMEPRMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX

20MG/ML

N015865 001

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

ROXANE

10MG/ML

N020315 001 Jul 09, 1993

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

SOLVAY

0.05MG/ML; 2%

A085010 001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%

N012125 002

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

GRAHAM CHEM

0.05MG/ML; 2%

A084850 002 Oct 21, 1983

POLOCAINE W/ LEVONORDEFIN

DENTSPLY PHARM

0.05MG/ML; 2%

A089517 001 Apr 14, 1988

LEVONORDEFIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%; 0.4%

N008592 007

LEVONORGESTREL

IMPLANT; IMPLANTATION

LEVONORGESTREL

WYETH PHARMS INC

75MG/IMPLANT

N020627 001 Aug 15, 1996

NORPLANT

POPULATION COUNCIL

36MG/IMPLANT

N019897 001 Dec 10, 1990

NORPLANT II

POPULATION COUNCIL

75MG/IMPLANT

N020544 001 Nov 01, 1996

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC

36MG/IMPLANT

N020088 001 Dec 10, 1990

TABLET; ORAL

PLAN B

DURAMED

0.75MG

N021045 001 Jul 28, 1999

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY

EQ 50MG BASE

N012928 006

EQ 100MG BASE

N012928 004

SUSPENSION; ORAL

NOVRAD

LILLY

EQ 50MG BASE/5ML

N012928 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

VALEANT PHARM INTL

2MG/ML

N008719 001 Dec 19, 1991

LEVOTHYROXINE SODIUM**

TABLET; ORAL

LEVOLET

VINTAGE

0.025MG

N021137 001 Jun 06, 2003

0.05MG

N021137 002 Jun 06, 2003

0.075MG

N021137 003 Jun 06, 2003

0.088MG

N021137 004 Jun 06, 2003

0.1MG

N021137 005 Jun 06, 2003

0.112MG

N021137 006 Jun 06, 2003

0.125MG

N021137 007 Jun 06, 2003

DISCONTINUED DRUG PRODUCT LIST

6 - 196 (of 331)

LEVOTHYROXINE SODIUM**

TABLET; ORAL					
LEVOLET					
VINTAGE		0.137MG	N021137	008	Jun 06, 2003
		0.15MG	N021137	009	Jun 06, 2003
		0.175MG	N021137	010	Jun 06, 2003
		0.2MG	N021137	011	Jun 06, 2003
		0.3MG	N021137	012	Jun 06, 2003
LEVOXYL					
-->	KING PHARMS	--> 0.3MG	N021301	012	May 25, 2001
NOVOTHYROX					
MERCK KGAA		0.025MG	N021292	001	May 31, 2002
		0.05MG	N021292	002	May 31, 2002
		0.075MG	N021292	003	May 31, 2002
		0.088MG	N021292	004	May 31, 2002
		0.1MG	N021292	005	May 31, 2002
		0.112MG	N021292	006	May 31, 2002
		0.125MG	N021292	007	May 31, 2002
		0.137MG	N021292	008	May 31, 2002
		0.15MG	N021292	009	May 31, 2002
		0.175MG	N021292	010	May 31, 2002
		0.2MG	N021292	011	May 31, 2002
		0.3MG	N021292	012	May 31, 2002

LIDOCAINE

AEROSOL; ORAL					
XYLOCAINE					
ASTRAZENECA		10%	N014394	001	
FILM, EXTENDED RELEASE; BUCCAL					
DENTIPATCH					
NOVEN		23MG/PATCH	N020575	001	May 21, 1996
OINTMENT; TOPICAL					
ALPHACAINE					
CARLISLE		5%	A084944	001	
		5%	A084946	001	
		5%	A084947	001	
LIDOCAINE					
GRAHAM CHEM		5%	A080210	001	
XYLOCAINE					
ASTRAZENECA		5%	N008048	001	
PATCH; TOPICAL					
DENTIPATCH					
NOVEN		46.1MG/PATCH	N020575	002	May 21, 1996
SOLUTION; TOPICAL					
XYLOCAINE					
ASTRAZENECA		5%	N014127	001	
SUPPOSITORY; RECTAL					
XYLOCAINE					
ASTRAZENECA		100MG	N013077	001	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION					
ALPHACAINE HYDROCHLORIDE					
CARLISLE		2%	A084721	001	
LIDOCAINE HYDROCHLORIDE					
ABBOTT		10%	A087980	001	Feb 02, 1983
		20%	A089362	001	May 25, 1988
ABRAXIS PHARM		1%	A080390	001	
		1%	A080420	001	
		1%	A086761	001	
		1.5%	A080420	005	
		2%	A080390	002	
		2%	A080420	002	
		2%	A080420	004	
		2%	A086761	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 197 (of 331)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

ABRAXIS PHARM	2%	N017508	001	
	4%	N017508	002	
	20%	N017508	004	
AKORN	1%	A085037	001	
	2%	A085037	002	
BAXTER HLTHCARE	1%	A080407	001	
	2%	A080407	002	
BEL MAR	1%	A080710	001	
	2%	A080760	001	
DELL LABS	1%	A083387	001	
	2%	A083388	001	
ELKINS SINN	0.5%	A085131	001	
	4%	A084626	001	
GD SEARLE LLC	1%	A083135	001	
	2%	A083135	002	
GRAHAM CHEM	2%	A080504	001	
HOSPIRA	1%	A040013	001	Jun 23, 1995
	1.5%	A088330	001	May 17, 1984
	2%	A088331	001	May 17, 1984
INTL MEDICATION	1%	A083173	001	
	1%	N017701	002	
	2%	A083173	002	
	2%	N017701	001	
	1GM/VIAL	N018543	001	
	2GM/VIAL	N018543	002	
MILES	1%	A080414	001	
	2%	A080414	002	
WATSON LABS	1%	A080377	001	
	1%	A083627	001	
	2%	A080377	002	
	2%	A083627	002	
WYETH AYERST	1%	A083083	001	
	2%	A083083	002	
LIDOCAINE HYDROCHLORIDE	0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	100MG/100ML	N018461	001	
LIDOCAINE HYDROCHLORIDE	0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	200MG/100ML	N018967	001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE	0.2% IN DEXTROSE 5%			
HOSPIRA	200MG/100ML	A083158	005	
LIDOCAINE HYDROCHLORIDE	0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	200MG/100ML	N018954	001	Jul 09, 1985
HOSPIRA	200MG/100ML	N018388	001	
LIDOCAINE HYDROCHLORIDE	0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	400MG/100ML	N018967	002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE	0.4% IN DEXTROSE 5%			
HOSPIRA	400MG/100ML	A083158	006	
LIDOCAINE HYDROCHLORIDE	0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	800MG/100ML	N018967	003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE	IN PLASTIC CONTAINER			
HOSPIRA	1.5%	A088326	001	Jul 31, 1984
	10%	A088367	001	Jul 31, 1984
	20%	A088368	001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE			
BAXTER HLTHCARE	1%	A084625	001	
	2%	A084625	002	
INTL MEDICATION	4%	N017702	002	
LIDOCATON				
PHARMATON	2%	A084727	001	Aug 17, 1983
XYLOCAINE				
ASTRAZENECA	1%	N010418	005	
	1.5%	N010418	009	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 198 (of 331)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
XYLOCAINE				
ASTRAZENECA	2%	N010418	007	
INJECTABLE; SPINAL				
XYLOCAINE 1.5% W/ DEXTROSE 7.5%				
APP PHARMS	1.5%	N016297	001	
XYLOCAINE 5% W/ GLUCOSE 7.5%				
ASTRAZENECA	5%	N010496	002	Jul 07, 1982
SOLUTION; ORAL				
LIDOCAINE HYDROCHLORIDE VISCOUS				
INTL MEDICATION	2%	A086389	001	Feb 02, 1982
SOLUTION; TOPICAL				
LARYNGOTRACHEAL ANESTHESIA KIT				
KENDALL IL	4%	A087931	001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE				
PACO	4%	A089688	001	Jun 30, 1989
LTA II KIT				
HOSPIRA	4%	A088542	001	Jul 31, 1984
PEDIATRIC LTA KIT				
ABBOTT	2%	A088572	001	Jul 31, 1984
SYSTEM; INTRADERMAL				
ZINGO				
ANESIVA	0.5MG	N022114	001	Aug 16, 2007

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION				
TERRAMYCIN				
PFIZER	2%;50MG/ML	A060567	001	
	2%;125MG/ML	A060567	002	

LIDOCAINE; PRILOCAINE

DISC; TOPICAL				
EMLA				
ASTRAZENECA	2.5%;2.5%	N020962	001	Feb 04, 1998

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL				
LINCOICIN				
PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316	001	
	EQ 500MG BASE	N050316	002	
INJECTABLE; INJECTION				
LINCOMYCIN HYDROCHLORIDE				
WATSON LABS	EQ 300MG BASE/ML	A063180	001	Apr 16, 1991

LINDANE

CREAM; TOPICAL				
KWELL				
REED AND CARNRICK	1%	A084218	001	
	1%	N006309	001	
LOTION; TOPICAL				
GAMENE				
SOLA BARNES HIND	1%	A084989	001	
KWELL				
REED AND CARNRICK	1%	A084218	002	
	1%	N006309	003	
LINDANE				
OLTA PHARMS	1%	A087313	001	
SCABENE				
STIEFEL	1%	A086769	001	
SHAMPOO; TOPICAL				
GAMENE				
SOLA BARNES HIND	1%	A084988	001	
KWELL				
REED AND CARNRICK	1%	A084219	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 199 (of 331)

LINDANESHAMPOO; TOPICAL
K WELL

REED AND CARNRICK

1%

N010718 001

SCABENE

STIEFEL

1%

A087940 001 Apr 08, 1983

LINEZOLIDTABLET; ORAL
ZYVOX

PHARMACIA AND UPJOHN 400MG

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

WATSON LABS

EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4;T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS

0.03MG;0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.06MG;0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.12MG;0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.18MG;0.045MG

N016680 004

THYROLAR-5

FOREST LABS

0.25MG;0.0625MG

N016807 006

LISINAPRIL

TABLET; ORAL

LISINAPRIL

TEVA

2.5MG

A075783 001 Jul 01, 2002

5MG

A075783 002 Jul 01, 2002

10MG

A075783 003 Jul 01, 2002

20MG

A075783 004 Jul 01, 2002

30MG

A075783 005 Jul 01, 2002

40MG

A075783 006 Jul 01, 2002

PRINIVIL

MERCK

2.5MG

N019558 006 Jan 28, 1994

LITHIUM CARBONATE

CAPSULE; ORAL

ESKALITH

NOVEN THERAP

300MG

N016860 001

LITHIUM CARBONATE

ABLE

150MG

A076823 001 Jun 29, 2004

300MG

A076121 001 Sep 27, 2001

300MG

A076823 002 Jun 29, 2004

600MG

A076823 003 Jun 29, 2004

USL PHARMA

300MG

A072542 001 Feb 01, 1989

WATSON LABS

300MG

A070407 001 Mar 19, 1987

LITHONATE

SOLVAY

300MG

N016782 001

TABLET; ORAL

ESKALITH

JDS PHARMS

300MG

N017971 001

LITHANE

BAYER PHARMS

300MG

N018833 001 Jul 18, 1985

LITHIUM CARBONATE

PFIZER

300MG

N016834 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 200 (of 331)

LITHIUM CARBONATE

TABLET; ORAL				
LITHOTABS				
SOLVAY	300MG	N016980	001	
TABLET, EXTENDED RELEASE; ORAL				
ESKALITH CR				
JDS PHARMS	450MG	N018152	001	Mar 29, 1982
LITHIUM CARBONATE				
ABLE	300MG	A076382	001	Apr 21, 2003
BARR	300MG	A076170	001	Jun 10, 2002
	450MG	A076366	001	Aug 21, 2003

LITHIUM CITRATE

SYRUP; ORAL				
LITHONATE				
SOLVAY	EQ 300MG CARBONATE/5ML	N017672	001	

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL				
MAXAQUIN				
PHARMACIA	EQ 400MG BASE	N020013	001	Feb 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL				
IMODIUM				
MCNEIL PED	2MG	N017690	001	
LOPERAMIDE HYDROCHLORIDE				
ROXANE	2MG	A073080	001	Nov 27, 1991
SANDOZ	2MG	A072993	001	Aug 28, 1992
TEVA	2MG	A073122	001	Aug 30, 1991
SOLUTION; ORAL				
IMODIUM				
JANSSEN PHARMA	1MG/5ML	N019037	001	Jul 31, 1984
LOPERAMIDE HYDROCHLORIDE				
ALPHARMA US PHARMS	1MG/5ML	A073187	001	Sep 15, 1992
DURAMED PHARMS BARR	1MG/5ML	A074991	001	Dec 29, 1997
TEVA	1MG/5ML	A073478	001	Jun 23, 1995
WATSON LABS	1MG/5ML	A073062	001	May 28, 1993
TABLET; ORAL				
LOPERAMIDE HYDROCHLORIDE				
ABLE	2MG	A073528	001	Nov 30, 1993
PERRIGO	2MG	A074194	001	Oct 30, 1992

LORACARBEF

CAPSULE; ORAL				
LORABID				
KING PHARMS	200MG	N050668	001	Dec 31, 1991
	400MG	N050668	002	Apr 05, 1996
FOR SUSPENSION; ORAL				
LORABID				
KING PHARMS	100MG/5ML	N050667	001	Dec 31, 1991
	200MG/5ML	N050667	002	Dec 31, 1991

LORATADINE

SYRUP; ORAL				
CLARITIN HIVES RELIEF				
SCHERING PLOUGH	1MG/ML	N020641	003	Nov 19, 2003
TABLET; ORAL				
LORATADINE				
PERRIGO	10MG	N021512	001	Jun 24, 2004

DISCONTINUED DRUG PRODUCT LIST

6 - 201 (of 331)

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AKORN	2MG/ML	A074974	001	Jul 23, 1998
BAXTER HLTHCARE	2MG/ML	A074496	001	Sep 28, 1998
	4MG/ML	A074496	002	Sep 28, 1998
DAVA PHARMS INC	2MG/ML	A074793	001	Mar 16, 2000
	4MG/ML	A074793	002	Mar 16, 2000
HOSPIRA	2MG/ML	A074280	001	May 27, 1994
	4MG/ML	A074280	002	May 27, 1994
	4MG/ML	A074300	003	Mar 19, 1997
MARSAM PHARMS LLC	1MG/0.5ML	A074551	003	Sep 12, 1996
	2MG/ML	A074535	001	Sep 12, 1996
	2MG/ML	A074551	001	Sep 12, 1996
	4MG/ML	A074535	002	Sep 12, 1996
	4MG/ML	A074551	002	Sep 12, 1996
TAYLOR	2MG/ML	A075025	001	Jul 23, 1998

SOLUTION; ORAL

LORAZEPAM

ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997

TABLET; ORAL

LORAZ

QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985

LORAZEPAM

AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	1MG	A070473	001	Dec 10, 1985
	2MG	A070474	001	Dec 10, 1985
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

PHARMOS	0.5%	N020841	001	Mar 09, 1998

LOVASTATIN

TABLET; ORAL

MEVACOR

MERCK	10MG	N019643	002	Mar 28, 1991

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

ANDRX LABS LLC	10MG	N021316	001	Jun 26, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 202 (of 331)

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

WATSON LABS

EQ 25MG BASE/ML

N017658 001

INJECTABLE; INJECTION

LOXITANE IM

WATSON LABS

EQ 50MG BASE/ML

N018039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

ACTAVIS TOTOWA

EQ 5MG BASE

A076868 001 Aug 04, 2005

EQ 10MG BASE

A076868 002 Aug 04, 2005

EQ 25MG BASE

A076868 003 Aug 04, 2005

EQ 50MG BASE

A076868 004 Aug 04, 2005

LOXITANE

WATSON LABS

EQ 5MG BASE

N017525 001

EQ 10MG BASE

N017525 002

EQ 25MG BASE

N017525 003

EQ 50MG BASE

N017525 004

TABLET; ORAL

LOXITANE

WATSON LABS

EQ 10MG BASE

N017525 006

EQ 25MG BASE

N017525 007

EQ 50MG BASE

N017525 008

LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS

0.185MG/ML

N016755 001

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN

30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML

N019006 001 Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN

30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML

N018252 001

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA

14MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML

N018406 001

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE

30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML

N019326 001 Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS

700MG;20MG;600MG

N021850 001 Mar 24, 2006

700MG;40MG;600MG

N021850 002 Mar 24, 2006

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

GE HEALTHCARE

37.9MG/ML

N020652 001 Nov 26, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 203 (of 331)

MANGANESE CHLORIDE TETRAHYDRATEFOR SOLUTION; ORAL
LUMENHANCE

BRACCO

3.49MG/GM

N020686 001

Dec 19, 1997

MANGANESE SULFATEINJECTABLE; INJECTION
MANGANESE SULFATE

ABRAXIS PHARM

EQ 0.1MG MANGANESE/ML

N019228 001

May 05, 1987

MANNITOLINJECTABLE; INJECTION
MANNITOL 10%

HOSPIRA

10GM/100ML

N016269 002

MILES

10GM/100ML

N016472 002

MANNITOL 15%

HOSPIRA

15GM/100ML

N016269 003

MILES

15GM/100ML

N016472 005

MANNITOL 20%

HOSPIRA

20GM/100ML

N016269 004

MILES

20GM/100ML

N016472 004

MANNITOL 25%

ABRAXIS PHARM

12.5GM/50ML

A086754 001

ASTRAZENECA

12.5GM/50ML

A089239 001

May 06, 1987

12.5GM/50ML

A089240 001

May 06, 1987

HOSPIRA

12.5GM/50ML

N016269 005

MERCK

12.5GM/50ML

N005620 001

WATSON LABS

12.5GM/50ML

A087460 001

Jun 27, 1983

MANNITOL 5%

HOSPIRA

5GM/100ML

N016269 001

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN

5GM/100ML

N016704 002

MANNITOL; SORBITOLSOLUTION; IRRIGATION
SORBITOL-MANNITOL

HOSPIRA

540MG/100ML;2.7GM/100ML

A080224 001

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA

540MG/100ML;2.7GM/100ML

N017636 001

MAPROTILINE HYDROCHLORIDETABLET; ORAL
LUDIOMIL

NOVARTIS

25MG

N017543 001

50MG

N017543 002

75MG

N017543 003

Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP

25MG

A072129 001

Jan 14, 1988

50MG

A072130 001

Jan 14, 1988

75MG

A072131 001

Jan 14, 1988

WATSON LABS

25MG

A071943 001

Dec 30, 1987

25MG

A072162 001

Jun 01, 1988

50MG

A071944 001

Dec 30, 1987

50MG

A072163 001

Jun 01, 1988

75MG

A071945 001

Dec 30, 1987

75MG

A072164 001

Jun 01, 1988

MASOPROCOLCREAM; TOPICAL
ACTINEX

UNIV AZ CANCER CTR

10%

N019940 001

Sep 04, 1992

DISCONTINUED DRUG PRODUCT LIST

6 - 204 (of 331)

MAZINDOL

TABLET; ORAL
MAZANOR

WYETH AYERST	1MG	N017980	002	
	2MG	N017980	001	
SANOREX				
NOVARTIS	1MG	N017247	001	
	2MG	N017247	002	

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
VERMOX

MCNEIL PED	100MG	N017481	001	

MEBUTAMATE

TABLET; ORAL
DORMATE

MEDPOINTE PHARM HLC	600MG	N017374	001	

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE

TARGACEPT	2.5MG	N010251	001	

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE; SUBCUTANEOUS
IPLEX

INSMED	36MG/0.6ML	N021884	001	Dec 12, 2005

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

ABC HOLDING	12.5MG	A085253	001	
	25MG	A085252	001	
ANABOLIC	25MG	A085891	001	
BUNDY	12.5MG	A084382	001	
	25MG	A084872	001	
IVAX SUB TEVA PHARMS	12.5MG	A083784	001	
	12.5MG	A084975	001	
	25MG	A084657	001	
KV PHARM	12.5MG	A085524	001	
	25MG	A085523	001	
PLIVA	12.5MG	A088732	001	Dec 11, 1985
	25MG	A088734	001	Dec 11, 1985
SUPERPHARM	12.5MG	A089113	001	Aug 20, 1985
	25MG	A089114	001	Aug 20, 1985
UDL	12.5MG	A088256	001	Jun 13, 1983
	25MG	A088257	001	Jun 13, 1983
VANGARD	12.5MG	A087877	001	Apr 20, 1982
	25MG	A087620	001	Jan 04, 1982
WATSON LABS	12.5MG	A085195	001	
	12.5MG	A085269	001	
TABLET, CHEWABLE; ORAL				
ANTIVERT				
PFIZER	25MG	N010721	005	
MECLIZINE HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	25MG	A084976	001	
NEXGEN PHARMA INC	25MG	A086392	001	
PLIVA	25MG	A088733	001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

JOHNSON AND JOHNSON	1%	N050518	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 205 (of 331)

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLODIUM

QUANTUM PHARMICS

EQ 50MG BASE

A071380 001 Jul 14, 1987

EQ 100MG BASE

A071381 001 Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP

EQ 50MG BASE

A071362 001 Feb 10, 1987

EQ 100MG BASE

A071363 001 Feb 10, 1987

BARR

EQ 50MG BASE

A072848 001 Mar 20, 1989

EQ 100MG BASE

A072809 001 Mar 20, 1989

PAR PHARM

EQ 50MG BASE

A072077 001 Mar 10, 1988

EQ 100MG BASE

A072078 001 Mar 10, 1988

SANDOZ

EQ 50MG BASE

A072262 001 Nov 29, 1988

EQ 100MG BASE

A072263 001 Nov 29, 1988

USL PHARMA

EQ 50MG BASE

A071007 001 Mar 25, 1988

EQ 100MG BASE

A071008 001 Mar 25, 1988

VITARINE

EQ 50MG BASE

A071710 001 Jun 15, 1988

EQ 100MG BASE

A071684 001 Jun 15, 1988

WATSON LABS

EQ 50MG BASE

A070400 001 Nov 25, 1986

EQ 50MG BASE

A071640 001 Aug 11, 1987

EQ 100MG BASE

A070401 001 Nov 25, 1986

EQ 100MG BASE

A071641 001 Aug 11, 1987

MECLOMEN

PARKE DAVIS

EQ 50MG BASE

N018006 001

EQ 100MG BASE

N018006 002

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

PHARMACIA AND UPJOHN 100MG/ML

N012541 002

TABLET; ORAL

AMEN

AMARIN PHARMS

10MG

A083242 001

CURRETAB

SOLVAY

10MG

A085686 001

CYCRIN

ESI

2.5MG

A081239 001 Oct 30, 1992

5MG

A081240 001 Oct 30, 1992

10MG

A089386 001 Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR

2.5MG

A040311 001 Dec 01, 1999

5MG

A040311 002 Dec 01, 1999

10MG

A040311 003 Dec 01, 1999

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS

ALLERGAN

1%

N016624 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

ROCHE

250MG

N019591 001 May 02, 1989

MEFLOQUINE HYDROCHLORIDE

US ARMY WALTER REED

250MG

N019578 001 May 02, 1989

MEGESTROL ACETATE

TABLET; ORAL

MEGACE

BRISTOL MYERS SQUIBB

20MG

N016979 001

40MG

N016979 002

MEGESTROL ACETATE

TEVA

40MG

A074745 001 Feb 27, 1998

USL PHARMA

20MG

A070646 001 Oct 02, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 206 (of 331)

MEGESTROL ACETATE

TABLET; ORAL				
MEGESTROL ACETATE				
USL PHARMA	40MG	A070647	001	Oct 02, 1987

MELOXICAM

TABLET; ORAL				
MELOXICAM				
MUTUAL PHARM	7.5MG	A077935	001	Jul 19, 2006
	15MG	A077935	002	Jul 19, 2006
ROXANE	7.5MG	A077925	001	Jul 19, 2006
	15MG	A077925	002	Jul 19, 2006
YABAO BIOPHARMS	7.5MG	A077933	001	Jul 19, 2006
	15MG	A077933	002	Jul 19, 2006

MEMANTINE HYDROCHLORIDE

TABLET; ORAL				
MEMANTINE				
SUN PHARM INDS (IN)	5MG	A090058	001	May 05, 2010
	10MG	A090058	002	May 05, 2010
MEMANTINE HYDROCHLORIDE				
DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010
	10MG	A090048	002	Apr 14, 2010

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION				
KAPPADIONE				
LILLY	10MG/ML	N005725	001	
SYNKAYVITE				
ROCHE	5MG/ML	N003718	004	
	10MG/ML	N003718	006	
	37.5MG/ML	N003718	008	
TABLET; ORAL				
SYNKAYVITE				
ROCHE	5MG	N003718	010	

MENADIONE

TABLET; ORAL				
MENADIONE				
LILLY	5MG	N002139	003	

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION				
HUMEGON				
ORGANON USA INC	75 IU/VIAL;75 IU/VIAL	N020328	001	Sep 01, 1994
	150 IU/VIAL;150 IU/VIAL	N020328	002	Sep 01, 1994
MENOTROPINS				
FERRING	75 IU/VIAL;75 IU/VIAL	A073598	001	Jan 30, 1997
	150 IU/VIAL;150 IU/VIAL	A073599	001	Jan 30, 1997
PERGONAL				
SERONO	75 IU/AMP;75 IU/AMP	N017646	001	
	150 IU/AMP;150 IU/AMP	N017646	002	May 20, 1985
REPRONEX				
FERRING	150 IU/VIAL;150 IU/VIAL	N021047	002	Aug 27, 1999

MEPENZOLATE BROMIDE

SOLUTION; ORAL				
CANTIL				
SANOFI AVENTIS US	25MG/5ML	N010679	004	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 207 (of 331)

MEPERIDINE HYDROCHLORIDEINJECTABLE; INJECTION
DEMEROL

SANOFI AVENTIS US	25MG/ML	N005010	007	
	50MG/ML	N005010	002	
	75MG/ML	N005010	009	
	100MG/ML	N005010	003	

MEPERIDINE HYDROCHLORIDE

ABBOTT

25MG/ML	A080388	001	
50MG/ML	A080385	001	
50MG/ML	A080387	001	
75MG/ML	A080389	001	
100MG/ML	A080386	001	

ASTRAZENECA

25MG/ML	A089781	001	Mar 31, 1989
50MG/ML	A089782	001	Mar 31, 1989
50MG/ML	A089783	001	Mar 31, 1989
50MG/ML	A089784	001	Mar 31, 1989
75MG/ML	A089785	001	Mar 31, 1989
100MG/ML	A089786	001	Mar 31, 1989
100MG/ML	A089787	001	Mar 31, 1989
100MG/ML	A089788	001	Mar 31, 1989

BAXTER HLTHCARE

25MG/ML	A088279	001	Jun 15, 1984
50MG/ML	A088280	001	Jun 15, 1984
75MG/ML	A088281	001	Jun 15, 1984
100MG/ML	A088282	001	Jun 15, 1984

INTL MEDICATION

10MG/ML	A086332	001	

PARKE DAVIS

50MG/ML	A080364	002	
75MG/ML	A080364	003	
100MG/ML	A080364	001	

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

10MG/ML	A040305	001	Mar 10, 1999

MALLINCKRODT

10MG/ML	A040163	001	May 12, 1997

SYRUP; ORAL

DEMEROL

SANOFI AVENTIS US	50MG/5ML	N005010	005	

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

DURAMED PHARMS BARR

50MG	A040318	001	Oct 05, 1999
100MG	A040318	002	Oct 05, 1999

MUTUAL PHARM

50MG	A080448	001	

100MG	A080448	002	

WYETH AYERST

50MG	A080454	001	

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

BAXTER HLTHCARE CORP	25MG/ML;25MG/ML	N011730	001	

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248	002	
	EQ 30MG BASE/ML	N008248	001	

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

NOVARTIS	100MG	N006008	001	

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY	3%	A084777	002	Apr 18, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 208 (of 331)

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

EASTMAN KODAK 3%

N012125 003

MEPIVACAINE HYDROCHLORIDE

GRAHAM CHEM 3%

A083559 001

INTL MEDICATION 1%

A087509 001

Oct 05, 1982

MEPREDNISONE

TABLET; ORAL

BETAPAR

SCHERING 4MG

N016053 002

MEPROBAMATE

CAPSULE; ORAL

EQUANIL

WYETH AYERST 400MG

N012455 002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC 200MG

N011284 001

400MG

N011284 002

TABLET; ORAL

AMOSENE

FERNDAL LABS 400MG

A084030 001

BAMATE

ALRA 200MG

A080380 001

400MG

A080380 002

EQUANIL

WYETH AYERST 200MG

N010028 005

400MG

N010028 004

MEPRIAM

TEVA 400MG

N016069 001

MEPROBAMATE

BARR 600MG

A084230 001

ELKINS SINN 200MG

N015426 002

400MG

N015426 001

HEATHER 400MG

N016928 003

600MG

A084329 001

IMPAX LABS 200MG

N014322 002

400MG

N014322 001

IVAX SUB TEVA PHARMS 200MG

N015438 001

400MG

N015438 002

600MG

A084181 001

IVC INDS 400MG

A084153 001

LANNETT 200MG

N014882 002

400MG

N014882 001

LEDERLE 400MG

A086299 001

LEE KM 400MG

A089538 001

Nov 25, 1987

MALLARD 400MG

N015072 002

MK LABS 200MG

N014368 004

400MG

N014368 002

MUTUAL PHARM 200MG

A080699 001

400MG

A080699 002

MYLAN 400MG

A083618 001

NEXGEN PHARMA INC 200MG

A084220 001

400MG

A084589 001

PARKE DAVIS 200MG

A084744 001

400MG

A084744 002

PERRIGO 200MG

A084546 001

400MG

A084547 001

PHARMAVITE 400MG

A084438 001

PUREPAC PHARM 200MG

A084804 001

400MG

A084804 002

PVT FORM 400MG

N014601 001

DISCONTINUED DRUG PRODUCT LIST

6 - 209 (of 331)

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

ROXANE	600MG	A084332	001	
SANDOZ	200MG	N014547	002	
	400MG	A080655	001	
	400MG	N014547	001	
SCHERER LABS	400MG	A083343	001	
SOLVAY	200MG	A084435	001	
STANLABS PHARM	200MG	N014474	002	
	400MG	N014474	004	
TABLICAPS	400MG	A083494	001	
USL PHARMA	200MG	A087825	001	Mar 18, 1982
	400MG	A087826	001	Mar 18, 1982
VALEANT PHARM INTL	200MG	N015139	006	
	400MG	N015139	005	
VANGARD	400MG	A088011	001	Jul 14, 1982
WATSON LABS	200MG	A085720	001	
	400MG	A085721	001	
	600MG	A084274	001	
	600MG	A085719	001	
WEST WARD	200MG	N015417	003	
	400MG	N015417	002	
WHITEWORTH TOWN PLSN	200MG	A083830	001	
	400MG	A083442	001	
MILTOWN				
MEDPOINTE PHARM HLC	200MG	N009698	004	
	400MG	N009698	002	
	600MG	A083919	001	
NEURAMATE				
HALSEY	200MG	N014359	002	
	400MG	N014359	001	
TRANMEP				
SOLVAY	400MG	A084369	001	
	400MG	N016249	001	

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION
MERSALYL-THEOPHYLLINE

WATSON LABS	100MG/ML;50MG/ML	A084875	001

MESALAMINE

SUPPOSITORY; RECTAL

CANASA				
AXCAN	500MG	N021252	001	Jan 05, 2001
ROWASA				
ALAVEN PHARM	500MG	N019919	001	Dec 18, 1990

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL
SERENTIL

NOVARTIS	EQ 25MG BASE/ML	N016997	001
INJECTABLE; INJECTION			
SERENTIL			
NOVARTIS	EQ 25MG BASE/ML	N016775	001
TABLET; ORAL			
SERENTIL			
NOVARTIS	EQ 10MG BASE	N016774	001
	EQ 25MG BASE	N016774	002
	EQ 50MG BASE	N016774	003
	EQ 100MG BASE	N016774	004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 210 (of 331)

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

WATSON LABS

0.1MG;2MG

N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

WATSON LABS

0.05MG;1MG

A071539 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS

0.05MG;1MG

A070758 001 Jul 01, 1988

NORINYL 1+50 21-DAY

WATSON LABS

0.05MG;1MG

N013625 002

NORINYL 1+80 21-DAY

GD SEARLE LLC

0.08MG;1MG

N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM

0.05MG;1MG

N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM

0.08MG;1MG

N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM

0.06MG;10MG

N012728 001

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM

0.1MG;2MG

N012728 005

TABLET; ORAL-28

NORETHIN 1/50M-28

WATSON LABS

0.05MG;1MG

A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS

0.05MG;1MG

A070759 001 Jul 01, 1988

NORINYL 1+80 28-DAY

GD SEARLE LLC

0.08MG;1MG

N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN

0.05MG;1MG

N016709 001

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM

0.08MG;1MG

N016715 002

MESTRANOL; NORETHYNODREL

TABLET; ORAL

ENOVID

GD SEARLE LLC

0.075MG;5MG

N010976 008

0.15MG;9.85MG

N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC

0.075MG;5MG

N010976 004

ENOVID-E

GD SEARLE LLC

0.1MG;2.5MG

N010976 006

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC

0.1MG;2.5MG

N010976 007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.65MG/INH

N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.4%

N018761 002 Oct 10, 1986

0.6%

N018761 001 Jun 30, 1983

5%

N017659 001

METAPROTERENOL SULFATE

ASTRAZENECA

0.4%

A071275 001 Jul 27, 1988

0.6%

A071018 001 Jul 27, 1988

DEY

0.33%

A071806 001 Aug 05, 1988

0.5%

A071805 001 Aug 05, 1988

5%

A070805 001 Aug 17, 1987

WOCKHARDT

5%

A072190 001 Jun 07, 1988

PROMETA

MURO

5%

A073340 001 Mar 30, 1992

DISCONTINUED DRUG PRODUCT LIST

6 - 211 (of 331)

METAPROTERENOL SULFATE

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM 10MG/5ML

N017571 001

METAPROTERENOL SULFATE

MORTON GROVE 10MG/5ML

A071656 001 Oct 13, 1987

TEVA 10MG/5ML

A072761 001 Feb 27, 1992

TEVA PHARMS 10MG/5ML

A073034 001 Aug 30, 1991

WOCKHARDT 10MG/5ML

A074702 001 Mar 24, 1997

PROMETA

MURO 10MG/5ML

A072023 001 Sep 15, 1988

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM 10MG

N015874 002

20MG

N015874 001

METAPROTERENOL SULFATE

AM THERAP 10MG

A072054 001 Jun 23, 1988

20MG

A072055 001 Jun 23, 1988

TEVA 10MG

A072519 001 Mar 30, 1990

20MG

A072520 001 Mar 30, 1990

USL PHARMA 10MG

A071013 001 Jan 25, 1988

20MG

A071014 001 Jan 25, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

MERCK EQ 10MG BASE/ML

N009509 002 Dec 22, 1987

METARAMINOL BITARTRATE

ABRAXIS PHARM EQ 10MG BASE/ML

A080431 001

ELKINS SINN EQ 10MG BASE/ML

A083363 001

GD SEARLE LLC EQ 10MG BASE/ML

A086418 001

EQ 20MG BASE/ML

A086418 002

METAXALONE

TABLET; ORAL

SKELAXIN

KING PHARMS 400MG

N013217 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

BRISTOL MYERS SQUIBB 625MG

N020357 003 Nov 05, 1998

750MG

N020357 004 Nov 05, 1998

METFORMIN HYDROCHLORIDE

BARR 500MG

A075971 001 Jan 25, 2002

850MG

A075971 002 Jan 25, 2002

1GM

A075971 003 Jan 25, 2002

IPCA LABS LTD 500MG

A078422 001 Aug 06, 2007

850MG

A078422 002 Aug 06, 2007

1GM

A078422 003 Aug 06, 2007

IVAX SUB TEVA PHARMS 500MG

A075975 001 Jan 24, 2002

625MG

A075975 004 Jan 24, 2002

750MG

A075975 005 Jan 24, 2002

850MG

A075975 002 Jan 24, 2002

1GM

A075975 003 Jan 24, 2002

TEVA 500MG

A076328 001 Dec 16, 2002

850MG

A076328 002 Dec 16, 2002

1GM

A076328 003 Dec 16, 2002

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

BARR 500MG

A076496 001 Nov 25, 2005

IVAX SUB TEVA PHARMS 500MG

A076545 001 Dec 01, 2003

MUTUAL PHARM 500MG

A077124 001 Dec 21, 2005

SANDOZ 500MG

A076223 001 Dec 14, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 212 (of 331)

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL				
AVANDAMET				
SB PHARMC0	500MG;EQ 1MG BASE	N021410	001	Oct 10, 2002

METHACYCLINE HYDROCHLORIDE

CAPSULE; ORAL				
RANDOMYCIN				
MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641	001	
	EQ 280MG BASE	A060641	002	
SYRUP; ORAL				
RANDOMYCIN				
MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641	003	

METHADONE HYDROCHLORIDE

SYRUP; ORAL				
DOLOPHINE HYDROCHLORIDE				
ROXANE	10MG/30ML	N006134	004	
TABLET; ORAL				
METHADONE HYDROCHLORIDE				
ROXANE	5MG	A088108	001	Mar 08, 1983
	10MG	A088109	001	Mar 08, 1983
	40MG	A074081	001	Apr 28, 1995
SANDOZ	5MG	A040241	001	May 29, 1998
TABLET, DISPERSIBLE; ORAL				
WESTADONE				
SANDOZ	2.5MG	N017108	001	
TABLET, EFFERVESCENT; ORAL				
WESTADONE				
SANDOZ	5MG	N017108	002	
	10MG	N017108	003	
	40MG	N017108	004	

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL				
METHAMPEX				
TEVA	10MG	A083889	001	
METHAMPHETAMINE HYDROCHLORIDE				
ABLE	5MG	A040529	001	Feb 25, 2004
REXAR	5MG	A084931	001	
	10MG	A084931	002	
TEVA	5MG	A086359	001	
TABLET, EXTENDED RELEASE; ORAL				
DESOXYN				
LUNDBECK INC	5MG	N005378	004	
	10MG	N005378	003	
	15MG	N005378	005	

METHANTHELINE BROMIDE

TABLET; ORAL				
BANTHINE				
SHIRE	50MG	N007390	001	

METHARBITAL

TABLET; ORAL				
GEMONIL				
ABBOTT	100MG	N008322	001	

METHAZOLAMIDE

TABLET; ORAL				
METHAZOLAMIDE				
APPLIED ANAL	25MG	A040011	001	Jul 17, 1997
	50MG	A040011	002	Jul 17, 1997
SANDOZ	25MG	A040102	001	Aug 28, 1996

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 213 (of 331)

METHAZOLAMIDETABLET; ORAL
METHAZOLAMIDE

SANDOZ 50MG

A040102 002 Aug 28, 1996

NEPTAZANE

LEDERLE 25MG

N011721 002 Nov 25, 1991

50MG

N011721 001

METHDILAZINETABLET, CHEWABLE; ORAL
TACARYL

WESTWOOD SQUIBB 3.6MG

N011950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS 4MG/5ML

A087122 001

TACARYL

WESTWOOD SQUIBB 4MG/5ML

N011950 007

TABLET; ORAL

TACARYL

WESTWOOD SQUIBB 8MG

N011950 006

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHICILLIN

APOTHECON

EQ 900MG BASE/VIAL

A061449 001

EQ 900MG BASE/VIAL

N050117 001

EQ 3.6GM BASE/VIAL

A061449 002

EQ 3.6GM BASE/VIAL

N050117 002

EQ 5.4GM BASE/VIAL

A061449 003

EQ 5.4GM BASE/VIAL

N050117 003

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

CEDAR PHARMS 15MG

A040619 003 Jul 12, 2005

20MG

A040547 004 Feb 18, 2005

MYLAN

20MG

A040350 003 Jun 07, 2001

TAPAZOLE

KING PHARMS

5MG

N007517 002

10MG

N007517 004

METHIXENE HYDROCHLORIDE

TABLET; ORAL

TREST

NOVARTIS 1MG

N013420 001

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

MARSAM PHARMS LLC 100MG/ML

A089849 001 Dec 27, 1991

TABLET; ORAL

DELAXIN

FERNDAL LABS 500MG

A085454 001

FORBAXIN

FOREST LABS 750MG

A085136 001

METHOCARBAMOL

ABLE 500MG

A040413 001 Mar 17, 2003

750MG

A040413 002 Mar 17, 2003

AM THERAP

500MG

A089417 001 Feb 11, 1987

750MG

A089418 001 Feb 11, 1987

ASCOT

500MG

A087660 001 Oct 27, 1982

750MG

A087661 001 Oct 27, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 214 (of 331)

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

CLONMEL HLTHCARE	500MG	A085961	001	
	750MG	A085963	001	
HEATHER	500MG	A084675	001	
	750MG	A084924	001	
IMPAX LABS	500MG	A084927	001	
	750MG	A084928	001	
INWOOD LABS	500MG	A085137	001	
IVAX SUB TEVA PHARMS	500MG	A084648	001	
	750MG	A084649	001	
KV PHARM	500MG	A085660	001	
	750MG	A085658	001	
MUTUAL PHARM	500MG	A084488	001	
	750MG	A084486	001	
MYLAN	500MG	A084259	001	
	750MG	A084323	001	
NYLOS	750MG	A085033	001	
PHARMERAL	500MG	A084231	002	
	750MG	A084471	001	
PIONEER PHARMS	500MG	A088731	001	Dec 13, 1985
	750MG	A089082	001	Dec 13, 1985
PUREPAC PHARM	500MG	A085718	001	
	750MG	A085718	002	
ROXANE	500MG	A088646	001	Feb 29, 1984
	750MG	A088647	001	Feb 29, 1984
SANDOZ	500MG	A087283	001	
	750MG	A087282	001	
SOLCO HLTHCARE	500MG	A086989	001	
	750MG	A086988	001	
SOLVAY	500MG	A084448	001	
	750MG	A084449	001	
SUPERPHARM	500MG	A087589	001	Jan 22, 1982
	750MG	A087590	001	Jan 22, 1982
TABLICAPS	500MG	A084846	001	
UPSHER SMITH	500MG	A087453	001	
	750MG	A087454	001	
WATSON LABS	500MG	A083605	001	
	750MG	A083605	002	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

JHP PHARMS

5GM/VIAL

N011559 003

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC

EQ 25MG BASE/ML

A089161 001 Mar 10, 1987

EQ 50MG BASE/VIAL

A089354 001 Jul 17, 1987

EQ 100MG BASE/VIAL

A089355 001 Jul 17, 1987

EQ 250MG BASE/VIAL

A089356 001 Jul 17, 1987

FOLEX

PHARMACIA AND UPJOHN

EQ 25MG BASE/VIAL

A087695 001 Apr 08, 1983

EQ 50MG BASE/VIAL

A087695 002 Apr 08, 1983

EQ 100MG BASE/VIAL

A087695 003 Apr 08, 1983

EQ 250MG BASE/VIAL

A088954 001 Oct 24, 1985

FOLEX PFS

PHARMACIA AND UPJOHN

EQ 25MG BASE/ML

A081242 001 Aug 23, 1991

EQ 25MG BASE/ML

A089180 001 Jan 03, 1986

METHOTREXATE LPF

HOSPIRA

EQ 25MG BASE/ML

N011719 007 Mar 31, 1982

DISCONTINUED DRUG PRODUCT LIST

6 - 215 (of 331)

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

APP PHARMS	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999
	EQ 1GM BASE/VIAL	A040266	001	Feb 26, 1999
HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005
	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N011719	013	Apr 13, 2005
	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005

METHOTREXATE SODIUM

ABRAXIS PHARM	EQ 2.5MG BASE/ML	A089323	001	Jun 13, 1986
	EQ 20MG BASE/VIAL	A088935	001	Oct 11, 1985
	EQ 25MG BASE/ML	A089263	001	Jun 13, 1986
	EQ 25MG BASE/ML	A089322	001	Jun 13, 1986
	EQ 50MG BASE/VIAL	A088936	001	Oct 11, 1985
	EQ 100MG BASE/VIAL	A088937	001	Oct 11, 1985
HOSPIRA	EQ 2.5MG BASE/ML	N011719	004	
	EQ 20MG BASE/VIAL	N011719	001	
	EQ 25MG BASE/ML	N011719	005	
	EQ 50MG BASE/VIAL	N011719	003	
	EQ 100MG BASE/VIAL	N011719	006	
NORBROOK	EQ 25MG BASE/ML	A088648	001	May 09, 1986
PHARMACHEMIE USA	EQ 25MG BASE/ML	A089158	001	Jul 08, 1988
METHOTREXATE SODIUM PRESERVATIVE FREE				
HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988
MEXATE				
BRISTOL	EQ 20MG BASE/VIAL	A086358	001	
	EQ 50MG BASE/VIAL	A086358	002	
	EQ 100MG BASE/VIAL	A086358	003	
	EQ 250MG BASE/VIAL	A086358	004	
MEXATE-AQ				
BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985
MEXATE-AQ PRESERVED				
BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887	001	Apr 14, 1989
TABLET; ORAL				
METHOTREXATE SODIUM				
DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233	001	Jun 17, 1999

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE	10MG/ML	N006772	002	
	20MG/ML	N006772	001	

METHOXSALLEN

CAPSULE; ORAL

METHOXSALLEN

SANDOZ	10MG	A087781	001	Jun 08, 1982

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

PVT FORM	2.5MG	A080970	001	

METHYLCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

MEDPOINTE PHARM HLC	5MG	N017364	001	

METHYLCLOTHIAZIDE

IVAX PHARMS	2.5MG	A087913	001	Jun 03, 1982
	5MG	A087786	001	May 18, 1982
MYLAN	2.5MG	A087671	001	Aug 17, 1982
PAR PHARM	2.5MG	A089135	001	Feb 12, 1986
	5MG	A089136	001	Feb 12, 1986
SANDOZ	2.5MG	A089835	001	Aug 18, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 216 (of 331)

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

SANDOZ	5MG	A089837	001	Aug 18, 1988
USL PHARMA	5MG	A088745	001	Mar 21, 1985
WATSON LABS	2.5MG	A085487	001	Mar 11, 1982
	2.5MG	A088750	001	Sep 06, 1984
	5MG	A085476	001	Mar 11, 1982

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT	5MG;25MG	N016047	001	

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC	2.5MG;0.1MG	N012708	005	

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK	250MG/5ML	N018389	001	

TABLET; ORAL

ALDOMET

MERCK	125MG	N013400	003	
	250MG	N013400	001	
	500MG	N013400	002	

METHYLDOPA

ACCORD HLTH	125MG	A070070	003	Oct 15, 1985
DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
	500MG	A071009	001	Dec 16, 1986
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
MUTUAL PHARM	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
PAR PHARM	125MG	A070535	001	Jan 02, 1987
	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
SANDOZ	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 217 (of 331)

METHYLDOPA

TABLET; ORAL
METHYLDOPA

WATSON LABS	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
ALDOMET

MERCK	50MG/ML	N013401	001	
METHYLDOPATE HYDROCHLORIDE				
ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001
	20MG	A040404	003	Mar 29, 2001
TABLET, EXTENDED RELEASE; ORAL				
METHYLPHENIDATE HYDROCHLORIDE				
ABLE	20MG	A076032	001	May 09, 2001

METHYLPREDNISOLONE

TABLET; ORAL
MEDROL

PHARMACIA AND UPJOHN	2MG	N011153	002	
	24MG	N011153	005	
METHYLPREDNISOLONE				
HEATHER	4MG	A085650	001	
PAR PHARM	16MG	A089207	001	Apr 25, 1988
	24MG	A089208	001	Apr 25, 1988
	32MG	A089209	001	Apr 25, 1988
SANDOZ	4MG	A087341	001	
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL
MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	
M-PREDROL				
BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 218 (of 331)

METHYLPREDNISOLONE ACETATEOINTMENT; TOPICAL
MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%	N012421	001
	1%	N012421	002

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATECREAM; TOPICAL
NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002
	1%;EQ 3.5MG BASE/GM	A060611	001

METHYLPREDNISOLONE SODIUM SUCCINATEINJECTABLE; INJECTION
A-METHAPRED

ABBOTT	EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
	EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
	EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
	EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991
HOSPIRA	EQ 40MG BASE/VIAL	A085853	001	
	EQ 125MG BASE/VIAL	A085855	001	
	EQ 500MG BASE/VIAL	A085854	001	
	EQ 1GM BASE/VIAL	A085852	001	

METHYLPREDNISOLONE
ELKINS SINN

EQ 125MG BASE/VIAL	A086906	002	
EQ 500MG BASE/VIAL	A086906	003	
EQ 1GM BASE/VIAL	A086906	004	
EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982
EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986
ELKINS SINN	EQ 40MG BASE/VIAL	A086906	001	
INTL MEDICATION	EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983
TEVA PARENTERAL	EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992
WATSON LABS	EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATEOINTMENT; OPHTHALMIC
NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001

METHYLTESTOSTERONECAPSULE; ORAL
METHYLTESTOSTERONE

HEATHER	10MG	A084967	001	
VIRILON				
STAR PHARMS FL	10MG	A087750	001	Nov 24, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 219 (of 331)

METHYLTESTOSTERONE

TABLET; BUCCAL			
ANDROID 5			
VALEANT PHARM INTL	5MG	A087222	001
ORETON			
SCHERING	10MG	A080281	001
TABLET; BUCCAL/SUBLINGUAL			
METANDREN			
NOVARTIS	5MG	N003240	004
	10MG	N003240	005
METHYLTESTOSTERONE			
IMPAX LABS	10MG	A084287	001
LILLY	10MG	A080256	001
PUREPAC PHARM	10MG	A080308	001
	10MG	A080475	001
PVT FORM	5MG	A083836	001
TABLICAPS	10MG	A085125	001
USL PHARMA	10MG	A080271	001
TABLET; ORAL			
METANDREN			
NOVARTIS	10MG	N003240	001
	25MG	N003240	003
METHYLTESTOSTERONE			
INWOOD LABS	10MG	A080839	001
	25MG	A080973	001
KV PHARM	10MG	A084312	001
LANNETT	10MG	A087092	001
	25MG	A087111	001
LILLY	25MG	A080256	002
PARKE DAVIS	10MG	A084244	001
	25MG	A084241	001
PUREPAC PHARM	10MG	A080309	001
	10MG	A080475	002
	25MG	A080310	001
	25MG	A080475	003
PVT FORM	5MG	A080214	001
	10MG	A080214	002
	25MG	A080214	003
TABLICAPS	10MG	A080313	001
	25MG	A085270	001
WATSON LABS	10MG	A080933	001
	25MG	A080931	001
WEST WARD	10MG	A084331	001
	25MG	A084331	002
	25MG	A084642	001
ORETON METHYL			
SCHERING	10MG	N003158	001
	25MG	N003158	002

Nov 05, 1982

Jan 27, 1983

METHYPRYLON

CAPSULE; ORAL			
NOLUDAR			
ROCHE	300MG	N009660	008
ELIXIR; ORAL			
NOLUDAR			
ROCHE	50MG/5ML	N009660	007
TABLET; ORAL			
NOLUDAR			
ROCHE	50MG	N009660	002
	200MG	N009660	004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 220 (of 331)

METHYSERGIDE MALEATE

TABLET; ORAL

SANSERT

NOVARTIS

2MG

N012516 001

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

METOCLOPRAMIDE INTENSOL

ROXANE

EQ 10MG BASE/ML

A072995 001 Jan 30, 1992

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD

EQ 5MG BASE/ML

A072155 001 Mar 30, 1992

EQ 5MG BASE/ML

A072244 001 Mar 30, 1992

EQ 5MG BASE/ML

A072247 001 May 18, 1992

HOSPIRA

EQ 5MG BASE/ML

A070505 001 Jun 23, 1989

EQ 5MG BASE/ML

A070506 001 Jun 22, 1989

EQ 5MG BASE/ML

A070847 001 Nov 07, 1988

EQ 5MG BASE/ML

A071291 001 Mar 03, 1989

EQ 5MG BASE/ML

A071990 001 Jan 18, 1989

EQ 5MG BASE/ML

A074147 001 Aug 02, 1996

LYPHOMED

EQ 10MG BASE/2ML

A070293 001 Jan 24, 1986

NORBROOK

EQ 10MG BASE/2ML

A070892 001 Aug 26, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A070623 001 Mar 02, 1987

EQ 10MG BASE/2ML

A070622 001 Mar 02, 1987

REGLAN

BAXTER HLTHCARE CORP

EQ 10MG BASE/ML

N017862 004 May 28, 1987

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

EQ 5MG BASE/5ML

A071340 001 Aug 18, 1988

MORTON GROVE

EQ 5MG BASE/5ML

A070949 001 Mar 06, 1987

PACO

EQ 5MG BASE/5ML

A071665 001 Dec 05, 1988

ROXANE

EQ 5MG BASE/5ML

A072038 001 Dec 05, 1988

TEVA

EQ 5MG BASE/5ML

A070819 001 Jul 10, 1987

EQ 5MG BASE/5ML

A071315 001 Jun 30, 1993

REGLAN

ROBINS AH

EQ 5MG BASE/5ML

N018821 001 Mar 25, 1983

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS

EQ 5MG BASE

A072384 001 Jun 02, 1988

EQ 10MG BASE

A070294 001 Jul 29, 1985

CLOPRA-"YELLOW"

QUANTUM PHARMICS

EQ 10MG BASE

A070632 001 Oct 28, 1985

MAXOLON

KING PHARMS

EQ 10MG BASE

A070106 001 Mar 04, 1986

METOCLOPRAMIDE HYDROCHLORIDE

CLONMEL HLTHCARE

EQ 10MG BASE

A072639 001 May 09, 1991

HALSEY

EQ 10MG BASE

A070906 001 Oct 28, 1986

INTERPHARM

EQ 10MG BASE

A071213 001 Sep 24, 1986

MUTUAL PHARM

EQ 10MG BASE

A070660 001 Feb 10, 1987

EQ 10MG BASE

A071536 001 Apr 28, 1993

PAR PHARM

EQ 10MG BASE

A070342 001 Mar 25, 1986

SANDOZ

EQ 5MG BASE

A072436 001 Jun 22, 1989

EQ 5MG BASE

A074478 001 Oct 05, 1995

EQ 10MG BASE

A070850 001 Feb 03, 1987

EQ 10MG BASE

A072215 001 Jan 30, 1990

EQ 10MG BASE

A074478 002 Oct 05, 1995

SCHERING

EQ 10MG BASE

A070598 001 Feb 02, 1987

SUPERPHARM

EQ 10MG BASE

A070926 001 Jun 26, 1987

USL PHARMA

EQ 10MG BASE

A070339 001 Jul 29, 1985

WATSON LABS

EQ 10MG BASE

A070363 001 Mar 02, 1987

EQ 10MG BASE

A070453 001 Jun 06, 1986

EQ 10MG BASE

A070511 001 Jan 22, 1986

EQ 10MG BASE

A070645 001 May 11, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 221 (of 331)

METOCLOPRAMIDE HYDROCHLORIDETABLET, ORALLY DISINTEGRATING; ORAL
REGLAN ODT

ALAVEN PHARM	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005

METOCURINE IODIDE

INJECTABLE; INJECTION

METUBINE IODIDE

LILLY	2MG/ML	N006632	003	

METOLAZONETABLET; ORAL
DIULO

GD SEARLE LLC	2.5MG	N018535	001	
	5MG	N018535	002	
	10MG	N018535	003	

METOLAZONE

ROXANE	10MG	A076482	002	Apr 29, 2004

WATSON LABS	10MG	A076891	001	Jul 21, 2004

MYKROX

UCB INC	0.5MG	N019532	001	Oct 30, 1987

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL

LOPRESSOR

NOVARTIS	EQ 100MG TARTRATE	N019786	001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786	002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786	003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786	004	Dec 27, 1989

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

APOTHECON	50MG	A074258	001	Jan 27, 1994
	100MG	A074258	002	Jan 27, 1994
MYLAN	50MG	A073666	001	Dec 21, 1993
	100MG	A073666	002	Dec 21, 1993
PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
	100MG	A074380	002	Jul 29, 1994
SOLCO HLTHCARE	50MG	A074453	001	Apr 27, 1995
	100MG	A074453	002	Apr 27, 1995
TEVA	50MG	A074143	001	Sep 30, 1994
	100MG	A074143	002	Sep 30, 1994
TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
	100MG	A074333	002	Jan 27, 1994

METRIZAMIDE

INJECTABLE; INJECTION

AMIPAQUE

GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

ABLE	375MG	A076505	001	Nov 13, 2003

INJECTABLE; INJECTION

METRO I.V.

B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982

METRONIDAZOLE

ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 222 (of 331)

METRONIDAZOLE

INJECTABLE; INJECTION

METRONIDAZOLE

ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
ELKINS SINN	500MG/100ML	N018907	001	Mar 30, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986

TABLET; ORAL

METROMIDOL

LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996

METRONIDAZOLE

ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517	001	
	500MG	N018517	002	May 05, 1982
LNK	250MG	N019029	001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
PAR PHARM	250MG	N018845	001	Aug 18, 1983
	500MG	N018930	001	Aug 18, 1983
SANDOZ	250MG	N018620	001	Mar 04, 1982
	250MG	N018740	001	Oct 22, 1982
	500MG	N018620	002	Jun 02, 1983
	500MG	N018740	002	Oct 22, 1982
SUPERPHARM	250MG	A070008	001	Dec 11, 1984
	500MG	A070009	001	Dec 11, 1984
WATSON LABS	250MG	N018599	001	Sep 17, 1982
	500MG	N018599	002	Feb 13, 1984
WORLD GEN	250MG	A070040	001	Jan 29, 1985
	500MG	A070039	001	Jan 29, 1985
PROTOSTAT				
ORTHO MCNEIL PHARM	250MG	N018871	001	Mar 02, 1983
	500MG	N018871	002	Mar 02, 1983
SATRIC				
SAVAGE LABS	250MG	A070029	001	Mar 19, 1985
	500MG	A070731	001	Jun 08, 1987
TABLET, EXTENDED RELEASE; ORAL				
METRONIDAZOLE				
ABLE	750MG	A076462	001	Jun 25, 2003

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295	001	Oct 15, 1985

METYRAPONE

TABLET; ORAL

METOPIRONE

NOVARTIS	250MG	N012911	001	

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

SANDOZ	150MG	A074450	001	May 16, 1996
	200MG	A074450	002	May 16, 1996
	250MG	A074450	003	May 16, 1996
MEXITIL				
BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985
	200MG	N018873	003	Dec 30, 1985
	250MG	N018873	004	Dec 30, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 223 (of 331)

MEZLOCILLIN SODIUM MONOHYDRATEINJECTABLE; INJECTION
MEZLIN

BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988

MICONAZOLEINJECTABLE; INJECTION
MONISTAT

JANSSEN PHARMA	10MG/ML	N018040	001	

MICONAZOLE NITRATECREAM; TOPICAL
MONISTAT-DERM

ORTHONEUTROGENA	2%	N017494	001	

CREAM; VAGINAL
MICONAZOLE NITRATE

TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992

LOTION; TOPICAL
MONISTAT-DERM

JOHNSON AND JOHNSON	2%	N017739	001	

TAMPON; VAGINAL
MONISTAT 5

PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989

MIDAZOLAM HYDROCHLORIDEINJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
ASTRAZENECA	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000

VERSED

HLR	EQ 1MG BASE/ML	N018654	002	May 26, 1987
	EQ 5MG BASE/ML	N018654	001	Dec 20, 1985

SYRUP; ORAL
VERSED

ROCHE	EQ 2MG BASE/ML	N020942	001	Oct 15, 1998

MILRINONE LACTATEINJECTABLE; INJECTION
MILRINONE LACTATE

BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075852	001	May 28, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 224 (of 331)

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

BIONICHE PHARMA EQ 1MG BASE/ML A076428 001 Jun 16, 2003

HOSPIRA EQ 1MG BASE/ML A075830 001 May 28, 2002

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) A075510 001 May 28, 2002

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) A076259 001 Aug 08, 2002

PRIMACOR

SANOFI AVENTIS US EQ 1MG BASE/ML N019436 001 Dec 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

SANOFI AVENTIS US EQ 10MG BASE/100ML N020343 001 Aug 09, 1994

EQ 15MG BASE/100ML N020343 002 Aug 09, 1994

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) N020343 003 Aug 09, 1994

EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) N020343 004 Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

MEDICIS EQ 50MG BASE A063066 001 Aug 14, 1990

MINOCIN

TRIAx PHARMS EQ 50MG BASE N050315 002

EQ 100MG BASE N050315 001

TRIAx PHARMS LLC EQ 75MG BASE N050649 003 Feb 12, 2001

INJECTABLE; INJECTION

MINOCIN

LEDERLE EQ 100MG BASE/VIAL A062139 001

SUSPENSION; ORAL

MINOCIN

TRIAx PHARMS EQ 50MG BASE/5ML N050445 001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

TRIAx PHARMS EQ 50MG BASE N050451 003 Aug 10, 1982

EQ 100MG BASE N050451 002 Aug 10, 1982

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

BAUSCH AND LOMB 2% A074643 001 Apr 09, 1996

COPLEY PHARM 2% A074500 001 May 23, 1996

SIGHT PHARMS 2% A074743 002 Oct 18, 1996

TEVA 2% A074589 001 Apr 05, 1996

MINOXIDIL (FOR WOMEN)

SIGHT PHARMS 2% A074743 001 Oct 18, 1996

TABLET; ORAL

LONITEN

PHARMACIA AND UPJOHN 2.5MG N018154 001

10MG N018154 003

MINODYL

QUANTUM PHARMICS 2.5MG A072153 001 Jul 13, 1988

10MG A071534 001 Mar 19, 1987

MINOXIDIL

ROYCE LABS 2.5MG A071799 001 Nov 10, 1987

10MG A071796 001 Nov 10, 1987

USL PHARMA 2.5MG A071537 001 Dec 16, 1988

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

IVAX SUB TEVA PHARMS 15MG A076244 001 Dec 22, 2003

30MG A076244 002 Dec 22, 2003

45MG A076244 003 Dec 22, 2003

ROXANE 15MG A076270 001 Jun 19, 2003

30MG A076270 002 Jun 19, 2003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 225 (of 331)

MIRTAZAPINETABLET; ORAL
MIRTAZAPINE

ROXANE	45MG	A076270	003	Jun 19, 2003
SANDOZ	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003

MITOMYCININJECTABLE; INJECTION
MITOMYCIN

HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995
MITOZYTREX				
SUPERGEN	5MG/VIAL	N050763	001	Nov 14, 2002
MUTAMYCIN				
BRISTOL	5MG/VIAL	N050450	001	
	20MG/VIAL	N050450	002	
BRISTOL MYERS	5MG/VIAL	A062336	001	
	20MG/VIAL	A062336	002	
	40MG/VIAL	A062336	003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDEINJECTABLE; INJECTION
NOVANTRONE

EMD SERONO	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	N019297	002	Dec 23, 1987
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N019297	003	Dec 23, 1987

MIVACURIUM CHLORIDEINJECTABLE; INJECTION
MIVACRON

ABBOTT	EQ 2MG BASE/ML	N020098	001	Jan 22, 1992
MIVACRON IN DEXTROSE 5%	IN PLASTIC CONTAINER			
ABBOTT	EQ 0.5MG BASE/ML	N020098	002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098	003	Jan 22, 1992
MIVACURIUM CHLORIDE				
PISGAH LABS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009

MOLINDONE HYDROCHLORIDECAPSULE; ORAL
MOBAN

ENDO PHARMS	5MG	N017111	001	
	10MG	N017111	002	
	25MG	N017111	003	

CONCENTRATE; ORAL
MOBAN

ENDO PHARMS	20MG/ML	N017938	001	

TABLET; ORAL
MOBAN

ENDO PHARMS	5MG	N017111	004	
	10MG	N017111	005	
	25MG	N017111	006	
	50MG	N017111	007	
	100MG	N017111	008	

MONOBENZONECREAM; TOPICAL
BENOQUIN

VALEANT PHARM INTL	20%	N008173	003	

MONOCTANOINLIQUID; PERFUSION, BILIARY
MOCTANIN

ETHITEK	100%	N019368	001	Oct 29, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 226 (of 331)

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

ETHMOZINE

SHIRE

200MG

N019753 001 Jun 19, 1990

250MG

N019753 002 Jun 19, 1990

300MG

N019753 003 Jun 19, 1990

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

HOSPIRA

0.5MG/ML

N019917 001 Oct 30, 1992

MALLINCKRODT

1MG/ML

N020631 001 Jul 03, 1996

2MG/ML

N020631 002 Jul 03, 1996

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

EKR THERAP

20MG/2ML (10MG/ML)

N021671 003 May 18, 2004

MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

LILLY

EQ 250MG BASE/VIAL

N050550 001

EQ 500MG BASE/VIAL

N050550 002

EQ 1GM BASE/VIAL

N050550 003

EQ 2GM BASE/VIAL

N050550 004

EQ 10GM BASE/VIAL

N050550 008

NABUMETONE

TABLET; ORAL

NABUMETONE

COPLEY PHARM

750MG

A075179 001 Jun 06, 2000

SANDOZ

500MG

A075590 001 Feb 25, 2002

750MG

A075590 002 Feb 25, 2002

RELAFEN

SMITHKLINE BEECHAM

500MG

N019583 001 Dec 24, 1991

750MG

N019583 002 Dec 24, 1991

NADOLOL

TABLET; ORAL

CORGARD

KING PHARMS

120MG

N018063 003

160MG

N018063 004

NADOLOL

IVAX SUB TEVA PHARMS

120MG

A074255 002 Jan 24, 1996

160MG

A074255 003 Jan 24, 1996

TEVA PHARMS

80MG

A074368 001 Aug 31, 1994

120MG

A074368 002 Aug 31, 1994

160MG

A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE

N050111 001

FOR SOLUTION; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE/5ML

N050199 001

INJECTABLE; INJECTION

NAFCILLIN SODIUM

APOTHECON

EQ 500MG BASE/VIAL

A061984 001

EQ 1GM BASE/VIAL

A061984 002

EQ 2GM BASE/VIAL

A061984 003

EQ 4GM BASE/VIAL

A061984 005

MARSAM PHARMS LLC

EQ 500MG BASE/VIAL

A062844 001 Oct 26, 1988

EQ 1GM BASE/VIAL

A062844 002 Oct 26, 1988

EQ 1.5GM BASE/VIAL

A062844 003 Oct 26, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 227 (of 331)

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

MARSAM PHARMS LLC

EQ 2GM BASE/VIAL

A062844 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062844 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A063008 001 Sep 29, 1988

SANDOZ

EQ 500MG BASE/VIAL

A062527 001 Aug 02, 1984

NALLPEN

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

A061999 001

EQ 1GM BASE/VIAL

A061999 002

EQ 1GM BASE/VIAL

A062755 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A061999 003

EQ 2GM BASE/VIAL

A062755 002 Dec 19, 1986

EQ 10GM BASE/VIAL

A061999 004

UNIPEN

WYETH AYERST

EQ 500MG BASE/VIAL

A062717 001 Dec 16, 1986

EQ 500MG BASE/VIAL

N050320 001

EQ 1GM BASE/VIAL

A062717 002 Dec 16, 1986

EQ 2GM BASE/VIAL

A062717 004 Dec 16, 1986

EQ 2GM BASE/VIAL

N050320 003

EQ 4GM BASE/VIAL

N050320 004

EQ 10GM BASE/VIAL

N050320 005

EQ 20GM BASE/VIAL

N050320 006

UNIPEN IN PLASTIC CONTAINER

WYETH AYERST

EQ 1GM BASE/VIAL

N050320 002

TABLET; ORAL

UNIPEN

WYETH AYERST

EQ 500MG BASE

N050462 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM

10MG/ML

A070751 001 Jul 02, 1986

20MG/ML

A070752 001 Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT

1.5MG/ML

N020200 001 Mar 12, 1993

20MG/ML

A070917 001 Feb 03, 1989

ASTRAZENECA

10MG/ML

A072070 001 Apr 10, 1989

10MG/ML

A072071 001 Apr 10, 1989

10MG/ML

A072072 001 Apr 10, 1989

20MG/ML

A072073 001 Apr 10, 1989

20MG/ML

A072074 001 Apr 10, 1989

20MG/ML

A072075 001 Apr 10, 1989

BARR

10MG/ML

A074471 001 Mar 19, 1998

20MG/ML

A074471 002 Mar 19, 1998

NUBAIN

ENDO PHARMS

10MG/ML

N018024 001

20MG/ML

N018024 002 May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US

250MG/5ML

N017430 001

TABLET; ORAL

NALIDIXIC ACID

MUTUAL PHARM

250MG

A070270 001 Jun 29, 1988

500MG

A070271 001 Jun 29, 1988

1GM

A070272 001 Jun 29, 1988

WATSON LABS

250MG

A071936 001 Jun 29, 1988

500MG

A072061 001 Jun 29, 1988

1GM

A071919 001 Jun 29, 1988

NEGGRAM

SANOFI AVENTIS US

250MG

N014214 002

500MG

N014214 004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 228 (of 331)

NALIDIXIC ACIDTABLET; ORAL
NEGGRAM

SANOFI AVENTIS US

1GM

N014214 005

NALMEFENE HYDROCHLORIDEINJECTABLE; INJECTION
REVEX

BAXTER HLTHCARE CORP

EQ 0.1MG BASE/ML
EQ 1MG BASE/MLN020459 001 Apr 17, 1995
N020459 002 Apr 17, 1995NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE

BAXTER HLTHCARE

0.4MG/ML
0.4MG/ML
0.4MG/ML
0.02MG/ML
0.02MG/ML
0.4MG/ML
0.4MG/MLA070298 001 Sep 24, 1986
A070299 001 Sep 24, 1986
A070496 001 Sep 24, 1986
A070188 001 Sep 24, 1986
A070189 001 Sep 24, 1986
A070190 001 Sep 24, 1986
A070191 001 Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM

0.02MG/ML
0.02MG/ML
0.4MG/ML
1MG/MLA070648 001 Nov 17, 1986
A070661 001 Nov 17, 1986
A070649 001 Nov 17, 1986
A071604 001 Dec 16, 1988

ASTRAZENECA

0.02MG/ML
0.02MG/ML
0.02MG/ML
0.02MG/ML
0.02MG/ML
0.4MG/ML
0.4MG/ML
0.4MG/ML
0.4MG/ML
0.4MG/ML
1MG/ML
1MG/ML
1MG/MLA072081 001 Apr 11, 1989
A072082 001 Apr 11, 1989
A072083 001 Apr 11, 1989
A072084 001 Apr 11, 1989
A072085 001 Apr 11, 1989
A072086 001 Apr 11, 1989
A072087 001 Apr 11, 1989
A072088 001 Apr 11, 1989
A072089 001 Apr 11, 1989
A072090 001 Apr 11, 1989
A072091 001 Apr 11, 1989
A072092 001 Apr 11, 1989
A072093 001 Apr 11, 1989

BAXTER HLTHCARE

0.02MG/ML
1MG/ML
1MG/ML
1MG/MLA071272 001 May 24, 1988
A071273 001 May 24, 1988
A071274 001 May 24, 1988
A071287 001 May 24, 1988

HOSPIRA

0.02MG/ML
0.02MG/ML
0.02MG/ML
0.4MG/MLA070171 001 Sep 24, 1986
A070252 001 Jan 16, 1987
A070253 001 Jan 16, 1987
A070255 001 Jan 07, 1987

INTL MEDICATION

0.4MG/ML
1MG/MLA070417 001 Sep 24, 1986
A072115 001 Apr 27, 1988

MARSAM PHARMS LLC

0.4MG/ML

A071811 001 Jul 19, 1988

SMITH AND NEPHEW

0.02MG/ML
0.4MG/ML
0.4MG/MLA071671 001 Nov 17, 1987
A071681 001 Nov 17, 1987
A071682 001 Nov 17, 1987

SOLOPAK

0.02MG/ML
0.4MG/MLA071672 001 Nov 17, 1987
A071683 001 Nov 17, 1987

WATSON LABS

0.4MG/ML

A071339 001 Nov 18, 1987

NARCAN

BRISTOL MYERS SQUIBB

0.4MG/ML
1MG/ML
1MG/MLA071083 001 Jul 28, 1988
A071084 001 Jul 28, 1988
A071311 001 Jul 28, 1988

ENDO PHARMS

0.02MG/ML
0.4MG/ML
1MG/MLN016636 002
N016636 001
N016636 003 Jun 14, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 229 (of 331)

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN NX

SANOFI AVENTIS US

EQ 0.5MG BASE;EQ 50MG BASE

N018733 001

Dec 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

ORGANON USA INC

50MG/ML

N013132 001

Jun 12, 1986

100MG/ML

N013132 002

Jun 12, 1986

200MG/ML

N013132 003

Jun 12, 1986

NANDROLONE DECANOATE

ABRAXIS PHARM

100MG/ML

A088290 001

Oct 03, 1983

200MG/ML

A088317 001

Oct 14, 1983

AKORN

100MG/ML

A087519 001

Sep 28, 1983

WATSON LABS

50MG/ML

A086385 001

Jan 13, 1984

50MG/ML

A087598 001

Oct 06, 1983

50MG/ML

A088554 001

Feb 10, 1986

100MG/ML

A086598 001

Jan 13, 1984

100MG/ML

A087599 001

Oct 06, 1983

200MG/ML

A088128 001

Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

ORGANON USA INC

25MG/ML

N011891 001

50MG/ML

N011891 002

NANDROLONE PHENPROPIONATE

WATSON LABS

25MG/ML

A086386 001

Jun 17, 1983

50MG/ML

A087488 001

Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAFAZAIR

BAUSCH AND LOMB

0.1%

A040073 001

May 25, 1994

PHARMAFAIR

0.1%

A088101 001

Apr 15, 1983

NAPHCON FORTE

ALCON

0.1%

A080229 001

OPCON

BAUSCH AND LOMB

0.1%

A087506 001

VASOCON

NOVARTIS

0.1%

A080235 002

Mar 24, 1983

NAPROXEN

TABLET; ORAL

NAPROXEN

DAVA PHARMS INC

250MG

A074105 001

Dec 21, 1993

375MG

A074105 002

Dec 21, 1993

500MG

A074105 003

Dec 21, 1993

HAMILTON PHARMS

250MG

A074110 001

Oct 30, 1992

375MG

A074110 002

Oct 30, 1992

500MG

A074110 003

Oct 30, 1992

IVAX SUB TEVA PHARMS

250MG

A074111 001

Feb 28, 1995

375MG

A074111 002

Feb 28, 1995

500MG

A074111 003

Feb 28, 1995

PLIVA

250MG

A074182 001

Jun 27, 1996

375MG

A074182 002

Jun 27, 1996

500MG

A074182 003

Jun 27, 1996

PUREPAC PHARM

250MG

A074263 001

Dec 21, 1993

375MG

A074263 002

Dec 21, 1993

500MG

A074263 003

Dec 21, 1993

ROXANE

250MG

A074211 001

Feb 28, 1994

375MG

A074211 002

Feb 28, 1994

500MG

A074211 003

Feb 28, 1994

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 230 (of 331)

NAPROXENTABLET; ORAL
NAPROXEN

TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993
WATSON LABS	250MG	A074163	001	Feb 10, 1995
	375MG	A074163	002	Feb 10, 1995
	500MG	A074163	003	Feb 10, 1995

NAPROXEN SODIUMTABLET; ORAL
NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544	001	Aug 22, 2003
	EQ 500MG BASE	A076544	002	Aug 22, 2003
HAMILTON PHARMS	EQ 250MG BASE	A074106	001	Aug 31, 1993
	EQ 500MG BASE	A074106	002	Aug 31, 1993
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230	001	Mar 14, 1995
	EQ 500MG BASE	A074230	002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367	001	Aug 31, 1994
	EQ 500MG BASE	A074367	002	Aug 31, 1994
PLIVA	EQ 250MG BASE	A074242	001	Jun 20, 1996
	EQ 500MG BASE	A074242	002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319	001	Mar 20, 1995
	EQ 500MG BASE	A074319	002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257	001	Dec 21, 1993
	EQ 500MG BASE	A074257	002	Dec 21, 1993
SANDOZ	EQ 250MG BASE	A074162	001	Dec 21, 1993
	EQ 250MG BASE	A074495	001	Dec 05, 1994
	EQ 500MG BASE	A074162	002	Dec 21, 1993
	EQ 500MG BASE	A074495	002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142	001	Dec 21, 1993
	EQ 500MG BASE	A074142	002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289	001	Jan 27, 1994
	EQ 500MG BASE	A074289	002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195	001	Dec 21, 1993
	EQ 500MG BASE	A074195	002	Dec 21, 1993
TABLET, EXTENDED RELEASE; ORAL NAPROXEN SODIUM				
WATSON LABS FLORIDA	EQ 375MG BASE	A075416	002	Apr 23, 2003
	EQ 500MG BASE	A075416	001	Aug 27, 2002

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS	1.75MG/INH	N019660	001	Dec 30, 1992

SOLUTION; INHALATION

TILADE

SANOFI AVENTIS US	0.5%	N020750	001	Oct 01, 1997

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	50MG	A075763	001	Sep 16, 2003
	100MG	A075763	002	Sep 16, 2003
	150MG	A075763	003	Sep 16, 2003
	200MG	A075763	004	Sep 16, 2003
	250MG	A075763	005	Sep 16, 2003

DISCONTINUED DRUG PRODUCT LIST

6 - 231 (of 331)

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

MYLAN	100MG	A076129	002	Sep 16, 2003
	150MG	A076129	003	Sep 16, 2003
	200MG	A076129	004	Sep 16, 2003
	250MG	A076129	005	Sep 16, 2003
	50MG	A076196	001	Sep 16, 2003
ROXANE	100MG	A076196	002	Sep 16, 2003
	150MG	A076196	003	Sep 16, 2003
	200MG	A076196	004	Sep 16, 2003
	250MG	A076196	005	Sep 16, 2003
	50MG	A076072	001	Sep 16, 2003
SANDOZ	50MG	A076302	001	Sep 16, 2003
	100MG	A076072	002	Sep 16, 2003
	100MG	A076302	002	Sep 16, 2003
	150MG	A076072	003	Sep 16, 2003
	150MG	A076302	003	Sep 16, 2003
	200MG	A076072	004	Sep 16, 2003
	200MG	A076302	004	Sep 16, 2003
	250MG	A076072	005	Sep 16, 2003
	250MG	A076302	005	Sep 16, 2003
	100MG	A076073	002	Sep 16, 2003
	150MG	A076073	003	Sep 16, 2003
	200MG	A076073	004	Sep 16, 2003
	250MG	A076073	005	Sep 16, 2003
	50MG	N020152	001	Dec 22, 1994
	100MG	N020152	002	Dec 22, 1994
	150MG	N020152	003	Dec 22, 1994
	200MG	N020152	004	Dec 22, 1994
	250MG	N020152	005	Dec 22, 1994
	300MG	N020152	006	Dec 22, 1994

SERZONE

BRISTOL MYERS SQUIBB

NEOMYCIN SULFATE

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN EQ 87.5MG BASE/5ML

N050285 001

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN EQ 350MG BASE

A060520 001

NEOBIOTIC

PFIZER EQ 350MG BASE

A060475 001

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB 500MG

A060365 001

LANNETT 500MG

A060607 001

LILLY 500MG

A060385 001

ROXANE 500MG

A062173 001

SANDOZ 500MG

A061586 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050176 002 Jan 14, 1985

OINTMENT; OPHTHALMIC

STATROL

ALCON EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050344 002

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON EQ 3.5MG BASE/ML;16,250 UNITS/ML

A062339 001 Nov 30, 1984

EQ 3.5MG BASE/ML;16,250 UNITS/ML

N050456 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 232 (of 331)

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC			
NEO-DELTA-CORTEF			
PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039	002
	EQ 3.5MG BASE/GM;0.5%	A061039	001
SUSPENSION/DROPS; OPHTHALMIC			
NEO-DELTA-CORTEF			
PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037	001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC			
NEO-HYDELTRASOL			
MERCK	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N050378	001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL			
MYTREX A			
SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062598	001 Jul 21, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE			
FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062600	001 Jul 21, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062595	001 Jul 21, 1986
OINTMENT; TOPICAL			
MYTREX A			
SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062609	001 May 23, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE			
FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062608	001 May 23, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062607	001 May 23, 1986

NETILMICIN SULFATE

INJECTABLE; INJECTION			
NETROMYCIN			
SCHERING	EQ 10MG BASE/ML	N050544	001 Feb 28, 1983
	EQ 25MG BASE/ML	N050544	002 Feb 28, 1983
	EQ 100MG BASE/ML	N050544	003 Feb 28, 1983

NIACIN

CAPSULE; ORAL			
WAMPOCAP			
MEDPOINTE PHARM HLC	500MG	N011073	003
TABLET; ORAL			
NIACIN			
EVERYLIFE	500MG	A083203	001
HALSEY	500MG	A083453	001
IMPAX LABS	500MG	A083115	001
IVAX SUB TEVA PHARMS	500MG	A083180	001
MK LABS	500MG	A083525	001
PUREPAC PHARM	500MG	A083271	001
SANDOZ	500MG	A083306	001
TABLICAPS	500MG	A084237	001
WATSON LABS	500MG	A083136	001
	500MG	A083305	001
	500MG	A085172	001
WEST WARD	500MG	A083718	001
NICOLAR			
SANOFI AVENTIS US	500MG	A083823	001
TABLET, EXTENDED RELEASE; ORAL			
NIACIN			
BARR	500MG	A076378	001 Apr 26, 2005
	750MG	A076378	002 Apr 26, 2005
	1GM	A076250	001 Apr 14, 2005
NIASPAN			
ABBOTT	375MG	N020381	001 Jul 28, 1997
NIASPAN TITRATION STARTER PACK			
ABBOTT	375MG;500MG;750MG	N020381	005 Jul 28, 1997

DISCONTINUED DRUG PRODUCT LIST

6 - 233 (of 331)

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL

TPN

INTL MINERALS

15MG/5ML;3.75MG/5ML;600MG/5ML

N008378 003

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

NICLOCIDE

BAYER PHARMS

500MG

N018669 001 May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL

MCNEIL CONS

15MG/16HR

N020536 001 Jul 03, 1996

PROSTEP

AVEVA

11MG/24HR

N019983 003 Dec 23, 1998

22MG/24HR

N019983 004 Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

WATSON LABS

EQ 2MG BASE

A076568 001 Jul 29, 2004

EQ 4MG BASE

A076569 002 Jul 29, 2004

NIFEDIPINE

CAPSULE; ORAL

ADALAT

BAYER PHARMS

10MG

N019478 001 Nov 27, 1985

20MG

N019478 002 Sep 17, 1986

NIFEDIPINE

CATALENT

20MG

A074045 001 Apr 30, 1992

CHASE LABS NJ

10MG

A072409 001 Jul 04, 1990

20MG

A073421 001 Jun 19, 1991

TEVA

10MG

A072651 001 Feb 19, 1992

PROCARDIA

PFIZER

20MG

N018482 002 Jul 24, 1986

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

MARTEC USA LLC

90MG

A075414 003 Mar 23, 2004

MYLAN

30MG

A075108 001 Dec 17, 1999

NILUTAMIDE

TABLET; ORAL

NILANDRON

SANOFI AVENTIS US

50MG

N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE; ORAL

NIMOTOP

BAYER PHARMS

30MG

N018869 001 Dec 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

SHIONOGI PHARMA

10MG

N020356 001 Feb 02, 1995

20MG

N020356 002 Feb 02, 1995

30MG

N020356 003 Feb 02, 1995

40MG

N020356 004 Feb 02, 1995

NITROFURANTOIN

CAPSULE; ORAL

NITROFURANTOIN

WATSON LABS

50MG

A084326 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 234 (of 331)

NITROFURANTOIN

CAPSULE; ORAL			
NITROFURANTOIN			
WATSON LABS	100MG	A084326	002
TABLET; ORAL			
FURADANTIN			
PROCTER AND GAMBLE	50MG	N008693	001
	100MG	N008693	002
FURALAN			
LANNETT	50MG	A080017	001
	100MG	A080017	002
NITROFURANTOIN			
ELKINS SINN	50MG	A080003	001
	100MG	A080003	002
IVAX SUB TEVA PHARMS	50MG	A080078	002
	100MG	A080078	001
SANDOZ	50MG	A080043	001
	100MG	A080043	002
WATSON LABS	50MG	A080447	001
	50MG	A085797	001
	100MG	A080447	002
	100MG	A085796	001
WHITEWORTH TOWN PLSN	100MG	A084085	002

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION			
IVADANTIN			
PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N012402	001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL			
NITROFURANTOIN			
MYLAN	100MG	A074967	002 Jul 09, 1997
SANDOZ	25MG	A074336	001 Jan 25, 1995
	50MG	A074336	002 Jan 25, 1995
	100MG	A074336	003 Jan 25, 1995
NITROFURANTOIN MACROCRYSTALLINE			
WATSON LABS	50MG	A070248	001 Jun 24, 1988
	100MG	A070249	001 Jun 24, 1988

NITROFURAZONE

CREAM; TOPICAL			
FURACIN			
SHIRE	0.2%	A083789	001
DRESSING; TOPICAL			
ACTIN-N			
SHERWOOD MEDCL	0.2%	N017343	001
OINTMENT; TOPICAL			
FURACIN			
SHIRE	0.2%	N005795	001
NITROFURAZONE			
AMBIX	0.2%	A086077	001
LANNETT	0.2%	A084393	001
PERRIGO NEW YORK	0.2%	A084968	001
TARO	0.2%	A086156	001
WENDT	0.2%	A086766	001
POWDER; TOPICAL			
FURACIN			
SHIRE	0.2%	A083791	001
SOLUTION; TOPICAL			
NITROFURAZONE			
PERRIGO NEW YORK	0.2%	A085130	001
WENDT	0.2%	A087081	001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 235 (of 331)

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

POHL BOSKAMP

0.4MG/SPRAY

N018705

001

Oct 31, 1985

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

MYLAN TECHNOLOGIES

0.1MG/HR

A074992

004

Nov 12, 1999

0.2MG/HR

A074992

003

Nov 12, 1999

0.4MG/HR

A074992

002

Nov 12, 1999

0.6MG/HR

A074992

001

Nov 12, 1999

TRANSDERM-NITRO

NOVARTIS

0.1MG/HR

N020144

001

Feb 27, 1996

0.2MG/HR

N020144

002

Feb 27, 1996

0.4MG/HR

N020144

003

Feb 27, 1996

0.6MG/HR

N020144

004

Feb 27, 1996

0.8MG/HR

N020144

005

Feb 27, 1996

INJECTABLE; INJECTION

NITRO IV

POHL BOSKAMP

5MG/ML

N018672

002

Aug 30, 1983

NITRO-BID

SANOFI AVENTIS US

5MG/ML

N018621

001

Jan 05, 1982

10MG/ML

A071159

001

Feb 28, 1990

NITROGLYCERIN

ABRAXIS PHARM

5MG/ML

A070077

001

Dec 13, 1985

5MG/ML

A071203

001

May 08, 1987

INTL MEDICATION

5MG/ML

A070026

001

Sep 10, 1985

LUITPOLD

5MG/ML

A071492

001

May 24, 1988

SMITH AND NEPHEW

5MG/ML

A070633

001

Jun 19, 1986

5MG/ML

A070634

001

Jun 19, 1986

NITROGLYCERIN IN DEXTROSE 5%

HOSPIRA

0.1MG/ML

A074083

001

Oct 26, 1994

NITROL

RORER

0.8MG/ML

N018774

001

Jan 19, 1983

NITRONAL

POHL BOSKAMP

1MG/ML

N018672

001

Aug 30, 1983

NITROSTAT

PARKE DAVIS

0.8MG/ML

N018588

001

5MG/ML

A070863

001

Jan 08, 1987

5MG/ML

N018588

002

Dec 23, 1983

10MG/ML

A070871

001

Jan 08, 1987

10MG/ML

A070872

001

Jan 08, 1987

TRIDIL

HOSPIRA

0.5MG/ML

N018537

002

Jun 16, 1983

5MG/ML

N018537

001

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

IVAX SUB TEVA PHARMS

150MG

A075461

001

Jul 08, 2002

300MG

A075461

002

Jul 08, 2002

NONOXYNOL -9

AEROSOL; VAGINAL

Delfen

PERSONAL PRODS

12.5%

N014349

002

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM

EQ 1MG BASE/ML

A040522

001

Sep 30, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 236 (of 331)

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
RAVOCAINE AND NOVOCAIN W/ LEVOPHED				
EASTMAN KODAK	EQ 0.033MG BASE/ML;2%;0.4%	N008592	003	

NORETHINDRONE

TABLET; ORAL				
NORLUTIN				
PARKE DAVIS	5MG	N010895	002	

NORETHINDRONE ACETATE

TABLET; ORAL				
NORLUTATE				
PARKE DAVIS	5MG	N012184	002	

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC				
CHIBROXIN				
MERCK	0.3%	N019757	001	Jun 17, 1991

NORGESTREL

TABLET; ORAL				
OVRETTE				
WYETH PHARMS INC	0.075MG	N017031	001	

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL				
AVENTYL HYDROCHLORIDE				
LILLY	EQ 10MG BASE	N014684	001	
	EQ 25MG BASE	N014684	002	
NORTRIPTYLINE HYDROCHLORIDE				
SANDOZ	EQ 10MG BASE	A074054	001	Dec 31, 1992
	EQ 10MG BASE	A074835	001	Jun 30, 1997
	EQ 25MG BASE	A074054	002	Dec 31, 1992
	EQ 25MG BASE	A074835	002	Jun 30, 1997
	EQ 50MG BASE	A074054	003	Dec 31, 1992
	EQ 50MG BASE	A074835	003	Jun 30, 1997
	EQ 75MG BASE	A074054	004	Dec 31, 1992
	EQ 75MG BASE	A074835	004	Jun 30, 1997
TEVA	EQ 10MG BASE	A073667	001	Apr 11, 1996
	EQ 25MG BASE	A073667	002	Apr 11, 1996
	EQ 50MG BASE	A073667	003	Apr 11, 1996
	EQ 75MG BASE	A073667	004	Apr 11, 1996

NYSTATIN

CREAM; TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/GM	A061810	001	
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062387	001	Jul 29, 1982
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061445	001	
NYSTATIN				
TARO	100,000 UNITS/GM	A062457	001	Jul 28, 1983
TEVA	100,000 UNITS/GM	A061966	001	
LOTION; TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/ML	N050233	001	
OINTMENT; TOPICAL				
MYCOSTATIN				
WESTWOOD SQUIBB	100,000 UNITS/GM	A060571	001	
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062731	001	Sep 22, 1986

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 237 (of 331)

NYSTATIN

OINTMENT; TOPICAL

NILSTAT

LEDERLE

100,000 UNITS/GM

A061444 001

PASTILLE; ORAL

MYCOSTATIN

BRISTOL MYERS SQUIBB

200,000 UNITS

N050619 001 Apr 09, 1987

POWDER; ORAL

BARSTATIN 100

BARLAN

100%

A062489 001 Apr 27, 1988

NILSTAT

DAVA PHARMS INC

100%

N050576 001 Dec 22, 1983

NYSTATIN

PADDOCK

100%

A062613 001 Nov 26, 1985

SUPPOSITORY; VAGINAL

NYSERT

WARNER CHILCOTT

100,000 UNITS

N050478 001

SUSPENSION; ORAL

MYCOSTATIN

APOTHECON

100,000 UNITS/ML

A061533 001

NYSTATIN

ALPHARMA US PHARMS

100,000 UNITS/ML

A062571 001 Oct 29, 1985

MORTON GROVE

100,000 UNITS/ML

A062835 001 Nov 19, 1987

PHARMADERM

100,000 UNITS/ML

A062518 001 Jul 06, 1984

PHARMAFAIR

100,000 UNITS/ML

A062541 001 Jan 16, 1985

ROXANE

100,000 UNITS/ML

A062832 001 Dec 27, 1991

TEVA

100,000 UNITS/ML

A062670 001 Jun 18, 1987

100,000 UNITS/ML

A062776 001 Dec 17, 1987

NYSTEX

SAVAGE LABS

100,000 UNITS/ML

A062519 001 Jul 06, 1984

TABLET; ORAL

MYCOSTATIN

BRISTOL MYERS SQUIBB

500,000 UNITS

A060574 001

NILSTAT

LEDERLE

500,000 UNITS

A061151 001

NYSTATIN

HERITAGE PHARMS INC

500,000 UNITS

A062474 001 Dec 22, 1983

QUANTUM PHARMICS

500,000 UNITS

A062525 001 Oct 29, 1984

SANDOZ

500,000 UNITS

A062065 001

USL PHARMA

500,000 UNITS

A062524 001 Nov 26, 1985

WATSON LABS

500,000 UNITS

A062402 001 Dec 16, 1982

TABLET; VAGINAL

KOROSTATIN

HOLLAND RANTOS

100,000 UNITS

A061718 001

MYCOSTATIN

BRISTOL MYERS SQUIBB

100,000 UNITS

A060577 001

NILSTAT

LEDERLE

100,000 UNITS

A061325 001

NYSTATIN

FOUGERA

100,000 UNITS

A062459 001 Nov 09, 1983

PHARMADERM

100,000 UNITS

A062460 001 Nov 09, 1983

QUANTUM PHARMICS

100,000 UNITS

A062509 001 Apr 03, 1984

SANDOZ

100,000 UNITS

A061965 001

TEVA

100,000 UNITS

A062502 001 Dec 23, 1983

WATSON LABS

100,000 UNITS

A062176 001

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYCOLOG-II

APOTHECON

100,000 UNITS/GM;0.1%

A060576 002 May 01, 1985

100,000 UNITS/GM;0.1%

A062606 001 May 15, 1985

MYCO-TRIACET II

TEVA

100,000 UNITS/GM;0.1%

A061954 002 Sep 20, 1985

MYTREX F

SAVAGE LABS

100,000 UNITS/GM;0.1%

A062597 001 Oct 08, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 238 (of 331)

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010	001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186	002	Jun 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657	001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%	A062347	001	Mar 30, 1987

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985

OINTMENT; TOPICAL

MYCOLOG-II

APOTHECON	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985

MYCO-TRIA CET II

TEVA	100,000 UNITS/GM;0.1%	A062045	002	Nov 26, 1985

MYTRES F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601	001	Oct 09, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280	002	Oct 10, 1985

PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656	001	Jul 30, 1986

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062603	001	Oct 09, 1985

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087	002	Mar 31, 1992
	40MG/ML	N020087	003	Mar 31, 1992

FLOXIN IN DEXTROSE 5%

ORTHO MCNEIL PHARM	400MG/100ML	N020087	001	Mar 31, 1992

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

ORTHO MCNEIL PHARM	4MG/ML	N020087	004	Mar 31, 1992
	400MG/100ML	N020087	005	Mar 31, 1992

OFLOXACIN

BEDFORD	40MG/ML	A075762	001	Jan 16, 2002

TABLET; ORAL

FLOXIN

ORTHO MCNEIL JANSSEN	200MG	N019735	001	Dec 28, 1990
	300MG	N019735	002	Dec 28, 1990
	400MG	N019735	003	Dec 28, 1990

OFLOXACIN

LARKEN LABS	200MG	A076093	001	Sep 02, 2003
	300MG	A076093	002	Sep 02, 2003
	400MG	A076093	003	Sep 02, 2003

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006
TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
TEVA	EQ 2MG BASE/ML	A076759	001	Nov 22, 2006

ZOFTRAN AND DEXTROSE IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N020403	001	Jan 31, 1995

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

GRACEWAY	100MG	N012157	001	

ORPHENADRINE CITRATE

ASCOT	100MG	A088067	001	Apr 06, 1983
SANDOZ	100MG	A085046	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 239 (of 331)

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
 ORPHENADRINE CITRATE
 WATSON LABS 100MG

A084303 001

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL
 DISIPAL
 3M 50MG

N010653 001

OXACILLIN SODIUM

CAPSULE; ORAL
 BACTOCILL

GLAXOSMITHKLINE EQ 250MG BASE
 EQ 250MG BASE
 EQ 500MG BASE
 EQ 500MG BASE

A061336 001
 A062241 001
 A061336 002
 A062241 002

OXACILLIN SODIUM
 APOTHECON

EQ 250MG BASE
 EQ 500MG BASE

A061450 002
 A061450 001

TEVA

EQ 250MG BASE
 EQ 500MG BASE

A062222 001
 A062222 002

PROSTAPHLIN

APOTHECON

EQ 500MG BASE

N050118 002

FOR SOLUTION; ORAL
 BACTOCILL

GLAXOSMITHKLINE EQ 250MG BASE/5ML

A062321 001

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/5ML

A061457 001

TEVA

EQ 250MG BASE/5ML

A062252 001

PROSTAPHLIN

APOTHECON

EQ 250MG BASE/5ML

N050194 001

INJECTABLE; INJECTION
 BACTOCILL

GLAXOSMITHKLINE EQ 500MG BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 2GM BASE/VIAL
 EQ 2GM BASE/VIAL
 EQ 4GM BASE/VIAL
 EQ 10GM BASE/VIAL

A061334 009 Mar 26, 1982
 A061334 006 Mar 26, 1982
 A062736 001 Dec 19, 1986
 A061334 007 Mar 26, 1982
 A062736 002 Dec 19, 1986
 A061334 008 Mar 26, 1982
 A061334 010

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/VIAL
 EQ 500MG BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 2GM BASE/VIAL
 EQ 4GM BASE/VIAL

N050195 001
 N050195 002
 N050195 003
 N050195 004
 N050195 005

ELKINS SINN

EQ 250MG BASE/VIAL
 EQ 500MG BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 2GM BASE/VIAL
 EQ 4GM BASE/VIAL
 EQ 10GM BASE/VIAL

A062711 001 Feb 03, 1989
 A062711 002 Feb 03, 1989
 A062711 003 Feb 03, 1989
 A062711 004 Feb 03, 1989
 A062711 005 Feb 03, 1989
 A062711 006 Feb 03, 1989

IBI

EQ 125MG BASE/VIAL
 EQ 250MG BASE/VIAL
 EQ 500MG BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 2GM BASE/VIAL

A062798 003 Dec 11, 1995
 A062798 004 Dec 11, 1995
 A062798 005 Dec 11, 1995
 A062798 001 Dec 11, 1995
 A062798 002 Dec 11, 1995

MARSAM PHARMS LLC

SANDOZ

EQ 10GM BASE/VIAL
 EQ 250MG BASE/VIAL
 EQ 500MG BASE/VIAL

A062984 001 Sep 29, 1988
 A061490 001
 A061490 002

WATSON LABS

EQ 250MG BASE/VIAL
 EQ 500MG BASE/VIAL
 EQ 1GM BASE/VIAL

A062856 001 Oct 26, 1988
 A062856 002 Oct 26, 1988
 A062856 003 Oct 26, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 240 (of 331)

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

WATSON LABS

EQ 2GM BASE/VIAL

A062856 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062856 005 Oct 26, 1988

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

SANOFI AVENTIS US

50MG/VIAL

N021492 001 Aug 09, 2002

100MG/VIAL

N021492 002 Aug 09, 2002

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

PFIZER

250MG

N018069 001

OXANDROLONE

TABLET; ORAL

OXANDROLONE

ROXANE

2.5MG

A077249 001 Jul 10, 2007

10MG

A077249 002 Jul 10, 2007

OXAPROZIN

TABLET; ORAL

OXAPROZIN

MYLAN

600MG

A075851 001 Aug 17, 2001

SANDOZ

600MG

A075842 001 Apr 12, 2001

600MG

A075850 001 Apr 27, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

GD SEARLE

600MG

N020776 001 Oct 17, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP

10MG

A071955 001 Mar 03, 1988

15MG

A071956 001 Mar 03, 1988

30MG

A071957 001 Mar 03, 1988

MUTUAL PHARM

10MG

A071026 002 Aug 10, 1987

15MG

A071026 003 Aug 10, 1987

30MG

A071026 001 Aug 10, 1987

MYLAN

10MG

A071713 001 Oct 20, 1987

15MG

A071714 001 Oct 20, 1987

30MG

A071715 001 Oct 20, 1987

SERAX

ALPHARMA US PHARMS

10MG

N015539 002

15MG

N015539 004

30MG

N015539 006

ZAXOPAM

QUANTUM PHARMICS

10MG

A070650 001 Mar 01, 1988

15MG

A070640 001 Mar 01, 1988

30MG

A070641 001 Mar 01, 1988

TABLET; ORAL

OXAZEPAM

MUTUAL PHARM

15MG

A070683 001 Jan 16, 1987

PARKE DAVIS

15MG

A071508 001 Feb 02, 1987

WATSON LABS

15MG

A071494 001 Apr 21, 1987

SERAX

ALPHARMA US PHARMS

15MG

N015539 008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 241 (of 331)

OXPRENOLOL HYDROCHLORIDECAPSULE; ORAL
TRASICOR

NOVARTIS

20MG

N018166 001 Dec 28, 1983

40MG

N018166 002 Dec 28, 1983

80MG

N018166 003 Dec 28, 1983

160MG

N018166 004 Dec 28, 1983

OXTRIPHYLLINESOLUTION; ORAL
CHOLEDYL

PARKE DAVIS

100MG/5ML

N009268 012 Nov 27, 1984

OXTRIPHYLLINE

MORTON GROVE

100MG/5ML

A088243 001 Dec 05, 1983

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS

50MG/5ML

N009268 011

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE

50MG/5ML

A088242 001 Dec 05, 1983

TABLET, DELAYED RELEASE; ORAL

CHOLEDYL

PARKE DAVIS

100MG

N009268 003

200MG

N009268 007

OXTRIPHYLLINE

WATSON LABS

100MG

A087866 001 Aug 25, 1983

200MG

A087835 001 Aug 25, 1983

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

ORTHO MCNEIL JANSSEN

5MG/5ML

N018211 001

TABLET; ORAL

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS

5MG

A072296 001 Dec 08, 1988

USL PHARMA

5MG

A070746 001 Mar 10, 1988

WATSON LABS

5MG

A072485 001 Apr 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

PURDUE PHARMA LP

10MG

N020553 001 Dec 12, 1995

15MG

N020553 006 Sep 18, 2006

20MG

N020553 002 Dec 12, 1995

30MG

N020553 007 Sep 18, 2006

40MG

N020553 003 Dec 12, 1995

60MG

N020553 008 Sep 18, 2006

80MG

N020553 004 Jan 06, 1997

160MG

N020553 005 Mar 15, 2000

ROXICODONE

ROXANE

10MG

N020932 001 Oct 26, 1998

30MG

N020932 002 Oct 26, 1998

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

ENDO PHARMS

1.5MG/ML

N011707 001

SUPPOSITORY; RECTAL

NUMORPHAN

ENDO PHARMS

5MG

N011738 004

OXYPHENBUTAZONE

TABLET; ORAL

OXYPHENBUTAZONE

WATSON LABS

100MG

A088399 001 Sep 17, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 242 (of 331)

OXYPHENBUTAZONE

TABLET; ORAL TANDEARIL NOVARTIS	100MG	N012542 004	Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL DARICON PFIZER	10MG	N011612 001	

OXYPHENONIUM BROMIDE

TABLET; ORAL ANTRENYL NOVARTIS	5MG	N008492 002	

OXYTETRACYCLINE

TABLET; ORAL TERRAMYCIN PFIZER	250MG	N050287 001	

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL TERRAMYCIN PFIZER	EQ 125MG BASE/5ML	A060595 001	

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL OXY-KESSO-TETRA FERRANTE	EQ 250MG BASE	A060179 001	
<u>OXYTETRACYCLINE HYDROCHLORIDE</u>			
IMPAX LABS	EQ 250MG BASE	A060760 001	
PROTER	EQ 250MG BASE	A060869 001	
PUREPAC PHARM	EQ 250MG BASE	A060634 001	
WEST WARD	EQ 250MG BASE	A060770 001	
TERRAMYCIN PFIZER	EQ 125MG BASE	N050286 001	
	EQ 250MG BASE	N050286 002	
<u>INJECTABLE; INJECTION</u>			
TERRAMYCIN PFIZER	EQ 250MG BASE/VIAL	A060586 001	
	EQ 500MG BASE/VIAL	A060586 002	

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC TERRAMYCIN W/ POLYMYXIN PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061841 001	
<u>TERRAMYCIN-POLYMYXIN</u>			
PFIZER	EQ 100MG BASE;100,000 UNITS	A061009 001	

OXYTOCIN

<u>INJECTABLE; INJECTION</u>			
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%			
ABBOTT	1USP UNITS/100ML	N019185 004	Mar 29, 1985
	2USP UNITS/100ML	N019185 003	Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%			
ABBOTT	2USP UNITS/100ML	N019185 002	Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%			
ABBOTT	1USP UNITS/100ML	N019185 001	Mar 29, 1985
<u>SYNTOCINON</u>			
NOVARTIS	10USP UNITS/ML	N018245 001	
<u>SOLUTION; NASAL</u>			
SYNTOCINON NOVARTIS	40USP UNITS/ML	N012285 001	

DISCONTINUED DRUG PRODUCT LIST

6 - 243 (of 331)

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

HOSPIRA	6MG/ML	A076233	001	Aug 01, 2002

PLIVA LACHEMA	6MG/ML	A077413	001	Mar 12, 2008

TEVA PARENTERAL	6MG/ML	A075297	001	Jan 25, 2002

TAXOL

BRISTOL MYERS SQUIBB	6MG/ML	N020262	001	Dec 29, 1992

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

ORTHO MCNEIL JANSSEN	12MG	N021999	004	Dec 19, 2006

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

ARELIA

NOVARTIS	60MG/VIAL	N020036	003	May 06, 1993

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL

COTAZYM

ORGANON USA INC	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS	N020580	001	Dec 09, 1996

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ASTRAZENECA	1MG/ML	A072210	001	Mar 31, 1988

	2MG/ML	A072211	001	Mar 31, 1988

	2MG/ML	A072212	001	Mar 31, 1988

	2MG/ML	A072213	001	Mar 31, 1988

ELKINS SINN	1MG/ML	A072058	001	Mar 23, 1988

	2MG/ML	A072059	001	Mar 23, 1988

	2MG/ML	A072060	001	Mar 23, 1988

HOSPIRA	2MG/ML	A072321	001	Jan 19, 1989

PAVULON

ORGANON USA INC	1MG/ML	N017015	002	

	2MG/ML	N017015	001	

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

ABBOTT	150MG	N006800	003	

	300MG	N006800	001	

SOLUTION; ORAL

PARADIONE

ABBOTT	300MG/ML	N006800	002	

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

LILLY	1MG	N012772	005	

	2MG	N012772	006	

PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTONYL

ABBOTT	10MG	N013448	002	

	25MG	N013448	003	

	50MG	N013448	004	

DISCONTINUED DRUG PRODUCT LIST

6 - 244 (of 331)

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN

KING PHARMS	EQ 250MG BASE	A062310	001
PARKEDALE	EQ 250MG BASE	A060521	001

SYRUP; ORAL
HUMATIN

PARKE DAVIS	EQ 125MG BASE/5ML	A060522	001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL

GLAXOSMITHKLINE	EQ 10MG BASE	N020885	001	Oct 09, 1998
	EQ 20MG BASE	N020885	002	Oct 09, 1998
	EQ 30MG BASE	N020885	003	Oct 09, 1998
	EQ 40MG BASE	N020885	004	Oct 09, 1998

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

ROXANE	EQ 10MG BASE	A078026	001	Jun 29, 2007
	EQ 20MG BASE	A078026	002	Jun 29, 2007
	EQ 30MG BASE	A078026	003	Jun 29, 2007
	EQ 40MG BASE	A078026	004	Jun 29, 2007
SANDOZ	EQ 10MG BASE	A075566	001	Mar 08, 2004
	EQ 20MG BASE	A075566	002	Mar 08, 2004
	EQ 30MG BASE	A075566	003	Mar 08, 2004
	EQ 40MG BASE	A075566	004	Mar 08, 2004
TEVA PHARMS	EQ 10MG BASE	A077082	001	Jun 29, 2007
	EQ 20MG BASE	A077082	002	Jun 29, 2007
	EQ 30MG BASE	A077082	003	Jun 29, 2007
	EQ 40MG BASE	A077082	004	Jun 29, 2007

PAXIL

GLAXOSMITHKLINE	EQ 50MG BASE	N020031	004	Dec 29, 1992

PEMOLINE

TABLET; ORAL
CYLERT

ABBOTT	18.75MG	N016832	001	
	37.5MG	N016832	002	
	75MG	N016832	003	

PEMOLINE

ACTAVIS TOTOWA	18.75MG	A075595	001	Feb 28, 2000
	37.5MG	A075595	002	Feb 28, 2000
	75MG	A075595	003	Feb 28, 2000
MALLINCKRODT	18.75MG	A075726	003	Mar 30, 2001
	37.5MG	A075726	002	Mar 30, 2001
	75MG	A075726	001	Mar 30, 2001
SANDOZ	18.75MG	A075286	001	Dec 27, 1999
	37.5MG	A075286	002	Jun 30, 1999
	75MG	A075286	003	Jun 30, 1999
TEVA PHARMS	18.75MG	A075030	003	Feb 22, 2000
	37.5MG	A075030	001	Jan 29, 1999
	75MG	A075030	002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328	001	Apr 19, 2000
	37.5MG	A075328	002	Apr 19, 2000
	75MG	A075328	003	Apr 19, 2000
WATSON LABS	18.75MG	A075287	001	Jun 13, 2001
	37.5MG	A075287	002	Sep 18, 2000
	75MG	A075287	003	Sep 18, 2000

TABLET, CHEWABLE; ORAL
CYLERT

ABBOTT	37.5MG	N017703	001	

PEMOLINE

ACTAVIS TOTOWA	37.5MG	A075678	001	Jul 26, 2000
TEVA PHARMS	37.5MG	A075555	001	Feb 18, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 245 (of 331)

PENBUTOLOL SULFATETABLET; ORAL
LEVATOL

SCHWARZ PHARMA

10MG

N018976

001

Dec 30, 1987

PENICILLAMINECAPSULE; ORAL
CUPRIMINE

ATON

125MG

N019853

002

PENICILLIN G BENZATHINEINJECTABLE; INJECTION
BICILLIN L-A

WYETH AYERST

300,000 UNITS/ML

N050131

001

SUSPENSION; ORAL
BICILLIN

WYETH AYERST

300,000 UNITS/5ML

N050126

002

TABLET; ORAL
BICILLIN

WYETH AYERST

200,000 UNITS

N050128

001

PENICILLIN G POTASSIUMFOR SOLUTION; ORAL
PENICILLIN

TEVA

200,000 UNITS/5ML

A060307

002

400,000 UNITS/5ML

A060307

004

PENICILLIN G POTASSIUM

MYLAN

200,000 UNITS/5ML

A060752

003

250,000 UNITS/5ML

A060752

002

400,000 UNITS/5ML

A060752

001

PUREPAC PHARM

250,000 UNITS/5ML

A061740

001

400,000 UNITS/5ML

A061740

002

PENICILLIN-2

TEVA

250,000 UNITS/5ML

A060307

003

PENTIDS '200'

APOTHECON

200,000 UNITS/5ML

A062149

001

PENTIDS '400'

APOTHECON

400,000 UNITS/5ML

A062149

002

PFIZERPEN G

PFIZER

400,000 UNITS/5ML

A060587

001

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

APOTHECON

1,000,000 UNITS/VIAL

A060362

001

5,000,000 UNITS/VIAL

A060362

003

10,000,000 UNITS/VIAL

A060362

004

20,000,000 UNITS/VIAL

A060362

002

CONSOLIDATED PHARM

500,000 UNITS/VIAL

A060806

001

1,000,000 UNITS/VIAL

A060806

002

5,000,000 UNITS/VIAL

A060806

003

10,000,000 UNITS/VIAL

A060806

004

LILLY

200,000 UNITS/VIAL

A060384

004

500,000 UNITS/VIAL

A060384

003

1,000,000 UNITS/VIAL

A060384

002

5,000,000 UNITS/VIAL

A060384

001

20,000,000 UNITS/VIAL

A060384

005

20,000,000 UNITS/VIAL

A060601

001

MARSAM PHARMS LLC

1,000,000 UNITS/VIAL

A062991

001

Sep 13, 1988

5,000,000 UNITS/VIAL

A062991

002

Sep 13, 1988

10,000,000 UNITS/VIAL

A062991

003

Sep 13, 1988

20,000,000 UNITS/VIAL

A062991

004

Sep 13, 1988

PARKE DAVIS

1,000,000 UNITS/VIAL

A062003

001

5,000,000 UNITS/VIAL

A062003

002

PFIZER

20,000,000 UNITS/VIAL

A060074

003

SANDOZ

1,000,000 UNITS/VIAL

A065079

001

Aug 30, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 246 (of 331)

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PFIZERPEN

PFIZER

1,000,000 UNITS/VIAL

A060657 001

TABLET; ORAL

PENICILLIN G POTASSIUM

APOTHECON

250,000 UNITS

A060392 003

IVAX SUB TEVA PHARMS

400,000 UNITS

A060073 004

LILLY

250,000 UNITS

A060403 001

MYLAN

200,000 UNITS

A060781 001

250,000 UNITS

A060781 002

400,000 UNITS

A060781 003

500,000 UNITS

A060781 005

800,000 UNITS

A060781 004

PUREPAC PHARM

200,000 UNITS

A061588 001

250,000 UNITS

A061588 002

400,000 UNITS

A061588 003

TEVA

200,000 UNITS

A060306 001

250,000 UNITS

A060306 002

400,000 UNITS

A060306 003

500,000 UNITS

A060306 004

WYETH AYERST

200,000 UNITS

A060413 001

250,000 UNITS

A060413 002

400,000 UNITS

A060413 003

PENTIDS '200'

APOTHECON

200,000 UNITS

A062155 001

PENTIDS '250'

APOTHECON

250,000 UNITS

A062155 002

PENTIDS '400'

APOTHECON

400,000 UNITS

A060392 004

400,000 UNITS

A062155 003

PENTIDS '800'

APOTHECON

800,000 UNITS

A060392 005

800,000 UNITS

A062155 004

PFIZERPEN G

PFIZER

50,000 UNITS

A060075 001

100,000 UNITS

A060075 002

200,000 UNITS

A060075 003

250,000 UNITS

A060075 004

400,000 UNITS

A060075 005

800,000 UNITS

A060075 006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.

LILLY

300,000 UNITS/ML

A060093 001

PENICILLIN G PROCAINE

CONSOLIDATED PHARM

300,000 UNITS/ML

A060800 001

600,000 UNITS/1.2ML

A060800 002

PARKE DAVIS

300,000 UNITS/ML

A062029 001

PFIZER

300,000 UNITS/VIAL

A060099 001

1,500,000 UNITS/VIAL

A060099 002

PFIZERPEN-AS

PFIZER

300,000 UNITS/ML

A060286 001

600,000 UNITS/ML

A060286 002

PENICILLIN G SODIUM

INJECTABLE; IM-IV

PENICILLIN G SODIUM

MARSAM PHARMS LLC

5,000,000 UNITS/VIAL

A063014 001

Sep 13, 1988

INJECTABLE; INJECTION

PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB

5,000,000 UNITS/VIAL

A061935 001

COPANOS

5,000,000 UNITS/VIAL

A061051 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 247 (of 331)

PENICILLIN G SODIUM

INJECTABLE; INJECTION

PENICILLIN G SODIUM

PHARMACIA AND UPJOHN 1,000,000 UNITS/VIAL

A061046 001

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN

LILLY

125MG/0.6ML

A060002 001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

A062270 001

EQ 250MG BASE/5ML

A062270 002

BETAPEN-VK

APOTHECON

EQ 125MG BASE/5ML

A061149 001

EQ 250MG BASE/5ML

A061149 002

LEDERCILLIN VK

LEDERLE

EQ 125MG BASE/5ML

A060136 001

EQ 250MG BASE/5ML

A060136 002

PENAPAR-VK

PARKE DAVIS

EQ 125MG BASE/5ML

A062002 001

EQ 250MG BASE/5ML

A062002 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 125MG BASE/5ML

A061529 001

EQ 250MG BASE/5ML

A061529 002

MYLAN

EQ 125MG BASE/5ML

A061624 002

EQ 250MG BASE/5ML

A061624 001

PUREPAC PHARM

EQ 125MG BASE/5ML

A061758 001

EQ 250MG BASE/5ML

A061758 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE/5ML

A060007 001

EQ 250MG BASE/5ML

A060007 002

PFIZERPEN VK

PFIZER

EQ 125MG BASE/5ML

A061815 001

EQ 250MG BASE/5ML

A061815 002

V-CILLIN K

LILLY

EQ 125MG BASE/5ML

A060004 001

EQ 250MG BASE/5ML

A060004 002

VEETIDS

APOTHECON

EQ 125MG BASE/5ML

A061410 001

EQ 250MG BASE/5ML

A061410 002

VEETIDS '125'

APOTHECON

EQ 125MG BASE/5ML

A061206 001

EQ 125MG BASE/5ML

A062153 001

VEETIDS '250'

APOTHECON

EQ 250MG BASE/5ML

A061206 002

EQ 250MG BASE/5ML

A062153 002

TABLET; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 250MG BASE

A062273 001

EQ 500MG BASE

A062273 002

BETAPEN-VK

BRISTOL

EQ 250MG BASE

A061150 001

EQ 500MG BASE

A061150 002

LEDERCILLIN VK

LEDERLE

EQ 250MG BASE

A060134 001

EQ 500MG BASE

A060134 002

PENAPAR-VK

PARKE DAVIS

EQ 250MG BASE

A062001 001

EQ 500MG BASE

A062001 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 250MG BASE

A061528 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 248 (of 331)

PENICILLIN V POTASSIUM

TABLET; ORAL

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

IVAX SUB TEVA PHARMS

EQ 500MG BASE

A061528 002

EQ 125MG BASE

A060518 001

EQ 250MG BASE

A060518 002

EQ 500MG BASE

A060518 003

MYLAN

EQ 250MG BASE

A061530 001

EQ 500MG BASE

A061530 002

PUREPAC PHARM

EQ 125MG BASE

A061571 001

EQ 250MG BASE

A061571 002

EQ 500MG BASE

A061571 003

PEN-VEE K

WYETH AYERST

EQ 125MG BASE

A060006 001

EQ 250MG BASE

A060006 002

EQ 500MG BASE

A060006 003

PFIZERPEN VK

PFIZER

EQ 250MG BASE

A061836 001

EQ 500MG BASE

A061836 002

UTICILLIN VK

PHARMACIA AND UPJOHN

EQ 250MG BASE

A061651 001

EQ 500MG BASE

A061651 002

V-CILLIN K

LILLY

EQ 125MG BASE

A060003 001

EQ 250MG BASE

A060003 002

EQ 500MG BASE

A060003 003

VEETIDS

APOTHECON

EQ 250MG BASE

A061411 001

EQ 500MG BASE

A061411 002

VEETIDS '250'

APOTHECON

EQ 250MG BASE

A061164 001

EQ 250MG BASE

A062156 002

VEETIDS '500'

APOTHECON

EQ 500MG BASE

A061164 002

EQ 500MG BASE

A062156 001

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

WYETH AYERST

0.25MG/ML

N017048 001

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

APP PHARMS

600MG/VIAL

N019887 002

Mar 22, 1996

INJECTABLE; INJECTION

PENTACARINAT

ARMOUR PHARM

300MG/VIAL

A073447 001

Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE

300MG/VIAL

A073617 001

Dec 18, 1995

HOSPIRA

300MG/VIAL

A073479 001

Jun 30, 1992

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN 50

SANOFI AVENTIS US

EQ 50MG BASE

N016732 001

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

HAMELN PHARMS

EQ 1GM BASE/5ML (EQ 200MG BASE/ML)

N021749 001

Aug 11, 2004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 249 (of 331)

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION			
YTTERBIUM YB 169 DTPA			
3M	2mCi/ML	N017518	001

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS			
PENTETATE ZINC TRISODIUM			
HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001 Aug 11, 2004

PENTOBARBITAL

ELIXIR; ORAL			
NEMBUTAL			
OVATION PHARMS	18.2MG/5ML	A083244	001

PENTOBARBITAL SODIUM

CAPSULE; ORAL			
NEMBUTAL SODIUM			
OVATION PHARMS	30MG	A084095	001
	50MG	A084093	001
	100MG	A083245	001
PENTOBARBITAL SODIUM			
LANNETT	50MG	A085937	001
	100MG	A085915	001
VITARINE	100MG	A083284	001
WHITEWORTH TOWN PLSN	100MG	A083338	001
SODIUM PENTOBARBITAL			
ANABOLIC	100MG	A084590	001
ELKINS SINN	100MG	A083368	001
EVERYLIFE	100MG	A083259	001
HALSEY	100MG	A084677	001
IVAX SUB TEVA PHARMS	50MG	A083461	001
	100MG	A083461	002
PARKE DAVIS	100MG	A084156	001
PERRIGO	100MG	A084560	001
PUREPAC PHARM	100MG	A083301	001
VALEANT PHARM INTL	100MG	A083264	001
WATSON LABS	100MG	A085791	001
WYETH AYERST	100MG	A083239	001
INJECTABLE; INJECTION			
PENTOBARBITAL SODIUM			
ELKINS SINN	50MG/ML	A083270	001
SODIUM PENTOBARBITAL			
WYETH AYERST	50MG/ML	A083261	001
SUPPOSITORY; RECTAL			
NEMBUTAL			
OVATION PHARMS	30MG	A083247	001 Jan 25, 1982
	60MG	A083247	002 Jan 25, 1982
	120MG	A083247	003 Jan 25, 1982
	200MG	A083247	004 Jan 25, 1982
TABLET; ORAL			
PENTOBARBITAL SODIUM			
VITARINE	100MG	A083285	001
SODIUM PENTOBARBITAL			
NEXGEN PHARMA INC	100MG	A084238	001

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION			
ANSOLYSEN			
WYETH AYERST	10MG/ML	N009372	001

DISCONTINUED DRUG PRODUCT LIST

6 - 250 (of 331)

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

ACTAVIS ELIZABETH	400MG	A074878	001	Jul 09, 1997
HERITAGE PHARMS INC	400MG	A074877	001	Jul 08, 1997
TEVA	400MG	A075199	001	Sep 03, 1999

PERFLUBRON

LIQUID; ORAL
IMAGENT

ALLIANCE PHARM	100%	N020091	001	Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS
US ARMY 50%;50%

		N021084	001	Feb 17, 2000

PERGOLIDE MESYLATE

TABLET; ORAL
PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094	001	Sep 04, 2003
	EQ 0.25MG BASE	A076094	002	Sep 04, 2003
	EQ 1MG BASE	A076094	003	Sep 04, 2003
PAR PHARM	EQ 0.05MG BASE	A076061	001	Nov 27, 2002
	EQ 0.25MG BASE	A076061	002	Nov 27, 2002
	EQ 1MG BASE	A076061	003	Nov 27, 2002
PERMAX				
VALEANT PHARM INTL	EQ 0.05MG BASE	N019385	001	Dec 30, 1988
	EQ 0.25MG BASE	N019385	002	Dec 30, 1988
	EQ 1MG BASE	N019385	003	Dec 30, 1988

PERMETHRIN

LOTION; TOPICAL
NIX

GLAXOSMITHKLINE	1%	N019435	001	Mar 31, 1986

PERPHENAZINE

CONCENTRATE; ORAL
PERPHENAZINE

PHARM ASSOC	16MG/5ML	A040360	001	May 25, 2001

TRILAFON

SCHERING	16MG/5ML	N011557	001	

INJECTABLE; INJECTION

TRILAFON

SCHERING	5MG/ML	N011213	002	

SYRUP; ORAL

TRILAFON

SCHERING	2MG/5ML	N011294	002	

TABLET; ORAL

PERPHENAZINE

IVAX PHARMS	2MG	A089707	001	Sep 10, 1987
	4MG	A089708	001	Sep 10, 1987
	8MG	A089456	001	Sep 10, 1987
	16MG	A089457	001	Sep 10, 1987

TRILAFON

SCHERING	2MG	N010775	001	
	4MG	N010775	002	
	8MG	N010775	003	
	16MG	N010775	004	

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING	8MG	N011361	002	

DISCONTINUED DRUG PRODUCT LIST

6 - 251 (of 331)

PHENACEMIDE

TABLET; ORAL PHENURONE ABBOTT	500MG	N007707	001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL AZO GANTANOL ROCHE	100MG;500MG	N013294	001	Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HYDROCHLORIDE ABLE	200MG, N/A, N/A; N/A, 800MG, 160MG	N021105	001	Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL AZO GANTRISIN ROCHE	50MG;500MG	N019358	001	Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL PHENAZINE MAST MM	35MG 35MG 35MG	A086523 A086524 A086525	001 001 001	
<u>PHENDIMETRAZINE TARTRATE</u>				
SANDOZ	35MG 35MG 35MG 35MG	A085633 A085694 A085695 A085702	001 001 001 001	
VITARINE	35MG 35MG 35MG 35MG 35MG 35MG 35MG 35MG 35MG 35MG	A085634 A085645 A085670 A086403 A086408 A086410 A087424	001 001 001 001 001 001 001	
SPRX-3 SOLVAY	35MG	A085897	001	
STATOBEX TEVA	35MG	A085507	001	
X-TROZINE SHIRE RICHWOOD	35MG	A087394	001	Sep 22, 1982
<u>CAPSULE, EXTENDED RELEASE; ORAL</u>				
MELFIAT-105 NUMARK	105MG	A087487	001	Oct 13, 1982
<u>PHENDIMETRAZINE TARTRATE</u>				
GRAHAM DM	105MG 105MG 105MG 105MG 105MG 105MG 105MG	A087214 A088020 A088028 A088062 A088063 A088111 A087378	001 001 001 001 001 001 001	May 26, 1982 Aug 16, 1982 Aug 16, 1982 Sep 13, 1982 Sep 10, 1982 Oct 18, 1982
SANDOZ SPRX-105 NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A. SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
<u>TABLET; ORAL</u>				
ADPHEN FERNDAL LABS	35MG	A083655	001	
ALPHAZINE SANDOZ	35MG	A085034	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 252 (of 331)

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

CAM-METRAZINE

ABC HOLDING	35MG	A085511	001
CAMALL	35MG	A085756	001
TG UNITED LABS	35MG	A083922	001
	35MG	A085318	001
	35MG	A085320	001
	35MG	A085321	001

DI-METREX

PVT FORM	35MG	A085698	001

MELFIAT

NUMARK	35MG	A083790	002

METRA

FOREST PHARMS	35MG	A083754	001

PHENAZINE

MAST MM	35MG	A087305	001

PHENAZINE-35

ABC HOLDING	35MG	A085512	001

PHENDIMETRAZINE TARTRATE

BARR	35MG	A083644	001
	35MG	A083684	001
	35MG	A083686	001
	35MG	A083687	001
	35MG	A084831	001
	35MG	A084834	001
	35MG	A084835	001

FERNDAL LABS	35MG	A086834	001

INWOOD LABS	35MG	A084740	001

	35MG	A084741	001

	35MG	A084742	001

	35MG	A084743	001

IVAX PHARMS	35MG	A085611	001

	35MG	A085612	001

IVAX SUB TEVA PHARMS	35MG	A083682	001

KV PHARM	35MG	A084138	001

	35MG	A084141	001

	35MG	A085525	001

MFG CHEMISTS	35MG	A085914	001

NEXGEN PHARMA INC	35MG	A086020	001

NUMARK	35MG	A083790	001

PVT FORM	35MG	A085199	001

	35MG	A085697	001

SANDOZ	35MG	A085402	001

	35MG	A085497	001

	35MG	A085830	001

	35MG	A086365	001

	35MG	A086370	001

SOLVAY	35MG	A083993	001

TG UNITED LABS	35MG	A085761	001

	35MG	A085941	001

USL PHARMA	35MG	A083805	001

	35MG	A084398	001

	35MG	A084399	001

VITARINE	35MG	A085519	001

	35MG	A086005	001

	35MG	A086106	001

WATSON LABS	35MG	A085767	001

	35MG	A085768	001

	35MG	A085770	001

	35MG	A085773	001

PLEGINE

WYETH AYERST	35MG	N012248	001

Sep 15, 1983

Jun 27, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 253 (of 331)

PHENDIMETRAZINE TARTRATE

TABLET; ORAL			
STATOBEX			
TEVA	35MG	A086013	001
STATOBEX-G			
TEVA	35MG	A085095	001
X-TROZINE			
SHIRE RICHWOOD	35MG	A086550	001
	35MG	A086551	001
	35MG	A086552	001
	35MG	A086553	001
	35MG	A086554	001

PHENINDIONE

TABLET; ORAL			
HEDULIN			
SANOFI AVENTIS US	50MG	N008767	002

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL			
PRELUDIN			
BOEHRINGER INGELHEIM	25MG	N010460	005
TABLET, EXTENDED RELEASE; ORAL			
PRELUDIN			
BOEHRINGER INGELHEIM	50MG	N011752	004
	75MG	N011752	003

PHENPROCOUNON

TABLET; ORAL			
LIQUAMAR			
ORGANON USA INC	3MG	N011228	001

PHENSUXIMIDE

CAPSULE; ORAL			
MILONTIN			
PARKE DAVIS	500MG	N008855	004

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL			
FASTIN			
GLAXOSMITHKLINE	30MG	N017352	001
OBESTIN-30			
FERNDAL LABS	30MG	A087144	001
OBY-TRIM			
SHIRE RICHWOOD	30MG	A087764	001 Mar 18, 1982
ONA-MAST			
MAST MM	30MG	A086511	001
	30MG	A086516	001
PHENTERMINE HYDROCHLORIDE			
ABC HOLDING	30MG	A085411	001
ABLE	15MG	A040497	001 Mar 13, 2003
	30MG	A040403	001 Aug 30, 2001
	30MG	A040427	001 Aug 30, 2001
CAMALL	15MG	A086735	001
	30MG	A087226	001
DURAMED PHARMS BARR	30MG	A088948	001 Apr 25, 1986
IVAX PHARMS	30MG	A086329	001
MUTUAL PHARM	37.5MG	A040527	001 Oct 23, 2003
SANDOZ	30MG	A087208	001
	30MG	A087223	001
	37.5MG	A088414	001 Oct 19, 1983
TEVA	30MG	A086911	001
	30MG	A087126	001
	30MG	A087777	001 Nov 01, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 254 (of 331)

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

TEVA	30MG	A088612	001	Apr 04, 1984
	30MG	A088613	001	Apr 09, 1984
	30MG	A088614	001	Apr 09, 1984
TG UNITED INC	30MG	A040083	001	Mar 07, 1997
TG UNITED LABS	18.75MG	A088576	001	May 23, 1984
	30MG	A085417	001	
	30MG	A086732	002	
	30MG	A087215	001	
	37.5MG	A087915	001	Dec 22, 1983
	37.5MG	A087918	001	Dec 22, 1983
	37.5MG	A087930	001	Oct 14, 1983
	37.5MG	A088610	001	Jun 04, 1984
	37.5MG	A088611	001	Jun 04, 1984
	37.5MG	A088625	001	Aug 23, 1984
USL PHARMA	30MG	A084487	001	Apr 09, 1982
	30MG	A088430	001	Mar 27, 1984
	30MG	A088797	001	Dec 10, 1984
VITARINE	30MG	A087202	001	
	30MG	A087235	001	
WATSON LABS	30MG	A086740	001	Mar 21, 1985

TABLET; ORAL

ONA-MAST

MAST MM	8MG	A086260	001	

PHENTERMINE HYDROCHLORIDE

ABLE	37.5MG	A040402	001	Aug 30, 2001
IVAX PHARMS	8MG	A085553	001	
SANDOZ	8MG	A085671	001	
	8MG	A085689	001	
TG UNITED LABS	8MG	A083923	001	
	8MG	A085319	001	
	37.5MG	A087805	001	Dec 06, 1982
	37.5MG	A088596	001	Apr 04, 1984
USL PHARMA	8MG	A083804	001	
	37.5MG	A088910	001	Jul 17, 1985
	37.5MG	A088917	001	Jul 17, 1985
VITARINE	8MG	A086453	001	
	8MG	A086456	001	
WATSON LABS	8MG	A085739	001	
TORA				
SOLVAY	8MG	A084035	001	

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN

UCB INC	EQ 15MG BASE	N011613	004	
	EQ 30MG BASE	N011613	002	

PHENTERMINE RESIN 30

QUANTUM PHARMICS	EQ 30MG BASE	A089120	001	Feb 04, 1988

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC	50%	N011695	002	

TABLET; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC	500MG	N011695	003	

PHENYLBUTAZONE

CAPSULE; ORAL

AZOLID

SANOFI AVENTIS US	100MG	A087260	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 255 (of 331)

PHENYLBUTAZONE

CAPSULE; ORAL					
BUTAZOLIDIN					
NOVARTIS	100MG	N008319	009		
PHENYLBUTAZONE					
IVAX PHARMS	100MG	A088218	001	Jun 24, 1983	
MUTUAL PHARM	100MG	A088994	001	Dec 04, 1985	
SANDOZ	100MG	A087774	001	Jun 16, 1982	
WATSON LABS	100MG	A087756	001	Dec 17, 1982	
TABLET; ORAL					
AZOLID					
SANOFI AVENTIS US	100MG	A087091	001		
BUTAZOLIDIN					
NOVARTIS	100MG	N008319	008		
PHENYLBUTAZONE					
MUTUAL PHARM	100MG	A088863	001	Dec 04, 1985	
SANDOZ	100MG	A084339	001		
WATSON LABS	100MG	A086151	001		
	100MG	A087674	001	Apr 21, 1982	

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL					
PHENERGAN VC					
ANI PHARMS	5MG/5ML; 6.25MG/5ML	N008604	003	Apr 02, 1984	
PHERAZINE VC					
HALSEY	5MG/5ML; 6.25MG/5ML	A088868	001	Mar 02, 1987	
PROMETHAZINE VC PLAIN					
CENCI	5MG/5ML; 6.25MG/5ML	A088815	001	Nov 22, 1985	
WOCKHARDT	5MG/5ML; 6.25MG/5ML	A088897	001	Jan 04, 1985	

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC					
PREFRIN-A					
ALLERGAN	0.12%; 0.1%	N007953	001		

PHENYTOIN

SUSPENSION; ORAL					
DILANTIN-30					
PARKE DAVIS	30MG/5ML	N008762	002		
PHENYTOIN					
ACTAVIS MID ATLANTIC	125MG/5ML	A089892	001	Sep 25, 1992	

PHENYTOIN SODIUM

CAPSULE; ORAL					
DIPHENYLAN SODIUM					
LANNETT	30MG PROMPT	A080857	001		
	100MG PROMPT	A080857	002		
EXTENDED PHENYTOIN SODIUM					
BARR	100MG EXTENDED	A040435	001	Jun 20, 2003	
PLIVA	100MG EXTENDED	A089441	001	Dec 18, 1986	
PHENYTEX					
WATSON LABS	100MG EXTENDED	A088711	001	Dec 21, 1984	
PHENYTOIN SODIUM					
PHARMERAL	100MG PROMPT	A085435	001		
WATSON LABS	100MG PROMPT	A085894	001		
PROMPT PHENYTOIN SODIUM					
IVAX SUB TEVA PHARMS	100MG PROMPT	A080259	001		
WATSON LABS	100MG PROMPT	A080905	001		
INJECTABLE; INJECTION					
DILANTIN					
PARKE DAVIS	50MG/ML	N010151	001		
PHENYTOIN SODIUM					
APP PHARMS	50MG/ML	A089003	001	May 31, 1985	
MARSAM PHARMS LLC	50MG/ML	A089501	001	Oct 13, 1987	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 256 (of 331)

PHENYTOIN SODIUMINJECTABLE; INJECTION
PHENYTOIN SODIUM

MARSAM PHARMS LLC	50MG/ML	A089779	001	Nov 27, 1992
SMITH AND NEPHEW	50MG/ML	A088519	001	Dec 19, 1984
	50MG/ML	A088521	001	Dec 18, 1984
SOLOPAK	50MG/ML	A088520	001	Dec 17, 1984
WARNER CHILCOTT	50MG/ML	A089900	001	Mar 30, 1990
WATSON LABS	50MG/ML	A085434	001	

PHYTONADIONEINJECTABLE; INJECTION
AQUAMEPHYTON

ATON	1MG/0.5ML	N012223	002	
	10MG/ML	N012223	001	
KONAKION				
ROCHE	1MG/0.5ML	N011745	001	
	10MG/ML	N011745	003	
PHYTONADIONE				
GLAXOSMITHKLINE	1MG/0.5ML	A084060	001	
	10MG/ML	A084060	002	
VITAMIN K1				
HOSPIRA	10MG/ML	A087956	001	Jul 25, 1983

PILOCARPINEINSERT, EXTENDED RELEASE; OPHTHALMIC
OCUSERT PILO-20

AKORN	5MG	N017431	001	
OCUSERT PILO-40				
AKORN	11MG	N017548	001	

PINACIDILCAPSULE, EXTENDED RELEASE; ORAL
PINDAC

LEO PHARM	12.5MG	N019456	001	Dec 28, 1989
	25MG	N019456	002	Dec 28, 1989

PINDOLOLTABLET; ORAL
PINDOLOL

GENPHARM	5MG	A074013	001	Sep 24, 1992
	10MG	A074018	001	Sep 24, 1992
IVAX SUB TEVA PHARMS	5MG	A073687	001	Feb 26, 1993
	10MG	A073687	002	Feb 26, 1993
MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994
	10MG	A074063	002	Jan 27, 1994
NOSTRUM LABS	5MG	A074474	001	Oct 28, 1996
	10MG	A074474	002	Oct 28, 1996
PUREPAC PHARM	5MG	A074125	001	Apr 28, 1993
	10MG	A074125	002	Apr 28, 1993
SANDOZ	5MG	A073608	001	Mar 29, 1993
	10MG	A073609	001	Mar 29, 1993
TEVA	5MG	A073661	001	Oct 31, 1993
	5MG	A074123	001	Apr 17, 1997
	10MG	A073661	002	Oct 31, 1993
	10MG	A074123	002	Apr 17, 1997
VISKEN				
NOVARTIS	5MG	N018285	001	Sep 03, 1982
	10MG	N018285	002	Sep 03, 1982

PIPECURONIUM BROMIDEINJECTABLE; INJECTION
ARDUAN

ORGANON USA INC	10MG/VIAL	N019638	001	Jun 26, 1990

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 257 (of 331)

PIPERACETAZINETABLET; ORAL
QUIDE

DOW PHARM

10MG

N013615 001

25MG

N013615 002

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

WYETH PHARMS INC

EQ 2GM BASE/VIAL

A062750 001

Oct 13, 1987

EQ 2GM BASE/VIAL

N050545 002

EQ 3GM BASE/VIAL

A062750 002

Oct 13, 1987

EQ 3GM BASE/VIAL

N050545 003

EQ 4GM BASE/VIAL

A062750 003

Oct 13, 1987

EQ 4GM BASE/VIAL

N050545 004

EQ 40GM BASE/VIAL

N050545 006

Sep 30, 1985

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE/5ML

N009102 001

BRYREL

SANOFI AVENTIS US

EQ 500MG BASE/5ML

N017796 001

MULTIFUGE

BLULINE

EQ 500MG BASE/5ML

N009452 001

PIPERAZINE CITRATE

ALPHARMA US PHARMS

EQ 500MG BASE/5ML

A080774 001

LANNETT

EQ 500MG BASE/5ML

A080963 001

LUITPOLD

EQ 500MG BASE/5ML

A080671 001

VERMIDOL

SOLVAY

EQ 500MG BASE/5ML

A080992 001

TABLET; ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE

N009102 003

PIPERAZINE CITRATE

IMPAX LABS

EQ 250MG BASE

A080874 001

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT

10MG

N016245 001

25MG

N016245 002

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

GRACEWAY

EQ 0.2MG BASE/INH

N019009 001

Dec 30, 1986

PIROXICAM

CAPSULE; ORAL

PIROXICAM

EGIS

10MG

A074808 001

Jul 08, 1997

20MG

A074808 002

Jul 08, 1997

GENPHARM

10MG

A074043 001

Sep 22, 1992

20MG

A074043 002

Sep 22, 1992

IVAX SUB TEVA PHARMS

10MG

A074148 001

Jun 03, 1996

20MG

A074148 002

Jun 03, 1996

MUTUAL PHARM

20MG

A073536 001

Mar 12, 1993

ROXANE

10MG

A073651 001

Feb 26, 1993

20MG

A073651 002

Feb 26, 1993

SCS

10MG

A074036 001

May 29, 1992

20MG

A074036 002

May 29, 1992

TEVA

10MG

A073637 001

Jan 28, 1994

20MG

A073638 001

Jan 28, 1994

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 258 (of 331)

PIROXICAMCAPSULE; ORAL
PIROXICAM

TEVA PHARMS

10MG

A074103 001

Aug 28, 1992

20MG

A074103 002

Aug 28, 1992

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER

2.5MG/VIAL

N050109 001

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST

40MG/AMP

N010753 001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

TEVA PHARMS

17GM/SC00PFUL

A077445 001

May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

OCL

HOSPIRA

6GM/100ML; 75MG/100ML; 168MG/100ML; 146MG/100ML; 1.29GM/100ML

N019284 001

Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

ALAVEN PHARM

120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET

N018983 005

Oct 26, 1984

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET

N018983 004

Oct 26, 1984

360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET

N018983 006

Oct 26, 1984

FOR SUSPENSION; ORAL

CO-LAV

BOCA PHARMA

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

A073428 001

Jan 28, 1992

COLOVAGE

DYNAPHARM

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET

A071320 001

Apr 20, 1988

E-Z-EM PREP LYTE

E Z EM

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A071278 001

Nov 21, 1988

GLYCOPREP

GOLDLINE

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A072319 001

Dec 23, 1988

GO-EVAC

BOCA PHARMA

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073433 001

Apr 28, 1992

PEG-LYTE

SANDOZ

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073098 001

Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE

EQ 500,000 U BASE/VIAL

A062036 001

POWDER; FOR RX COMPOUNDING

POLYMYXIN B SULFATE

PADDOCK

100,000,000 UNITS/BOT

A062455 001

Jul 27, 1983

DISCONTINUED DRUG PRODUCT LIST

6 - 259 (of 331)

POLYTHIAZIDE

TABLET; ORAL
RENESE
PFIZER

1MG
2MG
4MG

N012845 001
N012845 002
N012845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
MINIZIDE
PFIZER

0.5MG;EQ 1MG BASE
0.5MG;EQ 2MG BASE
0.5MG;EQ 5MG BASE

N017986 001
N017986 002
N017986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL
RENESE-R
PFIZER

2MG;0.25MG

N013636 001

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL
PASKALIUM
GLENWOOD

500MG

N009395 004

POWDER; ORAL
POTASSIUM AMINOSALICYLATE
HEXCEL

100%

A080098 001

TABLET; ORAL
PASKALIUM
GLENWOOD

1GM

N009395 003

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
K-LEASE
SAVAGE LABS

8MEQ
10MEQ

A073398 001 Jan 28, 1992
A072427 001 Mar 28, 1990

POTASSIUM CHLORIDE
KV PHARM
TEVA

10MEQ
8MEQ
10MEQ

A070980 001 Feb 17, 1987
A073531 001 Apr 26, 1996
A073532 001 Apr 26, 1996

FOR SUSPENSION, EXTENDED RELEASE; ORAL
MICRO-K LS
KV PHARM

20MEQ/PACKET

N019561 003 Aug 26, 1988

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
ABRAXIS PHARM

2MEQ/ML
2MEQ/ML
2MEQ/ML
2MEQ/ML
2MEQ/ML
2MEQ/ML

A080204 001
A084290 001
A086713 001
A086714 001
A087787 001 Apr 20, 1982
A087885 001 Feb 03, 1983
A088286 001 Sep 05, 1985
A087817 001 Oct 20, 1982

AKORN
APP PHARMS
BAXTER HLTHCARE
GD SEARLE LLC

2MEQ/ML
2MEQ/ML
1MEQ/ML
2MEQ/ML
2MEQ/ML
3MEQ/ML
3MEQ/ML
4MEQ/ML

A080203 001
A080203 001
A086219 001
A086219 002
A086220 002
A086219 003
A086220 001
A086219 004

HOSPIRA

1MEQ/ML
1MEQ/ML
1.5MEQ/ML
2MEQ/ML
2.4MEQ/ML

A080205 003
A083345 003
A083345 001
A083345 002
A080205 004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 260 (of 331)

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

HOSPIRA	3.2MEQ/ML	A080205	005	
LILLY	2MEQ/ML	N007865	002	
LUITPOLD	2MEQ/ML	A080221	001	
	2MEQ/ML	A080736	001	
	2MEQ/ML	A087584	001	
	2MEQ/ML	A087585	001	
MILES	1MEQ/ML	A080195	002	
	2MEQ/ML	A080195	001	
	3MEQ/ML	A080195	003	
	4MEQ/ML	A080195	004	
PHARMA SERVE NY	2MEQ/ML	A086297	001	
	2MEQ/ML	A087362	001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208	001	
	2MEQ/ML	A089163	001	Mar 10, 1988
	2MEQ/ML	A089421	001	Jan 02, 1987
	3MEQ/ML	A086210	001	

TABLET, EXTENDED RELEASE; ORAL

K+8

FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
KAON CL				
SAVAGE LABS	6.7MEQ	N017046	001	
POTASSIUM CHLORIDE				
COPLEY PHARM	8MEQ	A070618	001	Sep 09, 1987
SLOW-K				
NOVARTIS	8MEQ	N017476	002	
TEN-K				
NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;900MG/100ML	N019708	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML;900MG/100ML	N019708	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	110MG/100ML;900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML;900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML;900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML;900MG/100ML	N018722	001	Nov 09, 1982
BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	150MG/100ML;900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML;900MG/100ML	N018722	003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML;900MG/100ML	N018722	004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025	001	

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

MISSION PHARMA	10MEQ/PACKET	N019647	002	Oct 13, 1988
	20MEQ/PACKET	N019647	001	Oct 13, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 261 (of 331)

POTASSIUM IODIDE

SOLUTION; ORAL				
POTASSIUM IODIDE				
ROXANE	1GM/ML	N018551	001	Feb 19, 1982
TABLET; ORAL				
THYRO-BLOCK				
MEDPOINTE PHARM HLC	130MG	N018307	001	

POTASSIUM PERCHLORATE

CAPSULE; ORAL				
PERCHLORACAP				
MALLINCKRODT	200MG	N017551	001	

POVIDONE- IODINE

SOLUTION; TOPICAL				
E-Z PREP				
CLINIPAD	10%	N019382	001	Jul 25, 1989
SPONGE; TOPICAL				
E-Z PREP				
CLINIPAD	5%	N019382	002	Jul 25, 1989
E-Z PREP 220				
CLINIPAD	5%	N019382	003	Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION				
PRALIDOXIME CHLORIDE				
BAXTER HLTHCARE CORP	300MG/ML	N018799	001	Dec 13, 1982
TABLET; ORAL				
PROTOPAM CHLORIDE				
WYETH AYERST	500MG	N014122	002	

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL				
MIRAPEX				
BOEHRINGER INGELHEIM	1.25MG	N020667	004	Jul 01, 1997

PRAZEPAM

CAPSULE; ORAL				
CENTRAX				
PARKE DAVIS	5MG	N018144	001	
	10MG	N018144	002	
	20MG	N018144	003	May 10, 1982
PRAZEPAM				
USL PHARMA	5MG	A070427	001	Nov 06, 1987
	10MG	A070428	001	Nov 06, 1987
TABLET; ORAL				
CENTRAX				
PARKE DAVIS	10MG	N017415	001	

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL				
PRAZOSIN HYDROCHLORIDE				
AM THERAP	EQ 1MG BASE	A072782	001	May 16, 1989
	EQ 2MG BASE	A072783	001	May 16, 1989
	EQ 5MG BASE	A072784	001	May 16, 1989
CLONMEL HLTHCARE	EQ 1MG BASE	A072705	001	May 16, 1989
	EQ 2MG BASE	A072706	001	May 16, 1989
	EQ 5MG BASE	A072707	001	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991	001	May 16, 1989
	EQ 2MG BASE	A072921	001	May 16, 1989
	EQ 5MG BASE	A072992	001	May 16, 1989
SANDOZ	EQ 1MG BASE	A072576	001	May 16, 1989
	EQ 2MG BASE	A072577	001	May 16, 1989
	EQ 5MG BASE	A072578	001	May 16, 1989

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 262 (of 331)

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

WATSON LABS

EQ 1MG BASE

A072352 001 May 16, 1989

EQ 2MG BASE

A072333 001 May 16, 1989

EQ 5MG BASE

A072609 001 May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER

2.5MG

N019775 001 Jan 29, 1992

5MG

N019775 002 Jan 29, 1992

PREDNISOLONE

CREAM; TOPICAL

METI-DERM

SCHERING

0.5%

N010209 002

SYRUP; ORAL

PREDNISOLONE

IVAX SUB TEVA PHARMS

15MG/5ML

A040287 001 May 28, 1999

TEVA PHARMS

15MG/5ML

A040322 001 Jan 19, 2000

WE PHARMS

15MG/5ML

A040192 001 May 28, 1998

PRELONE

MURO

5MG/5ML

A089654 001 Jan 17, 1989

TABLET; ORAL

CORTALONE

HALSEY

1MG

A080304 003

2.5MG

A080304 002

5MG

A080304 001

DELTA-CORTEF

PHARMACIA AND UPJOHN

5MG

N009987 004

FERNISOLONE-P

FERNDAL LABS

5MG

A083941 001

PREDNISOLONE

BARR

5MG

A084426 002

BUNDY

5MG

A083675 001

ELKINS SINN

5MG

A080625 001

EVERYLIFE

1MG

A084439 001

2.5MG

A084439 002

5MG

A084439 003

FERRANTE

2.5MG

A080562 001

5MG

A080562 002

HEATHER

5MG

A080326 001

IMPAX LABS

5MG

A080780 001

INWOOD LABS

5MG

A080748 001

IVAX SUB TEVA PHARMS

5MG

A080378 001

LANNETT

5MG

A080531 002

MARSHALL PHARMA

5MG

A080307 001

PANRAY

1MG

A080351 001

5MG

A080351 002

PERRIGO

5MG

A084542 001

PHOENIX LABS NY

5MG

A080322 001

PUREPAC PHARM

5MG

A080325 001

PVT FORM

5MG

A080211 001

ROXANE

5MG

A080327 002

SANDOZ

5MG

A080339 001

5MG

A084773 001

SPERTI

1MG

A080358 001

2.5MG

A080358 002

5MG

A080358 003

SUPERPHARM

5MG

A088892 001 Feb 26, 1985

TABLICAPS

5MG

A085170 001

TEVA

5MG

A080398 001

UDL

5MG

A087987 001 Jan 18, 1983

VALEANT PHARM INTL

5MG

A080236 001

VITARINE

5MG

A080534 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 263 (of 331)

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

WATSON LABS

5MG

A085085 002

5MG

A085415 001

5MG

A085416 001

WEST WARD

5MG

A080324 001

WHITEWORTH TOWN PLSN

5MG

A080342 001

STERANE

PFIZER

5MG

N009996 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTELONE

SCHERING

25MG/ML

N010255 002

PREDNISOLONE ACETATE

AKORN

25MG/ML

A083032 001

50MG/ML

A084492 001

BEL MAR

25MG/ML

A083738 001

50MG/ML

A083738 002

CENT PHARMS

25MG/ML

A084717 001

50MG/ML

A084717 002

WATSON LABS

25MG/ML

A083398 001

25MG/ML

A083654 001

40MG/ML

A083767 001

50MG/ML

A083764 001

50MG/ML

A085781 001

STERANE

PFIZER

25MG/ML

N011446 001

SUSPENSION; ORAL

FLO-PRED

TARO

EQ 5MG BASE/5ML

N022067 001 Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

ALCON

0.125%

N017468 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

ALCON

0.25%;10%

A087771 001 Aug 06, 1993

METIMYD

SCHERING

0.5%;10%

N010210 002 Sep 09, 1984

PREDSULFAIR

PHARMAFAIR

0.5%;10%

A088032 001 Apr 15, 1983

VASOCIDIN

NOVARTIS

0.5%;10%

A088791 001 Oct 05, 1984

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

ALCON

0.25%;10%

A087547 001

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

SCHERING

0.5%;10%

N010210 001

PREDAMIDE

AKORN

0.5%;10%

A088059 001 Jul 29, 1983

PREDSULFAIR

PHARMAFAIR

0.5%;10%

A088007 001 Apr 19, 1983

PREDSULFAIR II

PHARMAFAIR

0.2%;10%

A088837 001 Dec 24, 1985

SULPHRIN

BAUSCH AND LOMB

0.5%;10%

A088089 001 Dec 28, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 264 (of 331)

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDELTRASOL

MERCK

EQ 20MG PHOSPHATE/ML

N011583 002

PREDNISOLONE SODIUM PHOSPHATE

WATSON LABS

EQ 20MG PHOSPHATE/ML

A080517 001

OINTMENT; OPHTHALMIC, OTIC

HYDELTRASOL

MERCK

EQ 0.25% PHOSPHATE

N011028 001

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

WE PHARMS

EQ 5MG BASE/5ML

A075181 001 Dec 23, 2002

SOLUTION/DROPS; OPHTHALMIC

INFLAMASE FORTE

NOVARTIS

EQ 0.9% PHOSPHATE

A080751 002

INFLAMASE MILD

NOVARTIS

EQ 0.11% PHOSPHATE

A080751 001

METRETON

SCHERING

EQ 0.5% PHOSPHATE

A083834 001

PREDAIR

PHARMAFAIR

EQ 0.11% PHOSPHATE

A088415 001 Feb 29, 1984

PREDAIR FORTE

PHARMAFAIR

EQ 0.9% PHOSPHATE

A088165 001 Mar 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AKORN

EQ 0.11% PHOSPHATE

A083358 001

EQ 0.9% PHOSPHATE

A083358 002

ALCON UNIVERSAL

EQ 0.11% PHOSPHATE

A081043 001 Oct 24, 1991

EQ 0.9% PHOSPHATE

A081044 001 Oct 24, 1991

BAUSCH AND LOMB

EQ 0.11% PHOSPHATE

A040065 001 Jul 29, 1994

SOLA BARNES HIND

EQ 0.11% PHOSPHATE

A084171 001

EQ 0.9% PHOSPHATE

A084168 001

EQ 0.9% PHOSPHATE

A084169 001

EQ 0.9% PHOSPHATE

A084172 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULSTER

AKORN

EQ 0.23% PHOSPHATE;10%

A074511 001 Jul 30, 1996

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

MERCK

20MG/ML

N010562 001

PREDNISOLONE TEBUTATE

WATSON LABS

20MG/ML

A083362 001 Feb 17, 1984

PREDNISONE

SOLUTION; ORAL

PREDNISONE

WOCKHARDT

5MG/5ML

A089726 001 Aug 02, 1988

SYRUP; ORAL

LIQUID PRED

MURO

5MG/5ML

A087611 002 Sep 07, 1982

TABLET; ORAL

CORTAN

HALSEY

20MG

A087480 001

DELTA-DOME

BAYER PHARMS

5MG

A080293 001

DELTASONE

PHARMACIA AND UPJOHN

2.5MG

N009986 005

5MG

N009986 002

10MG

N009986 006

20MG

N009986 007

50MG

N009986 008

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 265 (of 331)

PREDNISONE

TABLET; ORAL

FERNISONE

FERNDAL LABS

5MG

A083364 001

METICORTEN

SCHERING

1MG

N009766 002

5MG

N009766 001

ORASONE

SOLVAY

1MG

A083009 001

5MG

A083009 002

10MG

A083009 003

20MG

A083009 004

50MG

A085999 001

PARACORT

PARKE DAVIS

5MG

N010962 002

PREDNICEN-M

SCHWARZ PHARMA

5MG

A084655 001

PREDNISONE

AM THERAP

5MG

A089387 001

Nov 06, 1986

10MG

A089388 001

Nov 06, 1986

20MG

A089389 001

Nov 06, 1986

AMNEAL PHARMS NY

5MG

A089597 001

Oct 05, 1987

10MG

A089598 001

Oct 05, 1987

20MG

A089599 001

Oct 05, 1987

BUNDY

5MG

A083676 001

DURAMED PHARMS BARR

5MG

A088394 001

Oct 04, 1983

10MG

A088395 001

Oct 04, 1983

20MG

A088396 001

Oct 04, 1983

ELKINS SINN

5MG

A080491 001

20MG

A085811 001

EVERYLIFE

1MG

A084440 001

2.5MG

A084440 002

5MG

A084440 003

FERRANTE

2.5MG

A080563 001

5MG

A080563 002

HALSEY

5MG

A080300 001

HEATHER

5MG

A080320 001

10MG

A084341 001

20MG

A084417 001

20MG

A085543 001

50MG

A086946 001

IMPAX LABS

5MG

A080782 001

INWOOD LABS

1MG

A080328 001

2.5MG

A080306 001

5MG

A080279 001

IVAX SUB TEVA PHARMS

5MG

A080283 001

10MG

A084133 001

20MG

A084134 001

KV PHARM

5MG

A084236 001

LANNETT

5MG

A080514 001

20MG

A084275 001

LEDERLE

5MG

A086968 001

MARSHALL PHARMA

5MG

A080301 001

MUTUAL PHARM

5MG

A080701 001

10MG

A086595 001

20MG

A084634 001

50MG

A086596 001

NYLOS

5MG

A085115 001

PANRAY

1MG

A080350 001

2.5MG

A080350 002

5MG

A080350 003

PERRIGO

5MG

A083059 001

PHARMAVITE

5MG

A084662 002

PHOENIX LABS NY

5MG

A080321 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 266 (of 331)

PREDNISONETABLET; ORAL
PREDNISONE

PHOENIX LABS NY	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
ROXANE	20MG	N017109	001	
	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	
	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
SCHERER LABS	5MG	A080371	001	
SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WEST WARD	50MG	A088465	001	Jun 01, 1984
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	
SERVISONE				
LEDERLE	5MG	A080223	001	

PRILOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
CITANEST

ASTRAZENECA	1%	N014763	004	
	2%	N014763	005	
	3%	N014763	003	
CITANEST PLAIN				
ASTRAZENECA	4%	N014763	007	

PRIMIDONESUSPENSION; ORAL
MYSOLINE

XCEL PHARMS	250MG/5ML	N010401	001	
TABLET; ORAL				
PRIMIDONE				
WATSON LABS	250MG	A085052	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 267 (of 331)

PROBENECID

TABLET; ORAL

BENEMID

MERCK

500MG

N007898 004

PROBENECID

LEDERLE

500MG

A086917 001

WATSON LABS

500MG

A086150 002

Apr 23, 1982

PROBUCOL

TABLET; ORAL

LORELCO

SANOFI AVENTIS US

250MG

N017535 001

500MG

N017535 002

Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ASCOT

250MG

A087542 001

Jan 08, 1982

375MG

A087697 001

Mar 01, 1983

500MG

A087543 001

Jan 08, 1982

IVAX SUB TEVA PHARMS

250MG

A084604 001

375MG

A084595 001

500MG

A084606 001

LANNETT

250MG

A083693 001

500MG

A084696 001

LEDERLE

250MG

A086942 001

375MG

A086952 001

500MG

A086943 001

ROXANE

250MG

A088989 001

Apr 26, 1985

500MG

A088990 001

Apr 26, 1985

SANDOZ

250MG

A089219 001

Jul 01, 1986

375MG

A089220 001

Jul 01, 1986

500MG

A089221 001

Jul 01, 1986

VANGARD

250MG

A087643 001

Jun 01, 1982

500MG

A087875 001

Jun 01, 1982

WATSON LABS

250MG

A083287 001

250MG

A083795 001

250MG

A085167 001

375MG

A084403 001

375MG

A087020 001

500MG

A084280 001

500MG

A084357 001

500MG

A087021 001

PROCAN

PARKE DAVIS

250MG

A085804 001

375MG

A087502 001

500MG

A085079 001

PROCAPAN

PANRAY

250MG

A083553 002

PRONESTYL

APOTHECON

250MG

N007335 001

375MG

N007335 004

500MG

N007335 003

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A089415 001

Nov 17, 1986

500MG/ML

A089416 001

Nov 17, 1986

BAXTER HLTHCARE

100MG/ML

A089029 001

Apr 17, 1986

500MG/ML

A089030 001

Apr 17, 1986

HOSPIRA

500MG/ML

A089537 001

Aug 25, 1987

PHARMAFAIR

100MG/ML

A088824 001

Nov 20, 1985

500MG/ML

A088830 001

Nov 20, 1985

SMITH AND NEPHEW

100MG/ML

A088530 001

Mar 04, 1985

500MG/ML

A088531 001

Mar 04, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 268 (of 331)

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

SOLOPAK	500MG/ML	A088532	001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528	001	May 03, 1988
	500MG/ML	A089529	001	May 03, 1988
WATSON LABS	100MG/ML	A087079	001	
	500MG/ML	A087080	001	

PRONESTYL

APOTHECON	100MG/ML	N007335	002	
	500MG/ML	N007335	005	

TABLET; ORAL

PRONESTYL

APOTHECON	250MG	N017371	001	
	375MG	N017371	002	
	500MG	N017371	003	

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

COPLEY PHARM	500MG	A088974	001	Jul 22, 1985
	750MG	A089438	001	Mar 23, 1987
	1GM	A040111	001	Dec 13, 1996
INWOOD LABS	500MG	A089840	001	Mar 06, 1989
PLIVA	250MG	A088958	001	Dec 02, 1985
	500MG	A088959	001	Dec 02, 1985
SANDOZ	250MG	A089369	001	Aug 14, 1987
	500MG	A089284	001	Jun 23, 1986
	500MG	A089370	001	Jan 09, 1987
	750MG	A089371	001	Aug 14, 1987
WATSON LABS	250MG	A088533	001	Dec 03, 1984
	250MG	A089026	001	Oct 22, 1985
	500MG	A088534	001	Dec 03, 1984
	500MG	A089027	001	Oct 22, 1985
	750MG	A088535	001	Nov 03, 1984
	750MG	A089042	001	Oct 22, 1985
	1GM	A089520	001	Jan 15, 1987

PROCAN SR

PARKE DAVIS	250MG	A086468	001	
PARKEDALE	500MG	A086065	001	
	750MG	A087510	001	Apr 01, 1982
	1GM	A088489	001	Jan 16, 1985

PROCANBID

KING PHARMS	500MG	N020545	001	Jan 31, 1996
	1GM	N020545	002	Jan 31, 1996

PRONESTYL-SR

APOTHECON	500MG	A087361	001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA	1%	A085362	003	
	2%	A085362	004	
	10%	A086797	001	

PROCAINE HYDROCHLORIDE

ABRAXIS PHARM	1%	A080384	002	
	1%	A080421	001	
	2%	A080384	003	
	2%	A080421	002	
BEL MAR	1%	A080711	001	
	2%	A080756	001	
ELKINS SINN	1%	A083315	001	
	2%	A083315	002	
GD SEARLE LLC	1%	A086202	001	
	2%	A086202	002	
HOSPIRA	1%	A080416	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 269 (of 331)

PROCAINE HYDROCHLORIDEINJECTABLE; INJECTION
PROCAINE HYDROCHLORIDE

HOSPIRA	2%	A080416	002
MILES	1%	A080415	001
	2%	A080415	002
WATSON LABS	1%	A080658	001
	1%	A083535	001
	2%	A080658	002
	2%	A083535	002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDEINJECTABLE; INJECTION
ACHROMYCIN

LEDERLE	40MG/VIAL;100MG/VIAL	N050276	001
	40MG/VIAL;250MG/VIAL	N050276	003

TETRACYN

PFIZER	40MG/VIAL;100MG/VIAL	A060285	002
	40MG/VIAL;250MG/VIAL	A060285	003

PROCAINE MERETHOXYLLINE; THEOPHYLLINEINJECTABLE; INJECTION
DICURIN PROCAINE

LILLY	100MG/ML;50MG/ML	N008869	001

PROCHLORPERAZINESUPPOSITORY; RECTAL
COMPAZINE

GLAXOSMITHKLINE	2.5MG	N011127	003
	5MG	N011127	001
	25MG	N011127	002

PROCHLORPERAZINE

ABLE	2.5MG	A040407	001	Jul 11, 2001
	5MG	A040407	002	Jul 11, 2001
	25MG	A040407	003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATECONCENTRATE; ORAL
COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276	001

PROCHLORPERAZINE

ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153	001	Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE	EQ 10MG BASE/ML	A088598	001	Oct 25, 1984

INJECTABLE; INJECTION
COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/ML	N010742	002

PROCHLORPERAZINE

BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759	001	Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

BAXTER HLTHCARE	EQ 5MG BASE/ML	A089523	001	May 03, 1988

HOSPIRA	EQ 5MG BASE/ML	A089703	001	Apr 07, 1988

MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675	001	Dec 05, 1988

SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251	001	Dec 04, 1986

TEVA PARENTERAL	EQ 5MG BASE/ML	A040505	001	May 30, 2003

WATSON LABS	EQ 5MG BASE/ML	A089530	001	Jul 08, 1987

	EQ 5MG BASE/ML	A089605	001	Jul 08, 1987

	EQ 5MG BASE/ML	A089606	001	Jul 08, 1987

WYETH AYERST	EQ 5MG BASE/ML	A086348	001

SYRUP; ORAL
COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188	001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 270 (of 331)

PROCHLORPERAZINE EDISYLATE

SYRUP; ORAL

PROCHLORPERAZINE EDISYLATE

MORTON GROVE

EQ 5MG BASE/5ML

A088597 001

Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE

N011000 001

EQ 10MG BASE

N021019 001

Oct 06, 1999

EQ 15MG BASE

N011000 002

EQ 15MG BASE

N021019 002

Oct 06, 1999

EQ 30MG BASE

N011000 003

EQ 75MG BASE

N011000 004

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE

N010571 001

EQ 10MG BASE

N010571 002

EQ 25MG BASE

N010571 003

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE

A085580 001

EQ 10MG BASE

A085178 001

EQ 25MG BASE

A085579 001

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR

EQ 5MG BASE

A040207 001

May 01, 1997

EQ 5MG BASE

A089484 001

Jan 20, 1987

EQ 10MG BASE

A040207 002

May 01, 1997

EQ 10MG BASE

A089485 001

Jan 20, 1987

EQ 25MG BASE

A089486 001

Jan 20, 1987

IVAX SUB TEVA PHARMS

EQ 5MG BASE

A040162 001

Jan 20, 1998

EQ 10MG BASE

A040162 002

Jan 20, 1998

SANDOZ

EQ 25MG BASE

A040101 003

Jul 19, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS

2MG

N009818 005

5MG

N009818 003

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

ABBOTT PRODS

300MG

N019781 003

Oct 15, 1999

INJECTABLE; INJECTION

PROGESTERONE

LILLY

25MG/ML

N009238 002

50MG/ML

N009238 001

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA

38MG

N017553 001

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST

30MG/ML

N010942 001

100MG/ML

N010942 004

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS

25MG/ML

A084510 001

50MG/ML

A084517 001

SPARINE

BAXTER HLTHCARE CORP

25MG/ML

N010349 008

50MG/ML

N010349 006

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 271 (of 331)

PROMAZINE HYDROCHLORIDE

SYRUP; ORAL SPARINE			
WYETH AYERST	10MG/5ML	N010942	003
TABLET; ORAL SPARINE			
WYETH AYERST	10MG	N010348	006
	25MG	N010348	001
	50MG	N010348	002
	100MG	N010348	003
	200MG	N010348	004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION PHENERGAN			
WYETH AYERST	25MG/ML	N008857	002
	50MG/ML	N008857	003
PROMETHAZINE HYDROCHLORIDE			
ABBOTT	25MG/ML	A084223	001
	50MG/ML	A084222	001
AKORN	25MG/ML	A083955	002
	50MG/ML	A083955	001
BEDFORD LABS	25MG/ML	A040524	001 Mar 17, 2004
	50MG/ML	A040524	002 Mar 17, 2004
BIONICHE PHARMA	25MG/ML	A040471	001 Nov 21, 2002
HOSPIRA	50MG/ML	A040372	002 Jun 08, 2000
	50MG/ML	A083838	002
MARSAM PHARMS LLC	25MG/ML	A089463	001 May 02, 1988
	50MG/ML	A089477	001 May 02, 1988
SANDOZ	25MG/ML	A040593	001 Nov 08, 2006
	50MG/ML	A040593	002 Nov 08, 2006
WATSON LABS	25MG/ML	A083532	001
	25MG/ML	A084591	001
	50MG/ML	A080629	002
	50MG/ML	A083532	002
ZIPAN-25			
ALTANA	25MG/ML	A083997	001
ZIPAN-50			
ALTANA	50MG/ML	A083997	002
SUPPOSITORY; RECTAL PHENERGAN			
VICTORY PHARMA	12.5MG	N010926	002
	25MG	N010926	001
	50MG	N011689	001
PROMETHACON			
POLYMEDICA	25MG	A084901	001
	50MG	A084902	001
PROMETHAZINE HYDROCHLORIDE			
ABLE	12.5MG	A040504	001 Apr 11, 2003
	25MG	A040504	002 Apr 11, 2003
	50MG	A040449	001 Feb 27, 2003
SYRUP; ORAL MYMETHAZINE FORTIS			
USL PHARMA	25MG/5ML	A087996	001 Jan 18, 1983
PROMETH FORTIS			
ALPHARMA US PHARMS	25MG/5ML	A084772	001
PROMETH PLAIN			
ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953	001
PROMETHAZINE			
CENCI	6.25MG/5ML	A089013	001 Sep 20, 1985
PROMETHAZINE HYDROCHLORIDE			
KV PHARM	6.25MG/5ML	A085388	001
	25MG/5ML	A085385	001
PHARM ASSOC	6.25MG/5ML	A087518	001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 272 (of 331)

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

WHITEWORTH TOWN PLSN 6.25MG/5ML

A086395 001

PROMETHAZINE HYDROCHLORIDE PLAIN

ANI PHARMS 6.25MG/5ML
25MG/5ML

N008381 004

Apr 18, 1984

N008381 003

TABLET; ORAL

PHENERGAN

WYETH PHARMS INC

12.5MG

N007935 002

25MG

N007935 003

50MG

N007935 004

PROMETHAZINE HYDROCHLORIDE

ABBOTT

12.5MG

A084160 001

25MG

A084166 001

50MG

A084539 001

ABLE

12.5MG

A040558 001

Jul 01, 2004

25MG

A040558 002

Jul 01, 2004

50MG

A040558 003

Jul 01, 2004

IMPAX LABS

25MG

A084214 002

Jul 07, 1982

IVAX SUB TEVA PHARMS

12.5MG

A083604 001

25MG

A083603 001

50MG

A083613 001

LANNETT

12.5MG

A080949 001

25MG

A080949 002

50MG

A080949 003

MUTUAL PHARM

12.5MG

A084555 001

25MG

A084554 001

50MG

A084557 001

PVT FORM

12.5MG

A083214 001

25MG

A083658 001

SANDOZ

12.5MG

A084176 002

May 22, 2009

12.5MG

A084233 001

25MG

A085146 001

50MG

A085146 002

TABLICAPS

12.5MG

A084080 001

25MG

A084027 001

TEVA

25MG

A089109 001

Sep 10, 1985

WATSON LABS

12.5MG

A083401 001

12.5MG

A083712 001

12.5MG

A085986 001

25MG

A083204 001

25MG

A085684 001

50MG

A083403 001

50MG

A085664 001

REMSED

BRISTOL MYERS SQUIBB

25MG

A083176 002

50MG

A083176 001

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC

30MG/VIAL

N008843 001

TABLET; ORAL

PRO-BANTHINE

SHIRE

7.5MG

N008732 003

15MG

N008732 002

PROPANTHELINE BROMIDE

ASCOT

15MG

A087663 001

Oct 25, 1982

HEATHER

15MG

A085780 001

IMPAX LABS

15MG

A084541 002

MYLAN

15MG

A083706 001

PAR PHARM

15MG

A088377 001

Dec 08, 1983

PVT FORM

15MG

A080977 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 273 (of 331)

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

ROXANE	7.5MG	A080927	001
	15MG	A080927	002
SANDOZ	15MG	A080928	001
TABLICAPS	15MG	A084428	001
WATSON LABS	15MG	A083029	002
	15MG	A083151	001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR	0.5%	A088087	001	Jun 07, 1983

PARACAINE

OPTOPICS	0.5%	A087681	001	Aug 05, 1982

PROPARACAINE HYDROCHLORIDE

SOLA BARNES HIND	0.5%	A084144	001
	0.5%	A084151	001

PROPIOLACTONE

SOLUTION; IRRIGATION

BETAPRONE

FOREST LABS	N/A	N011657	001

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

BAXTER HLTHCARE CORP	20MG/ML	N012382	002

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

APP PHARMS	10MG/ML	N019627	001	Oct 02, 1989

PROPOFOL

BEDFORD	10MG/ML	A074848	001	Apr 19, 2005
TEVA PARENTERAL	10MG/ML	A075392	001	Sep 19, 2000

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

XANODYNE PHARM	32MG	N010997	001

KESSO-GESIC

MK LABS	65MG	A083544	001

PROPHENE 65

HALSEY	65MG	A083538	002

PROPOXYPHENE HYDROCHLORIDE

ALRA	65MG	A083184	001

IMPAX LABS	65MG	A083317	001

IVAX SUB TEVA PHARMS	32MG	A083597	001

MUTUAL PHARM	65MG	A083186	001

MYLAN	32MG	A083528	001

	65MG	A083299	001

NEXGEN PHARMA INC	65MG	A083185	001

PAR PHARM	65MG	A080269	001

PUREPAC PHARM	65MG	A083278	001

PVT FORM	32MG	A083464	001

	65MG	A083113	001

ROXANE	32MG	A083089	001

	65MG	A083089	002

SANDOZ	32MG	A084014	001

	65MG	A083125	002

	65MG	A083688	001

	65MG	A083870	002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 274 (of 331)

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

SANDOZ	65MG	A086495	001
VALEANT PHARM INTL	65MG	A080783	001
WATSON LABS	65MG	A080908	002
	65MG	A085190	001
WHITEWORTH TOWN PLSN	65MG	A084551	001
PROPOXYPHENE HYDROCHLORIDE 65			
WARNER CHILCOTT	65MG	A083786	001

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

AAIPHARMA LLC	50MG/5ML	N016861	001

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS	60MG	A072499	001	Apr 11, 1989
	80MG	A072500	001	Apr 11, 1989
	120MG	A072501	001	Apr 11, 1989
	160MG	A072502	001	Apr 11, 1989

CONCENTRATE; ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE	80MG/ML	A071388	001	May 15, 1987

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

SMITH AND NEPHEW	1MG/ML	A070135	001	Apr 15, 1986
	1MG/ML	A070137	001	Apr 15, 1986
SOLOPAK	1MG/ML	A070136	001	Apr 15, 1986

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

MORTON GROVE	20MG/5ML	A071984	001	Mar 03, 1989
	40MG/5ML	A071985	001	Mar 03, 1989

SUSPENSION; ORAL

INDERAL

WYETH AYERST	10MG/ML	N019536	001	Dec 12, 1986

TABLET; ORAL

INDERAL

AKRIMAX PHARMS	10MG	N016418	001	
	20MG	N016418	003	
	90MG	N016418	010	Oct 18, 1982

PROPRANOLOL HYDROCHLORIDE

CLONMEL HLTHCARE	10MG	A070125	001	Jul 30, 1985
	20MG	A070126	001	Jul 30, 1985
	40MG	A070127	001	Jul 30, 1985
	60MG	A071495	001	Dec 31, 1987
	80MG	A070128	001	Jul 30, 1985
	90MG	A071496	001	Dec 31, 1987
DURAMED PHARMS BARR	10MG	A070306	001	Sep 09, 1985
	20MG	A070307	001	Sep 09, 1985
	40MG	A070308	001	Sep 09, 1985
	60MG	A070309	001	Oct 01, 1986
	80MG	A070310	001	Sep 09, 1985
	90MG	A071327	001	Oct 01, 1986
INTERPHARM	10MG	A071368	001	May 05, 1987
	20MG	A071369	001	May 05, 1987
	40MG	A071370	001	May 05, 1987
	80MG	A071371	001	May 05, 1987
IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
	20MG	A072066	001	Jul 29, 1988
	40MG	A072067	001	Jul 29, 1988
	60MG	A072068	001	Jul 29, 1988
	80MG	A072069	001	Jul 29, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 275 (of 331)

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

LEDERLE	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MUTUAL PHARM	10MG	A070319	001	Oct 22, 1985
	20MG	A070320	001	Oct 22, 1985
	40MG	A070103	001	Oct 22, 1985
	60MG	A070321	001	Sep 24, 1986
	80MG	A070322	001	Aug 04, 1986
	60MG	A072275	001	Jun 09, 1989
MYLAN	60MG	A072275	001	Jun 09, 1989
PAR PHARM	90MG	A071288	001	Oct 22, 1986
PLIVA	90MG	A071977	001	Apr 06, 1988
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
	10MG	A070516	001	Jul 07, 1986
ROXANE	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
	90MG	A070521	001	Sep 24, 1986
	10MG	A070663	001	Jun 13, 1986
SANDOZ	10MG	A071658	001	Jul 05, 1988
	20MG	A070664	001	Jun 13, 1986
	20MG	A071687	001	Jul 05, 1988
	40MG	A070665	001	Jun 13, 1986
	40MG	A071688	001	Jul 05, 1988
	60MG	A070666	001	Oct 10, 1986
	60MG	A072197	001	Jul 05, 1988
	80MG	A070667	001	Jun 13, 1986
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
SCHERING	80MG	A070124	001	Aug 06, 1985
	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
SUPERPHARM	80MG	A071518	001	Jun 08, 1988
	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
TEVA	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
WARNER CHILCOTT	80MG	A070442	001	Sep 15, 1986
	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	10MG	A070548	001	Jul 10, 1986
WATSON LABS	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	20MG	A070549	001	Apr 11, 1986
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	40MG	A070550	001	Apr 11, 1986
	60MG	A070143	001	Jan 15, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 276 (of 331)

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

WATSON LABS

60MG

A070381 001 Mar 19, 1987

60MG

A071098 001 Oct 06, 1986

60MG

A071791 001 Jul 15, 1987

80MG

A070144 001 Jul 30, 1985

80MG

A070382 001 Mar 19, 1987

80MG

A070551 001 Jul 10, 1986

90MG

A071183 001 Oct 06, 1986

90MG

A071792 001 Jul 15, 1987

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE

50%

N009309 001

DIONOSIL OILY

GLAXOSMITHKLINE

60%

N009309 002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT

50MG

A084075 001

ANABOLIC

50MG

A080285 001

HALSEY

50MG

A080015 001

IMPAX LABS

50MG

A080159 001

IVAX SUB TEVA PHARMS

50MG

A080215 001

LANNETT

50MG

A080016 001

LILLY

50MG

N006213 001

MUTUAL PHARM

50MG

A083982 001

PERRIGO

50MG

A084543 001

TABLICAPS

50MG

A080840 001

WATSON LABS

50MG

A080932 001

50MG

A085201 001

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

BAXTER HLTHCARE

10MG/ML

A089474 001 Nov 05, 1986

10MG/ML

A089475 001 Nov 05, 1986

LILLY

10MG/ML

N006460 002

PHARMACIA AND UPJOHN

50MG/VIAL

N007413 001

250MG/VIAL

N007413 002 Aug 02, 1984

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBOTT

5%

N005932 012 Jan 31, 1985

HYPROTIGEN 5%

B BRAUN

5%

N006170 003 Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT

0.5MG/ML

N017638 001

THYREL TRH

FERRING

0.5MG/ML

N018087 001

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US

2MG

A083459 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 277 (of 331)

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

ODYSSEY PHARMS

5MG

N016012 001

10MG

N016012 002

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US

120MG

N017603 001

SUDAFED 12 HOUR

GLAXOSMITHKLINE

120MG

N017941 002

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACTIFED

GLAXOSMITHKLINE

120MG;5MG

N018996 001 Jun 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG;5MG

A071798 001 Mar 16, 1989

SYRUP; ORAL

ACTAHIST

CENCI

30MG/5ML;1.25MG/5ML

A088344 001 Feb 09, 1984

HISTAFED

CENCI

30MG/5ML;1.25MG/5ML

A088283 001 Apr 20, 1984

MYFED

USL PHARMA

30MG/5ML;1.25MG/5ML

A088116 001 Mar 04, 1983

TRILITRON

NEWTRON PHARMS

30MG/5ML;1.25MG/5ML

A088474 001 Feb 12, 1985

TABLET; ORAL

ALLERFED

PVT FORM

60MG;2.5MG

A088860 001 Jan 31, 1985

CORPHED

SANDOZ

60MG;2.5MG

A088602 001 Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ

60MG;2.5MG

A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS

60MG;2.5MG

A088515 001 Jan 09, 1985

TRIPHED

TEVA

60MG;2.5MG

A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS

60MG;2.5MG

A088318 002 Jan 13, 1984

WEST WARD

60MG;2.5MG

A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

60MG;2.5MG

A085273 001 Dec 12, 1984

SUPERPHARM

60MG;2.5MG

A088578 001 Feb 21, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG;5MG

A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

PSEUDO-12

UCB INC

EQ 60MG HCL/5ML

N019401 001 Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

BARR

30MG

A040512 002 Jul 20, 2005

60MG

A040512 001 Oct 08, 2003

SOLVAY

30MG

A089572 001 Nov 27, 1990

US ARMY

30MG

N020414 001 Feb 05, 2003

DISCONTINUED DRUG PRODUCT LIST

6 - 278 (of 331)

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION			
HEXA-BETALIN			
LILLY	100MG/ML	A080854	001
PYRIDOXINE HYDROCHLORIDE			
AKORN	100MG/ML	A087967	001
BEL MAR	100MG/ML	A080761	001
DELL LABS	50MG/ML	A083771	001
	100MG/ML	A083772	001
ELKINS SINN	100MG/ML	A080581	001
LUITPOLD	100MG/ML	A080669	001
WATSON LABS	100MG/ML	A080572	001
	100MG/ML	A083760	001

Oct 01, 1982

PYRILAMINE MALEATE

TABLET; ORAL			
PYRILAMINE MALEATE			
IMPAX LABS	25MG	A080808	001
WATSON LABS	25MG	A085231	001

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL			
FANSIDAR			
ROCHE	25MG;500MG	N018557	001

PYRITHIONE ZINC

LOTION; TOPICAL			
HEAD & SHOULDERS CONDITIONER			
WARNER CHILCOTT	0.3%	N019412	002

Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION; ORAL			
POVAN			
PARKE DAVIS	EQ 50MG BASE/5ML	N011964	001
TABLET; ORAL			
POVAN			
PARKE DAVIS	EQ 50MG BASE	N012485	002

QUAZEPAM

TABLET; ORAL			
DORAL			
QUESTCOR PHARMS	7.5MG	N018708	003

Feb 26, 1987

QUETIAPINE FUMARATE

TABLET; ORAL			
SEROQUEL			
ASTRAZENECA	EQ 150MG BASE	N020639	004

Dec 20, 1998

QUINESTROL

TABLET; ORAL			
ESTROVIS			
PARKE DAVIS	0.1MG	N016768	002
	0.2MG	N016768	003

QUINETHAZONE

TABLET; ORAL			
HYDROMOX			
LEDERLE	50MG	N013264	001

QUINETHAZONE; RESERPINE

TABLET; ORAL			
HYDROMOX R			
LEDERLE	50MG;0.125MG	N013927	001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 279 (of 331)

QUINIDINE GLUCONATE

TABLET; ORAL

QUINACT

BAYER HLTHCARE 266MG
400MGA085978 001
A086099 001

TABLET, EXTENDED RELEASE; ORAL

DURAQUIN

WARNER CHILCOTT 330MG

N017917 001

QUINAGLUTE

BAYER HLTHCARE 324MG

N016647 001

QUINALAN

LANNETT 324MG

A088081 001 Feb 10, 1986

QUINATIME

WATSON LABS 324MG

A087448 001

QUINIDINE GLUCONATE

ASCOT 324MG

A088582 001 Jun 17, 1985

HALSEY 324MG

A089476 001 Apr 10, 1987

ROXANE 324MG

A088431 001 Jan 06, 1984

SANDOZ 324MG

A089894 001 Dec 15, 1988

SUPERPHARM 324MG

A089164 001 Nov 21, 1985

WATSON LABS 324MG

A087785 001 Jan 24, 1983

QUINIDINE POLYGALACTURONATE

TABLET; ORAL

CARDIOQUIN

PHARM RES ASSOC 275MG

N011642 002

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY 200MG
300MGA085296 001
A085297 001

QUINIDINE SULFATE

LILLY 200MG

A085103 001

TABLET; ORAL

CIN-QUIN

SOLVAY 100MG
200MG
300MGA085299 001
A084932 001
A085298 001

QUINIDINE SULFATE

BARR 200MG

A084177 001

CLONMEL HLTHCARE 200MG

A087011 001

CONTRACT PHARMACAL 200MG

A083808 001

ELKINS SINN 200MG

A083622 001

EVERYLIFE 200MG

A083439 001

HALSEY 200MG

A083583 001

IMPAX LABS 200MG

A083347 001

IVAX SUB TEVA PHARMS 200MG

A084549 001

KING PHARMS 200MG

A085175 001

KV PHARM 200MG

A085276 001

LANNETT 200MG

A083743 001

LEDERLE 200MG

A086176 001

LILLY 200MG

A085038 001

MUTUAL PHARM 100MG

A081029 001 Apr 14, 1989

PERRIGO 200MG

A085322 001

PHARMAVITE 200MG

A084627 001

PUREPAC PHARM 200MG

A084003 001

ROXANE 200MG

A083640 001

300MG

A085632 001

SANDOZ 200MG

A084631 001

200MG

A084914 001

300MG

A089839 001 Sep 29, 1988

SCHERER LABS 200MG

A085068 001

SUPERPHARM 200MG

A088973 001 Apr 10, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 280 (of 331)

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A085140	002	
WEST WARD	200MG	A083862	001	
WHITEWORTH TOWN PLSN	200MG	A085444	001	

QUINORA

KEY PHARMS	200MG	A083576	001	
SCHERING	300MG	A085222	001	

TABLET, EXTENDED RELEASE; ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796	002	

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

EISAI INC	10MG	N020973	001	May 29, 2002

RABEPRAZOLE SODIUM

TEVA	20MG	A076822	001	Feb 21, 2007

RANITIDINE BISMUTH CITRATE

TABLET; ORAL

TRITEC

GLAXOSMITHKLINE	400MG	N020559	001	Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

GENPHARM	EQ 150MG BASE	A075564	001	Oct 27, 2000
	EQ 300MG BASE	A075564	002	Oct 27, 2000
TEVA	EQ 150MG BASE	A075557	001	Oct 31, 2003
	EQ 300MG BASE	A075557	002	Oct 31, 2003

ZANTAC 150

GLAXOSMITHKLINE	EQ 150MG BASE	N020095	001	Mar 08, 1994

ZANTAC 300

GLAXOSMITHKLINE	EQ 300MG BASE	N020095	002	Mar 08, 1994

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

GLAXOSMITHKLINE	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD	EQ 25MG BASE/ML	A074764	001	Nov 19, 2004

ZANTAC IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662	001	Aug 29, 1997
	EQ 300MG BASE	A074662	002	Aug 29, 1997
MYLAN	EQ 150MG BASE	A074552	001	Jul 30, 1998
	EQ 300MG BASE	A074552	002	Jul 30, 1998
RANBAXY	EQ 75MG BASE	A075132	001	Jan 14, 2000
	EQ 75MG BASE	A075254	001	Jan 14, 2000
	EQ 150MG BASE	A075000	001	Jan 30, 1998
	EQ 150MG BASE	A075439	001	Apr 19, 2000
	EQ 300MG BASE	A075000	002	Jan 30, 1998
	EQ 300MG BASE	A075439	002	Apr 19, 2000
SANDOZ	EQ 75MG BASE	A075519	001	Sep 26, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 281 (of 331)

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

GLAXOSMITHKLINE

EQ 150MG BASE

N020251 001

Mar 31, 1994

ZANTAC 75

BOEHRINGER INGELHEIM

EQ 75MG BASE

N020745 001

Feb 26, 1998

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

RAPLON

ORGANON USA INC

100MG/VIAL

N020984 001

Aug 18, 1999

200MG/VIAL

N020984 002

Aug 18, 1999

RAUWOLFIA SERPENTINA ROOT

TABLET; ORAL

HIWOLFIA

BOWMAN PHARMS

50MG

N009276 003

50MG

N009276 005

100MG

N009276 004

HYSERPIN

PHYS PRODS VA

50MG

N010581 001

KONGLUCOID

PANRAY

50MG

N009278 001

100MG

N009278 002

RAUDIXIN

APOTHECON

50MG

N008842 001

100MG

N008842 002

RAUSERPIN

FERNDAL LABS

50MG

N009926 002

100MG

N009926 004

RAUVAL

PAL PAK

50MG

N009108 002

100MG

N009108 004

RAUWOLFIA SERPENTINA

BUNDY

50MG

N009477 001

100MG

N009477 002

HALSEY

50MG

A080498 001

100MG

A080498 002

IMPAX LABS

50MG

N009273 001

100MG

N009273 002

IVAX SUB TEVA PHARMS

50MG

N011521 001

100MG

N011521 002

PUREPAC PHARM

50MG

A080842 001

100MG

A080842 002

PVT FORM

50MG

A080583 001

100MG

A080583 002

SOLVAY

50MG

A080500 001

100MG

A080500 002

TABLICAPS

50MG

A083867 001

100MG

A083444 001

VALEANT PHARM INTL

50MG

N009668 001

100MG

N009668 002

WATSON LABS

50MG

A080907 001

100MG

A080914 001

WOLFINA

FOREST PHARMS

50MG

N009255 008

100MG

N009255 006

RESCINNAMINE

CAPSULE; ORAL

CINNASIL

PANRAY

0.5MG

A084736 001

DISCONTINUED DRUG PRODUCT LIST

6 - 282 (of 331)

RESCINNAMINE

TABLET; ORAL
MODERIL

PFIZER	0.25MG	N010686	003
	0.5MG	N010686	006

RESERPINE

ELIXIR; ORAL
SERPASIL

NOVARTIS	0.2MG/4ML	N009115	005

INJECTABLE; INJECTION
SANDRIL

LILLY	2.5MG/ML	N010012	001

SERPASIL

NOVARTIS	2.5MG/ML	N009434	002

TABLET; ORAL
HISERPIA

BOWMAN PHARMS	0.1MG	N009631	002
	0.25MG	N009631	004

RAU-SED

BRISTOL MYERS SQUIBB	0.1MG	N009357	001
	0.25MG	N009357	004
	0.5MG	N009357	006
	1MG	N009357	008

RESERPINE

BARR	0.25MG	A080721	002

BELL PHARMA	0.1MG	A083058	001

	0.25MG	A083058	002

BUNDY	0.1MG	N009663	001

	0.25MG	N009663	003

ELKINS SINN	0.1MG	A083145	001

	0.25MG	A083145	002

EVERYLIFE	0.1MG	N010441	001

	0.25MG	N010441	002

	0.5MG	N010441	003

	1MG	N010441	004

HALSEY	0.1MG	A080457	002

	0.25MG	A080457	001

	1MG	A080457	003

IMPAX LABS	0.1MG	N009627	001

	0.25MG	N009627	002

IVAX SUB TEVA PHARMS	0.1MG	N011185	001

	0.25MG	N011185	002

MARSHALL PHARMA	0.1MG	A080492	001

	0.25MG	A080492	002

MK LABS	0.1MG	A080525	002

	0.25MG	A080525	001

MYLAN	1MG	A084974	001

PHARMAVITE	0.25MG	A084663	001

PUREPAC PHARM	0.1MG	A080753	002

	0.25MG	A080753	001

PVT FORM	0.1MG	A086117	001

	0.25MG	A080582	001

	0.25MG	A085775	001

	1MG	A080582	002

REXALL	0.25MG	A080637	001

ROXANE	0.1MG	N009859	001

	0.25MG	N009859	002

SOLVAY	0.25MG	A080446	001

TABLICAPS	0.25MG	A085207	001

TEVA	0.1MG	A089020	001	

	0.25MG	A089019	001	Mar 07, 1985

VALEANT PHARM INTL	0.1MG	N009667	001

	0.25MG	N009667	002

DISCONTINUED DRUG PRODUCT LIST

6 - 283 (of 331)

RESERPINE

TABLET; ORAL
RESERPINE

WATSON LABS	0.1MG	A080679	001
	0.25MG	A080393	001
	0.25MG	A085401	001
	1MG	A080749	001
WEST WARD	0.1MG	A080975	001
	0.25MG	A080975	002
	1MG	A080975	003
WHITEWORTH TOWN PLSN	0.1MG	A080723	001
	0.25MG	A080723	002
	1MG	A080723	003
SANDRIL LILLY	0.1MG	N009376	004
	0.25MG	N009376	001
SERPANRAY PANRAY	0.1MG	N009391	001
	0.25MG	N009391	002
	1MG	N009391	004
SERPASIL NOVARTIS	0.1MG	N009115	001
	0.25MG	N009115	003
	1MG	N009115	004
SERPATE VALE	0.1MG	N009453	001
	0.25MG	N009453	002
SERPIVITE VITARINE	0.25MG	N009645	002

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2 SANOFI AVENTIS US	0.1MG;2MG	N012972	001
METATENSIN #4 SANOFI AVENTIS US	0.1MG;4MG	N012972	002
NAQUIVAL SCHERING	0.1MG;4MG	N012265	003
TRICHLORMETHIAZIDE W/ RESERPINE WATSON LABS	0.1MG;4MG	A085248	001

RIBAVIRIN

TABLET; ORAL

COPEGUS ROCHE	400MG	N021511	002	Jun 21, 2005

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

FLUMADINE FOREST LABS	50MG/5ML	N019650	001	Sep 17, 1993

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL WARNER CHILCOTT	75MG	N020835	004	Apr 16, 2007

RISPERIDONE

TABLET; ORAL

RISPERDAL ORTHO MCNEIL JANSSEN	5MG	N020272	005	Dec 29, 1993
RISPERIDONE SYNTHON PHARMS	0.25MG	A078187	001	Oct 22, 2009
	0.5MG	A078187	002	Oct 22, 2009
	1MG	A078187	003	Oct 22, 2009

DISCONTINUED DRUG PRODUCT LIST

6 - 284 (of 331)

RISPERIDONE

TABLET; ORAL
RISPERIDONE

SYNTHON PHARMS	2MG	A078187	004	Oct 22, 2009
	3MG	A078187	005	Oct 22, 2009
	4MG	A078187	006	Oct 22, 2009

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A071188	001	Jul 23, 1987
	15MG/ML	A071189	001	Jul 23, 1987
HOSPIRA	10MG/ML	A071618	001	Feb 28, 1991
	15MG/ML	A071619	001	Feb 28, 1991

RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML	A071438	001	Jan 22, 1991

YUTOPAR

ASTRAZENECA	10MG/ML	N018580	001	
	15MG/ML	N018580	002	

TABLET; ORAL

YUTOPAR

ASTRAZENECA	10MG	N018555	001	

RITONAVIR

CAPSULE; ORAL
NORVIR

ABBOTT	100MG	N020680	001	Mar 01, 1996

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ZEMURON

SCHERING	10MG/ML (10MG/ML)	N020214	002	Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL
VIOXX

MERCK	12.5MG/5ML	N021052	001	May 20, 1999
	25MG/5ML	N021052	002	May 20, 1999

TABLET; ORAL

VIOXX

MERCK	12.5MG	N021042	001	May 20, 1999
	25MG	N021042	002	May 20, 1999
	50MG	N021042	003	Feb 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
REQUIP XL

SMITHKLINE BEECHAM	EQ 3MG BASE	N022008	002	Jun 13, 2008

ROSE BENGAL SODIUM I-131

INJECTABLE; INJECTION
ROBENGATOPE

BRACCO	0.5mCi/VIAL	N016224	001	
	1mCi/VIAL	N016224	002	
	2mCi/VIAL	N016224	003	

SODIUM ROSE BENGAL I 131

SORIN	0.5mCi/ML	N017318	001	

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NEUPRO

UCB INC	2MG/24HR	N021829	001	May 09, 2007
	4MG/24HR	N021829	002	May 09, 2007
	6MG/24HR	N021829	003	May 09, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 285 (of 331)

RUFINAMIDE

TABLET; ORAL

BANZEL

EISAI INC

100MG

N021911 001

Nov 14, 2008

SAFFLOWER OIL

INJECTABLE; INJECTION

LIPOSYN 10%

ABBOTT

10% (10GM/100ML)

N018203 001

LIPOSYN 20%

ABBOTT

20% (20GM/100ML)

N018614 001

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

SEREVENT

GLAXOSMITHKLINE

EQ 0.021MG BASE/INH

N020236 001

Feb 04, 1994

SAQUINAVIR

CAPSULE; ORAL

FORTOVASE

HOFFMANN LA ROCHE

200MG

N020828 001

Nov 07, 1997

SARALASIN ACETATE

INJECTABLE; INJECTION

SARENIN

PROCTER AND GAMBLE

EQ 0.6MG BASE/ML

N018009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

ANABOLIC

100MG

A084422 001

BARR

100MG

A084225 001

EVERYLIFE

100MG

A085895 001

HALSEY

100MG

A084676 001

IVAX PHARMS

100MG

A085869 001

KV PHARM

100MG

A085285 001

LANNETT

50MG

A085909 001

100MG

A085903 001

PARKE DAVIS

100MG

A084762 001

PERRIGO

100MG

A084561 001

PUREPAC PHARM

100MG

A085867 001

VALEANT PHARM INTL

100MG

A085477 001

VITARINE

100MG

A085898 001

100MG

A086273 001

WATSON LABS

100MG

A085792 001

WEST WARD

100MG

A084926 001

WHITEWORTH TOWN PLSN

100MG

A085798 001

WYETH AYERST

100MG

A086390 001

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN

100MG/VIAL

A083281 001

WYETH AYERST

50MG/ML

A083262 001

SECONAL SODIUM

LILLY

50MG/ML

N007392 002

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY

30MG

A086530 001

60MG

A086530 002

120MG

A086530 003

200MG

A086530 004

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 286 (of 331)

SECRETIN

INJECTABLE; INJECTION
SECRETIN-FERRING
FERRING

75CU/VIAL

N018290 001

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS
SECREFO
CHIRHOCLIN

16MCG/VIAL

N021136 001 Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
SELEGILINE HYDROCHLORIDE
AAIPHARMA LLC

5MG

A075145 001 Sep 15, 2003

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

ENDO PHARMS 5MG

A074565 001 Aug 02, 1996

IVAX SUB TEVA PHARMS 5MG

A074756 001 Nov 25, 1998

SIEGFRIED 5MG

A074672 001 Apr 01, 1997

SOMERSET 5MG

N019334 001 Jun 05, 1989

TEVA 5MG

A074537 001 Aug 02, 1996

5MG

A074744 001 Jan 27, 1997

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
EXSEL

ALLERGAN HERBERT 2.5%

A083892 001

SELENIUM SULFIDE

IVAX PHARMS 2.5%

A085777 001

TARO 2.5%

A086209 001

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION
SELENOMETHIONINE SE 75

GE HEALTHCARE 250uCi/ML

N017257 001

MALLINCKRODT 100uCi/ML

N017098 001

PHARMALUCENCE 500uCi/ML

N017322 001

SETHOTOPE

BRACCO 85-550uCi/ML

N017047 001

SERACTIDE ACETATE

INJECTABLE; INJECTION
ACTHAR GEL-SYNTHETIC
ARMOUR PHARM

40 UNITS/ML

N017861 001

80 UNITS/ML

N017861 002

SERMORELIN ACETATE

INJECTABLE; INJECTION
GEREF

EMD SERONO EQ 0.05MG BASE/AMP

N019863 001 Dec 28, 1990

EQ 0.5MG BASE/VIAL

N020443 001 Sep 26, 1997

EQ 1MG BASE/VIAL

N020443 002 Sep 26, 1997

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ACTAVIS ELIZABETH EQ 25MG BASE

A077345 001 Feb 06, 2007

EQ 50MG BASE

A077345 002 Feb 06, 2007

EQ 100MG BASE

A077345 003 Feb 06, 2007

MUTUAL PHARM EQ 25MG BASE

A077818 001 Feb 06, 2007

EQ 50MG BASE

A077818 002 Feb 06, 2007

EQ 100MG BASE

A077818 003 Feb 06, 2007

SANDOZ EQ 25MG BASE

A077713 001 Feb 06, 2007

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 287 (of 331)

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

SANDOZ	EQ 50MG BASE	A077713	002	Feb 06, 2007
	EQ 100MG BASE	A077713	003	Feb 06, 2007
WATSON LABS	EQ 25MG BASE	A077162	001	Feb 06, 2007
	EQ 50MG BASE	A077162	002	Feb 06, 2007
	EQ 100MG BASE	A077162	003	Feb 06, 2007
ZOLOFT				
PFIZER	EQ 150MG BASE	N019839	003	Dec 30, 1991
	EQ 200MG BASE	N019839	004	Dec 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

GENZYME	403MG	N020926	001	Oct 30, 1998

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

MERIDIA

ABBOTT	5MG	N020632	001	Nov 22, 1997
	10MG	N020632	002	Nov 22, 1997
	15MG	N020632	003	Nov 22, 1997

SILVER SULFADIAZINE

DRESSING; TOPICAL

SILDAFLO

FRANKLIN PHARMS	1%	N019608	001	Nov 30, 1989

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX

BRACCO	7.5MG/ML	N020773	001	Oct 29, 1998

SIMVASTATIN

TABLET, ORALLY DISINTEGRATING; ORAL

SIMVASTATIN

SYNTHON PHARMS	10MG	N021961	001	Oct 09, 2007
	20MG	N021961	002	Oct 09, 2007
	40MG	N021961	003	Oct 09, 2007
	80MG	N021961	004	Oct 09, 2007

SIROLIMUS

TABLET; ORAL

RAPAMUNE

WYETH PHARMS INC	5MG	N021110	003	Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

B BRAUN	100MG/ML;100MG/ML	N019530	001	Dec 23, 1987

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT	0.9MEQ/ML	N019443	001	Jun 03, 1986
	1MEQ/ML	N019443	002	Jun 03, 1986

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

LAFAYETTE PHARMS	460MG/GM;420MG/GM	N018509	001	Aug 07, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 288 (of 331)

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM 9MG/ML

A088909 001 Feb 07, 1985

SODIUM CHLORIDE

ABBOTT 20GM/100ML

N017013 001

B BRAUN 20GM/100ML

N017038 001

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 450MG/100ML

N018184 001

MILES 450MG/100ML

N018503 001

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT 9MG/ML

N019218 001

MILES 900MG/100ML

N018502 001 Jul 13, 1984

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

ABRAXIS PHARM 234MG/ML

N019329 001 Apr 22, 1987

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

B BRAUN 3GM/100ML

N019635 003 Mar 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML

N019635 004 Mar 09, 1988

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

BAXTER HLTHCARE 450MG/100ML

N018497 001 Feb 19, 1982

SODIUM CHLORIDE IN PLASTIC CONTAINER

MILES 900MG/100ML

N018247 001

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

BRACCO 2mCi/VIAL

N013993 002

SODIUM CHROMATE CR 51

MALLINCKRODT 100uCi/ML

N016708 001

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

GE HEALTHCARE 2mCi/ML

N017042 001

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

SYNCOR PHARMS 400uCi

N018671 003 May 27, 1982

SODIUM IODIDE I-131

CAPSULE; ORAL

IODOTOPE

BRACCO 1-130mCi

N010929 001

1-150mCi

N010929 003

SODIUM IODIDE I 131

CIS 50uCi

N017316 001

100uCi

N017316 002

MALLINCKRODT 0.8-100mCi

N016515 002

15-100uCi

N016517 002

SOLUTION; ORAL

IODOTOPE

BRACCO 7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS 50mCi/ML

N017315 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN 1.87GM/100ML

N018186 001

HOSPIRA 1.87GM/100ML

N018249 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 289 (of 331)

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL					
EXTRA-STRENGTH AIM					
CHESEBROUGH PONDS	1.2%		N019518	002	Aug 06, 1986
PASTE; DENTAL					
EXTRA-STRENGTH AIM					
CHESEBROUGH PONDS	1.2%		N019518	001	Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION					
NIPRIDE					
ROCHE	50MG/VIAL		N017546	001	
NITROPRESS					
ABBOTT	50MG/VIAL		A071555	001	Nov 16, 1987
	50MG/VIAL		N018450	001	
HOSPIRA	50MG/VIAL		A070566	001	Jun 09, 1986
SODIUM NITROPRUSSIDE					
ABRAXIS PHARM	50MG/VIAL		A070031	001	Jan 17, 1985
BAXTER HLTHCARE	50MG/VIAL		N018581	001	Jul 28, 1982

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL					
PHOSPHOTOPE					
BRACCO	1-8mCi/VIAL		N010927	001	
SODIUM PHOSPHATE P 32					
MALLINCKRODT	0.67mCi/ML		N011777	001	
	1.5mCi/VIAL		N011777	002	

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL					
SODIUM POLYSTYRENE SULFONATE					
WOCKHARDT	453.6GM/BOT		A088786	001	Sep 11, 1984
SUSPENSION; ORAL, RECTAL					
SODIUM POLYSTYRENE SULFONATE					
MORTON GROVE	15GM/60ML		A088717	001	Sep 11, 1984
ROXANE	15GM/60ML		A088453	001	Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION					
SODIUM SUCCINATE					
ELKINS SINN	30%		A080516	001	

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION					
SOTRADECOL					
ELKINS SINN	1%		N005970	004	
	3%		N005970	005	

SODIUM THIOSULFATE

INJECTABLE; INJECTION					
SODIUM THIOSULFATE					
US ARMY	250MG/ML		N020166	001	Feb 14, 1992

SOMATREM

INJECTABLE; INJECTION					
PROTROPIN					
GENENTECH	5MG/VIAL		N019107	001	Oct 17, 1985
	10MG/VIAL		N019107	002	Oct 24, 1989

SOMATROPIN

INJECTABLE; INJECTION					
ASELLACRIN 10					
SERONO	10 IU/VIAL		N017726	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 290 (of 331)

SOMATROPIN

INJECTABLE; INJECTION
ASELLACRIN 2

SERONO	2 IU/VIAL	N017726	002	Jul 21, 1983

CRESCORMON GENENTECH	4 IU/VIAL	N017992	001	

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

ACCRETROPIN CANGENE	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008

BIO-TROPIN FERRING	4.8MG/VIAL	N019774	001	May 25, 1995

HUMATROPE LILLY	2MG/VIAL	N019640	001	Jun 23, 1987

NORDITROPIN NOVO NORDISK INC	4MG/VIAL 8MG/VIAL	N019721	001	May 08, 1995
		N019721	002	May 08, 1995

NUTROPIN DEPOT GENENTECH	13.5MG/VIAL 18MG/VIAL 22.5MG/VIAL	N021075	001	Dec 22, 1999
		N021075	002	Dec 22, 1999
		N021075	003	Dec 22, 1999

SAIZEN EMD SERONO	4MG/VIAL 6MG/VIAL	N019764	005	Jan 16, 2007
		N019764	001	Oct 08, 1996

SEROSTIM EMD SERONO	8.8MG/VIAL	N020604	004	Sep 06, 2001

ZORBTIVE EMD SERONO	4MG/VIAL 5MG/VIAL 6MG/VIAL	N021597	001	Dec 01, 2003
		N021597	002	Dec 01, 2003
		N021597	003	Dec 01, 2003

INJECTABLE; SUBCUTANEOUS

SEROSTIM LQ EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER BAXTER HLTHCARE	3GM/100ML	N018512	001	May 27, 1982

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE BAYER HLTHCARE	320MG	N019865	004	Oct 30, 1992

BETAPACE AF BAYER HLTHCARE	40MG 60MG 100MG	N021151	006	Apr 02, 2003
		N021151	007	Apr 02, 2003
		N021151	005	Mar 14, 2003

SOTALOL HYDROCHLORIDE MUTUAL PHARM	80MG 80MG 120MG 120MG 160MG 160MG 240MG	A075515	001	Oct 15, 2001
		A076576	001	Apr 08, 2004
		A075515	004	Oct 15, 2001
		A076576	002	Apr 08, 2004
		A075515	002	Oct 15, 2001
		A076576	003	Apr 08, 2004
		A075515	003	Oct 15, 2001
WATSON LABS	80MG 120MG 160MG 240MG	A075238	001	Jul 13, 2000
		A075238	002	Jul 13, 2000
		A075238	003	Jul 13, 2000
		A075238	004	Jul 13, 2000

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 291 (of 331)

SOYBEAN OIL

INJECTABLE; INJECTION

SOYACAL 10%

ALPHA THERA

10%

N018465 001 Jun 29, 1983

SOYACAL 20%

ALPHA THERA

20%

N018786 001 Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE

10%

N018660 001 Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE

20%

N018758 001 Feb 15, 1983

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN

200MG

N020677 001 Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PHARMACIA AND UPJOHN EQ 4GM BASE/VIAL

N050347 002

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING

3MG

N020240 001 Dec 29, 1994

6MG

N020240 002 Dec 29, 1994

12MG

N020240 003 Dec 29, 1994

24MG

N020240 004 Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ASCOT

25MG

A087687 001 Oct 20, 1982

IVAX PHARMS

25MG

A087108 001

LEDERLE

25MG

A087634 001

MUTUAL PHARM

25MG

A087265 001

MYLAN

25MG

A087086 001

PUREPAC PHARM

25MG

A087998 001 Oct 14, 1983

25MG

A088053 001 Aug 25, 1983

SUPERPHARM

25MG

A089364 001 Nov 07, 1986

UPSHER SMITH

25MG

A087554 001

VANGARD

25MG

A087648 001 Feb 01, 1982

WARNER CHILCOTT

25MG

A087952 001 Nov 18, 1982

WATSON LABS

25MG

A086898 002 Mar 02, 1982

25MG

A087078 001

STANOZOLOL

TABLET; ORAL

WINSTROL

LUNDBECK INC

2MG

N012885 001 May 14, 1984

STAVUDINE

CAPSULE; ORAL

ZERIT

BRISTOL MYERS SQUIBB 5MG

N020412 001 Jun 24, 1994

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

BRISTOL MYERS SQUIBB 37.5MG

N021453 001 Dec 31, 2002

50MG

N021453 002 Dec 31, 2002

75MG

N021453 003 Dec 31, 2002

100MG

N021453 004 Dec 31, 2002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 292 (of 331)

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM

100%

A089099 001

Dec 29, 1987

100%

A089100 001

Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN

100%

N019077 001

Mar 02, 1984

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES

100%

N018246 001

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS

EQ 500MG BASE/ML

A060684 001

LILLY

EQ 1GM BASE/VIAL

A060107 001

EQ 1GM BASE/2ML

A060404 001

EQ 5GM BASE/VIAL

A060107 002

PFIZER

EQ 1GM BASE/VIAL

A060076 001

EQ 5GM BASE/VIAL

A060076 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ

50MG/ML

N008453 003

500MG/VIAL

N008453 001

1GM/VIAL

N008453 004

QUELICIN PRESERVATIVE FREE

HOSPIRA

50MG/ML

N008845 002

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION

100MG/VIAL

A085400 001

Feb 04, 1982

ORGANON USA INC

20MG/ML

A080997 001

SUOSTRIN

APOTHECON

20MG/ML

N008847 001

100MG/ML

N008847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS

EQ 0.05MG BASE/ML

A074406 001

Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN

10%

A084015 001

SODIUM SULAMYD

SCHERING

10%

N005963 002

SULFAIR 10

PHARMAFAIR

10%

A088000 001

Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN

30%

A080028 002

ISOPTO CETAMIDE

ALCON

15%

A080020 002

OCUSULF-10

MIZA PHARMS USA

10%

A080660 001

OCUSULF-30

MIZA PHARMS USA

30%

A080660 002

SODIUM SULAMYD

SCHERING

10%

N005963 001

30%

N005963 003

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 293 (of 331)

SULFACETAMIDE SODIUMSOLUTION/DROPS; OPHTHALMIC
SODIUM SULFACETAMIDE

AKORN	10%	A083021	001	
	15%	A083021	002	
	30%	A083021	003	
SOLA BARNES HIND	10%	A084143	001	
	10%	A084145	001	
	30%	A084146	001	
	30%	A084147	001	
SULF-10				
NOVARTIS	10%	A080025	001	
SULF-15				
NOVARTIS	15%	A089047	001	Oct 31, 1995
SULFACEL-15				
OPTOPICS	15%	A080024	001	
SULFACETAMIDE SODIUM				
AKORN	10%	A040215	001	May 25, 1999
	30%	A040216	001	May 25, 1999
ALCON	30%	A089068	001	May 05, 1987
PHARMAFAIR	10%	A088947	001	May 17, 1985
SULFAIR 10				
PHARMAFAIR	10%	A087949	001	Dec 13, 1982
SULFAIR FORTE				
PHARMAFAIR	30%	A088385	001	Oct 13, 1983
SULFAIR-15				
PHARMAFAIR	15%	A088186	001	May 25, 1983
SULTEN-10				
BAUSCH AND LOMB	10%	A087818	001	Feb 03, 1983

SULFACYTINETABLET; ORAL
RENOQUID
GLENWOOD

250MG N017569 001

SULFADIAZINETABLET; ORAL
SULFADIAZINE

ABBOTT	300MG	N004125	005	
EVERYLIFE	500MG	A080088	001	
IMPAX LABS	500MG	A080081	001	
LANNETT	500MG	A080084	001	
LEDERLE	500MG	N004054	001	
LILLY	500MG	N004122	002	

SULFADIAZINE SODIUMINJECTABLE; INJECTION
SULFADIAZINE SODIUM
LEDERLE

250MG/ML N004054 002

SULFADIAZINE; SULFAMERAZINESUSPENSION; ORAL
SULFONAMIDES DUPLEX
LILLY

250MG/5ML; 250MG/5ML N006317 007

SULFAMETERTABLET; ORAL
SULLA

BAYER HLTHCARE 500MG N016000 002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 294 (of 331)

SULFAMETHIZOLE

TABLET; ORAL

MICROSUL

FOREST PHARMS

1GM

A086012 001

PROKLAR

FOREST PHARMS

500MG

A080273 001

THIOSULFIL

WYETH AYERST

250MG

N008565 001

500MG

N008565 004

SULFAMETHOXAZOLE

SUSPENSION; ORAL

GANTANOL

ROCHE

500MG/5ML

N013664 002

TABLET; ORAL

GANTANOL

ROCHE

500MG

N012715 002

GANTANOL - DS

ROCHE

1GM

N012715 003

SULFAMETHOXAZOLE

ASCOT

500MG

A087662 001

Oct 20, 1982

BARR

500MG

A087189 001

Jul 25, 1983

HEATHER

500MG

A086163 001

SANDOZ

500MG

A085844 001

WATSON LABS

500MG

A085053 001

1GM

A086000 001

UROBAK

SHIONOGI

500MG

A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

MUTUAL PHARM

80MG/ML;16MG/ML

N018374 001

SEPTRA

MONARCH PHARMS

80MG/ML;16MG/ML

N018452 001

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM

80MG/ML;16MG/ML

A070223 001

Dec 29, 1987

BAXTER HLTHCARE

80MG/ML;16MG/ML

A070627 001

Dec 29, 1987

80MG/ML;16MG/ML

A070628 001

Dec 29, 1987

BEDFORD

80MG/ML;16MG/ML

A072383 001

Apr 29, 1992

HOSPIRA

80MG/ML;16MG/ML

A073199 001

Sep 11, 1992

WATSON LABS

80MG/ML;16MG/ML

A071556 001

Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

MUTUAL PHARM

200MG/5ML;40MG/5ML

N017560 001

BACTRIM PEDIATRIC

MUTUAL PHARM

200MG/5ML;40MG/5ML

N017560 002

SEPTRA

MONARCH PHARMS

200MG/5ML;40MG/5ML

N017598 001

SEPTRA GRAPE

MONARCH PHARMS

200MG/5ML;40MG/5ML

N017598 002

Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

TEVA

200MG/5ML;40MG/5ML

A070028 001

Jun 02, 1987

200MG/5ML;40MG/5ML

N018812 001

Jan 28, 1983

200MG/5ML;40MG/5ML

N018812 002

Jun 10, 1983

TEVA PHARMS

200MG/5ML;40MG/5ML

A077612 001

Nov 13, 2006

SULFATRIM

ACTAVIS MID ATLANTIC

200MG/5ML;40MG/5ML

N018615 002

Jan 07, 1983

SULMEPRIM

USL PHARMA

200MG/5ML;40MG/5ML

A070063 001

Aug 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA

200MG/5ML;40MG/5ML

A070064 001

Aug 01, 1986

TRIMETH/SULFA

ALPHARMA US PHARMS

200MG/5ML;40MG/5ML

A072289 001

May 23, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 295 (of 331)

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

TRIMETH/SULFA

ALPHARMA US PHARMS	200MG/5ML; 40MG/5ML	A072398	001	May 23, 1988
NASKA	200MG/5ML; 40MG/5ML	A072399	001	May 23, 1988

TABLET; ORAL

COTRIM

TEVA	400MG; 80MG	A070034	001	May 16, 1985

COTRIM D.S.

TEVA	800MG; 160MG	A070048	001	Mar 18, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

HEATHER	400MG; 80MG	N018946	001	Aug 10, 1984

	800MG; 160MG	N018946	002	Aug 10, 1984

INTERPHARM	400MG; 80MG	A071299	001	Oct 27, 1987

	800MG; 160MG	A071300	001	Oct 27, 1987

MARTEC USA LLC	400MG; 80MG	A072408	001	Dec 07, 1988

MUTUAL PHARM	400MG; 80MG	A070006	001	Nov 14, 1984

	400MG; 80MG	A071016	001	Aug 25, 1986

PLIVA	400MG; 80MG	A070215	001	Sep 10, 1985

	800MG; 160MG	A070216	001	Sep 10, 1985

ROXANE	400MG; 80MG	A072768	001	Aug 30, 1991

SANDOZ	400MG; 80MG	A070889	001	Nov 13, 1986

	400MG; 80MG	N018598	003	May 19, 1982

	800MG; 160MG	A070890	001	Nov 13, 1986

TEVA	400MG; 80MG	N018242	001	

	800MG; 160MG	N018242	002	

USL PHARMA	400MG; 80MG	A070203	001	Nov 08, 1985

	800MG; 160MG	A070204	001	Nov 08, 1985

WATSON LABS	400MG; 80MG	A070002	001	Nov 07, 1984

	400MG; 80MG	N018852	001	May 09, 1983

	800MG; 160MG	A070000	001	Nov 07, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

MARTEC USA LLC	800MG; 160MG	A072417	001	Dec 07, 1988

MUTUAL PHARM	800MG; 160MG	A070007	001	Nov 14, 1984

ROXANE	800MG; 160MG	A072769	001	Aug 30, 1991

WATSON LABS	800MG; 160MG	N018854	001	May 09, 1983

SULFATRIM-DS

SUPERPHARM	800MG; 160MG	A070066	001	Jun 24, 1985

SULFATRIM-SS

SUPERPHARM	400MG; 80MG	A070065	002	Jun 24, 1985

UROPLUS DS

SHIONOGI	800MG; 160MG	A071816	001	Sep 28, 1987

UROPLUS SS

SHIONOGI	400MG; 80MG	A071815	001	Sep 28, 1987

SULFANILAMIDE

CREAM; VAGINAL

SULFANILAMIDE

TEVA	15%	A088718	001	Sep 19, 1985

SUPPOSITORY; VAGINAL

AVC

AZUR PHARMA	1.05GM	N006530	004	Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION; ORAL

SULFABID

PHARM RES ASSOC	500MG/5ML	N013093	001	

TABLET; ORAL

SULFABID

PURDUE FREDERICK	500MG	N013092	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 296 (of 331)

SULFAPYRIDINE

TABLET; ORAL SULFAPYRIDINE LILLY	500MG	N000159	001

SULFASALAZINE

SUSPENSION; ORAL AZULFIDINE PHARMACIA AND UPJOHN	250MG/5ML	N018605	001	
TABLET; ORAL S.A.S. -500 SOLVAY	500MG	A083450	001	
SULFASALAZINE HERITAGE PHARMS INC	500MG	A080197	001	
MUTUAL PHARM	500MG	A089590	001	Oct 19, 1987
SANDOZ	500MG	A086184	001	
SUPERPHARM	500MG	A089339	001	Oct 26, 1987
WATSON LABS	500MG	A084964	001	
TABLET, DELAYED RELEASE; ORAL SULFASALAZINE WATSON LABS	500MG	A088052	001	May 24, 1983

SULFINPYRAZONE

CAPSULE; ORAL ANTURANE NOVARTIS	200MG	N011556	004	
SULFINPYRAZONE BARR	200MG	A087666	001	Sep 17, 1982
IVAX PHARMS	200MG	A087770	001	Nov 19, 1982
PAR PHARM	200MG	A088934	001	Sep 06, 1985
VANGARD	200MG	A088666	001	Feb 17, 1984
TABLET; ORAL ANTURANE NOVARTIS	100MG	N011556	003	
SULFINPYRAZONE BARR	100MG	A087665	001	Sep 17, 1982
IVAX PHARMS	100MG	A087769	001	Jun 01, 1982
PAR PHARM	100MG	A088933	001	Sep 06, 1985
WATSON LABS	100MG	A087667	001	May 26, 1982

SULFISOXAZOLE

TABLET; ORAL GANTRISIN ROCHE	500MG	N006525	001	
SOSOL MK LABS	500MG	A080036	001	
SOXAZOLE ALRA	500MG	A080366	001	
SULFALAR PARKE DAVIS	500MG	A084955	001	
SULFISOXAZOLE BARR	500MG	A084031	001	
HEATHER	500MG	A080189	001	
IMPAX LABS	500MG	A080109	001	
IVAX SUB TEVA PHARMS	500MG	A080142	001	
LANNETT	500MG	A080085	001	
LEDERLE	500MG	A087649	001	
PHARMERAL	500MG	A084385	001	
PUREPAC PHARM	500MG	A080087	001	
ROXANE	500MG	A080082	001	
SANDOZ	500MG	A085628	001	
VALEANT PHARM INTL	500MG	A080268	002	
VITARINE	500MG	A087332	001	
WATSON LABS	500MG	A085534	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 297 (of 331)

SULFISOXAZOLE

TABLET; ORAL				
SULFISOXAZOLE				
WEST WARD	500MG	A080379	001	
SULSOXIN				
SOLVAY	500MG	A080040	001	

SULFISOXAZOLE ACETYL

EMULSION; ORAL				
LIPO GANTRISIN				
ROCHE	EQ 1GM BASE/5ML	N009182	009	
SUSPENSION; ORAL				
GANTRISIN PEDIATRIC				
ROCHE	EQ 500MG BASE/5ML	N009182	004	
SYRUP; ORAL				
GANTRISIN				
ROCHE	EQ 500MG BASE/5ML	N009182	002	

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION				
GANTRISIN				
ROCHE	EQ 400MG BASE/ML	N006917	001	
OINTMENT; OPHTHALMIC				
GANTRISIN				
ROCHE	EQ 4% BASE	N008414	002	
SOLUTION/DROPS; OPHTHALMIC				
GANTRISIN				
ROCHE	EQ 4% BASE	N007757	002	
SULFISOXAZOLE DIOLAMINE				
SOLA BARNES HIND	EQ 4% BASE	A084148	001	

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL				
DIASONE SODIUM				
ABBOTT	165MG	N006044	003	

SULFUR

POWDER; TOPICAL				
BENSULFOID				
POYTHRESS	33.32%	N002918	001	

SULINDAC

TABLET; ORAL				
CLINORIL				
MERCK	150MG	N017911	001	
SULINDAC				
HERITAGE PHARMS INC	150MG	A073262	002	Sep 06, 1991
	200MG	A073262	001	Sep 06, 1991
SANDOZ	150MG	A072712	001	Aug 30, 1991
	200MG	A072713	001	Aug 30, 1991
TEVA	150MG	A072972	001	Feb 28, 1992
	200MG	A072973	001	Feb 28, 1992

SUMATRIPTAN

SPRAY; NASAL				
IMITREX				
GLAXOSMITHKLINE	10MG/SPRAY	N020626	002	Aug 26, 1997

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC				
PROFENAL				
ALCON	1%	N019387	001	Dec 23, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 298 (of 331)

SUTILAINS

OINTMENT; TOPICAL
TRAVASE
ABBOTT

82,000 UNITS/GM

N012828 001

TALBUTAL

TABLET; ORAL
LOTUSATE
SANOFI AVENTIS US

120MG

N009410 005

TAMOXIFEN CITRATE

SOLUTION; ORAL
SOLTAMOX

ROSEMONT

EQ 10MG BASE/5ML

N021807 001 Oct 29, 2005

TABLET; ORAL
NOLVADEX

ASTRAZENECA

EQ 10MG BASE

N017970 001

EQ 20MG BASE

N017970 002 Mar 21, 1994

TAMOXIFEN CITRATE

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075740 001 Feb 20, 2003

EQ 20MG BASE

A075740 002 Feb 20, 2003

PHARMACHEMIE

EQ 10MG BASE

A074539 001 Mar 31, 2003

ROXANE

EQ 10MG BASE

A076027 001 Feb 20, 2003

EQ 20MG BASE

A076027 002 Feb 20, 2003

TEVA

EQ 10MG BASE

A074504 001 Apr 28, 2003

EQ 20MG BASE

A074504 002 Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE; INJECTION
TC 99M-LUNGAGGREGATE

GE HEALTHCARE

5mCi/ML

N017848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS

N/A

N017916 001

AN-MAA

PHARMALUCENCE

N/A

N017792 001

LUNGAGGREGATE REAGENT

GE HEALTHCARE

N/A

N017838 001

MACROTEC

BRACCO

N/A

N017833 001

TECHNISCAN MAA

MALLINCKRODT

N/A

N017842 001

TECHNETIUM TC 99M MAA

GE HEALTHCARE

N/A

N017773 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE

PHARMALUCENCE

N/A

N018263 001 Mar 25, 1983

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M HSA

GE HEALTHCARE

N/A

N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION
INSTANT MICROSPHERES

3M

N/A

N017832 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 299 (of 331)

TECHNETIUM TC-99M APCITIDEINJECTABLE; INJECTION
ACUTECT

CIS BIO INTL SA N/A

N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDEINJECTABLE; INJECTION
NEO TECT KIT

CIS BIO INTL SA N/A

N021012 001 Aug 03, 1999

TECHNETIUM TC-99M ETIDRONATE KITINJECTABLE; INJECTION
CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE N/A

N017653 001

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE N/A

N017667 001

OSTEOSCAN

MALLINCKRODT N/A

N017454 001

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE N/A

N017562 001

TECHNETIUM TC-99M FERMENTETATE KITINJECTABLE; INJECTION
RENOTEC

BRACCO N/A

N017045 001

TECHNETIUM TC-99M GLUCEPTATE KITINJECTABLE; INJECTION
GLUCOSCAN

BRISTOL MYERS SQUIBB N/A

N017907 001

TECHNISCAN GLUCEPTATE

DRAXIMAGE N/A

N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KITINJECTABLE; INJECTION
TECHNISCAN HIDA

DRAXIMAGE N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATEINJECTABLE; INJECTION
DRAXIMAGE MDP-10

DRAXIMAGE N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION
AMERSCAN MDP KIT

GE HEALTHCARE N/A

N018335 001 Aug 05, 1982

OSTEOLITE

PHARMALUCENCE N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KITINJECTABLE; INJECTION
MPI DTPA KIT - CHELATE

GE HEALTHCARE N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE N/A

N017264 002

DISCONTINUED DRUG PRODUCT LIST

6 - 300 (of 331)

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION			
SODIUM POLYPHOSPHATE-TIN KIT			
GE HEALTHCARE	N/A	N017664	001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION			
PYROLITE			
PHARMALUCENCE	N/A	N017684	001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION			
PHOSPHOTEC			
BRACCO	N/A	N017680	001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION			
RBC-SCAN			
CADEMA	N/A	N020063	001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION			
MIRALUMA			
LANTHEUS MEDCL	N/A	N019785	003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL			
SODIUM PERTECHNETATE TC 99M			
GE HEALTHCARE	2-100mCi/ML	N017471	001
MALLINCKRODT	10-60mCi/ML	N017725	001
PHARMALUCENCE	12mCi/ML	N017321	001
	24mCi/ML	N017321	002
	48mCi/ML	N017321	003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL			
MINITEC			
BRACCO	0.22-2.22 CI/GENERATOR	N017339	001
TECHNETIUM TC 99M GENERATOR			
GE HEALTHCARE	830-16600mCi/GENERATOR	N017693	001

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL			
TECHNETIUM TC 99M SULFUR COLLOID			
GE HEALTHCARE	4mCi/ML	N017456	001
SOLUTION; ORAL			
TECHNETIUM TC 99M SULFUR COLLOID			
MALLINCKRODT	3mCi/ML	N017724	001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL			
TECHNECOLL			
MALLINCKRODT	N/A	N017059	001
TECHNETIUM TC 99M TSC			
GE HEALTHCARE	N/A	N017784	001
TESULOID			
BRACCO	N/A	N016923	001

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION			
CARDIOTEC			
BRACCO	N/A	N019928	001 Dec 19, 1990

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 301 (of 331)

TEGASEROD MALEATETABLET; ORAL
ZELNORM

NOVARTIS

EQ 2MG BASE

N021200 001 Jul 24, 2002

EQ 6MG BASE

N021200 002 Jul 24, 2002

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS

15MG

A070564 001 Oct 15, 1985

30MG

A070547 001 Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR

15MG

A071708 001 Sep 29, 1988

30MG

A071709 001 Sep 29, 1988

MUTUAL PHARM

15MG

A071174 001 Jul 10, 1986

30MG

A071175 001 Jul 10, 1986

USL PHARMA

15MG

A070489 001 Jul 07, 1986

30MG

A070490 001 Jul 07, 1986

WATSON LABS

15MG

A070383 001 Mar 23, 1987

30MG

A070384 001 Mar 23, 1987

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES

EQ 1MG BASE

A075384 001 Dec 01, 2000

EQ 2MG BASE

A075384 002 Dec 01, 2000

EQ 5MG BASE

A075384 003 Dec 01, 2000

EQ 10MG BASE

A075384 004 Dec 01, 2000

SANDOZ

EQ 1MG BASE

A075667 001 Jul 28, 2000

EQ 2MG BASE

A075667 002 Jul 28, 2000

EQ 5MG BASE

A075667 003 Jul 28, 2000

EQ 10MG BASE

A075667 004 Jul 28, 2000

TABLET; ORAL

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS

EQ 1MG BASE

A074530 001 Apr 21, 2000

EQ 2MG BASE

A074530 002 Apr 21, 2000

EQ 5MG BASE

A074530 003 Apr 21, 2000

EQ 10MG BASE

A074530 004 Apr 21, 2000

SANDOZ

EQ 1MG BASE

A074315 001 Dec 31, 1998

EQ 1MG BASE

A074657 001 Apr 28, 2000

EQ 2MG BASE

A074315 002 Dec 31, 1998

EQ 2MG BASE

A074657 002 Apr 28, 2000

EQ 5MG BASE

A074315 003 Dec 31, 1998

EQ 5MG BASE

A074657 003 Apr 28, 2000

EQ 10MG BASE

A074315 004 Dec 31, 1998

EQ 10MG BASE

A074657 004 Apr 28, 2000

TEVA

EQ 1MG BASE

A074446 001 May 18, 2000

EQ 2MG BASE

A074446 002 May 18, 2000

EQ 5MG BASE

A074446 003 May 18, 2000

EQ 10MG BASE

A074446 004 May 18, 2000

TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS

1%

N020846 001 Apr 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

NOVARTIS

1%

N020192 001 Dec 30, 1992

SOLUTION; TOPICAL

LAMISIL

NOVARTIS

1%

N020749 001 Oct 17, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 302 (of 331)

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

GEDEON RICHTER USA EQ 250MG BASE

A077065 001 Jul 02, 2007

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS 0.2MG/INH

N018762 001 Aug 17, 1984

BRICANYL

SANOFI AVENTIS US 0.2MG/INH

N018000 001 Mar 19, 1985

INJECTABLE; INJECTION

BRETHINE

AAIPHARMA LLC 1MG/ML

N018571 001

BRICANYL

SANOFI AVENTIS US 1MG/ML

N017466 001

TABLET; ORAL

BRETHINE

AAIPHARMA LLC 2.5MG
5MG

N017849 001

N017849 002

BRICANYL

SANOFI AVENTIS US 2.5MG
5MG

N017618 001

N017618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US 200 UNITS/VIAL

N019498 001 Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY 0.75MG/3ML (0.25MG/ML)

N021318 001 Nov 26, 2002

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB 100MG/ML

N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB 50MG
250MG

N016118 001

N016118 002

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

TESTODERM

ALZA 4MG/24HR
6MG/24HR

N019762 001 Oct 12, 1993

N019762 002 Oct 12, 1993

TESTODERM TTS

ALZA 5MG/24HR

N020791 001 Dec 18, 1997

GEL; TRANSDERMAL

TESTOSTERONE

PAR PHARM 1% (2.5GM/PACKET)
1% (5GM/PACKET)
WATSON LABS 1% (2.5GM/PACKET)
1% (5GM/PACKET)

A076744 001 May 23, 2007

A076744 002 May 23, 2007

A076737 001 Jan 27, 2006

A076737 002 Jan 27, 2006

INJECTABLE; INJECTION

TESTOSTERONE

WATSON LABS 25MG/ML
50MG/ML
100MG/ML

A086420 001 May 10, 1983

A086419 001 Aug 23, 1983

A086417 001 Jul 07, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 303 (of 331)

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION			
DEPO-TESTOSTERONE			
PHARMACIA AND UPJOHN	50MG/ML	A085635	001
TESTOSTERONE CYPIONATE			
WATSON LABS	100MG/ML	A084401	001
	100MG/ML	A086029	001
	200MG/ML	A084401	002

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION			
DELATESTYL			
ENDO PHARM	200MG/ML	N009165	001
TESTOSTERONE ENANTHATE			
WATSON LABS	100MG/ML	A083667	001
	100MG/ML	A085599	001
	200MG/ML	A083667	002

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION			
TESTOSTERONE PROPIONATE			
BEL MAR	25MG/ML	A080741	001
	50MG/ML	A080742	001
	100MG/ML	A080743	001
ELKINS SINN	25MG/ML	A080276	001
LILLY	50MG/ML	A080254	002
WATSON LABS	25MG/ML	A080188	001
	25MG/ML	A085490	001
	50MG/ML	A080188	002
	50MG/ML	A085490	002
	100MG/ML	A080188	003
	100MG/ML	A083595	003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL			
ACHROMYCIN V			
HERITAGE PHARMS INC	250MG	N050278	003
	500MG	N050278	001
BRISTACYCLINE			
BRISTOL	250MG	A061658	001
	250MG	A061888	001
	500MG	A061658	002
	500MG	A061888	002
CYCLOPAR			
WARNER CHILCOTT	250MG	A061725	001
	250MG	A062175	001
	250MG	A062332	001
	500MG	A061725	002
	500MG	A062332	002
PANMYCIN			
PHARMACIA AND UPJOHN	250MG	A060347	001
RETET			
SOLVAY	250MG	A061443	001
	500MG	A061443	002
ROBITET			
WYETH AYERST	250MG	A061734	001
	500MG	A061734	002
SUMYCIN			
APOTHECON	100MG	A060429	002
	125MG	A060429	004
	250MG	A060429	001
	500MG	A060429	003
TETRACHEL			
ANGUS	250MG	A060343	001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 304 (of 331)

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACHEL

ANGUS	500MG	A060343	003	

TETRACYCLINE HYDROCHLORIDE

ABBOTT	250MG	A061802	001	

	500MG	A061802	002	

ELKINS SINN	250MG	A060059	001	

FERRANTE	125MG	A060173	001	

	250MG	A060173	002	

HEATHER	250MG	A061148	001	

	500MG	A061148	002	

LABS ATRAL	250MG	A062752	001	Aug 12, 1988

	500MG	A062752	002	Aug 12, 1988

MAST MM	250MG	A062085	001	

MUTUAL PHARM	250MG	A060736	001	

	500MG	A060736	002	

MYLAN	250MG	A060783	001	

	500MG	A060783	002	

PUREPAC PHARM	250MG	A060290	001	

	500MG	A060290	002	

PVT FORM	250MG	A062686	001	Jul 24, 1986

	500MG	A062686	002	Jul 24, 1986

ROXANE	500MG	A061214	002	

SANDOZ	250MG	A061471	001	

SUPERPHARM	250MG	A062540	001	Mar 21, 1985

	500MG	A062540	002	Mar 21, 1985

VALEANT PHARM INTL	250MG	A060471	001	

	500MG	A060471	002	

WARNER CHILCOTT	250MG	A062300	001	

	500MG	A062300	002	

WATSON LABS	250MG	A062103	001	

	250MG	A062343	001	

	500MG	A062103	002	

	500MG	A062343	002	

WEST WARD	250MG	A060768	001	

	500MG	A060768	002	

WYETH AYERST	250MG	A061685	001	

	500MG	A061685	002	

TETRACYN

PFIPHARMECS	250MG	A060082	003	

	500MG	A060082	004	

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

ON SITE	12.7MG/FIBER	N050653	001	Mar 25, 1994

FOR SOLUTION; TOPICAL

TOPICYCLINE

SHIRE	2.2MG/ML	N050493	001	

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	250MG/VIAL	N050273	002	

	500MG/VIAL	N050273	003	

TETRACYN

PFIZER	250MG/VIAL	A060096	001	

	500MG/VIAL	A060096	002	

OINTMENT; OPHTHALMIC

ACHROMYCIN

STORZ	10MG/GM	N050266	001	

SUSPENSION; ORAL

ACHROMYCIN V

LEDERLE	125MG/5ML	N050263	002	

TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS	125MG/5ML	A060633	001	

FERRANTE	125MG/5ML	A060174	001	

PROTER	125MG/5ML	A060446	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 305 (of 331)

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

TETRACYCLINE HYDROCHLORIDE

PUREPAC PHARM	125MG/5ML	A060291	001

TETRACYN

PFIPHARMECS	125MG/5ML	A060095	001

TETRAMED

IVAX SUB TEVA PHARMS	125MG/5ML	A061468	001

SUSPENSION/DROPS; OPHTHALMIC

ACHROMYCIN

STORZ	1%	N050268	001

TABLET; ORAL

PANMYCIN

PHARMACIA AND UPJOHN	250MG	A061705	001

	500MG	A061705	002

SUMYCIN

PAR PHARM	50MG	A061147	003

	100MG	A061147	002

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

BRISTOL	EQ 100MG HCL	A061653	001

	EQ 250MG HCL	A061653	002

	EQ 250MG HCL	A061889	002

	EQ 250MG HCL	N050212	002

	EQ 500MG HCL	A061653	003

	EQ 500MG HCL	A061889	001

	EQ 500MG HCL	N050212	003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

BRACCO	1mCi/ML	N018548	001	Dec 30, 1982

TRACE LIFE	1mCi/ML	A075569	001	Nov 21, 2001

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

SANOFI AVENTIS US	100MG	A085264	001

	200MG	A085264	002

ELIXOPHYLLIN

FOREST LABS	100MG	A085545	001	Jul 31, 1984

	200MG	A083921	001	Jul 31, 1984

SOMOPHYLLIN-T

FISONS	100MG	A087155	001	Feb 25, 1985

	200MG	A087155	002	Feb 25, 1985

	250MG	A087155	003	Feb 25, 1985

THEOPHYLLINE

KV PHARM	100MG	A085263	001

	200MG	A085263	002

SCHERER RP	100MG	A084731	002	Nov 07, 1986

	200MG	A084731	001	Nov 07, 1986

	250MG	A084731	003	Nov 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986

AEROLATE JR

FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986

AEROLATE SR

FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986

ELIXOPHYLLIN SR

FOREST LABS	125MG	A086826	001	Jan 29, 1985

	250MG	A086826	002	Jan 29, 1985

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 306 (of 331)

THEOPHYLLINECAPSULE, EXTENDED RELEASE; ORAL
SLO-BID

SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
	75MG	A089539	001	May 10, 1989
	100MG	A087892	001	Jan 31, 1985
	125MG	A089540	001	May 10, 1989
	200MG	A087893	001	Jan 31, 1985
	300MG	A087894	001	Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
	125MG	A085203	001	May 24, 1982
	250MG	A085205	001	May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM	50MG	A087763	001	Feb 27, 1985
	100MG	A087194	001	
	200MG	A088382	001	Feb 27, 1985
	250MG	A087193	001	
	300MG	A088383	001	Feb 27, 1985

THEOBID

WHITBY	260MG	A085983	001	Mar 20, 1985

THEOBID JR.

WHITBY	130MG	A087854	001	Mar 20, 1985

THEOCLEAR L.A.-130

SCHWARZ PHARMA	130MG	A086569	001	May 27, 1982

THEOCLEAR L.A.-260

SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982

THEO-DUR

SCHERING	50MG	A088022	001	Sep 10, 1985
	75MG	A088015	001	Sep 10, 1985
	125MG	A088016	001	Sep 10, 1985
	200MG	A087995	001	Sep 10, 1985

THEOPHYLLINE

CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985
HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995
SANDOZ	260MG	A087462	001	May 11, 1982

THEOPHYLLINE-SR

SCHERER RP	300MG	A088255	001	Jun 12, 1986

THEOPHYL-SR

ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
	250MG	A086471	001	Feb 08, 1985

THEOVENT

SCHERING	125MG	A087010	001	Jan 31, 1985
	250MG	A087910	001	Jan 31, 1985

ELIXIR; ORAL

ELIXOMIN

CENCI	80MG/15ML	A088303	001	Jan 25, 1984

LANOPHYLLIN

LANNETT	80MG/15ML	A084578	001	

THEOLIXIR

PANRAY	80MG/15ML	A084559	001	

THEOPHYL-225

ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001	

THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988
CENCI	80MG/15ML	A087679	001	Apr 15, 1982
HALSEY	80MG/15ML	A085169	001	
PERRIGO	80MG/15ML	A085952	001	
PHARM ASSOC	80MG/15ML	A086720	001	
PRECISION DOSE	80MG/15ML	A085863	001	
ROXANE	80MG/15ML	A084739	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 307 (of 331)

THEOPHYLLINEELIXIR; ORAL
THEOPHYLLINE

TARO	80MG/15ML	A089626	001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748	001	

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984
	200MG/100ML	N019826	004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	4MG/ML	N019212	003	Nov 07, 1984
	400MG/100ML	N019212	002	Nov 07, 1984
	400MG/100ML	N019826	005	Aug 14, 1992

SOLUTION; ORAL

AEROLATE				
FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986
THEOLAIR				
3M	80MG/15ML	A086107	001	
THEOPHYLLINE				
ROXANE	80MG/15ML	A087449	001	Sep 15, 1983

SUSPENSION; ORAL

ELIXICON				
FOREST LABS	100MG/5ML	A085502	001	

SYRUP; ORAL

ACCURBRON				
SANOFI AVENTIS US	150MG/15ML	A088746	001	Nov 22, 1985
AQUAPHYLLIN				
FERNDAL LABS	80MG/15ML	A087917	001	Jan 18, 1983
SLO-PHYLLIN				
SANOFI AVENTIS US	80MG/15ML	A085187	001	
THEOCLEAR-80				
CENT PHARMS	80MG/15ML	A087095	001	Mar 01, 1982
THEOPHYLLINE				
ALPHARMA US PHARMS	80MG/15ML	A086001	001	
	150MG/15ML	A086545	001	

TABLET; ORAL

QUIBRON-T				
MONARCH PHARMS	300MG	A088656	001	Aug 22, 1985
SLO-PHYLLIN				
SANOFI AVENTIS US	100MG	A085202	001	
	200MG	A085204	001	
THEOCLEAR-100				
CENT PHARMS	100MG	A085353	002	
THEOCLEAR-200				
CENT PHARMS	200MG	A085353	001	
THEOPHYL-225				
ORTHO MCNEIL PHARM	225MG	A084726	001	

TABLET, CHEWABLE; ORAL

THEOPHYL				
ORTHO MCNEIL PHARM	100MG	A086506	001	Sep 12, 1985

TABLET, EXTENDED RELEASE; ORAL

DURAPHYL				
FOREST LABS	100MG	A088503	001	Apr 03, 1985
	200MG	A088504	001	Apr 03, 1985
	300MG	A088505	001	Apr 03, 1985

LABID

WARNER CHILCOTT	250MG	A087225	001	
QUIBRON-T/SR				
MONARCH PHARMS	300MG	A087563	001	Jun 21, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 308 (of 331)

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

SUSTAIRE

ROERIG

100MG

A085665 001

300MG

A085665 002

THEO-DUR

SCHERING

100MG

A085328 001

200MG

A086998 001

300MG

A085328 002

450MG

A089131 001

Jun 25, 1986

THEOLAIR-SR

3M

200MG

A088369 001

Jul 16, 1987

250MG

A086363 002

Jul 16, 1987

300MG

A088364 001

Jul 16, 1987

500MG

A089132 001

Jul 16, 1987

THEOPHYLLINE

ABLE

300MG

A040548 001

Apr 30, 2004

400MG

A040543 001

Apr 27, 2004

450MG

A040546 001

Apr 30, 2004

600MG

A040539 001

Apr 27, 2004

T-PHYL

PHARM RES ASSOC

200MG

A088253 001

Aug 17, 1983

UNI-DUR

SCHERING

400MG

A089822 001

Jan 04, 1995

600MG

A089823 001

Jan 04, 1995

UNIPHYL

PURDUE PHARM PRODS

400MG

A087571 001

Sep 01, 1982

600MG

A040086 001

Apr 15, 1996

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR; ORAL

SYNOHYLATE

CENT PHARMS

EQ 165MG BASE/15ML

N006333 008

TABLET; ORAL

ASBRON

NOVARTIS

EQ 150MG BASE

A085148 001

THIABENDAZOLE

SUSPENSION; ORAL

MINTEZOL

MERCK

500MG/5ML

N016097 001

TABLET, CHEWABLE; ORAL

MINTEZOL

MERCK

500MG

N016096 001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001

Oct 01, 1982

BAXTER HLTHCARE

100MG/ML

A080575 001

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A083534 001

200MG/ML

A083534 002

WYETH AYERST

100MG/ML

A080553 001

DISCONTINUED DRUG PRODUCT LIST

6 - 309 (of 331)

THIAMYLAL SODIUM

INJECTABLE; INJECTION
SURITAL

PARKEDALE	1GM/VIAL	N007600	003
	5GM/VIAL	N007600	005
	10GM/VIAL	N007600	009

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION
TORECAN

NOVARTIS	5MG/ML	N012754	002

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL
TORECAN

NOVARTIS	10MG	N013247	001

TABLET; ORAL
TORECAN

NOVARTIS	10MG	N012753	001

THIOPENTAL SODIUM

SUSPENSION; RECTAL
PENTOTHAL

ABBOTT	400MG/GM	N011679	001

THIORIDAZINE

SUSPENSION; ORAL
MELLARIL-S

NOVARTIS	EQ 25MG HCL/5ML	N017923	001
	EQ 100MG HCL/5ML	N017923	002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
MELLARIL

NOVARTIS	30MG/ML	N011808	012
	100MG/ML	N011808	018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A088229	001	Aug 23, 1983
ALPHARMA US PHARMS	30MG/ML	A087766	001	Apr 26, 1983
HI TECH PHARMA	30MG/ML	A040125	001	Aug 16, 1996
	100MG/ML	A040126	001	Aug 16, 1996
PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997
	100MG/ML	A040213	001	May 29, 1998
SANDOZ	30MG/ML	A088307	001	Nov 23, 1983
	100MG/ML	A088308	001	Nov 23, 1983
TEVA PHARMS	30MG/ML	A089602	001	Nov 09, 1987
	100MG/ML	A089603	001	Nov 09, 1987
WOCKHARDT	30MG/ML	A088258	001	Jul 25, 1983
	100MG/ML	A088227	001	Jul 05, 1983

THIORIDAZINE HYDROCHLORIDE INTENSOL

ROXANE	30MG/ML	A088941	001	Dec 16, 1985
	100MG/ML	A088942	001	Dec 16, 1985

TABLET; ORAL
MELLARIL

NOVARTIS	10MG	N011808	003
	15MG	N011808	016
	25MG	N011808	006
	50MG	N011808	011
	100MG	N011808	009
	150MG	N011808	017
	200MG	N011808	015

THIORIDAZINE HYDROCHLORIDE

IVAX PHARMS	10MG	A088270	001	Apr 14, 1983
	15MG	A088271	001	Apr 14, 1983

DISCONTINUED DRUG PRODUCT LIST

6 - 310 (of 331)

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

IVAX PHARMS	25MG	A088272	001	Apr 14, 1983
	50MG	A088194	001	Apr 14, 1983
	100MG	A088273	001	Oct 03, 1983
MUTUAL PHARM	10MG	A088375	001	Nov 18, 1983
	15MG	A088461	001	Nov 18, 1983
	25MG	A087264	001	Nov 18, 1983
	50MG	A088370	001	Nov 18, 1983
	100MG	A088379	001	Nov 16, 1983
	150MG	A088737	001	Sep 26, 1984
	200MG	A088738	001	Oct 16, 1984
MYLAN	10MG	A088332	001	Jun 27, 1983
	25MG	A088333	001	Jun 27, 1983
	50MG	A088334	001	Jun 27, 1983
	100MG	A088335	001	Nov 18, 1983
PAR PHARM	10MG	A088351	001	Dec 05, 1983
	15MG	A088352	001	Dec 05, 1983
	25MG	A088336	001	Dec 05, 1983
	50MG	A088322	001	Dec 05, 1983
	100MG	A088480	001	Dec 29, 1983
	150MG	A089764	001	Feb 09, 1988
	200MG	A089765	001	Feb 09, 1988
ROXANE	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985
SANDOZ	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
SUPERPHARM	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
TEVA	10MG	A088493	001	May 17, 1985
	100MG	A088456	001	May 17, 1985
WATSON LABS	10MG	A088412	001	Sep 12, 1983
	10MG	A088476	001	Nov 08, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983
	15MG	A088477	001	Nov 08, 1983
	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088478	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	25MG	A088755	001	Jul 24, 1984
	50MG	A088323	001	Jul 28, 1983
	50MG	A088479	001	Nov 08, 1983
	50MG	A088563	001	May 11, 1984
	100MG	A088284	001	Aug 25, 1983
	100MG	A088564	001	May 11, 1984
	100MG	A088736	001	Jul 24, 1984
	150MG	A088410	001	Mar 05, 1984
	150MG	A088869	001	Jun 28, 1985
	200MG	A088381	001	Mar 14, 1984
	200MG	A088872	001	Apr 26, 1985
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 311 (of 331)

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

IMMUNEX

15MG/VIAL

N020058 001

Dec 22, 1994

THIOTEPA

IMMUNEX

15MG/VIAL

N011683 001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

PFIZER

20MG

N016584 005

THIOTHIXENE

AM THERAP

1MG

A071884 001

Aug 12, 1987

2MG

A071885 001

Aug 12, 1987

5MG

A071886 001

Aug 12, 1987

10MG

A071887 001

Aug 12, 1987

20MG

A072200 001

Dec 17, 1987

WATSON LABS

1MG

A070600 001

Jun 05, 1987

2MG

A071626 001

Jun 25, 1987

5MG

A071627 001

Jun 25, 1987

10MG

A070603 001

Jun 05, 1987

10MG

A071628 001

Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER

EQ 5MG BASE/ML

N016758 001

THIOTHIXENE HYDROCHLORIDE

ALPHARMA US PHARMS

EQ 5MG BASE/ML

A070969 001

Oct 16, 1987

PACO

EQ 1MG BASE/ML

A071917 001

Sep 20, 1989

EQ 5MG BASE/ML

A071939 001

Dec 16, 1988

TEVA

EQ 5MG BASE/ML

A071184 001

Jun 22, 1987

TEVA PHARMS

EQ 5MG BASE/ML

A071554 001

Oct 16, 1987

THIOTHIXENE HYDROCHLORIDE INTENSOL

ROXANE

EQ 5MG BASE/ML

A073494 001

Jun 30, 1992

INJECTABLE; INJECTION

NAVANE

PFIZER

EQ 2MG BASE/ML

N016904 001

EQ 10MG BASE/VIAL

N016904 002

THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS

16MG

N002245 009

32MG

N002245 005

65MG

N002245 002

100MG

N002245 008

130MG

N002245 010

200MG

N002245 007

325MG

N002245 004

THYROGLOBULIN

IMPAX LABS

64.8MG

A080151 001

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US

10 IU/VIAL

N008682 001

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON

20MG

N020646 004

Sep 30, 1997

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 312 (of 331)

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N050497 001

EQ 3GM BASE/VIAL

A062690 001

Dec 19, 1986

EQ 3GM BASE/VIAL

N050497 002

EQ 6GM BASE/VIAL

N050497 003

EQ 20GM BASE/VIAL

N050497 004

EQ 30GM BASE/VIAL

N050497 005

Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO

125MG

N019979 001

Mar 24, 1993

250MG

N019979 002

Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

MYLAN

250MG

A075316 001

Nov 02, 1999

SANDOZ

250MG

A075318 001

Aug 20, 1999

WATSON LABS

250MG

A075309 001

Apr 26, 2000

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AKORN

EQ 0.25% BASE

A074465 001

Mar 25, 1997

FOUGERA

EQ 0.25% BASE

A074667 001

Mar 25, 1997

EQ 0.5% BASE

A074668 001

Mar 25, 1997

TABLET; ORAL

BLOCADREN

MERCK

5MG

N018017 001

10MG

N018017 002

20MG

N018017 004

TIMOLOL MALEATE

QUANTUM PHARMICS

5MG

A072466 001

May 19, 1989

10MG

A072467 001

May 19, 1989

20MG

A072468 001

May 19, 1989

SANDOZ

5MG

A072550 001

Apr 13, 1989

10MG

A072551 001

Apr 13, 1989

20MG

A072552 001

Apr 13, 1989

TEVA

5MG

A072648 001

Jun 16, 1993

10MG

A072649 001

Jun 16, 1993

20MG

A072650 001

Jun 16, 1993

USL PHARMA

5MG

A072001 001

Apr 11, 1989

10MG

A072002 001

Apr 11, 1989

20MG

A072003 001

Apr 11, 1989

WATSON LABS

5MG

A072269 001

Apr 11, 1989

5MG

A072917 001

Jul 31, 1991

10MG

A072270 001

Apr 11, 1989

10MG

A072918 001

Jul 31, 1991

20MG

A072271 001

Apr 11, 1989

20MG

A072919 001

Jul 31, 1991

TIOCONAZOLE

CREAM; TOPICAL

TZ-3

PFIZER

1%

N018682 001

Feb 18, 1983

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)

N020912 001

May 14, 1998

EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)

N020913 001

May 14, 1998

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 313 (of 331)

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

BARR	EQ 2MG BASE	A076371	001	Apr 09, 2003
	EQ 4MG BASE	A076371	002	Apr 09, 2003
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076321	001	Sep 30, 2004
	EQ 4MG BASE	A076321	002	Sep 30, 2004
ZANAFLEX				
ACORDA	EQ 2MG BASE	N020397	002	Feb 04, 2000

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

ALCON UNIVERSAL	0.3%	A063176	001	May 25, 1994

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY	EQ 10MG BASE/ML	A062008	004	
	EQ 10MG BASE/ML	A062707	001	Apr 29, 1987
	EQ 10MG BASE/ML	N050477	005	
	EQ 40MG BASE/ML	A062008	001	
	EQ 1.2GM BASE/VIAL	N050519	001	

TOBRAMYCIN SULFATE

APOTHECON	EQ 40MG BASE/ML	A064021	002	May 31, 1994
	EQ 40MG BASE/ML	A064026	001	May 31, 1994
ASTRAZENECA	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994
BAXTER HLTHCARE	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991
HOSPIRA	EQ 40MG BASE/ML	A063161	001	May 29, 1991
MARSAM PHARMS LLC	EQ 40MG BASE/ML	A062945	002	Aug 09, 1989

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA	400MG	N018257	001	Nov 09, 1984
	600MG	N018257	002	Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR	100MG	A070162	001	Jan 14, 1986
	250MG	A070163	001	Jan 14, 1986
	500MG	A070164	001	Jan 14, 1986
DURAMED PHARMS BARR	100MG	A070165	001	Jan 10, 1986
	250MG	A070166	001	Jan 10, 1986
	500MG	A070167	001	Jan 10, 1986
INTERPHARM	250MG	A071270	001	Sep 23, 1986
	500MG	A071271	001	Sep 23, 1986
IVAX SUB TEVA PHARMS	100MG	N018894	001	Nov 02, 1984
	250MG	N018894	002	Nov 02, 1984
	500MG	N018894	003	Nov 02, 1984
MUTUAL PHARM	100MG	A071357	001	Jul 16, 1987
	250MG	A071358	001	Jul 16, 1987
	500MG	A071359	001	Jul 16, 1987
PAR PHARM	100MG	A070159	001	Jan 06, 1986
	250MG	A070160	001	Jan 06, 1986
	500MG	A070161	001	Jan 06, 1986
SANDOZ	100MG	A071633	001	Dec 09, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 314 (of 331)

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

SANDOZ	250MG	A070289	001	Mar 13, 1986
	500MG	A070290	001	Mar 13, 1986
SUPERPHARM	250MG	A070763	001	Jun 16, 1986
	500MG	A070764	001	Jun 16, 1986
USL PHARMA	100MG	A071355	001	Jan 11, 1988
	250MG	A070168	001	Apr 02, 1986
	500MG	A070169	001	Apr 02, 1986
WATSON LABS	100MG	A070242	001	Aug 01, 1986
	100MG	A070513	001	Jan 09, 1986
	250MG	A070243	001	Aug 01, 1986
	500MG	A070244	001	Aug 01, 1986
TOLINASE				
PHARMACIA AND UPJOHN	100MG	N015500	002	
	250MG	N015500	004	
	500MG	N015500	005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION
PRISCOLINE

NOVARTIS	25MG/ML	N006403	005	Feb 22, 1985

TOLBUTAMIDE

TABLET; ORAL
ORINASE

PHARMACIA AND UPJOHN	250MG	N010670	002	
	500MG	N010670	001	
TOLBUTAMIDE				
ALRA	500MG	A086141	001	
ASCOT	500MG	A087541	001	Mar 01, 1983
BARR	500MG	A087121	001	
CLONMEL HLTHCARE	500MG	A086926	001	
IVAX PHARMS	500MG	A087093	001	
PARKE DAVIS	500MG	A086047	001	
PUREPAC PHARM	500MG	A088950	001	Jun 17, 1985
SANDOZ	500MG	A086574	001	
	500MG	N012678	001	
SUPERPHARM	500MG	A088893	001	Nov 19, 1984
VANGARD	500MG	A087876	001	Apr 20, 1982
WATSON LABS	250MG	A089110	001	May 29, 1987
	500MG	A089111	001	May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION
ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095	001	

TOLMETIN SODIUM

CAPSULE; ORAL
TOLECTIN DS

ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001	

TOLMETIN SODIUM

IVAX SUB TEVA PHARMS	EQ 400MG BASE	A073392	001	Jan 24, 1992
MUTUAL PHARM	EQ 400MG BASE	A073311	001	Nov 27, 1991
SANDOZ	EQ 400MG BASE	A073462	001	Apr 30, 1992
TEVA	EQ 400MG BASE	A073519	001	May 29, 1992

TABLET; ORAL
TOLECTIN

ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628	001	

TOLECTIN 600

ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628	002	Mar 08, 1989

DISCONTINUED DRUG PRODUCT LIST

6 - 315 (of 331)

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A073527	001	Jun 30, 1992
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A074399	001	Mar 28, 1996
SANDOZ	EQ 200MG BASE	A073588	001	Jul 31, 1992
	EQ 600MG BASE	A074002	001	Sep 27, 1993
TEVA	EQ 600MG BASE	A074729	001	Feb 27, 1997

TOLVAPTAN

TABLET; ORAL

SAMSCA

OTSUKA AMERICA PHARM	60MG	N022275	003	May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

ORTHO MCNEIL JANSSEN	50MG	N020844	003	Oct 26, 1998

TOPIRAMATE

BARR	15MG	A076448	001	Apr 15, 2009
	25MG	A076448	002	Apr 15, 2009

TABLET; ORAL

TOPAMAX

ORTHO MCNEIL JANSSEN	300MG	N020505	003	Dec 24, 1996
	400MG	N020505	006	Dec 24, 1996

TOPIRAMATE

BARR	25MG	A076315	001	Mar 27, 2009
	100MG	A076315	002	Mar 27, 2009
	200MG	A076315	003	Mar 27, 2009
PLIVA HRVATSKA DOO	25MG	A077905	001	Mar 30, 2009
	50MG	A077905	002	Mar 30, 2009
	100MG	A077905	003	Mar 30, 2009
	200MG	A077905	004	Mar 30, 2009
ROXANE	25MG	A076306	001	Mar 27, 2009
	50MG	A076306	002	Mar 27, 2009
	100MG	A076306	003	Mar 27, 2009
	200MG	A076306	004	Mar 27, 2009

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23, 1993
	20MG/2ML (10MG/ML)	N020137	001	Aug 23, 1993

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ASTA	50MG	A075974	001	Jul 12, 2002
IVAX SUB TEVA PHARMS	50MG	A075963	001	Jul 03, 2002
ULTRAM				
ORTHO MCNEIL JANSSEN	100MG	N020281	001	Mar 03, 1995

TRANEXAMIC ACID

TABLET; ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN	500MG	N019280	001	Dec 30, 1986

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

APOTHECON	50MG	N018207	001	
	100MG	N018207	002	
	150MG	N018207	003	Mar 25, 1985
	300MG	N018207	004	Nov 07, 1988

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 316 (of 331)

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AM THERAP	50MG	A071139	001	Oct 29, 1986
	100MG	A071140	001	Oct 29, 1986
MYLAN	50MG	A071405	001	Feb 27, 1991
	100MG	A071406	001	Feb 27, 1991
QUANTUM PHARMICS	100MG	A070921	001	Dec 01, 1986
SANDOZ	50MG	A072484	001	Apr 30, 1990
	100MG	A072483	001	Apr 30, 1990
TEVA	150MG	A074357	001	Apr 30, 1997
USL PHARMA	50MG	A070491	001	Apr 29, 1987
	100MG	A070492	001	Apr 29, 1987
WATSON LABS	50MG	A071112	001	Nov 17, 1986
	100MG	A071113	001	Nov 17, 1986
TRIALODINE				
QUANTUM PHARMICS	50MG	A070942	001	Dec 01, 1986

TRETINOIN

CAPSULE; ORAL

VESANOID

ROCHE	10MG	N020438	001	Nov 22, 1995

SOLUTION; TOPICAL

TRETINOIN

TEVA PHARMS	0.05%	A074873	001	Jun 19, 1998

SWAB; TOPICAL

RETIN-A

JOHNSON AND JOHNSON	0.05%	N016921	002	

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS	1MG	N011161	009	
	2MG	N011161	004	
	4MG	N011161	007	
	8MG	N011161	011	
	16MG	N011161	010	

KENACORT

BRISTOL MYERS SQUIBB	1MG	N011283	003	
	2MG	N011283	008	
	4MG	N011283	006	
	8MG	N011283	010	

TRIAMCINOLONE

BARR	2MG	A084286	001	
	2MG	A084318	001	
	4MG	A084267	001	
	4MG	A084319	001	
	8MG	A084268	001	
	8MG	A084320	001	
IMPAX LABS	4MG	A084340	001	
IVAX SUB TEVA PHARMS	4MG	A083750	001	
MYLAN	2MG	A084406	001	
PUREPAC PHARM	2MG	A084020	002	
	4MG	A084020	003	
ROXANE	2MG	A084708	001	
	4MG	A084709	001	
	8MG	A084707	001	
SANDOZ	4MG	A085601	001	
TEVA	4MG	A084775	001	
WATSON LABS	4MG	A084270	001	
	4MG	A085834	001	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 317 (of 331)

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; NASAL					
NASACORT					
SANOFI AVENTIS US	0.055MG/INH	N019798	001	Jul 11, 1991	
CREAM; TOPICAL					
ARISTOCORT					
ASTELLAS	0.025%	A083017	003		
	0.1%	A083016	004		
	0.5%	A083015	002		
ARISTOCORT A					
ASTELLAS	0.025%	A083017	004		
	0.025%	A088818	001	Oct 16, 1984	
	0.1%	A083016	005		
	0.1%	A088819	001	Oct 16, 1984	
	0.5%	A083015	003		
	0.5%	A088820	001	Oct 16, 1984	
FLUTEX					
IVAX PHARMS	0.025%	A085539	001		
	0.1%	A085539	002		
	0.5%	A085539	003		
KENALOG					
APOTHECON	0.5%	A083943	001		
KENALOG-H					
APOTHECON	0.1%	A086240	001		
TRIACET					
TEVA	0.1%	A084908	002		
TRIACORT					
SOLVAY	0.1%	A087113	001		
TRIAMCINOLONE ACETONIDE					
ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982	
AMBIX	0.025%	A087932	001	May 09, 1983	
G AND W LABS	0.1%	A089798	001	May 31, 1991	
MORTON GROVE	0.025%	A088094	001	Sep 01, 1983	
	0.1%	A088095	001	Sep 01, 1983	
	0.5%	A088096	001	Sep 01, 1983	
PHARMADERM	0.025%	A087990	001	Jul 07, 1983	
	0.1%	A087991	001	Jul 07, 1983	
	0.5%	A087992	001	Jul 07, 1983	
PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982	
	0.1%	A087912	001	Aug 10, 1982	
	0.5%	A087922	001	Aug 10, 1982	
TARO	0.025%	A040038	001	Oct 26, 1994	
TOPIDERM	0.025%	A089274	001	Feb 21, 1989	
	0.1%	A089275	001	Feb 21, 1989	
	0.5%	A089276	001	Feb 21, 1989	
TRIALEX					
IVAX PHARMS	0.025%	A087430	001	Nov 01, 1988	
	0.1%	A087429	001	Nov 01, 1988	
	0.5%	A087428	001	Nov 01, 1988	
TRYMEX					
SAVAGE LABS	0.025%	A088196	001	Mar 25, 1983	
	0.1%	A088197	001	Mar 25, 1983	
	0.5%	A088198	001	Mar 25, 1983	
GEL; TOPICAL					
ARISTOGEL					
ASTELLAS	0.1%	A083380	001		
INJECTABLE; INJECTION					
TRIAMCINOLONE ACETONIDE					
PARNELL	3MG/ML	N019503	001	Oct 16, 1987	
WATSON LABS	40MG/ML	A085825	001		
LOTION; TOPICAL					
KENALOG					
APOTHECON	0.025%	A084343	001		
	0.1%	A084343	002		
BRISTOL MYERS SQUIBB	0.025%	N011602	003		

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 318 (of 331)

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

KENALOG

BRISTOL MYERS SQUIBB 0.1%

N011602 001

TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.025%

A087191 001 Sep 08, 1982

0.1%

A087192 001 Sep 08, 1982

OINTMENT; TOPICAL

ARISTOCORT

ASTELLAS

0.1%

A080750 004

0.5%

A080745 002

ARISTOCORT A

ASTELLAS

0.1%

A080750 003

0.1%

A088780 001 Oct 01, 1984

0.5%

A080745 003

0.5%

A088781 001 Oct 05, 1984

FLUTEX

IVAX PHARMS

0.025%

A087375 001 Nov 01, 1988

0.1%

A087377 001 Nov 01, 1988

0.5%

A087376 001 Nov 01, 1988

KENALOG

APOTHECON

0.5%

A083944 001

TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.5%

A089913 001 Dec 23, 1988

G AND W LABS 0.025%

A089795 001 Dec 23, 1988

0.1%

A089796 001 Dec 23, 1988

MORTON GROVE 0.025%

A088090 001 Sep 01, 1983

0.1%

A088091 001 Sep 01, 1983

0.5%

A088092 001 Sep 01, 1983

PHARMADERM 0.025%

A088692 001 Aug 02, 1984

0.1%

A088690 001 Aug 02, 1984

TRYMEX

SAVAGE LABS

0.025%

A088693 001 Aug 02, 1984

0.1%

A088691 001 Aug 02, 1984

PASTE; DENTAL

KENALOG IN ORABASE

APOTHECON

0.1%

N012097 001

ORALONE

TARO

0.1%

A071383 001 Jul 06, 1987

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS 0.05MG/SPRAY

N020120 001 Feb 04, 2000

NASACORT HFA

SANOFI AVENTIS US 0.055MG/SPRAY

N020784 001 Apr 07, 2004

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

SANDOZ

25MG/ML

N011685 003

40MG/ML

N012802 001

TRIAMCINOLONE DIACETATE

AKORN

25MG/ML

A085122 001

40MG/ML

A086394 001

WATSON LABS

40MG/ML

A084072 001

40MG/ML

A085529 001

SYRUP; ORAL

ARISTOCORT

ASTELLAS

2MG/5ML

N011960 004

KENACORT

BRISTOL MYERS SQUIBB EQ 4MG BASE/5ML

N012515 001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 319 (of 331)

TRIAZOLAMTABLET; ORAL
HALCION

PHARMACIA AND UPJOHN 0.5MG

N017892 002 Nov 15, 1982

TRICHLORMETHIAZIDETABLET; ORAL
METAHYDRIN

SANOFI AVENTIS US

2MG

N012594 001 Jun 16, 1988

4MG

N012594 002 Jun 16, 1988

NAQUA

SCHERING

2MG

N012265 001

4MG

N012265 002

TRICHLOREX

LANNETT

4MG

A083436 001

4MG

A085630 001

TRICHLORMAS

MAST MM

4MG

A086259 001

TRICHLORMETHIAZIDE

IMPAX LABS

4MG

A083967 001

PAR PHARM

2MG

A087007 001

4MG

A087005 001

SANDOZ

4MG

A086171 001

TG UNITED LABS

4MG

A085568 001

WATSON LABS

2MG

A083847 001

2MG

A086458 001

4MG

A083462 001

4MG

A083855 001

4MG

A085962 001

TRICLOFOS SODIUMSOLUTION; ORAL
TRICLOS

SANOFI AVENTIS US

1.5GM/15ML

N016830 001

TABLET; ORAL
TRICLOS

SANOFI AVENTIS US

750MG

N016809 002

TRIDIHEXETHYL CHLORIDEINJECTABLE; INJECTION
PATHILON

LEDERLE

10MG/ML

N009729 001

TABLET; ORAL
PATHILON

LEDERLE

25MG

N009489 005

TRIFLUOPERAZINE HYDROCHLORIDECONCENTRATE; ORAL
STELAZINE

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N011552 006

TRIFLUOPERAZINE HYDROCHLORIDE

SANDOZ

EQ 10MG BASE/ML

A085787 001 Apr 15, 1982

WOCKHARDT

EQ 10MG BASE/ML

A088143 001 Jul 26, 1983

INJECTABLE; INJECTION
STELAZINE

GLAXOSMITHKLINE

EQ 2MG BASE/ML

N011552 005

TABLET; ORAL
STELAZINE

GLAXOSMITHKLINE

EQ 1MG BASE

N011552 001

EQ 2MG BASE

N011552 002

EQ 5MG BASE

N011552 003

EQ 10MG BASE

N011552 004

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR

EQ 1MG BASE

A088967 001 Apr 23, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 320 (of 331)

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR	EQ 2MG BASE	A088968	001	Apr 23, 1985
	EQ 5MG BASE	A088969	001	Apr 23, 1985
	EQ 10MG BASE	A088970	001	Apr 23, 1985
IVAX PHARMS	EQ 1MG BASE	A087612	001	Nov 19, 1982
	EQ 2MG BASE	A087613	001	Nov 19, 1982
	EQ 5MG BASE	A087328	001	Nov 19, 1982
	EQ 10MG BASE	A087614	001	Nov 19, 1982
SANDOZ	EQ 1MG BASE	A040153	001	Oct 25, 1996
	EQ 2MG BASE	A040153	002	Oct 25, 1996
	EQ 5MG BASE	A040153	003	Oct 25, 1996
	EQ 10MG BASE	A040153	004	Oct 25, 1996
WATSON LABS	EQ 1MG BASE	A085975	001	Jun 23, 1988
	EQ 2MG BASE	A085976	001	Jun 23, 1988
	EQ 5MG BASE	A085973	001	Jun 23, 1988
	EQ 10MG BASE	A088710	001	Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON	EQ 50MG HCL/5ML	N011491	004	

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON	3MG/ML	N011325	005	
	10MG/ML	N011325	004	
	20MG/ML	N011325	001	

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB	10MG	N011123	001	
	25MG	N011123	002	
	50MG	N011123	003	

TRIHXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE	5MG	N006773	010	
	5MG	N012947	001	

ELIXIR; ORAL

ARTANE

LEDERLE	2MG/5ML	N006773	009	

TRIHXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES	2MG/5ML	A089514	001	Apr 07, 1989

TABLET; ORAL

ARTANE

LEDERLE	2MG	N006773	005	
	5MG	N006773	003	

TREMIN

SCHERING	2MG	A080381	001	
	5MG	A080381	003	

TRIHXYPHENIDYL HYDROCHLORIDE

NYLOS	5MG	A085622	001	
VANGARD	2MG	A088035	001	Jul 30, 1982
WATSON LABS	2MG	A085117	001	
	5MG	A085105	001	

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION	30MG	N018719	002	Dec 31, 1984
	60MG	N018719	001	Dec 31, 1984

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 321 (of 331)

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 5MG BASE

N011316 004

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE/5ML

N011316 003

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS

EQ 2.5MG BASE/5ML

A085015 001 Feb 18, 1982

MORTON GROVE

EQ 2.5MG BASE/5ML

A088285 001 Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE

N011316 001

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBOTT

300MG

N005856 005

SOLUTION; ORAL

TRIDIONE

ABBOTT

200MG/5ML

N005856 002

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE

50MG/ML

N008983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

SMITH AND NEPHEW

100MG/ML

A088960 001 Apr 04, 1986

100MG/ML

A089043 001 Apr 04, 1986

SOLOPAK

100MG/ML

A089094 001 Apr 04, 1986

WATSON LABS

100MG/ML

A086577 001 Oct 19, 1982

100MG/ML

A087939 001 Dec 28, 1982

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS

100MG

N017943 001

200MG

N017943 003 Jul 14, 1982

TRIMETHOPRIM

MUTUAL PHARM

100MG

A070494 001 Jan 22, 1986

200MG

A070495 001 Sep 24, 1986

TRIMPEX

ROCHE

100MG

N017952 001

TRIMPEX 200

ROCHE

200MG

N017952 002 Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

FSC

EQ 25MG BASE/5ML

A074374 001 Jun 23, 1995

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY

EQ 25MG BASE/VIAL

N020326 001 Dec 17, 1993

EQ 200MG BASE/VIAL

N020326 002 Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

USL PHARMA

EQ 25MG BASE

A071283 001 Dec 08, 1987

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 322 (of 331)

TRIMIPRAMINE MALEATE

CAPSULE; ORAL				
TRIMIPRAMINE MALEATE				
USL PHARMA	EQ 50MG BASE	A071284	001	Dec 08, 1987
	EQ 100MG BASE	A071285	001	Dec 08, 1987

TRIOXSALEN

TABLET; ORAL				
TRISORALEN				
VALEANT PHARM INTL	5MG	N012697	001	

TRIPLENNAMINE CITRATE

ELIXIR; ORAL				
PBZ				
NOVARTIS	EQ 25MG HCL/5ML	N005914	004	

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL				
PBZ				
NOVARTIS	25MG	A083149	001	
	50MG	N005914	002	
TRIPLENNAMINE HYDROCHLORIDE				
ANABOLIC	50MG	A083037	001	
BARR	50MG	A080744	001	
HEATHER	50MG	A083989	001	
IMPAX LABS	50MG	A080785	001	
LANNETT	50MG	A083557	001	
NYLOS	50MG	A085412	001	
PARKE DAVIS	25MG	A083625	001	
	50MG	A083626	001	
WATSON LABS	50MG	A080713	001	
	50MG	A080790	001	
	50MG	A085188	001	
TABLET, EXTENDED RELEASE; ORAL				
PBZ-SR				
NOVARTIS	50MG	N010533	002	
	100MG	N010533	001	

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL				
GYNE-SULF				
G AND W LABS	3.7%;2.86%;3.42%	A088607	001	Jun 09, 1986
SULTRIN				
ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%	N005794	001	
TRIPLE SULFA				
ALPHARMA US PHARMS	3.7%;2.86%;3.42%	A087864	001	Sep 01, 1982
FOUGERA	3.7%;2.86%;3.42%	A086424	001	
PERRIGO NEW YORK	3.7%;2.86%;3.42%	A087285	001	Nov 15, 1982
TRYSUL				
SAVAGE LABS	3.7%;2.86%;3.42%	A087887	001	Jul 23, 1982
VAGILIA				
TEVA	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987
TABLET; VAGINAL				
SULTRIN				
ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG	N005794	002	
TRIPLE SULFA				
FOUGERA	184MG;143.75MG;172.5MG	A088463	001	Jan 03, 1985
PHARMADERM	184MG;143.75MG;172.5MG	A088462	001	Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL				
ACTIDIL				
GLAXOSMITHKLINE	1.25MG/5ML	N011496	002	Jul 01, 1983

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 323 (of 331)

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

MYIDYL

USL PHARMA 1.25MG/5ML

A087963 001 Jan 18, 1983

TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS 1.25MG/5ML

A085940 001

HALSEY 1.25MG/5ML

A088735 001 Jan 17, 1985

PHARM ASSOC 1.25MG/5ML

A087514 001 Feb 10, 1982

TABLET; ORAL

ACTIDIL

GLAXOSMITHKLINE 2.5MG

N011110 002 Jul 01, 1983

TRIPROLIDINE HYDROCHLORIDE

VITARINE 2.5MG

A085610 001

WATSON LABS 2.5MG

A085094 001

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL

LANTRISUL

LANNETT 167MG/5ML;167MG/5ML;167MG/5ML

A080123 002

NEOTRIZINE

LILLY 167MG/5ML;167MG/5ML;167MG/5ML

N006317 012

SULFALOID

FOREST PHARMS 167MG/5ML;167MG/5ML;167MG/5ML

A080100 001

SULFOSE

WYETH AYERST 167MG/5ML;167MG/5ML;167MG/5ML

A080013 002

TERFONYL

BRISTOL MYERS SQUIBB 167MG/5ML;167MG/5ML;167MG/5ML

N006904 002

TRIPLE SULFA

ALPHARMA US PHARMS 167MG/5ML;167MG/5ML;167MG/5ML

A080280 001

TRIPLE SULFAS

LEDERLE 167MG/5ML;167MG/5ML;167MG/5ML

N006920 003

TABLET; ORAL

NEOTRIZINE

LILLY 167MG;167MG;167MG

N006317 011

SULFALOID

FOREST PHARMS 167MG;167MG;167MG

A080099 001

SULFA-TRIPLE #2

IMPAX LABS 167MG;167MG;167MG

A080079 001

SULFOSE

WYETH AYERST 167MG;167MG;167MG

A080013 001

TERFONYL

BRISTOL MYERS SQUIBB 167MG;167MG;167MG

N006904 001

TRIPLE SULFA

PUREPAC PHARM 167MG;167MG;167MG

A080086 001

TRIPLE SULFAS

LEDERLE 167MG;167MG;167MG

N006920 002

TRIPLE SULFOID

PAL PAK 167MG;167MG;167MG

A080094 001

TROGLITAZONE

TABLET; ORAL

PRELAY

SANKYO 200MG

N020719 001 Jan 29, 1997

300MG

N020719 003 Aug 04, 1997

400MG

N020719 002 Jan 29, 1997

REZULIN

PFIZER PHARMS 200MG

N020720 001 Jan 29, 1997

300MG

N020720 003 Aug 04, 1997

400MG

N020720 002 Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX

PHARM RES ASSOC 10%

N011340 002

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 324 (of 331)

TROLEANDOMYCINCAPSULE; ORAL
TAO

PFIZER

EQ 250MG BASE

N050336 002

SUSPENSION; ORAL
TAO

PFIZER

EQ 125MG BASE/5ML

N050332 001

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

ALCON

0.5%

N012111 002

1%

N012111 004

MYDRIAFAIR

PHARMAFAIR

0.5%

A088274 001

Sep 16, 1983

1%

A088230 001

Sep 16, 1983

TROPICAMIDE

AKORN

1%

A088447 001

Aug 28, 1985

ALCON UNIVERSAL

1%

A089172 001

Dec 28, 1990

MIZA PHARMS USA

0.5%

A087636 001

Jul 30, 1982

1%

A087637 001

Aug 09, 1982

WATSON LABS

0.5%

A089171 001

Dec 28, 1990

TROVAFLOXACIN MESYLATE

TABLET; ORAL

TROVAN

PFIZER

EQ 100MG BASE

N020759 001

Dec 18, 1997

EQ 200MG BASE

N020759 002

Dec 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB

3MG/ML

N005657 001

HOSPIRA

3MG/ML

N006095 001

LILLY

3MG/ML

N006325 001

TYROPANOATE SODIUM

CAPSULE; ORAL

BILOPAQUE

GE HEALTHCARE

750MG

N013731 001

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

SUCAMPO PHARMS

0.15%

N021214 001

Aug 03, 2000

URACIL MUSTARD

CAPSULE; ORAL

URACIL MUSTARD

SHIRE

1MG

N012892 001

UREA

INJECTABLE; INJECTION

STERILE UREA

HOSPIRA

40GM/VIAL

N017698 001

UREAPHIL

HOSPIRA

40GM/VIAL

N012154 001

UREA C-13

FOR SOLUTION; ORAL

HELICOSOL

METABOLIC SOLUTIONS

125MG/VIAL

N021092 001

Dec 17, 1999

DISCONTINUED DRUG PRODUCT LIST

6 - 325 (of 331)

UREA C-13

FOR SOLUTION; ORAL		
MERETEK UBT KIT (W/ PRANACTIN)		
OTSUKA AMERICA	125MG/VIAL	N020586 001 Sep 17, 1996
PYLORI-CHEK BREATH TEST		
DXS DEVICES	100MG/VIAL	N020900 001 Feb 04, 1999

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR		
METRODIN		
SERONO	75 IU/AMP	N019415 002 Sep 18, 1986
	150 IU/AMP	N019415 003 Sep 18, 1986
INJECTABLE; SUBCUTANEOUS		
FERTINEX		
SERONO	75 IU/AMP	N019415 005 Aug 23, 1996
	150 IU/AMP	N019415 004 Aug 23, 1996

UROKINASE

INJECTABLE; INJECTION		
KINLYTIC		
MICROBIX BIOSYSTEMS	5,000 IU/VIAL	N021846 003
	9,000 IU/VIAL	N021846 002
	250,000 IU/VIAL	N021846 001

URSODIOL

CAPSULE; ORAL		
ACTIGALL		
WATSON PHARMS	150MG	N019594 001 Dec 31, 1987

VALDECOXIB

TABLET; ORAL		
BEXTRA		
GD SEARLE	10MG	N021341 002 Nov 16, 2001
	20MG	N021341 003 Nov 16, 2001

VALPROIC ACID

CAPSULE; ORAL		
VALPROIC ACID		
PAR PHARM	250MG	A070431 001 Feb 28, 1986
SCHERER RP	250MG	A070195 001 Jul 02, 1987
USL PHARMA	250MG	A070631 001 Jun 11, 1987
SYRUP; ORAL		
VALPROIC ACID		
APOTEX INC	250MG/5ML	A077105 001 Jul 29, 2005

VALSARTAN

CAPSULE; ORAL		
DIOVAN		
NOVARTIS	80MG	N020665 001 Dec 23, 1996
	160MG	N020665 002 Dec 23, 1996

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL		
VANCOCIN HYDROCHLORIDE		
VIROPHARMA	EQ 250MG BASE/5ML	A061667 002 Jul 13, 1983
	EQ 500MG BASE/6ML	A061667 001
VANCOLED		
LEDERLE	EQ 250MG BASE/5ML	A063321 002 Oct 15, 1993
	EQ 500MG BASE/6ML	A063321 003 Oct 15, 1993
INJECTABLE; INJECTION		
VANCOCIN HYDROCHLORIDE		
VIROPHARMA	EQ 500MG BASE/VIAL	A060180 001
	EQ 500MG BASE/VIAL	A062476 001 Mar 15, 1984
	EQ 500MG BASE/VIAL	A062716 001 Mar 13, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 326 (of 331)

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANOCIN HYDROCHLORIDE
VIOPHARMA

EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987
EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986
EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986
EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987
EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987
EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987

VANCOLED

BAXTER HLTHCARE

EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986
EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988
EQ 2GM BASE/VIAL	A062682	003	May 11, 1988
EQ 5GM BASE/VIAL	A062682	004	May 11, 1988
EQ 10GM BASE/VIAL	A062682	005	May 11, 1988

VANCOMYCIN HYDROCHLORIDE

BAXTER HLTHCARE

EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988
EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988

VANCOR

PHARMACIA AND UPJOHN

EQ 500MG BASE/VIAL	A062956	001	Aug 01, 1988
EQ 1GM BASE/VIAL	A062956	002	Aug 01, 1988

VASOPRESSIN TANNATE

INJECTABLE; INJECTION
PITRESSIN TANNATE
PARKE DAVIS

5PRESSOR UNITS/ML	N003402	001	

VECURONIUM BROMIDE

INJECTABLE; INJECTION
NORCURON

ORGANON USA INC

10MG/VIAL	N018776	002	Apr 30, 1984
20MG/VIAL	N018776	003	Jan 03, 1992

VECURONIUM BROMIDE

BAXTER HLTHCARE

10MG/VIAL	A075218	001	Aug 23, 1999
20MG/VIAL	A075218	002	Aug 23, 1999

HOSPIRA

4MG/VIAL	A075558	001	Sep 11, 2001

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR

WYETH PHARMS INC

EQ 100MG BASE	N020699	003	Oct 20, 1997

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC

EQ 12.5MG BASE	N020151	001	Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

SANDOZ

EQ 25MG BASE	A077515	001	Jun 13, 2008
EQ 37.5MG BASE	A077515	002	Jun 13, 2008
EQ 50MG BASE	A077515	003	Jun 13, 2008
EQ 75MG BASE	A077515	004	Jun 13, 2008
EQ 100MG BASE	A077515	005	Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
CALAN

GD SEARLE LLC

2.5MG/ML	N018925	001	Mar 30, 1984
2.5MG/ML	N019038	001	Mar 30, 1984

ISOPTIN

FSC

2.5MG/ML	N018485	001	

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM

2.5MG/ML	A070348	001	May 01, 1986

BEDFORD

2.5MG/ML	A072888	001	Jul 28, 1995

HOSPIRA

2.5MG/ML	A070739	001	May 06, 1987

2.5MG/ML

	A070740	001	May 06, 1987

LUITPOLD

2.5MG/ML	A070225	001	Nov 12, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 327 (of 331)

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION VERAPAMIL HYDROCHLORIDE

LUITPOLD	2.5MG/ML	A070617	001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233	001	Feb 26, 1993
	2.5MG/ML	A073485	001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696	001	Jul 31, 1987
	2.5MG/ML	A070697	001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695	001	Jul 31, 1987

TABLET; ORAL CALAN

GD SEARLE LLC	160MG	N018817	004	Feb 23, 1988

ISOPTIN

FSC	40MG	N018593	003	Nov 23, 1987
	80MG	N018593	001	Mar 08, 1982
	120MG	N018593	002	Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

HERITAGE PHARMS INC	80MG	A071880	001	Apr 05, 1988
	120MG	A071881	001	Apr 05, 1988
MUTUAL PHARM	80MG	A070482	001	Sep 24, 1986
	80MG	A071489	002	Jan 13, 1988
	120MG	A070483	001	Sep 24, 1986
	120MG	A071489	001	Jan 13, 1988
PLIVA	40MG	A072751	001	Feb 23, 1996
	80MG	A072124	001	Jan 26, 1989
	120MG	A072125	001	Jan 26, 1989
SANDOZ	40MG	A073168	001	Jul 31, 1992
	80MG	A071423	001	May 24, 1988
	120MG	A071424	001	May 25, 1988
WARNER CHILCOTT	80MG	A070340	001	Sep 24, 1986
	120MG	A070341	001	Sep 24, 1986
WATSON LABS	40MG	A072799	001	Apr 28, 1989
TABLET, EXTENDED RELEASE; VERAPAMIL HYDROCHLORIDE PLIVA	240MG	A072922	001	Mar 01, 1996

VERATRUM VIRIDE ROOT

TABLET; ORAL VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691	002	

VIDARABINE

INJECTABLE; INJECTION VIRA-A

PARKEDALE	EQ 187.4MG BASE/ML	N050523	001	

OINTMENT; OPHTHALMIC VIRA-A

PARKEDALE	3%	N050486	001	

VINBLASTINE SULFATE

INJECTABLE; INJECTION VELBAN

LILLY	10MG/VIAL	N012665	001	

VINBLASTINE SULFATE

ABRAXIS PHARM	10MG/VIAL	A089011	001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565	001	Aug 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION ONCOVIN

LILLY	1MG/VIAL	N014103	001	
	1MG/ML	N014103	003	Mar 07, 1984
	5MG/VIAL	N014103	002	

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 328 (of 331)

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCASAR PFS

TEVA PARENTERAL

1MG/ML

A071426 001

Jul 17, 1987

VINCREX

BRISTOL MYERS SQUIBB

5MG/VIAL

A070867 001

Jul 12, 1988

VINCRIStINE SULFATE

ABIC

1MG/ML

A070873 001

Feb 19, 1987

ABRAXIS PHARM

1MG/ML

A070411 001

Sep 10, 1986

APP PHARMS

1MG/ML

A076296 001

Dec 20, 2002

HOSPIRA

1MG/VIAL

A071559 001

Apr 11, 1988

2MG/VIAL

A071560 001

Apr 11, 1988

5MG/VIAL

A071561 001

Apr 11, 1988

VIOMYCIN SULFATE

INJECTABLE; INJECTION

VIOCIN SULFATE

PFIZER

EQ 1GM BASE/VIAL

A061086 001

EQ 5GM BASE/VIAL

A061086 002

VITAMIN A

CAPSULE; ORAL

AQUASOL A

ASTRAZENECA

25,000USP UNITS

A083080 002

50,000USP UNITS

A083080 001

VITAMIN A

BANNER PHARMACAPS

50,000USP UNITS

A083973 001

CHASE CHEM

50,000 IU

A083351 001

EVERYLIFE

50,000 IU

A083134 001

IMPAX LABS

50,000USP UNITS

A080952 001

WEST WARD

50,000USP UNITS

A080985 001

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

STERLING WINTHROP

EQ 50,000 UNITS BASE

A083187 001

ALPHALIN

LILLY

EQ 50,000 UNITS BASE

A080883 001

DEL-VI-A

DEL RAY LABS

EQ 50,000 UNITS BASE

A080830 001

VI-DOM-A

BAYER PHARMS

EQ 50,000 UNITS BASE

A080972 001

VITAMIN A

BANNER PHARMACAPS

EQ 50,000 UNITS BASE

A080702 001

BRISTOL MYERS SQUIBB

EQ 50,000 UNITS BASE

A080860 001

CHASE CHEM

EQ 50,000 UNITS BASE

A080746 001

EQ 50,000 UNITS BASE

A083207 001

ELKINS SINN

EQ 50,000 UNITS BASE

A085479 001

EVERYLIFE

EQ 50,000 UNITS BASE

A080943 001

EQ 50,000 UNITS BASE

A083114 001

IMPAX LABS

EQ 50,000 UNITS BASE

A080953 001

EQ 50,000 UNITS BASE

A080955 001

IVAX SUB TEVA PHARMS

EQ 50,000 UNITS BASE

A083035 001

EQ 50,000 UNITS BASE

A083190 001

MK LABS

EQ 25,000 UNITS BASE

A083457 002

EQ 50,000 UNITS BASE

A083457 001

WEST WARD

EQ 50,000 UNITS BASE

A080967 001

WHARTON LABS

EQ 50,000 UNITS BASE

A083665 001

VITAMIN A PALMITATE

ARCUM

EQ 50,000 UNITS BASE

A083311 001

EQ 50,000 UNITS BASE

A083321 001

BANNER PHARMACAPS

EQ 50,000 UNITS BASE

A083948 001

EQ 50,000 UNITS BASE

A083981 001

DISCONTINUED DRUG PRODUCT LIST

6 - 329 (of 331)

VITAMIN A PALMITATE

CAPSULE; ORAL			
VITAMIN A SOLUBILIZED			
TEVA	EQ 50,000 UNITS BASE	A080921	001
INJECTABLE; INJECTION			
VITAMIN A PALMITATE			
BEL MAR	EQ 50,000 UNITS BASE/ML	A080819	001

WARFARIN POTASSIUM

TABLET; ORAL			
ATHROMBIN-K			
PHARM RES ASSOC	2MG	N011771	007
	5MG	N011771	004
	10MG	N011771	005
	25MG	N011771	006

WARFARIN SODIUM

INJECTABLE; INJECTION			
COUMADIN			
BRISTOL MYERS SQUIBB	50MG/VIAL	N009218	020
	75MG/VIAL	N009218	012
TABLET; ORAL			
ATHROMBIN			
PHARM RES ASSOC	5MG	N011771	003
	10MG	N011771	002
	25MG	N011771	001
PANWARFIN			
ABBOTT	2MG	N017020	001
	2.5MG	N017020	002
	5MG	N017020	003
	7.5MG	N017020	004
	10MG	N017020	005
WARFARIN SODIUM			
SANDOZ	1MG	A040196	001 Sep 30, 1997
	2MG	A040196	002 Sep 30, 1997
	2.5MG	A040196	003 Sep 30, 1997
	3MG	A040196	008 Jul 26, 2000
	4MG	A040196	004 Sep 30, 1997
	5MG	A040196	005 Sep 30, 1997
	6MG	A040196	009 Jul 26, 2000
	7.5MG	A040196	006 Sep 30, 1997
	10MG	A040196	007 Sep 30, 1997
USL PHARMA	2MG	A088719	001 Jun 27, 1985
	2.5MG	A088720	001 Aug 06, 1985
	5MG	A088721	001 Jul 02, 1985
WATSON LABS	2MG	A086123	001 Aug 17, 1982
	2.5MG	A086120	001 Aug 17, 1982
	5MG	A086119	001 Aug 17, 1982
	7.5MG	A086118	001 Aug 17, 1982
	10MG	A086122	001 Aug 17, 1982

XENON XE-127

GAS; INHALATION			
XENON XE 127			
MALLINCKRODT	5mCi/VIAL	N018536	001 Oct 01, 1982
	10mCi/VIAL	N018536	002 Oct 01, 1982

XENON XE-133

GAS; INHALATION			
XENON XE 133			
GE HEALTHCARE	1 CI/AMP	N017256	002
	10mCi/VIAL	N017687	002
	20mCi/VIAL	N017687	003
GEN ELECTRIC	5-100 CI/CYLINDER	N017550	001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 330 (of 331)

XENON XE-133

GAS; INHALATION

XENON XE 133

GEN ELECTRIC

0.25-5 CI/AMP

N017550 003

MALLINCKRODT

10mCi/VIAL

N018327 001

Mar 09, 1982

20mCi/VIAL

N018327 002

Mar 09, 1982

XENON XE 133-V.S.S.

GE HEALTHCARE

10mCi/VIAL

N017687 001

INJECTABLE; INJECTION

XENON XE 133

GE HEALTHCARE

1.3-1.7 CI/AMP

N017256 001

LANTHEUS MEDCL

6.3mCi/ML

N017283 001

SOLUTION; INHALATION, INJECTION

XENEISOL

MALLINCKRODT

18-25mCi/AMP

N017262 002

XYLOSE

POWDER; ORAL

XYLO-PFAN

SAVAGE LABS

25GM/BOT

N017605 001

XYLOSE

LYNE

25GM/BOT

N018856 001

Mar 26, 1987

ZALCITABINE

TABLET; ORAL

HIVID

ROCHE

0.375MG

N020199 001

Jun 19, 1992

0.75MG

N020199 002

Jun 19, 1992

ZALEPLON

CAPSULE; ORAL

ZALEPLON

SANDOZ

5MG

A078095 001

Jun 06, 2008

10MG

A078095 002

Jun 06, 2008

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

AZUR PHARMA II

200MCG/2ML (100MCG/ML)

N021060 003

Dec 28, 2004

ZIDOVUDINE

TABLET; ORAL

RETROVIR

VIV HLTHCARE

200MG

N020518 001

Dec 19, 1995

ZIDOVUDINE

AUROBINDO PHARMA

60MG

N022294 001

Jul 23, 2009

ZILEUTON

TABLET; ORAL

ZYFLO

CORNERSTONE THERAP

300MG

N020471 001

Dec 09, 1996

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM

EQ 1MG ZINC/ML

N019229 002

May 05, 1987

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

NOVARTIS

EQ 4MG BASE/VIAL

N021223 001

Aug 20, 2001

31ST EDITION - 2011 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 331 (of 331)

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

MUTUAL PHARMA

5MG

A077288 001 Apr 23, 2007

10MG

A077288 002 Apr 23, 2007

SYNTHON PHARMS

5MG

A077540 001 Apr 23, 2007

10MG

A077540 002 Apr 23, 2007

WORLD GEN

5MG

A076062 001 Apr 23, 2007

10MG

A076062 002 Apr 23, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

TOVALT ODT

BIOVAIL LABS INTL

5MG

N021412 001 Apr 25, 2007

10MG

N021412 002 Apr 25, 2007

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

MUTUAL PHARM

25MG

A077635 001 Dec 22, 2005

50MG

A077635 002 Dec 22, 2005

100MG

A077635 003 Dec 22, 2005

ROXANE

25MG

A077648 001 Dec 22, 2005

50MG

A077648 002 Dec 22, 2005

100MG

A077648 003 Dec 22, 2005

TEVA PHARMS

25MG

A077641 003 Dec 22, 2005

50MG

A077641 002 Dec 22, 2005

100MG

A077641 001 Dec 22, 2005

WATSON LABS

25MG

A077650 001 Apr 20, 2006

50MG

A077650 002 Apr 20, 2006

100MG

A077650 003 Apr 20, 2006

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:
<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
 ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN; ASPIRIN;
 BUTALBITAL
 CAPSULE OR TABLET; ORAL
 160-165MG; 160-165MG; 50MG

ASPIRIN; CAFFEINE;
 CARISOPRODOL
 TABLET; ORAL
 160MG; 32MG; 200MG

ACETAMINOPHEN; ASPIRIN;
 BUTALBITAL
 CAPSULE OR TABLET; ORAL
 325MG; 325MG; 50MG

ASPIRIN; CAFFEINE;
 CARISOPRODOL;
 CODEINE PHOSPHATE
 TABLET; ORAL
 160MG; 32MG;
 200MG; 16MG

ACETAMINOPHEN; ASPIRIN;
 BUTALBITAL; CAFFEINE
 CAPSULE OR TABLET; ORAL
 160-165MG; 160-165MG; 50MG; 40MG

ASPIRIN;
 CARISOPRODOL
 TABLET; ORAL
 325MG; 200MG

ACETAMINOPHEN; ASPIRIN;
 BUTALBITAL; CAFFEINE
 CAPSULE OR TABLET; ORAL
 325MG; 325MG; 50MG; 40MG

ASPIRIN;
 CARISOPRODOL;
 CODEINE PHOSPHATE
 TABLET; ORAL
 325MG; 200MG; 16MG

ACETAMINOPHEN; BUTALBITAL
 CAPSULE OR TABLET; ORAL
 325MG; 50MG
 650MG; 50MG

ASPIRIN; MEPROBAMATE
 TABLET; ORAL
 325MG; 200MG

ACETAMINOPHEN; BUTALBITAL;
 CAFFEINE
 CAPSULE OR TABLET; ORAL
 325MG; 50MG; 40MG
 650MG; 50MG; 40MG
 500MG; 50MG; 40MG

ASPIRIN;
 METHOCARBAMOL
 TABLET; ORAL
 325MG; 400MG

AMINOPHYLLINE
 TABLET; ORAL
 100MG; 200MG

CHLOROTHIAZIDE
 TABLET; ORAL
 250MG

ASPIRIN; BUTALBITAL
 CAPSULE OR TABLET; ORAL
 325MG; 50MG
 650MG; 50MG

HYDROXYZINE
 HYDROCHLORIDE
 TABLET; ORAL
 10MG; 25MG;
 50MG; 100MG

ASPIRIN; BUTALBITAL; CAFFEINE
 CAPSULE OR TABLET; ORAL
 325MG; 50MG; 40MG
 650MG; 50MG; 40MG

PREDNISONE
 TABLET; ORAL
 1MG; 2.5MG;
 5MG; 10MG;
 20MG; 25MG; 50MG

APPENDIX A - PRODUCT NAME INDEX

A - 1

** 8 **

8-MOP, METHOXSALEN

** A **

ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIRAZOLE
ABLAVAR, GADOFOSVESET TRISODIUM
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEON, PERINDOPRIL ERBUMINE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
ACETOHEXAMIDE, ACETOHEXAMIDE
ACETYLCYSTEINE, ACETYLCYSTEINE
ACIPHEX, RABEPRAZOLE SODIUM
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR LS, KETOROLAC TROMETHAMINE
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR AND HYDROCORTISONE, ACYCLOVIR
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ACZONE, DAPSONE
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE

APPENDIX A - PRODUCT NAME INDEX

A - 2

**** A ****

ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADRENALICK, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVICOR, LOVASTATIN
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
AEROBID, FLUNISOLIDE
AEROSPAN HFA, FLUNISOLIDE
AFEDITAB CR, NIFEDIPINE
AFINITOR, EVEROLIMUS
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOLX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AK-FLUOR 10%, FLUORESCHEIN SODIUM
AKINETON, BIPERIDEN HYDROCHLORIDE
AKNE-MYCIN, ERYTHROMYCIN
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALA-CORT, HYDROCORTISONE
ALAMAST, PEMIROLAST POTASSIUM
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% IN D5-W, ALCOHOL
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALLEGRA D 24 HOUR, FEXOFENADINE HYDROCHLORIDE
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D 12 HOUR, FEXOFENADINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 3

**** A ****

ALLI, ORLISTAT (OTC)
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALLOPURINOL, ALLOPURINOL
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALSUMA, SUMATRIPTAN SUCCINATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALVESCO, CICLESONIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMCINONIDE, AMCINONIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIFOSTINE, AMIFOSTINE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

A - 4

**** A ****

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA, N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHOTEC, AMPHOTERICIN B
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMTURNIDE, ALISKIREN HEMIFUMARATE
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANESTACON, LIDOCAINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANSAID, FLURBIPROFEN
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)

APPENDIX A - PRODUCT NAME INDEX

A - 5

**** A ****

ANTIVERT, MECLIZINE HYDROCHLORIDE
ANTIZOL, FOMEPIZOLE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE
APHTHASOL, AMLEXANOX
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APRISO, MESALAMINE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARALEN, CHLOROQUINE PHOSPHATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
AREDIA, PAMIDRONATE DISODIUM
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIMIDEX, ANASTROZOLE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARTHROTEC, DICLOFENAC SODIUM
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE, ARTICAINE HYDROCHLORIDE
ASACOL HD, MESALAMINE
ASACOL, MESALAMINE
ASCLERA, POLIDOCANOL
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
ATELVIA, RISEDRONATE SODIUM
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ATIVAN, LORAZEPAM
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROVENT HFA, IPRATROPIUM BROMIDE
ATROVENT, IPRATROPIUM BROMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDAMET, METFORMIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 6

**** A ****

AVANDARYL, GLIMEPIRIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVENTYL HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
AVIANE-28, ETHINYL ESTRADIOL
AVINZA, MORPHINE SULFATE
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AXERT, ALMOTRIPTAN MALATE
AXID AR, NIZATIDINE (OTC)
AXID, NIZATIDINE
AXIRON, TESTOSTERONE
AYGESTIN, NORETHINDRONE ACETATE
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZACTAM, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZMACORT, TRIAMCINOLONE ACETONIDE
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZTREONAM, AZTREONAM
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE

**** B ****

BACIIM, BACITRACIN
BACI-RX, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BARACLUDE, ENTECAVIR
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENZAEPRIIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENZACLIN, BENZOYL PEROXIDE

APPENDIX A - PRODUCT NAME INDEX

A - 7

**** B ****

BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETIMOL, TIMOLOL
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BEYAZ, DROSPIRENONE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BILTRICIDE, PRAZIQUANTEL
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
BONIVA, IBANDRONATE SODIUM
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRAVELLE, UROFOLLITROPIN
BREATHTEK UBT FOR H-PYLORI, UREA C-13
BRETILIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETILIUM TOSYLATE
BRETILIUM TOSYLATE, BRETILIUM TOSYLATE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMDAY, BROMFENAC SODIUM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BROVANA, ARFORMOTEROL TARTRATE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 8

**** B ****

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPAR, BUSPIRONE HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUSULFEX, BUSULFAN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 BUTAPAP, ACETAMINOPHEN
 BUTISOL SODIUM, BUTABARBITAL SODIUM
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 BUTRANS, BUPRENORPHINE
 BYETTA, EXENATIDE SYNTHETIC
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABERGOLINE, CABERGOLINE
 CADUET, AMLODIPINE BESYLATE
 CAFECIT, CAFFEINE CITRATE
 CAFERGOT, CAFFEINE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALAN, VERAPAMIL HYDROCHLORIDE
 CALCIJEX, CALCITRIOL
 CALCIPOTRIENE, CALCIPOTRIENE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CALCIUM DISODIUM VERSEDATE, EDETATE CALCIUM DISODIUM
 CALDOLOR, IBUPROFEN
 CAMBIA, DICLOFENAC POTASSIUM
 CAMILA, NORETHINDRONE
 CAMPRAL, ACAMPROSATE CALCIUM
 CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
 CANASA, MESALAMINE
 CANCIDAS, CASPOFUNGIN ACETATE
 CANTIL, MEPENZOLATE BROMIDE
 CAPASTAT SULFATE, CAPREOMYCIN SULFATE
 CAPEX, FLUOCINOLONE ACETONIDE
 CAPITAL AND CODEINE, ACETAMINOPHEN
 CAPITAL SOLEIL 15, AVOBENZONE (OTC)
 CAPOTEN, CAPTOPRIL
 CAPOZIDE 25/15, CAPTOPRIL
 CAPOZIDE 25/25, CAPTOPRIL
 CAPOZIDE 50/15, CAPTOPRIL
 CAPOZIDE 50/25, CAPTOPRIL
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CAPTOPRIL, CAPTOPRIL
 CARAC, FLUOROURACIL
 CARAFATE, SUCRALFATE
 CARBAGLU, CARGLUMIC ACID
 CARBAMAZEPINE, CARBAMAZEPINE
 CARBATROL, CARBAMAZEPINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 9

**** C ****

CARBOPLATIN, CARBOPLATIN
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDURA XL, DOXAZOSIN MESYLATE
CARDURA, DOXAZOSIN MESYLATE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARMOL HC, HYDROCORTISONE ACETATE
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CARPINE, PILOCARPINE HYDROCHLORIDE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CASODEX, BICALUTAMIDE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CAYSTON, AZTREONAM
CEDAX, CEFTIBUTEN DIHYDRATE
CEENU, LOMUSTINE
CEFACLOR, CEFACLOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFZOLIN SODIUM
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFDINIR, CEFdinir
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTIN, CEFUROXIME AXETIL
CEFTRIAZONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAZONE SODIUM
CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
CEFTRIAZONE, CEFTRIAZONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM IN PLASTIC CONTAINER, CEFUROXIME SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE

APPENDIX A - PRODUCT NAME INDEX

A - 10

**** C ****

CELESTONE, BETAMETHASONE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CEREDASE, ALGLUCERASE
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETAMIDE, SULFACETAMIDE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETROTIDE, CETRORELIX
CHANTIX, VARENICLINE TARTRATE
CHEMET, SUCCIMER
CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB SWAB, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORZOXAZONE, CHLORZOXAZONE

APPENDIX A - PRODUCT NAME INDEX

A - 11

**** C ****

CHOLAC, LACTULOSE
CHOLEDYL SA, OXTRIPHYLLINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CHROMITOPES SODIUM, SODIUM CHROMATE CR-51
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO XR, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CISPLATIN, CISPLATIN
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CITANEST PLAIN DENTAL, PRILOCAINE HYDROCHLORIDE
CLADRIBINE, CLADRIBINE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLARAVIS, ISOTRETINOIN
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLENZ-LYTE, POLYETHYLENE GLYCOL 3350
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE BUTYRATE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 12

**** C ****

CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINORIL, SULINDAC
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOLAR, CLOFARABINE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLONIDINE, CLONIDINE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE

APPENDIX A - PRODUCT NAME INDEX

A - 13

**** C ****

CO-GESIC, ACETAMINOPHEN
COGNEX, TACRINE HYDROCHLORIDE
COLAZAL, BALSALAZIDE DISODIUM
COLCRYS, COLCHICINE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COL-PROBENECID, COLCHICINE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMBUNOX, IBUPROFEN
COMMIT, NICOTINE POLACRILEX (OTC)
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONSTULOSE, LACTULOSE
COPAXONE, GLATIRAMER ACETATE
COPEGUS, RIBAVIRIN
CORDARONE, AMIODARONE HYDROCHLORIDE
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL
CORGARD, NADOLOL
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COUMADIN, WARFARIN SODIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CREON, LIPASE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)

APPENDIX A - PRODUCT NAME INDEX

A - 14

**** C ****

CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOSAR-U, CYTARABINE
CYTOTEC, MISOPROSTOL
CYTOVENE, GANCICLOVIR SODIUM
CYTOXAN, CYCLOPHOSPHAMIDE

**** D ****

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DACOGEN, DECITABINE
DACTINOMYCIN, DACTINOMYCIN
DALMANE, FLURAZEPAM HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DARAPRIM, PYRIMETHAMINE
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON, PROPOXYPHENE HYDROCHLORIDE
DARVON-N, PROPOXYPHENE NAPSYLATE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAUNOXOME, DAUNORUBICIN CITRATE
DAYPRO, OXAPROZIN
DAYTRANA, METHYLPHENIDATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DELATESTRYL, TESTOSTERONE ENANTHATE
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 15

**** D ****

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DEMADEX, TORSEMIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSER, METYROSINE
DENAVIR, PENCICLOVIR SODIUM
DENDRID, IDOXURIDINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPOCYT, CYTARABINE
DEPODUR, MORPHINE SULFATE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DERMABET, BETAMETHASONE VALERATE
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMATOP, PREDNICARBATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONATE, DESONIDE
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN
DEXILANT, DEXLANSOPRAZOLE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

A - 16

**** D ****

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 17

**** D ****

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAMOX, ACETAZOLAMIDE
DIAMOX, ACETAZOLAMIDE SODIUM
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIDRONEL, ETIDRONATE DISODIUM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILT-CD, DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTZAC, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPIVEFRIN HYDROCHLORIDE, DIPIVEFRIN HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPROLENE AF, BETAMETHASONE DIPROPIONATE

APPENDIX A - PRODUCT NAME INDEX

A - 18

**** D ****

DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISPERMOX, AMOXICILLIN
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOLENE, PROPOXYPHENE HYDROCHLORIDE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORIBAX, DORIPENEM
DORYX, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXIL, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROXIA, HYDROXYUREA
DTIC-DOME, DACARBAZINE
DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUAC, BENZOYL PEROXIDE
DUETACT, GLIMEPIRIDE
DULERA, FORMOTEROL FUMARATE
DUODOTE, ATROPINE
DUONEB, ALBUTEROL SULFATE
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE

APPENDIX A - PRODUCT NAME INDEX

A - 19

**** D ****

DUTASTERIDE, DUTASTERIDE
DUVOID, BETHANECHOL CHLORIDE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYNACIRC CR, ISRADIPINE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYRENIUM, TRIAMTERENE

**** E ****

E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
EDECIN, ETHACRYNATE SODIUM
EDECIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
E-GLADES, ERYTHROMYCIN
EGRIFTA, TESAMORELIN ACETATE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELIDEL, PIMECROLIMUS
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELIPHOS, CALCIUM ACETATE
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENC, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE
EMBEDA, MORPHINE SULFATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMLA, LIDOCAINE
EMSAM, SELEGILINE
EMTRIVA, EMTRICITABINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDOMETRIN, PROGESTERONE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENDURON, METHYLCLOTHIAZIDE
ENFLURANE, ENFLURANE
ENJUVA, ESTROGENS, CONJUGATED SYNTHETIC B
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENTEREG, ALVIMOPAN

APPENDIX A - PRODUCT NAME INDEX

A - 20

**** E ****

ENTOCORT EC, BUDESONIDE
ENULOSE, LACTULOSE
EOVIST, GADOXETATE DISODIUM
EPIDUO, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINEPHRINE, EPINEPHRINE (OTC)
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERY-TAB, ERYTHROMYCIN
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHRO-STATIN, ERYTHROMYCIN
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESGIC-PLUS, ACETAMINOPHEN
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADERM, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRADIOL, ESTRADIOL
ESTRASORB, ESTRADIOL HEMIHYDRATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTRONE, ESTRONE
ESTROPIPATE, ESTROPIPATE
ESTROSTEP FE, ETHINYL ESTRADIOL
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHRANE, ENFLURANE
ETHYOL, AMIFOSTINE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE

APPENDIX A - PRODUCT NAME INDEX

A - 21

**** E ****

EURAX, CROTAMITON
EVAMIST, ESTRADIOL
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODextrin
E-Z SCRUB 201, POVIDONE-iodine (OTC)
E-Z SCRUB 241, POVIDONE-iodine (OTC)

**** F ****

FACTIVE, GEMIFLOXACIN MESYLATE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK), FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FAMVIR, FAMCICLOVIR
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FASLODEX, FULVESTRANT
FAZACLO ODT, CLOZAPINE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMTRACE, ESTRADIOL ACETATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL
FERIDEX I.V., FERUMOXIDES
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE

APPENDIX A - PRODUCT NAME INDEX

A - 22

**** F ****

FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
FIRMAGON, DEGARELIX ACETATE
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
FLAGYL, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE
FLOLAN, EPOPROSTENOL SODIUM
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE, FLUTICASONE PROPIONATE
FLO-PRED, PREDNISOLONE ACETATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOXIN OTIC, OFLOXACIN
FLOXURIDINE, FLOXURIDINE
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE, FLUCONAZOLE
FLUDARA, FLUDARABINE PHOSPHATE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE F-18
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUORESCITE, FLUORESCIN SODIUM
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE

APPENDIX A - PRODUCT NAME INDEX

A - 23

**** F ****

FORADIL CERTIHALER, FORMOTEROL FUMARATE
FORADIL, FORMOTEROL FUMARATE
FORANE, ISOFLURANE
FORTAMET, METFORMIN HYDROCHLORIDE
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
FORTESTA, TESTOSTERONE
FORTICAL, CALCITONIN SALMON RECOMBINANT
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMAX, ALENDRONATE SODIUM
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FULCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FUNGIZONE, AMPHOTERICIN B
FURADANTIN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM
FUZEON, ENFUVIRTIDE

**** G ****

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALZIN, ZINC ACETATE
GANCICLOVIR, GANCICLOVIR
GANCICLOVIR, GANCICLOVIR SODIUM
GANIRELIX ACETATE INJECTION, GANIRELIX ACETATE
GANITE, GALLIUM NITRATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GASTROMARK, FERUMOXIL
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMCITABINE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMZAR, GEMCITABINE HYDROCHLORIDE
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GILENYA, FINGOLIMOD

APPENDIX A - PRODUCT NAME INDEX

A - 24

**** G ****

GLEEVEC, IMATINIB MESYLATE
 GLIADEL, CARMUSTINE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLIPIZIDE, GLIPIZIDE
 GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
 GLUCAGON, GLUCAGON RECOMBINANT
 GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
 GLUCOPHAGE, METFORMIN HYDROCHLORIDE
 GLUCOTROL XL, GLIPIZIDE
 GLUCOTROL, GLIPIZIDE
 GLUCOVANCE, GLYBURIDE
 GLUMETZA, METFORMIN HYDROCHLORIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 GLYCOLAX, POLYETHYLENE GLYCOL 3350
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GLYNASE, GLYBURIDE
 GLYSET, MIGLITOL
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 GONAL-F RFF PEN, FOLLITROPIN ALFA/BETA
 GONAL-F RFF, FOLLITROPIN ALFA/BETA
 GONAL-F, FOLLITROPIN ALFA/BETA
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRANISTERON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
 GRISEOFULVIN, GRISEOFULVIN
 GRISEOFULVIN, GRISEOFULVIN, MICROCRYSTALLINE
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
 GUANABENZ ACETATE, GUANABENZ ACETATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 GYNAZOLE-1, BUTOCONAZOLE NITRATE
 GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)

**** H ****

H.P. ACTHAR GEL, CORTICOTROPIN
 HABITROL, NICOTINE (OTC)
 HALAVEN, ERIBULIN MESYLATE
 HALCION, TRIAZOLAM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 HALFLYTELY, BISACODYL
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HALOG, HALCINONIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEATHER, NORETHINDRONE
 HECTOROL, DOXERCALCIFEROL
 HELIDAC, BISMUTH SUBSALICYLATE
 HEMABATE, CARBOPROST TROMETHAMINE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

APPENDIX A - PRODUCT NAME INDEX

A - 25

**** H ****

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPATASOL 8%, AMINO ACIDS
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
HEPSERA, ADEFOVIR DIPIVOXIL
HERPLEX, IDOXURIDINE
HEXABRIX, IOXAGLATE MEGLUMINE
HEXALEN, ALTRETAMINE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HICON, SODIUM IODIDE I-131
HIPREX, METHENAMINE HIPPURATE
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50 PEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 PEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG PEN, INSULIN LISPRO RECOMBINANT
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYDASE, HYALURONIDASE
HYDERGINE, ERGOLOID MESYLATES
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDRO-RX, HYDROCORTISONE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE

APPENDIX A - PRODUCT NAME INDEX

A - 26

**** H ****

HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
HYTRIN, TERAZOSIN HYDROCHLORIDE
HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDKIT:HP, UREA C-13
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
IMPLANON, ETONOGESTREL
IMURAN, AZATHIOPRINE
INAPSINE, DROPERIDOL
INCRELEX, MECASERMIN RECOMBINANT
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN SR, INDOMETHACIN
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INDOMETHACIN, INDOMETHACIN
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INFUVITE PEDIATRIC, ASCORBIC ACID
INNOHEP, TINZAPARIN SODIUM
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 27

**** I ****

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INSPRA, EPLERENONE
INTAL, CROMOLYN SODIUM
INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
INVANZ, ERTAPENEM SODIUM
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVIRASE, SAQUINAVIR MESYLATE
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IPRIVASK, DESIRUDIN RECOMBINANT
IQUIX, LEVOFLOXACIN
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN, LEVONORDEFIN
ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
ISOFLURANE, ISOFLURANE
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE

APPENDIX A - PRODUCT NAME INDEX

A - 28

**** I ****

ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
IVY BLOCK, BENTOQUATAM (OTC)
IXEMPRA KIT, IXABEPILONE

**** J ****

JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
JENLOGA, CLONIDINE HYDROCHLORIDE
JEVTANA KIT, CABAZITAXEL
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)

**** K ****

K+10, POTASSIUM CHLORIDE
KADIAN, MORPHINE SULFATE
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KAON CL-10, POTASSIUM CHLORIDE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARIVA, DESOGESTREL
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KEFLEX, CEPHALEXIN
KEFZOL, CEFAZOLIN SODIUM
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETEK, TELITHROMYCIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
KLOTRIX, POTASSIUM CHLORIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
K-TAB, POTASSIUM CHLORIDE
KUVAN, SAPROPTERIN DIHYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 29

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAC-HYDRIN, AMMONIUM LACTATE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMOTRIGINE, LAMOTRIGINE
LAMPRENE, CLOFAZIMINE
LANORINAL, ASPIRIN
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LANSOPRAZOLE, LANSOPRAZOLE
LANTUS, INSULIN GLARGINE RECOMBINANT
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACFT, ALCAFTADINE
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LEFLUNOMIDE, LEFLUNOMIDE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEUSTATIN, CLADRIBINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
LEVATOL, PENBUTOLOL SULFATE
LEVEMIR, INSULIN DETEMIR RECOMBINANT
LEVETIRACETAM, LEVETIRACETAM
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LEVOFLOXACIN, LEVOFLOXACIN
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVO-T, LEVOTHYROXINE SODIUM
LEVOTHROID, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM

APPENDIX A - PRODUCT NAME INDEX

A - 30

**** L ****

LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE AND TETRACAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
LIDODERM, LIDOCAINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIPOSYN II 10%, SAFFLOWER OIL
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LIPOSYN III 30%, SOYBEAN OIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOMOTIL, ATROPINE SULFATE
LONOX, ATROPINE SULFATE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

A - 31

**** L ****

LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
LORAZEPAM, LORAZEPAM
LORTAB, ACETAMINOPHEN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUFYLLIN, DYPHYLLINE
LUMIGAN, BIMATOPROST
LUNESTA, ESZOPICLONE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUSEDRA, FOSPROPOFOL DISODIUM
LUVERIS, LUTROPIN ALFA
LUVOX CR, FLUVOXAMINE MALEATE
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LYBREL, ETHINYL ESTRADIOL
LYMPHAZURIN, ISOSULFAN BLUE
LYRICA, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID

**** M ****

M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. ADULT, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACUGEN, PEGAPTANIB SODIUM
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE, MAGNESIUM HYDROXIDE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE

APPENDIX A - PRODUCT NAME INDEX

A - 32

**** M ****

MALATHION, MALATHION
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARPLAN, ISOCARBOXAZID
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXAIR, PIRBUTEROL ACETATE
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MEBENDAZOLE, MEBENDAZOLE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE ES, MEGESTROL ACETATE
MEGACE, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, LUTEINIZING HORMONE
MENOSTAR, ESTRADIOL
MEN'S ROGAINE, MINOXIDIL (OTC)
MENTAX, BUTENAFINE HYDROCHLORIDE
MENTAX-TC, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPYRINE, MERCAPTOPYRINE

APPENDIX A - PRODUCT NAME INDEX

A - 33

**** M ****

MEROPENEM, MEROPENEM
MERREM I.V., MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAGLIP, GLIPIZIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METVIXIA, METHYL AMINOLEVULINATE HYDROCHLORIDE
MEVACOR, LOVASTATIN
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

APPENDIX A - PRODUCT NAME INDEX

A - 34

**** M ****

MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MICRONOR, NORETHINDRONE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIRIN, DESMOPRESSIN ACETATE
MINITRAN, NITROGLYCERIN
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MIOCHOL-E, ACETYLCOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRCETTE, DESOGESTREL
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MISOPROSTOL, MISOPROSTOL
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOBIC, MELOXICAM
MODICON 28, ETHINYL ESTRADIOL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONOPRIL, FOSINOPRIL SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE

APPENDIX A - PRODUCT NAME INDEX

A - 35

**** M ****

MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOVIPREP, ASCORBIC ACID
MOXATAG, AMOXICILLIN
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOZOBIL, PLERIXAFOR
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCELEX, CLOTRIMAZOLE
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOSTATIN, NYSTATIN
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
MYSOLINE, PRIMIDONE
MYTELASE, AMBENONIUM CHLORIDE
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)

**** N ****

NABUMETONE, NABUMETONE
NADOLOL AND BENDROFLUMETHAZIDE, BENDROFLUMETHIAZIDE
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALFON, FENOPROFEN CALCIUM
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 36

**** N ****

NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE MONOHYDRATE
NATACYN, NATAMYCIN
NATAZIA, ESTRADIOL VALERATE
NATEGLINIDE, NATEGLINIDE
NATRECOR, NESIRITIDE RECOMBINANT
NAVANE, THIOTHIXENE
NAVELBINE, VINORELBINE TARTRATE
NAVSTEL, CALCIUM CHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-FRADIN, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEO-RX, NEOMYCIN SULFATE
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
NEPHRAMINE 5.4%, AMINO ACIDS
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEXAVAR, SORAFENIB TOSYLATE
NEXCEDE, KETOPROFEN (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NILANDRON, NILUTAMIDE
NILSTAT, NYSTATIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NIPENT, PENTOSTATIN
NIRAVAM, ALPRAZOLAM
NISOLDIPINE, NISOLDIPINE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN

APPENDIX A - PRODUCT NAME INDEX

A - 37

**** N ****

NITROGLYCERIN, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
NORCO, ACETAMINOPHEN
NORDETTE-28, ETHINYL ESTRADIOL
NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT
NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT
NORDITROPIN, SOMATROPIN RECOMBINANT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHIDRONE, NORETHINDRONE
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 28-DAY, MESTRANOL
NORITATE, METRONIDAZOLE
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NOROXIN, NORFLOXACIN
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NOR-QD, NORETHINDRONE
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOVAMINE 11.4%, AMINO ACIDS
NOVAMINE 15%, AMINO ACIDS
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG, INSULIN ASPART RECOMBINANT
NOXAFIL, POSACONAZOLE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

APPENDIX A - PRODUCT NAME INDEX

A - 38

**** N ****

NUTRACORT, HYDROCORTISONE
NUTRESTORE, GLUTAMINE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT
NUVARING, ETHINYL ESTRADIOL
NUVIGIL, ARMODAFINIL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
NYSTOP, NYSTATIN

**** O ****

OCTOCAINE, EPINEPHRINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
OCUFEN, FLURBIPROFEN SODIUM
OCUFLOX, OFLOXACIN
OCUPRESS, CARTEOLOL HYDROCHLORIDE
OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OFORTA, FLUDARABINE PHOSPHATE
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLEPTRO, TRAZODONE HYDROCHLORIDE
OLUX E, CLOBETASOL PROPIONATE
OLUX, CLOBETASOL PROPIONATE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMNARIS, CICLESONIDE
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
OMNITROPE, SOMATROPIN RECOMBINANT
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONSOLIS, FENTANYL CITRATE
OPANA ER, OXYMORPHONE HYDROCHLORIDE
OPANA, OXYMORPHONE HYDROCHLORIDE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
OPTICROM, CROMOLYN SODIUM
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 39

**** 0 ****

OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPTIVAR, AZELASTINE HYDROCHLORIDE
ORABASE HCA, HYDROCORTISONE ACETATE
ORACEA, DOXYCYCLINE
ORACORT, TRIAMCINOLONE ACETONIDE
ORAMORPH SR, MORPHINE SULFATE
ORAP, PIMOZIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVerse, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORETIC, HYDROCHLOROTHIAZIDE
ORFADIN, NITISINONE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-EST, ESTROPIPATE
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORVATEN, MIDODRINE HYDROCHLORIDE
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMOPREP, SODIUM PHOSPHATE, DIBASIC ANHYDROUS
OTICAIR, HYDROCORTISONE
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
OVIDE, MALATHION
OVIDREL, CHORIOGONADOTROPIN ALFA
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXANDRIN, OXANDROLONE
OXANDROLONE, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXCARBAZEPINE, OXCARBAZEPINE
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN
OXISTAT, OXICONAZOLE NITRATE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 40

**** O ****

OXYTOCIN, OXYTOCIN
 OXYTROL, OXYBUTYNIN
 OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PAMINE FORTE, METHSCOPOLAMINE BROMIDE
 PAMINE, METHSCOPOLAMINE BROMIDE
 PANCREAZE, LIPASE
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PANIXINE DISPERDOSE, CEPHALEXIN
 PANRETIN, ALITRETINOIN
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARAFON FORTE DSC, CHLORZOXAZONE
 PARAGARD T 380A, COPPER
 PARCOPA, CARBIDOPA
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PARLODEL, BROMOCRIPTINE MESYLATE
 PARNATE, TRANLYCYPROMINE SULFATE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PASER, AMINOSALICYLIC ACID
 PATADAY, OLOPATADINE HYDROCHLORIDE
 PATANASE, OLOPATADINE HYDROCHLORIDE
 PATANOL, OLOPATADINE HYDROCHLORIDE
 PAXIL CR, PAROXETINE HYDROCHLORIDE
 PAXIL, PAROXETINE HYDROCHLORIDE
 PCE, ERYTHROMYCIN
 PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
 PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
 PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
 PEDIATRIC ADVIL, IBUPROFEN (OTC)
 PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE
 PEDIOTIC, HYDROCORTISONE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE, POLYETHYLENE GLYCOL 3350
 PEGANONE, ETHOTOIN
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PENLAC, CICLOPIROX
 PENNSAID, DICLOFENAC SODIUM
 PENTAM, PENTAMIDINE ISETHIONATE
 PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
 PENTASA, MESALAMINE
 PENTAZOCINE AND NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
 PENTOSTATIN, PENTOSTATIN
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PENTOXIL, PENTOXIFYLLINE
 PEPCID AC (GELTAB), FAMOTIDINE (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
 PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 PEPCID PRESERVATIVE FREE, FAMOTIDINE

APPENDIX A - PRODUCT NAME INDEX

A - 41

**** P ****

PEPCID, FAMOTIDINE
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERIOSTAT, DOXYCYCLINE HYCLATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PERSANTINE, DIPYRIDAMOLE
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHISOHEX, HEXACHLOROPHENE
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM
PIROXICAM, PIROXICAM
PITOCIN, OXYTOCIN
PLAN B ONE-STEP, LEVONORGESTREL
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAN B, LEVONORGESTREL
PLAN B, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLATINOL, CISPLATIN
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLETAL, CILOSTAZOL
PODOFILOX, PODOFILOX
POLOCAINE, MEPIVACAINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 42

**** P ****

POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLY-PRED, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYTRIM, POLYMYXIN B SULFATE
PONSTEL, MEFENAMIC ACID
PORTIA-28, ETHINYL ESTRADIOL
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

A - 43

**** P ****

POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 44

**** P ****

PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIMET, METFORMIN HYDROCHLORIDE
PRANDIN, REPAGLINIDE
PRAVACHOL, PRAVASTATIN SODIUM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PREFEST, ESTRADIOL
PREGNYL, GONADOTROPIN, CHORIONIC
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE
PRE-PEN, BENZYL PENICILLIN POLYLYSINE
PREPIDIL, DINOPROSTONE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVACID, LANSOPRAZOLE
PREVALITE, CHOLESTYRAMINE
PREVIFEM, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PREZISTA, DARUNAVIR ETHANOLATE
PRIALT, ZICONOTIDE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRILOSEC, OMEPRAZOLE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINIVIL, LISINAPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR HFA, ALBUTEROL SULFATE
PROAMATINE, MIDODRINE HYDROCHLORIDE
PROBALAN, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE

APPENDIX A - PRODUCT NAME INDEX

A - 45

**** P ****

PROBENECID, PROBENECID
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA XL, NIFEDIPINE
PROCARDIA, NIFEDIPINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROFEN, IBUPROFEN (OTC)
PROFERDEX, IRON DEXTRAN
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
PROMACTA, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAPENONE HYDROCHLORIDE, PROPAPENONE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE
PROPOFOL, PROPOFOL
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HYDROCHLORIDE, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROQUIN XR, CIPROFLOXACIN HYDROCHLORIDE
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE

APPENDIX A - PRODUCT NAME INDEX

A - 46

**** P ****

PULMICORT, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PURINETHOL, MERCAPTOPURINE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

**** Q ****

QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
QUALAQUIN, QUININE SULFATE
QUASENSE, ETHINYL ESTRADIOL
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUIXIN, LEVOFLOXACIN
QUTENZA, CAPSAICIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

**** R ****

RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANICLOR, CEFACLOX
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
RAZADYNE, GALANTAMINE HYDROBROMIDE
REBETOL, RIBAVIRIN
RECLAST, ZOLEDRONIC ACID
REFLUDAN, LEPIRUDIN RECOMBINANT
REGITINE, PHENTOLAMINE MESYLATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPA, ELETRIPTAN HYDROBROMIDE
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE
REMODULIN, TREPROSTINIL SODIUM
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOVA, TRETINOIN
REVELA, SEVELAMER CARBONATE
REPREXAIN, HYDROCODONE BITARTRATE
REPRONEX, LUTEINIZING HORMONE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
REQUIP, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE

APPENDIX A - PRODUCT NAME INDEX

A - 47

**** R ****

RESECTISOL IN PLASTIC CONTAINER, MANNITOL
 RESERPINE, RESERPINE
 RESTASIS, CYCLOSPORINE
 RESTORIL, TEMAZEPAM
 RETIN-A MICRO, TRETINOIN
 RETIN-A, TRETINOIN
 RETISERT, FLUOCINOLONE ACETONIDE
 RETROVIR, ZIDOVUDINE
 REVATIO, SILDENAFIL CITRATE
 REVIA, NALTREXONE HYDROCHLORIDE
 REVLIMID, LENALIDOMIDE
 REYATAZ, ATAZANAVIR SULFATE
 R-GENE 10, ARGININE HYDROCHLORIDE
 RHINOCORT, BUDESONIDE
 RIBASPHERE, RIBAVIRIN
 RIBAVARIN, RIBAVIRIN
 RIBAVIRIN, RIBAVIRIN
 RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
 RIDAURA, AURANOFIN
 RIFADIN, RIFAMPIN
 RIFAMATE, ISONIAZID
 RIFAMPIN AND ISONIAZID, ISONIAZID
 RIFAMPIN, RIFAMPIN
 RIFATER, ISONIAZID
 RILUTEK, RILUZOLE
 RILUZOLE, RILUZOLE
 RIMACTANE, RIFAMPIN
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
 RIMS0-50, DIMETHYL SULFOXIDE
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 RIOMET, METFORMIN HYDROCHLORIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERDAL CONSTA, RISPERIDONE
 RISPERDAL, RISPERIDONE
 RISPERIDONE, RISPERIDONE
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROBAXIN, METHOCARBAMOL
 ROBAXIN-750, METHOCARBAMOL
 ROBINUL FORTE, GLYCOPYRROLATE
 ROBINUL, GLYCOPYRROLATE
 ROCALTROL, CALCITRIOL
 ROCEPHIN, CEFTRIAXONE SODIUM
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROGAINE (FOR MEN), MINOXIDIL (OTC)
 ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
 ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 ROMAZICON, FLUMAZENIL
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROWASA, MESALAMINE
 ROXICET 5/500, ACETAMINOPHEN
 ROXICET, ACETAMINOPHEN
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 ROXILOX, ACETAMINOPHEN
 ROZEREM, RAMELTEON
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
 RYTHMOL, PROPAFENONE HYDROCHLORIDE
 RYZOLT, TRAMADOL HYDROCHLORIDE

**** S ****

SABRIL, VIGABATRIN

APPENDIX A - PRODUCT NAME INDEX

A - 48

**** S ****

SAFYRAL, DROSPIRENONE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SALURON, HYDROFLUMETHIAZIDE
SAMSCA, TOLVAPTAN
SANCTURA XR, TROSPIMUM CHLORIDE
SANCTURA, TROSPIMUM CHLORIDE
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL
SCLEROSOL, TALC
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECONAL SODIUM, SECOBARBITAL SODIUM
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELSUN, SELENIUM SULFIDE
SELZENTRY, MARAVIROC
SEMPREX-D, ACRIVASTINE
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAIN HYDROCHLORIDE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SEROMYCIN, CYCLOSERINE
SEROPHENE, CLOMIPHENE CITRATE
SEROQUEL XR, QUETIAPINE FUMARATE
SEROQUEL, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERPALAN, RESERPINE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVOFLURANE, SEVOFLURANE
SFROWASA, MESALAMINE
SHADE UVAGUARD, AVOBENZONE (OTC)
SILENOR, DOXEPIN HYDROCHLORIDE
SILVADENE, SILVER SULFADIAZINE
SIMCOR, NIACIN
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINOGRAPHIN, DIATRIZOATE MEGLUMINE
SKELAXIN, METAXALONE
SKELID, TILUDRONATE DISODIUM
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 49

**** S ****

SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM IODIDE I-131, SODIUM IODIDE I-131
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SOJOURN, SEVOFLURANE
SOLAGE, MEQUINOL
SOLARAZE, DICLOFENAC SODIUM
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTRET, ISOTRETINOIN
SPECTRACEF, CEFDITOREN PIVOXIL
SPIRIVA, TIOTROPIUM BROMIDE MONOHYDRATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STARLIX, NATEGLINIDE
STAVUDINE, STAVUDINE
STAVZOR, VALPROIC ACID
STAXYN, VARDENAFIL HYDROCHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERILE WATER, STERILE WATER FOR IRRIGATION
STIE-CORT, HYDROCORTISONE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIMATE, DESMOPRESSIN ACETATE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIANT, TESTOSTERONE

APPENDIX A - PRODUCT NAME INDEX

A - 50

**** S ****

STROMECTOL, IVERMECTIN
 STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUBOXONE, BUPRENORPHINE
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
 SUBUTEX, BUPRENORPHINE HYDROCHLORIDE
 SUCRAID, SACROSIDASE
 SUCRALFATE, SUCRALFATE
 SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 SULAR, NISOLDIPINE
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 SULFADIAZINE, SULFADIAZINE
 SULFAMETHOPRIM, SULFAMETHOXAZOLE
 SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULFAMYLON, MAFENIDE ACETATE
 SULFASALAZINE, SULFASALAZINE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE
 SUMYCIN, TETRACYCLINE HYDROCHLORIDE
 SUPPRELIN LA, HISTRELIN ACETATE
 SUPRANE, DESFLURANE
 SUPRAX, CEFIXIME
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS
 SURMONTIL, TRIMIPRAMINE MALEATE
 SURVANTA, BERACTANT
 SUSTIVA, EFAVIRENZ
 SUTENT, SUNITINIB MALATE
 SYMBICORT, BUDESONIDE
 SYMBYAX, FLUOXETINE HYDROCHLORIDE
 SYMLIN, PRAMLINTIDE ACETATE
 SYNACORT, HYDROCORTISONE
 SYNALAR, FLUOCINOLONE ACETONIDE
 SYNALGOS-DC, ASPIRIN
 SYNAREL, NAFARELIN ACETATE
 SYNERA, LIDOCAINE
 SYNERCID, DALFOPRISTIN
 SYNTHETIC CONJUGATED ESTROGENS A, ESTROGENS, CONJUGATED SYNTHETIC A
 SYNTHROID, LEVOTHYROXINE SODIUM
 SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TAB-PROFEN, IBUPROFEN (OTC)
 TACLONEX SCALP, BETAMETHASONE DIPROPIONATE
 TACLONEX, BETAMETHASONE DIPROPIONATE
 TACROLIMUS, TACROLIMUS
 TAGAMET HB, CIMETIDINE (OTC)
 TAGAMET, CIMETIDINE
 TALC, TALC
 TALWIN, PENTAZOCINE LACTATE
 TAMBOCOR, FLECAINIDE ACETATE
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TAPAZOLE, METHIMAZOLE

APPENDIX A - PRODUCT NAME INDEX

A - 51

**** T ****

TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TASMAR, TOLCAPONE
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAXOTERE, DOCETAXEL
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99 SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKAMLO, ALISKIREN HEMIFUMARATE
TEKURNA HCT, ALISKIREN HEMIFUMARATE
TEKURNA, ALISKIREN HEMIFUMARATE
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
TEMOZOLOMIDE, TEMOZOLOMIDE
TENEX, GUANFACINE HYDROCHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIL, CARBAMAZEPINE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTRED, METHYLTESTOSTERONE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE
TEV-TROPIN, SOMATROPIN RECOMBINANT
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THEO-24, THEOPHYLLINE

APPENDIX A - PRODUCT NAME INDEX

A - 52

**** T ****

THEOCHRON, THEOPHYLLINE
THEOLAIR, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE
THRIVE, NICOTINE POLACRILEX (OTC)
THYROGEN, THYROTROPIN ALFA
THYROLAR-0.25, LIOETHYRONINE SODIUM
THYROLAR-0.5, LIOETHYRONINE SODIUM
THYROLAR-1, LIOETHYRONINE SODIUM
THYROLAR-2, LIOETHYRONINE SODIUM
THYROLAR-3, LIOETHYRONINE SODIUM
THYROSAFE, POTASSIUM IODIDE (OTC)
THYROSHIELD, POTASSIUM IODIDE (OTC)
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIKOSYN, DOFETILIDE
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIOPRONIN, TIOPRONIN
TIROSINT, LEVOTHYROXINE SODIUM
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBRADEX ST, DEXAMETHASONE
TOBRADEX, DEXAMETHASONE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOPAMAX, TOPIRAMATE
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE

APPENDIX A - PRODUCT NAME INDEX

A - 53

**** T ****

TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOTECT, DEXRAZOXANE HYDROCHLORIDE
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRACLEER, BOSENTAN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANDATE, LABETALOL HYDROCHLORIDE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANDOLAPRIL, TRANDOLAPRIL
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
TRASYLOL, APROTININ
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVATAN, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TRELSTAR DEPOT, TRIPTORELIN PAMOATE
TRELSTAR LA, TRIPTORELIN PAMOATE
TRELSTAR, TRIPTORELIN PAMOATE
TRENTAL, PENTOXIFYLLINE
TRETINOIN, TRETINOIN
Trexall, METHOTREXATE SODIUM
Treximet, NAPROXEN SODIUM
TRI LO SPRINTec, ETHINYL ESTRADIOL
TRIACET, TRIAMCINOLONE ACETONIDE
TRIAcin-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDIONE, TRIMETHADIONE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRILEPTAL, OXCARBAZEPINE
TRILIPIX, CHOLINE FENOFIBRATE
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRILYTE, POLYETHYLENE GLYCOL 3350
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

APPENDIX A - PRODUCT NAME INDEX

A - 54

**** T ****

TRIMETHOPRIM, TRIMETHOPRIM
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIOSTAT, LIOTHYRONINE SODIUM
TRI-PREVIEW, ETHINYL ESTRADIOL
TRISENOX, ARSENIC TRIOXIDE
TRI-SPRINT, ETHINYL ESTRADIOL
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVARIS, TRIAMCINOLONE ACETONIDE
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRUVADA, EMTRICITABINE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
TWINJECT 0.15, EPINEPHRINE
TWINJECT 0.3, EPINEPHRINE
TWINSTA, AMLODIPINE BESYLATE
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL (CAPLET), ACETAMINOPHEN (OTC)
TYLENOL (GELTAB), ACETAMINOPHEN (OTC)
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLOX, ACETAMINOPHEN
TYVASO, TREPROSTINIL SODIUM
TYZEKA, TELBIVUDINE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

U-CORT, HYDROCORTISONE ACETATE
ULESFIA, BENZYL ALCOHOL
ULORIC, FEBUXOSTAT
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRACET, ACETAMINOPHEN
ULTRAM ER, TRAMADOL HYDROCHLORIDE
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNIRETIC, HYDROCHLOROTHIAZIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM
UNIVASC, MOEXIPRIL HYDROCHLORIDE
URECHOLINE, BETHANECHOL CHLORIDE
UREX, METHENAMINE HIPPURATE
UROKIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 55

**** U ****

URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UVADEX, METHOXSALEN

**** V ****

VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VALTROPIN, SOMATROPIN RECOMBINANT
VALTURNA, ALISKIREN HEMIFUMARATE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VANTAS, HISTRELIN ACETATE
VANTIN, CEFPODOXIME PROXETIL
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VASERETIC, ENALAPRIL MALEATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOTEC, ENALAPRIL MALEATE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB
VELIVET, DESOGESTREL
VELTIN, CLINDAMYCIN PHOSPHATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAMYST, FLUTICASONE FUROATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE
VESICARE, SOLIFENACIN SUCCINATE
VEXOL, RIMEXOLONE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VIBRA-TABS, DOXYCYCLINE HYCLATE
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN
VICOPROFEN, HYDROCODONE BITARTRATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIDEX EC, DIDANOSINE
VIDEX, DIDANOSINE

APPENDIX A - PRODUCT NAME INDEX

A - 56

**** V ****

VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
 VIMOVO, ESOMEPRAZOLE MAGNESIUM
 VIMPAT, LACOSAMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINCRISTINE SULFATE, VINCRISTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 VIRACEPT, NELFINAVIR MESYLATE
 VIRAMUNE, NEVIRAPINE
 VIRAZOLE, RIBAVIRIN
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE
 VIROPTIC, TRIFLURIDINE
 VISICOL, SODIUM PHOSPHATE, DIBASIC ANHYDROUS
 VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
 VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 VISIONBLUE, TRYPAN BLUE
 VISIPAQUE 270, IODIXANOL
 VISIPAQUE 320, IODIXANOL
 VISTARIL, HYDROXYZINE PAMOATE
 VISTIDE, CIDOFOVIR
 VISUDYNE, VERTEPORFIN
 VITAMIN D, ERGOCALCIFEROL
 VITAMIN K1, PHYTONADIONE
 VITRASE, HYALURONIDASE
 VITRASERT, GANCICLOVIR
 VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
 VIVELLE, ESTRADIOL
 VIVELLE-DOT, ESTRADIOL
 VIVITROL, NALTREXONE
 VOLTAREN, DICLOFENAC SODIUM
 VOLTAREN-XR, DICLOFENAC SODIUM
 VORICONAZOLE, VORICONAZOLE
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL
 VOSPIRE ER, ALBUTEROL SULFATE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 VPRIV, VELAGLUCERASE ALFA
 VUMON, TENIPOSIDE
 VUSION, MICONAZOLE NITRATE
 VYTORIN, EZETIMIBE
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

**** W ****

WARFARIN SODIUM, WARFARIN SODIUM
 WELCHOL, COLESEVELAM HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
 WELLBUTRIN, BUPROPION HYDROCHLORIDE
 WESTCORT, HYDROCORTISONE VALERATE

**** X ****

XALATAN, LATANOPROST
 XANAX XR, ALPRAZOLAM
 XANAX, ALPRAZOLAM
 XELODA, CAPECITABINE
 XENAZINE, TETRABENAZINE
 XENICAL, ORLISTAT
 XENON XE 133, XENON XE-133
 XIBROM, BROMFENAC SODIUM
 XIFAXAN, RIFAXIMIN
 XOLEGEL, KETOCONAZOLE
 XOPENEX HFA, LEVALBUTEROL TARTRATE

APPENDIX A - PRODUCT NAME INDEX

A - 57

**** X ****

XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE DENTAL WITH EPINEPHRINE, EPINEPHRINE
XYLOCAINE DENTAL, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYREM, SODIUM OXYBATE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

**** Y ****

YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

**** Z ****

ZADITOR, KETOTIFEN FUMARATE (OTC)
ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 25, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAVESCA, MIGLUSTAT
ZEBETA, BISOPROLOL FUMARATE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZEGERID, OMEPRAZOLE
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZEMPLAR, PARICALCITOL
ZEMURON, ROCURONIUM BROMIDE
ZENPEP, LIPASE
ZERIT, STAVUDINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINAPRIL
ZETIA, EZETIMIBE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOLADEX, GOSERELIN ACETATE
ZOLINZA, VORINOSTAT
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APPENDIX A - PRODUCT NAME INDEX

A - 58

**** Z ****

ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZUPLENZ, ONDANSETRON
ZYBAN, BUPROPION HYDROCHLORIDE
ZYCLARA, IMIQUIMOD
ZYDONE, ACETAMINOPHEN
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMEXID, GATIFLOXACIN
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 3 ******3M**

- * 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
- * 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)
- * 3M PHARMACEUTICALS INC
PROVENTIL-HFA, ALBUTEROL SULFATE

AAIPHARMA LLC

- * AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBOTT

- * ABBOTT LABORATORIES
ADVICOR, LOVASTATIN
AKINETON, BIPERIDEN HYDROCHLORIDE
AZMACORT, TRIAMCINOLONE ACETONIDE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
CYCLOSPORINE, CYCLOSPORINE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
KALETRA, LOPINAVIR
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SIMCOR, NIACIN
SYNTHROID, LEVOTHYROXINE SODIUM
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE
ULTANE, SEVOFLURANE
ZEMPLAR, PARICALCITOL
- * ABBOTT LABORATORIES CHEMICAL AND AGRICULTURAL PRODUCTS DIV
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
- * ABBOTT LABORATORIES HOSP PRODUCTS DIV
CALCIJEX, CALCITRIOL
- * ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV
BIAXIN, CLARITHROMYCIN
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE, DIVALPROEX SODIUM
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
ENDURON, METHYCLOTHIAZIDE
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERY-TAB, ERYTHROMYCIN
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
HYTRIN, TERAZOSIN HYDROCHLORIDE
K-TAB, POTASSIUM CHLORIDE
MAVIK, TRANDOLAPRIL
NORVIR, RITONAVIR
ORETIC, HYDROCHLOROTHIAZIDE
PCE, ERYTHROMYCIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
TARKA, TRANDOLAPRIL
TRICOR, FENOFIBRATE
TRIDIONE, TRIMETHADIONE
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

- * ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV
VICOPROFEN, HYDROCODONE BITARTRATE
ZEMPLAR, PARICALCITOL

ABBOTT LABS

- * ABBOTT ENDOCRINE INC SUB ABBOTT LABORATORIES
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
- * ABBOTT LABORATORIES
NORVIR, RITONAVIR
TRILIPIX, CHOLINE FENOFIBRATE

ABBOTT PRODS

- * ABBOTT PRODUCTS INC
ACEON, PERINDOPRIL ERBUMINE
ANDROGEL, TESTOSTERONE
CREON, LIPASE
MARINOL, DRONABINOL
PROMETRIUM, PROGESTERONE

ABRAXIS BIOSCIENCE

- * ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

ABRAXIS PHARM

- * ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
MAGNESIUM SULFATE, MAGNESIUM SULFATE

ACADEMIC PHARMS

- * ACADEMIC PHARMACEUTICALS INC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ACCORD HLTH

- * ACCORD HEALTH CARE INC
METHYLDOPA, METHYLDOPA

ACCORD HLTHCARE

- * ACCORD HEALTHCARE INC
GLIMEPIRIDE, GLIMEPIRIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
SIMVASTATIN, SIMVASTATIN
TOPIRAMATE, TOPIRAMATE

ACCORD HLTHCARE INC

- * ACCORD HEALTHCARE INC USA
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
CLONAZEPAM, CLONAZEPAM
ETOPOSIDE, ETOPOSIDE
FINASTERIDE, FINASTERIDE
GLIPIZIDE, GLIPIZIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
PACLITAXEL, PACLITAXEL

ACIC FINE CHEMS

- * ACIC FINE CHEMICALS INC
AMPICILLIN SODIUM, AMPICILLIN SODIUM

ACORDA

- * ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

ACS DOBFAR

- * ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFZOLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACS DOBFAR SPA
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
KEFZOL, CEFAZOLIN SODIUM

ACS DOBFAR INFO SA

* ACS DOBFAR INFO SA
CEPHALEXIN, CEPHALEXIN
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE

ACTAVIS

* ACTAVIS SOUTHATLANTIC LLC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
NIFEDIPINE, NIFEDIPINE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ACYCLOVIR, ACYCLOVIR
ALPRAZOLAM, ALPRAZOLAM
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CARBIDOPA AND LEVODOPA, CARBIDOPA
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KADIAN, MORPHINE SULFATE
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NABUMETONE, NABUMETONE
NAPROXEN, NAPROXEN
NIFEDIPINE, NIFEDIPINE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RAMIPRIL, RAMIPRIL
SPIRONOLACTONE, SPIRONOLACTONE
TEMAZEPAM, TEMAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS ELIZABETH LLC
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CAPITAL AND CODEINE, ACETAMINOPHEN
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CICLOPIROX, CICLOPIROX
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CONSTULOSE, LACTULOSE
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
ENULOSE, LACTULOSE
FLUOCINONIDE, FLUOCINONIDE
GRISEOFULVIN, GRISEOFULVIN, MICROCRYSTALLINE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MYKACET, NYSTATIN
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
SELENIUM SULFIDE, SELENIUM SULFIDE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ACTAVIS MID ATLANTIC LLC
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALNAC, BETAMETHASONE VALERATE

ACTAVIS PHARMA

* ACTAVIS PHARMA MANUFACTURING PRIVATE LTD
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS SOUTH

* ACTAVIS SOUTH ATLANTIC LLC
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CHLORZOXAZONE, CHLORZOXAZONE
CILOSTAZOL, CILOSTAZOL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL
GLYBURIDE, GLYBURIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISRADIPINE, ISRADIPINE
MELOXICAM, MELOXICAM
METHIMAZOLE, METHIMAZOLE
MIRTAZAPINE, MIRTAZAPINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTELION

* ACTELION LTD
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
TRACLEER, BOSENTAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

ACTELION PHARMS LTD

* ACTELION PHARMACEUTICALS LTD
VENTAVIS, ILOPROST
ZAVESCA, MIGLUSTAT

ACTON PHARMS

* ACTON PHARMACEUTICALS INC
AEROSPAN HFA, FLUNISOLIDE

ADOLOR

* ADOLOR CORP
ENTEREG, ALVIMOPAN

ADVENT PHARMS

* ADVENT PHARMACEUTICALS INC
CARISOPRODOL, CARISOPRODOL
IBUPROFEN, IBUPROFEN (OTC)

AEGIS PHARMS

* AEGIS PHARMACEUTICALS INC
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE

AESGEN

* AESGEN INC
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

AGOURON

* AGOURON PHARMACEUTICALS INC
VIRACEPT, NELFINAVIR MESYLATE

AKORN

* AKORN INC
ADENOSINE, ADENOSINE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AK-FLUOR 10%, FLUORESCHEIN SODIUM
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CROMOLYN SODIUM, CROMOLYN SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ENDOSOL EXTRA, CALCIUM CHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IC-GREEN, INDOCYANINE GREEN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN INC
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TROPICACYL, TROPICAMIDE

AKORN INC

* AKORN INC
APRACLOPIDINE HYDROCHLORIDE, APRACLOPIDINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
INAPSINE, DROPERIDOL

AKORN STRIDES

* AKORN STRIDES LLC
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
HALOPERIDOL, HALOPERIDOL LACTATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
RIFAMPIN, RIFAMPIN
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE

AKRIMAX PHARMS

* AKRIMAX PHARMACEUTICALS LLC
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
LO/OVRAL-28, ETHINYL ESTRADIOL

ALARA PHARM

* ALARA PHARMACEUTICAL CORPORATION
LEVO-T, LEVOTHYROXINE SODIUM

ALAVEN PHARM

* ALAVEN PHARMACEUTICAL LLC
ANADROL-50, OXYMETHOLONE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
ROWASA, MESALAMINE
SFROWASA, MESALAMINE

ALCON

* ALCON INC
AZOPT, BRINZOLAMIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CARPINE, PILOCARPINE HYDROCHLORIDE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLUORESCITE, FLUORESCIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
NAVSTEL, CALCIUM CHLORIDE
NEVANAC, NEPAFENAC
OFLOXACIN, OFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALCON INC
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TOBRADEX ST, DEXAMETHASONE
TRAVATAN Z, TRAVOPROST
TRAVATAN, TRAVOPROST
TRIESENCE, TRIAMCINOLONE ACETONIDE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE

* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALOMIDE, LODOXAMIDE TROMETHAMINE
BETADINE, POVIDONE-IODINE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CETAMIDE, SULFACETAMIDE SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
DENDRID, IDOXURIDINE
EMADINE, EMEDASTINE DIFUMARATE
FLAREX, FLUOROMETHOLONE ACETATE
IOPIDINE, APRACLOXIDINE HYDROCHLORIDE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MIOSTAT, CARBACHOL
MYDRIACYL, TROPICAMIDE
NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NATACYN, NATAMYCIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
OMNIPRED, PREDNISOLONE ACETATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRIFLURIDINE, TRIFLURIDINE
VEXOL, RIMEXOLONE

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE

ALCON RES

* ALCON RESEARCH LTD
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DUREZOL, DIFLUPREDNATE

ALCON UNIVERSAL

* ALCON UNIVERSAL LTD
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

ALEMBIC LTD

* ALEMBIC LTD
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEPROBAMATE, MEPROBAMATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALEMBIC LTD
METRONIDAZOLE, METRONIDAZOLE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ALKEM

* ALKEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKERMES

* ALKERMES INC
VIVITROL, NALTREXONE

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN

* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
Zymaxid, GATIFLOXACIN

* ALLERGAN INC
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
AZELEX, AZELAIC ACID
COMBIGAN, BRIMONIDINE TARTRATE
ELESTAT, EPINASTINE HYDROCHLORIDE
ELIMITE, PERMETHRIN
LATISSE, BIMATOPROST
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OPTICROM, CROMOLYN SODIUM
OZURDEX, DEXAMETHASONE
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS, CYCLOSPORINE
SANCTURA XR, TROSPIMUM CHLORIDE
SANCTURA, TROSPIMUM CHLORIDE
TAZORAC, TAZAROTENE
TRIVARIS, TRIAMCINOLONE ACETONIDE
Zymar, GATIFLOXACIN

* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
HERPLEX, IDOXURIDINE
OCUFEN, FLURBIPROFEN SODIUM
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

- * ALLERGAN PHARMACEUTICAL
PRED-G, GENTAMICIN SULFATE
PROPINE, DIPIVEFRIN HYDROCHLORIDE

ALLERGAN HERBERT

- * ALLERGAN HERBERT SKIN CARE DIV ALLERGAN INC
FLUOROPLEX, FLUOROURACIL

ALLERQUEST

- * ALLERQUEST LLC
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE

ALLOS

- * ALLOS THERAPEUTICS INC
FOLOTYN, PRALATREXATE

ALPHAPHARM

- * ALPHAPHARM PARTY LTD
ALPRAZOLAM, ALPRAZOLAM
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONAZEPAM, CLONAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE, GLIPIZIDE
INDAPAMIDE, INDAPAMIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NAPROXEN, NAPROXEN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM
ZONISAMIDE, ZONISAMIDE
- * ALPHAPHARM PTY LTD
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

ALPHARMA

- * ALPHARMA USPD INC
PREDNISOLONE, PREDNISOLONE
VALPROIC ACID, VALPROIC ACID

ALPHARMA KING

- * ALPHARMA PHARMACEUTICALS LLC KING PHARMACEUTICALS
EMBEDA, MORPHINE SULFATE

ALPHARMA US PHARMS

- * ALPHARMA US PHARMACEUTICALS DIVISION
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

ALRA

- * ALRA LABORATORIES INC
CHOLAC, LACTULOSE
CONSTILAC, LACTULOSE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC

- * ALTAIRE PHARMACEUTICALS INC
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)

ALTANA

- * ALTANA INC
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMCINONIDE, AMCINONIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALTANA INC
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CUTIVATE, FLUTICASONE PROPIONATE
DESONIDE, DESONIDE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
KETOCONAZOLE, KETOCONAZOLE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NYSTATIN, NYSTATIN
OXISTAT, OXICONAZOLE NITRATE
PREDNICARBATE, PREDNICARBATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
TERCONAZOLE, TERCONAZOLE
TOBRAMYCIN, TOBRAMYCIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ALTANA PHARMA

* ALTANA PHARMA AG
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

ALTERNA TCHP LLC

* ALTERNA TCHP LLC
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

ALVOGEN

* ALVOGEN INC
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

AMAG PHARMS INC

* AMAG PHARMACEUTICALS INC
FERAHEME, FERUMOXYTOL
FERIDEX I.V., FERUMOXIDES
GASTROMARK, FERUMOXIL

AMGEN

* AMGEN INC
SENSIPAR, CINACALCET HYDROCHLORIDE

AMIDE PHARM

* ACTAVIS TOTOWA LLC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

- * AMNEAL PHARMACEUTICAL
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

AMNEAL PHARMS

- * AMNEAL PHARMACEUTICALS
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
INDOMETHACIN, INDOMETHACIN
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
NIZATIDINE, NIZATIDINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
- * AMNEAL PHARMACEUTICALS LLC
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

AMNEAL PHARMS NY

- * AMNEAL PHARMACEUTICALS NY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REPREXAIN, HYDROCODONE BITARTRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

AMPHASTAR

- * AMPHASTAR PHARMACEUTICALS INC
CORTROSYN, COSYNTROPIN

AMPHASTAR PHARM

- * AMPHASTAR PHARMACEUTICAL INC
AMPHADASE, HYALURONIDASE

AMYLIN

- * AMYLIN PHARMACEUTICALS INC
BYETTA, EXENATIDE SYNTHETIC
SYMLIN, PRAMLINTIDE ACETATE

ANBEX

- * ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ANCHEN PHARMS

- * ANCHEN PHARMACEUTICALS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * ANCHEN PHARMACEUTICALS TAIWAN INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM

ANDRX LABS LLC

- * ANDRX LABS LLC
ALTOPREV, LOVASTATIN
FORTAMET, METFORMIN HYDROCHLORIDE

ANESTA AG

- * ANESTA AG
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE

ANI PHARMS

- * ANI PHARMACEUTICALS INC
CORTENEMA, HYDROCORTISONE
LACTULOSE, LACTULOSE
LUVOX, FLUVOXAMINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

APOTEX

- * APOTEX CORP
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
- * APOTEX INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIMETIDINE, CIMETIDINE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOSPORINE, CYCLOSPORINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DILT-CD, DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
LEVOFLOXACIN, LEVOFLOXACIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NIZATIDINE, NIZATIDINE
OMEPRazole, OMEPRazole
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

APOTEX CORP

* APOTEX CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CLARITHROMYCIN, CLARITHROMYCIN
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

APOTEX INC

* APOTEX INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CALCITONIN-SALMON, CALCITONIN SALMON
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
OXCARBAZEPINE, OXCARBAZEPINE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTIAZEM, DILTIAZEM HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

- * APOTEX INC ETOBICOKE SITE
 - LEFLUNOMIDE, LEFLUNOMIDE
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - LITHIUM CARBONATE, LITHIUM CARBONATE
 - LORATADINE, LORATADINE (OTC)
 - MELOXICAM, MELOXICAM
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 - MIRTAZAPINE, MIRTAZAPINE
 - OXAPROZIN, OXAPROZIN
 - SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 - SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 - TOPIRAMATE, TOPIRAMATE
 - TORSEMIDE, TORSEMIDE
 - ZONISAMIDE, ZONISAMIDE
- * APOTEX INC RICHMOND HILL
 - ALBUTEROL SULFATE, ALBUTEROL SULFATE
 - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 - DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 - FLUNISOLIDE, FLUNISOLIDE
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - LORATADINE, LORATADINE (OTC)
 - MEGESTROL ACETATE, MEGESTROL ACETATE
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - PREDNISOLONE, PREDNISOLONE
 - RISPERIDONE, RISPERIDONE

APOTHECON

- * APOTHECON INC DIV BRISTOL MYERS SQUIBB
 - CAPOZIDE 25/15, CAPTOPRIL
 - CAPOZIDE 25/25, CAPTOPRIL
 - CAPOZIDE 50/15, CAPTOPRIL
 - CAPOZIDE 50/25, CAPTOPRIL
 - FUNGIZONE, AMPHOTERICIN B
 - KENALOG, TRIAMCINOLONE ACETONIDE
 - KENALOG-10, TRIAMCINOLONE ACETONIDE
 - KENALOG-40, TRIAMCINOLONE ACETONIDE
 - KLOTRIX, POTASSIUM CHLORIDE
 - OPHTHAINE, PROPARACAINE HYDROCHLORIDE
 - PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
 - STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 - STADOL, BUTORPHANOL TARTRATE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

APP PHARMS

- * APP PHARMACEUTICALS
 - GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 - PROTAMINE SULFATE, PROTAMINE SULFATE
- * APP PHARMACEUTICALS LLC
 - ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 - ADENOSINE, ADENOSINE
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - ASTRAMORPH PF, MORPHINE SULFATE
 - AZITHROMYCIN, AZITHROMYCIN
 - AZTREONAM, AZTREONAM
 - BACITRACIN, BACITRACIN
 - BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* APP PHARMACEUTICALS LLC
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCITRIOL, CALCITRIOL
 CARBOPLATIN, CARBOPLATIN
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFOTAXIME, CEFOTAXIME SODIUM
 CEFOTETAN, CEFOTETAN DISODIUM
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPRIVAN, PROPOFOL
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXY 100, DOXYCYCLINE HYCLATE
 DOXY 200, DOXYCYCLINE HYCLATE
 EMLA, LIDOCAINE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GANCICLOVIR, GANCICLOVIR SODIUM
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN, INDOMETHACIN
 IOPAMIDOL-250, IOPAMIDOL
 IOPAMIDOL-300, IOPAMIDOL
 IOPAMIDOL-370, IOPAMIDOL
 KANAMYCIN SULFATE, KANAMYCIN SULFATE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* APP PHARMACEUTICALS LLC
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 MANNITOL 25%, MANNITOL
 MESNA, MESNA
 METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
 NEBUPENT, PENTAMIDINE ISETHIONATE
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 OXYTOCIN, OXYTOCIN
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENTAM, PENTAMIDINE ISETHIONATE
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROGESTERONE, PROGESTERONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 THIOTEPA, THIOTEPA
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALPROATE SODIUM, VALPROATE SODIUM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VIBISONE, CYANOCOBALAMIN
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINCRISTINE SULFATE, VINCRISTINE SULFATE
 VINOELBINE TARTRATE, VINOELBINE TARTRATE
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE

AR HOLDING CO INC

* AR HOLDING CO INC
 COLCRYL, COLCHICINE
 FIBRICOR, FENOFIBRIC ACID
 QUALAQUIN, QUININE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

AREVA PHARMS

- * AREVA PHARMACEUTICALS INC
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARMSTRONG PHARMS

- * ARMSTRONG PHARMACEUTICALS INC
EPINEPHRINE, EPINEPHRINE (OTC)

ASCEND

- * ASCEND THERAPEUTICS INC
ESTROGEL, ESTRADIOL

ASTELLAS

- * ASTELLAS PHARMA US INC
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
AMBISOME, AMPHOTERICIN B
LEXISCAN, REGADENOSON
MYCAMINE, MICAFUNGIN SODIUM
PROGRAF, TACROLIMUS
PROTOPIC, TACROLIMUS
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VESICARE, SOLIFENACIN SUCCINATE

ASTRAZENECA

- * ASTRAZENECA LP
ENTOCORT EC, BUDESONIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXIUM, ESOMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRILOSEC, OMEPRAZOLE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
RHINOCORT, BUDESONIDE
SEROQUEL, QUETIAPINE FUMARATE
SYMBICORT, BUDESONIDE
TENORMIN, ATENOLOL
TOPROL-XL, METOPROLOL SUCCINATE
- * ASTRAZENECA PHARMACEUTICALS LP
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
FASLODEX, FULVESTRANT
PULMICORT, BUDESONIDE
SEROQUEL XR, QUETIAPINE FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
- * ASTRAZENECA UK LTD
ACCOLATE, ZAFIRLUKAST
ARIMIDEX, ANASTROZOLE
CASODEX, BICALUTAMIDE
IRESSA, GEFITINIB
MERREM I.V., MEROPENEM
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINAPRIL
ZOLADEX, GOSERELIN ACETATE

ASTRAZENECA LP

- * ASTRAZENECA LP
VIMOVO, ESOMEPRAZOLE MAGNESIUM

ATON

- * ATON PHARMA INC
CUPRIMINE, PENICILLAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ATON PHARMA INC
DEMSEER, METYROSINE
EDECIN, ETHACRYNATE SODIUM
EDECIN, ETHACRYNIC ACID
LACRISERT, HYDROXYPROPYL CELLULOSE
LODOSYN, CARBIDOPA
MEPHYTON, PHYTONADIONE
SYPRINE, TRIENTINE HYDROCHLORIDE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE

AUROBINDO

* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINAPRIL, LISINAPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAPAZINE, MIRTAPAZINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARM

* AUROBINDO PHARMA USA INC
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

AUROBINDO PHARMA

* AUROBINDO PHARMA
AMPICILLIN AND SULBACTAM, AMPICILLIN

* AUROBINDO PHARMA LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATENOLOL, ATENOLOL
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARISOPRODOL, CARISOPRODOL
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFDINIR, CEFIDINIR
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFPodoxime PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIBAVARIN, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
STAVUDINE, STAVUDINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRANDOLAPRIL, TRANDOLAPRIL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LTD INC
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
MIRTAZAPINE, MIRTAZAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROSAL PHARMS

* AUROSAL PHARMACEUTICALS LLC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE

AUSTARPHARMA LLC

* AUSTARPHARMA LLC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS

* AUXILIUM PHARMACEUTICALS
TESTIM, TESTOSTERONE

AVACOR PRODS

* AVACOR PRODUCTS LLC
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVANIR PHARMS

* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

AVENT

- * AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

AVEVA

- * AVEVA DRUG DELIVERY SYSTEMS INC
CLONIDINE, CLONIDINE
NICOTINE, NICOTINE (OTC)

AXCAN

- * AXCAN PHARMA US INC
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
CANASA, MESALAMINE
CARAFATE, SUCRALFATE
PHOTOFRIN, PORFIMER SODIUM
URSO 250, URSODIOL
URSO FORTE, URSODIOL

AXCAN SCANDIPHARM

- * AXCAN SCANDIPHARM INC
PYLERA, BISMUTH SUBCITRATE POTASSIUM

AZTIQ PHARMA

- * AZTIQ PHARMA INC
TODAY, NONOXYNOL-9 (OTC)

AZUR PHARMA

- * AZUR PHARMA INTERNATIONAL LTD
AVC, SULFANILAMIDE
GASTROCROM, CROMOLYN SODIUM

AZUR PHARMA II

- * AZUR PHARMA INTERNATIONAL II LTD
ELESTRIN, ESTRADIOL
PRIALT, ZICONOTIDE

AZUR PHARMA INTL

- * AZUR PHARMA INTERNATIONAL III LTD
FAZACLO ODT, CLOZAPINE

B BRAUN

- * B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
BALANCED SALT, CALCIUM CHLORIDE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CEFAZOLIN AND DEXTROSE, CEFZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTITIN SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* B BRAUN MEDICAL INC

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE

FREAMINE HBC 6.9%, AMINO ACIDS

FREAMINE III 10%, AMINO ACIDS

FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS

FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS

FREAMINE III 8.5%, AMINO ACIDS

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE

GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

HEPATAMINE 8%, AMINO ACIDS

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL

MANNITOL 10%, MANNITOL

MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL

MANNITOL 15%, MANNITOL

MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 20%, MANNITOL

MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL

MANNITOL 5%, MANNITOL

METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE

NEPHRAMINE 5.4%, AMINO ACIDS

NUTRILIPID 10%, SOYBEAN OIL

NUTRILIPID 20%, SOYBEAN OIL

PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* B BRAUN MEDICAL INC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* B BRAUN MEDICAL INC
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROCALAMINE, AMINO ACIDS
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TROPHAMINE 10%, AMINO ACIDS
 TROPHAMINE, AMINO ACIDS

BANNER PHARMACAPS

* BANNER PHARMACAPS INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ETHOSUXIMIDE, ETHOSUXIMIDE
 IBUPROFEN AND DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDOL LIQUID GELS, IBUPROFEN (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BANNER PHARMACAPS INC
 NIMODIPINE, NIMODIPINE
 STAVZOR, VALPROIC ACID
 VALPROIC ACID, VALPROIC ACID
 VITAMIN D, ERGOCALCIFEROL
 ZONISAMIDE, ZONISAMIDE

BARR

* BARR LABORATORIES INC
 ALPRAZOLAM, ALPRAZOLAM
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARANELLE, ETHINYL ESTRADIOL
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BALZIVA-28, ETHINYL ESTRADIOL
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CAMILA, NORETHINDRONE
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORZOXAZONE, CHLORZOXAZONE
 CLARAVIS, ISOTRETINOIN
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE, CLONIDINE
 DANAZOL, DANAZOL
 DEMECLOXYCLINE HYDROCHLORIDE, DEMECLOXYCLINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 ASPARTATE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DIDANOSINE, DIDANOSINE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DUTASTERIDE, DUTASTERIDE
 ERRIN, NORETHINDRONE
 ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL
 ESTRADIOL, ESTRADIOL
 ESTROPIRATE, ESTROPIRATE
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 FENTANYL CITRATE, FENTANYL CITRATE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 ISONIAZID, ISONIAZID
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 KARIVA, DESOGESTREL
 KELNOR, ETHINYL ESTRADIOL
 LEFLUNOMIDE, LEFLUNOMIDE
 LESSINA-28, ETHINYL ESTRADIOL
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

- * BARR LABORATORIES INC
 - MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - METHOTREXATE SODIUM, METHOTREXATE SODIUM
 - MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 - NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 - NIMODIPINE, NIMODIPINE
 - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 - NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 - NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 - NORTREL 1/35-21, ETHINYL ESTRADIOL
 - NORTREL 1/35-28, ETHINYL ESTRADIOL
 - NORTREL 7/7/7, ETHINYL ESTRADIOL
 - ONDANSETRON, ONDANSETRON
 - OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 - PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 - PORTIA-28, ETHINYL ESTRADIOL
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 - SPRINTEC, ETHINYL ESTRADIOL
 - TEMOZOLOMIDE, TEMOZOLOMIDE
 - TRETINOIN, TRETINOIN
 - TREXALL, METHOTREXATE SODIUM
 - TRI LO SPRINTEC, ETHINYL ESTRADIOL
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 - TRI-LEGEST 21, ETHINYL ESTRADIOL
 - TRI-LEGEST FE, ETHINYL ESTRADIOL
 - TRI-SPRINTEC, ETHINYL ESTRADIOL
 - WARFARIN SODIUM, WARFARIN SODIUM
 - ZONISAMIDE, ZONISAMIDE
- * BARR PHARMACEUTICALS
 - LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BAUSCH AND LOMB

- * BAUSCH AND LOMB INC
 - ALAWAY, KETOTIFEN FUMARATE (OTC)
 - ALBUTEROL SULFATE, ALBUTEROL SULFATE
 - ALREX, LOTEPREDNOL ETABONATE
 - BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
 - CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 - DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 - FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
 - IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 - LOTEMAX, LOTEPREDNOL ETABONATE
 - OFLOXACIN, OFLOXACIN
 - OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 - RETISERT, FLUOCINOLONE ACETONIDE
 - TIMOLOL MALEATE, TIMOLOL MALEATE
 - VITRASERT, GANCICLOVIR
 - ZIRGAN, GANCICLOVIR
 - ZYLET, LOTEPREDNOL ETABONATE
- * BAUSCH AND LOMB PHARMACEUTICALS INC
 - ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
 - BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 - BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 - BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - CROLOM, CROMOLYN SODIUM
 - CROMOLYN SODIUM, CROMOLYN SODIUM
 - CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 - DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 - DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH AND LOMB PHARMACEUTICALS INC
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ADENOSINE, ADENOSINE
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP
 CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
 CYTOXAN, CYCLOPHOSPHAMIDE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 EXTRANEAL, ICODextrin
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPATASOL 8%, AMINO ACIDS
 IFEX, IFOSFAMIDE
 ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 HYDROCHLORIDE
 MESNEX, MESNA
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER, ONDANSETRON
 HYDROCHLORIDE
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

- * BAXTER HEALTHCARE CORP
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 RENAMIN W/O ELECTROLYTES, AMINO ACIDS
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERILE WATER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TIS-U-SOL, MAGNESIUM SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
 TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
- * BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
 ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 BUMETANIDE, BUMETANIDE
 CEFOXITIN, CEFOXITIN SODIUM
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DIGOXIN, DIGOXIN
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

- * BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
 - DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 - DIPYRIDAMOLE, DIPYRIDAMOLE
 - DOPRAM, DOXAPRAM HYDROCHLORIDE
 - DURAMORPH PF, MORPHINE SULFATE
 - FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 - FAMOTIDINE, FAMOTIDINE
 - FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 - FLUMAZENIL, FLUMAZENIL
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - HEPARIN SODIUM, HEPARIN SODIUM
 - INFUMORPH, MORPHINE SULFATE
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - MILRINONE LACTATE, MILRINONE LACTATE
 - MITOMYCIN, MITOMYCIN
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 - ROBINUL, GLYCOPYRROLATE
 - SUFENTANIL CITRATE, SUFENTANIL CITRATE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 - VINORELBINE TARTRATE, VINORELBINE TARTRATE
- * BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
 - FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 - PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

- * BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
 - ATIVAN, LORAZEPAM
 - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 - BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 - BREVIBLOC, ESMOLOL HYDROCHLORIDE
 - ETHRANE, ENFLURANE
 - FORANE, ISOFLURANE
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - OXYTOCIN, OXYTOCIN
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
 - REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
 - ROBAXIN, METHOCARBAMOL
 - SUPRANE, DESFLURANE

BAYER

- * BAYER HEALTHCARE LLC
 - ALEVE, NAPROXEN SODIUM (OTC)
 - ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
 - FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)

BAYER HLTHCARE

- * BAYER HEALTHCARE PHARMACEUTICALS INC
 - ADALAT CC, NIFEDIPINE
 - ANGELIQ, DROSPIRENONE
 - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
 - AVELOX, MOXIFLOXACIN HYDROCHLORIDE
 - BETAPACE AF, SOTALOL HYDROCHLORIDE
 - BETAPACE, SOTALOL HYDROCHLORIDE
 - BEYAZ, DROSPIRENONE
 - BILTRICIDE, PRAZIQUANTEL
 - CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 - CIPRO XR, CIPROFLOXACIN
 - CIPRO, CIPROFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAYER HEALTHCARE PHARMACEUTICALS INC
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE
 CLIMARA PRO, ESTRADIOL
 CLIMARA, ESTRADIOL
 DTIC-DOME, DACARBAZINE
 EOVI, GADOXETATE DISODIUM
 LEVITRA, VARDENAFIL HYDROCHLORIDE
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE
 MENOSTAR, ESTRADIOL
 MIRENA, LEVONORGESTREL
 MYCELEX, CLOTRIMAZOLE
 NATAZIA, ESTRADIOL VALERATE
 NEXAVAR, SORAFENIB TOSYLATE
 PRECOSE, ACARBOSE
 REFLUDAN, LEPYRUDIN RECOMBINANT
 SAFYRAL, DROSPIRENONE
 STAXYN, VARDENAFIL HYDROCHLORIDE
 TRASYL, APROTININ
 ULTRAVIST (PHARMACY BULK), IOPROMIDE
 ULTRAVIST 150, IOPROMIDE
 ULTRAVIST 240, IOPROMIDE
 ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
 ULTRAVIST 300, IOPROMIDE
 ULTRAVIST 370, IOPROMIDE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE

BAYER PHARMS

* BAYER PHARMACEUTICALS CORP
 MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 MYCELEX-7, CLOTRIMAZOLE (OTC)

BEAUFOR IPSEN

* BEAUFOR IPSEN PHARMA
 SOMATULINE DEPOT, LANREOTIDE ACETATE

BECTON DICKINSON

* BECTON DICKINSON AND CO
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
 E-Z SCRUB 201, POVIDONE-IODINE (OTC)
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BEDFORD

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMRINONE LACTATE, INAMRINONE LACTATE
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUMETANIDE, BUMETANIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CARBOPLATIN, CARBOPLATIN
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CYCLOSPORINE, CYCLOSPORINE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DACTINOMYCIN, DACTINOMYCIN
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 ENALAPRILAT, ENALAPRILAT
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ETOMIDATE, ETOMIDATE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOCARNITINE, LEVOCARNITINE
 LORAZEPAM, LORAZEPAM
 MESNA, MESNA
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOMYCIN, MITOMYCIN
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 THIOTEPA, THIOTEPA
 VALPROATE SODIUM, VALPROATE SODIUM
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

BEDFORD LABS

* BEDFORD LABORATORIES
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PENTOSTATIN, PENTOSTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE

BEIJING DOUBLE CRANE

* BEIJING DOUBLE CRANE PHARMACEUTICAL CO LTD
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
MELOXICAM, MELOXICAM

BELCHER PHARMS

* BELCHER PHARMACEUTICALS LLC
CEPHALEXIN, CEPHALEXIN

BEN VENUE

* BEN VENUE LABORATORIES INC
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

BEXIMCO USA

* BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BIO NUCLEONICS

* BIO NUCLEONICS INC
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

BIOALLIANCE PHARMA

* BIOALLIANCE PHARMA
ORAVIG, MICONAZOLE

BIOKEY

* BIOKEY INC
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM

BIOMARIN PHARM

* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROTERIN DIHYDROCHLORIDE

BIONICHE PHARMA

* BIONICHE PHARMA USA LLC
ALOPRIM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
COSYNTROPIN, COSYNTROPIN
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

- * BIONICHE PHARMA USA LLC
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
RIMSO-50, DIMETHYL SULFOXIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE

BIONICHE PHARMA USA

- * BIONICHE PHARMA USA LLC
CARBOPLATIN, CARBOPLATIN
DURACLON, CLONIDINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FOMEPIZOLE, FOMEPIZOLE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
ROCURIUM BROMIDE, ROCURIUM BROMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

BIONICHE TEORANTA

- * BIONICHE TEORANTA
ULTIVA, REMIFENTANIL HYDROCHLORIDE

BIOVAIL

- * BIOVAIL CORP INTERNATIONAL
TIAZAC, DILTIAZEM HYDROCHLORIDE
- * BIOVAIL LABORATORIES INC
ATIVAN, LORAZEPAM
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
NIFEDIPINE, NIFEDIPINE
PENTOXIFYLLINE, PENTOXIFYLLINE

BIOVAIL AMERICAS

- * BIOVAIL AMERICAS CORP
XENAZINE, TETRABENAZINE

BIOVAIL LABS INTL

- * BIOVAIL LABORATORIES INTERNATIONAL SRL
APLENZIN, BUPROPION HYDROBROMIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
ULTRAM ER, TRAMADOL HYDROCHLORIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE

BLAIREX

- * BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BOCA PHARMA

- * BOCA PHARMACAL INC
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
LEVETIRACETAM, LEVETIRACETAM
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

BOEHRINGER INGELHEIM

- * BOEHRINGER INGELHEIM
 - CATAPRES, CLONIDINE HYDROCHLORIDE
 - CATAPRES-TTS-1, CLONIDINE
 - CATAPRES-TTS-2, CLONIDINE
 - CATAPRES-TTS-3, CLONIDINE
 - MICARDIS HCT, HYDROCHLOROTHIAZIDE
 - MICARDIS, TELMISARTAN
 - MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
 - ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 - ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
- * BOEHRINGER INGELHEIM PHARMACEUTICALS INC
 - AGGRENOX, ASPIRIN
 - APTIVUS, TIPRANAVIR
 - ATROVENT HFA, IPRATROPIUM BROMIDE
 - ATROVENT, IPRATROPIUM BROMIDE
 - COMBIVENT, ALBUTEROL SULFATE
 - FLOMAX, TAMSULOSIN HYDROCHLORIDE
 - MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
 - MOBIC, MELOXICAM
 - PERSANTINE, DIPYRIDAMOLE
 - PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 - SPIRIVA, TIOTROPIUM BROMIDE MONOHYDRATE
 - TWYNSTA, AMLODIPINE BESYLATE
 - VIRAMUNE, NEVIRAPINE

BRACCO

- * BRACCO DIAGNOSTICS INC
 - CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
 - CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
 - CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
 - CHROMITOPES SODIUM, SODIUM CHROMATE CR-51
 - CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 - CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 - GASTROGRAFIN, DIATRIZOATE MEGLUMINE
 - ISOVUE-200, IOPAMIDOL
 - ISOVUE-250, IOPAMIDOL
 - ISOVUE-300, IOPAMIDOL
 - ISOVUE-370, IOPAMIDOL
 - ISOVUE-M 200, IOPAMIDOL
 - ISOVUE-M 300, IOPAMIDOL
 - KINEVAC, SINICALIDE
 - MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
 - MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 - MULTIHANCE, GADOBENATE DIMEGLUMINE
 - PROHANCE MULTIPACK, GADOTERIDOL
 - PROHANCE, GADOTERIDOL
 - RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
 - SINOGRAPHIN, DIATRIZOATE MEGLUMINE

BRAINTREE

- * BRAINTREE LABORATORIES INC
 - AXID, NIZATIDINE
 - GOLYTELY, POLYETHYLENE GLYCOL 3350
 - HALFLYTELY, BISACODYL
 - NULYTELY, POLYETHYLENE GLYCOL 3350
 - NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

- * BRAINTREE LABORATORIES INC
 - SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS

BREATH LTD

- * BREATH LTD
 - LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

BRECKENRIDGE PHARM

- * BRECKENRIDGE PHARMACEUTICAL INC
CILOSTAZOL, CILOSTAZOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
MELOXICAM, MELOXICAM
OXCARBAZEPINE, OXCARBAZEPINE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRIGHTSTONE

- * BRIGHTSTONE PHARMA INC
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

BRISTOL

- * BRISTOL LABORATORIES INC DIV BRISTOL MYERS CO
BICNU, CARMUSTINE

BRISTOL MYERS

- * BRISTOL MYERS CO
PLATINOL, CISPLATIN
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE

BRISTOL MYERS SQUIBB

- * BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
GLUCOVANCE, GLYBURIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
LYSODREN, MITOTANE
MEGACE, MEGESTROL ACETATE
PRAVACHOL, PRAVASTATIN SODIUM
- * BRISTOL MYERS SQUIBB CO
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
CEENU, LOMUSTINE
DROXIA, HYDROXYUREA
ESTRACE, ESTRADIOL
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
IXEMPRA KIT, IXABEPILONE
METAGLIP, GLIPIZIDE
MYCOSTATIN, NYSTATIN
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
VIDEX EC, DIDANOSINE
- * BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
BUSPAR, BUSPIRONE HYDROCHLORIDE
ESTRACE, ESTRADIOL
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MONOPRIL, FOSINOPRIL SODIUM
VIDEX, DIDANOSINE
VUMON, TENIPOSIDE
ZERIT, STAVUDINE
- * BRISTOL MYERS SQUIBB PHARMA CO
COUMADIN, WARFARIN SODIUM
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BRISTOL MYERS SQUIBB PHARMA CO
SUSTIVA, EFAVIRENZ

BRYAN

* BRYAN CORP
SCLEROSOL, TALC
TALC, TALC

CADENCE PHARMS

* CADENCE PHARMACEUTICALS INC
OFIRMEV, ACETAMINOPHEN

CADISTA PHARMS

* CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXCARBAZEPINE, OXCARBAZEPINE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
RISPERIDONE, RISPERIDONE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

CANYON

* CANYON PHARMACEUTICALS INC
IPRIVASK, DESIRUDIN RECOMBINANT

CARACO

* CARACO PHARMACEUTICAL LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONAZEPAM, CLONAZEPAM
CLOZAPINE, CLOZAPINE
DIGOXIN, DIGOXIN
ELIXOPHYLLIN, THEOPHYLLINE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
MELOXICAM, MELOXICAM
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
OXAPROZIN, OXAPROZIN
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
SYNALGOS-DC, ASPIRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CARACO PHARMACEUTICAL LABORATORIES LTD
THEOCHRON, THEOPHYLLINE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

CAREFUSION

* CAREFUSION 213 LLC
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

CARLSBAD

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN
MELOXICAM, MELOXICAM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CAROLINA MEDCL

* CAROLINA MEDICAL PRODUCTS CO
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CATALENT

* CATALENT PHARMA SOLUTIONS LLC
NIFEDIPINE, NIFEDIPINE
VALPROIC ACID, VALPROIC ACID

CEDAR PHARMS

* CEDAR PHARMACEUTICALS LLC
METHIMAZOLE, METHIMAZOLE

CELGENE

* CELGENE CORP
ISTODAX, ROMIDEPSIN
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

CEPHALON

* CEPHALON INC
ACTIQ, FENTANYL CITRATE
FENTORA, FENTANYL CITRATE
GABITRIL, TIAGABINE HYDROCHLORIDE
NUVIGIL, ARMODAFINIL
PROVIGIL, MODAFINIL
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CEPHAZONE PHARMA

* CEPHAZONE PHARMA LLC
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM

CEREXA

* CEREXA INC
TEFLARO, CEFTAROLINE FOSAMIL

CHATTEM

* CHATTEM INC
SELSUN, SELENIUM SULFIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEMISCH FBRK KRSSLR

* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

CHIRHOCLIN

* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
LIPOFEN, FENOFIBRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CIPLA

* CIPLA LTD
RAMIPRIL, RAMIPRIL
TRANOLAPRIL, TRANOLAPRIL
ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD

* CIPLA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
STAVUDINE, STAVUDINE
TOPIRAMATE, TOPIRAMATE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE

CITRUSPHRMA

* CITRUSPHRMA LLC
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

CLARIS LIFESCIENCES

* CLARIS LIFESCIENCES LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
DIPYRIDAMOLE, DIPYRIDAMOLE
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK), FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FULCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

- * CLARIS LIFESCIENCES LTD
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE

CLINIGEN HLTHCARE

- * CLINIGEN HEALTHCARE LTD
FOSCAVIR, FOSCARNET SODIUM

CLINTEC NUTR

- * CLINTEC NUTRITION CO SUB CLINIQUE
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

CLONMEL HLTHCARE

- * CLONMEL HEALTHCARE LTD
MORPHINE SULFATE, MORPHINE SULFATE

CNS THERAP

- * CNS THERAPEUTICS INC
GABLOFEN, BACLOFEN

CNTY LINE PHARMS

- * COUNTY LINE PHARMACEUTICALS LLC
UREX, METHENAMINE HIPPURATE

COASTAL PHARMS

- * COASTAL PHARMACEUTICALS INC
LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

COBALT LABS INC

- * COBALT LABORATORIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
LEVETIRACETAM, LEVETIRACETAM

COLGATE

- * COLGATE ORAL PHARMACEUTICALS INC
ORABASE HCA, HYDROCORTISONE ACETATE
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE

- * COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

COLLEGIUM PHARM

- * COLLEGIUM PHARMACEUTICAL INC
PODOFILOX, PODOFILOX

COLUMBIA LABS

- * COLUMBIA LABORATORIES INC
STRIANT, TESTOSTERONE

CONCORD LABS NJ

- * CONCORD LABORATORIES INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
PROBENECID AND COLCHICINE, COLCHICINE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN

CONNECTICS

- * CONNECTICS CORP
LUXIQ, BETAMETHASONE VALERATE

CONNETICS

- * CONNETICS CORP
OLUX, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

CONTRACT PHARMA

* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

CONTRACT PHARMACAL

* CONTRACT PHARMACAL CORP
CIMETIDINE, CIMETIDINE (OTC)
FOLIC ACID, FOLIC ACID
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PREDNISON, PREDNISON
PROFEN, IBUPROFEN (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

CONTROLLED THERAP

* CONTROLLED THERAPEUTICS (SCOTLAND) LTD
CERVIDIL, DINOPROSTONE

COREPHARMA

* COREPHARMA LLC
ALPRAZOLAM, ALPRAZOLAM
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARISOPRODOL, CARISOPRODOL
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ASPARTATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEVOCARNITINE, LEVOCARNITINE
MELOXICAM, MELOXICAM
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL
ZONISAMIDE, ZONISAMIDE

CORIA

* CORIA LABORATORIES LTD
NUTRACORT, HYDROCORTISONE

CORNERSTONE

* CORNERSTONE BIOPHARMA INC
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
SPECTRACEF, CEFDITOREN PIVOXIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CORNERSTONE THERAP

- * CORNERSTONE THERAPEUTICS INC
CUROSURF, PORACTANT ALFA
FACTIVE, GEMIFLOXACIN MESYLATE
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON

COVENANT PHARMA INC

- * COVENANT PHARMA INC
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
RIFAMPIN, RIFAMPIN

COVIDIEN

- * COVIDIEN
LYMPHAZURIN, ISOSULFAN BLUE
THERMAZENE, SILVER SULFADIAZINE

CP PHARMS

- * CP PHARMACEUTICALS CV
LYRICA, PREGABALIN

CPPI CV

- * CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CSL BEHRING

- * CSL BEHRING LLC
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIMATE, DESMOPRESSIN ACETATE

CUBIST

- * CUBIST PHARMACEUTICALS INC
CUBICIN, DAPTOMYCIN

CUMBERLAND PHARMS

- * CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN

CYPRESS BIOSCIENCE

- * CYPRESS BIOSCIENCE INC
SAVELLA, MILNACIPRAN HYDROCHLORIDE

CYPRESS PHARM

- * CYPRESS PHARMACEUTICAL INC
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ELIPHOS, CALCIUM ACETATE
LEVETIRACETAM, LEVETIRACETAM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

DAIICHI

- * DAIICHI PHARMACEUTICAL CORP
FLOXIN OTIC, OFLOXACIN

DAIICHI SANKYO

- * DAIICHI SANKYO INC
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO CO

- * DAIICHI SANKYO CO LTD
EVOXAC, CEVIMELINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

DANCO LABS LLC

* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DAVA INTL INC

* DAVA INTERNATIONAL INC
ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC

* DAVA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NAPROXEN, NAPROXEN
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DEL RAY LABS

* DEL RAY LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

DENCO ASSET

* DENCO ASSET LLC
DENA VIR, PENCICLOVIR SODIUM

DENTSPLY PHARM

* DENTSPLY PHARMACEUTICAL
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CITANEST PLAIN DENTAL, PRILOCAINE HYDROCHLORIDE
ORAQIX, LIDOCAINE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
XYLOCAINE DENTAL WITH EPINEPHRINE, EPINEPHRINE
XYLOCAINE DENTAL, LIDOCAINE HYDROCHLORIDE

DEPOMED INC

* DEPOMED INC
GLUMETZA, METFORMIN HYDROCHLORIDE
PROQUIN XR, CIPROFLOXACIN HYDROCHLORIDE

DEPROCO

* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

DEXCEL LTD

- * DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

- * DEXCEL PHARMA TECHNOLOGIES LTD
OMEPRazole, OMEPRazole (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DEY

- * DEY LP
ACCUNEB, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DUONEB, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

DEY PHARMA

- * DEY PHARMA LP
PERFOROMIST, FORMOTEROL FUMARATE

DIALYSIS SUPS

- * DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DORC

- * DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

DOW PHARM SCI

- * DOW PHARMACEUTICAL SCIENCES
ACANYA, BENZOYL PEROXIDE

DOW PHARM SCIENCES

- * DOW PHARMACEUTICAL SCIENCES INC
AKNE-MYCIN, ERYTHROMYCIN
ATRALIN, TRETINOIN
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLODERM, CLOCORTOLONE PIVALATE

DR REDDYS LA

- * DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

DR REDDYS LABS

- * DR REDDYS LABORATORIES LTD
OMEPRazole, OMEPRazole

DR REDDYS LABS INC

- * DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

* DR REDDYS LABORATORIES INC
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
OFLOXACIN, OFLOXACIN
OMEPRazole MAGNESIUM, OMEPRazole MAGNESIUM (OTC)
OMEPRazole, OMEPRazole
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PRIMIDONE, PRIMIDONE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

* DR REDDYS LABORATORIES LTD
TACROLIMUS, TACROLIMUS
TRANDOLAPRIL, TRANDOLAPRIL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZAFIRLUKAST, ZAFIRLUKAST
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

DRAXIMAGE

* DRAXIMAGE INC
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DTPA, TECHNETIUM TC-99M PENTETATE KIT
HICON, SODIUM IODIDE I-131
SODIUM IODIDE I-131, SODIUM IODIDE I-131
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

DURAMED

* DURAMED PHARMACEUTICALS INC
LOSEASONIQUE, ETHINYL ESTRADIOL
NORDETTE-28, ETHINYL ESTRADIOL
PLAN B ONE-STEP, LEVONORGESTREL
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAN B, LEVONORGESTREL
PLAN B, LEVONORGESTREL (OTC)
REVIA, NALTREXONE HYDROCHLORIDE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AVIANE-28, ETHINYL ESTRADIOL
CRYSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAMOX, ACETAZOLAMIDE
DIAMOX, ACETAZOLAMIDE SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VELIVET, DESOGESTREL
ZEBETA, BISOPROLOL FUMARATE
ZIAC, BISOPROLOL FUMARATE

DURAMED RES

* DURAMED RESEARCH INC
AYGESTIN, NORETHINDRONE ACETATE
PARAGARD T 380A, COPPER
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL

DUSA

* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

E5 PHARMA INC

* E5 PHARMA INC
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN

EASTMAN KODAK

* EASTMAN KODAK CO
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

EBEWE PHARMA

* EBEWE PHARMA
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
* EBEWE PHARMA GES MBH NFG KG
CARBOPLATIN, CARBOPLATIN
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EBEWE PHARMA GES MBH NFG KG
FLUOROURACIL, FLUOROURACIL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ECOLAB

* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR

* ECR PHARMACEUTICALS
DEXAMETHASONE, DEXAMETHASONE

EGIS

* EGIS PHARMACEUTICALS
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE

EISAI INC

* EISAI INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARICEPT, DONEPEZIL HYDROCHLORIDE
BANZEL, RUFINAMIDE
DACOGEN, DECITABINE
FRAGMIN, DALTEPARIN SODIUM
GLIADEL, CARMUSTINE
HALAVEN, ERIBULIN MESYLATE
HEXALEN, ALTRETAMINE
LUSEDRA, FOSPROPOFOL DISODIUM
PANRETIN, ALITRETINOIN
SALAGEN, PILOCARPINE HYDROCHLORIDE
TARGRETIN, BEXAROTENE
ZONEGRAN, ZONISAMIDE

EKR THERAP

* EKR THERAPEUTICS INC
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
DEPODUR, MORPHINE SULFATE

ELAN DRUG

* ELAN DRUG DELIVERY INC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

ELAN PHARM

* ELAN PHARMACEUTICAL RESEARCH CORP
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOPROFEN, KETOPROFEN

ELI LILLY AND CO

* ELI LILLY AND CO
AXIRON, TESTOSTERONE
EFFIENT, PRASUGREL HYDROCHLORIDE

ELI LILLY CO

* ELI LILLY CO
ADCIRCA, TADALAFIL
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** E **

ELKINS SINN

- * ELKINS SINN DIV AH ROBINS CO INC
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE

EMCURE PHARMS

- * EMCURE PHARMACEUTICALS LTD
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE USA

- * EMCURE PHARMACEUTICALS USA INC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

EMD SERONO

- * EMD SERONO INC
CETROTIDE, CETRORELIX
GONAL-F RFF PEN, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F, FOLLITROPIN ALFA/BETA
LUVERIS, LUTROPIN ALFA
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
OVIDREL, CHORIOGONADOTROPIN ALFA
SAIZEN, SOMATROPIN RECOMBINANT
SEROPHENE, CLOMIPHENE CITRATE
SEROSTIM, SOMATROPIN RECOMBINANT
ZORBTIVE, SOMATROPIN RECOMBINANT

ENDO PHARM

- * ENDO PHARMACEUTICAL SOLUTIONS INC
DELATESTRYL, TESTOSTERONE ENANTHATE
SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VANTAS, HISTRELIN ACETATE

ENDO PHARMS

- * ENDO PHARMACEUTICALS INC
FORTESTA, TESTOSTERONE
FROVA, FROVATRIPTAN SUCCINATE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OPANA ER, OXYMORPHONE HYDROCHLORIDE
OPANA, OXYMORPHONE HYDROCHLORIDE
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
ZYDONE, ACETAMINOPHEN

EPIC PHARMA

- * EPIC PHARMA INC
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
- * EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

ERGOJECT

- * ERGOJECT LLC
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE

ETHYPHARM

- * ETHYPHARM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

EURAND

- * EURAND AMERICA INC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EURAND INC
ZENPEP, LIPASE

EUSA PHARMA USA

* EUSA PHARMA (USA) INC
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
IDKIT:HP, UREA C-13

EXCELLIUM

* EXCELLIUM PHARMACEUTICAL INC
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LORAZEPAM, LORAZEPAM

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

EYETECH INC

* EYETECH INC
MACUGEN, PEGAPTANIB SODIUM

FALCON PHARMS

* FALCON PHARMACEUTICALS INC
TIMOLOL MALEATE, TIMOLOL MALEATE
* FALCON PHARMACEUTICALS LTD
DIPIVEFRIN HYDROCHLORIDE, DIPIVEFRIN HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBREX, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

FDC LTD

* FDC LTD
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
TIMOLOL MALEATE, TIMOLOL MALEATE

FEINSTEIN

* FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA, N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FERA PHARMS

* FERA PHARMACEUTICALS LLC
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

FERNDALE LABS

* FERNDALE LABORATORIES INC
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
MICORT-HC, HYDROCORTISONE ACETATE
PRAMOSONE, HYDROCORTISONE ACETATE

FERRING

* FERRING PHARMACEUTICALS INC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
BRAVELLE, UROFOLLITROPIN
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE
MENOPUR, LUTEINIZING HORMONE
MINIRIN, DESMOPRESSIN ACETATE
REPRONEX, LUTEINIZING HORMONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FERRING PHARMACEUTICALS INC
TEV-TROPIN, SOMATROPIN RECOMBINANT

FERRING PHARMS AS

* FERRING PHARMACEUTICALS AS
LYSTEDA, TRANEXAMIC ACID

FLEMING

* FLEMING AND CO PHARMACEUTICALS
THYROSHIELD, POTASSIUM IODIDE (OTC)

FOREST LABS

* FOREST LABORATORIES INC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
CAMPRAL, ACAMPROSATE CALCIUM
CELEXA, CITALOPRAM HYDROBROMIDE
COMBUNOX, IBUPROFEN
LEXAPRO, ESCITALOPRAM OXALATE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
TESSALON, BENZONATATE
THYROLAR-0.25, LIOTHYRONINE SODIUM
THYROLAR-0.5, LIOTHYRONINE SODIUM
THYROLAR-1, LIOTHYRONINE SODIUM
THYROLAR-2, LIOTHYRONINE SODIUM
THYROLAR-3, LIOTHYRONINE SODIUM

FOUGERA

* E FOUGERA DIV ALTANA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
* FRESENIUS USA INC
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FRESENIUS KABI ONCOL

* FRESENIUS KABI ONCOLOGY PLC
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
CARBOPLATIN, CARBOPLATIN
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

FRESENIUS MEDCL

- * FRESENIUS MEDICAL CARE NORTH AMERICA
CALCITRIOL, CALCITRIOL
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOSLO GELCAPS, CALCIUM ACETATE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FSC

- * FSC LABORATORIES INC
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

FUTURE PAK

- * FUTURE PAK LTD
K+10, POTASSIUM CHLORIDE

G AND W LABS

- * G AND W LABORATORIES INC
ACEPHEN, ACETAMINOPHEN (OTC)
CICLOPIROX, CICLOPIROX
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
INDOMETHACIN, INDOMETHACIN
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
MOMETASONE FUROATE, MOMETASONE FUROATE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

G AND W LABS INC

- * G AND W LABORATORIES INC
CICLOPIROX, CICLOPIROX

GALDERMA LABS

- * GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE
EPIDUO, ADAPALENE

GALDERMA LABS LP

- * GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE
- * GALDERMA LABORATORIES LP
CAPEX, FLUOCINOLONE ACETONIDE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
LIDOCAINE AND TETRACAINE, LIDOCAINE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GALDERMA LABORATORIES LP
METROLOTION, METRONIDAZOLE
METVIXIA, METHYL AMINOLEVULINATE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
PERIOSTAT, DOXYCYCLINE HYCLATE
TRI-LUMA, FLUOCINOLONE ACETONIDE
VECTICAL, CALCITRIOL

GALDERMA R AND D

* GALDERMA RESEARCH AND DEVELOPMENT INC
DIFFERIN, ADAPALENE

GALEN LTD

* GALEN LTD
FEMRING, ESTRADIOL ACETATE

GAMBRO RENAL PRODS

* GAMBRO RENAL PRODUCTS
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

GAVIS PHARMS

* GAVIS PHARMACEUTICALS LLC
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, ACETAMINOPHEN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PENTAZOCINE AND NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

GD SEARLE

* GD SEARLE LLC
CELEBREX, CELECOXIB
DAYPRO, OXAPROZIN

GD SEARLE LLC

* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ARTHROTEC, DICLOFENAC SODIUM
CALAN, VERAPAMIL HYDROCHLORIDE
COVERA-HS, VERAPAMIL HYDROCHLORIDE
CYTOTEC, MISOPROSTOL
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
FLAGYL, METRONIDAZOLE
INSPRA, EPLERENONE
LOMOTIL, ATROPINE SULFATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE

* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
METASTRON, STRONTIUM CHLORIDE SR-89
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GE HEALTHCARE
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVUE, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
SODIUM IODIDE I 123, SODIUM IODIDE I-123
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL

GEDEON RICHTER USA

* GEDEON RICHTER USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
FINASTERIDE, FINASTERIDE

GENENTECH

* GENENTECH INC
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT

GENERAMEDIX

* GENERAMEDIX INC
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

GENIX THERAP

* GENIX THERAPEUTICS INC
CALCITRIOL, CALCITRIOL

GENPHARM

* GENPHARM INC
ACYCLOVIR, ACYCLOVIR
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUCONAZOLE, FLUCONAZOLE
FLUTAMIDE, FLUTAMIDE
GLIMEPIRIDE, GLIMEPIRIDE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NIZATIDINE, NIZATIDINE
OXAPROZIN, OXAPROZIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* GENPHARM PHARMACEUTICALS INC
ATENOLOL, ATENOLOL

GENPHARM ULC

* GENPHARM ULC
ALENDRONATE SODIUM, ALENDRONATE SODIUM

GENTA

* GENTA INC
GANITE, GALLIUM NITRATE

GENZYME

* GENZYME CORP
CEREDASE, ALGLUCERASE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

*** GENZYME CORP**

CEREZYME, IMIGLUCERASE
CLOLAR, CLOFARABINE
FLUDARA, FLUDARABINE PHOSPHATE
HECTOROL, DOXERCALCIFEROL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
REVELA, SEVELAMER CARBONATE
THYROGEN, THYROTROPIN ALFA

GENZYME CORP

* GENZYME CORPORATION
HECTOROL, DOXERCALCIFEROL

GILEAD

* GILEAD SCIENCES INC
ATRIPLA, EFAVIRENZ
CAYSTON, AZTREONAM
DAUNOXOME, DAUNORUBICIN CITRATE
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VISTIDE, CIDOFOVIR

GLAND PHARMA LTD

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
HALOPERIDOL, HALOPERIDOL LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
ALTABAX, RETAPAMULIN
FLOVENT HFA, FLUTICASONE PROPIONATE
SEREVENT, SALMETEROL XINAFOATE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
ARIXTRA, FONDAPARINUX SODIUM
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AVODART, DUTASTERIDE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
CEFTIN, CEFUROXIME AXETIL
EPIVIR-HBV, LAMIVUDINE
FLONASE, FLUTICASONE PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAXOSMITHKLINE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
HYCANTIN, TOPOTECAN HYDROCHLORIDE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
JALYN, DUTASTERIDE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LAROTID, AMOXICILLIN
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
MYLERAN, BUSULFAN
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
PARNATE, TRANLYCYPROMINE SULFATE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PROMACTA, ELTROMBOPAG OLAMINE
RELENZA, ZANAMIVIR
REQUIP, ROPINIROLE HYDROCHLORIDE
TAGAMET HB, CIMETIDINE (OTC)
TAGAMET, CIMETIDINE
THIOGUANINE, THIOGUANINE
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TREXIMET, NAPROXEN SODIUM
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VENTOLIN HFA, ALBUTEROL SULFATE
VERAMYST, FLUTICASONE FUROATE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 25, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZYBAN, BUPROPION HYDROCHLORIDE

GLAXOSMITHKLINE CONS

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
ALLI, ORLISTAT (OTC)
COMMIT, NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
ALBENZA, ALBENDAZOLE
DARAPRIM, PYRIMETHAMINE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYNACIRC CR, ISRADIPINE
FLOLAN, EPOPROSTENOL SODIUM
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

- * GLAXOSMITHKLINE LLC
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
MEPRON, ATOVAQUONE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
RYTHMOL, PROPAFENONE HYDROCHLORIDE

GLENMARK GENERICS

- * GLENMARK GENERICS INC USA
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
DIPYRIDAMOLE, DIPYRIDAMOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
NILSTAT, NYSTATIN
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE
- * GLENMARK GENERICS LTD
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FELODIPINE, FELODIPINE
FLUCONAZOLE, FLUCONAZOLE
GABAPENTIN, GABAPENTIN
HEATHER, NORETHINDRONE
LAMOTRIGINE, LAMOTRIGINE
LITHIUM CARBONATE, LITHIUM CARBONATE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NORETHIDRONE, NORETHINDRONE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
- * GLENMARK GENERICS LTD INDIA
INDOMETHACIN, INDOMETHACIN
LITHIUM CARBONATE, LITHIUM CARBONATE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

- * GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
- * GLENMARK PHARMACEUTICALS LTD
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

GLENMARK PHARMS LTD

- * GLENMARK PHARMACEUTICALS LTD
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

GRACEWAY

- * GRACEWAY PHARMACEUTICALS LLC
ALDARA, IMIQUIMOD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GRACEWAY PHARMACEUTICALS LLC
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
ESTRASORB, ESTRADIOL HEMIHYDRATE
MAXAIR, PIRBUTEROL ACETATE
METROGEL-VAGINAL, METRONIDAZOLE
MINITRAN, NITROGLYCERIN
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
TAMBOCOR, FLECAINIDE ACETATE
THEOLAIR, THEOPHYLLINE
ZYCLARA, IMIQUIMOD

GRANULES INDIA

* GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

GRIFFEN

* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

GTX INC

* GTX INC
FARESTON, TOREMIFENE CITRATE

GUARDIAN DRUG

* GUARDIAN DRUG CO INC
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUERBET

* GUERBET LLC
HEXABRIX, IOXAGLATE MEGLUMINE
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN

HAEMONETICS

* HAEMONETICS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HALOCARBON PRODS

* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

HALOZYME THERAP

* HALOZYME THERAPEUTICS INC
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HANFORD GC

* GC HANFORD MANUFACTURING CO
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

HARMONY LABS

* HARMONY LABORATORIES
THEROXIDIL, MINOXIDIL (OTC)

HARRIS PHARM

* HARRIS PHARMACEUTICAL INC
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

HELSINN HLTHCARE

* HELSINN HEALTHCARE SA
ALOXI, PALONOSETRON HYDROCHLORIDE

HEMOPHARM USA

* HEMOPHARM USA CORP
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

HERCON LABS

* HERCON LABORATORIES CORP
NITROGLYCERIN, NITROGLYCERIN

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
CARISOPRODOL AND ASPIRIN, ASPIRIN
DOLENE, PROPOXYPHENE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
KETOPROFEN, KETOPROFEN
LEFLUNOMIDE, LEFLUNOMIDE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE

HETERO DRUGS

* HETERO DRUGS LTD
METHOCARBAMOL, METHOCARBAMOL
STAVUDINE, STAVUDINE
TORSEMIDE, TORSEMIDE

HETERO DRUGS LTD

* HETERO DRUGS LTD UNIT III
FINASTERIDE, FINASTERIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LITHIUM CARBONATE, LITHIUM CARBONATE
ZIDOVUDINE, ZIDOVUDINE

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH PHARMA

* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CICLOPIROX, CICLOPIROX
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CORMAX, CLOBETASOL PROPIONATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
ERYTHRO-STATIN, ERYTHROMYCIN
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEVOCARNITINE, LEVOCARNITINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
OFLOXACIN, OFLOXACIN
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HI TECH PHARMACAL CO INC
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 HYDROBROMIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
 VALPROIC ACID, VALPROIC ACID

HIKMA

* HIKMA FARMACEUTICA LDA
 CEFOTAXIME, CEFOTAXIME SODIUM

* HIKMA PHARMACEUTICALS
 AMOXICILLIN, AMOXICILLIN
 CARVEDILOL, CARVEDILOL
 CEFACLOL, CEFACLOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEPHALEXIN, CEPHALEXIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GLYBURIDE (MICRONIZED), GLYBURIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 ENALAPRILAT, ENALAPRILAT
 FLUMAZENIL, FLUMAZENIL
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GRANISTERON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 MILRINONE LACTATE, MILRINONE LACTATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROGESTERONE, PROGESTERONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 VALPROATE SODIUM, VALPROATE SODIUM

* HIKMA FARMACEUTICA PORTUGAL LDA
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

* HIKMA FARMACEUTICA SA
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 CEPHALEXIN, CEPHALEXIN
 GEMFIBROZIL, GEMFIBROZIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HIKMA PHARMACEUTICALS
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

HILL DERMAC

* HILL DERMACEUTICALS INC
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

HISAMITSU

* HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HITECH PHARMA

* HITECH PHARMACAL CORP
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
INVIRASE, SAQUINAVIR MESYLATE
ROCEPHIN, CEFTRIAXONE SODIUM
ROMAZICON, FLUMAZENIL
XELODA, CAPECITABINE
XENICAL, ORLISTAT

HOLOPACK INTL

* HOLOPACK INTERNATIONAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
* HOLOPACK INTERNATIONAL CORP
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

HOSPIRA

* HOSPIRA INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
ALCOHOL 5% IN D5-W, ALCOHOL
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
AMIDATE, ETOMIDATE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS

AMINOSYN II 7%, AMINO ACIDS

AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS

AMINOSYN II 8.5%, AMINO ACIDS

AMINOSYN-HBC 7%, AMINO ACIDS

AMINOSYN-HF 8%, AMINO ACIDS

AMINOSYN-PF 10%, AMINO ACIDS

AMINOSYN-PF 7%, AMINO ACIDS

AMINOSYN-RF 5.2%, AMINO ACIDS

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE

AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE

AQUASOL A, VITAMIN A PALMITATE

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE

ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE

AZITHROMYCIN, AZITHROMYCIN

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

BLEOMYCIN SULFATE, BLEOMYCIN SULFATE

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE

BUMETANIDE, BUMETANIDE

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE

BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

CARBOCAINE, MEPIVACAINE HYDROCHLORIDE

CARBOPLATIN, CARBOPLATIN

CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE

CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE

CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN

CIPROFLOXACIN, CIPROFLOXACIN

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

CORLOPAM, FENOLDOPAM MESYLATE

CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE

CYTARABINE, CYTARABINE

DACARBAZINE, DACARBAZINE

DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE

DEMEROL, MEPERIDINE HYDROCHLORIDE

DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE

DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 25%, DEXTROSE

DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE

DIAZEPAM, DIAZEPAM

DIGOXIN, DIGOXIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
 ENALAPRILAT, ENALAPRILAT
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ERYC, ERYTHROMYCIN
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
 FAMOTIDINE, FAMOTIDINE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FOSCARNET SODIUM, FOSCARNET SODIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
 IOPAMIDOL-200, IOPAMIDOL
 IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
 IOPAMIDOL-250, IOPAMIDOL
 IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
 IOPAMIDOL-300, IOPAMIDOL
 IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
 IOPAMIDOL-370, IOPAMIDOL
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISOFLURANE, ISOFLURANE
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

LIPOSYN II 10%, SAFFLOWER OIL

LIPOSYN II 20%, SAFFLOWER OIL

LIPOSYN III 10%, SOYBEAN OIL

LIPOSYN III 20%, SOYBEAN OIL

LIPOSYN III 30%, SOYBEAN OIL

LORAZEPAM, LORAZEPAM

LTA II KIT, LIDOCAINE HYDROCHLORIDE

M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID

M.V.I. ADULT, ASCORBIC ACID

M.V.I. PEDIATRIC, ASCORBIC ACID

M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE

MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE

MAGNESIUM SULFATE, MAGNESIUM SULFATE

MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE

MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 25%, MANNITOL

MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE

MARCAINE, BUPIVACAINE HYDROCHLORIDE

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE

METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

METHOTREXATE SODIUM, METHOTREXATE SODIUM

METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

METOPROLOL TARTRATE, METOPROLOL TARTRATE

METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE

MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE

MILRINONE LACTATE, MILRINONE LACTATE

MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE

MORPHINE SULFATE, MORPHINE SULFATE

NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE

NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE

NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN

NITROGLYCERIN, NITROGLYCERIN

NITROPRESS, SODIUM NITROPRUSSIDE

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

NOVAMINE 11.4%, AMINO ACIDS

NOVAMINE 15%, AMINO ACIDS

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

PACLITAXEL, PACLITAXEL

PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PANCURONIUM BROMIDE, PANCURONIUM BROMIDE

PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE

PHENYTOIN SODIUM, PHENYTOIN SODIUM

PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE

POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE

PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

PROPOFOL, PROPOFOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

- * HOSPIRA INC
 - QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
 - QUELICIN, SUCCINYLCHOLINE CHLORIDE
 - RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 - SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
 - SODIUM BICARBONATE, SODIUM BICARBONATE
 - SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
 - SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 - SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
 - STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 - STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 - SUFENTANIL CITRATE, SUFENTANIL CITRATE
 - TALWIN, PENTAZOCINE LACTATE
 - TAZICEF, CEFTAZIDIME
 - THAM, TROMETHAMINE
 - THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 - THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 - TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 - TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 - VECURONIUM BROMIDE, VECURONIUM BROMIDE
 - VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 - VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 - VINORELBINE TARTRATE, VINORELBINE TARTRATE
 - VITAMIN K1, PHYTONADIONE
 - ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
- * HOSPIRA WORLDWIDE, INC
 - BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE

HOSPIRA INC

- * HOSPIRA INC
 - GEMCITABINE, GEMCITABINE HYDROCHLORIDE
 - HEPARIN SODIUM, HEPARIN SODIUM
 - HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 - MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 - MEROPENEM, MEROPENEM
 - NIPENT, PENTOSTATIN
 - OXALIPLATIN, OXALIPLATIN
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

HOSPIRA WORLDWIDE

- * HOSPIRA WORLDWIDE PTY
 - OXALIPLATIN, OXALIPLATIN

HUAHAI US INC

- * HUAHAI US INC
 - BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 - CAPTOPRIL, CAPTOPRIL
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

IBI

- * ISTITUTO BIOCHIMICO ITALIANO SPA
 - AMPICILLIN SODIUM, AMPICILLIN SODIUM

IMPAX LABS

- * IMPAX LABORATORIES INC
 - ACARBOSE, ACARBOSE
 - ALPRAZOLAM, ALPRAZOLAM
 - ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* IMPAX LABORATORIES INC
BACLOFEN, BACLOFEN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
OMEPRAZOLE, OMEPRAZOLE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RILUZOLE, RILUZOLE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

IMPAX LABS INC

* IMPAX LABORATORIES INC
CABERGOLINE, CABERGOLINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

INALCO

* INALCO SPA
LACTULOSE, LACTULOSE

INDICUS PHARMA

* INDICUS PHARMA LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INO

* INO THERAPEUTICS INC
INOMAX, NITRIC OXIDE

INSIGHT PHARMS

* INSIGHT PHARMACEUTICALS CORP
NIX, PERMETHRIN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

INSPIRE

* INSPIRE PHARMACEUTICALS INC
AZASITE, AZITHROMYCIN

INST BIOCHEM

* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INST BIOCHIMIQUE

* INSTITUTE BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM

INSTITUT BIOCHIMIQUE

* INSTITUT BIOCHIMIQUE SA IBSA
TIROSINT, LEVOTHYROXINE SODIUM

INSTITUTO BIOCHEMICO

* INSTITUTO BIOCHEMICO ITALIANO SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM

INSTITUTO BIOCHIMICO

* INSTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

INTENDIS

* INTENDIS INC
DESONATE, DESONIDE
FINACEA, AZELAIC ACID

INTERGEL PHARM

* INTERGEL PHARMACEUTICAL INC
NIFEDIPINE, NIFEDIPINE

INTL MEDICATED

* INTERNATIONAL MEDICATED SYSTEMS LTD
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION

* INTERNATIONAL MEDICATION SYSTEM
AMINOPHYLLINE, AMINOPHYLLINE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE

INTL MEDICATION SYS

* INTERNATIONAL MEDICATION SYSTEMS LTD
LORAZEPAM, LORAZEPAM

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* INVAGEN PHARMACEUTICALS INC
FOLIC ACID, FOLIC ACID
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

INWOOD LABS

* INWOOD LABORATORIES INC SUB FOREST LABORATORIES INC
THEOPHYLLINE, THEOPHYLLINE

IPCA LABS LTD

* IPCA LABORATORIES LTD
ATENOLOL, ATENOLOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

IPR

* IPR PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
CRESTOR, ROSUVASTATIN CALCIUM
ZOMIG, ZOLMITRIPTAN

IPSEN BIOPHARM LTD

* IPSEN BIOPHARM LTD
APOKYN, APOMORPHINE HYDROCHLORIDE

IROKO PHARMS

* IROKO PHARMACEUTICALS LLC
INDOCIN, INDOMETHACIN

ISO TEX

* ISO TEX DIAGNOSTICS INC
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISTA PHARMS

* ISTA PHARMACEUTICALS
BEPREVE, BEPOTASTINE BESILATE
BROMDAY, BROMFENAC SODIUM
ISTALOL, TIMOLOL MALEATE
VITRASE, HYALURONIDASE
XIBROM, BROMFENAC SODIUM

ISTITUTO BIOCHIMICO

* ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI
PIPERACILLIN, PIPERACILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CABERGOLINE, CABERGOLINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GRISEOFULVIN, GRISEOFULVIN, MICROCRYSTALLINE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLDOPA, METHYLDOPA
MISOPROSTOL, MISOPROSTOL
NADOLOL, NADOLOL
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** J **

JACOBUS

- * JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

JAZZ

- * JAZZ PHARMACEUTICALS
LUVOX CR, FLUVOXAMINE MALEATE
XYREM, SODIUM OXYBATE

JHP PHARMS

- * JHP PHARMACEUTICALS LLC
BREVITAL SODIUM, METHOHEXITAL SODIUM
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
DANTRIUM, DANTROLENE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
KETALAR, KETAMINE HYDROCHLORIDE
PITOCIN, OXYTOCIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIOSTAT, LIOTHYRONINE SODIUM

JOHN O BUTLER CO

- * JOHN O BUTLER CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE

JOHNSON AND JOHNSON

- * JOHNSON AND JOHNSON CONSUMER COMPANIES INC
RETIN-A, TRETINOIN
- * JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
- * JOHNSON AND JOHNSON HEALTHCARE PRODUCTS
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

JSJ PHARMS

- * JSJ PHARMACEUTICALS LLC
TEXACORT, HYDROCORTISONE

KEY PHARMS

- * KEY PHARMACEUTICALS INC SUB SCHERING PLOUGH CORP
NITRO-DUR, NITROGLYCERIN

KIEL

- * KIEL LABORATORIES INC
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

KING PHARMS

- * KING PHARMACEUTICALS INC
ALSUMA, SUMATRIPTAN SUCCINATE
ALTACE, RAMIPRIL
AVINZA, MORPHINE SULFATE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
CORGARD, NADOLOL
CORZIDE, BENDROFLUMETHIAZIDE
CYTOMEL, LIOTHYRONINE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

- * KING PHARMACEUTICALS INC
INTAL, CROMOLYN SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE
SKELAXIN, METAXALONE
SYNERCID, DALFOPRISTIN
TIGAN, TRIMETHOENZAMIDE HYDROCHLORIDE
- * KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC SUB KING PHARMACEUTICALS INC
SONATA, ZALEPLON
TAPAZOLE, METHIMAZOLE
TUSSIGON, HOMATROPINE METHYLBROMIDE

KOWA

- * KOWA RESEARCH INSTITUTE INC
LIVALO, PITAVASTATIN CALCIUM

KREMERS URBAN PHARMS

- * KREMERS URBAN PHARMACEUTICALS INC
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
NITROGLYCERIN, NITROGLYCERIN
OMEPRazole, OMEPRazole

KUDCO IRELAND

- * KUDCO IRELAND LTD
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE

KV PHARM

- * KV PHARMACEUTICAL CO
BENZONATATE, BENZONATATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CLINDESSE, CLINDAMYCIN PHOSPHATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
EVAMIST, ESTRADIOL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
ONDANSETRON, ONDANSETRON
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

KVK TECH

- * KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LABOPHARM

* LABOPHARM INC
OLEPTRO, TRAZODONE HYDROCHLORIDE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANORINAL, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID
SERPALAN, RESERPINE
* LANNETT HOLDINGS INC
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
TERBUTALINE SULFATE, TERBUTALINE SULFATE
URSODIOL, URSODIOL

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
ABLAVAR, GADOFOSVESET TRISODIUM
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
XENON XE 133, XENON XE-133

LAVIPHARM LABS

* LAVIPHARM LABORATORIES INC
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL

LEHIGH VALLEY

* LEHIGH VALLEY TECHNOLOGIES INC
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

LEK PHARMS

* LEK PHARMACEUTICALS D D
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
LISINOPRIL, LISINOPRIL
OMEPRazole, OMEPRazole

LEK PHARMS DD

* LEK PHARMACEUTICALS DD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LEO PHARM

* LEO PHARMACEUTICAL PRODUCTS LTD
DOVONEX, CALCIPOTRIENE
TACLONEX, BETAMETHASONE DIPROPIONATE

LEO PHARM PRODS

* LEO PHARMACEUTICAL PRODUCTS LTD
TACLONEX SCALP, BETAMETHASONE DIPROPIONATE

LEO PHARMA AS

* LEO PHARMA AS
INNOHEP, TINZAPARIN SODIUM

LG LIFE

* LG LIFE SCIENCES LTD
VALTROPIN, SOMATROPIN RECOMBINANT

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50 PEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 PEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG PEN, INSULIN LISPRO RECOMBINANT
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE
* LILLY RESEARCH LABORATORIES DIV ELI LILLY AND CO
PROZAC, FLUOXETINE HYDROCHLORIDE
SARAFEM, FLUOXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

LLOYD

* LLOYD INC
LEVOTHROID, LEVOTHYROXINE SODIUM

LNK

* LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LOREAL USA

* LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CEFTRIAZONE, CEFTRIAZONE SODIUM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
FOMEPIZOLE, FOMEPIZOLE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NITROGLYCERIN, NITROGLYCERIN
OFLOXACIN, OFLOXACIN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROGESTERONE, PROGESTERONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
TORSEMIDE, TORSEMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUITPOLD PHARMACEUTICALS INC
VENOFER, IRON SUCROSE

LUNDBECK INC

* LUNDBECK INC
CHEMET, SUCCIMER
COGENTIN, BENZTROPINE MESYLATE
COSMEGEN, DACTINOMYCIN
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DIURIL, CHLOROTHIAZIDE SODIUM
INDOCIN, INDOMETHACIN SODIUM
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEOPROFEN, IBUPROFEN LYSINE
PEGANONE, ETHOTOIN
SABRIL, VIGABATRIN
TRANXENE, CLORAZEPATE DIPOTASSIUM

LUPIN

* LUPIN LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFPROZIL, CEFPROZIL
CEFTRIAZONE, CEFTRIAZONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINAPRIL, LISINAPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

* LUPIN ATLANTIS HOLDINGS SA
ANTARA (MICRONIZED), FENOFIBRATE

LUPIN LTD

* LUPIN LTD
FAMOTIDINE, FAMOTIDINE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
SUPRAX, CEFIXIME

LUPIN PHARMS

* LUPIN PHARMACEUTICALS INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
DESLOXATADINE, DESLOXATADINE
MELOXICAM, MELOXICAM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
SUPRAX, CEFIXIME

LYNE

* LYNE LABORATORIES INC
CALCITRIOL, CALCITRIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LYNE LABORATORIES INC
HYDROCORTISONE, HYDROCORTISONE
LEVOCARNITINE, LEVOCARNITINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

MALLINCKRODT

* MALLINCKRODT CHEMICAL INC
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORTAB, ACETAMINOPHEN
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

* MALLINCKRODT INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PENNSAID, DICLOFENAC SODIUM
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
TECHNETIUM TC-99 SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

* MALLINCKRODT MEDICAL INC
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MALLINCKRODT MEDICAL INC
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

MALLINCKRODT INC

* MALLINCKRODT INC
EXALGO, HYDROMORPHONE HYDROCHLORIDE

MARKSANS PHARMA

* MARKSANS PHARMA LTD
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

MARSAM PHARMS LLC

* MARSAM PHARMACEUTICALS LLC
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

MATRIX LABS INC

* MATRIX LABORATORIES INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

MATRIX LABS LTD

* MATRIX LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BACLOFEN, BACLOFEN
DIDANOSINE, DIDANOSINE
GABAPENTIN, GABAPENTIN
LANSOPRAZOLE, LANSOPRAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NABUMETONE, NABUMETONE
NIFEDIPINE, NIFEDIPINE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
STAVUDINE, STAVUDINE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIDOVUDINE, ZIDOVUDINE

MAYNE PHARMA

* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX, DOXYCYCLINE HYCLATE

MAYNE PHARMA INTL

* MAYNE PHARMA INTERNATIONAL FAULDING PHARM
DORYX, DOXYCYCLINE HYCLATE

MCNEIL

* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

MCNEIL CONS

* MCNEIL CONSUMER HEALTHCARE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
NIZORAL A-D, KETOCONAZOLE (OTC)
SINE-AID IB, IBUPROFEN (OTC)
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

- * MCNEIL CONSUMER HEALTHCARE
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TYLENOL (CAPLET), ACETAMINOPHEN (OTC)
TYLENOL (GELTAB), ACETAMINOPHEN (OTC)

MCNEIL CONSUMER

- * MCNEIL CONSUMER HEALTHCARE DIV MCNEIL PPC INC
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC, CETIRIZINE HYDROCHLORIDE

MCNEIL PED

- * MCNEIL PEDIATRICS
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE

MEAD JOHNSON

- * MEAD JOHNSON AND CO
CAFCIT, CAFFEINE CITRATE

MEDA PHARMS

- * MEDA PHARMACEUTICALS
ACYCLOVIR AND HYDROCORTISONE, ACYCLOVIR
EDLUAR, ZOLPIDEM TARTRATE
- * MEDA PHARMACEUTICALS INC
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
BUTISOL SODIUM, BUTABARBITAL SODIUM
CESAMET, NABILONE
CORTIFOAM, HYDROCORTISONE ACETATE
DEMADEX, TORSEMIDE
DEPEN, PENICILLAMINE
DIPENTUM, OLSALAZINE SODIUM
EPIFOAM, HYDROCORTISONE ACETATE
FELBATOL, FELBAMATE
LUFYLLIN, DYPHYLLINE
ONSOLIS, FENTANYL CITRATE
OPTIVAR, AZELASTINE HYDROCHLORIDE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
TRILYTE, POLYETHYLENE GLYCOL 3350
- * MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC
ASTEPRO, AZELASTINE HYDROCHLORIDE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
SOMA, CARISOPRODOL

MEDICINES CO

- * THE MEDICINES CO
ANGIOMAX, BIVALIRUDIN
CLEVIPREX, CLEVIDIPINE BUTYRATE

MEDICIS

- * MEDICIS PHARMACEUTICAL CORP
BUPHENYL, SODIUM PHENYLBUTYRATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DYNACIN, MINOCYCLINE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LOPROX, CICLOPIROX
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
VANOS, FLUOCINONIDE
ZIANA, CLINDAMYCIN PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MEDICURE

* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE

MEDIGENE

* MEDIGENE INC
VEREGEN, SINECATECHINS

MEDIMMUNE

* MEDIMMUNE
ETHYOL, AMIFOSTINE

MEDTRONIC

* MEDTRONIC INC
LIORESAL, BACLOFEN

MERCK

* MERCK AND CO INC
AMINOHIPURATE SODIUM, AMINOHIPURATE SODIUM
CANCIDAS, CASPOFUNGIN ACETATE
EMEND, APREPITANT
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMAX, ALENDRONATE SODIUM
HYZAAR, HYDROCHLOROTHIAZIDE
INVANZ, ERTAPENEM SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
STROMEKTOL, IVERMECTIN
ZOLINZA, VORINOSTAT

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
CLINORIL, SULINDAC
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
MEVACOR, LOVASTATIN
NOROXIN, NORFLOXACIN
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PEPCID PRESERVATIVE FREE, FAMOTIDINE
PEPCID, FAMOTIDINE
PRINIVIL, LISINAPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
ZOCOR, SIMVASTATIN

MERCK AND CO INC

* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE
FOSAMAX, ALENDRONATE SODIUM

MERCK CO INC

* MERCK CO INC
JANUVIA, SITAGLIPTIN PHOSPHATE

MERCK KGAA

* MERCK KGAA
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

MERCK SANTE SAS

* MERCK SANTE SAS
CYANOKIT, HYDROXOCOBALAMIN

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
CRIXIVAN, INDINAVIR SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MERCK SHARP AND DOHME CORP
ISENTRESS, RALTEGRAVIR POTASSIUM
PEPCID AC (GELTAB), FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)

MERIDIAN MEDCL

* MERIDIAN MEDICAL TECHNOLOGIES INC
DUODOTE, ATROPINE

MERIDIAN MEDCL TECHN

* MERIDIAN MEDICAL TECHNOLOGIES INC
ATROPEN, ATROPINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

MERZ PHARMS

* MERZ PHARMACEUTICALS LLC
ERYGEL, ERYTHROMYCIN
NAFTIN, NAFTIFINE HYDROCHLORIDE

METHAPHARM

* METHAPHARM INC
LEVETIRACETAM, LEVETIRACETAM
PROVOCHOLINE, METHACHOLINE CHLORIDE

MICRO LABS LTD

* MICRO LABS LTD
MEFENAMIC ACID, MEFENAMIC ACID

MIKAH PHARMA

* MIKAH PHARMA LLC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE

MIKART

* MIKART INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ESGIC-PLUS, ACETAMINOPHEN
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PYRAZINAMIDE, PYRAZINAMIDE
TRIHENYDROXYPHENIDYL HYDROCHLORIDE, TRIHENYDROXYPHENIDYL HYDROCHLORIDE

MILLENNIUM PHARMS

* MILLENNIUM PHARMACEUTICALS INC
VELCADE, BORTEZOMIB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MISSION PHARMA

* MISSION PHARMACAL CO
LITHOSTAT, ACETOHYDROXAMIC ACID
TINDAMAX, TINIDAZOLE
TIOPRONIN, TIOPRONIN
UROCIT-K, POTASSIUM CITRATE

MN PHARMS

* MN PHARMACEUTICALS
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

MONARCH PHARMS

* MONARCH PHARMACEUTICALS INC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
PEDIOTIC, HYDROCORTISONE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
THALITONE, CHLORTHALIDONE
VIROPTIC, TRIFLURIDINE

MORTON GROVE

* MORTON GROVE PHARMACEUTICALS INC
LACTULOSE, LACTULOSE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

MORTON GROVE PHARMS

* MORTON GROVE PHARMACEUTICALS INC
GENERLAC, LACTULOSE

MSP SINGAPORE

* MSP SINGAPORE CO LLC
VYTORIN, EZETIMIBE
ZETIA, EZETIMIBE

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVZAT

* MUSTAFA NEVZAT ILAC SANAYII AS
VECURONIUM BROMIDE, VECURONIUM BROMIDE

MUTUAL PHARM

* MUTUAL PHARMACEUTICAL CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
CARISOPRODOL, CARISOPRODOL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FELODIPINE, FELODIPINE
FOLIC ACID, FOLIC ACID
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MUTUAL PHARMACEUTICAL CO INC
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

MUTUAL PHARMA

* MUTUAL PHARMACAL CO
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
KETOCONAZOLE, KETOCONAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

MYLAN

* MYLAN LABORATORIES INC
ACYCLOVIR, ACYCLOVIR
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
ETODOLAC, ETODOLAC
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

* MYLAN PHARMACEUTICALS INC
ACARBOSE, ACARBOSE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMNESTEEM, ISOTRETINOIN
ANASTROZOLE, ANASTROZOLE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
AVITA, TRETINOIN
AZATHIOPRINE, AZATHIOPRINE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CHLOROTHIAZIDE, CHLOROTHIAZIDE
 CHLORPROPAMIDE, CHLORPROPAMIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLORPRES, CHLORTHALIDONE
 CLOZAPINE, CLOZAPINE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYSTAGON, CYSTEAMINE BITARTRATE
 DIAZEPAM, DIAZEPAM
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ESTRADIOL, ESTRADIOL
 ESTROPIPATE, ESTROPIPATE
 ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
 ETOPOSIDE, ETOPOSIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FAMOTIDINE, FAMOTIDINE
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIMEPIRIDE, GLIMEPIRIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLIPIZIDE, GLIPIZIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDAPAMIDE, INDAPAMIDE
 INDOMETHACIN, INDOMETHACIN
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LAMOTRIGINE, LAMOTRIGINE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOVASTATIN, LOVASTATIN
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MELOXICAM, MELOXICAM
 MENTAX, BUTENAFINE HYDROCHLORIDE
 MENTAX-TC, BUTENAFINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLDOPA, METHYLDOPA
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NADOLOL AND BENDROFLUMETHAZIDE, BENDROFLUMETHAZIDE
 NADOLOL, NADOLOL
 NAPROXEN, NAPROXEN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NIFEDIPINE, NIFEDIPINE
 NISOLDIPINE, NISOLDIPINE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NIZATIDINE, NIZATIDINE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXYBUTYRIN CHLORIDE, OXYBUTYRIN CHLORIDE
 PACLITAXEL, PACLITAXEL
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE, POLYETHYLENE GLYCOL 3350
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HYDROCHLORIDE, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
STAVUDINE, STAVUDINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TACROLIMUS, TACROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
URSODIOL, URSODIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZALEPLON, ZALEPLON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

MYLAN BERTEK

* MYLAN BERTEK PHARMACEUTICALS INC
AVITA, TRETINOIN
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MYLAN TECHNOLOGIES

- * MYLAN TECHNOLOGIES INC
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
NITROGLYCERIN, NITROGLYCERIN

NATCO PHARMA

- * NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

- * NATCO PHARMA LTD
ANASTROZOLE, ANASTROZOLE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE

NAUTILUS NEUROSCIENC

- * NAUTILUS NEUROSCIENCES INC
CAMBIA, DICLOFENAC POTASSIUM

NAVINTA LLC

- * NAVINTA LLC
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

NEPHRON

- * NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
- * NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

NEUROGESX

- * NEUROGESX INC
QUTENZA, CAPSAICIN

NEUROSCI INC

- * NEUROSCI INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

NEW RIVER

- * NEW RIVER PHARMACEUTICALS INC
PROFERDEX, IRON DEXTRAN

NEXGEN PHARMA

- * NEXGEN PHARMA INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHENODIOL, CHENODIOL
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC

- * NEXGEN PHARMA INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

NEXUS PHARMS

- * NEXUS PHARMACEUTICALS INC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NEXUS PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN

NITROMED

* NITROMED INC
BIDIL, HYDRALAZINE HYDROCHLORIDE

NORTHSTAR HLTHCARE

* NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

NOSTRUM

* NOSTRUM PHARMACEUTICALS INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

NOSTRUM LABS

* NOSTRUM LABORATORIES INC
PIROXICAM, PIROXICAM
SUCRALFATE, SUCRALFATE

NOVADEL

* NOVADEL PHARMA INC
NITROMIST, NITROGLYCERIN
ZOLPIMIST, ZOLPIDEM TARTRATE

NOVALAR

* NOVALAR PHARMACEUTICALS INC
ORAVVERSE, PHENTOLAMINE MESYLATE

NOVARTIS

* NOVARTIS CONSUMER HEALTH INC
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
HABITROL, NICOTINE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
NEXCEDE, KETOPROFEN (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
THRIVE, NICOTINE POLACRILEX (OTC)
TRANSDERM SCOP, SCOPOLAMINE
VAGISTAT-1, TIOCONAZOLE (OTC)
VOLTAREN, DICLOFENAC SODIUM
* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
AMTURNIDE, ALISKIREN HEMIFUMARATE
AREDIA, PAMIDRONATE DISODIUM
CATAFLAM, DICLOFENAC POTASSIUM
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
COMBIPATCH, ESTRADIOL
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
ELIDEL, PIMECROLIMUS
ENABLEX, DARIFENACIN HYDROBROMIDE
ESTRADERM, ESTRADIOL
EXELON, RIVASTIGMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NOVARTIS PHARMACEUTICALS CORP
 EXELON, RIVASTIGMINE TARTRATE
 EXFORGE HCT, AMLODIPINE BESYLATE
 EXFORGE, AMLODIPINE BESYLATE
 EXJADE, DEFERASIROX
 FAMVIR, FAMCICLOVIR
 FANAPT, ILOPERIDONE
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FORADIL CERTIHALER, FORMOTEROL FUMARATE
 FORADIL, FORMOTEROL FUMARATE
 GILENYA, FINGOLIMOD
 GLEEVEC, IMATINIB MESYLATE
 HYDERGINE, ERGOLOID MESYLATES
 LAMISIL, TERBINAFINE HYDROCHLORIDE
 LAMPRENE, CLOFAZIMINE
 LESCOL XL, FLUVASTATIN SODIUM
 LESCOL, FLUVASTATIN SODIUM
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
 LOPRESSOR, METOPROLOL TARTRATE
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE
 LOTREL, AMLODIPINE BESYLATE
 METHERGINE, METHYLERGONOVINE MALEATE
 METOPIRONE, METYRAPONE
 MIACALCIN, CALCITONIN SALMON
 MIOCHOL-E, ACETYLCHOLINE CHLORIDE
 MYFORTIC, MYCOPHENOLIC ACID
 NEORAL, CYCLOSPORINE
 OCUPRESS, CARTEOLOL HYDROCHLORIDE
 PARLODEL, BROMOCRIPTINE MESYLATE
 RECLAST, ZOLEDRONIC ACID
 REGITINE, PHENTOLAMINE MESYLATE
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
 SANDIMMUNE, CYCLOSPORINE
 SANDOSTATIN LAR, OCTREOTIDE ACETATE
 SANDOSTATIN, OCTREOTIDE ACETATE
 STARLIX, NATEGLINIDE
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
 TAVIST-1, CLEMASTINE FUMARATE (OTC)
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TEKAMLO, ALISKIREN HEMIFUMARATE
 TEKTRNA HCT, ALISKIREN HEMIFUMARATE
 TEKTRNA, ALISKIREN HEMIFUMARATE
 TRILEPTAL, OXCARBAZEPINE
 TYZEKA, TELBIVUDINE
 VALTRNA, ALISKIREN HEMIFUMARATE
 VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
 VIVELLE, ESTRADIOL
 VIVELLE-DOT, ESTRADIOL
 VOLTAREN, DICLOFENAC SODIUM
 VOLTAREN-XR, DICLOFENAC SODIUM
 ZADITOR, KETOTIFEN FUMARATE (OTC)
 ZOMETA, ZOLEDRONIC ACID
 ZORTRESS, EVEROLIMUS

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
 FEMARA, LETROZOLE
 TOBI, TOBRAMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
LEVONEST, ETHINYL ESTRADIOL

NOVEL LABS INC

* NOVEL LABORATORIES INC
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE, POLYETHYLENE GLYCOL 3350
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM

NOVEN

* NOVEN PHARMACEUTICALS INC
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
DAYTRANA, METHYLPHENIDATE

NOVEN THERAP

* NOVEN THERAPEUTICS LLC
LITHOBID, LITHIUM CARBONATE
PEXEVA, PAROXETINE MESYLATE

NOVEX

* NOVEX PHARMA
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOSPORINE, CYCLOSPORINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LACTULOSE, LACTULOSE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
OFLOXACIN, OFLOXACIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN, TOBRAMYCIN

NOVO NORDISK

* NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

NOVO NORDISK INC

* NOVO NORDISK INC
ACTIVELLA, ESTRADIOL
LEVEMIR, INSULIN DETEMIR RECOMBINANT
NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT
NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT
NORDITROPIN, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVO NORDISK INC
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG, INSULIN ASPART RECOMBINANT
PRANDIMET, METFORMIN HYDROCHLORIDE
PRANDIN, REPAGLINIDE
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL

* NOVOCOL PHARMACEUTICAL INC
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN, LEVONORDEFIN
ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE

NU PHARM

* NU PHARM INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM

NUTRITIONAL RESTART

* NUTRITIONAL RESTART PHARMACEUTICAL LP
NUTRESTORE, GLUTAMINE

NYCOMED US

* NYCOMED US INC
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ADAPALENE, ADAPALENE
ALVESCO, CICLESONIDE
CALCIPOTRIENE, CALCIPOTRIENE
CARMOL HC, HYDROCORTISONE ACETATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CUTIVATE, FLUTICASONE PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
IMIQUIMOD, IMIQUIMOD
LIDOCAINE AND PRILOCAINE, LIDOCAINE
MOMETASONE FUROATE, MOMETASONE FUROATE
OMNARIS, CICLESONIDE
PAMINE FORTE, METHSCOPOLAMINE BROMIDE
PAMINE, METHSCOPOLAMINE BROMIDE
SOLARAZE, DICLOFENAC SODIUM
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE
ZONALON, DOXEPIN HYDROCHLORIDE

ODYSSEY PHARMS

* ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM
NYSTATIN, NYSTATIN
SURMONTIL, TRIMIPRAMINE MALEATE
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM

* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
CHLORZOXAZONE, CHLORZOXAZONE
IBUPROFEN, IBUPROFEN
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 0 ****

OLTA PHARMS

* OLTA PHARMACEUTICALS CORP
LINDANE, LINDANE

OMAN PHARM PRODUCTS

* OMAN PHARMACEUTICAL PRODUCTS CO LLC
NEOMYCIN SULFATE, NEOMYCIN SULFATE

ONY

* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE

* ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFDINIR, CEFdinIR
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOXITIN, CEFoxITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
* ORCHID HEALTHCARE DIV ORCHID CHEMICALS AND PHARMACEUTICALS LTD
ZALEPLON, ZALEPLON

ORGANON USA INC

* ORGANON USA INC
CYCLESSA, DESOGESTREL
DESOGEN, DESOGESTREL
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
GANIRELIX ACETATE INJECTION, GANIRELIX ACETATE
IMPLANON, ETONOGESTREL
NUVARING, ETHINYL ESTRADIOL
PREGNYL, GONADOTROPIN, CHORIONIC
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE
SAPHRIS, ASENAPINE MALEATE

ORION

* ORION CORP
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 0 ****

ORIT LABS LLC

- * ORIT LABORATORIES LLC
BENZONATATE, BENZONATATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL

ORPHAN EUROPE

- * ORPHAN EUROPE
CARBAGLU, CARGLUMIC ACID

ORTHO BIOTECH

- * ORTHO BIOTECH PRODUCTS LP
DOXIL, DOXORUBICIN HYDROCHLORIDE
LEUSTATIN, CLADRIBINE

ORTHO DERMATOLOGICS

- * ORTHO DERMATOLOGICS
ERTACZO, SERTACONAZOLE NITRATE
RENOVA, TRETINOIN
RETIN-A MICRO, TRETINOIN

ORTHO MCNEIL JANSSEN

- * ORTHO MCNEIL JANSSEN PHARMACEUTICAL INC
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DORIBAX, DORIPENEM
HALDOL, HALOPERIDOL DECANOATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RISPERDAL, RISPERIDONE
TERAZOL 3, TERCONAZOLE
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLOX, ACETAMINOPHEN
ULTRACET, ACETAMINOPHEN
- * ORTHO MCNEIL JANSSEN PHARMACEUTICALS INC
AXERT, ALMOTRIPTAN MALATE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
ELMIRON, PENTOSAN POLYSULFATE SODIUM
HALDOL, HALOPERIDOL LACTATE
INVEGA, PALIPERIDONE
LEVAQUIN, LEVOFLOXACIN
MICRONOR, NORETHINDRONE
MODICON 28, ETHINYL ESTRADIOL
NIZORAL, KETOCONAZOLE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
PANCREAZE, LIPASE
PARAFON FORTE DSC, CHLORZOXAZONE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
TERAZOL 3, TERCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 0 ****

- * ORTHO MCNEIL JANSSEN PHARMACEUTICALS INC
TERAZOL 7, TERCONAZOLE
TOPAMAX, TOPIRAMATE
ULTRAM, TRAMADOL HYDROCHLORIDE

ORTHO MCNEIL PHARM

- * ORTHO MCNEIL PHARMACEUTICAL INC
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN

ORTHONEUTROGENA

- * ORTHONEUTROGENA
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE

OSI PHARMS

- * OSI PHARMACEUTICALS INC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA PHARM

- * OSMOTICA PHARMACEUTICAL CORP
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OTSUKA

- * OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE
PLETAL, CILOSTAZOL
- * OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC
ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA

- * OTSUKA AMERICA PHARMACEUTICALS INC
BREATHTEK UBT FOR H-PYLORI, UREA C-13

OTSUKA AMERICA PHARM

- * OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM

- * OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OUTLOOK PHARMS

- * OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

PACIFIC PHARMA

- * PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
- * PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

- * PACIRA PHARMACEUTICALS INC
DEPOCYT, CYTARABINE

PADDOCK

- * PADDOCK LABORATORIES INC
AMMONIUM LACTATE, AMMONIUM LACTATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ERYTHRA-DERM, ERYTHROMYCIN
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PADDOCK LABORATORIES INC
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

PADDOCK LABS

* PADDOCK LABORATORIES INC
CAFFEINE CITRATE, CAFFEINE CITRATE
CICLOPIROX, CICLOPIROX
CLENZ-LYTE, POLYETHYLENE GLYCOL 3350
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LORAZEPAM, LORAZEPAM
MIDAMOR, AMILORIDE HYDROCHLORIDE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

PALADIN LABS

* PALADIN LABS USA INC
ANTIZOL, FOMEPIZOLE

PAR PHARM

* PAR PHARMACEUTICAL
NABUMETONE, NABUMETONE
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZUPLENZ, ONDANSETRON

* PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
CABERGOLINE, CABERGOLINE
CALCITONIN-SALMON, CALCITONIN SALMON
CAPOTEN, CAPTOPRIL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESTAZOLAM, ESTAZOLAM
FLUTAMIDE, FLUTAMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYUREA, HYDROXYUREA
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR PHARMACEUTICAL INC
MEGACE ES, MEGESTROL ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NASCOBAL, CYANOCOBALAMIN
NATEGLINIDE, NATEGLINIDE
NYSTATIN, NYSTATIN
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXANDROLONE, OXANDROLONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
CELONTIN, METHSUXIMIDE
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
NARDIL, PHENELZINE SULFATE
NEURONTIN, GABAPENTIN
ZARONTIN, ETHOSUXIMIDE
* PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
ZARONTIN, ETHOSUXIMIDE

PEDIATRX

* PEDIATRX INC
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

PEDINOL

* PEDINOL PHARMACAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
NALFON, FENOPROFEN CALCIUM

PERNIX THERAP

* PERNIX THERAPEUTICS LLC
CEDAX, CEFTIBUTEN DIHYDRATE

PERRIGO

* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TAB-PROFEN, IBUPROFEN (OTC)
TIOCONAZOLE, TIOCONAZOLE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PERRIGO CO
CICLOPIROX, CICLOPIROX
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

* PERRIGO CO TENNESSEE INC
GRISEOFULVIN, GRISEOFULVIN, MICROCRYSTALLINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

* PERRIGO ISRAEL PHARMACEUTICALS LTD
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
IMIQUIMOD, IMIQUIMOD
MESALAMINE, MESALAMINE

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CENTANY, MUPIROCIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
KETOCONAZOLE, KETOCONAZOLE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO R AND D

* PERRIGO R AND D CO
CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

- * PERRIGO R AND D CO
 - CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 - CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 - GEMFIBROZIL, GEMFIBROZIL
 - IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 - IBUPROFEN, IBUPROFEN
 - IBUPROFEN, IBUPROFEN (OTC)
 - LEVONORGESTREL, LEVONORGESTREL
 - LEVONORGESTREL, LEVONORGESTREL (OTC)
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 - NAPROXEN, NAPROXEN
 - NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 - POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 - SIMVASTATIN, SIMVASTATIN

PERRIGO UK FINCO

- * PERRIGO UK FINCO LTD PARTNERSHIP
 - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

PERSONAL PRODS

- * PERSONAL PRODUCTS CO
 - MONISTAT 3, MICONAZOLE NITRATE

PFIZER

- * PFIZER CENTRAL RESEARCH
 - DIFLUCAN, FLUCONAZOLE
 - ZITHROMAX, AZITHROMYCIN
- * PFIZER CHEMICALS DIV PFIZER INC
 - DIFLUCAN, FLUCONAZOLE
 - ZITHROMAX, AZITHROMYCIN
- * PFIZER INC
 - ANTIVERT, MECLIZINE HYDROCHLORIDE
 - ARGATROBAN, ARGATROBAN
 - CADUET, AMLODIPINE BESYLATE
 - CARDURA XL, DOXAZOSIN MESYLATE
 - CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 - DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 - DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 - DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 - GEODON, ZIPRASIDONE HYDROCHLORIDE
 - GEODON, ZIPRASIDONE MESYLATE
 - GLUCOTROL XL, GLIPIZIDE
 - GLUCOTROL, GLIPIZIDE
 - LIPITOR, ATORVASTATIN CALCIUM
 - LYRICA, PREGABALIN
 - NAVANE, THIOETHIXENE
 - NORVASC, AMLODIPINE BESYLATE
 - PROCARDIA, NIFEDIPINE
 - REVATIO, SILDENAFIL CITRATE
 - RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
 - TOVIAZ, FESOTERODINE FUMARATE
 - UNASYN, AMPICILLIN SODIUM
 - VFEND, VORICONAZOLE
 - ZITHROMAX, AZITHROMYCIN
- * PFIZER LABORATORIES DIV PFIZER INC
 - CARDURA, DOXAZOSIN MESYLATE
 - DIABINESE, CHLORPROPAMIDE
 - FELDEN, PIROXICAM
 - MINIPRESS, PRAZOSIN HYDROCHLORIDE
 - PERMAPEN, PENICILLIN G BENZATHINE
 - PFIZERPEN, PENICILLIN G POTASSIUM
 - PROCARDIA XL, NIFEDIPINE
 - STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
 - TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

- * PFIZER LABORATORIES DIV PFIZER INC
UNASYN, AMPICILLIN SODIUM
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VIBRA-TABS, DOXYCYCLINE HYCLATE
VISTARIL, HYDROXYZINE PAMOATE
- * PFIZER PHARMACEUTICALS INC
ZOLOFT, SERTRALINE HYDROCHLORIDE
- * PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER GLOBAL

- * PFIZER GLOBAL RESEARCH DEVELOPMENT
ZMAX, AZITHROMYCIN

PFIZER INC

- * PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
ELLENCEN, EPIRUBICIN HYDROCHLORIDE
GEODON, ZIPRASIDONE HYDROCHLORIDE
NICOTROL, NICOTINE

PFIZER IRELAND

- * PFIZER IRELAND PHARMACEUTICALS
RELPAX, ELETRIPTAN HYDROBROMIDE
VIAGRA, SILDENAFIL CITRATE

PFIZER PHARMS

- * PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
DILANTIN, PHENYTOIN
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN

PHARM ASSOC

- * PHARMACEUTICAL ASSOC INC
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
- * PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

PHARMA SERVE NY

- * PHARMA SERVE INC SUB TORIGIAN LABORATORIES
AMINOPHYLLINE, AMINOPHYLLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

PHARMACHEMIE

* PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN
XANAX XR, ALPRAZOLAM

* PHARMACIA AND UPJOHN CO
ANSAID, FLURBIPROFEN
AROMASIN, EXEMESTANE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACITRACIN, BACITRACIN
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORTEF, HYDROCORTISONE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HEMABATE, CARBOPROST TROMETHAMINE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
MEDROL, METHYLPREDNISOLONE
MYCOBUTIN, RIFABUTIN
NICOTROL, NICOTINE
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
R-GENE 10, ARGININE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

- * PHARMACIA AND UPJOHN CO
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMAVERT, PEGVISOMANT
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
VANTIN, CEFPODOXIME PROXETIL
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID
- * PHARMACIA AND UPJOHN SUB PFIZER INC
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

PHARMADERM

- * PHARMADERM DIV ALTANA INC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN

PHARMAFORCE

- * PHARMAFORCE INC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
ZIDOVUDINE, ZIDOVUDINE

PHARMALUCENCE

- * PHARMALUCENCE INC
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT

PHARMASEAL

- * PHARMASEAL DIV BAXTER HEALTHCARE CORP
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

PHARMAX

- * PHARMAX GROUP INC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
FOLIC ACID, FOLIC ACID

PHARMAXIS

- * PHARMAXIS INC
ARIDOL KIT, MANNITOL

PHOTOCURE ASA

- * PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE

- * PIERRE FABRE MEDICAMENT
NAVELBINE, VINORELBINE TARTRATE

PIERREL

- * PIERREL S.P.A.
ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE, ARTICAINE HYDROCHLORIDE

PIRAMAL CRITICAL

- * PIRAMAL CRITICAL CARE INC
ENFLURANE, ENFLURANE
ISOFLURANE, ISOFLURANE
SOJOURN, SEVOFLURANE

PLANTEX

- * PLANTEX USA INC DIV IKAPHARM INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

PLIVA

* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARBOPLATIN, CARBOPLATIN
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN, NAPROXEN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO

* PLIVA HRVATSKA DOO
ADAPALENE, ADAPALENE
AZITHROMYCIN, AZITHROMYCIN
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

PLIVA LACHEMA

* PLIVA LACHEMA AS
CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PLIVA PHARM IND

* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

POHL BOSKAMP

* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYMEDICA

* POLYMEDICA INDUSTRIES INC
ANESTACON, LIDOCAINE HYDROCHLORIDE
NEOPAP, ACETAMINOPHEN (OTC)

PRASCO

* PRASCO LLC DBA PRASCO LABORATORIES
ECONAZOLE NITRATE, ECONAZOLE NITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

PRECISION DOSE

- * PRECISION DOSE INC
RISPERIDONE, RISPERIDONE

PRIMAPHARM

- * PRIMAPHARM INC
HYDASE, HYALURONIDASE

PRISM PHARMS

- * PRISM PHARMACEUTICALS INC
NEXTERONE, AMIODARONE HYDROCHLORIDE

PROCTER AND GAMBLE

- * PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO
DIDRONEL, ETIDRONATE DISODIUM

PROGENICS

- * PROGENICS PHARMACEUTICALS INC
RELISTOR, METHYLNALTREXONE BROMIDE

PROMETHEUS LABS

- * PROMETHEUS LABORATORIES INC
HELIDAC, BISMUTH SUBSALICYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
RIDAURA, AURANOFIN
TRANDATE, LABETALOL HYDROCHLORIDE
ZYLOPRIM, ALLOPURINOL

PROMIUS PHARMA

- * PROMIUS PHARMA LLC
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
TENEX, GUANFACINE HYDROCHLORIDE

PROVIDENT PHARM

- * PROVIDENT PHARMACEUTICAL INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

PULSION MEDCL

- * PULSION MEDICAL SYSTEMS AG
INDOCYANINE GREEN, INDOCYANINE GREEN

PURDUE GMP

- * PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY
SEROMYCIN, CYCLOSERINE

PURDUE PHARM PRODS

- * PURDUE PHARMACEUTICAL PRODUCTS LP
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE

PURDUE PHARMA

- * PURDUE PHARMA PRODUCTS LP
RYZOLT, TRAMADOL HYDROCHLORIDE

PURDUE PHARMA LP

- * PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

PUREPAC PHARM

- * PUREPAC PHARMACEUTICAL CO
DIPYRIDAMOLE, DIPYRIDAMOLE

QLT

- * QLT INC
VISUDYNE, VERTEPORFIN

QOL MEDCL

- * QOL MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** Q **

* QOL MEDICAL LLC
 ETHAMOLIN, ETHANOLAMINE OLEATE
 SUCRAID, SACROSIDASE

QPHARMA

* QPHARMA LLC
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 FLUNISOLIDE, FLUNISOLIDE

QUESTCOR PHARMS

* QUESTCOR PHARMACEUTICALS INC
 DORAL, QUAZEPAM
 H.P. ACTHAR GEL, CORTICOTROPIN

RANBAXY

* RANBAXY INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

* RANBAXY LABORATORIES INC
 EURAX, CROTAMITON
 EXELDERM, SULCONAZOLE NITRATE
 FAMOTIDINE, FAMOTIDINE (OTC)
 HALOG, HALCINONIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
 KENALOG, TRIAMCINOLONE ACETONIDE
 LAC-HYDRIN, AMMONIUM LACTATE
 RISPERIDONE, RISPERIDONE
 ULTRAVATE, HALOBETASOL PROPIONATE
 WESTCORT, HYDROCORTISONE VALERATE

* RANBAXY LABORATORIES LTD
 ACYCLOVIR, ACYCLOVIR
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CLARITHROMYCIN, CLARITHROMYCIN
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DISPERMOX, AMOXICILLIN
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 FENOFIBRATE, FENOFIBRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GABAPENTIN, GABAPENTIN
 GANCICLOVIR, GANCICLOVIR
 GLIMEPIRIDE, GLIMEPIRIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

- * RANBAXY LABORATORIES LTD
 - LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 - LORATADINE REDIDOSE, LORATADINE (OTC)
 - LORATADINE, LORATADINE (OTC)
 - LORAZEPAM, LORAZEPAM
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 - NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 - NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 - OFLOXACIN, OFLOXACIN
 - OXCARBAZEPINE, OXCARBAZEPINE
 - PANIXINE DISPERDOSE, CEPHALEXIN
 - PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 - PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 - QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 - RAMIPRIL, RAMIPRIL
 - RANICLOR, CEFACLOR
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - RISPERIDONE, RISPERIDONE
 - SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 - SIMVASTATIN, SIMVASTATIN
 - SOTRET, ISOTRETINOIN
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 - TOPIRAMATE, TOPIRAMATE
 - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 - ZIDOVUDINE, ZIDOVUDINE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * RANBAXY PHARMACEUTICALS INC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 - AMOXICILLIN, AMOXICILLIN
 - AVENTYL HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 - CEFACLOR, CEFACLOR
 - CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 - PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
 - RIOMET, METFORMIN HYDROCHLORIDE
 - SECONAL SODIUM, SECOBARBITAL SODIUM
 - SOTRET, ISOTRETINOIN

RARE DIS

- * RARE DISEASE THERAPEUTICS INC
 - ORFADIN, NITISINONE

RARE DIS THERAP

- * RARE DISEASE THERAPEUTICS INC
 - CYSTADANE, BETAINES HYDROCHLORIDE

RATIOPHARM

- * RATIOPHARM
 - RISPERIDONE, RISPERIDONE

RECIP

- * RECIP AB
 - THYROSAFE, POTASSIUM IODIDE (OTC)

RECKITT BENCKISER

- * RECKITT BENCKISER
 - DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
- * RECKITT BENCKISER INC
 - MUCINEX D, GUAIFENESIN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

- * RECKITT BENCKISER INC
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)
- * RECKITT BENCKISER PHARMACEUTICALS INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
SUBOXONE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBUTEX, BUPRENORPHINE HYDROCHLORIDE

REDDYS

- * DOCTOR REDDYS LABORATORIES LTD
DESLOMATADINE, DESLOMATADINE

REGEN

- * REGEN MEDICAL AMERICAS LLC
HIBICLEN, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

RHODES PHARMS

- * RHODES PHARMACEUTICALS LP
MORPHINE SULFATE, MORPHINE SULFATE

RHODIA

- * RHODIA LTD
ISOFLURANE, ISOFLURANE

ROCHE

- * HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM
COPEGUS, RIBAVIRIN
FUZEON, ENFUVIRTIDE
INVIRASE, SAQUINAVIR MESYLATE
KLONOPIN, CLONAZEPAM
TAMIFLU, OSELTAMIVIR PHOSPHATE
VALIUM, DIAZEPAM

ROCHE PALO

- * ROCHE PALO ALTO LLC
AEROBID, FLUNISOLIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CYTOVENE, GANCICLOVIR SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE

ROMARK

- * ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

ROSEDALE THERAPEUTIC

- * ROSEDALE THERAPEUTICS
ERGOMAR, ERGOTAMINE TARTRATE

ROSS LABS

- * ROSS LABORATORIES DIV ABBOTT LABORATORIES INC
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
SURVANTA, BERACTANT

ROXANE

- * ROXANE LABORATORIES INC
ACARBOSE, ACARBOSE
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
AZATHIOPRINE, AZATHIOPRINE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* ROXANE LABORATORIES INC
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CILOSTAZOL, CILOSTAZOL
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CODEINE SULFATE, CODEINE SULFATE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXAMETHASONE INTENSOL, DEXAMETHASONE
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM INTENSOL, DIAZEPAM
 DIAZEPAM, DIAZEPAM
 DIGOXIN, DIGOXIN
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUCONAZOLE, FLUCONAZOLE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LACTULOSE, LACTULOSE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LITHIUM CITRATE, LITHIUM CITRATE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORAZEPAM INTENSOL, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NAPROXEN, NAPROXEN
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PREDNISONE INTENSOL, PREDNISONE
 PREDNISONE, PREDNISONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROXICET 5/500, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* ROXANE LABORATORIES INC
ROXICET, ACETAMINOPHEN
ROXILOX, ACETAMINOPHEN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TORSEMIDE, TORSEMIDE
TRIAZOLAM, TRIAZOLAM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ROXRO PHARMA INC

* ROXRO PHARMA INC
SPRIX, KETOROLAC TROMETHAMINE

SAGE PRODS

* SAGE PRODUCTS INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGENT PHARMS

* SAGENT PHARMACEUTICALS INC
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

SAGENT STRIDES

* SAGENT STRIDES LLC
AZITHROMYCIN, AZITHROMYCIN
BACITRACIN, BACITRACIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MESNA, MESNA
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SALIX PHARMS

* SALIX PHARMACEUTICALS INC
ANUSOL HC, HYDROCORTISONE
APRISO, MESALAMINE
COLAZAL, BALSALAZIDE DISODIUM
DIURIL, CHLOROTHIAZIDE
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
MOVIPREP, ASCORBIC ACID
OSMOPREP, SODIUM PHOSPHATE, DIBASIC ANHYDROUS
PEPCID, FAMOTIDINE
VISICOL, SODIUM PHOSPHATE, DIBASIC ANHYDROUS
XIFAXAN, RIFAXIMIN

SAMSON MEDCL

* SAMSON MEDICAL TECHNOLOGIES LLC
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFUROXIME SODIUM IN PLASTIC CONTAINER, CEFUROXIME SODIUM

SANDOZ

* SANDOZ CANADA INC
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
COSYNTROPIN, COSYNTROPIN
DIGOXIN, DIGOXIN
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FLUMAZENIL, FLUMAZENIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ CANADA INC
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INFUVITE PEDIATRIC, ASCORBIC ACID
 ISONIAZID, ISONIAZID
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

* SANDOZ INC
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALPRAZOLAM, ALPRAZOLAM
 ALTAVERA, ETHINYL ESTRADIOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 ATENOLOL, ATENOLOL
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BUMETANIDE, BUMETANIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFERGOT, CAFFEINE
 CAPTOPRIL, CAPTOPRIL
 CARBOPLATIN, CARBOPLATIN
 CARISOPRODOL AND ASPIRIN, ASPIRIN
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFDINIR, CEFDINIR
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLOMATADINE, DESLOMATADINE
DEXTRORAMP SACCHARATE, AMP ASPARTATE, DEXTRORAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ASPARTATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
HALOPERIDOL, HALOPERIDOL
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOCIN SR, INDOMETHACIN
INDOMETHACIN, INDOMETHACIN
INTROVALE, ETHINYL ESTRADIOL
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVETIRACETAM, LEVETIRACETAM
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINAPRIL, LISINAPRIL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LONOX, ATROPINE SULFATE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC

LOVASTATIN, LOVASTATIN

MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE

METAXALONE, METAXALONE

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

METHAZOLAMIDE, METHAZOLAMIDE

METHIMAZOLE, METHIMAZOLE

METHOCARBAMOL, METHOCARBAMOL

METHYLPREDNISOLONE, METHYLPREDNISOLONE

METOLAZONE, METOLAZONE

METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

METOPROLOL TARTRATE, METOPROLOL TARTRATE

MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE

MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

MIRTAZAPINE, MIRTAZAPINE

MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

NABUMETONE, NABUMETONE

NADOLOL, NADOLOL

NAFCILLIN SODIUM, NAFCILLIN SODIUM

NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE

NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

NAPROXEN, NAPROXEN

NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

NIZATIDINE, NIZATIDINE

OFLOXACIN, OFLOXACIN

OMEPRazole, OMEPRazole

OMNITROPE, SOMATROPIN RECOMBINANT

ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

ONDANSETRON, ONDANSETRON

ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN

OXACILLIN SODIUM, OXACILLIN SODIUM

OXANDROLONE, OXANDROLONE

OXAPROZIN, OXAPROZIN

OXAZEPAM, OXAZEPAM

PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

PENICILLIN G SODIUM, PENICILLIN G SODIUM

PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

PERPHENAZINE, PERPHENAZINE

PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN

PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE

PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE

QUINIDINE SULFATE, QUINIDINE SULFATE

RAMIPRIL, RAMIPRIL

RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

RESERPINE, RESERPINE

RIBAVIRIN, RIBAVIRIN

RIFAMPIN, RIFAMPIN

RISPERIDONE, RISPERIDONE

SIMVASTATIN, SIMVASTATIN

SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

SPIRONOLACTONE, SPIRONOLACTONE

SULFADIAZINE, SULFADIAZINE

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE

SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

TACROLIMUS, TACROLIMUS

TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
TEMAZEPAM, TEMAZEPAM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SANOCHEMIA CORP USA

* SANOCHEMIA CORP USA
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL

* SANOFI AVENTIS US LLC
ALLEGRA D 24 HOUR, FEXOFENADINE HYDROCHLORIDE
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D 12 HOUR, FEXOFENADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
ANZEMET, DOLASETRON MESYLATE
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
ARALEN, CHLOROQUINE PHOSPHATE
ARAVA, LEFLUNOMIDE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
CANTIL, MEPENZOLATE BROMIDE
CARAC, FLUOROURACIL
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLOMID, CLOMIPHENE CITRATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMATOP, PREDNICARBATE
DIABETA, GLYBURIDE
DRISDOL, ERGOCALCIFEROL
ELOXATIN, OXALIPLATIN
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
GAVISCON, ALUMINUM HYDROXIDE (OTC)
HIPREX, METHENAMINE HIPPURATE
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KETEK, TELITHROMYCIN
KLARON, SULFACETAMIDE SODIUM
LANTUS, INSULIN GLARGINE RECOMBINANT
LASIX, FUROSEMIDE
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
MYTELASE, AMBENONIUM CHLORIDE
NASACORT AQ, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANOFI AVENTIS US LLC
NICODERM CQ, NICOTINE (OTC)
NILANDRON, NILUTAMIDE
NORITATE, METRONIDAZOLE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
OFORTA, FLUDARABINE PHOSPHATE
PENLAC, CICLOPIROX
PHISOHEX, HEXACHLOROPHENE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
SKELID, TILUDRONATE DISODIUM
TAXOTERE, DOCETAXEL
TRENTAL, PENTOXIFYLLINE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

SANTARUS

* SANTARUS INC
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE, MAGNESIUM HYDROXIDE
ZEGERID, OMEPRAZOLE

SANTEN

* SANTEN INC
ALAMAST, PEMIROLAST POTASSIUM
IQIUX, LEVOFLOXACIN
QUIXIN, LEVOFLOXACIN

SANTEN OY

* SANTEN OY
BETIMOL, TIMOLOL

SAVAGE LABS

* SAVAGE LABORATORIES INC DIV ALTANA INC
KAON CL-10, POTASSIUM CHLORIDE
PANDEL, HYDROCORTISONE PROBUTATE

SAVIENT PHARMS

* SAVIENT PHARMACEUTICALS INC
OXANDRIN, OXANDROLONE

SB PHARMCO

* SB PHARMCO PUERTO RICO INC
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDARYL, GLIMEPIRIDE
AVANDIA, ROSIGLITAZONE MALEATE
COREG CR, CARVEDILOL PHOSPHATE

SCHERING

* SCHERING
CLARINEX-D 12 HOUR, DESLORATADINE
* SCHERING CORP
ASMANEX TWISTHALER, MOMETASONE FUROATE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX, DESLORATADINE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DULERA, FORMOTEROL FUMARATE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
INTEGRILIN, EPTIFIBATIDE
LOTRISONE, BETAMETHASONE DIPROPIONATE
NOXAFIL, POSACONAZOLE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
REBETOL, RIBAVIRIN
TEMODAR, TEMOZOLOMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

- * SCHERING CORP
ZEMURON, ROCURONIUM BROMIDE
- * SCHERING CORP SUB SCHERING PLOUGH CORP
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELESTONE, BETAMETHASONE
DIPROLENE, BETAMETHASONE DIPROPIONATE
ELOCON, MOMETASONE FUROATE

SCHERING PLOUGH

- * SCHERING PLOUGH CORP
CLARINEX, DESLORATADINE
- * SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
NASONEX, MOMETASONE FUROATE MONOHYDRATE
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
SHADE UVAGUARD, AVOBENZONE (OTC)
ZEGEID OTC, OMEPRAZOLE (OTC)

SCHERING PLOUGH RES

- * SCHERING PLOUGH RESEARCH INSTITUTE
LOTRISONE, BETAMETHASONE DIPROPIONATE
REBETOL, RIBAVIRIN

SCHWARZ PHARMA

- * SCHWARZ PHARMA AG
EDEX, ALPROSTADIL
GLYCOLAX, POLYETHYLENE GLYCOL 3350
- * SCHWARZ PHARMA INC
DILATRATE-SR, ISOSORBIDE DINITRATE
LEVATOL, PENBUTOLOL SULFATE
NIRAVAM, ALPRAZOLAM
PARCOPA, CARBIDOPA
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL

SCIOS

- * SCIOS INC
NATRECOR, NESIRITIDE RECOMBINANT

SEPRACOR

- * SEPRACOR INC
LUNESTA, ESZOPICLONE

SEPTODONT

- * SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
OCTOCAINE, EPINEPHRINE

SEPTODONT INC

- * SEPTODONT INC
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SHASUN USA

* SHASUN USA INC
IBUPROFEN, IBUPROFEN

SHIONOGI PHARMA

* SHIONOGI PHARMA INC
ADRENALIN, EPINEPHRINE
COGNEX, TACRINE HYDROCHLORIDE
CUVPOSA, GLYCOPYRROLATE
FENOGLIDE, FENOFIBRATE
FURADANTIN, NITROFURANTOIN
JENLOGA, CLONIDINE HYDROCHLORIDE
KAPVAY, CLONIDINE HYDROCHLORIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
PONSTEL, MEFENAMIC ACID
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
SULAR, NISOLDIPINE
TWINJECT 0.15, EPINEPHRINE
TWINJECT 0.3, EPINEPHRINE
ULESFIA, BENZYL ALCOHOL

SHIRE

* SHIRE DEVELOPMENT INC
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
CARBATROL, CARBAMAZEPINE
FOSRENOL, LANTHANUM CARBONATE
INTUNIV, GUANFACINE HYDROCHLORIDE
LIALDA, MESALAMINE
PENTASA, MESALAMINE
PROAMATINE, MIDODRINE HYDROCHLORIDE
SALURON, HYDROFLUMETHIAZIDE

SHIRE DEVELOPMENT

* SHIRE DEVELOPMENT INC
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

* SHIRE HUMAN GENETIC THERAPIES INC
VPRIV, VELAGLUCERASE ALFA

SIGMA TAU

* SIGMA TAU PHARMACEUTICALS INC
ABELCET, AMPHOTERICIN B
ADAGEN, PEGADEMASE BOVINE
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
MATULANE, PROCARBAZINE HYDROCHLORIDE

SIGMAPHARM LABS LLC

* SIGMAPHARM LABORATORIES LLC
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE

SILARX

* SILARX PHARMACEUTICALS INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SILARX PHARMACEUTICALS INC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

SKINMEDICA

* SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

* SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SLATE PHARMS

* SLATE PHARMACEUTICALS INC
TESTOPEL, TESTOSTERONE

SMITHKLINE BEECHAM

* SMITHKLINE BEECHAM
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
* SMITHKLINE BEECHAM CORP
LAMICTAL XR, LAMOTRIGINE
* SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE
ARRANON, NELARABINE
AXID, NIZATIDINE
COREG, CARVEDILOL
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
HYCANTIN, TOPOTECAN HYDROCHLORIDE
LAMICTAL ODT, LAMOTRIGINE
LANOXIN, DIGOXIN
LEUKERAN, CHLORAMBUCIL
REQUIP XL, ROPINIROLE HYDROCHLORIDE
TYKERB, LAPATINIB DITOSYLATE

SOAPCO

* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOLCO HLTHCARE

* SOLCO HEALTHCARE US LLC
LEVETIRACETAM, LEVETIRACETAM

SOLUMED

* LES ENTREPRISES SOLUMED INC
CHLORASCRUB MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB SWAB, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

SOMAXON

* SOMAXON PHARMACEUTICALS INC
SILENOR, DOXEPIN HYDROCHLORIDE

SOMERSET

* SOMERSET PHARMACEUTICALS INC
ELDEPRYL, SELEGILINE HYDROCHLORIDE
EMSAM, SELEGILINE

SPEAR PHARMS

* SPEAR PHARMACEUTICALS INC
FLUOROURACIL, FLUOROURACIL
TRETINOIN, TRETINOIN

SPECTRUM PHARMS

* SPECTRUM PHARMACEUTICALS
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SPECTRUM PHARMACEUTICALS INC
FUSILEV, LEVOLEUCOVORIN CALCIUM

STAND HOMEOPATH

* STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STASON

* STASON INDUSTRIAL CORP
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

STASON PHARMS

* STASON PHARMACEUTICALS INC
ANASTROZOLE, ANASTROZOLE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

STAT TRADE

* STAT TRADE INC
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
NAPRELAN, NAPROXEN SODIUM

STERI PHARMA

* STERI PHARMA LLC
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CEPHALEXIN, CEPHALEXIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
UNITHROID, LEVOTHYROXINE SODIUM

STI PHARMA LLC

* STI PHARMA LLC
DEXAMETHASONE, DEXAMETHASONE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
TRIACIN-C, CODEINE PHOSPHATE

STIEFEL

* STIEFEL LABORATORIES INC
DECLOMYCIN, DEMECLOXYCLINE HYDROCHLORIDE
DUAC, BENZOYL PEROXIDE

STIEFEL GSK

* STIEFEL A GSK CO
HYDROCORTISONE, HYDROCORTISONE
VELTIN, CLINDAMYCIN PHOSPHATE

STIEFEL LABS INC

* STIEFEL LABORATORIES INC
E-GLADES, ERYTHROMYCIN
EVOCLIN, CLINDAMYCIN PHOSPHATE
EXTINA, KETOCONAZOLE
ITRACONAZOLE, ITRACONAZOLE
OLUX E, CLOBETASOL PROPIONATE
SOLAGE, MEQUINOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
VERDESO, DESONIDE
VUSION, MICONAZOLE NITRATE
XOLEGEL, KETOCONAZOLE

STRAKAN

* STRAKAN INTERNATIONAL LTD
SANCUSO, GRANISETRON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

STRIDES ARCOLAB

* STRIDES ARCOLAB LIMITED
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM

STRIDES ARCOLAB LTD

* STRIDES ARCOLAB LTD
ADENOSINE, ADENOSINE
ERGOCALCIFEROL, ERGOCALCIFEROL
ETOMIDATE, ETOMIDATE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MELOXICAM, MELOXICAM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

SUCAMPO PHARMS

* SUCAMPO PHARMACEUTICALS INC
AMITIZA, LUBIPROSTONE

SUMMERS

* SUMMERS LABORATORIES INC
CROTAN, CROTAMITON

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ORTHO-EST, ESTROPIRATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
BENZONATATE, BENZONATATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
GEMFIBROZIL, GEMFIBROZIL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
NIMODIPINE, NIMODIPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARISOPRODOL, CARISOPRODOL
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

- * SUN PHARMACEUTICAL INDUSTRIES LTD
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

SUN PHARMA GLOBAL

- * SUN PHARMA GLOBAL FZE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
- * SUN PHARMA GLOBAL INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALPRAZOLAM, ALPRAZOLAM
AMIFOSTINE, AMIFOSTINE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
CARBOPLATIN, CARBOPLATIN
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
VECURONIUM BROMIDE, VECURONIUM BROMIDE

SUNOVION

- * SUNOVION PHARMACEUTICALS INC
BROVANA, ARFORMOTEROL TARTRATE
LATUDA, LURASIDONE HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

SVC PHARMA

- * SVC PHARMA LP
DRONABINOL, DRONABINOL

SYNCOR PHARMS

- * SYNCOR PHARMACEUTICALS INC
SODIUM IODIDE I 123, SODIUM IODIDE I-123

SYNERX

- * SYNERX PHARMA LLC
ISOSULFAN BLUE, ISOSULFAN BLUE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

SYNERX PHARMA

- * SYNERX PHARMA LLC
CICLOPIROX, CICLOPIROX
FOMEPIZOLE, FOMEPIZOLE
MALATHION, MALATHION
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

SYNTHON PHARMS

- * SYNTHON PHARMACEUTICALS INC
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

TAKEDA GLOBAL

- * TAKEDA GLOBAL RESEARCH DEVELOPMENT CENTER INC
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
DUETACT, GLIMEPIRIDE
ROZEREM, RAMELTEON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

TAKEDA PHARMS

- * TAKEDA PHARMACEUTICALS NORTH AMERICA INC
DEXILANT, DEXLANSOPRAZOLE
ULORIC, FEBUXOSTAT

TAKEDA PHARMS NA

- * TAKEDA PHARMACEUTICALS NORTH AMERICA INC
ACTOS, PIOGLITAZONE HYDROCHLORIDE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN

TARO

- * TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PHENYTOIN, PHENYTOIN
- * TARO PHARMACEUTICALS INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
WARFARIN SODIUM, WARFARIN SODIUM
- * TARO PHARMACEUTICALS USA INC
ACETIC ACID, ACETIC ACID, GLACIAL
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICALS USA INC
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
FLO-PRED, PREDNISOLONE ACETATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOROURACIL, FLUOROURACIL
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
KETOZOLE, KETOCONAZOLE
LIDOCAINE, LIDOCAINE
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
ORACORT, TRIAMCINOLONE ACETONIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERCONAZOLE, TERCONAZOLE
TERIL, CARBAMAZEPINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
U-CORT, HYDROCORTISONE ACETATE

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FLUCONAZOLE, FLUCONAZOLE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE

TARO PHARMS IRELAND

* TARO PHARMACEUTICALS IRELAND LTD
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

TARO PHARMS NORTH

* TARO PHARMACEUTICALS NORTH AMERICA INC
OVIDE, MALATHION
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE

TAYLOR

* TAYLOR PHARMACEUTICALS
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE

TAYLOR PHARMA

* TAYLOR PHARMACAL CO
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TAYLOR PHARMACAL CO
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

TEDOR PHARM

* TEDOR PHARMA INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TERCICA

* TERCICA INC
INCRELEX, MECASERMIN RECOMBINANT

TEVA

* TEVA NEUROSCIENCE INC
AZILECT, RASAGILINE MESYLATE
COPAXONE, GLATIRAMER ACETATE

* TEVA PHARMACEUTICALS USA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETA-VAL, BETAMETHASONE VALERATE
BICALUTAMIDE, BICALUTAMIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CEFACLOL, CEFACLOL
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEPHALEXIN, CEPHALEXIN
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CILOSTAZOL, CILOSTAZOL
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLOTRIMAZOLE, CLOTRIMAZOLE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
EPITOL, CARBAMAZEPINE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIZATIDINE, NIZATIDINE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ORAP, PIMOZIDE
OXAPROZIN, OXAPROZIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN-VK, PENICILLIN V POTASSIUM
PIROXICAM, PIROXICAM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRELONE, PREDNISOLONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA INC
PROPOXYPHENE HYDROCHLORIDE, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PURINETHOL, MERCAPTOPURINE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIACET, TRIAMCINOLONE ACETONIDE
TRIMETHOPRIM, TRIMETHOPRIM
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

TEVA GLOBAL

* TEVA GLOBAL RESPIRATORY RESEARCH LLC
PROAIR HFA, ALBUTEROL SULFATE
PROGLYCEM, DIAZOXIDE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMPHOTERICIN B, AMPHOTERICIN B
AZITHROMYCIN, AZITHROMYCIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
CALCITRIOL, CALCITRIOL
CARBOPLATIN, CARBOPLATIN
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CISPLATIN, CISPLATIN
CROMOLYN SODIUM, CROMOLYN SODIUM
CYTOSAR-U, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PARENTERAL MEDICINES INC
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
 ETOPOSIDE, ETOPOSIDE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVOCARNITINE, LEVOCARNITINE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MESNA, MESNA
 METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 OXYTOCIN, OXYTOCIN
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 THIOTEPA, THIOTEPA
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 ZANOSAR, STREPTOZOCIN

TEVA PARNTL

* TEVA PARENTAL MEDICINE INC
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMCICLOVIR, FAMCICLOVIR
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEBENDAZOLE, MEBENDAZOLE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
METHAZOLAMIDE, METHAZOLAMIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
OXCARBAZEPINE, OXCARBAZEPINE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAMIPRIL, RAMIPRIL
RISEDRONATE SODIUM, RISEDRONATE SODIUM
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
VANDAZOLE, METRONIDAZOLE
ZALEPLON, ZALEPLON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

TEVA WOMENS

- * TEVA WOMENS HEALTH INC
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
MIRCETTE, DESOGESTREL
PREFEST, ESTRADIOL
SYNTHETIC CONJUGATED ESTROGENS A, ESTROGENS, CONJUGATED SYNTHETIC A

THE PHARMA NETWORK

- * THE PHARMA NETWORK LLC
BENZONATATE, BENZONATATE

THE PHARMANETWORK

- * THE PHARMANETWORK LLC
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

THERAKOS

- * THERAKOS INC
UVADEX, METHOXSALEN

THERATECHNOLOGIES

- * THERATECHNOLOGIES INC
EGRIFTA, TESAMORELIN ACETATE

THERAVANCE INC

- * THERAVANCE INC
VIBATIV, TELAVANCIN HYDROCHLORIDE

THREE RIVERS PHARMS

- * THREE RIVERS PHARMACEUTICALS LLC
AMPHOTEC, AMPHOTERICIN B
ANASTROZOLE, ANASTROZOLE
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

TIBOTEC

- * TIBOTEC INC
INTELENCE, ETRAVIRINE
PREZISTA, DARUNAVIR ETHANOLATE

TOLMAR

- * TOLMAR INC
ATRIDOX, DOXYCYCLINE HYCLATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
KETOCONAZOLE, KETOCONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

TOLMAR THERAP

- * TOLMAR THERAPEUTICS INC
ELIGARD, LEUPROLIDE ACETATE

TOPOTARGET

- * TOPOTARGET AS
TOTECT, DEXRAZOXANE HYDROCHLORIDE

TORPHARM

- * TORPHARM INC
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

TORRENT PHARM

- * TORRENT PHARMA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

TORRENT PHARMS

- * TORRENT PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TORRENT PHARMS LLC

- * TORRENT PHARMACEUTICALS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)

TRIAx PHARMS LLC

- * TRIAX PHARMACEUTICALS LLC
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
TRETINOIN, TRETINOIN

TRIS PHARMA INC

- * TRIS PHARMA INC
CLONIDINE, CLONIDINE
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
IBUPROFEN, IBUPROFEN (OTC)
LEVETIRACETAM, LEVETIRACETAM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

TYCO HLTHCARE

- * TYCO HEALTHCARE GROUP LP
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
RESTORIL, TEMAZEPAM
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
- * TYCO HEALTHCARE MALLINCKRODT
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

UCB INC

- * UCB INC
CO-GESIC, ACETAMINOPHEN
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
LORTAB, ACETAMINOPHEN
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONOKET, ISOSORBIDE MONONITRATE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
SEMPREX-D, ACRIVASTINE
THEO-24, THEOPHYLLINE
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UCB INC
UNIRETIC, HYDROCHLOROTHIAZIDE
UNIVASC, MOEXIPRIL HYDROCHLORIDE
VIMPAT, LACOSAMIDE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
ZAROXOLYN, METOLAZONE

UCYCLYD

* UCYCLYD PHARMA INC
AMMONUL, SODIUM BENZOATE

UDL LABS

* UDL LABORATORIES
SULFAMYLON, MAFENIDE ACETATE

ULURU

* ULURU INC
APHTHASOL, AMLEXANOX

UNICHEM

* UNICHEM LABORATORIES LTD
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MELOXICAM, MELOXICAM
TOPIRAMATE, TOPIRAMATE
ZALEPLON, ZALEPLON

UNICHEM PHARMS (USA)

* UNICHEM PHARMACEUTICALS (USA) INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIQUE PHARM LABS

* UNIQUE PHARMACEUTICAL LABORATORIES
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FLUCONAZOLE, FLUCONAZOLE

UNITED GUARDIAN

* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
REMODULIN, TREPROSTINIL SODIUM
TYVASO, TREPROSTINIL SODIUM

UPSHER SMITH

* UPSHER SMITH LABORATORIES INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
FORTICAL, CALCITONIN SALMON RECOMBINANT
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
NIACOR, NIACIN
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
PACERONE, AMIODARONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UPSHER SMITH LABORATORIES INC
PENTOXIL, PENTOXIFYLLINE
PREVALITE, CHOLESTYRAMINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
SORINE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZALEPLON, ZALEPLON

US WORLDMEDS

* US WORLDMEDS LLC
DANTROLENE SODIUM, DANTROLENE SODIUM

USL PHARMA

* USL PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
FLUOXYMESTERONE, FLUOXYMESTERONE
JANTOVEN, WARFARIN SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

VALEANT

* VALEANT PHARMACEUTICALS INTERNATIONAL
ANCOBON, FLUCYTOSINE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
CAPITAL AND CODEINE, ACETAMINOPHEN
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
FLUOROURACIL, FLUOROURACIL
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MOTOFEN, ATROPINE SULFATE
MYSOLINE, PRIMIDONE
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN

VALEANT PHARM INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
8-MOP, METHOXSALEN
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
DALMANE, FLURAZEPAM HYDROCHLORIDE
EFUDEX, FLUOROURACIL
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
TASMAR, TOLCAPONE
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TESTRED, METHYLTESTOSTERONE
VIRAZOLE, RIBAVIRIN
ZELAPAR, SELEGILINE HYDROCHLORIDE

VALIDUS PHARMS

* VALIDUS PHARMACEUTICALS LLC
ROCALTROL, CALCITRIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

VALIDUS PHARMS INC

- * VALIDUS PHARMACEUTICALS INC
EQUETRO, CARBAMAZEPINE
MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC

- * VANDA PHARMACEUTICALS INC
FANAPT, ILOPERIDONE

VEROSCIENCE

- * VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERSAPHARM

- * VERSAPHARM INC
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ERYTHROMYCIN, ERYTHROMYCIN
RIFAMPIN, RIFAMPIN

VICTORY PHARMA

- * VICTORY PHARMA INC
KEFLEX, CEPHALEXIN
MOXATAG, AMOXICILLIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

VICURON

- * VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

VIIV HLTHCARE

- * VIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

VINTAGE

- * VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOLIC ACID, FOLIC ACID
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRISEOFULVIN, GRISEOFULVIN
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LISINOPRIL, LISINOPRIL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VINTAGE PHARMACEUTICALS LLC
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PREVIFEM, ETHINYL ESTRADIOL
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
RISPERIDONE, RISPERIDONE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRI-PREVIFEM, ETHINYL ESTRADIOL
VALPROIC ACID, VALPROIC ACID
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

* VINTAGE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
CARISOPRODOL, CARISOPRODOL
CLONAZEPAM, CLONAZEPAM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HYDROCHLORIDE, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

- * VINTAGE PHARMACEUTICALS INC
SULFASALAZINE, SULFASALAZINE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

VIROPHARMA

- * VIROPHARMA INC
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

VISTA PHARMS

- * VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAKON PHARMS LLC

- * VISTAKON PHARMACEUTICALS LLC
LASTACFT, ALCAFTADINE

VISTAPHARM

- * VISTAPHARM INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
LACTULOSE, LACTULOSE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
NYSTATIN, NYSTATIN
PHENYTOIN, PHENYTOIN

VIVUS

- * VIVUS INC
MUSE, ALPROSTADIL

WARNER CHILCOTT

- * WARNER CHILCOTT BERMUDA LTD
CHOLEDYL SA, OXTRIPHYLLINE
- * WARNER CHILCOTT CO LLC
ACTONEL, RISEDRONATE SODIUM
ATELVIA, RISEDRONATE SODIUM
- * WARNER CHILCOTT INC
ERYC, ERYTHROMYCIN
ESTRACE, ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMTRACE, ESTRADIOL ACETATE
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
SARAFEM, FLUOXETINE HYDROCHLORIDE

WARNER CHILCOTT CO

- * WARNER CHILCOTT CO INC
LO LOESTRIN FE, ETHINYL ESTRADIOL

WARNER CHILCOTT INC

- * WARNER CHILCOTT PHARMACEUTICALS INC
ASACOL HD, MESALAMINE
ASACOL, MESALAMINE

WATSON LABS

- * WATSON LABORATORIES
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, ACETAMINOPHEN
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
CARBOPLATIN, CARBOPLATIN
CARVEDILOL, CARVEDILOL
FOLIC ACID, FOLIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NORCO, ACETAMINOPHEN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OXAPROZIN, OXAPROZIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETOHEXAMIDE, ACETOHEXAMIDE
ACYCLOVIR, ACYCLOVIR
AFEDITAB CR, NIFEDIPINE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
ALORA, ESTRADIOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ANDRODERM, TESTOSTERONE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CABERGOLINE, CABERGOLINE
CAPTOPRIL, CAPTOPRIL
CARBOPLATIN, CARBOPLATIN
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORZOXAZONE, CHLORZOXAZONE
CICLOPIROX, CICLOPIROX
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
COL-PROBENECID, COLCHICINE
CORDRAN, FLURANDRENOLIDE
CRINONE, PROGESTERONE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ESTAZOLAM, ESTAZOLAM
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRADIOL, ESTRADIOL
ESTRONE, ESTRONE
ESTROPIPATE, ESTROPIPATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISRADIPINE, ISRADIPINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WATSON LABORATORIES INC
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LISINOPRIL, LISINOPRIL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOW-OGESTREL-21, ETHINYL ESTRADIOL
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MELOXICAM, MELOXICAM
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 MEPROBAMATE, MEPROBAMATE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
 METHYLDOPA, METHYLDOPA
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MICROZIDE, HYDROCHLOROTHIAZIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NIZATIDINE, NIZATIDINE
 NORCO, ACETAMINOPHEN
 NORETHIN 1/35E-21, ETHINYL ESTRADIOL
 NORETHIN 1/35E-28, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 NORINYL 1+50 28-DAY, MESTRANOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXAZEPAM, OXAZEPAM
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
 PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PINDOLOL, PINDOLOL
 PIROXICAM, PIROXICAM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC
PREDNISOLONE, PREDNISOLONE
PREDNISON, PREDNISON
PRIMIDONE, PRIMIDONE
PROBENECID, PROBENECID
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUASENSE, ETHINYL ESTRADIOL
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RAPAFLO, SILODOSIN
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TACROLIMUS, TACROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TEMAZEPAM, TEMAZEPAM
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDOLAPRIL, TRANDOLAPRIL
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRELSTAR DEPOT, TRIPTORELIN PAMOATE
TRELSTAR LA, TRIPTORELIN PAMOATE
TRELSTAR, TRIPTORELIN PAMOATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIVORA-28, ETHINYL ESTRADIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL

* WATSON LABS INC
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS (UTAH)

* WATSON LABORATORIES INC
INFED, IRON DEXTRAN
NOR-QD, NORETHINDRONE
OXYTROL, OXYBUTYNIN
PROGESTERONE, PROGESTERONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

WATSON LABS FLORIDA

* WATSON LABORATORIES INC FLORIDA
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GLIMEPIRIDE, GLIMEPIRIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
KETOPROFEN, KETOPROFEN
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIRTAZAPINE, MIRTAZAPINE
OMEPRazole, OMEPRazole
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE

WATSON PHARMS

* WATSON PHARMACEUTICALS
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
* WATSON PHARMACEUTICALS INC
ACTIGALL, URSODIOL
CONDYLOX, PODOFILOX
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
MONODOX, DOXYCYCLINE

WE PHARMS

* WE PHARMACEUTICALS INC
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

WEILL MEDCL COLL

* WEILL MEDICAL COLLEGE CORNELL UNIV
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE F-18

WELLSPRING PHARM

* WELLSPRING PHARMACEUTICAL CORP
DIBENZYLIN, PHENOXYBENZAMINE HYDROCHLORIDE
DUVOID, BETHANECHOL CHLORIDE
DYRENIUM, TRIAMTERENE

WEST WARD

* WEST WARD INC
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
* WEST WARD PHARMACEUTICAL CORP
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
AMINOPHYLLINE, AMINOPHYLLINE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CAPTOPRIL, CAPTOPRIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST WARD PHARMACEUTICAL CORP
 CARISOPRODOL, CARISOPRODOL
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 CHLOROTHIAZIDE, CHLOROTHIAZIDE
 CORTISONE ACETATE, CORTISONE ACETATE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 ISONIAZID, ISONIAZID
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MEFLUQUINE HYDROCHLORIDE, MEFLUQUINE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROPOXYPHENE HYDROCHLORIDE, PROPOXYPHENE HYDROCHLORIDE
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 ZALEPLON, ZALEPLON

WEST WARD PHARM CORP

* WEST WARD PHARMACEUTICAL CORP
 PREDNISONE, PREDNISONE

WEST WARD PHARMS

* WEST WARD PHARMACEUTICALS CORP
 RISPERIDONE, RISPERIDONE

WESTWARD

* WESTWARD PHARMACEUTICAL CORP
 NAPROXEN, NAPROXEN
 RIFAMPIN AND ISONIAZID, ISONIAZID

WOCKHARDT

* WOCKHARDT AMERICAS INC
 CAPTOPRIL, CAPTOPRIL
 FAMOTIDINE, FAMOTIDINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

* WOCKHARDT EU OPERATIONS (SWISS) AG
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETIC ACID, ACETIC ACID, GLACIAL
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOSPORINE, CYCLOSPORINE
 DEXAMETHASONE, DEXAMETHASONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

- * WOCKHARDT EU OPERATIONS (SWISS) AG
 - DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 - DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 - ERYTHROMYCIN, ERYTHROMYCIN
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - FUROSEMIDE, FUROSEMIDE
 - HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 - HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 - LEVETIRACETAM, LEVETIRACETAM
 - LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 - LINDANE, LINDANE
 - LITHIUM CITRATE, LITHIUM CITRATE
 - LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 - LORATADINE, LORATADINE (OTC)
 - MEGESTROL ACETATE, MEGESTROL ACETATE
 - METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 - METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 - MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 - MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 - NYSTATIN, NYSTATIN
 - OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 - PHENYTOIN, PHENYTOIN
 - PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 - PREDNISOLONE, PREDNISOLONE
 - PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 - PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 - PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 - SELENIUM SULFIDE, SELENIUM SULFIDE
 - TRETINOIN, TRETINOIN
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 - VALPROIC ACID, VALPROIC ACID
- * WOCKHARDT LTD
 - ADENOSINE, ADENOSINE
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 - AZITHROMYCIN, AZITHROMYCIN
 - BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 - BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 - CARVEDILOL, CARVEDILOL
 - CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 - CEFOTAXIME, CEFOTAXIME SODIUM
 - CEFPROZIL, CEFPROZIL
 - CEFTAZIDIME, CEFTAZIDIME
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - CEFUROXIME AXETIL, CEFUROXIME AXETIL
 - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 - CLARITHROMYCIN, CLARITHROMYCIN
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
 - EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 - FAMOTIDINE, FAMOTIDINE (OTC)
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - FUROSEMIDE, FUROSEMIDE
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - LEVETIRACETAM, LEVETIRACETAM
 - LISINAPRIL, LISINAPRIL
 - METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - NIACIN, NIACIN
 - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WOCKHARDT LTD
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

WOCKHARDT USA

* WOCKHARDT USA INC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
* WOCKHARDT USA LLC
ENALAPRIL MALEATE, ENALAPRIL MALEATE
TOPIRAMATE, TOPIRAMATE

WORLD GEN

* WORLD GEN LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CEFACLOL, CEFACLOL

WRASER PHARMS

* WRASER PHARMACEUTICALS LLC
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WYETH CONS

* WYETH CONSUMER HEALTHCARE
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ALAVERT, LORATADINE (OTC)
AXID AR, NIZATIDINE (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
PEDIATRIC ADVIL, IBUPROFEN (OTC)

WYETH PHARMS INC

* WYETH PHARMACEUTICALS INC
CORDARONE, AMIODARONE HYDROCHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
LYBREL, ETHINYL ESTRADIOL
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
RAPAMUNE, SIROLIMUS
TORISEL, TEMSIROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WYETH PHARMACEUTICALS INC
TRECATOR, ETHIONAMIDE
TYGACIL, TIGECYCLINE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM

X GEN PHARMS

* X GEN PHARMACEUTICALS INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
AMPHOTERICIN B, AMPHOTERICIN B
BACIIM, BACITRACIN
BACI-RX, BACITRACIN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDRO-RX, HYDROCORTISONE
LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
NEO-FRADIN, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEO-RX, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLY-RX, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

XANODYNE PHARM

* XANODYNE PHARMACEUTICS INC
AMICAR, AMINOCAPROIC ACID
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON, PROPOXYPHENE HYDROCHLORIDE
DARVON-N, PROPOXYPHENE NAPSYLATE
ORAMORPH SR, MORPHINE SULFATE
ZIPSOR, DICLOFENAC POTASSIUM

XANODYNE PHARMS

* XANODYNE PHARMACEUTICALS INC
ROXICODONE, OXYCODONE HYDROCHLORIDE

XTTRIUM

* XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

YUNG SHIN PHARM

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
CEFACTOR, CEFACLOX
CEPHALEXIN, CEPHALEXIN

ZAMBON SPA

* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZARS PHARM

* ZARS PHARMA INC
SYNERA, LIDOCAINE

ZOGENIX INC

* ZOGENIX INC
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENZAEPRIIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CARVEDILOL, CARVEDILOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FINASTERIDE, FINASTERIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
INDOMETHACIN, INDOMETHACIN
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

APPENDIX C**UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL	LOTION/SHAMPOO
AEROSOL, FOAM	OIL
AEROSOL, METERED	OIL/DROPS
CAPSULE	OINTMENT
CAPSULE, DELAYED REL PELLETS	OINTMENT, AUGMENTED
CAPSULE, DELAYED RELEASE	PASTE
CAPSULE, EXTENDED RELEASE	PATCH
CLOTH	PELLET
CONCENTRATE	POWDER
CREAM	POWDER, EXTENDED RELEASE
CREAM, AUGMENTED	POWDER, METERED
ELIXIR	RING
EMULSION	SHAMPOO
ENEMA	SOLUTION
FILM	SOLUTION FOR SLUSH
FILM, EXTENDED RELEASE	SOLUTION, GEL FORMING/DROPS
FOR SOLUTION	SOLUTION, METERED
FOR SOLUTION, TABLET, FOR SOLUTION	SOLUTION/DROPS
FOR SOLUTION; TABLET, DELAYED RELEASE	SPONGE
FOR SUSPENSION	SPRAY
FOR SUSPENSION, DELAYED RELEASE	SPRAY, METERED
FOR SUSPENSION, EXTENDED RELEASE	SUPPOSITORY
GAS	SUSPENSION
GEL	SUSPENSION, EXTENDED RELEASE
GEL, AUGMENTED	SUSPENSION/DROPS
GEL, METERED	SWAB
GRANULE	SYRUP
GRANULE, DELAYED RELEASE	SYSTEM, EXTENDED RELEASE
GUM, CHEWING	TABLET
IMPLANT	TABLET, CHEWABLE
INHALANT	TABLET, COATED PARTICLES
INJECTABLE	TABLET, DELAYED RELEASE
INJECTABLE, LIPID COMPLEX	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING
INJECTABLE, LIPOSOMAL	TABLET, EFFERVESCENT
INSERT	TABLET, EXTENDED RELEASE
INSERT, EXTENDED RELEASE	TABLET, FOR SUSPENSION
INTRAUTERINE DEVICE	TABLET, ORALLY DISINTEGRATING
JELLY	TAPE
LIQUID	TROCHE/LOZENGE
LOTION	
LOTION, AUGMENTED	

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ROUTES OF ADMINISTRATION***

BUCCAL	INTRAVITREAL
DENTAL	IRRIGATION
ENDOCERVICAL	IV (INFUSION)
EPIDURAL	IV (INFUSION)-SC
FOR RX COMPOUNDING	IV-SC
IM-IV	N/A
IM-IV-SC	NASAL
IMPLANTATION	OPHTHALMIC
IM-SC	ORAL
INHALATION	ORAL-21
INJECTION	ORAL-28
INTRA-ARTICULAR, INTRAMUSCULAR,	OTIC
INTRAVITREAL	PERFUSION, CARDIAC
INTRACRANIAL	PERIODONTAL
INTRAMUSCULAR	RECTAL
INTRAOCULAR	SPINAL
INTRAPERITONEAL	SUBCUTANEOUS
INTRAPLEURAL	SUBLINGUAL
INTRATHECAL	TOPICAL
INTRATRACHEAL	TRANSDERMAL
INTRAUTERINE	TRANSMUCOSAL
INTRAVENOUS	URETHRAL
INTRAVESICAL	VAGINAL

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ABBREVIATIONS***

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
INH	INHALATION
IU	INTERNATIONAL UNITS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act and those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name followed the trade name. Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second 505(b)(1) application except in the case of Orphan Drug exclusivity. Applications qualifying for periods of exclusivity are:

- (1) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application under Section 505 (b) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.
- (2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new application or 505(b)(2) application for the drug product with indications or use, this does not preclude the approval of an ANDA or 505(b)(2) application not covered by the exclusivity.
- (3) A supplement to a new drug application for a drug containing a previously approved active ingredient including (any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. The approval of a subsequent ANDA or 505(b)(2) application for a change approved in the supplement may not be

made effective for three years from the date of approval of the original supplement.

The Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using FDA Form 3524a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the agency within 30 days of approval on FDA Form 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement". Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published. FDA form 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents which include formulation/composition patents; use patents for a particular approved indication or method of using the product; and certain other patents as detailed on FDA Form 3542. This information, as provided by the sponsor on FDA form 3542, will be published as described above.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under section 4(b)(1) of the Q1 Act. A guidance for industry on this subject is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048345.pdf>

Upon approval, patent numbers and expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published on a daily basis in the Electronic Orange Book, <http://www.fda.gov/cder/ob/default.htm>. The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Electronic Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N020977 001	5034394	Dec 18, 2011	DS DP			
	5034394*PED	Jun 18, 2012				
	6294540	May 14, 2018	DS DP		U-65	
	6294540*PED	Nov 14, 2018			U-65	
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N020978 001	5034394	Dec 18, 2011	DS DP			
	5034394*PED	Jun 18, 2012				
	6294540	May 14, 2018	DS DP		U-65	
	6294540*PED	Nov 14, 2018			U-65	
	6641843	Feb 04, 2019	DP			
	6641843*PED	Aug 04, 2019				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N021652 001	5034394	Dec 18, 2011	DS DP			
	5034394*PED	Jun 18, 2012				
	5905082	May 18, 2016	DS DP			
	5905082*PED	Nov 18, 2016				
	6294540	May 14, 2018	DS DP		U-257	
	6294540*PED	Nov 14, 2018				
	6417191	Mar 28, 2016	DP		U-257	
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>						
N021205 001	5034394	Dec 18, 2011	DS DP			
	5034394*PED	Jun 18, 2012				
	5905082	May 18, 2016	DS DP		U-248	
	5905082*PED	Nov 18, 2016				
	6294540	May 14, 2018	DS DP		U-65	
	6294540*PED	Nov 14, 2018			U-65	
	6417191	Mar 28, 2016	DP		U-248	
<u>ABARELIX - PLENAXIS</u>						
N021320 001	5843901	Dec 01, 2015	DS DP			
	5968895	Dec 11, 2016				
	6180608	Dec 11, 2016			DP	U-549
	6423686	Jun 07, 2015	DS			
	6455499	Jun 07, 2015				U-549
	6699833	Dec 11, 2016			DP	
<u>ACETAMINOPHEN - OFIRMEV</u>						
N022450 001	6028222	Aug 05, 2017	DP		NP	Nov 02, 2013
	6992218	Jun 06, 2021	DP			
<u>ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)</u>						
N020802 001	5972916	Jul 14, 2017				U-296
<u>ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE - ULTRACET</u>						
N021123 001	RE39221	Aug 09, 2011	DS DP			U-55
<u>ACETYLCHOLINE CHLORIDE - MIOCHOL-E</u>						
N020213 001	6261546	Apr 29, 2019				U-506
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001					ODE	Jan 23, 2011
<u>ACYCLOVIR; HYDROCORTISONE - ACYCLOVIR AND HYDROCORTISONE</u>						
N022436 001	6514980	Jan 24, 2017	DP		NC	Jul 31, 2012
	7223387	Feb 28, 2021	DP			
	RE39264	Feb 02, 2016	DP			U-1006
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	7579377	Feb 23, 2025				U-818
	7737181	Aug 29, 2024	DP			
	7834060	Mar 12, 2023				U-1078
	7838558	Mar 12, 2023	DP			
<u>ADAPALENE - DIFFERIN</u>						
N022502 001					NDF	Mar 17, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	7820186	Nov 23, 2025	DP		NC	Dec 08, 2011
<u>ADEFOVIR DIPIVOXIL - HEPSERA</u>						
N021449 001	5663159	Sep 02, 2014	DS DP		NPP	Dec 19, 2010
	6451340	Jul 23, 2018	DS DP U-470			
<u>ADENOSINE - ADENOSCAN</u>						
N020059 001	5731296	Mar 24, 2015	U-221			
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N020760 001	5763454	Jun 15, 2015	U-282			
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N020760 002	5763454	Jun 15, 2015	U-282			
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001	5529766	Jun 25, 2013	U-505			
	5558094	Feb 28, 2012	U-505			
	5573751	Apr 25, 2012				
	6723303	Apr 20, 2021	DP			
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N020949 001	6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N020949 002	6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	5605674	Feb 25, 2014	DP		NPP	Sep 16, 2011
	5695743	Jul 06, 2010	DP U-491			
	7105152	Sep 12, 2023	DP			
	7566445	Jun 04, 2017	DP			
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N020503 001	5225183	Jul 06, 2010				
	5439670	Jul 06, 2010				
	5605674	Feb 25, 2014				
	5695743	Jul 06, 2010	U-491			
	5766573	Jun 16, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	6131566	Apr 14, 2015	DP U-589			
	6131566	Apr 14, 2015	DP U-716			
	6131566*PED	Oct 14, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6532955	Apr 14, 2015	DP			
	6532955*PED	Oct 14, 2015				
	6558651	Dec 19, 2016	DP U-716			
	6558651*PED	Jun 19, 2017				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-716			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 06, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT</u>						
N020291 001	5603918	Jun 09, 2015				
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB</u>						
N020950 001	6632842	Dec 28, 2021	U-532			
<u>ALCAFTADINE - LASTACFT</u>						
N022134 001	5468743	Nov 21, 2012	DS DP		NCE	Jul 28, 2015
<u>ALCOHOL; CHLORHEXIDINE GLUCONATE - AVAGARD</u>						
N021074 001	5897031	Jun 21, 2016				
	6090395	Jun 22, 2015	DP			
	6534069	Jun 22, 2015	DP			
	6623744	Jun 23, 2015	U-1008			
	7081246	Aug 03, 2016	DP			
	7566460	Jun 22, 2015	DP U-1008			
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 001	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
	6194004	Dec 02, 2012				
	6194004*PED	Jun 02, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 002	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 003	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 004	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 005	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N021575 001	5462932	May 17, 2014				
	5462932*PED	Nov 17, 2014				
	5994329	Jul 17, 2018			Y	
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018			Y	
	6015801*PED	Jan 17, 2019				
	6225294	Jul 17, 2018			Y	
	6225294*PED	Jan 17, 2019				
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N021762 001	5358941	Dec 02, 2012	DP			
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012	DP			
	5681590*PED	Jun 02, 2013				
	5994329	Jul 17, 2018		U-647		
	5994329*PED	Jan 17, 2019				
	6090410	Dec 02, 2012	DP			
	6090410*PED	Jun 02, 2013	DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N021762 002	5358941	Dec 02, 2012	DP			
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012	DP			
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012	DP			
	6090410*PED	Jun 02, 2013	DP			
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>						
N021287 001	4661491	Jan 18, 2011	U-706		M-97	Dec 15, 2013
	4661491*PED	Jul 18, 2011			PED	Jun 15, 2014
	6149940	Aug 22, 2017				
	6149940*PED	Feb 22, 2018				
<u>ALISKIREN HEMIFUMARATE - TEKTRONA</u>						
N021985 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE - TEKTRNA</u>						
N021985 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 001					NC NCE	Aug 26, 2013 Mar 15, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 002					NC NCE	Aug 26, 2013 Mar 15, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 003					NC NCE	Aug 26, 2013 Mar 15, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 004					NC NCE	Aug 26, 2013 Mar 15, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 001					NCE NC	Nov 05, 2012 Dec 21, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 002					NCE NC	Nov 05, 2012 Dec 21, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 003					NCE NC	Nov 05, 2012 Dec 21, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 004					NCE NC	Nov 05, 2012 Dec 21, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 005					NCE NC	Nov 05, 2012 Dec 21, 2013
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRNA HCT</u>						
N022107 001	5559111	Jul 21, 2018	DS DP U-3		I-600 NCE NC	Jul 16, 2012 Mar 05, 2012 Jan 18, 2011
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRNA HCT</u>						
N022107 002	5559111	Jul 21, 2018	DS DP U-3		I-600 NCE NC	Jul 16, 2012 Mar 05, 2012 Jan 18, 2011
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRNA HCT</u>						
N022107 003	5559111	Jul 21, 2018	DS DP U-3		I-600 NCE NC	Jul 16, 2012 Mar 05, 2012 Jan 18, 2011
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRNA HCT</u>						
N022107 004	5559111	Jul 21, 2018	DS DP U-3		I-600 NCE NC	Jul 16, 2012 Mar 05, 2012 Jan 18, 2011
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTRNA</u>						
N022217 001	5399578 5559111	Mar 21, 2012 Jul 21, 2018	DS DP U-3 DS DP U-3		NCE NC	Mar 05, 2012 Sep 16, 2012
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTRNA</u>						
N022217 002	5399578 5559111	Mar 21, 2012 Jul 21, 2018	DS DP U-3 DS DP U-3		NCE NC	Mar 05, 2012 Sep 16, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALITRETINOIN - PANRETIN</u>						
N020886 001	5932622	Aug 03, 2016	U-562			
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N021001 001	5565447	May 07, 2015	DS DP U-969			
	5565447*PED	Nov 07, 2015				
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N021001 002	5565447	May 07, 2015	DS DP U-969			
	5565447*PED	Nov 07, 2015				
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N021107 001	5360800	Jan 13, 2013	DS DP U-405		D-113	Apr 01, 2011
	6284770	Oct 05, 2018	U-405			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N021107 002	5360800	Jan 13, 2013	DS DP U-405		D-113	Apr 01, 2011
	6284770	Oct 05, 2018	U-405			
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 003	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 004	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 001	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 002	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 003	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 004	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N021212 001	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N021212 002	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>ALPROSTADIL - MUSE</u>						
N020700 001	5242391	Sep 07, 2010	U-155			
	5474535	Dec 12, 2012	U-155			
	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N020700 002	5242391	Sep 07, 2010	U-155			
	5474535	Dec 12, 2012	U-155			
	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N020700 003	5242391	Sep 07, 2010	U-155			
	5474535	Dec 12, 2012	U-155			
	5886039	Mar 23, 2016	DP U-155			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPROSTADIL - MUSE</u>						
N020700 004	5242391	Sep 07, 2010	U-155			
	5474535	Dec 12, 2012	U-155			
	5886039	Mar 23, 2016	DP U-155			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	5250542	Mar 29, 2011	DS DP U-878		NCE	May 20, 2013
	5434171	Dec 08, 2013	DS DP U-878			
	6469030	Nov 29, 2020	U-879			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	5703017	Dec 30, 2014	DS		NCE	Jun 15, 2012
	5840722	Nov 24, 2015	U-821		ODE	Jun 15, 2014
	5932730	Oct 07, 2015	DS			
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015	U-1080			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	5703017	Dec 30, 2014	DS		NCE	Jun 15, 2012
	5840722	Nov 24, 2015	U-821		ODE	Jun 15, 2014
	5932730	Oct 07, 2015	DS			
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015	U-1080			
<u>AMIFOSTINE - ETHYOL</u>						
N020221 001	5424471	Jul 31, 2012				
	5591731	Jul 31, 2012				
	5994409	Dec 08, 2017	U-305			
<u>AMIFOSTINE - ETHYOL</u>						
N020221 002	5424471	Jul 31, 2012				
	5591731	Jul 31, 2012				
	5994409	Dec 08, 2017	U-305			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	5079262	Sep 30, 2013	U-289		M-82	Mar 12, 2013
	5954703	Oct 31, 2017	U-289			
	6709446	May 01, 2018	U-289			
	7723910	Jun 17, 2019	U-289			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N022325 001	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N022325 002	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N022325 003	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMLEXANOX - APHTHASOL</u>						
N020511 001	5362737	Nov 08, 2011	U-243			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N022026 001	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N022026 002	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N022026 003	6828339	Nov 20, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 001	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 002	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 003	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 004	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 005	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 006	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 007	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 008	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 009	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 010	5273995	Dec 28, 2010	DS DP			U-162
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP			U-213
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018				U-552
	RE40667	Dec 28, 2010	DS DP			U-162
	RE40667*PED	Jun 28, 2011				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 011	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 002	6162802	Dec 19, 2017			U-367	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 003	6162802	Dec 19, 2017			U-367	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 004	6162802	Dec 19, 2017			U-367	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 005	6162802	Dec 19, 2017			U-367	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 006	6162802	Dec 19, 2017	DS DP		U-185	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 007	6162802	Dec 19, 2017	DS DP		U-185	
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 001	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 002	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 003	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 004	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 005	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 001	5616599	Apr 25, 2016	DS DP U-3		NC	Sep 26, 2010
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 002	5616599	Apr 25, 2016	DS DP U-3		NC	Sep 26, 2010
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 003	5616599	Apr 25, 2016	DS DP U-3		NC	Sep 26, 2010
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 004	5616599	Apr 25, 2016	DS DP U-3		NC	Sep 26, 2010
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 001	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 002	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 003	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 004	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 002	5399578	Mar 21, 2012	DS DP U-3		I-567	Jun 23, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 003	5399578	Mar 21, 2012	DS DP U-3		I-567	Jun 23, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 004	5399578	Mar 21, 2012	DS DP U-3		I-567	Jun 23, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 005	5399578	Mar 21, 2012	DS DP U-3		I-567	Jun 23, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMMONIA, N-13 - AMMONIA N 13</u>						
N022119	001				NCE W	Aug 23, 2012 Aug 23, 2012
<u>AMOXICILLIN - MOXATAG</u>						
N050813	001	6544555	Oct 13, 2020	DS DP	U-897	
		6669948	Oct 13, 2020	DS DP	U-897	
		6723341	Oct 13, 2020	DS DP	U-897	
<u>AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE - PREVPAC</u>						
N050757	001	5013743*PED	Aug 12, 2010			
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N050785	001	6746692	Apr 04, 2020	DP		
		6783773	Apr 04, 2020	DP		
		6878386	Apr 04, 2020		U-926	
		7217430	Apr 04, 2020	DP	U-926	
		7250176	Apr 04, 2020		U-926	
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N011522	007	6384020	Jul 06, 2020			
		6384020*PED	Jan 06, 2021			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N011522	012	6384020	Jul 06, 2020			
		6384020*PED	Jan 06, 2021			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N011522	013	6384020	Jul 06, 2020			
		6384020*PED	Jan 06, 2021			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N011522	008	6384020	Jul 06, 2020			
		6384020*PED	Jan 06, 2021			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N011522	010	6384020	Jul 06, 2020			
		6384020*PED	Jan 06, 2021			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N011522	009	6384020	Jul 06, 2020			
		6384020*PED	Jan 06, 2021			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N011522	011	6384020	Jul 06, 2020			
		6384020*PED	Jan 06, 2021			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303	001	6322819	Oct 21, 2018			
		6322819*PED	Apr 21, 2019			
		6605300	Oct 21, 2018			
		6605300*PED	Apr 21, 2019			
		RE41148	Oct 21, 2018	DP		
		RE41148*PED	Apr 21, 2019			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303	006	6322819	Oct 21, 2018			
		6322819*PED	Apr 21, 2019			
		6605300	Oct 21, 2018			
		6605300*PED	Apr 21, 2019			
		RE41148	Oct 21, 2018	DP		
		RE41148*PED	Apr 21, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHOTERICIN B - ABELCET</u>						
N050724 001	5616334	Apr 01, 2014	DS			
	6406713	Jun 18, 2019	DS			
<u>AMPHOTERICIN B - AMBISOME</u>						
N050740 001	5874104	Feb 23, 2016	DP		U-922	
	5965156	Oct 12, 2016	DP		U-922	
<u>AMPRENAVIR - AGENERASE</u>						
N021007 001	5585397	Dec 17, 2013				
	5646180	Jul 08, 2014			U-257	
	5723490	Mar 03, 2015			U-257	
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N021007 002	5585397	Dec 17, 2013				
	5646180	Jul 08, 2014			U-257	
	5723490	Mar 03, 2015			U-257	
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N021039 001	5585397	Dec 17, 2013				
	5646180	Jul 08, 2014			U-257	
	5723490	Mar 03, 2015			U-257	
<u>ANASTROZOLE - ARIMIDEX</u>						
N020541 001						
					M-61	Dec 05, 2011
					PED	Jun 05, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ANIDULAFUNGIN - ERAXIS</u>						
N021632 001	5965525	Feb 17, 2020	DS DP U-540		NCE	Feb 17, 2011
	6384013	Mar 19, 2012	DS			
	6743777	Mar 19, 2012	DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7198796	Jun 13, 2022	DP			
	7709444	Apr 12, 2021	DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N021632 002	5965525	Feb 17, 2020	DS DP U-540		NCE	Feb 17, 2011
	6384013	Mar 19, 2012	DS			
	6743777	Mar 19, 2012	DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7198796	Jun 13, 2022	DP			
	7709444	Apr 12, 2021	DP U-540			
<u>APOMORPHINE HYDROCHLORIDE - APOKYN</u>						
N021264 001					ODE	Apr 20, 2011
<u>APOMORPHINE HYDROCHLORIDE - APOKYN</u>						
N021264 002					ODE	Apr 20, 2011
<u>APREPITANT - EMEND</u>						
N021549 001	5145684	Jan 25, 2011	DP		M-82	Mar 19, 2013
	5538982	Jul 23, 2013				
	5719147	Apr 17, 2015	DS DP U-745			
	6048859	Jun 29, 2012	U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	6235735	Jun 29, 2012	U-746			
	6235735	Jun 29, 2012	U-747			
	7214692	Sep 18, 2012	U-853			
<u>APREPITANT - EMEND</u>						
N021549 002	5145684	Jan 25, 2011	DP		M-82	Mar 19, 2013
	5538982	Jul 23, 2013				
	5719147	Apr 17, 2015	DS DP U-745			
	6048859	Jun 29, 2012	U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	6235735	Jun 29, 2012	U-747			
	6235735	Jun 29, 2012	U-746			
	7214692	Sep 18, 2012	U-853			
<u>APREPITANT - EMEND</u>						
N021549 003	5145684	Jan 25, 2011	DP		M-82	Mar 19, 2013
	5538982	Jul 23, 2013				
	5719147	Apr 17, 2015	DS DP U-745			
	6048859	Jun 29, 2012	U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	6235735	Jun 29, 2012	U-746			
	6235735	Jun 29, 2012	U-747			
	7214692	Sep 18, 2012	U-853			
<u>ARBUTAMINE HYDROCHLORIDE - GENESA</u>						
N020420 001	5234404	Aug 10, 2010			U-220	
	5395970	Mar 07, 2012				
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	5795564	Apr 03, 2012			U-793	
	6040344	Nov 12, 2016	DS			
	6068833	Apr 03, 2012			U-793	
	6472563	Nov 09, 2021	DS			
	6589508	Apr 03, 2012			U-793	
	6720453	Nov 09, 2021	DS			
	6866839	Apr 03, 2012			U-793	
	7145036	Nov 09, 2021	DS			
<u>ARGATROBAN - ARGATROBAN</u>						
N020883 001	5214052	Jun 30, 2014			M-75	May 05, 2011

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE		
ARIPIPRAZOLE - ABILIFY											
N021436 001	5006528 5006528*PED	Oct	20,	2014	DS	DP	U-761	D-115	May	06,	2011
		Apr	20,	2015				D-110	Oct	29,	2010
								I-616	Nov	19,	2012
								I-559	May	06,	2011
								I-555	Feb	27,	2011
								I-545	Nov	16,	2010
								PED	Aug	27,	2011
								PED	Apr	29,	2011
ARIPIPRAZOLE - ABILIFY											
N021436 002	5006528 5006528*PED	Oct	20,	2014	DS	DP	U-761	D-115	May	06,	2011
		Apr	20,	2015				D-110	Oct	29,	2010
								I-616	Nov	19,	2012
								I-559	May	06,	2011
								I-555	Feb	27,	2011
								I-545	Nov	16,	2010
								PED	Aug	27,	2011
								PED	Apr	29,	2011
ARIPIPRAZOLE - ABILIFY											
N021436 003	5006528 5006528*PED	Oct	20,	2014	DS	DP	U-761	D-115	May	06,	2011
		Apr	20,	2015				D-110	Oct	29,	2010
								I-616	Nov	19,	2012
								I-559	May	06,	2011
								I-555	Feb	27,	2011
								I-545	Nov	16,	2010
								PED	Aug	27,	2011
								PED	Apr	29,	2011
ARIPIPRAZOLE - ABILIFY											
N021436 004	5006528 5006528*PED	Oct	20,	2014	DS	DP	U-761	D-115	May	06,	2011
		Apr	20,	2015				D-110	Oct	29,	2010
								I-616	Nov	19,	2012
								I-559	May	06,	2011
								I-555	Feb	27,	2011
								I-545	Nov	16,	2010
								PED	Aug	27,	2011
								PED	Apr	29,	2011
ARIPIPRAZOLE - ABILIFY											
N021436 005	5006528 5006528*PED	Oct	20,	2014	DS	DP	U-761	D-115	May	06,	2011
		Apr	20,	2015				D-110	Oct	29,	2010
								I-616	Nov	19,	2012
								I-559	May	06,	2011
								I-555	Feb	27,	2011
								I-545	Nov	16,	2010
								PED	Aug	27,	2011
								PED	Apr	29,	2011
ARIPIPRAZOLE - ABILIFY											
N021436 006	5006528 5006528*PED	Oct	20,	2014	DS	DP	U-761	D-115	May	06,	2011
		Apr	20,	2015				D-110	Oct	29,	2010
								I-616	Nov	19,	2012
								I-559	May	06,	2011
								I-555	Feb	27,	2011
								I-545	Nov	16,	2010
								PED	Aug	27,	2011
								PED	Apr	29,	2011

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N021713 001	5006528	Oct 20, 2014	DS DP	U-761	D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
	6977257	Apr 24, 2022	DS DP		I-559	May 06, 2011
	6977257*PED	Oct 24, 2022			I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 002	5006528	Oct 20, 2014	DS DP	U-761	D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
					I-559	May 06, 2011
					I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 003	5006528	Oct 20, 2014	DS DP	U-761	D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
					I-559	May 06, 2011
					I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 004	5006528	Oct 20, 2014	DS DP	U-761	D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
					I-559	May 06, 2011
					I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 005	5006528	Oct 20, 2014	DS DP	U-761	D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
					I-559	May 06, 2011
					I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIRAZOLE - ABILIFY</u>						
N021866 001	5006528	Oct 20, 2014	DS DP	U-763	D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
	7115587	Jul 21, 2024	DS DP	U-764	I-559	May 06, 2011
	7115587*PED	Jan 21, 2025			I-555	Feb 27, 2011
	7550445	Jul 21, 2024	DP		I-545	Nov 16, 2010
	7550445*PED	Jan 21, 2025			PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 001	4927855*PED	Oct 22, 2010	DS DP			
	7132570	Dec 18, 2023				
	7132570*PED	Jun 18, 2024	DP			
	7297346	Nov 29, 2023				
	7297346*PED	May 29, 2024	DP	U-820		
	RE37516	Oct 06, 2014				
	RE37516*PED	Apr 06, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE			PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>ARMODAFINIL - NUVIGIL</u>										
N021875 002	4927855*PED	Oct	22,	2010	DS	DP				
	7132570	Dec	18,	2023						
	7132570*PED	Jun	18,	2024	DP					
	7297346	Nov	29,	2023						
	7297346*PED	May	29,	2024						
	RE37516	Oct	06,	2014	DP	U-820				
RE37516*PED	Apr	06,	2015							
<u>ARMODAFINIL - NUVIGIL</u>										
N021875 003	4927855*PED	Oct	22,	2010	DS	DP				
	7132570	Dec	18,	2023						
	7132570*PED	Jun	18,	2024	DP					
	7297346	Nov	29,	2023						
	7297346*PED	May	29,	2024						
	RE37516	Oct	06,	2014	DP	U-820				
RE37516*PED	Apr	06,	2015							
<u>ARMODAFINIL - NUVIGIL</u>										
N021875 004	4927855*PED	Oct	22,	2010	DS	DP				
	7132570	Dec	18,	2023						
	7132570*PED	Jun	18,	2024	DP					
	7297346	Nov	29,	2023						
	7297346*PED	May	29,	2024						
	RE37516	Oct	06,	2014	DP	U-820				
RE37516*PED	Apr	06,	2015							
<u>ARMODAFINIL - NUVIGIL</u>										
N021875 005	4927855*PED	Oct	22,	2010	DS	DP				
	7132570	Dec	18,	2023						
	7132570*PED	Jun	18,	2024	DP					
	7297346	Nov	29,	2023						
	7297346*PED	May	29,	2024						
	RE37516	Oct	06,	2014	DP	U-820				
RE37516*PED	Apr	06,	2015							
<u>ARSENIC TRIOXIDE - TRISENOX</u>										
N021248 001	6723351	Nov	10,	2018						U-573
	6855339	Nov	10,	2018						U-617
	6861076	Nov	10,	2018						U-617
	6884439	Nov	10,	2018						U-651
	6982096	Nov	10,	2018						U-651
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>										
N022268 001	5677331	Oct	14,	2014	DP	U-977		NCE ODE	Apr 07, 2014 Apr 07, 2016	
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E - M.V.I.-12 (WITHOUT VITAMIN K)										
N008809 006								ODE	Sep 09, 2011	
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP										
N021881 001	7169381	Sep	01,	2024	DS	DP				
	7658914	Sep	01,	2024	DS	DP				
<u>ASENAPINE MALEATE - SAPHRIS</u>										
N022117 001	5763476	Jun	09,	2015		DP	U-326	I-629	Sep 03, 2013	
	7741358	Apr	06,	2026	DS	DP	U-1064	I-628 NCE	Sep 03, 2013 Aug 13, 2014	
<u>ASENAPINE MALEATE - SAPHRIS</u>										
N022117 002	5763476	Jun	09,	2015		DP	U-326	I-629	Sep 03, 2013	
	7741358	Apr	06,	2026	DS	DP	U-1064	I-628 NCE	Sep 03, 2013 Aug 13, 2014	
<u>ASPIRIN; DIPYRIDAMOLE - AGGRENOX</u>										
N020884 001	6015577	Jan	18,	2017			U-302			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 001	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 002	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 003	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 004	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 005	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 006	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001	5849911	Jun 20, 2017	DS DP U-167		D-116	Sep 30, 2011
	6087383	Dec 21, 2018	DS DP		NPP	Mar 25, 2011
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002	5849911	Jun 20, 2017	DS DP U-167		D-116	Sep 30, 2011
	6087383	Dec 21, 2018	DS DP		NPP	Mar 25, 2011
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003	5849911	Jun 20, 2017	DS DP U-167		D-116	Sep 30, 2011
	6087383	Dec 21, 2018	DS DP		NPP	Mar 25, 2011
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004	5849911	Jun 20, 2017	DS DP U-167		D-116	Sep 30, 2011
	6087383	Dec 21, 2018	DS DP		NPP	Mar 25, 2011
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 001	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 002	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 003	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 004	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 005	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 006	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 007	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 008	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 001	5273995	Dec 28, 2010	DS DP	U-162		
	5273995*PED	Jun 28, 2011		U-162		
	5686104	Nov 11, 2014		DP	U-213	
	5686104*PED	May 11, 2015			U-213	
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013		DP		
	6126971*PED	Jul 19, 2013				
	RE40667	Dec 28, 2010	DS DP	U-162		
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 002	5273995	Dec 28, 2010	DS DP	U-162		
	5273995*PED	Jun 28, 2011		U-162		
	5686104	Nov 11, 2014		DP	U-213	
	5686104*PED	May 11, 2015			U-213	
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013		DP		
	6126971*PED	Jul 19, 2013				
	RE40667	Dec 28, 2010	DS DP	U-162		
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 003	5273995	Dec 28, 2010	DS DP	U-162		
	5273995*PED	Jun 28, 2011		U-162		
	5686104	Nov 11, 2014		DP	U-213	
	5686104*PED	May 11, 2015			U-213	
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013		DP		
	6126971*PED	Jul 19, 2013				
	RE40667	Dec 28, 2010	DS DP	U-162		
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 004	5273995	Dec 28, 2010	DS DP	U-162		
	5273995*PED	Jun 28, 2011		U-162		
	5686104	Nov 11, 2014		DP	U-213	
	5686104*PED	May 11, 2015			U-213	
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013		DP		
	6126971*PED	Jul 19, 2013				
	RE40667	Dec 28, 2010	DS DP	U-162		
	RE40667*PED	Jun 28, 2011				
<u>ATOVAQUONE - MEPRON</u>						
N020500 001	6649659	Jul 10, 2016	DS DP	U-69		
	6649659*PED	Jan 10, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE</u>						
N021078 001	5998449	Nov 25, 2013	U-990			
	5998449*PED	May 25, 2014				
	6166046	Nov 25, 2013	U-406			
	6166046*PED	May 25, 2014				
	6291488	Nov 25, 2013	U-406			
	6291488*PED	May 25, 2014				
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE PEDIATRIC</u>						
N021078 002	5998449	Nov 25, 2013	U-990			
	5998449*PED	May 25, 2014				
	6166046	Nov 25, 2013				
	6166046*PED	May 25, 2014				
	6291488	Nov 25, 2013	U-406			
	6291488*PED	May 25, 2014				
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE - ANTHELIOS SX</u>						
N021502 001	5587150	Dec 24, 2013	DP U-752			
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE - ANTHELIOS 40</u>						
N022009 001					NP	Mar 31, 2011
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE - ANTHELIOS 40</u>						
N022009 002					NP	Oct 29, 2012
<u>AZACITIDINE - VIDAZA</u>						
N050794 001					ODE	May 19, 2011
<u>AZELAIC ACID - FINACEA</u>						
N021470 001	6534070	Nov 18, 2018				
<u>AZELASTINE HYDROCHLORIDE - ASTELIN</u>						
N020114 001	5164194	Nov 01, 2010	U-207			
	5164194	Nov 01, 2010	U-730			
	5164194*PED	May 01, 2011				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N022203 001					NP	Oct 15, 2011
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N022371 001					NP	Aug 31, 2012
<u>AZELASTINE HYDROCHLORIDE - AZELASTINE HYDROCHLORIDE</u>						
A077954 001					PC	Dec 28, 2010
<u>AZELASTINE HYDROCHLORIDE - OPTIVAR</u>						
N021127 001	5164194	Nov 01, 2010				
	5164194*PED	May 01, 2011				
<u>AZITHROMYCIN - AZASITE</u>						
N050810 001	6159458	Nov 04, 2017	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050693 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050710 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050710 002	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050711 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050730 001	6268489	Jul 31, 2018	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050733 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050784 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZMAX</u>						
N050797 001	6068859	May 30, 2017	DP			
	6268489	Jul 31, 2018	DS			
	6984403	Feb 14, 2024	DP	U-282		
<u>AZTREONAM - CAYSTON</u>						
N050814 001	7208141	Dec 20, 2021	DP	U-1031		
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP	U-1031		
<u>BACLOFEN - KEMSTRO</u>						
N021589 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BACLOFEN - KEMSTRO</u>						
N021589 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N020610 001	7452872	Aug 24, 2026		U-141	ODE	Dec 20, 2013
	7452872*PED	Feb 24, 2027			PED	Jun 20, 2014
	7625884	Aug 24, 2026		U-141		
	7625884*PED	Feb 24, 2027				
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N020911 002	5605674	Feb 25, 2014				
	5683677	Nov 04, 2014				
	5695743	Jul 06, 2010				
	5776432	Jul 07, 2015				
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N020911 001	5605674	Feb 25, 2014				
	5683677	Nov 04, 2014				
	5695743	Jul 06, 2010				
	5776432	Jul 07, 2015				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					I-580	Oct 31, 2011
					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					I-580	Oct 31, 2011
					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N050819 001	5733886	Mar 31, 2015	DP	U-124		
	6117843	Feb 18, 2012	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC</u>						
N050741 001	5466446	Feb 16, 2014	DS	DP		
<u>BENZYL ALCOHOL - ULESFIA</u>						
N022129 001	5858383	Aug 11, 2017		U-970	NCE	Apr 09, 2014
	6139859	Aug 11, 2017		U-970		
	6793931	Jul 11, 2022	DP	U-970		
	7294342	May 19, 2024		U-970		
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N022288 001	6780877	Dec 25, 2017	DS	DP	NCE	Sep 08, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N022308 001	5447926	Sep 05, 2012	DS DP U-80		NCE	May 28, 2014
	6685958	Jun 29, 2021	DP U-80			
	6699492	Mar 31, 2019	DP U-80			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N021852 001	5763426	Jun 09, 2015	DS DP			
	6753013	Jan 27, 2020	DP U-193			
	6753013	Jan 27, 2020	DP U-88			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX SCALP</u>						
N022185 001	6753013	Jan 27, 2020	DP U-193		NDF	May 09, 2011
	6753013	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-88			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
N020934 001	6126920	Mar 01, 2016	U-484			
	7078058	May 24, 2017	DP			
<u>BETAXOLOL HYDROCHLORIDE - BETOPTIC S</u>						
N019845 001					PED	Dec 08, 2010
<u>BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE - BETOPTIC PILO</u>						
N020619 001	5635172	Jun 03, 2014	U-191			
<u>BEXAROTENE - TARGRETIN</u>						
N021055 001	5780676	Jul 14, 2015	U-509			
	5962731	Oct 05, 2016	U-475			
	6043279	Apr 22, 2012	U-509			
	6320074	Apr 22, 2012	DS U-509			
	7655699	Apr 22, 2012	DS DP U-509			
<u>BEXAROTENE - TARGRETIN</u>						
N021056 001	5780676	Jul 14, 2015	U-510			
	5962731	Oct 05, 2016	U-510			
	6043279	Apr 22, 2012	U-510			
	6320074	Apr 22, 2012	DS U-510			
	7655699	Apr 22, 2012	DS DP U-510			
<u>BICALUTAMIDE - CASODEX</u>						
N020498 001					M-81 PED	Dec 19, 2011 Jun 19, 2012
<u>BIMATOPROST - LATISSE</u>						
N022369 001	6403649	Sep 21, 2012	DS		NP	Dec 24, 2011
	7351404	May 25, 2024	U-939			
	7388029	Jan 21, 2022	U-938			
<u>BIMATOPROST - LUMIGAN</u>						
N021275 001	5688819	Aug 19, 2014	U-446			
	6403649	Sep 21, 2012	DS DP U-446			
<u>BIMATOPROST - LUMIGAN</u>						
N022184 001	5688819	Aug 19, 2014	U-1081		NP	Aug 31, 2013
	6403649	Sep 21, 2012	DS U-1081			
	7851504	Jun 13, 2027	DS DP			
<u>BISACODYL - HALFLYTELY</u>						
N021551 003	7291324	Oct 22, 2022	U-837		NP	Jul 16, 2013
<u>BISACODYL; POLYETHYLENE GLYCOL 3 - HALFLYTELY</u>						
N021551 002	7291324	Oct 22, 2022	U-837		NP	Sep 24, 2010
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
N050786 001	6350468	Dec 14, 2018	U-956			
	6350468	Dec 14, 2018	U-932			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Aug 13, 2011	DS DP U-1040			
	5196404*PED	Feb 13, 2012				
	7582727	Jul 27, 2028	DP			
	7582727*PED	Jan 27, 2029				
	7598343	Jul 27, 2028	DP			
	7598343*PED	Jan 27, 2029				
<u>BORTEZOMIB - VELCADE</u>						
N021602 001	5780454	May 03, 2017	DP		I-564	Jun 20, 2011
	6083903	Oct 28, 2014	DP		ODE	Mar 25, 2012
	6297217	Oct 28, 2014				
	6297217	Oct 28, 2014			U-885	
	6297217	Oct 28, 2014			U-884	
	6297217	Oct 28, 2014			U-515	
	6617317	Oct 28, 2014	DS DP			
	6713446	Jan 25, 2022	DP			
	6747150	Oct 28, 2014	DP			
	6958319	Jan 25, 2022	DP			
	7119080	Oct 28, 2014	DP			
<u>BOSENTAN - TRACLEER</u>						
N021290 001	5292740	Nov 20, 2015			I-607	Aug 07, 2012
<u>BOSENTAN - TRACLEER</u>						
N021290 002	5292740	Nov 20, 2015			I-607	Aug 07, 2012
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021262 001	5424078	Jun 13, 2012				
	5424078*PED	Dec 13, 2012				
	6562873	Jul 10, 2021				
	6562873*PED	Jan 10, 2022				
	6627210	Jul 18, 2021	DP			
	6627210*PED	Jan 18, 2022				
	6641834	Jul 28, 2021	DP			
	6641834*PED	Jan 28, 2022				
	6673337	Jul 26, 2021	DP			
	6673337*PED	Jan 26, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021770 001	5424078	Jun 13, 2012	DP			
	5424078*PED	Dec 13, 2012				
	6562873	Jul 10, 2021	DP			
	6562873*PED	Jan 10, 2022				
	6627210	Jul 18, 2021	DP			
	6627210*PED	Jan 18, 2022				
	6641834	Jul 28, 2021	DP			
	6641834*PED	Jan 28, 2022				
	6673337	Jul 26, 2021	DP			
	6673337*PED	Jan 26, 2022				
<u>BRIMONIDINE TARTRATE - BRIMONIDINE TARTRATE</u>						
N021764 001	7265117	Aug 19, 2025	DP			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	7030149	Apr 19, 2022			NC	Oct 30, 2010
	7320976	Apr 19, 2022			U-849	
	7323463	Jan 19, 2023	DP			
	7642258	Apr 19, 2022	DS DP U-1024			
<u>BRINZOLAMIDE - AZOPT</u>						
N020816 001	5240923	Aug 31, 2010	DS DP U-224			
	5240923*PED	Mar 01, 2011				
	5378703	Apr 01, 2012	DS DP U-224			
	5378703*PED	Oct 01, 2012				
	5461081	Oct 24, 2012	DP U-225			
	5461081*PED	Apr 24, 2013				
<u>BROMFENAC SODIUM - BROMDAY</u>						
N021664 002					NP	Oct 16, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N020866 001	5468755	Nov 21, 2012	DP	U-976	NP	May 05, 2012
	5679685	Oct 21, 2014				
	5716957	Feb 10, 2015				
	5756513	Nov 21, 2012				
	5866584	Nov 21, 2012				
<u>BUDESONIDE - ENTOCORT EC</u>						
N021324 001	5643602	Jul 01, 2014	DP	U-655		
	5643602*PED	Jan 01, 2015				
	6423340	Nov 15, 2010				
	6423340*PED	May 15, 2011				
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N021949 001	6027714	Jan 09, 2018	DP	U-787		
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N021949 002	6027714	Jan 09, 2018	DP	U-787		
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N020929 001	6598603	Dec 23, 2018	DP	U-529		
	6598603*PED	Jun 23, 2019				
	6899099	Dec 23, 2018		U-529		
	6899099*PED	Jun 23, 2019				
	7524834	Nov 11, 2018		U-966		
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N020929 002	6598603	Dec 23, 2018	DP	U-529		
	6598603*PED	Jun 23, 2019				
	6899099	Dec 23, 2018		U-529		
	6899099*PED	Jun 23, 2019				
	7524834	Nov 11, 2018		U-966		
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N020929 003	6598603	Dec 23, 2018	DP	U-529		
	6598603*PED	Jun 23, 2019				
	6899099	Dec 23, 2018		U-529		
	6899099*PED	Jun 23, 2019				
	7524834	Nov 11, 2018		U-966		
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - RHINOCORT</u>						
N020746 001	6291445	Apr 29, 2017	DP		Y	
	6291445*PED	Oct 29, 2017				
	6686346	Apr 29, 2017		U-557	Y	
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017		U-699	Y	
	6986904*PED	Oct 29, 2017				
<u>BUDESONIDE - RHINOCORT</u>						
N020746 002	6291445	Apr 29, 2017	DP	U-557		
	6291445*PED	Oct 29, 2017				
	6686346	Apr 29, 2017				
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017				
	6986904*PED	Oct 29, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	5349945	Nov 12, 2011	DP		I-582	Feb 27, 2012
	5674860	Oct 07, 2014	DP	U-1075		
	5972919	Dec 17, 2012	DP	U-1075		
	6123924	Sep 26, 2017	DP			
	6641800	Sep 23, 2012	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP	U-1073		
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	5349945	Nov 12, 2011	DP		I-582	Feb 27, 2012
	5674860	Oct 07, 2014	DP	U-1075		
	5972919	Dec 17, 2012	DP	U-1075		
	6123924	Sep 26, 2017	DP			
	6641800	Sep 23, 2012	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP	U-1073		
<u>BUPRENORPHINE - BUTRANS</u>						
N021306 001	5240711	Nov 28, 2010	DP		NDF	Jun 30, 2013
	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015		U-1072		
	RE41408	Sep 29, 2017		U-1072		
	RE41489	Sep 29, 2017		U-1072		
	RE41571	Sep 29, 2017		U-1072		
<u>BUPRENORPHINE - BUTRANS</u>						
N021306 002	5240711	Nov 28, 2010	DP		NDF	Jun 30, 2013
	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015		U-1072		
	RE41408	Sep 29, 2017		U-1072		
	RE41489	Sep 29, 2017		U-1072		
	RE41571	Sep 29, 2017		U-1072		
<u>BUPRENORPHINE - BUTRANS</u>						
N021306 003	5240711	Nov 28, 2010	DP		NDF	Jun 30, 2013
	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015		U-1072		
	RE41408	Sep 29, 2017		U-1072		
	RE41489	Sep 29, 2017		U-1072		
	RE41571	Sep 29, 2017		U-1072		
<u>BUPRENORPHINE; NALOXONE - SUBOXONE</u>						
N022410 001					NDF	Aug 30, 2013
<u>BUPRENORPHINE; NALOXONE - SUBOXONE</u>						
N022410 002					NDF	Aug 30, 2013
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026		U-997		
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026		U-997		
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 003	7241805	Jun 27, 2026	DP	U-997		
	7569610	Jun 27, 2026				
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 001	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 002	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 003	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 004	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N021515 001	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N021515 002	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - ZYBAN</u>						
N020711 002	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - ZYBAN</u>						
N020711 003	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUSULFAN - BUSULFEX</u>						
N020954 001	5430057	Sep 30, 2013		U-263		
	5430057*PED	Mar 30, 2014		U-263		
	5559148	Sep 30, 2013		U-264		
	5559148*PED	Mar 30, 2014		U-264		
<u>BUTENAFINE HYDROCHLORIDE - MENTAX</u>						
N020524 001	5021458	Oct 18, 2010		U-177		
<u>BUTOCONAZOLE NITRATE - GYNAZOLE-1</u>						
N019881 001	5266329	Nov 30, 2010		U-457		
	5993856	Nov 17, 2017	DP	U-457		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CABAZITAXEL - JEVTANA KIT</u>						
N201023 001	5438072	Nov 22, 2013	DP		NCE	Jun 17, 2015
	5698582	Jul 03, 2012	DP			
	5847170	Mar 26, 2016	DS DP			
	6331635	Mar 26, 2016	DS DP			
	6372780	Mar 26, 2016		U-1067		
	6387946	Mar 26, 2016		U-1067		
	7241907	Dec 10, 2025	DS			
<u>CALCIPOTRIENE - DOVONEX</u>						
N020554 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			
<u>CALCIPOTRIENE - DOVONEX</u>						
N020611 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			
<u>CALCIPOTRIENE - SORILUX</u>						
N022563 001					NDF	Oct 06, 2013
<u>CALCITONIN SALMON - MIACALCIN</u>						
N020313 002	5733569	Mar 31, 2015		U-227		
	5759565	Mar 31, 2015				
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N021406 001	6440392	Feb 02, 2021	DP	U-227		
	RE40812	Feb 02, 2021	DP			
<u>CALCITRIOL - CALCIJEX</u>						
N018874 001	6051567	Aug 02, 2019				
	6051567*PED	Feb 02, 2020				
	6265392	Aug 02, 2019				
	6265392*PED	Feb 02, 2020				
	6274169	Aug 02, 2019				
	6274169*PED	Feb 02, 2020				
<u>CALCITRIOL - CALCIJEX</u>						
N018874 002	6051567	Aug 02, 2019				
	6051567*PED	Feb 02, 2020				
	6265392	Aug 02, 2019				
	6265392*PED	Feb 02, 2020				
	6274169	Aug 02, 2019				
	6274169*PED	Feb 02, 2020				
<u>CALCITRIOL - VECTICAL</u>						
N022087 001					NDF	Jan 23, 2012
<u>CALCIUM ACETATE - PHOSLO</u>						
N021160 002	6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N021160 003	6576665	Apr 03, 2021				
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
N020958 001	5075114*PED	Nov 23, 2010				
	5229137	May 16, 2012		U-349		
	5229137*PED	Nov 16, 2012				
	5989588	Sep 30, 2015		U-349		
	5989588*PED	Mar 30, 2016		U-349		
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
N021823 001	5583122	Dec 10, 2013	DS DP U-353			
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018			U-353	
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018			U-353	
	6015801*PED	Jan 17, 2019				
	6096342	Nov 21, 2011	DP			
	6096342*PED	May 21, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018			U-595	
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				
<u>CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N022193 001	5409904	Apr 25, 2012	DP U-891		NP	Jul 24, 2011
	5578578	Apr 25, 2012	DP			
	7084130	Nov 29, 2021	DP U-891			
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 001	5196444	Jun 04, 2012	DS DP U-3			
	5196444	Jun 04, 2012	DS DP U-660			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-660			
	5705517*PED	Oct 18, 2011				
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 002	5196444	Jun 04, 2012	DS DP U-660			
	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-660			
	5705517*PED	Oct 18, 2011				
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 003	5196444	Jun 04, 2012	DS DP U-660			
	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-660			
	5705517*PED	Oct 18, 2011				
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 004	5196444	Jun 04, 2012	DS DP U-3			
	5196444	Jun 04, 2012	DS DP U-660			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-660			
	5705517*PED	Oct 18, 2011				
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N021093 001	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-3			
	5705517*PED	Oct 18, 2011				
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N021093 002	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-3			
	5705517*PED	Oct 18, 2011				
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N021093 003	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-3			
	5705517*PED	Oct 18, 2011				
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CAPECITABINE - XELODA</u>						
N020896 001	4966891	Jan 13, 2011				U-272
	5472949	Dec 14, 2013				U-271
<u>CAPECITABINE - XELODA</u>						
N020896 002	4966891	Jan 13, 2011				U-272
	5472949	Dec 14, 2013				U-271
<u>CAPSAICIN - QUTENZA</u>						
N022395 001	6239180	Nov 06, 2016	DP		NCE ODE	Nov 16, 2014 Nov 16, 2016
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 001	5238924	Aug 24, 2010				U-92
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 002	5238924	Aug 24, 2010				U-92
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 003	5238924	Aug 24, 2010				U-92
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 004	5238924	Aug 24, 2010				U-92
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 005	5238924	Aug 24, 2010				U-92
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 006	5238924	Aug 24, 2010				U-92
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 007	5238924	Aug 24, 2010				U-92

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 001	5326570	Jul 05, 2011	U-215			
	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 002	5326570	Jul 05, 2011	U-215			
	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 003	5326570	Jul 05, 2011	U-215			
	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - EQUETRO</u>						
N021710 001	5326570	Jul 23, 2011	DP U-627			
	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N021710 002	5326570	Jul 23, 2011	DP U-627			
	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N021710 003	5326570	Jul 23, 2011	DP U-627			
	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - TEGRETOL-XR</u>						
N020234 001	5284662	Feb 08, 2011				
<u>CARBAMAZEPINE - TEGRETOL-XR</u>						
N020234 002	5284662	Feb 08, 2011				
<u>CARBAMAZEPINE - TEGRETOL-XR</u>						
N020234 003	5284662	Feb 08, 2011				
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N021485 002	5135950	Oct 31, 2010	DS DP U-219			
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N021485 006	5135950	Oct 31, 2010	DS DP U-219			
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N021485 003	5135950	Oct 31, 2010	DS DP U-219			
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N021485 004	5135950	Oct 31, 2010	DS DP U-219			
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N021485 001	5135950	Oct 31, 2010	DS DP U-219			
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N021485 005	5135950	Oct 31, 2010	DS DP U-219			
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARGLUMIC ACID - CARBAGLU</u>						
N022562	001				NCE	Mar 18, 2015
<u>CARISOPRODOL - SOMA</u>						
N011792	004				NP	Sep 13, 2010
<u>CARVEDILOL - COREG</u>						
N020297	001	RE40000 Dec 07, 2015	U-233		PED	Aug 23, 2010
		RE40000*PED				
<u>CARVEDILOL - COREG</u>						
N020297	002	RE40000 Dec 07, 2015	U-233		PED	Aug 23, 2010
		RE40000*PED				
<u>CARVEDILOL - COREG</u>						
N020297	003	RE40000 Dec 07, 2015	U-233		PED	Aug 23, 2010
		RE40000*PED				
<u>CARVEDILOL - COREG</u>						
N020297	004	RE40000 Dec 07, 2015	U-233		PED	Aug 23, 2010
		RE40000*PED				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012	001	5902821 Feb 07, 2016	U-313			
		5902821 Feb 07, 2016	U-777			
		5902821*PED Aug 07, 2016				
		6022562 Oct 17, 2015	DP			
		6022562*PED Apr 17, 2016				
		7268156 Jun 27, 2023	DS DP	U-313		
		7268156 Jun 27, 2023	DS DP	U-3		
		7268156*PED Dec 27, 2023				
		RE40000 Jun 07, 2015		U-777		
		RE40000*PED Dec 07, 2015				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012	002	5902821 Feb 07, 2016	U-313			
		5902821 Feb 07, 2016	U-777			
		5902821*PED Aug 07, 2016				
		6022562 Oct 17, 2015	DP			
		6022562*PED Apr 17, 2016				
		7268156 Jun 27, 2023	DS DP	U-3		
		7268156 Jun 27, 2023	DS DP	U-313		
		7268156*PED Dec 27, 2023				
		RE40000 Jun 07, 2015		U-777		
		RE40000*PED Dec 07, 2015				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012	003	5902821 Feb 07, 2016	U-777			
		5902821 Feb 07, 2016	U-313			
		5902821*PED Aug 07, 2016				
		6022562 Oct 17, 2015	DP			
		6022562*PED Apr 17, 2016				
		7268156 Jun 27, 2023	DS DP	U-313		
		7268156 Jun 27, 2023	DS DP	U-3		
		7268156*PED Dec 27, 2023				
		RE40000 Jun 07, 2015		U-777		
		RE40000*PED Dec 07, 2015				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012	004	5902821 Feb 07, 2016	U-777			
		5902821 Feb 07, 2016	U-313			
		5902821*PED Aug 07, 2016				
		6022562 Oct 17, 2015	DP			
		6022562*PED Apr 17, 2016				
		7268156 Jun 27, 2023	DS DP	U-313		
		7268156 Jun 27, 2023	DS DP	U-3		
		7268156*PED Dec 27, 2023				
		RE40000 Jun 07, 2015		U-777		
		RE40000*PED Dec 07, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N021227 001	5378804	Mar 16, 2013	DS			
	5378804*PED	Sep 16, 2013				
	5514650	Jan 26, 2015	DP		U-607	
	5514650*PED	Jul 26, 2015				
	5792746	Mar 16, 2013	DS	DP	U-607	
	5792746*PED	Sep 16, 2013				
	5952300	Mar 28, 2017	DP			
	5952300*PED	Sep 28, 2017				
	6136783	Mar 28, 2017			U-607	
	6136783*PED	Sep 28, 2017				
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N021227 002	5378804	Mar 16, 2013	DS			
	5378804*PED	Sep 16, 2013				
	5514650	Jan 26, 2015	DP		U-607	
	5514650*PED	Jul 26, 2015				
	5792746	Mar 16, 2013	DS	DP	U-607	
	5792746*PED	Sep 16, 2013				
	5952300	Mar 28, 2017	DP			
	5952300*PED	Sep 28, 2017				
	6136783	Mar 28, 2017			U-607	
	6136783*PED	Sep 28, 2017				
<u>CEFDINIR - OMNICEF</u>						
N050739 001	4935507	Dec 04, 2011	DS			
<u>CEFDINIR - OMNICEF</u>						
N050749 001	4935507	Dec 04, 2011	DS			
<u>CEFDINIR - OMNICEF</u>						
N050749 002	4935507	Dec 04, 2011	DS			
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>						
N021222 001	5958915	Oct 14, 2016				
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>						
N021222 002	5958915	Oct 14, 2016	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 001	6417175	Dec 17, 2018	DS	DP	U-282	
	6906055	Dec 15, 2021	DS	DP		NCE Oct 29, 2015
	7419973	Dec 15, 2021		DP		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 002	6417175	Dec 17, 2018	DS	DP	U-282	
	6906055	Dec 15, 2021	DS	DP		NCE Oct 29, 2015
	7419973	Dec 15, 2021		DP		
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050685 002	5599557	Apr 30, 2013	DP			
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686 001	5599557	Feb 04, 2014	DP		U-578	
	5599557	Feb 04, 2014	DP		U-282	
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686 002	5599557	Feb 04, 2014	DP		U-282	
	5599557	Feb 04, 2014	DP		U-578	
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5466823	Nov 30, 2013	DS			
	5466823*PED	May 30, 2014				
	5563165	Nov 30, 2013				
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-299	
	5760068	Jun 02, 2015			U-672	
	5760068*PED	Dec 02, 2015				
	5972986	Oct 14, 2017			U-299	
	5972986*PED	Apr 14, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5466823	Nov 30, 2013	DS			
	5466823*PED	May 30, 2014				
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068	Jun 02, 2015			U-299	
	5760068*PED	Dec 02, 2015				
	5972986	Oct 14, 2017			U-299	
	5972986*PED	Apr 14, 2018				
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5466823	Nov 30, 2013	DS			
	5466823*PED	May 30, 2014				
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068	Jun 02, 2015			U-299	
	5760068*PED	Dec 02, 2015				
	5972986	Oct 14, 2017			U-299	
	5972986*PED	Apr 14, 2018				
<u>CELECOXIB - CELEBREX</u>						
N020998 004	5466823	Nov 30, 2013	DS			
	5466823*PED	May 30, 2014				
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068*PED	Dec 02, 2015				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 001	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 002	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 003	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 004	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 005	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 006	5006530	Jun 26, 2011				
	5177080	Jan 26, 2011				
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N021621 003	6455533	Jul 02, 2018	DP		U-295	
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N021621 004	6455533	Jul 02, 2018	DP		U-295	
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N021621 005	6455533	Jul 02, 2018	DP		U-295	
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N021621 006	6455533	Jul 02, 2018	DP		U-295	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N021150 002	6469009	Jul 13, 2019	DP	U-295		
	6489329	Apr 08, 2016	DP			
	7014867	Jun 10, 2022	DP			
	7226614	Jun 10, 2022		U-295		
<u>CETRORELIX - CETROTIDE</u>						
N021197 001	5198533	Oct 24, 2010	DS DP			
	6319192	Apr 23, 2019		U-426		
	6863891	Feb 22, 2014		U-426		
	7605121	Feb 22, 2014	DP			
<u>CETRORELIX - CETROTIDE</u>						
N021197 002	5198533	Oct 24, 2010	DS DP			
	6319192	Apr 23, 2019		U-426		
	6863891	Feb 22, 2014		U-426		
	7605121	Feb 22, 2014	DP			
<u>CEVIMELINE HYDROCHLORIDE - EVOXAC</u>						
N020989 002	5340821	Jul 07, 2013		U-309		
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7066916	Feb 17, 2024		U-737		
	7427574	Apr 25, 2026	DP			
	7595021	May 12, 2023	DP	U-1022		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N020832 001	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N020832 004	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N020832 006	5690958	Sep 30, 2016	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>						
N020832 003	5538353	Aug 25, 2015	DP			
	5690958	Sep 30, 2016	DP			
	5752363	Apr 22, 2017	DP			
	5772346	Apr 22, 2017	DP			
	D386849	Nov 25, 2011	DP			
	D396911	Aug 11, 2012	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP</u>						
N021555 001	5690958	Sep 30, 2016	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 002	5690958	Sep 30, 2016	DP			
	6729786	Mar 14, 2023	DP			
	6991393	Mar 14, 2023	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
	7241065	Mar 14, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 005	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	6991393	Jan 31, 2024	DP			
	7241065	Mar 14, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 007	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	6991393	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORASCUB MAXI SWABSTICK</u>						
N021524 003	D468424	Jan 07, 2017				
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N022224 001	7259186	Jan 07, 2025	DS		NP	Dec 15, 2011
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N022224 002	7259186	Jan 07, 2025	DS		NP	Dec 15, 2011
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N021149 001	5767251	Jun 16, 2015				
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N021149 002	5767251	Jun 16, 2015	DS			
	6706681	Mar 16, 2021	DP			
<u>CICLESONIDE - ALVESCO</u>						
N021658 002	5482934	Oct 24, 2017	DS DP	U-1002	NDF	Jan 10, 2011
	5605674	Feb 25, 2014	DP		NCE	Oct 20, 2011
	5683677	Nov 04, 2014	DP			
	5695743	Jul 06, 2010	DP	U-1001		
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLESONIDE - ALVESCO</u>						
N021658 003	5482934	Oct 24, 2017	DS DP	U-1002	NDF	Jan 10, 2011
	5605674	Feb 25, 2014	DP		NCE	Oct 20, 2011
	5683677	Nov 04, 2014	DP			
	5695743	Jul 06, 2010	DP	U-1001		
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLESONIDE - OMNARIS</u>						
N022004 001	5482934	Oct 24, 2017	DS DP	U-557	I-548	Nov 21, 2010
	6767901	Oct 21, 2020	DP		NCE	Oct 20, 2011
	6939559	Apr 21, 2019	DP			
	7235247	Apr 21, 2019	DP			
<u>CICLOPIROX - LOPROX</u>						
N020519 001	7018656	Sep 05, 2018	DP			
	7026337	Apr 02, 2018		U-714		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001	6011068	Dec 14, 2016	DS DP		ODE	Mar 08, 2011
	6031003	Dec 14, 2016		U-559		
	6211244	Oct 23, 2015	DS DP	U-560		
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP	U-1098		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002	6011068	Dec 14, 2016	DS DP		ODE	Mar 08, 2011
	6031003	Dec 14, 2016				
	6211244	Oct 23, 2015	DS DP	U-560		
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP	U-1098		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003	6011068	Dec 14, 2016	DS DP		ODE	Mar 08, 2011
	6031003	Dec 14, 2016		U-559		
	6211244	Oct 23, 2015	DS DP	U-560		
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP	U-1098		
<u>CIPROFLOXACIN - CIPRO</u>						
N020780 001	5695784	Dec 09, 2014				
	5695784*PED	Jun 09, 2015				
	6136347	Jan 06, 2013		U-362		
	6136347*PED	Jul 06, 2013				
<u>CIPROFLOXACIN - CIPRO</u>						
N020780 002	5695784	Dec 09, 2014				
	5695784*PED	Jun 09, 2015				
	6136347	Jan 06, 2013		U-362		
	6136347*PED	Jul 06, 2013				
<u>CIPROFLOXACIN HYDROCHLORIDE - CETRAXAL</u>						
N021918 001					NDF	May 01, 2012
<u>CIPROFLOXACIN HYDROCHLORIDE - CIPRO</u>						
N019537 001	5286754	Feb 15, 2011				
	5286754*PED	Aug 15, 2011				
<u>CIPROFLOXACIN HYDROCHLORIDE - CIPRO</u>						
N019537 002	5286754	Feb 15, 2011				
	5286754*PED	Aug 15, 2011				
<u>CIPROFLOXACIN HYDROCHLORIDE - CIPRO</u>						
N019537 003	5286754	Feb 15, 2011				
	5286754*PED	Aug 15, 2011				
<u>CIPROFLOXACIN HYDROCHLORIDE - CIPRO</u>						
N019537 004	5286754	Feb 15, 2011				
	5286754*PED	Aug 15, 2011				
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N021744 001	5972389	Sep 19, 2016	DP	U-663		
	6340475	Sep 19, 2016	DP	U-663		
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP	U-663		
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>						
N020805 001	5843930	Jun 06, 2015		U-646		
	5965549	Jun 06, 2015	DP			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473 001	7709022	Jun 23, 2021	DP			
	7709022*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473 002	7709022	Jun 23, 2021	DP			
	7709022*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N021537 001	6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
<u>CISAPRIDE MONOHYDRATE - PROPULSID QUICKSOLV</u>						
N020767 001	5648093	Jul 15, 2014				
<u>CISATRACURIUM BESYLATE - NIMBEX</u>						
N020551 001	5453510	Sep 26, 2012		U-127		
<u>CISATRACURIUM BESYLATE - NIMBEX PRESERVATIVE FREE</u>						
N020551 002	5453510	Sep 26, 2012		U-127		
<u>CISATRACURIUM BESYLATE - NIMBEX PRESERVATIVE FREE</u>						
N020551 003	5453510	Sep 26, 2012		U-127		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLARITHROMYCIN - BIAIXIN XL</u>						
N050775 001	6010718	Apr 11, 2017	DP U-924			
	6551616	Jul 15, 2017	U-924			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5739152	Apr 14, 2015	DP U-893		NCE	Aug 01, 2013
	5856346	Jan 05, 2016	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5739152	Apr 14, 2015	DP U-893		NCE	Aug 01, 2013
	5856346	Jan 05, 2016	DS DP U-893			
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N050767 001	6495157	Jul 20, 2020	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N050782 001	6387383	Aug 03, 2020	DP U-818			
<u>CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE</u>						
A090785 001					PC	Sep 27, 2010
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N050793 001	5266329	Nov 30, 2010	DP			
	5993856	Nov 17, 2017	DP U-137			
	6899890	Apr 27, 2023	DP U-137			
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N050801 001	7141237	Jan 23, 2024	DS DP			
	7374747	Aug 09, 2026	DS DP U-921			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - VELTIN</u>						
N050803 001	5690923	Nov 25, 2014	DP			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N050802 001	6387383	Aug 03, 2020	DP U-916			
	RE41134	Feb 24, 2015	DP U-1033			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021535 001	6106848	Sep 22, 2017				
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021644 001	7316810	Jun 17, 2019	DP			
	7700081	Jan 03, 2022	U-1044			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021835 001	5972920	Feb 12, 2018	DP			
	5990100	Mar 24, 2018	DP U-742			
<u>CLOBETASOL PROPIONATE - OLUX</u>						
N021142 001	6126920	Mar 01, 2016	U-484			
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N022013 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
<u>CLOFARABINE - CLOLAR</u>						
N021673 001	5661136	Jan 14, 2018	U-626		ODE	Dec 28, 2011
	5661136*PED	Jul 14, 2018			PED	Jun 28, 2012
<u>CLONIDINE HYDROCHLORIDE - JENLOGA</u>						
N022331 001	5869100	Oct 13, 2013	DP		NP	Sep 29, 2012
<u>CLONIDINE HYDROCHLORIDE - JENLOGA</u>						
N022331 002	5869100	Oct 13, 2013	DP			
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N022331 003	5869100	Oct 13, 2013	DP		NP	Sep 28, 2013
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N022331 004	5869100	Oct 13, 2013	DP		NP	Sep 28, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE			PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE		
CLOPIDOGREL BISULFATE - PLAVIX											
N020839 001	4847265	Nov	17,	2011	DS	DP	U-432	Y			
	5576328	Jan	31,	2014							
	6429210	Jun	10,	2019	DS	DP					
	6504030	Jun	10,	2019	DS						
CLOPIDOGREL BISULFATE - PLAVIX											
N020839 002	4847265	Nov	17,	2011	DS	DP					
	6429210	Jun	10,	2019	DS	DP					
	6504030	Jun	10,	2019	DS						
CLOZAPINE - FAZACLO ODT											
N021590 001	6024981	Apr	09,	2018		DP					
	6106861	Dec	05,	2017		DP					
	6221392	Apr	09,	2018		DP					
CLOZAPINE - FAZACLO ODT											
N021590 002	6024981	Apr	09,	2018		DP					
	6106861	Dec	05,	2017		DP					
	6221392	Apr	09,	2018		DP					
CLOZAPINE - FAZACLO ODT											
N021590 003	6024981	Apr	09,	2018		DP					
	6106861	Dec	05,	2017		DP					
	6221392	Apr	09,	2018		DP					
CLOZAPINE - FAZACLO ODT											
N021590 004	6024981	Apr	09,	2018		DP					
	6106861	Dec	05,	2017		DP					
	6221392	Apr	09,	2018		DP					
CLOZAPINE - FAZACLO ODT											
N021590 005	6024981	Apr	09,	2018		DP					
	6106861	Dec	05,	2017		DP					
	6221392	Apr	09,	2018		DP					
CLOZAPINE - FAZACLO ODT											
N021590 006	6024981	Apr	09,	2018		DP					
	6106861	Dec	05,	2017		DP					
	6221392	Apr	09,	2018		DP					
COLCHICINE - COLCRYS											
N022352 001	7601758	Feb	10,	2029		U-1007		I-603 ODE	Jul	30,	2012
	7619004	Dec	03,	2028		U-1020			Jul	29,	2016
	7820681	Feb	17,	2029		U-1020					
COLESEVELAM HYDROCHLORIDE - WELCHOL											
N021141 001	5607669	Jun	10,	2014		U-323					
	5607669*PED	Dec	10,	2014							
	5679717	Apr	29,	2014		U-323					
	5679717*PED	Oct	29,	2014							
	5693675	Dec	02,	2014							
	5693675*PED	Jun	02,	2015							
	5917007	Apr	29,	2014		U-323					
	5917007*PED	Oct	29,	2014							
	5919832	Jun	10,	2014							
	5919832*PED	Dec	10,	2014							
	6066678	Jun	10,	2014		U-323					
	6066678*PED	Dec	10,	2014							
	6433026	Jun	10,	2014							
	6433026*PED	Dec	10,	2014							

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N021176 001	5607669	Jun 10, 2014		U-323	I-608	Oct 02, 2012
	5607669*PED	Dec 10, 2014			I-553	Jan 18, 2011
	5679717	Apr 29, 2014		U-323	PED	Apr 02, 2013
	5679717*PED	Oct 29, 2014			PED	Jul 18, 2011
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-323		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-323		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022		U-851		
	7229613*PED	Oct 17, 2022				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 001	5607669	Jun 10, 2014		U-757	I-608	Oct 02, 2012
	5607669*PED	Dec 10, 2014			I-553	Jan 18, 2011
	5679717	Apr 29, 2014		U-757	PED	Apr 02, 2013
	5679717*PED	Oct 29, 2014			PED	Jul 18, 2011
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-757		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-757		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022		U-493		
	7229613*PED	Oct 17, 2022				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 002	5607669	Jun 10, 2014		U-757	I-608	Oct 02, 2012
	5607669*PED	Dec 10, 2014			I-553	Jan 18, 2011
	5679717	Apr 29, 2014		U-757	PED	Apr 02, 2013
	5679717*PED	Oct 29, 2014			PED	Jul 18, 2011
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-757		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-757		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022		U-493		
	7229613*PED	Oct 17, 2022				
<u>COLESTIPOL HYDROCHLORIDE - COLESTID</u>						
N020222 001	5490987	Feb 13, 2013	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N021697 001	5723606	Dec 15, 2019	DS DP U-868		NCE	Dec 29, 2010
	5723606	Dec 15, 2019	DS DP U-698			
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER</u>						
N021697 002	5723606	Dec 15, 2019	DS DP U-698		NCE	Dec 29, 2010
	5723606	Dec 15, 2019	DS DP U-868			
<u>CYANOCOBALAMIN - CALOMIST</u>						
N022102 001					NP	Jul 22, 2010
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N021642 001	7229636	Jun 11, 2024	DP U-817			
	7404489	Mar 12, 2024	DP			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N021777 001	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N021777 002	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		
<u>CYCLOSPORINE - NEORAL</u>						
N050715 001	5342625	Aug 30, 2011	DP			
	5741512	Aug 30, 2011	DP	U-906		
	5985321	Sep 26, 2014	DP			
	6258808	Jun 25, 2012	DP			
	6262022	Jun 25, 2012	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N050715 002	5342625	Aug 30, 2011	DP			
	5741512	Aug 30, 2011	DP	U-906		
	5985321	Sep 26, 2014	DP			
	6258808	Jun 25, 2012	DP			
	6262022	Jun 25, 2012	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N050715 003	5342625	Aug 30, 2011	DP			
	5741512	Aug 30, 2011	DP	U-906		
	5985321	Sep 26, 2014	DP			
	6258808	Jun 25, 2012	DP			
	6262022	Jun 25, 2012	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N050716 001	5342625	Aug 30, 2011	DP			
	5741512	Aug 30, 2011	DP	U-906		
	5985321	Sep 26, 2014	DP			
	6258808	Jun 25, 2012	DP			
	6262022	Jun 25, 2012	DP			
<u>CYCLOSPORINE - RESTASIS</u>						
N050790 001	5474979	May 17, 2014	DP			
<u>CYTARABINE - DEPOCYT</u>						
N021041 001	5455044	May 14, 2013		U-806		
	5723147	Mar 03, 2015	DP	U-806		
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 001	6087380	Feb 18, 2018	DS DP U-1089		NCE	Oct 19, 2015
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 002	6087380	Feb 18, 2018	DS DP U-1089		NCE	Oct 19, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DALFAMPRIDINE - AMPYRA</u>						
N022250 001	5370879	Dec 06, 2011	DP		NCE	Jan 22, 2015
	5540938	Jul 30, 2013	U-1030		ODE	Jan 22, 2017
<u>DANAPAROID SODIUM - ORGARAN</u>						
N020430 001	5164377	Oct 03, 2010				
<u>DAPSONE - ACZONE</u>						
N021794 001	5863560	Sep 11, 2016	DP		M-76	Mar 14, 2011
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 001	6468967	Sep 24, 2019			U-282	
	6852689	Sep 24, 2019			U-282	
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	6468967	Sep 24, 2019			U-282	
	6852689	Sep 24, 2019			U-282	
	RE39071	Jun 15, 2016	DS DP		U-728	
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N021513 001	5096890	Mar 13, 2015	DS DP		U-631	
	6106864	Aug 21, 2016	DP		U-630	
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N021513 002	5096890	Mar 13, 2015	DS DP		U-631	
	6106864	Aug 21, 2016	DP		U-630	
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946	Dec 01, 2015	DP		U-744	D-129 Dec 13, 2013
	5843946	Dec 01, 2015	DP		U-935	D-119 Dec 18, 2011
	5843946	Dec 01, 2015	DP		U-903	I-578 Oct 21, 2011
	6037157	Jun 26, 2016			U-935	NCE Jun 23, 2011
	6248775	Aug 13, 2014	DS			
	6335460	Aug 25, 2012	DS DP		U-935	
	6335460	Aug 25, 2012	DS DP		U-744	
	6335460	Aug 25, 2012	DS DP		U-903	
	6703403	Jun 26, 2016			U-935	
	7470506	Jun 23, 2019			U-935	
	7700645	Dec 26, 2026	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946	Dec 01, 2015	DP		U-935	D-129 Dec 13, 2013
	5843946	Dec 01, 2015	DP		U-903	D-119 Dec 18, 2011
	5843946	Dec 01, 2015	DP		U-744	I-578 Oct 21, 2011
	6037157	Jun 26, 2016			U-935	NCE Jun 23, 2011
	6248775	Aug 13, 2014	DS			
	6335460	Aug 25, 2012	DS DP		U-903	
	6335460	Aug 25, 2012	DS DP		U-935	
	6335460	Aug 25, 2012	DS DP		U-744	
	6703403	Jun 26, 2016			U-935	
	7470506	Jun 23, 2019			U-935	
	7700645	Dec 26, 2026	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946	Dec 01, 2015	DP		U-744	D-129 Dec 13, 2013
	5843946	Dec 01, 2015	DP		U-903	D-119 Dec 18, 2011
	5843946	Dec 01, 2015	DP		U-935	D-118 Oct 21, 2011
	6037157	Jun 26, 2016			U-935	I-578 Oct 21, 2011
	6248775	Aug 13, 2014	DS			NCE Jun 23, 2011
	6335460	Aug 25, 2012	DS DP		U-935	
	6335460	Aug 25, 2012	DS DP		U-903	
	6703403	Jun 26, 2016			U-935	
	7470506	Jun 23, 2019			U-935	
	7700645	Dec 26, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	6037157	Jun 26, 2016	U-935		D-119	Dec 18, 2011
	6248775	Aug 13, 2014	DS		NS	Dec 18, 2011
	6335460	Aug 25, 2012	DS DP			
	6703403	Jun 26, 2016	U-935			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	6037157	Jun 26, 2016	U-935		D-119	Dec 18, 2011
	6248775	Aug 13, 2014	DS		NS	Dec 18, 2011
	6335460	Aug 25, 2012	DS DP			
	6703403	Jun 26, 2016	U-935			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N021986 001	6596746	Jun 28, 2020	DS DP U-780		D-120	May 21, 2012
	6596746	Jun 28, 2020	DS DP U-748		D-109	Nov 06, 2010
	7125875	Apr 13, 2020	U-780		M-94	Oct 28, 2013
	7125875	Apr 13, 2020	U-779		M-70	Nov 06, 2010
	7153856	Apr 28, 2020	U-780		NCE	Jun 28, 2011
	7491725	Mar 28, 2026	DS DP		ODE	Jun 28, 2013
					ODE	Jun 28, 2013
<u>DASATINIB - SPRYCEL</u>						
N021986 002	6596746	Jun 28, 2020	DS DP U-780		D-120	May 21, 2012
	6596746	Jun 28, 2020	DS DP U-748		D-109	Nov 06, 2010
	7125875	Apr 13, 2020	U-780		M-94	Oct 28, 2013
	7125875	Apr 13, 2020	U-779		M-70	Nov 06, 2010
	7153856	Apr 28, 2020	U-780		NCE	Jun 28, 2011
	7491725	Mar 28, 2026	DS DP		ODE	Jun 28, 2013
					ODE	Jun 28, 2013
<u>DASATINIB - SPRYCEL</u>						
N021986 003	6596746	Jun 28, 2020	DS DP U-748		D-120	May 21, 2012
	6596746	Jun 28, 2020	DS DP U-780		D-109	Nov 06, 2010
	7125875	Apr 13, 2020	U-780		M-94	Oct 28, 2013
	7125875	Apr 13, 2020	U-779		M-70	Nov 06, 2010
	7153856	Apr 28, 2020	U-780		NCE	Jun 28, 2011
	7491725	Mar 28, 2026	DS DP		ODE	Jun 28, 2013
					ODE	Jun 28, 2013
<u>DASATINIB - SPRYCEL</u>						
N021986 004	6596746	Jun 28, 2020	DS DP U-780		D-120	May 21, 2012
	6596746	Jun 28, 2020	DS DP U-748		D-109	Nov 06, 2010
	7125875	Apr 13, 2020	U-780		M-94	Oct 28, 2013
	7125875	Apr 13, 2020	U-779		M-70	Nov 06, 2010
	7153856	Apr 28, 2020	U-780		NCE	Jun 28, 2011
	7491725	Mar 28, 2026	DS DP		ODE	Jun 28, 2013
					ODE	Jun 28, 2013
<u>DASATINIB - SPRYCEL</u>						
N021986 005	7491725	Mar 28, 2026	DS DP		D-120	May 21, 2012
					M-94	Oct 28, 2013
					NCE	Jun 28, 2011
					ODE	Jun 28, 2013
					ODE	Jun 28, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N021986 006	7491725	Mar 28, 2026	DS DP		D-120 M-94 NCE ODE ODE	May 21, 2012 Oct 28, 2013 Jun 28, 2011 Jun 28, 2013 Jun 28, 2013
<u>DECITABINE - DACOGEN</u>						
N021790 001					D-123 NCE ODE	Mar 11, 2013 May 02, 2011 May 02, 2013
<u>DEFERASIROX - EXJADE</u>						
N021882 001	6465504 6596750	Apr 05, 2019 Jun 24, 2017	DS DP DS	U-735	NCE ODE	Nov 02, 2010 Nov 02, 2012
<u>DEFERASIROX - EXJADE</u>						
N021882 002	6465504 6596750	Apr 05, 2019 Jun 24, 2017	DS DP DS	U-735	NCE ODE	Nov 02, 2010 Nov 02, 2012
<u>DEFERASIROX - EXJADE</u>						
N021882 003	6465504 6596750	Apr 05, 2019 Jun 24, 2017	DS DP DS	U-735	NCE ODE	Nov 02, 2010 Nov 02, 2012
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	Apr 11, 2017	DS DP	U-943	NCE	Dec 24, 2013
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	Apr 11, 2017	DS DP	U-943	NCE	Dec 24, 2013
<u>DELAVIDINE MESYLATE - RESCRIPTOR</u>						
N020705 001	5563142	Oct 08, 2013				
<u>DELAVIDINE MESYLATE - RESCRIPTOR</u>						
N020705 002	5563142 6177101	Oct 08, 2013 Jun 07, 2019				
<u>DESFLURANE - SUPRANE</u>						
N020118 001	5617906 5617906*PED	Apr 08, 2014 Oct 08, 2014	DP			
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>						
N021271 001	5733874	Mar 31, 2015				
<u>DESLOTATADINE - CLARINEX</u>						
N021165 001	6100274 6100274*PED 7211582 7211582*PED 7214683 7214683*PED 7214684 7214684*PED 7405223 7405223*PED	Jul 07, 2019 Jan 07, 2020 Dec 30, 2014 Jun 30, 2015 Dec 30, 2014 Jun 30, 2015 Dec 30, 2014 Jun 30, 2015 Jul 07, 2019 Jan 07, 2020		U-809 DP U-138 U-886		
<u>DESLOTATADINE - CLARINEX</u>						
N021300 001	6514520 6514520*PED 7211582 7211582*PED 7214683 7214683*PED 7214684 7214684*PED	Jun 01, 2018 Dec 01, 2018 Dec 30, 2014 Jun 30, 2015 Dec 30, 2014 Jun 30, 2015 Dec 30, 2014 Jun 30, 2015	DP		U-809 DP U-138	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DES Loratadine - Clarinex</u>						
N021312 001	5178878*PED	Jul 12, 2010				
	5607697	Jun 07, 2015	DP			
	5607697*PED	Dec 07, 2015				
	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	7211582	Dec 30, 2014		U-809		
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP	U-1017		
	7618649*PED	Jun 19, 2021				
<u>DES Loratadine - Clarinex</u>						
N021312 002	5178878*PED	Jul 12, 2010				
	5607697	Jun 07, 2015	DP			
	5607697*PED	Dec 07, 2015				
	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	7211582	Dec 30, 2014		U-809		
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP	U-1017		
	7618649*PED	Jun 19, 2021				
<u>DES Loratadine; Pseudoephedrine Sulfate - Clarinex D 24 Hour</u>						
N021605 001	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	6979463	Mar 28, 2022	DP			
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP	U-1017		
	7618649*PED	Jun 19, 2021				
	7820199	Mar 28, 2022	DP			
	7820199*PED	Sep 28, 2022				
<u>DES Loratadine; Pseudoephedrine Sulfate - Clarinex-D 12 Hour</u>						
N021313 001	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	6709676	Feb 18, 2021	DP	U-707		
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP	U-1017		
	7618649*PED	Jun 19, 2021				
<u>Desmopressin Acetate - DDAVP</u>						
N017922 001	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
<u>Desmopressin Acetate - DDAVP</u>						
N017922 002	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
<u>Desmopressin Acetate - DDAVP</u>						
N018938 001	5500413	Jun 29, 2013				
	5763407	Jun 29, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N018938 002	5500413	Jun 29, 2013				
	5763407	Jun 29, 2013				
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N019955 001	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
	7022340	Apr 30, 2023	DP			
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N019955 002	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
	7022340	Apr 30, 2023	DP			
<u>DESMOPRESSIN ACETATE - DDAVP (NEEDS NO REFRIGERATION)</u>						
N017922 003	5482931	Jun 29, 2013				
	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
N021795 001	7022340	Apr 30, 2023	DP		NP	May 08, 2011
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
N021795 002	7022340	Apr 30, 2023	DP		NP	May 08, 2011
<u>DESONIDE - DESONATE</u>						
N021844 001	6387383	Aug 03, 2020	DS DP	U-783		
<u>DESONIDE - VERDESO</u>						
N021978 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 001	6673838	Feb 11, 2022	DS DP	U-860	NCE	Mar 01, 2013
	7291347	Feb 11, 2022	DP			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 002	6673838	Feb 11, 2022	DS DP	U-860	NCE	Mar 01, 2013
	7291347	Feb 11, 2022	DP			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	6726918	Oct 20, 2020	DP	U-985	NDF	Jun 17, 2012
	6726918	Oct 20, 2020	DP	U-708		
	6899717	Nov 01, 2023		U-708		
	6899717	Nov 01, 2023		U-985		
	7033605	Oct 20, 2020	DP	U-708		
	7625582	Nov 28, 2021		U-985		
	7767223	Jul 11, 2025	DP			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N050818 001	7795316	Aug 03, 2028	DP	U-1082		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	6462058	Jun 15, 2020	DS DP U-951		NP	Jan 30, 2012
	6462058	Jun 15, 2020	DS DP U-950		PED	Jul 30, 2012
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276	Jun 15, 2020	DS DP U-949			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020		U-950		
	6939971	Jun 15, 2020		U-951		
	6939971	Jun 15, 2020		U-949		
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7790755	Aug 02, 2026	DP			
	7790755*PED	Feb 02, 2027				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	6462058	Jun 15, 2020	DS DP U-949		NP	Jan 30, 2012
	6462058	Jun 15, 2020	DS DP U-950		PED	Jul 30, 2012
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020		U-949		
	6939971	Jun 15, 2020		U-951		
	6939971	Jun 15, 2020		U-950		
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7790755	Aug 02, 2026	DP			
	7790755*PED	Feb 02, 2027				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038 001	4910214	Jul 15, 2013	DS DP U-421		I-577	Oct 17, 2011
	5344840	Sep 06, 2011	U-912			
	6716867	Mar 31, 2019	U-572			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N021278 001	5908850	Dec 04, 2015		U-422		
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N021278 002	5908850	Dec 04, 2015		U-422		
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N021278 003	5908850	Dec 04, 2015		U-422		
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 001	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015		U-678	M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 002	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 003	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 004	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 005	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP	U-678	M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 006	5837284	Dec 04, 2015	DP	U-677	D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP	U-678	M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N022025 001	6727253	Mar 13, 2020	U-829		NP	Sep 06, 2010
					ODE	Sep 06, 2014
<u>DEXRAZOXANE HYDROCHLORIDE - ZINECARD</u>						
N020212 001	5242901	Sep 07, 2010	U-339			
<u>DEXRAZOXANE HYDROCHLORIDE - ZINECARD</u>						
N020212 002	5242901	Sep 07, 2010	U-339			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-685		
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-685		
	7838032	Apr 28, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA						
N021879 001	5166207	Jun 17, 2011	U-1093		NC	Oct 29, 2013
	5206248	Mar 27, 2012	U-1093			
	7659282	Aug 13, 2026	U-1093			
	RE38115	Jan 26, 2016	DP			
DEXTROMETHORPHAN POLISTIREX - DELSYM						
N018658 001	5980882	Apr 16, 2017	DP			
DIAZEPAM - DIASTAT						
N020648 001	5462740	Sep 17, 2013	DP			
DIAZEPAM - DIASTAT						
N020648 002	5462740	Sep 17, 2013	DP			
DIAZEPAM - DIASTAT						
N020648 003	5462740	Sep 17, 2013	DP			
DIAZEPAM - DIASTAT						
N020648 004	5462740	Sep 17, 2013	DP			
DIAZEPAM - DIASTAT						
N020648 005	5462740	Sep 17, 2013	DP			
DIAZEPAM - DIASTAT ACUDIAL						
N020648 006	5462740	Sep 17, 2013	DP			
DIAZEPAM - DIASTAT ACUDIAL						
N020648 007	5462740	Sep 17, 2013	DP			
DICLOFENAC EPOLAMINE - FLECTOR						
N021234 001	5607690	Apr 13, 2014	DP			
DICLOFENAC POTASSIUM - CAMBIA						
N022165 001	6974595	May 15, 2017	U-436		NDF	Jun 17, 2012
	7482377	May 15, 2017	DS DP U-436			
	7759394	Jun 16, 2026	DS DP U-436			
DICLOFENAC POTASSIUM - ZIPSOR						
N022202 001	6365180	Jul 15, 2019	DP U-980		NDF	Jun 16, 2012
	7662858	Feb 24, 2029	U-1035			
DICLOFENAC SODIUM - DICLOFENAC SODIUM						
N020809 001	5603929	Nov 16, 2014	U-239			
	5653972	Nov 16, 2014	U-239			
DICLOFENAC SODIUM - PENNSAID						
N020947 001					NDF	Nov 04, 2012
DICLOFENAC SODIUM - SOLARAZE						
N021005 001	5639738	Jun 17, 2014	U-402			
	5792753	Aug 11, 2015				
	5852002	Jun 17, 2014	U-402			
	5914322	Aug 11, 2015				
	5929048	Jul 27, 2016	U-402			
	5985850	Nov 16, 2016				
DICLOFENAC SODIUM - VOLTAREN						
N022122 001					NP	Oct 17, 2010
DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC						
N020607 001	5601843	Feb 11, 2014				
DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC						
N020607 002	5601843	Feb 11, 2014				
DIDANOSINE - VIDEX						
N020154 002	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIDANOSINE - VIDEX</u>						
N020154 003	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				
<u>DIDANOSINE - VIDEX</u>						
N020154 004	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				
<u>DIDANOSINE - VIDEX</u>						
N020154 005	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				
<u>DIDANOSINE - VIDEX</u>						
N020154 006	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	6133251	Oct 25, 2016	DP U-112		NP	May 06, 2013
	6133251	Oct 25, 2016	DP U-1			
	6133251	Oct 25, 2016	DP U-828			
	6884793	Oct 25, 2016	DP			
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001	6114319	May 12, 2018	DP		NCE	Jun 23, 2013
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 001	5286497	May 20, 2011				
	5364620	Nov 14, 2011	U-3			
	5439689	Aug 08, 2012	U-107			
	5470584	May 20, 2011				
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 002	5286497	May 20, 2011				
	5364620	Nov 14, 2011	U-3			
	5439689	Aug 08, 2012	U-107			
	5470584	May 20, 2011				
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 003	5286497	May 20, 2011				
	5364620	Nov 14, 2011	U-3			
	5439689	Aug 08, 2012	U-107			
	5470584	May 20, 2011				
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 004	5286497	May 20, 2011				
	5364620	Nov 14, 2011	U-3			
	5439689	Aug 08, 2012	U-107			
	5470584	May 20, 2011				
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 005	5286497	May 20, 2011	DP			
	5439689	Aug 08, 2012	DP U-107			
	5470584	May 20, 2011	DP			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 001	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 002	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 003	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 004	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 005	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 006	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		
<u>DILTIAZEM HYDROCHLORIDE - DILACOR XR</u>						
N020092 001	5422123	Jun 06, 2012				
<u>DILTIAZEM HYDROCHLORIDE - DILACOR XR</u>						
N020092 002	5422123	Jun 06, 2012				
<u>DILTIAZEM HYDROCHLORIDE - DILACOR XR</u>						
N020092 003	5422123	Jun 06, 2012				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 001	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 002	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 003	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 004	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 001	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 002	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 003	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 004	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 005	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 006	5529791	Jun 25, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMYRISTOYL LECITHIN; PERFLEXANE - IMAGENT</u>						
N021191 001	5605673	Feb 25, 2014				
	5626833	May 16, 2014	U-458			
	5639443	Jun 17, 2014				
	5695741	Dec 09, 2014	U-458			
	5720938	Feb 24, 2015				
	5798091	Aug 25, 2015	U-458			
	6280704	Jul 30, 2013				
	6280705	Jul 30, 2013				
	6287539	Jul 30, 2013				
<u>DINOPROSTONE - CERVIDIL</u>						
N020411 001	5269321	Jul 14, 2012	DP U-110			
<u>DIVALPROEX SODIUM - DEPAKOTE</u>						
N019680 001					M-34 PED	Mar 24, 2011 Sep 24, 2011
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N021168 001	6419953	Dec 18, 2018			M-34	Mar 24, 2011
	6419953*PED	Jun 18, 2019			PED	Sep 24, 2011
	6511678	Dec 18, 2018				
	6511678*PED	Jun 18, 2019				
	6528090	Dec 18, 2018	DP			
	6528090*PED	Jun 18, 2019				
	6528091	Dec 18, 2018	U-106			
	6528091*PED	Jun 18, 2019				
	6713086	Dec 18, 2018	DP U-579			
	6713086*PED	Jun 18, 2019				
	6720004	Dec 18, 2018	DP			
	6720004*PED	Jun 18, 2019				
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N021168 002	6511678	Dec 18, 2018			M-34	Mar 24, 2011
	6511678*PED	Jun 18, 2019			PED	Sep 24, 2011
	6528090	Dec 18, 2018	DP			
	6528090*PED	Jun 18, 2019				
	6713086	Dec 18, 2018	DP U-579			
	6713086*PED	Jun 18, 2019				
	6720004	Dec 18, 2018	DP			
	6720004*PED	Jun 18, 2019				
<u>DOCETAXEL - TAXOTERE</u>						
N020449 001	4814470*PED	Nov 14, 2010			I-543	Sep 28, 2010
	5438072	Nov 22, 2013	DP		I-542	Sep 28, 2010
	5438072*PED	May 22, 2014			M-61	May 13, 2013
	5698582	Jul 03, 2012	DP		PED	Nov 13, 2013
	5698582*PED	Jan 03, 2013			PED	Mar 28, 2011
	5714512	Jul 03, 2012	DP		PED	Mar 28, 2011
	5714512*PED	Jan 03, 2013			PED	Mar 28, 2011
	5750561	Jul 03, 2012	DP			
	5750561*PED	Jan 03, 2013				
<u>DOCETAXEL - TAXOTERE</u>						
N020449 003	4814470*PED	Nov 14, 2010			I-542	Sep 28, 2010
	5698582	Jul 03, 2012	DP		I-543	Sep 28, 2010
	5698582*PED	Jan 03, 2013			M-61	May 13, 2013
	5714512	Jul 03, 2012	DP		PED	Mar 28, 2011
	5714512*PED	Jan 03, 2013			PED	Mar 28, 2011
	5750561	Jul 03, 2012	DP		PED	Mar 28, 2011
	5750561*PED	Jan 03, 2013			PED	Nov 13, 2013
<u>DOCETAXEL - TAXOTERE</u>						
N020449 004	4814470*PED	Nov 14, 2010			I-542	Sep 28, 2010
	5698582	Jul 03, 2012	DP		I-543	Sep 28, 2010
	5698582*PED	Jan 03, 2013			M-61	May 13, 2013
	5714512	Jul 03, 2012	DP		PED	Mar 28, 2011
	5714512*PED	Jan 03, 2013			PED	Mar 28, 2011
	5750561	Jul 03, 2012	DP		PED	Mar 28, 2011
	5750561*PED	Jan 03, 2013			PED	Nov 13, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCOSANOL - ABREVA</u>						
N020941 001	4874794	Apr 28, 2014	U-815			
	5534554	Dec 13, 2013	DP U-815			
<u>DOFETILIDE - TIKOSYN</u>						
N020931 001	4959366	Sep 25, 2012	DS DP U-652			
	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N020931 002	4959366	Sep 25, 2012	DS DP U-652			
	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N020931 003	4959366	Sep 25, 2012	DS DP U-652			
	6124363	Oct 09, 2018				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020623 001	4906755	Jul 02, 2011				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020623 002	4906755	Jul 02, 2011				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020624 001	4906755	Jul 02, 2011				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020624 002	4906755	Jul 02, 2011				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020624 003	4906755	Jul 02, 2011				
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N020690 001	4895841	Nov 25, 2010				
	5985864	Dec 30, 2016				
	6140321	Dec 30, 2016				
	6245911	Dec 01, 2018				
	6372760	Mar 31, 2019		Y		
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N020690 002	4895841	Nov 25, 2010				
	5985864	Dec 30, 2016				
	6140321	Dec 30, 2016				
	6245911	Dec 01, 2018				
	6372760	Mar 31, 2019		Y		
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N022568 001	4895841	Nov 25, 2010	DS DP U-322		NP	Jul 23, 2013
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N021720 001	4895841	Nov 25, 2010	DS DP U-713			
	7727548	Jun 23, 2022	DP U-1062			
	7727552	Mar 26, 2018	DP			
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N021720 002	4895841	Nov 25, 2010	DS DP U-713			
	7727548	Jun 23, 2022	DP U-1062			
	7727552	Mar 26, 2018	DP			
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A076786 001					PC	May 28, 2011
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A076786 002					PC	May 28, 2011
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Aug 14, 2012	DS DP U-282		NCE	Oct 12, 2012
<u>DORIPENEM - DORIBAX</u>						
N022106 002					NCE	Oct 12, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	5502047	Mar 26, 2013	U-620		NP	Mar 17, 2013
	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	6217909	Jan 09, 2015	DP			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	5502047	Mar 26, 2013	U-620		NP	Mar 17, 2013
	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	6217909	Jan 09, 2015	DP			
<u>DOXERCALCIFEROL - HECTOROL</u>						
N020862 001	5602116	Feb 11, 2014	U-278			
	5602116	Feb 11, 2014	U-987			
	6903083	Jul 18, 2021	DS DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N020862 002	5602116	Feb 11, 2014	U-987			
	5602116	Feb 11, 2014	U-278			
	6903083	Jul 18, 2021	DS DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N020862 003	5602116	Feb 11, 2014	U-987			
<u>DOXERCALCIFEROL - HECTOROL</u>						
N021027 001	5602116	Feb 11, 2014	U-321		Y	
	5707980	Aug 17, 2010	U-321		Y	
	6903083	Jul 18, 2021	DS DP			
	7148211	Sep 14, 2023	DP			
<u>DOXERCALCIFEROL - HECTOROL</u>						
N021027 002	5602116	Feb 11, 2014	U-321			
	7148211	Sep 14, 2023	DP			
<u>DOXORUBICIN HYDROCHLORIDE - DOXIL</u>						
N050718 001					ODE	May 17, 2014
<u>DOXORUBICIN HYDROCHLORIDE - DOXIL</u>						
N050718 002					ODE	May 17, 2014
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	5789395	Aug 30, 2016	U-925			
	5919775	Aug 30, 2016	U-925			
	7211267	Apr 05, 2022	U-925			
	7232572	Apr 05, 2022	U-925			
	7749532	Dec 19, 2027	DP U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 001	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 002	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 003	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A090431 001					PC	Jun 28, 2011
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A090431 002					PC	Jun 28, 2011

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A090505 001					PC	Jun 28, 2011
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A090505 002					PC	Jun 28, 2011
<u>DRONABINOL - MARINOL</u>						
N018651 001	6703418	Feb 26, 2011	U-563			
<u>DRONABINOL - MARINOL</u>						
N018651 002	6703418	Feb 26, 2011	U-563			
<u>DRONABINOL - MARINOL</u>						
N018651 003	6703418	Feb 26, 2011	U-563			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2011	DS DP U-992		NCE	Jul 01, 2014
	7323493	Jun 19, 2018	DP			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 002	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N021098 001	5569652	Oct 29, 2013	U-1			
	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N021676 001	5569652	Oct 29, 2013	U-1			
	5798338	Jul 10, 2015	DP			
	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DP			
	6958326	Dec 20, 2021	DP			
	6987101	Dec 22, 2017	U-758			
	7163931	Dec 20, 2021	U-1			
	RE37564	Jun 30, 2014	DP			
	RE37838	Jun 30, 2014	DP			
	RE38253	Jun 30, 2014	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N022532 001	5798338	Jul 10, 2015	DP		NC	Sep 24, 2013
	6441168	Apr 17, 2020	DS		NP	Sep 24, 2013
	6958326	Dec 30, 2021	DP			
	7163931	Mar 03, 2022	U-1			
	RE37564	Jun 30, 2014	DP			
	RE37838	Jun 30, 2014	DP			
	RE38253	Jun 30, 2014	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001					NP	Dec 16, 2013
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-1094		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-799		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-882		I-566	Jun 13, 2011
	5023269	Jun 11, 2013	DS DP U-398		M-71	Nov 28, 2010
	5023269	Jun 11, 2013	DS DP U-839			
	5023269	Jun 11, 2013	DS DP U-797			
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5508276	Jul 18, 2014	DP			
	6596756	Sep 10, 2019	U-882			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-398		I-566	Jun 13, 2011
	5023269	Jun 11, 2013	DS DP U-796		M-71	Nov 28, 2010
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-797			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-799			
	5023269	Jun 11, 2013	DS DP U-1094			
	5508276	Jul 18, 2014	DP			
	6596756	Sep 10, 2019	U-882			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-799		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-398		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-1094		I-566	Jun 13, 2011
	5023269	Jun 11, 2013	DS DP U-839		M-71	Nov 28, 2010
	5023269	Jun 11, 2013	DS DP U-882			
	5023269	Jun 11, 2013	DS DP U-797			
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5508276	Jul 18, 2014	DP			
	6596756	Sep 10, 2019	U-882			
<u>DUTASTERIDE - AVODART</u>						
N021319 001	5565467	Nov 20, 2015	DS DP		I-565	Jun 19, 2011
	5846976	Sep 17, 2013	U-476			
	5998427	Sep 17, 2013	DS DP U-477			
<u>DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE - JALYN</u>						
N022460 001	5565467	Nov 20, 2015	DS DP			
	5846976	Sep 17, 2013	U-1065			
	5998427	Sep 17, 2013	DS DP U-1066			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 001	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014	U-257			
	5811423	Aug 07, 2012	DS DP U-256			
	6238695	Apr 06, 2019	DP			
	6555133	Apr 06, 2019	U-248			
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 002	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014	U-257			
	5811423	Aug 07, 2012	DS DP U-256			
	6238695	Apr 06, 2019	DP			
	6555133	Apr 06, 2019	U-248			
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 003	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014	U-257			
	5811423	Aug 07, 2012	DS DP U-256			
	6238695	Apr 06, 2019	DP			
	6555133	Apr 06, 2019	U-248			
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 001	5519021	May 21, 2013				
	5663169	Sep 02, 2014				
	5811423	Aug 07, 2012			U-256	
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
EFAVIRENZ - SUSTIVA								
N021360 002	5519021	May	21, 2013	DS DP				
	5663169	Sep	02, 2014			U-248		
	5811423	Aug	07, 2012			U-256		
	6639071	Feb	14, 2018	DS				
	6939964	Jan	20, 2018	DS				
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA								
N021937 001	5210085*PED	Nov	11, 2010					
	5519021	May	21, 2013	DS DP				
	5663169	Sep	02, 2014			U-750		
	5811423	Aug	07, 2012			U-750		
	5814639	Sep	29, 2015	DS DP				
	5814639*PED	Mar	29, 2016					
	5914331	Jul	02, 2017	DS				
	5914331*PED	Jan	02, 2018					
	5922695	Jul	25, 2017	DS		U-750		
	5935946	Jul	25, 2017	DS DP		U-750		
	5977089	Jul	25, 2017	DS DP		U-750		
	6043230	Jul	25, 2017			U-750		
	6639071	Feb	14, 2018	DS				
	6642245	Nov	04, 2020			U-750		
	6642245*PED	May	04, 2021					
6703396	Mar	09, 2021	DS DP					
6703396*PED	Sep	09, 2021						
6939964	Jan	20, 2018	DS					
7402588*PED	Aug	01, 2010						
EFLORNITHINE HYDROCHLORIDE - VANIQA								
N021145 001	5648394	Jul	15, 2014			U-334		
ELETRIPTAN HYDROBROMIDE - RELPAX								
N021016 001	5545644	Dec	26, 2016	DS DP		U-876		
	6110940	Aug	29, 2017					
ELETRIPTAN HYDROBROMIDE - RELPAX								
N021016 002	5545644	Dec	26, 2016	DS DP		U-876		
	6110940	Aug	29, 2017					
ELTROMBOPAG OLAMINE - PROMACTA								
N022291 001	6280959	Oct	30, 2018	DS DP		U-930	NCE	Nov 20, 2013
	7160870	Dec	08, 2021	DS DP		U-930	ODE	Nov 20, 2015
	7332481	May	24, 2021			U-930		
	7452874	May	24, 2021	DS DP				
	7473686	May	24, 2021	DS DP		U-930		
	7547719	Mar	04, 2024	DS DP		U-930		
	7790704	May	24, 2021			U-930		
	7795293	May	21, 2023			U-930		
ELTROMBOPAG OLAMINE - PROMACTA								
N022291 002	6280959	Oct	30, 2018	DS DP		U-930	NCE	Nov 20, 2013
	7160870	Dec	08, 2021	DS DP		U-930	ODE	Nov 20, 2015
	7332481	May	24, 2021			U-930		
	7452874	May	24, 2021	DS DP				
	7473686	May	24, 2021	DS DP		U-930		
	7547719	Mar	04, 2024	DS DP		U-930		
	7790704	May	24, 2021			U-930		
	7795293	May	21, 2023			U-930		
ELTROMBOPAG OLAMINE - PROMACTA								
N022291 003	6280959	Oct	30, 2018	DS DP		U-930	NCE	Nov 20, 2013
	7160870	Dec	08, 2021	DS DP		U-930	ODE	Nov 20, 2015
	7332481	May	24, 2021			U-930		
	7452874	May	24, 2021	DS DP				
	7473686	May	24, 2021	DS DP		U-930		
	7547719	Mar	04, 2024	DS DP		U-930		
	7790704	May	24, 2021			U-930		
	7795293	May	21, 2023			U-930		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMEDASTINE DIFUMARATE - EMADINE</u>						
N020706 001	5441958	Dec 08, 2013				U-404
<u>EMTRICITABINE - EMTRIVA</u>						
N021500 001	5210085*PED	Nov 11, 2010				
	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020				U-257
	6642245	Nov 04, 2020				U-541
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7402588*PED	Aug 01, 2010				
<u>EMTRICITABINE - EMTRIVA</u>						
N021896 001	5210085*PED	Nov 11, 2010				
	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020				U-257
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5210085*PED	Nov 11, 2010				
	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS DP			U-248
	5914331*PED	Jan 02, 2018	DS			
	5922695	Jul 25, 2017	DS			U-248
	5922695	Jul 25, 2017	DS			U-541
	5935946	Jul 25, 2017	DS DP			U-248
	5935946	Jul 25, 2017	DS DP			U-541
	5977089	Jul 25, 2017	DS DP			U-541
	5977089	Jul 25, 2017	DS			U-248
	6043230	Jul 25, 2017				U-248
	6043230	Jul 25, 2017				U-541
	6642245	Nov 04, 2020				U-248
	6642245	Nov 04, 2020				U-541
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7402588*PED	Aug 01, 2010				
<u>ENFUVIRTIDE - FUZEON</u>						
N021481 001	5464933	Jun 07, 2013				
	6133418	Nov 17, 2014	DS DP			
	6475491	Jun 07, 2015				U-248
<u>ENOXAPARIN SODIUM - LOVENOX</u>						
N020164 009	5389618	Feb 14, 2012	DS DP			U-545
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 001	5389618	Feb 14, 2012	DS DP			U-545
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 002	5389618	Feb 14, 2012	DS DP			U-545
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 003	5389618	Feb 14, 2012	DS DP			U-545
	RE38743	Feb 14, 2012	DS DP			U-545

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 004	5389618	Feb 14, 2012	DS DP U-545			
	RE38743	Feb 14, 2012	DS DP U-545			
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 005	5389618	Feb 14, 2012	DS DP U-545			
	RE38743	Feb 14, 2012	DS DP U-545			
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 006	5389618	Feb 14, 2012	DS DP U-545			
	RE38743	Feb 14, 2012	DS DP U-545			
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 007	5389618	Feb 14, 2012	DS DP U-545			
	RE38743	Feb 14, 2012	DS DP U-545			
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 008	5389618	Feb 14, 2012	DS DP U-545			
	RE38743	Feb 14, 2012	DS DP U-545			
<u>ENTACAPONE - COMTAN</u>						
N020796 001	5135950	Oct 31, 2010	DS DP U-219			
	5446194	Oct 19, 2013	DS			
	6599530	Sep 14, 2018	DP U-219			
<u>ENTECAVIR - BARACLUDE</u>						
N021797 001	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
<u>ENTECAVIR - BARACLUDE</u>						
N021797 002	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
<u>ENTECAVIR - BARACLUDE</u>						
N021798 001	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
<u>EPINASTINE HYDROCHLORIDE - ELESTAT</u>						
N021565 001	7429602	Nov 29, 2020		U-765	Y	
<u>EPINEPHRINE - ADRENALCLIK</u>						
N020800 003	5665071	May 27, 2013	DP			
<u>EPINEPHRINE - ADRENALCLIK</u>						
N020800 004	5665071	May 27, 2013	DP			
<u>EPINEPHRINE - EPIPEN</u>						
N019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N019430 002	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N020800 002	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N020800 001	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N021504 001	5246418	Sep 30, 2013	DS DP			
	5873850	Sep 30, 2013	DS DP			
	6377847	Sep 30, 2013	DS DP			
	6385488	Sep 30, 2013	DS DP			
	6629968	Jun 30, 2020	DS DP			
	6635045	Jun 29, 2021	DS DP			
	6862473	Sep 30, 2013	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPLERENONE - INSPRA</u>						
N021437 001	6410054	Dec 08, 2019	U-537		M-72	Jan 31, 2011
	6410054	Dec 08, 2019	U-3		PED	Jul 31, 2011
	6410054*PED	Jun 08, 2020				
	6410524	Nov 05, 2019	U-467			
	6410524*PED	May 05, 2020				
	6495165	Dec 08, 2019	U-537			
	6495165	Dec 08, 2019	U-3			
	6495165*PED	Jun 08, 2020				
	6534093	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093*PED	Jun 08, 2020				
	6558707	Dec 08, 2019	DP U-537			
	6558707*PED	Jun 08, 2020				
	6747020	Nov 05, 2019	U-587			
	6747020*PED	May 05, 2020				
	6863902	Apr 10, 2020	DP U-664			
	6863902*PED	Oct 10, 2020				
	7157101	Dec 08, 2019	DP U-664			
	7157101*PED	Jun 08, 2020				
<u>EPLERENONE - INSPRA</u>						
N021437 002	6410054	Dec 08, 2019	U-3		M-72	Jan 31, 2011
	6410054	Dec 08, 2019	U-537		PED	Jul 31, 2011
	6410054*PED	Jun 08, 2020				
	6410524	Nov 05, 2019	U-467			
	6410524*PED	May 05, 2020				
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6495165*PED	Jun 08, 2020				
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6534093*PED	Jun 08, 2020				
	6558707	Dec 08, 2019	DP U-537			
	6558707*PED	Jun 08, 2020				
	6747020	Nov 05, 2019	U-587			
	6747020*PED	May 05, 2020				
	6863902	Apr 10, 2020	DP U-664			
	6863902*PED	Oct 10, 2020				
	7157101	Dec 08, 2019	DP U-664			
	7157101*PED	Jun 08, 2020				
<u>EPLERENONE - INSPRA</u>						
N021437 003	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410054*PED	Jun 08, 2020				
	6410524	Nov 05, 2019	U-467			
	6410524*PED	May 05, 2020				
	6495165	Dec 08, 2019	U-537			
	6495165	Dec 08, 2019	U-3			
	6495165*PED	Jun 08, 2020				
	6534093	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093*PED	Jun 08, 2020				
	6558707	Dec 08, 2019	DP U-537			
	6558707*PED	Jun 08, 2020				
	6747020	Nov 05, 2019	U-587			
	6747020*PED	May 05, 2020				
	6863902	Apr 10, 2020	DP U-664			
	6863902*PED	Oct 10, 2020				
	7157101	Dec 08, 2019	DP U-664			
	7157101*PED	Jun 08, 2020				
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N020738 004	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N020738 005	5656650	Aug 12, 2014	U-3			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N020738 006	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N021268 001	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N021268 002	5656650	Aug 12, 2014	U-3			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N020718 001	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N020718 002	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	6214865	Jun 16, 2019	DS		NCE	Nov 15, 2015
	6469182	Jun 16, 2019		U-1096		
	7470720	Jun 16, 2019	DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 001	5747498	Nov 08, 2018	DS DP	U-659	I-624	Apr 16, 2013
	6900221	Nov 09, 2020	DS DP	U-1046	M-79	Sep 19, 2011
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-659		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 002	5747498	Nov 08, 2018	DS DP	U-659	I-624	Apr 16, 2013
	6900221	Nov 09, 2020	DS DP	U-659	M-79	Sep 19, 2011
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-659		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 003	5747498	Nov 08, 2018	DS DP	U-659	I-624	Apr 16, 2013
	6900221	Nov 09, 2020	DS DP	U-1046	M-79	Sep 19, 2011
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-659		
	RE41065	Nov 08, 2018	DS DP			
<u>ERTAPENEM SODIUM - INVANZ</u>						
N021337 001	5478820	Nov 21, 2015	DS DP	U-160		
	5478820*PED	May 21, 2016				
	5652233	Feb 02, 2013	DS DP	U-160		
	5652233*PED	Aug 02, 2013				
	5952323	May 15, 2017		DP		
	5952323*PED	Nov 15, 2017				
	7342005	Feb 02, 2013		DP		
	7342005*PED	Aug 02, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021323 001	6916941	Aug 12, 2022	DS DP		NPP	Mar 19, 2012
	6916941*PED	Feb 12, 2023	DS DP			
	7420069	Aug 12, 2022	DP			
	7420069*PED	Feb 12, 2023				
	RE34712	Sep 14, 2011	DS DP			
	RE34712*PED	Mar 14, 2012				
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021323 002	6916941	Aug 12, 2022	DS DP		NPP	Mar 19, 2012
	6916941*PED	Feb 12, 2023	DS DP			
	7420069	Aug 12, 2022	DP			
	7420069*PED	Feb 12, 2023				
	RE34712	Sep 14, 2011	DS DP			
	RE34712*PED	Mar 14, 2012				
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021323 003	6916941	Aug 12, 2022	DS DP		NPP	Mar 19, 2012
	6916941*PED	Feb 12, 2023	DS DP			
	7420069	Aug 12, 2022	DP			
	7420069*PED	Feb 12, 2023				
	RE34712	Sep 14, 2011	DS DP			
	RE34712*PED	Mar 14, 2012				
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021365 001	RE34712	Sep 14, 2011	DS DP		NPP	Mar 19, 2012
	RE34712*PED	Mar 14, 2012				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N019386 006	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N019386 007	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N019386 005	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N019386 004	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021153 001	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-770			
	5690960*PED	May 25, 2015	U-373			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-770			
	5714504*PED	Aug 03, 2015	U-373			
	5877192	May 27, 2014	DP U-770			
	5877192	May 27, 2014	DP U-729			
	5877192	May 27, 2014	DP U-373			
	5877192*PED	Nov 27, 2014	U-373			
	5900424	May 04, 2016	DS U-770			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-373			
	5900424*PED	Nov 04, 2016	U-373			
	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
	6369085	May 25, 2018	DS DP U-770			
	6369085	May 25, 2018	DS DP U-729			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-770			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-469			
	6428810*PED	May 03, 2020	U-469			
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021153 002	5690960	Nov 25, 2014	DP U-770			
	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-729			
	5690960*PED	May 25, 2015	U-373			
	5714504	Feb 03, 2015	DP U-770			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-373			
	5714504*PED	Aug 03, 2015	U-373			
	5877192	May 27, 2014	DP U-729			
	5877192	May 27, 2014	DP U-373			
	5877192	May 27, 2014	DP U-770			
	5877192*PED	Nov 27, 2014	U-373			
	5900424	May 04, 2016	DS U-770			
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-729			
	5900424*PED	Nov 04, 2016	U-373			
	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
	6369085	May 25, 2018	DS DP U-770			
	6369085	May 25, 2018	DS DP U-729			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-770			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-469			
	6428810*PED	May 03, 2020	U-469			
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5690960	Nov 25, 2014	DP U-729		M-86	Jun 18, 2012
	5690960	Nov 25, 2014	DP U-773		PED	Dec 18, 2012
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-773			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014		U-773		
	5877192	May 27, 2014		U-729		
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-773			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-729			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5690960	Nov 25, 2014	DP U-729		M-86	Jun 18, 2012
	5690960	Nov 25, 2014	DP U-773		PED	Dec 18, 2012
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-773			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014		U-729		
	5877192	May 27, 2014		U-773		
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-773			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-773			
	6369085	May 25, 2018	DS DP U-729			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-729			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N022101 001	5690960	Nov 25, 2014	DP U-858		NPP	Feb 27, 2011
	5690960*PED	May 25, 2015			PED	Aug 27, 2011
	5714504	Feb 03, 2015	DP U-858			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014		U-858		
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-858			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-858			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-858			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015	DP U-1053		NC	Apr 30, 2013
	5900424	May 04, 2016	DS U-1053			
	6369085	May 25, 2018	DS DP U-1053			
	6875872	May 27, 2014	DS			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015	DP U-1053		NC	Apr 30, 2013
	5900424	May 04, 2016	DS U-1053			
	6369085	May 25, 2018	DS DP U-1053			
	6875872	May 27, 2014	DS			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N021689 001	5877192	May 27, 2014	U-643			
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2014	DP U-643			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N021689 002	5877192	May 27, 2014	U-643			
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2014	DP U-643			
<u>ESTRADIOL - ALORA</u>						
N020655 001	5122383	May 17, 2011				
	5164190	Dec 11, 2010				
	5212199	May 17, 2011				
	5227169	May 17, 2011				
<u>ESTRADIOL - ALORA</u>						
N020655 002	5122383	May 17, 2011				
	5164190	Dec 11, 2010				
	5212199	May 17, 2011				
	5227169	May 17, 2011				
<u>ESTRADIOL - ALORA</u>						
N020655 003	5122383	May 17, 2011				
	5164190	Dec 11, 2010				
	5212199	May 17, 2011				
	5227169	May 17, 2011				
<u>ESTRADIOL - ALORA</u>						
N020655 004	5122383	May 17, 2011				
	5164190	Dec 11, 2010				
	5212199	May 17, 2011				
	5227169	May 17, 2011				
<u>ESTRADIOL - ELESTRIN</u>						
N021813 001	7198801	Jun 25, 2022	DP			
	7470433	Aug 03, 2021	DP			
<u>ESTRADIOL - EVAMIST</u>						
N022014 001	6299900	Feb 19, 2017	DP U-889		NDF	Jul 27, 2010
	6299900	Feb 19, 2017	DP U-888			
	6818226	Feb 19, 2017	DP U-889			
	6818226	Feb 19, 2017	DP U-888			
	6923983	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-888			
	6978945	Nov 30, 2021	DP			
<u>ESTRADIOL - MENOSTAR</u>						
N021674 001	5891868	Nov 21, 2017	DP U-594			
	6692763	Nov 21, 2017	DP U-594			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - VAGIFEM</u>						
N020908 002	7018992	Sep 17, 2022	U-1023		D-122	Nov 25, 2012
<u>ESTRADIOL - VIVELLE</u>						
N020323 001	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE</u>						
N020323 002	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE</u>						
N020323 003	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE</u>						
N020323 004	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE</u>						
N020323 005	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 005	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 006	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 007	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 008	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 009	5474783	Dec 12, 2012	DP			
	5656286	Aug 12, 2014	DP			
	5958446	Dec 12, 2012	DP			
	6024976	Jan 07, 2014	DP			
<u>ESTRADIOL ACETATE - FEMRING</u>						
N021367 001	5855906	Dec 19, 2015	U-508			
<u>ESTRADIOL ACETATE - FEMRING</u>						
N021367 002	5855906	Dec 19, 2015	U-508			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 001	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025	U-904			
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 002	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025	U-904			
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 003	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025	U-904			
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL HEMIHYDRATE - ESTRASORB</u>						
N021371 001	5629021	Jan 31, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL; LEVONORGESTREL - CLIMARA PRO</u>						
N021258 001	5252334	Oct 12, 2010	DP			
	5676968	Oct 14, 2014	DP			
	5770219	Oct 12, 2010	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N020870 001	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N020870 002	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N021040 001	5382573	Jan 17, 2012				
	6747019	Mar 20, 2020		U-311		
	7320970	Mar 30, 2020	DP	U-844		
<u>ESTROGENS, CONJUGATED - PREMARIN</u>						
N020216 001					I-579	Nov 07, 2011
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992 001	5908638	Jul 26, 2015	DP			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992 002	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992 003	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992 004	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992 005	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - SYNTHETIC CONJUGATED ESTROGENS A</u>						
N021788 001					NP	Nov 28, 2011
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 001	6660726	Mar 08, 2021	DS DP	U-905		
	6660726	Mar 08, 2021	DS DP	U-904		
	6855703	Feb 12, 2021	DS DP	U-905		
	6855703	Feb 12, 2021	DS DP	U-904		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 002	6660726	Mar 08, 2021	DS DP	U-905		
	6660726	Mar 08, 2021	DS DP	U-904		
	6855703	Feb 12, 2021	DS DP	U-905		
	6855703	Feb 12, 2021	DS DP	U-904		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 003	6660726	Mar 08, 2021	DS DP	U-904		
	6660726	Mar 08, 2021	DS DP	U-905		
	6855703	Feb 12, 2021	DS DP	U-904		
	6855703	Feb 12, 2021	DS DP	U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 004	6660726	Mar 08, 2021	DS DP	U-905		
	6660726	Mar 08, 2021	DS DP	U-904		
	6855703	Feb 12, 2021	DS DP	U-905		
	6855703	Feb 12, 2021	DS DP	U-904		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 005	6660726	Mar 08, 2021	DS DP U-905			
	6660726	Mar 08, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPHASE 14/14</u>						
N020527 002	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527 001	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527 003	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527 004	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527 005	5547948	Jan 17, 2015				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926	Jan 16, 2012			U-620	
	6444673	Feb 14, 2014	DS DP			
	6864257	Aug 30, 2012			U-629	
	7381724	Jan 16, 2012	DS DP		U-629	
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926	Jan 16, 2012			U-620	
	6444673	Feb 14, 2014	DS DP			
	6864257	Aug 30, 2012			U-629	
	7381724	Jan 16, 2012	DS DP		U-629	
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6319926	Jan 16, 2012			U-620	
	6444673	Feb 14, 2014	DS DP			
	6864257	Aug 30, 2012			U-629	
	7381724	Jan 16, 2012	DS DP		U-629	
<u>ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING</u>						
N021187 001	5989581	Apr 08, 2018				
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262 001	7615545	Jun 15, 2023	U-1		NP	Oct 24, 2011
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL</u>						
N021864 001	6500814	Sep 03, 2018	U-1			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N020946 001	6156742	Dec 05, 2020	U-374			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONALE</u>						
N021544 001	5898032	Jun 23, 2017	U-1			
	RE39861	Jun 23, 2017	U-828			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7320969	Jan 30, 2024	U-828			
	7615545	Jun 15, 2023	U-1			
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>						
N021180 001	5876746	Nov 20, 2015	DP U-514			
	5972377	Jun 07, 2015	U-514			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE</u>						
N021490 001	6667050	Apr 06, 2019	DP U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N022573 001					NP	Dec 22, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N022501 001	5552394	Jul 22, 2014	U-1090		NP	Oct 21, 2013
	7704984	Feb 02, 2029	U-1090			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>						
N021871 001	5552394	Jul 22, 2014	U-1			
<u>ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO TRI-CYCLEN LO</u>						
N021241 001	6214815	Jun 09, 2019	U-112			
	6214815*PED	Dec 09, 2019				
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019	U-256		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Nov 05, 2019	DS DP U-256			
	7037917	Nov 05, 2019	DS DP U-1016			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2014	DS DP		I-630	Oct 29, 2013
	6004973	Jul 12, 2016	DP		NCE	Mar 30, 2014
	7297703	Dec 06, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2014	DS DP		I-630	Oct 29, 2013
	6004973	Jul 12, 2016	DP		NCE	Mar 30, 2014
	7297703	Dec 06, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003					I-630	Oct 29, 2013
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2014	DS DP U-1049		NP	Apr 20, 2013
	6004973	Jul 12, 2016	DP U-1049		NCE	Mar 30, 2014
	6239124	Aug 11, 2017	U-1049			
	6440990	Sep 24, 2013	DP U-1049			
	6455518	Jul 29, 2017	U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2014	DS DP U-1049		NP	Apr 20, 2013
	6004973	Jul 12, 2016	DP U-1049		NCE	Mar 30, 2014
	6239124	Aug 11, 2017	U-1049			
	6440990	Sep 24, 2013	DP U-1049			
	6455518	Jul 29, 2017	U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2014	DS DP U-1049		NP	Apr 20, 2013
	6004973	Jul 12, 2016	DP U-1049		NCE	Mar 30, 2014
	6239124	Aug 11, 2017	U-1049			
	6440990	Sep 24, 2013	DP U-1049			
	6455518	Jul 29, 2017	U-1049			
<u>EXEMESTANE - AROMASIN</u>						
N020753 001	4808616	Apr 01, 2011	DS DP U-658			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016	U-653			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018	U-687			
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018	U-1074			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	Dec 01, 2016	U-653			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018	U-687			
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018	U-1074			
<u>EZETIMIBE - ZETIA</u>						
N021445 001	5846966	Sep 21, 2013	U-474		M-54	Jun 05, 2011
	5846966	Sep 21, 2013	U-473		PED	Dec 05, 2011
	5846966*PED	Mar 21, 2014				
	7030106	Jan 25, 2022	DP			
	7030106*PED	Jul 25, 2022				
	7612058	Jan 25, 2022	U-1027			
	7612058*PED	Jul 25, 2022				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001	5846966	Sep 21, 2013	DP U-473		M-54	Jun 05, 2011
	5846966	Sep 21, 2013	DP U-593		PED	Dec 05, 2011
	5846966*PED	Mar 21, 2014				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002	5846966	Sep 21, 2013	DP U-593		M-54	Jun 05, 2011
	5846966	Sep 21, 2013	DP U-473		PED	Dec 05, 2011
	5846966*PED	Mar 21, 2014				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003	5846966	Sep 21, 2013	DP U-473		M-54	Jun 05, 2011
	5846966	Sep 21, 2013	DP U-593			
	5846966*PED	Mar 21, 2014				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004	5846966	Sep 21, 2013	DP U-473		M-54	Jun 05, 2011
	5846966	Sep 21, 2013	DP U-593		PED	Dec 05, 2011
	5846966*PED	Mar 21, 2014				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001	5246937	Sep 21, 2010	U-96		M-54	Dec 24, 2012
	5246937*PED	Mar 21, 2011			PED	Jun 24, 2013
	5840763	Sep 01, 2015	U-96			
	5840763*PED	Mar 01, 2016				
	5866581	Oct 04, 2014	U-96			
	5866581*PED	Apr 04, 2015				
	5916893	Sep 01, 2015	U-96			
	5916893*PED	Mar 01, 2016				
	6124304	Oct 04, 2014	U-96			
	6124304*PED	Apr 04, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002	5246937	Sep 21, 2010	U-96		M-54	Dec 24, 2012
	5246937*PED	Mar 21, 2011			PED	Jun 24, 2013
	5840763	Sep 01, 2015	U-96			
	5840763*PED	Mar 01, 2016				
	5866581	Oct 04, 2014	U-96			
	5866581*PED	Apr 04, 2015				
	5916893	Sep 01, 2015	U-96			
	5916893*PED	Mar 01, 2016				
	6124304	Oct 04, 2014	U-96			
	6124304*PED	Apr 04, 2015				
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003	5246937	Sep 21, 2010	U-96		M-54	Dec 24, 2012
	5246937*PED	Mar 21, 2011			PED	Jun 24, 2013
	5840763	Sep 01, 2015	U-96			
	5840763*PED	Mar 01, 2016				
	5866581	Oct 04, 2014	U-96			
	5866581*PED	Apr 04, 2015				
	5916893	Sep 01, 2015	U-96			
	5916893*PED	Mar 01, 2016				
	6124304	Oct 04, 2014	U-96			
	6124304*PED	Apr 04, 2015				
<u>FAMOTIDINE - FLUXID</u>						
N021712 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE - FLUXID</u>						
N021712 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE - PEPCID AC</u>						
N020325 001	5854267	Dec 29, 2015	U-267			
	5854267*PED	Jun 29, 2016	U-267			
<u>FAMOTIDINE - PEPCID AC</u>						
N020801 001	5075114	Oct 23, 2010				
	5075114*PED	Nov 23, 2010				
	5667794	May 02, 2015		Y		
	5667794*PED	Nov 02, 2015				
	5854267	Dec 29, 2015	U-267			
	5854267*PED	Jun 29, 2016				
<u>FAMOTIDINE - PEPCID AC</u>						
N020801 002	5075114*PED	Nov 23, 2010				
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				
<u>FAMOTIDINE - PEPCID AC (GELTAB)</u>						
N020902 001	5854267	Dec 29, 2015	U-368			
	5854267*PED	Jun 29, 2016	U-368			
<u>FEBUXOSTAT - ULORIC</u>						
N021856 001	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FEBUXOSTAT - ULORIC</u>						
N021856 002	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 001	7101574	Aug 20, 2020	DS DP			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 003	7101574	Aug 20, 2020	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	7658944	Dec 09, 2024	DP			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	7658944	Dec 09, 2024	DP			
<u>FENOFIBRATE - LIPOFEN</u>						
N021612 001	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - LIPOFEN</u>						
N021612 002	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - LIPOFEN</u>						
N021612 003	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - TRICOR</u>						
N021203 001	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
<u>FENOFIBRATE - TRICOR</u>						
N021203 003	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
<u>FENOFIBRATE - TRICOR</u>						
N021656 001	5145684	Jan 25, 2011	DP U-615			
	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023			U-847	
<u>FENOFIBRATE - TRICOR</u>						
N021656 002	5145684	Jan 25, 2011	DP U-615			
	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023			U-847	
<u>FENOFIBRATE - TRIGLIDE</u>						
N021350 001	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - TRIGLIDE</u>						
N021350 002	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 001	7569612	Aug 20, 2027			U-1000	
	7741373	Aug 20, 2027			U-1059	
	7741374	Aug 20, 2027			U-1061	
	7741374	Aug 20, 2027			U-1060	
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 002	7569612	Aug 20, 2027			U-1000	
	7741373	Aug 20, 2027			U-1059	
	7741374	Aug 20, 2027			U-1060	
	7741374	Aug 20, 2027			U-1061	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 006	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 31, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 31, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 31, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 31, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 31, 2019	U-767			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N021338 001	5697896	Dec 16, 2014	DP			
	5843014	Dec 01, 2015	DP			
	6169920	Jan 02, 2018	DP			
	6171294	Jun 05, 2015			U-736	
	6181963	Nov 02, 2019	DP			
	6195582	Jan 28, 2019	DP		U-736	
	6216033	Jun 05, 2015	DP			
	6317629	Jun 02, 2012	DP			
	6425892	Jun 05, 2015			U-736	
	6842640	Jun 02, 2015	DP			
	6881208	Apr 19, 2022			U-736	
	6975902	Apr 01, 2024	DP			
	7018370	Jun 05, 2015			U-736	
	7027859	Sep 26, 2014	DP			
	7302293	Jun 05, 2015	DP			
<u>FERRIC HEXACYANOFERRATE(II) - RADIOGARDASE (PRUSSIAN BLUE)</u>						
N021626 001					ODE	Oct 02, 2010
<u>FERUMOXIDES - FERIDEX I.V.</u>						
N020416 001	5248492	Sep 28, 2010				
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	6599498	Mar 08, 2020	DS DP		NP	Jun 30, 2012
	7553479	Mar 08, 2020	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
FESOTERODINE FUMARATE - TOVIAZ										
N022030 001	6858650	May	11,	2019	DS		U-913	NCE	Oct	31, 2013
	7384980	Oct	14,	2019	DS	DP	U-913			
	7807715	Jun	06,	2027		DP	U-913			
FESOTERODINE FUMARATE - TOVIAZ										
N022030 002	6858650	May	11,	2019	DS		U-913	NCE	Oct	31, 2013
	7384980	Oct	14,	2019	DS	DP	U-913			
	7807715	Jun	06,	2027		DP	U-913			
FEXOFENADINE HYDROCHLORIDE - ALLEGRA										
N020625 001	5578610	Nov	26,	2013			U-192			
	5578610*PED	May	26,	2014			U-192			
	5738872	Feb	28,	2015						
	5738872*PED	Aug	28,	2015						
	5855912	Feb	28,	2015						
	5855912*PED	Aug	28,	2015						
	5932247	Feb	28,	2015						
	5932247*PED	Aug	28,	2015						
	6037353	Mar	14,	2017			U-138			
	6037353*PED	Sep	14,	2017			U-138			
	6113942	Feb	28,	2015						
	6113942*PED	Aug	28,	2015						
	6187791	May	11,	2012			U-138			
	6187791*PED	Nov	11,	2012			U-138			
	6399632	May	11,	2012			U-468			
	6399632*PED	Nov	11,	2012			U-468			
	7135571	May	18,	2014	DS					
	7135571*PED	Nov	18,	2014						
	7138524	May	18,	2014	DS					
	7138524*PED	Nov	18,	2014						
FEXOFENADINE HYDROCHLORIDE - ALLEGRA										
N020872 001	5578610	Nov	26,	2013	DS	DP	U-684			
	5578610	Nov	26,	2013	DS	DP	U-139			
	5578610*PED	May	26,	2014			U-139			
	5855912	Feb	28,	2015		DP				
	5855912*PED	Aug	28,	2015						
	5932247	Feb	28,	2015		DP				
	5932247*PED	Aug	28,	2015						
	6037353	Mar	14,	2017			U-684			
	6037353	Mar	14,	2017			U-138			
	6037353*PED	Sep	14,	2017			U-138			
	6113942	Feb	28,	2015		DP				
	6113942*PED	Aug	28,	2015						
	6187791	May	11,	2012			U-138			
	6187791	May	11,	2012			U-684			
	6187791*PED	Nov	11,	2012			U-138			
	6399632	May	11,	2012			U-468			
	6399632	May	11,	2012			U-684			
	6399632*PED	Nov	11,	2012			U-468			
	7135571	May	18,	2014	DS					
	7135571*PED	Nov	18,	2014						
	7138524	May	18,	2014	DS					
	7138524*PED	Nov	18,	2014						
	7662835	May	18,	2014			U-139			
	7662835*PED	Nov	18,	2014						
	7666881	May	18,	2014			U-139			
	7666881*PED	Nov	18,	2014						

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 002	5578610	Nov 26, 2013	DS DP			U-139
	5578610	Nov 26, 2013	DS DP			U-684
	5578610*PED	May 26, 2014				U-139
	5855912	Feb 28, 2015		DP		
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015		DP		
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017				U-684
	6037353	Mar 14, 2017				U-138
	6037353*PED	Sep 14, 2017				U-138
	6113942	Feb 28, 2015		DP		
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012				U-138
	6187791	May 11, 2012				U-684
	6187791*PED	Nov 11, 2012				U-138
	6399632	May 11, 2012				U-468
	6399632	May 11, 2012				U-684
	6399632*PED	Nov 11, 2012				U-468
	7135571	May 18, 2014	DS			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	7662835	May 18, 2014				U-139
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014				U-139
	7666881*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 004	5578610	Nov 26, 2013	DS DP			U-684
	5578610	Nov 26, 2013	DS DP			U-139
	5578610*PED	May 26, 2014				U-139
	5855912	Feb 28, 2015		DP		
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015		DP		
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017				U-684
	6037353	Mar 14, 2017				U-138
	6037353*PED	Sep 14, 2017				U-138
	6113942	Feb 28, 2015		DP		
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012				U-138
	6187791	May 11, 2012				U-684
	6187791*PED	Nov 11, 2012				U-138
	6399632	May 11, 2012				U-684
	6399632	May 11, 2012				U-468
	6399632*PED	Nov 11, 2012				U-468
	7135571	May 18, 2014	DS			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	7662835	May 18, 2014				U-139
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014				U-139
	7666881*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N021909 001	5578610	Nov 26, 2013	DS DP			U-823
	5738872	Feb 28, 2015		DP		
	6037353	Mar 14, 2017				U-823
	6187791	May 11, 2012				U-823
	6399632	May 11, 2012				U-823
	7138524	May 18, 2014	DS			
	7662835	May 18, 2014				U-139
	7662835*PED	Nov 18, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N021963 001	5578610	Nov 26, 2013	DS DP		U-772	
	6037353	Mar 14, 2017			U-772	
	6187791	May 11, 2012			U-772	
	6399632	May 11, 2012			U-772	
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR</u>						
N021704 001	5578610	Nov 26, 2013	DS DP		U-612	
	5578610*PED	May 26, 2014				
	6004582	May 29, 2018	DP			
	6037353	Mar 17, 2017			U-612	
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012			U-612	
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012			U-612	
	6399632*PED	Nov 11, 2012				
	6613357	Dec 25, 2020	DP		U-612	
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	7662835	May 18, 2014			U-139	
	7662835*PED	Nov 18, 2014				
	RE39069	May 29, 2018	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR</u>						
N020786 001	5578610	Nov 26, 2013				
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015				
	5855912*PED	Aug 28, 2015				
	6037353	Mar 14, 2017			U-138	
	6037353*PED	Sep 14, 2017			U-138	
	6039974	Jul 31, 2018				
	6113942	Feb 28, 2015				
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012			U-138	
	6187791*PED	Nov 11, 2012			U-138	
	6399632	May 11, 2012			U-468	
	6399632*PED	Nov 11, 2012			U-468	
	7135571	May 18, 2014	DS			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	7662835	May 18, 2014			U-139	
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014			U-139	
	7666881*PED	Nov 18, 2014				
<u>FINASTERIDE - PROPECIA</u>						
N020788 001	5547957	Oct 15, 2013			U-236	
	5571817	Nov 05, 2013			U-259	
	5886184	Nov 19, 2012				
<u>FINASTERIDE - PROSCAR</u>						
N020180 001	5886184	Nov 19, 2012	DS			
	5942519	Oct 23, 2018			U-280	
	6046183	Mar 20, 2011	DP		U-577	
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	5604229	Feb 18, 2014	DS		U-1086	NCE Sep 21, 2015
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N022273 001	7148207	Dec 20, 2022	DP		U-944	NDF Dec 18, 2011
	7547776	Dec 10, 2018	DS			ODE Dec 18, 2015
<u>FLUOCINOLONE ACETONIDE - DERMA-SMOOTH/FS</u>						
N019452 001					NPP	Dec 12, 2010

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
N021737 001	6217895	Mar 22, 2019	DP U-708		ODE	Apr 08, 2012
	6548078	Mar 22, 2019	DP U-708			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023	U-861			
	7794738	Sep 11, 2022	U-1084			
<u>FLUOROURACIL - CARAC</u>						
N020985 001	6670335	Jun 02, 2021	DP U-68			
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N018936 001	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N018936 003	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N018936 006	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>						
N021235 001	5910319	May 29, 2017	U-396			
	5985322	May 29, 2017	U-397			
	RE39030	May 29, 2017	DP U-397			
	RE39030	May 29, 2017	DP U-396			
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 001	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017	U-962			
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 002	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	5945416	Mar 24, 2017	DS DP	Y		
	6960577	Nov 01, 2017	U-962			
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 003	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	5945416	Mar 24, 2017	DS DP	Y		
	6960577	Nov 01, 2017	U-962			
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 004	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	5945416	Mar 24, 2017	DS DP	Y		
	6960577	Nov 01, 2017	U-962			
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 005	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	5945416	Mar 24, 2017	DS DP	Y		
	6960577	Nov 01, 2017	U-962			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	6858596	Aug 03, 2021	DP U-808			
	7101866	Aug 03, 2021	DS DP U-808			
	7541350	Aug 03, 2021	DP U-988			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N021152 001	7300669	Oct 20, 2019	DP U-835			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
N020833 002	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
N020833 003	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
N020833 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Jun 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 003	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015	U-710			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015	U-582			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015	U-583			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-581		
	6743413*PED	Dec 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N021077 001	5590645	Mar 01, 2011	DP		I-558	Apr 30, 2011
	5590645*PED	Sep 01, 2011			M-84	Mar 31, 2012
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
	RE40045	Sep 07, 2010	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N021077 002	5590645	Mar 01, 2011	DP		I-558	Apr 30, 2011
	5590645*PED	Sep 01, 2011			M-84	Mar 31, 2012
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
	RE40045	Sep 07, 2010	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N021077 003	5590645	Mar 01, 2011	DP		I-558	Apr 30, 2011
	5590645*PED	Sep 01, 2011			M-84	Mar 31, 2012
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
	RE40045	Sep 07, 2010	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 001	5658549	Aug 19, 2014	DP		U-738	
	5658549*PED	Feb 19, 2015			U-738	
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6143277	Apr 14, 2015	DP		U-738	
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP		U-738	
	6253762*PED	Oct 14, 2015			U-738	
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6524555	Apr 14, 2015	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021			U-841	
	6743413*PED	Dec 01, 2021			U-841	
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	RE40045	Sep 07, 2010	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
N021254 002	5658549	Aug 19, 2014	DP		U-738	
	5658549*PED	Feb 19, 2015	DP		U-738	
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6143277	Apr 14, 2015	DP		U-738	
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP		U-738	
	6253762*PED	Oct 14, 2015	DP		U-738	
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6524555	Apr 14, 2015	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021			U-841	
	6743413*PED	Dec 01, 2021			U-841	
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	RE40045	Sep 07, 2010	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	5658549	Aug 19, 2014	DP		U-738	
	5658549*PED	Feb 19, 2015	DP		U-738	
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6143277	Apr 14, 2015	DP		U-738	
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP		U-738	
	6253762*PED	Oct 14, 2015	DP		U-738	
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6524555	Apr 14, 2015	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021			U-841	
	6743413*PED	Dec 01, 2021			U-841	
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	RE40045	Sep 07, 2010	DP			
<u>FLUVASTATIN SODIUM - LESCOL</u>						
N020261 001	5354772	Oct 11, 2011			U-413	
	5354772	Oct 11, 2011			U-109	
	5354772*PED	Apr 11, 2012				
	5356896	Dec 12, 2011				
	5356896*PED	Jun 12, 2012				
<u>FLUVASTATIN SODIUM - LESCOL</u>						
N020261 002	5354772	Oct 11, 2011			U-413	
	5354772	Oct 11, 2011			U-109	
	5354772*PED	Apr 11, 2012				
	5356896	Dec 12, 2011				
	5356896*PED	Jun 12, 2012				
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N021192 001	5354772	Oct 11, 2011			U-109	
	5354772	Oct 11, 2011			U-413	
	5354772*PED	Apr 11, 2012				
	5356896	Dec 12, 2011				
	5356896*PED	Jun 12, 2012				
	6242003	Apr 13, 2020				
	6242003*PED	Oct 13, 2020				
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
N021519 001						

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
N021519	002				M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
N021519	003				M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N022033	001 7465462	May 10, 2020	DP U-929		NDF	Feb 28, 2011
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N022033	002 7465462	May 10, 2020	DP U-929		NDF	Feb 28, 2011
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N020582	001 5270057	Mar 20, 2011				
	5767251	Jun 16, 2015				
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N020582	002 5270057	Mar 20, 2011				
	5767251	Jun 16, 2015				
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211	001 5767251	Jun 16, 2015	DS		I-306	Jun 28, 2013
	5929028	Jan 14, 2018	DP U-567			
	7563763	Aug 23, 2019	U-993			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211	002 5767251	Jun 16, 2015	DS		I-306	Jun 28, 2013
	5929028	Jan 14, 2018	DP U-567			
	7563763	Aug 23, 2019	U-993			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211	003 7563763	Aug 23, 2019		U-993		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211	004 7563763	Aug 23, 2019		U-993	I-306	Jun 28, 2013
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273	001				I-306	Jun 28, 2013
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273	002				I-306	Jun 28, 2013
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	001 5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	002 5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	003 5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	004 5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	005 5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N021765	001 5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N021765	003 5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF</u>						
N021765	002 5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N021684 001	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N021684 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N021684 003	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOMEPIZOLE - ANTIZOL</u>						
N020696 001	7553863	Jun 30, 2027	DS DP			
<u>FOMIVIRSEN SODIUM - VITRAVENE PRESERVATIVE FREE</u>						
N020961 001	5264423	Nov 23, 2010		U-522		
	5276019	Jan 04, 2011		U-522		
	5442049	Aug 15, 2012				
	5595978	Aug 15, 2012		U-522		
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N020831 001	6488027	Mar 08, 2019				
	6887459	Nov 28, 2020		U-762		
<u>FORMOTEROL FUMARATE - FORADIL CERTIHALER</u>						
N021592 001	6182655	Dec 05, 2016	DP			
	6645466	Nov 10, 2019	DP			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N022007 001	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	DP	U-813		
	7348362	Jun 22, 2021	DP			
	7462645	Jun 22, 2021	DP	U-813		
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N022518 001	5889015	Jan 27, 2014		U-1068		
	5889015*PED	Jul 27, 2014			NC	Jun 22, 2013
	6057307	Jan 27, 2014	DP	U-1068		
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP	U-1068		
	6677323	Jan 27, 2014		U-1068		
	7067502	May 21, 2020	DP	U-1068		
	7566705	May 08, 2020	DP	U-1068		
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N022518 002	5889015	Jan 27, 2014		U-1068		
	5889015*PED	Jul 27, 2014			NC	Jun 22, 2013
	6057307	Jan 27, 2014	DP	U-1068		
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP	U-1068		
	6677323	Jan 27, 2014		U-1068		
	7067502	May 21, 2020	DP	U-1068		
	7566705	May 08, 2020	DP	U-1068		
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001	6436989	Dec 24, 2017	DS DP	U-257		
	6514953	Jul 15, 2019	DS DP	U-257		
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001	6436989	Dec 24, 2017	DS DP	U-257		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 001	5512570	Mar 04, 2014	DS DP		NCE	Jan 25, 2013
	5538982	Jul 23, 2013				
	5691336	Mar 04, 2014				
	5716942	Feb 10, 2015				
	7214692	Sep 18, 2012				
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002					D-128 NCE	Nov 12, 2013 Jan 25, 2013
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jun 07, 2018	DS DP	U-945	NCE	Dec 12, 2013
<u>FROVATRIPTAN SUCCINATE - FROVA</u>						
N021006 001	5464864	Nov 07, 2015		U-436		
	5616603	Apr 01, 2014		U-436		
	5637611	Jun 10, 2014		U-436		
	5827871	Oct 27, 2015		U-436		
	5962501	Dec 16, 2013		U-436		
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021		U-596	D-126	Sep 09, 2013
	7456160	Jan 09, 2021		U-596		
<u>GABAPENTIN - NEURONTIN</u>						
N020235 001	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020235 002	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020235 003	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020882 001	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020882 002	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N021129 001	6054482	Apr 25, 2017		DP		
	6054482*PED	Oct 25, 2017				
	7256216	May 28, 2022				
	7256216*PED	Nov 28, 2022				
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N021357 001	4916246	Apr 10, 2012	DS		NPP	Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N021357 002	4916246	Apr 10, 2012	DS		NPP	Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N021357 003	4916246	Apr 10, 2012	DS		NPP	Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N021357 004	4916246	Apr 10, 2012	DS		NPP	Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE MULTIPACK</u>						
N021358 001	4916246	Apr 10, 2012	DS			
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE MULTIPACK</u>						
N021358 002	4916246	Apr 10, 2012	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADODIAMIDE - OMNISCAN</u>						
N020123 001	5362475	Nov 08, 2011	DS			
	5560903	Oct 01, 2013	DP			
<u>GADODIAMIDE - OMNISCAN</u>						
N022066 001	5560903	Oct 01, 2013	DP			
<u>GADODIAMIDE - OMNISCAN</u>						
N022066 002	5362475	Nov 08, 2011	DS			
	5560903	Oct 01, 2013	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001					NCE	Dec 22, 2013
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002					NCE	Dec 22, 2013
<u>GADOPENTETATE DIMEGLUMINE - MAGNEVIST</u>						
N019596 001	5362475	Nov 08, 2011				
	5560903	Oct 01, 2013				
<u>GADOPENTETATE DIMEGLUMINE - MAGNEVIST</u>						
N021037 001	5362475	Nov 08, 2011				
	5560903	Oct 01, 2013				
<u>GADOTERIDOL - PROHANCE</u>						
N020131 001	5474756	Dec 12, 2012		U-480		
	5846519	Dec 08, 2015				
	6143274	Dec 12, 2012		U-480		
<u>GADOTERIDOL - PROHANCE MULTIPACK</u>						
N021489 001	5474756	Dec 12, 2012		U-536		
	5846519	Dec 08, 2015				
	6143274	Dec 12, 2012		U-536		
<u>GADOXETATE DISODIUM - EOVI</u>						
N022090 001					NCE	Jul 03, 2013
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N021169 001	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP	U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N021169 002	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP	U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N021169 003	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP	U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N021615 001	7160559	Dec 20, 2019	DP			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N021615 002	7160559	Dec 20, 2019	DP			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N021615 003	7160559	Dec 20, 2019	DP			
<u>GANCICLOVIR - VITRASERT</u>						
N020569 001	5378475	Jan 03, 2012				
<u>GANCICLOVIR - ZIRGAN</u>						
N022211 001					NDF	Sep 15, 2012
					ODE	Sep 15, 2016
<u>GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION</u>						
N021057 001	4801577	Feb 05, 2012	DS	DP		
	5767082	Jun 16, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
GATIFLOXACIN - ZYMAR								
N021493 001	5880283	Dec	05, 2015	DP				
	5880283*PED	Jun	05, 2016					
	6333045	Aug	20, 2019					
	6333045*PED	Feb	20, 2020					
GATIFLOXACIN - ZYMAXID								
N022548 001	5880283	Dec	05, 2015	DS		NP	May 18, 2013	
	5880283*PED	Jun	05, 2016	DS	DP			
	6333045	Aug	20, 2019					
	6333045*PED	Feb	20, 2020					
GEFITINIB - IRESSA								
N021399 001	5457105	Jan	19, 2013	DS	DP	U-881		
	5616582	Jan	19, 2013					
	5770599	May	05, 2017					
GEMCITABINE HYDROCHLORIDE - GEMZAR								
N020509 001	4808614*PED	Nov	15, 2010			U-146		
	5464826	Nov	07, 2012					
	5464826*PED	May	07, 2013					
GEMCITABINE HYDROCHLORIDE - GEMZAR								
N020509 002	4808614*PED	Nov	15, 2010			U-146		
	5464826	Nov	07, 2012					
	5464826*PED	May	07, 2013					
GEMIFLOXACIN MESYLATE - FACTIVE								
N021158 001	5633262	Jun	15, 2015	DS	DP			
	5776944	Apr	04, 2017					
	5962468	Jun	15, 2015					U-282
	6262071	Sep	21, 2019					U-513
	6331550	Sep	21, 2019					U-511
	6340689	Sep	14, 2019					U-512
	6455540	Sep	21, 2019					U-511
	6723734	Mar	20, 2018					
	6803376	Sep	21, 2019					U-608
	6803376	Sep	21, 2019					U-609
GEMTUZUMAB OZOGAMICIN - MYLOTARG								
N021174 001	5585089	Dec	17, 2013					
	5606040	Feb	25, 2014					
	5693762	Dec	02, 2014					
	5739116	Apr	14, 2015					
	5767285	Jun	16, 2015					
	5773001	Jun	30, 2015					U-320
GLATIRAMER ACETATE - COPAXONE								
N020622 001	5981589	May	24, 2014			I-594	Feb 27, 2012	
	6054430	May	24, 2014					
	6342476	May	24, 2014					U-441
	6362161	May	24, 2014					U-441
	6620847	May	24, 2014					DS
	6939539	May	24, 2014					DS
	7199098	May	24, 2014					DS
GLATIRAMER ACETATE - COPAXONE								
N020622 002	5981589	May	24, 2014			I-594	Feb 27, 2012	
	6054430	May	24, 2014					
	6342476	May	24, 2014					U-441
	6362161	May	24, 2014					U-441
	6620847	May	24, 2014					DS
	6939539	May	24, 2014					DS
	7199098	May	24, 2014					DS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 001	4687777	Jan 17, 2011	DS			
	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 002	4687777	Jan 17, 2011	DS			
	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 001	5002953	Sep 17, 2011	DS DP		U-690	
	5002953	Sep 17, 2011	DS DP		U-781	
	5002953*PED	Mar 17, 2012			U-781	
	5741803	Apr 21, 2015	DS DP		U-781	
	5741803	Apr 21, 2015	DS DP		U-690	
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 002	5002953	Sep 17, 2011	DS DP		U-690	
	5002953	Sep 17, 2011	DS DP		U-781	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP		U-690	
	5741803	Apr 21, 2015	DS DP		U-781	
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 003	5002953	Sep 17, 2011	DS DP		U-690	
	5002953	Sep 17, 2011	DS DP		U-781	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP		U-690	
	5741803	Apr 21, 2015	DS DP		U-781	
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 004	5002953	Sep 17, 2011	DS DP		U-840	
	5002953*PED	Mar 17, 2012				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 005	5002953	Sep 17, 2011	DS DP		U-840	
	5002953*PED	Mar 17, 2012				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N020329 001	5591454	Jan 07, 2014			U-150	
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N020329 002	5591454	Jan 07, 2014			U-150	
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N020329 003	5591454	Jan 07, 2014			U-111	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLUTAMINE - NUTRESTORE</u>						
N021667 001	5288703	Oct 07, 2011	U-898		ODE	Jun 10, 2011
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N021178 001	6303146	Jul 14, 2019	U-412			
	6303146*PED	Jan 14, 2020	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N021178 002	6303146	Jul 14, 2019	U-412			
	6303146*PED	Jan 14, 2020	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N021178 003	6303146	Jul 14, 2019	U-412			
	6303146*PED	Jan 14, 2020	U-412			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001	7638552	Aug 20, 2023	U-1076		NP	Jul 28, 2013
	7816396	Aug 20, 2023	U-1076			
<u>GLYCOPYRROLATE - ROBINUL</u>						
N012827 001	7091236	Apr 24, 2024	U-877			
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N012827 002	7091236	Apr 24, 2024	U-877			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N019726 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N020578 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GRANISETRON - SANCUSO</u>						
N022198 001	7608282	Oct 22, 2024	DP U-1011		NE NDF	Sep 12, 2011 Sep 12, 2011
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 001	5952340	Sep 14, 2016	U-519			
	6294548	May 04, 2019				
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 002	5952340	Sep 14, 2016	U-519			
	6294548	May 04, 2019				
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 004	5952340	Sep 14, 2016	U-519			
	6294548	May 04, 2019				
<u>GREPAFLOXACIN HYDROCHLORIDE - RAXAR</u>						
N020695 001	5563138	Oct 08, 2013				
<u>GUAIFENESIN - MUCINEX</u>						
N021282 001	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN - MUCINEX</u>						
N021282 002	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N021585 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			
	7838032	Apr 28, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N021585 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-686		
	7838032	Apr 28, 2020	DP			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 001	5854290	Sep 21, 2015		U-494	NP	Sep 02, 2012
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP	U-494		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 002	5854290	Sep 21, 2015		U-494	NP	Sep 02, 2012
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP	U-494		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 003	5854290	Sep 21, 2015		U-494	NP	Sep 02, 2012
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP	U-494		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 004	5854290	Sep 21, 2015		U-494	NP	Sep 02, 2012
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP	U-494		
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N022555 001	6034267	Mar 08, 2016		U-1087	NP	May 28, 2013
	7247655	Mar 08, 2016	DP	U-1087		
	7348361	Apr 22, 2019	DP	U-1087		
	7530461	Jan 11, 2017	DP	U-1087		
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N022058 001	5266325	Nov 30, 2010	DP		ODE	May 03, 2014
	5292515	Mar 08, 2011	DP			
<u>HISTRELIN ACETATE - VANTAS</u>						
N021732 001	5266325	Nov 30, 2010	DP			
	5292515	Mar 08, 2011	DP			
<u>HYALURONIDASE - HYDASE</u>						
N021716 001					NCE	Oct 25, 2010
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N021859 001	7767429	Sep 23, 2027	DS DP		NCE	Dec 02, 2010
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N020727 001	6465463	Sep 08, 2020		U-71		
	6784177	Sep 08, 2020		U-71		
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 001	5270317	Sep 30, 2011			I-549	Nov 16, 2010
	5270317*PED	Mar 30, 2012				
	5994348	Jun 07, 2015				
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 002	5270317	Sep 30, 2011			I-549	Nov 16, 2010
	5270317*PED	Mar 30, 2012				
	5994348	Jun 07, 2015				
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 003	5270317	Sep 30, 2011			I-549	Nov 16, 2010
	5270317*PED	Mar 30, 2012				
	5994348	Jun 07, 2015				
	5994348*PED	Dec 07, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 004	5270317	Sep 30, 2011	DS DP		I-549	Nov 16, 2010
	5270317*PED	Mar 30, 2012				
	5994348	Jun 07, 2015	DP			
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u>						
A077157 001					PC	Oct 03, 2010
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u>						
A077157 003					PC	Oct 03, 2010
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532 002	5616599	Apr 25, 2016	DS DP U-500			
	5616599*PED	Oct 25, 2016				
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532 003	5616599	Apr 25, 2016	DS DP U-500			
	5616599*PED	Oct 25, 2016				
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532 005	5616599	Apr 25, 2016	DS DP U-500			
	5616599*PED	Oct 25, 2016				
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N021162 001	5591762	Jan 07, 2014	DS DP U-3			
	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N021162 002	5591762	Jan 07, 2014	DS DP U-3			
	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N021162 003	5591762	Jan 07, 2014	DS DP U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 001	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 002	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 003	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 004	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 005	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE; IBUPROFEN - VICOPROFEN</u>						
N020716 001	6348216	Jun 10, 2017				
	6599531	Jun 10, 2017				
<u>HYDROCORTISONE BUTYRATE - LOCROID</u>						
N022076 001	7378405	Dec 19, 2026	DP			
<u>HYDROCORTISONE BUTYRATE - LOCROID LIPOCREAM</u>						
N020769 001	5635497	Jun 03, 2014			I-613	Oct 19, 2012
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019034 003	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019034 004	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019034 005	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019891 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019892 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019892 002	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019892 003	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N019034 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N019034 002	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 001	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 002	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 003	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 001	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	5968551	Dec 24, 2011	DP			
	6294195	Dec 24, 2011	DP			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 002	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	5968551	Dec 24, 2011	DP			
	6294195	Dec 24, 2011	DP			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 003	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP	U-616		
	5968551	Dec 24, 2011	DP			
	6294195	Dec 24, 2011	DP			
	6335033	Nov 04, 2014	DP	U-616		
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP	U-616		
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 004	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP	U-616		
	5968551	Dec 24, 2011	DP			
	6294195	Dec 24, 2011	DP			
	6335033	Nov 04, 2014	DP	U-616		
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP	U-616		
	6743442	Nov 04, 2014	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041 002	5834448	Nov 14, 2016	DP	U-789	ODE	Dec 15, 2013
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021455 001	4927814	Mar 17, 2012	DS	DP	U-642	
	4927814	Mar 17, 2012	DS	DP	U-700	
	6143326	Apr 21, 2017			U-642	
	6294196	Oct 07, 2019	DP			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021455 002	4927814	Mar 17, 2012	DS	DP	U-642	
	4927814	Mar 17, 2012	DS	DP	U-700	
	6294196	Oct 07, 2019		DP		
	7192938	May 06, 2023			U-798	
	7410957	May 06, 2023			U-887	
	7718634	May 06, 2023			U-642	
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021858 001	4927814	Mar 17, 2012	DS	DP	U-700	
	5662918	Sep 02, 2014		DP		
<u>IBUPROFEN - CALDOLOR</u>						
N022348 001	6727286	Nov 27, 2021	DP	U-981	NP	Jun 11, 2012
<u>IBUPROFEN - CALDOLOR</u>						
N022348 002	6727286	Nov 27, 2021	DP	U-981	NP	Jun 11, 2012
<u>IBUPROFEN - CHILDREN'S MOTRIN</u>						
N020516 001	5374659	Dec 20, 2011				
	5374659*PED	Jun 20, 2012				
<u>IBUPROFEN - CHILDREN'S MOTRIN</u>						
N020601 001	5215755*PED	Dec 01, 2010				
<u>IBUPROFEN - CHILDREN'S MOTRIN</u>						
N020603 001	5374659	Dec 20, 2011				
	5374659*PED	Jun 20, 2012				
<u>IBUPROFEN - JUNIOR STRENGTH MOTRIN</u>						
N020601 003	5215755*PED	Dec 01, 2010				
<u>IBUPROFEN - MIDOL LIQUID GELS</u>						
N021472 001	6251426	Jun 25, 2018				
<u>IBUPROFEN - MOTRIN</u>						
N019842 001	5374659	Dec 20, 2011				
	5374659*PED	Jun 20, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBUPROFEN - MOTRIN</u>						
N020135 001	5215755*PED	Dec 01, 2010				
	5320855	Jun 14, 2011				
	5320855*PED	Dec 14, 2011				
<u>IBUPROFEN - MOTRIN</u>						
N020135 002	5215755*PED	Dec 01, 2010				
	5320855	Jun 14, 2011				
	5320855*PED	Dec 14, 2011				
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	6342530	Nov 14, 2020	DS DP U-794		ODE	Apr 13, 2013
	6344479	Mar 20, 2021	DS DP U-794			
<u>IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE - ADVIL CONGESTION RELIEF</u>						
N022565 001	5087454	Jul 30, 2010	DP			
<u>IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD</u>						
N021128 001	6211246	Jun 10, 2019				
<u>ICODEXTRIN - EXTRANEAL</u>						
N021321 001	6077836	Jun 20, 2017		U-495		
	6248726	Jun 19, 2018		U-495		
<u>ILOPERIDONE - FANAPT</u>						
N022192 001	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 002	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 003	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 004	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 005	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 006	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 007	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPROST - VENTAVIS</u>						
N021779 001					ODE	Dec 29, 2011
<u>ILOPROST - VENTAVIS</u>						
N021779 002					ODE	Dec 29, 2011
<u>ILOPROST - VENTAVIS</u>						
N021779 003					ODE	Dec 29, 2011
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021335 001	5521184	Jan 04, 2015	DS DP			
	5521184*PED	Jul 04, 2015				
	6894051	May 23, 2019	DS DP U-649			
	6894051*PED	Nov 23, 2019				
	6958335	Dec 19, 2021		U-791		
	6958335*PED	Jun 19, 2022				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021335 002	5521184	Jan 04, 2015	DS DP U-649			
	5521184*PED	Jul 04, 2015				
	6894051	May 23, 2019	DS DP U-649			
	6894051*PED	Nov 23, 2019				
	6958335	Dec 19, 2021		U-791		
	6958335*PED	Jun 19, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001	5521184	Jan 04, 2015	DS DP		I-583	Dec 19, 2011
	5521184*PED	Jul 04, 2015			ODE	Oct 19, 2013
	6894051	May 23, 2019	DS DP U-649		ODE	Oct 19, 2013
	6894051*PED	Nov 23, 2019			ODE	Oct 19, 2013
	6958335	Dec 19, 2021		U-791	ODE	Oct 19, 2013
	6958335*PED	Jun 19, 2022			ODE	Oct 19, 2013
	7544799	Jan 16, 2019	DS DP		ODE	Oct 19, 2013
	7544799*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002	5521184	Jan 04, 2015			I-583	Dec 19, 2011
	5521184*PED	Jul 04, 2015			ODE	Oct 19, 2013
	6894051	May 23, 2019	DS DP U-649		ODE	Oct 19, 2013
	6894051*PED	Nov 23, 2019			ODE	Oct 19, 2013
	6958335	Dec 19, 2021		U-791	ODE	Oct 19, 2013
	6958335*PED	Jun 19, 2022			ODE	Oct 19, 2013
	7544799	Jan 16, 2019	DS DP		ODE	Oct 19, 2013
	7544799*PED	Jul 16, 2019				
<u>IMIGLUCERASE - CERESZYME</u>						
N020367 001	5549892	Aug 27, 2013		U-252		
<u>IMIGLUCERASE - CERESZYME</u>						
N020367 002	5549892	Aug 27, 2013		U-252		
<u>IMIQUIMOD - ALDARA</u>						
N020723 001	5238944	Aug 24, 2010				
	5238944*PED	Feb 24, 2011				
	7696159	Apr 01, 2024	DS	U-1048		
	7696159	Apr 01, 2024	DS	U-1047		
	7696159*PED	Oct 01, 2024				
<u>IMIQUIMOD - IMIQUIMOD</u>						
A078548 001					PC	Aug 24, 2010
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001					NP	Mar 25, 2013
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 001	5413999	May 09, 2012		U-132		
	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021		U-554		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 003	5413999	May 09, 2012		U-132		
	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021		U-554		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 005	5413999	May 09, 2012		U-132		
	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021		U-554		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 006	5413999	May 09, 2012		U-132		
	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021		U-554		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 50/50</u>						
N021810 001	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5834422	Sep 28, 2013		DP U-471		
	5840680	Sep 28, 2013	DS DP	U-471		
	5866538	Jun 20, 2017		DP		
	5866538*PED	Dec 20, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172 001	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5834422	Sep 28, 2013	DP U-471			
	5840680	Sep 28, 2013	DS DP U-471			
	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG</u>						
N020986 001	5618913	Jun 07, 2014	DS DP		D-112	Mar 14, 2011
	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017				
	5866538*PED	Dec 20, 2017				
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	5750497	May 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
	6011007	Feb 02, 2014	DS DP U-668			
	6869930	Feb 02, 2014	DS DP U-668			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	5656722	Aug 12, 2014	DS DP U-948			
	5656722*PED	Feb 12, 2015				
	7476652	Jul 23, 2023	DP			
	7476652*PED	Jan 23, 2024				
	7713930	Jun 13, 2023	DP			
	7713930*PED	Dec 13, 2023				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 001	6221633	Jun 18, 2018	DS DP U-471		NPP	Oct 24, 2011
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 002	6221633	Jun 18, 2018	DS DP U-471		NPP	Oct 24, 2011
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003	6221633	Jun 18, 2018	DS DP U-471		NPP	Oct 24, 2011
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50</u>						
N021018 001	5461031	Jun 26, 2014				
	5474978	Jun 16, 2014				
	5514646	May 07, 2013				
	5747642	Jun 16, 2014				
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25</u>						
N021017 001	5461031	Jun 16, 2014				
	5474978	Jun 16, 2014				
	5514646	May 07, 2013				
	5747642	Jun 16, 2014				
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N020563 001	5474978	Jun 16, 2014	U-534			
	5514646	May 07, 2013	U-534			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N020563 002	5474978	Jun 16, 2014	U-534			
	5514646	May 07, 2013	U-534			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N021868 001	5740794	Apr 21, 2015	DP			
	5997848	Mar 07, 2014		U-704		
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019		U-704		
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014		U-704		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N021868 002	5740794	Apr 21, 2015	DP			
	5997848	Mar 07, 2014		U-704		
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019		U-704		
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014		U-704		
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N022290 001					NCE	Sep 19, 2013
					ODE	Sep 19, 2015
<u>IODIXANOL - VISIPAQUE 270</u>						
N020351 001	5349085	Sep 20, 2011				
	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 270</u>						
N020808 001	5349085	Sep 20, 2011				
	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
N020351 002	5349085	Sep 20, 2011				
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
N020808 002	5349085	Sep 20, 2011				
	RE36418	Jul 12, 2011	DP			
<u>IOPROMIDE - ULTRAVIST (PHARMACY BULK)</u>						
N021425 002					I-619	Dec 30, 2012
<u>IOPROMIDE - ULTRAVIST 370</u>						
N020220 001					I-619	Dec 30, 2012
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N021527 001	5676930	Oct 14, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5695743	Jul 06, 2010	DP	U-610		
	6739333	May 26, 2020	DP			
	6983743	May 26, 2020	DP			
<u>IRBESARTAN - AVAPRO</u>						
N020757 001	5270317	Sep 30, 2011				
	5270317*PED	Mar 30, 2012				
	6342247	Jun 07, 2015				
	6342247*PED	Dec 07, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IRBESARTAN - AVAPRO</u>						
N020757 002	5270317	Sep 30, 2011				
	5270317*PED	Mar 30, 2012				
	6342247	Jun 07, 2015				
	6342247*PED	Dec 07, 2015				
<u>IRBESARTAN - AVAPRO</u>						
N020757 003	5270317	Sep 30, 2011				
	5270317*PED	Mar 30, 2012				
	6342247	Jun 07, 2015				
	6342247*PED	Dec 07, 2015				
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N020571 001	6403569	Apr 28, 2020		U-449		
	6403569*PED	Oct 28, 2020				
	6794370	May 01, 2020		U-606		
	6794370*PED	Nov 01, 2020				
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N020571 002	6403569	Apr 28, 2020		U-449		
	6403569*PED	Oct 28, 2020				
	6794370	May 01, 2020		U-606		
	6794370*PED	Nov 01, 2020				
<u>IRON DEXTRAN - DEXFERRUM</u>						
A040024 001	5624668	Sep 29, 2015				
<u>ITRACONAZOLE - ITRACONAZOLE</u>						
N022484 001	6509038	May 12, 2017	DP U-1054		NP	Apr 29, 2013
	7081255	May 12, 2017	DP U-1054			
<u>ITRACONAZOLE - SPORANOX</u>						
N020083 001	5633015	May 27, 2014				
<u>ITRACONAZOLE - SPORANOX</u>						
N020657 001	5707975	Jan 13, 2015				
	6407079	Jun 18, 2019				
<u>ITRACONAZOLE - SPORANOX</u>						
N020966 001	6407079	Jun 18, 2019				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	May 26, 2018	DS DP U-961			
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6670384	Jan 23, 2022	DP U-959		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-960			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	May 26, 2018	DS DP U-961			
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	7553835	Oct 19, 2018	DP U-245			
<u>KETOCONAZOLE - NIZORAL A-D</u>						
N020310 001	5456851	Apr 07, 2014				
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	7179475	Dec 04, 2018	DP U-792			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N022427 001	7842714	Aug 15, 2029	DS DP		NP	Jul 22, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N022382 001	6333044	Dec 25, 2018	DP U-1057		NDF	May 14, 2013
	7476689	Oct 11, 2012	DP U-1056			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 001	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 002	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 003	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 004	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022254 001	5654301	Aug 05, 2014	DS DP U-911		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-911			
<u>LACOSAMIDE - VIMPAT</u>						
N022255 001	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LAMIVUDINE - EPIVIR</u>						
N020564 001	5905082	May 18, 2016	DS DP U-248			
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N020564 003	5905082	May 18, 2016				
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N020596 001	6004968	Mar 20, 2018				
	6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N021003 001	5905082	May 18, 2016				
	5905082*PED	Nov 18, 2016				
	RE39155	Jul 02, 2013			U-250	
	RE39155*PED	Jan 02, 2014				
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N021004 001	6004968	Mar 20, 2018				
	6004968*PED	Sep 20, 2018				
	RE39155	Jul 02, 2013			U-250	
	RE39155*PED	Jan 02, 2014				
<u>LAMIVUDINE; ZIDOVUDINE - COMBIVIR</u>						
N020857 001	5859021	May 15, 2012	DS DP U-248			
	5905082	May 18, 2016	DS DP U-248			
	5905082*PED	Nov 18, 2016			U-248	
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N020764 001	5698226	Jan 29, 2012				
	5698226*PED	Jul 29, 2012				
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N020764 002	5698226	Jan 29, 2012				
	5698226*PED	Jul 29, 2012				
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N020764 003	5698226	Jan 29, 2012				
	5698226*PED	Jul 29, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N020764 004	5698226	Jan 29, 2012				
	5698226*PED	Jul 29, 2012				
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 001					I-622	Jan 29, 2013
					NDF	May 29, 2012
					PED	Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 002					I-622	Jan 29, 2013
					NDF	May 29, 2012
					PED	Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 003					I-622	Jan 29, 2013
					NDF	May 29, 2012
					PED	Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 004					I-622	Jan 29, 2013
					NDF	May 29, 2012
					PED	Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 005					I-622	Jan 29, 2013
					NDF	May 29, 2012
					PED	Nov 29, 2012
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2015	DP U-831		NCE	Aug 30, 2012
					ODE	Aug 30, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2015	DP U-831		NCE	Aug 30, 2012
					ODE	Aug 30, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2015	DP U-831		NCE	Aug 30, 2012
					ODE	Aug 30, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N020406 001	5013743*PED	Aug 12, 2010			M-85	Oct 28, 2011
					PED	Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
N020406 002	5013743*PED	Aug 12, 2010			M-85	Oct 28, 2011
					PED	Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
N021281 001	5013743*PED	Aug 12, 2010			M-85	Oct 28, 2011
					PED	Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
N021281 002	5013743*PED	Aug 12, 2010			M-85	Oct 28, 2011
					PED	Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	5013743*PED	Aug 12, 2010			M-85	Oct 28, 2011
	5464632	Nov 07, 2012			PED	Apr 28, 2012
	5464632*PED	May 07, 2013				
	6328994	May 17, 2019				
	6328994*PED	Nov 17, 2019				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	5013743*PED	Aug 12, 2010			M-85	Oct 28, 2011
	5464632	Nov 07, 2012			PED	Apr 28, 2012
	5464632*PED	May 07, 2013				
	6328994	May 17, 2019				
	6328994*PED	Nov 17, 2019				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID 24 HR</u>						
N022327 001					NP	May 18, 2012
<u>LANSOPRAZOLE - PREVACID IV</u>						
N021566 001	7396841	Aug 17, 2021	DP U-947			
	7396841*PED	Feb 17, 2022				
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 001	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 002	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 003	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 004	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N022059 001	6391874	Jul 11, 2017	DS DP U-800		I-620	Jan 29, 2013
	6713485	Sep 29, 2020	DS DP U-800		NCE	Mar 13, 2012
	6727256	Jan 08, 2019	DS DP U-800			
	6828320	Jul 11, 2017	U-800			
	7157466	Nov 19, 2021	DS DP			
<u>LATANOPROST - XALATAN</u>						
N020597 001	5296504	Mar 22, 2011	DP U-778			
	5422368	Mar 22, 2011	DP U-778	Y		
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS U-866		NCE	Dec 27, 2010
	6045501	Aug 28, 2018	U-694		ODE	Jun 29, 2013
	6281230	Jul 24, 2016	U-769		ODE	Dec 27, 2012
	6315720	Oct 23, 2020	U-694			
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018	U-694			
	6561977	Oct 23, 2020	U-694			
	6755784	Oct 23, 2020	U-694			
	6908432	Aug 28, 2018	U-694			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1079			
	7465800	Apr 22, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS	U-866	NCE	Dec 27, 2010
	6045501	Aug 28, 2018		U-694	ODE	Jun 29, 2013
	6281230	Jul 24, 2016		U-769	ODE	Dec 27, 2012
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1079		
	7465800	Apr 22, 2026	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS	U-866	NCE	Dec 27, 2010
	6045501	Aug 28, 2018		U-694	ODE	Jun 29, 2013
	6281230	Jul 24, 2016		U-769		
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1079		
	7465800	Apr 22, 2026	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS	U-866	NCE	Dec 27, 2010
	6045501	Aug 28, 2018		U-694	ODE	Jun 29, 2013
	6281230	Jul 24, 2016		U-769		
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1079		
	7465800	Apr 22, 2026	DS DP			
<u>LETROZOLE - FEMARA</u>						
N020726 001	4978672	Jun 03, 2011		U-203		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021343 001	5278201	Jan 11, 2011				
	5324519	Oct 20, 2011				
	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP	U-801		
	6565874	Oct 28, 2018	DP	U-801		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP	U-801		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021379 001	5278201	Jan 11, 2011				
	5324519	Oct 20, 2011				
	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP	U-801		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP	U-801		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021488 001	5278201	Jan 11, 2011				
	5324519	Oct 20, 2011				
	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP	U-801		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP	U-801		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021731 001	5278201	Jan 11, 2011	DP			
	5324519	Jun 28, 2011	DP			
	5599552	Feb 04, 2014	DP	U-621		
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP	U-621		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018		U-621		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N019732 001	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020011 001	5575987	Sep 02, 2013				
	5631021	May 20, 2014				
	5716640	Sep 02, 2013				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 001	5480656	Jan 02, 2013				
	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5643607	Jan 02, 2013				
	5716640	Sep 02, 2013				
	5814342	Feb 01, 2011				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 002	5480656	Jan 02, 2013				
	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5643607	Jan 02, 2013				
	5716640	Sep 02, 2013				
	5814342	Feb 01, 2011				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020708 001	5480656	Jan 02, 2013				
	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5643607	Jan 02, 2013				
	5716640	Sep 02, 2013				
	5814342	Feb 01, 2011				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 002	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 003	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 004	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2013				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 005	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 006	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - VIADUR</u>						
N021088 001	5728396	Jan 30, 2017		U-316		
	5932547	Jun 13, 2017				
	5985305	Jan 30, 2017				
	6113938	Jul 24, 2018				
	6124261	Jun 13, 2017				
	6132420	Jan 30, 2017				
	6156331	Jan 30, 2017				
	6235712	Jun 13, 2017				
	6375978	Dec 17, 2018				
	6395292	Jan 30, 2017				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 001	5362755	Mar 25, 2013		U-332		
	5547994	Aug 20, 2013		U-332		
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 002	5362755	Mar 25, 2013		U-332		
	5547994	Aug 20, 2013		U-332		
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 003	5362755	Mar 25, 2013		U-332		
	5547994	Aug 20, 2013		U-332		
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 004	5362755	Mar 25, 2013		U-332		
	5547994	Aug 20, 2013		U-332		
	6451289	Mar 21, 2021	DP			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N021730 001	5225183	Jul 06, 2010	DP			
	5362755	Mar 25, 2013		U-636		
	5439670	Jul 06, 2010	DP			
	5547994	Aug 20, 2013		U-636		
	5605674	Feb 25, 2014	DP			
	5695743	Jul 06, 2010	DP	U-636		
	5836299	Nov 17, 2015	DP			
	7256310	Oct 08, 2024	DS DP	U-636		
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 001					PED	Sep 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 002					PED	Sep 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 003					PED	Sep 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 004					PED	Sep 19, 2010

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPBRA</u>						
N021505	001				PED	Sep 19, 2010
<u>LEVETIRACETAM - KEPBRA</u>						
N021872	001				PED	Sep 19, 2010
<u>LEVETIRACETAM - KEPBRA XR</u>						
N022285	001	7858122			NDF	Sep 12, 2011
	7858122*PED	Sep 17, 2028 Mar 17, 2029				
<u>LEVETIRACETAM - KEPBRA XR</u>						
N022285	002	7858122			NDF	Sep 12, 2011
	7858122*PED	Sep 17, 2028 Mar 17, 2029				
<u>LEVOBETAXOLOL HYDROCHLORIDE - BETAXON</u>						
N021114	001	5540918		DP		
	5540918*PED	Jul 30, 2013 Jan 30, 2014				
<u>LEVOPROVACINE HYDROCHLORIDE - CHIROCAINE</u>						
N020997	001	5708011		U-276		
<u>LEVOPROVACINE HYDROCHLORIDE - CHIROCAINE</u>						
N020997	002	5708011		U-276		
<u>LEVOPROVACINE HYDROCHLORIDE - CHIROCAINE</u>						
N020997	003	5708011		U-276		
<u>LEVOCARNITINE - CARNITOR</u>						
N020182	001	6335369		U-433		
	6429230	Jan 18, 2021		U-433		
	6696493	Jan 18, 2021		U-433		
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022064	001	5698558		U-812	NPP	Aug 21, 2012
	5698558*PED	Sep 24, 2012 Mar 24, 2013			PED	Nov 25, 2010
					PED	Feb 21, 2013
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022157	001	5698558		U-852	NPP	Aug 21, 2012
	5698558*PED	Sep 24, 2012 Mar 24, 2013			PED	Nov 25, 2010
					PED	Feb 21, 2013
<u>LEVOFLOXACIN - IQIUX</u>						
N021571	001	5053407		DS DP U-600		
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020634	001	5053407			D-108	Sep 14, 2010
	5053407*PED	Dec 20, 2010 Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020634	002	5053407			D-108	Sep 14, 2010
	5053407*PED	Dec 20, 2010 Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020634	003	5053407			D-108	Sep 14, 2010
	5053407*PED	Dec 20, 2010 Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020635	001	5053407			D-108	Sep 14, 2010
	5053407*PED	Dec 20, 2010 Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020635 004	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N021721 001	5053407	Dec 20, 2010	DS U-36		D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
	6806256	Feb 26, 2022	DP		PED	Mar 10, 2011
	6806256*PED	Aug 26, 2022				
<u>LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
N020635 002	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
N020635 003	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
N020635 005	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - QUIXIN</u>						
N021199 001	5053407	Dec 20, 2010				
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001	6500829	Dec 31, 2019	DS DP		NP	Mar 07, 2011
					ODE	Mar 07, 2015
<u>LEVONORGESTREL - MIRENA</u>						
N021225 001	5785053	Dec 05, 2015	DP		I-610	Oct 01, 2012
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N021998 001					NP	Jul 10, 2012
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 007	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 008	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 009	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 010	6399101	Mar 30, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 011	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 001	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 002	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 003	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 004	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 005	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 006	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 007	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 008	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 009	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 010	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 011	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 012	6555581	Feb 15, 2022	DP		U-759	
	7067148	Feb 15, 2022				
	7101569	Aug 14, 2022				
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 004	7723390	Mar 14, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N022121 001	7723390	Mar 14, 2024	DP			
<u>LIDOCAINE - DENTIPATCH</u>						
N020575 001	5234957	Feb 27, 2011				
	5332576	Jul 26, 2011				
	5446070	Feb 27, 2011				
<u>LIDOCAINE - DENTIPATCH</u>						
N020575 002	5234957	Feb 27, 2011				
	5332576	Jul 26, 2011				
	5446070	Feb 27, 2011				
<u>LIDOCAINE - LIDODERM</u>						
N020612 001	5411738	May 02, 2012				
	5601838	May 02, 2012				
	5741510	Mar 30, 2014	DP		U-488	
	5827529	Oct 27, 2015			U-486	
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N022221 001					NDF	Oct 07, 2011
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N022114 001	5630796	May 20, 2014				
	5899880	May 04, 2016	DP		NPP	Jan 08, 2012
	6004286	Mar 17, 2017	DP			
	6881200	Jun 11, 2016	DP			
<u>LIDOCAINE; PRILOCAINE - ORAQIX</u>						
N021451 001	6031007	Apr 01, 2017	DP	U-553		
<u>LIDOCAINE; TETRACAINE - LIDOCAINE AND TETRACAINE</u>						
N021717 001	5919479	Jul 28, 2015	DP			
	6528086	Sep 28, 2019	DP			
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623 001	5658583	Jul 28, 2015	DP			
	5919479	Jul 28, 2015	DP			
	6306431	Jul 28, 2015	DP			
	6465006	Jul 28, 2015	DP			
	6546281	Jul 28, 2015	DP			
	6780426	Jul 28, 2015	DP			
<u>LINEZOLID - ZYVOX</u>						
N021130 001	5688792	Nov 18, 2014	DS	U-319		
	5688792*PED	May 18, 2015				
	6514529	Mar 15, 2021				
	6514529*PED	Sep 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINEZOLID - ZYVOX</u>						
N021130	002	5688792	Nov 18, 2014	DS	U-319	
		5688792*PED	May 18, 2015			
		6514529	Mar 15, 2021	DP		
		6514529*PED	Sep 15, 2021			
		6559305	Jan 29, 2021	DS		
		6559305*PED	Jul 29, 2021			
<u>LINEZOLID - ZYVOX</u>						
N021131	001	5688792	Nov 18, 2014		U-319	
		5688792*PED	May 18, 2015			
		6559305	Jan 29, 2021	DS		
		6559305*PED	Jul 29, 2021			
<u>LINEZOLID - ZYVOX</u>						
N021132	001	5688792	Nov 18, 2014	DS	U-319	
		5688792*PED	May 18, 2015			
		6559305	Jan 29, 2021	DS		
		6559305*PED	Jul 29, 2021			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341	001	6268343	Aug 22, 2017	DS DP	U-968	NCE Jan 25, 2015
		6458924	Aug 22, 2017	DS DP	U-968	
		7235627	Aug 22, 2017	DS DP		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977	001	7105486	Jun 29, 2023		U-727	M-82 Apr 05, 2013
		7223735	Jun 29, 2023	DP		NPP Nov 10, 2013
		7655630	Feb 24, 2023	DS		NPP Apr 23, 2011
		7659253	Feb 24, 2023	DS DP	U-727	NCE Feb 23, 2012
		7659254	Feb 24, 2023		U-1034	
		7662787	Feb 24, 2023	DS		
		7671030	Feb 24, 2023	DP	U-727	
		7671031	Feb 28, 2023		U-727	
		7674774	Mar 18, 2023	DP	U-842	
		7678770	Mar 25, 2023		U-842	
		7678771	Mar 25, 2023	DP	U-842	
		7687466	Feb 24, 2023	DP		
		7687467	Apr 08, 2023	DP	U-842	
		7700561	Jun 29, 2023	DP		
		7718619	Feb 24, 2023	DP	U-842	
		7723305	Feb 24, 2023	DP	U-842	
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977	002	7105486	Jun 29, 2023		U-727	M-82 Apr 05, 2013
		7223735	Jun 29, 2023	DP		NPP Nov 10, 2013
		7655630	Feb 24, 2023	DS		NPP Apr 23, 2011
		7659253	Feb 24, 2023	DS DP	U-727	NCE Feb 23, 2012
		7659254	Feb 24, 2023		U-1034	
		7662787	Feb 24, 2023	DS		
		7671030	Feb 24, 2023	DP	U-727	
		7671031	Feb 28, 2023		U-727	
		7674774	Mar 18, 2023	DP	U-842	
		7678770	Mar 25, 2023		U-842	
		7678771	Mar 25, 2023	DP	U-842	
		7687466	Feb 24, 2023	DP		
		7687467	Apr 08, 2023	DP	U-842	
		7700561	Jun 29, 2023	DP		
		7718619	Feb 24, 2023	DP	U-842	
		7723305	Feb 24, 2023	DP	U-842	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7105486	Jun 29, 2023		U-727	M-82	Apr 05, 2013
	7223735	Jun 29, 2023		DP	NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS		NPP	Apr 23, 2011
	7659253	Feb 24, 2023	DS	U-727	NCE	Feb 23, 2012
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7105486	Jun 29, 2023		U-842	M-82	Apr 05, 2013
	7223735	Jun 29, 2023		DP	NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS		NPP	Apr 23, 2011
	7659253	Feb 24, 2023	DS	U-727	NCE	Feb 23, 2012
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671031	Feb 28, 2023		U-727		
	7678770	Mar 25, 2023		U-842		
	7687466	Feb 24, 2023		DP		
	7700561	Jun 29, 2023		DP		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7105486	Jun 29, 2023		U-842	M-82	Apr 05, 2013
	7223735	Jun 29, 2023		DP	NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS		NPP	Apr 23, 2011
	7659253	Feb 24, 2023	DS	U-727	NCE	Feb 23, 2012
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7105486	Jun 29, 2023		U-842	M-82	Apr 05, 2013
	7223735	Jun 29, 2023		DP	NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS		NPP	Apr 23, 2011
	7659253	Feb 24, 2023	DS	U-727	NCE	Feb 23, 2012
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		
<u>LODOXAMIDE TROMETHAMINE - ALOMIDE</u>						
N020191 001	5457126	Oct 10, 2012		U-117		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N020448 001	5489436	Feb 06, 2013	DP			
	6814978	Aug 26, 2021	DP			
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N020606 001	5248505	Jul 28, 2010				Y
	5489436	Feb 06, 2013				
	5612054	Sep 28, 2010				Y
	5679376	Oct 21, 2014				Y
	5716641	May 21, 2012	U-226			Y
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N021140 001	6103260	Jul 17, 2017	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021226 001	5541206	Jul 30, 2013			U-348	
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014			U-352	
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014			U-344	
	5674882*PED	Apr 07, 2015				
	5886036	Nov 19, 2013	DS DP			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015			U-351	
	5914332*PED	Jun 13, 2016				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016			U-346	
	6037157*PED	Dec 26, 2016				
	6232333	Nov 07, 2017				
	6232333*PED	May 07, 2018				
	6284767	Feb 15, 2016	DP		U-401	
	6284767	Feb 15, 2016	DP		U-688	
	6284767*PED	Aug 15, 2016				
	6458818	Nov 07, 2017				
	6458818*PED	May 07, 2018				
	6521651	Nov 07, 2017	DP			
	6521651*PED	May 07, 2018				
	6703403	Jun 26, 2016			U-257	
	6703403*PED	Dec 26, 2016				
	7141593	May 22, 2020	DP			
	7141593*PED	Nov 22, 2020				
	7432294	May 22, 2020	DP			
	7432294*PED	Nov 22, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021251 001	5484801	Jan 28, 2014	DP		D-124	Apr 27, 2013
	5484801*PED	Jul 28, 2014				
	5541206	Jul 30, 2013	DS DP U-895			
	5541206	Jul 30, 2013	DS DP U-348			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014			U-352	
	5635523	Jun 03, 2014			U-895	
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014	DS			
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014			U-344	
	5674882	Oct 07, 2014			U-895	
	5674882*PED	Apr 07, 2015				
	5886036	Nov 19, 2013	DS DP U-895			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015	DS DP U-351			
	5914332	Dec 13, 2015	DS DP U-895			
	5914332*PED	Jun 13, 2016				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016			U-895	
	6037157	Jun 26, 2016			U-346	
	6037157*PED	Dec 26, 2016				
	6284767	Feb 15, 2016	DP U-895			
	6284767	Feb 15, 2016	DP U-401			
	6284767*PED	Aug 15, 2016				
	6703403	Jun 26, 2016			U-257	
	6703403	Jun 26, 2016			U-895	
	6703403*PED	Dec 26, 2016				
	6911214	Nov 28, 2021	DP U-895			
	6911214*PED	May 28, 2022				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	5541206	Jul 30, 2013	DS DP U-688		D-124	Apr 27, 2013
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014			U-688	
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014	DS DP			
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014			U-688	
	5674882*PED	Apr 07, 2015				
	5886036	Nov 19, 2013	DS DP U-895			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015	DS DP U-688			
	5914332*PED	Jun 13, 2016				
	6037157	Jun 26, 2016			U-688	
	6037157*PED	Dec 26, 2016				
	6284767	Feb 15, 2016	DP U-688			
	6284767*PED	Aug 15, 2016				
	6703403	Jun 26, 2016			U-688	
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	5541206	Jul 30, 2013	DS DP U-688		D-124	Apr 27, 2013
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014	U-688			
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014	DS DP			
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014	U-688			
	5674882*PED	Apr 07, 2015				
	5886036	Nov 19, 2013	DS DP U-895			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015	DS DP U-688			
	5914332*PED	Jun 13, 2016				
	6037157	Jun 26, 2016	U-688			
	6037157*PED	Dec 26, 2016				
	6284767	Feb 15, 2016	DP U-688			
	6284767*PED	Aug 15, 2016				
	6703403	Jun 26, 2016	U-688			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				
<u>LORATADINE - CLARITIN</u>						
N020641 002	6132758	Jun 01, 2018				
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE - CLARITIN-D 24 HOUR</u>						
N020470 002	5314697	Oct 23, 2012				
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 001	5210079*PED	Nov 11, 2010	U-496			
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 002	5210079*PED	Nov 11, 2010	U-496			
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 003	5210079*PED	Nov 11, 2010	U-496			
<u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u>						
A076958 001					PC	Oct 03, 2010
<u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u>						
A076958 002					PC	Oct 03, 2010
<u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u>						
A076958 003					PC	Oct 03, 2010
<u>LOTEPREDNOL ETABONATE - ALREX</u>						
N020803 001	4996335	Mar 09, 2012				
	4996335*PED	Sep 09, 2012				
	5540930	Oct 25, 2013				
	5540930*PED	Apr 25, 2014				
	5747061	Oct 25, 2013	DP U-576			
	5747061*PED	Apr 25, 2014				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N020583 001	4996335	Mar 09, 2012				
	4996335*PED	Sep 09, 2012				
	5540930	Oct 25, 2013				
	5540930*PED	Apr 25, 2014				
	5747061	Oct 25, 2013	DP U-575			
	5747061*PED	Apr 25, 2014				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N020841 001	5540930	Oct 25, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN - ZYLET</u>						
N050804 001	4996335	Mar 09, 2012	DS DP U-920			
	4996335*PED	Sep 09, 2012				
	5540930	Oct 25, 2013	DP			
	5540930*PED	Apr 25, 2014				
	5747061	Oct 25, 2013	DP U-920			
	5747061*PED	Apr 25, 2014				
<u>LOVASTATIN - ALTOPREV</u>						
N021316 001	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018			U-456	
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N021316 002	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018			U-456	
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N021316 003	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018			U-456	
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N021316 004	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018			U-456	
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 001	6080428	May 27, 2017			U-447	
	6129930	Sep 20, 2013			U-448	
	6406715	Sep 20, 2013	DP		U-450	
	6469035	Mar 15, 2018			U-768	
	6676967	Sep 20, 2013			U-548	
	6746691	Sep 20, 2013			U-586	
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 002	6080428	May 27, 2017			U-447	
	6129930	Sep 20, 2013			U-448	
	6406715	Sep 20, 2013	DP		U-450	
	6469035	Mar 15, 2018			U-768	
	6676967	Sep 20, 2013			U-548	
	6746691	Sep 20, 2013			U-586	
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 003	6080428	May 27, 2017			U-447	
	6129930	Sep 20, 2013			U-448	
	6406715	Sep 20, 2013	DP		U-450	
	6469035	Mar 15, 2018			U-768	
	6676967	Sep 20, 2013			U-548	
	6746691	Sep 20, 2013			U-586	
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 004	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018			U-768	
	6818229	Sep 20, 2013	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	5284858	Jul 14, 2014	DS			
	5317032	May 31, 2011			NCE	Jan 31, 2011
	6414016	Sep 05, 2020			U-874	
	6583174	Oct 16, 2020	DP		U-874	
	7064148	Aug 30, 2022			U-739	
	7417067	Oct 16, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	5284858	Jul 14, 2014	DS		I-557	Apr 28, 2011
	5317032	May 31, 2011		U-874	NS	Apr 28, 2011
	6414016	Sep 05, 2020		U-874	NCE	Jan 31, 2011
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022		U-873		
	7064148	Aug 30, 2022		U-739		
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024		U-1085		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001	5532372	Jul 02, 2013	DS		NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002	5532372	Jul 02, 2013	DS		NCE	Oct 28, 2015
<u>LUTROPIN ALFA - LUVERIS</u>						
N021322 001	5767251	Jun 16, 2015	DS		ODE	Oct 08, 2011
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N021910 001	5945449	Oct 31, 2017	DP	U-785	ODE	Jul 26, 2013
	7300674	Mar 04, 2023	DP	U-785		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35</u>						
N021910 002	5945449	Oct 31, 2017	DP	U-785	ODE	Jul 26, 2013
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N022456 001	6489346	Jul 16, 2016	DP	U-588		
	6489346	Jul 16, 2016	DP	U-1021		
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP	U-1021		
	6699885	Jul 16, 2016	DP	U-588		
	7399772	Jul 16, 2016	DP	U-1021		
	7399772	Jul 16, 2016	DP	U-588		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N022456 002	6489346	Jul 16, 2016	DP	U-1021		
	6489346	Jul 16, 2016	DP	U-588		
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP	U-588		
	6699885	Jul 16, 2016	DP	U-1021		
	7399772	Jul 16, 2016	DP	U-588		
	7399772	Jul 16, 2016	DP	U-1021		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021850 001	6489346	Jul 16, 2016	DS	DP	U-588	
	6645988	Jul 16, 2016	DS	DP	U-588	
	6699885	Jul 16, 2016			U-588	
	7399772	Jul 16, 2016			U-588	
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021850 002	6489346	Jul 16, 2016	DS	DP	U-623	
	6645988	Jul 16, 2016	DS	DP	U-623	
	6699885	Jul 16, 2016			U-623	
	7399772	Jul 16, 2016			U-623	
<u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N022372 001	6946149	Apr 30, 2022	DP	U-837	NC	Aug 05, 2013
<u>MALATHION - OVIDE</u>						
N018613 001	7560445	Feb 01, 2027	DS	DP	U-986	
<u>MANGAFODIPIR TRISODIUM - TESLASCAN</u>						
N020652 001	4933456	Nov 27, 2011				
<u>MANNITOL - ARIDOL KIT</u>						
N022368 001	5817028	Feb 23, 2015		U-1091	NP	Oct 05, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
N022128	001 6586430	Dec 01, 2019	DS DP U-824		NPP	May 28, 2013
	6667314	Aug 06, 2021	DS DP U-824		NCE	Aug 06, 2012
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N022128	002 6586430	Dec 01, 2019	DS DP U-824		NPP	May 28, 2013
	6667314	Aug 06, 2021	DS DP U-824		NCE	Aug 06, 2012
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MECASERMIN RECOMBINANT - INCRELEX</u>						
N021839	001 5681814	Sep 18, 2017	DP		NCE	Aug 30, 2010
	5824642	Jul 08, 2014	U-681		ODE	Aug 30, 2012
	6207640	Apr 07, 2014	U-681			
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>						
N021884	001 5681818	Oct 28, 2014	U-697		ODE	Dec 12, 2012
<u>MEDROXYPROGESTERONE ACETATE - DEPO-PROVERA</u>						
N020246	001				M-96	Oct 15, 2013
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104</u>						
N021583	001 6495534	May 15, 2020	DP			
<u>MEGESTROL ACETATE - MEGACE</u>						
N020264	001 5338732	Aug 16, 2011				
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N021778	001 5145684	Jan 25, 2011	DP U-673			
	6592903	Sep 21, 2020	DP			
	7101576	Apr 22, 2024	U-755			
<u>MELOXICAM - MOBIC</u>						
N020938	001				ODE	Aug 11, 2012
					PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>						
N020938	002				ODE	Aug 11, 2012
					PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>						
N021530	001 6184220	Mar 25, 2019	DP		ODE	Aug 11, 2012
	6184220*PED	Sep 25, 2019			PED	Feb 11, 2013
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N021487	001 5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N021487	002 5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N021627	001 5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525	001 5061703	Apr 11, 2015	U-539		NDF	Jun 21, 2013
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525	002 5061703	Apr 11, 2015	U-539		NDF	Jun 21, 2013
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525	003 5061703	Apr 11, 2015	U-539		NDF	Jun 21, 2013
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525	004 5061703	Apr 11, 2015	U-539		NDF	Jun 21, 2013
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N022029	001				NDF	Feb 20, 2011
					NC	Feb 20, 2011

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MESALAMINE - APRISO</u>						
N020922 001	5194247 6353029	Dec 10, 2013 Aug 24, 2020	DP U-294			
<u>MESALAMINE - ASACOL</u>						
N019651 001	5541170 5541171	Jul 30, 2013 Jul 30, 2013	U-141 U-141			
<u>MESALAMINE - ASACOL HD</u>						
N021830 001	5541170 5541171 6893662	Jul 30, 2013 Jul 30, 2013 Nov 15, 2021	DP U-141 DP U-141 DP U-141		NP	May 29, 2011
<u>MESALAMINE - LIALDA</u>						
N022000 001	6773720	Jun 08, 2020	DP			
<u>MESALAMINE - SFROWASA</u>						
N019618 002	7645801	Jul 24, 2027	DS DP			
<u>MESNA - MESNEX</u>						
N020855 001	5252341 5262169	Jul 16, 2011 Jul 16, 2011				
<u>METAXALONE - SKELAXIN</u>						
N013217 001	6407128 6683102	Dec 03, 2021 Dec 03, 2021	U-189 U-189			
<u>METAXALONE - SKELAXIN</u>						
N013217 003	6407128 6683102 7122566 7714006	Dec 03, 2021 Dec 03, 2021 Feb 06, 2026 Dec 03, 2021	U-189 U-189 U-915 U-1050			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	6099859 6495162 6790459 6866866	Mar 20, 2018 Mar 20, 2018 Mar 17, 2021 Mar 17, 2021	DP DP U-604 DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	6099859 6495162 6790459 6866866	Mar 20, 2018 Mar 20, 2018 Mar 17, 2021 Mar 17, 2021	DP DP U-604 DP			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N021202 001	6475521 6660300	Mar 19, 2018 Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N021202 004	6475521 6660300	Mar 19, 2018 Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N021748 001	6340475 6488962 6635280 6723340	Sep 19, 2016 Jun 20, 2020 Sep 19, 2016 Oct 25, 2021	DS DP U-669 DS DP DS DP DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N021748 002	6488962 7780987	Jun 20, 2020 Mar 23, 2025	DS DP DS DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N021591 001	6890957	Sep 14, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP		U-1055	
	6166042	Jun 19, 2016			U-679	
	6166043	Jun 19, 2016			U-679	
	6172090	Jun 19, 2016			U-679	
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP		U-1055	
	6166042	Jun 19, 2016			U-679	
	6166043	Jun 19, 2016			U-679	
	6172090	Jun 19, 2016			U-679	
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP		U-973	
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016			U-973	
	6166043	Jun 19, 2016			U-973	
	6172090	Jun 19, 2016			U-973	
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021			U-974	
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP		U-973	
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016			U-973	
	6166043	Jun 19, 2016			U-973	
	6172090	Jun 19, 2016			U-973	
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021			U-974	
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
<u>METFORMIN HYDROCHLORIDE; REPAGLINIDE - PRANDIMET</u>						
N022386 001	6677358	Jun 12, 2018	DP		U-546	
<u>METFORMIN HYDROCHLORIDE; REPAGLINIDE - PRANDIMET</u>						
N022386 002	6677358	Jun 12, 2018	DP		U-546	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 001	5002953	Sep 17, 2011	DS	DP	U-691	
	5002953	Sep 17, 2011	DS	DP	U-690	
	5002953	Sep 17, 2011	DS	DP	U-734	
	5002953	Sep 17, 2011	DS	DP	U-493	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS	DP	U-493	Y
	5741803	Apr 21, 2015	DS	DP	U-734	Y
	5741803*PED	Oct 21, 2015				
	5965584	Jun 19, 2016			U-493	Y
	6166042	Jun 19, 2016			U-493	Y
	6288095	Feb 11, 2017			U-493	Y
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 002	5002953	Sep 17, 2011	DS DP U-734			
	5002953	Sep 17, 2011	DS DP U-691			
	5002953	Sep 17, 2011	DS DP U-493			
	5002953	Sep 17, 2011	DS DP U-690			
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803*PED	Oct 21, 2015				
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 003	5002953	Sep 17, 2011	DS DP U-734			
	5002953	Sep 17, 2011	DS DP U-691			
	5002953	Sep 17, 2011	DS DP U-690			
	5002953	Sep 17, 2011	DS DP U-493			
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803*PED	Oct 21, 2015				
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 004	5002953	Sep 17, 2011	DS DP U-691			
	5002953	Sep 17, 2011	DS DP U-690			
	5002953	Sep 17, 2011	DS DP U-493			
	5002953	Sep 17, 2011	DS DP U-734			
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 005	5002953	Sep 17, 2011	DS DP U-690			
	5002953	Sep 17, 2011	DS DP U-493			
	5002953	Sep 17, 2011	DS DP U-691			
	5002953	Sep 17, 2011	DS DP U-734			
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN - KOMBIGLYZE XR</u>						
N200678 001	6395767	Feb 16, 2021	DS DP U-1097		NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN - KOMBIGLYZE XR</u>						
N200678 002	6395767	Feb 16, 2021	DS DP U-1097		NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN - KOMBIGLYZE XR</u>						
N200678 003	6395767	Feb 16, 2021	DS DP U-1097		NCE	Jul 31, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 001	6303661	Apr 24, 2017			M-69	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP	U-802	M-68	Oct 12, 2010
	6890898	Feb 02, 2019		U-1036	NCE	Oct 16, 2011
	6890898	Feb 02, 2019		U-803		
	6890898	Feb 02, 2019		U-1038		
	7078381	Feb 02, 2019		U-1036		
	7078381	Feb 02, 2019		U-1038		
	7078381	Feb 02, 2019		U-803		
	7125873	Jul 26, 2022	DP	U-1036		
	7125873	Jul 26, 2022	DP	U-803		
	7125873	Jul 26, 2022	DP	U-1038		
	7326708	Apr 11, 2026	DS DP	U-802		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 002	6303661	Apr 24, 2017		U-802	M-69	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP	U-802	M-68	Oct 12, 2010
	6890898	Feb 02, 2019		U-1036	NCE	Oct 16, 2011
	6890898	Feb 02, 2019		U-1038		
	6890898	Feb 02, 2019		U-803		
	7078381	Feb 02, 2019		U-1038		
	7078381	Feb 02, 2019		U-1036		
	7078381	Feb 02, 2019		U-803		
	7125873	Jul 26, 2022	DP	U-1038		
	7125873	Jul 26, 2022	DP	U-803		
	7125873	Jul 26, 2022	DP	U-1036		
	7326708	Apr 11, 2026	DS DP	U-802		
<u>METHYL AMINOLEVULINATE HYDROCHLORIDE - METVIXIA</u>						
N021415 001	6034267	Mar 08, 2016		U-804	M-77	Jun 26, 2011
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001					NCE	Apr 24, 2013
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 001	5958446	Dec 12, 2012	DP		NPP	Jun 29, 2013
	6210705	Sep 30, 2018	DP	U-727		
	6348211	Sep 30, 2018	DP	U-727		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 002	5958446	Dec 12, 2012	DP		NPP	Jun 29, 2013
	6210705	Sep 30, 2018	DP	U-727		
	6348211	Sep 30, 2018	DP	U-727		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 003	5958446	Dec 12, 2012	DP		NPP	Jun 29, 2013
	6210705	Sep 30, 2018	DP	U-727		
	6348211	Sep 30, 2018	DP	U-727		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 004	5958446	Dec 12, 2012	DP		NPP	Jun 29, 2013
	6210705	Sep 30, 2018	DP	U-727		
	6348211	Sep 30, 2018	DP	U-727		
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	6919373	Jul 31, 2017		U-666	M-88	Nov 04, 2012
	6919373*PED	Jan 31, 2018			NPP	Jun 27, 2011
	6930129	Jul 31, 2017		U-666		
	6930129*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	6919373	Jul 31, 2017		U-666	M-88	Nov 04, 2012
	6919373*PED	Jan 31, 2018			NPP	Jun 27, 2011
	6930129	Jul 31, 2017		U-666		
	6930129*PED	Jan 31, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	6919373	Jul 31, 2017	U-666		M-88	Nov 04, 2012
	6919373*PED	Jan 31, 2018			NPP	Jun 27, 2011
	6930129	Jul 31, 2017	U-666			
	6930129*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	6919373	Jul 31, 2017	U-666		M-88	Nov 04, 2012
	6919373*PED	Jan 31, 2018			NPP	Jun 27, 2011
	6930129	Jul 31, 2017	U-666			
	6930129*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 001	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 002	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 003	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 004	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N021419 001	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N021419 002	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 001	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 002	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 003	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 004	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N022246 001	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N022246 002	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N021793 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N021793 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
N019962 001					M-61 PED	Jul 18, 2010 Jan 18, 2011
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
N019962 002					M-61 PED	Jul 18, 2010 Jan 18, 2011
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
N019962 003					M-61 PED	Jul 18, 2010 Jan 18, 2011
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
N019962 004					M-61 PED	Jul 18, 2010 Jan 18, 2011
<u>METRONIDAZOLE - FLAGYL ER</u>						
N020868 001	6103262	Aug 15, 2017	DP U-137			
<u>METRONIDAZOLE - METROGEL</u>						
N021789 001	6881726	Feb 21, 2022	DP U-743			
	7348317	Feb 21, 2022	DP U-743			
<u>METRONIDAZOLE - METROGEL-VAGINAL</u>						
N020208 001	5536743	Jul 16, 2013	U-137			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N021506 002	5376634	Dec 27, 2011	DS DP		I-554	Jan 22, 2011
	6107458	Mar 16, 2019	DS DP U-845			
	6107458	Mar 16, 2019	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-845			
	6774104	Jan 08, 2021	DP U-650			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N021506 003	5376634	Dec 27, 2011	DS DP		I-554	Jan 22, 2011
	6107458	Mar 16, 2019	DS DP U-845			
	6107458	Mar 16, 2019	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104	Jan 08, 2021	DP U-650			
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	6916485	Sep 11, 2022	DP U-1051		NDF	Apr 16, 2013
	7651698	Jan 08, 2026	U-1051			
<u>MICONAZOLE NITRATE - MICONAZOLE NITRATE</u>						
A079114 001					PC	Dec 24, 2010
<u>MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N021308 001	5514698	Mar 21, 2014		Y		
	6153635	Nov 28, 2020		Y		
<u>MIGLUSTAT - ZAVESCA</u>						
N021348 001	5472969	May 13, 2013			ODE	Jul 31, 2010
	5525616	Jun 11, 2013				
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	5908838	Feb 19, 2018	U-917			
	7790705	Nov 20, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	5908838	Feb 19, 2018	U-917			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Nov 20, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	5908838	Feb 19, 2018	U-917			
	7790705	Nov 20, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	5908838	Feb 19, 2018	U-917			
	7790705	Nov 20, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	5908838	Feb 19, 2018	U-917			
	7790705	Nov 20, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	5908838	Feb 19, 2018	U-917			
	7790705	Nov 20, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	5908838	Feb 19, 2018	U-917			
	7790705	Nov 20, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	5908838	Feb 19, 2018	U-917			
	7790705	Nov 20, 2025	U-1078			
<u>MINOXIDIL - MEN'S ROGAINE</u>						
N021812 001	6946120	Apr 20, 2019	DP U-702			
<u>MODAFINIL - PROVIGIL</u>						
N020717 001	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	U-255			
	RE37516*PED	Apr 06, 2015				
<u>MODAFINIL - PROVIGIL</u>						
N020717 002	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	U-255			
	RE37516*PED	Apr 06, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	5394868	Jun 25, 2012	DP		NPP	Feb 01, 2011
	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014	U-645			
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014	U-645			
	6949532*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	5394868	Jun 25, 2012	DP		NPP	Feb 01, 2011
	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014	U-645			
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014	U-645			
	6949532*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001	5837699	Jan 27, 2014	DP U-625		I-626	May 26, 2013
	5837699*PED	Jul 27, 2014				
	6127353	Oct 03, 2017	DS DP			
	6127353*PED	Apr 03, 2018				
	6723713	Jan 27, 2014	U-625			
	6723713*PED	Jul 27, 2014				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002	5565473	Feb 03, 2012	DS DP U-807			
	5565473	Feb 03, 2012	DS DP U-228			
	5565473	Feb 03, 2012	DS DP U-675			
	5565473*PED	Aug 03, 2012	U-228			
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001	5565473	Feb 03, 2012	DS DP U-228			
	5565473	Feb 03, 2012	DS DP U-807			
	5565473	Feb 03, 2012	DS DP U-675			
	5565473*PED	Aug 03, 2012	U-228			
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002	5565473	Feb 03, 2012	DS DP U-675			
	5565473	Feb 03, 2012	DS DP U-807			
	5565473	Feb 03, 2012	DS DP U-228			
	5565473*PED	Aug 03, 2012	U-228			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001	5565473	Feb 03, 2012	DS DP U-807			
	5565473	Feb 03, 2012	DS DP U-675			
	5565473*PED	Aug 03, 2012				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 001	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 002	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 003	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 004	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 006	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N021671 001	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931089	Jul 14, 2015			U-584	
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N021671 002	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931089	Jul 14, 2015			U-584	
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N021671 003	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931089	Jul 14, 2015			U-584	
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	7682633	Jun 19, 2027	U-443		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	7682633	Jun 19, 2027	U-443		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	7682633	Jun 19, 2027	U-443		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	7682633	Jun 19, 2027	U-443		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	7682633	Jun 19, 2027	U-443		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	7682633	Jun 19, 2027	U-443		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N021085 001	4990517	Dec 08, 2011	DS DP U-298			
	5607942	Mar 04, 2014	U-298			
	5849752	Dec 05, 2016	U-298			
	6610327	Oct 29, 2019	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N021277 001	4990517	Dec 08, 2011	DS DP U-298			
	5607942	Mar 04, 2014	U-298			
	5849752	Dec 05, 2016	U-298			
	6548079	Jul 25, 2020	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	4990517	Dec 08, 2011	DS DP U-709		NP	Nov 19, 2013
	4990517*PED	Jun 08, 2012			PED	May 19, 2014
	5607942	Mar 04, 2014	DS DP U-709			
	5607942*PED	Sep 04, 2014				
	5716830*PED	Mar 29, 2020				
	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	DP U-709			
	7671070*PED	Mar 20, 2020				
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N021598 001	4990517	Dec 08, 2011	DS DP U-709			
	4990517*PED	Jun 08, 2012				
	5607942	Mar 04, 2014	DS DP U-709			
	5607942*PED	Sep 04, 2014				
	6716830	Sep 29, 2019	DP			
	6716830*PED	Mar 29, 2020				
	7671070	Sep 29, 2019	U-709			
	7671070*PED	Mar 29, 2020				
<u>MUPIROICIN - CENTANY</u>						
N050788 001	6013657	Jul 08, 2018	DP			
<u>MYCOPHENOLATE MOFETIL - CELLCEPT</u>						
N050759 001	5688529	Nov 18, 2014	DP			
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE - CELLCEPT</u>						
N050758 001	5543408	Sep 15, 2013	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791 001	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Apr 10, 2017	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791 002	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Apr 10, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALTREXONE - VIVITROL</u>						
N021897 001	5792477	May 02, 2017	DP		I-631	Oct 12, 2013
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6264987	May 19, 2020	DP			
	6331317	Nov 12, 2019	DP			
	6379703	Dec 30, 2018	DP			
	6379704	May 19, 2020	DP			
	6395304	Nov 12, 2019	DP			
	6403114	May 02, 2017	DP			
	6495164	May 25, 2020	DP			
	6495166	Nov 12, 2019	DP			
	6534092	May 19, 2020	DP			
	6537586	Nov 12, 2019	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
	6713090	Nov 12, 2019	DP			
	6939033	Nov 12, 2019	DP			
	7799345	May 25, 2020	DP			
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N020353 001	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N020353 002	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N020353 003	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N021926 001	6060499	Aug 14, 2017	DP U-867		NC	Apr 15, 2011
	6586458	Aug 14, 2017	DP U-867			
	7332183	Oct 02, 2025	DP U-867			
<u>NARATRIPTAN HYDROCHLORIDE - AMERGE</u>						
N020763 001	4997841	Jul 07, 2010	U-232			
<u>NARATRIPTAN HYDROCHLORIDE - AMERGE</u>						
N020763 002	4997841	Jul 07, 2010	U-232			
<u>NATEGLINIDE - STARLIX</u>						
N021204 001	5463116	Oct 21, 2012				
	5488150	Jan 30, 2013				
	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NATEGLINIDE - STARLIX</u>						
N021204 002	5463116	Oct 21, 2012				
	5488150	Jan 30, 2013				
	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 002	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Apr 08, 2020	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 003	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Apr 08, 2020	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 004	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Apr 08, 2020	DP U-3			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 005	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Apr 08, 2020	DP U-3			
<u>NEDOCROMIL SODIUM - ALOCRIIL</u>						
N021009 001	RE38628	Aug 22, 2012	U-304			
<u>NELARABINE - ARRANON</u>						
N021877 001	5424295	Jun 13, 2012	DS DP		NCE	Oct 28, 2010
	5492897	Feb 20, 2013	U-689		ODE	Oct 28, 2012
	5747472	Feb 20, 2013	U-695			
	5747472	Feb 20, 2013	U-696			
	5747472	Feb 20, 2013	U-689			
	5821236	Feb 20, 2013	U-695			
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N020778 001	5484926	Oct 07, 2013				
	5484926*PED	Apr 07, 2014				
	5952343	Oct 07, 2013	U-257			
	5952343*PED	Apr 07, 2014	U-257			
	6162812	Oct 07, 2013	U-248			
	6162812*PED	Apr 07, 2014	U-248			
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N020779 001	5484926	Oct 07, 2013				
	5484926*PED	Apr 07, 2014				
	5952343	Oct 07, 2013	U-257			
	5952343*PED	Apr 07, 2014	U-257			
	6162812	Oct 07, 2013	U-248			
	6162812*PED	Apr 07, 2014	U-248			
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N021503 001	5484926	Oct 07, 2013				
	5484926*PED	Apr 07, 2014				
	5952343	Oct 07, 2013	U-257			
	5952343*PED	Apr 07, 2014	U-257			
	6162812	Oct 07, 2013	U-248			
	6162812*PED	Apr 07, 2014	U-248			
<u>NEPAFENAC - NEVANAC</u>						
N021862 001	5475034	Jun 06, 2014	U-100		NCE	Aug 19, 2010
	7834059	Jan 31, 2027	U-1095			
<u>NESIRITIDE RECOMBINANT - NATRECOR</u>						
N020920 001	5114923	May 19, 2014	DS DP U-855			
<u>NEVIRAPINE - VIRAMUNE</u>						
N020636 001	5366972	Nov 22, 2011	U-167			
	5366972*PED	May 22, 2012				
<u>NEVIRAPINE - VIRAMUNE</u>						
N020933 001	5366972	Nov 22, 2011				
	5366972*PED	May 22, 2012				
<u>NIACIN - NIASPAN</u>						
N020381 001	6080428	May 27, 2017	U-331			
	6129930	Sep 20, 2013	U-354			
	6406715	Sep 20, 2013	U-450			
	6746691	Sep 20, 2013	U-586			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013	U-712			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 002	6080428	May 27, 2017				
	6129930	Sep 20, 2013				
	6406715	Sep 20, 2013				
	6469035	Mar 15, 2018				
	6676967	Sep 20, 2013				
	6746691	Sep 20, 2013				
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013				
<u>NIACIN - NIASPAN</u>						
N020381 003	6080428	May 27, 2017				
	6129930	Sep 20, 2013				
	6406715	Sep 20, 2013				
	6469035	Mar 15, 2018				
	6676967	Sep 20, 2013				
	6746691	Sep 20, 2013				
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013				
<u>NIACIN - NIASPAN</u>						
N020381 004	6080428	May 27, 2017				
	6129930	Sep 20, 2013				
	6406715	Sep 20, 2013				
	6469035	Mar 15, 2018				
	6676967	Sep 20, 2013				
	6746691	Sep 20, 2013				
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013				
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>						
N020381 005	6080428	May 27, 2017				
	6129930	Sep 20, 2013				
	6406715	Sep 20, 2013				
	6746691	Sep 20, 2013				
	7011848	Sep 20, 2013				
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 001	6080428	May 27, 2017				
	6129930	Sep 20, 2013	DP			
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018				
	6676967	Sep 20, 2013				
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013				
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 002	6080428	May 27, 2017				
	6129930	Sep 20, 2013	DP			
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018				
	6676967	Sep 20, 2013				
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013				
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 003	6080428	May 27, 2017				
	6129930	Sep 20, 2013	DP			
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018				
	6676967	Sep 20, 2013				
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 004	6080428	May 27, 2017		U-862	NC	Feb 15, 2011
	6129930	Sep 20, 2013	DP	U-862		
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018		U-863		
	6676967	Sep 20, 2013		U-862		
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013		U-862		
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 005	6080428	May 27, 2017		U-862	NC	Feb 15, 2011
	6129930	Sep 20, 2013	DP	U-862		
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018		U-863		
	6676967	Sep 20, 2013		U-862		
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013		U-862		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 004	7612102	Dec 26, 2027	DP		U-1029	
	7659291	Apr 18, 2027				
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 003	7612102	Dec 26, 2027	DP		U-1029	
	7659291	Apr 18, 2027				
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 002	7612102	Dec 26, 2027	DP		U-1029	
	7659291	Apr 18, 2027				
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 005	7612102	Dec 26, 2027	DP		U-1029	
	7659291	Apr 18, 2027				
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	5508038	Apr 16, 2013				
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	5508038	Apr 16, 2013				
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	5508038	Apr 16, 2013				
<u>NICOTINE - NICOTROL</u>						
N020385 001	5656255	Aug 12, 2014				
<u>NICOTINE POLACRILEX - COMMIT</u>						
N021330 001	5110605	Aug 21, 2010				
<u>NICOTINE POLACRILEX - COMMIT</u>						
N021330 002	5110605	Aug 21, 2010				
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N022360 001	5110605	Aug 21, 2010	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N022360 002	5110605	Aug 21, 2010	DP			
<u>NIFEDIPINE - ADALAT CC</u>						
N020198 001	5264446	Nov 23, 2010				
<u>NIFEDIPINE - ADALAT CC</u>						
N020198 002	5264446	Nov 23, 2010				
<u>NIFEDIPINE - ADALAT CC</u>						
N020198 003	5264446	Nov 23, 2010				
<u>NIFEDIPINE - PROCARDIA XL</u>						
N019684 001	5264446	Nov 23, 2010				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIFEDIPINE - PROCARDIA XL</u>						
N019684	002 5264446	Nov 23, 2010				
<u>NIFEDIPINE - PROCARDIA XL</u>						
N019684	003 5264446	Nov 23, 2010				
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068	001 7169791	Jul 04, 2023	DS DP U-836		I-627 NCE ODE	Jun 17, 2013 Oct 29, 2012 Oct 29, 2014
<u>NISOLDIPINE - SULAR</u>						
N020356	005 5422123	Jun 06, 2012	DP			
	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N020356	006 5422123	Jun 06, 2012	DP			
	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N020356	007 5422123	Jun 06, 2012	DP			
	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N020356	008 5422123	Jun 06, 2012	DP			
	5626874	Nov 30, 2014	DP			
<u>NITAZOXANIDE - ALINIA</u>						
N021497	001 5387598	Feb 07, 2012	DP U-524			
	5578621	Nov 26, 2013	DP U-525			
	5968961	May 07, 2017	DP			
	6020353	Sep 18, 2014	DS DP			
<u>NITAZOXANIDE - ALINIA</u>						
N021498	001 5387598	Feb 07, 2012			U-524	
	5578621	Sep 08, 2014			U-525	
	5965590	Jul 03, 2017			U-523	
	5968961	May 07, 2017				
	6020353	Sep 08, 2014				
	6117894	May 07, 2017				
<u>NITISINONE - ORFADIN</u>						
N021232	001 5550165	Aug 27, 2013				
<u>NITISINONE - ORFADIN</u>						
N021232	002 5550165	Aug 27, 2013				
<u>NITISINONE - ORFADIN</u>						
N021232	003 5550165	Aug 27, 2013				
<u>NITRIC OXIDE - INOMAX</u>						
N020845	002 5485827	Jan 23, 2013			U-297	
	5485827*PED	Jul 23, 2013				
	5873359	Jan 23, 2013			U-297	
	5873359*PED	Jul 23, 2013				
<u>NITRIC OXIDE - INOMAX</u>						
N020845	003 5485827	Jan 23, 2013			U-297	
	5485827*PED	Jul 23, 2013				
	5873359	Jan 23, 2013			U-297	
	5873359*PED	Jul 23, 2013				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705	002 5186925	Mar 06, 2011	DP			
<u>NITROGLYCERIN - NITROMIST</u>						
N021780	001 5869082	Apr 16, 2016	DP			
<u>NITROGLYCERIN - NITROSTAT</u>						
N021134	001 6500456	Sep 16, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITROGLYCERIN - NITROSTAT</u>						
N021134 002	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N021134 003	6500456	Sep 16, 2018				
<u>NIZATIDINE - AXID</u>						
N021494 001	6930119	Jul 17, 2022	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 001	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 002	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 003	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 004	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 005	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N021008 001	5538739	Jul 23, 2013	DP		M-73	Mar 03, 2011
	5538739*PED	Jan 23, 2014				
	5639480	Jun 17, 2014	DP			
	5639480*PED	Dec 17, 2014				
	5688530	Nov 18, 2014		U-268		
	5688530*PED	May 18, 2015				
	5922338	Jul 13, 2016	DP			
	5922338*PED	Jan 13, 2017				
	5922682	Jul 13, 2016	DP			
	5922682*PED	Jan 13, 2017				
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N021008 002	5538739	Jul 23, 2013			M-73	Mar 03, 2011
	5538739*PED	Jan 23, 2014				
	5639480	Jun 17, 2014	DP			
	5639480*PED	Dec 17, 2014				
	5688530	Nov 18, 2014		U-268		
	5688530*PED	May 18, 2015				
	5922338	Jul 13, 2016	DP			
	5922338*PED	Jan 13, 2017				
	5922682	Jul 13, 2016	DP			
	5922682*PED	Jan 13, 2017				
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N021008 003	5538739	Jul 23, 2013			M-73	Mar 03, 2011
	5538739*PED	Jan 23, 2014				
	5639480	Jun 17, 2014	DP			
	5639480*PED	Dec 17, 2014				
	5688530	Nov 18, 2014		U-268		
	5688530*PED	May 18, 2015				
	5922338	Jul 13, 2016	DP			
	5922338*PED	Jan 13, 2017				
	5922682	Jul 13, 2016	DP			
	5922682*PED	Jan 13, 2017				
<u>OFLOXACIN - FLOXIN OTIC</u>						
N020799 001	5401741	Mar 27, 2012	U-407			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA</u>						
N020592 001	5229382	Apr 23, 2011	DS DP	U-547	I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP	U-149	NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014		U-176	PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011		U-364		
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015		U-307		
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011		U-364		
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011		U-360		
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011		U-363		
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015		U-308		
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017		U-963		
<u>OLANZAPINE - ZYPREXA</u>						
N020592 002	5229382	Apr 23, 2011	DS DP	U-547	I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP	U-149	NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014		U-176	PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011		U-364		
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015		U-307		
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011		U-364		
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011		U-360		
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011		U-363		
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015		U-308		
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017		U-963		
<u>OLANZAPINE - ZYPREXA</u>						
N020592 003	5229382	Apr 23, 2011	DS DP	U-547	I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP	U-149	NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014		U-176	PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011		U-364		
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015		U-307		
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011		U-364		
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011		U-360		
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011		U-363		
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015		U-308		
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017		U-963		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA</u>						
N020592 004	5229382	Apr 23, 2011	DS DP U-547		I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP U-149		NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014	U-176		PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011	U-364			
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015	U-307			
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011	U-364			
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011	U-360			
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011	U-363			
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015	U-308			
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017	U-963			
<u>OLANZAPINE - ZYPREXA</u>						
N020592 005	5229382	Apr 23, 2011	DS DP U-547		I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP U-149		NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014	U-176		PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011	U-364			
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015	U-307			
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011	U-364			
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011	U-360			
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011	U-363			
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015	U-308			
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017	U-963			
<u>OLANZAPINE - ZYPREXA</u>						
N020592 006	5229382	Apr 23, 2011	DS DP U-547		I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP U-149		NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014	U-176		PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011	U-364			
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015	U-307			
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011	U-364			
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011	U-360			
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011	U-363			
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015	U-308			
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017	U-963			
<u>OLANZAPINE - ZYPREXA</u>						
N021253 001	5229382	Apr 23, 2011	DS DP U-571			
	5229382*PED	Oct 23, 2011				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 001	5229382	Apr 23, 2011	U-324		I-591	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017	U-964			
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 002	5229382	Apr 23, 2011	U-324		I-591	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017	U-964			
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 003	5229382	Apr 23, 2011	U-324		I-591	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017	U-964			
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 004	5229382	Apr 23, 2011	U-324		I-591	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017	U-964			
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N022173 001	5229382	Apr 23, 2011	DS DP U-543		NP	Dec 11, 2012
	5229382	Apr 23, 2011	DS DP U-1026			
	5229382*PED	Oct 23, 2011				
	6169084	Sep 30, 2018	DS DP U-1026			
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N022173 002	5229382	Apr 23, 2011	DS DP U-543		NP	Dec 11, 2012
	5229382	Apr 23, 2011	DS DP U-1026			
	5229382*PED	Oct 23, 2011				
	6169084	Sep 30, 2018	DS DP U-1026			
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N022173 003	5229382	Apr 23, 2011	DS DP U-543		NP	Dec 11, 2012
	5229382	Apr 23, 2011	DS DP U-1026			
	5229382*PED	Oct 23, 2011				
	6169084	Sep 30, 2018	DS DP U-1026			
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 001	5616599	Apr 25, 2016	DS DP U-500		NPP	Feb 04, 2013
	5616599*PED	Oct 25, 2016			PED	Aug 04, 2010
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 003	5616599	Apr 25, 2016	DS DP U-500		NPP	Feb 04, 2013
	5616599*PED	Oct 25, 2016			PED	Aug 04, 2010
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 004	5616599	Apr 25, 2016	DS DP U-500		NPP	Feb 04, 2013
	5616599*PED	Oct 25, 2016			PED	Aug 04, 2010
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N021545 001	5116863	Dec 18, 2010	DS DP			
	5116863*PED	Jun 18, 2011				
	5641805	Jun 06, 2015			U-765	
	5641805*PED	Dec 06, 2015				
	6995186	Nov 12, 2023	DP		U-765	
	6995186*PED	May 12, 2024				
	7402609	Jun 19, 2022	DP			
	7402609*PED	Dec 19, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLOPATADINE HYDROCHLORIDE - PATANASE						
N021861 001	5116863	Dec 18, 2010	DS DP		NPP	Dec 01, 2012
	5116863*PED	Jun 18, 2011			NDF	Apr 15, 2011
					PED	Jun 01, 2013
					PED	Oct 15, 2011
OLOPATADINE HYDROCHLORIDE - PATANOL						
N020688 001	5116863	Dec 18, 2010	U-184			
	5116863*PED	Jun 18, 2011				
	5641805	Jun 06, 2015				
	5641805*PED	Dec 06, 2015				
OMEGA-3-ACID ETHYL ESTERS - LOVAZA						
N021654 001	5502077	Mar 26, 2013	DS	U-822	M-87	Sep 16, 2012
	5656667	Apr 10, 2017	DS DP	U-822		
	7732488	Jan 30, 2025	DS DP			
OMEPRAZOLE - PRILOSEC						
N019810 001	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6150380	Nov 10, 2018				
	6150380*PED	May 10, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
OMEPRAZOLE - PRILOSEC						
N019810 002	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6150380	Nov 10, 2018				
	6150380*PED	May 10, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
OMEPRAZOLE - PRILOSEC						
N019810 003	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6150380	Nov 10, 2018				
	6150380*PED	May 10, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
OMEPRAZOLE MAGNESIUM - PRILOSEC						
N022056 001	5690960	Nov 25, 2014	DS	DP U-864	NPP	Mar 20, 2011
	5900424	May 04, 2016		U-864	PED	Sep 20, 2011
	6428810	Nov 03, 2019		DP U-864		
OMEPRAZOLE MAGNESIUM - PRILOSEC						
N022056 002	5690960	Nov 25, 2014	DS	DP U-864	NPP	Mar 20, 2011
	5900424	May 04, 2016		U-864	PED	Sep 20, 2011
	6428810	Nov 03, 2019		DP U-864		
OMEPRAZOLE MAGNESIUM - PRILOSEC OTC						
N021229 001	5690960	Nov 25, 2014				
	5753265	Jun 07, 2015				
	5817338	Oct 06, 2015				
	5900424	May 04, 2016				
	6403616	Nov 15, 2019				
	6428810	Nov 03, 2019				
OMEPRAZOLE; SODIUM BICARBONATE - OMEPRAZOLE AND SODIUM BICARBONATE						
A078966 001					PC	Dec 28, 2010
OMEPRAZOLE; SODIUM BICARBONATE - OMEPRAZOLE AND SODIUM BICARBONATE						
A078966 002					PC	Dec 28, 2010

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021636 001	5840737	Jul 16, 2016				U-588
	6489346	Jul 16, 2016	DS DP			U-588
	6645988	Jul 16, 2016	DS DP			
	6699885	Jul 16, 2016				U-588
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016				U-588
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021636 002	5840737	Jul 16, 2016				U-623
	5840737	Jul 16, 2016				U-624
	6489346	Jul 16, 2016	DS DP			U-623
	6489346	Jul 16, 2016	DS DP			U-624
	6645988	Jul 16, 2016	DS DP			
	6699885	Jul 16, 2016				U-623
	6699885	Jul 16, 2016				U-624
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016				U-624
	7399772	Jul 16, 2016				U-623
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021849 001	6489346	Jul 16, 2016	DS DP			U-588
	6645988	Jul 16, 2016	DS DP			
	6699885	Jul 16, 2016				U-588
	7399772	Jul 16, 2016				U-588
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021849 002	6489346	Jul 16, 2016	DS DP			U-623
	6645988	Jul 16, 2016	DS DP			
	6699885	Jul 16, 2016				U-623
	7399772	Jul 16, 2016				U-623
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N022281 001	6489346	Jul 15, 2016	DP			U-1025
	6645988	Jul 15, 2016	DP			
	6699885	Jul 15, 2016	DP			
	7399772	Jul 15, 2016				U-1025
<u>ONDANSETRON - ZOFTRAN ODT</u>						
N020781 001	5955488	Nov 14, 2015				
	5955488*PED	May 14, 2016				
	6063802	Nov 14, 2015				
	6063802*PED	May 14, 2016				
<u>ONDANSETRON - ZOFTRAN ODT</u>						
N020781 002	5955488	Nov 14, 2015				
	5955488*PED	May 14, 2016				
	6063802	Nov 14, 2015				
	6063802*PED	May 14, 2016				
<u>ONDANSETRON HYDROCHLORIDE - ZOFTRAN</u>						
N020103 001	5344658	Sep 06, 2011				
	5344658*PED	Mar 06, 2012				
<u>ONDANSETRON HYDROCHLORIDE - ZOFTRAN</u>						
N020103 002	5344658	Sep 06, 2011				
	5344658*PED	Mar 06, 2012				
<u>ONDANSETRON HYDROCHLORIDE - ZOFTRAN</u>						
N020103 003	5344658	Sep 06, 2011				
	5344658*PED	Mar 06, 2012				
<u>ONDANSETRON HYDROCHLORIDE - ZOFTRAN</u>						
N020605 001	5854270	Nov 20, 2015	DP			U-44
	5854270*PED	May 20, 2016				
<u>ORLISTAT - ALLI</u>						
N021887 001	6004996	Jan 06, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ORLISTAT - XENICAL</u>						
N020766 001	6004996	Jan 06, 2018				
	6004996*PED	Jul 06, 2018				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	5763483	Dec 27, 2016			M-90	Feb 22, 2013
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016				
	5866601*PED	Aug 02, 2016				
	5952375	Feb 02, 2016				
	5952375*PED	Aug 02, 2016				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002					M-90	Feb 22, 2013
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	5763483	Dec 27, 2016	U-376		M-90	Feb 22, 2013
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016				
	5866601*PED	Aug 02, 2016				
	5952375	Feb 02, 2016				
	5952375*PED	Aug 02, 2016				
<u>OXALIPLATIN - ELOXATIN</u>						
N021492 001	5290961	Jan 12, 2013	DS		PED	Jul 10, 2010
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
<u>OXALIPLATIN - ELOXATIN</u>						
N021492 002	5290961	Jan 12, 2013	DS		PED	Jul 10, 2010
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
<u>OXALIPLATIN - ELOXATIN</u>						
N021759 001	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
	5716988	Aug 07, 2015		DP		
	5716988*PED	Feb 07, 2016				
<u>OXALIPLATIN - ELOXATIN</u>						
N021759 002	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
	5716988	Aug 07, 2015		DP		
	5716988*PED	Feb 07, 2016				
<u>OXALIPLATIN - ELOXATIN</u>						
N021759 003	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
	5716988	Aug 07, 2015		DP		
	5716988*PED	Feb 07, 2016				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXANDROLONE - OXANDRIN</u>						
N013718 001	5872147	Dec 05, 2017	U-585			
	6090799	Jul 18, 2017	U-585			
	6576659	Dec 05, 2017	U-585			
	6670351	Oct 20, 2012	U-585			
	6828313	Dec 05, 2017	U-585			
<u>OXANDROLONE - OXANDRIN</u>						
N013718 002	5872147	Dec 05, 2017	U-585			
	6090799	Jul 18, 2017	U-585			
	6576659	Dec 05, 2017	U-585			
	6670351	Oct 20, 2012	U-585			
	6828313	Dec 05, 2017	U-585			
<u>OXAPROZIN POTASSIUM - DAYPRO ALTA</u>						
N020776 001	6030643	May 16, 2017	U-497			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021014 001	7037525	Feb 12, 2018	U-724			
	7037525*PED	Aug 12, 2018				
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021014 002	7037525	Feb 12, 2018	U-724			
	7037525*PED	Aug 12, 2018				
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021014 003	7037525	Feb 12, 2018	U-724			
	7037525*PED	Aug 12, 2018				
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	7037525	Feb 12, 2018	U-724			
	7037525*PED	Aug 12, 2018				
<u>OXYBUTYNIN - OXYTROL</u>						
N021351 002	5164190	Dec 11, 2010				
	5601839	Apr 26, 2015				
	5834010	Apr 26, 2015				
	6743441	Apr 26, 2020	DP U-318			
	7081249	Apr 26, 2020	DP U-318			
	7081250	Apr 26, 2020	DP U-318			
	7081251	Apr 26, 2020	DP U-318			
	7081252	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	DS DP U-318			
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N020897 001	5674895	May 22, 2015				
	5674895*PED	Nov 22, 2015				
	5840754	May 22, 2015				
	5840754*PED	Nov 22, 2015				
	5912268	May 22, 2015				
	5912268*PED	Nov 22, 2015				
	6262115	May 22, 2015	U-393			
	6262115*PED	Nov 22, 2015	U-393			
	6919092	May 22, 2015	DP U-667			
	6919092*PED	Nov 22, 2015				
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N020897 002	5674895	May 22, 2015				
	5674895*PED	Nov 22, 2015				
	5840754	May 22, 2015				
	5840754*PED	Nov 22, 2015				
	5912268	May 22, 2015				
	5912268*PED	Nov 22, 2015				
	6262115	May 22, 2015	U-393			
	6262115*PED	Nov 22, 2015	U-393			
	6919092	May 22, 2015	DP U-667			
	6919092*PED	Nov 22, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N020897 003	5674895	May 22, 2015				
	5674895*PED	Nov 22, 2015				
	5840754	May 22, 2015				
	5840754*PED	Nov 22, 2015				
	5912268	May 22, 2015				
	5912268*PED	Nov 22, 2015				
	6262115	May 22, 2015			U-393	
	6262115*PED	Nov 22, 2015			U-393	
	6919092	May 22, 2015	DP		U-667	
	6919092*PED	Nov 22, 2015				
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	7029694	Apr 26, 2020	DP			
	7179483	Apr 26, 2020			NDF	Jan 27, 2012
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 001	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 002	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 003	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 004	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 005	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 006	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 007	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 008	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	5508042	Apr 16, 2013			U-443	
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	5508042	Apr 16, 2013			U-443	
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	5508042	Apr 16, 2013			U-443	
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	5508042	Apr 16, 2013			U-443	
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	5508042	Apr 16, 2013			U-443	
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	5508042	Apr 16, 2013			U-443	
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	5508042	Apr 16, 2013			U-443	
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 001	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP		U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 002	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP		U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 003	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP		U-826	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 004	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 005	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 006	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 007	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	5439686	Feb 22, 2013	DP			
	5498421	Mar 12, 2013	DP U-634			
	6096331	Feb 22, 2013	DP U-633			
	6506405	Feb 22, 2013	DP U-633			
	6537579	Feb 22, 2013	U-632			
	6749868	Feb 22, 2013	DP			
	6753006	Feb 22, 2013	DP			
	7820788	Mar 03, 2024	DP U-1092			
<u>PALIPERIDONE - INVEGA</u>						
N021999 001	5158952	Apr 09, 2012	DP U-90		I-605	Jul 31, 2012
	5158952*PED	Oct 09, 2012			I-606	Jul 31, 2012
					NCE	Dec 19, 2011
					PED	Jun 19, 2012
					PED	Jan 31, 2013
					PED	Jan 31, 2013
<u>PALIPERIDONE - INVEGA</u>						
N021999 002	5158952	Apr 09, 2012	DP U-90		I-605	Jul 31, 2012
	5158952*PED	Oct 09, 2012			I-606	Jul 31, 2012
					NCE	Dec 19, 2011
					PED	Jun 19, 2012
					PED	Jan 31, 2013
					PED	Jan 31, 2013
<u>PALIPERIDONE - INVEGA</u>						
N021999 003	5158952	Apr 09, 2012	DP U-90		I-605	Jul 31, 2012
	5158952*PED	Oct 09, 2012			I-606	Jul 31, 2012
					NCE	Dec 19, 2011
					PED	Jun 19, 2012
					PED	Jan 31, 2013
					PED	Jan 31, 2013
<u>PALIPERIDONE - INVEGA</u>						
N021999 004	5158952	Apr 09, 2012	DP U-90		NCE	Dec 19, 2011
	5158952*PED	Oct 09, 2012			PED	Jun 19, 2012
<u>PALIPERIDONE - INVEGA</u>						
N021999 006	5158952	Apr 09, 2012	DP U-90		I-605	Jul 31, 2012
	5158952*PED	Oct 09, 2012			I-606	Jul 31, 2012
					NCE	Dec 19, 2011
					PED	Jun 19, 2012
					PED	Jan 31, 2013
					PED	Jan 31, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001	5254556	Oct 27, 2011	DS DP U-543		NDF	Jul 31, 2012
	5254556*PED	Apr 27, 2012			NCE	Dec 19, 2011
	5352459	Dec 16, 2012	DP		PED	Jun 19, 2012
	5352459*PED	Jun 16, 2013			PED	Jan 31, 2013
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002	5254556	Oct 27, 2011	DS DP U-543		NDF	Jul 31, 2012
	5254556*PED	Apr 27, 2012			NCE	Dec 19, 2011
	5352459	Dec 16, 2012	DP		PED	Jun 19, 2012
	5352459*PED	Jun 16, 2013			PED	Jan 31, 2013
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 003	5254556	Oct 27, 2011	DS DP U-543		NDF	Jul 31, 2012
	5254556*PED	Apr 27, 2012			NCE	Dec 19, 2011
	5352459	Dec 16, 2012	DP		PED	Jun 19, 2012
	5352459*PED	Jun 16, 2013			PED	Jan 31, 2013
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 004	5254556	Oct 27, 2011	DS DP U-543		NDF	Jul 31, 2012
	5254556*PED	Apr 27, 2012			NCE	Dec 19, 2011
	5352459	Dec 16, 2012	DP		PED	Jun 19, 2012
	5352459*PED	Jun 16, 2013			PED	Jan 31, 2013
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 005	5254556	Oct 27, 2011	DS DP U-543		NDF	Jul 31, 2012
	5254556*PED	Apr 27, 2012			NCE	Dec 19, 2011
	5352459	Dec 16, 2012	DP		PED	Jun 19, 2012
	5352459*PED	Jun 16, 2013			PED	Jan 31, 2013
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 001	5202333	Apr 13, 2015	DS DP U-528			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 002	5202333	Apr 13, 2015	DS DP U-901		I-556 NS	Mar 01, 2011 Mar 01, 2011
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N022233 001	5202333	Apr 13, 2015	DS DP U-528		NDF	Aug 22, 2011
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 001					I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2013 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 002					I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2013 Apr 30, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725	003				I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2013 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523	001				NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523	002				NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523	003				NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523	004				NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	001	7658918	Feb 20, 2028	DP	NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	002	7658918	Feb 20, 2028	DP	NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	003	7658918	Feb 20, 2028	DP	NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	004	7658918	Feb 20, 2028	DP	NCE	Aug 27, 2014
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N020987	001	4758579	Jul 19, 2010		I-614	Nov 12, 2012
		4758579*PED	Jan 19, 2011		M-54	Nov 12, 2012
		5997903	Dec 07, 2016		PED	May 12, 2013
		5997903*PED	Jun 07, 2017		PED	May 12, 2013
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N020987	002	4758579	Jul 19, 2010		I-614	Nov 12, 2012
		4758579*PED	Jan 19, 2011		M-54	Nov 12, 2012
		5997903	Dec 07, 2016		PED	May 12, 2013
		5997903*PED	Jun 07, 2017		PED	May 12, 2013
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N022020	001	4758579	Jul 19, 2010	DS DP	I-614	Nov 12, 2012
		4758579*PED	Jan 19, 2011		M-54	Nov 12, 2012
		7544370	Jun 07, 2026	DP	PED	May 12, 2013
		7544370*PED	Dec 07, 2026		PED	May 12, 2013
		7550153	Sep 30, 2024			
		7550153*PED	Mar 30, 2025		U-859	
		7553498	Sep 30, 2024			
		7553498*PED	Mar 30, 2025		U-859	
		7838027	Sep 30, 2024	DP	U-859	
		7838027*PED	Mar 30, 2025			
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N020988	001	4758579	Jul 19, 2010			
		4758579*PED	Jan 19, 2011			
		6780881	Nov 17, 2021	DP		
		6780881*PED	May 17, 2022			
		7351723	Nov 17, 2021	DP		
		7351723*PED	May 17, 2022			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PARICALCITOL - ZEMPLAR						
N020819 001	5246925	Apr 17, 2012	U-314 DP			
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013				
	5587497*PED	Jun 24, 2014				
	6136799	Apr 08, 2018				
	6136799*PED	Oct 08, 2018				
	6361758	Apr 08, 2018				
	6361758*PED	Oct 08, 2018				
PARICALCITOL - ZEMPLAR						
N020819 002	5246925	Apr 17, 2012	U-314 DP			
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013				
	5587497*PED	Jun 24, 2014				
	6136799	Apr 08, 2018				
	6136799*PED	Oct 08, 2018				
	6361758	Apr 08, 2018				
	6361758*PED	Oct 08, 2018				
PARICALCITOL - ZEMPLAR						
N021606 001	5246925	Apr 17, 2012	U-671 DS		I-599	Jun 29, 2012
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013				
	5587497*PED	Jun 24, 2014				
PARICALCITOL - ZEMPLAR						
N021606 002	5246925	Apr 17, 2012	U-671 DS		I-599	Jun 29, 2012
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013				
	5587497*PED	Jun 24, 2014				
PARICALCITOL - ZEMPLAR						
N021606 003	5246925	Apr 17, 2012	U-671 DS		I-599	Jun 29, 2012
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013				
	5587497*PED	Jun 24, 2014				
PAROXETINE HYDROCHLORIDE - PAXIL						
N020031 001	5872132	May 19, 2015	U-286 U-431 U-286 U-431 U-358 U-358			
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017				
	6121291	Mar 17, 2017				
	6121291*PED	Sep 17, 2017				
	6121291*PED	Sep 17, 2017				
	6133289	May 19, 2015				
	6133289*PED	Nov 19, 2015				
PAROXETINE HYDROCHLORIDE - PAXIL						
N020031 002	5872132	May 19, 2015	U-286 U-431 U-431 U-286 U-358 U-358			
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017				
	6121291	Mar 17, 2017				
	6121291*PED	Sep 17, 2017				
	6121291*PED	Sep 17, 2017				
	6133289	May 19, 2015				
	6133289*PED	Nov 19, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 003	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 004	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 005	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020710 001	5811436	Sep 22, 2015				
	5811436*PED	Mar 22, 2016				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 001	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 002	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 003	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 004	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6062927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 001	5422123	Jun 06, 2012				
	5422123*PED	Dec 06, 2012				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6133289*PED	Nov 19, 2015		U-286		
	6548084	Jul 19, 2016				
	6548084*PED	Jan 19, 2017				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 002	5422123	Jun 06, 2012				
	5422123*PED	Dec 06, 2012				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6133289*PED	Nov 19, 2015		U-286		
	6548084	Jul 19, 2016				
	6548084*PED	Jan 19, 2017				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 003	5422123	Jun 06, 2012				
	5422123*PED	Dec 06, 2012				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6133289*PED	Nov 19, 2015		U-286		
	6548084	Jul 19, 2016				
	6548084*PED	Jan 19, 2017				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N021299 001	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-286		
	5874447	Jun 10, 2017		U-518		
	6703408	Oct 21, 2022	DP			
	7598271	Feb 11, 2023	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N021299 002	5874447	Jun 10, 2017			U-46	
	5874447	Jun 10, 2017			U-518	
	5874447	Jun 10, 2017			U-286	
	6703408	Oct 21, 2022	DP			
	7598271	Feb 11, 2023	DS DP			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N021299 003	5874447	Jun 10, 2017			U-46	
	5874447	Jun 10, 2017			U-286	
	5874447	Jun 10, 2017			U-518	
	6703408	Oct 21, 2022	DP			
	7598271	Feb 11, 2023	DS DP			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N021299 004	5874447	Jun 10, 2017			U-46	
	5874447	Jun 10, 2017			U-286	
	5874447	Jun 10, 2017			U-518	
	6703408	Oct 21, 2022	DP			
	7598271	Feb 11, 2023	DS DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	7105530	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	7262203	Dec 19, 2021	DS DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	7105530	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	7262203	Dec 19, 2021	DS DP			
<u>PEGAPTANIB SODIUM - MACUGEN</u>						
N021756 001	5919455	Oct 27, 2013	DS			
	5932462	Aug 03, 2016	DS			
	6011020	Jan 04, 2017	DS			
	6051698	May 19, 2015	DS		U-622	
	6113906	Oct 27, 2013	DS			
<u>PEGVISOMANT - SOMAVERT</u>						
N021106 001	5350836	Sep 27, 2011			U-507	
	5681809	Sep 27, 2011			U-507	
	5849535	Mar 25, 2017	DS			
	5958879	Sep 27, 2011			U-507	
	6057292	Sep 21, 2015			U-507	
	6583115	Sep 27, 2011			U-507	
<u>PEGVISOMANT - SOMAVERT</u>						
N021106 002	5350836	Sep 27, 2011			U-507	
	5681809	Sep 27, 2011			U-507	
	5849535	Mar 25, 2017	DS			
	5958879	Sep 27, 2011			U-507	
	6057292	Sep 21, 2015			U-507	
	6583115	Sep 27, 2011			U-507	
<u>PEGVISOMANT - SOMAVERT</u>						
N021106 003	5350836	Sep 27, 2011			U-507	
	5681809	Sep 27, 2011			U-507	
	5849535	Mar 25, 2017	DS			
	5958879	Sep 27, 2011			U-507	
	6057292	Sep 21, 2015			U-507	
	6583115	Sep 27, 2011			U-507	
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001	5217974	Mar 29, 2011			U-551	
	5217974*PED	Sep 29, 2011				
	5344932	Jul 24, 2016	DS DP		I-601	Jul 02, 2012
	5344932*PED	Jan 24, 2017			I-571	Sep 26, 2011
	7772209	Nov 24, 2021			ODE	Feb 04, 2011
	7772209*PED	May 24, 2022			PED	Aug 04, 2011
					PED	Mar 26, 2012
					PED	Jan 02, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002	5217974	Mar 29, 2011		U-551	I-601	Jul 02, 2012
	5217974*PED	Sep 29, 2011			I-571	Sep 26, 2011
	5344932	Jul 24, 2016	DS DP		ODE	Feb 04, 2011
	5344932*PED	Jan 24, 2017			PED	Aug 04, 2011
	7772209	Nov 24, 2021		U-1077	PED	Mar 26, 2012
	7772209*PED	May 24, 2022			PED	Jan 02, 2013
<u>PEMIROLAST POTASSIUM - ALAMAST</u>						
N021079 001	5034230	Jan 02, 2011	DP	U-184		
	5034230*PED	Jul 02, 2011		U-184		
<u>PENCICLOVIR SODIUM - DENAVIR</u>						
N020629 001	5075445	Sep 24, 2010				
	5840763	Sep 01, 2015		U-501		
	5866581	Oct 04, 2014		U-501		
	5916893	Sep 01, 2015		U-501		
	6124304	Oct 04, 2014		U-501		
	6469015	Oct 22, 2019		U-501		
	6573378	Sep 24, 2010				
	6579981	Jun 17, 2020		U-501		
<u>PENTETATE CALCIUM TRISODIUM - PENTETATE CALCIUM TRISODIUM</u>						
N021749 001					ODE	Aug 11, 2011
<u>PENTETATE ZINC TRISODIUM - PENTETATE ZINC TRISODIUM</u>						
N021751 001					ODE	Aug 11, 2011
<u>PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE - SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS</u>						
N021084 001	5607979	May 30, 2015				
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	5547656	Apr 05, 2011				
	5769080	Jul 20, 2010				
	6033645	Jun 19, 2016		U-665		
	6528039	Apr 05, 2011	DS			
	6773696	Apr 05, 2011	DS			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N022159 001	6764678	May 11, 2021		U-967	NP	May 09, 2011
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			
	7569230	Oct 17, 2023		U-967		
	7575757	Apr 21, 2025	DP			
<u>PIMECROLIMUS - ELIDEL</u>						
N021302 001	5912238	Jun 15, 2016				
	5912238*PED	Dec 15, 2016				
	6352998	Oct 26, 2015				
	6352998*PED	Apr 26, 2016				
	6423722	Jun 26, 2018				
	6423722*PED	Dec 26, 2018				
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N021073 001	4687777	Jan 17, 2011				
	5965584	Jun 19, 2016		U-753		
	6150383	Jun 19, 2016		U-418		
	6150384	Jun 19, 2016		U-419		
	6166042	Jun 19, 2016		U-414		
	6166043	Jun 19, 2016		U-415		
	6172090	Jun 19, 2016		U-416		
	6211205	Jun 19, 2016		U-410		
	6271243	Jun 19, 2016		U-411		
	6303640	Aug 09, 2016		U-425		
	6329404	Jun 19, 2016		U-753		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N021073 002	4687777	Jan 17, 2011				
	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N021073 003	4687777	Jan 17, 2011				
	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	6900184	Apr 14, 2023	DS DP	U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	6900184	Apr 14, 2023	DS DP	U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	6900184	Apr 14, 2023	DS DP	U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	6900184	Apr 14, 2023	DS DP	U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	6207661	Feb 22, 2019	DS DP			
	6900184	Apr 14, 2023	DS DP	U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	6207661	Feb 22, 2019	DS DP			
	6900184	Apr 14, 2023	DS DP	U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	6207661	Feb 22, 2019	DS DP			
	6900184	Apr 14, 2023	DS DP	U-282		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 001	5753675	May 19, 2015	DS DP	U-998	NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Jan 05, 2016	DS	U-998		
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024		U-998		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 002	5753675	May 19, 2015	DS DP	U-998	NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Jan 05, 2016	DS	U-998		
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024		U-998		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 003	5753675	May 19, 2015	DS DP	U-998	NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Jan 05, 2016	DS	U-998		
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024		U-998		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	5583131	Dec 10, 2013	DP		NCE	Dec 15, 2013
	6987102	Jul 22, 2023	U-936		ODE	Dec 15, 2015
<u>POLIDOCANOL - ASCLERA</u>						
N021201 001					NCE	Mar 30, 2015
<u>POLIDOCANOL - ASCLERA</u>						
N021201 002					NCE	Mar 30, 2015
<u>PORFIMER SODIUM - PHOTOFRIN</u>						
N020451 001	5438071	Aug 01, 2012			ODE	Aug 01, 2010
<u>POSACONAZOLE - NOXAFIL</u>						
N022003 001	5661151	Jul 19, 2019	DS DP	U-760	NCE	Sep 15, 2011
	5703079	Aug 26, 2014	DS DP	U-760		
	6958337	Oct 05, 2018	DS DP	U-760		
<u>PRALATREXATE - FOLOTYN</u>						
N022468 001	6028071	Jul 16, 2017	DS DP	U-1004	NCE	Sep 24, 2014
	7622470	May 31, 2025		U-1015	ODE	Sep 24, 2016
<u>PRALATREXATE - FOLOTYN</u>						
N022468 002	6028071	Jul 16, 2017	DS DP	U-1004	NCE	Sep 24, 2014
	7622470	May 31, 2025		U-1015	ODE	Sep 24, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 001	4886812	Oct 08, 2010	DS DP			
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 002	4886812	Oct 08, 2010	DS DP			
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 003	4886812	Oct 08, 2010	DS DP			
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 004	4886812	Oct 08, 2010	DS DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 005	4886812	Oct 08, 2010	DS DP			
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 006	4886812	Oct 08, 2010	DS DP			
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 007	4886812	Oct 08, 2010	DS DP			
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 001	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 002	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 003	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 004	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 005	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 001					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 002					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 003					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 004					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 005					PC	Jul 03, 2010
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N021332 001	5686411	Mar 16, 2019	DS DP	U-638		
	5814600	Sep 29, 2015		U-639		
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017		U-640		
	6608029	Sep 07, 2013		U-641		
	6610824	Mar 08, 2011	DS			
	7271238	Mar 08, 2011	DS	U-638		
	7271238	Mar 08, 2011	DS	U-637		
	7407934	Mar 08, 2011		U-640		
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N021332 002	5686411	Mar 16, 2019	DS DP	U-638		
	5814600	Sep 29, 2015		U-638		
	5814600	Sep 29, 2015		U-637		
	5814600	Sep 29, 2015		U-639		
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017		U-637		
	6114304	Sep 05, 2017		U-640		
	6608029	Sep 07, 2013		U-637		
	6608029	Sep 07, 2013		U-640		
	6608029	Sep 07, 2013		U-641		
	6610824	Mar 03, 2011	DS			
	7271238	Mar 08, 2011	DS	U-638		
	7271238	Mar 08, 2011	DS	U-637		
	7407934	Mar 08, 2011		U-637		
	7407934	Mar 08, 2011		U-640		
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N021332 003	5686411	Mar 16, 2019	DS DP	U-638		
	5814600	Sep 29, 2015		U-639		
	5814600	Sep 29, 2015		U-637		
	5814600	Sep 29, 2015		U-638		
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017		U-640		
	6114304	Sep 05, 2017		U-637		
	6608029	Sep 07, 2013		U-640		
	6608029	Sep 07, 2013		U-637		
	6608029	Sep 07, 2013		U-641		
	6610824	Mar 03, 2011	DS			
	7271238	Mar 08, 2011	DS	U-637		
	7271238	Mar 08, 2011	DS	U-638		
	7407934	Mar 08, 2011		U-637		
	7407934	Mar 08, 2011		U-640		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 001	5288726	Sep 08, 2012	DS DP U-991		NCE	Jul 10, 2014
	6693115	Jul 03, 2021	DS DP U-991			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 002	5288726	Sep 08, 2012	DS DP U-991		NCE	Jul 10, 2014
	6693115	Jul 03, 2021	DS DP U-991			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 002	5622985	Apr 22, 2014			U-335	
	5622985*PED	Oct 22, 2014			U-335	
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 003	5622985	Apr 22, 2014			U-335	
	5622985*PED	Oct 22, 2014			U-335	
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 004	5622985	Apr 22, 2014			U-335	
	5622985*PED	Oct 22, 2014			U-335	
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 008	5622985	Apr 22, 2014			U-335	
	5622985*PED	Oct 22, 2014			U-335	
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6102254	Mar 11, 2013	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6102254	Mar 11, 2013	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 001	6024981	Apr 09, 2018	DP		Y	
	6221392	Apr 09, 2018	DP		Y	
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 002	6024981	Apr 09, 2018	DP		Y	
	6221392	Apr 09, 2018	DP		Y	
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 003	6024981	Apr 09, 2018	DP		Y	
	6221392	Apr 09, 2018	DP		Y	
	6740341	Nov 24, 2019	DP			
<u>PREGABALIN - LYRICA</u>						
N021446 001	5563175	Oct 08, 2013			U-661	
	6001876	Dec 30, 2018			U-55	
	6001876	Dec 30, 2018			U-819	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018			U-1099	
<u>PREGABALIN - LYRICA</u>						
N021446 002	5563175	Oct 08, 2013			U-661	
	6001876	Dec 30, 2018			U-819	
	6001876	Dec 30, 2018			U-55	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018			U-1099	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N021446 003	5563175	Oct 08, 2013				U-661
	6001876	Dec 30, 2018				U-55
	6001876	Dec 30, 2018				U-819
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018				U-1099
<u>PREGABALIN - LYRICA</u>						
N021446 004	5563175	Oct 08, 2013				U-661
	6001876	Dec 30, 2018				U-819
	6001876	Dec 30, 2018				U-55
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018				U-1099
<u>PREGABALIN - LYRICA</u>						
N021446 005	5563175	Oct 08, 2013				U-661
	6001876	Dec 30, 2018				U-55
	6001876	Dec 30, 2018				U-819
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018				U-1099
<u>PREGABALIN - LYRICA</u>						
N021446 006	5563175	Oct 08, 2013				U-661
	6001876	Dec 30, 2018				U-55
	6001876	Dec 30, 2018				U-819
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018				U-1099
<u>PREGABALIN - LYRICA</u>						
N021446 007	5563175	Oct 08, 2013				U-661
	6001876	Dec 30, 2018				U-819
	6001876	Dec 30, 2018				U-55
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018				U-1099
<u>PREGABALIN - LYRICA</u>						
N021446 008	5563175	Oct 08, 2013				U-661
	6001876	Dec 30, 2018				U-819
	6001876	Dec 30, 2018				U-55
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018				U-1099
<u>PREGABALIN - LYRICA</u>						
N022488 001	5563175	Oct 08, 2013				U-661
	6001876	Dec 30, 2018				U-819
	6001876	Dec 30, 2018				U-55
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018				U-1099
<u>PROCAINAMIDE HYDROCHLORIDE - PROCANBID</u>						
N020545 001	5656296	Aug 12, 2014				
<u>PROCAINAMIDE HYDROCHLORIDE - PROCANBID</u>						
N020545 002	5656296	Aug 12, 2014				
<u>PROGESTERONE - CRINONE</u>						
N020701 001	5543150	Sep 15, 2013				U-209
<u>PROGESTERONE - CRINONE</u>						
N020701 002	5543150	Sep 15, 2013				U-209
<u>PROGESTERONE - ENDOMETRIN</u>						
N022057 001	7300664	Nov 17, 2019				U-856
	7320800	Nov 17, 2019				U-856
	7393543	Nov 17, 2019	DP			U-880
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N021416 001	5681588	Oct 28, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N021416 002	5681588	Oct 28, 2014				
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N021416 003	5681588	Oct 28, 2014				
<u>PROPOFOL - DIPRIVAN</u>						
N019627 002	5714520	Mar 22, 2015				
	5714520*PED	Sep 22, 2015				
	5731355	Mar 22, 2015		U-217		
	5731355*PED	Sep 22, 2015		U-217		
	5731356	Mar 22, 2015		U-218		
	5731356*PED	Sep 22, 2015		U-218		
	5908869	Mar 22, 2015		U-270		
	5908869*PED	Sep 22, 2015		U-270		
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	6500454	Dec 31, 2022				
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	6500454	Dec 31, 2022				
<u>QUAZEPAM - DORAL</u>						
N018708 001	7608616	Jun 03, 2028		U-1012		
<u>QUAZEPAM - DORAL</u>						
N018708 003	7608616	Jun 03, 2028		U-1012		
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
N020639 001	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			NPP	Dec 02, 2012
					NPP	Dec 02, 2012
					PED	Jun 02, 2013
					PED	Jun 02, 2013
					PED	Nov 13, 2011
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
N020639 002	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			NPP	Dec 02, 2012
					NPP	Dec 02, 2012
					PED	Jun 02, 2013
					PED	Jun 02, 2013
					PED	Nov 13, 2011
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
N020639 003	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			NPP	Dec 02, 2012
					NPP	Dec 02, 2012
					PED	Jun 02, 2013
					PED	Jun 02, 2013
					PED	Nov 13, 2011
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
N020639 004	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			NPP	Dec 02, 2012
					NPP	Dec 02, 2012
					PED	Jun 02, 2013
					PED	Jun 02, 2013
					PED	Nov 13, 2011

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE					
<u>QUETIAPINE FUMARATE - SEROQUEL</u>															
N020639 005	4879288	Sep	26,	2011	DS	DP	U-550		I-560	May	13,	2011			
	4879288*PED	Mar	26,	2012					NPP	Dec	02,	2012			
									NPP	Dec	02,	2012			
									PED	Jun	02,	2013			
									PED	Jun	02,	2013			
									PED	Nov	13,	2011			
<u>QUETIAPINE FUMARATE - SEROQUEL</u>															
N020639 006	4879288	Sep	26,	2011	DS	DP	U-550		I-560	May	13,	2011			
	4879288*PED	Mar	26,	2012					NPP	Dec	02,	2012			
									NPP	Dec	02,	2012			
									PED	Jun	02,	2013			
									PED	Jun	02,	2013			
									PED	Nov	13,	2011			
<u>QUETIAPINE FUMARATE - SEROQUEL</u>															
N020639 007	4879288	Sep	26,	2011	DS	DP	U-550		I-560	May	13,	2011			
	4879288*PED	Mar	26,	2012					NPP	Dec	02,	2012			
									NPP	Dec	02,	2012			
									PED	Jun	02,	2013			
									PED	Jun	02,	2013			
									PED	Nov	13,	2011			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>															
N022047 001	4879288	Sep	26,	2011	DS	DP	U-814		D-117	Oct	08,	2011			
	4879288	Sep	26,	2011					DS	DP	U-839	I-618	Dec	02,	2012
	4879288	Sep	26,	2011					DS	DP	U-601	I-576	Oct	08,	2011
	4879288*PED	Mar	26,	2012								I-575	Oct	08,	2011
	5948437	May	28,	2017						DP	U-601	I-575	Oct	08,	2011
	5948437	May	28,	2017						DP	U-839	I-574	Oct	08,	2011
	5948437	May	28,	2017						DP	U-814	PED	Nov	17,	2010
	5948437*PED	Nov	28,	2017								PED	Apr	08,	2012
												PED	Apr	08,	2012
												PED	Apr	08,	2012
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>															
N022047 002	4879288	Sep	26,	2011	DS	DP	U-839		D-117	Oct	08,	2011			
	4879288	Sep	26,	2011					DS	DP	U-601	I-618	Dec	02,	2012
	4879288	Sep	26,	2011					DS	DP	U-814	I-576	Oct	08,	2011
	4879288*PED	Mar	26,	2012								I-575	Oct	08,	2011
	5948437	May	28,	2017						DP	U-814	I-575	Oct	08,	2011
	5948437	May	28,	2017						DP	U-839	I-574	Oct	08,	2011
	5948437	May	28,	2017						DP	U-601	PED	Nov	17,	2010
	5948437*PED	Nov	28,	2017								PED	Apr	08,	2012
												PED	Apr	08,	2012
												PED	Apr	08,	2012
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>															
N022047 003	4879288	Sep	26,	2011	DS	DP	U-814		D-117	Oct	08,	2011			
	4879288	Sep	26,	2011					DS	DP	U-601	I-618	Dec	02,	2012
	4879288	Sep	26,	2011					DS	DP	U-839	I-576	Oct	08,	2011
	4879288*PED	Mar	26,	2012								I-575	Oct	08,	2011
	5948437	May	28,	2017						DP	U-601	I-575	Oct	08,	2011
	5948437	May	28,	2017						DP	U-839	I-574	Oct	08,	2011
	5948437	May	28,	2017						DP	U-814	PED	Nov	17,	2010
	5948437*PED	Nov	28,	2017								PED	Apr	08,	2012
												PED	Apr	08,	2012
												PED	Apr	08,	2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N022047 004	4879288	Sep 26, 2011	DS DP U-839		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-814		I-618	Dec 02, 2012
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		PED	Nov 17, 2010
	5948437	May 28, 2017	DP U-839		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Apr 08, 2012
					PED	Apr 08, 2012
					PED	Apr 08, 2012
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N022047 005	4879288	Sep 26, 2011	DS DP U-601		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-839		I-618	Dec 02, 2012
	4879288	Sep 26, 2011	DS DP U-814		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		PED	Nov 17, 2010
	5948437	May 28, 2017	DP U-839		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Apr 08, 2012
					PED	Apr 08, 2012
					PED	Apr 08, 2012
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 001	5684016	Nov 04, 2014	U-210			
	5684016*PED	May 04, 2015	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 002	5684016	Nov 04, 2014	U-210			
	5684016*PED	May 04, 2015	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 003	5684016	Nov 04, 2014	U-210			
	5684016*PED	May 04, 2015	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 004	5684016	Nov 04, 2014	U-210			
	5684016*PED	May 04, 2015	U-210			
<u>QUININE SULFATE - QALAQVIN</u>						
N021799 001					ODE	Aug 12, 2012
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>						
N020973 001	5045552	May 08, 2013	U-385			
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>						
N020973 002	5045552	May 08, 2013	U-385		NPP	Jun 30, 2011
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N020815 001	5393763	Jul 28, 2012	U-114	Y	I-539	Sep 13, 2010
	5457117	Jul 28, 2012	U-114	Y	ODE	Sep 13, 2014
	5478847	Mar 02, 2014	U-114	Y		
	5811120	Mar 02, 2014				
	5972383	Mar 02, 2014				
	6458811	Mar 10, 2017	DS DP U-825			
	6797719	Mar 10, 2017	DP			
	6894064	Mar 10, 2017	DP			
	6906086	Jul 28, 2012				
	6906086	Jul 28, 2012				
	RE38968	Jul 28, 2012				
	RE38968	Jul 28, 2012				
	RE39049	Jul 28, 2012				
	RE39049	Jul 28, 2012				
	RE39050	Mar 02, 2014				
	RE39050	Mar 02, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 09, 2023	DS DP		NCE	Oct 12, 2012
	7217713	Oct 21, 2022		U-257		
	7435734	Oct 21, 2022		U-900		
	7435734	Oct 21, 2022		U-257		
	7754731	Mar 11, 2029	DS DP	U-257		
<u>RAMELTEON - ROZEREM</u>						
N021782 001	6034239	Jul 22, 2019	DS DP	U-674	M-82 NCE	Oct 27, 2011 Jul 22, 2010
<u>RAMIPRIL - ALTACE</u>						
N019901 001	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N019901 002	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N019901 003	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N019901 004	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N022021 001	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N022021 002	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N022021 003	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N022021 004	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RANITIDINE BISMUTH CITRATE - TRITEC</u>						
N020559 001	5256684	Oct 26, 2010		U-199		
	5403830	Apr 04, 2012		U-200		
	5407688	Apr 04, 2012		U-201		
	5456925	Oct 10, 2012				
	5601848	Feb 11, 2014		U-202		
	5629297	May 13, 2014		U-186		
<u>RANITIDINE HYDROCHLORIDE - ZANTAC 150</u>						
N020095 001	5028432*PED	Aug 22, 2010				
<u>RANITIDINE HYDROCHLORIDE - ZANTAC 150</u>						
N021698 002	5098715	Dec 20, 2010		DP		
<u>RANITIDINE HYDROCHLORIDE - ZANTAC 300</u>						
N020095 002	5028432*PED	Aug 22, 2010				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6303607	May 27, 2019		U-705	NCE	Jan 27, 2011
	6369062	May 27, 2019	DP			
	6479496	May 27, 2019		U-705		
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019		U-705		
	6562826	May 27, 2019		U-705		
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019		U-705		
	6852724	May 27, 2019		U-705		
	6864258	May 27, 2019		U-705		
<u>RANOLAZINE - RANEXA</u>						
N021526 002	6303607	May 27, 2019		U-705	NCE	Jan 27, 2011
	6369062	May 27, 2019	DP			
	6479496	May 27, 2019		U-705		
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019		U-705		
	6562826	May 27, 2019		U-705		
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019		U-705		
	6852724	May 27, 2019		U-705		
	6864258	May 27, 2019		U-705		
<u>RAPACURONIUM BROMIDE - RAPLON</u>						
N020984 001	5418226	Apr 14, 2013				
<u>RAPACURONIUM BROMIDE - RAPLON</u>						
N020984 002	5418226	Apr 14, 2013				
<u>RASAGILINE MESYLATE - AZILECT</u>						
N021641 001	5387612	Feb 07, 2012		U-219	NCE	May 16, 2011
	5453446	Feb 07, 2017		U-219		
	5457133	Feb 07, 2012	DS DP			
	5532415	Jul 02, 2013	DS			
	5786390	Feb 07, 2012		DP		
	6126968	Sep 18, 2016		DP		
	7572834	Dec 05, 2026		DP		
	7815942	Aug 27, 2027	DS DP	U-219		
<u>RASAGILINE MESYLATE - AZILECT</u>						
N021641 002	5387612	Feb 07, 2012		U-219	NCE	May 16, 2011
	5453446	Feb 07, 2017		U-219		
	5457133	Feb 07, 2012	DS DP			
	5532415	Jul 02, 2013	DS			
	5786390	Feb 07, 2012		DP		
	6126968	Sep 18, 2016		DP		
	7572834	Dec 05, 2026		DP		
	7815942	Aug 27, 2027	DS DP	U-219		
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	6403567	Jun 22, 2019	DS DP	U-869	NCE	Apr 10, 2013
	6642210	Jun 22, 2019	DS DP	U-869		
	7144872	Jun 22, 2019	DS DP	U-116		
	7144872	Jun 22, 2019	DS DP	U-870		
	7144872	Jun 22, 2019	DS DP	U-869		
	7183264	Jun 22, 2019		DP U-116		
	7183264	Jun 22, 2019		DP U-870		
	7183264	Jun 22, 2019		DP U-869		
	7582617	Jun 22, 2019		U-1003		
	7655636	Jun 22, 2019		U-869		
	7655637	Jun 22, 2019	DS DP	U-869		
	7683037	Jun 22, 2019		U-1042		
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N020630 001	5019583	Jul 12, 2010	DS DP	U-952		
	5019583*PED	Jan 12, 2011				
	5866591	Sep 10, 2017	DP			
	5866591*PED	Mar 10, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N020630 002	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
	5866591	Sep 10, 2017	DP			
	5866591*PED	Mar 10, 2018				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N020630 003	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
	5866591	Sep 10, 2017	DP			
	5866591*PED	Mar 10, 2018				
<u>REPAGLINIDE - PRANDIN</u>						
N020741 001	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	6677358	Jun 12, 2018	DS DP U-968			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE39128	Oct 27, 2018	DS DP U-805		NCE	Apr 12, 2012
<u>RIBAVIRIN - REBETOL</u>						
N020903 001	6172046	Sep 21, 2017	U-1014		ODE	Jul 29, 2010
	6172046	Sep 21, 2017	U-377		PED	Jan 29, 2011
	6172046*PED	Mar 21, 2018	U-377			
	6177074	Nov 01, 2016	U-1013			
	6177074	Nov 01, 2016	U-454			
	6177074*PED	May 01, 2017	U-454			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6461605*PED	May 01, 2017	U-478			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6472373*PED	Mar 21, 2018	U-479			
	6524570	Nov 01, 2016	U-1013			
	6524570	Nov 01, 2016	U-499			
	6524570*PED	May 01, 2017	U-499			
<u>RIBAVIRIN - REBETOL</u>						
N020903 002	6172046	Sep 21, 2017	U-1014		ODE	Jul 29, 2010
	6172046	Sep 21, 2017	U-377		PED	Jan 29, 2011
	6172046*PED	Mar 21, 2018	U-377			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6177074*PED	May 01, 2017	U-454			
	6461605	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605*PED	May 01, 2017	U-478			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6472373*PED	Mar 21, 2018	U-479			
	6524570	Nov 01, 2016	U-1013			
	6524570	Nov 01, 2016	U-499			
	6524570*PED	May 01, 2017	U-499			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBAVIRIN - REBETOL</u>						
N021546 001	6172046	Sep 21, 2017	U-521		ODE	Jul 29, 2010
	6172046	Sep 21, 2017	U-1014		PED	Jan 29, 2011
	6172046*PED	Mar 21, 2018	U-521			
	6177074	Nov 01, 2016	U-1013			
	6177074*PED	May 01, 2017				
	6461605	Nov 01, 2016	U-521			
	6461605	Nov 01, 2016	U-1013			
	6461605*PED	May 01, 2017	U-521			
	6472373	Sep 21, 2017	U-521			
	6472373*PED	Mar 21, 2018	U-521			
	6524570	Nov 01, 2016	U-1013			
	6524570*PED	May 01, 2017				
	6790837	Apr 05, 2023	DP			
	6790837*PED	Oct 05, 2023	U-1014			
<u>RIBAVIRIN - VIRAZOLE</u>						
N018859 001	6150337	Nov 21, 2017	U-400			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	7045620	Jun 19, 2024	DS		NP	Mar 24, 2013
					ODE	Mar 24, 2017
<u>RILUZOLE - RILUTEK</u>						
N020599 001	5527814	Jun 18, 2013				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 001	5583122	Dec 10, 2013	U-222		M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 002	5583122	Dec 10, 2013	U-222		M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 003	5583122	Dec 10, 2013	DS DP U-756		M-61	Jul 23, 2012
	5583122	Dec 10, 2013	DS DP U-222		PED	Jan 23, 2013
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018	U-353			
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018	U-353			
	6015801*PED	Jan 17, 2019				
	6096342	Nov 22, 2011	DP			
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018	U-595			
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 004	5583122	Dec 10, 2013	DS DP U-353		M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	6096342	Nov 22, 2011	DP U-353		PED	Oct 16, 2010
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 005	5583122	Dec 10, 2013	DS DP U-353		M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			NS	Apr 22, 2011
	6165513	Jun 10, 2018	DP		PED	Jan 23, 2013
	6165513*PED	Dec 10, 2018			PED	Oct 22, 2011
	7192938	May 06, 2023	U-353			
	7192938*PED	Nov 06, 2023				
	7718634	May 06, 2023	U-662			
	7718634*PED	Nov 06, 2023				
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N022560 001	5583122	Dec 10, 2013	DS DP U-662		NDF	Oct 08, 2013
	5583122*PED	Jun 10, 2014				
	5622721	Apr 21, 2014	DP U-662			
	7645459	Jan 09, 2028	DP U-662			
	7645460	Jan 09, 2028	DP U-662			
<u>RISPERIDONE - RISPERDAL</u>						
N020272 001					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					PED	Feb 22, 2011
					PED	Feb 22, 2011
<u>RISPERIDONE - RISPERDAL</u>						
N020272 002					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					PED	Feb 22, 2011
					PED	Feb 22, 2011
<u>RISPERIDONE - RISPERDAL</u>						
N020272 003					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					PED	Feb 22, 2011
					PED	Feb 22, 2011
<u>RISPERIDONE - RISPERDAL</u>						
N020272 004					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					PED	Feb 22, 2011
					PED	Feb 22, 2011
<u>RISPERIDONE - RISPERDAL</u>						
N020272 005					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					PED	Feb 22, 2011
					PED	Feb 22, 2011
<u>RISPERIDONE - RISPERDAL</u>						
N020272 007					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					PED	Feb 22, 2011
					PED	Feb 22, 2011
<u>RISPERIDONE - RISPERDAL</u>						
N020272 008					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					PED	Feb 22, 2011
					PED	Feb 22, 2011
<u>RISPERIDONE - RISPERDAL</u>						
N020588 001	5453425	Jul 11, 2014	DP		I-541	Aug 22, 2010
	5453425*PED	Jan 11, 2015			I-540	Aug 22, 2010
	5616587	Jul 11, 2014		Y	PED	Feb 22, 2011
	5616587*PED	Jan 11, 2015			PED	Feb 22, 2011
	RE39181	Jul 11, 2014	DP			
	RE39181*PED	Jan 11, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
RISPERIDONE - RISPERDAL								
N021444 001	5648093	Jul	15, 2014	DP		I-541	Aug	22, 2010
	5648093*PED	Jan	15, 2015			I-540	Aug	22, 2010
	6224905	Jun	10, 2017	DP		PED	Feb	22, 2011
	6224905*PED	Dec	10, 2017			PED	Feb	22, 2011
RISPERIDONE - RISPERDAL								
N021444 002	5648093	Jul	15, 2014	DP		I-541	Aug	22, 2010
	5648093*PED	Jan	15, 2015			I-540	Aug	22, 2010
	6224905	Jun	10, 2017	DP		PED	Feb	22, 2011
	6224905*PED	Dec	10, 2017			PED	Feb	22, 2011
RISPERIDONE - RISPERDAL								
N021444 003	5648093	Jul	15, 2014	DP		I-541	Aug	22, 2010
	5648093*PED	Jan	15, 2015			I-540	Aug	22, 2010
	6224905	Jun	10, 2017	DP		PED	Feb	22, 2011
	6224905*PED	Dec	10, 2017			PED	Feb	22, 2011
RISPERIDONE - RISPERDAL								
N021444 004	5648093	Jul	15, 2014	DP		I-541	Aug	22, 2010
	5648093*PED	Jan	15, 2015			I-540	Aug	22, 2010
	6224905	Jun	10, 2017	DP		PED	Feb	22, 2011
	6224905*PED	Dec	10, 2017			PED	Feb	22, 2011
RISPERIDONE - RISPERDAL								
N021444 005	5648093	Jul	15, 2014	DP		I-541	Aug	22, 2010
	5648093*PED	Jan	15, 2015			I-540	Aug	22, 2010
	6224905	Jun	10, 2017	DP		PED	Feb	22, 2011
	6224905*PED	Dec	10, 2017			PED	Feb	22, 2011
RISPERIDONE - RISPERDAL CONSTA								
N021346 001	5688801	Nov	18, 2014		U-972	I-597	May	15, 2012
	5688801	Nov	18, 2014		U-543	I-596	May	15, 2012
	5688801*PED	May	18, 2015					
	5792477	May	02, 2017	DP				
	5792477*PED	Nov	02, 2017					
	5916598	May	02, 2017	DP				
	5916598*PED	Nov	02, 2017					
	5965168	Nov	19, 2013	DP				
	5965168*PED	May	19, 2014					
	6110921	Nov	19, 2013		U-543			
	6110921*PED	May	19, 2014					
	6194006	Dec	30, 2018	DP				
	6194006*PED	Jun	30, 2019					
	6368632	Nov	19, 2013		U-543			
	6368632*PED	May	19, 2014					
	6379703	Dec	30, 2018	DP				
	6379703*PED	Jun	30, 2019					
	6403114	May	02, 2017	DP				
	6403114*PED	Nov	02, 2017					
	6596316	Dec	30, 2018	DP				
	6596316*PED	Jun	30, 2019					
	6667061	May	25, 2020	DP				
	6667061*PED	Nov	25, 2020					
	7547452	Nov	19, 2013	DP				
	7547452*PED	May	19, 2014					

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 002	5688801	Nov 18, 2014		U-543	I-597	May 15, 2012
	5688801	Nov 18, 2014		U-972	I-596	May 15, 2012
	5688801*PED	May 18, 2015				
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110921	Nov 19, 2013		U-543		
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013		U-543		
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 003	5688801	Nov 18, 2014		U-543	I-597	May 15, 2012
	5688801	Nov 18, 2014		U-972	I-596	May 15, 2012
	5688801*PED	May 18, 2015				
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110921	Nov 19, 2013		U-543		
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013		U-543		
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 004	5688801	Nov 18, 2014		U-543	I-597	May 15, 2012
	5688801	Nov 18, 2014		U-972	I-596	May 15, 2012
	5688801*PED	May 18, 2015				
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110503	May 02, 2017	DP			
	6110503*PED	Nov 02, 2017				
	6110921	Nov 19, 2013		U-543		
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013		U-543		
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RITONAVIR - NORVIR</u>						
N020659 001	5484801	Jan 28, 2014				
	5484801*PED	Jul 28, 2014				
	5541206	Jul 30, 2013		U-140		
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014		U-190		
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014				
	5674882*PED	Apr 07, 2015				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016				
	6037157*PED	Dec 26, 2016				
	6703403	Jun 26, 2016		U-564		
	6703403*PED	Dec 26, 2016				
<u>RITONAVIR - NORVIR</u>						
N020680 001	5541206	Jul 30, 2013		U-140		
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014		U-190		
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5948436	Sep 13, 2013				
	5948436*PED	Mar 13, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N020945 001	5541206	Jul 30, 2013	U-348			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014	U-347			
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014	U-895			
	5674882*PED	Apr 07, 2015				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016	U-895			
	6037157*PED	Dec 26, 2016				
	6232333	Nov 07, 2017				
	6232333*PED	May 07, 2018				
	6703403	Jun 26, 2016	U-564			
	6703403*PED	Dec 26, 2016				
	7141593	May 22, 2020	DP			
	7141593*PED	Nov 22, 2020				
	7432294	May 22, 2020	DP			
	7432294*PED	Nov 22, 2020				
<u>RITONAVIR - NORVIR</u>						
N022417 001	5541206	Jul 30, 2013	DS DP U-688			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014	U-688			
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014	DS			
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014	U-688			
	5674882*PED	Apr 07, 2015				
	6037157	Jun 26, 2016	U-688			
	6037157*PED	Dec 26, 2016				
	6703403	Jun 26, 2016	U-688			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				
<u>RIVASTIGMINE - EXELON</u>						
N022083 001	4948807	Aug 14, 2012	DS		U-322	NDF Jul 06, 2010
	5602176	Feb 11, 2014	DS DP		U-322	
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE - EXELON</u>						
N022083 002	4948807	Aug 14, 2012	DS		U-322	NDF Jul 06, 2010
	5602176	Feb 11, 2014	DS DP		U-322	
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 003	4948807	Aug 14, 2012	DS		U-322	
	5602176	Feb 11, 2014			U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 004	4948807	Aug 14, 2012	DS		U-322	
	5602176	Feb 11, 2014			U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 005	4948807	Aug 14, 2012	DS		U-322	
	5602176	Feb 11, 2014			U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 006	4948807	Aug 14, 2012	DS		U-322	
	5602176	Feb 11, 2014			U-322	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N021025 001	4948807	Aug 14, 2012	DS	U-322		
	5602176	Feb 11, 2014				
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077129 001					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077129 002					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077129 003					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077129 004					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077130 001					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077130 002					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077130 003					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077130 004					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077131 001					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077131 002					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077131 003					PC	Dec 28, 2010
<u>RIVASTIGMINE TARTRATE - RIVASTIGMINE TARTRATE</u>						
A077131 004					PC	Dec 28, 2010
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5298520	Jun 29, 2012		U-240		
	5602162	Feb 11, 2014				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5298520	Jun 29, 2012		U-240		
	5602162	Feb 11, 2014				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5298520	Jun 29, 2012		U-240		
	5457895	Oct 01, 2013				
	5602162	Feb 11, 2014				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5298520	Jun 29, 2012		U-240		
	5457895	Oct 01, 2013				
	5602162	Feb 11, 2014				
<u>ROCURONIUM BROMIDE - ZEMURON</u>						
N020214 001					NPP	Aug 28, 2011
					PED	Feb 28, 2012
<u>ROCURONIUM BROMIDE - ZEMURON</u>						
N020214 002					NPP	Aug 28, 2011
					PED	Feb 28, 2012
<u>ROCURONIUM BROMIDE - ZEMURON</u>						
N020214 003					NPP	Aug 28, 2011
					PED	Feb 28, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFECOXIB - VIOXX</u>						
N021042 001	5474995	Jun 24, 2013	DS DP U-602			
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-602	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013	DS DP U-602			
	6239173*PED	Dec 24, 2013				
<u>ROFECOXIB - VIOXX</u>						
N021042 002	5474995	Jun 24, 2013	DS DP U-602			
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-602	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013	DS DP U-602			
	6239173*PED	Dec 24, 2013				
<u>ROFECOXIB - VIOXX</u>						
N021042 003	5474995	Jun 24, 2013	DS DP U-602			
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-602	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013	DS DP U-602			
	6239173*PED	Dec 24, 2013				
<u>ROFECOXIB - VIOXX</u>						
N021052 001	5474995	Jun 24, 2013			U-266	
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-266	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013				
	6239173*PED	Dec 24, 2013				
<u>ROFECOXIB - VIOXX</u>						
N021052 002	5474995	Jun 24, 2013			U-266	
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-266	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013				
	6239173*PED	Dec 24, 2013				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Jul 06, 2011	DS DP		NCE	Nov 05, 2014
	7608280	Aug 22, 2021	DS		ODE	Nov 05, 2016
	7611724	Aug 22, 2021	DS			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 001	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 002	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 003	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 004	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 005	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 006	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPIVACAINE HYDROCHLORIDE MONOHYDRATE - NAROPIN</u>						
N020533 001	4870086	Sep 24, 2010				
	5670524	May 26, 2014	DS DP	U-833		
	5834489	May 26, 2014	DS DP	U-838		
<u>ROPIVACAINE HYDROCHLORIDE MONOHYDRATE - NAROPIN</u>						
N020533 003	4870086	Sep 24, 2010				
	5670524	May 26, 2014	DS DP	U-833		
	5834489	May 26, 2014	DS DP	U-838		
<u>ROPIVACAINE HYDROCHLORIDE MONOHYDRATE - NAROPIN</u>						
N020533 004	4870086	Sep 24, 2010				
	5670524	May 26, 2014	DS DP	U-833		
	5834489	May 26, 2014	DS DP	U-838		
<u>ROPIVACAINE HYDROCHLORIDE MONOHYDRATE - NAROPIN</u>						
N020533 005	4870086	Sep 24, 2010				
	5670524	May 26, 2014	DS DP	U-833		
	5834489	May 26, 2014	DS DP	U-838		
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N021071 002	5002953	Sep 17, 2011	DS DP	U-329		
	5002953	Sep 17, 2011	DS DP	U-628		
	5002953	Sep 17, 2011	DS DP	U-840		
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP	U-329	Y	
	5741803	Apr 21, 2015	DS DP	U-628	Y	
	5741803*PED	Oct 21, 2015				
	6288095	Feb 11, 2017		U-420	Y	
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N021071 003	5002953	Sep 17, 2011	DS DP	U-628		
	5002953	Sep 17, 2011	DS DP	U-840		
	5002953	Sep 17, 2011	DS DP	U-329		
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP	U-628	Y	
	5741803	Apr 21, 2015	DS DP	U-329	Y	
	5741803*PED	Oct 21, 2015				
	6288095	Feb 11, 2017		U-420	Y	
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N021071 004	5002953	Sep 17, 2011	DS DP	U-329		
	5002953	Sep 17, 2011	DS DP	U-840		
	5002953	Sep 17, 2011	DS DP	U-628		
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP	U-628	Y	
	5741803	Apr 21, 2015	DS DP	U-329	Y	
	5741803*PED	Oct 21, 2015				
	6288095	Feb 11, 2017		U-420	Y	
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE		
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>											
N021366 002	6316460	Aug 04, 2020	DP				I-621	Feb 08, 2013			
	6316460*PED	Feb 04, 2021				I-611	Oct 16, 2012				
	6858618	Dec 17, 2021	U-618			I-573	Nov 06, 2011				
	6858618*PED	Jun 17, 2022				I-547	Nov 08, 2010				
	7030152	Apr 02, 2018	DS	U-1032	PED	Apr 16, 2013					
	RE37314	Jan 08, 2016			PED	May 08, 2011					
	RE37314*PED	Jul 08, 2016			PED	May 08, 2012					
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>											
N021366 003	6316460	Aug 04, 2020	DP				I-621	Feb 08, 2013			
	6316460*PED	Feb 04, 2021				I-611	Oct 16, 2012				
	6858618	Dec 17, 2021	U-618			I-573	Nov 06, 2011				
	6858618*PED	Jun 17, 2022				I-547	Nov 08, 2010				
	7030152	Apr 02, 2018	DS	U-1032	PED	Apr 16, 2013					
	RE37314	Jan 08, 2016			PED	May 08, 2011					
	RE37314*PED	Jul 08, 2016			PED	May 06, 2012					
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>											
N021366 004	6316460	Aug 04, 2020	DP				I-621	Feb 08, 2013			
	6316460*PED	Feb 04, 2021				I-611	Oct 16, 2012				
	6858618	Dec 17, 2021	U-618			I-573	Nov 06, 2011				
	6858618*PED	Jun 17, 2022				I-547	Nov 08, 2010				
	7030152	Apr 02, 2018	DS	U-1032	PED	Apr 16, 2013					
	RE37314	Jan 08, 2016			PED	May 08, 2011					
	RE37314*PED	Jul 08, 2016			PED	May 06, 2012					
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>											
N021366 005	6316460	Aug 04, 2020	DP				I-621	Feb 08, 2013			
	6316460*PED	Feb 04, 2021				I-611	Oct 16, 2012				
	6858618	Dec 17, 2021	U-618			I-573	Nov 06, 2011				
	6858618*PED	Jun 17, 2022				I-547	Nov 08, 2010				
	7030152	Apr 02, 2018	DS	U-1032	PED	Apr 16, 2013					
	RE37314	Jan 08, 2016			PED	May 08, 2011					
	RE37314*PED	Jul 08, 2016			PED	May 06, 2012					
<u>ROTIGOTINE - NEUPRO</u>											
N021829 001	6884434	Mar 18, 2019	DP			NCE	May 09, 2012				
	7413747	Mar 18, 2019	DP								
<u>ROTIGOTINE - NEUPRO</u>											
N021829 002	6884434	Mar 18, 2019	DP			NCE	May 09, 2012				
	7413747	Mar 18, 2019	DP								
<u>ROTIGOTINE - NEUPRO</u>											
N021829 003	6884434	Mar 18, 2019	DP			NCE	May 09, 2012				
	7413747	Mar 18, 2019	DP								
<u>RUFINAMIDE - BANZEL</u>											
N021911 001	6740669	Aug 17, 2020	DS	DP		NCE	Nov 14, 2013				
						ODE	Nov 14, 2015				
<u>RUFINAMIDE - BANZEL</u>											
N021911 002	6740669	Aug 17, 2020	DS	DP		NCE	Nov 14, 2013				
						ODE	Nov 14, 2015				
<u>RUFINAMIDE - BANZEL</u>											
N021911 003	6740669	Aug 17, 2020	DS	DP		NCE	Nov 14, 2013				
						ODE	Nov 14, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
N020692 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	7566462	Nov 16, 2025	DP		NCE	Dec 13, 2012
	7566714	Nov 17, 2024		U-989	ODE	Dec 13, 2014
	7612073	Nov 17, 2024		U-1010		
	7727987	Nov 17, 2024	DP			
<u>SAQUINAVIR - FORTOVASE</u>						
N020828 001	5196438	Nov 19, 2010				
	5196438*PED	May 19, 2011				
	6008228	Jun 06, 2015				
	6008228*PED	Dec 06, 2015				
	6352717	Nov 16, 2019				
	6352717*PED	May 16, 2020				
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N020628 001	5196438	Nov 19, 2010				
	5196438*PED	May 19, 2011				
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N021785 001	5196438	Nov 19, 2010	DS DP	U-834		
	5196438*PED	May 19, 2011				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 001	6395767	Feb 16, 2021	DS DP	U-995	NCE	Jul 31, 2014
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 002	6395767	Feb 16, 2021	DS DP	U-995	NCE	Jul 31, 2014
<u>SELEGILINE - EMSAM</u>						
N021336 001	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N021336 002	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N021336 003	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE HYDROCHLORIDE - ZELAPAR</u>						
N021479 001	5648093	Jul 15, 2014	DP			
	6423342	Mar 01, 2016	DP			
<u>SERTACONAZOLE NITRATE - ERTACZO</u>						
N021385 001	5135943	May 31, 2014	DS DP	U-786		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 001	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 002	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 003	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 004	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 005	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N020990 001	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
	6727283	Oct 11, 2019	DP	U-580		
	6727283*PED	Apr 11, 2020				
	7067555	Nov 10, 2019	DP			
	7067555*PED	May 10, 2020				
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022127 001	5496545	Aug 11, 2013	DP	U-246	NE	Oct 19, 2010
	5667775	Sep 16, 2014		U-246		
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP	U-246		
	7014846	Aug 11, 2013	DP	U-246		
	7459151	Aug 11, 2013		U-246		
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022318 001	5496545	Aug 11, 2013	DP	U-246	NDF	Aug 12, 2012
	5667775	Sep 16, 2014		U-246	NE	Oct 19, 2010
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP	U-246		
	7014846	Aug 11, 2013	DP	U-246		
	7459151	Aug 11, 2013		U-246		
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022318 002	5496545	Aug 11, 2013	DP	U-246	NDF	Aug 12, 2012
	5667775	Sep 16, 2014		U-246	NE	Oct 19, 2010
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP	U-246		
	7014846	Aug 11, 2013	DP	U-246		
	7459151	Aug 11, 2013		U-246		
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N020926 001	5496545	Aug 11, 2013		U-246		
	5667775	Sep 16, 2014		U-246		
	6509013	Aug 11, 2013				
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N021179 001	5496545	Aug 11, 2013		U-246	M-67	Oct 19, 2010
	5667775	Sep 16, 2014		U-246		
	6509013	Aug 11, 2013				
	6733780	Oct 18, 2020	DP			
	7014846	Aug 11, 2013	DP	U-246		
	7459151	Aug 11, 2013		U-246		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N021179 002	5496545	Aug 11, 2013	U-246		M-67	Oct 19, 2010
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013				
	6733780	Oct 18, 2020	DP			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVOFLURANE - ULTANE</u>						
N020478 001	5990176	Jan 27, 2017				
	5990176*PED	Jul 27, 2017				
	6074668	Jan 09, 2018				
	6074668*PED	Jul 09, 2018				
	6288127	Jan 27, 2017				
	6288127*PED	Jul 27, 2017				
	6444859	Jan 27, 2017				
	6444859*PED	Jul 27, 2017				
<u>SIBUTRAMINE HYDROCHLORIDE - MERIDIA</u>						
N020632 001	5436272	Jul 25, 2012	U-439			
	5436272*PED	Jan 25, 2013				
<u>SIBUTRAMINE HYDROCHLORIDE - MERIDIA</u>						
N020632 002	5436272	Jul 25, 2012	U-439			
	5436272*PED	Jan 25, 2013				
<u>SIBUTRAMINE HYDROCHLORIDE - MERIDIA</u>						
N020632 003	5436272	Jul 25, 2012	U-439			
	5436272*PED	Jan 25, 2013				
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	6469012	Oct 22, 2019	U-155			
<u>SILODOSIN - RAPAFLO</u>						
N022206 001	5387603	Dec 01, 2018	DS DP		NCE	Oct 08, 2013
	5403847	Nov 13, 2012	U-902			
	5780485	Nov 13, 2012	U-902			
	6015819	Nov 13, 2012	U-902			
<u>SILODOSIN - RAPAFLO</u>						
N022206 002	5387603	Dec 01, 2018	DS DP		NCE	Oct 08, 2013
	5403847	Nov 13, 2012	U-902			
	5780485	Nov 13, 2012	U-902			
	6015819	Nov 13, 2012	U-902			
<u>SINCALIDE - KINEVAC</u>						
N017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N021902 001	5795911	Oct 31, 2020	U-172			
	5968973	Apr 10, 2017	U-172			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIROLIMUS - RAPAMUNE</u>						
N021083 001	5100899	Jul 07, 2013	U-290			
	5100899*PED	Jan 07, 2014				
	5212155*PED	Nov 18, 2010				
	5403833	Apr 04, 2012	U-293			
	5403833*PED	Oct 04, 2012				
	5536729	Sep 30, 2013	DP			
	5536729*PED	Mar 30, 2014				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 001	5100899	Jul 07, 2013	U-290			
	5100899*PED	Jan 07, 2014				
	5145684	Jan 25, 2011	DP U-857			
	5145684*PED	Jul 25, 2011				
	5212155*PED	Nov 18, 2010				
	5403833	Apr 04, 2012	U-293			
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 002	5100899	Jul 07, 2013	U-290			
	5100899*PED	Jan 07, 2014				
	5145684	Jan 25, 2011	DP U-857			
	5145684*PED	Jul 25, 2011				
	5212155*PED	Nov 18, 2010				
	5403833	Apr 04, 2012	U-293			
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 003	5100899	Jul 07, 2013	U-290			
	5100899*PED	Jan 07, 2014				
	5145684	Jan 25, 2011	DP U-857			
	5145684*PED	Jul 25, 2011				
	5212155*PED	Nov 18, 2010				
	5403833	Apr 04, 2012	U-293			
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 004	5100899	Jul 07, 2013	U-290			
	5100899*PED	Jan 07, 2014				
	5145684	Jan 25, 2011	DP U-857			
	5145684*PED	Jul 25, 2011				
	5212155*PED	Nov 18, 2010				
	5403833	Apr 04, 2012	U-293			
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 001	6303661	Apr 24, 2017	U-774		M-68	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP U-774		M-69	Oct 12, 2010
	6890898	Feb 02, 2019	U-775		NCE	Oct 16, 2011
	6890898	Feb 02, 2019	U-1039			
	6890898	Feb 02, 2019	U-1036			
	7078381	Feb 02, 2019	U-775			
	7078381	Feb 02, 2019	U-1037			
	7078381	Feb 02, 2019	U-1036			
	7078381	Feb 02, 2019	U-1038			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7326708	Apr 11, 2026	DS DP U-802			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 002	6303661	Apr 24, 2017			M-68	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP	U-774	M-69	Oct 12, 2010
	6890898	Feb 02, 2019		U-1036	NCE	Oct 16, 2011
	6890898	Feb 02, 2019		U-1039		
	6890898	Feb 02, 2019		U-775		
	7078381	Feb 02, 2019		U-775		
	7078381	Feb 02, 2019		U-1038		
	7078381	Feb 02, 2019		U-1037		
	7078381	Feb 02, 2019		U-1036		
	7125873	Jul 26, 2022		U-775		
	7125873	Jul 26, 2022		U-1037		
	7125873	Jul 26, 2022		U-1036		
	7125873	Jul 26, 2022		U-1038		
	7326708	Apr 11, 2026	DS DP	U-802		
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 003	6303661	Apr 24, 2017			M-68	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP	U-774	M-69	Oct 12, 2010
	6890898	Feb 02, 2019		U-775	NCE	Oct 16, 2011
	6890898	Feb 02, 2019		U-1036		
	6890898	Feb 02, 2019		U-1039		
	7078381	Feb 02, 2019		U-775		
	7078381	Feb 02, 2019		U-1037		
	7078381	Feb 02, 2019		U-1038		
	7078381	Feb 02, 2019		U-1036		
	7125873	Jul 26, 2022		U-1038		
	7125873	Jul 26, 2022		U-775		
	7125873	Jul 26, 2022		U-1036		
	7125873	Jul 26, 2022		U-1037		
	7326708	Apr 11, 2026	DS DP	U-802		
<u>SODIUM BENZOATE; SODIUM PHENYLACETATE - AMMONUL</u>						
N020645 001					ODE	Feb 17, 2012
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	6780889	Jul 04, 2020	DP		ODE	Nov 18, 2012
	7262219	Jul 04, 2020	DP			
	7668730	Mar 07, 2024		U-1028		
	7765106	Jun 16, 2024		U-1069		
	7765107	Jun 16, 2024		U-1070		
	7851506	Dec 22, 2019		U-1101		
	7851506	Dec 22, 2019		U-1102		
<u>SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N021892 001	5616346	May 18, 2013	DP	U-715		
	7687075	Jun 22, 2028	DS DP			
<u>SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - VISICOL</u>						
N021097 001	5616346	May 18, 2013		U-359		
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N021518 001	6017927	Nov 19, 2018	DS DP			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N021518 002	6017927	Nov 19, 2018	DS DP			
<u>SOMATROPIN RECOMBINANT - ACCRETROPIN</u>						
N021538 001					NP	Jan 23, 2011
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 001	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 002	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 003	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 005	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 008	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 009	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 010	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 011	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 012	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 013	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 001					I-585 ODE	Mar 12, 2012 Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 004	5612315	Mar 18, 2014	DP		I-585 ODE	Mar 12, 2012 Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 005	5612315	Mar 18, 2014	DP		I-585 ODE	Mar 12, 2012 Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 006	5612315	Mar 18, 2014	DP		I-585 ODE	Mar 12, 2012 Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 007	5612315	Mar 18, 2014	DP		I-585 ODE	Mar 12, 2012 Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N021148 001	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015			I-551	Sep 20, 2010
					ODE	May 31, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N021148 002	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015			I-551	Sep 20, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N021148 003	5633352	May 27, 2014	U-340		I-572	Oct 31, 2011
	5849700	Dec 15, 2015			I-551	Sep 20, 2010
	5849704	Dec 15, 2015			ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPOR</u>						
N021148 008	5849700	Dec 15, 2015	DP U-1041		I-551	Sep 20, 2010
	5849704	Dec 15, 2015			I-572	Oct 31, 2011
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPOR</u>						
N021148 009	5849700	Dec 15, 2015	DP U-1041		I-551	Sep 20, 2010
	5849704	Dec 15, 2015			I-572	Oct 31, 2011
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPOR</u>						
N021148 010	5849700	Dec 15, 2015	DP U-1041		I-551	Sep 20, 2010
	5849704	Dec 15, 2015			I-572	Oct 31, 2011
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 004	5849700	Dec 15, 2015	DP U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015			I-551	Sep 20, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 005	5849700	Dec 15, 2015	DP U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015			I-551	Sep 20, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 006	5849700	Dec 15, 2015	DP U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015			I-551	Sep 20, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 007	5849700	Dec 15, 2015	DP U-340		I-551	Sep 20, 2010
	5849704	Dec 15, 2015			I-572	Oct 31, 2011
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ</u>						
N020522 001	5763394	Jun 09, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ PEN</u>						
N020522 002	5763394	Jun 09, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N021075 001	5654010	Aug 05, 2014	U-340			
	5656297	Jul 25, 2014				
	5912015	Mar 12, 2012				
	6051259	Dec 02, 2012				
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N021075 002	5654010	Aug 05, 2014	U-340			
	5656297	Jul 25, 2014				
	5912015	Mar 12, 2012				
	6051259	Dec 02, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N021075 003	5654010	Aug 05, 2014	U-340			
	5656297	Jul 25, 2014				
	5912015	Mar 12, 2012				
	6051259	Dec 02, 2012				
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N019764 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N019764 003	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 001	5898030	Apr 27, 2016	DP		M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 002	5898030	Apr 27, 2016	DP		M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 003	5898030	Apr 27, 2016	DP		M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 004	5898030	Apr 27, 2016	DP		M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - SEROSTIM LQ</u>						
N020604 005					M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N021597 001					ODE	Dec 01, 2010
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N021597 002					ODE	Dec 01, 2010
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N021597 003					ODE	Dec 01, 2010
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N021597 004	5288703	Oct 07, 2011	U-898 DP		ODE	Dec 01, 2010
	5898030	Apr 27, 2016				
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	7235576	Jan 12, 2020	DS DP DS		I-546	Nov 16, 2010
	7351834	Jan 12, 2020			NCE	Dec 20, 2010
					ODE	Nov 16, 2014
					ODE	Dec 20, 2012
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N022306 001					ODE	Jul 02, 2016
<u>STAVUDINE - ZERIT XR</u>						
N021453 001	7135465	Feb 18, 2023	DP U-167			
	7135465*PED	Aug 18, 2023				
<u>STAVUDINE - ZERIT XR</u>						
N021453 002	7135465	Feb 18, 2023	DP U-167			
	7135465*PED	Aug 18, 2023				
<u>STAVUDINE - ZERIT XR</u>						
N021453 003	7135465	Feb 18, 2023	DP U-167			
	7135465*PED	Aug 18, 2023				
<u>STAVUDINE - ZERIT XR</u>						
N021453 004	7135465	Feb 18, 2023	DP U-167			
	7135465*PED	Aug 18, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN - IMITREX</u>						
N020626 001	5307953	Dec 02, 2012				
	5307953*PED	Jun 02, 2013				
	5554639	Sep 10, 2013	U-232			
	5554639*PED	Mar 10, 2014				
	5705520	Dec 10, 2011	U-232			
	5705520*PED	Jun 10, 2012				
<u>SUMATRIPTAN - IMITREX</u>						
N020626 002	5307953	Dec 02, 2012				
	5307953*PED	Jun 02, 2013				
	5554639	Sep 10, 2013	U-232			
	5554639*PED	Mar 10, 2014				
	5705520	Dec 10, 2011	U-232			
	5705520*PED	Jun 10, 2012				
<u>SUMATRIPTAN - IMITREX</u>						
N020626 003	5307953	Dec 02, 2012				
	5307953*PED	Jun 02, 2013				
	5554639	Sep 10, 2013	U-232			
	5554639*PED	Mar 10, 2014				
	5705520	Dec 10, 2011	U-232			
	5705520*PED	Jun 10, 2012				
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N022377 001	7811254	Aug 26, 2027	DP U-1083			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	5891086	Jul 27, 2014	DP			
	5957886	Mar 08, 2016	DP			
	6135979	Mar 21, 2017	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 001	6573293	Feb 15, 2021	DS DP U-703		NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 002	6573293	Feb 15, 2021	DS DP U-703		NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 003	6573293	Feb 15, 2021	DS DP U-703		NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 004	6573293	Feb 15, 2021	DS DP U-703		NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>TACROLIMUS - PROGRAF</u>						
N050708 001					ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>						
N050708 002					ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>						
N050708 003					ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>						
N050709 001	5260301	Feb 28, 2011	DP		ODE	Mar 29, 2013
<u>TACROLIMUS - PROTOPIC</u>						
N050777 001	5385907	Jan 31, 2012	DP			
	5665727	Sep 09, 2014	U-919			
<u>TACROLIMUS - PROTOPIC</u>						
N050777 002	5385907	Jan 31, 2012	DP			
	5665727	Sep 09, 2014	U-919			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - ADCIRCA</u>						
N022332 001	5859006	Nov 21, 2017	DS DP U-975		NP	May 22, 2012
	6821975	Nov 19, 2020	DS DP		ODE	May 22, 2016
	7182958	Apr 26, 2020	DP			
<u>TADALAFIL - CIALIS</u>						
N021368 001	5859006	Nov 21, 2017	DS DP		D-111	Jan 07, 2011
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N021368 002	5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N021368 003	5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N021368 004	5859006	Nov 21, 2017	DS DP		D-111	Jan 07, 2011
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			
<u>TAMOXIFEN CITRATE - SOLTAMOX</u>						
N021807 001	6127425	Jun 26, 2018	DP			
<u>TAMSULOSIN HYDROCHLORIDE - FLOMAX</u>						
N020579 001					M-54 PED	Dec 22, 2012 Jun 22, 2013
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 001	6071970	Jun 06, 2017			NCE	Nov 20, 2013
	RE39593	Jun 18, 2018	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 002	6071970	Jun 06, 2017			NCE	Nov 20, 2013
	RE39593	Jun 18, 2018	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 003	6071970	Jun 06, 2017			NCE	Nov 20, 2013
	RE39593	Jun 18, 2018	DS DP U-931			
<u>TAZAROTENE - AVAGE</u>						
N021184 003	5089509	Jun 13, 2011	U-481			
<u>TAZAROTENE - TAZORAC</u>						
N020600 001	5089509	Jun 13, 2011	U-481			
	5089509	Jun 13, 2011	U-193			
	5914334	Jun 07, 2014	U-517			
	6258830	Jun 07, 2014	U-517			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZAROTENE - TAZORAC</u>						
N020600 002	5089509	Jun 13, 2011	U-193			
	5089509	Jun 13, 2011	U-481			
	5914334	Jun 07, 2014	U-517			
	6258830	Jun 07, 2014	U-517			
<u>TAZAROTENE - TAZORAC</u>						
N021184 001	5089509	Jun 13, 2011	U-481			
<u>TAZAROTENE - TAZORAC</u>						
N021184 002	5089509	Jun 13, 2011	U-481			
<u>TECHNETIUM TC-99M APCITIDE - ACUTECT</u>						
N020887 001	5443815	Aug 22, 2012				
	5508020	Apr 16, 2013				
	5645815	Jul 08, 2014				
<u>TECHNETIUM TC-99M BICISATE KIT - NEUROLITE</u>						
N020256 001	5431900	Jul 11, 2012	U-336			
<u>TECHNETIUM TC-99M SESTAMIBI KIT - CARDIOLITE</u>						
N019785 001					M-54 PED	Apr 30, 2011 Oct 30, 2011
<u>TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC</u>						
N019928 001	6056941	Jul 28, 2019	DP			
<u>TEGASEROD MALEATE - ZELNORM</u>						
N021200 001	5510353	Apr 26, 2013	U-466			
<u>TEGASEROD MALEATE - ZELNORM</u>						
N021200 002	5510353	Apr 26, 2013	U-466			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	6635618	Sep 22, 2021	DS DP	U-728	NCE	Sep 11, 2014
	6858584	Aug 24, 2022	DP			
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021		U-1005		
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP	U-728		
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021		U-282		
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	6635618	Sep 22, 2021	DS DP	U-728	NCE	Sep 11, 2014
	6858584	Aug 24, 2022	DP			
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021		U-1005		
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP	U-728		
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021		U-282		
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	6395716	Aug 10, 2019		U-782	NCE	Oct 25, 2011
	6444652	Aug 10, 2019		U-782		
	6566344	Aug 10, 2019		U-782		
	6569837	Oct 25, 2020		U-782		
	6569837	Oct 25, 2020		U-999		
	7589079	Sep 11, 2023	DS DP	U-999		
	7795238	Aug 10, 2019		U-999		
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	6395716	Aug 10, 2019		U-999	NCE	Oct 25, 2011
	6444652	Aug 10, 2019		U-999		
	6566344	Aug 10, 2019		U-999		
	6569837	Oct 25, 2020		U-999		
	7795238	Aug 10, 2019		U-999		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELITHROMYCIN - KETEK</u>						
N021144 001	5635485 D459798	Apr 01, 2018 Sep 24, 2015	DS DP U-578 DP			
<u>TELITHROMYCIN - KETEK</u>						
N021144 002	5635485 D459798	Apr 01, 2018 Sep 24, 2015	DS DP U-578 DP			
<u>TELMISARTAN - MICARDIS</u>						
N020850 001	5591762 6358986	Jan 07, 2014 Jan 10, 2020		U-3		
<u>TELMISARTAN - MICARDIS</u>						
N020850 002	5591762 6358986	Jan 07, 2014 Jan 10, 2020	DS DP U-3		I-612	Oct 16, 2012
<u>TELMISARTAN - MICARDIS</u>						
N020850 003	5591762 6358986	Jan 07, 2014 Jan 10, 2020		U-3		
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 001	5260291 5260291*PED	Aug 11, 2013 Feb 11, 2014	DS DP U-619		ODE	Mar 15, 2012
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 002	5260291 5260291*PED	Aug 11, 2013 Feb 11, 2014	DS DP U-619		ODE	Mar 15, 2012
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 003	5260291 5260291*PED	Aug 11, 2013 Feb 11, 2014	DS DP U-619		ODE	Mar 15, 2012
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 004	5260291 5260291*PED	Aug 11, 2013 Feb 11, 2014	DS DP U-619		ODE	Mar 15, 2012
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 005	5260291 5260291*PED	Aug 11, 2013 Feb 11, 2014	DS DP U-619		ODE	Mar 15, 2012
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 006	5260291 5260291*PED	Aug 11, 2013 Feb 11, 2014	DS DP U-619		ODE	Mar 15, 2012
<u>TEMOZOLOMIDE - TEMODAR</u>						
N022277 001	5260291 5260291*PED 6987108 7786118	Aug 11, 2013 Feb 11, 2014 Sep 08, 2023 Feb 21, 2023	DS DP U-619 DP DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92 M-91 NCE ODE	Jul 09, 2013 Apr 26, 2013 May 30, 2012 May 30, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	5922695	Jul 25, 2017	DS U-250		I-569	Aug 11, 2011
	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-250			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-250			
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 001	5294615	Apr 29, 2013	U-3			
	5294615	Apr 29, 2013	U-165			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 002	5294615	Apr 29, 2013	U-3			
	5294615	Apr 29, 2013	U-165			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 003	5294615	Apr 29, 2013	U-3			
	5294615	Apr 29, 2013	U-165			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 004	5294615	Apr 29, 2013	U-3			
	5294615	Apr 29, 2013	U-165			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 001	5294615	Apr 29, 2013	U-3			
	5294615	Apr 29, 2013	U-165			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 002	5294615	Apr 29, 2013	U-165			
	5294615	Apr 29, 2013	U-3			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 003	5294615	Apr 29, 2013	U-3			
	5294615	Apr 29, 2013	U-165			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 004	5294615	Apr 29, 2013	U-3			
	5294615	Apr 29, 2013	U-165			
	5412095	Apr 29, 2013				
<u>TERBINAFINE - LAMISIL</u>						
N020846 001	5681849	Oct 28, 2014	DP			
	5681849*PED	Apr 28, 2015				
	5856355	May 18, 2012	DP U-540			
	5856355	May 18, 2012	DP U-504			
	5856355	May 18, 2012	DP U-502			
	5856355*PED	Nov 18, 2012				
	6005001	May 18, 2012	DP U-502			
	6005001	May 18, 2012	DP U-540			
	6005001	May 18, 2012	DP U-504			
	6005001*PED	Nov 18, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERBINAFINE - LAMISIL AT</u>						
N021958 001	5681849	Oct 28, 2014	DP			
	5681849*PED	Apr 28, 2015				
	5856355	May 18, 2012	DP U-504			
	5856355	May 18, 2012	DP U-540			
	5856355*PED	Nov 18, 2012				
<u>TERBINAFINE HYDROCHLORIDE - LAMISIL AT</u>						
N021124 001	5681849	Oct 28, 2014				
	5681849*PED	Apr 28, 2015				
<u>TERBINAFINE HYDROCHLORIDE - LAMISIL AT</u>						
N021124 002	5681849	Oct 28, 2014				
	5681849*PED	Apr 28, 2015				
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N021318 001	6770623	Dec 08, 2018	DP U-597		I-602	Jul 22, 2012
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-790			
	7351414	Aug 19, 2019	U-865			
	7550434	Dec 08, 2018	DP U-982			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N021318 002	6770623	Dec 08, 2018	DP U-982		I-602	Jul 22, 2012
	6977077	Aug 19, 2019	U-982			
	6977077	Aug 19, 2019	U-994			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7163684	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-984			
	7550434	Dec 08, 2018	DP U-982			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 001	5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - ANDRODERM</u>						
N020489 001	5152997	Dec 11, 2010	U-490			
	5164190	Dec 11, 2010				
<u>TESTOSTERONE - ANDRODERM</u>						
N020489 002	5152997	Dec 11, 2010	U-490			
	5164190	Dec 11, 2010				
<u>TESTOSTERONE - ANDROGEL</u>						
N021015 001	6503894	Aug 30, 2020	U-490			
	6503894*PED	Mar 01, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N021015 002	6503894	Aug 30, 2020	U-490			
	6503894*PED	Mar 01, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N021015 003	6503894	Aug 30, 2020	U-490			
	6503894*PED	Mar 01, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N022504 001	6299900	Feb 19, 2017	DP U-1103		NP	Nov 23, 2013
	6818226	Feb 19, 2017	DP U-1103			
	6923983	Feb 19, 2017	DP U-1103			
<u>TESTOSTERONE - FORTESTA</u>						
N021463 001					NP	Dec 29, 2013
<u>TESTOSTERONE - STRIANT</u>						
N021543 001	6248358	Aug 23, 2019	U-527			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	7320968	Jan 18, 2025	U-843			
	7608605	Apr 21, 2023	U-1009			
	7608606	Apr 21, 2023	U-1009			
	7608607	Apr 21, 2023	U-1009			
	7608608	Apr 21, 2023	U-1009			
	7608609	Apr 21, 2023	U-1009			
	7608610	Apr 21, 2023	U-1009			
<u>TESTOSTERONE - TESTODERM</u>						
N019762 001	5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM</u>						
N019762 002	5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM TTS</u>						
N020791 001	6348210	Nov 10, 2019	U-440			
<u>TETRABENAZINE - XENAZINE</u>						
N021894 001					NCE	Aug 15, 2013
					ODE	Aug 15, 2015
<u>TETRABENAZINE - XENAZINE</u>						
N021894 002					NCE	Aug 15, 2013
					ODE	Aug 15, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	5629327	May 13, 2014	U-731		ODE	May 25, 2013
	6045501	Aug 28, 2018	U-731			
	6045501	Aug 28, 2018	U-371			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-733			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7723361	Mar 01, 2013	U-1058			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	5629327	May 13, 2014	U-731		ODE	May 25, 2013
	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-733			
	6869399	Oct 23, 2020	U-371			
	6908432	Aug 28, 2018	U-731			
	6908432	Aug 28, 2018	U-371			
	7141018	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7723361	Mar 01, 2013	U-1058			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	5629327	May 13, 2014	U-731		ODE	May 25, 2013
	6045501	Aug 28, 2018	U-731			
	6045501	Aug 28, 2018	U-371			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-731			
	6315720	Oct 23, 2020	U-442			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-733			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6908432	Aug 28, 2018	U-731			
	6908432	Aug 28, 2018	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-371			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7723361	Mar 01, 2013	U-1058			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	5629327	May 13, 2014	U-731		ODE	May 23, 2013
	6045501	Aug 28, 2018	U-731			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-731			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-731			
	7435745	Nov 03, 2017	U-899			
	7723361	Mar 01, 2013	U-1058			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THYROTROPIN ALFA - THYROGEN						
N020898 001	5840566	Nov 24, 2015	DS DP U-556		I-552	Dec 14, 2010
	6365127	Nov 24, 2015			ODE	Dec 14, 2014
TIAGABINE HYDROCHLORIDE - GABITRIL						
N020646 001	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
TIAGABINE HYDROCHLORIDE - GABITRIL						
N020646 002	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
TIAGABINE HYDROCHLORIDE - GABITRIL						
N020646 003	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
TIAGABINE HYDROCHLORIDE - GABITRIL						
N020646 004	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
TIAGABINE HYDROCHLORIDE - GABITRIL						
N020646 005	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
TIGECYCLINE - TYGACIL						
N021821 001	RE40086	Jun 25, 2013	DS DP	U-282	I-588	Mar 20, 2012
	RE40183	Apr 09, 2016			I-587	Mar 20, 2012
					I-586	Mar 20, 2012
TIMOLOL - BETIMOL						
N020439 001	5231095	Jul 27, 2010				
TIMOLOL - BETIMOL						
N020439 002	5231095	Jul 27, 2010				
TIMOLOL MALEATE - ISTALOL						
N021516 001	6335335	Nov 02, 2018	DP			
TIMOLOL MALEATE - TIMOLOL MALEATE						
N020963 001	6174524	Mar 26, 2019	DP		PED	Dec 08, 2010
	6174524*PED	Sep 26, 2019				
TIMOLOL MALEATE - TIMOLOL MALEATE						
N020963 002	6174524	Mar 26, 2019	DP			
	6174524*PED	Sep 26, 2019				
TINIDAZOLE - TINDAMAX						
N021618 001					ODE	May 17, 2011
					ODE	May 17, 2011
TINIDAZOLE - TINDAMAX						
N021618 002					ODE	May 17, 2011
					ODE	May 17, 2011

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	5478578	Dec 26, 2012	DP		M-89	Dec 17, 2012
	6777423	Sep 24, 2021	DS DP			
	6908928	Nov 25, 2022	DS DP	U-566		
	7070800	Jan 22, 2022	DP	U-566		
	7309707	Mar 10, 2023	DS DP			
	7642268	Sep 24, 2021	DS DP			
	RE38912	Oct 11, 2021	DP			
	RE39820	Jan 30, 2018	DS DP	U-566		
<u>TIPRANAVIR - APTIVUS</u>						
N021814 001	5852195	Jun 22, 2019	DS		I-568	Jun 23, 2011
	5852195*PED	Dec 22, 2019			PED	Dec 23, 2011
	6147095	Oct 29, 2019		U-670	PED	Dec 22, 2010
	6147095*PED	Apr 29, 2020				
	6169181	May 06, 2014	DS			
	6169181*PED	Nov 06, 2014				
	6231887	Jul 27, 2018	DP			
	6231887*PED	Jan 27, 2019				
<u>TIPRANAVIR - APTIVUS</u>						
N022292 001	5852195	Jun 22, 2019	DS		I-568	Jun 23, 2011
	5852195*PED	Dec 22, 2019			PED	Dec 23, 2011
	6147095	Oct 29, 2019		U-670	PED	Dec 22, 2010
	6147095*PED	Apr 29, 2020				
	6169181	May 06, 2014	DS			
	6169181*PED	Nov 06, 2014				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020912 001	5292756	May 14, 2012		U-230		
	5658929	Sep 27, 2010				
	5733919	Oct 23, 2016				
	5880136	Sep 27, 2010		U-254		
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020913 001	5292756	May 14, 2012		U-230		
	5658929	Sep 27, 2010				
	5733919	Oct 23, 2016				
	5880136	Sep 27, 2010		U-254		
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020913 002	5292756	May 14, 2012		U-230		
	5658929	Sep 27, 2010				
	5733919	Oct 23, 2016				
	5880136	Sep 27, 2010		U-254		
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020913 003	5292756	May 14, 2012		U-230		
	5658929	Sep 27, 2010				
	5733919	Oct 23, 2016				
	5880136	Sep 27, 2010		U-254		
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 001	6455557	Nov 28, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 002	6455557	Nov 28, 2021				
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 003	6455557	Nov 28, 2021				
<u>TOBRAMYCIN - TOBI</u>						
N050753 001	5508269	Oct 19, 2014	DP U-909			
<u>TOLCAPONE - TASMAR</u>						
N020697 001	5236952	Jan 29, 2012				
	5476875	Dec 19, 2012	U-219			
<u>TOLCAPONE - TASMAR</u>						
N020697 002	5236952	Jan 29, 2012				
	5476875	Dec 19, 2012	U-219			
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 001	5382600	Mar 25, 2012				
	5382600*PED	Sep 25, 2012				
	5559269	Nov 05, 2013	U-318	Y		
	5559269*PED	May 05, 2014				
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 002	5382600	Mar 25, 2012				
	5382600*PED	Sep 25, 2012				
	5559269	Nov 05, 2013	U-318	Y		
	5559269*PED	May 05, 2014				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228 001	5382600	Mar 25, 2012				
	5382600*PED	Sep 25, 2012				
	6630162	Nov 11, 2019	DP U-544			
	6630162*PED	May 11, 2020				
	6770295	Aug 26, 2019	DP U-544			
	6770295*PED	Feb 26, 2020				
	6911217	Aug 26, 2019	DP U-544			
	6911217*PED	Feb 26, 2020	DP U-544			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228 002	5382600	Mar 25, 2012				
	5382600*PED	Sep 25, 2012				
	6630162	Nov 11, 2019	DP U-544			
	6630162*PED	May 11, 2020				
	6770295	Aug 26, 2019	DP U-544			
	6770295*PED	Feb 26, 2020				
	6911217	Aug 26, 2019	DP U-544			
	6911217*PED	Feb 26, 2020	DP U-544			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 001	5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	5753677	May 19, 2015	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 002	5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	5753677	May 19, 2015	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 003	5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	5753677	May 19, 2015	U-978			
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 003	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 006	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7125560	Mar 01, 2019	U-766			
	7125560*PED	Sep 01, 2019				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7125560	Mar 01, 2019	U-766			
	7125560*PED	Sep 01, 2019				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N020844 003	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7125560	Mar 01, 2019	U-766			
	7125560*PED	Sep 01, 2019				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020671 001	5004758*PED	Nov 28, 2010				
	5674872	Oct 07, 2014	U-910			
	5674872*PED	Apr 07, 2015				
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	5004758*PED	Nov 28, 2010			NDF	Oct 11, 2010
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	5004758*PED	Nov 28, 2010			NDF	Oct 11, 2010
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 001	5591452	May 10, 2014	DP		NP	Dec 30, 2011
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 002	5591452	May 10, 2014	DP		NP	Dec 30, 2011
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 003	5591452	May 10, 2014	DP		NP	Dec 30, 2011
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
N021693 001	5464632	Mar 22, 2013	DP			
	6106861	Dec 05, 2017	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
N022370 001	7858118	Apr 11, 2022	DP	U-1104		
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
N022370 002	7858118	Apr 11, 2022	DP	U-1104		
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
N022370 003	7858118	Apr 11, 2022	DP	U-1104		
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N020281 001	6339105	Oct 12, 2019	U-435			
	6339105*PED	Apr 12, 2020	U-435			
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N020281 002	6339105	Oct 12, 2019	U-435			
	6339105*PED	Apr 12, 2020	U-435			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRANDOLAPRIL - MAVIK</u>						
N020528 001	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL - MAVIK</u>						
N020528 002	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL - MAVIK</u>						
N020528 003	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 001	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 002	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 003	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 004	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 001					PC	Dec 05, 2010
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 002					PC	Dec 05, 2010
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 003					PC	Dec 05, 2010
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 004					PC	Mar 19, 2011
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001					NDF	Nov 13, 2012
<u>TRAVOPROST - TRAVATAN</u>						
N021257 001	5510383	Aug 03, 2013	DP U-383			
	5631287	Dec 22, 2014	U-382			
	5849792	Dec 22, 2014	DP U-383			
	5889052	Dec 02, 2014	DP U-383			
	6011062	Dec 22, 2014	DP			
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	5510383	Aug 03, 2013	DP U-383			
	5889052	Dec 02, 2014	DP U-383			
	6503497	May 06, 2012	DP			
	6849253	May 06, 2012	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
	7829120	Mar 27, 2027	DP U-796			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
	7829120	Mar 27, 2027	DP U-796			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 001	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 002	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 003	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL SODIUM - REMODULIN						
N021272 004	5153222	Oct 06, 2014	DS	U-455		
	6765117	Oct 24, 2017				
TREPROSTINIL SODIUM - TYVASO						
N022387 001	5153222	Oct 16, 2014	DS	U-1019	NDF	Jul 30, 2012
	6521212	Nov 13, 2018		U-1018	ODE	Jul 30, 2016
	6756033	Nov 13, 2018		U-1018		
	6765117	Oct 24, 2017				
TRETINOIN - ATRALIN						
N022070 001	5670547	Sep 23, 2014	DP		NP	Jul 26, 2010
TRETINOIN - RENOVA						
N021108 001	6531141	Mar 07, 2020				
TRETINOIN - RETIN-A MICRO						
N020475 001	5955109	Sep 21, 2016	DP	U-134		
TRETINOIN - RETIN-A MICRO						
N020475 002	5955109	Sep 21, 2016		U-134		
TRIAMCINOLONE ACETONIDE - NASACORT AQ						
N020468 001	5976573	Jul 03, 2016	DP	U-896	NPP	Sep 19, 2011
	5976573	Jul 03, 2016	DP	U-295		
	6143329	Jul 03, 2016	DP	U-896		
TRIAMCINOLONE ACETONIDE - TRIESENCE						
N022048 001	6395294	Jan 13, 2020	DP	U-846	NP	Nov 29, 2010
TRIMETHOPRIM HYDROCHLORIDE - PRIMSOL						
A074973 001	5763449	Aug 07, 2016				
	5962461	Aug 07, 2016				
TRIMETREXATE GLUCURONATE - NEUTREXIN						
N020326 001	6017922	May 18, 2018				
TRIMETREXATE GLUCURONATE - NEUTREXIN						
N020326 002	6017922	May 18, 2018				
TRIPTORELIN PAMOATE - TRELSTAR						
N022437 001	5776885	Jul 07, 2015	DP		NP	Mar 10, 2013
TRIPTORELIN PAMOATE - TRELSTAR DEPOT						
N020715 001	5225205	Jul 20, 2010				
	5776885	Jul 07, 2015				
TRIPTORELIN PAMOATE - TRELSTAR LA						
N021288 001	5225205	Jul 20, 2010	DP			
	5776885	Jul 07, 2015				
TROGLITAZONE - PRELAY						
N020719 001	5602133	Sep 15, 2013		U-173		
	5859037	Nov 13, 2017		U-251		
	6011049	Nov 13, 2017		U-301		
	6046202	Sep 15, 2013		U-317		
TROGLITAZONE - PRELAY						
N020719 002	5602133	Sep 15, 2013		U-173		
	5859037	Nov 13, 2017		U-251		
	6011049	Nov 13, 2017		U-301		
	6046202	Sep 15, 2013		U-317		
TROGLITAZONE - PRELAY						
N020719 003	5602133	Sep 15, 2013		U-173		
	5859037	Nov 13, 2017		U-251		
	6011049	Nov 13, 2017		U-301		
	6046202	Sep 15, 2013		U-317		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TROGLITAZONE - REZULIN</u>						
N020720 001	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - REZULIN</u>						
N020720 002	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - REZULIN</u>						
N020720 003	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROSPIMUM CHLORIDE - SANCTURA XR</u>						
N022103 001	7410978	Feb 01, 2025	DP		NDF	Aug 03, 2010
	7759359	Nov 04, 2024	U-1071			
	7763635	Nov 04, 2024	U-1071			
	7781448	Nov 04, 2024	U-1071			
	7781449	Nov 04, 2024	U-1071			
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N020759 001	5164402	Dec 18, 2011	U-282			
	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N020759 002	5164402	Dec 18, 2011	U-282			
	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					ODE	Dec 16, 2011
<u>ULIPRISTAL ACETATE - ELLA</u>						
N022474 001					NCE	Aug 13, 2015
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N021214 001	5208256	May 21, 2011	DP U-333			
	5221763	Jul 15, 2012	DS			
	6458836	Jul 09, 2021	U-333			
<u>UROFOLLITROPIN - FERTINEX</u>						
N019415 004	5767067	Jun 16, 2015				
<u>UROFOLLITROPIN - FERTINEX</u>						
N019415 005	5767067	Jun 16, 2015				
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N020487 001	5879706	Jan 19, 2016	DP U-894		I-570	Sep 02, 2011
	5879706	Jan 19, 2016	DP U-530		NPP	Sep 02, 2011
	5879706*PED	Jul 19, 2016			PED	Mar 02, 2012
	6107302	Jan 19, 2016	DS U-530		PED	Mar 02, 2012
	6107302	Jan 19, 2016	DS U-894			
	6107302*PED	Jul 19, 2016				
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N020487 002	5879706	Jan 19, 2016	DP U-530		I-570	Sep 02, 2011
	5879706	Jan 19, 2016	DP U-894		NPP	Sep 02, 2011
	5879706*PED	Jul 19, 2016			PED	Mar 02, 2012
	6107302	Jan 19, 2016	DS U-530		PED	Mar 02, 2012
	6107302	Jan 19, 2016	DS U-894			
	6107302*PED	Jul 19, 2016				
<u>VALDECOXIB - BEXTRA</u>						
N021341 002	5633272	Feb 13, 2015	U-462			
	7135489	Aug 12, 2017	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VALDECOXIB - BEXTRA						
N021341 003	5633272	Feb 13, 2015	DS DP	U-462		
	7135489	Aug 12, 2017				
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N021304 001	6083953	Mar 29, 2015	DS DP	U-384	D-125	Aug 05, 2013
	6083953	Mar 29, 2015	DS DP	U-854	I-604	Aug 28, 2012
	6083953*PED	Sep 29, 2015			PED	Feb 28, 2013
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N022257 001	6083953	Mar 29, 2015	DS DP	U-384	D-125	Aug 05, 2013
	6083953	Mar 29, 2015	DS DP	U-854	NDF	Aug 28, 2012
					PED	Feb 28, 2013
VALSARTAN - DIOVAN						
N020665 001	5399578	Mar 21, 2012		U-3		
	5399578*PED	Sep 21, 2012				
VALSARTAN - DIOVAN						
N020665 002	5399578	Mar 21, 2012		U-3		
	5399578*PED	Sep 21, 2012				
VALSARTAN - DIOVAN						
N021283 001	5399578	Mar 21, 2012			I-550	Nov 29, 2010
	5399578*PED	Sep 21, 2012			PED	May 29, 2011
	5972990	Oct 26, 2016		U-692		
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017		U-3		
	6294197*PED	Dec 18, 2017				
VALSARTAN - DIOVAN						
N021283 002	5399578	Mar 21, 2012			I-550	Nov 29, 2010
	5399578*PED	Sep 21, 2012			PED	May 29, 2011
	5972990	Oct 26, 2016		U-692		
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017		U-3		
	6294197*PED	Dec 18, 2017				
VALSARTAN - DIOVAN						
N021283 003	5399578	Mar 21, 2012			I-550	Nov 29, 2010
	5399578*PED	Sep 21, 2012			PED	May 29, 2011
	5972990	Oct 26, 2016		U-692		
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017		U-3		
	6294197*PED	Dec 18, 2017				
VALSARTAN - DIOVAN						
N021283 004	5399578	Mar 21, 2012			I-550	Nov 29, 2010
	5399578*PED	Sep 21, 2012			PED	May 29, 2011
	5972990	Oct 26, 2016		U-692		
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017		U-3		
	6294197*PED	Dec 18, 2017				
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N021400 001	6362178	Oct 31, 2018	DS DP	U-533		
	7696206	Oct 31, 2018	DS DP	U-533		
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N021400 002	6362178	Oct 31, 2018	DS DP	U-533		
	7696206	Oct 31, 2018	DS DP	U-533		
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N021400 003	6362178	Oct 31, 2018	DS DP	U-533		
	7696206	Oct 31, 2018	DS DP	U-533		
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N021400 004	6362178	Oct 31, 2018	DS DP	U-533		
	7696206	Oct 31, 2018	DS DP	U-533		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N200179 001	6362178	Oct 31, 2018	U-155		NDF	Jun 17, 2013
	7696206	Oct 31, 2018	U-155			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 001	6410550	May 10, 2020	DS DP U-56		NCE	May 10, 2011
	6890927	May 06, 2022	DS DP U-56			
	7265119	Aug 03, 2022	DS DP U-56			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 002	6410550	May 10, 2020	DS DP U-56		NCE	May 10, 2011
	6890927	May 06, 2022	DS DP U-56			
	7265119	Aug 03, 2022	DS DP U-56			
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N022575 001					NCE	Feb 26, 2015
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N022575 002					NCE	Feb 26, 2015
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 001	5916923	Jun 28, 2013	U-398		I-561	Dec 14, 2010
	5916923*PED	Dec 28, 2013	U-398			
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6310101	Jun 28, 2013	U-46			
	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-535			
	6403120*PED	Sep 20, 2017	U-451			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958*PED	Sep 20, 2017	U-535			
	6419958*PED	Sep 20, 2017	U-459			
	6444708	Jun 28, 2013	U-398			
	6444708*PED	Dec 28, 2013	U-398			
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 002	5916923	Jun 28, 2013	U-398		I-561	Dec 14, 2010
	5916923*PED	Dec 28, 2013	U-398			
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6310101	Jun 28, 2013	U-46			
	6403120	Mar 20, 2017	U-451			
	6403120	Mar 20, 2017	U-535			
	6403120*PED	Sep 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958	Mar 20, 2017	U-535			
	6419958*PED	Sep 20, 2017	U-459			
	6419958*PED	Sep 20, 2017	U-535			
	6444708	Jun 28, 2013	U-398			
	6444708*PED	Dec 28, 2013	U-398			
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 003	5916923	Jun 28, 2013	U-398		I-561	Dec 14, 2010
	5916923*PED	Dec 28, 2013	U-398			
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-535			
	6403120*PED	Sep 20, 2017	U-451			
	6419958	Mar 20, 2017	U-459			
	6419958	Mar 20, 2017	U-535			
	6419958*PED	Sep 20, 2017	U-459			
	6419958*PED	Sep 20, 2017	U-535			
	6444708	Jun 28, 2013	U-398			
	6444708*PED	Dec 28, 2013	U-398			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 004	5916923	Jun 28, 2013	U-398		I-561	Dec 14, 2010
	5916923*PED	Dec 28, 2013	U-398			
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6310101	Jun 28, 2013	U-46			
	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-535			
	6403120*PED	Sep 20, 2017	U-451			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958*PED	Sep 20, 2017	U-535			
	6419958*PED	Sep 20, 2017	U-459			
	6444708	Jun 28, 2013	U-398			
	6444708*PED	Dec 28, 2013	U-398			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
A076565 001					PC	Dec 28, 2010
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
A076565 002					PC	Dec 28, 2010
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
A076565 003					PC	Dec 28, 2010
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 001	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 002	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 003	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 004	6403120	Mar 20, 2017	U-839			
	6403120	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N020552 001	5160744	Jun 27, 2011				
	5232705	Aug 31, 2010				
	5252338	Jun 27, 2011				
	6096339	Apr 04, 2017	U-365			
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N020552 002	5160744	Jun 27, 2011				
	5232705	Aug 31, 2010				
	5252338	Jun 27, 2011				
	6096339	Apr 04, 2017	U-365			
<u>VERTEPORFIN - VISUDYNE</u>						
N021119 001	5095030	Sep 09, 2011	DS			
	5707608	Aug 02, 2015				
	5756541	Mar 11, 2016	U-357			
	5770619	Jan 06, 2015	U-357			
	5798349	Aug 25, 2015	U-357			
	6074666	Feb 05, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VIGABATRIN - SABRIL</u>						
N020427	001				NCE	Aug 21, 2014
<u>VIGABATRIN - SABRIL</u>						
N022006	001				NCE	Aug 21, 2014
					ODE	Aug 21, 2016
<u>VORICONAZOLE - VFEND</u>						
N021266	001	5364938	Nov 15, 2011	DS		
		5567817	May 24, 2016	DS DP	U-540	
		5773443	Jan 25, 2011	DS DP	U-540	
<u>VORICONAZOLE - VFEND</u>						
N021266	002	5364938	Nov 15, 2011	DS		
		5567817	May 24, 2016	DS DP	U-540	
		5773443	Jan 25, 2011	DS DP	U-540	
<u>VORICONAZOLE - VFEND</u>						
N021267	001	5364938	Nov 15, 2011	DS		
		5567817	May 24, 2016	DS DP	U-540	
		5773443	Jan 25, 2011	DS DP	U-540	
		6632803	Jun 02, 2018	DP		
<u>VORICONAZOLE - VFEND</u>						
N021630	001	5364938	Nov 15, 2011	DS		
		5567817	May 24, 2016	DS DP	U-540	
		5773443	Jan 25, 2011	DS DP	U-540	
<u>VORINOSTAT - ZOLINZA</u>						
N021991	001	6087367	Oct 04, 2011		U-776	NCE Oct 06, 2011
		7399787	Feb 09, 2025		U-892	ODE Oct 06, 2013
		7456219	Nov 14, 2026	DS		
		7652069	Mar 04, 2023	DS		
		7732490	Mar 04, 2023		U-892	
		7851509	Feb 21, 2024		DP U-892	
		RE38506	Nov 29, 2011	DS DP		
<u>ZAFIRLUKAST - ACCOLATE</u>						
N020547	001	4859692	Sep 26, 2010			
		5294636	Dec 11, 2011			
		5319097	Dec 11, 2011			
		5482963	Jan 09, 2013			
		5583152	Sep 26, 2010			
		5612367	Mar 18, 2014		U-189	
		6143775	Dec 11, 2011			
<u>ZAFIRLUKAST - ACCOLATE</u>						
N020547	003	4859692	Sep 26, 2010			
		5294636	Dec 11, 2011			
		5319097	Dec 11, 2011			
		5482963	Jan 09, 2013			
		5583152	Sep 26, 2010			
		5612367	Mar 18, 2014		U-189	
		6143775	Dec 11, 2011			
<u>ZANAMIVIR - RELENZA</u>						
N021036	001	5360817	Jul 26, 2013	DS DP		
		5648379	Jul 15, 2014		U-722	
		5648379	Jul 15, 2014		U-721	
		5648379	Jul 15, 2014		U-274	
		6294572	Dec 15, 2014	DS DP		
<u>ZICONOTIDE - PRIALT</u>						
N021060	001	5364842	Dec 30, 2016		U-55	
		5364842	Dec 30, 2016		U-48	
		5795864	Jun 27, 2015	DP		
		5859186	Dec 30, 2011		U-48	
		5859186	Dec 30, 2011		U-55	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE - PRIALT</u>						
N021060 002	5364842	Dec 30, 2016				U-48
	5364842	Dec 30, 2016				U-55
	5795864	Jun 27, 2015	DP			
	5859186	Dec 30, 2011				U-55
	5859186	Dec 30, 2011				U-48
<u>ZICONOTIDE - PRIALT</u>						
N021060 003	5364842	Dec 30, 2016				U-48
	5364842	Dec 30, 2016				U-55
	5795864	Jun 27, 2015	DP			
	5859186	Dec 30, 2011				U-55
	5859186	Dec 30, 2011				U-48
<u>ZICONOTIDE - PRIALT</u>						
N021060 004	5364842	Dec 30, 2016				U-48
	5364842	Dec 30, 2016				U-55
	5795864	Jun 27, 2015	DP			
	5859186	Dec 30, 2011				U-48
	5859186	Dec 30, 2011				U-55
<u>ZILEUTON - ZYFLO</u>						
N020471 001	4873259	Dec 10, 2010				U-168
<u>ZILEUTON - ZYFLO</u>						
N020471 003	4873259	Dec 10, 2010				U-168
<u>ZILEUTON - ZYFLO CR</u>						
N022052 001	4873259	Dec 09, 2010	DS			
	5422123	Jun 06, 2012		DP		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N020825 001	4831031	Mar 02, 2012	DS	DP	U-720	
	5312925	Sep 01, 2012	DS	DP		I-615 Nov 20, 2012
	6150366	May 27, 2019		DP		
	6245766	Dec 18, 2018			U-601	
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N020825 002	4831031	Mar 02, 2012	DS	DP	U-720	
	5312925	Sep 01, 2012	DS	DP		I-615 Nov 20, 2012
	6150366	May 27, 2019		DP		
	6245766	Dec 18, 2018			U-601	
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N020825 003	4831031	Mar 02, 2012	DS	DP	U-720	
	5312925	Sep 01, 2012	DS	DP		I-615 Nov 20, 2012
	6150366	May 27, 2019		DP		
	6245766	Dec 18, 2018			U-601	
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N020825 004	4831031	Mar 02, 2012	DS	DP	U-720	
	5312925	Sep 01, 2012	DS	DP		I-615 Nov 20, 2012
	6150366	May 27, 2019		DP		
	6245766	Dec 18, 2018			U-601	
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N021483 001	4831031	Mar 02, 2012	DS	DP	U-720	
	5312925	Sep 01, 2012	DS	DP	U-720	
	6150366	May 27, 2019		DP	U-719	
	6245766	Dec 18, 2018			U-601	
	7175855	May 18, 2020		DP		
<u>ZIPRASIDONE MESYLATE - GEODON</u>						
N020919 001	4831031	Mar 02, 2012	DS	DP	U-720	
	6110918	Mar 26, 2017				
	6232304	Apr 01, 2017				
	6399777	Apr 01, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE		
<u>ZOLEDRONIC ACID - RECLAST</u>											
N021817 001	4939130	Sep	02,	2012	DS	DP	U-662	I-595	May	29,	2012
	4939130*PED	Mar	02,	2013				I-584	Mar	15,	2012
								I-581	Dec	19,	2011
								I-271	Aug	17,	2010
								PED	Feb	17,	2011
								PED	Oct	16,	2010
<u>ZOLEDRONIC ACID - ZOMETA</u>											
N021223 001	4939130	Sep	02,	2012	DS	DP	U-53				
	4939130*PED	Mar	02,	2013							
<u>ZOLEDRONIC ACID - ZOMETA</u>											
N021223 002	4939130	Sep	02,	2012	DS	DP	U-53	M-61	Mar	20,	2011
	4939130*PED	Mar	02,	2013				PED	Sep	20,	2011
<u>ZOLMITRIPTAN - ZOMIG</u>											
N020768 001	5466699	Nov	14,	2012							
	5466699*PED	May	14,	2013							
	5863935	Nov	14,	2012							
	5863935*PED	May	14,	2013							
<u>ZOLMITRIPTAN - ZOMIG</u>											
N020768 002	5466699	Nov	14,	2012							
	5466699*PED	May	14,	2013							
	5863935	Nov	14,	2012							
	5863935*PED	May	14,	2013							
<u>ZOLMITRIPTAN - ZOMIG</u>											
N021450 004	5466699	Nov	14,	2012			U-436				
	5466699*PED	May	14,	2013							
	6750237	Nov	28,	2020							
	6750237*PED	May	28,	2021							
	7220767	Nov	28,	2020							
	7220767*PED	May	28,	2021							
<u>ZOLMITRIPTAN - ZOMIG-ZMT</u>											
N021231 001	5466699	Nov	14,	2012							
	5466699*PED	May	14,	2013							
<u>ZOLMITRIPTAN - ZOMIG-ZMT</u>											
N021231 002	5466699	Nov	14,	2012							
	5466699*PED	May	14,	2013							
<u>ZOLPIDEM TARTRATE - AMBIEN</u>											
N019908 001								PED	Sep	29,	2010
<u>ZOLPIDEM TARTRATE - AMBIEN</u>											
N019908 002								PED	Sep	29,	2010
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>											
N021774 001	6514531	Dec	01,	2019							
	6514531*PED	Jun	01,	2020							
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>											
N021774 002	6514531	Dec	01,	2019							
	6514531*PED	Jun	01,	2020							
<u>ZOLPIDEM TARTRATE - EDLUAR</u>											
N021997 001	6761910	Sep	24,	2019		DP	U-674				
<u>ZOLPIDEM TARTRATE - EDLUAR</u>											
N021997 002	6761910	Sep	24,	2019		DP	U-674				
<u>ZOLPIDEM TARTRATE- ZOLPIMIST</u>											
N022196 001	7632517	Oct	01,	2017			U-70				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

ADB 1 of 48

PATENT & EXCLUSIVITY ABBREVIATIONS

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY

PATENT AND EXCLUSIVITY TERMS

ADB 2 of 48

EXCLUSIVITY DOSING SCHEDULE

- D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
- D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
- D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2 TO 1 HOUR BEFORE EATING" TO "... RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
- D-40 ONCE-A-DAY DOSING REGIMEN
- D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
- D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
- D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
- D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
- D-46 NEW DOSING REGIMEN OF 80MG DAILY
- D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
- D-48 ADMINISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL
- D-49 PEDIATRIC DOSING GUIDELINES
- D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
- D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
- D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
- D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
- D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
- D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
- D-56 ADDITION OF POSTPRANDIAL DOSING
- D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
- D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
- D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
- D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
- D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
- D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
- D-70 80MG ONCE DAILY DOSING REGIMEN
- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE

PATENT AND EXCLUSIVITY TERMS

ADB 3 of 48

EXCLUSIVITY DOSING SCHEDULE

- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
- D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
- D-93 ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
- D-94 NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD)
- D-95 BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
- D-96 ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
- D-97 PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
- D-98 DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
- D-99 ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
- D-100 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
- D-101 ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- D-102 NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERGIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
- D-103 NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
- D-104 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
- D-105 USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-106 FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
- D-107 PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-108 TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
- D-109 PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
- D-110 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
- D-111 PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
- D-112 PROVIDES FOR PEDIATRIC PUMP USE
- D-113 ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
- D-114 NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
- D-115 STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- D-116 ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULFATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS

PATENT AND EXCLUSIVITY TERMS

ADB 4 of 48

EXCLUSIVITY DOSING SCHEDULE

- D-117 50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
- D-118 TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
- D-119 DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
- D-120 DOSING REGIMEN ADJUSTMENTS
- D-121 CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
- D-122 USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
- D-123 ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
- D-124 ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
- D-125 EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
- D-126 CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
- D-127 DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE
- D-128 SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
- D-129 800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNIVIR RESISTANCE ASSOCIATED SUBSTITUTIONS

EXCLUSIVITY INDICATION

- I-1 DYSMENORRHEA
- I-2 CHOLANGIOPANCREATOGRAPHY
- I-3 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
- I-4 PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
- I-5 HYSTEROSALPINGOGRAPHY
- I-6 TREATMENT OF JUVENILE ARTHRITIS
- I-7 BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
- I-8 ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
- I-9 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-10 PREVENTION OF POSTOPERATIVE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
- I-11 RELIEF OF MILD TO MODERATE PAIN
- I-12 TREATMENT OF CUTANEOUS CANDIDIASIS
- I-13 URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
- I-14 SEBORRHEIC DERMATITIS
- I-15 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
- I-16 STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
- I-17 MANAGEMENT OF CONGESTIVE HEART FAILURE
- I-18 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
- I-19 HERNIOGRAPHY
- I-20 KNEE ARTHROGRAPHY
- I-21 HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
- I-22 RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
- I-23 SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- I-24 TREATMENT OF RHEUMATOID ARTHRITIS
- I-25 ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
- I-26 TREATMENT OF LIVER FLUKES
- I-27 ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
- I-28 SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
- I-29 METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
- I-30 TREATMENT OF TINEA PEDIS
- I-31 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES

PATENT AND EXCLUSIVITY TERMS

ADB 5 of 48

EXCLUSIVITY INDICATION

I-32 PEDIATRIC MYELOGRAPHY
I-33 ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34 ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35 PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36 ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37 RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39 TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40 PRIMARY NOCTURNAL ENURESIS
I-41 MIGRAINE HEADACHE PROPHYLAXIS
I-42 HERPES ZOSTER
I-43 HERPES SIMPLEX ENCEPHALITIS
I-44 MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45 ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46 USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47 TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48 PEDIATRIC ANGIOCARDIOGRAPHY
I-49 TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50 FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51 TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52 PEDIATRIC EXCRETORY UROGRAPHY
I-53 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54 RENAL CONCENTRATION CAPACITY TEST
I-55 HYPERTENSION
I-56 EROSIIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58 INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59 ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60 SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61 FEMALE ANDROGENETIC ALOPECIA
I-62 PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63 ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64 PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65 PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66 UNCOMPLICATED GONORRHEA
I-67 TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68 CENTRAL PRECOCIOUS PUBERTY
I-69 SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70 USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71 VARICELLA INFECTIONS (CHICKENPOX)
I-72 PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73 INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75 TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIIVE ESOPHAGITIS
I-76 PREVENTION OF OSTEOPOROSIS
I-77 DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78 CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79 MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80 DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81 PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS

PATENT AND EXCLUSIVITY TERMS

ADB 6 of 48

EXCLUSIVITY INDICATION

I-82 TREATMENT OF TRAVELERS' DIARRHEA
I-83 ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84 INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85 TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86 TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87 RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88 MANAGEMENT OF ENDOMETRIOSIS
I-89 EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90 INTENSIVE CARE UNIT SEDATION
I-91 MONOTHERAPY USE FOR HYPERTENSION
I-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94 USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95 TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97 ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98 TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102 TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103 PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106 TREATMENT OF ACROMEGALY
I-107 VAGINAL CANDIDIASIS
I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109 TYPHOID FEVER
I-110 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111 TREATMENT OF PAGET'S DISEASE OF BONE
I-112 MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113 TREATMENT OF PROSTATITIS
I-114 USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115 USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
I-117 TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121 EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122 PSORIASIS OF THE SCALP
I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129 TREATMENT OF ALCOHOL DEPENDENCE
I-130 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS

PATENT AND EXCLUSIVITY TERMS

ADB 7 of 48

EXCLUSIVITY INDICATION

- I-131 PERIPHERAL ARTERIOGRAPHY
- I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
- I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
- I-134 HEART FAILURE POST MYOCARDIAL INFARCTION
- I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
- I-136 IDIOPATHIC CHRONIC URTICARIA
- I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
- I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
- I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
- I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
- I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
- I-142 LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
- I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
- I-145 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
- I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
- I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
- I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
- I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
- I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
- I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
- I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
- I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN]
- I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
- I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
- I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
- I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
- I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
- I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
- I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS
- I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
- I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE
- I-163 TREATMENT OF PHOTOPHOBIA
- I-164 CHRONIC BACTERIAL PROSTATITIS
- I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
- I-166 TREATMENT OF BULIMIA
- I-167 COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
- I-168 MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
- I-169 USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
- I-170 PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
- I-171 RELIEF OF SYMPTOMS OF THE COMMON COLD
- I-172 TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
- I-173 PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
- I-174 PELVIC INFLAMMATORY DISEASE
- I-175 TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
- I-176 TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION

PATENT AND EXCLUSIVITY TERMS

ADB 8 of 48

EXCLUSIVITY INDICATION

- I-177 TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
- I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
- I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
- I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
- I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
- I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
- I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
- I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
- I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
- I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
- I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
- I-190 PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
- I-191 ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
- I-192 THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
- I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
- I-194 CONGESTIVE HEART FAILURE
- I-195 FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
- I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER
- I-198 FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
- I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES
- I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
- I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
- I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
- I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-205 INITIAL ANTICONSULSANT TREATMENT OF STATUS EPILEPTICUS
- I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
- I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
- I-209 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
- I-210 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
- I-211 FOR USE IN PEDIATRIC POPULATION
- I-212 TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
- I-213 TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
- I-214 TREATMENT OF OSTEOPOROSIS
- I-215 PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
- I-216 FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

PATENT AND EXCLUSIVITY TERMS

ADB 9 of 48

EXCLUSIVITY INDICATION

- I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
- I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
- I-220 TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
- I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
- I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
- I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
- I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
- I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
- I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
- I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
- I-229 PRILOSEC (OMEPRazole), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
- I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
- I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
- I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
- I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
- I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
- I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

PATENT AND EXCLUSIVITY TERMS

ADB 10 of 48

EXCLUSIVITY INDICATION

- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER
- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
- I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
- I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
- I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
- I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
- I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
- I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
- I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOID IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
- I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
- I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
- I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
- I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
- I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER
- I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
- I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
- I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
- I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
- I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
- I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
- I-288 CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
- I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL

PATENT AND EXCLUSIVITY TERMS

ADB 11 of 48

EXCLUSIVITY INDICATION

- I-290 PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
- I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
- I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
- I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
- I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
- I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
- I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
- I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
- I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
- I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
- I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
- I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
- I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
- I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
- I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
- I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
- I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
- I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
- I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
- I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
- I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
- I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
- I-321 JUVENILE RHEUMATOID ARTHRITIS
- I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
- I-323 COLORECTAL CANCER
- I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
- I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
- I-326 GENERALIZED ANXIETY DISORDER
- I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
- I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
- I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-330 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTEMS IN PATIENTS WITH GERD
- I-331 TREATMENT OF MODERATE ACNE VULGARIS
- I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)

PATENT AND EXCLUSIVITY TERMS

ADB 12 of 48

EXCLUSIVITY INDICATION

- I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
- I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
- I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
- I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
- I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME
- I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
- I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
- I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
- I-341 BREAST CANCER COMBINATION THERAPY
- I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-343 USE OF COREG FOR SEVERE HEART FAILURE
- I-344 ACNE VULGARIS
- I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- I-346 TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
- I-347 TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
- I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
- I-349 ACUTE CORONARY SYNDROME
- I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
- I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
- I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
- I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
- I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
- I-355 PREMENSTRUAL DYSPHORIC DISORDER
- I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-358 TREATMENT OF PANIC DISORDER
- I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
- I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
- I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
- I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- I-372 NOSOCOMIAL PNEUMONIA
- I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS

PATENT AND EXCLUSIVITY TERMS

ADB 13 of 48

EXCLUSIVITY INDICATION

- I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
- I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
- I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD"INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....
- I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
- I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
- I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
- I-409 ESOPHAGEAL CANDIDIASIS

PATENT AND EXCLUSIVITY TERMS

ADB 14 of 48

EXCLUSIVITY INDICATION

- I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
- I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
- I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-414 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-415 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
- I-416 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
- I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
- I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS

PATENT AND EXCLUSIVITY TERMS

ADB 15 of 48

EXCLUSIVITY INDICATION

- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
- I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
- I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
- I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION $\leq 40\%$) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
- I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
- I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
- I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
- I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
- I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
- I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
- I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
- I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
- I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
- I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
- I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN
- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
- I-475 PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS

PATENT AND EXCLUSIVITY TERMS

ADB 16 of 48

EXCLUSIVITY INDICATION

- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
- I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
- I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
- I-487 INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
- I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
- I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
- I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
- I-491 INFLUENZA PROPHYLAXIS
- I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
- I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
- I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
- I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
- I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
- I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
- I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
- I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
- I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
- I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
- I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-508 PREMENSTRUAL DYSPHONIC DISORDER
- I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- I-510 ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)
- I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
- I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
- I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
- I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
- I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
- I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS

ADB 17 of 48

EXCLUSIVITY INDICATION

- I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
- I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
- I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
- I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
- I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
- I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
- I-524 GENERALIZED ANXIETY DISORDER (GAD)
- I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
- I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
- I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
- I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
- I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
- I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA
- I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
- I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
- I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER
- I-535 MANAGEMENT OF FIBROMYALGIA
- I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
- I-537 LONG TERM TREATMENT OF PANIC DISORDER
- I-538 SHORT TERM TREATMENT OF PANIC DISORDER
- I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
- I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
- I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
- I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
- I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
- I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
- I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
- I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
- I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
- I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
- I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESES
- I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
- I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
- I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD

PATENT AND EXCLUSIVITY TERMS

ADB 18 of 48

EXCLUSIVITY INDICATION

- I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
- I-561 LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
- I-562 MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
- I-563 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-564 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- I-565 USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-566 MANAGEMENT OF FIBROMYALGIA
- I-567 INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-568 USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
- I-569 TREATMENT OF CHRONIC HEPATITIS B
- I-570 TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
- I-571 NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQUAMOUS NON-SMALL CELL LUNG CANCER
- I-572 TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
- I-573 TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
- I-574 MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
- I-575 MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
- I-576 ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
- I-577 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES
- I-578 EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
- I-579 TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
- I-580 INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
- I-581 TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- I-582 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- I-583 ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)
- I-584 TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICIDS FOR AT LEAST 12 MONTHS
- I-585 TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
- I-586 COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
- I-587 ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
- I-588 ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
- I-589 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
- I-590 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
- I-591 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
- I-592 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
- I-593 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
- I-594 INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
- I-595 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-596 USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- I-597 MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- I-598 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
- I-599 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
- I-600 FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

PATENT AND EXCLUSIVITY TERMS

ADB 19 of 48

EXCLUSIVITY INDICATION

- I-601 MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
- I-602 TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
- I-603 GOUT FLARES
- I-604 PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
- I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
- I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
- I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
- I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
- I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
- I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
- I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
- I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
- I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
- I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
- I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
- I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
- I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
- I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
- I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
- I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
- I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
- I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
- I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER
- I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
- I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
- I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
- I-631 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
- I-632 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

EXCLUSIVITY MISCELLANEOUS

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE

PATENT AND EXCLUSIVITY TERMS

ADB 20 of 48

EXCLUSIVITY MISCELLANEOUS

- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
- M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
- M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
- M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
- M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
- M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
- M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
- M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
- M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- M-12 NEW LANGUAGE FOR PEDIATRIC USE
- M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
- M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION
- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
- M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
- M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
- M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
- M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"

PATENT AND EXCLUSIVITY TERMS

ADB 21 of 48

EXCLUSIVITY MISCELLANEOUS

- M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
- M-43 INCLUSION OF RESULTS OF STUDY-"PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
- M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
- M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING - EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
- M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
- M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
- M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
- M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
- M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
- M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
- M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
- M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
- M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
- M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
- M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
- M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
- M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
- M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
- M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
- M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
- M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
- M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
- M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
- M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
- M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
- M-75 PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)

PATENT AND EXCLUSIVITY TERMS

ADB 22 of 48

EXCLUSIVITY MISCELLANEOUS

- M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
- M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
- M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
- M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE
- M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
- M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
- M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES
- M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
- M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
- M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
- M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
- M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
- M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
- M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
- M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
- M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, Crossover, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMAIRILIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
- M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMAIRILIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION
- M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
- M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
- M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
- M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
- M-97 LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION

PATENT USE

- U-1 PREVENTION OF PREGNANCY
- U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
- U-3 TREATMENT OF HYPERTENSION
- U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
- U-5 METHOD OF PRODUCING BRONCHODILATION
- U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
- U-7 INCREASING CARDIAC CONTRACTILITY
- U-8 ACUTE MYOCARDIAL INFARCTION
- U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
- U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS
- U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
- U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
- U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT

PATENT AND EXCLUSIVITY TERMS

ADB 23 of 48

PATENT USE

- U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
- U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE
- U-16 USE IN LUNG SCANNING PROCEDURES
- U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
- U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
- U-19 TREATMENT OF INFLAMMATION
- U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
- U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
- U-22 METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
- U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
- U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
- U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
- U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
- U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
- U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
- U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
- U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
- U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
- U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
- U-33 TREATING VIRAL INFECTIONS IN A MAMMAL
- U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
- U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
- U-36 METHODS OF TREATING BACTERIAL ILLNESSES
- U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE
- U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
- U-39 ANGINA PECTORIS
- U-40 METHOD OF TREATMENT OF BURNS
- U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS
- U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
- U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
- U-44 RELIEF OF NAUSEA AND VOMITING
- U-45 TREATMENT OF INFLAMMATION AND ANALGESIA
- U-46 TREATMENT OF PANIC DISORDER
- U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE
- U-48 ANALGESIA
- U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
- U-50 USE IN TREATING INFLAMMATORY DERMATOSES
- U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
- U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
- U-53 HYPERCALCEMIA OF MALIGNANCY
- U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
- U-55 TREATMENT OF PAIN
- U-56 AID TO SMOKING CESSATION
- U-57 OPHTHALMIC USE OF NORFLOXACIN
- U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
- U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA
- U-60 NASAL ADMINISTRATION OF BUTORPHANOL
- U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
- U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
- U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
- U-64 TREATMENT OF VIRAL INFECTIONS
- U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV

PATENT AND EXCLUSIVITY TERMS

ADB 24 of 48

PATENT USE

U-66 TRIPHASIC REGIMEN

U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL

U-68 TREATMENT OF ACTINIC KERATOSIS

U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS

U-70 TREATMENT OF TRANSIENT INSOMNIA

U-71 METHOD OF TREATMENT OF HEART FAILURE

U-72 TREATMENT OF MIGRAINE

U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES

U-74 METHOD OF PROVIDING HYPNOTIC EFFECT

U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS

U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM

U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-78 ULCERATIVE COLITIS

U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD

U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS

U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS

U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE

U-83 TREATMENT OF SEIZURES

U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS

U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY

U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS

U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS

U-89 TREATMENT OR PROPHYLAXIS OF EMESIS

U-90 TREATMENT OF PYSCHOTIC DISORDERS

U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS

U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY

U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT

U-94 TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED

U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS

U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT

U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL

U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM

U-100 METHOD OF TREATING OCULAR INFLAMMATION

U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED

U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

U-103 TREATMENT OF OCULAR HYPERTENSION

U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

U-105 EMESIS

U-106 TREATMENT OF EPILEPSY

U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS

U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIIVE ESOPHAGITIS

U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE

U-110 USE AS A RETRIEVABLE PERSSARY

U-111 DIABETES

U-112 CONTRACEPTION

U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE

U-114 USE FOR INHIBITING BONE RESORPTION

U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS

U-116 METHOD OF MYOCARDIAL IMAGING

U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES

PATENT AND EXCLUSIVITY TERMS

ADB 25 of 48

PATENT USE

U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119 TREATMENT OF NASAL HYPERSECRETION
U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPTHALMIC LASER SURGICAL PROCEDURES
U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124 TREATMENT OF ACNE
U-125 TREATMENT NEUROGENERATIVE DISEASES
U-126 TREATMENT OF GASTRITIS
U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128 METHOD FOR TREATMENT OF TUMORS
U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131 PHOTODAMAGED SKIN
U-132 INHIBITING HIV PROTEASE
U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134 TREATMENT OF ACNE VULGARIS
U-135 ANTITUMOR AGENT
U-136 PROCESS FOR WASTE NITROGEN REMOVAL
U-137 METHOD OF TREATING BACTERIAL VAGINOSIS
U-138 TREATMENT OF ALLERGIC RHINITIS
U-139 TREATMENT OF ALLERGIC REACTIONS
U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141 TREATMENT OF ULCERATIVE COLITIS
U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF ¹³C₂
U-148 DEVICE FOR COLLECTING A BREATH SAMPLE
U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155 TREATMENT OF ERECTILE DYSFUNCTION
U-156 METHOD OF PROVIDING ANESTHESIA
U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158 ANGINA
U-159 TREATMENT OF INTERSTITIAL CYSTITIS
U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166 TREATMENT OF H. PYLORI-ASSOCIATED DUODENAL ULCER
U-167 METHOD FOR TREATING HIV-1 INFECTION
U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING

PATENT AND EXCLUSIVITY TERMS

ADB 26 of 48

PATENT USE

U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172 TREATMENT OF GENITAL WARTS
U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174 USE AS AN ANTIHISTAMINE AGENT
U-175 METHOD OF TREATING MALIGNANT TUMORS
U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177 FUNGICIDE
U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185 METHOD OF TREATING HYPERTENSION
U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H.PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192 USE IN TREATING ALLERGIC REACTIONS
U-193 PSORIASIS
U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205 METHOD FOR TREATING HEARTBURN
U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207 USE AS NASAL SPRAY
U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS

PATENT AND EXCLUSIVITY TERMS

ADB 27 of 48

PATENT USE

- U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
- U-217 METHOD OF PRODUCING ANESTHESIA
- U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
- U-219 TREATMENT OF PARKINSON'S DISEASE
- U-220 METHOD OF DIAGNOSIS
- U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
- U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
- U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
- U-224 CONTROLLING INTRAOCULAR PRESSURE
- U-225 METHOD FOR DELIVERY
- U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
- U-227 NASAL ADMINISTRATION
- U-228 ASTHMA
- U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
- U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
- U-231 USE IN PARKINSON'S DISEASE
- U-232 METHOD OF TREATING MIGRAINE
- U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
- U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
- U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
- U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
- U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....
- U-239 TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
- U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS
- U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
- U-243 TOPICAL ADMINISTRATION
- U-244 PLATELET AGGREGATION INHIBITORS
- U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
- U-246 PHOSPHATE BINDING
- U-247 TREATMENT OF RHEUMATOID ARTHRITIS
- U-248 TREATMENT OF HIV
- U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
- U-250 TREATMENT OF HEPATITIS B INFECTION
- U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
- U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
- U-253 ORAL TRANSMUCOSAL USE
- U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
- U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
- U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
- U-257 TREATMENT OF HIV INFECTION
- U-258 TREATMENT OF NEURODEGENERATIVE DISEASES
- U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
- U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
- U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
- U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE

PATENT AND EXCLUSIVITY TERMS

ADB 28 of 48

PATENT USE

- U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
- U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
- U-265 USE AS LAXATIVE
- U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
- U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
- U-268 ACROMEGALY
- U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
- U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
- U-271 METHOD OF TREATING TUMORS
- U-272 METHOD OF TREATING CARCINOMA
- U-273 CUTANEOUS T-CELL LYMPHOMA
- U-274 ZANAMIVIR FOR INHALATION
- U-275 METHOD OF USE OF THE DRUG SUBSTANCE
- U-276 METHOD OF USE OF LEVOBUPIVACAINE
- U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
- U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
- U-279 METHOD OF USE OF THE APPROVED PRODUCT
- U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
- U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
- U-282 METHOD OF TREATING BACTERIAL INFECTIONS
- U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
- U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
- U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
- U-286 DEPRESSION
- U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS
- U-288 THERAPY OF INFLUENZA
- U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
- U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
- U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
- U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
- U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
- U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS
- U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
- U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
- U-298 METHOD OF COMBATING BACTERIA IN A PATIENT
- U-299 TREATMENT OF ADENOMATOUS POLYPS
- U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
- U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
- U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
- U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
- U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
- U-305 METHODS FOR USING THE DRUG PRODUCT
- U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY

PATENT AND EXCLUSIVITY TERMS

ADB 29 of 48

PATENT USE

- U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
- U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
- U-309 TREATING SJOEGREN SYNDROME
- U-310 TREATMENT OF XEROSTOMIA
- U-311 HORMONE REPLACEMENT
- U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
- U-313 TREATMENT OF CONGESTIVE HEART FAILURE
- U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
- U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
- U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
- U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
- U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
- U-319 TREATMENT OF MICROBIAL INFECTIONS
- U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
- U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
- U-322 TREATMENT OF ALZHEIMER'S DEMENTIA
- U-323 USE AS A BILE ACID SEQUESTRANT
- U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
- U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
- U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
- U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE
- U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
- U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-330 TREATMENT OF NAUSEA AND VOMITING
- U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM
- U-333 METHOD OF TREATING OCULAR HYPERTENSION
- U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
- U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
- U-336 DIAGNOSTIC RADIOIMAGING
- U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
- U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
- U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
- U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
- U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
- U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
- U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
- U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
- U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
- U-348 METHOD OF USE FOR INHIBITING HIV INFECTION
- U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
- U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR

PATENT AND EXCLUSIVITY TERMS

ADB 30 of 48

PATENT USE

- U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS
- U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
- U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
- U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
- U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
- U-359 METHOD OF USE OF VISICOL
- U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
- U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
- U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
- U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
- U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
- U-367 TREATMENT OF CARDIOVASCULAR DISORDERS
- U-368 HEARTBURN
- U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
- U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
- U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
- U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
- U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
- U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
- U-376 TREATMENT OF INFLUENZA
- U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
- U-378 METHOD FOR TREATING INCONTINENCE
- U-379 METHOD OF TREATING ONYCHROMYCOSIS
- U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
- U-381 TREATMENT OF HYPERPHOSPHATEMIA
- U-382 METHOD OF STABILIZING PROSTAGLANDIN
- U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
- U-384 TREATMENT OF CMV RETINITIS
- U-385 TREATMENT OF PEPTIC ULCERS
- U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
- U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
- U-388 SMOKING CESSATION AID APPLIED TO THE SKIN
- U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
- U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
- U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 31 of 48

PATENT USE

U-392 TREATMENT OF PATIENTS FOR INFLAMMATION
U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394 METHOD OF USE OF ALPHAGAN
U-395 METHOD OF USE OF ALPHAGAN P
U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402 TREATMENT OF ACTINIC KERATOSES
U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407 METHOD OF TREATING OTOPATHY
U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412 TREATMENT OF TYPE 2 DIABETES
U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420 METHOD OF TREATMENT OF TYPE II DIABETES
U-421 USE FOR SEDATION
U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431 POSTTRAUMATIC STRESS DISORDER

PATENT AND EXCLUSIVITY TERMS

ADB 32 of 48

PATENT USE

- U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
- U-433 USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
- U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
- U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION
- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 TREATMENT OF MIGRAINE
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT
- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
- U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
- U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
- U-463 VENOGRAPHY
- U-464 PERIPHERAL ARTERIOGRAPHY
- U-465 CT IMAGING OF THE HEAD
- U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME
- U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
- U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
- U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
- U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
- U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
- U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
- U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL

PATENT AND EXCLUSIVITY TERMS

ADB 33 of 48

PATENT USE

- U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
- U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
- U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
- U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
- U-480 CONTRAST AGENT FOR MRI
- U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
- U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
- U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
- U-489 EXPECTORANT
- U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-491 METHOD OF DELIVERING A DRUG TO THE LUNG
- U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
- U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA

PATENT AND EXCLUSIVITY TERMS

ADB 34 of 48

PATENT USE

U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC MYCOPLASMA BACTERIA
U-514 PREVENTION OF OVULATION IN A WOMAN
U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518 OBSESSIVE COMPULSIVE DISORDER
U-519 POST OPERATIVE NAUSEA AND VOMITING
U-520 PREMENOPAUSAL OSTEOPOROSIS
U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
U-524 METHOD OF TREATING DIARRHEA
U-525 METHOD OF TREATING PARASITIC INFECTIONS
U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533 ERECTILE DYSFUNCTION
U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
U-536 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540 TREATMENT OF FUNGAL INFECTIONS
U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
U-543 TREATMENT OF SCHIZOPHRENIA
U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)

PATENT AND EXCLUSIVITY TERMS

ADB 35 of 48

PATENT USE

- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
- U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

PATENT AND EXCLUSIVITY TERMS

ADB 36 of 48

PATENT USE

- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDER
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
- U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-613 REDUCTION OF SERUM PHOSPHATE
- U-614 TREATMENT OF SEXUAL DYSFUNCTION
- U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
- U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
- U-619 TREATMENT OF MALIGNANT NEOPLASM
- U-620 TREATMENT OF INSOMNIA
- U-621 METHOD OF TREATING CANCER
- U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
- U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
- U-625 ALLERGIC RHINITIS OR NASAL POLYPS
- U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
- U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
- U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
- U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
- U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
- U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING

PATENT AND EXCLUSIVITY TERMS

ADB 37 of 48

PATENT USE

- U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
- U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
- U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
- U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
- U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
- U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
- U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
- U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA
- U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
- U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS
- U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
- U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS
- U-645 TREATMENT OF ASTHMA
- U-646 METHOD OF TREATING OTITIS
- U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
- U-649 A METHOD FOR TREATING A TUMOR DISEASE
- U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
- U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
- U-652 TREATMENT OF CARDIAC ARRHYTHMIA
- U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
- U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4
- U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
- U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
- U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
- U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
- U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
- U-661 TREATMENT OF SEIZURE DISORDER
- U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
- U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
- U-666 METHOD OF TREATING ADHD
- U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
- U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
- U-669 INDICATION OF TYPE II DIABETES
- U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
- U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
- U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
- U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
- U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
- U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
- U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

PATENT AND EXCLUSIVITY TERMS

ADB 38 of 48

PATENT USE

- U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
- U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
- U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY
- U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
- U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
- U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-685 EXPECTORANT AND COUGH SUPPRESSANT
- U-686 EXPECTORANT AND NASAL DECONGESTANT
- U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
- U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
- U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
- U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY
- U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA
- U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
- U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT
- U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
- U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION
- U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
- U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- U-707 ALLERGIC RHINITIS
- U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- U-709 METHOD OF COMBATING BACTERIA IN A PATIENT
- U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
- U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
- U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
- U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER

PATENT AND EXCLUSIVITY TERMS

ADB 39 of 48

PATENT USE

U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-718 TREATMENT OF FUNGAL INFECTIONS

U-719 TREATMENT OF PSYCHOSIS

U-720 TREATMENT OF NEUROLEPTIC DISEASES

U-721 TREATMENT OF INFLUENZA

U-722 PROPHYLAXIS OF INFLUENZA

U-723 PROPHYLACTIC TREATMENT OF MIGRAINE

U-724 METHOD OF TREATING SEIZURES

U-725 ALLERGIC RHINITIS AND URTICARIA

U-726 ALLERGIC RHINITIS

U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

U-728 METHOD FOR TREATING BACTERIAL INFECTION

U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS

U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)

U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE

U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS

U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD

U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE

U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE

U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER

U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT

U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER

U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.

U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA

U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS

U-745 TREATMENT OR PREVENTION OF EMESIS

U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING

U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER

U-749 METHOD OF CONTRACEPTION

U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS

U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA

U-752 SUNSCREEN

U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES

U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA

U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-757 USE AS A BILE ACID SEQUESTANT FOR LOWERING CHOLESTEROL

U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER

U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE

U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA

U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

U-763 ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION

U-764 TREATMENT OF SCHIZOPHRENIA

U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS

U-766 TREATMENT OF SEIZURES

U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 40 of 48

PATENT USE

- U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
- U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT
- U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
- U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
- U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
- U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
- U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
- U-780 A METHOD FOR THE TREATMENT OF CANCER
- U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
- U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
- U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
- U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
- U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
- U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
- U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
- U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
- U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
- U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
- U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
- U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
- U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
- U-796 METHOD OF TREATING DEPRESSION
- U-797 METHOD OF TREATING ANXIETY
- U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
- U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE
- U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
- U-801 METHOD OF TREATING CANCER
- U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
- U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN

PATENT AND EXCLUSIVITY TERMS

ADB 41 of 48

PATENT USE

- U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
- U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
- U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
- U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
- U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
- U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
- U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
- U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-814 TREATMENT OF SCHIZOPHRENIA
- U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING
- U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
- U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN
- U-818 TOPICAL TREATMENT OF ACNE VULGARIS
- U-819 MANAGEMENT OF FIBROMYALGIA
- U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNIA SYNDROME, AND SHIFT WORK SLEEP DISORDER
- U-821 METHOD OF INHIBITING ENTHOHELIN RECEPTORS BY ADMINISTERING AMBRISANTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.
- U-822 USE IN LIPID MANAGEMENT
- U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE
- U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
- U-825 USE FOR PREVENTION OF BREAST CANCER
- U-826 RELIEF OF MODERATE TO SEVERE PAIN
- U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
- U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
- U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
- U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
- U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE
- U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.
- U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
- U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION
- U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
- U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS
- U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
- U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
- U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS
- U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
- U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
- U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE
- U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
- U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES
- U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
- U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

PATENT AND EXCLUSIVITY TERMS

ADB 42 of 48

PATENT USE

- U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
- U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
- U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- U-853 TREATMENT OR PREVENTION OF EMESIS
- U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
- U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-857 INHIBITION OF TRANSPLANT REJECTION
- U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
- U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
- U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
- U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
- U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
- U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
- U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
- U-867 TREATMENT OF MIGRAINE
- U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
- U-869 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
- U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
- U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
- U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
- U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
- U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
- U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
- U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
- U-879 A METHOD OF TREATING OR PREVENTING ILEUS
- U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER
- U-882 MANAGEMENT OF FIBROMYALGIA (FM)
- U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
- U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
- U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS
- U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
- U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
- U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

PATENT AND EXCLUSIVITY TERMS

ADB 43 of 48

PATENT USE

- U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE
- U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
- U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
- U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
- U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
- U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
- U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
- U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
- U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
- U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
- U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
- U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS
- U-907 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
- U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
- U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
- U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
- U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
- U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
- U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
- U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
- U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS
- U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
- U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
- U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
- U-919 FOR THE TREATMENT OF DERMATITIS
- U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
- U-921 TREATMENT OF ACNE VULGARIS
- U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS
- U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
- U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS
- U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
- U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
- U-927 METHOD FOR INCREASING TEAR PRODUCTION
- U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE
- U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
- U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN
- U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
- U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

PATENT AND EXCLUSIVITY TERMS

ADB 44 of 48

PATENT USE

- U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
- U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
- U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
- U-937 TREATMENT OF PROSTATE CANCER
- U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
- U-941 METHOD TO TREAT OVARIAN CANCER
- U-942 METHOD TO TREAT MULTIPLE MYELOMA
- U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
- U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
- U-946 TREATMENT OF BREAST CANCER
- U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS
- U-948 TREATMENT OF DIABETES MELLITUS
- U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
- U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
- U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
- U-952 USE AS AN ANALGESIC
- U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
- U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
- U-955 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
- U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
- U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
- U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
- U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
- U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
- U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
- U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
- U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
- U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-969 TREATMENT OF MIGRAINE
- U-970 TOPICAL TREATMENT OF LICE INFESTATIONS
- U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
- U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

PATENT AND EXCLUSIVITY TERMS

ADB 45 of 48

PATENT USE

- U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
- U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-975 TREATMENT OF PULMONARY HYPERTENSION
- U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
- U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
- U-978 METHOD OF TREATING HYPONATREMIA
- U-979 RELIEF OF MUSCLE SPASM
- U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-982 A METHOD OF TREATING OSTEOPOROSIS
- U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
- U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
- U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
- U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
- U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
- U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
- U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
- U-990 TREATMENT OF PROTOZOAL INFECTION
- U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
- U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
- U-993 METHOD OF TREATING INFERTILITY
- U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
- U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
- U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
- U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
- U-998 ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
- U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
- U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
- U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION
- U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS
- U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
- U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
- U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
- U-1007 METHOD OF TREATING GOUT FLARES
- U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
- U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE
- U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
- U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
- U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
- U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

PATENT AND EXCLUSIVITY TERMS

ADB 46 of 48

PATENT USE

- U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
- U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
- U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
- U-1019 TREATMENT OF PULMONARY HYPERTENSION
- U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
- U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
- U-1022 FOR THE PREPARATIO NOF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
- U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
- U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
- U-1025 TREATING FREQUENT HEARTBURN
- U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
- U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
- U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
- U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
- U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
- U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
- U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
- U-1033 TOPICAL TREATMENT OF ACNE VULGARIS
- U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
- U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
- U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
- U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
- U-1039 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
- U-1040 INHIBITION OF THROMBIN IN A PATIENT
- U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
- U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
- U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN
- U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS
- U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY
- U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
- U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
- U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
- U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
- U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
- U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS
- U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
- U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
- U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
- U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
- U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
- U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
- U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
- U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

PATENT AND EXCLUSIVITY TERMS

ADB 47 of 48

PATENT USE

- U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
- U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
- U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
- U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
- U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
- U-1067 TREATMENT OF CANCER
- U-1068 TREATMENT OF ASTHMA
- U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
- U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE
- U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIMUM SALT FORMULATION
- U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
- U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD
- U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
- U-1075 USE FOR THE TREATMENT OF ASTHMA
- U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SALIVARRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
- U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION
- U-1078 TREATMENT OF ACNE
- U-1079 REVLMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
- U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
- U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1082 USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
- U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
- U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
- U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
- U-1086 TREATMENT OF AUTOIMMUNE DISEASE
- U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
- U-1088 RELIEF OF MUSCLE SPASM
- U-1089 INHIBITION OF THROMBIN
- U-1090 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
- U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
- U-1092 TREATMENT OF BREAST CANCER
- U-1093 TREATMENT OF PSEUDOBULBAR AFFECT
- U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
- U-1095 METHOD OF TREATING OCULAR INFLAMMATION
- U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
- U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
- U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
- U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
- U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
- U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
- U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
- U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

PATENT AND EXCLUSIVITY TERMS

ADB 48 of 48

PATENT USE

U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN